PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	GWILT, DJ				GWILT, DJ			CARDIOLOGISTS IN CASUALTY	LANCET			English	Editorial Material							ACUTE MYOCARDIAL-INFARCTION; EMERGENCY ROOM; CHEST PAIN				GWILT, DJ (corresponding author), MILTON KEYNES DIST GEN HOSP, MILTON KEYNES, BUCKS, ENGLAND.							[Anonymous], 1988, LANCET, V2, P349; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; AUFDERHEIDE TP, 1992, AM J CARDIOL, V69, P991, DOI 10.1016/0002-9149(92)90852-P; GOLDMAN L, 1988, NEW ENGL J MED, V318, P797, DOI 10.1056/NEJM198803313181301; HEDEN B, 1994, AM J CARDIOL, V74, P5, DOI 10.1016/0002-9149(94)90482-0; HIMBERT D, 1993, AM J CARDIOL, V71, P377, DOI 10.1016/0002-9149(93)90435-F; KAUL S, 1994, ANN INTERN MED, V121, P976, DOI 10.7326/0003-4819-121-12-199412150-00013; LEE HS, 1994, BRIT HEART J, V71, P311; LEE TH, 1987, AM J CARDIOL, V60, P219, DOI 10.1016/0002-9149(87)90217-7; MCLEOD AA, 1994, BRIT HEART J, V72, P303; OKEEFE JH, 1993, AM J CARDIOL, V72, pG107, DOI 10.1016/0002-9149(93)90115-S; PEELS CH, 1990, AM J CARDIOL, V65, P687, DOI 10.1016/0002-9149(90)90143-O; TIMMIS AD, 1990, BMJ-BRIT MED J, V301, P941, DOI 10.1136/bmj.301.6758.941; VARETTO T, 1993, J AM COLL CARDIOL, V22, P1804, DOI 10.1016/0735-1097(93)90761-O; WEISSMAN I, 1995, ANN INTERN MED, V123, P314, DOI 10.7326/0003-4819-123-4-199508150-00013	15	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 16	1995	346	8990					1571	1572		10.1016/S0140-6736(95)91923-6	http://dx.doi.org/10.1016/S0140-6736(95)91923-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK481	7500745	Bronze			2022-12-24	WOS:A1995TK48100004
J	TSAI, CC; FOLLIS, KE; SABO, A; BECK, TW; GRANT, RF; BISCHOFBERGER, N; BENVENISTE, RE; BLACK, R				TSAI, CC; FOLLIS, KE; SABO, A; BECK, TW; GRANT, RF; BISCHOFBERGER, N; BENVENISTE, RE; BLACK, R			PREVENTION OF SIV INFECTION IN MACAQUES BY (R)-9-(2-PHOSPHONYLMETHOXYPROPYL)ADENINE	SCIENCE			English	Article							SIMIAN IMMUNODEFICIENCY VIRUS; ACYCLIC NUCLEOSIDE PHOSPHONATES; RHESUS-MONKEYS; ANTIRETROVIRAL AGENTS; INVITRO; PROPHYLAXIS; RESISTANCE; ZIDOVUDINE; LENTIVIRUS; METABOLISM	The efficacy of pre- and postexposure treatment with the antiviral compound (R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA) was tested against simian immunodeficiency virus (SIV) in macaques as a model for human immunodeficiency virus (HIV). PMPA was administered subcutaneously once daily beginning either 48 hours before, 4 hours after, or 24 hours after virus inoculation. Treatment continued for 4 weeks and the virologic, immunologic, and clinical status of the macaques was monitored for up to 56 weeks. PMPA prevented SIV infection in all macaques without toxicity, whereas all control macaques became infected. These results suggest a potential role for PMPA prophylaxis against early HIV infection in cases of known exposure.	GILEAD SCI INC,FOSTER CITY,CA 94404; NCI,FREDERICK,MD 21701; NIAID,DIV AIDS,BETHESDA,MD 20852	Gilead Sciences; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	TSAI, CC (corresponding author), UNIV WASHINGTON,REG PRIMATE RES CTR,SEATTLE,WA 98195, USA.				NCRR NIH HHS [RR00166] Funding Source: Medline; NIAID NIH HHS [N01-AI-15120] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI015120] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALZARINI J, 1991, AIDS, V5, P21, DOI 10.1097/00002030-199101000-00003; BALZARINI J, 1993, ANTIMICROB AGENTS CH, V37, P332, DOI 10.1128/AAC.37.2.332; BENVENISTE RE, 1986, J VIROL, V60, P483, DOI 10.1128/JVI.60.2.483-490.1986; CALIENDO AM, 1994, CLIN INFECT DIS, V18, P516, DOI 10.1093/clinids/18.4.516; DECLERCQ E, 1986, NATURE, V323, P464, DOI 10.1038/323464a0; FAZELY F, 1991, J ACQ IMMUN DEF SYND, V4, P1093; Follis Kathryn E., 1994, Journal of Medical Primatology, V23, P255; GARDNER MB, 1991, ANTIVIR RES, V15, P267, DOI 10.1016/0166-3542(91)90009-G; HO HT, 1992, MOL PHARMACOL, V41, P197; LEGRAND R, 1994, AIDS RES HUM RETROV, V10, P1279, DOI 10.1089/aid.1994.10.1279; LUNDGREN B, 1991, J ACQ IMMUN DEF SYND, V4, P489; MARTIN LN, 1993, J INFECT DIS, V168, P825, DOI 10.1093/infdis/168.4.825; MCCLURE HM, 1990, ANN NY ACAD SCI, V616, P287; MONTANER JSG, 1993, AIDS, V7, P189, DOI 10.1097/00002030-199302000-00006; MONTANER JSG, 1995, LANCET, V345, P377, DOI 10.1016/S0140-6736(95)90356-9; PAUWELS R, 1988, ANTIMICROB AGENTS CH, V32, P1025, DOI 10.1128/AAC.32.7.1025; RICHMAN DD, 1993, ANTIMICROB AGENTS CH, V37, P1207, DOI 10.1128/AAC.37.6.1207; RICHMANN DD, 1994, AIDS, V7, P135; SRINIVAS RV, 1993, ANTIMICROB AGENTS CH, V37, P2247, DOI 10.1128/AAC.37.10.2247; TOKARS JI, 1993, ANN INTERN MED, V118, P193; Tsai C.-E., UNPUB; TSAI CC, 1993, J ACQ IMMUN DEF SYND, V6, P1086; TSAI CC, 1990, ANTIVIR RES, V14, P87, DOI 10.1016/0166-3542(90)90046-A; TSAI CC, 1994, J INFECT DIS, V169, P260, DOI 10.1093/infdis/169.2.260; TSAI CC, 1994, J MED PRIMATOL, V23, P175, DOI 10.1111/j.1600-0684.1994.tb00119.x; TSAI CC, 1995, J INFECT DIS, V171, P1338, DOI 10.1093/infdis/171.5.1338; TSAI CC, 1993, LAB ANIM SCI, V43, P441; VANROMPAY KKA, 1992, ANTIMICROB AGENTS CH, V36, P2381, DOI 10.1128/AAC.36.11.2381; VELLA S, 1994, AIDS, V8, pS25, DOI 10.1097/00002030-199409001-00006; WYAND MS, 1992, AIDS RES HUM RETROV, V8, P349, DOI 10.1089/aid.1992.8.349	30	462	482	0	19	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 17	1995	270	5239					1197	1199		10.1126/science.270.5239.1197	http://dx.doi.org/10.1126/science.270.5239.1197			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE905	7502044				2022-12-24	WOS:A1995TE90500056
J	NEUMANN, HPH; ENG, C; MULLIGAN, LM; GLAVAC, D; ZAUNER, I; PONDER, BAJ; CROSSEY, PA; MAHER, ER; BRAUCH, H				NEUMANN, HPH; ENG, C; MULLIGAN, LM; GLAVAC, D; ZAUNER, I; PONDER, BAJ; CROSSEY, PA; MAHER, ER; BRAUCH, H			CONSEQUENCES OF DIRECT GENETIC TESTING FOR GERMLINE MUTATIONS IN THE CLINICAL MANAGEMENT OF FAMILIES WITH MULTIPLE ENDOCRINE NEOPLASIA, TYPE-II	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VONHIPPEL-LINDAU DISEASE; RET PROTOONCOGENE; PHEOCHROMOCYTOMAS; FEATURES	Objective.-Multiple endocrine neoplasia, type II (MEN-II) is an autosomal dominant disorder characterized by tumors of thyroid C cells and pheochromocytoma. Recently, germline mutations in the RET proto-oncogene have been identified in patients with MEN-II. The aims of this study were (1) to define the mutations in clinically diagnosed MEN-II families, (2) to compare the results of genetic and biochemical testing, and (3) to evaluate the impact of mutation analyses for the members of these families. Design.-Register-based survey study of clinically affected and unaffected members of MEN-II families. Setting.-Register of families from Germany and Spain with pheochromocytomas. Two research laboratories at Cambridge University in the United Kingdom. Patients.-We investigated consenting affected and unaffected members belonging to a series of 10 families who met the clinical criteria for MEN-II. Main Outcome Measures.-(1) Presence or absence of germline mutation in the RET proto-oncogene in affected and unaffected members of the 10 families, and (2) in the absence of RET mutation in a given family, presence or absence of germline mutation in the von Hippel-Lindau (VHL) gene, which is the susceptibility gene involved in a closely related syndrome, von Hippel-Lindau disease. Results.-In eight of these families, RET mutations were identified. The specific mutations were detected in all affected members. The remaining two families without RET mutations were subsequently shown to have a mutation within the VHL gene. The VHL mutations were identified in both families and represent a previously undescribed base change, After identification of the mutation, premorbid genetic testing was performed in all MEN-II and VHL families, resulting in detection of asymptomatic carriers in the MEN-II families. Clinically, the two VHL families differed from the eight MEN-II families by the presence of a C-cell tumor in only one individual from each family and extra-adrenal pheochromocytoma in three of nine affected individuals in the two families combined. Conclusions.-The diagnosis of MEN-II should be confirmed by molecular genetic analysis and the diagnosis of VHL syndrome should be considered for families with an absence of RET mutations and a preponderance of pheochromocytomas.	UNIV CAMBRIDGE,DEPT PATHOL,CRC,HUMAN CANC GENET RES GRP,CAMBRIDGE,ENGLAND; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT MED,BOSTON,MA 02115; QUEENS UNIV,DEPT PAEDIAT,KINGSTON,ON,CANADA; QUEENS UNIV,DEPT PATHOL,KINGSTON,ON K7L 3N6,CANADA; TECH UNIV MUNICH,DEPT PATHOL,W-8000 MUNICH,GERMANY; NATL INST CHEM,LJUBLJANA,SLOVENIA; UNIV CAMBRIDGE,DEPT PATHOL,MOLEC GENET GRP,CAMBRIDGE,ENGLAND; UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT CLIN GENET,CAMBRIDGE,ENGLAND	University of Cambridge; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Queens University - Canada; Queens University - Canada; Technical University of Munich; National Institute of Chemistry - Slovenia; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	NEUMANN, HPH (corresponding author), UNIV FREIBURG,DEPT HYPERTENS & NEPHROL,HUGSTETTER STR 55,D-79106 FREIBURG,GERMANY.		MAHER, EAMONN R/A-9507-2008	MAHER, EAMONN R/0000-0002-6226-6918; Eng, Charis/0000-0002-3693-5145; Brauch, Hiltrud/0000-0001-7531-2736				BRAUCH H, 1995, HUM GENET, V95, P551, DOI 10.1007/BF00223868; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CHEN F, 1995, HUM MUTAT, V5, P66, DOI 10.1002/humu.1380050109; CROSSEY PA, 1994, HUM MOL GENET, V8, P1303; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; ENG C, 1995, ONCOGENE, V10, P509; HOFFMAN RW, 1982, ARCH INTERN MED, V142, P1962, DOI 10.1001/archinte.142.10.1962; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; LAMIELL JM, 1989, MEDICINE, V68, P1; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LIPS CJM, 1994, NEW ENGL J MED, V331, P828, DOI 10.1056/NEJM199409293311302; MAHER ER, 1990, Q J MED, V77, P1151, DOI 10.1093/qjmed/77.2.1151; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; MULLIGAN LM, IN PRESS J INTERN ME; NEUMANN HPH, 1993, NEW ENGL J MED, V329, P1531, DOI 10.1056/NEJM199311183292103; NEUMANN HPH, 1987, VASA-J VASCULAR DIS, V16, P220; NEUMANN HPH, 1991, LANCET, V337, P1052, DOI 10.1016/0140-6736(91)91705-Y; SCHIMKE RN, 1990, AM J MED GENET, V37, P375, DOI 10.1002/ajmg.1320370317; WHALEY JM, 1994, AM J HUM GENET, V55, P1092	21	78	80	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 11	1995	274	14					1149	1151						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY056	7563486				2022-12-24	WOS:A1995RY05600030
J	MARINO, JP; GREGORIAN, RS; CSANKOVSZKI, G; CROTHERS, DM				MARINO, JP; GREGORIAN, RS; CSANKOVSZKI, G; CROTHERS, DM			BENT HELIX FORMATION BETWEEN RNA HAIRPINS WITH COMPLEMENTARY LOOPS	SCIENCE			English	Article							COLE1 PLASMID REPLICATION; ROP ROM PROTEIN; NMR-SPECTROSCOPY; ANTISENSE RNA; SPIN-ECHO; TAR RNA; BINDING; CONFORMATION; PSEUDOKNOTS; POLYMERASE	The initial interaction between the CoIE1 plasmid specific transcripts RNA I and RNA II, which function as antisense regulators of plasmid replication, comprises a transient complex between complementary loops found within the RNA secondary structures. Multidimensional heteronuclear magnetic resonance spectroscopy was used to characterize complexes formed between model RNA hairpins having seven nucleotide complementary loops. Seven base pairs are formed in the loop-loop helix, with continuous helical stacking of the loop residues on the 3' side of their helical stems. A sharp bend in the loop-loop helix, documented by gel electrophoresis, narrows the major groove and allows bridging of the phosphodiester backbones across the major groove in order to close the hairpin loops at their 5'-ends. The bend is further enhanced by the binding of Rom, a ColE1 encoded protein that regulates replication.	YALE UNIV, DEPT CHEM, NEW HAVEN, CT 06511 USA	Yale University				Csankovszki, Gyorgyi/0000-0001-5918-034X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021966, R01GM021966] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 21966] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANNER DW, 1987, J MOL BIOL, V196, P657, DOI 10.1016/0022-2836(87)90039-8; BANNER DW, 1983, MECHANISMS DNA REPLI, P327; BATEY RT, 1992, NUCLEIC ACIDS RES, V20, P4515, DOI 10.1093/nar/20.17.4515; BHATTACHARYYA A, 1990, NATURE, V343, P484, DOI 10.1038/343484a0; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; CASCONE PJ, 1993, SCIENCE, V260, P801, DOI 10.1126/science.8484119; CASTAGNOLI L, 1989, EMBO J, V8, P621, DOI 10.1002/j.1460-2075.1989.tb03417.x; CHANG KY, 1994, P NATL ACAD SCI USA, V91, P8705, DOI 10.1073/pnas.91.18.8705; CHASTAIN M, 1991, PROG NUCLEIC ACID RE, V41, P131; CROTHERS DM, 1992, METHOD ENZYMOL, V212, P46; CROTHERS DM, 1991, METHOD ENZYMOL, V208, P118; EBERLE W, 1991, Journal of Biomolecular NMR, V1, P71, DOI 10.1007/BF01874570; EBERLE W, 1990, BIOCHEMISTRY-US, V29, P7402, DOI 10.1021/bi00484a007; EGUCHI Y, 1991, J MOL BIOL, V220, P831, DOI 10.1016/0022-2836(91)90356-B; EGUCHI Y, 1991, ANNU REV BIOCHEM, V60, P631, DOI 10.1146/annurev.bi.60.070191.003215; GREGORIAN RS, IN PRESS J MOL BIOL; GREGORIAN RS, 1994, THESIS YALE U; KAHN JD, 1992, P NATL ACAD SCI USA, V89, P6343, DOI 10.1073/pnas.89.14.6343; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM JL, 1993, NATURE, V356, P512; LEFFERS H, 1987, J MOL BIOL, V195, P43, DOI 10.1016/0022-2836(87)90326-3; LEGAULT P, 1994, J MAGN RESON SER B, V103, P82, DOI 10.1006/jmrb.1994.1012; MAIZELS N, 1994, P NATL ACAD SCI USA, V91, P6729, DOI 10.1073/pnas.91.15.6729; MARINO JP, 1995, THESIS YALE U; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; MUESING M, 1984, GENE, V31, P155, DOI 10.1016/0378-1119(84)90206-3; NIKONOWICZ EP, 1992, NUCLEIC ACIDS RES, V20, P4507, DOI 10.1093/nar/20.17.4507; OTTING G, 1990, Q REV BIOPHYS, V23, P39, DOI 10.1017/S0033583500005412; PERSSON C, 1990, EMBO J, V9, P3767, DOI 10.1002/j.1460-2075.1990.tb07590.x; PLEIJ CWA, 1985, NUCLEIC ACIDS RES, V13, P1717, DOI 10.1093/nar/13.5.1717; PUGLISI JD, 1991, ACCOUNTS CHEM RES, V24, P152, DOI 10.1021/ar00005a005; PUGLISI JD, 1993, P NATL ACAD SCI USA, V90, P3680, DOI 10.1073/pnas.90.8.3680; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; SAENGER W, 1988, PRINCIPLES NUCLEIC A; SCHIMMEL P, 1994, P NATL ACAD SCI USA, V91, P11283, DOI 10.1073/pnas.91.24.11283; SIMONS RW, 1988, ANNU REV GENET, V22, P567, DOI 10.1146/annurev.ge.22.120188.003031; SKLENAR V, 1987, J MAGN RESON, V74, P469, DOI 10.1016/0022-2364(87)90269-1; SZEWCZAK AA, 1993, FEBS LETT, V327, P261, DOI 10.1016/0014-5793(93)81000-P; TANG RS, 1990, BIOCHEMISTRY-US, V29, P5232, DOI 10.1021/bi00474a003; TOMIZAWA J, 1990, J MOL BIOL, V212, P695, DOI 10.1016/0022-2836(90)90231-A; TOMIZAWA J, 1984, CELL, V38, P861, DOI 10.1016/0092-8674(84)90281-2; TOMIZAWA J, 1990, J MOL BIOL, V212, P683, DOI 10.1016/0022-2836(90)90230-J; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; Wuthrich K., 1986, NMR PROTEINS NUCL AC; WYATT JR, 1990, J MOL BIOL, V214, P455, DOI 10.1016/0022-2836(90)90193-P; WYATT JR, 1993, RNA WORLD, P465	47	113	114	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 9	1995	268	5216					1448	1454		10.1126/science.7539549	http://dx.doi.org/10.1126/science.7539549			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC190	7539549				2022-12-24	WOS:A1995RC19000026
J	STANGER, BZ; LEDER, P; LEE, TH; KIM, E; SEED, B				STANGER, BZ; LEDER, P; LEE, TH; KIM, E; SEED, B			RIP - A NOVEL PROTEIN CONTAINING A DEATH DOMAIN THAT INTERACTS WITH FAS/APO-1 (CD95) IN YEAST AND CAUSES CELL-DEATH	CELL			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR RECEPTOR SUPERFAMILY; FAS ANTIGEN; MONOCLONAL-ANTIBODY; SURFACE ANTIGEN; CONSERVED FEATURES; DNA FRAGMENTATION; CROSS-LINKING; KINASE FAMILY; TNF RECEPTOR	Ligation of the extracellular domain of the cell surface receptor Fas/APO-1 (CD95) elicits a characteristic programmed death response in susceptible cells. Using a genetic selection based on protein-protein interaction in yeast, we have identified two gene products that associate with the intracellular domain of Pas: Pas itself, and a novel 74 kDa protein we have named RIP, for receptor interacting protein. RIP also interacts weakly with the p55 tumor necrosis factor receptor (TNFR1) intracellular domain, but not with a mutant version of Pas corresponding to the murine lpr(cg) mutation. RIP contains an N-terminal region with homology to protein kinases and a C-terminal region containing a cytoplasmic motif (death domain) present in the Pas and TNFR1 intracellular domains. Transient overexpression of RIP causes transfected cells to undergo the morphological changes characteristic of apoptosis. Taken together, these properties indicate that RIP is a novel form of apoptosis-inducing protein.	HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02115 USA; MASSACHUSETTS GEN HOSP, DEPT MOLEC BIOL, BOSTON, MA 02114 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	STANGER, BZ (corresponding author), HARVARD UNIV, SCH MED, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043031] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43031] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALDERSON MR, 1993, J EXP MED, V178, P2231, DOI 10.1084/jem.178.6.2231; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEMENT MV, 1994, J EXP MED, V180, P557, DOI 10.1084/jem.180.2.557; CRISPE IN, 1994, IMMUNITY, V1, P347; DHEIN J, 1992, J IMMUNOL, V149, P3166; EISCHEN CM, 1994, J IMMUNOL, V153, P1947; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENG XH, 1993, BIOCHIM BIOPHYS ACTA, V1172, P200, DOI 10.1016/0167-4781(93)90295-O; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANKS SK, 1991, METHOD ENZYMOL, V200, P525; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; HELLER RA, 1993, CELL, V73, P216, DOI 10.1016/0092-8674(93)90223-D; HELLER RA, 1992, CELL, V70, P47; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KLAS C, 1993, INT IMMUNOL, V5, P625, DOI 10.1093/intimm/5.6.625; KOJIMA H, 1994, IMMUNITY, V1, P357, DOI 10.1016/1074-7613(94)90066-3; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEE SC, 1993, J BIOL CHEM, V268, P12164; LEITHAUSER F, 1993, LAB INVEST, V69, P415; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MATSUZAWA A, 1990, J EXP MED, V171, P519, DOI 10.1084/jem.171.2.519; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7053; Miller J.H., 1972, EXPT MOL GENETICS; NEKART PA, 1994, IMMUNITY, V1, P343; OEHM A, 1992, J BIOL CHEM, V267, P10709; OWENSCHAUB LB, 1992, CELL IMMUNOL, V140, P197, DOI 10.1016/0008-8749(92)90187-T; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; Rose M. D., 1990, METHODS YEAST GENETI, P155; Sambrook J., 1989, MOL CLONING LAB MANU; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; SHEN MM, 1992, P NATL ACAD SCI USA, V89, P8240, DOI 10.1073/pnas.89.17.8240; SINGER GG, 1994, IMMUNITY, V1, P365, DOI 10.1016/1074-7613(94)90067-1; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WONG GHW, 1994, J IMMUNOL, V152, P1751; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	56	842	896	0	28	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 19	1995	81	4					513	523		10.1016/0092-8674(95)90072-1	http://dx.doi.org/10.1016/0092-8674(95)90072-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QZ710	7538908	Bronze			2022-12-24	WOS:A1995QZ71000008
J	KUCHROO, VK; DAS, MP; BROWN, JA; RANGER, AM; ZAMVIL, SS; SOBEL, RA; WEINER, HL; NABAVI, N; GLIMCHER, LH				KUCHROO, VK; DAS, MP; BROWN, JA; RANGER, AM; ZAMVIL, SS; SOBEL, RA; WEINER, HL; NABAVI, N; GLIMCHER, LH			B7-1 AND B7-2 COSTIMULATORY MOLECULES ACTIVATE DIFFERENTIALLY THE TH1/TH2 DEVELOPMENTAL PATHWAYS - APPLICATION TO AUTOIMMUNE-DISEASE THERAPY	CELL			English	Article							EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MYELIN PROTEOLIPID PROTEIN; CTLA-4 COUNTER-RECEPTOR; CELL ACTIVATION; BASIC-PROTEIN; LYMPHOCYTE-T; EXPRESSION; CD28; MICE; IDENTIFICATION	CD4 T helper precursor cells mature along two alternative pathways, Th1 and Th2. Here we show that these pathways are differentially activated by two costimulatory molecules, B7-1 and B7-2. Using anti-B7 antibodies, this developmental step was manipulated both in vitro and in vivo in experimental allergic encephalomyelitis (EAE). Anti-B7-1 reduced the incidence of disease while anti-B7-2 increased disease severity. Neither antibody affected overall T cell induction but rather altered cytokine profile. Administration of anti-B7-1 at immunization resulted in predominant generation of Th2 clones whose transfer both prevented induction of EAE and abrogated established disease. Since cotreatment with anti-IL-4 antibody prevented disease amelioration, costimulatory molecules may directly affect initial cytokine secretion. Thus, interaction of B7-1 and B7-2 with shared counterreceptors CD28 and CTLA-4 results in very different outcomes in clinical disease by influencing commitment of precursors to a Th1 or Th2 lineage.	BRIGHAM & WOMENS HOSP,CTR NEUROL DIS,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT CANC BIOL,BOSTON,MA 02115; STANFORD UNIV,SCH MED,DEPT PATHOL,PALO ALTO,CA 94304; VET AFFAIRS MED CTR,LAB SERV,PALO ALTO,CA 94304; HOFFMANN LA ROCHE INC,RES CTR,DEPT INFLAMMAT & AUTOIMMUNE DIS,NUTLEY,NJ 07110	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Roche Holding	KUCHROO, VK (corresponding author), HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115, USA.			Sobel, Raymond/0000-0002-0477-9002	NIAID NIH HHS [AI-21569] Funding Source: Medline; NINDS NIH HHS [NS-30843, NS-26773] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI021569, R01AI021569] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS030843, R01NS026773, R37NS030843, R01NS030843] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AZUMA M, 1993, NATURE, V366, P76, DOI 10.1038/366076a0; BARON JL, 1993, J EXP MED, V177, P57, DOI 10.1084/jem.177.1.57; BASKAR S, 1995, IN PRESS J EXP MED; CHEN CY, 1994, IMMUNITY, V1, P147, DOI 10.1016/1074-7613(94)90108-2; CHEN CY, 1994, J IMMUNOL, V152, P2105; CHEN LP, 1992, CELL, V71, P1093, DOI 10.1016/S0092-8674(05)80059-5; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; COHEN J, 1993, SCIENCE, V262, P175, DOI 10.1126/science.8211135; FINCK BK, 1994, SCIENCE, V265, P1225, DOI 10.1126/science.7520604; FREEMAN GJ, 1993, SCIENCE, V262, P907, DOI 10.1126/science.7694362; FREEMAN GJ, 1993, SCIENCE, V262, P909, DOI 10.1126/science.7694363; FREEMAN GJ, 1991, J EXP MED, V174, P625, DOI 10.1084/jem.174.3.625; GOVERMAN J, 1993, CELL, V72, P551, DOI 10.1016/0092-8674(93)90074-Z; GUERDER S, 1994, IMMUNITY, V1, P155; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; HATHCOCK KS, 1994, J EXP MED, V180, P631, DOI 10.1084/jem.180.2.631; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; JIANG H, 1992, SCIENCE, V256, P1213, DOI 10.1126/science.256.5060.1213; KHOURY SJ, 1992, J EXP MED, V176, P1355, DOI 10.1084/jem.176.5.1355; KUCHROO VK, 1993, J IMMUNOL, V151, P4371; LAFAILLE JJ, 1994, CELL, V78, P399, DOI 10.1016/0092-8674(94)90419-7; LAURSEN RA, 1984, P NATL ACAD SCI-BIOL, V81, P2912, DOI 10.1073/pnas.81.9.2912; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; LINSLEY PS, 1994, IMMUNITY, V1, P793, DOI 10.1016/S1074-7613(94)80021-9; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; NABAVI N, 1992, NATURE, V360, P266, DOI 10.1038/360266a0; NEWMAN S, 1987, P NATL ACAD SCI USA, V84, P886, DOI 10.1073/pnas.84.3.886; NUNES JA, 1994, J EXP MED, V180, P1067, DOI 10.1084/jem.180.3.1067; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; POWRIE F, 1993, IMMUNOL TODAY, V14, P270, DOI 10.1016/0167-5699(93)90044-L; PRASAD KVS, 1994, P NATL ACAD SCI USA, V91, P2834, DOI 10.1073/pnas.91.7.2834; RAZIWOLF Z, 1992, P NATL ACAD SCI USA, V89, P4210, DOI 10.1073/pnas.89.9.4210; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; SIMON AK, 1994, P NATL ACAD SCI USA, V91, P8562, DOI 10.1073/pnas.91.18.8562; SOBEL RA, 1989, J NEUROPATHOL EXP NE, V49, P468; TOWNSEND SE, 1993, SCIENCE, V259, P368, DOI 10.1126/science.7678351; TRINCHIERI G, 1993, IMMUNOL TODAY, V14, P335, DOI 10.1016/0167-5699(93)90230-I; TUOHY VK, 1989, J IMMUNOL, V142, P1523; TURKA LA, 1992, P NATL ACAD SCI USA, V89, P11102, DOI 10.1073/pnas.89.22.11102; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; YOSHIMOTO T, 1994, J EXP MED, V179, P1285, DOI 10.1084/jem.179.4.1285; ZAMVIL SS, 1990, ANNU REV IMMUNOL, V8, P579, DOI 10.1146/annurev.iy.08.040190.003051	45	1618	1703	1	26	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 10	1995	80	5					707	718		10.1016/0092-8674(95)90349-6	http://dx.doi.org/10.1016/0092-8674(95)90349-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QM399	7534215	Bronze			2022-12-24	WOS:A1995QM39900007
J	WUCHERPFENNIG, KW; STROMINGER, JL				WUCHERPFENNIG, KW; STROMINGER, JL			MOLECULAR MIMICRY IN T-CELL-MEDIATED AUTOIMMUNITY - VIRAL PEPTIDES ACTIVATE HUMAN T-CELL CLONES SPECIFIC FOR MYELIN BASIC-PROTEIN	CELL			English	Article							GLUTAMIC-ACID DECARBOXYLASE; MULTIPLE-SCLEROSIS PATIENTS; EPSTEIN-BARR VIRUS; LYMPHOCYTE-T; SUPERANTIGEN MAM; RECOGNITION; ENCEPHALOMYELITIS; ARTHRITIS; LINES; HEMAGGLUTININ	Structural similarity between viral T cell epitopes and self-peptides could lead to the induction of an autoaggressive T cell response. Based on the structural requirements for both MHC class II binding and TCR recognition of an immunodominant myelin basic protein (MBP) peptide, criteria for a data base search were developed in which the degeneracy of amino acid side chains required for MHC class II binding and the conservation of those required for T cell activation were considered. A panel of 129 peptides that matched the molecular mimicry motif was tested on seven MBP-specific T cell clones from multiple sclerosis patients. Seven viral and one bacterial peptide efficiently activated three of these clones. Only one peptide could have been identified as a molecular mimic by sequence alignment. The observation that a single T cell receptor can recognize quite distinct but structurally related peptides from multiple pathogens has important implications for understanding the pathogenesis of autoimmunity.			WUCHERPFENNIG, KW (corresponding author), HARVARD UNIV, DEPT MOLEC & CELLULAR BIOL, CAMBRIDGE, MA 02138 USA.				NATIONAL CANCER INSTITUTE [R35CA047554] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI045198] Funding Source: NIH RePORTER; NCI NIH HHS [CA47554] Funding Source: Medline; NIAID NIH HHS [N01 AI 45198] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEGRETTA M, 1990, SCIENCE, V247, P718, DOI 10.1126/science.1689076; BAIG S, 1989, CLIN EXP IMMUNOL, V78, P390; BROCKE S, 1993, NATURE, V365, P642, DOI 10.1038/365642a0; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BROWN LR, 1991, J IMMUNOL, V147, P2677; BURNS J, 1983, CELL IMMUNOL, V81, P435, DOI 10.1016/0008-8749(83)90250-2; BURROWS SR, 1994, J EXP MED, V179, P1155, DOI 10.1084/jem.179.4.1155; BUSCH R, 1991, J IMMUNOL, V147, P1292; CHAMBERS TM, 1989, VIROLOGY, V172, P180, DOI 10.1016/0042-6822(89)90119-0; COLE BC, 1993, ARTHRITIS RHEUM-US, V36, P994, DOI 10.1002/art.1780360717; CONRAD B, 1994, NATURE, V371, P351, DOI 10.1038/371351a0; DATTA AK, 1980, J BIOL CHEM, V255, P5120; EPSTEIN MA, 1977, LANCET, V2, P1270; FRIEDMAN SM, 1991, J EXP MED, V174, P891, DOI 10.1084/jem.174.4.891; FUJINAMI RS, 1985, SCIENCE, V230, P1043, DOI 10.1126/science.2414848; HICKEY WF, 1991, J NEUROSCI RES, V28, P254, DOI 10.1002/jnr.490280213; JOHNSON RT, 1984, NEW ENGL J MED, V310, P137, DOI 10.1056/NEJM198401193100301; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAUFMAN DL, 1993, NATURE, V366, P69, DOI 10.1038/366069a0; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; Koetssier, 1985, HDB CLIN NEUROLOGY, V3, P259; KURTZKE JF, 1979, ANN NEUROL, V5, P6, DOI 10.1002/ana.410050104; LEHMANN PV, 1992, NATURE, V358, P155, DOI 10.1038/358155a0; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; MARTIN R, 1990, J IMMUNOL, V145, P540; OLDSTONE MBA, 1987, CELL, V50, P819, DOI 10.1016/0092-8674(87)90507-1; OLERUP O, 1989, P NATL ACAD SCI USA, V86, P7113, DOI 10.1073/pnas.86.18.7113; OTA K, 1990, NATURE, V346, P183, DOI 10.1038/346183a0; PETTE M, 1990, P NATL ACAD SCI USA, V87, P7968, DOI 10.1073/pnas.87.20.7968; RAY CG, 1980, CLIN ENDOCRINOL, V12, P375, DOI 10.1111/j.1365-2265.1980.tb02723.x; REAY PA, 1994, J IMMUNOL, V152, P3946; ROSE NR, 1986, ANN NY ACAD SCI, V475, P146, DOI 10.1111/j.1749-6632.1986.tb20864.x; SCHLUESENER HJ, 1985, J IMMUNOL, V135, P3128; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SEBZDA E, 1994, SCIENCE, V263, P1615, DOI 10.1126/science.8128249; SPIELMAN RS, 1982, EPIDEMIOL REV, V4, P45, DOI 10.1093/oxfordjournals.epirev.a036251; SPRUANCE S, 1945, J CLIN MICROBIOL, V22, P366; STADT D, 1990, EUR NEUROL, V30, P305, DOI 10.1159/000117361; TISCH R, 1993, NATURE, V366, P72, DOI 10.1038/366072a0; TOVEY MG, 1978, NATURE, V276, P270, DOI 10.1038/276270a0; VANEDEN W, 1985, P NATL ACAD SCI USA, V82, P5117; VANEDEN W, 1988, NATURE, V331, P171, DOI 10.1038/331171a0; VOGT AB, 1994, J IMMUNOL, V153, P1665; WEKERLE H, 1986, TRENDS NEUROSCI, V9, P271, DOI 10.1016/0166-2236(86)90077-9; WUCHERPFENNIG KW, 1994, J IMMUNOL, V152, P5581; WUCHERPFENNIG KW, 1991, IMMUNOL TODAY, V12, P277, DOI 10.1016/0167-5699(91)90126-E; WUCHERPFENNIG KW, 1994, J EXP MED, V179, P279, DOI 10.1084/jem.179.1.279; ZAMVIL SS, 1990, ANNU REV IMMUNOL, V8, P579, DOI 10.1146/annurev.iy.08.040190.003051; ZHANG JW, 1994, J EXP MED, V179, P973, DOI 10.1084/jem.179.3.973	49	1213	1238	0	46	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 10	1995	80	5					695	705		10.1016/0092-8674(95)90348-8	http://dx.doi.org/10.1016/0092-8674(95)90348-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QM399	7534214	Green Published, Bronze			2022-12-24	WOS:A1995QM39900006
J	KLENERMAN, P; ROWLANDJONES, S; MCADAM, S; EDWARDS, J; DAENKE, S; LALLOO, D; KOPPE, B; ROSENBERG, W; BOYD, D; EDWARDS, A; GIANGRANDE, P; PHILLIPS, RE; MCMICHAEL, AJ				KLENERMAN, P; ROWLANDJONES, S; MCADAM, S; EDWARDS, J; DAENKE, S; LALLOO, D; KOPPE, B; ROSENBERG, W; BOYD, D; EDWARDS, A; GIANGRANDE, P; PHILLIPS, RE; MCMICHAEL, AJ			CYTOTOXIC T-CELL ACTIVITY ANTAGONIZED BY NATURALLY-OCCURRING HIV-1 GAG VARIANTS	NATURE			English	Article							LYMPHOCYTES-T; RECEPTOR; PEPTIDES; INDIVIDUALS; RECOGNITION; VIRUS	MOST asymptomatic individuals infected with HIV-1 have a cytotoxic T lymphocyte (CTL) response to the virus Gag proteins which can be demonstrated in vitro(1,2). Epitopes have been mapped in p17 Gag and p24 Gag restricted by HLA-B8 (p17-3 and p24-13) and -B27 (p24-14)(2,3). Viruses isolated from patients who make CTL responses to these peptides vary within the genetic sequences encoding these epitopes and some mutations lead to reduction in killing activity in vitro(4). This mas attributed to either failure of the variant epitope to bind major histocompatibility complex class I or failure of T-cell receptors to bind the presented peptide. But peptide variants of class I-restricted epitopes cause 'antagonism', that is, the presence of a variant epitope (in the form of peptide) inhibits normal lysis of targets presenting the original epitope(5,6). This mirrors similar findings in class II-restricted systems(7-10). Here we report that naturally occurring variant forms of p17-3, p24-13 and p24-14 may cause antagonism of CTL lines derived from the same individuals. The effect is present if the epitopes are derived from synthetic peptides and when they are processed from full-length proteins expressed by either recombinant vaccinia constructs or replicating HIV.	UNIV OXFORD,INST MOLEC MED,OXFORD OX3 9DU,ENGLAND; RADCLIFFE INFIRM,DEPT GENITOURINARY MED,OXFORD OX3 7LJ,ENGLAND; CHURCHILL HOSP,OXFORD HAEMOPHILIA CTR,OXFORD OX3 7LV,ENGLAND	University of Oxford; Radcliffe Infirmary	KLENERMAN, P (corresponding author), UNIV OXFORD,NUFFIELD DEPT CLIN MED,DIV MOLEC SCI,OXFORD OX3 9DU,ENGLAND.		Rosenberg, William/ABA-1071-2021	Rosenberg, William/0000-0002-2732-2304; klenerman, paul/0000-0003-4307-9161; Daenke, Susan/0000-0003-3290-6627; Lalloo, David/0000-0001-7680-2200	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		DEMAGISTRIS MT, 1992, CELL, V68, P625, DOI 10.1016/0092-8674(92)90139-4; DOUGHERTY JP, 1988, J VIROL, V62, P2817, DOI 10.1128/JVI.62.8.2817-2822.1988; EVAVOLD BD, 1991, SCIENCE, V252, P1308, DOI 10.1126/science.1833816; EVAVOLD BD, 1993, IMMUNOL TODAY, V14, P602, DOI 10.1016/0167-5699(93)90200-5; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; JAMESON SC, 1993, J EXP MED, V177, P1541, DOI 10.1084/jem.177.6.1541; MACKETT M, 1984, J VIROL, V49, P854; Maniatis T., 1982, MOL CLONING; MYERS G, 1992, HUMAN RETROVIRUSES A; NIXON DF, 1988, NATURE, V336, P484, DOI 10.1038/336484a0; NIXON DF, 1991, AIDS, V5, P1049; OSTROV D, 1993, J IMMUNOL, V150, P4277; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; RACIOPPI L, 1993, J EXP MED, V177, P1947; ROWLANDJONES SL, 1993, EUR J IMMUNOL, V23, P1999, DOI 10.1002/eji.1830230841; SUTTON J, 1993, EUR J IMMUNOL, V23, P447, DOI 10.1002/eji.1830230222; WALKER BD, 1988, SCIENCE, V240, P64, DOI 10.1126/science.2451288; ZHANG LQ, 1991, AIDS, V5, P675, DOI 10.1097/00002030-199106000-00006	18	401	409	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 2	1994	369	6479					403	407		10.1038/369403a0	http://dx.doi.org/10.1038/369403a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NP174	7515165				2022-12-24	WOS:A1994NP17400058
J	LEVINE, A; BASHANAHREND, A; BUDAIHADRIAN, O; GARTENBERG, D; MENASHEROW, S; WIDES, R				LEVINE, A; BASHANAHREND, A; BUDAIHADRIAN, O; GARTENBERG, D; MENASHEROW, S; WIDES, R			ODD OZ - A NOVEL DROSOPHILA PAIR RULE GENE	CELL			English	Article							ELEMENT INSERTIONAL MUTAGENESIS; MEDIATED ENHANCER DETECTION; HOMOEOTIC MUTATIONS; EXPRESSION; PROTEIN; TENASCIN; PATTERN; SEGMENTATION; MELANOGASTER; POLARITY	We have identified a novel pair rule gene in Drosophila, odd Oz (odz). Every odd-numbered body segment is deleted in odz mutant embryos. The odz gene product is strongly expressed in the embryonic central nervous system and heart, and both of these tissues are malformed in mutant embryos. odz represents the only known pair rule gene that does not encode a transcription factor. Instead, it encodes a protein with EGF-like repeats homologous to those of the extracellular matrix protein tenascin. The protein is also a putative transmembrane tyrosine kinase substrate. On the basis of its structure, odz must act in a cellularized embryo. This is consistent with odz expression, whose temporal appearance is indicative of a very late-acting pair rule gene.			LEVINE, A (corresponding author), BAR ILAN UNIV,DEPT LIFE SCI,IL-52900 RAMAT GAN,ISRAEL.							AKAM M, 1987, DEVELOPMENT, V101, P1; BAUMGARTNER S, 1993, MECH DEVELOP, V40, P165, DOI 10.1016/0925-4773(93)90074-8; BAUMGARTNER S, 1990, MECH DEVELOP, V33, P1, DOI 10.1016/0925-4773(90)90130-E; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CHIQUETEHRISMANN R, 1990, FASEB J, V4, P2598, DOI 10.1096/fasebj.4.9.1693347; COOLEY L, 1988, TRENDS GENET, V4, P254, DOI 10.1016/0168-9525(88)90032-7; DOE CQ, 1988, SCIENCE, V239, P170, DOI 10.1126/science.2892267; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; HARTENSTEIN AY, 1992, DEVELOPMENT, V116, P1203; HAYNIE JL, 1983, DEV BIOL, V100, P399, DOI 10.1016/0012-1606(83)90234-8; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; Hooper J.E., 1992, Results and Problems in Cell Differentiation, V18, P1; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KARPEN GH, 1992, GENETICS, V132, P737; KENNISON JA, 1987, GENETICS, V116, P75; KILCHHERR F, 1986, NATURE, V321, P493, DOI 10.1038/321493a0; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MLODZIK M, 1992, METHODS NEUROSCIENCE, V9, P397; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PATEL NH, 1989, GENE DEV, V3, P890, DOI 10.1101/gad.3.6.890; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RUBIN GM, 1983, NUCLEIC ACIDS RES, V11, P6341, DOI 10.1093/nar/11.18.6341; SAGA Y, 1991, GENE, V104, P177, DOI 10.1016/0378-1119(91)90248-A; Sambrook J., 1989, MOL CLONING LAB MANU; SATO T, 1983, GENETICS, V105, P357; SPRING J, 1989, CELL, V59, P325, DOI 10.1016/0092-8674(89)90294-8; STJOHNSTON D, 1992, CELL, V68, P201; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; THOMAS U, 1991, DEVELOPMENT, V111, P749; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WIDES RJ, 1990, EUR J BIOCHEM, V189, P637, DOI 10.1111/j.1432-1033.1990.tb15532.x; Wieschaus E., 1986, P199; WILSON C, 1989, GENE DEV, V3, P1301, DOI 10.1101/gad.3.9.1301; ZAK NB, 1990, DEVELOPMENT, V109, P865; ZINN K, 1988, CELL, V53, P577, DOI 10.1016/0092-8674(88)90574-0	39	129	132	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 20	1994	77	4					587	598		10.1016/0092-8674(94)90220-8	http://dx.doi.org/10.1016/0092-8674(94)90220-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NM832	7514504				2022-12-24	WOS:A1994NM83200013
J	RAMIREZSOLIS, R; LIU, PT; BRADLEY, A				RAMIREZSOLIS, R; LIU, PT; BRADLEY, A			CHROMOSOME ENGINEERING IN MICE	NATURE			English	Article							SITE-SPECIFIC RECOMBINATION; GENE; DROSOPHILA; GENOME; TUMORS	CHROMOSOMAL rearrangements are the major cause of inherited human disease and fetal loss(1). Translocations(2) and loss of heterorygosity(3) are important genetic changes causally involved in neoplasia. Chromosomal variants, such as deficiencies, are commonly exploited in genetic screens in organisms such as Dlosophila because a small portion of the genome is functionally hemizygous(4) In the mouse, deficiencies are not generally available, thus genetic screens for recessive mutations are cumbersome(5). We report here that defined deficiencies, inversions and duplications extending to 3-4 cM can be constructed in embryonic stem cells, This was achieved by consecutive targeting of loxP recombination substrates to thf end points of a genetic interval followed by Cre-induced recombination, This reconstructs a positive selectable marker which facilitates direct selection of clones with a chromosome structure specific to the relative orientation of the loxP sites, Duplication and deletion alleles have been transmitted into the mouse germ line. The availability of mice with defined regions of segmental haploidy will allow their use in genetic screens and enable accurate models of human 'chromosomal' diseases to be generated.	BAYLOR COLL MED, DEPT MOLEC & HUMAN GENET, HOUSTON, TX 77030 USA; BAYLOR COLL MED, HOWARD HUGHES MED INST, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute				Bradley, Allan/0000-0002-2349-8839; Ramirez-Solis, Ramiro/0000-0003-4182-173X				CROPP CS, 1994, CANCER RES, V54, P2548; Epstein C.J, 1986, CONSEQUENCES CHROMOS; FULLER PJ, 1987, MOL ENDOCRINOL, V1, P306, DOI 10.1210/mend-1-4-306; GAO X, 1995, CANCER RES, V55, P1002; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; GOLIC KG, 1991, SCIENCE, V252, P958, DOI 10.1126/science.2035025; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; HOLDENERKENNY B, 1992, BIOESSAYS, V14, P831, DOI 10.1002/bies.950141208; LASKO D, 1991, ANNU REV GENET, V25, P281, DOI 10.1146/annurev.ge.25.120191.001433; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; MEDBERRY SL, 1995, NUCLEIC ACIDS RES, V23, P485, DOI 10.1093/nar/23.3.485; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MORI T, 1994, CANCER RES, V54, P1638; Muller H J, 1927, Science, V66, P84, DOI 10.1126/science.66.1699.84; NEUHAUSEN SL, 1994, CANCER RES, V54, P6069; QIN MM, 1994, P NATL ACAD SCI USA, V91, P1706, DOI 10.1073/pnas.91.5.1706; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAMIREZSOLIS R, 1992, ANAL BIOCHEM, V201, P331, DOI 10.1016/0003-2697(92)90347-A; Rinchik E.M., 1990, GENOME ANAL, P121; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; RUBOCK MJ, 1990, P NATL ACAD SCI USA, V87, P4751, DOI 10.1073/pnas.87.12.4751; SAITO H, 1993, CANCER RES, V53, P3382; SAUER B, 1993, METHOD ENZYMOL, V225, P890; SAUER B, 1989, NUCLEIC ACIDS RES, V17, P147, DOI 10.1093/nar/17.1.147; SMITH AJH, 1995, NAT GENET, V9, P376, DOI 10.1038/ng0495-376; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STERNBERG N, 1981, J MOL BIOL, V150, P467, DOI 10.1016/0022-2836(81)90375-2; THE VL, 1989, MOL ENDOCRINOL, V3, P1301, DOI 10.1210/mend-3-8-1301; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; ZHANG HB, 1994, MOL CELL BIOL, V14, P2404, DOI 10.1128/MCB.14.4.2404	30	394	437	1	8	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	DEC 14	1995	378	6558					720	724		10.1038/378720a0	http://dx.doi.org/10.1038/378720a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK379	7501018				2022-12-24	WOS:A1995TK37900053
J	RAO, ZH; BELYAEV, AS; FRY, E; ROY, P; JONES, IM; STUART, DI				RAO, ZH; BELYAEV, AS; FRY, E; ROY, P; JONES, IM; STUART, DI			CRYSTAL-STRUCTURE OF SIV MATRIX ANTIGEN AND IMPLICATIONS FOR VIRUS ASSEMBLY	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS; PROTEIN	SIMIAN immunodeficiency virus (SIV) is closely related to human immunodeficiency virus (HIV)(1), their matrix antigens (MAs) sharing some 50% sequence identity. MA is a component of Pr55Gag, the sole protein required for assembly of the virion shell(2). MA targets Pr55 to the plasma membrane(3), and facilitates incorporation of the virus envelope protein(4) and assembly of the Pr55Gag shell(5). Cleavage of Pr55 by the viral protease produces the mature protein of relative molecular mass 17-18K, which underlies the host-derived membrane and is important in both virus entry(6) and nuclear localization of the virion core(7). Here we report the crystal structure of SIV MA. The molecule forms a trimer consistent with oligomerization in vitro(8), the observed virion architecture(9), and various biological properties of MA.	UNIV OXFORD,MOLEC BIOPHYS LAB,OXFORD OX1 3QU,ENGLAND; NERC,INST VIROL & ENVIRONM MICROBIOL,OXFORD OX1 3SR,ENGLAND; UNIV ALABAMA,SCH PUBL HLTH,BIRMINGHAM,AL 35294; OXFORD CTR MOLEC SCI,OXFORD OX1 3QT,ENGLAND	University of Oxford; UK Centre for Ecology & Hydrology (UKCEH); UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); University of Alabama System; University of Alabama Birmingham; University of Oxford			Rao, Zihe/HCH-6944-2022	Roy, Polly/0000-0001-6535-6911; Stuart, David/0000-0002-3426-4210; Fry, Elizabeth/0000-0001-9754-5303				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BELYAEV AS, 1994, J MOL BIOL, V241, P744, DOI 10.1006/jmbi.1994.1550; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; DANIEL MD, 1985, SCIENCE, V228, P1201, DOI 10.1126/science.3159089; DELACHAMBRE M, 1989, EMBO J, V8, P2653; EHRLICH LS, 1994, VIROLOGY, V204, P515, DOI 10.1006/viro.1994.1565; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FREED EO, 1995, J VIROL, V69, P1984, DOI 10.1128/JVI.69.3.1984-1989.1995; FREED EO, 1994, J VIROL, V68, P5311, DOI 10.1128/JVI.68.8.5311-5320.1994; Fry E, 1990, SEMIN VIROL, V1, P439; GRIMES J, 1995, NATURE, V373, P167, DOI 10.1038/373167a0; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEVINE M, 1984, ACTA CRYSTALLOGR A, V40, P600, DOI 10.1107/S0108767384001239; MASSIAH MA, 1994, J MOL BIOL, V244, P194; MATTHEWS S, 1994, NATURE, V370, P666, DOI 10.1038/370666a0; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MORIKAWA Y, 1995, J VIROL, V69, P4519, DOI 10.1128/JVI.69.7.4519-4523.1995; NERMUT MV, 1993, AIDS RES HUM RETROV, V9, P929, DOI 10.1089/aid.1993.9.929; NERMUT MV, 1994, VIROLOGY, V198, P288, DOI 10.1006/viro.1994.1032; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OTWINOWSKI Z, 1993, P CCP4 STUDY WEEKEND, P1; PRONGAY AJ, 1990, P NATL ACAD SCI USA, V87, P9980, DOI 10.1073/pnas.87.24.9980; SMITH TJ, 1986, SCIENCE, V233, P1233; YU XF, 1992, J VIROL, V66, P5667, DOI 10.1128/JVI.66.9.5667-5670.1992; YUAN X, 1993, J VIROL, V67, P6387, DOI 10.1128/JVI.67.11.6387-6394.1993	29	174	174	2	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 14	1995	378	6558					743	747		10.1038/378743a0	http://dx.doi.org/10.1038/378743a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK379	7501025				2022-12-24	WOS:A1995TK37900060
J	COON, SL; ROSEBOOM, PH; BALER, R; WELLER, JL; NAMBOODIRI, MAA; KOONIN, EV; KLEIN, DC				COON, SL; ROSEBOOM, PH; BALER, R; WELLER, JL; NAMBOODIRI, MAA; KOONIN, EV; KLEIN, DC			PINEAL SEROTONIN N-ACETYLTRANSFERASE - EXPRESSION CLONING AND MOLECULAR ANALYSIS	SCIENCE			English	Article							RAT PINEAL; GLAND; MELATONIN; DECREASE	Pineal serotonin N-acetyltransferase (arylalkylamine N-acetyltransferase, or AA-NAT) generates the large circadian rhythm in melatonin, the hormone that coordinates daily and seasonal physiology in some mammals. Complementary DNA encoding ovine AA-NAT was cloned. The abundance of AA-NAT messenger RNA (mRNA) during the day was high in the ovine pineal gland and somewhat lower in retina. AA-NAT mRNA was found unexpectedly in the pituitary gland and in some brain regions. The night-to-day ratio of ovine pineal AA-NAT mRNA is less than 2. In contrast, the ratio exceeds 150 in rats. AA-NAT represents a family within a large superfamily of acetyltransferases.	NICHHD, DEV NEUROBIOL LAB, NEUROBIOL SECT, BETHESDA, MD 20892 USA; GEORGETOWN UNIV, DEPT BIOL, WASHINGTON, DC 20057 USA; NATL LIB MED, NATL CTR BIOTECHNOL INFORMAT, BETHESDA, MD 20894 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Georgetown University; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)				Klein, David/0000-0002-1792-5806				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Arendt J., 1995, MELATONIN MAMMALIAN, p[201, 27]; AXELROD J, 1974, SCIENCE, V184, P1341, DOI 10.1126/science.184.4144.1341; BALER R, UNPUB; BALER R, IN PRESS J BIOL CHEM; BERNARD M, 1995, BRAIN RES, V696, P37, DOI 10.1016/0006-8993(95)00651-6; DEGUCHI T, 1975, J NEUROCHEM, V24, P1083, DOI 10.1111/j.1471-4159.1975.tb03682.x; DISTRIA M, 1994, GEN COMP ENDOCR, V96, P6, DOI 10.1006/gcen.1994.1153; DOLLINS AB, 1994, P NATL ACAD SCI USA, V91, P1824, DOI 10.1073/pnas.91.5.1824; IUVONE PM, 1986, J NEUROCHEM, V46, P82, DOI 10.1111/j.1471-4159.1986.tb12928.x; JANAVS JL, 1991, BRAIN RES, V540, P138, DOI 10.1016/0006-8993(91)90500-U; KARSCH FJ, 1991, SUPRACHIASMATIC NUCL, P217; KLEIN DC, 1970, SCIENCE, V169, P1093, DOI 10.1126/science.169.3950.1093; KLEIN DC, 1985, CIBA F SYMP, V117, P38; KLEIN DC, 1972, SCIENCE, V177, P532, DOI 10.1126/science.177.4048.532; KLEIN DC, 1992, BIOCHEM SOC T, V20, P299, DOI 10.1042/bst0200299; KLEIN DC, 1978, SCIENCE, V199, P309, DOI 10.1126/science.202027; MEFFORD IN, 1983, ENDOCRINOLOGY, V113, P1582, DOI 10.1210/endo-113-5-1582; NAMBOODIRI MAA, 1985, J NEUROCHEM, V45, P832, DOI 10.1111/j.1471-4159.1985.tb04069.x; NAMBOODIRI MAA, 1981, SCIENCE, V213, P571, DOI 10.1126/science.7017937; NAMBOODIRI MAA, 1980, J BIOL CHEM, V255, P6032; NAMBOODIRI MAA, 1984, J COMP BIOCH B, V80, P731; O'Brien PJ, 1986, PINEAL RETINAL RELAT; RIODAN JF, 1972, METHODS ENZYMOL B, V25, P494; ROLLAG MD, 1976, ENDOCRINOLOGY, V98, P482, DOI 10.1210/endo-98-2-482; ROSEBOOM PH, UNPUB; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; SKENE DJ, 1992, BIOCHEM SOC T, V20, P312, DOI 10.1042/bst0200312; TATUSOV RL, 1994, P NATL ACAD SCI USA, V91, P12091, DOI 10.1073/pnas.91.25.12091; TERCERO JC, 1992, J BIOL CHEM, V267, P20270; VOISIN P, 1984, J BIOL CHEM, V259, P913; WATANABE M, 1992, J BIOL CHEM, V267, P8429; YU L, 1993, J NEUROCHEM, V60, P1436, DOI 10.1111/j.1471-4159.1993.tb03306.x; ZATZ M, 1978, BIOCHEM PHARMACOL, V27, P2549, DOI 10.1016/0006-2952(78)90324-6; ZAWILSKA JB, 1992, NEUROSCI LETT, V135, P21	37	295	305	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 8	1995	270	5242					1681	1683		10.1126/science.270.5242.1681	http://dx.doi.org/10.1126/science.270.5242.1681			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ293	7502081				2022-12-24	WOS:A1995TJ29300053
J	HERMISTON, ML; GORDON, JI				HERMISTON, ML; GORDON, JI			INFLAMMATORY BOWEL-DISEASE AND ADENOMAS IN MICE EXPRESSING A DOMINANT-NEGATIVE N-CADHERIN	SCIENCE			English	Article							TRANSGENIC MICE; CELL LINEAGE; APC GENE; DIFFERENTIATION; ASSOCIATION; MUTATION; PROTEIN	Cadherins mediate cell adhesion and are essential for normal development. Embryonic stem cells were transfected with a dominant negative N-cadherin mutant (NCAD Delta) under the control of promoters active in small intestinal epithelial cells and then introduced into C57BL/6 mouse blastocysts. Analysis of adult chimeric mice revealed that expression of NCAD Delta along the entire crypt-villus axis, but not in the villus epithelium alone, produced an inflammatory bowel disease resembling Crohn's disease. NCAD Delta perturbed proliferation, migration, and death programs in crypts, which lead to adenomas. This model provides insights about cadherin function in an adult organ and the factors underlying inflammatory bowel disease and intestinal neoplasia.	WASHINGTON UNIV, SCH MED, DEPT MOLEC BIOL & PHARMACOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL)					NIDDK NIH HHS [DK39760, DK30292] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK030292, R01DK030292] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHNEN DJ, 1994, J PATHOL, V173, P317, DOI 10.1002/path.1711730406; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; GORDON JI, 1994, CURR OPIN CELL BIOL, V6, P795, DOI 10.1016/0955-0674(94)90047-7; HERMISTON ML, 1993, P NATL ACAD SCI USA, V90, P8866, DOI 10.1073/pnas.90.19.8866; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; HERMISTON ML, UNPUB; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; KEMIER R, 1993, TRENDS GENET, V9, P317; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; KOMANO H, 1995, P NATL ACAD SCI USA, V92, P6147, DOI 10.1073/pnas.92.13.6147; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; LARUE L, 1994, P NATL ACAD SCI USA, V91, P8263, DOI 10.1073/pnas.91.17.8263; LEVIN B, 1995, INFLAMM BOWEL DIS, P461; LEVINE E, 1994, DEVELOPMENT, V120, P901; MOMBAERTS P, 1993, CELL, V75, P275, DOI 10.1016/0092-8674(93)80069-Q; MOSER AR, 1992, J CELL BIOL, V116, P1517, DOI 10.1083/jcb.116.6.1517; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; NATHKE IS, 1994, J CELL BIOL, V125, P1341, DOI 10.1083/jcb.125.6.1341; PODOLSKY DK, 1991, NEW ENGL J MED, V325, P928, DOI 10.1056/NEJM199109263251306; RANSCHT B, 1994, CURR OPIN CELL BIOL, V6, P740, DOI 10.1016/0955-0674(94)90102-3; RIDDELL RH, 1995, INFLAMM BOWEL DIS, P517; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; RUBINFELD B, 1995, J BIOL CHEM, V270, P5549, DOI 10.1074/jbc.270.10.5549; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; SCHMIDT GH, 1988, DEVELOPMENT, V103, P785; SIMON TC, 1993, J BIOL CHEM, V268, P18345; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TRAHAIR JF, 1989, J CELL BIOL, V109, P3231, DOI 10.1083/jcb.109.6.3231; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; WRIGHT NA, 1990, NATURE, V343, P82, DOI 10.1038/343082a0	32	561	578	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 17	1995	270	5239					1203	1207		10.1126/science.270.5239.1203	http://dx.doi.org/10.1126/science.270.5239.1203			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE905	7502046				2022-12-24	WOS:A1995TE90500058
J	RABOUILLE, C; LEVINE, TP; PETERS, JM; WARREN, G				RABOUILLE, C; LEVINE, TP; PETERS, JM; WARREN, G			AN NSF-LIKE ATPASE, P97, AND NSF MEDIATE CISTERNAL REGROWTH FROM MITOTIC GOLGI FRAGMENTS	CELL			English	Article							HELA-CELLS; VESICULAR TRANSPORT; PUTATIVE ATPASES; MEMBRANE-FUSION; PROTEIN; FAMILY; YEAST; GENE; MEMBER; IDENTIFICATION	Golgi cisternae regrew in a cell-free system from mitotic Golgi fragments incubated with buffer alone. Pretreatment with NEM or salt washing inhibited regrowth, but this could be restored either by p97, an NSF-like ATPase, or by NSF together with SNAPs and p115, a vesicle docking protein. The morphology of cisternae regrown with p97 and NSF-SNAPs-p115 differed, suggesting that they play distinct roles in rebuilding Golgi cisternae after mitosis.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School	RABOUILLE, C (corresponding author), IMPERIAL CANC RES FUND,CELL BIOL LAB,44 LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.			Levine, Timothy/0000-0002-7231-0775				ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; ACHARYA U, 1995, J CELL BIOL, V129, P577, DOI 10.1083/jcb.129.3.577; BARROSO M, 1995, P NATL ACAD SCI USA, V92, P527, DOI 10.1073/pnas.92.2.527; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DAHAN S, 1994, J CELL BIOL, V127, P1859, DOI 10.1083/jcb.127.6.1859; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; ELAZAR Z, 1994, J CELL BIOL, V124, P415, DOI 10.1083/jcb.124.4.415; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; GODA Y, 1991, J CELL BIOL, V112, P823, DOI 10.1083/jcb.112.5.823; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; KIRSCHNER MW, 1995, CELL, V81, P279; KOLLER KJ, 1987, NATURE, V325, P542, DOI 10.1038/325542a0; LATTERICH M, 1994, CELL, V78, P87, DOI 10.1016/0092-8674(94)90575-4; LATTERICH M, 1995, CELL, V82, P885, DOI 10.1016/0092-8674(95)90268-6; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LUCOCQ JM, 1989, J CELL BIOL, V109, P463, DOI 10.1083/jcb.109.2.463; LUCOCQ JM, 1987, J CELL BIOL, V104, P865, DOI 10.1083/jcb.104.4.865; LUCOCQ JM, 1987, EMBO J, V6, P3239, DOI 10.1002/j.1460-2075.1987.tb02641.x; MISTELI T, 1994, J CELL BIOL, V125, P269, DOI 10.1083/jcb.125.2.269; MISTELI T, 1995, J CELL BIOL, V130, P1; NAKAJIMA H, 1991, J CELL BIOL, V113, P245, DOI 10.1083/jcb.113.2.245; PAPPIN DJC, 1993, CURR BIOL, V3, P327, DOI 10.1016/0960-9822(93)90195-T; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; PETERS JM, 1992, J MOL BIOL, V223, P557, DOI 10.1016/0022-2836(92)90670-F; PETERS JM, 1991, THESIS U HEIDELBERG; PLEASURE IT, 1993, NATURE, V365, P459, DOI 10.1038/365459a0; RABOUILLE C, 1995, J CELL BIOL, V129, P605, DOI 10.1083/jcb.129.3.605; RODRIGUEZ L, 1994, MOL BIOL CELL, V5, P773, DOI 10.1091/mbc.5.7.773; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SAPPERSTEIN SK, 1995, P NATL ACAD SCI USA, V92, P522, DOI 10.1073/pnas.92.2.522; SLUSAREWICZ P, 1994, CELL BIOL LAB HDB, P509; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SOUTER E, 1993, J CELL BIOL, V122, P533, DOI 10.1083/jcb.122.3.533; STUART RA, 1993, J BIOL CHEM, V268, P4050; THORSNESS PE, 1993, YEAST, V9, P1267, DOI 10.1002/yea.320091114; WARREN G, 1993, ANNU REV BIOCHEM, V62, P323, DOI 10.1146/annurev.bi.62.070193.001543; WARREN G, 1985, TRENDS BIOCHEM SCI, V10, P439, DOI 10.1016/0968-0004(85)90027-1; WATERS MG, 1992, J CELL BIOL, V118, P1015, DOI 10.1083/jcb.118.5.1015; WATTENBERG BW, 1992, J CELL BIOL, V118, P1321, DOI 10.1083/jcb.118.6.1321; WEIDMAN P, 1993, CELL, V75, P123, DOI 10.1016/S0092-8674(05)80089-3; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; ZHANG L, 1994, J CELL BIOL, V127, P1871, DOI 10.1083/jcb.127.6.1871	46	304	311	1	9	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 22	1995	82	6					905	914		10.1016/0092-8674(95)90270-8	http://dx.doi.org/10.1016/0092-8674(95)90270-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RW693	7553851	Bronze			2022-12-24	WOS:A1995RW69300007
J	ROCHE, S; FUMAGALLI, S; COURTNEIDGE, SA				ROCHE, S; FUMAGALLI, S; COURTNEIDGE, SA			REQUIREMENT FOR SRC FAMILY PROTEIN-TYROSINE KINASES IN G(2) FOR FIBROBLAST CELL-DIVISION	SCIENCE			English	Article							GROWTH-FACTOR; C-SRC; IDENTIFICATION; ASSOCIATION; RECEPTOR	The protein tyrosine kinase c-Src is transiently activated at the transition from the G(2) phase to mitosis in the cell cycle of mammalian fibroblasts. Fyn and Yes, the other members of the Src family present in fibroblasts, were also found to be activated at mitosis. In cells microinjected with a neutralizing antibody specific for Src, Fyn, and Yes (anti-cst.1) during G(2), cell division was inhibited by 75 percent. The block occurred before nuclear envelope breakdown. Antibodies specific for phosphatidylinositol-3 kinase alpha and phospholipase C-gamma 1 had no effect. Microinjection of the Src homology 2 (SH2) domain of Fyn was also inhibitory. Functional redundancy between members of the Src family was observed; a Src-specific antibody had no effect in NIH 3T3 cells but inhibited cell division in fibroblasts in which the only functional Src family kinase was Src itself. Thus, Src family kinases and proteins associating with their SH2 domains are required for entry into mitosis.	EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,D-69012 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			FUMAGALLI, Stefano/C-2914-2019	roche, serge/0000-0003-3413-3859; Fumagalli, Stefano/0000-0001-5832-8680				Atherton-Fessler S, 1993, Semin Cell Biol, V4, P433, DOI 10.1006/scel.1993.1051; CHACKALAPARAMPI.I, 1988, CELL, V52, P801; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; Courtneidge Sara A., 1994, Trends in Cell Biology, V4, P345, DOI 10.1016/0962-8924(94)90074-4; DAVIS LI, 1986, CELL, V45, P699, DOI 10.1016/0092-8674(86)90784-1; DURKIN JP, 1991, CELL SIGNAL, V3, P93, DOI 10.1016/0898-6568(91)90015-M; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; FUMAGALLI S, UNPUB; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HEIDER H, 1994, EUR J BIOCHEM, V219, P513, DOI 10.1111/j.1432-1033.1994.tb19966.x; KORNBLUTH S, 1994, J CELL BIOL, V125, P705, DOI 10.1083/jcb.125.4.705; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; ROCHE S, UNPUB; SMITH MR, 1990, SCIENCE, V247, P1074, DOI 10.1126/science.2408147; STEIN PL, 1994, GENE DEV, V8, P1999, DOI 10.1101/gad.8.17.1999; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; TAYLOR SJ, 1993, CURR OPIN GENET DEV, V3, P26, DOI 10.1016/S0959-437X(05)80337-5; TAYLOR SJ, 1994, NATURE, V368, P871; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696	23	236	240	0	2	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 15	1995	269	5230					1567	1569		10.1126/science.7545311	http://dx.doi.org/10.1126/science.7545311			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU813	7545311				2022-12-24	WOS:A1995RU81300038
J	BRENMAN, JE; CHAO, DS; XIA, HH; ALDAPE, K; BREDT, DS				BRENMAN, JE; CHAO, DS; XIA, HH; ALDAPE, K; BREDT, DS			NITRIC-OXIDE SYNTHASE COMPLEXED WITH DYSTROPHIN AND ABSENT FROM SKELETAL-MUSCLE SARCOLEMMA IN DUCHENNE MUSCULAR-DYSTROPHY	CELL			English	Article							TUMOR-SUPPRESSOR PROTEIN; MEMBRANE-PROTEIN; REACTIVE OXYGEN; MDX MOUSE; PURIFICATION; BRAIN; CALMODULIN; TORPEDO; TISSUE; KINASE	Nitric oxide (NO) is synthesized in skeletal muscle by neuronal-type NO synthase (nNOS), which is localized to sarcolemma of fast-twitch fibers. Synthesis of NO in active muscle opposes contractile force. We show that nNOS partitions with skeletal muscle membranes owing to association of nNOS with dystrophin, the protein mutated in Duchenne muscular dystrophy (DMD). The dystrophin complex interacts with an N-terminal domain of nNOS that contains a GLGF motif. mdx mice and humans with DMD evince a selective loss of nNOS protein and catalytic activity from muscle membranes, demonstrating a novel role for dystrophin in localizing a signaling enzyme to the myocyte sarcolemma. Aberrant regulation of nNOS may contribute to preferential degeneration of fast-twitch muscle fibers in DMD.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PATHOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,PROGRAM BIOMED SCI,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	BRENMAN, JE (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PHYSIOL,SAN FRANCISCO,CA 94143, USA.			Chao, Daniel/0000-0002-3544-5283				ADAMS ME, 1993, NEURON, V11, P531, DOI 10.1016/0896-6273(93)90157-M; AHN AH, 1994, P NATL ACAD SCI USA, V91, P4446, DOI 10.1073/pnas.91.10.4446; AHN AH, 1995, J CELL BIOL, V128, P363, DOI 10.1083/jcb.128.3.363; AOKI C, 1993, BRAIN RES, V620, P97, DOI 10.1016/0006-8993(93)90275-R; BREDT DS, 1994, NEURON, V13, P301, DOI 10.1016/0896-6273(94)90348-4; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BRYANT PJ, 1992, CELL, V68, P621, DOI 10.1016/0092-8674(92)90136-Z; BULFIELD G, 1984, P NATL ACAD SCI-BIOL, V81, P1189, DOI 10.1073/pnas.81.4.1189; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; DAVISON A, 1988, MOL CELL BIOCHEM, V84, P199, DOI 10.1007/BF00421055; DAWSON TM, 1992, ANN NEUROL, V32, P297, DOI 10.1002/ana.410320302; Ervasti JM, 1993, CURR OPIN CELL BIOL, V5, P82, DOI 10.1016/S0955-0674(05)80012-2; ERVASTI JM, 1991, J BIOL CHEM, V266, P9161; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; HAUNG Z, 1994, SCIENCE, V265, P1883; HECKER M, 1994, J NEUROCHEM, V62, P1524; HIBBS JB, 1987, SCIENCE, V235, P473, DOI 10.1126/science.2432665; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; KOBZIK L, 1994, NATURE, V372, P546, DOI 10.1038/372546a0; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; LEE KH, 1994, J BIOL CHEM, V269, P14371; MARFATIA SM, 1994, J BIOL CHEM, V269, P8631; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; MITCHELL RD, 1983, J CELL BIOL, V96, P1008, DOI 10.1083/jcb.96.4.1008; MONACO AP, 1986, NATURE, V323, P646, DOI 10.1038/323646a0; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; NAKANE M, 1993, FEBS LETT, V316, P175, DOI 10.1016/0014-5793(93)81210-Q; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NITKIN RM, 1987, J CELL BIOL, V105, P2471, DOI 10.1083/jcb.105.6.2471; OHLENDIECK K, 1991, J CELL BIOL, V112, P135, DOI 10.1083/jcb.112.1.135; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; RAFAEL JA, 1994, HUM MOL GENET, V3, P1725, DOI 10.1093/hmg/3.10.1725; REID MB, 1992, J APPL PHYSIOL, V73, P1797, DOI 10.1152/jappl.1992.73.5.1797; REID MB, 1992, J APPL PHYSIOL, V73, P1805, DOI 10.1152/jappl.1992.73.5.1805; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; SCHUMAN EM, 1994, ANNU REV NEUROSCI, V17, P153, DOI 10.1146/annurev.neuro.17.1.153; SEALOCK R, 1991, J CELL BIOL, V113, P1133, DOI 10.1083/jcb.113.5.1133; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUNADA Y, 1994, J BIOL CHEM, V269, P13729; SUZUKI A, 1995, J CELL BIOL, V128, P373, DOI 10.1083/jcb.128.3.373; SUZUKI A, 1994, EUR J BIOCHEM, V220, P283, DOI 10.1111/j.1432-1033.1994.tb18624.x; WAGNER KR, 1993, NEURON, V10, P511, DOI 10.1016/0896-6273(93)90338-R; WANG T, 1995, NATURE, V374, P262, DOI 10.1038/374262a0; WEBSTER C, 1988, CELL, V52, P503, DOI 10.1016/0092-8674(88)90463-1; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; WU HH, 1994, SCIENCE, V265, P1593, DOI 10.1126/science.7521541; YANG B, 1995, J BIOL CHEM, V270, P4975, DOI 10.1074/jbc.270.10.4975	56	808	826	1	16	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 8	1995	82	5					743	752		10.1016/0092-8674(95)90471-9	http://dx.doi.org/10.1016/0092-8674(95)90471-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RU755	7545544	Bronze			2022-12-24	WOS:A1995RU75500009
J	SHAKIL, AO; CONRYCANTILENA, C; ALTER, HJ; HAYASHI, P; KLEINER, DE; TEDESCHI, V; KRAWCZYNSKI, K; CONJEEVARAM, HS; SALLIE, R; DIBISCEGLIE, AM; MELPOLDER, JC; HOOFNAGLE, JH				SHAKIL, AO; CONRYCANTILENA, C; ALTER, HJ; HAYASHI, P; KLEINER, DE; TEDESCHI, V; KRAWCZYNSKI, K; CONJEEVARAM, HS; SALLIE, R; DIBISCEGLIE, AM; MELPOLDER, JC; HOOFNAGLE, JH			VOLUNTEER BLOOD-DONORS WITH ANTIBODY TO HEPATITIS-C VIRUS - CLINICAL, BIOCHEMICAL, VIROLOGICAL, AND HISTOLOGIC FEATURES	ANNALS OF INTERNAL MEDICINE			English	Article						HEPATITIS C; HEPATITIS C VIRUSES; HEPATITIS ANTIBODIES; BLOOD DONORS; ALANINE AMINOTRANSFERASE	NON-B-HEPATITIS; NON-A-HEPATITIS; LIVER-DISEASE; POSTTRANSFUSION HEPATITIS; UNITED-STATES; INFECTION; SERUM; HCV; RNA; HISTORY	Objective: To assess the clinical significance of antibody to hepatitis C virus (anti-HCV) in volunteer blood donors. Design: Prospective cohort study. Setting: National Institutes of Health Clinical Center, a tertiary referral research hospital. Patients: 60 anti-HCV-positive blood donors, divided into three groups of 20 persons each: Group I had normal alanine aminotransferase levels, group II had levels elevated to values less than twice the normal range, and group HI had levels elevated to values greater than twice the normal range. Measurements: Medical history, results of laboratory and virologic testing, and percutaneous liver biopsy findings. Results: Participants with normal alanine aminotransferase levels were older and more often female than those with abnormal levels. The source of infection, duration of disease, symptom score, and amount of alcohol consumed were similar in the three groups. Hepatitis C virus RNA was detectable in 85% of participants, more commonly in the groups with elevated alanine aminotransferase levels (95%) than in the group with normal levels (65%); however, titers were similar in all groups. Examination of liver biopsy specimens showed chronic hepatitis in 54 participants (90%) and cirrhosis in 1 participant. The only normal liver biopsy specimens (n = 3) were those from participants who were HCV RNA negative and had normal alanine aminotransferase levels. Conclusions: Most blood donors with anti-HCV have chronic hepatitis C regardless of their serum alanine aminotransferase levels. Donors with normal alanine aminotransferase levels and no HCV RNA in their serum generally have normal liver histologic findings or minimal changes and have probably recovered from HCV infection.	NIH, LIVER DIS SECT, BETHESDA, MD 20892 USA; CTR DIS CONTROL & PREVENT, ATLANTA, GA USA	National Institutes of Health (NIH) - USA; Centers for Disease Control & Prevention - USA			Shaikh, Obaid/AAL-5339-2021; Kleiner, David E/N-2770-2013	Shaikh, Obaid/0000-0002-4955-9222; Kleiner, David E/0000-0003-3442-4453				AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901; ALBERTI A, 1991, ANN INTERN MED, V114, P1010, DOI 10.7326/0003-4819-114-12-1010; ALBERTI A, 1992, LANCET, V340, P697, DOI 10.1016/0140-6736(92)92234-7; ALONSO C, 1994, TRANSFUSION, V34, P527, DOI 10.1046/j.1537-2995.1994.34694295070.x; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER MJ, 1992, NEW ENGL J MED, V327, P1899, DOI 10.1056/NEJM199212313272702; ALTER MJ, 1993, INFECT AGENT DIS, V2, P155; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CONRYCANTILENA C, 1992, TRANSFUSION, V32, pS46; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1002/hep.1840190629; DONAHUE JG, 1992, NEW ENGL J MED, V327, P369, DOI 10.1056/NEJM199208063270601; ESTEBAN JI, 1991, ANN INTERN MED, V115, P443, DOI 10.7326/0003-4819-115-6-443; HARDIMAN RP, 1993, AUST NZ J MED, V23, P176, DOI 10.1111/j.1445-5994.1993.tb01813.x; HOOFNAGLE JH, 1994, ADV INTERNAL MED, V39, P241; IRVING WL, 1994, BRIT MED J, V308, P695, DOI 10.1136/bmj.308.6930.695; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; KORETZ RL, 1993, ANN INTERN MED, V119, P110, DOI 10.7326/0003-4819-119-2-199307150-00003; KRAWCZYNSKI K, 1992, GASTROENTEROLOGY, V103, P622, DOI 10.1016/0016-5085(92)90856-T; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LAI ME, 1993, J MED VIROL, V41, P282, DOI 10.1002/jmv.1890410405; LAU JYN, 1993, LANCET, V341, P1501, DOI 10.1016/0140-6736(93)90635-T; LELBACH WK, 1975, ANN NY ACAD SCI, V252, P85, DOI 10.1111/j.1749-6632.1975.tb19146.x; MCGUINNESS PH, 1993, HEPATOLOGY, V18, P485, DOI 10.1002/hep.1840180303; MUTIMER D, 1993, GUT, pS54; NAITO M, 1994, HEPATOLOGY, V19, P871, DOI 10.1002/hep.1840190411; NORDOY I, 1994, SCAND J GASTROENTERO, V29, P77, DOI 10.3109/00365529409090441; OKAMOTO H, 1990, JPN J EXP MED, V60, P167; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; SELZER ML, 1971, AM J PSYCHIAT, V127, P1653, DOI 10.1176/ajp.127.12.1653; SKINNER HA, 1982, J STUD ALCOHOL, V43, P1157, DOI 10.15288/jsa.1982.43.1157; STUYVER L, 1993, J GEN VIROL, V74, P1093, DOI 10.1099/0022-1317-74-6-1093; TAKANO S, 1994, GASTROENTEROLOGY, V107, P805, DOI 10.1016/0016-5085(94)90130-9; Urdea M S, 1991, Nucleic Acids Symp Ser, P197; WANG JT, 1993, ARCH PATHOL LAB MED, V117, P152; WEINER AJ, 1990, LANCET, V335, P1, DOI 10.1016/0140-6736(90)90134-Q; YUN ZB, 1993, J MED VIROL, V39, P57, DOI 10.1002/jmv.1890390111; 1991, MMWR MORBMORTAL WKLY, V40, P1	38	226	234	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1995	123	5					330	337		10.7326/0003-4819-123-5-199509010-00002	http://dx.doi.org/10.7326/0003-4819-123-5-199509010-00002			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ988	7542854				2022-12-24	WOS:A1995RQ98800002
J	KOLESNIKOV, SS; MARGOLSKEE, RF				KOLESNIKOV, SS; MARGOLSKEE, RF			A CYCLIC-NUCLEOTIDE-SUPPRESSIBLE CONDUCTANCE ACTIVATED BY TRANSDUCIN IN TASTE CELLS	NATURE			English	Article							ADENYLATE-CYCLASE; GATED CONDUCTANCE; RECEPTOR-CELLS; OUTER SEGMENT; PROTEIN; PHOSPHODIESTERASE; MEMBRANE; STIMULI; GMP	TASTE can be divided into four primary sensations: salty, sour, sweet and bitter, Salty and sour are directly transduced by apical channels(1-4), whereas sweet and bitter utilize cyclic nucleotide second messengers(5-11). We have shown that rod transducin is present in mammalian taste receptor cells, where it is activated by a bitter receptor and in turn activates a phosphodiesterase(12). Here we introduce into frog taste cells peptides derived from transducin's phosphodiesterase-interaction region, which cause an inward whole-cell current in a subset of cells, We find that the peptides' effects are reversibly suppressed by IBMX and forskolin, indicative of a transducin-activated phosphodiesterase. Cyclic nucleotides suppress the whole-cell current, indicating that cyclic nucleotides may regulate taste-cell conductance. IBMX modifies taste-cell responses to two taste stimuli, implicating phosphodiesterase in taste transduction. Submicromolar cyclic nucleotides directly suppress the conductance of inside-out patches derived from the taste-cell plasma membrane, independently of protein phosphorylation. The channels are unusual in that they are suppressed, rather than activated by cyclic nucleotides, We propose that transducin, via phosphodiesterase, decreases cyclic nucleotide levels to activate the cyclic-nucleotide-suppressible conductance, leading to Ca2+ influx and taste-cell depolarization.	ROCHE INST MOLEC BIOL,ROCHE RES CTR,NUTLEY,NJ 07110; RUSSIAN ACAD SCI,INST CELL BIOPHYS,PUSHCHINO 142292,RUSSIA	Roche Holding; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Cell Biophysics RAS			Kolesnikov, Stasnislav S/C-8468-2015	Margolskee, Robert/0000-0002-9572-2887				AVENET P, 1989, J MEMBRANE BIOL, V112, P1, DOI 10.1007/BF01871158; AVENET P, 1988, NATURE, V331, P351, DOI 10.1038/331351a0; AVENET P, 1989, J MEMBRANE BIOL, V97, P223; BIEL M, 1994, P NATL ACAD SCI USA, V91, P3505, DOI 10.1073/pnas.91.9.3505; CUMMINGS TA, 1993, J NEUROPHYSIOL, V70, P2326, DOI 10.1152/jn.1993.70.6.2326; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FESENKO EE, 1985, NATURE, V313, P310, DOI 10.1038/313310a0; Gilbertson Timothy A., 1993, Current Opinion in Neurobiology, V3, P532, DOI 10.1016/0959-4388(93)90052-Z; HAYNES L, 1985, NATURE, V317, P61, DOI 10.1038/317061a0; HESENKO EF, 1993, NATURE, V19, P1428; KALINOSKI DL, 1989, CHEM SENSES RECEPTOR, P85; KINNAMON SC, 1988, TRENDS NEUROSCI, V11, P491, DOI 10.1016/0166-2236(88)90010-0; KOLESNIKOV SS, 1991, FEBS LETT, V290, P167, DOI 10.1016/0014-5793(91)81251-3; KURIHARA K, 1972, FEBS LETT, V27, P279, DOI 10.1016/0014-5793(72)80640-9; Margolskee Robert F., 1993, Current Opinion in Neurobiology, V3, P526, DOI 10.1016/0959-4388(93)90051-Y; MCBRIDE DW, 1991, J MEMBRANE BIOL, V124, P85, DOI 10.1007/BF01871367; MCLAUGHLIN SK, 1992, NATURE, V357, P563, DOI 10.1038/357563a0; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; PRICE S, 1973, NATURE, V241, P54, DOI 10.1038/241054a0; RARICK HM, 1992, SCIENCE, V256, P1031, DOI 10.1126/science.1317058; RUIZAVILA L, 1995, NATURE, V376, P80, DOI 10.1038/376080a0; SKLAR PB, 1986, J BIOL CHEM, V261, P5538; SPICKOFSKY N, 1994, NAT STRUCT BIOL, V1, P771, DOI 10.1038/nsb1194-771; STRIEM B J, 1991, Cellular Physiology and Biochemistry, V1, P46, DOI 10.1159/000154592; STRIEM BJ, 1989, BIOCHEM J, V260, P121, DOI 10.1042/bj2600121; STRYER L, 1991, J BIOL CHEM, V266, P10711; TANG JM, 1990, PFLUG ARCH EUR J PHY, V416, P347, DOI 10.1007/BF00392072; TONOSAKI K, 1988, NATURE, V331, P354, DOI 10.1038/331354a0	28	100	105	1	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 6	1995	376	6535					85	88		10.1038/376085a0	http://dx.doi.org/10.1038/376085a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH111	7541117				2022-12-24	WOS:A1995RH11100067
J	ZUNIGAPFLUCKER, JC; JIANG, D; LENARDO, MJ				ZUNIGAPFLUCKER, JC; JIANG, D; LENARDO, MJ			REQUIREMENT FOR TNF-ALPHA AND IL-1-ALPHA IN FETAL THYMOCYTE COMMITMENT AND DIFFERENTIATION	SCIENCE			English	Article							HEMATOPOIETIC STEM-CELLS; TUMOR-NECROSIS-FACTOR; POLYMERASE CHAIN-REACTION; CYTOKINE GENE-EXPRESSION; T-CELLS; PRECURSOR CELLS; C-KIT; INTERLEUKIN-2 RECEPTORS; IMMATURE THYMOCYTES; THYMUS DEVELOPMENT	CD25 expression occurs early in thymocyte differentiation. The mechanism of induction of CD25 before T cell receptor rearrangement and the importance of this mechanism for T cell development are unknown. In a thymus reconstitution assay, tumor necrosis factor alpha (TNF-alpha) and interleukin-1 alpha (IL-1 alpha), two cytokines produced within the thymic microenvironment, induced CD25 expression on early immature thymocytes. Either TNF-alpha or IL-1 alpha was necessary for further thymocyte maturation and CD4(+)CD8(+) differentiation. In irradiated mice reconstituted with CD117(+)CD25(+) thymocytes, commitment to the T cell lineage was marked by the loss of precursor multipotency.	NIAID, IMMUNOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Zuniga-Pflucker, Juan C/H-1295-2012	Zuniga-Pflucker, Juan Carlos/0000-0003-2538-3178				ANTICA M, 1993, J IMMUNOL, V151, P5887; BELL SE, 1991, EUR J IMMUNOL, V21, P2931, DOI 10.1002/eji.1830211206; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; CARDING SR, 1991, IMMUNOL TODAY, V12, P239, DOI 10.1016/0167-5699(91)90037-T; CEREDIG R, 1985, NATURE, V314, P98, DOI 10.1038/314098a0; CHEN D, 1993, MOL CELL BIOL, V13, P228, DOI 10.1128/MCB.13.1.228; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DINARELLO CA, 1989, ADV IMMUNOL, V44, P153, DOI [10.1016/s0065-2776(08)60642-2, 10.1016/S0065-2776(08)60642-2, DOI 10.1016/S0065-2776(08)60642-2]; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207; GIROIR BP, 1992, P NATL ACAD SCI USA, V89, P4864, DOI 10.1073/pnas.89.11.4864; GODFREY DI, 1992, J IMMUNOL, V149, P2281; GODFREY DI, 1994, J IMMUNOL, V152, P4783; GODFREY DI, 1993, J IMMUNOL, V150, P4244; GODFREY DI, 1993, IMMUNOL TODAY, V14, P547, DOI 10.1016/0167-5699(93)90186-O; HENNEY CS, 1989, IMMUNOL TODAY, V10, P170, DOI 10.1016/0167-5699(89)90175-8; HUSMANN LA, 1988, J IMMUNOL, V141, P736; IKUTA K, 1992, P NATL ACAD SCI USA, V89, P1502, DOI 10.1073/pnas.89.4.1502; IKUTA K, 1990, CELL, V62, P863, DOI 10.1016/0092-8674(90)90262-D; IVANOV V, 1992, INT IMMUNOL, V4, P729, DOI 10.1093/intimm/4.7.729; JENKINSON EJ, 1982, EUR J IMMUNOL, V12, P583, DOI 10.1002/eji.1830120710; JORDAN CT, 1990, CELL, V61, P953, DOI 10.1016/0092-8674(90)90061-I; KINGSTON R, 1985, NATURE, V317, P811, DOI 10.1038/317811a0; MONTGOMERY RA, 1991, J IMMUNOL, V147, P554; MOORE NC, 1993, EUR J IMMUNOL, V23, P922, DOI 10.1002/eji.1830230424; MOORE T, 1994, J IMMUNOL, V153, P4978; NIKOLICZUGIC J, 1991, IMMUNOL TODAY, V12, P65, DOI 10.1016/0167-5699(91)90160-U; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; RAULET DH, 1985, NATURE, V314, P101, DOI 10.1038/314101a0; ROCK KL, 1989, IMMUNOL REV, V111, P195, DOI 10.1111/j.1600-065X.1989.tb00547.x; ROTHENBERG EV, 1992, ADV IMMUNOL, V51, P85, DOI 10.1016/S0065-2776(08)60487-3; ROTHENBERG EV, 1994, EUR J IMMUNOL, V24, P24, DOI 10.1002/eji.1830240105; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; SCOLLAY R, 1991, CURR OPIN IMMUNOL, V3, P204, DOI 10.1016/0952-7915(91)90051-2; SCOLLAY R, 1988, IMMUNOL REV, V104, P81, DOI 10.1111/j.1600-065X.1988.tb00760.x; SEN J, 1994, J EXP MED, V180, P2321, DOI 10.1084/jem.180.6.2321; SHIMONKEVITZ RP, 1987, NATURE, V329, P157, DOI 10.1038/329157a0; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; SUDA T, 1990, J IMMUNOL, V144, P3039; WATSON JD, 1989, J IMMUNOL, V143, P1215; WU L, 1991, J EXP MED, V174, P1617, DOI 10.1084/jem.174.6.1617; WU L, 1991, NATURE, V349, P71, DOI 10.1038/349071a0; ZUNIGAPFLUCKER JC, 1993, J EXP MED, V178, P1139, DOI 10.1084/jem.178.4.1139; ZUNIGAPFLUCKER JC, UNPUB	45	125	127	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 30	1995	268	5219					1906	1909		10.1126/science.7541554	http://dx.doi.org/10.1126/science.7541554			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF990	7541554				2022-12-24	WOS:A1995RF99000040
J	LEVITSKAYA, J; CORAM, M; LEVITSKY, V; IMREH, S; STEIGERWALDMULLEN, PM; KLEIN, G; KURILLA, MG; MASUCCI, MG				LEVITSKAYA, J; CORAM, M; LEVITSKY, V; IMREH, S; STEIGERWALDMULLEN, PM; KLEIN, G; KURILLA, MG; MASUCCI, MG			INHIBITION OF ANTIGEN-PROCESSING BY THE INTERNAL REPEAT REGION OF THE EPSTEIN-BARR-VIRUS NUCLEAR ANTIGEN-1	NATURE			English	Article							LYMPHOCYTES-T; DNA-BINDING; INVIVO; RECOGNITION; EXPRESSION; SEQUENCE; EBNA-1; ESCAPE; CELLS	THE Epstein-Barr virus (EBV)-encoded nuclear antigen (EBNA1) is expressed in latently EBV-infected B lymphocytes that persist for life in healthy virus carriers(1,2) and is the only viral protein regularly detected in all malignancies associated with EBV(3,4). Major histocompatibility complex (MHC) class I-restricted, EBNA1-specific cytotoxic T lymphocyte (CTL) responses have not been demonstrated(3,5). Using recombinant vaccinia viruses encoding chimaeric proteins containing an immunodominant human leukocyte antigen A11-restricted CTL epitope, amino acids 416-424 of the EBNA4 protein(6), inserted within the intact EBNA1, or within an EBNA1 deletion mutant devoid of the internal Gly-Ala repetitive sequence, we demonstrate that the Gly-Ala repeats generate a cis-acting inhibitory signal that interferes with antigen processing and MHC class I-restricted presentation. Insertion of the Gly-Ala repeats downstream of the 416-424 epitope inhibited CTL recognition of a chimaeric EBNA4 protein. The results highlight a previously unknown mechanism of viral escape from CTL surveillance, and support the view that the resistance of cells expressing EBNA1 to rejection mediated by CTL is a critical requirement for EBV persistence and pathogenesis.	KAROLINSKA INST,CTR MICROBIOL & TUMOR BIOL,S-17177 STOCKHOLM,SWEDEN; UNIV VIRGINIA,HLTH SCI CTR,DEPT PATHOL,CHARLOTTESVILLE,VA 22908	Karolinska Institutet; University of Virginia			Masucci, Maria/AAC-6666-2019; Masucci, Maria G/B-8588-2009	Masucci, Maria/0000-0002-5541-2809; 				BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BANGHAM CRM, 1986, J IMMUNOL, V137, P3973; BERTOLETTI A, 1994, NATURE, V369, P407, DOI 10.1038/369407a0; BURGERT HG, 1987, P NATL ACAD SCI USA, V84, P1356, DOI 10.1073/pnas.84.5.1356; BYRNE JA, 1984, J VIROL, V51, P682, DOI 10.1128/JVI.51.3.682-686.1984; CHEN F, IN PRESS J VIROL; CHEN MR, 1993, J VIROL, V67, P4875, DOI 10.1128/JVI.67.8.4875-4885.1993; Clechanover A., 1994, CELL, V79, P13; DECAMPOSLIMA PO, 1994, J EXP MED, V179, P1297, DOI 10.1084/jem.179.4.1297; DILLNER J, 1984, P NATL ACAD SCI-BIOL, V81, P4652, DOI 10.1073/pnas.81.15.4652; GAVIOLI R, 1993, J VIROL, V67, P1572, DOI 10.1128/JVI.67.3.1572-1578.1993; KLEIN G, 1994, CELL, V77, P791, DOI 10.1016/0092-8674(94)90125-2; KLENERMAN P, 1994, NATURE, V369, P403, DOI 10.1038/369403a0; LEE PY, 1993, J VIROL, V67, P4252, DOI 10.1128/JVI.67.7.4252-4263.1993; LUKACHER AE, 1984, J EXP MED, V160, P814, DOI 10.1084/jem.160.3.814; Masucci Maria G., 1994, Trends in Microbiology, V2, P125, DOI 10.1016/0966-842X(94)90599-1; MICHALEK MT, 1993, NATURE, V363, P552, DOI 10.1038/363552a0; MOSKOPHIDIS D, 1993, NATURE, V362, P758, DOI 10.1038/362758a0; MURRAY RJ, 1992, J EXP MED, V176, P157, DOI 10.1084/jem.176.1.157; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; RAWLINS DR, 1985, CELL, V42, P859, DOI 10.1016/0092-8674(85)90282-X; REEDMAN BM, 1973, INT J CANCER, V11, P499, DOI 10.1002/ijc.2910110302; Rickinson A. M., 1992, NEW LOOK TUMOR IMMUN, P53; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; STEIGEWALDMULLE.PM, IN PRESS J GEN VIROL; TIEMEY RJ, 1994, J VIROL, V68, P7374; TISHON A, 1993, VIROLOGY, V195, P397, DOI 10.1006/viro.1993.1389; TSUBOTA H, 1989, J EXP MED, V169, P1421, DOI 10.1084/jem.169.4.1421	29	638	672	0	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 22	1995	375	6533					685	688		10.1038/375685a0	http://dx.doi.org/10.1038/375685a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE576	7540727				2022-12-24	WOS:A1995RE57600061
J	PINET, V; VERGELLI, M; MARTIN, R; BAKKE, O; LONG, EO				PINET, V; VERGELLI, M; MARTIN, R; BAKKE, O; LONG, EO			ANTIGEN PRESENTATION MEDIATED BY RECYCLING OF SURFACE HLA-DR MOLECULES	NATURE			English	Article							CLASS-II MOLECULES; INVARIANT-CHAIN; PROTEIN-SYNTHESIS; MHC MOLECULES; MICE LACKING; LIVING CELLS; ENDOCYTOSIS; PEPTIDES; EXPRESSION; IA	CLASS II histocompatibility molecules associate with peptides derived from antigens that are processed in endocytic compartments. Antigen presentation to class II-restricted T cells generally requires newly synthesized class II molecules(1), associated invariant chain(2,3), and HLA-DM(4,5). Exceptions to these rules have been reported(6-10), but without description of an underlying mechanism. Here we show that presentation of immunodominant epitopes in the haemagglutinin protein of influenza virus and in myelin basic protein correlates,vith recycling of surface KLA-DR molecules. Truncation of either one of the alpha or beta cytoplasmic tails virtually eliminated internalization of HLA-DR molecules and presentation of haemagglutinin from inactive virus particles. In contrast, the invariant chain-dependent presentation of matrix antigen from the same virus particles was unaffected by these truncations. Thus HLA-DR cytoplasmic tails are not required for the conventional presentation pathway, but jointly contribute a signal for an alternative pathway involving internalization of HLA-DR molecules.	NIAID,IMMUNOGENET LAB,ROCKVILLE,MD 20852; NINCDS,NEUROIMMUNOL BRANCH,BETHESDA,MD 20892; UNIV OSLO,DEPT BIOL,N-0316 OSLO,NORWAY	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Oslo			Long, Eric O/G-5475-2011; PINET, Valérie/G-6085-2012	Long, Eric O/0000-0002-7793-3728; PINET, Valérie/0000-0002-4044-6440; Bakke, Oddmund/0000-0003-4843-7626				ADORINI L, 1989, NATURE, V342, P800, DOI 10.1038/342800a0; BIKOFF EK, 1993, J EXP MED, V177, P1699, DOI 10.1084/jem.177.6.1699; BODMER H, 1994, SCIENCE, V263, P1284, DOI 10.1126/science.7510069; BROOKS AG, 1994, J IMMUNOL, V153, P5382; CHICZ RM, 1992, NATURE, V358, P764, DOI 10.1038/358764a0; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; DAVIDSON HW, 1991, CELL, V67, P105, DOI 10.1016/0092-8674(91)90575-J; DAVIS JE, 1990, J IMMUNOL, V144, P990; FLING SP, 1994, NATURE, V368, P554, DOI 10.1038/368554a0; GERMAIN RN, 1993, NATURE, V363, P725, DOI 10.1038/363725a0; HARDING CV, 1989, J IMMUNOL, V142, P12; KAKIUCHI T, 1990, J IMMUNOL, V145, P1653; KLAUSNER RD, 1983, J BIOL CHEM, V258, P4715; LANZAVECCHIA A, 1992, NATURE, V357, P249, DOI 10.1038/357249a0; LONG EO, 1994, J IMMUNOL, V153, P1487; MARTIN R, 1992, J IMMUNOL, V148, P1359; MORRIS P, 1994, NATURE, V368, P551, DOI 10.1038/368551a0; NABAVI N, 1989, J IMMUNOL, V142, P1444; NADIMI F, 1991, EUR J IMMUNOL, V21, P1255, DOI 10.1002/eji.1830210524; NELSON CA, 1994, NATURE, V371, P250, DOI 10.1038/371250a0; PINET V, 1994, J IMMUNOL, V152, P4852; RADKA SF, 1984, HUM IMMUNOL, V10, P177, DOI 10.1016/0198-8859(84)90038-7; REID PA, 1992, IMMUNOLOGY, V77, P539; RICCIO P, 1994, NEUROREPORT, V5, P689, DOI 10.1097/00001756-199402000-00007; ROCHE PA, 1993, P NATL ACAD SCI USA, V90, P8581, DOI 10.1073/pnas.90.18.8581; ROTHBARD JB, 1991, ANNU REV IMMUNOL, V9, P527, DOI 10.1146/annurev.iy.09.040191.002523; SIMONSEN A, 1993, INT IMMUNOL, V5, P903, DOI 10.1093/intimm/5.8.903; STEBBINS CC, 1995, J EXP MED, V181, P223, DOI 10.1084/jem.181.1.223; STPIERRE Y, 1989, J IMMUNOL, V143, P808; VIVILLE S, 1993, CELL, V72, P635, DOI 10.1016/0092-8674(93)90081-Z	30	241	243	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 15	1995	375	6532					603	606		10.1038/375603a0	http://dx.doi.org/10.1038/375603a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD287	7540726				2022-12-24	WOS:A1995RD28700055
J	ROTHSTEIN, TL; WANG, JKM; PANKA, DJ; FOOTE, LC; WANG, ZH; STANGER, B; CUI, H; JU, ST; MARSHAKROTHSTEIN, A				ROTHSTEIN, TL; WANG, JKM; PANKA, DJ; FOOTE, LC; WANG, ZH; STANGER, B; CUI, H; JU, ST; MARSHAKROTHSTEIN, A			PROTECTION AGAINST FAS-DEPENDENT TH1-MEDIATED APOPTOSIS BY ANTIGEN RECEPTOR ENGAGEMENT IN B-CELLS	NATURE			English	Article							CD40 LIGAND; LYMPHOCYTES; ANTIBODY; SIGNAL; MICE	CYTOTOXIC CD4(+) Th1-cells induce cell death by triggering a Fas-dependent apoptotic pathway(1-6). Potential targets include activated B cells(3,7), but it is not known whether the mode of B-cell stimulation influences susceptibility to Th1-mediated cytotoxicity. Here we report that CD40-ligand-stimulated B cells were extremely sensitive, whereas anti-IgM-stimulated B cells were resistant, to Fas-mediated apoptosis, B cells stimulated by both CD4DL and anti-IgM were not susceptible to cytolysis, demonstrating that anti-IgM-mediated protection is an active, dominant process. Resistance to Th1-mediated cytotoxicity was similarly observed in CD40L-stimulated 3-83 (anti-H-2K(k,b))(8) transgenic B cells co-cultured with H-2K(k) or H-2K(b) (but not H-2K(d)) splenocytes, These results indicate that B cells can participate in regulating their own destruction. Protection against Fas-dependent apoptosis afforded by immunoglobulin-receptor engagement may constitute a fail-safe mechanism that eliminates bystander B cells activated by CD40L-expressing T cells, but ensures survival of antigen-specific B cells.	BOSTON UNIV,MED CTR,DEPT MICROBIOL,BOSTON,MA 02118; BOSTON UNIV,MED CTR,DEPT PATHOL,BOSTON,MA 02118; BOSTON UNIV,MED CTR,EVANS MEM DEPT CLIN RES,BOSTON,MA 02118; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115	Boston University; Boston University; Boston University; Harvard University; Harvard Medical School	ROTHSTEIN, TL (corresponding author), BOSTON UNIV,MED CTR,DEPT MED,88 E NEWTON ST,BOSTON,MA 02118, USA.							BALK SP, 1981, J IMMUNOL, V126, P2177; DANIEL PT, 1994, J IMMUNOL, V152, P5624; ERB P, 1990, J IMMUNOL, V144, P790; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FRANCIS DA, 1995, INT IMMUNOL, V7, P151, DOI 10.1093/intimm/7.2.151; HANABUCHI S, 1994, P NATL ACAD SCI USA, V91, P4930, DOI 10.1073/pnas.91.11.4930; HEATH AW, 1993, CELL IMMUNOL, V152, P468, DOI 10.1006/cimm.1993.1305; HENKART PA, 1994, IMMUNITY, V1, P343, DOI 10.1016/1074-7613(94)90063-9; HOLDER MJ, 1993, EUR J IMMUNOL, V23, P2368, DOI 10.1002/eji.1830230948; JU ST, 1990, J IMMUNOL, V144, P23; JU ST, 1994, P NATL ACAD SCI USA, V91, P4185, DOI 10.1073/pnas.91.10.4185; LANE P, 1993, J EXP MED, V177, P1209, DOI 10.1084/jem.177.4.1209; LYNCH DH, 1994, IMMUNITY, V1, P131, DOI 10.1016/1074-7613(94)90106-6; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OWENSCHAUB LB, 1992, CELL IMMUNOL, V140, P197, DOI 10.1016/0008-8749(92)90187-T; OWENSCHAUB LB, 1994, CANCER RES, V54, P1580; PARRY SL, 1994, J IMMUNOL, V152, P2821; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; RUSSELL DM, 1991, NATURE, V354, P308, DOI 10.1038/354308a0; SANTOSARGUMEDO L, 1994, CELL IMMUNOL, V156, P272, DOI 10.1006/cimm.1994.1174; STALDER T, 1994, J IMMUNOL, V152, P1127; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; TAYLOR RB, 1971, NATURE-NEW BIOL, V233, P225, DOI 10.1038/newbio233225a0; TRENN G, 1987, NATURE, V330, P72, DOI 10.1038/330072a0; TSUBATA T, 1993, NATURE, V364, P645, DOI 10.1038/364645a0; VIGNAUX F, 1994, EUR J IMMUNOL, V24, P923, DOI 10.1002/eji.1830240421; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0	28	416	417	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 9	1995	374	6518					163	165		10.1038/374163a0	http://dx.doi.org/10.1038/374163a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL397	7533263				2022-12-24	WOS:A1995QL39700059
J	STUCKI, A; CORDEY, AS; MONAI, N; DEFLAUGERGUES, JC; SCHAPIRA, H; SPERTINI, O				STUCKI, A; CORDEY, AS; MONAI, N; DEFLAUGERGUES, JC; SCHAPIRA, H; SPERTINI, O			CLEAVED L-SELECTIN CONCENTRATIONS IN MENINGEAL LEUKEMIA	LANCET			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; CEREBROSPINAL-FLUID; CHILDHOOD; RELAPSE; CELLS	Involvement of the central nervous system has important therapeutic implications in acute leukaemia. Because the identification of blast cells in cerebrospinal fluid (CSF) is often difficult, there is a need for sensitive markers of leukaemic infiltration. Since the shed form of L-selectin (sL-selectin) is frequently increased in acute leukaemia (sL-selectin(+) leukaemia), we examined whether assay of sL-selectin in CSF could improve our ability to detect such meningeal involvement. CSF sL-selectin was significantly (p<0.001) higher in 15 patients with sL-selectin(+) meningeal leukaemia (median 60 ng/ml, range 34-150) than in 20 patients with acute leukaemia without meningeal involvement (12 ng/mL, 1-39) or 88 control patients (14 ng/ml, 0-37). Serial measurements of sL-selectin in patients with sL-selectin(+) leukaemic meningitis showed increased CSF concentrations of the cleaved receptor in 4 patients with therapy-resistant meningeal leukaemia and sustained normal concentrations in 9 patients in remission. Our results suggest that CSF sL-selectin may be a useful marker in the detection of meningeal involvement by blast cells in patients with sL-selectin(+) leukaemia.	CHU VAUDOIS,DIV HAEMATOL,CH-1011 LAUSANNE,SWITZERLAND; CHU VAUDOIS,SERV NEUROL,CH-1011 LAUSANNE,SWITZERLAND	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)								ADAMS DH, 1994, LANCET, V343, P831, DOI 10.1016/S0140-6736(94)92029-X; BENETT JM, 1985, ANN INTERN MED, V103, P620; BIGNER SH, 1981, ACTA CYTOL, V25, P335; BLEYER WA, 1988, PEDIATR CLIN N AM, V35, P789; DONELLY SC, 1994, LANCET, V344, P215; DUNN OJ, 1964, TECHNOMETRICS, V6, P241, DOI 10.2307/1266041; KOMADA Y, 1990, BLOOD, V76, P112; LASKY LA, 1992, SCIENCE, V258, P962; MAHMOUD HH, 1993, NEW ENGL J MED, V329, P314, DOI 10.1056/NEJM199307293290504; NIES BA, 1965, CANCER, V18, P546, DOI 10.1002/1097-0142(196505)18:5<546::AID-CNCR2820180503>3.0.CO;2-E; OCHS JJ, 1985, J CLIN ONCOL, V3, P622, DOI 10.1200/JCO.1985.3.5.622; ORTEGA JA, 1987, J CLIN ONCOL, V5, P1646, DOI 10.1200/JCO.1987.5.10.1646; PINKEL D, 1994, BLOOD, V84, P355, DOI 10.1182/blood.V84.2.355.bloodjournal842355; SAIKIA TK, 1993, AM J HEMATOL, V43, P10, DOI 10.1002/ajh.2830430104; SPERTINI O, 1994, BLOOD, V84, P1249, DOI 10.1182/blood.V84.4.1249.bloodjournal8441249; SPERTINI O, 1992, J IMMUNOL METHODS, V156, P115, DOI 10.1016/0022-1759(92)90017-N; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9	17	30	32	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 4	1995	345	8945					286	289		10.1016/S0140-6736(95)90276-7	http://dx.doi.org/10.1016/S0140-6736(95)90276-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QE731	7530792				2022-12-24	WOS:A1995QE73100010
J	LAU, LL; JAMIESON, BD; SOMASUNDARAM, T; AHMED, R				LAU, LL; JAMIESON, BD; SOMASUNDARAM, T; AHMED, R			CYTOTOXIC T-CELL MEMORY WITHOUT ANTIGEN	NATURE			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; PERSISTING ANTIGEN; SELECTION	Memory is a hallmark of the immune system and ever since its recognition there has been considerable interest in understanding how immunity is maintained(1-5). The current model is that long-term memory is dependent on persistent antigenic stimulation(6-11). We report here results that challenge this view and provide evidence that antigen is not essential for the maintenance of CD8(+) T-cell memory. We show that memory CD8(+) cytotoxic T lymphocytes persist indefinitely in the absence of priming antigen, retain the memory phenotype (CD44(hi)), and provide protection against virus challenge. These findings suggest a re-evaluation of our current thinking on mechanisms involved in maintaining immunity and have implications towards designing effective vaccination strategies.	UNIV CALIF LOS ANGELES, SCH MED, DEPT MICROBIOL & IMMUNOL, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								Ahmed R, 1992, Semin Immunol, V4, P105; AHMED R, 1984, J EXP MED, V160, P521, DOI 10.1084/jem.160.2.521; ASHTONRICKARDT PG, 1993, CELL, V73, P1041, DOI 10.1016/0092-8674(93)90281-T; BEVERLEY PCL, 1990, CURR TOP MICROBIOL, V159, P111; BRADLEY LM, 1993, IMMUNOL TODAY, V14, P197, DOI 10.1016/0167-5699(93)90161-D; CELADA F, 1971, PROG ALLERGY, V15, P223; GRAY D, 1991, J EXP MED, V174, P969, DOI 10.1084/jem.174.5.969; GRAY D, 1988, NATURE, V336, P70, DOI 10.1038/336070a0; HOGQUIST KA, 1993, J EXP MED, V177, P1469, DOI 10.1084/jem.177.5.1469; JAMIESON BD, 1989, J EXP MED, V169, P1993, DOI 10.1084/jem.169.6.1993; MACDONALD HR, 1990, CURR TOP MICROBIOL, V159, P97; MACKAY CR, 1993, ADV IMMUNOL, V53, P217, DOI 10.1016/S0065-2776(08)60501-5; Matloubian M., 1993, J VIROL, V67, P7340; OEHEN S, 1992, J EXP MED, V176, P1273, DOI 10.1084/jem.176.5.1273; PAUL W, 1993, FUNDAMENTAL IMMUNOLO, P1211; SPRENT J, 1993, CURR OPIN IMMUNOL, V5, P433, DOI 10.1016/0952-7915(93)90065-Z; TABI Z, 1988, CELL IMMUNOL, V113, P268, DOI 10.1016/0008-8749(88)90026-3; TASWELL C, 1981, J IMMUNOL, V126, P1614; TEW JG, 1980, IMMUNOL REV, V53, P175; WHITTON JL, 1988, VIROLOGY, V162, P321, DOI 10.1016/0042-6822(88)90471-0; ZINKERNAGEL RM, 1990, CURR TOP MICROBIOL, V159, P65	21	583	595	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 23	1994	369	6482					648	652		10.1038/369648a0	http://dx.doi.org/10.1038/369648a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT459	7516038				2022-12-24	WOS:A1994NT45900055
J	BRILLANTES, AMB; ONDRIAS, K; SCOTT, A; KOBRINSKY, E; ONDRIASOVA, E; MOSCHELLA, MC; JAYARAMAN, T; LANDERS, M; EHRLICH, BE; MARKS, AR				BRILLANTES, AMB; ONDRIAS, K; SCOTT, A; KOBRINSKY, E; ONDRIASOVA, E; MOSCHELLA, MC; JAYARAMAN, T; LANDERS, M; EHRLICH, BE; MARKS, AR			STABILIZATION OF CALCIUM-RELEASE CHANNEL (RYANODINE RECEPTOR) FUNCTION BY FK506-BINDING PROTEIN	CELL			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; SKELETAL-MUSCLE; MOLECULAR-CLONING; SMOOTH-MUSCLE; MALIGNANT HYPERTHERMIA; ENDOPLASMIC-RETICULUM; PROLYL ISOMERASE; PLANAR BILAYERS; FEET STRUCTURES; CYCLOSPORINE-A	FK506-binding protein (FKBP12) was originally identified as the cytosolic receptor for the immunosuppressant drugs FK506 and rapamycin. The cellular function of FKBP12, a ubiquitously expressed 12,000-dalton proline isomerase, has been unknown. FKBP12 copurifies with the 565,000-dalton ryanodine receptor (RyR), four of which form intracellular Ca2+ release channels of the sarcoplasmic and endoplasmic reticula. By coexpressing the RyR and FKBP12 in insect cells, we have demonstrated that FKBP12 modulates channel gating by increasing channels with full conductance levels (by >400%), decreasing open probability after caffeine activation (from 0.63 +/- 0.09 to 0.04 +/- 0.02), and increasing mean open time (from 4.4 +/- 0.6 ms to 75 +/- 41 ms). FK506 or rapamycin, inhibitors of FKBP12 isomerase activity, reverse these stabilizing effects. These results provide the first natural cellular function for FKBP12, and establish that the functional Ca2+ release channel complex includes FKBP12.	CUNY MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL,NEW YORK,NY 10029; UNIV CONNECTICUT,CTR HLTH,DEPT MED,FARMINGTON,CT 06030; UNIV CONNECTICUT,CTR HLTH,DEPT PHYSIOL,FARMINGTON,CT 06030	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of Connecticut; University of Connecticut	BRILLANTES, AMB (corresponding author), CUNY MT SINAI SCH MED,DEPT MED,PROGRAM MOLEC MED,NEW YORK,NY 10029, USA.		/AAX-8408-2021	/0000-0001-9657-9704; Ondrias, Karol/0000-0001-8329-3563; Ondriasova, Elena/0000-0002-2990-990X				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BRANDL CJ, 1986, P NATL ACAD SCI USA, V83, P917, DOI 10.1073/pnas.83.4.917; CATTERALL WA, 1991, CELL, V64, P871, DOI 10.1016/0092-8674(91)90309-M; CHEN SRW, 1993, BIOCHEMISTRY-US, V32, P3743, DOI 10.1021/bi00065a029; CHU A, 1990, MOL PHARMACOL, V37, P735; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CORONADO R, 1992, METHOD ENZYMOL, V207, P699; DEFRANCO AL, 1991, NATURE, V352, P754, DOI 10.1038/352754a0; DUMONT FJ, 1990, J IMMUNOL, V144, P251; FILL M, 1991, BIOCHEM J, V273, P449, DOI 10.1042/bj2730449; FILL M, 1991, BIOPHYS J, V59, P1085, DOI 10.1016/S0006-3495(91)82323-2; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FRANZINIARMSTRONG C, 1983, J MUSCLE RES CELL M, V4, P233, DOI 10.1007/BF00712033; FRESKGARD PO, 1992, SCIENCE, V258, P466, DOI 10.1126/science.1357751; FUJII J, 1991, SCIENCE, V253, P448, DOI 10.1126/science.1862346; GILLO B, 1993, BLOOD, V81, P783; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HAWKES MJ, 1992, J BIOL CHEM, V267, P6702; HERRMANNFRANK A, 1991, PFLUG ARCH EUR J PHY, V418, P353, DOI 10.1007/BF00550873; HYMEL L, 1988, P NATL ACAD SCI USA, V85, P441, DOI 10.1073/pnas.85.2.441; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; INUI M, 1987, J BIOL CHEM, V262, P15637; INUI M, 1987, J BIOL CHEM, V262, P1740; JAYARAMAN T, 1993, J BIOL CHEM, V268, P25385; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; KAO JPY, 1989, J BIOL CHEM, V264, P8179; KUME S, 1993, CELL, V73, P555, DOI 10.1016/0092-8674(93)90142-D; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LEE YS, 1991, J MEMBRANE BIOL, V122, P155, DOI 10.1007/BF01872638; LESH RE, 1993, CIRC RES, V72, P481, DOI 10.1161/01.RES.72.2.481; LINDSAY ARG, 1991, BIOCHIM BIOPHYS ACTA, V1064, P89, DOI 10.1016/0005-2736(91)90415-5; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU QY, 1989, BIOPHYS J, V55, P415, DOI 10.1016/S0006-3495(89)82835-8; MARKS AR, 1990, J BIOL CHEM, V265, P13143; MARKS AR, 1990, J BIOL CHEM, V265, P20719; MARKS AR, 1991, J CELL BIOL, V114, P303, DOI 10.1083/jcb.114.2.303; MARKS AR, 1989, P NATL ACAD SCI USA, V86, P8683, DOI 10.1073/pnas.86.22.8683; MAYRLEITNER M, 1991, CELL CALCIUM, V12, P505, DOI 10.1016/0143-4160(91)90032-A; MCPHERSON PS, 1991, NEURON, V7, P17, DOI 10.1016/0896-6273(91)90070-G; MCPHERSON SM, 1992, J CELL BIOL, V116, P1111, DOI 10.1083/jcb.116.5.1111; MEISSNER G, 1992, MOL CELL BIOCHEM, V114, P119; MEISSNER G, 1991, ADV EXP MED BIOL, V304, P241; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MORICE WG, 1993, J BIOL CHEM, V268, P3734; Morris R.E., 1992, TRANSPLANT REV-ORLAN, P39; MOSCHELLA MC, 1993, J CELL BIOL, V120, P1137, DOI 10.1083/jcb.120.5.1137; MOUREY RJ, 1990, BIOCHEM J, V272, P383, DOI 10.1042/bj2720383; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; OTSU K, 1990, J BIOL CHEM, V265, P13472; PENNER R, 1989, FEBS LETT, V259, P217, DOI 10.1016/0014-5793(89)81532-7; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; RANATUNGA KW, 1982, J PHYSIOL-LONDON, V329, P465, DOI 10.1113/jphysiol.1982.sp014314; ROSS CA, 1989, NATURE, V339, P468, DOI 10.1038/339468a0; ROUSSEAU E, 1989, AM J PHYSIOL, V256, P328; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SMITH JS, 1986, J GEN PHYSIOL, V88, P573, DOI 10.1085/jgp.88.5.573; SMITH KA, 1988, INTERLEUKIN, V2, P1; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; SUCHYNA TM, 1993, NATURE, V365, P847, DOI 10.1038/365847a0; SUKO J, 1993, BIOCHIM BIOPHYS ACTA, V1175, P193, DOI 10.1016/0167-4889(93)90023-I; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TIEBOSCH A, 1990, TRANSPLANT P, V22, P1652; TIMERMAN AP, 1993, J BIOL CHEM, V268, P22992; WHITING PH, 1991, TRANSPLANTATION, V52, P203, DOI 10.1097/00007890-199108000-00004; WILLIAMS AJ, 1992, J MUSCLE RES CELL M, V13, P7, DOI 10.1007/BF01738423; WITCHER DR, 1991, J BIOL CHEM, V266, P11144; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	75	692	707	0	27	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 20	1994	77	4					513	523		10.1016/0092-8674(94)90214-3	http://dx.doi.org/10.1016/0092-8674(94)90214-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NM832	7514503				2022-12-24	WOS:A1994NM83200007
J	GUO, YJ; WU, MC; CHEN, H; WANG, XN; LIU, GL; LI, GL; MA, J; SY, MS				GUO, YJ; WU, MC; CHEN, H; WANG, XN; LIU, GL; LI, GL; MA, J; SY, MS			EFFECTIVE TUMOR VACCINE GENERATED BY FUSION OF HEPATOMA-CELLS WITH ACTIVATED B-CELLS	SCIENCE			English	Article							RECEPTOR	Fusion of BERH-2 rat hepatocellular carcinoma cells with activated B cells produced hybrid cells that lost their tumorigenicity and became immunogenic. Syngeneic rats injected with BERH-2-B hybrid cells became resistant to challenge with parental BERH-2 cells, and rats with established BERH-2 hepatomas were cured by subsequent injection of BERH-2-B cells. Both CD4+ and CD8+ cells were essential for the induction of protective immunity; however, only CD8+ cells were required for the eradication of BERH-2 tumors. The generation of hybrid tumor cells that elicit antitumor immune responses may be a useful strategy for cancer immunotherapy.	CASE WESTERN RESERVE UNIV,INST PATHOL,CLEVELAND,OH 44106	Case Western Reserve University	GUO, YJ (corresponding author), EASTERN INST HEPATOBILIARY SURG,CTR TUMOR IMMUNOL & BIOTHERAPY,SHANGHAI 200433,PEOPLES R CHINA.							ALAN J, 1988, IMMUNOCHEMISTRY PRAC, pCH2; BLANKENSTEIN T, 1991, J EXP MED, V173, P1047, DOI 10.1084/jem.173.5.1047; CHEN LP, 1992, CELL, V71, P1093, DOI 10.1016/S0092-8674(05)80059-5; CHESTNUT RW, 1981, J IMMUNOL, V128, P1075; ELIOT BE, 1989, ADV CANCER RES, V53, P181; FEARON ER, 1990, CELL, V60, P397, DOI 10.1016/0092-8674(90)90591-2; GEORGE JT, 1993, CANCER RES, V53, P2374; Guo Y., UNPUB; GUO YJ, 1988, J MIL MED COLL PEOPL, V3, P272; LANZAVECCHIA A, 1990, ANNU REV IMMUNOL, V8, P773, DOI 10.1146/annurev.immunol.8.1.773; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; MUUL LM, 1987, J IMMUNOL, V138, P989; OSBAND ME, 1990, IMMUNOL TODAY, V11, P193, DOI 10.1016/0167-5699(90)90080-S; RESTIFO NP, 1993, J EXP MED, V177, P265, DOI 10.1084/jem.177.2.265; TEPPER RI, 1989, CELL, V57, P503, DOI 10.1016/0092-8674(89)90925-2; TOWNSEND SE, 1993, SCIENCE, V259, P368, DOI 10.1126/science.7678351; TROJAN J, 1993, SCIENCE, V259, P94, DOI 10.1126/science.8418502; WATANABE Y, 1989, P NATL ACAD SCI USA, V86, P9459	18	143	184	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 28	1994	263	5146					518	520		10.1126/science.7507262	http://dx.doi.org/10.1126/science.7507262			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT966	7507262				2022-12-24	WOS:A1994MT96600032
J	FOSS, HM; ROBERTS, CJ; CLAEYS, KM; SELKER, EU				FOSS, HM; ROBERTS, CJ; CLAEYS, KM; SELKER, EU			ABNORMAL CHROMOSOME BEHAVIOR IN NEUROSPORA MUTANTS DEFECTIVE IN DNA METHYLATION	SCIENCE			English	Article							TANDEM DUPLICATION; CRASSA; RECOMBINATION; 5-AZACYTIDINE; SEQUENCES; INDUCTION; SIGNAL; CYCLE	The function and regulation of DNA methylation in eukaryotes remain unclear. Genes affecting methylation were identified in the fungus Neurospora crassa. A mutation in one gene, dim-2, resulted in the loss of all detectable DNA methylation. Abnormal segregation of the methylation defects in crosses led to the discovery that the methylation mutants frequently generate strains with extra chromosomes or chromosomal parts. Starvation for S-adenosylmethionine, the presumed methyl group donor for DNA methylation, also produced aneuploidy. These results suggest that DNA methylation plays a role in the normal control of chromosome behavior.	UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403; UNIV OREGON,DEPT BIOL,EUGENE,OR 97403	University of Oregon; University of Oregon					NIGMS NIH HHS [GM-35690] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035690, R37GM035690] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BOND DJ, 1987, MUTAT RES, V181, P257, DOI 10.1016/0027-5107(87)90103-5; BULL JH, 1984, NATURE, V310, P701, DOI 10.1038/310701a0; COCK JM, 1990, J PHYCOL, V26, P361, DOI 10.1111/j.0022-3646.1990.00361.x; CULP LA, 1971, BIOCHIM BIOPHYS ACTA, V247, P220, DOI 10.1016/0005-2787(71)90672-1; Davis RH, 1970, METHODS ENZYMOL A, V17A, P47; FOSS H, 1989, FUNGAL GENET NEWSL, V36, P82; FOSS HM, UNPUB; GOUNARI F, 1987, GENE DEV, V1, P899, DOI 10.1101/gad.1.9.899; GRAYBURN WS, 1989, MOL CELL BIOL, V9, P4416, DOI 10.1128/MCB.9.10.4416; HAACK KJ, UNPUB; HAGEMANN A, UNPUB; HORI T, 1983, MUTAT RES, V121, P47, DOI 10.1016/0165-7992(83)90085-4; JACOBSON ES, 1977, J BACTERIOL, V132, P747, DOI 10.1128/JB.132.2.747-748.1977; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; METZENBERG RL, 1985, P NATL ACAD SCI USA, V82, P2067, DOI 10.1073/pnas.82.7.2067; NEVES N, 1992, GENOME, V35, P650, DOI 10.1139/g92-098; NEWMEYER D, 1967, GENETICS, V56, P771; PERKINS DD, 1975, GENETICS, V80, P87; PERKINS DD, 1986, GENETICS, V114, P791; PERKINS DD, 1982, MICROBIOL REV, V46, P426, DOI 10.1128/MMBR.46.4.426-570.1982; PITTENGER TH, 1954, GENETICS, V39, P326; POOT M, 1990, HUM GENET, V84, P258; ROBERTS CJ, UNPUB; RUSSELL PJ, 1987, J BACTERIOL, V169, P2902, DOI 10.1128/jb.169.6.2902-2905.1987; SCHROEDER AL, 1991, MOL GEN GENET, V231, P41, DOI 10.1007/BF00293819; SELKER E, UNPUB; SELKER EU, 1987, SCIENCE, V238, P48, DOI 10.1126/science.2958937; SELKER EU, 1987, MOL CELL BIOL, V7, P1032, DOI 10.1128/MCB.7.3.1032; SELKER EU, 1985, P NATL ACAD SCI USA, V82, P8114, DOI 10.1073/pnas.82.23.8114; SELKER EU, 1990, TRENDS BIOCHEM SCI, V15, P103, DOI 10.1016/0968-0004(90)90193-F; SELKER EU, 1990, ANNU REV GENET, V24, P579, DOI 10.1146/annurev.ge.24.120190.003051; SHAFER DA, 1984, AM J HUM GENET, V30, P534; SMITH DA, 1974, GENETICS, V76, P1; SMITH DA, 1975, GENETICS, V80, P125; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STABEN C, 1990, P NATL ACAD SCI USA, V87, P4917, DOI 10.1073/pnas.87.13.4917; THRELKELD SF, 1970, GENET RES, V16, P29, DOI 10.1017/S0016672300002251; VIEGASPEQUIGNOT E, 1976, HUM GENET, V34, P247, DOI 10.1007/BF00295287; VONGS A, 1993, SCIENCE, V260, P1926, DOI 10.1126/science.8316832	41	110	115	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 10	1993	262	5140					1737	1741		10.1126/science.7505062	http://dx.doi.org/10.1126/science.7505062			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML220	7505062				2022-12-24	WOS:A1993ML22000043
J	SPENCER, K; MALLARD, AS; COOMBES, EJ; MACRI, JN				SPENCER, K; MALLARD, AS; COOMBES, EJ; MACRI, JN			PRENATAL SCREENING FOR TRISOMY-18 WITH FREE BETA-HUMAN CHORIONIC-GONADOTROPIN AS A MARKER	BRITISH MEDICAL JOURNAL			English	Article							SERUM ALPHA-FETOPROTEIN; MATERNAL SERUM; DOWNS-SYNDROME; CHROMOSOME-ABNORMALITIES; UNCONJUGATED ESTRIOL; HUMAN CHORIOGONADOTROPIN; PREGNANCY; AGE; RATES; RISK	Objective-To determine the relation between maternal serum alpha fetoprotein and free beta human chorionic gonadotrophin concentrations in pregnancies complicated by trisomy 18 and establish whether prenatal biochemical screening for this condition could be developed in a way similar to that proposed for trisomy 21. Design-Serum alpha fetoprotein and free beta human chorionic gonadotrophin concentrations in women with singleton pregnancies affected by cytogenetically confirmed trisomy 18, uncomplicated by neural tube defect or ventral wall defect, were identified from prospective trisomy 21 screening programmes. Additionally, stored maternal serum from similar pregnancies was analysed retrospectively. Analyte concentrations from singleton unaffected pregnancies were identified from a prospective screening programme as controls. Statistical parameters of the affected and unaffected populations were compiled. Setting-Biochemical screening laboratories in Britain and the United States. Subjects-52 women with singleton pregnancies complicated by trisomy 18; control population of 6661 women with unaffected singleton pregnancies. Main outcome measures-Median values of each analyte and their distribution in the affected and unaffected populations; detection rate of trisomy 18 and the false positive rate. Results-Maternal serum alpha fetoprotein and free beta human chorionic gonadotrophin concentrations were significantly lower in pregnancies complicated by trisomy 18 (median values 0.71 and 0.37 respectively). By using a multivariate risk algorithm incorporating maternal age risk of trisomy 18 and the concentration of the two biochemical markers it was predicted that 50% of trisomy 18 cases (unaffected by neural tube defect or ventral wall defect) could be detected with a 1% false positive rate. Conclusion-Second trimester biochemical screening for trisomy 18 could be a valuable addition to trisomy 21 screening programmes.	ROYAL CORNWALL HOSP,DEPT CLIN BIOCHEM,TRURO,CORNWALL,ENGLAND; QUEEN ALEXANDRA HOSP,DEPT CHEM PATHOL,PORTSMOUTH,HANTS,ENGLAND; NTD LABS INC,DIV RES,NEW YORK,NY 11514	Royal Cornwall Hospital; Portsmouth Hospitals NHS Trust; Queen Alexandra Hospital	SPENCER, K (corresponding author), OLDCHURCH HOSP,DEPT CLIN BIOCHEM,ENDOCRINE UNIT,ROMFORD RM7 0BE,ESSEX,ENGLAND.							Aitken D. A., 1993, Clinical Chemistry, V39, P1170; BOGART MH, 1987, PRENATAL DIAG, V7, P623, DOI 10.1002/pd.1970070904; CANICK JA, 1990, PRENATAL DIAG, V10, P546, DOI 10.1002/pd.1970100813; CROSSLEY JA, 1991, PRENATAL DIAG, V11, P83, DOI 10.1002/pd.1970110204; CUCKLE HS, 1987, BRIT J OBSTET GYNAEC, V94, P387, DOI 10.1111/j.1471-0528.1987.tb03115.x; DARNULE A, 1990, AM J HUM GENET S, V47, pA272; FERGUSONSMITH MA, 1984, PRENATAL DIAG, V4, P5, DOI 10.1002/pd.1970040704; GREENBERG F, 1992, AM J OBSTET GYNECOL, V166, P1388, DOI 10.1016/0002-9378(92)91610-M; HEYL PS, 1990, OBSTET GYNECOL, V76, P1025; HOOK EB, 1981, OBSTET GYNECOL, V58, P282; HOOK EB, 1983, AM J HUM GENET, V35, P110; LINDENBAUM RH, 1987, PRENATAL DIAG, V7, P511, DOI 10.1002/pd.1970070707; MACRI JN, 1990, AM J OBSTET GYNECOL, V163, P1248, DOI 10.1016/0002-9378(90)90700-H; MACRI JN, 1993, ANN CLIN BIOCHEM, V30, P94, DOI 10.1177/000456329303000117; MACRI JN, 1993, PRENATAL DIAG, V13, P557, DOI 10.1002/pd.1970130704; MERKATZ IR, 1984, AM J OBSTET GYNECOL, V148, P886, DOI 10.1016/0002-9378(84)90530-1; NORGAARDPEDERSEN B, 1990, CLIN GENET, V37, P35; PALOMAKI GE, 1992, PRENATAL DIAG, V12, P925, DOI 10.1002/pd.1970121112; REYNOLDS TM, 1990, ANN CLIN BIOCHEM, V27, P452, DOI 10.1177/000456329002700506; SPENCER K, 1985, BRIT MED J, V290, P1940, DOI 10.1136/bmj.290.6486.1940; SPENCER K, 1993, BRIT MED J, V307, P764, DOI 10.1136/bmj.307.6907.764; SPENCER K, 1992, ANN CLIN BIOCHEM, V29, P506, DOI 10.1177/000456329202900504; SPENCER K, 1991, CLIN CHEM, V37, P809; SPENCER K, 1992, LANCET, V339, P1480, DOI 10.1016/0140-6736(92)92073-O; SPENCER K, 1992, BRIT MED J, V305, P769, DOI 10.1136/bmj.305.6856.769; SPENCER K, 1992, ANN CLIN BIOCHEM, V29, P349, DOI 10.1177/000456329202900319; STAPLES AJ, 1991, AM J HUM GENET, V49, P1025; WALD NJ, 1988, BRIT MED J, V297, P883, DOI 10.1136/bmj.297.6653.883	28	39	40	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 4	1993	307	6917					1455	1458		10.1136/bmj.307.6917.1455	http://dx.doi.org/10.1136/bmj.307.6917.1455			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK797	7506599	Bronze, Green Published			2022-12-24	WOS:A1993MK79700021
J	MILLER, D; MADGE, N; DIAMOND, J; WADSWORTH, J; ROSS, E				MILLER, D; MADGE, N; DIAMOND, J; WADSWORTH, J; ROSS, E			PERTUSSIS IMMUNIZATION AND SERIOUS ACUTE NEUROLOGICAL ILLNESSES IN CHILDREN	BRITISH MEDICAL JOURNAL			English	Article							VACCINE; IMMUNIZATION	Objective-To determine long term outcome in children who had a severe acute neurological illness in early childhood associated with pertussis immunisation. Design-Follow up study of cases and matched controls. Setting-Assessment of children at home and at school throughout Britain. Subjects-Children recruited into the national childhood encephalopathy study in 1976-9 were followed up, with one of their two original matched controls, in 1986-9. Main outcome measures-Performance in educational attainment tests; behaviour problems reported by teachers and parents; continuing convulsions; evidence of other neurological or physical dysfunction. Results-Over 80% of cases and controls were traced. Case children were significantly more likely than controls to have died or to have some form of educational, behavioural, neurological, or physical dysfunction a decade after their illness. The prevalence of one or more of these adverse outcomes in case children who had been immunised with diphtheria, tetanus, and pertussis vaccine within seven days before onset of their original illness was similar to that in case children who had not been immunised recently. The relative risk for recent diphtheria, tetanus, and pertussis immunisation in children who had died or had any dysfunction in comparison with controls was 5.5 (95% confidence interval 1.6 to 23.7). However, the number of cases associated with vaccine (12) was extremely small and statistically vulnerable, and other possible agents or predisposing factors could not be excluded. Conclusions-Diphtheria, tetanus, and pertussis vaccine may on rare occasions be associated with the development of severe acute neurological illnesses that can have serious sequelae. Some cases may occur by chance or have other causes. The role of pertussis vaccine as a prime or concomitant factor in the aetiology of these illnesses cannot be determined in any individual case. The balance of possible risk against known benefits from pertussis immunisation supports continued use of the vaccine.	UNIV LONDON,KINGS COLL HOSP,SCH MED & DENT,DEPT COMMUNITY PAEDIAT,LONDON,ENGLAND	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London	MILLER, D (corresponding author), UNIV LONDON,SCH MED,ST MARYS HOSP,ACAD DEPT PUBL HLTH,LONDON W2 1PG,ENGLAND.			Madge, Nicola/0000-0003-3028-7690				ALDERSLADE R, 1981, WHOOPING COUGH, P79; [Anonymous], 1983, MANUAL RAVENS PROGR; BELLMAN MH, 1985, CHILD CARE HLTH DEV, V11, P309, DOI 10.1111/j.1365-2214.1985.tb00472.x; BELLMAN MH, 1983, LANCET, V1, P1031; BOWIE C, 1990, LANCET, V335, P397, DOI 10.1016/0140-6736(90)90220-Y; BRIMER A, 1984, WIDE SPAN READING TE; FINE PEM, 1992, AM J EPIDEMIOL, V136, P121, DOI 10.1093/oxfordjournals.aje.a116479; GALE JL, 1990, DHSS FDA901162 DEP H, P228; GRIFFITH AH, 1989, VACCINE, V7, P199, DOI 10.1016/0264-410X(89)90229-6; HOWSON CP, 1991, ADVERSE EFFECTS PERT, P65; KULENKAMPFF M, 1974, ARCH DIS CHILD, V49, P46, DOI 10.1136/adc.49.1.46; Madge N, 1993, Dev Med Child Neurol Suppl, V68, P1; MARCUSE EK, 1990, VACCINE, V8, P531, DOI 10.1016/0264-410X(90)90003-5; MIETTINEN OS, 1970, BIOMETRICS, V26, P75, DOI 10.2307/2529046; MILLER D, 1990, LANCET, V335, P655, DOI 10.1016/0140-6736(90)90438-B; MILLER D, 1988, Tokai Journal of Experimental and Clinical Medicine, V13, P145; MILLER DL, 1982, EPIDEMIOL REV, V4, P1; MILLER DL, 1989, VACCINE, V7, P487, DOI 10.1016/0264-410X(89)90268-5; MILLER DL, 1981, BRIT MED J, V282, P1595, DOI 10.1136/bmj.282.6276.1595; MILLER DL, 1985, DEV BIOL STAND, V16, P389; RAVEN JC, 1982, MANUAL RAVENS PROGR; RUTTER M, 1967, J CHILD PSYCHOL PSYC, V8, P1, DOI 10.1111/j.1469-7610.1967.tb02175.x; RUTTER M, 1970, ED HLTH BEHAVIOR; STEWART GT, 1977, LANCET, V1, P234; VERNON PE, 1906, GRADED ARITHMETIC MA; VERNON PE, 1977, GRADED WORD SPELLING; WENTZ KR, 1991, PEDIATRICS, V87, P287; 1981, WHOOPING COUGH REPOR, P170	28	65	72	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 6	1993	307	6913					1171	1176		10.1136/bmj.307.6913.1171	http://dx.doi.org/10.1136/bmj.307.6913.1171			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF824	7504540	Green Published, Bronze			2022-12-24	WOS:A1993MF82400020
J	JAY, GT; CHOW, MSS				JAY, GT; CHOW, MSS			INTERACTION OF EPINEPHRINE AND BETA-BLOCKERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							PROPRANOLOL; HYPERTENSION; BLOCKADE				JAY, GT (corresponding author), UNIV CONNECTICUT,HARTFORD,CT 06112, USA.							DZUBOW LM, 1986, J AM ACAD DERMATOL, V15, P71, DOI 10.1016/S0190-9622(86)70145-X; FOSTER CA, 1983, PLAST RECONSTR SURG, V72, P74, DOI 10.1097/00006534-198307000-00017; GANDY W, 1989, ANN EMERG MED, V18, P98, DOI 10.1016/S0196-0644(89)80324-5; HANSBROUGH JF, 1980, ANN INTERN MED, V92, P717, DOI 10.7326/0003-4819-92-5-717_2; HOFFMAN B B, 1990, P187; HOUBEN H, 1982, CLIN PHARMACOL THER, V31, P685, DOI 10.1038/clpt.1982.96; MACKIE K, 1991, J CLIN MONITOR, V7, P213, DOI 10.1007/BF01619262; MALTBAEK N, 1984, ACTA MED SCAND S677, V215, P21; REEVES RA, 1984, CLIN PHARMACOL THER, V35, P461, DOI 10.1038/clpt.1984.60; Smith TW, 1988, HEART DIS, P524; VANZWIETEN PA, 1990, CARDIOVASCULAR PHARM, P1; WHELAN TV, 1987, ANN INTERN MED, V106, P327, DOI 10.7326/0003-4819-106-2-327_1	12	1	1	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 20	1995	274	23					1830	&		10.1001/jama.274.23.1830	http://dx.doi.org/10.1001/jama.274.23.1830			0	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK147	7500521				2022-12-24	WOS:A1995TK14700007
J	ROMAO, MJ; ARCHER, M; MOURA, I; MOURA, JJG; LEGALL, J; ENGH, R; SCHNEIDER, M; HOF, P; HUBER, R				ROMAO, MJ; ARCHER, M; MOURA, I; MOURA, JJG; LEGALL, J; ENGH, R; SCHNEIDER, M; HOF, P; HUBER, R			CRYSTAL-STRUCTURE OF THE XANTHINE OXIDASE-RELATED ALDEHYDE OXIDOREDUCTASE FROM D-GIGAS	SCIENCE			English	Article							DESULFOVIBRIO-GIGAS; ELECTRON-TRANSFER; MOLYBDENUM COFACTOR; PULSE-RADIOLYSIS; DEHYDROGENASE; PROTEIN; MECHANISM; OXIDOREDUCTASE; EXAFS; CRYSTALLIZATION	The crystal structure of the aldehyde oxido-reductase (Mop) from the sulfate reducing anaerobic Gram-negative bacterium Desulfovibrio gigas has been determined at 2.25 Angstrom resolution by multiple isomorphous replacement and refined. The protein, a homodimer of 907 amino acid residues subunits, is a member of the xanthine oxidase family. The protein contains a molybdopterin cofactor (Mo-co) and two different [2Fe-2S] centers. It is folded into four domains of which the first two bind the iron sulfur centers and the last two are involved in Mo-co binding, Mo-co is a molybdenum molybdopterin cytosine dinucleotide. Molybdopterin forms a tricyclic system with the pterin bicycle annealed to a pyran ring. The molybdopterin dinucleotide is deeply buried in the protein, The cis-dithiolene group of the pyran ring binds the molybdenum, which is coordinated by three more (oxygen) ligands.	MAX PLANCK INST BIOCHEM, D-82152 MARTINSRIED, GERMANY; INST TECNOL QUIM & BIOQUIM, P-2780 OEIRAS, PORTUGAL; DEPT QUIM, P-1096 LISBON, PORTUGAL; UNIV NOVA LISBOA, DEPT QUIM, P-2825 MONTE DE CAPARICA, PORTUGAL; UNIV NOVA LISBOA, FAC CIENCIAS & TECNOL, CQFB, P-2825 MONTE DE CAPARICA, PORTUGAL; UNIV GEORGIA, DEPT BIOCHEM & MOLEC BIOL, ATHENS, GA 30602 USA	Max Planck Society; Universidade Nova de Lisboa; Universidade Nova de Lisboa; University System of Georgia; University of Georgia			Moura, Isabel/D-6339-2013; Moura, José J G/D-6426-2013; Romao, Maria J/A-4115-2013; UCIBIO, U Cienc Biom Apl/F-7948-2017	Moura, Isabel/0000-0003-0971-4977; Moura, José J G/0000-0002-4726-2388; Romao, Maria J/0000-0002-3004-0543; UCIBIO, U Cienc Biom Apl/0000-0002-3004-0543; Archer, Margarida/0000-0001-8419-5420; Engh, Richard/0000-0002-6207-0560				BARATA BAS, 1992, EUR J BIOCHEM, V204, P773, DOI 10.1111/j.1432-1033.1992.tb16693.x; BARATA BAS, 1993, BIOCHEMISTRY-US, V32, P11559, DOI 10.1021/bi00094a012; Bray R. C., 1980, BIOL MAGN RESON, V2, P45; BRAY RC, 1982, BIOCHEMISTRY-US, V21, P5992, DOI 10.1021/bi00266a041; BRUNGER AT, 1990, X PLOR VERSION 2 1 M; CALDEIRA J, 1995, J INORG BIOCHEM, V59, P739; CHAN MK, 1995, SCIENCE, V267, P1463, DOI 10.1126/science.7878465; CRAMER SP, 1981, J AM CHEM SOC, V103, P7721, DOI 10.1021/ja00416a005; CRAMER SP, 1985, J AM CHEM SOC, V107, P8164, DOI 10.1021/ja00312a059; CRAMER SP, 1984, J INORG BIOCHEM, V20, P275, DOI 10.1016/0162-0134(84)85026-6; DUGGAN DE, 1975, J MED CHEM, V18, P900, DOI 10.1021/jm00243a008; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FUKUYAMA K, 1980, NATURE, V286, P522, DOI 10.1038/286522a0; GREENWOOD RJ, 1993, J AM CHEM SOC, V115, P5385, DOI 10.1021/ja00066a005; GUTTERIDGE S, 1978, BIOCHEM J, V175, P887, DOI 10.1042/bj1750887; HABER R, 1994, ACTA CRYSTALLOGR D, V50, P760; Hille R., 1985, Metal Ions in Biology, V7, P443; HILLE R, 1993, ACS SYM SER, V535, P22; HILLE R, 1991, J BIOL CHEM, V266, P5608; HILLE R, 1987, J BIOL CHEM, V262, P10914; HILLE R, 1984, J BIOL CHEM, V259, P1570; HILLE R, 1982, J BIOL CHEM, V257, P8898; HUNT J, 1993, J BIOL CHEM, V268, P18685; JOHNSON JL, 1990, ARCH BIOCHEM BIOPHYS, V283, P542, DOI 10.1016/0003-9861(90)90681-N; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KEITH TP, 1987, GENETICS, V116, P67; KOBAYASHI K, 1993, J BIOL CHEM, V268, P24642; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MASSEY V, 1970, J BIOL CHEM, V245, P6595; MEYER O, 1993, ACS SYM SER, V535, P50; MOURA JJG, 1978, BIOCHEM J, V173, P419, DOI 10.1042/bj1730419; NISHINO T, 1989, J BIOL CHEM, V264, P5468; OERTLING WA, 1990, J BIOL CHEM, V265, P17446; RAJAGOPALAN KV, 1993, ACS SYM SER, V535, P38; RAJAGOPALAN KV, 1991, ADV ENZYMOL RAMB, V64, P215; ROMAO MJ, 1993, EUR J BIOCHEM, V215, P729, DOI 10.1111/j.1432-1033.1993.tb18085.x; RYPNIEWSKI WR, 1991, BIOCHEMISTRY-US, V30, P4126, DOI 10.1021/bi00231a003; SPENCE JT, 1982, BIOCHEMISTRY-US, V21, P1656, DOI 10.1021/bi00536a028; Steigemann W., 1974, THESIS TU MUNCHEN GE; STIEFEL EI, 1993, ACS SYM SER, V535, P1; THOENES U, 1994, EUR J BIOCHEM, V220, P901, DOI 10.1111/j.1432-1033.1994.tb18693.x; Turk D., 1992, THESIS TU MUNCHEN GE; TURNER N, 1987, BIOCHEM J, V243, P755, DOI 10.1042/bj2430755; TURNER NA, 1989, BIOCHEM J, V260, P563, DOI 10.1042/bj2600563; WALKER MC, 1991, BIOCHEMISTRY-US, V30, P5912, DOI 10.1021/bi00238a015; WOOTTON JC, 1991, BIOCHIM BIOPHYS ACTA, V1057, P157, DOI 10.1016/S0005-2728(05)80100-8; ZHIGUONG X, 1992, J AM CHEM SOC, V114, P9194; 1994, 4 COLL COMP PROJ	49	457	461	0	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 17	1995	270	5239					1170	1176						7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE905	7502041				2022-12-24	WOS:A1995TE90500047
J	DOBSON, S; SCHEIFELE, D; BELL, A				DOBSON, S; SCHEIFELE, D; BELL, A			ASSESSMENT OF A UNIVERSAL, SCHOOL-BASED HEPATITIS-B VACCINATION PROGRAM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To assess a hepatitis B vaccination program offered to all grade 6 students in British Columbia in 1992. Design.-Cohort study. Setting.-British Columbia, Canada. Participants.-All grade 6 students were offered vaccine. Subsets of 454 and 259 students participated in studies of minor adverse events and seroresponse, respectively. Intervention.-The vaccine used was Engerix-B, 20 mu g, given at intervals of 0, 1, and 6 months. Main Outcome Measures.-Province-wide acceptance and series completion rates and reports of severe adverse events. Minor adverse events and immunogenicity in subsamples. Results.-A total of 127 922 vaccine doses were administered. initial enrollment totaled 43 358 students or 95.4% of those eligible. The series was completed by 41 594 students (95.6%). Minor adverse events were infrequent in the cohort assessed: no absenteeism or physician visits resulted from vaccination. Sixty-nine reported severe adverse events met surveillance definitions, the major categories being injection site reactions (23% of reports), fainting (20%), and rashes (17%). There was one instance of anaphylaxis. Only 13 of these events resulted in recommendations to discontinue the series. Of students tested following the series, 98% had levels of antibody to hepatitis B surface antigen considered to be protective (greater than or equal to 10 IU/L), the geometric mean titer being 690 IU/L (95% confidence interval, 498 to 957 IU/J). Conclusion.-Our experience indicates that school-based programs for universal vaccination of preadolescents can be highly acceptable and efficient.	BRITISH COLUMBIA CTR DIS CONTROL, DIV EPIDEMIOL, VANCOUVER, BC, CANADA		DOBSON, S (corresponding author), BRITISH COLUMBIA CHILDRENS HOSP, CTR VACCINE EVALUAT, 4500 OAK ST, ROOM L427, VANCOUVER, BC V5Z 4H4, CANADA.			Scheifele, David/0000-0001-6078-7843				ALTER MJ, 1990, JAMA-J AM MED ASSOC, V263, P1218, DOI 10.1001/jama.263.9.1218; ANDRE FE, 1989, AM J MED, V87, pS14, DOI 10.1016/0002-9343(89)90525-1; [Anonymous], 1991, MMWR Recomm Rep, V40, P1; DELAGE G, 1992, CAN FAM PHYSICIAN, V38, P2656; HALL CB, 1992, PEDIATRICS, V89, P795; HUTTON F, 1993, BC HLTH DIS SURVEILL, V2, P2; SCHIFF GM, 1995, J ADOLESCENT HEALTH, V16, P12, DOI 10.1016/1054-139X(94)00105-N; WEST DJ, 1989, AM J INFECT CONTROL, V17, P172, DOI 10.1016/0196-6553(89)90213-7; WONG VK, 1994, PEDIATR INFECT DIS J, V13, P936, DOI 10.1097/00006454-199410000-00019; 1995, INFECT DIS CHILD, V8, P14; 1994, MMWR-MORBID MORTAL W, V43, P605; 1991, CAN DIS WKLY REP, V17, P165; 1992, CAN MED ASSOC J, V146, P25; 1994, CAN COMMUN DIS REP, V20, P105	14	69	69	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 18	1995	274	15					1209	1213		10.1001/jama.274.15.1209	http://dx.doi.org/10.1001/jama.274.15.1209			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ120	7563510				2022-12-24	WOS:A1995RZ12000029
J	RICKERT, RC; RAJEWSKY, K; ROES, J				RICKERT, RC; RAJEWSKY, K; ROES, J			IMPAIRMENT OF T-CELL-DEPENDENT B-CELL RESPONSES AND B-1 CELL-DEVELOPMENT IN CD19-DEFICIENT MICE	NATURE			English	Article							COMPLEMENT RECEPTOR TYPE-2; HUMAN LYMPHOCYTES-B; ANTIGEN RECEPTOR; IMMUNE-RESPONSE; ANTIBODY; INVIVO; CD19; LIGANDS; GROWTH; IGM	CD19 is the hallmark differentiation antigen of the B lineage. Its early expression has implicated a role for CD19 during the antigen-independent phases of B-cell development, whereas in mature B cells CD19 can act synergistically with surface immunoglobulin to induce activation(1). We have generated CD19-deficient mice and found that development of conventional B cells is unperturbed. However, mature CD19(-/-) B cells show a profound deficiency in responding to protein antigens that require T-cell help. This is accompanied by a lack of germinal centre formation and affinity maturation of serum antibodies. Thus CD19 is crucial for both initial B-cell activation by T-cell-dependent antigens and the maturation and/or selection of the activated cells into the memory compartment. An impairment in ligand-driven selection may also be responsible for the observation of a striking reduction in the B-1 (formerly Ly-1) B-cell subset, thought to develop under the control of self-antigens and bacterial antigens (reviewed in ref. 2).			RICKERT, RC (corresponding author), UNIV COLOGNE,INST GENET,WEYERTAL 121,D-50931 COLOGNE,GERMANY.			Rajewsky, Klaus/0000-0002-6633-6370; Roes, Jurgen/0000-0003-3235-2345				BOHNSACK JF, 1988, J IMMUNOL, V141, P2569; BRADBURY LE, 1992, J IMMUNOL, V149, P2841; CARTER RH, 1992, SCIENCE, V256, P105, DOI 10.1126/science.1373518; CARTER RH, 1988, J IMMUNOL, V141, P457; CARTER RH, 1989, J IMMUNOL, V143, P1755; CUMANO A, 1986, EMBO J, P2459; FEARON DT, 1993, CURR OPIN IMMUNOL, V5, P341, DOI 10.1016/0952-7915(93)90051-S; FORSTER I, 1987, EUR J IMMUNOL, V17, P521, DOI 10.1002/eji.1830170414; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; HARDY RR, 1994, ADV IMMUNOL, V55, P297; HEBELL T, 1991, SCIENCE, V254, P102, DOI 10.1126/science.1718035; HEYMAN B, 1990, J EXP MED, V172, P665, DOI 10.1084/jem.172.2.665; HEYMAN B, 1994, NEW ASPECTS COMPLEME, P59; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; JUNG S, 1993, SCIENCE, V259, P984, DOI 10.1126/science.8438159; LIU Y, 1991, INT IMMUNOL, V3, P323, DOI 10.1093/intimm/3.4.323; MATSUMOTO AK, 1991, J EXP MED, V173, P55, DOI 10.1084/jem.173.1.55; MCHEYZERWILLIAM.MG, 1993, J EXP MED, V178, P295; MELCHERS F, 1985, NATURE, V317, P264, DOI 10.1038/317264a0; MERCOLINO TJ, 1988, J EXP MED, V168, P687, DOI 10.1084/jem.168.2.687; RETH M, 1978, EUR J IMMUNOL, V8, P393, DOI 10.1002/eji.1830080605; ROES J, 1993, J EXP MED, V177, P45, DOI 10.1084/jem.177.1.45; TEDDER TE, 1994, IMMUNOL TODAY, V15, P437, DOI 10.1016/0167-5699(94)90274-7; THYPHRONITIS G, 1991, J IMMUNOL, V147, P224; TORRES R, IN PRESS COLOGNE GUI; TSOKOS GC, 1990, J IMMUNOL, V144, P1640; VANNOESEL CJM, 1993, IMMUNOL TODAY, V14, P8, DOI 10.1016/0167-5699(93)90316-D; WELLS SM, 1994, J IMMUNOL, V153, P5503; ZHOU LJ, 1992, IMMUNOGENETICS, V35, P102, DOI 10.1007/BF00189519	29	573	590	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 27	1995	376	6538					352	355		10.1038/376352a0	http://dx.doi.org/10.1038/376352a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL443	7543183				2022-12-24	WOS:A1995RL44300050
J	KANNO, K; SASAKI, S; HIRATA, Y; ISHIKAWA, S; FUSHIMI, K; NAKANISHI, S; BICHET, DG; MARUMO, F				KANNO, K; SASAKI, S; HIRATA, Y; ISHIKAWA, S; FUSHIMI, K; NAKANISHI, S; BICHET, DG; MARUMO, F			URINARY-EXCRETION OF AQUAPORIN-2 IN PATIENTS WITH DIABETES-INSIPIDUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							KIDNEY COLLECTING TUBULE; WATER CHANNEL; RECEPTOR GENE; RAT-KIDNEY; VASOPRESSIN; MUTATIONS; CELLS; PERMEABILITY; ENDOSOMES	Background. Urine-concentrating ability is regulated by vasopressin. Recently, the specific water-channel protein of the renal collecting duct, known as aquaporin-2, was cloned. However, it is not certain whether this molecule is responsive to vasopressin. Methods. We measured the urinary excretion of aquaporin-2 and its response to vasopressin in 11 normal subjects and 9 patients with central or nephrogenic diabetes insipidus. The urine samples were collected during periods of dehydration and hydration and after the administration of vasopressin. Urine samples were analyzed for aquaporin-2 by the Western blot assay and immunogold labeling, and the amount of aquaporin-2 was determined by radioimmunoassay. Results. Aquaporin-2 was detectable in the urine in both soluble and membrane-bound forms. In the five normal subjects tested, the mean (+/-SE) urinary excretion of aquaporin-2 was 11.2+/-2.2 pmol per milligram of creatinine after a period of dehydration, and it decreased to 3.9+/-1.9 pmol per milligram of creatinine (P=0.03) during the second hour after a period of hydration. In the six other normal subjects, an infusion of desmopressin (1-desamino-8-D-arginine vasopressin) increased the urinary excretion of aquaporin-2 from 0.8+/-0.3 to 11.2+/-1.6 pmol per milligram of creatinine (P<0.001). The five patients with central diabetes insipidus also had increases in urinary excretion of aquaporin-2 in response to the administration of vasopressin, but the four patients with X-linked or non-X-linked nephrogenic diabetes insipidus did not. Conclusions. Aquaporin-2 is detectable in the urine, and changes in the urinary excretion of this protein can be used as an index of the action of vasopressin on the kidney.	TOKYO MED & DENT UNIV,SCH MED,DEPT INTERNAL MED 2,BUNKYO KU,TOKYO 113,JAPAN; JICHI MED SCH,DEPT ENDOCRINOL & METAB,MINAMI KAWACHI,TOCHIGI,JAPAN; JT INC,CENT PHARMACEUT RES INST,PHARMACEUT BASIC RES LABS,KANAGAWA,JAPAN; UNIV MONTREAL,HOP SACRE COEUR,CTR RECH,MONTREAL,PQ,CANADA	Tokyo Medical & Dental University (TMDU); Jichi Medical University; Universite de Montreal			Nakanishi, Setsuko/G-5871-2015	Nakanishi, Setsuko/0000-0003-4909-2113				AGRE P, 1993, AM J PHYSIOL, V265, pF463; AGRE P, 1993, AM J PHYSIOL, V265, pF461, DOI 10.1152/ajprenal.1993.265.3.F461; BICHET DG, 1993, J CLIN INVEST, V92, P1262, DOI 10.1172/JCI116698; BICHET DG, 1988, NEW ENGL J MED, V318, P881, DOI 10.1056/NEJM198804073181403; BROWN D, 1989, AM J PHYSIOL, V256, pF1, DOI 10.1152/ajprenal.1989.256.1.F1; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; DIGIOVANNI SR, 1994, P NATL ACAD SCI USA, V91, P8984, DOI 10.1073/pnas.91.19.8984; FUSHIMI K, 1994, AM J PHYSIOL-RENAL, V267, pF573, DOI 10.1152/ajprenal.1994.267.4.F573; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; HANDLER JS, 1988, AM J PHYSIOL, V255, pF375, DOI 10.1152/ajprenal.1988.255.3.F375; HARRIS HW, 1991, J CLIN INVEST, V88, P1, DOI 10.1172/JCI115263; HAYASHI M, 1994, J CLIN INVEST, V94, P1778, DOI 10.1172/JCI117525; HIRATA Y, 1988, BIOCHEM BIOPH RES CO, V154, P868, DOI 10.1016/0006-291X(88)90220-3; LANGLEY JM, 1991, AM J MED GENET, V38, P90, DOI 10.1002/ajmg.1320380120; Lonergan Michele, 1993, Journal of the American Society of Nephrology, V4, P264; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P11663, DOI 10.1073/pnas.90.24.11663; PAN Y, 1992, NAT GENET, V2, P103, DOI 10.1038/ng1092-103; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1994, SCIENCE, V265, P1585, DOI 10.1126/science.7521540; ROSENTHAL W, 1992, NATURE, V359, P233, DOI 10.1038/359233a0; SASAKI S, 1994, J CLIN INVEST, V93, P1250, DOI 10.1172/JCI117079; SASAKI S, 1994, J CLIN INVEST, V94, P216; SHI LB, 1990, J GEN PHYSIOL, V96, P789, DOI 10.1085/jgp.96.4.789; UCHIDA S, 1994, J BIOL CHEM, V269, P23451; VANDENOUWELAND AMW, 1992, NAT GENET, V2, P99, DOI 10.1038/ng1092-99; VANLIEBURG AF, 1994, AM J HUM GENET, V55, P648; VERKMAN AS, 1989, AM J PHYSIOL, V257, pC837, DOI 10.1152/ajpcell.1989.257.5.C837; VERKMAN AS, 1988, NATURE, V333, P268, DOI 10.1038/333268a0; Wade J B, 1981, Ann N Y Acad Sci, V372, P106, DOI 10.1111/j.1749-6632.1981.tb15464.x	29	237	244	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 8	1995	332	23					1540	1545		10.1056/NEJM199506083322303	http://dx.doi.org/10.1056/NEJM199506083322303			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB196	7537863	Bronze			2022-12-24	WOS:A1995RB19600003
J	SPENCE, RA; KATI, WM; ANDERSON, KS; JOHNSON, KA				SPENCE, RA; KATI, WM; ANDERSON, KS; JOHNSON, KA			MECHANISM OF INHIBITION OF HIV-1 REVERSE-TRANSCRIPTASE BY NONNUCLEOSIDE INHIBITORS	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PYRIDINONE DERIVATIVES; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; KINETIC-ANALYSIS; ZIDOVUDINE AZT; BINDING-SITE; AIDS VIRUS; TYPE-1; DNA	The mechanism of inhibition of HIV-1 reverse transcriptase by three nonnucleoside inhibitors is described. Nevirapine, O-TIBO, and Cl-TIBO each bind to a hydrophobic pocket in the enzyme-DNA complex close to the active site catalytic residues. Pre-steady-state kinetic analysis was used to establish the mechanism of inhibition by these noncompetitive inhibitors. Analysis of the pre-steady-state burst of DNA polymerization indicated that inhibitors blocked the chemical reaction, but did not interfere with nucleotide binding or the nucleotide-induced conformational change. Rather, in the presence of saturating concentrations of the inhibitors, the nucleoside triphosphate bound tightly (K-d, 100 nM), but nonproductively. The data suggest that an inhibitor combining the functionalities of a nonnucleoside inhibitor and a nucleotide analog could bind very lightly and specifically to reverse transcriptase and could be effective in the treatment of AIDS.	PENN STATE UNIV, DEPT BIOCHEM & MOLEC BIOL, UNIVERSITY PK, PA 16802 USA; ABBOTT LABS, DEPT ANTIINFECT RES, ABBOTT PK, IL 60064 USA; YALE UNIV, SCH MED, DEPT PHARMACOL, NEW HAVEN, CT 06510 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Abbott Laboratories; Yale University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049551, R01GM044613] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM084741, GM49551, GM44613] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTHAUS IW, 1993, J BIOL CHEM, V268, P6119; ANDERSON KS, 1988, BIOCHEMISTRY-US, V27, P7395, DOI 10.1021/bi00419a034; BALZARINI J, 1993, VIROLOGY, V192, P246, DOI 10.1006/viro.1993.1027; CARROLL SS, 1993, J BIOL CHEM, V268, P276; COHEN KA, 1991, J BIOL CHEM, V266, P14670; DEBYSER Z, 1991, P NATL ACAD SCI USA, V88, P1451, DOI 10.1073/pnas.88.4.1451; DECLERCQ E, 1994, BIOCHEM PHARMACOL, V47, P155, DOI 10.1016/0006-2952(94)90001-9; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; DUEWEKE TJ, 1993, P NATL ACAD SCI USA, V90, P4713, DOI 10.1073/pnas.90.10.4713; FRANK KB, 1991, J BIOL CHEM, V266, P14232; GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817; GOLDMAN ME, 1991, P NATL ACAD SCI USA, V88, P6863, DOI 10.1073/pnas.88.15.6863; GOPALAKRISHNAN V, 1994, J BIOL CHEM, V269, P4110; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; JOHNSON KA, 1986, METHOD ENZYMOL, V134, P677; JOHNSTON L, 1992, INT J SOCIOL LAW, V20, P1; KATI WM, 1992, J BIOL CHEM, V267, P25988; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1992, ANTIMICROB AGENTS CH, V36, P2664, DOI 10.1128/AAC.36.12.2664; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; LOWE DM, 1991, FEBS LETT, V282, P231, DOI 10.1016/0014-5793(91)80484-K; MELLORS JW, 1992, MOL PHARMACOL, V41, P446; MELLORS JW, 1993, MOL PHARMACOL, V43, P11; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273; MULLER B, 1989, J BIOL CHEM, V264, P13975; NUNBERG JH, 1991, J VIROL, V65, P4887, DOI 10.1128/JVI.65.9.4887-4892.1991; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; RICHMAN D, 1991, ANTIMICROB AGENTS CH, V35, P305, DOI 10.1128/AAC.35.2.305; RICHMAN D, 1991, P NATL ACAD SCI USA, V88, P11241, DOI 10.1073/pnas.88.24.11241; RICHMAN DD, 1990, J ACQ IMMUN DEF SYND, V3, P743; RICHMAN DD, 1994, J VIROL, V68, P1660, DOI 10.1128/JVI.68.3.1660-1666.1994; RITTINGER K, UNPUB; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; STEITZ TA, 1993, CURR OPIN STRUC BIOL, V3, P31, DOI 10.1016/0959-440X(93)90198-T; TAYLOR PB, 1994, J BIOL CHEM, V269, P6325; TRAMONTANO E, 1992, BIOCHEM PHARMACOL, V43, P1371; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030; WU JC, 1991, BIOCHEMISTRY-US, V30, P2022, DOI 10.1021/bi00222a003; YARCHOAN R, 1989, NEW ENGL J MED, V321, P726, DOI 10.1056/NEJM198909143211106	47	426	445	1	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 17	1995	267	5200					988	993		10.1126/science.7532321	http://dx.doi.org/10.1126/science.7532321			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG990	7532321	Green Accepted			2022-12-24	WOS:A1995QG99000028
J	GHOSH, G; VANDUYNE, G; GHOSH, S; SIGLER, PB				GHOSH, G; VANDUYNE, G; GHOSH, S; SIGLER, PB			STRUCTURE OF NF-KAPPA-B P50 HOMODIMER BOUND TO A KAPPA-B SITE	NATURE			English	Article							DNA-BINDING SUBUNIT; CRYSTAL-STRUCTURE; PROTEIN MODELS; COGNATE DNA; REL; INHIBITION; ACTIVATION; COMPLEX; ERRORS; MOTIF	The 2.3-Angstrom crystal structure of the transcription factor NF-kappa B p50 homodimer bound to a palindromic kappa B site reveals that the Rel homology region folds into two distinct domains, similar to those in the immunoglobulin superfamily. The p50 dimer envelopes an undistorted B-DNA helix, making specific contacts along the 10-base-pair kappa B recognition site mainly through loops connecting secondary structure elements in both domains. The carboxy-terminal domains form a dimerization interface between beta-sheets using residues that are strongly conserved in the Rel family.	YALE UNIV, HOWARD HUGHES MED INST, NEW HAVEN, CT 06510 USA; YALE UNIV, DEPT MOLEC BIOPHYS & BIOCHEM, NEW HAVEN, CT 06510 USA; YALE UNIV, IMMUNOBIOL SECT, NEW HAVEN, CT 06510 USA	Howard Hughes Medical Institute; Yale University; Yale University; Yale University								BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BRESSLER P, 1993, J VIROL, V67, P288, DOI 10.1128/JVI.67.1.288-293.1993; BROWNELL E, 1989, ONCOGENE, V4, P935; BRUNGER AT, 1993, XPLOR VERSION 3 1 SY; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DIMITRIS T, 1992, CELL, V71, P777; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GRILLI M, 1993, INT REV CYTOL, V143, P1; HARPAZ Y, 1994, J MOL BIOL, V238, P528, DOI 10.1006/jmbi.1994.1312; HULTMARK D, 1994, NATURE, V367, P116, DOI 10.1038/367116a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KOPP E, 1994, ADV IMMUNOL, V58, P1; KUMAR S, 1993, P NATL ACAD SCI USA, V90, P8962, DOI 10.1073/pnas.90.19.8962; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LIU J, 1994, P NATL ACAD SCI USA, V91, P908, DOI 10.1073/pnas.91.3.908; Liu J, 1994, CHEM BIOL, V1, P47, DOI 10.1016/1074-5521(94)90040-X; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; TOLEDANO MB, 1993, MOL CELL BIOL, V13, P852, DOI 10.1128/MCB.13.2.852; TONY Y, 1993, CELL, V75, P753; VANROEY P, 1989, P NATL ACAD SCI USA, V86, P6587, DOI 10.1073/pnas.86.17.6587; WINKLER FK, 1993, EMBO J, V12, P1781, DOI 10.1002/j.1460-2075.1993.tb05826.x; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P	39	506	532	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 26	1995	373	6512					303	310		10.1038/373303a0	http://dx.doi.org/10.1038/373303a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD404	7530332				2022-12-24	WOS:A1995QD40400048
J	HAY, RJ				HAY, RJ			SICK LIBRARY SYNDROME	LANCET			English	Editorial Material							MYCOTOXINS				HAY, RJ (corresponding author), GUYS HOSP,ST JOHNS INST DERMATOL,LONDON,ENGLAND.							BHAT RV, 1977, INDIAN J MED RES, V66, P55; BROOK SJ, 1994, J CLIN EPIDEMIOL, V47, P1171; CROFT WA, 1986, ATMOS ENVIRON, V20, P549, DOI 10.1016/0004-6981(86)90096-X; HENDRY KM, 1993, J TOXICOL ENV HEALTH, V38, P183, DOI 10.1080/15287399309531711; HUXLEY A, 1962, ISLAND, P140; LEON FE, 1995, J CLIN EPIDEMIOL, V48, P1183, DOI 10.1016/0895-4356(95)00006-P; NORTHRUP SC, 1978, ENCY HDB, V3, P91; SMORAGIEWICZ W, 1993, INT ARCH OCC ENV HEA, V65, P113, DOI 10.1007/BF00405729	8	3	3	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 16	1995	346	8990					1573	1574		10.1016/S0140-6736(95)91925-2	http://dx.doi.org/10.1016/S0140-6736(95)91925-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK481	7500747	Bronze			2022-12-24	WOS:A1995TK48100006
J	WAGNER, RL; APRILETTI, JW; MCGRATH, ME; WEST, BL; BAXTER, JD; FLETTERICK, RJ				WAGNER, RL; APRILETTI, JW; MCGRATH, ME; WEST, BL; BAXTER, JD; FLETTERICK, RJ			A STRUCTURAL ROLE FOR HORMONE IN THE THYROID-HORMONE RECEPTOR	NATURE			English	Article							V-ERBA; ESTROGEN-RECEPTOR; NUCLEAR RECEPTOR; DNA-BINDING; C-ERBA; SUPERFAMILY; REFINEMENT; ACTIVATION; MODEL	The crystal structure of the rat a, thyroid hormone receptor ligand-binding domain bound with a thyroid hormone agonist reveals that ligand is completely buried within the domain as part of the hydrophobic core. In addition, the carboxy-terminal activation domain forms an amphipathic helix, with its hydrophobic face constituting part of the hormone binding cavity. These observations suggest a structural role for ligand, in establishing the active conformation of the receptor, that is likely to underlie hormonal regulation of gene expression for the nuclear receptors.	UNIV CALIF SAN FRANCISCO, METAB RES UNIT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; KHEPRI PHARMACEUT INC, San Francisco, CA 94080 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	WAGNER, RL (corresponding author), UNIV CALIF SAN FRANCISCO, GRAD GRP BIOPHYS, SAN FRANCISCO, CA 94143 USA.		Wood, David W/B-2992-2012	West, Brian/0000-0002-5320-3691				APRILETTI JW, 1995, PROTEIN EXPRES PURIF, V6, P363, DOI 10.1006/prep.1995.1048; AUFLIEGNER M, 1993, MOL CELL BIOL, V13, P5725, DOI 10.1128/MCB.13.9.5725; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BENDIK I, 1995, J BIOL CHEM, V270, P3107, DOI 10.1074/jbc.270.7.3107; BHAT MK, 1995, BIOCHEM BIOPH RES CO, V210, P464, DOI 10.1006/bbrc.1995.1683; BLAKE CCF, 1977, NATURE, V268, P115, DOI 10.1038/268115a0; BLAKE CCF, 1978, J MOL BIOL, V121, P339, DOI 10.1016/0022-2836(78)90368-6; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; CHATTERJEE VKK, 1994, J CLIN ENDOCR METAB, V78, P990, DOI 10.1210/jcem.78.4.8157732; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jorgensen E.C., 1978, Hormonal Proteins and Peptides, V6, P107; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LATHAM KR, 1981, J BIOL CHEM, V256, P2088; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LENG XH, 1995, MOL CELL BIOL, V15, P255, DOI 10.1128/MCB.15.1.255; LIN KH, 1991, MOL ENDOCRINOL, V5, P485, DOI 10.1210/mend-5-4-485; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MCGRATH ME, 1994, J MOL BIOL, V237, P236, DOI 10.1006/jmbi.1994.1224; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; RATINEJAD F, 1995, NATURE, V375, P203; REFETOFF S, 1993, ENDOCR REV, V14, P348, DOI 10.1210/er.14.3.348; RIBEIRO RC, 1992, MOL ENDOCRINOL, V6, P1142, DOI 10.1210/me.6.7.1142; RIBEIRO RCJ, 1995, ANN NY ACAD SCI, V758, P366, DOI 10.1111/j.1749-6632.1995.tb24843.x; RIBEIRO RCJ, 1995, ANNU REV MED, V46, P443, DOI 10.1146/annurev.med.46.1.443; SAATCIOGLU F, 1993, MOL CELL BIOL, V13, P3675, DOI 10.1128/MCB.13.6.3675; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; SELMI S, 1991, J BIOL CHEM, V266, P11589; TONE Y, 1994, J BIOL CHEM, V269, P31157; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P	49	771	795	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 14	1995	378	6558					690	697		10.1038/378690a0	http://dx.doi.org/10.1038/378690a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK379	7501015				2022-12-24	WOS:A1995TK37900043
J	BACH, EA; SZABO, SJ; DIGHE, AS; ASHKENAZI, A; AGUET, M; MURPHY, KM; SCHREIBER, RD				BACH, EA; SZABO, SJ; DIGHE, AS; ASHKENAZI, A; AGUET, M; MURPHY, KM; SCHREIBER, RD			LIGAND-INDUCED AUTOREGULATION OF IFN-GAMMA RECEPTOR-BETA CHAIN EXPRESSION IN T-HELPER CELL SUBSETS	SCIENCE			English	Article							INTERFERON-GAMMA; IDENTIFICATION; ANTIBODIES	Interferon gamma (IFN-gamma) responsiveness in certain cells depends on the state of cellular differentiation or activation. Here an in vitro developmental system was used to show that IFN-gamma produced during generation of the CD4(+) T helper cell type 1 (T(H)1) subset extinguishes expression of the IFN-gamma receptor beta subunit, resulting in T(H)1 cells that are unresponsive to IFN-gamma. This beta chain loss also occurred in IFN-gamma-treated T(H)2 cells and thus represents a specific response of CD4(+) T cells to IFN-gamma rather than a T(H)1-specific differentiation event. These results define a mechanism of cellular desensitization where a cytokine down-regulates expression of a receptor subunit required primarily for signaling and not ligand binding.	WASHINGTON UNIV,SCH MED,CTR IMMUNOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; GENENTECH INC,DEPT MOLEC BIOL,S SAN FRANCISCO,CA 94080	Washington University (WUSTL); Washington University (WUSTL); Roche Holding; Genentech			Dighe, Anand/AAP-9640-2020; Ashkenazi, Avi/ABG-2712-2020; Schreiber, Robert D/A-1276-2013; Schreiber, Robert/Q-7550-2019	Ashkenazi, Avi/0000-0002-6890-4589; Schreiber, Robert D/0000-0001-6311-0432; Schreiber, Robert/0000-0003-1590-2341; Dighe, Anand/0000-0003-4130-0758; Bach, Erika/0000-0002-5997-4489				BACH E, UNPUB; FARRAR MA, 1991, J BIOL CHEM, V266, P19626; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; FARRAR MA, 1992, P NATL ACAD SCI USA, V89, P11706, DOI 10.1073/pnas.89.24.11706; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; HEMMI S, 1994, CELL, V76, P803, DOI 10.1016/0092-8674(94)90355-7; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; LECLAIRE RD, 1992, J LEUKOCYTE BIOL, V51, P507, DOI 10.1002/jlb.51.5.507; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P5401; PEREZ VL, 1995, INT IMMUNOL, V7, P869, DOI 10.1093/intimm/7.5.869; PERNIS A, 1995, SCIENCE, V269, P245, DOI 10.1126/science.7618088; REINER SL, 1994, J EXP MED, V179, P447, DOI 10.1084/jem.179.2.447; SCHREIBER RD, 1994, GUIDEBOOK CYTOKINES, P120; SHEEHAN KCF, 1989, J IMMUNOL, V142, P3884; SOH J, 1994, CELL, P796; SZABO SJ, 1995, IMMUNITY, V2, P665, DOI 10.1016/1074-7613(95)90011-X	18	194	195	0	9	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 17	1995	270	5239					1215	1218		10.1126/science.270.5239.1215	http://dx.doi.org/10.1126/science.270.5239.1215			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE905	7502050				2022-12-24	WOS:A1995TE90500062
J	FISHER, RP; JIN, P; CHAMBERLIN, HM; MORGAN, DO				FISHER, RP; JIN, P; CHAMBERLIN, HM; MORGAN, DO			ALTERNATIVE MECHANISMS OF CAK ASSEMBLY REQUIRE AN ASSEMBLY FACTOR OR AN ACTIVATING KINASE	CELL			English	Article							MYC TRANSGENIC MICE; ZINC-FINGER; VIRUS TYPE-1; CATALYTIC SUBUNIT; PROTEIN-KINASE; COILED COILS; RING FINGER; IDENTIFICATION; MOTIF; PURIFICATION	We have cloned a mouse cDNA that encodes p36, a novel subunit of the CDK-activating kinase (CAK). p36 contains a C3HC4 zinc-binding domain or RING finger and is associated both with a TFIIH-bound form of CAK and with a free trimeric form. p36 promotes the assembly of CDK7 and cyclin H in vitro, stabilizing the transient CDK7-cyclin H complex. Stabilization and activation of CAK by p36 is independent of the phosphorylation state of T170, the conserved activating residue of CDK7. Assembly of active CDK7-cyclin H dimers can also occur through an alternative p36-independent pathway that requires phosphorylation of T170 by a CAK-activating kinase, or CAKAK. Thus, CDK7-cyclin H complex formation can be achieved by multiple mechanisms.			FISHER, RP (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, BOX 0444, SAN FRANCISCO, CA 94143 USA.			Morgan, David/0000-0001-8753-4416				BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; BROWN AJ, 1994, MOL BIOL CELL, V5, P921, DOI 10.1091/mbc.5.8.921; CHAN WK, 1991, CHEM ENG PROG, V87, P63; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DESAI D, 1995, MOL CELL BIOL, V15, P345, DOI 10.1128/MCB.15.1.345; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EVERETT RD, 1988, J MOL BIOL, V202, P87, DOI 10.1016/0022-2836(88)90521-9; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; GERBER MR, 1995, P NATL ACAD SCI USA, V92, P4651, DOI 10.1073/pnas.92.10.4651; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GU Y, 1990, NEURON, V5, P147, DOI 10.1016/0896-6273(90)90305-Y; HARLOW E, 1988, ANTIBODIES LABORATOR; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LABBE JC, 1994, EMBO J, V13, P5155, DOI 10.1002/j.1460-2075.1994.tb06845.x; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; LUSTIG KD, 1993, P NATL ACAD SCI USA, V90, P5113, DOI 10.1073/pnas.90.11.5113; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; O'Reilly DR, 1993, BACULOVIRUS EXPRESSI; PATARCA R, 1988, P NATL ACAD SCI USA, V85, P2733, DOI 10.1073/pnas.85.8.2733; POON RYC, 1994, J CELL SCI, V107, P2789; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; REDDY BA, 1991, DEV BIOL, V148, P107, DOI 10.1016/0012-1606(91)90321-S; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; ROSENBLATT J, 1993, J MOL BIOL, V230, P1317, DOI 10.1006/jmbi.1993.1248; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHLEKHATTAR R, 1995, NATURE, V374, P283; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SVEJSTRUP JQ, 1994, J BIOL CHEM, V269, P28044; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; TASSAN JP, 1995, IN PRESS EMBO J; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VONARNIM AG, 1993, J BIOL CHEM, V268, P19626	47	212	215	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 6	1995	83	1					47	57		10.1016/0092-8674(95)90233-3	http://dx.doi.org/10.1016/0092-8674(95)90233-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RY583	7553872	Bronze			2022-12-24	WOS:A1995RY58300009
J	MEREDITH, J; TAKADA, Y; FORNARO, M; LANGUINO, LR; SCHWARTZ, MA				MEREDITH, J; TAKADA, Y; FORNARO, M; LANGUINO, LR; SCHWARTZ, MA			INHIBITION OF CELL-CYCLE PROGRESSION BY THE ALTERNATIVELY SPLICED INTEGRIN BETA(1C)	SCIENCE			English	Article							EXTRACELLULAR-MATRIX; CYTOPLASMIC DOMAIN; BETA-1; EXPRESSION; ADHESION; VARIANT; SUBUNIT; FORM	Integrins regulate cell growth, differentiation, and behavior in many systems. Integrin beta(1C) (beta(1S)) is an alternatively spliced variant of integrin beta(1) with a specific cytoplasmic domain and is expressed in several human tissues. Human beta(1C) transiently expressed in mouse 10T1/2 fibroblasts showed a diffuse pattern of cell surface staining, whereas beta(1) localized to focal adhesions. Moderate concentrations of beta(1C) had no effect on actin stress fibers or focal adhesions, but markedly inhibited DNA synthesis. Inhibition by beta(1C) mapped to the late G(1) phase of the cell cycle, near the G(1)-S boundary. Thus, alternative splicing of beta(1) results in transmission of distinct signals that may regulate growth in vivo.	YALE UNIV, SCH MED, DEPT PATHOL, NEW HAVEN, CT 06520 USA	Yale University	MEREDITH, J (corresponding author), SCRIPPS RES INST, DEPT VASC BIOL, LA JOLLA, CA 92037 USA.			Languino, Lucia/0000-0001-9011-7031; schwartz, martin/0000-0002-2071-1243; takada, yoshikazu/0000-0001-5481-9589	NHLBI NIH HHS [P01 HL48728] Funding Source: Medline; NIGMS NIH HHS [R01 GM47214, R01GM47157] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048728] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047214, R01GM047157] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALZAC F, 1993, J CELL BIOL, V121, P171, DOI 10.1083/jcb.121.1.171; BODARY S C, 1991, Journal of Cell Biology, V115, p289A; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; DANA N, 1991, P NATL ACAD SCI USA, V88, P3106, DOI 10.1073/pnas.88.8.3106; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; FORNARO M, UNPUB; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; HEMLER ME, 1984, J IMMUNOL, V132, P3011; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; LANGUINO LR, 1992, J BIOL CHEM, V267, P7116; LANGUINO LR, UNPUB; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MEREDITH JC, UNPUB; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PFEFFER LM, 1991, P NATL ACAD SCI USA, V88, P7988, DOI 10.1073/pnas.88.18.7988; SCHWARTZ M A, 1992, Trends in Cell Biology, V2, P304, DOI 10.1016/0962-8924(92)90120-C; SCHWARTZ MA, 1994, J BIOL CHEM, V269, P11133; SELTZER JL, 1994, EXP CELL RES, V213, P365, DOI 10.1006/excr.1994.1211; SOLOWSKA J, 1991, J CELL BIOL, V114, P1079, DOI 10.1083/jcb.114.5.1079; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913	24	116	117	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 15	1995	269	5230					1570	1572		10.1126/science.7545312	http://dx.doi.org/10.1126/science.7545312			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU813	7545312				2022-12-24	WOS:A1995RU81300039
J	BOHLER, C; NIELSEN, PE; ORGEL, LE				BOHLER, C; NIELSEN, PE; ORGEL, LE			TEMPLATE SWITCHING BETWEEN PNA AND RNA OLIGONUCLEOTIDES	NATURE			English	Article							DIRECTED SYNTHESIS	THE origin of the RNA world(1) is not easily understood, as effective prebiotic syntheses of the components of RNA, the beta-ribofuranoside-5'-phosphates, are hard to envisage(2). Recognition of this difficulty has led to the proposal(1,3) that other genetic systems, the components of which are more easily formed, may have preceded RNA. This raises the question of how transitions between one genetic system and another could occur. Peptide nucleic acid (PNA) resembles RNA in its ability to form double-helical complexes stabilized by Watson-Crick hydrogen bonding between adenine and thymine and between cytosine and guanine(4-6), but has a backbone that is held together by amide rather than by phosphodiester bonds. Oligonucleotides based on RNA are known to act as templates that catalyse the non-enzymatic synthesis of their complements from activated mononucleotides(7-9), we now show that RNA oligonucleotides facilitate the synthesis of complementary PNA strands and vice versa. This suggests that a transition between different genetic systems can occur without less of information.	SALK INST BIOL STUDIES,SAN DIEGO,CA 92186; PANUM INST,IMBG,CTR BIOMOLEC RECOGNIT,DK-2100 COPENHAGEN N,DENMARK	Salk Institute								CAIRNSSMITH AG, 1982, GENETIC TAKEOVER; CAIRNSSMITH AG, 1977, ENCY IGNORANCE; CHEN CB, 1985, J MOL BIOL, V181, P271, DOI 10.1016/0022-2836(85)90091-9; EGHOLM M, 1993, NATURE, V365, P566, DOI 10.1038/365566a0; Gesteland RF., 1993, RNA WORLD NATURE MOD; HILL AR, 1993, ORIGINS LIFE EVOL B, V23, P285, DOI 10.1007/BF01582078; INOUE T, 1981, J AM CHEM SOC, V103, P7666, DOI 10.1021/ja00415a051; INOUE T, 1984, J MOL BIOL, V178, P669, DOI 10.1016/0022-2836(84)90244-4; JOYCE GF, 1984, NATURE, V310, P602, DOI 10.1038/310602a0; JOYCE GF, 1987, COLD SPRING HARB SYM, V52, P41, DOI 10.1101/SQB.1987.052.01.008; JOYCE GF, 1984, J MOL BIOL, V176, P279, DOI 10.1016/0022-2836(84)90425-X; Joyce GF., 1993, COLD SPRING HARB MON, V24, P1; NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210; ORGEL LE, 1992, NATURE, V358, P203, DOI 10.1038/358203a0; WITTUNG P, 1994, NATURE, V368, P561, DOI 10.1038/368561a0	15	189	194	4	39	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 17	1995	376	6541					578	581		10.1038/376578a0	http://dx.doi.org/10.1038/376578a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RP756	7543656				2022-12-24	WOS:A1995RP75600046
J	KOCH, AE; HALLORAN, MM; HASKELL, CJ; SHAH, MR; POLVERINI, PJ				KOCH, AE; HALLORAN, MM; HASKELL, CJ; SHAH, MR; POLVERINI, PJ			ANGIOGENESIS MEDIATED BY SOLUBLE FORMS OF E-SELECTIN AND VASCULAR CELL-ADHESION MOLECULE-1	NATURE			English	Article							HUMAN-ENDOTHELIAL-CELLS; TUMOR NECROSIS FACTOR; EXPRESSION; DISTINCT; EPITOPES; LEWIS	ENDOTHELIAL adhesion molecules facilitate the entry of leukocytes into inflamed tissues. This in turn promotes neovascularization, a process central to the progression of rheumatoid arthritis, tumour growth and wound repair(1). Here we test the hypothesis that soluble endothelial adhesion molecules promote angiogenesis(2-4), Human recombinant soluble E-selectin and soluble vascular cell adhesion molecule-1 induced chemotaxis of human endothelial cells in vitro and were angiogenic in rat cornea. Soluble E-selectin acted on endothelial cells in part through a sialyl Lewis-X-dependent mechanism, while soluble vascular cell adhesion molecule-1 acted on endothelial cells in part through a very late antigen (VLA)-4 dependent mechanism, The chemotactic activity of rheumatoid synovial fluid for endothelial cells, and also its angiogenic activity, were blocked by antibodies to either soluble E-selectin or soluble vascular cell adhesion molecule-1. These results suggest a novel function for soluble endothelial adhesion molecules as mediators of angiogenesis.	LAKESIDE VET ADM MED CTR,CHICAGO,IL 60611; UNIV MICHIGAN,SCH DENT,MOLEC PATHOGENESIS LAB,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	KOCH, AE (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT MED,ARTHRIT & CONNECT TISSUE DIS SECT,303 E CHICAGO AVE,CHICAGO,IL 60611, USA.		Koch, Alisa E/B-6894-2011; Polverini, Peter/AAJ-8392-2020					BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BUSSOLINO F, 1989, NATURE, V337, P471, DOI 10.1038/337471a0; CARLOS TM, 1990, BLOOD, V76, P965; CARSON CW, 1994, J RHEUMATOL, V21, P605; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; GAMBLE JR, 1993, J CELL BIOL, V121, P931, DOI 10.1083/jcb.121.4.931; GILLARD BK, 1987, ARCH BIOCHEM BIOPHYS, V256, P435, DOI 10.1016/0003-9861(87)90600-X; JOHNSON BA, 1993, ARTHRITIS RHEUM, V36, P137, DOI 10.1002/art.1780360203; KLAGSBRUN M, 1991, REV PHYSL, V53, P217; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; KOCH AE, 1991, LAB INVEST, V64, P313; KOCH AE, 1993, CLIN IMMUNOL IMMUNOP, V69, P29, DOI 10.1006/clin.1993.1146; KOCH AE, 1994, J IMMUNOL, V152, P149; LEIBOVICH SJ, 1994, P NATL ACAD SCI USA, V91, P4190, DOI 10.1073/pnas.91.10.4190; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; LO SK, 1991, J EXP MED, V173, P1493, DOI 10.1084/jem.173.6.1493; LOBB RR, 1991, J IMMUNOL, V147, P124; MASSIA SP, 1992, J BIOL CHEM, V267, P14109; MUNRO JM, 1992, AM J PATHOL, V141, P1392; NGUYEN M, 1993, NATURE, V365, P267, DOI 10.1038/365267a0; OSBORN L, 1992, J EXP MED, V176, P99, DOI 10.1084/jem.176.1.99; PAAVONEN T, 1992, AM J PATHOL, V141, P1259; POBER JS, 1986, J IMMUNOL, V136, P1680; PULIDO R, 1991, J BIOL CHEM, V266, P10241; Winer BJ., 1971, STAT PRINCIPLES EXPT, V2nd ed	25	511	551	2	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 10	1995	376	6540					517	519		10.1038/376517a0	http://dx.doi.org/10.1038/376517a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN622	7543654	Green Submitted			2022-12-24	WOS:A1995RN62200045
J	KREDER, KJ				KREDER, KJ			COMBINATION-DRUG THERAPY FOR BENIGN PROSTATIC HYPERPLASIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											KREDER, KJ (corresponding author), UNIV IOWA,IOWA CITY,IA 52242, USA.			Kreder, Karl/0000-0002-8981-5286					0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 26	1995	274	4					359	359		10.1001/jama.274.4.359	http://dx.doi.org/10.1001/jama.274.4.359			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ898	7541871				2022-12-24	WOS:A1995RJ89800045
J	LEIGHTON, PA; INGRAM, RS; EGGENSCHWILER, J; EFSTRATIADIS, A; TILGHMAN, SM				LEIGHTON, PA; INGRAM, RS; EGGENSCHWILER, J; EFSTRATIADIS, A; TILGHMAN, SM			DISRUPTION OF IMPRINTING CAUSED BY DELETION OF THE H19 GENE REGION IN MICE	NATURE			English	Article							GROWTH FACTOR-II; EARLY MOUSE EMBRYOGENESIS; BETA-GLOBIN; PGK-1 GENE; XIST GENE; EXPRESSION; RNA; DNA; PROMOTER; FRAGMENTS	The imprinted H19 gene, which encodes an untranslated RNA, lies at the end of a cluster of Imprinted genes in the mouse. Imprinting of the insulin-2 and insulin-like growth factor 2 genes, which lie about 100 kilobases upstream of H19, can be disrupted by maternal inheritance of a targeted deletion of the H19 gene and its flanking sequence. Animals inheriting the H19 mutation from their mothers are 27% heavier than those inheriting It from their fathers. Paternal inheritance of the disruption has no effect, which presumably reflects the normally silent state of the paternal gene. The somatic overgrowth of heterozygotes for the maternal deletion is attributed to a gain of function of insulin-like growth factor 2, rather than a loss of function of H19.	PRINCETON UNIV, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA; COLUMBIA UNIV, DEPT GENET & DEV, NEW YORK, NY 10032 USA	Princeton University; Columbia University	LEIGHTON, PA (corresponding author), PRINCETON UNIV, HOWARD HUGHES MED INST, PRINCETON, NJ 08544 USA.			eggenschwiler, jonathan/0000-0001-6444-8865				ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; Bartolomei M.S., 1992, SEMIN DEV BIOL, V3, P107; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; BRANDEIS M, 1993, EMBO J, V12, P3669, DOI 10.1002/j.1460-2075.1993.tb06041.x; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; BRUNKOW ME, 1991, GENE DEV, V5, P1092, DOI 10.1101/gad.5.6.1092; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOI ORB, 1988, CELL, V55, P17, DOI 10.1016/0092-8674(88)90005-0; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; DUDOV KP, 1984, CELL, V37, P457, DOI 10.1016/0092-8674(84)90376-3; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; EFSTRATIADIS A, 1994, CURR OPIN GENET DEV, V4, P265, DOI 10.1016/S0959-437X(05)80054-1; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERGUSONSMITH AC, 1993, NATURE, V362, P751, DOI 10.1038/362751a0; FOLEY KP, 1992, GENE DEV, V6, P730, DOI 10.1101/gad.6.5.730; GIDDINGS SJ, 1994, NAT GENET, V6, P310, DOI 10.1038/ng0394-310; GUILLEMOT F, 1995, NAT GENET, V9, P235, DOI 10.1038/ng0395-235; GUILLEMOT F, 1994, GIDD, V371, P333; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; HENDRICH BD, 1993, HUM MOL GENET, V2, P663, DOI 10.1093/hmg/2.6.663; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; KAY GF, 1993, CELL, V72, P171, DOI 10.1016/0092-8674(93)90658-D; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; LEE JE, 1990, DEVELOPMENT, V110, P151; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; OHLSSON H, 1991, MOL ENDOCRINOL, V5, P897, DOI 10.1210/mend-5-7-897; PACHNIS V, 1988, EMBO J, V7, P673, DOI 10.1002/j.1460-2075.1988.tb02862.x; PFEIFER K, 1994, GENE DEV, V8, P1867, DOI 10.1101/gad.8.16.1867; POIRIER F, 1991, DEVELOPMENT, V113, P1105; REIS A, 1994, AM J HUM GENET, V54, P741; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; ROSEMAN RR, 1993, EMBO J, V12, P435, DOI 10.1002/j.1460-2075.1993.tb05675.x; SOLTER D, 1988, ANNU REV GENET, V22, P127; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; SUTCLIFFE JS, 1994, NAT GENET, V8, P52, DOI 10.1038/ng0994-52; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TREMBLAY KD, 1995, NAT GENET, V9, P407, DOI 10.1038/ng0495-407; WEVRICK R, 1994, HUM MOL GENET, V3, P1877, DOI 10.1093/hmg/3.10.1877; YOOWARREN H, 1988, MOL CELL BIOL, V8, P4707, DOI 10.1128/MCB.8.11.4707; ZACHAR V, 1993, NUCLEIC ACIDS RES, V21, P2017, DOI 10.1093/nar/21.8.2017; ZEMEL S, 1992, NAT GENET, V2, P61, DOI 10.1038/ng0992-61	50	659	669	0	17	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 4	1995	375	6526					34	39		10.1038/375034a0	http://dx.doi.org/10.1038/375034a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW604	7536897				2022-12-24	WOS:A1995QW60400046
J	CHEN, CY; SARNOW, P				CHEN, CY; SARNOW, P			INITIATION OF PROTEIN-SYNTHESIS BY THE EUKARYOTIC TRANSLATIONAL APPARATUS ON CIRCULAR RNAS	SCIENCE			English	Article							5' NONTRANSLATED REGION; INTERNAL RIBOSOMAL ENTRY; MESSENGER-RNA; VIRUS-RNA; POLIOVIRUS RNA; PICORNAVIRUS RNA; BINDING-PROTEIN; SITE; SEQUENCE; ELEMENTS	The ribosome scanning model predicts that eukaryotic ribosomal 40S subunits enter all messenger RNAs at their 5' ends. Here, it is reported that eukaryotic ribosomes can initiate translation on circular RNAs, but only if the RNAs contain internal ribosome entry site elements, Long-repeating polypeptide chains were synthesized from RNA circles with continuous open reading frames. These results indicate that ribosomes can translate such RNA circles for multiple consecutive rounds and that the free 5' end of a messenger RNA is not necessarily the entry point for 40S subunits.	UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,DYDE LAB,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver				Sarnow, Peter/0000-0002-2043-2770				CAPEL B, 1993, CELL, V73, P1019, DOI 10.1016/0092-8674(93)90279-Y; CHANG JY, 1985, EUR J BIOCHEM, V151, P217, DOI 10.1111/j.1432-1033.1985.tb09091.x; COCQUERELLE C, 1993, FASEB J, V7, P155, DOI 10.1096/fasebj.7.1.7678559; COOPER G, 1994, J BIOTECHNOL, V33, P123, DOI 10.1016/0168-1656(94)90105-8; DUKE GM, 1992, J VIROL, V66, P1602, DOI 10.1128/JVI.66.3.1602-1609.1992; EDERY I, 1983, J BIOL CHEM, V258, P1398; FORD E, 1994, P NATL ACAD SCI USA, V91, P3117, DOI 10.1073/pnas.91.8.3117; GRABOWSKI PJ, 1981, CELL, V23, P467, DOI 10.1016/0092-8674(81)90142-2; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; HAMBIDGE SJ, 1991, J VIROL, V65, P6312, DOI 10.1128/JVI.65.11.6312-6315.1991; HELLEN CUT, 1993, P NATL ACAD SCI USA, V90, P7642, DOI 10.1073/pnas.90.16.7642; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; JANG SK, 1989, J VIROL, V63, P1651, DOI 10.1128/JVI.63.4.1651-1660.1989; KONARSKA M, 1981, EUR J BIOCHEM, V114, P221, DOI 10.1111/j.1432-1033.1981.tb05139.x; KOZAK M, 1992, CRIT REV BIOCHEM MOL, V27, P385, DOI 10.3109/10409239209082567; KOZAK M, 1979, NATURE, V280, P82, DOI 10.1038/280082a0; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LUZ N, 1990, FEBS LETT, V169, P311; MACEJAK DG, 1990, NEW ASPECTS OF POSITIVE-STRAND RNA VIRUSES, P152; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; MEEROVITCH K, 1991, J VIROL, V65, P5895, DOI 10.1128/JVI.65.11.5895-5901.1991; MEEROVITCH K, 1993, J VIROL, V67, P3798, DOI 10.1128/JVI.67.7.3798-3807.1993; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MOLLA A, 1992, NATURE, V356, P255, DOI 10.1038/356255a0; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; OH SK, 1992, GENE DEV, V6, P1643, DOI 10.1101/gad.6.9.1643; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PESTOVA TV, 1991, J VIROL, V65, P6194, DOI 10.1128/JVI.65.11.6194-6204.1991; PILIPENKO EV, 1992, CELL, V68, P119, DOI 10.1016/0092-8674(92)90211-T; ROBERTSON HD, 1992, CURR TOP MICROBIOL, V176, P213; TAHARA SM, 1981, J BIOL CHEM, V256, P7691; TSUKIYAMAKOHARA K, 1992, J VIROL, V66, P1476, DOI 10.1128/JVI.66.3.1476-1483.1992	33	498	554	4	71	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 21	1995	268	5209					415	417		10.1126/science.7536344	http://dx.doi.org/10.1126/science.7536344			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU572	7536344				2022-12-24	WOS:A1995QU57200039
J	VONAHSEN, U; NOLLER, HF				VONAHSEN, U; NOLLER, HF			IDENTIFICATION OF BASES IN 16S-RIBOSOMAL RNA ESSENTIAL FOR TRANSFER-RNA BINDING AT THE 30S-RIBOSOMAL P-SITE	SCIENCE			English	Article							ANTICODON INTERACTION SITE; TRANSFER-RNA; SUBUNIT; LOCALIZATION; CROSSLINKING; NUCLEOTIDES	Previous studies suggest that the mechanism of action of the ribosome in translation involves crucial transfer RNA (tRNA)-ribosomal RNA (rRNA) interactions. Here, a selection scheme was developed to identify bases in 16S rRNA that are essential for tRNA binding to the P site of the small (30S) ribosamal subunit. Modification of the N-1 and N-2 positions of 2-methylguanine 966 and of the N-7 position of guanine 1401 interfered with messenger RNA (mRNA)-dependent binding of tRNA to the P site. Modification of the same positions as well as of the N-1 and N-2 positions of guanine 926 interfered with mRNA-independent binding of tRNA at high magnesium ion concentration. These results suggest that these three bases are involved in intermolecular contacts between ribosomes and tRNA.	UNIV CALIF SANTA CRUZ, SINSHEIMER LABS, SANTA CRUZ, CA 95064 USA	University of California System; University of California Santa Cruz					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM017129, R01GM017129] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM17129] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CUNNINGHAM PR, 1992, BIOCHEMISTRY-US, V31, P7629, DOI 10.1021/bi00148a026; DENMAN R, 1988, NUCLEIC ACIDS RES, V16, P165, DOI 10.1093/nar/16.1.165; GORNICKI P, 1984, J BIOL CHEM, V259, P493; GRAJEVSKAJA RA, 1973, FEBS LETT, V33, P11, DOI 10.1016/0014-5793(73)80147-4; HERR W, 1979, J MOL BIOL, V130, P433, DOI 10.1016/0022-2836(79)90433-9; HUTTENHOFER A, 1992, P NATL ACAD SCI USA, V89, P7851, DOI 10.1073/pnas.89.17.7851; KIRILLOV SV, 1980, NUCLEIC ACIDS RES, V8, P183, DOI 10.1093/nar/8.1.183; LARSEN N, 1993, NUCLEIC ACIDS RES, V21, P3021, DOI 10.1093/nar/21.13.3021; MOAZED D, 1990, J MOL BIOL, V211, P135, DOI 10.1016/0022-2836(90)90016-F; MOAZED D, 1986, CELL, V47, P985, DOI 10.1016/0092-8674(86)90813-5; NIRENBERG MW, 1964, SCIENCE, V145, P1399, DOI 10.1126/science.145.3639.1399; NOLLER HF, 1972, P NATL ACAD SCI USA, V69, P3115, DOI 10.1073/pnas.69.11.3115; PRINCE JB, 1982, P NATL ACAD SCI-BIOL, V79, P5450, DOI 10.1073/pnas.79.18.5450; ROSE SJ, 1983, J MOL BIOL, V167, P103, DOI 10.1016/S0022-2836(83)80036-9; STERN S, 1988, METHOD ENZYMOL, V164, P481; STERN S, 1988, J MOL BIOL, V204, P447, DOI 10.1016/0022-2836(88)90588-8; VONAHSEN U, UNPUB; WAGENKNECHT T, 1988, J MOL BIOL, V203, P753, DOI 10.1016/0022-2836(88)90207-0	18	103	105	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 13	1995	267	5195					234	237		10.1126/science.7528943	http://dx.doi.org/10.1126/science.7528943			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB153	7528943				2022-12-24	WOS:A1995QB15300034
J	LEAPE, LL				LEAPE, LL			ERROR IN MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOSPITALIZED-PATIENTS; ADVERSE EVENTS; MISTAKES; CARE; PREVENTION; FAILURES				LEAPE, LL (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, 677 HUNTINGTON AVE, BOSTON, MA 02115 USA.							ALLNUTT MF, 1987, BRIT J ANAESTH, V59, P856, DOI 10.1093/bja/59.7.856; ANDERSON RE, 1989, JAMA-J AM MED ASSOC, V261, P1610, DOI 10.1001/jama.261.11.1610; BATES DW, IN PRESS J GEN INTER; BEDELL SE, 1991, JAMA-J AM MED ASSOC, V265, P2815, DOI 10.1001/jama.265.21.2815; BERWICK DM, 1989, MILBANK Q, V67, P262, DOI 10.2307/3350141; BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; CAMERON HM, 1981, J PATHOL, V133, P273, DOI 10.1002/path.1711330402; CHRISTENSEN JF, 1992, J GEN INTERN MED, V7, P424, DOI 10.1007/BF02599161; CLASSEN DC, 1991, JAMA-J AM MED ASSOC, V266, P2847, DOI 10.1001/jama.266.20.2847; COOPER JB, 1984, ANESTHESIOLOGY, V60, P34, DOI 10.1097/00000542-198401000-00008; CULLEN DJ, 1992, ANESTH ANALG, V74, P181, DOI 10.1213/00000539-199202000-00002; Deming W. E, 1982, QUALITY PRODUCTIVITY; DUBOIS RW, 1988, ANN INTERN MED, V109, P582, DOI 10.7326/0003-4819-109-7-582; FOLLI HL, 1987, PEDIATRICS, V79, P718; GABA DM, 1989, INT ANESTHESIOL CLIN, V27, P137, DOI 10.1097/00004311-198902730-00002; GOLDMAN L, 1983, NEW ENGL J MED, V308, P1000, DOI 10.1056/NEJM198304283081704; GOPHER D, 1989, 33RD ANN M HUM FACT; HILFIKER D, 1984, NEW ENGL J MED, V310, P118, DOI 10.1056/NEJM198401123100211; Leape L L, 1993, QRB Qual Rev Bull, V19, P144; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; LESAR TS, 1990, JAMA-J AM MED ASSOC, V263, P2329, DOI 10.1001/jama.263.17.2329; MCINTYRE N, 1983, BRIT MED J, V287, P1919, DOI 10.1136/bmj.287.6409.1919; Nightingale F., 1863, NOTES ON HOSP, V3rd; NORMAN DA, 1984, ERR IS HUMAN; ORKIN FK, 1993, MONITORING ANESTHESI; PALMER RH, 1983, MED DECIS MAKING, V3, P299, DOI 10.1177/0272989X8300300306; Perrow C., 1984, NORMAL ACCIDENTS LIV; RAJU TNK, 1989, LANCET, V2, P374; RASMUSSEN J, 1974, ERGONOMICS, V17, P293, DOI 10.1080/00140137408931355; RESON J, 1992, HUMAN ERROR; SCHIMMEL EM, 1964, ANN INTERN MED, V60, P100, DOI 10.7326/0003-4819-60-1-100; STEEL K, 1981, NEW ENGL J MED, V304, P638, DOI 10.1056/NEJM198103123041104; TVERSKY A, 1981, SCIENCE, V211, P453, DOI 10.1126/science.7455683; WU AW, 1991, JAMA-J AM MED ASSOC, V265, P2089, DOI 10.1001/jama.265.16.2089; Yerkes RM, 1908, J COMP NEUROL PSYCHO, V18, P459, DOI 10.1002/cne.920180503	36	1473	1510	0	45	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 21	1994	272	23					1851	1857		10.1001/jama.272.23.1851	http://dx.doi.org/10.1001/jama.272.23.1851			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW980	7503827				2022-12-24	WOS:A1994PW98000034
J	DING, JM; CHEN, D; WEBER, ET; FAIMAN, LE; REA, MA; GILLETTE, MU				DING, JM; CHEN, D; WEBER, ET; FAIMAN, LE; REA, MA; GILLETTE, MU			RESETTING THE BIOLOGICAL CLOCK - MEDIATION OF NOCTURNAL CIRCADIAN SHIFTS BY GLUTAMATE AND NO	SCIENCE			English	Article							NITRIC-OXIDE SYNTHASE; CYCLIC-GMP FORMATION; SUPRACHIASMATIC NUCLEUS; RECEPTOR ANTAGONISTS; RAT HYPOTHALAMUS; GOLDEN-HAMSTER; NMDA RECEPTORS; FOS EXPRESSION; PHASE-SHIFTS; OPTIC-NERVE	Circadian rhythms of mammals are timed by an endogenous clock with a period of about 24 hours located in the suprachiasmatic nucleus (SCN) of the hypothalamus. Light synchronizes this clock to the external environment by daily adjustments in the phase of the circadian oscillation. The mechanism has been thought to involve the release of excitatory amino acids from retinal afferents to the SCN. Brief treatment of rat SCN in vitro with glutamate (Glu), N-methyl-D-aspartate (NMDA), or nitric oxide (NO) generators produced lightlike phase shifts of circadian rhythms. The SCN exhibited calcium-dependent nitric oxide synthase (NOS) activity. Antagonists of NMDA or NOS pathways blocked Glu effects in vitro, and intracerebroventricular injection of a NOS inhibitor in vivo blocked the light-induced resetting of behavioral rhythms. Together, these data indicate that Glu release, NMDA receptor activation, NOS stimulation, and NO production link light activation of the retina to cellular changes within the SCN mediating the phase resetting of the biological clock.	UNIV ILLINOIS,DEPT CELL & STRUCT BIOL,URBANA,IL 61801; UNIV ILLINOIS,DEPT PHYSIOL,URBANA,IL 61801; UNIV ILLINOIS,NEUROSCI PROGRAM,URBANA,IL 61801; ARMSTRONG LAB,BIOL RHYTHMS & INTEGRAT NEUROSCI RES INST,BROOKS AFB,TX 78235	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; United States Department of Defense; United States Air Force					NINDS NIH HHS [NS22155, R01 NS022155] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022155] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMIR S, 1992, BRAIN RES, V586, P336, DOI 10.1016/0006-8993(92)91644-T; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; BREDT DS, 1991, NEURON, V7, P615, DOI 10.1016/0896-6273(91)90374-9; BRUNE B, 1989, J BIOL CHEM, V264, P8455; BRUNE B, 1993, LIFE SCI, V54, P61; CASTEL M, 1993, EUR J NEUROSCI, V5, P368, DOI 10.1111/j.1460-9568.1993.tb00504.x; Chen D.-Y., UNPUB; COLWELL CS, 1990, BRAIN RES, V523, P117, DOI 10.1016/0006-8993(90)91643-U; COLWELL CS, 1992, J BIOL RHYTHM, V7, P125, DOI 10.1177/074873049200700204; COSTA A, 1993, BRAIN RES, V605, P187, DOI 10.1016/0006-8993(93)91739-F; DAWSON TM, 1994, J NEUROSCI, V14, P5147; DECOURSEY PJ, 1960, SCIENCE, V131, P33, DOI 10.1126/science.131.3392.33; DEMASTER EG, 1989, BIOCHEM BIOPH RES CO, V163, P527, DOI 10.1016/0006-291X(89)92169-4; DEVRIES MJ, 1993, BRAIN RES, V612, P213; Ding J. M., 1993, Society for Neuroscience Abstracts, V19, P1815; DWYER MA, 1991, BIOCHEM BIOPH RES CO, V176, P1136, DOI 10.1016/0006-291X(91)90403-T; EAST SJ, 1990, EUR J PHARMACOL, V184, P311, DOI 10.1016/0014-2999(90)90623-E; Edmunds LN, 1988, CELLULAR MOL BASES B; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GELPERIN A, 1994, NATURE, V369, P61, DOI 10.1038/369061a0; Gillette MU, 1991, SUPRACHIASMATIC NUCL, P125; GILLETTE MU, CIBA F S, V183, P134; HALEY JE, 1992, NEURON, V8, P221; HAMADA T, 1993, AM J PHYSIOL, V265, pR1199, DOI 10.1152/ajpregu.1993.265.5.R1199; HASTINGS MH, 1985, NEUROENDOCRINOLOGY, V40, P316, DOI 10.1159/000124093; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; IGNARRO LJ, 1990, PHARMACOL TOXICOL, V67, P1, DOI 10.1111/j.1600-0773.1990.tb00772.x; JOHNSON RF, 1988, BRAIN RES, V462, P301, DOI 10.1016/0006-8993(88)90558-6; KAMISAKI Y, 1994, BRAIN RES, V644, P128, DOI 10.1016/0006-8993(94)90355-7; KIM YI, 1991, J PHYSIOL-LONDON, V444, P269, DOI 10.1113/jphysiol.1991.sp018877; Klein D.C., 1991, SUPRACHIASMATIC NUCL; KOWALUK EA, 1990, J PHARMACOL EXP THER, V255, P1256; LIOU SY, 1986, BRAIN RES BULL, V16, P527, DOI 10.1016/0361-9230(86)90182-6; MARTIN W, 1985, J PHARMACOL EXP THER, V232, P708; MEDANIC M, 1992, J PHYSIOL-LONDON, V450, P629, DOI 10.1113/jphysiol.1992.sp019147; MEIJER JH, 1988, NEUROSCI LETT, V86, P177, DOI 10.1016/0304-3940(88)90567-8; MEIJER JH, 1989, PHYSIOL REV, V69, P671, DOI 10.1152/physrev.1989.69.3.671; MEIJER JH, 1993, BRAIN RES, V603, P284, DOI 10.1016/0006-8993(93)91249-R; MOFFETT JR, 1990, P NATL ACAD SCI USA, V87, P8065, DOI 10.1073/pnas.87.20.8065; MOFFETT JR, 1991, BRAIN RES, V538, P86, DOI 10.1016/0006-8993(91)90380-E; MONTAGUE PR, 1994, SCIENCE, V263, P973, DOI 10.1126/science.7508638; MOORE RY, 1971, J COMP NEUROL, V146, P1; MORIN LP, 1994, BRAIN RES REV, V67, P102; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; ODELL TJ, 1994, SCIENCE, V265, P542, DOI 10.1126/science.7518615; PAPE HC, 1992, NEURON, V9, P441, DOI 10.1016/0896-6273(92)90182-D; PICKARD GE, 1982, J COMP NEUROL, V211, P65, DOI 10.1002/cne.902110107; PITTENDRIGH CS, 1981, HDB BEHAV NEUROBIOL, V4, P59; PROSSER RA, 1989, J NEUROSCI, V9, P1073; PROSSER RA, 1989, P NATL ACAD SCI USA, V86, P6912; REA MA, 1993, J BIOL RHYTHM, V8, pS59; REA MA, 1993, AM J PHYSIOL, V265, pR1191, DOI 10.1152/ajpregu.1993.265.5.R1191; SHIBATA S, 1986, NEUROPHARMACOLOGY, V25, P403, DOI 10.1016/0028-3908(86)90235-2; SHIBATA S, 1994, AM J PHYSIOL, V267, pR360, DOI 10.1152/ajpregu.1994.267.2.R360; SHIBATA S, 1992, BRAIN RES, V597, P257, DOI 10.1016/0006-8993(92)91482-T; SHIRAKAWA T, 1994, NEUROSCI LETT, V178, P47, DOI 10.1016/0304-3940(94)90286-0; SIEGEL G, 1991, BASIC NEUROCHEMISTRY, P558; SOUTHAM E, 1992, NEUROSCI LETT, V137, P241, DOI 10.1016/0304-3940(92)90413-2; SOUTHAM E, 1991, NEUROSCI LETT, V130, P107, DOI 10.1016/0304-3940(91)90239-P; SUMMER TL, 1984, AM J PHYSIOL, V246, pR299, DOI 10.1152/ajpregu.1984.246.3.R299; TAKEUCHI Y, 1991, BRAIN RES, V563, P127, DOI 10.1016/0006-8993(91)91524-5; VANDENPOL AN, 1991, J NEUROSCI, V11, P2087; VINCENT SR, 1992, TRENDS NEUROSCI, V15, P108, DOI 10.1016/0166-2236(92)90021-Y; VINCENT SR, 1992, NEUROSCIENCE, V46, P755, DOI 10.1016/0306-4522(92)90184-4; WATANABE A, 1994, BRAIN RES, V646, P161, DOI 10.1016/0006-8993(94)90071-X; WENDLAND B, 1994, P NATL ACAD SCI USA, V91, P2151, DOI 10.1073/pnas.91.6.2151	69	485	494	1	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 9	1994	266	5191					1713	1717		10.1126/science.7527589	http://dx.doi.org/10.1126/science.7527589			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW308	7527589				2022-12-24	WOS:A1994PW30800042
J	LIU, MY; CHEN, TY; AHAMED, B; LI, J; YAU, KW				LIU, MY; CHEN, TY; AHAMED, B; LI, J; YAU, KW			CALCIUM-CALMODULIN MODULATION OF THE OLFACTORY CYCLIC NUCLEOTIDE-GATED CATION CHANNEL	SCIENCE			English	Article							OUTER RENAL MEDULLA; ION CHANNELS; FUNCTIONAL EXPRESSION; PHOTORECEPTOR CELLS; POTASSIUM CHANNEL; BINDING DOMAIN; PROTEIN; ACTIVATION; MEMBRANE; ROD	Although several ion channels have been reported to be directly modulated by calcium-calmodulin, they have not been conclusively shown to bind calmodulin, nor are the modulatory mechanisms understood. Study of the olfactory cyclic nucleotide-activated cation channel, which is modulated by calcium-calmodulin, indicates that calcium-calmodulin directly binds to a specific domain on the amino terminus of the channel. This binding reduces the effective affinity of the channel for cyclic nucleotides, apparently by acting on channel gating, which is tightly coupled to ligand binding. The data reveal a control mechanism that resembles those underlying the regulation of enzymes by calmodulin. The results also point to the amino-terminal part of the olfactory channel as an element for gating, which may have general significance in the operation of ion channels with similar overall structures.	JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROSCI, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, HOWARD HUGHES MED INST, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT OPHTHALMOL, BALTIMORE, MD 21205 USA	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University					NATIONAL EYE INSTITUTE [R37EY006837, R01EY006837] Funding Source: NIH RePORTER; NEI NIH HHS [EY 06837] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BERTRAND B, 1994, J BIOL CHEM, V269, P13703; BONIGK W, 1993, NEURON, V10, P865, DOI 10.1016/0896-6273(93)90202-3; BRADLEY J, 1994, P NATL ACAD SCI USA, V91, P8890, DOI 10.1073/pnas.91.19.8890; CHEN TY, 1994, NATURE, V368, P545, DOI 10.1038/368545a0; CHEN TY, 1994, P NATL ACAD SCI USA, V91, P11757, DOI 10.1073/pnas.91.24.11757; CHEN TY, 1993, NATURE, V362, P764, DOI 10.1038/362764a0; COLQUHOUN D, 1993, NATURE, V366, P510, DOI 10.1038/366510b0; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; EISENBERG D, 1984, P NATL ACAD SCI-BIOL, V81, P140, DOI 10.1073/pnas.81.1.140; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; ENYEDI A, 1989, J BIOL CHEM, V264, P12313; FALCHETTO R, 1991, J BIOL CHEM, V266, P2930; GOULDING EH, 1993, NATURE, V364, P61, DOI 10.1038/364061a0; GOULDING EH, 1992, NEURON, V8, P45, DOI 10.1016/0896-6273(92)90107-O; GUY HR, 1991, SCIENCE, V254, P730, DOI 10.1126/science.1658932; HARDIE RC, 1992, NEURON, V8, P643, DOI 10.1016/0896-6273(92)90086-S; HAYNES LW, 1990, J PHYSIOL-LONDON, V429, P451, DOI 10.1113/jphysiol.1990.sp018267; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; Hille B., 1992, IONIC CHANNELS EXCIT; HSU YT, 1993, NATURE, V361, P76, DOI 10.1038/361076a0; HU YF, 1994, BIOCHEM BIOPH RES CO, V201, P1050, DOI 10.1006/bbrc.1994.1808; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JAN LY, 1990, NATURE, V345, P672, DOI 10.1038/345672a0; JARRETT HW, 1991, J BIOL CHEM, V266, P362; Kaczmarek LK, 1987, NEUROMODULATION BIOC; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; KINCAID RL, 1982, J BIOL CHEM, V257, P638; KLAERKE DA, 1987, J MEMBRANE BIOL, V95, P105, DOI 10.1007/BF01869155; KLAERKE DA, 1987, FEBS LETT, V216, P211, DOI 10.1016/0014-5793(87)80691-9; KRAMER RH, 1992, NEURON, V9, P897, DOI 10.1016/0896-6273(92)90242-6; KRINKS MH, 1984, ADV CYCLIC NUCL PROT, V16, P31; KUBALSKI A, 1989, J MEMBRANE BIOL, V112, P91, DOI 10.1007/BF01871167; KURAHASHI T, 1990, BRAIN RES, V515, P261, DOI 10.1016/0006-8993(90)90605-B; LEVITAN IB, 1994, ANNU REV PHYSIOL, V56, P193, DOI 10.1146/annurev.ph.56.030194.001205; LI M, 1994, CURR BIOL, V4, P110, DOI 10.1016/S0960-9822(94)00026-6; LIMAN ER, 1994, NEURON, V13, P611, DOI 10.1016/0896-6273(94)90029-9; LUDWIG J, 1990, FEBS LETT, V270, P24, DOI 10.1016/0014-5793(90)81226-E; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MATTHEWS G, 1988, J PHYSIOL-LONDON, V403, P389, DOI 10.1113/jphysiol.1988.sp017255; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEANS AR, 1988, RECENT PROG HORM RES, V44, P223; MUNIER H, 1991, FEBS LETT, V190, P409; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PHILLIPS AM, 1992, NEURON, V8, P631, DOI 10.1016/0896-6273(92)90085-R; REED R, COMMUNICATION; SAIMI Y, 1990, SCIENCE, V249, P1441, DOI 10.1126/science.2169650; SAIMI Y, 1993, HDB MEMBRANE CHANNEL, P435; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH JS, 1989, CIRC RES, V64, P352, DOI 10.1161/01.RES.64.2.352; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; STRYER L, 1987, CHEM SCRIPTA, V27B, P161; VANBERKUM MFA, 1990, J BIOL CHEM, V265, P3750; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P13710	53	232	237	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 25	1994	266	5189					1348	1354		10.1126/science.266.5189.1348	http://dx.doi.org/10.1126/science.266.5189.1348			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT632	7526466				2022-12-24	WOS:A1994PT63200034
J	BEZRUKOV, SM; VODYANOY, I; PARSEGIAN, VA				BEZRUKOV, SM; VODYANOY, I; PARSEGIAN, VA			COUNTING POLYMERS MOVING THROUGH A SINGLE-ION CHANNEL	NATURE			English	Article							PROBING ALAMETHICIN CHANNELS; WATER-SOLUBLE POLYMERS; MEMBRANES; MODEL	THE change in conductance of a small electrolyte-filled capillary owing to the passage of sub-micrometre-sized particles has long been used for particle counting and sizing. A commercial device for such measurements, the Coulter counter, is able to detect particles of sizes down to several tenths of a micrometre(1-3). Nuclepore technology (in which pores are etched particle tracks) has extended the lower limit of size detection to 60-nm particles by using a capillary of diameter 0.45 mu m (ref. 4). Here we show that natural channel-forming peptides incorporated into a bilayer lipid membrane can be used to detect the passage of single molecules with gyration radii as small as 5-15 Angstrom. From our experiments with alamethicin pores we infer both the average number and the diffusion coefficients of poly(ethylene glycol) molecules in the pore. Our approach provides a means of observing the statistics and mechanics of flexible polymers moving within the confines of precisely defined single-molecule structures.	NIH,DCRT,STRUCT BIOL LAB,BETHESDA,MD 20892; RUSSIAN ACAD SCI,INST NUCL PHYS,ST PETERSBURG 188350,RUSSIA; OFF NAVAL RES,ARLINGTON,VA 22217	National Institutes of Health (NIH) - USA; National Research Centre - Kurchatov Institute; Institute of High Energy Physics - IHEP; Russian Academy of Sciences; United States Department of Defense; United States Navy	BEZRUKOV, SM (corresponding author), NIDDK,DIV INTRAMURAL RES,BETHESDA,MD 20892, USA.							ALLEN T, 1967, PARTICLE SIZE ANAL, P110; BALASUBRAMANIAN TM, 1981, J AM CHEM SOC, V103, P6127, DOI 10.1021/ja00410a024; BEAN CP, 1972, MEMBRANES, P1; BEZRUKOV SM, 1993, BIOPHYS J, V64, P16, DOI 10.1016/S0006-3495(93)81336-5; BEZRUKOV SM, IN PRESS ADV CHEM SE, V235; BUNVILLE LG, 1984, MODERN METHODS PARTI, P1; COUPER A, 1969, T FARADAY SOC, V65, P2486, DOI 10.1039/tf9696502486; DEBLOIS RW, 1977, J COLLOID INTERF SCI, V61, P323, DOI 10.1016/0021-9797(77)90395-2; FEHER G, 1973, P NATL ACAD SCI USA, V70, P870, DOI 10.1073/pnas.70.3.870; GORDON LGM, 1975, PHILOS T ROY SOC B, V270, P433, DOI 10.1098/rstb.1975.0021; HALL JE, 1984, BIOPHYS J, V45, P233, DOI 10.1016/S0006-3495(84)84151-X; HEINEMANN SH, 1989, BIOCHIM BIOPHYS ACTA, V987, P8, DOI 10.1016/0005-2736(89)90448-3; HESS P, 1984, NATURE, V309, P453, DOI 10.1038/309453a0; KRASILNIKOV OV, 1992, FEMS MICROBIOL IMMUN, V105, P93; KUBITSCHEK HE, 1958, NATURE, V182, P234, DOI 10.1038/182234a0; KUGA S, 1981, J CHROMATOGR, V206, P449, DOI 10.1016/S0021-9673(00)88914-1; MONTAL M, 1972, P NATL ACAD SCI USA, V69, P3561, DOI 10.1073/pnas.69.12.3561; SANSOM MSP, 1993, EUR BIOPHYS J BIOPHY, V22, P105, DOI 10.1007/BF00196915; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; VODYANOY I, 1993, BIOPHYS J, V65, P2097, DOI 10.1016/S0006-3495(93)81245-1	20	336	389	1	71	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 28	1994	370	6487					279	281		10.1038/370279a0	http://dx.doi.org/10.1038/370279a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ229	7518571				2022-12-24	WOS:A1994NZ22900058
J	GHADIRI, MR; GRANJA, JR; BUEHLER, LK				GHADIRI, MR; GRANJA, JR; BUEHLER, LK			ARTIFICIAL TRANSMEMBRANE ION CHANNELS FROM SELF-ASSEMBLING PEPTIDE NANOTUBES	NATURE			English	Article							SYNTHETIC PROTEINS; MEMBRANES; TRANSPORT; VESICLES; DESIGN; GRAMICIDIN; LIPOSOMES; BILAYERS; MODEL	NATURALLY occurring membrane channels and pores are formed from a large family of diverse proteins, peptides and organic secondary metabolites whose vital biological functions include control of ion flow, signal transduction, molecular transport and production of cellular toxins. But despite the availability of a large amount of biochemical information about these molecules(1), the design and synthesis of artificial systems that can mimic the biological function of natural compounds remains a formidable task(2-12). Here we present a simple strategy for the design of artificial membrane ion channels based on a self-assembled cylindrical beta-sheet peptide architecture(13). Our systems-essentially stacks of peptide rings-display good channel-mediated ion-transport activity with rates exceeding 10(7) ions s(-1), rivalling the performance of many naturally occurring counterparts. Such molecular assemblies should find use in the design of novel cytotoxic agents, membrane transport vehicles and drug-delivery systems.	SCRIPPS RES INST, DEPT MOLEC BIOL & CELL BIOL, LA JOLLA, CA 92307 USA	Scripps Research Institute	GHADIRI, MR (corresponding author), SCRIPPS RES INST, DEPT CHEM, LA JOLLA, CA 92307 USA.		Granja, Juan R/P-7646-2014	Granja, Juan R/0000-0002-5842-7504				AKERFELDT KS, 1993, ACCOUNTS CHEM RES, V26, P191, DOI 10.1021/ar00028a009; ALLEN LC, 1975, P NATL ACAD SCI USA, V72, P4701, DOI 10.1073/pnas.72.12.4701; ANZAI K, 1991, BIOCHIM BIOPHYS ACTA, V1064, P256, DOI 10.1016/0005-2736(91)90310-5; BAMBERG E, 1974, BIOCHIM BIOPHYS ACTA, V367, P127, DOI 10.1016/0005-2736(74)90037-6; CARMICHAEL VE, 1989, J AM CHEM SOC, V111, P767, DOI 10.1021/ja00184a075; CLEMENT NR, 1981, BIOCHEMISTRY-US, V20, P1544, DOI 10.1021/bi00509a021; CLEMENT NR, 1981, BIOCHEMISTRY-US, V20, P1539, DOI 10.1021/bi00509a020; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; FUHRHOP JH, 1988, J AM CHEM SOC, V110, P6840, DOI 10.1021/ja00228a037; FYLES TM, 1993, J AM CHEM SOC, V115, P12315, DOI 10.1021/ja00079a011; GHADIRI MR, 1993, NATURE, V366, P324, DOI 10.1038/366324a0; GROVE A, 1993, J AM CHEM SOC, V115, P5919, DOI 10.1021/ja00067a004; Hille B., 1992, IONIC CHANNELS EXCIT; JAYASURIYA N, 1990, J AM CHEM SOC, V112, P5844, DOI 10.1021/ja00171a026; KHAZANOVICH N, IN PRESS J AM CHEM S; LAUGER P, 1985, ANGEW CHEM INT EDIT, V24, P905, DOI 10.1002/anie.198509051; LAUGER P, 1985, ANGEW CHEM, V97, P939; MONTAL M, 1990, FASEB J, V4, P2623, DOI 10.1096/fasebj.4.9.1693348; MONTAL M, 1990, P NATL ACAD SCI USA, V87, P6929, DOI 10.1073/pnas.87.18.6929; NABEDRYK E, 1982, BIOPHYS J, V38, P243, DOI 10.1016/S0006-3495(82)84555-4; NAKANO A, 1990, J AM CHEM SOC, V112, P1287, DOI 10.1021/ja00159a083; New RR, 1990, LIPOSOMES; OLSON F, 1979, BIOCHIM BIOPHYS ACTA, V557, P9, DOI 10.1016/0005-2736(79)90085-3; Pregel M. J., 1992, ANGEW CHEM, V104, P1695; PREGEL MJ, 1992, ANGEW CHEM INT EDIT, V31, P1637, DOI 10.1002/anie.199216371; ROKS MFM, 1992, MACROMOLECULES, V25, P5398, DOI 10.1021/ma00046a042; ROVERO P, 1991, TETRAHEDRON LETT, V32, P2639, DOI 10.1016/S0040-4039(00)78806-X; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; SUAREZISLA BA, 1983, BIOCHEMISTRY-US, V22, P2319, DOI 10.1021/bi00279a003; SZOKA F, 1978, P NATL ACAD SCI USA, V75, P4194, DOI 10.1073/pnas.75.9.4194; WEINSTEIN JN, 1977, SCIENCE, V195, P489, DOI 10.1126/science.835007	32	809	843	9	263	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 26	1994	369	6478					301	304		10.1038/369301a0	http://dx.doi.org/10.1038/369301a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NN109	7514275				2022-12-24	WOS:A1994NN10900043
J	TAYLOR, SJ; SHALLOWAY, D				TAYLOR, SJ; SHALLOWAY, D			AN RNA-BINDING PROTEIN ASSOCIATED WITH SRC THROUGH ITS SH2 AND SH3 DOMAINS IN MITOSIS	NATURE			English	Article							MOLECULAR-CLONING; ACTIVATION; P60C-SRC; PHOSPHORYLATION; PP60C-SRC	THE tyrosine kinase activity of c-Src is stimulated during mitosis by dephosphorylation of its regulatory tyrosine residue(1-3). This is associated with increased accessibility of its Src homology-2 (SH2) domain for binding a phosphotyrosine-containing peptide(4). But physiological targets of activated c-Src in mitosis have not yet been identified. Here we report that a 68K protein (p68) becomes tyrosine-phosphorylated and physically associates with Src during mitosis in mouse fibroblasts. p68 independently binds the Src SH2 and SH3 domains in vitro and both domains are required for p68 phosphorylation and binding in vivo. p68 is closely related to the p62 protein that is associated with the Ras GTPase-activating protein (GAP)(5) and selectively binds, directly or indirectly, polyribonucleotides. Because the Src SH3 domain also binds heterogeneous nuclear ribonucleoprotein K, these results raise the intriguing possibility that c-Src may regulate the processing, trafficking or translation of RNA in a cell-cycle-dependent manner.			TAYLOR, SJ (corresponding author), CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,ITHACA,NY 14853, USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ASHLEY CT, 1993, SCIENCE, V262, P563, DOI 10.1126/science.7692601; BAGRODIA S, 1993, MOL CELL BIOL, V13, P1464, DOI 10.1128/MCB.13.3.1464; BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BAGRODIA S, 1994, J BIOL CHEM, V269, P10247; BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; ENGEBRECHT J, 1991, CELL, V66, P1257, DOI 10.1016/0092-8674(91)90047-3; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; GIBSON TJ, 1993, FEBS LETT, V324, P361, DOI 10.1016/0014-5793(93)80152-K; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; KAECH S, 1991, NATURE, V350, P431, DOI 10.1038/350431a0; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; PINOLROMA S, 1991, SCIENCE, V253, P312, DOI 10.1126/science.1857966; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; TAYLOR SJ, 1993, CURR OPIN GENET DEV, V3, P26, DOI 10.1016/S0959-437X(05)80337-5; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; XING Z, IN PRESS MOL BIOL CE	26	391	400	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 28	1994	368	6474					867	871		10.1038/368867a0	http://dx.doi.org/10.1038/368867a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH717	7512694				2022-12-24	WOS:A1994NH71700075
J	SILVENNOINEN, O; IHLE, JN; SCHLESSINGER, J; LEVY, DE				SILVENNOINEN, O; IHLE, JN; SCHLESSINGER, J; LEVY, DE			INTERFERON-INDUCED NUCLEAR SIGNALING BY JAK PROTEIN-TYROSINE KINASES	NATURE			English	Article								INTERFERONS IFN-alpha/beta and IFN-gamma act through independent cell-surface receptors, inducing gene expression through tyrosine phosphorylation of cytoplasmic transcription factors1-5. IFN-alpha stimulates phosphorylation and nuclear localization of the 84/91K and 113K subunits of latent ISGF3 (interferon-stimulated gene factor 3), which combine with the 48K DNA-binding subunit6,7 to bind regulatory elements of IFN-alpha-responsive genes8-10. IFN-gamma activates p91 alone2, inducing IFN-gamma-responsive genes through a distinct DNA element11,12. Genetic complementation studies implicated the tyrosine kinase Tyk2 in IFN-alpha signalling13 and, more recently, the related Jak2 kinase in IFN-gamma signalling14. We now present biochemical evidence for Jak-family kinase involvement in IFN signal transduction. Jak1 was activated in response to IFN-alpha and IFN-gamma; Jak2 responded exclusively to IFN-gamma. Overexpression of either Jak1 or Jak2 stimulated p91 DNA-binding activity and p91-dependent transcription. Overexpression also activated endogenous Jak kinases, suggesting that interactions between Jak kinases are required during interferon signalling.	NYU, SCH MED, KAPLAN COMPREHENS, CANC CTR, NEW YORK, NY 10016 USA; NYU, SCH MED, DEPT PHARMACOL, NEW YORK, NY 10016 USA; NYU, SCH MED, DEPT PATHOL, NEW YORK, NY 10016 USA; ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA	New York University; New York University; New York University; St Jude Children's Research Hospital			Levy, David/AAG-6202-2019; Levy, David/GPS-4945-2022	Levy, David/0000-0002-7320-7788; 				CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GUTCH MJ, 1992, P NATL ACAD SCI USA, V89, P11411, DOI 10.1073/pnas.89.23.11411; KESSLER DS, 1991, J BIOL CHEM, V266, P23471; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SCHUAI K, 1992, SCIENCE, V258, P1808; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; VEALS SA, 1993, MOL CELL BIOL, V13, P196, DOI 10.1128/MCB.13.1.196; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WATING D, 1993, NATURE, V366, P166; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	28	325	332	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 9	1993	366	6455					583	585		10.1038/366583a0	http://dx.doi.org/10.1038/366583a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML218	7504785				2022-12-24	WOS:A1993ML21800075
J	LI, B; TOM, JYK; OARE, D; YEN, R; FAIRBROTHER, WJ; WELLS, JA; CUNNINGHAM, BC				LI, B; TOM, JYK; OARE, D; YEN, R; FAIRBROTHER, WJ; WELLS, JA; CUNNINGHAM, BC			MINIMIZATION OF A POLYPEPTIDE HORMONE	SCIENCE			English	Article							HUMAN GROWTH-HORMONE; NATRIURETIC PEPTIDE RECEPTORS; EXTRACELLULAR DOMAIN; FUNCTIONAL EPITOPE; CYCLASE ACTIVATION; ANTIBODY; MUTAGENESIS; INHIBITORS; PROTEINS; ANALOGS	A stepwise approach for reducing the size of a polypeptide hormone, atrial natriuretic peptide (ANP), from 28 residues to 15 while retaining high biopotency is described. Systematic structural and functional analysis identified a discontinuous functional epitope for receptor binding and activation, most of which was placed onto a smaller ring (Cys(6) to Cys(17)) that was created by repositioning the ANP native disulfide bond (Cys(7) to Cys(23)). High affinity was subsequently restored by optimizing the remaining noncritical residues by means of phage display. Residues that flanked the mini-ring structure were then deleted in stages, and affinity losses were rectified by additional phage-sorting experiments. Thus, structural and functional data on hormones, coupled with phage display methods, can be used to shrink the hormones to moieties more amenable to small-molecule design.	GENENTECH INC,DEPT PROT ENGN,S SAN FRANCISCO,CA 94080; GENENTECH INC,BIOORGAN CHEM,S SAN FRANCISCO,CA 94080; GENENTECH INC,MED & ANALYT CHEM,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech			Wells, Jim A/O-9854-2016					BASS S, 1990, PROTEINS, V8, P309, DOI 10.1002/prot.340080405; BENNETT BD, 1991, J BIOL CHEM, V266, P23060; BOVY PR, 1989, J BIOL CHEM, V264, P20309; BOVY PR, 1992, J MED CHEM, V35, P808; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; COREY DR, 1994, P NATL ACAD SCI USA, V91, P4106, DOI 10.1073/pnas.91.10.4106; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; CUNNINGHAM BC, 1990, SCIENCE, V247, P1461, DOI 10.1126/science.2321008; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; CUNNINGHAM BC, 1994, EMBO J, V13, P2508, DOI 10.1002/j.1460-2075.1994.tb06540.x; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FAIRBROTHER WJ, 1994, BIOCHEMISTRY-US, V33, P8897, DOI 10.1021/bi00196a006; JANIN J, 1990, J BIOL CHEM, V265, P16027; JIN L, 1992, J MOL BIOL, V226, P851, DOI 10.1016/0022-2836(92)90636-X; JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0; KELLEY RF, 1993, BIOCHEMISTRY-US, V32, P6828, DOI 10.1021/bi00078a005; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAM PYS, 1994, SCIENCE, V263, P380, DOI 10.1126/science.8278812; LOWMAN HB, 1993, J MOL BIOL, V234, P564, DOI 10.1006/jmbi.1993.1612; LUNNEY EA, 1994, J MED CHEM, V37, P2664, DOI 10.1021/jm00043a006; MAACK T, 1992, ANNU REV PHYSIOL, V54, P11, DOI 10.1146/annurev.physiol.54.1.11; MCDOWELL RS, 1994, J AM CHEM SOC, V116, P5069, DOI 10.1021/ja00091a007; NAVIA MA, 1992, CURR OPIN STRUC BIOL, V2, P202; NUSS JM, 1993, PROTEINS, V15, P121, DOI 10.1002/prot.340150204; NUTT RF, 1989, SYNTHETIC PEPTIDES A, P267; NUTT RF, 1988, PEPTIDES CHEM BIOL, P444; PRESTA L, 1994, ANNU REP MED CHEM, V29, P317; SCARBOROUGH RM, 1986, J BIOL CHEM, V261, P2960; SHOICHET BK, 1993, SCIENCE, V259, P1445, DOI 10.1126/science.8451640; TULIP WR, 1994, BIOCHEMISTRY-US, V33, P7986, DOI 10.1021/bi00192a002; VONGELDERN TW, 1992, J MED CHEM, V35, P808, DOI 10.1021/jm00083a003; VONITZSTEIN M, 1993, NATURE, V363, P418, DOI 10.1038/363418a0; Wells J. A., 1992, CURR OPIN STRUC BIOL, V2, P597; WELLS JA, 1994, P NATL ACAD SCI USA, V91, P4110, DOI 10.1073/pnas.91.10.4110; WELLS JA, 1991, METHODS ENZYMOL, V202	36	123	142	0	9	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 8	1995	270	5242					1657	1660		10.1126/science.270.5242.1657	http://dx.doi.org/10.1126/science.270.5242.1657			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ293	7502074				2022-12-24	WOS:A1995TJ29300046
J	MORISHITA, T; MITSUZAWA, H; NAKAFUKU, M; NAKAMURA, S; HATTORI, S; ANRAKU, Y				MORISHITA, T; MITSUZAWA, H; NAKAFUKU, M; NAKAMURA, S; HATTORI, S; ANRAKU, Y			REQUIREMENT OF SACCHAROMYCES-CEREVISIAE RAS FOR COMPLETION OF MITOSIS	SCIENCE			English	Article							PROTEIN-KINASE; ADENYLATE-CYCLASE; SHUTTLE VECTORS; YEAST; GENE; INTERACTS; ENCODES; RSR1	In the yeast Saccharomyces cerevisiae, Ras regulates adenylate cyclase, which is essential for progression through the G(1) phase of the cell cycle. However, even when the adenosine 3',5'-monophosph (cAMP) pathway was bypassed, the double disruption of RAS1 and RAS2 resulted in defects in growth at both low and high temperatures. Furthermore, the simultaneous disruption of RAS1, RAS2, and the RAS-related gene RSR1 was lethal at any temperature. The triple-disrupted cells were arrested late in the mitotic (M) phase, which was accompanied by an accumulation of cells with divided chromosomes and sustained histone H1 kinase activity. The lethality of the triple disruption was suppressed by the multicopies of CDC5, CDC15, DBF2, SPO12, and TEM1, all of which function in the completion of the M phase. Mammalian ras also suppressed the lethality, which suggests that a similar signaling pathway exists in higher eukaryotes. These results demonstrate that S. cerevisiae Ras functions in the completion of the M phase in a manner independent of the Ras-cAMP pathway.	NATL CTR NEUROL & PSYCHIAT,NATL INST NEUROSCI,DIV BIOCHEM & CELLULAR BIOL,KODAIRA 187,TOKYO,JAPAN; UNIV TOKYO,GRAD SCH SCI,DEPT PLANT SCI,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,INST MOLEC & CELLULAR BIOSCI,BUNKYO KU,TOKYO 113,JAPAN	National Center for Neurology & Psychiatry - Japan; University of Tokyo; University of Tokyo			Nakafuku, Masato/J-3068-2013	Nakafuku, Masato/0000-0001-7783-9005				AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BECKNER SK, 1985, NATURE, V317, P71, DOI 10.1038/317071a0; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; Broach J R, 1990, Adv Cancer Res, V54, P79, DOI 10.1016/S0065-230X(08)60809-X; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; CHANT J, 1991, CELL, V65, P1213, DOI 10.1016/0092-8674(91)90016-R; DAAR I, 1991, SCIENCE, V253, P74, DOI 10.1126/science.1829549; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FUKUI Y, 1986, CELL, V44, P329, DOI 10.1016/0092-8674(86)90767-1; GIBBS JB, 1987, J BIOL CHEM, V262, P10426; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; MORISHITA T, UNPUB; POWERS S, 1991, CELL, V65, P1231; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; RODRIGUEZVICIAN.P, 1994, NATURE, V370, P527; RUGGIERI R, 1992, MOL CELL BIOL, V12, P758, DOI 10.1128/MCB.12.2.758; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCHWEITZER B, 1991, YEAST, V7, P265, DOI 10.1002/yea.320070308; SHIRAYAMA M, 1994, MOL CELL BIOL, V14, P7476, DOI 10.1128/MCB.14.11.7476; SHIRAYAMA M, 1994, YEAST, V10, P451, DOI 10.1002/yea.320100404; SIKORSKI RS, 1989, GENETICS, V122, P19; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; TODA T, 1987, ONCOGENES CANCER, P253; TOYN JH, 1993, GENETICS, V135, P963; TOYN JH, 1994, EMBO J, V13, P1103, DOI 10.1002/j.1460-2075.1994.tb06359.x; WIGLER M, 1988, COLD SPRING HARB SYM, V53, P649, DOI 10.1101/SQB.1988.053.01.074	31	57	58	0	2	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 17	1995	270	5239					1213	1215		10.1126/science.270.5239.1213	http://dx.doi.org/10.1126/science.270.5239.1213			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE905	7502049				2022-12-24	WOS:A1995TE90500061
J	PUGLISI, JD; CHEN, L; BLANCHARD, S; FRANKEL, AD				PUGLISI, JD; CHEN, L; BLANCHARD, S; FRANKEL, AD			SOLUTION STRUCTURE OF A BOVINE IMMUNODEFICIENCY VIRUS TAT-TAR PEPTIDE-RNA COMPLEX	SCIENCE			English	Article							LONG TERMINAL REPEAT; CRYSTAL-STRUCTURE; NMR-SPECTROSCOPY; MINOR-GROOVE; RECOGNITION; SYNTHETASE; DNA; CONFORMATION; SPECIFICITY; RESOLUTION	The Tat protein of bovine immunodeficiency virus (BIV) binds to its target RNA, TAR, and activates transcription. A 14-amino acid arginine-rich peptide corresponding to the RNA-binding domain of BIV Tat binds specifically to BIV TAR, and biochemical and in vivo experiments have identified the amino acids and nucleotides required for binding, The solution structure of the RNA-peptide complex has now been determined by nuclear magnetic resonance spectroscopy. TAR forms a virtually continuous A-form helix with two unstacked bulged nucleotides. The peptide adopts a beta-turn conformation and sits in the major groove of the RNA. Specific contacts are apparent between critical amino acids in the peptide and bases and phosphates in the RNA. The structure is consistent with ail biochemical data and demonstrates ways in which proteins can recognize the major groove of RNA.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,GLADSTONE INST VIROL & IMMUNOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; The J David Gladstone Institutes	PUGLISI, JD (corresponding author), UNIV CALIF SANTA CRUZ,DEPT CHEM & BIOCHEM,SANTA CRUZ,CA 95064, USA.		Blanchard, Scott C./A-5804-2009	Blanchard, Scott C./0000-0003-2717-9365	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029135, F32AI008591] Funding Source: NIH RePORTER; NIAID NIH HHS [AI29135, AI08591] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BATEY RT, 1992, NUCLEIC ACIDS RES, V20, P4515, DOI 10.1093/nar/20.17.4515; BATTISTE JL, 1994, BIOCHEMISTRY-US, V33, P2741, DOI 10.1021/bi00176a001; BREG JN, 1990, NATURE, V346, P586, DOI 10.1038/346586a0; CARPENTER S, 1993, J VIROL, V67, P4399, DOI 10.1128/JVI.67.7.4399-4403.1993; CAVARELLI J, 1993, NATURE, V362, P181, DOI 10.1038/362181a0; CHEN L, 1995, P NATL ACAD SCI USA, V92, P5077, DOI 10.1073/pnas.92.11.5077; CHEN L, 1994, BIOCHEMISTRY-US, V33, P2708, DOI 10.1021/bi00175a046; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P8172, DOI 10.1021/bi00487a027; Creighton T. E., 1993, PROTEINS STRUCTURES; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KING CY, 1993, P NATL ACAD SCI USA, V90, P11990, DOI 10.1073/pnas.90.24.11990; NIKONOWICZ EP, 1993, J MOL BIOL, V232, P1141, DOI 10.1006/jmbi.1993.1466; NIKONOWICZ EP, 1992, NUCLEIC ACIDS RES, V20, P4507, DOI 10.1093/nar/20.17.4507; OTTING G, 1990, Q REV BIOPHYS, V23, P39, DOI 10.1017/S0033583500005412; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; PALLANSCH LA, 1992, J VIROL, V66, P2647, DOI 10.1128/JVI.66.5.2647-2652.1992; PETERSON RD, 1994, BIOCHEMISTRY-US, V33, P5357, DOI 10.1021/bi00184a001; Puglisi JD, 1995, METHOD ENZYMOL, V261, P323; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; RAUMANN BE, 1994, NATURE, V367, P754, DOI 10.1038/367754a0; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SANTORO J, 1992, J MAGN RESON, V97, P202, DOI 10.1016/0022-2364(92)90250-B; SHUMACHER MA, 1994, SCIENCE, V266, P763; SMALLCOMBE SH, 1993, J AM CHEM SOC, V115, P4776, DOI 10.1021/ja00064a043; SOMERS WS, 1992, NATURE, V359, P387, DOI 10.1038/359387a0; TAN RY, 1995, P NATL ACAD SCI USA, V92, P5282, DOI 10.1073/pnas.92.12.5282; TAN RY, 1993, CELL, V73, P1031, DOI 10.1016/0092-8674(93)90280-4; TAO JS, 1992, P NATL ACAD SCI USA, V89, P2723, DOI 10.1073/pnas.89.7.2723; VALEGARD K, 1994, NATURE, V371, P623, DOI 10.1038/371623a0; WEEKS KM, 1992, BIOCHEMISTRY-US, V31, P10281, DOI 10.1021/bi00157a015; WEEKS KM, 1993, SCIENCE, V261, P1574, DOI 10.1126/science.7690496; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; XU WG, 1995, CELL, V80, P639, DOI 10.1016/0092-8674(95)90518-9	36	317	328	1	21	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 17	1995	270	5239					1200	1203		10.1126/science.270.5239.1200	http://dx.doi.org/10.1126/science.270.5239.1200			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE905	7502045				2022-12-24	WOS:A1995TE90500057
J	DESJARLAIS, DC; HAGAN, H; FRIEDMAN, SR; FRIEDMANN, P; GOLDBERG, D; FRISCHER, M; GREEN, S; TUNVING, K; LJUNGBERG, B; WODAK, A; ROSS, M; PURCHASE, D; MILLSON, ME; MYERS, T				DESJARLAIS, DC; HAGAN, H; FRIEDMAN, SR; FRIEDMANN, P; GOLDBERG, D; FRISCHER, M; GREEN, S; TUNVING, K; LJUNGBERG, B; WODAK, A; ROSS, M; PURCHASE, D; MILLSON, ME; MYERS, T			MAINTAINING LOW HIV SEROPREVALENCE IN POPULATIONS OF INJECTING DRUG-USERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SYRINGE EXCHANGE; INFECTION; AIDS; PREVENTION; BEHAVIORS; SAMPLES; GLASGOW; SWEDEN; HEALTH	Objectives.-To describe prevention activities and risk behavior in cities where human immunodeficiency virus (HIV) was introduced into the local population of injecting drug users (IDUs), but where seroprevalence has nevertheless remained low (<5%) during at least 5 years. Design and Setting.-A literature search identified five such cities: Glasgow, Scotland; Lund, Sweden; Sydney, New South Wales, Australia; Tacoma, Wash; and Toronto, Ontario, Case histories were prepared for each city, including data on prevention activities and current levels of risk behavior among IDUs. Participants.-Injecting drug users recruited from both drug treatment and nontreatment settings in each city. Interventions.-A variety of HIV prevention activities for IDUs had been implemented in each of the five cities. Results.-There were three common prevention components present in all five cities: (1) implementation of prevention activities when HIV seroprevalence was still low, (2) provision of sterile injection equipment, and (3) community outreach to IDUs, Moderate levels of risk behavior continued with one third or more of the IDUs reporting recent unsafe injections. Conclusions.-In low-seroprevalence areas, it appears possible to severely limit transmission of HIV among populations of IDUs, despite continuing risk behavior among a substantial proportion of the population. Pending further studies, the common prevention components (beginning early, community outreach, and access to sterile injection equipment) should be implemented wherever populations of IDUs are at risk for rapid spread of HIV.	NATL DEV & RES INST INC,NEW YORK,NY; TACOMA PIERCE CTY HLTH DEPT,TACOMA,WA; POINT DEFIANCE AIDS PREVENT PROJECT,TACOMA,WA; RUCHILL HOSP,COMMUNICABLE DIS SCOTLAND UNIT,GLASGOW G20 9NB,LANARK,SCOTLAND; LUND UNIV,DEPT PSYCHIAT & NEUROCHEM,S-22101 LUND,SWEDEN; LUND UNIV,DEPT INFECT DIS,S-22101 LUND,SWEDEN; ST VINCENTS HOSP,ALCOHOL & DRUG SERV,SYDNEY,NSW 2010,AUSTRALIA; NATL CTR HIV SOCIAL RES,SYDNEY,NSW,AUSTRALIA; UNIV TORONTO,DEPT PREVENT MED & BIOSTAT,TORONTO,ON,CANADA; UNIV TORONTO,DEPT HLTH ADM,TORONTO,ON,CANADA	National Development & Research Institutes, Inc; Lund University; Lund University; St Vincents Hospital Sydney; University of Toronto; University of Toronto	DESJARLAIS, DC (corresponding author), BETH ISRAEL MED CTR,INST CHEM DEPENDENCY,11 BEACH ST,NEW YORK,NY 10013, USA.			Ross, Michael/0000-0002-5718-9989	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA003574] Funding Source: NIH RePORTER; NIDA NIH HHS [DA03574] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ANDERSON RM, 1991, NATURE, V352, P581, DOI 10.1038/352581a0; BAKER M, 1991, 7TH INT C AIDS FLOR; BROWN BS, 1993, HDB RISK AIDS; CARR SV, 1992, AIDS, V6, P1553, DOI 10.1097/00002030-199212000-00028; CHITWOOD DD, 1994, AM J PUBLIC HEALTH, V84, P350, DOI 10.2105/AJPH.84.3.350; CHRISTENSSON B, 1991, INT J ADDICT, V26, P1293, DOI 10.3109/10826089109062161; CORDERO LA, 1986, REV ROUM MATH PURE A, V31, P9; DESJARLAIS DC, 1994, AM J PUBLIC HEALTH, V84, P452, DOI 10.2105/AJPH.84.3.452; DESJARLAIS DC, 1992, AIDS, V6, P1053, DOI 10.1097/00002030-199210000-00001; DESJARLAIS DC, 1989, JAMA-J AM MED ASSOC, V261, P1008, DOI 10.1001/jama.261.7.1008; DESJARLAIS DC, 1994, FINAL REPORT WHO PRO; DESJARLAIS DC, 1992, AIDS OTHER MANIFESTA, P645; DESJARLAIS DC, 1994, 10TH INT C AIDS YOK; DICLEMENTE RJ, 1994, PREVENTING AIDS THEO; Dolan K A, 1993, Drug Alcohol Rev, V12, P133, DOI 10.1080/09595239300185561; EKSTRAND ML, 1990, AM J PUBLIC HEALTH, V80, P973, DOI 10.2105/AJPH.80.8.973; FRIEDMAN S R, 1991, AIDS Care, V3, P239, DOI 10.1080/09540129108253069; FRIEDMAN SR, 1993, AIDS, V7, pS263, DOI 10.1097/00002030-199301001-00037; FRISCHER M, 1992, AIDS, V6, P1371, DOI 10.1097/00002030-199211000-00022; FRISCHER M, 1992, INT J STD AIDS, V3, P288, DOI 10.1177/095646249200300412; FRISCHER M, 1993, INT J ADDICT, V28, P129, DOI 10.3109/10826089309039619; FRISCHER M, 1993, ADDICTION, V88, P681, DOI 10.1111/j.1360-0443.1993.tb02081.x; HAGAN H, 1993, ADDICTION, V88, P1691, DOI 10.1111/j.1360-0443.1993.tb02044.x; HAGAN H, 1991, Journal of Addictive Diseases, V10, P81, DOI 10.1300/J069v10n04_06; HAGAN H, 1993, HIV 1 SEROPREVALENCE; Kaldor J, 1993, Drug Alcohol Rev, V12, P175, DOI 10.1080/09595239300185611; Lamothe F, 1992, Can Commun Dis Rep, V18, P98; LAMPINEN TM, 1992, AIDS, V6, P123, DOI 10.1097/00002030-199201000-00017; LJUNGBERG B, 1991, J ACQ IMMUN DEF SYND, V4, P890; LURIE P, 1993, PUBLIC HLTH IMPACT N, V1; MILLSON P, 1991, NHRDP66064333AIDS NA; MILLSON P, 1993, 9 INT C AIDS BERL; MILLSON P, 1992, 2ND ANN CAN NAT C HI; NAIK TN, 1991, AIDS, V5, P117, DOI 10.1097/00002030-199101000-00026; NEAIGUS A, 1994, SOC SCI MED, V38, P67, DOI 10.1016/0277-9536(94)90301-8; OSMOND DH, 1992, ONDCP B, V7; PAPAEVANGELOU G, 1991, 7 INT C AIDS FLOR; ROBERTSON JR, 1986, BRIT MED J, V292, P527, DOI 10.1136/bmj.292.6519.527; ROSS MW, 1992, AIDS CARE, V4, P139, DOI 10.1080/09540129208253085; ROSS MW, IN PRESS J R SOC HLT; ROSS MW, IN PRESS AIDS CARE; STALL R, 1993, J ACQ IMMUN DEF SYND, V3, P1181; STIMSON GV, 1995, 6TH INT C RED DRUG R; STIMSON GV, IN PRESS SOC SCI MED; STIMSON GV, 1990, 6TH INT C AIDS SAN F; TAYLOR A, IN PRESS ADDICTION; TUNVING K, 1992, 8TH INT C AIDS AMST; VANICHSENI S, 1990, 6TH INT C AIDS SAN F	48	189	193	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 18	1995	274	15					1226	1231		10.1001/jama.274.15.1226	http://dx.doi.org/10.1001/jama.274.15.1226			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RZ120	7563513				2022-12-24	WOS:A1995RZ12000032
J	LEIJTEN, FSS; HARNICKDEWEERD, JE; POORTVLIET, DCJ; DEWEERD, AW				LEIJTEN, FSS; HARNICKDEWEERD, JE; POORTVLIET, DCJ; DEWEERD, AW			THE ROLE OF POLYNEUROPATHY IN MOTOR CONVALESCENCE AFTER PROLONGED MECHANICAL VENTILATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CRITICAL ILLNESS POLYNEUROPATHY; MULTIPLE-ORGAN FAILURE; ILL PATIENTS; SEPSIS; DEFINITIONS; NEUROPATHY; SEVERITY	Objective.-To test the hypothesis that prolonged motor recovery after longterm ventilation may be due to polyneuropathy and can be foreseen at an early stage by electromyography (EMG). Design.-Cohort study with an entry period of 18 months. Polyneuropathy was identified by EMG studies in the intensive care unit (ICU). During a 1-year followup, amount of time was recorded to reach a rehabilitation end point. Setting.-The general ICU of a community hospital. Patients.-Fifty patients younger than 75 years who were receiving mechanical ventilation for more than 7 days. Main Outcome Measures.-A rehabilitation end point was defined as return of normal muscle strength and ability to walk 50 m independently. Results.-In 29 of 50 patients, an EMG diagnosis of polyneuropathy was made in the ICU. Patients with polyneuropathy had a higher mortality in the ICU (14 vs 4; P=.03), probably related to multiple organ failure (22 vs 11; P=.08) oraminoglycoside treatment of suspected gram-negative sepsis (17 vs 4; P=.05). Rehabilitation was more prolonged in 12 patients with polyneuropathy than in 12 without polyneuropathy (P=.001). Of nine patients with delays beyond 4 weeks, eight had polyneuropathy, five of whom had persistent motor handicap after 1 year. In particular, axonal polyneuropathy with conduction slowing on EMG indicated a poor prognosis. Conclusions.-Polyneuropathy in the critically ill is related to multiple organ failure and gram-negative sepsis, is associated with higher mortality, and causes important rehabilitation problems. EMG recordings in the ICU can identify patients at risk.	WESTEINDE ZIEKENHUIS,DEPT NEUROL,THE HAGUE,NETHERLANDS; WESTEINDE ZIEKENHUIS,DEPT CLIN NEUROPHYSIOL,THE HAGUE,NETHERLANDS; WESTEINDE ZIEKENHUIS,DEPT ANESTHESIOL & INTENS CARE,THE HAGUE,NETHERLANDS									[Anonymous], 1976, AIDS INVESTIGATION P; ASBURY AK, 1990, ANN NEUROL, V27, pS21, DOI 10.1002/ana.410270707; BARAT M, 1987, REV NEUROL, V143, P823; BOLTON CF, 1986, J NEUROL NEUROSUR PS, V49, P563, DOI 10.1136/jnnp.49.5.563; BOLTON CF, 1984, J NEUROL NEUROSUR PS, V47, P1223, DOI 10.1136/jnnp.47.11.1223; Bolton CF, 1983, NEUROLOGY CLEVELA S2, V33, P186; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; COAKLEY JH, 1993, INTENS CARE MED, V19, P323, DOI 10.1007/BF01694705; CORONEL B, 1990, CRIT CARE MED, V18, P486, DOI 10.1097/00003246-199005000-00004; DECOUL AAW, 1983, CLIN NEUROL NEUROSUR, V85, P197; DECOUL AAWO, 1985, CLIN NEUROL NEUROSUR, V87, P17, DOI 10.1016/0303-8467(85)90060-5; DECOUL AAWO, 1991, CLIN NEUROL NEUROSUR, V93, P27, DOI 10.1016/0303-8467(91)90005-A; DODSON BA, 1995, CRIT CARE MED, V23, P815, DOI 10.1097/00003246-199505000-00007; GORIS RJA, 1985, ARCH SURG-CHICAGO, V120, P1109; GORSON KC, 1993, CRIT CARE MED, V21, P267, DOI 10.1097/00003246-199302000-00020; KELLY BJ, 1993, CHEST, V104, P1818, DOI 10.1378/chest.104.6.1818; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LEIJTEN FSS, 1994, CLIN NEUROL NEUROSUR, V96, P10, DOI 10.1016/0303-8467(94)90023-X; LEMAIRE F, 1993, INTENS CARE MED, V19, pS69, DOI 10.1007/BF01708804; MESSA JBL, 1990, INTENS CARE MED, V16, P159, DOI 10.1007/BF01724794; NIJHOLT JLA, 1987, HDB CLIN NEUROLOGY, V7, P575; REPINE JE, 1992, LANCET, V339, P466, DOI 10.1016/0140-6736(92)91067-I; RIVNER MH, 1983, NEUROLOGY S2, V33, P164; Roelofs RI, 1983, NEUROLOGY S, V33, P240; SEISER A, 1992, WIEN KLIN WOCHENSCHR, V104, P294; SPITZER AR, 1992, MUSCLE NERVE, V15, P682, DOI 10.1002/mus.880150609; SPRUNG CL, 1991, CRIT CARE MED, V19, P849; WILLIAMS AC, 1986, BRIT MED J, V293, P790, DOI 10.1136/bmj.293.6550.790-a; WITT NJ, 1991, CHEST, V99, P176, DOI 10.1378/chest.99.1.176; ZOCHODNE DW, 1987, BRAIN, V110, P819, DOI 10.1093/brain/110.4.819	30	201	204	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 18	1995	274	15					1221	1225		10.1001/jama.274.15.1221	http://dx.doi.org/10.1001/jama.274.15.1221			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ120	7563512				2022-12-24	WOS:A1995RZ12000031
J	SCHUMACHER, MA; CHOI, KY; LU, F; ZALKIN, H; BRENNAN, RG				SCHUMACHER, MA; CHOI, KY; LU, F; ZALKIN, H; BRENNAN, RG			MECHANISM OF COREPRESSOR-MEDIATED SPECIFIC DNA-BINDING BY THE PURINE REPRESSOR	CELL			English	Article							ESCHERICHIA-COLI; CYTR REPRESSOR; MET REPRESSOR; X-RAY; PROTEIN; LIGAND; COMPLEX; CAMP; CRP; CRYSTALLIZATION	The modulation of the affinity of DNA-binding proteins by small molecule effecters for cognate DNA sites is common to both prokaryotes and eukaryotes. However, the mechanisms by which effector binding to one domain affects DNA binding by a distal domain are poorly understood structurally. In initial studies to provide insight into the mechanism of effector-modulated DNA binding of the lactose repressor family, we determined the crystal structure of the purine repressor bound to a corepressor and purF operator. To extend our understanding, we have determined the structure of the corepressor-free corepressor-binding domain of the purine repressor at 2.2 Angstrom resolution. In the unliganded state, structural changes in the corepressor-binding pocket cause each subunit to rotate open by as much as 23 degrees, the consequences of which are the disengagement of the minor groove-binding hinge helices and repressor-DNA dissociation.	PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus	SCHUMACHER, MA (corresponding author), OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOLEC BIOL,PORTLAND,OR 97201, USA.			Brennan, Richard/0000-0001-7647-485X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049244, R37GM024658, R01GM024658] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-49244, GM-24658] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON BF, 1990, NATURE, V344, P784, DOI 10.1038/344784a0; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; CAREAGA CL, 1995, BIOCHEMISTRY-US, V34, P3048, DOI 10.1021/bi00009a036; CHOI KY, 1992, J BACTERIOL, V174, P6207, DOI 10.1128/JB.174.19.6207-6214.1992; CHOI KY, 1994, J BIOL CHEM, V269, P24066; CHOI KY, 1994, J BACTERIOL, V176, P1767, DOI 10.1128/jb.176.6.1767-1772.1994; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FRIEDMAN AM, 1995, SCIENCE, V268, P1721, DOI 10.1126/science.7792597; GRALLA JD, 1992, TRANSCRIPTIONAL REGU, V2, P629; Hammer-Jespersen K., 1983, METABOLISM NUCLEOTID, P203; HUECK CJ, 1995, MOL MICROBIOL, V15, P395, DOI 10.1111/j.1365-2958.1995.tb02252.x; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MAUZY CA, 1992, PROTEIN SCI, V1, P843, DOI 10.1002/pro.5560010702; MOLLEGAARD NE, 1993, J BIOL CHEM, V268, P17471; NAGADOI A, 1995, IN PRESS STRUCTURE; OH BH, 1993, J BIOL CHEM, V268, P11348; OLAH GA, 1993, J BIOL CHEM, V268, P16241; OTWINOWSKI Z, 1988, NATURE, V334, P321; PACE HC, 1990, P NATL ACAD SCI USA, V87, P1870, DOI 10.1073/pnas.87.5.1870; PEARL L, 1994, EMBO J, V13, P5810, DOI 10.1002/j.1460-2075.1994.tb06924.x; PEDERSEN H, 1992, J MOL BIOL, V227, P396, DOI 10.1016/0022-2836(92)90896-R; PHILLIPS K, 1994, STRUCTURE, V2, P309, DOI 10.1016/S0969-2126(00)00032-0; Quiocho FA, 1991, CURR OPIN STRUC BIOL, V1, P922, DOI 10.1016/0959-440X(91)90087-A; RAFFERTY JB, 1989, NATURE, V341, P705, DOI 10.1038/341705a0; ROLFES RJ, 1990, J BACTERIOL, V172, P5637, DOI 10.1128/jb.172.10.5637-5642.1990; SACK JS, 1989, J MOL BIOL, V206, P171, DOI 10.1016/0022-2836(89)90531-7; SAIER MH, 1995, TRENDS BIOCHEM SCI, V20, P267, DOI 10.1016/S0968-0004(00)89041-6; SCHUMACHER MA, 1992, J MOL BIOL, V225, P1131, DOI 10.1016/0022-2836(92)90111-V; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; SHARFF AJ, 1992, BIOCHEMISTRY-US, V31, P10657, DOI 10.1021/bi00159a003; SOGAARDANDERSEN L, 1993, CELL, V75, P557, DOI 10.1016/0092-8674(93)90389-8; SOMERS WS, 1992, NATURE, V359, P387, DOI 10.1038/359387a0; SOMERVILLE R, 1992, PROG NUCLEIC ACID RE, V42, P1, DOI 10.1016/S0079-6603(08)60572-3; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WEICKERT MJ, 1992, J BIOL CHEM, V267, P15869; ZALKIN H, 1992, PROG NUCLEIC ACID RE, V42, P259, DOI 10.1016/S0079-6603(08)60578-4	42	91	94	0	5	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 6	1995	83	1					147	155		10.1016/0092-8674(95)90243-0	http://dx.doi.org/10.1016/0092-8674(95)90243-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RY583	7553867	Bronze			2022-12-24	WOS:A1995RY58300019
J	LINGNER, J; COOPER, JP; CECH, TR				LINGNER, J; COOPER, JP; CECH, TR			TELOMERASE AND DNA END REPLICATION - NO LONGER A LAGGING-STRAND PROBLEM	SCIENCE			English	Editorial Material							TERMINAL TRANSFERASE-ACTIVITY; 3' TERMINUS; S-PHASE; SEQUENCES; MOLECULES; ORIGIN				LINGNER, J (corresponding author), UNIV COLORADO,DEPT CHEM & BIOCHEM,HOWARD HUGHES MED INST,BOULDER,CO 80309, USA.			Lingner, Joachim/0000-0002-2853-5803; cooper, julia promisel/0000-0003-2171-2587				BATEMAN AJ, 1975, NATURE, V253, P379, DOI 10.1038/253379a0; BLACKBURN EH, 1984, ANNU REV BIOCHEM, V53, P163, DOI 10.1146/annurev.bi.53.070184.001115; BLASCO MA, 1995, SCIENCE, V269, P1267, DOI 10.1126/science.7544492; CAVALIER.T, 1974, NATURE, V250, P467, DOI 10.1038/250467a0; COLLINS K, 1995, CELL, V81, P677, DOI 10.1016/0092-8674(95)90529-4; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HENDERSON ER, 1989, MOL CELL BIOL, V9, P345, DOI 10.1128/MCB.9.1.345; KLOBUTCHER LA, 1981, P NATL ACAD SCI-BIOL, V78, P3015, DOI 10.1073/pnas.78.5.3015; LEE MS, 1993, COLD SPRING HARB SYM, V58, P707, DOI 10.1101/SQB.1993.058.01.078; LINGNER J, UNPUB; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; Nakamura T., UNPUB; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WELLINGER RJ, 1993, MOL CELL BIOL, V13, P4057, DOI 10.1128/MCB.13.7.4057; WELLINGER RJ, 1993, CELL, V72, P51, DOI 10.1016/0092-8674(93)90049-V; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; ZAHLER AM, 1988, NUCLEIC ACIDS RES, V16, P6953, DOI 10.1093/nar/16.14.6953	20	306	319	0	30	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 15	1995	269	5230					1533	1534		10.1126/science.7545310	http://dx.doi.org/10.1126/science.7545310			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU813	7545310				2022-12-24	WOS:A1995RU81300029
J	VESPA, J; WATSON, F				VESPA, J; WATSON, F			WHO IS NUTRITIONALLY VULNERABLE IN BOSNIA-HERZEGOVINA	BRITISH MEDICAL JOURNAL			English	Article								Objective-To monitor nutritional status and food security in order to identify nutritionally vulnerable groups. Design-Members of five different household groups (urban and rural residents, displaced people in collective centres and private accommodation, elderly people living without younger family) and ail residents of two old people's homes were prospectively followed. Households were selected from 20 local communities and nine collective centres. Setting-Monitoring carried out in three besieged areas of Bosnia-Hercegovina (Sarajevo, Tuzla, and Zenica). Subjects-1739 individuals sampled. Interventions-Data collected every month from December 1993 to May 1994, Information on household food security was collected through structured questionnaires. AU subjects were weighed and their heights measured, Weight for age Z scores were calculated far children; body mass index was calculated for adults and elderly people. Results-From December 1993 to February 1994, before a temporary cease fire, access to food was reduced, In February 1994 no significant signs of undernutrition were detected among children or adults, but elderly people had higher than expected levels of undernutrition (15.5% with body mass index <18.5), a higher rate of weight loss than adults (1.2 kg over two months), and a higher prevalence of self reported illness. Conclusions-Elderly people in Bosnia-Hercegovina are at greater risk of undernutrition than other age groups, Undernutrition may be precipitated in elderly people by sickness, cold, stress, and problems related to food preparation, The health and welfare of elderly people during the emergency in Bosnia-Hercegovina require special attention, and integrated age care programmes are needed.	WHO,REG OFF EUROPE,ZAGREB AREA OFF,ZAGREB 4100,CROATIA	World Health Organization								BENNET GJ, 1992, ESSENTIALS HLTH CARE, P108; DEAN AD, 1990, EPI INFO SOFTWARE VE; EVNAS JG, 1992, OXFORD TXB GERIATRIC, P4; Gregory F., 1990, DIETARY NUTR SURVEY; JAMES WPT, 1994, J EUR CLIN NUTR S3, V48, P179; MURPHY E, 1985, PREVENTION DISEASE E, P156; ROBERTSON A, 1994, NUTRITION VACCINATIO; SHETTY PS, 1994, FAO56 FOOD NUTR PAP; 1992, REPORT HLTH SOCIAL S, V43; 1976, NCHS GROWTH CHARTS; 1992, MWMK, V41, P809; 1994, REPORT FOOD DELIVERI	12	24	24	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 9	1995	311	7006					652	654		10.1136/bmj.311.7006.652	http://dx.doi.org/10.1136/bmj.311.7006.652			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU753	7549631	Green Published			2022-12-24	WOS:A1995RU75300015
J	ROTHE, M; SARMA, V; DIXIT, VW; GOEDDEL, DV				ROTHE, M; SARMA, V; DIXIT, VW; GOEDDEL, DV			TRAF2-MEDIATED ACTIVATION OF NF-KAPPA-B BY TNF RECEPTOR-2 AND CD40	SCIENCE			English	Article							NECROSIS-FACTOR RECEPTORS	TNF receptor-associated factor (TRAF) proteins are candidate signal transducers that associate with the cytoplasmic domains of members of the tumor necrosis factor (TNF) receptor superfamily. The role of TRAFs in the TNF-R2 and CD40 signal transduction pathways, which result in the activation of transcription factor NF-kappa B, was investigated. Overexpression of TRAF2, but not TRAF1 or TRAF3, was sufficient to induce NF-kappa B activation. A truncated derivative of TRAF2 lacking an amino-terminal RING finger domain was a dominant-negative inhibitor of NF-kappa B activation mediated by TNF-R2 and CD40. Thus, TRAF2 is a common mediator of TNF-R2 and CD40 signaling.	TULARIK INC,DEPT MOLEC BIOL,S SAN FRANCISCO,CA 94080; UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NATIONAL CANCER INSTITUTE [R01CA064803] Funding Source: NIH RePORTER; NCI NIH HHS [CA64803] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; BERBERICH I, 1994, J IMMUNOL, V153, P4357; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; CHANG G, 1995, SCIENCE, V267, P1494; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hsu H.-J., UNPUB; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; HU HM, 1994, J BIOL CHEM, V269, P30069; LAEGREID A, 1994, J BIOL CHEM, V269, P7785; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PENNICA D, 1992, J BIOL CHEM, V267, P21172; ROTHE J, 1992, IMMUNOL RES, V11, P81, DOI 10.1007/BF02918612; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; ROTHE M, UNPUB; SARMA V, 1995, J BIOL CHEM, V270, P12343, DOI 10.1074/jbc.270.21.12343; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997	24	948	983	1	17	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 8	1995	269	5229					1424	1427		10.1126/science.7544915	http://dx.doi.org/10.1126/science.7544915			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT806	7544915				2022-12-24	WOS:A1995RT80600045
J	LEV, S; MORENO, H; MARTINEZ, R; CANOLL, P; PELES, E; MUSACCHIO, JM; PLOWMAN, GD; RUDY, B; SCHLESSINGER, J				LEV, S; MORENO, H; MARTINEZ, R; CANOLL, P; PELES, E; MUSACCHIO, JM; PLOWMAN, GD; RUDY, B; SCHLESSINGER, J			PROTEIN-TYROSINE KINASE PYK2 INVOLVED IN CA2+-INDUCED REGULATION OF ION-CHANNEL AND MAP KINASE FUNCTIONS	NATURE			English	Article							NERVE GROWTH-FACTOR; POTASSIUM CHANNEL; ACETYLCHOLINE-RECEPTOR; PC12 CELLS; RAS; PHOSPHORYLATION; ACTIVATION; GENE; TRANSFORMATION; DOMAINS	The protein tyrosine kinase PYK2, which is highly expressed in the central nervous system, is rapidly phosphorylated on tyrosine residues in response to various stimuli that elevate the intracellular calcium concentration, as well as by protein kinase C activation. Activation of PYK2 leads to modulation of ion channel function and activation of the MAP kinase signalling pathway. PYK2 activation may provide a mechanism for a variety of short- and long-term calcium-dependent signalling events in the nervous system.	NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016; NYU,MED CTR,DEPT PHYSIOL,NEW YORK,NY 10016; SUGEN INC,REDWOOD CITY,CA 94063	New York University; New York University			Lev, Sima/AAP-7880-2020; PLOWMAN, Greg D/E-2012-2011	Lev, Sima/0000-0002-2108-3330; Peles, Elior/0000-0002-3325-0597; Plowman, Gregory D/0000-0002-6465-309X; Rudy, Bernardo/0000-0001-5748-6900				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CHANDY KG, 1991, NATURE, V352, P26, DOI 10.1038/352026b0; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COVARRUBIAS M, 1994, NEURON, V13, P1403, DOI 10.1016/0896-6273(94)90425-1; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; FASOLATO C, 1988, J BIOL CHEM, V263, P17350; GHOSH A, 1994, J NEUROBIOL, V25, P294, DOI 10.1002/neu.480250309; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hille B., 1992, IONIC CHANNELS EXCIT; HUANG XY, 1993, CELL, V75, P1145, DOI 10.1016/0092-8674(93)90324-J; HUCKLE WR, 1992, P NATL ACAD SCI USA, V89, P8837, DOI 10.1073/pnas.89.18.8837; HUGANIR RL, 1990, NEURON, V5, P555, DOI 10.1016/0896-6273(90)90211-W; IVERSON LE, 1990, J NEUROSCI, V10, P2903; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; LAMMERS R, 1993, J BIOL CHEM, V248, P24456; LEV S, 1992, J BIOL CHEM, V267, P15970; Levitan IB, 1991, NEURON CELL MOL BIOL; LI M, 1993, SCIENCE, V261, P1439, DOI 10.1126/science.8396273; LI N, 1993, NATURE, V263, P85; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MANES E, 1993, NATURE, V363, P364; MARIAS R, 1993, CELL, V73, P381; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATTINGLY RR, 1994, MOL CELL BIOL, V14, P7943, DOI 10.1128/MCB.14.12.7943; MCKINNON D, 1989, J BIOL CHEM, V264, P8230; MESSING RO, 1989, J NEUROSCI, V9, P507; Moreno H., 1994, Society for Neuroscience Abstracts, V20, P725; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; PAULMICHL M, 1991, P NATL ACAD SCI USA, V88, P7892, DOI 10.1073/pnas.88.17.7892; PAWSON A, 1993, CURR BIOL, V3, P4345; PROUD D, 1988, ANNU REV IMMUNOL, V6, P49, DOI 10.1146/annurev.iy.06.040188.000405; REPP H, 1993, P NATL ACAD SCI USA, V90, P3403, DOI 10.1073/pnas.90.8.3403; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; Wagner K R, 1991, Curr Opin Neurobiol, V1, P65, DOI 10.1016/0959-4388(91)90011-U; WALLACE BG, 1991, NEURON, V6, P869, DOI 10.1016/0896-6273(91)90227-Q; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	50	1252	1275	0	37	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 31	1995	376	6543					737	745		10.1038/376737a0	http://dx.doi.org/10.1038/376737a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR836	7544443				2022-12-24	WOS:A1995RR83600031
J	ELLIS, LM; FIDLER, IJ				ELLIS, LM; FIDLER, IJ			ANGIOGENESIS AND BREAST-CANCER METASTASIS	LANCET			English	Editorial Material							INDEPENDENT PROGNOSTIC INDICATOR; TUMOR ANGIOGENESIS; CARCINOMA		UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CELL BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center	ELLIS, LM (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT SURG,HOUSTON,TX 77030, USA.							BOSARI S, 1992, HUM PATHOL, V23, P755, DOI 10.1016/0046-8177(92)90344-3; FIDLER IJ, 1990, CANCER RES, V50, P6130; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; GASPARINI G, 1994, J CLIN ONCOL, V12, P454, DOI 10.1200/JCO.1994.12.3.454; GASPARINI G, 1995, J CLIN ONCOL, V13, P765, DOI 10.1200/JCO.1995.13.3.765; Hall N R, 1992, Surg Oncol, V1, P223, DOI 10.1016/0960-7404(92)90068-V; HARRIS JR, 1991, BREAST DISEASES, P327; HORAK ER, 1992, LANCET, V340, P1120, DOI 10.1016/0140-6736(92)93150-L; KITADAI Y, IN PRESS CLIN CANCER; OBERMAIR A, 1994, CHIRURG, V65, P611; Paget S., 1889, LANCET, V1, P571, DOI DOI 10.1016/S0140-6736(00)49915-0; Singh R. K., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P87; TOI M, 1993, INT J CANCER, V55, P371, DOI 10.1002/ijc.2910550305; VANHOEF MEHM, 1993, EUR J CANCER, V29A, P1141; VISSCHER DW, 1993, ANAL QUANT CYTOL, V15, P88; WEIDNER N, 1992, JNCI-J NATL CANCER I, V84, P1875, DOI 10.1093/jnci/84.24.1875; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101	18	58	60	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 12	1995	346	8972					388	390		10.1016/S0140-6736(95)92774-3	http://dx.doi.org/10.1016/S0140-6736(95)92774-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN656	7542721	Bronze			2022-12-24	WOS:A1995RN65600003
J	CASTANO, AR; TANGRI, S; MILLER, JEW; HOLCOMBE, HR; JACKSON, MR; HUSE, WD; KRONENBERG, M; PETERSON, PA				CASTANO, AR; TANGRI, S; MILLER, JEW; HOLCOMBE, HR; JACKSON, MR; HUSE, WD; KRONENBERG, M; PETERSON, PA			PEPTIDE BINDING AND PRESENTATION BY MOUSE CD1	SCIENCE			English	Article							LYMPHOCYTES-T; MOLECULES; CELLS; RECOGNITION; SPECIFICITY; ANTIGENS; AFFINITY; HLA-DR1; GENES	CD1 molecules are distantly related to the major histocompatibility complex (MHC) class proteins. They are of unknown function. Screening random peptide phage display libraries with soluble empty mouse CD1 (mCD1) identified a peptide binding motif. It consists of three anchor positions occupied by aromatic or bulky hydrophobic amino acids, Equilibrium binding studies demonstrated that mCD1 binds peptides containing the appropriate motif with relatively high affinity. However, in contrast to classical MHC class I molecules, strong binding to mCD1 required relatively long peptides. Peptide-specific, mCD1-restricted T cell responses can be raised, which suggests that the findings are of immunological significance.	Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; UNIV CALIF LOS ANGELES, DEPT MICROBIOL & IMMUNOL, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90095 USA; IXSYS, SAN DIEGO, CA 92121 USA	Scripps Research Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles			Castaño, A. Raul/A-5905-2012	Castaño, A. Raul/0000-0003-2107-8862				BALK SP, 1991, J IMMUNOL, V146, P768; BALK SP, 1991, SCIENCE, V253, P1411, DOI 10.1126/science.1716785; BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0; BENDELAC A, 1995, SCIENCE, V268, P83; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BRADBURY A, 1988, EMBO J, V7, P3081, DOI 10.1002/j.1460-2075.1988.tb03173.x; CALABI F, 1989, EUR J IMMUNOL, V19, P285, DOI 10.1002/eji.1830190211; CALABI F, 1986, NATURE, V323, P540, DOI 10.1038/323540a0; CASTANO AM, UNPUB; CHICZ RM, 1992, NATURE, V358, P764, DOI 10.1038/358764a0; FAHNESTOCK ML, 1994, BIOCHEMISTRY-US, V33, P8149, DOI 10.1021/bi00192a020; FANG TAT, 1990, J IMMUNOL, V144, P1744; FITHIAN E, 1981, P NATL ACAD SCI-BIOL, V78, P2541, DOI 10.1073/pnas.78.4.2541; HAMMER J, 1992, J EXP MED, V176, P1007, DOI 10.1084/jem.176.4.1007; HAMMER J, 1993, CELL, V74, P197, DOI 10.1016/0092-8674(93)90306-B; HARBOW E, 1988, ANTIBODIES LABORATOR, P336; HUNT DF, 1992, SCIENCE, V256, P1817, DOI 10.1126/science.1319610; JACKSON MR, 1992, P NATL ACAD SCI USA, V89, P12117, DOI 10.1073/pnas.89.24.12117; MILLER JA, UNPUB; MULLER R, 1983, METHOD ENZYMOL, V92, P589; PORCELLI S, 1989, NATURE, V341, P447, DOI 10.1038/341447a0; PORCELLI S, 1992, NATURE, V360, P593, DOI 10.1038/360593a0; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SAITO Y, 1993, J BIOL CHEM, V268, P21309; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; SHAWAR SM, 1991, J EXP MED, V174, P941, DOI 10.1084/jem.174.4.941; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; SYKULEV Y, 1994, IMMUNITY, V1, P15, DOI 10.1016/1074-7613(94)90005-1; TANGRI S, UNPUB; TEITELL M, UNPUB; TERHORST C, 1981, CELL, V23, P771, DOI 10.1016/0092-8674(81)90441-4; VANDERIJN M, 1984, HUM IMMUNOL, V9, P201, DOI 10.1016/0198-8859(84)90025-9; WANG CB, IN PRESS	33	223	236	0	11	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 14	1995	269	5221					223	226		10.1126/science.7542403	http://dx.doi.org/10.1126/science.7542403			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ029	7542403				2022-12-24	WOS:A1995RJ02900040
J	UMBHAUER, M; MARSHALL, CJ; MASON, CS; OLD, RW; SMITH, JC				UMBHAUER, M; MARSHALL, CJ; MASON, CS; OLD, RW; SMITH, JC			MESODERM INDUCTION IN XENOPUS CAUSED BY ACTIVATION OF MAP KINASE	NATURE			English	Article							MIDBLASTULA TRANSITION; SPEMANN ORGANIZER; RAF-1 KINASE; EXPRESSION; FGF; EMBRYOS; TRANSCRIPTION; P21RAS; NOGGIN; LAEVIS	MESODERM induction is a critical early step in vertebrate development, involving changes in gene expression and morphogenesis(1), In Xenopus, normal mesoderm formation depends on signalling through the fibroblast growth factor (FGF) tyrosine kinase receptor(2-4). One important signalling pathway from receptor tyrosine kinases involves p21(ras) (ref, 5). Ras associates with the serine kinase c-Raf-1 in a GTP-dependent manner, and this complex phosphorylates and activates MAPK/ERK kinase (MEK), a protein kinase with dual specificity, MEK then activates p42(mapk); and (at least in mammals) p44(mapk), members of the mitogen-activated protein (MAP) kinase family(6), FGF activates MAP kinase during mesoderm induction(7-9), and the use of dominant-negative constructs suggests that mesoderm induction by FGF requires both Res and Raf(10,11). However, these experiments Bo not reveal whether Ras and Raf do act through MAP kinase to induce mesoderm or whether another pathway, such as the phosphatidylinositol 3-kinase cascade(12), is involved. Here we show that expression of active forms of MEK or of MAP kinase induces ventral mesoderm of the hind elicited by FGF, Overexpression of a Xenopus MAP kinase phosphatase Mocks mesoderm induction by FGF, and causes characteristic defects in mesoderm formation in intact embryos, whereas inhibition of the P13 kinase and p70 S6 kinase pathways has no effect on mesoderm induction by FGF, FGF induces different types of mesoderm in a dose-dependent manner(13); strikingly, this is mimicked by expressing different levels of activated MEK. Together, these experiments demonstrate that activation of MAP kinases is necessary and sufficient for mesoderm formation.	INST CANC RES,CRC,CTR CELLULAR & MOLEC BIOL,LONDON SW3 6JB,ENGLAND; UNIV WARWICK,DEPT BIOL SCI,COVENTRY CV4 7AL,W MIDLANDS,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Warwick	UMBHAUER, M (corresponding author), NATL INST MED RES,DIV DEV BIOL,THE RIDGEWAY,MILL HILL,LONDON NW7 1AA,ENGLAND.			Umbhauer, Muriel/0000-0001-7419-8070; Smith, Jim/0000-0003-2413-9392; Mason, Clive/0000-0003-3179-6622				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; AMAYA E, 1993, DEVELOPMENT, V118, P477; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BASSEZ T, 1990, DEVELOPMENT, V110, P966; BOTT CM, 1994, FEBS LETT, V352, P201, DOI 10.1016/0014-5793(94)00958-9; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CORNELL RA, 1994, DEVELOPMENT, V120, P453; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CUNLIFFE V, 1994, EMBO J, V13, P349, DOI 10.1002/j.1460-2075.1994.tb06268.x; GRAVES LM, 1994, P NATL ACAD SCI USA, V91, P1662, DOI 10.1073/pnas.91.5.1662; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; GREEN JBA, 1990, DEVELOPMENT, V108, P229; HARTLEY RS, 1994, DEV BIOL, V163, P521, DOI 10.1006/dbio.1994.1168; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; ISAACS HV, 1994, EMBO J, V13, P4469, DOI 10.1002/j.1460-2075.1994.tb06769.x; KRIEG PA, 1987, P NATL ACAD SCI USA, V84, P2331, DOI 10.1073/pnas.84.8.2331; LABONNE C, 1994, DEVELOPMENT, V120, P463; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MOHUN TJ, 1986, EMBO J, V5, P3185, DOI 10.1002/j.1460-2075.1986.tb04628.x; MOHUN TJ, 1984, NATURE, V311, P716, DOI 10.1038/311716a0; Nieuwkoop P. D., 1975, NORMAL TABLE XENOPUS; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUPP RAW, 1991, CELL, V65, P927, DOI 10.1016/0092-8674(91)90545-A; SMITH JC, 1993, EMBO J, V12, P4463, DOI 10.1002/j.1460-2075.1993.tb06135.x; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH JC, 1993, CELLULAR INTERACTION, P181; SMITH WC, 1993, NATURE, V361, P547, DOI 10.1038/361547a0; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0	34	203	204	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 6	1995	376	6535					58	62		10.1038/376058a0	http://dx.doi.org/10.1038/376058a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH111	7541116				2022-12-24	WOS:A1995RH11100061
J	DENHAAN, JMM; SHERMAN, NE; BLOKLAND, E; HUCZKO, E; KONING, F; DRIJFHOUT, JW; SKIPPER, J; SHABANOWITZ, J; HUNT, DF; ENGELHARD, VH; GOULMY, E				DENHAAN, JMM; SHERMAN, NE; BLOKLAND, E; HUCZKO, E; KONING, F; DRIJFHOUT, JW; SKIPPER, J; SHABANOWITZ, J; HUNT, DF; ENGELHARD, VH; GOULMY, E			IDENTIFICATION OF A GRAFT-VERSUS-HOST DISEASE-ASSOCIATED HUMAN MINOR HISTOCOMPATIBILITY ANTIGEN	SCIENCE			English	Article							TOXIC LYMPHOCYTES-T; MARROW TRANSPLANTATION; MASS-SPECTROMETRY; TISSUE DISTRIBUTION; UNRELATED DONORS; PEPTIDES; HLA; CELLS; PROTEIN; BETA-2-MICROGLOBULIN	Minor histocompatibility antigen disparities between human leukocyte antigen (HLA)-matched bone marrow donors and recipients are a major risk factor for graft versus host disease (GVHD). An HLA-A2.1-restricted cytotoxic T cell clone that recognized the minor histocompatibility antigen HA-2 was previously isolated from a patient with severe GVHD after HLA-identical bone marrow transplantation. The HLA-A2.1-bound peptide representing HA-2 has now been identified. This peptide appears to originate from a member of the non-filament-forming class I myosin family. Because HA-2 has a phenotype frequency of 95 percent in the HLA-A2.1-positive population, it is a candidate for immunotherapeutic intervention in bone marrow transplantation.	UNIV LEIDEN HOSP,DEPT IMMUNOHAEMATOL,2300 RC LEIDEN,NETHERLANDS; UNIV LEIDEN HOSP,BLOOD BANK,2300 RC LEIDEN,NETHERLANDS; UNIV VIRGINIA,DEPT CHEM,CHARLOTTESVILLE,VA 22903; UNIV VIRGINIA,DEPT PATHOL,CHARLOTTESVILLE,VA 22903; UNIV VIRGINIA,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,BEIRNE CARTER CTR IMMUNOL RES,CHARLOTTESVILLE,VA 22908	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); University of Virginia; University of Virginia; University of Virginia; University of Virginia			den Haan, Joke MM/A-4281-2010; Hunt, Donald F/I-6936-2012; Drijfhout, Jan Wouter/ABA-6318-2021	den Haan, Joke MM/0000-0002-4421-6917; Hunt, Donald F/0000-0003-2815-6368; Drijfhout, Jan Wouter/0000-0003-4808-5296; Engelhard, Victor/0000-0002-1741-0925; Koning, Frits/0000-0002-4007-5715; Sherman, Nicholas/0000-0003-3206-3113	NIAID NIH HHS [AI20963, AI33993] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI033993, R01AI020963, R01AI033993, R37AI020963] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEATTY PG, 1991, TRANSPLANTATION, V51, P443, DOI 10.1097/00007890-199102000-00034; BEATTY PG, 1989, GRAFT VERSUS HOST DI, P415; BEMENT WM, 1994, J MOL BIOL, V243, P356, DOI 10.1006/jmbi.1994.1662; BEMENT WM, 1994, P NATL ACAD SCI USA, V91, P6549, DOI 10.1073/pnas.91.14.6549; BORTIN MM, 1991, TRANSPLANT P, V23, P61; BORTIN MM, 1970, TRANSPLANTATION, V9, P571, DOI 10.1097/00007890-197006000-00006; CHEN Y, 1994, J IMMUNOL, V152, P2874; COUDRIER E, 1992, FEBS LETT, V307, P87, DOI 10.1016/0014-5793(92)80907-X; COX AL, 1994, SCIENCE, V264, P716, DOI 10.1126/science.7513441; DEBUEGER M, 1992, J IMMUNOL, V149, P1788; DEBUEGER M, 1993, EUR J IMMUNOL, V23, P614, DOI 10.1002/eji.1830230305; DENHAAN JMM, UNPUB; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FRANKSSON L, 1993, EUR J IMMUNOL, V23, P2606, DOI 10.1002/eji.1830231034; GOULMY E, 1983, NATURE, V302, P159, DOI 10.1038/302159a0; GOULMY E, UNPUB; GOULMY E, 1988, TRANSPLANT REV, V2, P29, DOI DOI 10.1016/S0955-470X(88)80005-3; HENDERSON RA, 1993, P NATL ACAD SCI USA, V90, P10275, DOI 10.1073/pnas.90.21.10275; HUCZKO EL, 1993, J IMMUNOL, V151, P2572; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; IRLE C, 1985, TRANSPLANTATION, V40, P329, DOI 10.1097/00007890-198509000-00021; IRSCHICK EU, 1992, BLOOD, V79, P1622; KURTZ ME, 1985, J IMMUNOL, V135, P2847; LOVELAND B, 1990, CELL, V60, P971, DOI 10.1016/0092-8674(90)90345-F; MANDELBOIM O, 1994, NATURE, V369, P67, DOI 10.1038/369067a0; MARTIN PJ, 1991, BONE MARROW TRANSPL, V8, P217; MOOSEKER M, 1993, CURR BIOL, V3, P245, DOI 10.1016/0960-9822(93)90346-P; NIEDERWIESER D, 1993, BLOOD, V81, P2200; PERARNAU B, 1990, NATURE, V346, P751, DOI 10.1038/346751a0; RAMMENSEE HG, 1986, NATURE, V319, P502, DOI 10.1038/319502a0; ROTZSCHKE O, 1990, SCIENCE, V249, P283, DOI 10.1126/science.1695760; RUPPERT J, 1993, CELL, V74, P829; SCHREUDER GMT, 1993, IMMUNOGENETICS, V38, P98, DOI 10.1007/BF00190897; SEKIMATA M, 1992, INT IMMUNOL, V4, P301, DOI 10.1093/intimm/4.2.301; Titus MA, 1993, CURR OPIN CELL BIOL, V5, P77, DOI 10.1016/S0955-0674(05)80011-0; TSOI MS, 1983, TRANSPLANT P, V15, P1484; TSOI MS, 1980, J IMMUNOL, V125, P2258; UDAKA K, 1992, CELL, V69, P989, DOI 10.1016/0092-8674(92)90617-L; UENAKA A, 1994, J EXP MED, V180, P1599, DOI 10.1084/jem.180.5.1599; VANDERHARST D, 1994, BLOOD, V84, P1060; VANELS CACM, 1992, IMMUNOGENETICS, V35, P161, DOI 10.1007/BF00185109; VANELS CACM, 1990, TRANSPLANTATION, V50, P62, DOI 10.1097/00007890-199007000-00011; WALLNY HJ, 1990, NATURE, V343, P275, DOI 10.1038/343275a0	44	327	350	0	5	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 9	1995	268	5216					1476	1480		10.1126/science.7539551	http://dx.doi.org/10.1126/science.7539551			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC190	7539551	Green Submitted			2022-12-24	WOS:A1995RC19000034
J	CHINNAIYAN, AM; OROURKE, K; TEWARI, M; DIXIT, VM				CHINNAIYAN, AM; OROURKE, K; TEWARI, M; DIXIT, VM			FADD, A NOVEL DEATH DOMAIN-CONTAINING PROTEIN, INTERACTS WITH THE DEATH DOMAIN OF FAS AND INITIATES APOPTOSIS	CELL			English	Article							INTERLEUKIN-1-BETA CONVERTING ENZYME; CELL-DEATH; MONOCLONAL-ANTIBODY; GENE CED-3; ANTIGEN; INHIBITOR; INDUCTION; RECEPTOR; ENCODES	Using the cytoplasmic domain of Pas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Pas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8. FADD contains a death domain homologous to the death domains of Pas and TNFR-1. A point mutation in FADD, analogous to the lpr mutation of Fas, abolishes its ability to bind Pas, suggesting a death domain to death domain interaction. Overexpression of FADD in MCF7 and BJAB cells induces apoptosis, which, like Pas-induced apoptosis, is blocked by CrmA, a specific inhibitor of the interleukin-1 beta-converting enzyme; These findings suggest that FADD may play an important role in the proximal signal transduction of Fas.			CHINNAIYAN, AM (corresponding author), UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109, USA.		dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326				BAGLIONI C, 1992, TUMOR NECROSIS FACTO; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CLEMENT MV, 1994, J EXP MED, V180, P557, DOI 10.1084/jem.180.2.557; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; HARPER JW, 1993, CELL, V75, P805; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HU HM, 1994, J BIOL CHEM, V369, P30069; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; OROURKE KM, 1992, J BIOL CHEM, V267, P24921; PETERS LL, 1993, SEMIN HEMATOL, V30, P85; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; RON D, 1992, BIOTECHNIQUES, V13, P866; RON D, 1992, BIOTECHNIQUES, V14, P221; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Sambrook J., 1989, MOL CLONING LAB MANU; SONG HY, 1994, J BIOL CHEM, V269, P22492; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	34	2045	2152	3	64	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 19	1995	81	4					505	512		10.1016/0092-8674(95)90071-3	http://dx.doi.org/10.1016/0092-8674(95)90071-3			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QZ710	7538907	Bronze			2022-12-24	WOS:A1995QZ71000007
J	PANDEY, A; SHAO, HN; MARKS, RM; POLVERINI, PJ; DIXIT, VM				PANDEY, A; SHAO, HN; MARKS, RM; POLVERINI, PJ; DIXIT, VM			ROLE OF B61, THE LIGAND FOR THE ECK RECEPTOR TYROSINE KINASE, IN TNF-ALPHA-INDUCED ANGIOGENESIS	SCIENCE			English	Article							NECROSIS-FACTOR-ALPHA; RESPONSE GENE; PROTEIN; CLONING	B61, a cytokine-inducible endothelial gene product, is the ligand for the Eck receptor protein tyrosine kinase (RPTK), Expression of a B61-immunoglobulin chimera showed that B61 could act as an angiogenic factor in vivo and a chemoattractant for endothelial cells in vitro, The Eck RPTK was activated by tumor necrosis factor-alpha (TNF-alpha) through induction of B61, and an antibody to B61 attenuated angiogenesis induced by TNF-alpha but not by basic fibroblast growth factor, This finding suggests the existence of an autocrine or paracrine loop involving activation of the Eck RPTK by its inducible ligand B61 after an inflammatory stimulus, the net effect of which would be to promote angiogenesis, a hallmark of chronic inflammation,	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH DENT,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Polverini, Peter/AAJ-8392-2020; dixit, vishva m/A-4496-2012; Pandey, Akhilesh/B-4127-2009	dixit, vishva m/0000-0001-6983-0326; Pandey, Akhilesh/0000-0001-9943-6127	NHLBI NIH HHS [HL 39926] Funding Source: Medline; NIAID NIH HHS [P0 1AI331890004] Funding Source: Medline; NIDDK NIH HHS [DK 39255] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039926] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK039255] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BAGLIONI C, 1992, TUMOR NECROSIS FACTO, P425; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; FAJARDO LF, 1992, AM J PATHOL, V140, P539; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MONTRUCCHIO G, 1994, J EXP MED, V180, P377, DOI 10.1084/jem.180.1.377; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; PANDEY A, 1994, J BIOL CHEM, V269, P30154; PANDEY A, UNPUB; SARMA V, 1992, J IMMUNOL, V148, P3302; SHAO HN, 1995, J BIOL CHEM, V270, P5636, DOI 10.1074/jbc.270.10.5636; SHAO HN, 1994, J BIOL CHEM, V269, P26606; STREITER RM, 1992, AM J PATHOL, V141, P1279	17	343	374	0	2	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 28	1995	268	5210					567	569		10.1126/science.7536959	http://dx.doi.org/10.1126/science.7536959			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QV407	7536959				2022-12-24	WOS:A1995QV40700037
J	ATKISON, P; JOUBERT, G; BARRON, A; GRANT, D; PARADIS, K; SEIDMAN, E; WALL, W; ROSENBERG, H; HOWARD, J; WILLIAMS, S; STILLER, C				ATKISON, P; JOUBERT, G; BARRON, A; GRANT, D; PARADIS, K; SEIDMAN, E; WALL, W; ROSENBERG, H; HOWARD, J; WILLIAMS, S; STILLER, C			HYPERTROPHIC CARDIOMYOPATHY ASSOCIATED WITH TACROLIMUS IN PEDIATRIC TRANSPLANT PATIENTS	LANCET			English	Note							LIVER-TRANSPLANTATION; ALLOGRAFT RECIPIENTS; RENAL-FUNCTION; CYCLOSPORINE; FK-506	Reported side-effects of tacrolimus, a potent immunosuppressive agent, have not included cardiotoxicity. We describe 5 consecutive paediatric transplant recipients (3 small bowel with or without liver and 2 liver) who received tacrolimus. 2 developed congestive heart failure and hypertrophic obstructive cardiomyopathy which resolved after changing to cyclosporin. In the other 3 patients the cardiomyopathy regressed or improved with a lower dose of tacrolimus or after stopping the drug.	UNIV MONTREAL,HOP ST JUSTINE,MONTREAL,PQ H3T 1C5,CANADA	Universite de Montreal	ATKISON, P (corresponding author), UNIV WESTERN ONTARIO,CHILDRENS HOSP WESTERN ONTARIO,800 COMMISSIONERS RD E,LONDON,ON N6C 2V5,CANADA.							ABUELMAGD K, 1992, TRANSPLANT P, V24, P1243; DEMETRIS AJ, 1992, TRANSPLANTATION, V53, P1056, DOI 10.1097/00007890-199205000-00017; MCCAULEY J, 1990, TRANSPLANT P, V22, P17; MCDIARMID SV, 1993, TRANSPLANTATION, V56, P847, DOI 10.1097/00007890-199310000-00014; Noto S, 1994, TRANSPLANT P, V26, P855; TEXTOR SC, 1993, TRANSPLANTATION, V55, P855; THIRU S, 1987, TRANSPLANT P, V19, P98; WHITINGTON PF, 1994, SEMIN LIVER DIS, V14, P303, DOI 10.1055/s-2007-1007320; WIEDERRECHT G, 1994, ANN NY ACAD SCI, V696, P9; 1994, LANCET, V344, P423	10	168	171	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 8	1995	345	8954					894	896		10.1016/S0140-6736(95)90011-X	http://dx.doi.org/10.1016/S0140-6736(95)90011-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR067	7535875				2022-12-24	WOS:A1995QR06700011
J	KUIDA, K; LIPPKE, JA; KU, G; HARDING, MW; LIVINGSTON, DJ; SU, MSS; FLAVELL, RA				KUIDA, K; LIPPKE, JA; KU, G; HARDING, MW; LIVINGSTON, DJ; SU, MSS; FLAVELL, RA			ALTERED CYTOKINE EXPORT AND APOPTOSIS IN MICE DEFICIENT IN INTERLEUKIN-1-BETA CONVERTING-ENZYME	SCIENCE			English	Article							DEATH GENE CED-3; CELL-DEATH; PRECURSOR; PROTEASE; ELEGANS; BCL-2; FAS; SPECIFICITY; ACTIVATION; IL-1-ALPHA	The interleukin-1 beta (IL-1 beta) converting enzyme (ICE) processes the inactive IL-1 beta precursor to the proinflammatory cytokine. Adherent monocytes from mice harboring a disrupted ICE gene (ICE(-/-)) did not export IL-1 beta or interleukin-1 alpha (IL-1 alpha) after stimulation with lipopolysaccharide. Export of tumor necrosis factor-alpha and interleukin-6 (IL-6) from these cells was also diminished. Thymocytes from ICE(-/-) mice were sensitive to apoptosis induced by dexamethasone or ionizing radiation, but were resistant to apoptosis induced by Fas antibody. Despite this defect in apoptosis, ICE(-/-) mice proceed normally through development.	VERTEX PHARMACEUT INC,CAMBRIDGE,MA 02139; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,IMMUNOBIOL SECT,NEW HAVEN,CT 06510	Vertex Pharmaceuticals; Howard Hughes Medical Institute; Yale University; Yale University			Roszak, Joanna/F-4003-2010					AURON PE, 1984, P NATL ACAD SCI-BIOL, V81, P7907, DOI 10.1073/pnas.81.24.7907; BLACK RA, 1989, FEBS LETT, V247, P386, DOI 10.1016/0014-5793(89)81376-6; BLACK RA, 1988, J BIOL CHEM, V263, P9437; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CARRUTH LM, 1991, J BIOL CHEM, V266, P12162; CASANO FJ, 1994, GENOMICS, V20, P474, DOI 10.1006/geno.1994.1203; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COHEN JJ, 1984, J IMMUNOL, V132, P38; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; DINARELLO CA, 1994, FASEB J, V8, P1314, DOI 10.1096/fasebj.8.15.8001745; FAUCHEU C, UNPUB; FERNANDESALNEMR.T, 1994, J BIOL CHEM, V269, P30761; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; HAZUDA DJ, 1990, J BIOL CHEM, V265, P6318; HOWARD AD, 1991, J IMMUNOL, V147, P2964; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; JU ST, 1994, P NATL ACAD SCI USA, V91, P4185, DOI 10.1073/pnas.91.10.4185; KOBAYASHI Y, 1990, P NATL ACAD SCI USA, V87, P5548, DOI 10.1073/pnas.87.14.5548; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MOLINEAUX SM, 1993, P NATL ACAD SCI USA, V90, P1809, DOI 10.1073/pnas.90.5.1809; NAKAYAMA K, 1993, SCIENCE, V261, P1584, DOI 10.1126/science.8372353; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; PERREGAUX D, 1992, J IMMUNOL, V149, P1294; PERREGAUX D, 1994, J BIOL CHEM, V269, P15195; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SIDERS WM, 1993, J BIOL CHEM, V268, P22170; SLEATH PR, 1990, J BIOL CHEM, V265, P14526; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; VELS DJ, 1993, CELL, V75, P229; VOELKELJOHNSON C, 1995, J IMMUNOL, V154, P1707; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WEAVER VM, 1993, BIOCHEM CELL BIOL, V71, P488, DOI 10.1139/o93-071; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	42	1451	1484	0	28	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 31	1995	267	5206					2000	2003		10.1126/science.7535475	http://dx.doi.org/10.1126/science.7535475			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QQ068	7535475				2022-12-24	WOS:A1995QQ06800046
J	ELLING, CE; NIELSEN, SM; SCHWARTZ, TW				ELLING, CE; NIELSEN, SM; SCHWARTZ, TW			CONVERSION OF ANTAGONIST-BINDING SITE TO METAL-ION SITE IN THE TACHYKININ NK-1 RECEPTOR	NATURE			English	Article							NEUROKININ-1 RECEPTOR; PROTEIN; NK1; IDENTIFICATION; EPITOPES; DOMAINS; DESIGN	MUTATIONAL analysis of the tachykinin NK-1 (refs 1-7), NK-2 (ref. 8) and angiotensin AT-1 (refs 9, 10) receptors indicates that non-peptide antagonists act through residues located between the seven transmembrane segments, whereas natural peptide agonists bind to residues scattered in the exterior part of the receptor(1-4,11-13). The presumed contact points for the prototype NK-1 antagonist CP96,345 cluster on opposing faces of the outer portions of transmembrane helices V and VI (refs 1-5). Here we show that systematic introduction of histidyl residues at this antagonist-binding site in the human NK-1 receptor gradually converts it into a high-affinity metal-ion-binding site without affecting agonist binding. In a double mutant with histidine residues substituted at the top of transmembrane segments V and VI, respectively, Zn2+ inhibits binding of radiolabelled agonist peptide and efficiently blocks phosphoinositol turnover induced by substance P. We propose that Zn2+ and CP96,345 act as 'allosteric competitive' antagonists by stabilizing inactive conformations of the mutant and the wild-type receptor respectively. Introduction of metal-ion-binding sites could be used as a general tool in the structural and functional characterization of helix-helix interactions in G-protein-coupled receptors, as well as in other membrane proteins.	RIGSHOSP,DEPT CLIN BIOCHEM,MOLEC ENDOCRINOL LAB,DK-2100 COPENHAGEN,DENMARK	Rigshospitalet; University of Copenhagen				Schwartz, Thue W./0000-0002-0261-6904				BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BETZ SF, 1993, CURR OPIN STRUC BIOL, V3, P601, DOI 10.1016/0959-440X(93)90090-8; CASCIERI MA, 1994, J BIOL CHEM, V269, P6587; CHAKRABARTI P, 1990, PROTEIN ENG, V4, P57, DOI 10.1093/protein/4.1.57; CHIDIAC P, 1994, MOL PHARMACOL, V45, P490; FONG TM, 1994, J BIOL CHEM, V269, P2728; FONG TM, 1992, J BIOL CHEM, V267, P25664; FONG TM, 1993, NATURE, V362, P350; GETHER U, 1993, NATURE, V362, P345, DOI 10.1038/362345a0; GETHER U, 1993, J BIOL CHEM, V268, P7893; GETHER U, 1993, P NATL ACAD SCI USA, V90, P6194, DOI 10.1073/pnas.90.13.6194; GETHER U, 1994, J BIOL CHEM, V269, P23959; GETHER U, 1994, MOL PHARMACOL, V45, P500; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P3; HANDEL TM, 1993, SCIENCE, V261, P879, DOI 10.1126/science.8346440; HJORTH SA, 1994, J BIOL CHEM, V269, P30953; HUANG RRC, 1994, BIOCHEMISTRY-US, V33, P3007, DOI 10.1021/bi00176a033; JERIGAN R, 1994, CURR OPIN STRUCT BIO, V4, P256; JOHANSEN TE, 1990, FEBS LETT, V267, P289, DOI 10.1016/0014-5793(90)80947-H; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; REGAN L, 1993, ANNU REV BIOPH BIOM, V22, P257, DOI 10.1146/annurev.bb.22.060193.001353; ROSENKILDE MM, 1994, J BIOL CHEM, V269, P28160; SAMAMA P, 1993, MOL PHARMACOL, V45, P390; SCHAMBYE HT, 1994, P NATL ACAD SCI USA, V91, P7046, DOI 10.1073/pnas.91.15.7046; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; STAPPERT J, 1992, NUCLEIC ACIDS RES, V20, P624, DOI 10.1093/nar/20.3.624; SURYANARAYANA S, 1992, J BIOL CHEM, V267, P21991; ZHOU W, 1994, MOL PHARMACOL, V45, P165; ZOFFMANN S, 1993, FEBS LETT, V336, P506, DOI 10.1016/0014-5793(93)80865-R	30	160	164	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 2	1995	374	6517					74	77		10.1038/374074a0	http://dx.doi.org/10.1038/374074a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK079	7532789				2022-12-24	WOS:A1995QK07900056
J	MCDOWELL, JC; ROBERTS, JW; JIN, DJ; GROSS, C				MCDOWELL, JC; ROBERTS, JW; JIN, DJ; GROSS, C			DETERMINATION OF INTRINSIC TRANSCRIPTION TERMINATION EFFICIENCY BY RNA-POLYMERASE ELONGATION RATE	SCIENCE			English	Article							ESCHERICHIA-COLI RNA; OPERON LEADER REGION; PHAGE-LAMBDA; BACTERIOPHAGE-LAMBDA; PAUSE SITE; INVITRO; RHO; GENE; REQUIREMENTS; SEQUENCES	Transcription terminators recognized by several RNA polymerases include a DNA segment encoding uridine-rich RNA and, for bacterial RNA polymerase, a hairpin loop located immediately upstream. Here, mutationally altered Escherichia coli RNA polymerase enzymes that have different termination efficiencies were used to show that the extent of transcription through the uridine-rich encoding segment is controlled by the substrate concentration of nucleoside triphosphate. This result implies that the rate of elongation determines the probability of transcript release. Moreover, the position of release sites suggests an important spatial relation between the RNA hairpin and the boundary of the terminator.	CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,ITHACA,NY 14853; NCI,MOLEC BIOL LAB,BETHESDA,MD 20892; UNIV WISCONSIN,DEPT BACTERIOL,MADISON,WI 53706	Cornell University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Wisconsin System; University of Wisconsin Madison								ALTMANN CR, 1994, P NATL ACAD SCI USA, V91, P3784, DOI 10.1073/pnas.91.9.3784; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BOGENHAGEN DF, 1981, CELL, V24, P261, DOI 10.1016/0092-8674(81)90522-5; CHAN CL, 1993, J MOL BIOL, V233, P25, DOI 10.1006/jmbi.1993.1482; CHAN CL, 1994, TRANSCRIPTION MECHAN, P297; DEDRICK RL, 1987, J BIOL CHEM, V262, P9098; FARNHAM PJ, 1981, NUCLEIC ACIDS RES, V9, P563, DOI 10.1093/nar/9.3.563; FARNHAM PJ, 1980, CELL, V20, P739, DOI 10.1016/0092-8674(80)90320-7; FISHER RF, 1983, J BIOL CHEM, V258, P8146; Friedman DI., 1983, LAMBDA 2, P21; GRAYHACK EJ, 1985, CELL, V42, P259, DOI 10.1016/S0092-8674(85)80121-5; GUO HC, 1990, J BACTERIOL, V173, P1554; JIN DJ, 1988, J MOL BIOL, V202, P245, DOI 10.1016/0022-2836(88)90455-X; JIN DJ, 1991, J BIOL CHEM, V266, P14478; JIN DJ, 1992, P NATL ACAD SCI USA, V89, P1453, DOI 10.1073/pnas.89.4.1453; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; LANDICK R, 1984, J BIOL CHEM, V259, P1550; LAU LF, 1983, J BIOL CHEM, V258, P9391; LEVIN JR, 1987, J MOL BIOL, V196, P61, DOI 10.1016/0022-2836(87)90511-0; MARTIN FH, 1980, NUCLEIC ACIDS RES, V8, P2295, DOI 10.1093/nar/8.10.2295; MASON SW, 1992, J BIOL CHEM, V267, P19418; MCDOWELL JC, UNPUB; MORGAN WD, 1983, J BIOL CHEM, V258, P9565; REYNOLDS R, 1992, J MOL BIOL, V224, P53, DOI 10.1016/0022-2836(92)90575-5; REYNOLDS R, 1992, J MOL BIOL, V224, P31, DOI 10.1016/0022-2836(92)90574-4; ROBERTS J, 1992, TRANSCRIPTIONAL REGU, P389; ROSENBERG M, 1978, NATURE, V272, P414, DOI 10.1038/272414a0; VONHIPPEL PH, 1991, P NATL ACAD SCI USA, V88, P2307, DOI 10.1073/pnas.88.6.2307; WIEST DK, 1990, MOL CELL BIOL, V10, P5782, DOI 10.1128/MCB.10.11.5782; YAGER TD, 1987, CELLULAR MOL BIOL, P1241; YANG XJ, 1989, P NATL ACAD SCI USA, V86, P5301, DOI 10.1073/pnas.86.14.5301	31	107	112	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 4	1994	266	5186					822	825		10.1126/science.7526463	http://dx.doi.org/10.1126/science.7526463			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP753	7526463				2022-12-24	WOS:A1994PP75300046
J	NIGHTINGALE, SL				NIGHTINGALE, SL			CONFERENCE ON FDA-REGULATED PRODUCTS AND PREGNANT-WOMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 19	1994	272	15					1160	1160		10.1001/jama.272.15.1160	http://dx.doi.org/10.1001/jama.272.15.1160			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL212	7523738				2022-12-24	WOS:A1994PL21200010
J	WU, HH; WILLIAMS, CV; MCLOON, SC				WU, HH; WILLIAMS, CV; MCLOON, SC			INVOLVEMENT OF NITRIC-OXIDE IN THE ELIMINATION OF A TRANSIENT RETINOTECTAL PROJECTION IN DEVELOPMENT	SCIENCE			English	Article							LONG-TERM POTENTIATION; RECEPTOR ANTAGONISTS DISRUPT; RETINAL GANGLION-CELLS; MOUSE CENTRAL NEURONS; NMDA RECEPTORS; INTERCELLULAR MESSENGER; ACTIVATED CHANNELS; NADPH DIAPHORASE; IMPULSE ACTIVITY; DEVELOPING CHICK	The adult pattern of axonal connections from the eye to the brain arises during development through the refinement of a roughly ordered set of connections. In the chick visual system, refinement normally results in the loss of the ipsilateral retinotectal connections. Inhibition of nitric oxide synthesis reduced the loss of these transient connections. Because nitric oxide is expressed by tectal cells with which retinal axons connect and because reduction of nitric oxide synthesis by tectal cells resulted in a change in the connections of retinal axons, nitric oxide probably serves as a messenger from tectal cells back to retinal axons during development.	UNIV MINNESOTA,DEPT CELL BIOL & NEUROANAT,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities					NATIONAL EYE INSTITUTE [R01EY005371, T32EY007133] Funding Source: NIH RePORTER; NEI NIH HHS [EY05371, EY07133] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AHMAD I, 1994, NEURON, V12, P155, DOI 10.1016/0896-6273(94)90160-0; ASCHER P, 1988, J PHYSIOL-LONDON, V399, P207; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; CLINE HT, 1989, NEURON, V3, P413, DOI 10.1016/0896-6273(89)90201-8; CLINE HT, 1987, P NATL ACAD SCI USA, V84, P4342, DOI 10.1073/pnas.84.12.4342; CONNOR JA, 1986, P NATL ACAD SCI USA, V83, P6179, DOI 10.1073/pnas.83.16.6179; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; DAWSON TM, 1991, P NATL ACAD SCI USA, V88, P7797, DOI 10.1073/pnas.88.17.7797; DWYER MA, 1991, BIOCHEM BIOPH RES CO, V176, P1136, DOI 10.1016/0006-291X(91)90403-T; FIELDS RD, 1990, J NEUROSCI, V10, P2950; FOX K, 1993, TRENDS NEUROSCI, V16, P116, DOI 10.1016/0166-2236(93)90136-A; GALLI L, 1988, SCIENCE, V242, P90, DOI 10.1126/science.3175637; GALLY JA, 1990, P NATL ACAD SCI USA, V87, P3547, DOI 10.1073/pnas.87.9.3547; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; HAHM JO, 1991, NATURE, V351, P568, DOI 10.1038/351568a0; HALEY JE, 1992, NEURON, V8, P211, DOI 10.1016/0896-6273(92)90288-O; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; IADECOLA C, 1994, NEUROCHEM RES, V19, P501, DOI 10.1007/BF00967330; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; JESSELL TM, 1993, CELL 72 NEURON S, V10, P1; KANDEL ER, 1992, SCIENCE, V258, P243, DOI 10.1126/science.1411522; KOBAYASHI T, 1990, DEV BRAIN RES, V57, P29, DOI 10.1016/0165-3806(90)90181-W; LONART G, 1992, EUR J PHARMACOL, V220, P271, DOI 10.1016/0014-2999(92)90759-W; MAFFEI L, 1990, P NATL ACAD SCI USA, V87, P2861, DOI 10.1073/pnas.87.7.2861; MATTSON MP, 1987, J NEUROSCI, V7, P4034; MAYER ML, 1985, J PHYSIOL-LONDON, V361, P65, DOI 10.1113/jphysiol.1985.sp015633; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCLOON SC, 1982, EXP BRAIN RES, V45, P277; MCLOON SC, 1982, SCIENCE, V215, P1418, DOI 10.1126/science.7063855; MEISTER M, 1991, SCIENCE, V252, P939, DOI 10.1126/science.2035024; MONCADA S, 1991, PHARMACOL REV, V43, P109; MONTAGUE PR, 1994, SCIENCE, V263, P973, DOI 10.1126/science.7508638; NELSON PG, 1989, SCIENCE, V244, P565; NICHOLS RA, 1990, NATURE, V343, P647, DOI 10.1038/343647a0; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; OLEARY DDM, 1983, DEV BRAIN RES, V10, P93, DOI 10.1016/0165-3806(83)90124-4; Prusky G., 1992, Society for Neuroscience Abstracts, V18, P1311; REH TA, 1985, J NEUROSCI, V5, P1132; SANDELL JH, 1985, J COMP NEUROL, V238, P466, DOI 10.1002/cne.902380410; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SHATZ CJ, 1988, SCIENCE, V242, P87, DOI 10.1126/science.3175636; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; SIMON DK, 1992, P NATL ACAD SCI USA, V89, P10593, DOI 10.1073/pnas.89.22.10593; STRYKER MP, 1986, J NEUROSCI, V6, P2117; TANAKA K, 1991, NEUROSCI LETT, V127, P129, DOI 10.1016/0304-3940(91)90911-C; THANOS S, 1984, J COMP NEUROL, V224, P407, DOI 10.1002/cne.902240308; WILLIAMS CV, 1994, J NEUROSCI, V14, P1746, DOI 10.1523/JNEUROSCI.14-03-01746.1994; WILLIAMS CV, 1991, J NEUROSCI, V11, P445; WU HH, IN PRESS SOC NEUR AB; ZHUO M, 1993, SCIENCE, V260, P1946, DOI 10.1126/science.8100368	53	210	213	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 9	1994	265	5178					1593	1596		10.1126/science.7521541	http://dx.doi.org/10.1126/science.7521541			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PF336	7521541				2022-12-24	WOS:A1994PF33600040
J	FINCK, BK; LINSLEY, PS; WOFSY, D				FINCK, BK; LINSLEY, PS; WOFSY, D			TREATMENT OF MURINE LUPUS WITH CTLA4IG	SCIENCE			English	Article							T-CELL ACTIVATION; COSTIMULATORY SIGNAL; MONOCLONAL-ANTIBODY; CTLA-4; CD28; ANTIGEN; LIGAND; RECEPTOR; INTERLEUKIN-2; PROLIFERATION	The interaction of B7-related molecules on antigen-presenting cells with CD28 or CTLA-4 antigens on T cells provides a second signal for T cell activation. Selective inhibition of the B7-CD28 or B7-CTLA-4 interactions produces antigen-specific T cell unresponsiveness in vitro and suppresses immune function in vivo. To determine whether selective inhibition of the B7-CD28 or B7-CTLA-4 interactions could suppress spontaneous autoimmune disease, a B7-binding protein was generated by genetic fusion of the extracellular domain of murine CTLA-4 to the Fe portion of a mouse immunoglobulin G2a monoclonal antibody (muCTLA4lg). In lupus-prone NZB/NZW filial generation (F-1) mice, treatment with muCTLA4lg blocked autoantibody production and prolonged life, even when treatment was delayed until the most advanced stage of clinical illness. These findings suggest a possible role for human CTLA4lg in the treatment of autoimmune diseases in humans.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94121; VET ADM MED CTR,SAN FRANCISCO,CA 94121; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); Bristol-Myers Squibb								AZUMA M, 1993, NATURE, V366, P76, DOI 10.1038/366076a0; BRUNET JF, 1987, NATURE, V328, P267, DOI 10.1038/328267a0; FELL HP, 1992, J BIOL CHEM, V267, P15552; FINCK BK, UNPUB; FREEMAN GJ, 1993, SCIENCE, V262, P909, DOI 10.1126/science.7694363; GIMMI CD, 1991, P NATL ACAD SCI USA, V88, P6575, DOI 10.1073/pnas.88.15.6575; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; HATHCOCK KS, 1993, SCIENCE, V262, P905, DOI 10.1126/science.7694361; Isaacs J D, 1990, Semin Immunol, V2, P449; LANE P, 1994, J EXP MED, V179, P819, DOI 10.1084/jem.179.3.819; LEDBETTER JA, 1990, BLOOD, V75, P1531; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399; MORELAND LW, 1994, ARTHRITIS RHEUM, V37, P834, DOI 10.1002/art.1780370610; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; NORTON SD, 1992, J IMMUNOL, V149, P1556; RONCHESE F, 1994, J EXP MED, V179, P809, DOI 10.1084/jem.179.3.809; STEINBERG AD, 1991, ANN INTERN MED, V115, P548, DOI 10.7326/0003-4819-115-7-548; SWAIN SL, 1984, J IMMUNOL, V132, P1118; TAN P, 1993, J EXP MED, V177, P165, DOI 10.1084/jem.177.1.165; TURKA LA, 1992, P NATL ACAD SCI USA, V89, P11102, DOI 10.1073/pnas.89.22.11102; WALLACE PM, IN PRESS TRANSPLANTA; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113; WOFSY D, 1985, J EXP MED, V161, P378, DOI 10.1084/jem.161.2.378	26	629	695	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 26	1994	265	5176					1225	1227		10.1126/science.7520604	http://dx.doi.org/10.1126/science.7520604			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PD422	7520604				2022-12-24	WOS:A1994PD42200035
J	MILLER, FG; QUILL, TE; BRODY, H; FLETCHER, JC; GOSTIN, LO; MEIER, DE				MILLER, FG; QUILL, TE; BRODY, H; FLETCHER, JC; GOSTIN, LO; MEIER, DE			REGULATING PHYSICIAN-ASSISTED DEATH	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							EUTHANASIA; LIFE; SUICIDE; PATIENT; DOCTOR; AID		GENESEE HOSP,ROCHESTER,NY 14607; MICHIGAN STATE UNIV,E LANSING,MI 48824; GEORGETOWN JOHNS HOPKINS PROGRAM LAW & PUBL HLTH,WASHINGTON,DC 20001; CUNY MT SINAI SCH MED,NEW YORK,NY 10029	Michigan State University; Johns Hopkins University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	MILLER, FG (corresponding author), UNIV VIRGINIA,HLTH SCI CTR,SCH MED,BOX 348,CHARLOTTESVILLE,VA 22908, USA.		Brody, Howard/GQA-6310-2022					ANNAS GJ, 1990, JAMA-J AM MED ASSOC, V263, P858, DOI 10.1001/jama.263.6.858; BATTIN MP, 1994, LEAST WORST DEATH ES, P130; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2658, DOI 10.1001/jama.267.19.2658; BRODY H, 1992, NEW ENGL J MED, V327, P1384, DOI 10.1056/NEJM199211053271912; CELOCRUZ MT, 1992, AM J LAW MED, V18, P369; EGAN T, 1994, NY TIMES        0307, pA1; Glantz L H, 1987, Law Med Health Care, V15, P231; GOMEZ CF, 1991, REGULATING DEATH; GOSTIN L, 1991, MILBANK Q, V69, P143, DOI 10.2307/3350124; Gostin Lawrence O, 1993, J Law Med Ethics, V21, P94, DOI 10.1111/j.1748-720X.1993.tb01234.x; Margolick David, 1994, N Y Times Web, pB8; McGough P M, 1993, Camb Q Healthc Ethics, V2, P63; MEIER D, 1994, PHYSICIAN ASSISTED D, P5; MILLER FG, 1993, PERSPECT BIOL MED, V36, P159; PIJNENBORG L, 1993, LANCET, V341, P1196, DOI 10.1016/0140-6736(93)91014-D; QUILL T. E., 1993, DEATH DIGNITY; QUILL TE, 1993, JAMA-J AM MED ASSOC, V270, P870, DOI 10.1001/jama.270.7.870; QUILL TE, 1992, NEW ENGL J MED, V327, P1380, DOI 10.1056/NEJM199211053271911; TENHAVE HA, 1992, EUTHANASIA NORMAL ME, V22, P34; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; 1992, HARVARD LAW REV, V105, P2021	21	103	104	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 14	1994	331	2					119	123		10.1056/NEJM199407143310211	http://dx.doi.org/10.1056/NEJM199407143310211			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW712	7516037				2022-12-24	WOS:A1994NW71200011
J	STANGL, R; ALTENDORFHOFMANN, A; CHARNLEY, RM; SCHEELE, J				STANGL, R; ALTENDORFHOFMANN, A; CHARNLEY, RM; SCHEELE, J			FACTORS INFLUENCING THE NATURAL-HISTORY OF COLORECTAL LIVER METASTASES	LANCET			English	Article							HEPATIC METASTASES; REGIONAL CHEMOTHERAPY; CARCINOMA; CANCER; RESECTION; SURVIVAL; INTRAARTERIAL; PROGNOSIS; TRIAL; COLON	Palliative treatment of unresectable colorectal liver metastases is common and often justified with reference to historical data on the natural history of the disease. However, in view of the improved diagnostic accuracy of modern imaging techniques, these previously published series do not provide sufficient guidance to judge the prognostic efficacy of palliative treatment. In the late 1970s we started prospectively to collect data on consecutive patients with colorectal liver metastases according to a standard protocol. We now present data derived from this series on factors that may affect outcome in untreated patients. Between January, 1980, and December, 1990, 1099 consecutive patients were recorded, of whom 566 (51.5%) received no treatment for their hepatic tumour. Excluding 34 early deaths and 48 patients with a second malignant tumour, 484 patients provided the basis for analysis. All patients were followed up to July 1, 1993, or death. At the closing date of the study only 1 untreated patient was still alive. The impact of various factors on survival was analysed by univariate and multivariate analyses. Six independent determinants of survival were identified in the following order: percentage liver volume replaced by tumour (LVRT), grade of malignancy of the primary tumour, presence of extra hepatic disease, mesenteric lymph-node involvement, serum carcino-embryonic antigen, and age. The subsequent combination of the independently significant factors, separately for patients with up to or more than 25% LVRT, yielded a prognostic tree that displayed median survival times of various subgroups of 3.8 to 21.3 months. These findings provide a framework to estimate the survival expectancy of untreated patients, thereby allowing improved assessment of the prognostic significance of palliative therapeutic approaches.	UNIV ERLANGEN NURNBERG,CHIRURG KLIN & POLIKLIN,D-91054 ERLANGEN,GERMANY	University of Erlangen Nuremberg								ADSON MA, 1987, WORLD J SURG, V11, P511, DOI 10.1007/BF01655817; ADSON MA, 1984, ARCH SURG-CHICAGO, V119, P647; BALCH CM, 1984, CHIRURG, V55, P485; BENGMARK S, 1969, CANCER, V23, P198, DOI 10.1002/1097-0142(196901)23:1<198::AID-CNCR2820230126>3.0.CO;2-J; BENGTSSON G, 1981, AM J SURG, V141, P586, DOI 10.1016/0002-9610(81)90057-X; BROOKMEYER R, 1982, BIOMETRICS, V38, P29, DOI 10.2307/2530286; CHANG AE, 1989, J SURG ONCOL, V40, P245, DOI 10.1002/jso.2930400409; FINAN PJ, 1985, BRIT J SURG, V72, P373, DOI 10.1002/bjs.1800720514; FLANAGAN L, 1967, AM J SURG, V113, P551, DOI 10.1016/0002-9610(67)90206-1; GENNARI L, 1986, ANN SURG, V203, P49, DOI 10.1097/00000658-198601000-00009; GOSLIN R, 1982, DIS COLON RECTUM, V25, P749, DOI 10.1007/BF02553304; HUNT TM, 1990, BRIT J SURG, V77, P779; JAFFE BM, 1968, SURG GYNECOL OBSTETR, V127, P1; LAHR CJ, 1983, J CLIN ONCOL, V1, P720, DOI 10.1200/JCO.1983.1.11.720; NIELSEN J, 1971, ACTA CHIR SCAND, V137, P463; PETRELLI NJ, 1984, DIS COLON RECTUM, V27, P249, DOI 10.1007/BF02553797; PETTAVEL J, 1984, LIVER METASTASES, P154; SAFI F, 1989, CANCER-AM CANCER SOC, V64, P379, DOI 10.1002/1097-0142(19890715)64:2<379::AID-CNCR2820640207>3.0.CO;2-8; SCHEELE J, 1990, BRIT J SURG, V77, P1241, DOI 10.1002/bjs.1800771115; SCHEELE J, 1991, SURGERY, V110, P13; SCHEELE J, 1991, ZBL CHIR, V116, P1215; SUGARBAKER PH, 1986, J SURG ONCOL, V31, P94, DOI 10.1002/jso.2930310204; WAGNER JS, 1984, ANN SURG, V199, P502, DOI 10.1097/00000658-198405000-00002; WANEBO HJ, 1978, AM J SURG, V135, P81, DOI 10.1016/0002-9610(78)90014-4; Wood C B, 1976, Clin Oncol, V2, P285; WOOD CB, 1984, LIVER METASTASIS BAS, P47	26	579	607	0	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 4	1994	343	8910					1405	1410		10.1016/S0140-6736(94)92529-1	http://dx.doi.org/10.1016/S0140-6736(94)92529-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP955	7515134				2022-12-24	WOS:A1994NP95500015
J	WILLNOW, TE; SHENG, ZQ; ISHIBASHI, S; HERZ, J				WILLNOW, TE; SHENG, ZQ; ISHIBASHI, S; HERZ, J			INHIBITION OF HEPATIC CHYLOMICRON REMNANT UPTAKE BY GENE-TRANSFER OF A RECEPTOR ANTAGONIST	SCIENCE			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; PROTEIN ALPHA-2-MACROGLOBULIN RECEPTOR; APOLIPOPROTEIN-E; LDL-RECEPTOR; PLASMINOGEN-ACTIVATOR; PROTEIN-ALPHA-2-MACROGLOBULIN RECEPTOR; MULTIFUNCTIONAL RECEPTOR; CULTURED-CELLS; HIGH-AFFINITY; IN-VIVO	The low density lipoprotein receptor-related protein (LRP) has been proposed to mediate in concert with the LDL receptor (LDLR) the uptake of dietary lipoproteins into the hepatocytes. This hypothesis was tested by transient inactivation of LRP in vivo. Receptor-associated protein (RAP), a dominant negative regulator of LRP function, was transferred by an adenoviral vector to the livers of mice lacking LDLR (LDLR(-/-)). The inactivation of LRP by RAP was associated with a marked accumulation of chylomicron remnants in LDLR(-/-) mice and to a lesser degree in normal mice, suggesting that both LDLR and LRP are involved in remnant clearance.	UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Willnow, Thomas/0000-0001-9515-7921	NHLBI NIH HHS [HL20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; CHAN L, 1992, J BIOL CHEM, V267, P25621; CHOI SY, 1993, J BIOL CHEM, V268, P15804; GAMBLE W, 1978, J LIPID RES, V19, P1068; GINSBERG HS, 1991, P NATL ACAD SCI USA, V88, P1651, DOI 10.1073/pnas.88.5.1651; GOFF SP, 1993, CURR OPIN GENET DEV, V3, P71, DOI 10.1016/S0959-437X(05)80343-0; HAMILTON RL, 1990, J LIPID RES, V31, P1589; HAVEL RJ, 1989, METABOLIC BASIS INHE, P1129; HERZ J, 1993, CELL, V73, P428, DOI 10.1016/0092-8674(93)90130-I; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; HERZ J, 1991, J BIOL CHEM, V266, P21232; Herz Joachim, 1993, Current Opinion in Lipidology, V4, P107, DOI 10.1097/00041433-199304000-00006; HUSSAIN MM, 1991, J BIOL CHEM, V266, P13936; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; JI ZS, 1993, J BIOL CHEM, V268, P10160; KITA T, 1982, P NATL ACAD SCI-BIOL, V79, P3623, DOI 10.1073/pnas.79.11.3623; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P21862; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; LEBOEUF RC, 1990, J LIPID RES, V31, P91; Mahley R. W., 1991, CURR OPIN LIPIDOL, V2, P170; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; MOKUNO H, 1994, J BIOL CHEM, V269, P13238; NAGATA Y, 1988, J BIOL CHEM, V263, P15151; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; ORLANDO RA, 1992, P NATL ACAD SCI USA, V89, P6698, DOI 10.1073/pnas.89.15.6698; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; RUBINSZTEIN DC, 1990, J CLIN INVEST, V86, P1306, DOI 10.1172/JCI114839; SCHAEFER EJ, 1986, J CLIN INVEST, V78, P1206, DOI 10.1172/JCI112704; SCOTT J, 1989, MOL BIOL MED, V6, P65; SHAFI S, 1994, J LIPID RES, V35, P709; SMITH TAG, 1993, NAT GENET, V5, P397, DOI 10.1038/ng1293-397; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; WARSHAWSKY I, 1993, J CLIN INVEST, V92, P937, DOI 10.1172/JCI116669; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, UNPUB; WINDLER EET, 1988, BIOCHEM J, V252, P553, DOI 10.1042/bj2520553; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	46	264	265	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 3	1994	264	5164					1471	1474		10.1126/science.7515194	http://dx.doi.org/10.1126/science.7515194			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NP221	7515194				2022-12-24	WOS:A1994NP22100046
J	SCOLNIK, D; NULMAN, I; ROVET, J; GLADSTONE, D; CZUCHTA, D; GARDNER, HA; GLADSTONE, R; ASHBY, P; WEKSBERG, R; EINARSON, T; KOREN, G				SCOLNIK, D; NULMAN, I; ROVET, J; GLADSTONE, D; CZUCHTA, D; GARDNER, HA; GLADSTONE, R; ASHBY, P; WEKSBERG, R; EINARSON, T; KOREN, G			NEURODEVELOPMENT OF CHILDREN EXPOSED IN-UTERO TO PHENYTOIN AND CARBAMAZEPINE MONOTHERAPY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PREGNANCY; WOMEN; DRUG	Objective.-To compare pregnancy outcome prospectively after phenytoin and carbamazepine monotherapy with outcome in matched mother-child pairs exposed to nonteratogens to evaluate the relative fetal safety of these drugs. Design.-A prospective, controlled, and blinded observational study. Patients.-Thirty-six mother-child pairs exposed to carbamazepine monotherapy and 34 pairs exposed to phenytoin monotherapy, all prospectively studied, were compared with mother-child pairs exposed to nonteratogens. The controls were matched for maternal age, time of consultation, obstetric history, and socioeconomic status. Main Outcome Measure.-The primary end point of interest was the children's global IQ measured by either the Bayley or the McCarthy scale according to their ages. Setting.-A teratology consultation program and two neurology services in Toronto, Ontario. Results.- Children exposed to phenytoin in utero had a mean (+/-SD) global IQ 10 points lower (95% confidence interval, 4.9 to 15.8 points) than their matched controls (113.4+/-13.1 and 103.1+/-25.1; P=.038). The Reynell language development scores followed a similar trend, with children exposed to phenytoin scoring significantly lower than their controls. Phenytoin-exposed children had a global IQ of 84 or less significantly more often than the control group (P<.01). Children exposed in utero to carbamazepine did not differ from their controls on any of the neurobehavioral tests. Conclusions.-Our study suggests a clinically important negative effect of phenytoin on neurobehavioral development, independent of maternal or environmental factors, causing a substantial number of children to achieve a lower score than expected on cognitive tests. No similar effects could be shown after gestational use of carbamazepine.	HOSP SICK CHILDREN,DIV CLIN PHARMACOL,TORONTO M5G 1X8,ON,CANADA; HOSP SICK CHILDREN,DIV CLIN PHARMACOL TOXICOL,MOTHERISK PROGRAM,TORONTO,ON,CANADA; HOSP SICK CHILDREN,DEPT PEDIAT,TORONTO M5G 1X8,ON,CANADA; HOSP SICK CHILDREN,DEPT PSYCHOL,TORONTO,ON,CANADA; HOSP SICK CHILDREN,RES INST,TORONTO M5G 1X8,ON,CANADA; GEN HOSP,GENET SERV,OSHAWA,ON,CANADA; GEN HOSP,DEPT NEUROL,N YORK,ON,CANADA; TORONTO HOSP,DEPT NEUROL,WESTERN DIV,TORONTO,ON,CANADA; UNIV TORONTO,DEPT PEDIAT,TORONTO,ON,CANADA; UNIV TORONTO,DEPT PHARMACOL,TORONTO,ON,CANADA; UNIV TORONTO,DEPT PHARM,TORONTO,ON,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Ottawa; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University of Toronto			Koren, Gideon/AAG-7726-2019	Koren, Gideon/0000-0002-9234-0875; Gladstone, David/0000-0003-0612-5544				Bayley N., 1993, BAYLEY SCALES INFANT, Vsecond; BERTOLLINI R, 1987, EUR J EPIDEMIOL, V3, P164; ESCUETA AVD, 1992, NEUROLOGY S5, V42, P149; FELDMAN Y, 1989, TERATOLOGY, V40, P37, DOI 10.1002/tera.1420400106; GAILY E, 1990, DEV MED CHILD NEUROL, V32, P403; GLADSTONE DJ, 1992, REPROD TOXICOL, V6, P257, DOI 10.1016/0890-6238(92)90181-R; HANSON JW, 1975, J PEDIATR-US, V87, P285, DOI 10.1016/S0022-3476(75)80604-4; Hollingshead August B., 1958, SOCIAL CLASS MENTAL; JONES KL, 1989, NEW ENGL J MED, V320, P1661, DOI 10.1056/NEJM198906223202505; KANEKO S, 1991, REPROD TOXICOL, V5, P179, DOI 10.1016/0890-6238(91)90050-P; McCarthy D, 1972, MANUAL MCCARTHY SCAL; Reynell J., 1977, REYNELL DEV LANGUAGE; ROBERT E, 1982, LANCET, V2, P937, DOI 10.1016/s0140-6736(82)90908-4; ROZA FW, 1991, NEW ENGL J MED, V324, P674; SAUNDERS M, 1989, BRIT MED J, V299, P581, DOI 10.1136/bmj.299.6699.581; SCHARDEIN JL, 1985, CHEM INDUCED BIRTH D, P142; STRICKLER SM, 1985, LANCET, V2, P746; VINING EPG, 1987, EPILEPSIA, V28, pS18, DOI 10.1111/j.1528-1157.1987.tb05767.x; VORHEES CV, 1986, NEUROTOXICOLOGY, V7, P235; Wechsler D, 1981, ADULT INTELLIGENCE S	20	190	193	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 9	1994	271	10					767	770		10.1001/jama.271.10.767	http://dx.doi.org/10.1001/jama.271.10.767			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY288	7509419				2022-12-24	WOS:A1994MY28800031
J	DILWORTH, SM; BREWSTER, CEP; JONES, MD; LANFRANCONE, L; PELICCI, G; PELICCI, PG				DILWORTH, SM; BREWSTER, CEP; JONES, MD; LANFRANCONE, L; PELICCI, G; PELICCI, PG			TRANSFORMATION BY POLYOMA-VIRUS MIDDLE T-ANTIGEN INVOLVES THE BINDING AND TYROSINE PHOSPHORYLATION OF SHC	NATURE			English	Article							PHOSPHATIDYLINOSITOL KINASE-ACTIVITY; SITE-DIRECTED MUTAGENESIS; PROTEIN; INVITRO; PP60C-SRC; 3-KINASE; DOMAIN; CELLS	POLYOMA virus middle T-antigen converts normal fibroblasts to a fully transformed, tumorigenic phenotype1. It achieves this, at least in part, by binding and activating one of the non-receptor tyrosine kinases, pp60c-src, pp62c-yes or pp59c-fyn (reviewed in refs 2 and 3). As a result, middle T-antigen itself is phosphorylated on tyrosine residues4,5, one of which (Tyr 315) acts as a binding site for the SH2 domains of phosphatidylinositol-3'OH kinase 85K sub-unit6-8. Here we show that another tyrosine phosphorylation site in middle T-antigen (Tyr 250; refs 4, 5) acts as a binding region for the SH2 domain of the transforming protein Shc9. This results in Shc also becoming tyrosine-phosphorylated and binding to the SH2 domain of Grb2 (ref. 10). This probably stimulates p21ras activity through the mammalian homologue of the Drosophila guanine-nucleotide-exchange factor Sos (reviewed in ref. 11). We suggest that middle T-antigen transforms cells by acting as a functional homologue of an activated tyrosine kinase-associated growth-factor receptor.	ROYAL POSTGRAD MED SCH, DEPT VIROL, LONDON W12 0NN, ENGLAND; UNIV PERUGIA, IST CLIN MED 1, I-06100 PERUGIA, ITALY	Imperial College London; University of Perugia	DILWORTH, SM (corresponding author), ROYAL POSTGRAD MED SCH, DEPT CHEM PATHOL, DU CANE RD, LONDON W12 0NN, ENGLAND.		Pelicci, Giuliana/AAA-8921-2022; Pelicci, Pier Giuseppe/AAL-6572-2020; Lanfrancone, Luisa/AAC-8671-2019	Pelicci, Giuliana/0000-0003-0986-8255; Lanfrancone, Luisa/0000-0002-4523-3815				AUGER KR, 1992, J BIOL CHEM, V267, P5408; CARMICHAEL G, 1984, P NATL ACAD SCI-BIOL, V81, P679, DOI 10.1073/pnas.81.3.679; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; COURTNEIDGE SA, 1986, CANCER SURV, V5, P173; DILWORTH SM, 1993, J VIROL, V67, P2235, DOI 10.1128/JVI.67.4.2235-2244.1993; DILWORTH SM, 1982, EMBO J, V1, P1319, DOI 10.1002/j.1460-2075.1982.tb01317.x; DRUKER BJ, 1990, J VIROL, V64, P4454, DOI 10.1128/JVI.64.9.4454-4461.1990; GRIFFIN BE, 1979, COLD SPRING HARB SYM, V44, P271; HARVEY R, 1984, MOL CELL BIOL, V4, P1334, DOI 10.1128/MCB.4.7.1334; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUNTER T, 1984, EMBO J, V3, P73, DOI 10.1002/j.1460-2075.1984.tb01763.x; JELINEK MA, 1992, ONCOGENE, V7, P1687; KAPLAN DR, 1989, BIOCHIM BIOPHYS ACTA, V948, P345, DOI 10.1016/0304-419X(89)90006-1; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARKLAND W, 1986, J VIROL, V59, P384, DOI 10.1128/JVI.59.2.384-391.1986; MARKLAND W, 1987, BIOCHIM BIOPHYS ACTA, V907, P299, DOI 10.1016/0304-419X(87)90011-4; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RAPTIS L, 1991, J VIROL, V65, P5203, DOI 10.1128/JVI.65.10.5203-5210.1991; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SEGATTO O, 1993, ONCOGENE, V8, P2105; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; TREISMAN R, 1981, NATURE, V292, P595, DOI 10.1038/292595a0; YOAKIM M, 1992, J VIROL, V66, P5485, DOI 10.1128/JVI.66.9.5485-5491.1992; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	29	199	200	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 6	1994	367	6458					87	90		10.1038/367087a0	http://dx.doi.org/10.1038/367087a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MP865	7509037				2022-12-24	WOS:A1994MP86500066
J	GRIFFITH, TS; BRUNNER, T; FLETCHER, SM; GREEN, DR; FERGUSON, TA				GRIFFITH, TS; BRUNNER, T; FLETCHER, SM; GREEN, DR; FERGUSON, TA			FAS LIGAND-INDUCED APOPTOSIS AS A MECHANISM OF IMMUNE PRIVILEGE	SCIENCE			English	Article							CELL-DEATH	The eye is a privileged site that cannot tolerate destructive inflammatory responses. inflammatory cells entering the anterior chamber of the eye in response to viral infection underwent apoptosis that was dependent on Fas (CD95)-Fas ligand (FasL) and produced no tissue damage. In contrast, viral infection in gld mice, which lack functional Fast, resulted in an inflammation and invasion of ocular tissue without apoptosis. Fas-positive but not Fas-negative tumor cells were killed by apoptosis when placed within isolated anterior segments of the eyes of normal but not Fast-negative mice. Fast messenger RNA and protein were detectable in the eye. Thus, Fas-FasL interactions appear to be:an important mechanism for the maintenance of immune privilege.	WASHINGTON UNIV,SCH MED,DEPT OPHTHALMOL & VISUAL SCI,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; LA JOLLA INST ALLERGY & IMMUNOL,DIV CELLULAR IMMUNOL,LA JOLLA,CA 92037	Washington University (WUSTL); Washington University (WUSTL); La Jolla Institute for Immunology			Green, Douglas R/N-8083-2018	Green, Douglas R/0000-0002-7332-1417	NATIONAL EYE INSTITUTE [P30EY002687] Funding Source: NIH RePORTER; NEI NIH HHS [EY06765, EY02687] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ATHERTON SS, 1987, INVEST OPHTH VIS SCI, V28, P859; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CASPI RR, 1986, J IMMUNOL, V136, P928; FERGUSON TA, 1995, J IMMUNOL, V155, P1746; GAO EK, UNPUB; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GREENE HSN, 1949, CANCER RES, V9, P728; GRIFFITH TS, UNPUB; HOOPER P, 1991, CURR EYE RES, V10, P363, DOI 10.3109/02713689108996342; IWAI K, 1994, BLOOD, V4, P1201; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; MEDAWAR PB, 1948, BRIT J EXP PATHOL, V29, P58; MOGIL RJ, 1995, INT IMMUNOL, V7, P1451, DOI 10.1093/intimm/7.9.1451; NIEDERKORN JY, 1983, J IMMUNOL, V131, P2587; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; SHI YF, 1989, NATURE, V339, P625, DOI 10.1038/339625a0; SINGER GG, 1994, IMMUNITY, V1, P365, DOI 10.1016/1074-7613(94)90067-1; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SPANGRUDE GJ, 1994, CURRENT PROTOCOLS IM, V1; STREILEIN JW, 1992, J NEUROIMMUNOL, V39, P185, DOI 10.1016/0165-5728(92)90253-H; SUDA T, 1995, J IMMUNOL, V154, P3806; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; van Dooremaal J. C., 1873, A VONGRAEFES ARCH OP, V19, P359; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WILBANKS GA, 1992, EUR J IMMUNOL, V22, P165, DOI 10.1002/eji.1830220125	26	1737	1812	2	57	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 17	1995	270	5239					1189	1192		10.1126/science.270.5239.1189	http://dx.doi.org/10.1126/science.270.5239.1189			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE905	7502042				2022-12-24	WOS:A1995TE90500053
J	ALEXANDER, M; GRUMBACH, K; SELBY, J; BROWN, AF; WASHINGTON, E				ALEXANDER, M; GRUMBACH, K; SELBY, J; BROWN, AF; WASHINGTON, E			HOSPITALIZATION FOR CONGESTIVE-HEART-FAILURE - EXPLAINING RACIAL-DIFFERENCES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; MORTALITY CROSSOVER; PREVALENCE; POPULATION; SYSTEM; RATES; CARE	Objective.-To determine whether the higher rate of hospitalization among African Americans for congestive heart failure (CHF) could be explained by racial differences in the prevalence of clinical risk factors for CHF. Design.-Retrospective cohort study. Setting.-A large health maintenance organization (HMO). Patients.-A sample of 64 877 enrollees (27% African American and 73% white) of the Northern California Kaiser Permanente Medical Care Program who took at least one multiphasic health checkup (MHC) at or after the age of 40 years and were free of CHF at that time. Main Outcome Measures.-First hospitalization with a principal diagnosis of CHF. Results.-Among cohort members younger than 60 years at baseline MHC, the age-adjusted risk ratio (RR) (African American/white) for CHF hospitalization was 2.14 for men and 2.73 for women, while for persons 60 years of age and older at MHC, the age-adjusted RR was 1.48 for both sexes. Cox proportional hazards models were used to adjust for risk factors and length of follow-up. In persons aged 60 years and older, the race difference was explained by greater prevalence of hypertension and diabetes in African Americans (RR=1.12; 95% confidence interval [CI], 0.94 to 1.34 after adjustment for hypertension and diabetes). In those younger than 60 years, findings differed by sex. For men, African-American race was no longer a significant predictor of CHF after adjusting for hypertension, diabetes, left ventricular hypertrophy on electrocardiogram, and body mass index (adjusted RR=1.16; 95% CI, 0.86 to 1.56). However, among younger women, African Americans continued at increased risk despite adjustment for these variables as well as smoking, plasma cholesterol, renal function, alcohol use, and myocardial infarction (adjusted RR=1.49; 95% CI, 1.00 to 2.21). Conclusions.-In this HMO population, the race differences in first hospitalization for CHF are largely explained by known clinical and behavioral risk factors, although in younger women these risk factors do not completely explain the excess risk among African Americans. These findings highlight the role of hypertension and diabetes in the development of CHF, particularly among African Americans.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT FAMILY & COMMUNITY MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT OBSTET GYNECOL & REPROD SCI,SAN FRANCISCO,CA 94143; KAISER PERMANENTE MED CARE PROGRAM NO CALIF REG,DIV RES,OAKLAND,CA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Kaiser Permanente	ALEXANDER, M (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,MED EFFECTIVENESS RES CTR DIVERSE POPULAT,BOX 0856,SAN FRANCISCO,CA 94143, USA.		Grumbach, Kevin/L-9222-2016	Brown, Arleen/0000-0001-9948-8955	AHRQ HHS [HS07373] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ARELLANO MG, 1984, AM J PUBLIC HEALTH, V74, P1324, DOI 10.2105/AJPH.74.12.1324; AYANIAN JZ, 1993, JAMA-J AM MED ASSOC, V269, P2642, DOI 10.1001/jama.269.20.2642; BILLINGS J, 1993, HEALTH AFFAIR, V12, P162, DOI 10.1377/hlthaff.12.1.162; BINDMAN AB, 1992, JAMA-J AM MED ASSOC, V268, P2426, DOI 10.1001/jama.268.17.2426; COLLEN MF, 1973, INT C SERIES, P332; GARFIELD SR, 1970, NEW ENGL J MED, V283, P1087, DOI 10.1056/NEJM197011122832006; GARFIELD SR, 1970, SCI AM, V222, P15, DOI 10.1038/scientificamerican0470-15; GARRISON GE, 1966, AM J EPIDEMIOL, V83, P338, DOI 10.1093/oxfordjournals.aje.a120589; GHALI JK, 1988, ARCH INTERN MED, V148, P2013, DOI 10.1001/archinte.148.9.2013; GHALI JK, 1990, ARCH INTERN MED, V150, P769, DOI 10.1001/archinte.150.4.769; GILLUM RF, 1987, AM HEART J, V113, P1043, DOI 10.1016/0002-8703(87)90077-9; GILLUM RF, 1991, CARDIOVASCULAR DIS B, P3; GRAVES EJ, 1994, ADV DATA VITAL HLTH, V249; JOHNSON PA, 1993, ANN INTERN MED, V118, P593, DOI 10.7326/0003-4819-118-8-199304150-00004; KAHN KL, 1994, JAMA-J AM MED ASSOC, V271, P1169, DOI 10.1001/jama.271.15.1169; KAPLAN GA, 1987, AM J PUBLIC HEALTH, V77, P307, DOI 10.2105/AJPH.77.3.307; KRIEGER N, 1992, AM J PUBLIC HEALTH, V82, P703, DOI 10.2105/AJPH.82.5.703; NAM CB, 1978, SOC BIOL, V25, P306, DOI 10.1080/19485565.1978.9988352; PETERSON ED, 1994, JAMA-J AM MED ASSOC, V271, P1175, DOI 10.1001/jama.271.15.1175; RODEHEFFER RJ, 1993, MAYO CLIN PROC, V68, P1143, DOI 10.1016/S0025-6196(12)60063-9; SCHOCKEN DD, 1992, J AM COLL CARDIOL, V20, P301, DOI 10.1016/0735-1097(92)90094-4; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; WEISSMAN JS, 1992, JAMA-J AM MED ASSOC, V268, P2388, DOI 10.1001/jama.268.17.2388; WHITTLE J, 1993, NEW ENGL J MED, V329, P621, DOI 10.1056/NEJM199308263290907; WING S, 1985, J GERONTOL, V40, P78, DOI 10.1093/geronj/40.1.78; YUSEF S, 1989, HYPERTENSION S1, V13, P74; 1994, MMWR-MORBID MORTAL W, V43, P77	27	98	98	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 4	1995	274	13					1037	1042		10.1001/jama.274.13.1037	http://dx.doi.org/10.1001/jama.274.13.1037			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RX108	7563454				2022-12-24	WOS:A1995RX10800026
J	ZINKERNAGEL, RM				ZINKERNAGEL, RM			MHC-RESTRICTED T-CELL RECOGNITION - THE BASIS OF IMMUNE SURVEILLANCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LYMPHOCYTIC CHORIOMENINGITIS; MEDIATED CYTOTOXICITY; ANTIGENS; DISEASE; THYMUS; HLA				ZINKERNAGEL, RM (corresponding author), UNIV ZURICH HOSP,INST EXPTL IMMUNOL,SCHMELZBERGSTR 12,CH-8091 ZURICH,SWITZERLAND.							DAUSSET J, 1977, HLA DISEASE, V9; DOHERTY PC, 1974, TRANSPLANT REV-DENMA, V19, P89; DOHERTY PC, 1995, JAMA-J AM MED ASSOC, V274, P1067, DOI 10.1001/jama.274.13.1067; DOHERTY PC, 1975, LANCET, V2, P1406; FINK PJ, 1978, J EXP MED, V148, P766, DOI 10.1084/jem.148.3.766; GOULMY E, 1977, NATURE, V266, P544, DOI 10.1038/266544a0; KATZ DH, 1973, J EXP MED, V137, P1405, DOI 10.1084/jem.137.6.1405; KLEIN J, 1979, SCIENCE, V203, P516, DOI 10.1126/science.104386; MCMICHAEL AJ, 1977, NATURE, V270, P524, DOI 10.1038/270524a0; MILLER JF, 1961, LANCET, V2, P748; OLDSTONE MB, 1973, J EXP MED, V137, P1201, DOI 10.1084/jem.137.5.1201; ROSENTHA.AS, 1973, J EXP MED, V138, P1194, DOI 10.1084/jem.138.5.1194; SHEARER GM, 1974, EUR J IMMUNOL, V4, P527, DOI 10.1002/eji.1830040802; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0; ZINKERNA.RM, 1974, NATURE, V251, P547, DOI 10.1038/251547a0; ZINKERNAGEL RM, 1978, J EXP MED, V147, P882, DOI 10.1084/jem.147.3.882; ZINKERNAGEL RM, 1979, ANNU REV MICROBIOL, V33, P201, DOI 10.1146/annurev.mi.33.100179.001221; ZINKERNAGEL RM, 1991, IMMUNOL REV, V122, P133, DOI 10.1111/j.1600-065X.1991.tb00601.x	19	3	3	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 4	1995	274	13					1069	1071		10.1001/jama.274.13.1069	http://dx.doi.org/10.1001/jama.274.13.1069			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX108	7563462				2022-12-24	WOS:A1995RX10800034
J	PUKKALA, E; AUVINEN, A; WAHLBERG, G				PUKKALA, E; AUVINEN, A; WAHLBERG, G			INCIDENCE OF CANCER AMONG FINNISH AIRLINE CABIN ATTENDANTS, 1967-92	BRITISH MEDICAL JOURNAL			English	Article							RADIATION EXPOSURE; COSMIC-RADIATION; BREAST-CANCER; RISK	Objective-To assess whether occupational exposure among commercial airline cabin attendants are associated with risk of cancer. Design-Record linkage study. Setting-Finland. Subjects-1577 female and 187 male cabin attendants who had worked for the Finnish airline companies. Main outcome measure-Standardised incidence ratio; expected number of cases based on national cancer incidences. Results-A significant excess of breast cancer (standardised incidence ratio 1.87 (95% confidence interval 1.15 to 2.23)) and bone cancer (15.10 (1.82 to 54.40)) was found among female workers. The risk of breast cancer was most prominent 15 years after recruitment. Risks of leukaemia (3.57 (0.43 to 12.9)) and skin melanoma (2.11 (0.43 to 6.15) were not significantly raised. Among men, one lymphoma and one Kaposi's sarcoma were found (expected number of cases 1.6). Conclusions-Although the lifestyle of cabin attendants is different fi om that of the reference population-for example, in terms of social status and parity-concentration of the excess risks to primary sites sensitive to radiation suggests that ionising radiation during flights may add to the cancer risk of all flight personnel. Otherwise the lifestyle of cabin attendants did not seem to affect their risks of cancer. Estimates of the effect of reproductive risk factors only partly explained the increased risk of breast cancer. If present estimates of health hazards due to radiation are also valid for cosmic radiation, then the radiation doses of cabin attendants seem too small to account entirely for the observed excess risk.	FINNISH CTR RADIAT NUCL SAFETY,SF-00881 HELSINKI,FINLAND; FINNISH FLIGHT ATTENDANTS ASSOC,SF-00520 HELSINKI,FINLAND	Radiation & Nuclear Safety Authority (STUK)	PUKKALA, E (corresponding author), FINNISH CANC REGISTRY,LIISANKATU 21 B,SF-00170 HELSINKI,FINLAND.		Auvinen, Anssi/AAD-9311-2020; Auvinen, Anssi/AAL-2111-2020	Auvinen, Anssi/0000-0003-1125-4818				[Anonymous], 1990, HLTH EFFECTS EXPOSUR; [Anonymous], 1994, SOURCES EFFECTS IONI; BAND PR, 1990, AVIAT SPACE ENVIR MD, V61, P299; BOUVILLE A, 1988, RADIAT PROT DOSIM, V24, P293; EWERTZ M, 1990, INT J CANCER, V46, P597, DOI 10.1002/ijc.2910460408; FRIEDBERG W, 1989, AVIAT SPACE ENVIR MD, V60, P1104; HIGGINSON J, 1992, HUMAN CANCER EPIDEMI; LAND CE, 1994, CANCER CAUSE CONTROL, V5, P167, DOI 10.1007/BF01830263; MONTAGNE C, 1993, RADIAT PROT DOSIM, V48, P79; OBRIEN K, 1972, HEALTH PHYS, V22, P225, DOI 10.1097/00004032-197203000-00002; PARETZKE HG, 1993, RADIAT PROT DOSIM, V48, P33; Pukkala E, 1992, GEOGRAPHICAL ENV EPI, P125; Pukkala E, 1995, CONTRIBUTIONS EPIDEM, V7; SINCLAIR WK, 1985, RADIAT PROT DOSIM, V13, P319; SOINI I, 1977, INT J EPIDEMIOL, V6, P365, DOI 10.1093/ije/6.4.365; TEPPO L, 1994, ACTA ONCOL, V33, P365, DOI 10.3109/02841869409098430; THOMPSON DE, 1994, RAD RES S, V37, pS17; 1994, LANCET, V344, P1039	18	187	191	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 9	1995	311	7006					649	652		10.1136/bmj.311.7006.649	http://dx.doi.org/10.1136/bmj.311.7006.649			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU753	7549630	Green Published			2022-12-24	WOS:A1995RU75300014
J	JACOBSON, MD; RAFF, MC				JACOBSON, MD; RAFF, MC			PROGRAMMED CELL-DEATH AND BCL-2 PROTECTION IN VERY-LOW OXYGEN	NATURE			English	Article							APOPTOSIS; INDUCTION	PROGRAMMED cell death (PCD) is a fundamental feature of animal cells', but the mechanism remains unknown, Similarly, the Bcl-2 oncoprotein can suppress PCD in a variety of cell types and circumstances(2), but it is not known how it does so, It has been suggested that PCD involves the generation of reactive oxygen species (ROS) and that Bcl-2 protects against PCD by inhibiting the generation or action of ROS(3-6). To determine whether ROS are required for PCD, we cultured cells in a near-anaerobic atmosphere where the generation of ROS would be expected not to occur, or at least to be greatly reduced, We find that these conditions inhibit PCD induced by ROS-generating agents but do not inhibit PCD induced by other means, Furthermore, we show that Bcl-2 can protect cells from PCD in these anaerobic conditions. These results suggest that ROS are not required for PCD, and that Bcl-2 protects against PCD in ways that do not depend on the inhibition of ROS production or activity.	UNIV LONDON UNIV COLL,MRC,MOLEC CELL BIOL LAB,LONDON WC1E 6BT,ENGLAND; UNIV LONDON UNIV COLL,DEPT BIOL,LONDON WC1E 6BT,ENGLAND	University of London; University College London; University of London; University College London	JACOBSON, MD (corresponding author), UNIV LONDON UNIV COLL,MRC,DEV NEUROBIOL PROGRAMME,TORRINGTON PL,LONDON WC1E 6BT,ENGLAND.							ABELLO PA, 1994, ARCH SURG-CHICAGO, V129, P134; ABRAMS JS, 1988, J IMMUNOL, V140, P131; BAUDRY M, 1993, BIOCHEM BIOPH RES CO, V192, P964, DOI 10.1006/bbrc.1993.1509; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CADENAS E, 1989, ANNU REV BIOCHEM, V58, P79, DOI 10.1146/annurev.bi.58.070189.000455; DEXTER TM, 1994, PHIL T R SOC B, V345, P231; Franklin J. L., 1994, Society for Neuroscience Abstracts, V20, P432; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; LENNON SV, 1991, CELL PROLIFERAT, V24, P203, DOI 10.1111/j.1365-2184.1991.tb01150.x; MARVEL J, 1994, ONCOGENE, V9, P1117; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NOUROOZZADEH J, 1994, ANAL BIOCHEM, V220, P403, DOI 10.1006/abio.1994.1357; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RATAN RR, 1994, J NEUROCHEM, V62, P376; RATAN RR, 1994, J NEUROSCI, V14, P4385; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SANDSTROM PA, 1994, J LEUKOCYTE BIOL, V55, P221, DOI 10.1002/jlb.55.2.221; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; TAMAOKI T, 1990, BIO-TECHNOL, V8, P732, DOI 10.1038/nbt0890-732; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; WOLFE JT, 1994, FEBS LETT, V352, P58, DOI 10.1016/0014-5793(94)00920-1; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112	29	628	647	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 27	1995	374	6525					814	816		10.1038/374814a0	http://dx.doi.org/10.1038/374814a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QV315	7536895				2022-12-24	WOS:A1995QV31500048
J	CHENG, GH; CLEARY, AM; YE, ZS; HONG, DI; LEDERMAN, S; BALTIMORE, D				CHENG, GH; CLEARY, AM; YE, ZS; HONG, DI; LEDERMAN, S; BALTIMORE, D			INVOLVEMENT OF CRAF1, A RELATIVE OF TRAF, IN CD40 SIGNALING	SCIENCE			English	Article							FOLLICULAR DENDRITIC CELLS; X-LINKED IMMUNODEFICIENCY; HYPER-IGM SYNDROME; B-CELLS; T-CELLS; ACTIVATION MOLECULE; LYMPHOCYTES-B; LIGAND; ANTIGEN; EXPRESSION	CD40 is a receptor on the surface of B lymphocytes, the activation of which leads to B cell survival, growth, and differentiation. A yeast two-hybrid screen identified a gene, CRAF1, encoding a protein that interacts directly with the CD40 cytoplasmic tail through a region of similarity to the tumor necrosis factor-alpha (TNF-alpha) receptor-associated factors. Overexpression of a truncated CRAF1 gene inhibited CD40-mediated up-regulation of CD23. A region of CRAF1 was similar to the TNF-alpha receptor-associated factors TRAF1 and TRAF2 and so defined a shared TRAF-C domain that was necessary and sufficient for CD40 binding and homodimerization. The CRAF1 sequence also predicted a long amphipathic helix, a pattern of five zinc fingers, and a zinc ring finger. It is likely that other members of the TNF receptor superfamily use CRAF-related proteins in their signal transduction processes.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; COLUMBIA UNIV,DEPT MED,NEW YORK,NY 10032; ROCKEFELLER UNIV,NEW YORK,NY 10021	Massachusetts Institute of Technology (MIT); Columbia University; Rockefeller University				Lederman, Seth/0000-0003-2781-1455	NATIONAL CANCER INSTITUTE [R01CA055713] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007367] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA55713] Funding Source: Medline; NIGMS NIH HHS [5-T32-GM07367] Funding Source: Medline; PHS HHS [A122346] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALDERSON MR, 1993, J EXP MED, V178, P669, DOI 10.1084/jem.178.2.669; ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; BERBERICH I, 1994, J IMMUNOL, V15, P4357; CALLARD RE, 1994, J IMMUNOL, V153, P3295; CHENG G, UNPUB; CLARK EA, 1986, P NATL ACAD SCI USA, V83, P4494, DOI 10.1073/pnas.83.12.4494; CLARK EA, 1992, J IMMUNOL, V148, P3327; CLEARY AM, UNPUB; CRAWFORD DH, 1993, IMMUNOLOGY, V80, P40; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; DURIE FH, 1994, IMMUNOL TODAY, V15, P406, DOI 10.1016/0167-5699(94)90269-0; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FREMONT PS, 1991, CELL, V64, P483; GALY AHM, 1992, J IMMUNOL, V149, P775; GAUCHAT JF, 1993, FEBS LETT, V315, P259, DOI 10.1016/0014-5793(93)81175-Y; GORDON J, 1988, J IMMUNOL, V140, P1425; GRAF D, 1992, EUR J IMMUNOL, V22, P3191, DOI 10.1002/eji.1830221226; GRILLI M, 1991, INT REV CYTOL, V143, P1; GRUBER MF, 1989, J IMMUNOL, V142, P4144; HART DNJ, 1988, J EXP MED, V168, P157, DOI 10.1084/jem.168.1.157; HEATH AW, 1993, CELL IMMUNOL, V152, P468, DOI 10.1006/cimm.1993.1305; HOLDER MJ, 1993, EUR J IMMUNOL, V23, P2368, DOI 10.1002/eji.1830230948; HOLLENBAUGH D, 1992, EMBO J, V11, P4313, DOI 10.1002/j.1460-2075.1992.tb05530.x; HU HM, 1994, J BIOL CHEM, V269, P30069; INUI S, 1990, EUR J IMMUNOL, V20, P1747, DOI 10.1002/eji.1830200819; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANE P, 1993, J EXP MED, V177, P1209, DOI 10.1084/jem.177.4.1209; LEDERMAN S, 1992, J IMMUNOL, V149, P3817; LEDERMAN S, 1992, J EXP MED, V175, P1091, DOI 10.1084/jem.175.4.1091; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; Miller J.H., 1972, EXPT MOL GENETICS; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; PARRY SL, 1994, J IMMUNOL, V152, P2821; PAULIE S, 1985, CANCER IMMUNOL IMMUN, V20, P23; RAMESH N, 1993, INT IMMUNOL, V5, P769, DOI 10.1093/intimm/5.7.769; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SCHRIEVER F, 1989, J EXP MED, V169, P2043, DOI 10.1084/jem.169.6.2043; SIEGEL JP, 1990, J IMMUNOL METHODS, V132, P287, DOI 10.1016/0022-1759(90)90040-3; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SPRIGGS MK, 1992, J EXP MED, V176, P1543, DOI 10.1084/jem.176.6.1543; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; TARAGLIS LA, 1993, CELL, V74, P845; TSUBATA T, 1993, NATURE, V364, P645, DOI 10.1038/364645a0; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6; YELLIN MJ, 1994, J IMMUNOL, V153, P666	51	432	457	0	12	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 10	1995	267	5203					1494	1498		10.1126/science.7533327	http://dx.doi.org/10.1126/science.7533327			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL497	7533327				2022-12-24	WOS:A1995QL49700037
J	MAGRELLI, A; LANGENKEMPER, K; DEHIO, C; SCHELL, J; SPENA, A				MAGRELLI, A; LANGENKEMPER, K; DEHIO, C; SCHELL, J; SPENA, A			SPLICING OF THE ROLA TRANSCRIPT OF AGROBACTERIUM-RHIZOGENES IN ARABIDOPSIS	SCIENCE			English	Article							PRE-MESSENGER-RNA; INTRONS; GENE; DNA; SEQUENCES; BACTERIA; PLASMID; BACTERIOPHAGE-T4; IDENTIFICATION; EXPRESSION	The rolA gene encoded on the Ri plasmid A4 of Agrobacterium rhizogenes is one of the transferred (T-L-DNA) genes involved in the pathogenesis of hairy-root disease in plants. The function of the 100-amino acid protein product of rolA is unknown, although its expression causes physiological and developmental alterations in transgenic plants. The rolA gene of A. rhizogenes contains an intron in its untranslated leader region that has features typical of plant pre-messenger RNA introns. Transcription and splicing of the rolA pre-messenger RNA occur in the plant cell.	MAX PLANCK INST ZUCHTUNGSFORSCH,D-50829 COLOGNE,GERMANY	Max Planck Society			Magrelli, Armando/A-5478-2010; Dehio, Christoph/R-8277-2016; Dehio, Christoph/AAD-5572-2019; Magrelli, Armando/K-4330-2019	Magrelli, Armando/0000-0002-5036-3710; Dehio, Christoph/0000-0001-7288-1052; Dehio, Christoph/0000-0001-7288-1052; Magrelli, Armando/0000-0002-5036-3710				CARNEIRO M, 1993, PLANT J, V3, P785, DOI 10.1111/j.1365-313X.1993.00785.x; CHU FK, 1984, P NATL ACAD SCI-BIOL, V81, P3049, DOI 10.1073/pnas.81.10.3049; CSANK C, 1990, NUCLEIC ACIDS RES, V18, P5133, DOI 10.1093/nar/18.17.5133; DEHIO C, 1993, MOL GEN GENET, V241, P359, DOI 10.1007/BF00284689; FERAT JL, 1993, NATURE, V364, P358, DOI 10.1038/364358a0; GOODALL GJ, 1990, PLANT MOL BIOL, V14, P727, DOI 10.1007/BF00016505; GOODALL GJ, 1989, CELL, V58, P473, DOI 10.1016/0092-8674(89)90428-5; GOODRICHBLAIR H, 1990, CELL, V63, P417, DOI 10.1016/0092-8674(90)90174-D; JANSSENS A, 1984, MOL GEN GENET, V195, P341, DOI 10.1007/BF00332769; KOVACS SA, 1993, J BACTERIOL, V175, P1871, DOI 10.1128/JB.175.7.1871-1878.1993; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LAMBOWITZ AM, 1993, ANNU REV BIOCHEM, V62, P587, DOI 10.1146/annurev.bi.62.070193.003103; LEGRAIN P, 1989, CELL, V57, P573, DOI 10.1016/0092-8674(89)90127-X; MAGRELLI A, UNPUB; Maniatis T, 1989, DECONTAMINATION DILU; MICHAEL T, IN PRESS METHODS MOL; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; REINHOLDHUREK B, 1992, NATURE, V357, P173, DOI 10.1038/357173a0; SCHRODER G, 1983, EMBO J, V2, P403, DOI 10.1002/j.1460-2075.1983.tb01437.x; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; SHARP PA, 1987, SCIENCE, V235, P766, DOI 10.1126/science.3544217; SINKAR VP, 1988, GENE DEV, V2, P688, DOI 10.1101/gad.2.6.688; SJOBERG BM, 1986, EMBO J, V5, P2031, DOI 10.1002/j.1460-2075.1986.tb04460.x; SLIGHTOM JL, 1986, J BIOL CHEM, V261, P108; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; WHITE FF, 1985, J BACTERIOL, V164, P33, DOI 10.1128/JB.164.1.33-44.1985; XU MQ, 1990, SCIENCE, V250, P1566, DOI 10.1126/science.2125747	27	21	23	0	9	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 23	1994	266	5193					1986	1988		10.1126/science.7528444	http://dx.doi.org/10.1126/science.7528444			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PZ267	7528444				2022-12-24	WOS:A1994PZ26700028
J	MULDER, JWR; KRUYT, PM; SEWNATH, M; OOSTING, J; SELDENRIJK, CA; WEIDEMA, WF; OFFERHAUS, GJA; PALS, ST				MULDER, JWR; KRUYT, PM; SEWNATH, M; OOSTING, J; SELDENRIJK, CA; WEIDEMA, WF; OFFERHAUS, GJA; PALS, ST			COLORECTAL-CANCER PROGNOSIS AND EXPRESSION OF EXON-V6-CONTAINING CD44 PROTEINS	LANCET			English	Note							METASTASIS-ASSOCIATED VARIANT; CARCINOMAS; HOMOLOG	CD44 variants containing v6 confer metastatic potential to rat carcinoma cell-lines. In man, CD44v6 is increasingly expressed during colorectal tumour progression. In 68 colorectal carcinoma patients, survival analysis showed that CD44v6 expression in the tumours was associated with tumour-related death. In patients who had an apparently radical resection of their primary tumour, CD44v6 expression had prognostic value independent of Dukes' stage. CD44v6 expression may reflect propensity for metastasis after apparently curative surgery, making adjuvant therapy an option in these patients.	UNIV AMSTERDAM,ACAD MED CTR,DEPT PATHOL,1105 AZ AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT CLIN EPIDEMIOL,1105 AZ AMSTERDAM,NETHERLANDS; REINIER DE GRAAF HOSP,DEPT SURG,DELFT,NETHERLANDS; REINIER DE GRAAF HOSP,DEPT PATHOL,DELFT,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Reinier de Graaf Hospital; Reinier de Graaf Hospital				Pals, Steven/0000-0002-1419-0939				ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HEIDER KH, 1993, J CELL BIOL, V120, P227, DOI 10.1083/jcb.120.1.227; KOOPMAN G, 1993, J EXP MED, V177, P897, DOI 10.1084/jem.177.4.897; MATSUMURA Y, 1992, LANCET, V340, P1053, DOI 10.1016/0140-6736(92)93077-Z; MOERTEL CG, 1994, NEW ENGL J MED, V330, P1136; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; TANABE KK, 1993, LANCET, V341, P725, DOI 10.1016/0140-6736(93)90490-8; WIELENGA VJM, 1993, CANCER RES, V53, P4754; 1990, JAMA-J AM MED ASSOC, V264, P1444	10	302	315	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 26	1994	344	8935					1470	1472		10.1016/S0140-6736(94)90290-9	http://dx.doi.org/10.1016/S0140-6736(94)90290-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT995	7526103				2022-12-24	WOS:A1994PT99500009
J	PLEY, HW; FLAHERTY, KM; MCKAY, DB				PLEY, HW; FLAHERTY, KM; MCKAY, DB			MODEL FOR AN RNA TERTIARY INTERACTION FRONT THE STRUCTURE OF AN INTERMOLECULAR COMPLEX BETWEEN A GAAA TETRALOOP AND AN RNA HELIX	NATURE			English	Article							ARCHITECTURE; SEQUENCE; LOOPS	IN large structured RNAs, RNA hairpins in which the strands of the duplex stem are connected by a tetraloop of the consensus sequence 5'-GNRA (where N is any nucleotide, and R is either G or A) are unusually frequent(1). In group I introns there is a covariation in sequence between nucleotides in the third and fourth positions of the loop with specific distant base pairs in putative RNA duplex stems(2): GNAA loops correlate with successive 5'-C-C.G-G base pairs in stems, whereas GNGA loops correlate with 5'-C-U.G-A. This has led to the suggestion that GNRA tetraloops may be involved in specific long-range tertiary interactions, with each A in position 3 or 4 of the loop interacting with a C-G base pair in the duplex, and G in position 3 interacting with a U-A base pair. This idea is supported experimentally for the GAAA loop of the P5b extension of the group I intron of Tetrahymena thermophila(3) and the L9 GUGA terminal loop of the td intron of bacteriophage T4 (ref. 4). NMR has revealed the overall structure of the tetraloop for 12-nucleotide hairpins with GCAA and GAAA loops(5) and models have been proposed for the interaction of GNRA tetraloops with base pairs in the minor groove of A-form RNA(2,4). Here we describe the crystal structure of an intermolecular complex between a GAAA tetraloop and an RNA helix. The interactions we observe correlate with tbe specificity of GNRA tetraloops inferred from phylogenetic studies, suggesting that this complex is a legitimate model for intramolecular tertiary interactions mediated by GNRA tetraloops in large structured RNAs.	STANFORD UNIV,SCH MED,DEPT BIOL STRUCT,BECKMAN LABS STRUCT BIOL,STANFORD,CA 94305	Stanford University								HEUS HA, 1991, SCIENCE, V253, P191, DOI 10.1126/science.1712983; JAEGER L, 1994, J MOL BIOL, V236, P1271, DOI 10.1016/0022-2836(94)90055-8; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MURPHY FL, 1994, J MOL BIOL, V236, P49, DOI 10.1006/jmbi.1994.1117; PLEY HW, 1994, NATURE, V372, P68, DOI 10.1038/372068a0; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P8467, DOI 10.1073/pnas.87.21.8467	6	263	265	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 3	1994	372	6501					111	113		10.1038/372111a0	http://dx.doi.org/10.1038/372111a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ348	7526219				2022-12-24	WOS:A1994PQ34800085
J	MCCANN, RM; HALL, WJ; GROTHJUNCKER, A				MCCANN, RM; HALL, WJ; GROTHJUNCKER, A			COMFORT CARE FOR TERMINALLY ILL PATIENTS - THE APPROPRIATE USE OF NUTRITION AND HYDRATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PARENTERAL-NUTRITION; ELDERLY PATIENTS; CANCER; DEPRIVATION	Objective.-To determine the frequency of symptoms of hunger and thirst in a group of terminally ill patients and determine whether these symptoms could be palliated without forced feeding, forced hydration, or parenteral alimentation. Design.-Prospective evaluation of consecutively admitted terminally ill patients treated in a comfort care unit. Setting.-Ten-bed comfort care unit in a 471-bed long-term care facility. Participants.-Mentally aware, competent patients with terminal illnesses monitored from time of admission to time of death while residing in the comfort care unit. Main Outcome Measures.-Symptoms of hunger, thirst, and dry mouth were recorded, and the amounts and types of food and fluids necessary to relieve these symptoms were documented. The subjective level of comfort was assessed longitudinally in all patients. Results.-Of the 32 patients monitored during the 12 months of study, 20 patients (63%) never experienced any hunger, white 11 patients (34%) had symptoms only initially. Similarly, 20 patients (62%) experienced either no thirst or thirst only initially during their terminal illness. In all patients, symptoms of hunger, thirst, and dry mouth could be alleviated, usually with smalt amounts of food, fluids, and/or by the application of ice chips and lubrication to the lips. Comfort care included use of narcotics for relief of pain or shortness of breath in 94% of patients. Conclusions.-In this series, patients terminally ill with cancer generally did not experience hunger and those who did needed only small amounts of food for alleviation. Complaints of thirst and dry mouth were relieved with mouth care and sips of liquids far less than that needed to prevent dehydration. Food and fluid administration beyond the specific requests of patients may play a minimal role in providing comfort to terminally ill patients.	UNIV ROCHESTER, SCH MED & DENT, DEPT MED, ROCHESTER, NY 14642 USA; ST JOHNS HOME, ROCHESTER, NY USA	University of Rochester								[Anonymous], 1992, ANN INTERN MED, V117, P947; BILLINGS JA, 1985, J AM GERIATR SOC, V33, P808, DOI 10.1111/j.1532-5415.1985.tb04196.x; CIOCON JO, 1988, ARCH INTERN MED, V148, P429, DOI 10.1001/archinte.148.2.429; CLAMON GH, 1985, CANCER TREAT REP, V69, P167; FELIG P, 1969, J CLIN INVEST, V48, P584, DOI 10.1172/JCI106017; FELIG P, 1970, NEW ENGL J MED, V282, P166; Gershan J A, 1985, Crit Care Nurse, V5, P32; HAMM RJ, 1984, PHYSIOL BEHAV, V33, P499, DOI 10.1016/0031-9384(84)90176-8; HAMM RJ, 1985, PHYSIOL BEHAV, V35, P879, DOI 10.1016/0031-9384(85)90254-9; HARDY C, 1986, J AM GERIATR SOC, V34, P219, DOI 10.1111/j.1532-5415.1986.tb04207.x; HEBER D, 1986, CANCER-AM CANCER SOC, V58, P1867, DOI 10.1002/1097-0142(19861015)58:8+<1867::AID-CNCR2820581413>3.0.CO;2-A; KERNDT PR, 1982, WESTERN J MED, V137, P379; KORETZ RL, 1984, J CLIN ONCOL, V2, P534, DOI 10.1200/JCO.1984.2.5.534; LO B, 1986, ARCH INTERN MED, V146, P1613, DOI 10.1001/archinte.146.8.1613; MCHUGH JT, 1990, ISSUES LAW MED, V6, P89; NIXON DW, 1981, CANCER TREAT REP, V65, P121; NORBERG A, 1980, BRIT MED J, V280, P377, DOI 10.1136/bmj.280.6211.377; OWEN OE, 1983, CLIN ENDOCRINOL META, V12, P359, DOI 10.1016/S0300-595X(83)80046-2; PHILLIPS PA, 1984, NEW ENGL J MED, V311, P753, DOI 10.1056/NEJM198409203111202; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1983, DECIDING FOREGO LIFE; PRINTZ LA, 1988, GERIATRICS, V43, P84; QUILL TE, 1989, ARCH INTERN MED, V149, P1937, DOI 10.1001/archinte.149.9.1937; SAUDEK CD, 1976, AM J MED, V60, P117, DOI 10.1016/0002-9343(76)90540-4; SULLIVAN RJ, 1993, J GEN INTERN MED, V8, P220, DOI 10.1007/BF02599271; VANDERPOOL H, 1978, ENCY BIOETHICS, P1373; 1988, GUIDELINES WITHHOLDI; 1989, WITHHOLDING WITHDRAW	27	327	336	0	23	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 26	1994	272	16					1263	1266		10.1001/jama.272.16.1263	http://dx.doi.org/10.1001/jama.272.16.1263			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN068	7523740				2022-12-24	WOS:A1994PN06800031
J	CYSTER, JG; HARTLEY, SB; GOODNOW, CC				CYSTER, JG; HARTLEY, SB; GOODNOW, CC			COMPETITION FOR FOLLICULAR NICHES EXCLUDES SELF-REACTIVE CELLS FROM THE RECIRCULATING B-CELL REPERTOIRE	NATURE			English	Article							LYMPHOCYTES-B; TRANSGENIC MICE; BONE-MARROW; CLONAL DELETION; GENES; EXPRESSION; TOLERANCE; LYSOZYME; ANTIGEN; MOUSE	Two different approaches to follow clones of B lymphocytes in a diverse preimmune repertoire reveal a new process for eliminating self-reactive cells in the periphery which depends on competition between cells with different specificities. A key feature of this censoring mechanism is the selective exclusion of self-antigen-binding B cells from the normal migration route into lymphoid follicles, resulting in their premature death. This is a striking example of homeostasis by cellular competition for limiting niches and may explain the paradoxical association between immunodeficiency and autoimmunity.	STANFORD UNIV, BECKMAN CTR, SCH MED, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA	Howard Hughes Medical Institute; Stanford University	CYSTER, JG (corresponding author), STANFORD UNIV, BECKMAN CTR, SCH MED, DEPT MICROBIOL & IMMUNOL, STANFORD, CA 94305 USA.		Goodnow, Christopher C/V-8108-2018	Goodnow, Christopher C/0000-0001-5296-6155				ADELSTEIN S, 1991, SCIENCE, V251, P1223, DOI 10.1126/science.1900950; AHEARN JM, 1989, ADV IMMUNOL, V46, P183, DOI 10.1016/S0065-2776(08)60654-9; ALLMAN DM, 1993, J IMMUNOL, V151, P4431; AUGUST CS, 1989, IMMUNOLOGICAL DISORD, P634; BELL EB, 1975, EUR J IMMUNOL, V5, P1; BONA CA, 1988, ANNU REV IMMUNOL, V6, P327, DOI 10.1146/annurev.iy.06.040188.001551; COOKE MP, 1994, J EXP MED, V179, P425, DOI 10.1084/jem.179.2.425; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; ERIKSON J, 1991, NATURE, V349, P331, DOI 10.1038/349331a0; FORSTER I, 1990, P NATL ACAD SCI USA, V87, P4781, DOI 10.1073/pnas.87.12.4781; FORSTER I, 1991, EUR J IMMUNOL, V21, P1779, DOI 10.1002/eji.1830210732; FREITAS AA, 1990, INT IMMUNOL, V2, P15, DOI 10.1093/intimm/2.1.15; GOODNOW CC, 1992, ANNU REV IMMUNOL, V10, P489, DOI 10.1146/annurev.iy.10.040192.002421; GOODNOW CC, 1989, NATURE, V342, P385, DOI 10.1038/342385a0; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; GOWANS JL, 1964, PROC R SOC SER B-BIO, V159, P257, DOI 10.1098/rspb.1964.0001; GRAY D, 1988, J EXP MED, V167, P805, DOI 10.1084/jem.167.3.805; GU H, 1991, J EXP MED, V173, P1357, DOI 10.1084/jem.173.6.1357; GUTMAN GA, 1973, TRANSPLANTATION, V16, P621, DOI 10.1097/00007890-197312000-00014; HARTLEY SB, 1993, CELL, V72, P325, DOI 10.1016/0092-8674(93)90111-3; HARTLEY SB, 1991, NATURE, V353, P765, DOI 10.1038/353765a0; HOWARD JC, 1972, J EXP MED, V135, P185, DOI 10.1084/jem.135.2.185; Kearney J F, 1992, Int Rev Immunol, V8, P247, DOI 10.3109/08830189209055577; KOOPMAN G, 1992, IMMUNOL REV, V126, P21, DOI 10.1111/j.1600-065X.1992.tb00629.x; LIU YJ, 1991, EUR J IMMUNOL, V21, P2951, DOI 10.1002/eji.1830211209; LORTAN JE, 1987, EUR J IMMUNOL, V17, P1311, DOI 10.1002/eji.1830170914; MACLENNAN ICM, 1990, CURR TOP MICROBIOL, V159, P37; MAKELA O, 1965, IMMUNOLOGY, V8, P539; MASON DY, 1992, INT IMMUNOL, V4, P163, DOI 10.1093/intimm/4.2.163; NEMAZEE D, 1991, IMMUNOL REV, V122, P117, DOI 10.1111/j.1600-065X.1991.tb00600.x; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; NIEUWENHUIS P, 1976, CELL IMMUNOL, V23, P254, DOI 10.1016/0008-8749(76)90191-X; OKAMOTO M, 1992, J EXP MED, V175, P71, DOI 10.1084/jem.175.1.71; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; OPSTELTEN D, 1983, J IMMUNOL, V131, P2635; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; PELLAS TC, 1990, AM J ANAT, V187, P347, DOI 10.1002/aja.1001870404; PICKER LJ, 1992, ANNU REV IMMUNOL, V10, P561, DOI 10.1146/annurev.immunol.10.1.561; POPPEMA S, 1992, IMMUNOL REV, V126, P163, DOI 10.1111/j.1600-065X.1992.tb00636.x; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; ROLINK A, 1993, ADV IMMUNOL, V53, P123, DOI 10.1016/S0065-2776(08)60499-X; SMITHGILL SJ, 1987, J IMMUNOL, V139, P4135; SPRENT J, 1972, EUR J IMMUNOL, V2, P384, DOI 10.1002/eji.1830020420; STORB U, 1987, ANNU REV IMMUNOL, V5, P151, DOI 10.1146/annurev.iy.05.040187.001055; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; VANDENEERTWEGH AJM, 1993, J EXP MED, V178, P1555, DOI 10.1084/jem.178.5.1555; YANCOPOULOS GD, 1984, NATURE, V311, P727, DOI 10.1038/311727a0	47	476	478	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 29	1994	371	6496					389	395		10.1038/371389a0	http://dx.doi.org/10.1038/371389a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PJ285	7522305				2022-12-24	WOS:A1994PJ28500033
J	LI, VW; FOLKERTH, RD; WATANABE, H; YU, CN; RUPNICK, M; BARNES, P; SCOTT, RM; BLACK, PM; SALLAN, SE; FOLKMAN, J				LI, VW; FOLKERTH, RD; WATANABE, H; YU, CN; RUPNICK, M; BARNES, P; SCOTT, RM; BLACK, PM; SALLAN, SE; FOLKMAN, J			MICROVESSEL COUNT AND CEREBROSPINAL-FLUID BASIC FIBROBLAST GROWTH-FACTOR IN CHILDREN WITH BRAIN-TUMORS	LANCET			English	Article							CAPILLARY ENDOTHELIAL-CELLS; CONTRAST ENHANCEMENT; ANGIOGENESIS; METASTASIS; AFFINITY; MEMBRANE; BINDING; CULTURE; TUMORS	Tumour growth is angiogenesis-dependent; brain tumours have more intense neovascularisation than other tumours and produce basic fibroblast growth factor, a potent angiogenic mediator. Because little is known about the release of basic fibroblast growth factor from brain tumours into extracellular fluids, we tested cerebrospinal fluid (CSF) from 26 children and young adults with brain tumours and 18 controls for basic fibroblast growth factor and for proliferative activity on cultured capillary endothelial cells. We also measured the density of microvessels in tumours by immunohistochemical staining. Basic fibroblast growth factor was detected in the CSF of 62% (16 of 26) patients with brain tumours but in none of the controls. Specimens with basic fibroblast growth factor stimulated DNA synthesis of capillary endothelial cells in vitro. Endothelial proliferative activity was blocked by neutralising antibodies to basic fibroblast growth factor. Basic fibroblast growth factor correlated with mitogenic activity in CSF in vitro (p less than or equal to 0.0001), and with density of microvessels in histological sections (p less than or equal to 0.005). A microvessel count of greater than or equal to 68 per 200 x field was associated with tumour recurrence (p = 0.005) and with mortality (p = 0.02). Basic fibroblast growth factor in brain tumours may mediate angiogenesis as measured by microvessel density in histological sections, so has potential as both a marker for neoplasia and a target for tumour treatments. Furthermore, evaluation of cerebrospinal fluid basic fibroblast growth factor, along with microvessel quantitation in biopsied tumours, may provide improved prognostic information for the management of patients with brain tumours.	CHILDRENS HOSP, DEPT SURG, BOSTON, MA 02115 USA; CHILDRENS HOSP, DEPT NEUROSURG, BOSTON, MA 02115 USA; CHILDRENS HOSP, DEPT PATHOL, BOSTON, MA 02115 USA; CHILDRENS HOSP, DEPT RADIOL, BOSTON, MA 02115 USA; CHILDRENS HOSP, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA USA; TAKEDA CHEM IND LTD, OSAKA 532, JAPAN	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Takeda Chemical Industries				Yu, Channing/0000-0002-3231-2565	NATIONAL CANCER INSTITUTE [T32CA009535, R01CA037395, R37CA037395] Funding Source: NIH RePORTER; NCI NIH HHS [5T32CA09535-06, CA37395-09] Funding Source: Medline; NINDS NIH HHS [NINDS NS-92-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BIGNER SH, 1992, J NEUROPATH EXP NEUR, V51, P235, DOI 10.1097/00005072-199205000-00001; BREM H, 1980, SURG FORUM, V31, P471; BREM S, 1992, CANCER, V70, P2673, DOI 10.1002/1097-0142(19921201)70:11<2673::AID-CNCR2820701118>3.0.CO;2-F; CONNOLLY DT, 1986, ANAL BIOCHEM, V152, P136, DOI 10.1016/0003-2697(86)90131-4; Finklestein S P, 1990, Restor Neurol Neurosci, V1, P387, DOI 10.3233/RNN-1990-1603; FOLKMAN J, 1979, P NATL ACAD SCI USA, V76, P5217, DOI 10.1073/pnas.76.10.5217; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOLKMAN J, 1988, AM J PATHOL, V130, P393; GOSPODAROWICZ D, 1976, P NATL ACAD SCI USA, V73, P4120, DOI 10.1073/pnas.73.11.4120; HAMADA J, 1992, BRIT J CANCER, V66, P349, DOI 10.1038/bjc.1992.269; HESSELINK JR, 1988, RADIOL CLIN N AM, V26, P873; HORI A, 1991, CANCER RES, V51, P6180; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Klagsbrun M, 1989, Prog Growth Factor Res, V1, P207, DOI 10.1016/0955-2235(89)90012-4; LOPEZPOUSA S, 1981, EXPERIENTIA, V37, P413; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; NAKAGAWA H, 1992, J NEURO-ONCOL, V12, P111; PINKUS GS, 1986, AM J CLIN PATHOL, V85, P269, DOI 10.1093/ajcp/85.3.269; RAK JW, IN PRESS J CELL PHYS; Russell D., 1989, PATHOLOGY TUMORS NER; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; SHING Y, 1991, METHOD ENZYMOL, V198, P91; SHING Y, 1992, INVEST OPHTH VIS SCI, V33, pA1683; TAKAHASHI A, 1993, NEUROSCI LETT, V160, P214, DOI 10.1016/0304-3940(93)90416-I; TAKAHASHI JA, 1990, P NATL ACAD SCI USA, V87, P5710, DOI 10.1073/pnas.87.15.5710; WALICKE PA, 1988, J NEUROSCI, V8, P2618; WATANABE H, 1991, BIOCHEM BIOPH RES CO, V175, P229, DOI 10.1016/S0006-291X(05)81224-0; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; ZAGZAG D, 1989, AM J ROENTGENOL, V153, P141, DOI 10.2214/ajr.153.1.141	30	200	214	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 9	1994	344	8915					82	86		10.1016/S0140-6736(94)91280-7	http://dx.doi.org/10.1016/S0140-6736(94)91280-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV732	7516992				2022-12-24	WOS:A1994NV73200008
J	DAS, KM; PRASAD, I; GARLA, S; AMENTA, PS				DAS, KM; PRASAD, I; GARLA, S; AMENTA, PS			DETECTION OF A SHARED COLON EPITHELIAL EPITOPE ON BARRETT EPITHELIUM BY A NOVEL MONOCLONAL-ANTIBODY	ANNALS OF INTERNAL MEDICINE			English	Article						EPITHELIUM; BARRETT ESOPHAGUS; EPITOPES; COLON; ESOPHAGITIS, PEPTIC	COLUMNAR-LINED ESOPHAGUS; ADENOCARCINOMA; DIAGNOSIS	Objective: To determine if there is a reactive epitope common to colonic epithelium and Barrett epithelium, a premalignant metaplastic columnar-lined esophagus, usually arising as a complication of chronic reflux esophagitis. Design: A monoclonal antibody, 7E(12)H(12) (IgM isotype), developed against a colonic epithelial protein was used in a sensitive immunoperoxidase assay using formalin-fixed, paraffin-embedded tissue. One hundred sixteen tissue specimens from the esophagus, stomach, duodenum, and jejunum were examined. Twenty-two biopsy specimens were taken from 22 patients with benign Barrett epithelium, and 12 specimens were obtained from 12 patients with adenocarcinoma of the esophagus arising in Barrett epithelium. The remaining 85 tissue specimens were obtained from various parts of the upper gastrointestinal tract of patients with or without disease states. Results: 21 of 22 (95%) Barrett epithelium specimens and all 12 adenocarcinomas arising from Barrett epithelium reacted with the 7E(12)H(12) monoclonal antibody. Other tissues from esophagus, gastroesophageal junction, stomach, duodenum, or jejunum did not react. Squamous cell carcinoma of the esophagus also did not react. Conclusions: Barrett epithelium shares phenotypic expression of colonic epithelium. The 7E(12)H(12) monoclonal antibody may provide insight into the origin and cellular lineage of Barrett epithelium.	ROBERT WOOD JOHNSON UNIV HOSP, NEW BRUNSWICK, NJ USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	DAS, KM (corresponding author), UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT MED, 1 ROBERT WOOD JOHNSON PL, NEW BRUNSWICK, NJ 08903 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044314] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK 44314] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMENTA PS, 1987, METHOD ENZYMOL, V145, P133; CAMERON AJ, 1985, NEW ENGL J MED, V313, P857, DOI 10.1056/NEJM198510033131404; DAS KM, 1987, J IMMUNOL, V139, P77; FEURLE GE, 1990, DIGEST DIS SCI, V35, P86, DOI 10.1007/BF01537228; GOTTFRIED MR, 1989, AM J CLIN PATHOL, V92, P741, DOI 10.1093/ajcp/92.6.741; Goyal RK, 1985, BARRETTS ESOPHAGUS P, P1; Haggitt RC, 1985, BARRETTS ESOPHAGUS P, P153; HALSTENSEN TS, 1993, GUT, V34, P650, DOI 10.1136/gut.34.5.650; HAMILTON SR, 1987, AM J CLIN PATHOL, V87, P301, DOI 10.1093/ajcp/87.3.301; KALISH RJ, 1984, GASTROENTEROLOGY, V86, P461; LEVINE DS, 1989, LAB INVEST, V60, P418; MCCLAVE SA, 1987, GASTROINTEST ENDOSC, V33, P413, DOI 10.1016/S0016-5107(87)71676-9; POST AB, 1993, AM J GASTROENTEROL, V88, P877; ROBERTSON DAF, 1989, BRIT MED J, V298, P650, DOI 10.1136/bmj.298.6674.650; SONTAG SJ, 1985, LANCET, V1, P946; SPECHLER SJ, 1986, NEW ENGL J MED, V315, P362, DOI 10.1056/NEJM198608073150605	16	75	76	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1994	120	9					753	756		10.7326/0003-4819-120-9-199405010-00006	http://dx.doi.org/10.7326/0003-4819-120-9-199405010-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH251	7511878				2022-12-24	WOS:A1994NH25100006
J	CHEN, TY; YAU, KW				CHEN, TY; YAU, KW			DIRECT MODULATION BY CA2+-CALMODULIN OF CYCLIC NUCLEOTIDE-ACTIVATED CHANNEL OF RAT OLFACTORY RECEPTOR NEURONS	NATURE			English	Article							SENSITIVE ADENYLATE-CYCLASE; GATED CHANNELS; CELLS; CILIA; TRANSDUCTION; CONDUCTANCE; ODORANTS; NEWT; CURRENTS; CALCIUM	OLFACTORY receptor neurons depolarize in response to odorant stimulation of their sensory cilia1-3. One transduction mechanism involves a G-protein-mediated increase in adenylate cyclase activity4-8, raising the internal cyclic AMP concentration to open a cyclic nucleotide-activated cation channel on the plasma membrane9-14. An influx of Ca2+ through this channel, which is permeable to both monovalent and divalent cations, triggers olfactory adaptation15. Previous work has indicated that at least art of this Ca2+ mediated adaptation resides in the channel itself15-17, but the mechanism remains unclear and controversial16-18. Here we use the cloned channel from rat19 expressed in a cell line and the native channel from rat olfactory receptor cells to show that Ca2+ reduces the apparent affinity of the channel for cAMP by up to 20-fold in the presence of calmodulin, an abundant protein in olfactory cilia20. This decrease in apparent affinity appears to involve a direct interaction between Ca2+-calmodulin and the channel, and it can reduce the activation of the channel by cAMP by up to a few hundred-fold, suggesting that it may be a key component of the Ca2+-triggered olfactory adaptation.	JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205	Howard Hughes Medical Institute; Johns Hopkins University	CHEN, TY (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205, USA.							ANHOLT RRH, 1990, BIOCHEMISTRY-US, V29, P4049, DOI 10.1021/bi00469a004; BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BOEKHOFF I, 1990, EMBO J, V9, P2453, DOI 10.1002/j.1460-2075.1990.tb07422.x; BORISY FF, 1992, J NEUROSCI, V12, P915; BRADLEY J, 1992, NEUR ABSTR, V18, P596; CHEN TY, 1993, NATURE, V362, P764, DOI 10.1038/362764a0; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; FIRESTEIN S, 1989, SCIENCE, V244, P79, DOI 10.1126/science.2704991; FIRESTEIN S, 1991, NEURON, V6, P825, DOI 10.1016/0896-6273(91)90178-3; FRINGS S, 1991, J GEN PHYSIOL, V97, P1, DOI 10.1085/jgp.97.1.1; FRINGS S, 1992, J GEN PHYSIOL, V100, P45, DOI 10.1085/jgp.100.1.45; HSU YT, 1993, NATURE, V361, P76, DOI 10.1038/361076a0; JAWORSKY DE, IN PRESS J NEUROSCI; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; KLEENE SJ, 1994, BRIT J PHARMACOL, V111, P469, DOI 10.1111/j.1476-5381.1994.tb14760.x; KLEENE SJ, 1993, J MEMBRANE BIOL, V131, P237, DOI 10.1007/BF02260112; KLEENE SJ, 1991, J NEUROSCI, V11, P3624; KRAMER RH, 1992, NEURON, V9, P897, DOI 10.1016/0896-6273(92)90242-6; KURAHASHI T, 1990, J PHYSIOL-LONDON, V430, P355, DOI 10.1113/jphysiol.1990.sp018295; KURAHASHI T, 1990, BRAIN RES, V515, P261, DOI 10.1016/0006-8993(90)90605-B; KURAHASHI T, 1989, J PHYSIOL-LONDON, V419, P177, DOI 10.1113/jphysiol.1989.sp017868; KURAHASHI T, 1993, NATURE, V363, P71, DOI 10.1038/363071a0; LIMAN ER, 1994, BIOPHYS J, V66, pA350; LOWE G, 1991, J PHYSIOL-LONDON, V442, P147, DOI 10.1113/jphysiol.1991.sp018787; LOWE G, 1993, NATURE, V366, P283, DOI 10.1038/366283a0; LOWE G, 1993, J PHYSIOL-LONDON, V462, P175, DOI 10.1113/jphysiol.1993.sp019550; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; PACE U, 1985, NATURE, V316, P255, DOI 10.1038/316255a0; SKLAR PB, 1986, J BIOL CHEM, V261, P5538; ZUFALL F, 1991, P ROY SOC B-BIOL SCI, V246, P225, DOI 10.1098/rspb.1991.0148	31	269	274	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 7	1994	368	6471					545	548		10.1038/368545a0	http://dx.doi.org/10.1038/368545a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE335	7511217				2022-12-24	WOS:A1994NE33500054
J	YU, RC; CHU, C; BULUWELA, L; CHU, AC				YU, RC; CHU, C; BULUWELA, L; CHU, AC			CLONAL PROLIFERATION OF LANGERHANS CELLS IN LANGERHANS CELL HISTIOCYTOSIS	LANCET			English	Note								X-chromosome-inactivation assays can be used to assess clonality. We used such an assay at the human androgen-receptor gene locus in th ree female patients with histologically proven Langerhans cell histiocytosis. All patients were heterozygous for this locus. Cells bearing the Langerhans cell phenotype were purified from involved tissue after fluorescence-activated cell sorting with monoclonal antibodies against the CD1a complex. After Hhal digestion of DNA, these CD1a positive cells demonstrated a non-random X-chromosome-inactivation pattern, whereas CD1a negative cells in the same tissue showed a random pattern. Our data suggest that Langerhans cell histiocytosis represents a clonal proliferation of cells bearing the Langerhans cell phenotype.	ROYAL HOSP SICK CHILDREN, DEPT CHILD HLTH, GLASGOW G3 8SJ, SCOTLAND; CHARING CROSS & WESTMINSTER MED SCH, DEPT BIOCHEM, LONDON W6, ENGLAND	University of Glasgow; Imperial College London	YU, RC (corresponding author), ROYAL POSTGRAD MED SCH, DERMATOL UNIT, LONDON W12 0NN, ENGLAND.							ALLEN RC, 1992, AM J HUM GENET, V51, P1229; [Anonymous], 1987, Lancet, V1, P208; BIRBECK MS, 1961, J INVEST DERMATOL, V37, P51, DOI 10.1038/jid.1961.80; FITHIAN E, 1981, P NATL ACAD SCI-BIOL, V78, P2541, DOI 10.1073/pnas.78.4.2541; MCLELLAND J, 1989, BRIT J DERMATOL, V120, P485, DOI 10.1111/j.1365-2133.1989.tb01321.x; STINGL G, 1978, J IMMUNOL, V121, P2005	6	292	306	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 26	1994	343	8900					767	768		10.1016/S0140-6736(94)91842-2	http://dx.doi.org/10.1016/S0140-6736(94)91842-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC351	7510816				2022-12-24	WOS:A1994NC35100014
J	WIEDLOCHA, A; FALNES, PO; MADSHUS, IH; SANDVIG, K; OLSNES, S				WIEDLOCHA, A; FALNES, PO; MADSHUS, IH; SANDVIG, K; OLSNES, S			DUAL-MODE OF SIGNAL-TRANSDUCTION BY EXTERNALLY ADDED ACIDIC FIBROBLAST GROWTH-FACTOR	CELL			English	Article							DIPHTHERIA-TOXIN ENTRY; NUCLEAR TRANSLOCATION SEQUENCE; TYROSINE KINASE-ACTIVITY; FACTOR-I; VERO CELLS; LOW PH; A-FRAGMENT; HEPARIN; PROTEINS; ASSOCIATION	Acidic fibroblast growth factor (aFGF), fused to diphtheria toxin and translocated into cells, stimulated DNA synthesis in toxin-resistant cells lacking functional aFGF receptors while having a high number of diphtheria toxin receptors. In NIH 3T3 cells that lack diphtheria toxin receptors, but have receptors for aFGF, both aFGF and the fusion protein induced tyrosine phosphorylation, but only aFGF as such entered the nuclei and stimulated DNA synthesis. The results indicate that signaling occurs partly through cell surface receptors and partly by transport of the growth factor into the cell.			WIEDLOCHA, A (corresponding author), NORWEGIAN RADIUM HOSP,INST CANC RES,N-0310 OSLO 3,NORWAY.		Falnes, Pål Ø./AAA-4581-2020	Falnes, Pal/0000-0001-8114-6025				BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BOYER B, 1993, J CELL BIOL, V120, P767, DOI 10.1083/jcb.120.3.767; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CAO Y, 1993, J CELL SCI, V104, P77; COLLIER RJ, 1975, BACTERIOL REV, V39, P54, DOI 10.1128/MMBR.39.1.54-85.1975; COPELAND RA, 1991, ARCH BIOCHEM BIOPHYS, V289, P53, DOI 10.1016/0003-9861(91)90441-K; COUGHLIN SR, 1988, J BIOL CHEM, V263, P988; CUEVAS P, 1991, SCIENCE, V254, P1208, DOI 10.1126/science.1957172; DRAPER RK, 1980, J CELL BIOL, V87, P849, DOI 10.1083/jcb.87.3.849; FALNES PO, 1994, IN PRESS J BIOL CHEM; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FRIESEL R, 1989, MOL CELL BIOL, V9, P1857, DOI 10.1128/MCB.9.5.1857; HUANG SS, 1986, J BIOL CHEM, V261, P9568; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; IMAMURA T, 1992, J BIOL CHEM, V267, P5676; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACIAG T, 1984, SCIENCE, V225, P902; MCGILL S, 1989, EMBO J, V8, P2843, DOI 10.1002/j.1460-2075.1989.tb08431.x; MIDDLEBROOK JL, 1978, J BIOL CHEM, V253, P7325; MOSKAUG JO, 1988, J BIOL CHEM, V263, P2518; MUESCH A, 1990, TRENDS BIOCHEM SCI, V15, P86, DOI 10.1016/0968-0004(90)90186-F; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; OLSNES S, 1986, J BIOL CHEM, V261, P1553; OLSNES S, 1988, TRENDS BIOCHEM SCI, V13, P348, DOI 10.1016/0968-0004(88)90105-3; Olsnes S., 1988, IMMUNOTOXINS, P39; OLWIN BB, 1992, J CELL BIOL, V118, P6323; ORTEGA S, 1991, J BIOL CHEM, V266, P5842; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; SANDVIG K, 1981, J BIOL CHEM, V256, P9068; SANDVIG K, 1980, J CELL BIOL, V87, P828, DOI 10.1083/jcb.87.3.828; SANO H, 1990, J CELL BIOL, V110, P1417, DOI 10.1083/jcb.110.4.1417; STENMARK H, 1991, J CELL BIOL, V113, P1025, DOI 10.1083/jcb.113.5.1025; STENMARK H, 1992, BIOCHEM J, V281, P619, DOI 10.1042/bj2810619; SUNDAN A, 1982, J BIOL CHEM, V257, P9733; TAMM I, 1991, P NATL ACAD SCI USA, V88, P3372, DOI 10.1073/pnas.88.8.3372; THORNTON SC, 1983, SCIENCE, V222, P623, DOI 10.1126/science.6635659; WIEDLOCHA A, 1992, EMBO J, V11, P4835, DOI 10.1002/j.1460-2075.1992.tb05589.x; ZHAN X, 1992, BIOCHEM BIOPH RES CO, V188, P982, DOI 10.1016/0006-291X(92)91328-N; ZHAN X, 1993, J BIOL CHEM, V268, P9611	42	222	229	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 25	1994	76	6					1039	1051		10.1016/0092-8674(94)90381-6	http://dx.doi.org/10.1016/0092-8674(94)90381-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ND246	7511061				2022-12-24	WOS:A1994ND24600010
J	KERWIN, R				KERWIN, R			ADVERSE REACTION REPORTING AND NEW ANTIPSYCHOTICS	LANCET			English	Editorial Material							CLOZAPINE				KERWIN, R (corresponding author), INST PSYCHIAT,LONDON SE5 8AF,ENGLAND.							Aretz H T, 1987, Am J Cardiovasc Pathol, V1, P3; GERLACH J, 1991, SCHIZOPHRENIA BULL, V17, P289, DOI 10.1093/schbul/17.2.289; KANE J, 1988, ARCH GEN PSYCHIAT, V45, P789; LARGACTIL, 1993, ABPI DATA SHEET COMP, P1266; MALMBERG A, 1993, MOL PHARMACOL, V43, P749; PETERS NS, 1991, J ROY SOC MED, V84, P1; PILOWSKY LS, 1992, LANCET, V340, P199, DOI 10.1016/0140-6736(92)90467-H; VINCENT PC, 1986, DRUGS, V31, P52, DOI 10.2165/00003495-198631010-00004; 1993, CURR PROB PHARM B, V19, P9	9	7	7	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 11	1993	342	8885					1440	1440		10.1016/0140-6736(93)92929-N	http://dx.doi.org/10.1016/0140-6736(93)92929-N			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML217	7504153				2022-12-24	WOS:A1993ML21700005
J	JONTES, JD; WILSONKUBALEK, EM; MILLIGAN, RA				JONTES, JD; WILSONKUBALEK, EM; MILLIGAN, RA			A 32-DEGREES TAIL SWING IN BRUSH-BORDER MYOSIN-I ON ADP RELEASE	NATURE			English	Article							MUSCLE-CONTRACTION; ACTOMYOSIN ATPASE; EPITHELIAL-CELLS; ACTIN; CALMODULIN; PROTEIN; COMPLEX; ORGANIZATION; CYTOSKELETON; MECHANISM	BRUSH border myosin I (BBMI) is a single-headed, unconventional myosin from intestinal microvilli, composed of a heavy chain of relative molecular mass 119,000 (M(r) 119K) and three calmodulin light chains(1-3). Although believed to have a largely structural role, it exhibits the normal actin-activated ATPase and motility properties of a member of the myosin superfamily(4,5). Here we present three-dimensional maps of BBMI-decorated actin filaments with and without bound MgADP. While the motor domain remains in a state similar to rigor, the light-chain-binding domain swings through similar to 32 degrees, resulting in a similar to 50-Angstrom movement at the end of the region visualized (the second calmodulin light chain). This could correspond to similar to 72-Angstrom movement of the entire domain, Although qualitatively similar to the movement observed in myosin II6, the magnitude of the change is sufficiently different to suggest that structural changes during the actomyosin ATPase cycle differ among myosins, possibly reflecting adaptation for specialized functional demands.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute								BRENNER B, 1987, ANNU REV PHYSIOL, V49, P655; COLLINS K, 1990, J CELL BIOL, V110, P1137, DOI 10.1083/jcb.110.4.1137; COOKE R, 1986, CRIT REV BIOCHEM MOL, V21, P53, DOI 10.3109/10409238609113609; DEROSIER DJ, 1970, J MOL BIOL, V52, P355, DOI 10.1016/0022-2836(70)90036-7; DRENCKHAHN D, 1988, J CELL BIOL, V107, P1037, DOI 10.1083/jcb.107.3.1037; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; EISENBERG E, 1980, ANNU REV PHYSIOL, V42, P293, DOI 10.1146/annurev.ph.42.030180.001453; EISENBERG E, 1985, SCIENCE, V227, P999, DOI 10.1126/science.3156404; FATH KR, 1993, J CELL BIOL, V120, P117, DOI 10.1083/jcb.120.1.117; FISHER AJ, 1995, BIOPHYS J, V68, pS19; GARCIA A, 1989, J CELL BIOL, V109, P2895, DOI 10.1083/jcb.109.6.2895; GEEVES MA, 1992, PHILOS T ROY SOC B, V336, P63, DOI 10.1098/rstb.1992.0045; GOODY RS, 1983, BIOCHIM BIOPHYS ACTA, V726, P13, DOI 10.1016/0304-4173(83)90009-5; Hill T.L., 1974, Progress Biophys Molec Biol, V28, P267, DOI 10.1016/0079-6107(74)90020-0; HOWE CL, 1983, J CELL BIOL, V97, P974, DOI 10.1083/jcb.97.4.974; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; MATSUDAIRA PT, 1979, J CELL BIOL, V83, P667, DOI 10.1083/jcb.83.3.667; POLLARD TD, 1991, ANNU REV PHYSIOL, V53, P653, DOI 10.1146/annurev.ph.53.030191.003253; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; REEDY MC, 1988, J MOL BIOL, V204, P357, DOI 10.1016/0022-2836(88)90582-7; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; WHITTAKER M, 1995, ULTRAMICROSCOPY, V58, P245, DOI 10.1016/0304-3991(95)00057-8; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0; WOLENSKI JS, 1993, J CELL BIOL, V122, P613, DOI 10.1083/jcb.122.3.613; [No title captured]	26	166	167	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 14	1995	378	6558					751	753		10.1038/378751a0	http://dx.doi.org/10.1038/378751a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK379	7501027				2022-12-24	WOS:A1995TK37900062
J	EHRENHOFERMURRAY, AE; GOSSEN, M; PAK, DTS; BOTCHAN, MR; RINE, J				EHRENHOFERMURRAY, AE; GOSSEN, M; PAK, DTS; BOTCHAN, MR; RINE, J			SEPARATION OF ORIGIN RECOGNITION COMPLEX FUNCTIONS BY CROSS-SPECIES COMPLEMENTATION	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; DNA-REPLICATION; TRANSCRIPTIONAL STATES; S-CEREVISIAE; YEAST; GENE; VECTORS	Transcriptional silencing at the HMRa locus of Saccharomyces cerevisiae requires the function of the origin recognition complex (ORC), the replication initiator of yeast. Expression of a Drosophila melanogaster Orc2 complementary DNA in the yeast orc2-1 strain, which is defective for replication and silencing, complemented the silencing defect but not the replication defect; this result indicated that the replication and silencing functions of ORC were separable. The orc2-1 mutation mapped to the region of greatest homology between the Drosophila and yeast proteins. The silent state mediated by DmOrc2 was epigenetic; it was propagated during mitotic divisions in a relatively stable way, whereas the nonsilent state was metastable. In contrast, the silent state was erased during meiosis.	UNIV CALIF BERKELEY,DEPT CELL & MOLEC BIOL,DIV GENET,BERKELEY,CA 94720; UNIV CALIF BERKELEY,DEPT CELL & MOLEC BIOL,DIV BIOCHEM & MOLEC BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley; University of California System; University of California Berkeley			Gossen, Manfred/K-9602-2013	Gossen, Manfred/0000-0002-1761-4063	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM031105, R01GM031105] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31105] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOSSEN M, 1995, SCIENCE, V270, P1674, DOI 10.1126/science.270.5242.1674; GRIGLIATTI T, 1991, METHOD CELL BIOL, V35, P587; HAMPTON RY, 1994, J CELL BIOL, V125, P299, DOI 10.1083/jcb.125.2.299; KLEBE RJ, 1983, GENE, V25, P333, DOI 10.1016/0378-1119(83)90238-X; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MCNALLY FJ, 1991, MOL CELL BIOL, V11, P5648, DOI 10.1128/MCB.11.11.5648; PATTERSON M, 1986, MOL CELL BIOL, V6, P1590, DOI 10.1128/MCB.6.5.1590; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3; RASTAN S, 1994, CURR OPIN GENET DEV, V4, P292, DOI 10.1016/S0959-437X(05)80056-5; RIVIER DH, 1992, SCIENCE, V256, P659, DOI 10.1126/science.1585179; SCHENA M, 1991, METHOD ENZYMOL, V194, P389; Weiler KS, 1995, ANNU REV GENET, V29, P577, DOI 10.1146/annurev.ge.29.120195.003045; ZHOU C, 1989, J BIOL CHEM, V264, P9022	22	56	56	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 8	1995	270	5242					1671	1674		10.1126/science.270.5242.1671	http://dx.doi.org/10.1126/science.270.5242.1671			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ293	7502078				2022-12-24	WOS:A1995TJ29300050
J	NIGHTINGALE, SL				NIGHTINGALE, SL			CIDOFOVIR AVAILABLE UNDER TREATMENT IND FOR CMV RETINITIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 11	1995	274	14					1109	1109						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY056	7563473				2022-12-24	WOS:A1995RY05600008
J	ENARI, M; HUG, H; NAGATA, S				ENARI, M; HUG, H; NAGATA, S			INVOLVEMENT OF AN ICE-LIKE PROTEASE IN FAS-MEDIATED APOPTOSIS	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; DEATH GENE CED-3; CELL-DEATH; COWPOX VIRUS; ANTI-FAS; EXPRESSION; ENZYME; INHIBITOR; RECEPTOR; ENCODES	FAS is a type-I membrane protein that transduces an apoptotic signal(1,2). Binding of Fas ligand or agonistic anti-Fas antibody to Fas kills the cells by apoptosis(3). Studies in the nematode Caenorhabditis elegans have suggested that proteases such as interleukin-1 beta-converting enzyme (ICE) or the product of the C. elegans cell-death gene ced-3 are involved in apoptotic signal transduction(4). The activity of ICE can be inhibited by the product of crmA, a cytokine-response modifier gene encoded by cowpox virus(5-7). We report here that expression of crmA inhibits cytotoxicity induced by anti-pas antibody or tumour necrosis factor (TNF). We have found a specific ICE inhibitor tetrapeptide (acetyl-Tyr-Val-Ala-Asp-chloromethylketone)(8,9) that also prevents apoptosis induced by anti-Fas antibody. These results suggest an involvement of an ICE-like protease in Fas-mediated apoptosis and TNF-induced cytotoxicity.	YOKOHAMA CITY UNIV,GRAD SCH INTEGRATED SCI,YOKOHAMA,KANAGAWA 236,JAPAN	Yokohama City University	ENARI, M (corresponding author), OSAKA BIOSCI INST,6-2-4 FURUEDAI,SUITA,OSAKA 565,JAPAN.		Nagata, Shigekazu/AAG-3203-2019; Enari, Masato/E-5507-2014	Nagata, Shigekazu/0000-0001-9758-8426; Enari, Masato/0000-0003-4293-3848				CEHM A, 1992, J BIOL CHEM, V267, P10709; FERNANDESALNEMR.T, 1994, J BIOL CHEM, V269, P30761; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1993, J IMMUNOL, V151, P621; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; KUMAR S, 1991, J BIOL CHEM, V266, P20960; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NISHIZAWA M, 1990, J BIOL CHEM, V265, P5897; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; PICKUP DJ, 1986, P NATL ACAD SCI USA, V83, P7698, DOI 10.1073/pnas.83.20.7698; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; WONG GHW, 1994, J IMMUNOL, V152, P1751; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	30	800	835	1	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 4	1995	375	6526					78	81		10.1038/375078a0	http://dx.doi.org/10.1038/375078a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW604	7536900				2022-12-24	WOS:A1995QW60400059
J	GOOD, MF				GOOD, MF			HARNESSING CYTOTOXIC T-LYMPHOCYTES FOR VACCINE DESIGN	LANCET			English	Editorial Material							FALCIPARUM CIRCUMSPOROZOITE PROTEIN; PLASMODIUM-FALCIPARUM; MALARIA SPOROZOITES; CELLS				GOOD, MF (corresponding author), ROYAL BRISBANE HOSP,QUEENSLAND INST MED RES,BRISBANE,QLD 4029,AUSTRALIA.							AIDOO M, 1995, LANCET, V345, P1003, DOI 10.1016/S0140-6736(95)90754-8; DAME JB, 1984, SCIENCE, V225, P593, DOI 10.1126/science.6204383; DOOLAN DL, 1991, INT IMMUNOL, V3, P511, DOI 10.1093/intimm/3.6.511; GOOD MF, 1988, IMMUNOL TODAY, V9, P351, DOI 10.1016/0167-5699(88)91336-9; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; KUMAR S, 1988, NATURE, V334, P258, DOI 10.1038/334258a0; MALIK A, 1991, P NATL ACAD SCI USA, V88, P3300, DOI 10.1073/pnas.88.8.3300; NUSSENZWEIG RS, 1984, PHILOS T ROY SOC B, V307, P117, DOI 10.1098/rstb.1984.0113; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; QUAKYI IA, 1994, J IMMUNOL, V153, P2082; SCHOFIELD L, 1987, NATURE, V330, P664, DOI 10.1038/330664a0; SEDEGAH M, 1992, J IMMUNOL, V149, P966; UDHAYAKUMAR V, 1994, INFECT IMMUN, V62, P1410, DOI 10.1128/IAI.62.4.1410-1413.1994; WEISS WR, 1988, P NATL ACAD SCI USA, V85, P573, DOI 10.1073/pnas.85.2.573	14	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 22	1995	345	8956					999	1000		10.1016/S0140-6736(95)90750-5	http://dx.doi.org/10.1016/S0140-6736(95)90750-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QU573	7536872				2022-12-24	WOS:A1995QU57300002
J	POTOSKY, AL; MILLER, BA; ALBERTSEN, PC; KRAMER, BS				POTOSKY, AL; MILLER, BA; ALBERTSEN, PC; KRAMER, BS			THE ROLE OF INCREASING DETECTION IN THE RISING INCIDENCE OF PROSTATE-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GEOGRAPHIC-VARIATION; TRENDS	Objective.-To assess the reasons for the dramatic surge in prostate cancer incidence from 1986 to 1991. Design.-Population-based study of incidence rates and procedures used to detect and diagnose prostate cancer derived from Medicare claims data and the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program from 1986 to 1991. Setting.-Four SEER areas (Connecticut; Atlanta, Ga; Detroit, Mich; and Seattle-Puget Sound, Wash) covering approximately 6% of the US population. Participants.-A 5% random sample of male fee-for-service Medicare beneficiaries aged 65 years and older without cancer, and all men with prostate cancer diagnosed at 65 years of age and older residing in the four areas. Main Outcome Measures.-The age-adjusted rates of prostate cancer incidence, prostate needle biopsy, transurethral resection of the prostate, serum prostate-specific antigen (PSA) testing, and transrectal ultrasound. Results.-The age-adjusted incidence rate of prostate cancer among men aged 65 years and older in the four SEER areas rose 82% from 1986 to 1991, with the largest annual increases occurring in 1990 (20%) and 1991 (19%). Prostate needle biopsy rates increased while the use of transurethral resection of the prostate declined from 1986 to 1991. The rising needle biopsy rate has been driven by an exponential increase in PSA testing in the general population from 1988 to 1991 and, to a much lesser extent, the increasing use of transrectal ultrasound since 1986. The use of PSA or transrectal ultrasound has increased across age and race groups and in different geographic areas. However, there remain wide geographic variations in the use of PSA screening. Conclusions.-The recent dramatic epidemic of prostate cancer is likely the result of the increasing detection of tumors resulting from increased PSA screening. The magnitude and rapidity of the incidence rise suggest that changes in the intensity of medical surveillance is the most plausible explanation for this trend. Implications.-The rapid diffusion of screening interventions that have the ability to detect latent asymptomatic disease leads to important concerns regarding costs and patient quality of life for men aged 65 years and older, Geographic variability in the adoption of PSA testing underscores uncertainty and disagreement about its value for reducing prostate cancer mortality. More research is required to determine the effectiveness of screening for prostate cancer.	NCI,CANC STAT BRANCH,SURVEILLANCE PROGRAM,BETHESDA,MD; NCI,DIV CANC PREVENT & CONTROL,EARLY DETECT & COMMUNITY ONCOL PROGRAM,BETHESDA,MD; UNIV CONNECTICUT,CTR HLTH,DIV UROL,FARMINGTON,CT	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Connecticut	POTOSKY, AL (corresponding author), NCI,APPL RES BRANCH,6130 EXECUT BLVD,EPN ROOM 313,BETHESDA,MD 20892, USA.							ALDER J, 1993, NEWSWEEK        1227, P40; AUSTIN DF, 1989, NEW ENGL J MED, V321, P1197; BLACK WC, 1993, NEW ENGL J MED, V328, P1237, DOI 10.1056/NEJM199304293281706; BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; BOSLAND MC, 1988, ADV CANCER RES, V51, P1, DOI 10.1016/S0065-230X(08)60220-1; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; DEMERS RY, 1994, ARCH INTERN MED, V154, P1211, DOI 10.1001/archinte.154.11.1211; DEVESA SS, 1987, J NATL CANCER I, V79, P701; FARROW DC, 1992, NEW ENGL J MED, V326, P1097, DOI 10.1056/NEJM199204233261701; Fleming C, 1993, JAMA, V269, P2650; FOWLER FJ, 1993, UROLOGY, V42, P622, DOI 10.1016/0090-4295(93)90524-E; GILLILAND F, 1994, CANCER EPIDEM BIOMAR, V3, P105; JOHANSSON JE, 1992, JAMA-J AM MED ASSOC, V267, P2191, DOI 10.1001/jama.267.16.2191; KRAHN MD, 1994, JAMA-J AM MED ASSOC, V272, P773, DOI 10.1001/jama.272.10.773; KRAMER BS, 1993, ANN INTERN MED, V119, P914, DOI 10.7326/0003-4819-119-9-199311010-00009; LEVY IG, 1993, CAN MED ASSOC J, V149, P617; LUYAO GL, 1993, JAMA-J AM MED ASSOC, V269, P2633, DOI 10.1001/jama.269.20.2633; LUYAO GL, 1994, LANCET, V343, P251, DOI 10.1016/S0140-6736(94)91109-6; METTLIN C, 1993, CA-CANCER J CLIN, V43, P42, DOI 10.3322/canjclin.43.1.42; NATTINGER AB, 1992, NEW ENGL J MED, V26, P1102; NOMURA AMY, 1991, EPIDEMIOL REV, V13, P200, DOI 10.1093/oxfordjournals.epirev.a036069; OPTENBERG SA, 1990, UROL CLIN N AM, V17, P719; POTOSKY AL, 1990, J NATL CANCER I, V82, P1624, DOI 10.1093/jnci/82.20.1624; POTOSKY AL, 1993, MED CARE, V31, P732; PROROK PC, 1981, J CHRON DIS, V34, P159, DOI 10.1016/0021-9681(81)90026-6; RIES LA, 1994, NIH942789 NCI PUBL; ROOS NP, 1980, MED CARE, V20, P945; SERVAAS C, 1992, SATURDAY EVENING POS, V264, P58; SIWEK J, 1991, WASHINGTON POST 0709, pZ15; Stuart M E, 1992, HMO Pract, V6, P5; Wasson J H, 1993, Arch Fam Med, V2, P487, DOI 10.1001/archfami.2.5.487; WENNBERG JE, 1991, JAMA-J AM MED ASSOC, V265, P1306, DOI 10.1001/jama.265.10.1306; WHITMORE WF, 1993, JAMA-J AM MED ASSOC, V269, P2676, DOI 10.1001/jama.269.20.2676	33	520	534	1	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 15	1995	273	7					548	552		10.1001/jama.273.7.548	http://dx.doi.org/10.1001/jama.273.7.548			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF686	7530782				2022-12-24	WOS:A1995QF68600024
J	[Anonymous]				[Anonymous]			DYING FOR PALLIATIVE CARE	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1696	1699						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7529608				2022-12-24	WOS:A1994PY71700021
J	STEINBACH, S; SUN, L; JIANG, RZ; FLUME, P; GILLIGAN, P; EGAN, TM; GOLDSTEIN, R				STEINBACH, S; SUN, L; JIANG, RZ; FLUME, P; GILLIGAN, P; EGAN, TM; GOLDSTEIN, R			TRANSMISSIBILITY OF PSEUDOMONAS-CEPACIA INFECTION IN CLINIC PATIENTS AND LUNG-TRANSPLANT RECIPIENTS WITH CYSTIC-FIBROSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UROPATHOGENIC ESCHERICHIA-COLI; FIELD GEL-ELECTROPHORESIS; POLYMERASE CHAIN-REACTION; MOLECULAR EPIDEMIOLOGY; PREOPERATIVE ASSESSMENT; COLONIZATION; ADHESIN; GENE	Background. In patients with cystic fibrosis, infection with Pseudomonas cepacia is associated with poor outcomes. However, the extent of person-to-person transmission and the source of P. cepacia infection after lung transplantation are not well defined. Using DNA-based typing systems, we sought to determine the genetic relatedness of P. cepacia infection at one cystic fibrosis center. Methods. We analyzed 65 P. cepacia isolates gathered over a period of eight years at a single cystic fibrosis center from 17 clinic patients and from 5 patients who underwent double-lung transplantation. The isolates were analyzed by ribotyping and chromosomal fingerprinting based on pulsed-field gel electrophoresis. Results. Analyses of serial isolates revealed that each clinic patient and transplant recipient harbored a different P. cepacia clone that was persistent. In the transplant recipients, the preoperative and postoperative isolates were identical. In the two patients with disseminated infection after lung transplantation, isolates from multiple sites were identical and indicated clonal expansion of the previous respiratory P. cepacia strain. Pulsed-field gel electrophoresis proved both more discriminative and more practical than ribotyping as a means of defining the genetic relatedness of the P. cepacia isolates. Conclusions. Our serial analyses in patients with cystic fibrosis at one center found distinct strains of P. cepacia persistently infecting each patient and no evidence of person-to-person transmission of this organism. P. cepacia infection after lung transplantation was due to the persistence of the strain present before transplantation.	BOSTON UNIV,SCH MED,MOLEC GENET SECT,MAXWELL FINLAND LAB INFECT DIS,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02118; BOSTON CITY HOSP,BOSTON,MA; UNIV N CAROLINA,SCH MED & HOSP,CTR CYST FIBROSIS,CHAPEL HILL,NC; UNIV N CAROLINA,SCH MED & HOSP,CLIN MICROBIOL LAB,CHAPEL HILL,NC; UNIV N CAROLINA,SCH MED & HOSP,CHAPEL HILL,NC	Boston University; Boston University; Boston Medical Center; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill				Egan, Thomas/0000-0002-1382-8881	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050838] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON DJ, 1991, J CLIN MICROBIOL, V29, P648, DOI 10.1128/JCM.29.3.648-649.1991; ARBEIT RD, 1990, J INFECT DIS, V161, P230, DOI 10.1093/infdis/161.2.230; ARTHUR M, 1989, INFECT IMMUN, V57, P314, DOI 10.1128/IAI.57.2.314-321.1989; ARTHUR M, 1989, INFECT IMMUN, V57, P303, DOI 10.1128/IAI.57.2.303-313.1989; ARTHUR M, 1990, INFECT IMMUN, V58, P471, DOI 10.1128/IAI.58.2.471-479.1990; BERG KL, 1987, J BACTERIOL, V169, P1691, DOI 10.1128/jb.169.4.1691-1701.1987; BINGEN EH, 1993, J CLIN MICROBIOL, V31, P2589, DOI 10.1128/JCM.31.10.2589-2593.1993; DEHOYOS AL, 1992, J THORAC CARDIOV SUR, V103, P295; DELEVAL MR, 1991, J THORAC CARDIOV SUR, V101, P633; DICE LR, 1945, ECOLOGY, V26, P297, DOI 10.2307/1932409; FLUME PA, 1994, AM J RESP CRIT CARE, V149, P1601, DOI 10.1164/ajrccm.149.6.7516251; GLADMAN G, 1992, ARCH DIS CHILD, V67, P192, DOI 10.1136/adc.67.2.192; GOVAN JRW, 1993, LANCET, V342, P15, DOI 10.1016/0140-6736(93)91881-L; HERITIER F, 1992, EUR RESPIR J, V5, P1262; HOPFL P, 1989, EUR J BIOCHEM, V185, P355, DOI 10.1111/j.1432-1033.1989.tb15123.x; Knight S R, 1992, Semin Thorac Cardiovasc Surg, V4, P107; KOSTMAN JR, 1992, J CLIN MICROBIOL, V30, P2084, DOI 10.1128/JCM.30.8.2084-2087.1992; LIPUMA JJ, 1990, LANCET, V336, P1094, DOI 10.1016/0140-6736(90)92571-X; LIPUMA JJ, 1988, J PEDIATR-US, V113, P859, DOI 10.1016/S0022-3476(88)80018-0; MORRISON DL, 1990, CLIN CHEST MED, V11, P207; NEI M, 1979, P NATL ACAD SCI USA, V76, P5269, DOI 10.1073/pnas.76.10.5269; NOYES BE, 1994, J PEDIATR-US, V124, P261, DOI 10.1016/S0022-3476(94)70315-9; PREVOST G, 1992, J CLIN MICROBIOL, V30, P967, DOI 10.1128/JCM.30.4.967-973.1992; RABKIN CS, 1989, REV INFECT DIS, V11, P600; RAMIREZ JC, 1992, J THORAC CARDIOV SUR, V103, P287; SCOTT J, 1988, LANCET, V2, P192; SNELL GI, 1993, CHEST, V103, P466, DOI 10.1378/chest.103.2.466; THOMASSEN MJ, 1985, AM REV RESPIR DIS, V131, P791; THOMASSEN MJ, 1986, AM REV RESPIR DIS, V134, P669	29	88	89	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 13	1994	331	15					981	987		10.1056/NEJM199410133311504	http://dx.doi.org/10.1056/NEJM199410133311504			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK504	7521938				2022-12-24	WOS:A1994PK50400004
J	LOWIN, B; HAHNE, M; MATTMANN, C; TSCHOPP, J				LOWIN, B; HAHNE, M; MATTMANN, C; TSCHOPP, J			CYTOLYTIC T-CELL CYTOTOXICITY IS MEDIATED THROUGH PERFORIN AND FAS LYTIC PATHWAYS	NATURE			English	Article							LYMPHOCYTES-T; APOPTOSIS; ANTIBODY; MICE	THE recent generation of perforin knock-out mice(1,2) has demonstrated a crucial role for the pore-forming perforin in cytolytic T-lymphocyte (CTL)-mediated cytolysis. Perforin-deficient mice failed to clear lymphocytic choriomeningitis virus in vivo, yet substantial killing activity still remained in perforin-free CTLs in vitro, indicating the presence of (a) further lytic pathway(s). Fas is an apoptosis-signalling receptor molecule on the surface of a number of different cells. Here we report that both perforin-deficient and Fas-ligand-deficient CTLs show impaired lytic activity on all target cells tested, The killing activity was completely abolished when both pathways were inactivated by using target cells from Fas-receptor-deficient lpr mice and perforin-free CTL effector cells. Fas-ligand-based killing activity was triggered upon T-cell receptor occupancy and was directed to the cognate target cell. Thus, two complementary, specific cytotoxic mechanisms are functional in CTLs, one based on the secretion of lytic proteins and one which depends on cell-surface ligand-receptor interaction.	UNIV LAUSANNE,INST BIOCHEM,CH-1066 EPALINGES,SWITZERLAND	University of Lausanne								CEROTTINI JC, 1974, J EXP MED, V140, P703, DOI 10.1084/jem.140.3.703; COLIGAN JE, 1992, CURRENT PROTOCOLS IM, P3121; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; ITOH N, 1993, J EXP MED, V178, P461; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; KUPFER A, 1986, J EXP MED, V163, P489, DOI 10.1084/jem.163.3.489; LOWIN B, IN PRESS P NATN ACAD; MARYANSKI JL, 1980, J IMMUNOL, V124, P42; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; PETERS PJ, 1989, EUR J IMMUNOL, V19, P1469, DOI 10.1002/eji.1830190819; RAMSDELL F, 1994, EUR J IMMUNOL, V24, P928, DOI 10.1002/eji.1830240422; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; RUSSELL JH, 1993, P NATL ACAD SCI USA, V90, P4409, DOI 10.1073/pnas.90.10.4409; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; TSCHOPP J, 1989, NATURE, V337, P272, DOI 10.1038/337272a0; UCKER DS, 1992, MOL CELL BIOL, V12, P3060, DOI 10.1128/MCB.12.7.3060; VIGNAUX F, 1994, EUR J IMMUNOL, V24, P923, DOI 10.1002/eji.1830240421	19	961	980	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 25	1994	370	6491					650	652		10.1038/370650a0	http://dx.doi.org/10.1038/370650a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PD310	7520535				2022-12-24	WOS:A1994PD31000050
J	PALLER, AS				PALLER, AS			HISTOLOGY OF LIPOID PROTEINOSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							METABOLISM; INVITRO; SKIN				PALLER, AS (corresponding author), NORTHWESTERN UNIV,SCH MED,CHICAGO,IL, USA.							BAUER EA, 1981, J INVEST DERMATOL, V76, P119, DOI 10.1111/1523-1747.ep12525454; FLEISCHMAJER R, 1984, J INVEST DERMATOL, V82, P252, DOI 10.1111/1523-1747.ep12260200; FLEISCHMAJER R, 1969, J INVEST DERMATOL, V52, P495, DOI 10.1038/jid.1969.84; HARPER JI, 1985, BRIT J DERMATOL, V113, P145, DOI 10.1111/j.1365-2133.1985.tb02056.x; MOY LS, 1987, J AM ACAD DERMATOL, V16, P1193, DOI 10.1016/S0190-9622(87)70157-1; NEWTON JA, 1991, CLIN EXP DERMATOL, V16, P350, DOI 10.1111/j.1365-2230.1991.tb00399.x; OLSEN DR, 1988, J INVEST DERMATOL, V90, P734, DOI 10.1111/1523-1747.ep12560934; SHORE RN, 1974, ARCH DERMATOL, V110, P591, DOI 10.1001/archderm.110.4.591	8	14	16	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 17	1994	272	7					564	565						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB229	7519275				2022-12-24	WOS:A1994PB22900039
J	BALK, SP; BURKE, S; POLISCHUK, JE; FRANTZ, ME; YANG, L; PORCELLI, S; COLGAN, SP; BLUMBERG, RS				BALK, SP; BURKE, S; POLISCHUK, JE; FRANTZ, ME; YANG, L; PORCELLI, S; COLGAN, SP; BLUMBERG, RS			BETA(2)-MICROGLOBULIN-INDEPENDENT MHC CLASS IB MOLECULE EXPRESSED BY HUMAN INTESTINAL EPITHELIUM	SCIENCE			English	Article							T-CELL RECEPTOR; INTRAEPITHELIAL LYMPHOCYTES; SURFACE EXPRESSION; IMMUNE RECOGNITION; HEAVY-CHAINS; BETA-2-MICROGLOBULIN; ANTIGEN; CD1; ASSOCIATION; COMPLEX	A major histocompatibility complex class Ib protein, CD1d, is expressed by human intestinal epithelial cells (IECs) and is a ligand for CD8(+) T cells. CD1d was found to be expressed on the surface of human IECs as a 37-kilodalton protein that was beta(2)-microglobulin (beta(2)M) independent with no N-linked carbohydrate. Transfection into a beta(2)M(-) cell line confirmed that CD1d could be expressed at the cell surface in the absence of beta(2)M. These data indicate that IECs use a specialized pathway for CD1d synthesis and that a beta(2)M-independent class Ib protein may be the normal ligand for some intestinal T cells.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV GASTROENTEROL,BOSTON,MA 02115; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DIV HEMATOL ONCOL,BOSTON,MA 02215; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT RHEUMATOL IMMUNOL,LYMPHOCYTE BIOL SECT,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT ANESTHESIA,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School			Colgan, Sean P./B-4573-2009		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033911] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044319] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI33911] Funding Source: Medline; NIDDK NIH HHS [R01 DK44319] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMIOT M, 1986, J IMMUNOL, V136, P1752; BALK SP, 1991, J IMMUNOL, V146, P768; BALK SP, 1991, SCIENCE, V253, P1411, DOI 10.1126/science.1716785; BILSLAND CAG, 1991, EUR J IMMUNOL, V21, P71, DOI 10.1002/eji.1830210112; BLEICHER PA, 1990, SCIENCE, V250, P679, DOI 10.1126/science.1700477; BLUMBERG RL, UNPUB; BLUMBERG RS, 1993, J IMMUNOL, V150, P5144; BLUMBERG RS, 1991, EUR J IMMUNOL, V21, P473, DOI 10.1002/eji.1830210233; BLUMBERG RS, 1991, J IMMUNOL, V147, P2518; BLUMBERG RS, 1990, J BIOL CHEM, V265, P14036; CALABI F, 1991, TISSUE ANTIGENS, V37, P1, DOI 10.1111/j.1399-0039.1991.tb01836.x; CAPPS GG, 1993, J IMMUNOL, V151, P159; CORREA I, 1992, P NATL ACAD SCI USA, V89, P653, DOI 10.1073/pnas.89.2.653; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; HEDRICK SM, 1992, CELL, V70, P177, DOI 10.1016/0092-8674(92)90092-Q; HERSHBERG R, 1990, P NATL ACAD SCI USA, V87, P9727, DOI 10.1073/pnas.87.24.9727; HRLOW E, 1988, ANTIBODIES, P641; KATZOUMI P, 1993, AM J PHYSIOL, V264, pC1327; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDOLFI NF, 1985, J IMMUNOL, V134, P423; MIYAZAKI J, 1986, J EXP MED, V163, P856, DOI 10.1084/jem.163.4.856; NEEFJES JJ, 1988, EUR J IMMUNOL, V18, P801, DOI 10.1002/eji.1830180522; PANJA A, 1993, J EXP MED, V178, P1115, DOI 10.1084/jem.178.3.1115; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; ROCK KL, 1991, CELL, V65, P611, DOI 10.1016/0092-8674(91)90093-E; RUBOCKI RJ, 1991, J IMMUNOL, V146, P2352; SHAWAR SM, 1994, ANNU REV IMMUNOL, V12, P839, DOI 10.1146/annurev.immunol.12.1.839; SMITH JD, 1992, J EXP MED, V175, P191, DOI 10.1084/jem.175.1.191; STROMINGER JL, 1989, CELL, V57, P895, DOI 10.1016/0092-8674(89)90326-7; STROYNOWSKI I, 1990, ANNU REV IMMUNOL, V8, P501, DOI 10.1146/annurev.iy.08.040190.002441; SYDORA BC, 1993, J IMMUNOL, V150, P2179; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAUNK J, 1992, GASTROENTEROLOGY, V102, P69, DOI 10.1016/0016-5085(92)91785-3; VANKERCKHOVE C, 1992, J EXP MED, V175, P57, DOI 10.1084/jem.175.1.57; WILLIAMS DB, 1989, J IMMUNOL, V142, P2796; WU M, 1991, J EXP MED, V174, P213, DOI 10.1084/jem.174.1.213; YEWDELL JW, 1992, ADV IMMUNOL, V52, P1, DOI 10.1016/S0065-2776(08)60875-5; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	39	146	147	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 8	1994	265	5169					259	262		10.1126/science.7517575	http://dx.doi.org/10.1126/science.7517575			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV957	7517575				2022-12-24	WOS:A1994NV95700044
J	YU, HT; CHEN, JK; FENG, SB; DALGARNO, DC; BRAUER, AW; SCHREIBER, SL				YU, HT; CHEN, JK; FENG, SB; DALGARNO, DC; BRAUER, AW; SCHREIBER, SL			STRUCTURAL BASIS FOR THE BINDING OF PROLINE-RICH PEPTIDES TO SH3 DOMAINS	CELL			English	Article							RECEPTOR TYROSINE KINASES; NMR-SPECTROSCOPY; GENE-PRODUCT; AMINO-ACID; PROTEIN; SRC; MAGNETIZATION; EXPRESSION; SPECTRA; CLONING	A common RXL motif was found in proline rich ligands that were selected from a biased combinatorial peptide library on the basis of their ability to bind specifically to the SH3 domains from phosphatidylinositol 3-kinase (PI3K) or c-Src. The solution structure of the PI3K SH3 domain complexed to one of these ligands, RKLPPRPSK (RLP1), was determined. Structure-based mutations were introduced into the PI3K SH3 domain and the RLP1 ligand, and the influence of these mutations on binding was evaluated. We conclude that SH3 domains recognize proline-rich motifs possessing the left-handed type II polyproline (PPII) helix conformation. Two proline residues directly contact the receptor. Other prolines in the ligands appear to function as a molecular scaffold, promoting the formation of the PPII helix. Three nonproline residues consisting of combinations of arginine and leucine interact extensively with the SH3 domain and appear to confer ligand specificity.	ARIAD PHARMACEUT INC, CAMBRIDGE, MA 02139 USA	Takeda Pharmaceutical Company Ltd; Takeda Oncology	YU, HT (corresponding author), HARVARD UNIV, DEPT CHEM, CAMBRIDGE, MA 02138 USA.		Chen, James/G-9972-2011	Chen, James/0000-0002-9220-8436; Yu, Hongtao/0000-0002-8861-049X	NIGMS NIH HHS [GM-44993] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044993] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADZHUBEI AA, 1993, J MOL BIOL, V229, P472, DOI 10.1006/jmbi.1993.1047; BABA T, 1989, FEBS LETT, V244, P296, DOI 10.1016/0014-5793(89)80549-6; BARFOD ET, 1993, J BIOL CHEM, V268, P26059; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; BOOKER GW, 1993, CELL, V73, P813, DOI 10.1016/0092-8674(93)90259-S; BRUNGER AT, 1988, XPLOR VERSION 20 MAN; BRUNGER AT, 1992, XPLOR VERSION 30 MAN; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHENTLEY LC, 1993, J AM CHEM SOC, V115, P12591; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; FURKA A, 1991, INT J PEPT PROT RES, V37, P487, DOI 10.1111/j.1399-3011.1991.tb00765.x; GEOGHEGAN KF, 1992, BIOCONJUGATE CHEM, V3, P138, DOI 10.1021/bc00014a008; GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; IKURA M, 1992, J AM CHEM SOC, V114, P2433, DOI 10.1021/ja00033a019; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KAY LE, 1990, J MAGN RESON, V86, P110, DOI 10.1016/0022-2364(90)90215-U; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOHDA D, 1993, CELL, V72, P953, DOI 10.1016/0092-8674(93)90583-C; KOYAMA S, 1993, FEBS LETT, V324, P93, DOI 10.1016/0014-5793(93)81539-C; KOYAMA S, 1993, CELL, V72, P945, DOI 10.1016/0092-8674(93)90582-B; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; LEVY JB, 1987, MOL CELL BIOL, V7, P4142, DOI 10.1128/MCB.7.11.4142; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MACURA S, 1981, J MAGN RESON, V43, P259, DOI 10.1016/0022-2364(81)90037-8; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MARTINEZ R, 1987, SCIENCE, V237, P441; MICHNICK SW, 1991, SCIENCE, V252, P836, DOI 10.1126/science.1709301; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; NAHARRO G, 1984, SCIENCE, V223, P63, DOI 10.1126/science.6318314; NEMETH SP, 1989, MOL CELL BIOL, V9, P1109, DOI 10.1128/MCB.9.3.1109; NOBLE MEM, 1993, EMBO J, V12, P2617, DOI 10.1002/j.1460-2075.1993.tb05922.x; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; OTTING G, 1990, Q REV BIOPHYS, V23, P39, DOI 10.1017/S0033583500005412; PARMLEY SF, 1988, GENE, V73, P305, DOI 10.1016/0378-1119(88)90495-7; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; Potts W M, 1988, Oncogene Res, V3, P343; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SEIDEL DC, 1992, MOL CELL BIOL, V12, P1835; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; TAMKUN MM, 1991, FASEB J, V5, P331, DOI 10.1096/fasebj.5.3.2001794; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WAGES DS, 1992, J VIROL, V66, P1866, DOI 10.1128/JVI.66.4.1866-1874.1992; WEBER C, 1991, BIOCHEMISTRY-US, V30, P6563, DOI 10.1021/bi00240a029; WENG ZG, 1993, J BIOL CHEM, V268, P14956; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; ZUIDERWEG ERP, 1989, BIOCHEMISTRY-US, V28, P2387, DOI 10.1021/bi00432a008	62	938	995	3	58	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	MAR 11	1994	76	5					933	945		10.1016/0092-8674(94)90367-0	http://dx.doi.org/10.1016/0092-8674(94)90367-0			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NA890	7510218				2022-12-24	WOS:A1994NA89000018
J	JONES, BW; FETTER, RD; TEAR, G; GOODMAN, CS				JONES, BW; FETTER, RD; TEAR, G; GOODMAN, CS			GLIAL-CELLS MISSING - A GENETIC SWITCH THAT CONTROLS GLIAL VERSUS NEURONAL FATE	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; GROWTH CONE GUIDANCE; RAT CEREBRAL-CORTEX; DROSOPHILA EMBRYOS; COMMON PROGENITOR; NEURAL CREST; LINEAGE; MIDLINE; CNS; EXPRESSION	The glial cells missing (gem) gene in Drosophila encodes a novel nuclear protein that is transiently expressed early in the development of nearly all glia, In loss-of-function gem mutant alleles, nearly all glia fail to differentiate, and, where we can follow them in the PNS, are transformed into neurons. In gain-of-function gem conditions using transgenic constructs that drive ectopic gem expression, many presumptive neurons are transformed into glia. Thus, gem appears to function as a binary genetic switch for glia versus neurons. In the presence of gem protein, presumptive neurons become glia, while in its absence, presumptive glia become neurons.			JONES, BW (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV NEUROBIOL,HOWARD HUGHES MED INST,BERKELEY,CA 94720, USA.		Tear, Guy/C-5444-2009					ABRAMS JM, 1993, DEVELOPMENT, V117, P29; AULD VJ, 1995, CELL, V81, P757, DOI 10.1016/0092-8674(95)90537-5; BODMER R, 1989, NEURON, V3, P21, DOI 10.1016/0896-6273(89)90112-8; BOSSING T, 1994, DEVELOPMENT, V120, P1895; BRAND AH, 1993, DEVELOPMENT, V118, P401; CAMPBELL G, 1994, DEVELOPMENT, V120, P2957; Campos-Ortega Jose A., 1993, P1091; CONDRON BG, 1994, J NEUROSCI, V14, P5766; CONDRON BG, 1995, CURR BIOL, V5, P51, DOI 10.1016/S0960-9822(95)00016-9; CONDRON BG, 1994, NEURON, V13, P541, DOI 10.1016/0896-6273(94)90024-8; CREWS ST, 1988, CELL, V52, P143, DOI 10.1016/0092-8674(88)90538-7; DAVIS AA, 1994, NATURE, V372, P263, DOI 10.1038/372263a0; DOE CQ, 1991, CELL, V65, P451, DOI 10.1016/0092-8674(91)90463-9; EBENS AJ, 1993, CELL, V74, P15, DOI 10.1016/0092-8674(93)90291-W; FRANK E, 1991, DEVELOPMENT, V111, P895; FUJITA SC, 1982, P NATL ACAD SCI-BIOL, V79, P7929, DOI 10.1073/pnas.79.24.7929; GALILEO DS, 1990, P NATL ACAD SCI USA, V87, P458, DOI 10.1073/pnas.87.1.458; GHYSEN A, 1986, ROUX ARCH DEV BIOL, V195, P281, DOI 10.1007/BF00376060; Goodman Corey S., 1993, P1131; GROVE EA, 1993, DEVELOPMENT, V117, P553; HALTER DA, 1995, DEVELOPMENT, V121, P317; HATTEN ME, 1988, DEV BIOL, V125, P280, DOI 10.1016/0012-1606(88)90211-4; HOLT CE, 1988, NEURON, V1, P15, DOI 10.1016/0896-6273(88)90205-X; HOSOYA T, 1995, CELL, V82, P1025, DOI 10.1016/0092-8674(95)90281-3; JACOBS JR, 1989, NEURON, V2, P1625; JACOBS JR, 1989, J NEUROSCI, V9, P2402; Jan Yuh Nung, 1993, P1207; KANIA A, 1995, GENETICS, V139, P1663; KLAES A, 1994, CELL, V78, P149, DOI 10.1016/0092-8674(94)90581-9; KLAMBT C, 1991, CELL, V64, P801, DOI 10.1016/0092-8674(91)90509-W; KLAMBT C, 1991, GLIA, V4, P205, DOI 10.1002/glia.440040212; KLAMBT C, 1993, DEVELOPMENT, V117, P163; KOPCZYNSKI CC, 1992, J CELL BIOL, V199, P503; LANE ME, 1993, GENE DEV, V7, P1228; LEBER SM, 1990, J NEUROSCI, V10, P2451; LEDOUARIN N, 1991, GLIA, V4, P175; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; LIN DM, 1994, NEURON, V13, P1055, DOI 10.1016/0896-6273(94)90045-0; LUSKIN MB, 1993, J NEUROSCI, V13, P1730; SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T; STEMPLE DL, 1992, CELL, V71, P973, DOI 10.1016/0092-8674(92)90393-Q; TEPASS U, 1994, DEVELOPMENT, V120, P1829; TROPEA M, 1988, GLIA, V1, P380, DOI 10.1002/glia.440010605; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; UDOLPH G, 1993, DEVELOPMENT, V118, P765; UEMURA T, 1989, CELL, V58, P349, DOI 10.1016/0092-8674(89)90849-0; WALSH C, 1992, SCIENCE, V255, P434, DOI 10.1126/science.1734520; WETTS R, 1988, DEV BIOL, V136, P254; WILLIAMS BP, 1995, NEURON, V14, P1181, DOI 10.1016/0896-6273(95)90265-1; XIONG WC, 1995, NEURON, V14, P581, DOI 10.1016/0896-6273(95)90314-3; XIONG WC, 1994, GENE DEV, V8, P981, DOI 10.1101/gad.8.8.981; ZINN K, 1988, CELL, V53, P577, DOI 10.1016/0092-8674(88)90574-0	52	389	396	0	10	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 22	1995	82	6					1013	1023		10.1016/0092-8674(95)90280-5	http://dx.doi.org/10.1016/0092-8674(95)90280-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RW693	7553843	Bronze			2022-12-24	WOS:A1995RW69300017
J	LATTERICH, M; FROHLICH, KU; SCHEKMAN, R				LATTERICH, M; FROHLICH, KU; SCHEKMAN, R			MEMBRANE-FUSION AND THE CELL-CYCLE - CDC48P PARTICIPATES IN THE FUSION OF ER MEMBRANES	CELL			English	Article							DIVISION-CYCLE; VESICULAR TRANSPORT; PUTATIVE ATPASES; GENETIC CONTROL; GOLGI STACK; YEAST; PROTEIN; FAMILY; MEMBER; VCP	The fusion of endoplasmic reticulum (ER) membranes in yeast is an essential process required for normal progression of the nuclear cell cycle, karyogamy, and the maintenance of an intact organellar compartment. We showed previously that this process requires a novel fusion machinery distinct from the classic membrane docking/fusion machinery containing Sec17p (alpha-SNAP) and Sec18p (NSF), Here we show that Cdc48p, a cell-cycle protein with homology to Sec18p, is required in ER fusion. A temperature-sensitive cdc48 mutant is conditionally defective in ER fusion in vitro. Addition of purified Cdc48p restores the fusion of isolated cdc48 mutant ER membranes, We propose that Cdc48p is part of an evolutionarily conserved fusion/docking machinery involved in multiple homotypic fusion events.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA; UNIV TUBINGEN, DEPT PHYSIOL CHEM, D-72076 TUBINGEN, GERMANY	University of California System; University of California Berkeley; Eberhard Karls University of Tubingen	LATTERICH, M (corresponding author), UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, BERKELEY, CA 94720 USA.							ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; Bernardi G, 1971, METHOD ENZYMOL, V22, P325; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; CULOTTI J, 1971, EXP CELL RES, V67, P389, DOI 10.1016/0014-4827(71)90424-1; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; EAKLE KA, 1988, MOL CELL BIOL, V8, P4098, DOI 10.1128/MCB.8.10.4098; EGERTON M, 1992, EMBO J, V11, P3533, DOI 10.1002/j.1460-2075.1992.tb05436.x; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; FROHLICH KU, 1995, IN PRESS BIOCH BIOPH; GRIFF IC, 1992, J BIOL CHEM, V267, P12106; HARTWELL LH, 1970, P NATL ACAD SCI USA, V66, P352, DOI 10.1073/pnas.66.2.352; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; KOLLER KJ, 1987, NATURE, V325, P542, DOI 10.1038/325542a0; KURIHARA LJ, 1994, J CELL BIOL, V126, P911, DOI 10.1083/jcb.126.4.911; LATTERICH M, 1994, CELL, V78, P87, DOI 10.1016/0092-8674(94)90575-4; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MOIR D, 1982, GENETICS, V100, P547; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; PLEASURE IT, 1993, NATURE, V365, P459, DOI 10.1038/365459a0; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; REXACH MF, 1994, J CELL BIOL, V126, P1133, DOI 10.1083/jcb.126.5.1133; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROSE MD, 1991, ANNU REV MICROBIOL, V45, P539; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; RSOE MD, 1990, METHODS YEAST GENETI; Sambrook J., 1989, MOL CLONING LAB MANU; SCHULTE RJ, 1994, J IMMUNOL, V153, P5465; SOGAARD M, 1994, CELL, V78, P938; THORSNESS PE, 1993, YEAST, V9, P1267, DOI 10.1002/yea.320091114; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; ZHANG L, 1994, J CELL BIOL, V127, P1871, DOI 10.1083/jcb.127.6.1871	35	325	329	1	8	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 22	1995	82	6					885	893		10.1016/0092-8674(95)90268-6	http://dx.doi.org/10.1016/0092-8674(95)90268-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RW693	7553849	Bronze			2022-12-24	WOS:A1995RW69300005
J	SANDVIK, L; ERIKSSEN, G; THAULOW, E				SANDVIK, L; ERIKSSEN, G; THAULOW, E			LONG-TERM EFFECTS OF SMOKING ON PHYSICAL-FITNESS AND LUNG-FUNCTION - A LONGITUDINAL-STUDY OF 1393 MIDDLE-AGED NORWEGIAN MEN FOR 7 YEARS	BRITISH MEDICAL JOURNAL			English	Article							CIGARETTE-SMOKING; BLOOD-PRESSURE; EXERCISE; SMOKERS; CARDIOMYOPATHY; OBSTRUCTION; EPINEPHRINE; NONSMOKERS; POPULATION; PREDICTOR	Objective-To study association between smoking habits and long term decline in physical fitness and lung function in middle aged men who remained healthy. Design-Baseline and follow up measurements performed during 1972-5 and 1980-2 respectively. Setting-National University Hospital of Oslo, Norway. Subjects-1393 men aged 40-59 at baseline who were all healthy at baseline and at follow up. Main outcome measures-Forced expiratory volume in one second and physical fitness (defined as total work done during a symptom limited bicycle ergometer test divided by body weight. Results-Initial fitness was substantially lower among 347 persistent smokers than among 791 persistent non-smokers (1349 J/kg v 1618 J/kg), as was initial forced expiratory volume (3341 ml v 3638 ml). Mean (95% confidence interval) decline in fitness over 7.2 years was 217 (185 to 249) J/kg among smokers compared with 86 (59 to 113) J/kg among non-smokers (P<0.001). Corresponding declines in forced expiratory volume were 271 (226 to 316) ml in smokers and 116 (85 to 147) ml in non-smokers (P<0.001). Differences between smokers and non-smokers remained practically unchanged after adjustment for age and level of physical activity. Changes in fitness and forced expiratory volume among 199 men who had stopped smoking mimicked the findings for persistent non-smokers, and 56 men who started smoking presented findings close to those of persistent smokers. Conclusion-Decline in physical fitness and lung function among healthy middle aged men was considerably greater among smokers than among nonsmokers and could not be explained by differences in age and physical activity.	CENT HOSP AKERSHUS,DEPT MED,N-1474 NORDBYHAGEN,NORWAY	University of Oslo								Astrand PO., 1986, TXB WORK PHYSL, P391; BURROWS B, 1987, NEW ENGL J MED, V317, P1309, DOI 10.1056/NEJM198711193172103; CONWAY TL, 1992, PREV MED, V21, P723, DOI 10.1016/0091-7435(92)90079-W; COOPER MJH, 1968, JAMA-J AM MED ASSOC, V203, P123; CRYER PE, 1976, NEW ENGL J MED, V295, P573, DOI 10.1056/NEJM197609092951101; Dressendorfer R H, 1983, Phys Sportsmed, V11, P108, DOI 10.1080/00913847.1986.11708539; EKELUND LG, 1988, NEW ENGL J MED, V319, P1379, DOI 10.1056/NEJM198811243192104; ERIKSSEN G, 1994, 67TH AM HEART ASS AN; ERIKSSEN J, 1977, SCAND J CLIN LAB INV, V37, P243, DOI 10.3109/00365517709091489; ERIKSSEN J, 1978, ACTA MED SCAND, V203, P532; ERIKSSEN J, 1978, THESIS U HOSPITAL OS; FLETCHER C, 1977, BMJ-BRIT MED J, V1, P1645, DOI 10.1136/bmj.1.6077.1645; GREEN MS, 1986, AM HEART J, V111, P932, DOI 10.1016/0002-8703(86)90645-9; GYNTELBERG F, 1973, DAN MED BULL, V20, P1; HAF JI, 1974, PROGR CARDIOVASC DIS, V17, P73; HANDA K, 1990, ATHEROSCLEROSIS, V84, P189, DOI 10.1016/0021-9150(90)90090-6; Hoad N A, 1992, J R Army Med Corps, V138, P115; JOHNSON BD, 1992, J APPL PHYSIOL, V73, P874, DOI 10.1152/jappl.1992.73.3.874; LAUSTIOLA KE, 1988, CIRCULATION, V78, P1234, DOI 10.1161/01.CIR.78.5.1234; MCHENRY PI, 1977, AM J CARDIOL, V39, P393; PENNY WJ, 1986, INT J CARDIOL, V11, P293, DOI 10.1016/0167-5273(86)90034-3; POWERS SK, 1989, J APPL PHYSIOL, V66, P2491, DOI 10.1152/jappl.1989.66.6.2491; SANDVIK L, 1993, NEW ENGL J MED, V328, P533, DOI 10.1056/NEJM199302253280803; SHAVER LG, 1973, J AM COLL HEALTH ASS, V21, P489; SIDNEY S, 1993, MED SCI SPORT EXER, V25, P911; SINGAL PK, 1982, CAN J PHYSIOL PHARM, V60, P1390, DOI 10.1139/y82-207; TRAPJENSEN J, 1988, AM HEART J, V115, P263, DOI 10.1016/0002-8703(88)90647-3; YATES JC, 1981, AM HEART J, V102, P210, DOI 10.1016/S0002-8703(81)80012-9; 1990, PHS DHSS CDS908416 P; 1984, DHHS PHS8450205 PUBL	30	64	67	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 16	1995	311	7007					715	718		10.1136/bmj.311.7007.715	http://dx.doi.org/10.1136/bmj.311.7007.715			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RV874	7549684	Green Published			2022-12-24	WOS:A1995RV87400018
J	LAWSON, MA; MAXFIELD, FR				LAWSON, MA; MAXFIELD, FR			CA2+ AND CALCINEURIN-DEPENDENT RECYCLING OF AN INTEGRIN TO THE FRONT OF MIGRATING NEUTROPHILS	NATURE			English	Article							POLYMORPHONUCLEAR LEUKOCYTES; ACTIVATED PLATELETS; CELL-ADHESION; ALPHA-ACTININ; SUBUNIT; VITRONECTIN; RECEPTOR; FIBRONECTIN; ADHERENCE; LAMININ	CHEMOATTRACTANTS stimulate neutrophil migration by activating signalling pathways(1) including repeated transient increases in intracellular free calcium, [Ca2+](i) (refs 2, 3). A motile neutrophil sends out many pseudopods, some of which adhere to the substrate; to continue moving forward the cell must release these attachments(4,5). Adhesion can be actively regulated, and neutrophils in which [Ca2+](i) transients are inhibited become stuck on fibronectin or vitronectin(6,7), extracellular matrix proteins that neutrophils encounter in vivo. Function-blocking antibodies to beta 3 integrins or the alpha v beta 3 heterodimer restore motility on vitronectin to [Ca2+](i)-buffered cells (B, Hendey, M.A.L., E. Marcantonio and F.R.M., manuscript submitted), indicating that an alpha v beta 3-like integrin is responsible for the [Ca2+](i)-sensitive adhesion. We show that the density of alpha v beta 3 integrins in the adherent membrane of neutrophils migrating on vitronectin is much higher at the leading edge than at the rear, but [Ca2+](i) buffering or inhibition of Ca2+-calmodulin-activated protein phosphatase 2B (calcineurin) leads to accumulation of alpha v beta 3 on the adherent surface at the rear of the cell. We show that the polarized distribution of alpha v beta 3 integrins in migrating neutrophils is maintained by [Ca2+](i)-dependent release of adhesion followed by endocytosis of these integrins and recycling to the leading edge.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032	Columbia University			Maxfield, Fred/M-6747-2019; Maxfield, Fred/A-1718-2011	Maxfield, Fred/0000-0003-4396-8866; 				ABELDA SM, 1994, FASEB J, V8, P504; ABERCROMBIE M, 1970, EXP CELL RES, V62, P389, DOI 10.1016/0014-4827(70)90570-7; ALTANKOV G, 1993, J CELL BIOL, V120, P1449, DOI 10.1083/jcb.120.6.1449; BERTAGNOLLI ME, 1993, J CELL BIOL, V121, P1329, DOI 10.1083/jcb.121.6.1329; BOYLES J, 1979, J CELL BIOL, V82, P347, DOI 10.1083/jcb.82.2.347; BRETCHER MS, 1988, J CELL BIOL, V106, P235, DOI 10.1083/jcb.106.2.235; BRETSCHER MS, 1992, EMBO J, V11, P405, DOI 10.1002/j.1460-2075.1992.tb05068.x; BRETSCHER MS, 1984, SCIENCE, V224, P261; CHAMBERS JD, 1993, J LEUKOCYTE BIOL, V53, P462, DOI 10.1002/jlb.53.4.462; CHERESH DA, 1987, J BIOL CHEM, V262, P1434; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cb.04.110188.003245; DIAMOND MS, 1994, CURR BIOL, V4, P506, DOI 10.1016/S0960-9822(00)00111-1; GHOSH RN, 1994, J CELL SCI, V107, P2177; HASTON WS, 1987, J CELL SCI, V88, P495; HENDEY B, 1992, SCIENCE, V258, P296, DOI 10.1126/science.1384129; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; HOPKINS CR, 1994, J CELL BIOL, V125, P1265, DOI 10.1083/jcb.125.6.1265; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JACONI MEE, 1991, J CELL BIOL, V112, P1249, DOI 10.1083/jcb.112.6.1249; KOUNS WC, 1991, J BIOL CHEM, V266, P13891; MARKS PW, 1990, J CELL BIOL, V110, P43, DOI 10.1083/jcb.110.1.43; MARKS PW, 1991, J CELL BIOL, V112, P149, DOI 10.1083/jcb.112.1.149; MASSIA SP, 1993, J BIOL CHEM, V268, P8053; MAXFIELD F, 1993, TRENDS CELL BIOL, V4, P386; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; SCHMIDT CE, 1994, BIOPHYS J, V67, P461, DOI 10.1016/S0006-3495(94)80502-8; SINGER II, 1989, J CELL BIOL, V109, P3169, DOI 10.1083/jcb.109.6.3169; YLANNE J, 1990, BLOOD, V76, P570	28	476	479	0	18	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 7	1995	377	6544					75	79		10.1038/377075a0	http://dx.doi.org/10.1038/377075a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT725	7544874				2022-12-24	WOS:A1995RT72500060
J	FISCHER, U; HUBER, J; BOELENS, WC; MATTAJ, IW; LUHRMANN, R				FISCHER, U; HUBER, J; BOELENS, WC; MATTAJ, IW; LUHRMANN, R			THE HIV-1 REV ACTIVATION DOMAIN IS A NUCLEAR EXPORT SIGNAL THAT ACCESSES AN EXPORT PATHWAY USED BY SPECIFIC CELLULAR RNAS	CELL			English	Article							VIRAL MESSENGER-RNA; VIRUS TYPE-1 REV; TRANS-ACTIVATOR; PROTEINS; BINDING; MUTANTS; IDENTIFICATION; LOCALIZATION; EXPRESSION; DEFINITION	HIV-1 Rev protein directs nuclear export of pre-mRNAs and mRNAs containing its binding site, the Rev response element (RRE). To define how Rev acts, we used conjugates between bovine serum albumin (BSA) and peptides comprising the Rev activation domain (BSA-R). BSA-R inhibited Rev-mediated nuclear RNA export, whereas a mutant activation domain peptide conjugate did not. BSA-R did not affect the export of mRNA, tRNA, or ribosomal subunits, but did inhibit export of 5S rRNA and spliceosomal U snRNAs. BSA-R was itself exported from the nucleus in an active, saturable manner. Thus, the Rev activation domain constitutes a nuclear export signal that redirects RRE-containing viral RNAs to a non-mRNA export pathway.	EUROPEAN MOLEC BIOL LAB,D-69117 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)	FISCHER, U (corresponding author), INST MOLEKBIOL & TUMORFORSCH,EMIL MANNKOPFF STR 2,D-35037 MARBURG,GERMANY.		Fischer, Utz/AAT-8422-2020; Fischer, Utz/A-4090-2016; Boelens, Wilbert/D-8877-2012	Fischer, Utz/0000-0002-1465-6591; Fischer, Utz/0000-0002-1465-6591; Mattaj, Iain/0000-0002-5537-8284				BATAILLE N, 1990, J CELL BIOL, V111, P1571, DOI 10.1083/jcb.111.4.1571; BERGER J, 1991, VIROLOGY, V183, P630, DOI 10.1016/0042-6822(91)90992-K; BRAY M, 1994, P NATL ACAD SCI USA, V91, P1256, DOI 10.1073/pnas.91.4.1256; CHANG DD, 1989, CELL, V59, P789, DOI 10.1016/0092-8674(89)90602-8; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; EMERMAN M, 1989, CELL, V57, P1155, DOI 10.1016/0092-8674(89)90053-6; FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; FISCHER U, 1994, J CELL BIOL, V125, P971, DOI 10.1083/jcb.125.5.971; FISCHER U, 1994, EMBO J, V13, P4105, DOI 10.1002/j.1460-2075.1994.tb06728.x; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; GUDDAT U, 1990, CELL, V60, P619, DOI 10.1016/0092-8674(90)90665-2; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; IZAURRALDE E, 1992, J CELL BIOL, V118, P1287, DOI 10.1083/jcb.118.6.1287; IZAURRALDE E, 1995, CELL, V81, P153, DOI 10.1016/0092-8674(95)90323-2; IZAURRALDE E, 1994, CELL, V78, P657, DOI 10.1016/0092-8674(94)90530-4; IZAURRALDE E, 1995, IN PRESS NATURE; JARMOLOWSKI A, 1994, J CELL BIOL, V124, P627, DOI 10.1083/jcb.124.5.627; KALLAND KH, 1994, MOL CELL BIOL, V14, P7436, DOI 10.1128/MCB.14.11.7436; KHANNAGUPTA A, 1989, P NATL ACAD SCI USA, V86, P1791, DOI 10.1073/pnas.86.6.1791; KJEMS J, 1993, J VIROL, V67, P4769, DOI 10.1128/JVI.67.8.4769-4776.1993; KJEMS J, 1991, REV CELL, V67, P169; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGRAIN P, 1989, CELL, V57, P573, DOI 10.1016/0092-8674(89)90127-X; MALIM MH, 1991, J VIROL, V65, P4248, DOI 10.1128/JVI.65.8.4248-4254.1991; MALIM MH, 1993, MOL CELL BIOL, V13, P6180, DOI 10.1128/MCB.13.10.6180; MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MANDELL RB, 1990, J CELL BIOL, V111, P1775, DOI 10.1083/jcb.111.5.1775; MERMER B, 1990, NUCLEIC ACIDS RES, V18, P2037, DOI 10.1093/nar/18.8.2037; MEYER BE, 1994, GENE DEV, V8, P1538, DOI 10.1101/gad.8.13.1538; PINOLROMA S, 1991, SCIENCE, V253, P312, DOI 10.1126/science.1857966; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; POWERS MA, 1995, CELL, V79, P931; RIMSKY L, 1988, NATURE, V335, P738, DOI 10.1038/335738a0; SCHMIDTZACHMANN MS, 1993, CELL, V74, P493, DOI 10.1016/0092-8674(93)80051-F; STUTZ F, 1994, EMBO J, V13, P4096, DOI 10.1002/j.1460-2075.1994.tb06727.x; VENKATESH LK, 1990, VIROLOGY, V178, P327, DOI 10.1016/0042-6822(90)90414-M; WEICHSELBRAUN I, 1992, J VIROL, V66, P2583, DOI 10.1128/JVI.66.4.2583-2587.1992; WOLFF B, 1995, EXP CELL RES, V217, P31, DOI 10.1006/excr.1995.1060; ZASLOFF M, 1983, P NATL ACAD SCI-BIOL, V80, P6436, DOI 10.1073/pnas.80.21.6436	42	963	991	0	30	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 11	1995	82	3					475	483		10.1016/0092-8674(95)90436-0	http://dx.doi.org/10.1016/0092-8674(95)90436-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RP242	7543368	Bronze			2022-12-24	WOS:A1995RP24200017
J	CANO, RJ; BORUCKI, MK				CANO, RJ; BORUCKI, MK			REVIVAL AND IDENTIFICATION OF BACTERIAL-SPORES IN 25-MILLION-YEAR-OLD TO 40-MILLION-YEAR-OLD DOMINICAN AMBER	SCIENCE			English	Article							LARVAL PROVISIONS; APIS-MELLIFERA; GENUS BACILLUS; STINGLESS BEE; SOLITARY BEES; MICROORGANISMS; POLLEN; MICROBIOLOGY; HONEY; DNA	A bacterial spore was revived, cultured, and identified from the abdominal contents of extinct bees preserved for 25 to 40 million years in buried Dominican amber. Rigorous surface decontamination of the amber and aseptic procedures were used during the recovery of the bacterium. Several lines of evidence indicated that the isolated bacterium was of ancient origin and not an extant contaminant. The characteristic enzymatic, biochemical, and 16S ribosomal DNA profiles indicated that the ancient bacterium is most closely related to extant Bacillus sphaericus.			CANO, RJ (corresponding author), CALIF POLYTECH STATE UNIV SAN LUIS OBISPO,SAN LUIS OBISPO,CA 93407, USA.							CANO RJ, 1994, APPL ENVIRON MICROB, V60, P2164, DOI 10.1128/AEM.60.6.2164-2167.1994; CANO RJ, 1993, NATURE, V363, P536, DOI 10.1038/363536a0; CANO RJ, 1993, BIOTECHNIQUES, V15, P8; Claus D., 1986, BERGEYS MANUAL SYSTE; Felsenstein J, 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; GEST H, 1987, MICROBIOL SCI, V4, P69; GILLIAM M, 1978, APIDOLOGIE, V9, P213, DOI 10.1051/apido:19780305; GILLIAM M, 1990, APIDOLOGIE, V21, P89, DOI 10.1051/apido:19900201; GILLIAM M, 1985, BIOTROPICA, V17, P28, DOI 10.2307/2388374; GILLIAM M, 1979, APIDOLOGIE, V10, P269, DOI 10.1051/apido:19790304; GILLIAM M, 1976, J INVERTEBR PATHOL, V28, P275, DOI 10.1016/0022-2011(76)90137-3; GILLIAM M, 1984, APIDOLOGIE, V15, P1, DOI 10.1051/apido:19840101; GILLIAM M, 1990, APIDOLOGIE, V21, P99, DOI 10.1051/apido:19900202; GILLIAM M, 1988, MICROBIOS, V55, P95; GILLIAM M, 1991, J INVERTEBR PATHOL, V58, P286, DOI 10.1016/0022-2011(91)90077-4; Gordon RE, 1973, THE GENUS BACILLUS; GOUY M, 1990, RIBOSOME; KENNEDY MJ, 1994, MICROBIOL-SGM, V140, P2513, DOI 10.1099/00221287-140-10-2513; Li W-H., 1991, FUNDAMENTALS MOL EVO; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MACHADO J O, 1971, Ciencia e Cultura (Sao Paulo), V23, P625; MORAN NA, 1993, P ROY SOC B-BIOL SCI, V253, P167, DOI 10.1098/rspb.1993.0098; NEEFS JM, 1990, NUCLEIC ACIDS RES, V18, P2237, DOI 10.1093/nar/18.suppl.2237; OCHMAN H, 1987, J MOL EVOL, V26, P74, DOI 10.1007/BF02111283; Poinar G, 1992, LIFE AMBER; POTTS M, 1994, MICROBIOL REV, V58, P755, DOI 10.1128/MMBR.58.4.755-805.1994; Roubik D.W., 1989, ECOLOGY NATURAL HIST, DOI DOI 10.1126/SCIENCE.248.4958.1026; SEAWARD MRD, 1976, NATURE, V261, P407, DOI 10.1038/261407a0; SETLOW P, 1988, ANNU REV MICROBIOL, V42, P319, DOI 10.1146/annurev.mi.42.100188.001535; SETLOW P, 1993, APPL BACTERIOL S S, V76, pS49; WILLE ALVARO, 1964, REV BIOL TROP, V12, P187; WOESE CR, 1991, EVOLUTION MOL LEVEL	32	372	406	0	109	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 19	1995	268	5213					1060	1064		10.1126/science.7538699	http://dx.doi.org/10.1126/science.7538699			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY934	7538699				2022-12-24	WOS:A1995QY93400044
J	DEFELIPE, C; PINNOCK, RD; HUNT, SP				DEFELIPE, C; PINNOCK, RD; HUNT, SP			MODULATION OF CHEMOTROPISM IN THE DEVELOPING SPINAL-CORD BY SUBSTANCE-P	SCIENCE			English	Article							DEVELOPING AXONS; NEURONS; GROWTH; EXTENSION; RECEPTORS; GUIDANCE; CELLS	Developing axons find their targets through direct contact with cues in the extracellular environment and in response to gradients of diffusible factors. The floor plate, a neuroepithelial structure, guides developing commissural axons in the spinal cord by release of chemoattractants. Floor plate cells express neurokinin-1 receptors, and a transiently appearing subpopulation of commissural axons contains substance P, the neuropeptide ligand for this receptor, Substance P increases the amount of axon outgrowth from dorsal horn explants cocultured with floor plate explants. Results of experiments with embryonic rats suggest that substance P released from pioneering neuronal pathways may regulate the release of chemoattractants from floor plate cells.	MRC,DIV NEUROBIOL,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND; PARKE DAVIS & CO,NEUROSCI RES UNIT,CAMBRIDGE CB2 2QB,ENGLAND	MRC Laboratory Molecular Biology; University of Cambridge			HUNT, STEPHEN P/C-1646-2008; de Felipe, Carmen/D-3813-2012	Hunt, Stephen/0000-0001-9453-5505				ALTMAN J, 1984, DEV RAT SPINAL CORD; BOLOVENTA P, 1990, DEVELOPMENT, V109, P435; CAJAL SRY, 1909, HIST SYSTEME NERVEUX, V1, P592; CAMPBELL RM, 1993, DEVELOPMENT, V119, P1217; DEFELIPE C, UNPUB; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; DODD J, 1988, SCIENCE, V242, P692, DOI 10.1126/science.3055291; GHOSH A, 1993, DEVELOPMENT, V117, P1031; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEFFNER CD, 1990, SCIENCE, V247, P217, DOI 10.1126/science.2294603; HOKFELT T, 1991, NEURON, V7, P867, DOI 10.1016/0896-6273(91)90333-U; JESSELL TM, 1988, NEURON, V1, P3, DOI 10.1016/0896-6273(88)90204-8; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; LUMSDEN AGS, 1983, NATURE, V306, P786, DOI 10.1038/306786a0; MAGGI CA, 1993, J AUTON PHARMACOL, V13, P23, DOI 10.1111/j.1474-8673.1993.tb00396.x; NAGY JI, 1982, NEUROSCIENCE, V7, P89, DOI 10.1016/0306-4522(82)90155-5; NARUMI S, 1978, J NEUROCHEM, V30, P1321, DOI 10.1111/j.1471-4159.1978.tb10462.x; NILSSON J, 1985, NATURE, V315, P61, DOI 10.1038/315061a0; PERNOW B, 1983, PHARMACOL REV, V35, P85; PLACZEK M, 1990, DEVELOPMENT, V110, P19; SEABROOK GR, 1993, NEUROSCI LETT, V152, P9, DOI 10.1016/0304-3940(93)90470-6; TESSIERLAVIGNE M, 1991, TRENDS NEUROSCI, V14, P303, DOI 10.1016/0166-2236(91)90142-H; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; VIGNA SR, 1994, J NEUROSCI, V14, P834	24	44	44	0	0	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 10	1995	267	5199					899	902		10.1126/science.7531367	http://dx.doi.org/10.1126/science.7531367			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG207	7531367				2022-12-24	WOS:A1995QG20700063
J	DSOUZA, SE; HAAS, TA; PIOTROWICZ, RS; BYERSWARD, V; MCGRATH, DE; SOULE, HR; CIERNIEWSKI, C; PLOW, EF; SMITH, JW				DSOUZA, SE; HAAS, TA; PIOTROWICZ, RS; BYERSWARD, V; MCGRATH, DE; SOULE, HR; CIERNIEWSKI, C; PLOW, EF; SMITH, JW			LIGAND AND CATION-BINDING ARE DUAL FUNCTIONS OF A DISCRETE SEGMENT OF THE INTEGRIN BETA(3) SUBUNIT - CATION DISPLACEMENT IS INVOLVED IN LIGAND-BINDING	CELL			English	Article							FIBRINOGEN GAMMA-CHAIN; GLYCOPROTEIN-IIB-IIIA; CALCIUM-BINDING; PLATELET INTEGRIN; GPIIB-IIIA; VITRONECTIN RECEPTOR; ADHESION RECEPTOR; CELL-ADHESION; RECOGNITION SITE; BONE-RESORPTION	The alpha(IIb)beta(3) integrin binds Arg-Gly-Asp-containing (RGD-containing) ligands in a cation-dependent interaction. A fourteen amino acid sequence, beta(3)(118-131), and an antibody to it, inhibited ligand binding functions of alpha(IIb)beta s, and a 1:1 stoichiometric beta(3)(118-131)-RGD complex was detected by mass spectroscopy. Cation binding to Ps(118-131) was demonstrated by terbium luminescence and mass spectroscopy. Notably, ligand displaced cation from the beta(3)(118-131) peptide and also from purified alpha(IIb)beta(3). Thus, beta(3)(118-131), a highly conserved region in integrin beta subunits, binds both ligand and cation. Formation of a ternary complex between cation, ligand, and receptor, with subsequent displacement of cation from beta(3)(118-131)and a second site within the receptor, may be central to the mechanism of ligand recognition by integrins.	Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA; CORVAS INT INC, SAN DIEGO, CA 92121 USA	Scripps Research Institute	DSOUZA, SE (corresponding author), CLEVELAND CLIN FDN, DEPT MOLEC CARDIOL, CTR THROMBOSIS & VASC RES, FF20, CLEVELAND, OH 44195 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038292, R29HL043721, R01HL043721] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-43721, HL-38292] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDRIEUX A, 1991, J BIOL CHEM, V266, P14202; BACA M, 1992, J AM CHEM SOC, V114, P3992, DOI 10.1021/ja00036a066; BAIROCH A, 1989, PROSITE DICT PROTEIN; BRITTAIN HG, 1976, J AM CHEM SOC, V98, P8255, DOI 10.1021/ja00441a060; CALVETE JJ, 1988, BIOCHEM J, V250, P697, DOI 10.1042/bj2500697; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; DAVIES J, 1989, J CELL BIOL, V109, P1817, DOI 10.1083/jcb.109.4.1817; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DSOUZA SE, 1991, NATURE, V350, P66, DOI 10.1038/350066a0; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GARCIAGONZALEZ M, 1988, J IMMUNOL METHODS, V111, P17, DOI 10.1016/0022-1759(88)90054-3; GARVEY JS, 1977, METHOD IMMUNOL, V1, P89; GINSBERG M, 1985, J BIOL CHEM, V260, P3931; GINSBERG MH, 1993, THROMB HAEMOSTASIS, V70, P87; GINSBERG MH, 1986, J CLIN INVEST, V78, P1103, DOI 10.1172/JCI112667; Goding JW, 1983, MONOCLONAL ANTIBODIE; GRZESIAK JJ, 1992, J CELL BIOL, V117, P1109, DOI 10.1083/jcb.117.5.1109; HOGUE CWV, 1992, J BIOL CHEM, V267, P13340; Horrocks W.D. Jr., 1983, PROG INORG CHEM, V31, P1; HUTCHENS TW, 1992, FEBS LETT, V309, P170, DOI 10.1016/0014-5793(92)81088-4; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KIRCHHOFER D, 1991, J BIOL CHEM, V266, P4471; KLOCZEWIAK M, 1982, BIOCHEM BIOPH RES CO, V107, P181, DOI 10.1016/0006-291X(82)91686-2; KLOCZEWIAK M, 1983, THROMB RES, V29, P249, DOI 10.1016/0049-3848(83)90147-0; LAKKAKORPI PT, 1991, J CELL BIOL, V115, P1179, DOI 10.1083/jcb.115.4.1179; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; MARGUERIE GA, 1981, BIOCHEMISTRY-US, V20, P1074, DOI 10.1021/bi00508a005; MARGUERIE GA, 1983, ANN NY ACAD SCI, V408, P556, DOI 10.1111/j.1749-6632.1983.tb23272.x; MARTINI JL, 1993, EUR J BIOCHEM, V211, P467, DOI 10.1111/j.1432-1033.1993.tb17572.x; Morrison M, 1980, Methods Enzymol, V70, P214; PHILLIPS DR, 1988, BLOOD, V71, P831; PLOW EF, 1992, SEMIN THROMB HEMOST, V18, P324, DOI 10.1055/s-2007-1002571; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; PLOW EF, 1982, P NATL ACAD SCI-BIOL, V79, P3711, DOI 10.1073/pnas.79.12.3711; PRADOS R, 1974, J INORG NUCL CHEM, V36, P689, DOI 10.1016/0022-1902(74)80135-1; RIVAS GA, 1991, BIOCHEM J, V276, P35, DOI 10.1042/bj2760035; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SAVAGE B, 1991, J BIOL CHEM, V266, P11227; SMITH JW, 1988, J BIOL CHEM, V263, P18726; SMITH JW, 1991, J BIOL CHEM, V266, P11429; SMITH JW, 1994, J BIOL CHEM, V269, P960; SMYTH SS, 1993, BLOOD, V81, P2827; SNYDER AP, 1981, BIOCHEMISTRY-US, V20, P3334, DOI 10.1021/bi00515a003; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; STEINER B, 1989, J BIOL CHEM, V264, P13102; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; TAYLOR DB, 1992, J BIOL CHEM, V267, P11729; TUCKWELL DS, 1992, BIOCHEM J, V285, P325, DOI 10.1042/bj2850325; VANKOOYK Y, 1991, J CELL BIOL, V112, P345, DOI 10.1083/jcb.112.2.345	55	215	217	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 18	1994	79	4					659	667		10.1016/0092-8674(94)90551-7	http://dx.doi.org/10.1016/0092-8674(94)90551-7			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PT481	7525080				2022-12-24	WOS:A1994PT48100013
J	OAKLANDER, AL; EKENBERG, SJ				OAKLANDER, AL; EKENBERG, SJ			SMALL-SCALE MAGNETIC ISOLATION OF MESSENGER-RNA AND SYNTHESIS OF CDNA IN 96-WELL PLATES	NATURE			English	Article							REVERSE-TRANSCRIPTASE-PCR	Multiple small biological samples can be simultaneously prepared for RT-PCR by magnetically isolating mRNA and synthesizing cDNA in 96-well plates. The resulting accuracy, high throughput and ease of use facilitate commercial and clinical applications.	PROMEGA CORP,MADISON,WI	Promega Corporation	OAKLANDER, AL (corresponding author), JOHNS HOPKINS MED INST,DEPT NEUROL,BALTIMORE,MD 21205, USA.							Chelly Jamel, 1994, P97; Dilworth D D, 1992, PCR Methods Appl, V1, P279; HOPPE BL, 1992, BIOTECHNIQUES, V12, P679; KOTEWICZ ML, 1988, NUCLEIC ACIDS RES, V16, P265, DOI 10.1093/nar/16.1.265; NORTHRUP MA, 1993, 7TH P INT C SOL STAT; SELA M, 1957, BIOCHIM BIOPHYS ACTA, V26, P502, DOI 10.1016/0006-3002(57)90096-3; Yamaguchi M, 1992, PCR Methods Appl, V1, P286	7	8	9	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 13	1994	371	6498					631	632		10.1038/371631a0	http://dx.doi.org/10.1038/371631a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PL559	7523954				2022-12-24	WOS:A1994PL55900060
J	SAWAYA, MR; PELLETIER, H; KUMAR, A; WILSON, SH; KRAUT, J				SAWAYA, MR; PELLETIER, H; KUMAR, A; WILSON, SH; KRAUT, J			CRYSTAL-STRUCTURE OF RAT DNA-POLYMERASE-BETA - EVIDENCE FOR A COMMON POLYMERASE MECHANISM	SCIENCE			English	Article							ESCHERICHIA-COLI; BINDING DOMAIN; REVERSE-TRANSCRIPTASE; 3-DIMENSIONAL STRUCTURE; ANGSTROM RESOLUTION; KLENOW FRAGMENT; RNA-POLYMERASE; IDENTIFICATION; PROTEIN; SYNTHETASE	Structures of the 31-kilodalton catalytic domain of rat DNA polymerase beta (pol beta) and the whole 39-kilodalton enzyme were determined at 2.3 and 3.6 angstrom resolution, respectively. The 31-kilodalton domain is composed of fingers, palm, and thumb subdomains arranged to form a DNA binding channel reminiscent of the polymerase domains of the Klenow fragment of Escherichia coli DNA polymerase I, HIV-1 reverse transcriptase, and bacteriophage T7 RNA polymerase. The amino-terminal 8-kilodalton domain is attached to the fingers subdomain by a flexible hinge. The two invariant aspartates found in all polymerase sequences and implicated in catalytic activity have the same geometric arrangement within structurally similar but topologically distinct palms, indicating that the polymerases have maintained, or possibly re-evolved, a common nucleotidyl transfer mechanism. The location of Mn2+ and deoxyadenosine triphosphate in pot beta confirms the role of the invariant aspartates in metal ion and deoxynucleoside triphosphate binding.	UNIV TEXAS,MED BRANCH,SEALY CTR MOLEC SCI,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston	SAWAYA, MR (corresponding author), UNIV CALIF SAN DIEGO,DEPT CHEM,LA JOLLA,CA 92093, USA.		Wilson, Samuel H/E-6644-2019	Wilson, Samuel H/0000-0002-1702-5293	NCI NIH HHS [CA17374] Funding Source: Medline; NIEHS NIH HHS [ES06839] Funding Source: Medline; NIGMS NIH HHS [GM10928] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA017374] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM010928] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASU A, 1989, BIOCHEMISTRY-US, V28, P6305, DOI 10.1021/bi00441a023; BEESE LS, 1993, BIOCHEMISTRY-US, V32, P14095, DOI 10.1021/bi00214a004; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BONNER G, 1992, EMBO J, V11, P3767, DOI 10.1002/j.1460-2075.1992.tb05462.x; BORK P, 1992, PROTEIN SCI, V1, P1677, DOI 10.1002/pro.5560011216; BRUNGER A, 1992, X PLOR MANUAL; CASASFINET JR, 1991, J BIOL CHEM, V266, P19618; COLL M, 1991, EMBO J, V10, P1; DATE T, 1991, BIOCHEMISTRY-US, V30, P5286, DOI 10.1021/bi00235a023; DAVIES JF, 1994, CELL, V76, P1123, DOI 10.1016/0092-8674(94)90388-3; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; EVANS RK, 1989, BIOCHEMISTRY-US, V28, P713, DOI 10.1021/bi00428a045; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; GOUAUX JE, 1990, BIOCHEMISTRY-US, V29, P7702, DOI 10.1021/bi00485a020; HAMLIN R, 1985, METHOD ENZYMOL, V114, P416; HEGDE RS, 1992, NATURE, V359, P505, DOI 10.1038/359505a0; HERZBERG O, 1992, P NATL ACAD SCI USA, V89, P2499, DOI 10.1073/pnas.89.6.2499; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUMAR A, 1990, J BIOL CHEM, V265, P2124; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; MATSUKAGE A, 1987, J BIOL CHEM, V262, P8960; MORAS D, 1993, NATURE, V364, P572, DOI 10.1038/364572a0; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; ORENGO CA, 1993, STRUCTURE, V1, P105, DOI 10.1016/0969-2126(93)90026-D; PASTORE A, 1992, J MOL BIOL, V224, P427, DOI 10.1016/0022-2836(92)91005-A; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; PRASAD R, IN PRESS J BIOL CHEM; RAABE T, 1991, NATURE, V353, P229, DOI 10.1038/353229a0; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; STRAUSS P, 1993, FASEB J, V7, pA1291; SWINDELLS MB, 1993, NATURE, V362, P299, DOI 10.1038/362299a0; TANABE K, 1979, BIOCHEMISTRY-US, V18, P3401, DOI 10.1021/bi00582a029; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VRIEND G, 1991, PROTEINS, V11, P52, DOI 10.1002/prot.340110107; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WANG TSF, 1982, BIOCHEMISTRY-US, V21, P1597, DOI 10.1021/bi00536a021; WILSON KP, 1992, P NATL ACAD SCI USA, V89, P9257, DOI 10.1073/pnas.89.19.9257; WILSON KS, 1986, P NATL ACAD SCI USA, V83, P7251, DOI 10.1073/pnas.83.19.7251; Wilson SH, 1990, EUKARYOTIC NUCLEUS, V1, P199; YAMASHITA MM, 1989, J BIOL CHEM, V264, P17681	52	415	428	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 24	1994	264	5167					1930	1935		10.1126/science.7516581	http://dx.doi.org/10.1126/science.7516581			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT847	7516581				2022-12-24	WOS:A1994NT84700045
J	WEYAND I; GODDE, M; FRINGS, S; WEINER, J; MULLER, F; ALTENHOFEN, W; HATT, H; KAUPP, UB				WEYAND, I; GODDE, M; FRINGS, S; WEINER, J; MULLER, F; ALTENHOFEN, W; HATT, H; KAUPP, UB			CLONING AND FUNCTIONAL EXPRESSION OF A CYCLIC-NUCLEOTIDE-GATED CHANNEL FROM MAMMALIAN SPERM	NATURE			English	Article							OLFACTORY EPITHELIUM; ROD PHOTORECEPTORS; IONIC SELECTIVITY; EXCISED PATCHES; MEMBRANE; RECEPTOR; PORES; CELL; DNA	CYCLIC nucleotide-gated (CNG) channels serve as downstream targets of signalling pathways in vertebrate photoreceptor cells and olfactory sensory neurons (see ref. 1 for review). Ca2+ ions that enter through CNG channels(2-5) intimately control these signalling pathways by regulating synthesis(6) or hydrolysis(7) of cyclic nucleotides, and by decreasing ligand sensitivity of CNG channels(8). Several lines of evidence suggest that cyclic nucleotides and Ca2+ play important roles in chemotaxis of invertebrate sperm and fertilization (see ref. 9 for review), whereas their mechanisms of action in vertebrate sperm are largely unknown. Here we report the cloning and functional expression of a novel CNG channel from bovine testis. The channel polypeptide was functionally localized in sperm, but is also specifically expressed in cone photoreceptor cells. These channels might be involved in chemotaxis of sperm by controlling Ca2+ entry through a cyclic-nucleotide signalling pathway.	RUHR UNIV BOCHUM, INST PHYSIOL, D-44780 BOCHUM, GERMANY	Ruhr University Bochum	WEYAND I (corresponding author), FORSCHUNGSZENTRUM JULICH, INST BIOL INFORMAT VERARBEITUNG, POSTFACH 1913, D-52425 JULICH, GERMANY.		Mueller, Frank/I-7196-2013	Mueller, Frank/0000-0001-7264-1227				ALTENHOFEN W, 1991, P NATL ACAD SCI USA, V88, P9868, DOI 10.1073/pnas.88.21.9868; BONIGK W, 1993, NEURON, V10, P865, DOI 10.1016/0896-6273(93)90202-3; CERVETTO L, 1988, J PHYSIOL-LONDON, V406, P181, DOI 10.1113/jphysiol.1988.sp017375; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN TY, 1993, NATURE, V362, P764, DOI 10.1038/362764a0; COOK NJ, 1989, J BIOL CHEM, V264, P6996; DAWSON TM, 1993, SCIENCE, V259, P825, DOI 10.1126/science.8381559; EISMANN E, 1994, P NATL ACAD SCI USA, V91, P1109, DOI 10.1073/pnas.91.3.1109; FRANKE C, 1987, NEUROSCI LETT, V77, P199, DOI 10.1016/0304-3940(87)90586-6; GARBERS DL, 1989, ANNU REV BIOCHEM, V58, P719, DOI 10.1146/annurev.bi.58.070189.003443; HAYNES LW, 1986, NATURE, V321, P66, DOI 10.1038/321066a0; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; HINSCH KD, 1992, BIOL REPROD, V47, P337, DOI 10.1095/biolreprod47.3.337; HODGKIN AL, 1985, J PHYSIOL-LONDON, V358, P447, DOI 10.1113/jphysiol.1985.sp015561; HSU YT, 1993, NATURE, V361, P76, DOI 10.1038/361076a0; JAN LY, 1990, NATURE, V345, P672, DOI 10.1038/345672a0; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; KAUPP UB, 1991, TRENDS NEUROSCI, V14, P150; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KURAHASHI T, 1991, NEUROREPORT, V2, P5, DOI 10.1097/00001756-199101000-00001; KURAHASHI T, 1993, NATURE, V363, P71, DOI 10.1038/363071a0; LOWE G, 1993, NATURE, V366, P283, DOI 10.1038/366283a0; LUDWIG J, 1990, FEBS LETT, V270, P24, DOI 10.1016/0014-5793(90)81226-E; METHFESSEL C, 1986, PFLUG ARCH EUR J PHY, V407, P577, DOI 10.1007/BF00582635; MOLDAY RS, 1991, J BIOL CHEM, V266, P21917; VANDERHAEGHEN P, 1993, J CELL BIOL, V123, P1441, DOI 10.1083/jcb.123.6.1441; WARD CR, 1993, DEV BIOL, V158, P9, DOI 10.1006/dbio.1993.1165; ZIMMERMAN AL, 1986, NATURE, V321, P70, DOI 10.1038/321070a0	30	232	243	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 28	1994	368	6474					859	863		10.1038/368859a0	http://dx.doi.org/10.1038/368859a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH717	7512693				2022-12-24	WOS:A1994NH71700073
J	GHIARA, JB; STURA, EA; STANFIELD, RL; PROFY, AT; WILSON, IA				GHIARA, JB; STURA, EA; STANFIELD, RL; PROFY, AT; WILSON, IA			CRYSTAL-STRUCTURE OF THE PRINCIPAL NEUTRALIZATION SITE OF HIV-1	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MOUTH-DISEASE VIRUS; MONOCLONAL-ANTIBODY; V3 DOMAIN; DETERMINANT; GP120; INFECTIVITY; SEQUENCE; PROTEIN; RESOLUTION	The crystal structure of a complex between a 24-amino acid peptide from the third variable (V3) loop of human immunodeficiency virus-type 1 (HIV-1) gp120 and the Fab fragment of a broadly neutralizing antibody (59.1) was determined to 3 angstrom resolution. The tip of the V3 loop containing the Gly-Pro-Gly-Arg-Ala-Phe sequence adopts a double-turn conformation, which may be the basis ot its conservation in many HIV-1 isolates. A complete map of the HIV-1 principal neutralizing determinant was constructed by stitching together structures of V3 loop peptides bound to 59.1 and to an isolate-specific (MN) neutralizing antibody (50.1). Structural conservation of the overlapping epitopes suggests that this biologically relevant conformation could be of use in the design of synthetic vaccines and drugs to inhibit HIV-1 entry and virus-related cellular fusion.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; REPLIGEN CORP, CAMBRIDGE, MA 02139 USA	Scripps Research Institute			Stanfield, Robyn/AAH-3190-2019; Stura, Enrico A./A-2793-2010	Stura, Enrico A./0000-0001-6718-2118; stanfield, robyn/0000-0001-9521-9184	NIGMS NIH HHS [GM-46192] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHARYA R, 1989, NATURE, V337, P709, DOI 10.1038/337709a0; BAXT B, 1980, VIROLOGY, V104, P42, DOI 10.1016/0042-6822(80)90364-5; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; CALLEBAUT C, 1993, SCIENCE, V262, P2045, DOI 10.1126/science.7903479; CHANDRASEKHAR K, 1991, BIOCHEMISTRY-US, V30, P9187, DOI 10.1021/bi00102a009; COHEN J, 1993, SCIENCE, V262, P1971, DOI 10.1126/science.7903478; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; EMINI EA, 1992, NATURE, V355, P728, DOI 10.1038/355728a0; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FOX G, 1989, J GEN VIROL, V70, P625, DOI 10.1099/0022-1317-70-3-625; FREED EO, 1991, J VIROL, V65, P190, DOI 10.1128/JVI.65.1.190-194.1991; GELIN BR, 1979, BIOCHEMISTRY-US, V18, P1256, DOI 10.1021/bi00574a022; GORNY MK, 1992, J VIROL, V66, P7538, DOI 10.1128/JVI.66.12.7538-7542.1992; GRIMAILA RJ, 1992, J VIROL, V66, P1875, DOI 10.1128/JVI.66.4.1875-1883.1992; HATTORI T, 1989, FEBS LETT, V248, P48, DOI 10.1016/0014-5793(89)80429-6; HELSETH E, 1990, J VIROL, V64, P2416, DOI 10.1128/JVI.64.5.2416-2420.1990; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; ISOGAI Y, 1980, BIOPOLYMERS, V19, P1183, DOI 10.1002/bip.1980.360190607; IVANOFF LA, 1992, VIROLOGY, V187, P423, DOI 10.1016/0042-6822(92)90444-T; JAVAHERIAN K, 1990, SCIENCE, V250, P1590, DOI 10.1126/science.1703322; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1982, COMPUTATIONAL CRYSTA, P303; Kabat EA, 1991, SEQUENCES PROTEINS I; LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; Moore J P, 1991, AIDS, V5 Suppl 2, pS21, DOI 10.1097/00002030-199101001-00004; PAGE KA, 1992, J VIROL, V66, P524, DOI 10.1128/JVI.66.1.524-533.1992; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RINI JM, 1993, P NATL ACAD SCI USA, V90, P6325, DOI 10.1073/pnas.90.13.6325; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SHERIFF S, 1987, J MOL BIOL, V197, P273, DOI 10.1016/0022-2836(87)90124-0; SHERIFF S, 1993, IMMUNOMETHODS, V3, P191; SKINNER MA, 1988, J VIROL, V62, P4195, DOI 10.1128/JVI.62.11.4195-4200.1988; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; STANFIELD RL, UNPUB; Stanfield RL., 1993, IMMUNOMETHODS, V3, P211, DOI 10.1006/immu.1993.1055; VERONESE FD, 1993, J BIOL CHEM, V268, P25894; Weiss R. A., 1992, Seminars in Virology, V3, P79; WHITESCHARF ME, 1993, VIROLOGY, V192, P197, DOI 10.1006/viro.1993.1022; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479; WILSON IA, 1991, METHOD ENZYMOL, V203, P153; WILSON IA, 1993, CURR OPIN STRUC BIOL, V3, P113, DOI 10.1016/0959-440X(93)90210-C	43	244	254	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 1	1994	264	5155					82	85		10.1126/science.7511253	http://dx.doi.org/10.1126/science.7511253			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ND536	7511253				2022-12-24	WOS:A1994ND53600034
J	KAMIJO, R; HARADA, H; MATSUYAMA, T; BOSLAND, M; GERECITANO, J; SHAPIRO, D; LE, J; KOH, SI; KIMURA, T; GREEN, SJ; MAK, TW; TANIGUCHI, T; VILCEK, J				KAMIJO, R; HARADA, H; MATSUYAMA, T; BOSLAND, M; GERECITANO, J; SHAPIRO, D; LE, J; KOH, SI; KIMURA, T; GREEN, SJ; MAK, TW; TANIGUCHI, T; VILCEK, J			REQUIREMENT FOR TRANSCRIPTION FACTOR IRF-1 IN NO SYNTHASE INDUCTION IN MACROPHAGES	SCIENCE			English	Article							IFN-INDUCIBLE GENES; DNA-BINDING PROTEIN; NITRIC-OXIDE; BCG INFECTION; MYCOBACTERIUM-TUBERCULOSIS; MURINE MACROPHAGES; INTERFERON-ALPHA; BETA; ACTIVATION; CELLS	Production of nitric oxide (NO) by macrophages is important for the killing of intracellular infectious agents. Interferon (IFN)-gamma and lipopolysaccharide stimulate NO production by transcriptionally up-regulating the inducible NO synthase (iNOS). Macrophages from mice with a targeted disruption of the IFN regulatory factor-1 (IRF-1) gene (IRF-1(-/-) mice) produced little or no NO and synthesized barely detectable iNOS messenger RNA in response to stimulation. Two adjacent IRF-1 response elements were identified in the iNOS promoter. Infection with Mycobacterium bovis (BCG) was more severe in IRF-1(-/-) mice than in wild-type mice. Thus, IRF-1 is essential for iNOS activation in murine macrophages.	NYU MED CTR,DEPT MICROBIOL,NEW YORK,NY 10016; NYU MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016; OSAKA UNIV,INST MOLEC & CELLULAR BIOL,OSAKA 565,JAPAN; UNIV TORONTO,PRINCESS MARGARET HOSP,ONTARIO CANC INST,DEPT MED BIOPHYS,TORONTO M4X 1K9,ON,CANADA; UNIV TORONTO,PRINCESS MARGARET HOSP,ONTARIO CANC INST,DEPT IMMUNOL,TORONTO M4X 1K9,ON,CANADA; NYU MED CTR,INST ENVIRONM MED,TUXEDO PK,NY 10987; NYU MED CTR,KAPLAN CANC CTR,TUXEDO PK,NY; ENTREMED INC,ROCKVILLE,MD 20850	New York University; New York University; Osaka University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; New York University; New York University			Harada, Hisashi/H-2815-2019	Harada, Hisashi/0000-0001-5993-1289; Kimura, Tohru/0000-0001-9227-0996; le, junming/0000-0003-4726-521X; Green, Shawn J./0000-0003-4361-5454	NCI NIH HHS [P30CA13343, R35CA49731] Funding Source: Medline; PHS HHS [A128993] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA049731, P30CA013343] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; BECKERMAN KP, 1993, J IMMUNOL, V150, P888; BEUTLER B, 1986, J EXP MED, V164, P1791, DOI 10.1084/jem.164.5.1791; BLANDEN RV, 1969, J EXP MED, V129, P1079, DOI 10.1084/jem.129.5.1079; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHAN J, 1992, J EXP MED, V175, P1111, DOI 10.1084/jem.175.4.1111; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLIART MA, 1986, J EXP MED, V164, P2113; CROEN KD, 1993, J CLIN INVEST, V91, P2446, DOI 10.1172/JCI116479; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; DENG WL, 1993, J IMMUNOL, V151, P322; DING AH, 1988, J IMMUNOL, V141, P2407; DUNGWORTH DL, 1985, PATHOLOGY DOMESTIC A, V2, P413; FLYNN JL, 1992, P NATL ACAD SCI USA, V89, P12013, DOI 10.1073/pnas.89.24.12013; FUJITA T, 1987, CELL, V49, P357, DOI 10.1016/0092-8674(87)90288-1; FUJITA T, 1989, P NATL ACAD SCI USA, V86, P9936, DOI 10.1073/pnas.86.24.9936; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; GREEN SJ, 1993, INFECT IMMUN, V61, P689, DOI 10.1128/IAI.61.2.689-698.1993; GREEN SJ, 1993, CURR OPIN INFECT DIS, V6, P384; GREEN SJ, 1990, J IMMUNOL, V144, P278; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; KAMIJO R, 1993, J EXP MED, V178, P1435, DOI 10.1084/jem.178.4.1435; KAMIJO R, UNPUB; KAMLJO R, 1993, P NATL ACAD SCI USA, V90, P6626; KINDLER V, 1989, CELL, V56, P731, DOI 10.1016/0092-8674(89)90676-4; KRUPIAH G, 1993, SCIENCE, V261, P1445; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LIEW FY, 1991, IMMUNOPARASITOL TOD, pA17, DOI 10.1016/S0167-5699(05)80006-4; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; PELLETIER M, 1982, J IMMUNOL, V129, P2179; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; STUEHR DJ, 1987, J IMMUNOL, V139, P518; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; VODOVOTZ Y, 1993, J EXP MED, V178, P605, DOI 10.1084/jem.178.2.605; WATANABE N, 1991, NUCLEIC ACIDS RES, V19, P4421, DOI 10.1093/nar/19.16.4421; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779	45	775	795	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 18	1994	263	5153					1612	1615		10.1126/science.7510419	http://dx.doi.org/10.1126/science.7510419			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB673	7510419				2022-12-24	WOS:A1994NB67300032
J	PRAGNELL, M; DEWAARD, M; MORI, Y; TANABE, T; SNUTCH, TP; CAMPBELL, KP				PRAGNELL, M; DEWAARD, M; MORI, Y; TANABE, T; SNUTCH, TP; CAMPBELL, KP			CALCIUM-CHANNEL BETA-SUBUNIT BINDS TO A CONSERVED MOTIF IN THE I-II CYTOPLASMIC LINKER OF THE ALPHA(1)-SUBUNIT	NATURE			English	Article							FUNCTIONAL EXPRESSION; SKELETAL-MUSCLE; MOLECULAR-CLONING; ALPHA-1 SUBUNIT; ALPHA-1-SUBUNIT; ALPHA-2-SUBUNIT	THE beta-subunit is an integral component of purified voltage-sensitive Ca2+ channels(1-3). Modulation of Ca2+ channel activity by the beta-subunit, which includes significant increases in transmembrane current and/or changes in kinetics, is observed on coexpression of six alpha(1)-subunit genes with four beta-subunit genes in all alpha(1)-beta combinations tested(4-12). Recent reports suggest that this regulation is not due to targeting of the alpha(1)-subunit to the plasma membrane but is probably a result of a conformational change induced by the beta-subunit(11,13). Here we report that the beta-subunit binds to the cytoplasmic linker between repeats I and II of the dihydropyridine-sensitive alpha(1)-subunits from skeletal (alpha(1S)) and cardiac muscles (alpha(1C-a)), and also with the more distantly related neuronal alpha(1A) and omega-conotoxin GVIA-sensitive alpha 1B-subunits. Sequence analysis of the beta-subunit binding site identifies a conserved motif (QQ-E--L-GY--WI---E) positioned 24 amino acids from the IS6 transmembrane domain in each alpha(1)-subunit. Mutations within this motif reduce the stimulation of peak currents by the beta-subunit and alter inactivation kinetics and voltage-dependence of activation. Conservation of the beta-subunit binding motif in these functonally distinct calcium channels suggests a critical role for the I-II cytoplasmic linker of the alpha(1)-subunit in channel modulation by the beta-subunit.	UNIV IOWA,COLL MED,PROGRAM NEUROSCI,IOWA CITY,IA 52242; KYOTO UNIV,DEPT MED CHEM,KYOTO 606,JAPAN; YALE UNIV,HOWARD HUGHES MED INST,DEPT CELLULAR & MOLEC PHYSIOL,NEW HAVEN,CT 06536; UNIV BRITISH COLUMBIA,BIOTECHNOL LAB,VANCOUVER V6T 1Z3,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT ZOOL,VANCOUVER V6T 1Z3,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT NEUROSCI,VANCOUVER V6T 1Z3,BC,CANADA	University of Iowa; Kyoto University; Howard Hughes Medical Institute; Yale University; University of British Columbia; University of British Columbia; University of British Columbia	PRAGNELL, M (corresponding author), UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT PHYSIOL & BIOPHYS,400 EMRB,IOWA CITY,IA 52242, USA.		Tuluc, Petronel/C-2527-2011; Snutch, Terrance P/L-3464-2019; De Waard, Michel/G-7406-2014	Snutch, Terrance P/0000-0001-5182-1296; De Waard, Michel/0000-0002-2782-9615; Campbell, Kevin/0000-0003-2066-5889				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BIEL M, 1990, FEBS LETT, V269, P409, DOI 10.1016/0014-5793(90)81205-3; CAMPBELL KP, 1988, TRENDS NEUROSCI, V11, P425, DOI 10.1016/0166-2236(88)90193-2; CASTELLANO A, 1993, J BIOL CHEM, V268, P12359; CASTELLANO A, 1993, J BIOL CHEM, V268, P3450; CATTERALL WA, 1988, J BIOL CHEM, V263, P3535; DUBEL SJ, 1992, P NATL ACAD SCI USA, V89, P5058, DOI 10.1073/pnas.89.11.5058; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; GRABNER M, 1991, P NATL ACAD SCI USA, V88, P727, DOI 10.1073/pnas.88.3.727; HORNE WA, 1993, P NATL ACAD SCI USA, V90, P3787, DOI 10.1073/pnas.90.9.3787; HUI A, 1991, NEURON, V7, P35, DOI 10.1016/0896-6273(91)90072-8; LACERDA AE, 1991, NATURE, V352, P527, DOI 10.1038/352527a0; LEUNG AT, 1987, J BIOL CHEM, V262, P7943; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NEELY A, 1993, SCIENCE, V262, P575, DOI 10.1126/science.8211185; NISHIMURA S, 1993, FEBS LETT, V324, P283, DOI 10.1016/0014-5793(93)80135-H; PEREZREYES E, 1992, J BIOL CHEM, V267, P1792; PRAGNELL M, 1991, FEBS LETT, V291, P253, DOI 10.1016/0014-5793(91)81296-K; SOONG TW, 1993, SCIENCE, V260, P1133, DOI 10.1126/science.8388125; STEA A, 1993, NEUROPHARMACOLOGY, V32, P1103, DOI 10.1016/0028-3908(93)90005-N; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q; WITCHER DR, 1993, SCIENCE, V261, P486, DOI 10.1126/science.8392754	23	532	551	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 3	1994	368	6466					67	70		10.1038/368067a0	http://dx.doi.org/10.1038/368067a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MY569	7509046				2022-12-24	WOS:A1994MY56900055
J	YOUNG, ACM; ZHANG, WG; SACCHETTINI, JC; NATHENSON, SG				YOUNG, ACM; ZHANG, WG; SACCHETTINI, JC; NATHENSON, SG			THE 3-DIMENSIONAL STRUCTURE OF H-2D(B) AT 2.4 ANGSTROM RESOLUTION - IMPLICATIONS FOR ANTIGEN-DETERMINANT SELECTION	CELL			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-I MOLECULES; TOXIC LYMPHOCYTES-T; INFLUENZA NUCLEOPROTEIN; SELF-PEPTIDES; TRANSPLANTATION ANTIGENS; SYNTHETIC PEPTIDES; BINDING MOTIF; SIDE-CHAINS; MHC	Solution at 2.4 angstrom resolution of the structure of H-2D(b) with the influenza virus peptide NP366-374 (ASNENMETM) and comparison with the H-2K(b)-VSV (RGYVYQGL) structure allow description of the molecular details of MHC class I peptide binding interactions for mice of the H-2b haplotype, revealing a strategy that maximizes the repertoire of peptides that can be presented. The H-2D(b) cleft has a mouse-specific hydrophobic ridge that causes a compensatory arch in the backbone of the peptide, exposing the arch residues to TCR contact and requiring the peptide to be at least 9 residues. This ridge occurs in about 40% of the known murine D and L allelic molecules, classifying them as a structural subgroup.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT CELL BIOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI007289, R37AI007289, R01AI007289] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045859] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-10792, AI-07289] Funding Source: Medline; NIGMS NIH HHS [GM45859] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASTIN J, 1987, J EXP MED, V165, P1508, DOI 10.1084/jem.165.6.1508; BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.biochem.59.1.253; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BOYD LF, 1992, IMMUNOLOGY, V89, P2242; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CONNOLLY JM, 1990, P NATL ACAD SCI USA, V87, P2137, DOI 10.1073/pnas.87.6.2137; CORR M, 1992, J EXP MED, V176, P1681, DOI 10.1084/jem.176.6.1681; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; FALK K, 1991, J EXP MED, V174, P425, DOI 10.1084/jem.174.2.425; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GUO HC, 1992, NATURE, V360, P364, DOI 10.1038/360364a0; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MARYANSKI JL, 1989, COLD SH Q B, V54, P545; MARYANSKI JL, 1990, CELL, V60, P63, DOI 10.1016/0092-8674(90)90716-R; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; NATHENSON SG, 1981, ANNU REV BIOCHEM, V50, P1025, DOI 10.1146/annurev.bi.50.070181.005113; OTTEN GR, 1992, J IMMUNOL, V148, P3723; POTTEN JK, 1992, I IMMUNOLOGY, V148, P953; PULLEN JK, 1992, J IMMUNOL, V148, P953; ROMERO P, 1991, J EXP MED, V174, P603, DOI 10.1084/jem.174.3.603; SALTER RD, 1989, NATURE, V338, P345, DOI 10.1038/338345a0; SAPER MA, 1991, J MOL BIOL, V219, P227; SHIBATA K, 1992, P NATL ACAD SCI USA, V89, P3135, DOI 10.1073/pnas.89.7.3135; SILVER ML, 1992, NATURE, V360, P367, DOI 10.1038/360367a0; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; TROWSDALE J, 1992, EUR J IMMUNOGENET, V19, P45; VANBLEEK GM, 1991, P NATL ACAD SCI USA, V88, P11032, DOI 10.1073/pnas.88.24.11032; VANBLEEK GM, 1990, NATURE, V348, P213; ZHANG WG, 1992, P NATL ACAD SCI USA, V89, P8403, DOI 10.1073/pnas.89.17.8403; Zinkernagel R M, 1979, Adv Immunol, V27, P51, DOI 10.1016/S0065-2776(08)60262-X	39	244	249	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 14	1994	76	1					39	50		10.1016/0092-8674(94)90171-6	http://dx.doi.org/10.1016/0092-8674(94)90171-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MR495	7506996				2022-12-24	WOS:A1994MR49500005
J	MANNUCCI, PM; GDOVIN, S; GRINGERI, A; COLOMBO, M; MELE, A; SCHINAIA, N; CIAVARELLA, N; EMERSON, SU; PURCELL, RH				MANNUCCI, PM; GDOVIN, S; GRINGERI, A; COLOMBO, M; MELE, A; SCHINAIA, N; CIAVARELLA, N; EMERSON, SU; PURCELL, RH			TRANSMISSION OF HEPATITIS-A TO PATIENTS WITH HEMOPHILIA BY FACTOR-VIII CONCENTRATES TREATED WITH ORGANIC-SOLVENT AND DETERGENT TO INACTIVATE VIRUSES	ANNALS OF INTERNAL MEDICINE			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; EPIDEMIOLOGY; STRAINS; RNA; PCR	Objective: To determine whether an outbreak of hepatitis A virus (HAV) infection that occurred in 52 patients with hemophilia in Italy was acquired through infusion of contaminated factor VIII or through environmental enteric transmission. Design: A case-control study and a molecular analysis of HAV sequences from implicated lots of factor VIII and from infected patients. Patients: The first 29 patients with hemophilia and jaundice in whom hepatitis A developed were compared with one to three matched controls with hemophilia but no jaundice. Measurements: Type of concentrate and batches infused, number of doses, contacts with persons who had jaundice or hepatitis A, travel abroad to countries reported to have a high attack rate for hepatitis A, and consumption of raw shellfish. Hepatitis A viral sequences sought by polymerase chain reaction in lots of factor VIII and in serial serum samples from two patients with hemophilia in whom hepatitis A developed. Amplification by polymerase chain reaction of cDNA transcribed with reverse transcriptase from matched sets of factor VIII and recipient serum samples. Determination of nucleotide sequence of amplified hepatitis A virus genome. Main Results: Case patients were neither more nor less likely than controls to have traveled to high-risk countries, consumed raw shellfish, or had contact with persons with jaundice. Case patients were more likely than controls to have received a factor VIII concentrate treated with a solvent-detergent mixture to inactivate viruses (odds ratio, infinity; 95% CI, 4.5 to infinity) and to have had larger infusions of the concentrate during the presumed HAV incubation period (odds ratio, 8.54; CI, 2.78 to 27.5). Hepatitis A viral sequences were found in 5 of 12 tested lots of factor VIII. Genomic sequences of HAV obtained for two matched sets of factor VIII and recipient serum samples were identical within each set but different for the two sets. Conclusion: Hepatitis A was transmitted by a factor VIII concentrate treated by a virucidal method (solvent-detergent) that ineffectively inactivates nonenveloped viruses.							NIAID NIH HHS [N01-AI-05069] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AZZI A, 1992, AM J HEMATOL, V39, P228, DOI 10.1002/ajh.2830390315; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN JI, 1987, P NATL ACAD SCI USA, V84, P2497, DOI 10.1073/pnas.84.8.2497; COHEN JI, 1987, J VIROL, V61, P50, DOI 10.1128/JVI.61.1.50-59.1987; FROSNER GG, 1979, AM J EPIDEMIOL, V110, P63; GERRITZEN A, 1992, LANCET, V340, P1231, DOI 10.1016/0140-6736(92)92937-B; HIJIKATA M, 1993, J VIROL, V67, P1953, DOI 10.1128/JVI.67.4.1953-1958.1993; HOROWITZ B, 1985, TRANSFUSION, V25, P516, DOI 10.1046/j.1537-2995.1985.25686071422.x; JANSEN RW, 1990, P NATL ACAD SCI USA, V87, P2867, DOI 10.1073/pnas.87.8.2867; KREUZ W, 1993, LANCET, V341, P446, DOI 10.1016/0140-6736(93)93050-B; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; MANNUCCI PM, 1992, LANCET, V339, P819, DOI 10.1016/0140-6736(92)91955-8; MELE A, 1991, ITAL J GASTROENTEROL, V23, P341; NORMANN A, 1992, LANCET, V340, P1232, DOI 10.1016/0140-6736(92)92938-C; PEERLINCK K, 1993, LANCET, V341, P179, DOI 10.1016/0140-6736(93)90044-H; PURCELL RH, 1984, VIRAL HEPATITIS LIVE, P9; Sambrook J., 1989, MOL CLONING LAB MANU; SCHWINN H, 1989, ARZNEIMITTEL-FORSCH, V39-2, P1302; SHERERTZ RJ, 1984, ARCH INTERN MED, V144, P1579, DOI 10.1001/archinte.144.8.1579; TEMPERLEY IJ, 1992, LANCET, V340, P1466; THOMAS DG, 1975, COMPUT BIOMED RES, V8, P423, DOI 10.1016/0010-4809(75)90048-8; TSAREV SA, 1993, J INFECT DIS, V168, P369, DOI 10.1093/infdis/168.2.369; TSAREV SA, 1991, J GEN VIROL, V72, P1677, DOI 10.1099/0022-1317-72-7-1677; WINSHIP PR, 1989, NUCLEIC ACIDS RES, V17, P1266, DOI 10.1093/nar/17.3.1266; 1992, LANCET, V339, P1198	25	176	180	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1994	120	1					1	7		10.7326/0003-4819-120-1-199401010-00001	http://dx.doi.org/10.7326/0003-4819-120-1-199401010-00001			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MP280	7504424				2022-12-24	WOS:A1994MP28000001
J	ASCH, AS; LIU, I; BRICCETTI, FM; BARNWELL, JW; KWAKYEBERKO, F; DOKUN, A; GOLDBERGER, J; PERNAMBUCO, M				ASCH, AS; LIU, I; BRICCETTI, FM; BARNWELL, JW; KWAKYEBERKO, F; DOKUN, A; GOLDBERGER, J; PERNAMBUCO, M			ANALYSIS OF CD36 BINDING DOMAINS - LIGAND SPECIFICITY CONTROLLED BY DEPHOSPHORYLATION OF AN ECTODOMAIN	SCIENCE			English	Article							PLATELET MEMBRANE GLYCOPROTEIN; FALCIPARUM-INFECTED ERYTHROCYTES; CIRCUMSPOROZOITE PROTEIN; IIB-IIIA; IV CD36; THROMBOSPONDIN; RECEPTOR; COLLAGEN; PHOSPHORYLATION; ADHESION	The protein CD36 is a membrane receptor for thrombospondin (TSP), malaria-infected erythrocytes, and collagen. Three functional sequences were identified within a single disulfide loop of CD36: one that mediates TSP binding (amino acids 87 to 99) and two that support malarial cytoadhesion (amino acids 8 to 21 and 97 to 110). One of these peptides (p87-99) is a consensus protein kinase C (PKC) phosphorylation site. Dephosphorylation of constitutively phosphorylated CD36 in resting platelets and a megakaryocytic cell line led to the loss of collagen adhesion and platelet reactivity to collagen, with a reciprocal increase in TSP binding. PKC-mediated phosphorylation of this ectodomain resulted in a loss of TSP binding and the reciprocal acquisition of collagen binding. In site-directed mutagenesis studies, when the threonine phosphorylation site was changed to alanine, CD36 was expressed in a dephosphorylated state and bound to TSP constitutively.	NYU,SCH MED,DEPT MOLEC PARASITOL,NEW YORK,NY 10010	New York University	ASCH, AS (corresponding author), CORNELL UNIV,MED CTR,COLL MED,DIV HEMATOL ONCOL,NEW YORK,NY 10021, USA.				NHLBI NIH HHS [HL18828, HL44389, HL02541] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044389, P50HL018828] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASCH A, UNPUB; ASCH AS, 1992, BIOCHEM BIOPH RES CO, V182, P1208, DOI 10.1016/0006-291X(92)91860-S; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; BARNWELL JW, 1985, J IMMUNOL, V135, P3494; BARNWELL JW, 1989, J CLIN INVEST, V84, P765, DOI 10.1172/JCI114234; CERAMI C, 1992, CELL, V70, P1021, DOI 10.1016/0092-8674(92)90251-7; ERDODI F, 1992, ARCH BIOCHEM BIOPHYS, V298, P682, DOI 10.1016/0003-9861(92)90466-A; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; FEUERSTEIN N, 1983, J BIOL CHEM, V258, P786; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; GREENBERG SM, 1988, BLOOD, V72, P1968; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; KEHREL B, 1988, BLOOD, V71, P1074; KIEFFER N, 1988, BIOCHIM BIOPHYS ACTA, V967, P408, DOI 10.1016/0304-4165(88)90104-3; KUNICKI TJ, 1988, J BIOL CHEM, V263, P4516; Legrand C, 1991, Platelets, V2, P99, DOI 10.3109/09537109109113695; LEUNG LLK, 1992, J BIOL CHEM, V267, P18244; MARCUS AJ, 1966, J CLIN INVEST, V45, P14, DOI 10.1172/JCI105318; MCGREGOR JL, 1989, J BIOL CHEM, V264, P501; MORTON LF, 1987, BIOCHEM J, V248, P483, DOI 10.1042/bj2480483; NAIK UP, 1991, BIOCHIM BIOPHYS ACTA, V1092, P256, DOI 10.1016/0167-4889(91)90165-T; NIEUWENHUIS HK, 1986, BLOOD, V68, P692; NIEUWENHUIS HK, 1985, NATURE, V318, P470, DOI 10.1038/318470a0; OCKENHOUSE CF, 1989, SCIENCE, V243, P1469, DOI 10.1126/science.2467377; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; RICH KA, 1990, SCIENCE, V249, P1574, DOI 10.1126/science.2120774; STOMSKI FC, 1992, EXP CELL RES, V198, P85, DOI 10.1016/0014-4827(92)90152-X; TANDON NN, 1989, J BIOL CHEM, V264, P7576; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x	31	182	187	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 26	1993	262	5138					1436	1440		10.1126/science.7504322	http://dx.doi.org/10.1126/science.7504322			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MJ046	7504322				2022-12-24	WOS:A1993MJ04600038
J	BURRIGHT, EN; CLARK, HB; SERVADIO, A; MATILLA, T; FEDDERSEN, RM; YUNIS, WS; DUVICK, LA; ZOGHBI, HY; ORR, HT				BURRIGHT, EN; CLARK, HB; SERVADIO, A; MATILLA, T; FEDDERSEN, RM; YUNIS, WS; DUVICK, LA; ZOGHBI, HY; ORR, HT			SCA1 TRANSGENIC MICE - A MODEL FOR NEURODEGENERATION CAUSED BY AN EXPANDED CAG TRINUCLEOTIDE REPEAT	CELL			English	Article							BULBAR MUSCULAR-ATROPHY; ANDROGEN RECEPTOR GENE; SPINOCEREBELLAR ATAXIA; PURKINJE-CELLS; LARGE KINDREDS; EXPRESSION; DEFINITION; DELETION; PROMOTER; ANTIGEN	Spinocerebellar ataxia type 1 (SCA1) is an autosomal dominant inherited disorder characterized by degeneration of cerebellar Purkinje cells, spinocerebellar tracts, and selective brainstem neurons owing to the expansion of an unstable CAG trinucleotide repeat. To gain insight into the pathogenesis of the SCA1 mutation and the intergenerational stability of trinucleotide repeats in mice, we have generated transgenic mice expressing the human SCA1 gene with either a normal or an expanded CAG tract. Both transgenes were stable in parent to offspring transmissions. While all six transgenic lines expressing the unexpanded human SCA1 allele had normal Purkinje cells, transgenic animals from five of six lines with the expanded SCA1 allele developed ataxia and Purkinje cell degeneration. These data indicate that expanded CAG repeats expressed in Purkinje cells are sufficient to produce degeneration and ataxia and demonstrate that a mouse model can be established for neurodegeneration caused by CAG repeat expansions.	UNIV MINNESOTA, DEPT LAB MED & PATHOL, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, DEPT NEUROL, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, DEPT BIOCHEM, MINNEAPOLIS, MN 55455 USA; BAYLOR COLL MED, DEPT PEDIAT, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT MOLEC & HUMAN GENET, HOUSTON, TX 77030 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Baylor College of Medicine; Baylor College of Medicine	BURRIGHT, EN (corresponding author), UNIV MINNESOTA, INST HUMAN GENET, MINNEAPOLIS, MN 55455 USA.		MATILLA-DUEÑAS, ANTONI/C-7980-2011	MATILLA-DUEÑAS, ANTONI/0000-0002-3514-4181; Zoghbi, Huda/0000-0002-0700-3349; Orr, Harry/0000-0001-6118-741X	NINDS NIH HHS [NS27699, NS33718, NS09724-01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS033718, R01NS027699] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARBIZU T, 1983, J NEUROL SCI, V59, P371, DOI 10.1016/0022-510X(83)90022-9; BANFI S, 1994, NAT GENET, V7, P513, DOI 10.1038/ng0894-513; BANFI S, 1993, GENOMICS, V18, P627, DOI 10.1016/S0888-7543(05)80365-9; BINGHAM PM, 1995, NAT GENET, V9, P191, DOI 10.1038/ng0295-191; BURKE JR, 1994, NAT GENET, V7, P521, DOI 10.1038/ng0894-521; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHONG SS, 1995, NAT GENET, V10, P344, DOI 10.1038/ng0795-344; CHUNG MY, 1993, NAT GENET, V5, P254, DOI 10.1038/ng1193-254; FEDDERSEN RM, 1992, NEURON, V9, P955, DOI 10.1016/0896-6273(92)90247-B; FEDDERSEN RM, 1995, MOL CELL NEUROSCI, V6, P153, DOI 10.1006/mcne.1995.1014; GACY AM, 1995, CELL, V81, P533; GANDELMAN KY, 1992, AM J HUM GENET, V51, P571; HAINES JL, 1984, NEUROLOGY, V34, P1542, DOI 10.1212/WNL.34.12.1542; HANLEY T, 1991, BIOTECHNIQUES, V10, P56; Hogan B., 1986, MANIPULATING MOUSE E; JODICE C, 1994, AM J HUM GENET, V54, P959; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; KOEPPEN AH, 1984, OLIVOPONTOCEREBELLAR, P13; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; KWIATKOWSKI TJ, 1993, AM J HUM GENET, V53, P391; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; Lebowitz P, 1979, Curr Top Microbiol Immunol, V87, P43; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MATILLA T, 1993, HUM MOL GENET, V2, P2123, DOI 10.1093/hmg/2.12.2123; NAGAFUCHI S, 1994, NAT GENET, V6, P14, DOI 10.1038/ng0194-14; NASIR J, 1995, CELL, V81, P811, DOI 10.1016/0092-8674(95)90542-1; OBERDICK J, 1990, SCIENCE, V248, P223, DOI 10.1126/science.2109351; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; QUIGLEY CA, 1992, J CLIN ENDOCR METAB, V74, P927, DOI 10.1210/jc.74.4.927; RANUM LPW, 1994, AM J HUM GENET, V55, P244; RANUM LPW, 1991, AM J HUM GENET, V49, P31; SERVADIO A, 1995, NAT GENET, V10, P94, DOI 10.1038/ng0595-94; SMEYNE RJ, 1991, SCIENCE, V254, P719, DOI 10.1126/science.1948052; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; VANDAELE S, 1991, GENE DEV, V5, P1136, DOI 10.1101/gad.5.7.1136; WEXLER NS, 1987, NATURE, V326, P194, DOI 10.1038/326194a0; Zoghbi H. Y., 1995, METABOLIC MOL BASES, P4559; ZOGHBI HY, 1995, SEMIN CELL BIOL, V6, P29, DOI 10.1016/1043-4682(95)90012-8; ZOGHBI HY, 1988, ANN NEUROL, V23, P580, DOI 10.1002/ana.410230609; ZOGHBI HY, 1991, AM J HUM GENET, V49, P23	41	481	507	1	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 22	1995	82	6					937	948		10.1016/0092-8674(95)90273-2	http://dx.doi.org/10.1016/0092-8674(95)90273-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RW693	7553854	Bronze			2022-12-24	WOS:A1995RW69300010
J	WESTENDORP, MO; FRANK, R; OCHSENBAUER, C; STRICKER, K; DHEIN, J; WALCZAK, H; DEBATIN, KM; KRAMMER, PH				WESTENDORP, MO; FRANK, R; OCHSENBAUER, C; STRICKER, K; DHEIN, J; WALCZAK, H; DEBATIN, KM; KRAMMER, PH			SENSITIZATION OF T-CELLS TO CD95-MEDIATED APOPTOSIS BY HIV-1 TAT AND GP120	NATURE			English	Article							MONOCLONAL-ANTIBODY; INFECTION; AIDS; PROTEIN; CD4	THE depletion of CD4(+) T cells in AIDS is correlated with high turnover of the human immunodeficiency virus HIV-1(1,2) acid associated with apoptosis(3-5). The molecular mechanism of apoptosis in HIV infection, however, is largely unknown, T-cell apoptosis might be affected by viral proteins such as HIV-1 Tat(6-9) and gp120 (refs 10, 11). T-cell-receptor (TCR)-induced apoptosis was recently shown to involve the CD95 (APO-1/Fas) receptor(12). We show here that HIV-1 Tat strongly sensitizes TCR- and CD4(gp120)-induced apoptosis by upregulation of CD95 ligand expression. Concentrations of Tat found to be effective in cultures of HIV-1-infected cells were also observed in sera from HIV-1-infected individuals. Taken together, our results indicate that HIV-1 Tat and gp120 accelerate CD95-mediated, activation-induced T-cell apoptosis, a mechanism that may contribute to CD4(+) T-cell depletion(5,13,14) in AIDS.	GERMAN CANC RES CTR, TUMORIMMUNOL PROGRAM, D-69120 HEIDELBERG, GERMANY; UNIV HEIDELBERG, CTR BIOL MOLEC, W-6900 HEIDELBERG, GERMANY; UNIV HEIDELBERG, CHILDRENS HOSP, W-6900 HEIDELBERG, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg			Walczak, Henning/AAV-2214-2020; Debatin, Klaus-Michael/J-9704-2014	Walczak, Henning/0000-0002-6312-4591; Debatin, Klaus-Michael/0000-0002-8397-1886; Dhein, Jens/0000-0002-7200-2967				AMEISEN JC, 1995, CELL DEATH DIFFER, V2, P285; BANDA NK, 1992, J EXP MED, V176, P1099, DOI 10.1084/jem.176.4.1099; CULLEN BR, 1993, CELL, V73, P417, DOI 10.1016/0092-8674(93)90126-B; DEBATIN KM, 1994, BLOOD, V83, P3101, DOI 10.1182/blood.V83.10.3101a.3101a; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; FINKEL TH, 1995, NAT MED, V1, P129, DOI 10.1038/nm0295-129; Gougeon M L, 1995, Cell Death Differ, V2, P1; HAIGWOOD NL, 1990, VACCINES 90, P313; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; KRAFT M, 1995, PEPTIDES 1994, P349; LEVY JA, 1993, MICROBIOL REV, V57, P183, DOI 10.1128/MMBR.57.1.183-289.1993; LEVY JA, 1984, SCIENCE, V225, P840, DOI 10.1126/science.6206563; LU YY, 1994, J VIROL, V68, P390, DOI 10.1128/JVI.68.1.390-399.1994; OYAIZU N, 1993, BLOOD, V82, P3392; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; SANCHEZPESCADOR R, 1985, SCIENCE, V227, P484, DOI 10.1126/science.2578227; SCALA G, 1994, J EXP MED, V179, P961, DOI 10.1084/jem.179.3.961; SCANDELLA CJ, 1993, AIDS RES HUM RETROV, V9, P1233, DOI 10.1089/aid.1993.9.1233; SGONC R, 1994, TRENDS GENET, V10, P41, DOI 10.1016/0168-9525(94)90140-6; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VISCIDI RP, 1989, SCIENCE, V246, P1606, DOI 10.1126/science.2556795; WANG ZQ, 1994, EUR J IMMUNOL, V24, P1549, DOI 10.1002/eji.1830240714; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WESTENDORP MO, 1994, J VIROL, V68, P4177, DOI 10.1128/JVI.68.7.4177-4185.1994; WESTENDORP MO, 1995, EMBO J, V14, P546, DOI 10.1002/j.1460-2075.1995.tb07030.x; WILK T, 1992, VIROLOGY, V189, P167, DOI 10.1016/0042-6822(92)90692-I; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; ZAULI G, 1993, CANCER RES, V53, P4481	30	877	904	0	17	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 8	1995	375	6531					497	500		10.1038/375497a0	http://dx.doi.org/10.1038/375497a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC188	7539892				2022-12-24	WOS:A1995RC18800050
J	FRANCIS, CM; CARUANA, L; KEARNEY, P; LOVE, M; SUTHERLAND, GR; STARKEY, IR; SHAW, TRD; MCMURRAY, JJV				FRANCIS, CM; CARUANA, L; KEARNEY, P; LOVE, M; SUTHERLAND, GR; STARKEY, IR; SHAW, TRD; MCMURRAY, JJV			OPEN ACCESS ECHOCARDIOGRAPHY IN MANAGEMENT OF HEART-FAILURE IN THE COMMUNITY	BRITISH MEDICAL JOURNAL			English	Article							GASTROSCOPY	Objective-To assess the value of an open access echocardiography service. Design-Study of new open access service for general practitioners, who were invited to refer who patients taking diuretics for suspected heart failure, untreated patients with symptoms of possible heart failure, and asymptomatic patients with risk factors for left ventricular systolic dysfunction. Setting-Regional cardiology centre. Subjects-259 consecutive patients. Main outcome measure-Presence or absence of left ventricular systolic dysfunction and consequent changes in clinical management. Results-119 treated patients, 99 untreated patients, and nine asymptomatic patients were referred over five months. 32 were considered to be inappropriately referred. Among the treated patients, 31 had impaired left ventricular systolic function and five had valvular disease; angiotensin converting enzyme inhibitors were recommended for 34 of these patients, In addition, 53 were thought not to need diuretics. Eight untreated patients had impaired systolic function and six valvular disease. Conclusions-The service was well used by general practitioners and led to advice to change management in more than two thirds of patients.	WESTERN GEN HOSP,DEPT CARDIOL,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh			mcmurray, John/B-2467-2013	mcmurray, John/0000-0002-6317-3975				ALBIN G, 1990, AM J CARDIOL, V65, P1031, DOI 10.1016/0002-9149(90)91009-U; BRAMBLE MG, 1993, GUT, V34, P422, DOI 10.1136/gut.34.3.422; CHOY AMJ, 1994, BRIT HEART J, V72, P16; CLARKE KW, 1994, BRIT HEART J, V71, P584; DARGIE HJ, 1994, BMJ-BRIT MED J, V308, P321, DOI 10.1136/bmj.308.6924.321; DEJONGE JW, 1994, BMJ-BRIT MED J, V308, P511, DOI 10.1136/bmj.308.6927.511; GASSCH WH, 1994, JAMA-J AM MED ASSOC, V271, P1276; Hart W, 1993, BR J MED EC, V6, P91; KERRIGAN DD, 1990, BRIT MED J, V300, P374, DOI 10.1136/bmj.300.6721.374; MCCLEMENTS BM, 1994, BRIT HEART J, V71, P531; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; REMES J, 1991, EUR HEART J, V12, P315, DOI 10.1093/oxfordjournals.eurheartj.a059896; SUTTON MS, 1994, CIRCULATION, V89, P68, DOI 10.1161/01.CIR.89.1.68; THOMAS JD, 1991, CIRCULATION, V84, P977, DOI 10.1161/01.CIR.84.3.977; Vuille C., 1994, PRINCIPLES PRACTICE, P575; WHEELDON NM, 1993, Q J MED, V86, P17; ZERMANSKY A, 1993, BRIT MED J, V306, P1750, DOI 10.1136/bmj.306.6894.1750-b; 1991, NEW ENGL J MED, V325, P293; 1994, BRIT HEART J, V72, P303; 1992, NEW ENGL J MED, V327, P685	20	136	136	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 11	1995	310	6980					634	636		10.1136/bmj.310.6980.634	http://dx.doi.org/10.1136/bmj.310.6980.634			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL984	7503841	Green Published			2022-12-24	WOS:A1995QL98400019
J	KAUFMANN, M; HEIDER, KH; SINN, HP; VONMINCKWITZ, G; PONTA, H; HERRLICH, P				KAUFMANN, M; HEIDER, KH; SINN, HP; VONMINCKWITZ, G; PONTA, H; HERRLICH, P			CD44 VARIANT EXON EPITOPES IN PRIMARY BREAST-CANCER AND LENGTH OF SURVIVAL	LANCET			English	Article							METASTASIS-ASSOCIATED VARIANT; EXPRESSION; CARCINOMAS; AMPLIFICATION; ONCOGENE; HOMOLOG; RELAPSE	CD44 designates a group of closely related cell-surface proteins generated by alternative splicing. We have previously shown that splice variants carrying sequences encoded by exon v6 are preferentially expressed in metastatic animal cancer cell lines and that they confer metastatic behaviour on non-metastatic animal tumour cell lines. In this study we set out to assess the expression of CD44 epitopes specific for variant exon sequences in human breast cancer and their potential for determining prognosis. We used affinity-purified polyclonal sera and four monoclonal antibodies raised against the human homologues of CD44 variant exon sequences to investigate the presence of CD44 on 100 primary invasive breast tumours, 12 local recurrences, 18 lymph node metastases, and normal tissue controls. Whereas normal mammary ductal epithelial cells and cells derived from hyperplastic lesions do not express CD44 variant exons, expression of v3, v5, and v6 epitopes was found in most tumour samples. The Dill (exon v6) epitope was present in 84% of the primary tumours and in 100% of axillary lymph node metastases and local recurrences. The presence of these CD44 epitopes is correlated with poor overall survival. 15 patients with exon-v6-negative tumours had good survival compared with 76 patients with exon-v6-positive tumours (p=0.005; log rank test). Multivariate analysis showed that the CD44 epitope encoded by exon v6 was a good marker for prognosis independent of progesterone receptor, lymph node status, tumour size, and grade.	FORSCHUNGSZENTRUM KARLSRUHE,INST GENET,KARLSRUHE,GERMANY; UNIV HEIDELBERG,DEPT PATHOL,D-69115 HEIDELBERG,GERMANY	Helmholtz Association; Karlsruhe Institute of Technology; Ruprecht Karls University Heidelberg	KAUFMANN, M (corresponding author), UNIV HEIDELBERG,DEPT OBSTET & GYNAECOL,D-69115 HEIDELBERG,GERMANY.		Sinn, Hans-Peter/C-5661-2008	Sinn, Hans-Peter/0000-0003-2836-6699				ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; BERGER MS, 1988, CANCER RES, V48, P1238; CLARK GM, 1989, NEW ENGL J MED, V320, P627, DOI 10.1056/NEJM198903093201003; COX DR, 1972, J R STAT SOC B, V34, P187; DALL P, 1994, CANCER RES, V54, P3337; HARWERTH IM, 1992, J BIOL CHEM, V267, P15160; HEIDER KH, 1993, CANCER RES, V53, P4197; HEIDER KH, 1993, J CELL BIOL, V120, P227, DOI 10.1083/jcb.120.1.227; Hermanek P, 1987, TNM CLASSIFICATION M; JOENSUU H, 1993, AM J PATHOL, V143, P867; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOOPMAN G, 1993, J EXP MED, V177, P897, DOI 10.1084/jem.177.4.897; MATSUMURA Y, 1992, LANCET, V340, P1053, DOI 10.1016/0140-6736(92)93077-Z; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; SAINSBURY JRC, 1987, LANCET, V1, P1398; SINN HP, IN PRESS BREAST CANC; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TANABE KK, 1993, LANCET, V341, P725, DOI 10.1016/0140-6736(93)90490-8; VONMINCKWITZ G, 1994, BREAST, V2, P229; WIELENGA VJM, 1993, CANCER RES, V53, P4754	21	358	374	1	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 11	1995	345	8950					615	619		10.1016/S0140-6736(95)90521-9	http://dx.doi.org/10.1016/S0140-6736(95)90521-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM075	7534855				2022-12-24	WOS:A1995QM07500009
J	TANAKA, T; AKIRA, S; YOSHIDA, K; UMEMOTO, M; YONEDA, Y; SHIRAFUJI, N; FUJIWARA, H; SUEMATSU, S; YOSHIDA, N; KISHIMOTO, T				TANAKA, T; AKIRA, S; YOSHIDA, K; UMEMOTO, M; YONEDA, Y; SHIRAFUJI, N; FUJIWARA, H; SUEMATSU, S; YOSHIDA, N; KISHIMOTO, T			TARGETED DISRUPTION OF THE NF-IL6 GENE DISCLOSES ITS ESSENTIAL ROLE IN BACTERIA KILLING AND TUMOR-CYTOTOXICITY BY MACROPHAGES	CELL			English	Article							C/EBP FAMILY MEMBERS; NF-KAPPA-B; LISTERIA-MONOCYTOGENES; TRANSCRIPTION FACTOR; INTERFERON-GAMMA; NECROSIS-FACTOR; INFLAMMATORY CYTOKINES; MYELOMONOCYTIC CELLS; BINDING PROTEIN; NUCLEAR FACTOR	To investigate the role of NF-IL6 in vivo, we have generated NF-IL6 (-/-) mice by gene targeting. NF-IL6 (-/-) mice were highly susceptible to infection by Listeria monocytogenes. Electron microscopic observation revealed the escape of a large number of pathogens from the phagosome to the cytoplasm in activated macrophages from NF-IL6 (-/-) mice. Furthermore, the tumor cytotoxicity of macrophages from NF-IL6 (-/-) mice was severely impaired. However, cytokines involved in macrophage activation, such as TNF and IFN gamma, were induced normally in NF-IL6 (-/-) mice. Nitric oxide (NO) formation was induced to a similar extent in macrophages from both wild-type and NF-IL6 (-/-) mice. These results demonstrate the crucial role of NF-IL6 in macrophage bactericidal and tumoricidal activities as well as the existence of a NO-independent mechanism of these activities. We also demonstrate that NF-IL6 is essential for the induction of G-CSF in macrophages and fibroblasts.	OSAKA UNIV, INST MOLEC & CELLULAR BIOL, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, SCH MED, DEPT ANAT & CELL BIOL, SUITA, OSAKA 565, JAPAN; OSAKA MED CTR MATERNAL & CHILD HLTH, RES INST, OSAKA 59002, JAPAN; OSAKA UNIV, SCH MED, DEPT MED 3, SUITA, OSAKA 565, JAPAN	Osaka University; Osaka University; Osaka University			Tanaka, Takashi/O-8254-2015; Kishimoto, Tadamitsu/C-8470-2009; Akira, Shizuo/C-3134-2009					ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; ADAMS DO, 1987, IMMUNOL REV, V97, P5, DOI 10.1111/j.1600-065X.1987.tb00514.x; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; BRETZ JD, 1994, P NATL ACAD SCI USA, V91, P7306, DOI 10.1073/pnas.91.15.7306; BUCHMEIER NA, 1985, P NATL ACAD SCI USA, V82, P7404, DOI 10.1073/pnas.82.21.7404; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DING AH, 1988, J IMMUNOL, V141, P2407; HARPE JD, 1985, J IMMUNOL METHODS, V78, P323; HAVELL EA, 1987, J IMMUNOL, V139, P4225; HIBBS JB, 1987, J IMMUNOL, V138, P550; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; ISSHIKI H, 1990, MOL CELL BIOL, V10, P2757, DOI 10.1128/MCB.10.6.2757; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KAPLAN AM, 1981, METHODS STUDYING MON, P775; KATZ S, 1993, EMBO J, V12, P1321, DOI 10.1002/j.1460-2075.1993.tb05777.x; KAUFMANN SHE, 1993, ANNU REV IMMUNOL, V11, P129, DOI 10.1146/annurev.iy.11.040193.001021; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; KIDERLEN AF, 1984, EUR J IMMUNOL, V14, P964, DOI 10.1002/eji.1830141019; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; MELTZER MS, 1981, METHODS STUDYING MON, P785; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; NATSUKA S, 1992, BLOOD, V79, P460; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; NISHIZAWA M, 1990, MOL CELL BIOL, V10, P2002, DOI 10.1128/MCB.10.5.2002; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; PORTNOY DA, 1989, J EXP MED, V170, P2141, DOI 10.1084/jem.170.6.2141; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; SCOTT LM, 1992, BLOOD, V80, P1725; SERUSHAGO BA, 1992, IMMUNOLOGY, V75, P475; Shannon MF, 1992, GROWTH FACTORS, V7, DOI 10.3109/08977199209046923; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; STERNECK E, 1992, EMBO J, V11, P115, DOI 10.1002/j.1460-2075.1992.tb05034.x; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; TSUNAWAKI S, 1984, J BIOL CHEM, V259, P4305; UMEMOTO M, 1993, ACTA OTO-LARYNGOL, P66; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D; ZHANG Y, 1993, MOL CELL BIOL, V13, P3831, DOI 10.1128/MCB.13.6.3831	50	472	479	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 27	1995	80	2					353	361		10.1016/0092-8674(95)90418-2	http://dx.doi.org/10.1016/0092-8674(95)90418-2			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QD924	7530603	Bronze			2022-12-24	WOS:A1995QD92400018
J	IOST, I; DREYFUS, M				IOST, I; DREYFUS, M			MESSENGER-RNAS CAN BE STABILIZED BY DEAD-BOX PROTEINS	NATURE			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; ESCHERICHIA-COLI; MESSENGER-RNA; LACZ GENE; TRANSLATION; TRANSCRIPTION; INITIATION; EXPRESSION; HELICASE; DEGRADATION	EUBACTERIAL messenger RNAs are synthesized and translated simultaneously; moreover the speed of ribosomes usually matches that of RNA polymerase(1,2). We report here that when in Escherichia coli the host RNA polymerase is replaced by the eightfold faster bacteriophage T7 enzyme for the transcription of the lacZ gene, the beta-galactosidase yield per transcript is depressed 100-fold. But the overexpression of DEAD-box proteins(3) greatly improves this low yield by stabilizing the corresponding transcripts. More generally, it stabilizes inefficiently translated E. coli mRNAs. Ribosome-free mRNA regions, such as those lying behind the fast T7 enzyme or between successive ribosomes on inefficiently translated transcripts, are often unstable(4) and we propose that DEAD-box proteins protect them from endonucleases. These results pinpoint the importance of transcription-translation synchronization for mRNA stability, and reveal an undocumented property of DEAD-box RNA helicases. These proteins have been implicated in a variety of processes involving RNA(5) but not mRNA stability.	ECOLE NORMALE SUPER, CNRS D1302, GENET MOLEC LAB, F-75230 PARIS 05, FRANCE	UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)			Iost, Isabelle/M-7149-2014	Iost, Isabelle/0000-0001-9061-4177				BECHHOFER DH, 1987, P NATL ACAD SCI USA, V84, P498, DOI 10.1073/pnas.84.2.498; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; CHAPON C, 1982, EMBO J, V1, P369, DOI 10.1002/j.1460-2075.1982.tb01176.x; CHEVRIERMILLER M, 1990, NUCLEIC ACIDS RES, V18, P5787, DOI 10.1093/nar/18.19.5787; CORMACK RS, 1992, J MOL BIOL, V228, P1078, DOI 10.1016/0022-2836(92)90316-C; FORD MJ, 1988, NATURE, V332, P736, DOI 10.1038/332736a0; IGGO R, 1990, NUCLEIC ACIDS RES, V18, P5413, DOI 10.1093/nar/18.18.5413; IOST I, 1992, J BACTERIOL, V174, P619, DOI 10.1128/jb.174.2.619-622.1992; JACQUET M, 1971, J MOL BIOL, V60, P453, DOI 10.1016/0022-2836(71)90181-1; KALMAN M, 1991, NEW BIOL, V3, P886; LESAGE P, 1992, J MOL BIOL, V228, P366, DOI 10.1016/0022-2836(92)90827-7; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; LOPEZ PJ, 1994, NUCLEIC ACIDS RES, V22, P1186, DOI 10.1093/nar/22.7.1186; MACDONALD LE, 1993, J MOL BIOL, V232, P1030, DOI 10.1006/jmbi.1993.1458; MILLER OL, 1970, SCIENCE, V169, P392, DOI 10.1126/science.169.3943.392; NILSSON G, 1987, P NATL ACAD SCI USA, V84, P4890, DOI 10.1073/pnas.84.14.4890; NISHI K, 1988, NATURE, V336, P496, DOI 10.1038/336496a0; PAUSE A, 1993, MOL CELL BIOL, V13, P6789, DOI 10.1128/MCB.13.11.6789; Petersen C, 1993, CONTROL MESSENGER RN, P117; PLUMBRIDGE JA, 1983, J MOL BIOL, V167, P227, DOI 10.1016/S0022-2836(83)80333-7; Putzer Harald, 1995, P293; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; SPRINGER M, 1985, J MOL BIOL, V185, P93, DOI 10.1016/0022-2836(85)90185-8; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; STUEBER D, 1982, EMBO J, V1, P1399, DOI 10.1002/j.1460-2075.1982.tb01329.x; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TOONE WM, 1991, J BACTERIOL, V173, P3291, DOI 10.1128/jb.173.11.3291-3302.1991; YARCHUK O, 1992, J MOL BIOL, V226, P581, DOI 10.1016/0022-2836(92)90617-S; YARCHUK O, 1991, BIOCHIMIE, V73, P1533, DOI 10.1016/0300-9084(91)90188-7	29	107	122	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 10	1994	372	6502					193	196		10.1038/372193a0	http://dx.doi.org/10.1038/372193a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ688	7526223				2022-12-24	WOS:A1994PQ68800060
J	SEIWERT, SD; STUART, K				SEIWERT, SD; STUART, K			RNA EDITING - TRANSFER OF GENETIC INFORMATION FROM GRNA TO PRECURSOR MESSENGER-RNA IN-VITRO	SCIENCE			English	Article							AUG INITIATION CODONS; MESSENGER-RNA; TRYPANOSOMA-BRUCEI; KINETOPLASTID MITOCHONDRIA; B TRANSCRIPTS; INVITRO; MOLECULES; NUCLEOTIDES; URIDINES; SEQUENCE	RNA editing in the mitochondrion of Trypanosoma brucei extensively alters the adenosine triphosphate synthase (ATPase) subunit 6 precursor messenger RNA (pre-mRNA) by addition of 447 uridines and removal of 28 uridines. in vivo, the guide RNA gA6[14] is thought to specify the deletion of two uridines from the editing site closest to the 3' end. in this study, an in vitro system was developed that accurately removed uridines from this editing site in synthetic ATPase 6 pre-mRNA when gA6[14] and ATP were added. Mutations in both the guide RNA and the pre-mRNA editing site suggest that base-pairing interactions control the number of uridines deleted in vitro. Thus, guide RNAs are required for RNA editing and for the transfer of genetic information to pre-mRNAs.	SEATTLE BIOMED RES INST,SEATTLE,WA 98109; YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06536; UNIV WASHINGTON,DEPT PATHOBIOL,SEATTLE,WA 98195	Center for Infectious Disease Research; Yale University; University of Washington; University of Washington Seattle					NIGMS NIH HHS [GM 42188] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM JM, 1988, CELL, V55, P267, DOI 10.1016/0092-8674(88)90049-9; AUGUSTIN S, 1990, NATURE, V343, P383, DOI 10.1038/343383a0; BAKALARA N, 1989, J BIOL CHEM, V264, P18679; BENNE R, 1986, CELL, V46, P819, DOI 10.1016/0092-8674(86)90063-2; BENNE R, 1993, ALTERATION PROTEIN C; BHAT GJ, 1990, CELL, V61, P885, DOI 10.1016/0092-8674(90)90199-O; BLUM B, 1991, CELL, V65, P543, DOI 10.1016/0092-8674(91)90087-F; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BLUM B, 1992, P NATL ACAD SCI USA, V89, P11944, DOI 10.1073/pnas.89.24.11944; CECH TR, 1991, CELL, V64, P667, DOI 10.1016/0092-8674(91)90494-J; DECKER CJ, 1990, CELL, V61, P1001, DOI 10.1016/0092-8674(90)90065-M; DRISCOLL DM, 1989, CELL, V58, P519, DOI 10.1016/0092-8674(89)90432-7; FEAGIN JE, 1987, CELL, V49, P337, DOI 10.1016/0092-8674(87)90286-8; FEAGIN JE, 1988, P NATL ACAD SCI USA, V85, P539, DOI 10.1073/pnas.85.2.539; FEAGIN JE, 1988, CELL, V53, P413, DOI 10.1016/0092-8674(88)90161-4; GORINGER HU, 1994, P NATL ACAD SCI USA, V91, P1776, DOI 10.1073/pnas.91.5.1776; HAJDUK SL, 1993, FASEB J, V7, P54, DOI 10.1096/fasebj.7.1.8422975; HARDY SF, 1984, NATURE, V308, P375, DOI 10.1038/308375a0; HARRIS M, 1992, MOL CELL BIOL, V12, P2591, DOI 10.1128/MCB.12.6.2591; HARRIS ME, 1992, CELL, V68, P1091, DOI 10.1016/0092-8674(92)90080-V; HARRIS ME, 1990, J BIOL CHEM, V265, P11368; HERNANDEZ N, 1983, CELL, V35, P89, DOI 10.1016/0092-8674(83)90211-8; KOSLOWSKY DJ, 1991, CELL, V67, P537, DOI 10.1016/0092-8674(91)90528-7; KOSLOWSKY DJ, 1992, NATURE, V356, P807, DOI 10.1038/356807a0; KOSLOWSKY DJ, 1992, MOL CELL BIOL, V12, P2043, DOI 10.1128/MCB.12.5.2043; KOSLOWSKY DJ, 1990, CELL, V62, P901, DOI 10.1016/0092-8674(90)90265-G; LANDWEBER LF, 1994, P NATL ACAD SCI USA, V91, P918, DOI 10.1073/pnas.91.3.918; Maniatis T., 1982, MOL CLONING; MASLOV DA, 1992, CELL, V70, P459, DOI 10.1016/0092-8674(92)90170-H; MASLOV DA, 1994, NATURE, V368, P345, DOI 10.1038/368345a0; PERIS M, 1994, EMBO J, V13, P1664, DOI 10.1002/j.1460-2075.1994.tb06430.x; POLLARD VW, 1992, EMBO J, V11, P4429, DOI 10.1002/j.1460-2075.1992.tb05543.x; READ LK, 1992, NUCLEIC ACIDS RES, V20, P2341, DOI 10.1093/nar/20.9.2341; READ LK, 1994, MOL CELL BIOL, V14, P2629, DOI 10.1128/MCB.14.4.2629; SEIWERT S, UNPUB; SHAW JM, 1988, CELL, V53, P401, DOI 10.1016/0092-8674(88)90160-2; SHU HH, 1994, NUCLEIC ACIDS RES, V22, P1696, DOI 10.1093/nar/22.9.1696; SIMPSON L, 1994, SCIENCE, V264, P1870, DOI 10.1126/science.8009214; STUART K, 1991, ANNU REV MICROBIOL, V45, P327, DOI 10.1146/annurev.mi.45.100191.001551; WOODSON SA, 1989, CELL, V57, P335, DOI 10.1016/0092-8674(89)90971-9; ZAUG AJ, 1984, SCIENCE, V224, P574, DOI 10.1126/science.6200938	41	131	133	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 7	1994	266	5182					114	117		10.1126/science.7524149	http://dx.doi.org/10.1126/science.7524149			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK582	7524149				2022-12-24	WOS:A1994PK58200036
J	BRAM, RJ; CRABTREE, GR				BRAM, RJ; CRABTREE, GR			CALCIUM SIGNALING IN T-CELLS STIMULATED BY A CYCLOPHILIN B-BINDING PROTEIN	NATURE			English	Article							CYCLOSPORINE-A; ANTIGEN RECEPTOR; TYROSINE KINASE; LYMPHOCYTES-T; ACTIVATION; CALCINEURIN; IDENTIFICATION; TRANSDUCTION; EXPRESSION; PREDICTION	THE immunosuppressant drug cyclosporin A blocks a calcium-dependent signal from the T-cell receptor (TCR) that normally leads to T-cell activation(1-3). When bound to cyclophilin, cyclosporin A binds and inactivates the key signalling intermediate calcineurin(4-6). To identify potential cellular homologues of cyclosporin A that might regulate calcium signalling, we have cloned human genes encoding cyclophilin B-binding-proteins using the yeast two-hybrid system(7,8). One gene product, when overexpressed in Jurkat T cells, specifically induced transcription from the interleukin-2 enhancer, by activating the T-cell-specific transcription factors NF-AT and NF-IL2A. This protein, termed calcium-signal modulating cyclophilin ligand (CAML), acts downstream of the TCR and upstream of calcineurin by causing an influx of calcium. CAML appears to be a new participant in the calcium-signal transduction pathway, implicating cyclophilin B in calcium signalling, even in the absence of cyclosporin.	ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, DEPT PEDIAT, MEMPHIS, TN 38105 USA; STANFORD UNIV, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA; STANFORD UNIV, DEPT PATHOL, STANFORD, CA 94305 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; Howard Hughes Medical Institute; Stanford University; Stanford University	BRAM, RJ (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT EXPTL ONCOL, 332 N LAUDERDALE ST, MEMPHIS, TN 38105 USA.							ARBER S, 1992, J CELL BIOL, V116, P113, DOI 10.1083/jcb.116.1.113; BOREL JF, 1976, AGENTS ACTIONS, V6, P468, DOI 10.1007/BF01973261; BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CLIPSTONE NA, 1993, ANN NY ACAD SCI, V696, P20; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GIBRAT JF, 1987, J MOL BIOL, V198, P425, DOI 10.1016/0022-2836(87)90292-0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HUBBARD MJ, 1989, BIOCHEMISTRY-US, V28, P1868, DOI 10.1021/bi00430a066; June C H, 1990, Methods Cell Biol, V33, P37; KARTTUNEN J, 1991, P NATL ACAD SCI USA, V88, P3972, DOI 10.1073/pnas.88.9.3972; KAY JE, 1983, IMMUNOLOGY, V50, P441; KOZAK M, 1984, NATURE, V308, P241, DOI 10.1038/308241a0; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; RABINOVITCH PS, 1986, J IMMUNOL, V137, P952; SAMUELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; ULLMAN KS, 1991, SCIENCE, V254, P558, DOI 10.1126/science.1683003; VERWEIJ CL, 1990, J BIOL CHEM, V265, P15788	30	146	160	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 22	1994	371	6495					355	358		10.1038/371355a0	http://dx.doi.org/10.1038/371355a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH254	7522304				2022-12-24	WOS:A1994PH25400059
J	PONZETTO, C; BARDELLI, A; ZHEN, Z; MAINA, F; DALLAZONCA, P; GIORDANO, S; GRAZIANI, A; PANAYOTOU, G; COMOGLIO, PM				PONZETTO, C; BARDELLI, A; ZHEN, Z; MAINA, F; DALLAZONCA, P; GIORDANO, S; GRAZIANI, A; PANAYOTOU, G; COMOGLIO, PM			A MULTIFUNCTIONAL DOCKING SITE MEDIATES SIGNALING AND TRANSFORMATION BY THE HEPATOCYTE GROWTH-FACTOR SCATTER FACTOR-RECEPTOR FAMILY	CELL			English	Article							PHOSPHOLIPASE-C-GAMMA; FACTOR SCATTER FACTOR; MET HGF RECEPTOR; TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; PDGF RECEPTOR; SH2 DOMAINS; CELL-LINE; AUTOPHOSPHORYLATION; IDENTIFICATION	Signaling by tyrosine kinase receptors is mediated by selective interactions between individual Src homology 2 (SH2) domains of cytoplasmic effecters and specific phosphotyrosine residues in the activated receptor. Here, we report the existence in the hepatocyte growth factor/scatter factor (HGF/SF) receptor of a multifunctional docking site made of the tandemly arranged degenerate sequence YVH/NV. Phosphorylation of this site mediates intermediate- to high-affinity interactions with multiple SH2-containing signal transducers, including phosphatidylinositol 3-kinase, phospholipase C gamma, pp60(c-src), and the GRB-2-Sos complex. Mutation of the two tyrosines results in loss of biological function, as shown by abrogation of the transforming activity in the oncogenic counterpart of the receptor. The same bidentate motif is conserved in the evolutionarily related receptors Sea and Ron, suggesting that in all members of the HGF/SF receptor family, signal transduction is channeled through a multifunctional binding site.	LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND	Ludwig Institute for Cancer Research	PONZETTO, C (corresponding author), UNIV TURIN, SCH MED, DEPT BIOCHEM SCI & ONCOL, I-10126 TURIN, ITALY.		graziani, andrea/B-2554-2009; Graziani, Andrea/AAB-6301-2022; Maina, Flavio/J-9962-2019; Giordano, Silvia/J-9858-2018; BARDELLI, Alberto/J-9721-2018	graziani, andrea/0000-0002-6302-2317; Graziani, Andrea/0000-0002-6302-2317; Maina, Flavio/0000-0001-6100-4695; Giordano, Silvia/0000-0003-1854-1086; BARDELLI, Alberto/0000-0003-1647-5070; Comoglio, Paolo/0000-0002-7056-5328	Fondazione Telethon Funding Source: Custom	Fondazione Telethon(Fondazione Telethon)		BARDELLI A, 1992, ONCOGENE, V7, P1973; BHARGAVA M, 1992, CELL GROWTH DIFFER, V3, P11; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COMOGLIO PM, 1993, HEPATOCYTE GROWTH FA, P131; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; DIRENZO MF, 1991, ONCOGENE, V6, P1997; DIRENZO MF, 1992, ONCOGENE, V7, P2549; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; HUFF JL, 1993, P NATL ACAD SCI USA, V90, P6140, DOI 10.1073/pnas.90.13.6140; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LONGATI P, 1994, ONCOGENE, V9, P49; Matsumoto K, 1993, EXS, V65, P225; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; PANAYOTOU G, 1993, MOL CELL BIOL, V13, P3567, DOI 10.1128/MCB.13.6.3567; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PONZETTO C, 1991, ONCOGENE, V6, P553; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; RONSIN C, 1993, ONCOGENE, V8, P1195; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; SONNENBERG E, 1993, HEPATOCYTE GROWTH FA, P381; STERN CD, 1990, DEVELOPMENT, V110, P1271; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VILLAMORUZZI E, 1993, J BIOL CHEM, V268, P18176; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	55	899	942	0	35	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 22	1994	77	2					261	271		10.1016/0092-8674(94)90318-2	http://dx.doi.org/10.1016/0092-8674(94)90318-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NH634	7513258				2022-12-24	WOS:A1994NH63400011
J	MONTAGUE, PR; GANCAYCO, CD; WINN, MJ; MARCHASE, RB; FRIEDLANDER, MJ				MONTAGUE, PR; GANCAYCO, CD; WINN, MJ; MARCHASE, RB; FRIEDLANDER, MJ			ROLE OF NO PRODUCTION IN NMDA RECEPTOR-MEDIATED NEUROTRANSMITTER RELEASE IN CEREBRAL-CORTEX	SCIENCE			English	Article							LONG-TERM POTENTIATION; NITRIC-OXIDE SYNTHASE; D-ASPARTATE RECEPTORS; GLUTAMATE NEUROTOXICITY; NEURONAL MESSENGER; NERVOUS-SYSTEM; INTERCELLULAR MESSENGER; NORADRENALINE RELEASE; VISUAL-CORTEX; RAT-BRAIN	L-Glutamate and norepinephrine are examples of a major excitatory neurotransmitter and a neuromodulator in the cerebral cortex, respectively. Little is known of how chemical signaling between the anatomically distinct chemical pathways occurs. Specific activation of the N-methyl-D-aspartate (NMDA) class of glutamate receptor in synaptosomal preparations from guinea pig cerebral cortex caused release of both of these chemicals, and this release was blocked by agents that inhibit nitric oxide (NO) production or remove NO from the extracellular space. Furthermore, neurotransmitter release correlated with cortical NO production after NMDA receptor stimulation. These results suggest that NO production and its extracellular movement may be links in the pathway from NMDA receptor activation to changes in chemical signaling in surrounding synaptic terminals in the cerebral cortex.	UNIV ALABAMA, NEUROBIOL RES CTR, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, DEPT PHARMACOL, BIRMINGHAM, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham					NEI NIH HHS [EY05116, EY06714] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BEAR MF, 1990, J NEUROSCI, V10, P909; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BELLAN JA, 1993, EUR J PHARMACOL, V234, P273, DOI 10.1016/0014-2999(93)90964-J; BETTACHE N, 1993, BIOPHYS J, V64, pA190; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1988, J NEUROSCI, V8, P185; CHOI DW, 1990, J NEUROSCI, V10, P2493; CLINE HT, 1987, P NATL ACAD SCI USA, V84, P4342, DOI 10.1073/pnas.84.12.4342; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; DAWSON TM, 1992, ANN NEUROL, V32, P297, DOI 10.1002/ana.410320302; DAWSON VL, 1993, J NEUROSCI, V13, P2651; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; DWYER MA, 1991, BIOCHEM BIOPH RES CO, V176, P1136, DOI 10.1016/0006-291X(91)90403-T; ERRINGTON ML, 1987, NEUROSCIENCE, V20, P279, DOI 10.1016/0306-4522(87)90019-4; FARACI FM, 1993, CIRC RES, V72, P476, DOI 10.1161/01.RES.72.2.476; FARACI FM, 1990, AM J PHYSIOL, V259, pH1216, DOI 10.1152/ajpheart.1990.259.4.H1216; FEELISCH M, 1987, EUR J PHARMACOL, V139, P19, DOI 10.1016/0014-2999(87)90493-6; FERKANY JW, 1982, NATURE, V298, P757, DOI 10.1038/298757a0; FINK K, 1990, EUR J PHARMACOL, V185, P115, DOI 10.1016/0014-2999(90)90219-V; FREGNAC Y, 1994, IN PRESS J NEUROPHYS, V71, P146; FRIEDLANDER MJ, 1993, PROG BRAIN RES, V95, P207, DOI 10.1016/S0079-6123(08)60370-2; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; GALLY JA, 1990, P NATL ACAD SCI USA, V87, P3547, DOI 10.1073/pnas.87.9.3547; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GARTHWAITE J, 1989, EUR J PHARM-MOLEC PH, V172, P413, DOI 10.1016/0922-4106(89)90023-0; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GORDON B, 1988, PROG NEUROBIOL, V30, P171, DOI 10.1016/0301-0082(88)90005-6; HALEY JE, 1992, NEURON, V8, P211, DOI 10.1016/0896-6273(92)90288-O; HARRIS EW, 1984, BRAIN RES, V323, P132, DOI 10.1016/0006-8993(84)90275-0; IADECOLA C, 1993, TRENDS NEUROSCI, V16, P206, DOI 10.1016/0166-2236(93)90156-G; IZUMI Y, 1992, SCIENCE, V257, P1273, DOI 10.1126/science.1519065; KOVACH AGB, 1992, J PHYSIOL-LONDON, V449, P183, DOI 10.1113/jphysiol.1992.sp019081; LADECOLA C, 1993, BRAIN RES, V606, P148; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MANZONI O, 1993, J NEUROCHEM, V61, P368, DOI 10.1111/j.1471-4159.1993.tb03580.x; MANZONI O, 1992, NEURON, V8, P653, DOI 10.1016/0896-6273(92)90087-T; Montague PR, 1991, CEREB CORTEX, V1, P199, DOI 10.1093/cercor/1.3.199; MOORE PK, 1993, BRIT J PHARMACOL, V108, P296, DOI 10.1111/j.1476-5381.1993.tb12798.x; MUSLEH WY, 1993, SYNAPSE, V13, P370, DOI 10.1002/syn.890130409; NICHOLS RA, 1989, J NEUROCHEM, V52, P521, DOI 10.1111/j.1471-4159.1989.tb09151.x; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; RADI R, 1991, J BIOL CHEM, V266, P4244; REGIDOR J, 1993, NEUROREPORT, V4, P112, DOI 10.1097/00001756-199301000-00030; SCHARFMAN HE, 1990, P NATL ACAD SCI USA, V87, P4548, DOI 10.1073/pnas.87.12.4548; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SHULZ D, 1992, J NEUROSCI, V12, P1301; SNYDER SH, 1992, SCIENCE, V257, P494, DOI 10.1126/science.1353273; SNYDER SH, 1991, TRENDS PHARMACOL SCI, V12, P125, DOI 10.1016/0165-6147(91)90526-X; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STEVENS CF, 1993, NATURE, V364, P147, DOI 10.1038/364147a0; SUTOR B, 1989, J NEUROPHYSIOL, V61, P621, DOI 10.1152/jn.1989.61.3.621; THOMSON AM, 1986, NEUROSCIENCE, V17, P37, DOI 10.1016/0306-4522(86)90223-X; THOMSON AM, 1986, J PHYSIOL-LONDON, V370, P531, DOI 10.1113/jphysiol.1986.sp015949; TSUMOTO T, 1987, NATURE, V327, P513, DOI 10.1038/327513a0; VALTSCHANOFF JG, 1993, J COMP NEUROL, V331, P111, DOI 10.1002/cne.903310107; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; VINCENT SR, 1992, TRENDS NEUROSCI, V15, P108, DOI 10.1016/0166-2236(92)90021-Y; VINCENT SR, 1992, NEUROSCIENCE, V46, P755, DOI 10.1016/0306-4522(92)90184-4; WANG JKT, 1992, J NEUROCHEM, V58, P204, DOI 10.1111/j.1471-4159.1992.tb09297.x; WILLIAMS JH, 1993, SEMIN NEUROSCI, V5, P149, DOI 10.1016/S1044-5765(05)80048-X; WINN MJ, 1991, J CARDIOVASC PHARM, V18, P68, DOI 10.1097/00005344-199107000-00010; WINN MJ, 1992, J PHARMACOL TOXICOL, V28, P49, DOI 10.1016/1056-8719(92)90065-9; WU WT, 1993, NEUROSCI LETT, V153, P121, DOI 10.1016/0304-3940(93)90303-3; ZHOU M, 1993, SCIENCE, V260, P1946	68	466	473	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 18	1994	263	5149					973	977		10.1126/science.7508638	http://dx.doi.org/10.1126/science.7508638			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX165	7508638				2022-12-24	WOS:A1994MX16500038
J	HUANG, MX; CHALFIE, M				HUANG, MX; CHALFIE, M			GENE INTERACTIONS AFFECTING MECHANOSENSORY TRANSDUCTION IN CAENORHABDITIS-ELEGANS	NATURE			English	Article							SODIUM-CHANNEL; EXPRESSION; NEURONS; PROTEIN	GENETIC screening has identified a group of mec (mechanosensory) genes that are required for the function of a set of six touch-receptor neurons in the nematode Caenorhabditis elegans1,2. Such genes potentially encode components of the mechanosensory apparatus. We have cloned one of these genes, mec-10, which is a member of the degenerin gene family (genes such as mec-4 and deg-1 (refs 3, 4) that can be mutated to cause neurodegeneration). Because components of an amiloride-sensitive sodium channel (alpha, beta and gammarENaC) from rat6-8 share considerable sequence similarity with the C. elegans genes, it is likely that degenerins may function as channel proteins. Here we show that two degenerin homologues (mec-4 and mec-10) are expressed in the same cells, although each provides a unique function. Based on genetic data of mutations affecting mec-10-induced degeneration, we propose that the products of three genes (mec-4, mec-10 and mec-6) form a complex needed for mechanosensation, and that several other mec genes may be important in regulating the putative channel complex.			HUANG, MX (corresponding author), COLUMBIA UNIV,DEPT BIOL SCI,1012 FAIRCHILD CTR,NEW YORK,NY 10027, USA.							BARBRY P, 1990, P NATL ACAD SCI USA, V87, P7347, DOI 10.1073/pnas.87.19.7347; BENOS DJ, 1987, J BIOL CHEM, V262, P10613; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CHALFIE M, 1990, NATURE, V345, P410, DOI 10.1038/345410a0; CHALFIE M, 1981, DEV BIOL, V82, P358, DOI 10.1016/0012-1606(81)90459-0; CHALFIE M, 1989, SCIENCE, V243, P1027, DOI 10.1126/science.2646709; CHALFIE M, 1993, NATURE, V361, P504, DOI 10.1038/361504a0; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; HONG KS, 1994, NATURE, V367, P470, DOI 10.1038/367470a0; KAPLAN JM, 1993, P NATL ACAD SCI USA, V90, P2227, DOI 10.1073/pnas.90.6.2227; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; MITANI S, 1993, DEVELOPMENT, V119, P373; PALOZZOLO MJ, 1990, GENE, V88, P25; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING LAB MANU; SAVAGE C, 1989, GENE DEV, V3, P870, DOI 10.1101/gad.3.6.870; STAUB O, 1992, J CELL BIOL, V119, P1497, DOI 10.1083/jcb.119.6.1497; SULSTON J, 1988, CAENORHABDITIS ELEGA; WAY JC, 1989, GENE DEV, V3, P1823, DOI 10.1101/gad.3.12a.1823; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239	24	337	362	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 3	1994	367	6462					467	470		10.1038/367467a0	http://dx.doi.org/10.1038/367467a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU679	7509039				2022-12-24	WOS:A1994MU67900056
J	Salerno, SM; Landry, FJ; Schick, JD; Schoomaker, EB				Salerno, SM; Landry, FJ; Schick, JD; Schoomaker, EB			The effect of multiple neuroimaging studies on classification, treatment, and outcome of acute ischemic stroke	ANNALS OF INTERNAL MEDICINE			English	Article							RESONANCE; INFARCTION	Objective: To examine the effect of serial neuroimaging studies on the diagnosis, therapy, and outcome of patients with acute stroke. Design: Retrospective case series. Setting: Tertiary care teaching hospital. Patients: 206 adult patients (mean age +/- SD, 66.0 +/- 10.8 years) hospitalized with a diagnosis of acute stroke between 1990 and 1993. Measurements: Strokes were retrospectively assigned to five categories (large-vessel, small-vessel, cardioembolic, other, or unknown) using standardized criteria based on the history, physical examination, ancillary test results, and first computed tomographic (CT) or magnetic resonance imaging (MRI) study of the head. Strokes were reclassified after the results of further neuroimaging studies, if any, were reviewed. The type and timing of therapy and the patient outcome at hospital discharge were documented. Results: The additional studies changed stroke classification in only 20.0% of the 140 patients who had two or more neuroimaging studies. All classification changes were from the unknown cause category to a category with a specific cause. In most patients receiving treatment (93.2%), therapy began before an additional CT or MRI study was obtained. In patients who had one neuroimaging study, 70.1% went home, 24.0% went to a skilled nursing facility, and 5.9% died; the corresponding percentages in persons who had multiple studies were 73.3%, 24.4%, and 2.2% (P > 0.1). Conclusions: Serial neuroimaging studies did not alter the classification of strokes for which an initial diagnosis had already been made. However, they were useful in determining the cause of strokes initially classified as having an unknown cause. Therapy was almost always begun immediately after the first CT or MRI study was obtained. Outcome at hospital discharge was not significantly related to the number of neuroimaging studies obtained.	MADIGAN ARMY MED CTR, DEPT MED, TACOMA, WA 98431 USA	Madigan Army Medical Center								ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35; BRYAN RN, 1991, AM J NEURORADIOL, V12, P611; DIXON AK, 1991, BRIT MED J, V302, P79, DOI 10.1136/bmj.302.6768.79; HOMMEL M, 1990, STROKE, V21, P546, DOI 10.1161/01.STR.21.4.546; KENT DL, 1994, ANN INTERN MED, V120, P856, DOI 10.7326/0003-4819-120-10-199405150-00007; KERTESZ A, 1987, NEUROLOGY, V37, P1580, DOI 10.1212/WNL.37.10.1580; MATCHAR DB, 1994, ANN INTERN MED, V121, P41, DOI 10.7326/0003-4819-121-1-199407010-00008; SHUAIB A, 1992, NEUROLOGY, V42, P816, DOI 10.1212/WNL.42.4.816; TEASDALE GM, 1989, BRIT MED J, V299, P349, DOI 10.1136/bmj.299.6695.349; WALL SD, 1982, AM J ROENTGENOL, V138, P307, DOI 10.2214/ajr.138.2.307	10	8	8	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	1				21	26		10.7326/0003-4819-124-1_Part_1-199601010-00004	http://dx.doi.org/10.7326/0003-4819-124-1_Part_1-199601010-00004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL943	7503473				2022-12-24	WOS:A1996TL94300004
J	VOGEL, A; RODRIGUEZ, C; WARNKEN, W; BELMONTE, JCI				VOGEL, A; RODRIGUEZ, C; WARNKEN, W; BELMONTE, JCI			DORSAL CELL FATE SPECIFIED BY CHICK LMX1 DURING VERTEBRATE LIMB DEVELOPMENT	NATURE			English	Article							APICAL ECTODERMAL RIDGE; BUD; EMBRYO; DROSOPHILA; MESODERM; GENE	THE positional cues that govern the fate of cells along the dorsoventral axis of the developing vertebrate limb are established in the mesoderm before outgrowth of limb buds. In Drosophila, a LIM/homeodomain gene, apterous, expressed in the dorsal compartment of the wing disc, specifies dorsal cell fate(1,2). Here we report the isolation of a vertebrate LIM-homeodomain containing gene, Chick Lmx1 (C-Lmx1). Transcripts for C-Lmx1 are detected in the presumptive dorsal limb mesoderm and are restricted thereafter to the dorsal mesoderm of the developing chick bud. C-Lmx1 expression is regulated by the overlying ectoderm where Wnt7a messenger RNA is localized(3). Wnt7a, required for normal development of the dorsoventral axis in mouse limbs(4), can induce ectopic expression of C-Lmx1 in ventral mesoderm, Misexpression of C-Lmx1 during limb outgrowth causes ventral to dorsal transformations of limb mesoderm, We propose that C-Lmx1 specifies dorsal cell fate during chick limb development.			VOGEL, A (corresponding author), SALK INST BIOL STUDIES, GENE EXPRESS LAB, 10010 N TORREY PINES RD, LA JOLLA, CA 92037 USA.							COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; DEALY CN, 1993, MECH DEVELOP, V43, P175, DOI 10.1016/0925-4773(93)90034-U; DHOUAILLY D, 1972, DEV BIOL, V28, P162, DOI 10.1016/0012-1606(72)90134-0; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; DUBOULE D, 1994, TRENDS GENET, V10, P358, DOI 10.1016/0168-9525(94)90132-5; Duboule D, 1991, CURR OPIN GENET DEV, V1, P211, DOI 10.1016/S0959-437X(05)80072-3; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; Hamburger V, 1938, J EXP ZOOL, V77, P379, DOI 10.1002/jez.1400770304; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; IZPISUABELMONTE JC, 1993, CELL, V74, P645, DOI 10.1016/0092-8674(93)90512-O; KIENY M, 1960, J EMBRYOL EXP MORPH, V8, P457; KLINGENSMITH J, 1994, DEV BIOL, V166, P396, DOI 10.1006/dbio.1994.1325; LOGAN C, 1992, DEV GENET, V13, P345, DOI 10.1002/dvg.1020130505; MACCABE JA, 1974, DEV BIOL, V39, P69, DOI 10.1016/S0012-1606(74)80009-6; MCCABE JA, 1973, DEV BIOL, V31, P323, DOI 10.1016/0012-1606(73)90269-8; MORGAN BA, 1992, NATURE, V358, P236, DOI 10.1038/358236a0; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; PAUTOU MP, 1973, CR ACAD SCI D NAT, V277, P1225; SAUNDERS JW, 1976, DEV BIOL, V50, P16, DOI 10.1016/0012-1606(76)90063-4; SAUNDERS JW, 1974, DEV BIOL, V38, P41, DOI 10.1016/0012-1606(74)90257-7; TICKLE C, 1995, CURR OPIN GENET DEV, V5, P478, DOI 10.1016/0959-437X(95)90052-I; YANG YZ, 1995, CELL, V80, P939, DOI 10.1016/0092-8674(95)90297-X	23	248	252	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 14	1995	378	6558					716	720		10.1038/378716a0	http://dx.doi.org/10.1038/378716a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK379	7501017				2022-12-24	WOS:A1995TK37900052
J	CHONG, L; VANSTEENSEL, B; BROCCOLI, D; ERDJUMENTBROMAGE, H; HANISH, J; TEMPST, P; DELANGE, T				CHONG, L; VANSTEENSEL, B; BROCCOLI, D; ERDJUMENTBROMAGE, H; HANISH, J; TEMPST, P; DELANGE, T			A HUMAN TELOMERIC PROTEIN	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; BINDING-PROTEIN; DNA-BINDING; RAP1; CENTROMERE; YEAST; IDENTIFICATION; VARIABILITY; STABILITY; REPEATS	Telomeres are multifunctional elements that shield chromosome ends from degradation and end-to-end fusions, prevent activation of DNA damage checkpoints, and modulate the maintenance of telomeric DNA by telomerase. A major protein component of human telomeres has been identified and cloned. This factor, TRF, contains one Myb-type DNA-binding repeat and an amino-terminal acidic domain. Immunofluorescent labeling shows that TRF specifically colocalizes with telomeric DNA in human interphase cells and is located at chromosome ends during metaphase. The presence of TRF along the telomeric TTAGGG repeat army demonstrates that human telomeres form a specialized nucleoprotein complex.	ROCKEFELLER UNIV, CELL BIOL & GENET LAB, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, PROGRAM MOLEC BIOL, NEW YORK, NY 10021 USA	Rockefeller University; Memorial Sloan Kettering Cancer Center			de Lange, Titia/B-8263-2011	de Lange, Titia/0000-0002-9267-367X; Erdjument-Bromage, Hediye/0000-0003-0224-3594	NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049046, R37GM049046] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA08748-29] Funding Source: Medline; NIGMS NIH HHS [GM49046] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLSHIRE RC, 1988, NATURE, V332, P656, DOI 10.1038/332656a0; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARANOWSKIJ N, 1994, EMBO J, V13, P5383, DOI 10.1002/j.1460-2075.1994.tb06873.x; BAUERLE PA, 1988, CELL, V53, P211; Broccoli D., UNPUB; Chong L. S., UNPUB; COMPTON DA, 1991, J CELL BIOL, V112, P1083, DOI 10.1083/jcb.112.6.1083; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; COOKE HJ, 1986, COLD SPRING HARB SYM, V51, P213, DOI 10.1101/SQB.1986.051.01.026; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; DELANGE T, 1992, EMBO J, V11, P717, DOI 10.1002/j.1460-2075.1992.tb05104.x; DELANGE T, 1995, TELOMERES, P265; DELANGE T, UNPUB; DELANGE T, IN PRESS SEMIN CELL; DELMAS V, 1993, P NATL ACAD SCI USA, V90, P2414, DOI 10.1073/pnas.90.6.2414; DOHONY KF, 1993, CELL, V73, P761; EARNSHAW WC, 1987, J CELL BIOL, V104, P817, DOI 10.1083/jcb.104.4.817; ELICONE C, 1994, J CHROMATOGR A, V676, P121, DOI 10.1016/0021-9673(94)00089-1; ERDJUMENTBROMAGE H, 1994, PROTEIN SCI, V3, P2435, DOI 10.1002/pro.5560031227; FANG G, 1995, TELOMERES, P69; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; GABRIELSEN OS, 1991, SCIENCE, V253, P1140, DOI 10.1126/science.1887237; HAHN S, 1993, CELL, V72, P481, DOI 10.1016/0092-8674(93)90064-W; HANISH JP, 1994, P NATL ACAD SCI USA, V91, P8861, DOI 10.1073/pnas.91.19.8861; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1995, TELOMERES, P247; HASTIE ND, 1989, TRENDS GENET, V5, P326, DOI 10.1016/0168-9525(89)90137-6; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; KAUFMAN PD, 1995, CELL, V81, P1105, DOI 10.1016/S0092-8674(05)80015-7; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KIPLING D, 1990, NATURE, V347, P400, DOI 10.1038/347400a0; KLEIN F, 1992, J CELL BIOL, V117, P935, DOI 10.1083/jcb.117.5.935; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYRION G, 1993, GENE DEV, V7, P1146, DOI 10.1101/gad.7.7a.1146; KYRION G, 1992, MOL CELL BIOL, V12, P5159, DOI 10.1128/MCB.12.11.5159; LECHNER J, 1991, CELL, V64, P717, DOI 10.1016/0092-8674(91)90501-O; LECHNER J, 1994, EMBO J, V13, P5203, DOI 10.1002/j.1460-2075.1994.tb06851.x; LEJNINE S, 1995, P NATL ACAD SCI USA, V92, P2393, DOI 10.1073/pnas.92.6.2393; LUSTIG AJ, 1990, SCIENCE, V250, P549, DOI 10.1126/science.2237406; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; Rhodes D., COMMUNICATION; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; SHORE D, 1994, TRENDS GENET, V10, P408, DOI 10.1016/0168-9525(94)90058-2; SIBON OCM, 1994, HISTOCHEMISTRY, V101, P223, DOI 10.1007/BF00269548; STARLING JA, 1990, NUCLEIC ACIDS RES, V18, P6881, DOI 10.1093/nar/18.23.6881; STILLMAN B, COMMUNICATION; SUSSEL L, 1991, P NATL ACAD SCI USA, V88, P7749, DOI 10.1073/pnas.88.17.7749; Tempst Paul, 1994, Methods (Orlando), V6, P248, DOI 10.1006/meth.1994.1027; TOMMERUP H, 1994, MOL CELL BIOL, V14, P5777, DOI 10.1128/MCB.14.9.5777; VANSTEENSEL B, UNPUB; ZAKIAN VA, 1995, TELOMERES, P107; ZHONG Z, 1992, MOL CELL BIOL, V12, P4834, DOI 10.1128/MCB.12.11.4834	58	614	662	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 8	1995	270	5242					1663	1667		10.1126/science.270.5242.1663	http://dx.doi.org/10.1126/science.270.5242.1663			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ293	7502076				2022-12-24	WOS:A1995TJ29300048
J	INAGAKI, N; GONOI, T; CLEMENT, JP; NAMBA, N; INAZAWA, J; GONZALEZ, G; AGUILARBRYAN, L; SEINO, S; BRYAN, J				INAGAKI, N; GONOI, T; CLEMENT, JP; NAMBA, N; INAZAWA, J; GONZALEZ, G; AGUILARBRYAN, L; SEINO, S; BRYAN, J			RECONSTITUTION OF I-KATP - AN INWARD RECTIFIER SUBUNIT PLUS THE SULFONYLUREA RECEPTOR	SCIENCE			English	Article							SENSITIVE K+ CHANNELS; PANCREATIC BETA-CELLS; REGULATED POTASSIUM CHANNEL; FUNCTIONAL EXPRESSION; INTRACELLULAR ATP; B-CELLS; DIAZOXIDE; CLONING	A member of the inwardly rectifying potassium channel family was cloned here. The channel, called BIR (Kir6.2), was expressed in large amounts in rat pancreatic islets and glucose-responsive insulin-secreting cell lines. Coexpression with the sulfonylurea receptor SUR reconstituted an inwardly rectifying potassium conductance of 76 picosiemens that was sensitive to adenosine triphosphate (ATP) (I-KATP) and was inhibited by sulfonylureas and activated by diazoxide. The data indicate that these pancreatic beta cell potassium channels are a complex composed of at least two subunits-BIR, a member of the inward rectifier potassium channel family, and SUR, a member of the ATP-binding cassette superfamily. Gene mapping data show that these two potassium channel subunit genes are clustered on human chromosome 11 at position 11p15.1.	CHIBA UNIV,SCH MED,CTR BIOMED SCI,DIV MOLEC MED,CHUO KU,CHIBA 260,JAPAN; CHIBA UNIV,PATHOGEN FUNGI & MICROBIAL TOXICOSES RES CTR,CHUO KU,CHIBA 260,JAPAN; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030; KYOTO PREFECTURAL UNIV MED,DEPT HYG,KAMIKYO KU,KYOTO 602,JAPAN	Chiba University; Chiba University; Baylor College of Medicine; Baylor College of Medicine; Kyoto Prefectural University of Medicine			, gonoi/GRS-0648-2022; gonoi, tohru/AAC-5181-2021	, gonoi/0000-0003-3655-7911; gonoi, tohru/0000-0003-3655-7911; Inagaki, Nobuya/0000-0001-8261-2593	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044311] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44311] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; ASHCROFT SJH, 1992, BIOCHIM BIOPHYS ACTA, V1175, P45, DOI 10.1016/0167-4889(92)90008-Y; ASHFORD MLJ, 1994, NATURE, V370, P456, DOI 10.1038/370456a0; CHANDY KG, 1993, TRENDS PHARMACOL SCI, V14, P434, DOI 10.1016/0165-6147(93)90181-I; COOK DL, 1988, DIABETES, V37, P495, DOI 10.2337/diabetes.37.5.495; COOK DL, 1984, NATURE, V311, P271, DOI 10.1038/311271a0; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; FINDLAY I, 1985, J MEMBRANE BIOL, V88, P165, DOI 10.1007/BF01868430; GONOI T, UNPUB; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; INAGAKI N, 1994, P NATL ACAD SCI USA, V91, P2679, DOI 10.1073/pnas.91.7.2679; INAGAKI N, 1995, J BIOL CHEM, V270, P5691, DOI 10.1074/jbc.270.11.5691; INAGAKI N, UNPUB; INAZAWA J, 1993, GENOMICS, V17, P153, DOI 10.1006/geno.1993.1297; JAN LY, 1994, NATURE, V371, P119, DOI 10.1038/371119a0; KERR ID, 1995, NATURE, V372, P112; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; MISLER S, 1986, P NATL ACAD SCI USA, V83, P7119, DOI 10.1073/pnas.83.18.7119; NAMBA N, UNPUB; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; RAJAN AS, 1993, J BIOL CHEM, V268, P15221; RORSMAN P, 1985, PFLUG ARCH EUR J PHY, V405, P305, DOI 10.1007/BF00595682; STANFIELD PR, 1994, J PHYSIOL-LONDON, V478, P1; STURGESS NC, 1988, BRIT J PHARMACOL, V95, P83, DOI 10.1111/j.1476-5381.1988.tb16551.x; SUTCLIFFE MJ, 1994, NATURE, V369, P616, DOI 10.1038/369616b0; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; TRUBE G, 1986, PFLUG ARCH EUR J PHY, V407, P493, DOI 10.1007/BF00657506; TSUURA Y, 1992, DIABETES, V42, P861; WIBLE BA, 1994, NATURE, V371, P246, DOI 10.1038/371246a0; WIBRAND F, 1992, P NATL ACAD SCI USA, V89, P5133, DOI 10.1073/pnas.89.11.5133; YAMASHITA H, 1992, ANAL SCI, V8, P251, DOI 10.2116/analsci.8.251	35	1494	1554	1	40	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 17	1995	270	5239					1166	1170		10.1126/science.270.5239.1166	http://dx.doi.org/10.1126/science.270.5239.1166			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE905	7502040				2022-12-24	WOS:A1995TE90500046
J	IPUGE, YAI; RIEDER, HL; ENARSON, DA				IPUGE, YAI; RIEDER, HL; ENARSON, DA			ADVERSE CUTANEOUS REACTIONS TO THIACETAZONE FOR TUBERCULOSIS TREATMENT IN TANZANIA	LANCET			English	Article							HYPERSENSITIVITY REACTIONS; PULMONARY TUBERCULOSIS; HIV-INFECTION; CHEMOTHERAPY	Because thiacetazone has been linked with serious adverse cutaneous reactions, we undertook 1 year of systematic surveillance for cutaneous thiacetazone-associated adverse reactions within the national tuberculosis programme of Tanzania, For individual cases, we collected information on age, sex, interval between commencing thiacetazone-containing treatment and occurrence of adverse reaction, most severe clinical presentation (toxic epidermal necrolysis, rash without necrolysis, itching without rash), and outcome (dead or alive) within 2 weeks of onset, Univariate and multivariate analyses were done of variables relevant to outcome. 1273 patients with adverse reactions were reported, The frequency of fatal outcome from any cutaneous reaction was 3.1 per 1000 among all tuberculosis patients, and 19.1% among patients with toxic epidermal necrolysis. About 60% of all adverse reactions and deaths occurred within 20 days of starling thiacetazone. Case fatality from adverse cutaneous reactions was considerably less frequent than reported previously, suggesting that improved management might allow retention of thiacetazone in the armamentarium of national tuberculosis programmes even where infection with HIV is prevalent,	MINIST HLTH,TANZANIA NATL TB LEPROSY PROGRAMME,DAR ES SALAAM,TANZANIA; INT UNION AGAINST TB & LUNG DIS,PARIS,FRANCE									[Anonymous], 1980, Tubercle, V61, P59; [Anonymous], 1983, Tubercle, V64, P153; Chum H. J., 1994, Tubercle and Lung Disease, V75, P24, DOI 10.1016/0962-8479(94)90769-2; COLEBUNDERS RL, 1989, AM REV RESPIR DIS, V139, P1082, DOI 10.1164/ajrccm/139.5.1082; DATTA M, 1993, TUBERCLE LUNG DIS, V74, P180, DOI 10.1016/0962-8479(93)90008-L; DOMAGK G, 1946, NATURWISSENSCHAFTEN, V33, P315, DOI 10.1007/BF00624524; DUKES CS, 1992, TROP GEOGR MED, V44, P308; ELLIOTT AM, 1990, BRIT MED J, V301, P412, DOI 10.1136/bmj.301.6749.412; Enarson D A, 1991, Bull Int Union Tuberc Lung Dis, V66, P195; ENARSON DA, 1994, TUBERCULOSIS GUIDE L; ERIKI PP, 1991, AM REV RESPIR DIS, V143, P185, DOI 10.1164/ajrccm/143.1.185; KELLY P, 1994, T ROY SOC TROP MED H, V88, P113, DOI 10.1016/0035-9203(94)90529-0; KOCHI A, 1991, TUBERCLE, V72, P1, DOI 10.1016/0041-3879(91)90017-M; LUO C, 1994, TUBERCLE LUNG DIS, V75, P110, DOI 10.1016/0962-8479(94)90039-6; Miller A B, 1966, Tubercle, V47, P33; MURRAY CJL, 1991, LANCET, V338, P1305, DOI 10.1016/0140-6736(91)92600-7; NUNN P, 1993, T ROY SOC TROP MED H, V87, P578, DOI 10.1016/0035-9203(93)90096-9; NUNN P, 1991, LANCET, V337, P627; RAVIGLIONE MC, 1988, ARCH INTERN MED, V148, P2683, DOI 10.1001/archinte.148.12.2683; Rouillon A, 1991, Bull Int Union Tuberc Lung Dis, V66, P159; 1960, TUBERCLE, V41, P399; 1987, MANUAL NATIONAL TUBE; 1993, 29 INT UN TUB LUNG D; 1966, TUBERCLE, V47, P315; 1963, TUBERCLE, V44, P301; 1966, TUBERCLE, V47, P1; 1994, 32 INT UN TUB LUNG D; 1970, TUBERCLE, V51, P123; 1985, AM REV RESPIR DIS, V131, P727	29	16	16	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 9	1995	346	8976					657	660		10.1016/S0140-6736(95)92278-4	http://dx.doi.org/10.1016/S0140-6736(95)92278-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU048	7544858				2022-12-24	WOS:A1995RU04800007
J	SAEZ, E; RUTBERG, SE; MUELLER, E; OPPENHEIM, H; SMOLUK, J; YUSPA, SH; SPIEGELMAN, BM				SAEZ, E; RUTBERG, SE; MUELLER, E; OPPENHEIM, H; SMOLUK, J; YUSPA, SH; SPIEGELMAN, BM			C-FOS IS REQUIRED FOR MALIGNANT PROGRESSION OF SKIN TUMORS	CELL			English	Article							MOUSE SKIN; TRANSGENIC MICE; GENE-EXPRESSION; CELL CARCINOMAS; PHORBOL ESTERS; RETINOIC ACID; NULL MUTATION; BENIGN-TUMORS; HUMAN-BREAST; JUN	The proto-oncogene c-fos is a major nuclear target for signal transduction pathways involved in the regulation of cell growth, differentiation, and transformation. Using the multistep skin carcinogenesis model, we have directly tested the ability of c-fos-deficient mice to develop cancer. Upon treatment with a tumor promoter, c-fos knockout mice carrying a v-H-ras transgene were able to develop benign tumors with similar kinetics and relative incidence as wild-type animals. However, c-fos-deficient papillomas quickly became very dry and hyperkeratinized, taking on an elongated, horny appearance. While wild-type papillomas eventually progressed into malignant tumors, c-fos-deficient tumors failed to undergo malignant conversion. Experiments in which v-H-ras-expressing keratinocytes were grafted onto nude mice suggest that c-fos-deficient cells have an intrinsic defect that hinders tumorigenesis. These results demonstrate that a member of the AP-1 family of transcription factors is required for the development of a malignant tumor.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; NCI,CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB,BETHESDA,MD 20892	Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	SAEZ, E (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,44 BINNEY ST,BOSTON,MA 02115, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027295] Funding Source: NIH RePORTER; NICHD NIH HHS [HD27295] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BIUNNO I, 1988, BRIT J CANCER, V57, P464, DOI 10.1038/bjc.1988.108; BORCHERS AH, 1994, EXP CELL RES, V213, P143, DOI 10.1006/excr.1994.1183; BREMNER R, 1994, MOL CARCINOGEN, V11, P90, DOI 10.1002/mc.2940110206; BUCHMANN A, 1991, CANCER RES, V51, P4097; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DE LUCA LM, 1993, CARCINOGENESIS, V14, P539, DOI 10.1093/carcin/14.3.539; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; FISHER C, 1991, DEVELOPMENT, V11, P253; FRENCH JE, 1994, MOL CARCINOGEN, V11, P215, DOI 10.1002/mc.2940110407; GIMENEZCONTI I, 1990, CARCINOGENESIS, V11, P1995, DOI 10.1093/carcin/11.11.1995; HANSEN LA, 1994, MOL CARCINOGEN, V9, P143, DOI 10.1002/mc.2940090306; HANSEN LA, 1994, P NATL ACAD SCI USA, V91, P7822, DOI 10.1073/pnas.91.16.7822; HENNIGAN RF, 1994, ONCOGENE, V9, P3591; HENNINGS H, 1993, P SOC EXP BIOL MED, V202, P1; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; HONOKI K, 1992, MOL CARCINOGEN, V6, P122, DOI 10.1002/mc.2940060207; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KLAGSBRUN M, 1993, CURR BIOL, V3, P699, DOI 10.1016/0960-9822(93)90073-W; KLEINSZANTO AJP, 1989, CARCINOGENESIS, V10, P2169, DOI 10.1093/carcin/10.11.2169; KRIEG P, 1988, CARCINOGENESIS, V9, P95, DOI 10.1093/carcin/9.1.95; LEDER A, 1990, P NATL ACAD SCI USA, V87, P9178, DOI 10.1073/pnas.87.23.9178; Liotta L A, 1990, Semin Cancer Biol, V1, P99; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MATRISIAN LM, 1986, P NATL ACAD SCI USA, V83, P9413, DOI 10.1073/pnas.83.24.9413; MCDONNELL S, 1990, CANCER METAST REV, V9, P305; MEHREL T, 1990, CELL, V61, P1103, DOI 10.1016/0092-8674(90)90073-N; NISCHT R, 1988, MOL CARCINOGEN, V1, P96, DOI 10.1002/mc.2940010205; PAWELETZ N, 1994, CRIT REV ONCOGENESIS, V5, P69, DOI 10.1615/CritRevOncog.v5.i1.40; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; RUTHER U, 1989, ONCOGENE, V4, P861; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHUH AC, 1990, NATURE, V346, P756, DOI 10.1038/346756a0; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; SMOLA H, 1993, J CELL BIOL, V122, P417, DOI 10.1083/jcb.122.2.417; SPALDING JW, 1993, CARCINOGENESIS, V14, P1335, DOI 10.1093/carcin/14.7.1335; STRAWHECKER JM, 1992, CARCINOGENESIS, V13, P2075, DOI 10.1093/carcin/13.11.2075; STRICKLAND JE, 1993, CARCINOGENESIS, V14, P205, DOI 10.1093/carcin/14.2.205; URABE A, 1992, J PATHOL, V168, P281, DOI 10.1002/path.1711680307; VOLM M, 1992, INT J ONCOL, V1, P69; WALKER RA, 1991, J PATHOL, V163, P323, DOI 10.1002/path.1711630409; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WODRICH W, 1993, CARCINOGENESIS, V14, P1121, DOI 10.1093/carcin/14.6.1121; YUSPA SH, 1994, CANCER RES, V54, P1178; YUSPA SH, 1976, CANCER RES, V36, P4062; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207	60	322	332	0	9	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 8	1995	82	5					721	732		10.1016/0092-8674(95)90469-7	http://dx.doi.org/10.1016/0092-8674(95)90469-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RU755	7545543	Bronze			2022-12-24	WOS:A1995RU75500007
J	HAMILL, RJ; HOUSTON, ED; GEORGHIOU, PR; WRIGHT, CE; KOZA, MA; CADLE, RM; GOEPFERT, PA; LEWIS, DA; ZENON, GJ; CLARRIDGE, JE				HAMILL, RJ; HOUSTON, ED; GEORGHIOU, PR; WRIGHT, CE; KOZA, MA; CADLE, RM; GOEPFERT, PA; LEWIS, DA; ZENON, GJ; CLARRIDGE, JE			AN OUTBREAK OF BURKHOLDERIA (FORMERLY PSEUDOMONAS) CEPACIA RESPIRATORY-TRACT COLONIZATION AND INFECTION ASSOCIATED WITH NEBULIZED ALBUTEROL THERAPY	ANNALS OF INTERNAL MEDICINE			English	Note							POLYMERASE CHAIN-REACTION; BENZALKONIUM CHLORIDE; EPIDEMIOLOGY	Objective: To investigate an outbreak of Burkholderia (formerly Pseudomonas) cepacia respiratory tract colonization and infection in mechanically ventilated patients. Design: A retrospective case-control and bacteriologic study, Setting: Veterans Affairs medical center. Patients: 42 mechanically ventilated patients who developed respiratory tract colonization or infection with B. cepacia and 135 ventilator-dependent controls who were not colonized and did not develop infections. Measurements: Clinical and demographic data; benzalkonium chloride concentrations and pH levels in albuterol sulfate solutions; repetitive-element polymerase chain reaction (PCR)-mediated molecular fingerprinting on eight patient isolates and three environmental B. cepacia isolates that were available for study. Results: 42 patients had B. cepacia respiratory tract colonization or infection. Observation of intensive care unit and respiratory care personnel showed faulty infection control procedures (for example, the same multiple-dose bottle of albuterol was used for many mechanically ventilated patients). More case patients (39 [92.9%]) than controls (95 [70.4%]; P = 0.006) received nebulized albuterol, and case patients (67.5 treatments) received more treatments than controls (18 treatments; P < 0.001). In-use albuterol solutions had pH values that were unstable, and benzalkonium chloride concentrations declined over time to levels capable of supporting bacterial growth. Medication nebulizers and in-use bottles of albuterol harbored B. cepacia. Molecular fingerprints of patient isolates and environmental B. cepacia isolates were identical using repetitive-element PCR. No further isolates of B. cepacia were identified after institution of appropriate infection control procedures. Conclusions: Multiple-dose medications and reliance on benzalkonium chloride as a medication preservative provide a mechanism for nosocomial spread of microorganisms, particularly if infection control procedures are not carefully followed. Repetitive-element PCR is a useful fingerprinting technique for molecular epidemiologic studies of B. cepacia.	TEXAS SO UNIV, HOUSTON, TX 77004 USA	Texas Southern University	HAMILL, RJ (corresponding author), BAYLOR COLL MED, VET AFFAIRS MED CTR, INFECT DIS SECT 111G, 2002 HOLCOMBE BLVD, HOUSTON, TX 77030 USA.							BARKER MJ, 1990, AM J INFECT CONTROL, V18, P139; BINGEN EH, 1993, J CLIN MICROBIOL, V31, P2589, DOI 10.1128/JCM.31.10.2589-2593.1993; CRAVEN DE, 1984, AM J MED, V77, P834, DOI 10.1016/0002-9343(84)90520-5; DONOWITZ LG, 1991, INFECT CONT HOSP EP, V12, P186, DOI 10.2307/30146937; FRANK MJ, 1976, JAMA-J AM MED ASSOC, V236, P2418, DOI 10.1001/jama.236.21.2418; GEFTIC SG, 1979, APPL ENVIRON MICROB, V37, P505, DOI 10.1128/AEM.37.3.505-510.1979; GEORGHIOU PR, 1995, CLIN INFECT DIS, V20, P84, DOI 10.1093/clinids/20.1.84; JARVIS WR, 1987, EUR J EPIDEMIOL, V3, P233, DOI 10.1007/BF00149729; KARABIT MS, 1988, INT J PHARM, V46, P141, DOI 10.1016/0378-5173(88)90019-1; KUNDSIN RB, 1957, ARCH SURG-CHICAGO, V75, P1036; MARTONE WJ, 1987, EUR J EPIDEMIOL, V3, P222, DOI 10.1007/BF00149728; RABKIN CS, 1989, REV INFECT DIS, V11, P600; REBOLI AC, 1994, J CLIN MICROBIOL, V32, P2635, DOI 10.1128/JCM.32.11.2635-2640.1994; REBOLI AC, 1993, 1993 INF DIS  SOC AM, V17, P555; RICHARDSON NE, 1977, J PHARM PHARMACOL, V29, P717, DOI 10.1111/j.2042-7158.1977.tb11448.x; SIMMONS BP, 1982, INFECT CONT HOSP EP, V3, P327, DOI 10.1017/S0195941700056423; THOMAS JM, 1989, MOD SYN MET, V5, P249; VERSALOVIC J, 1991, NUCLEIC ACIDS RES, V19, P6823, DOI 10.1093/nar/19.24.6823; WOODS CR, 1993, J CLIN MICROBIOL, V31, P1927, DOI 10.1128/JCM.31.7.1927-1931.1993; WOODS CR, 1992, J CLIN MICROBIOL, V30, P2921, DOI 10.1128/JCM.30.11.2921-2929.1992	20	94	96	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1995	122	10					762	766		10.7326/0003-4819-122-10-199505150-00005	http://dx.doi.org/10.7326/0003-4819-122-10-199505150-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX147	7536401				2022-12-24	WOS:A1995QX14700005
J	MCDOWALL, KJ; KABERDIN, VR; WU, SW; COHEN, SN; LINCHAO, S				MCDOWALL, KJ; KABERDIN, VR; WU, SW; COHEN, SN; LINCHAO, S			SITE-SPECIFIC RNASE-E CLEAVAGE OF OLIGONUCLEOTIDES AND INHIBITION BY STEM-LOOPS	NATURE			English	Article							ESCHERICHIA-COLI; MESSENGER-RNA; RIBOSOMAL-RNA; DEGRADATION; REPLICATION	THE enzyme RNase E (ref. 1) cuts RNA at specific sites within single-stranded segments(2-6). The role of adjacent regions of secondary structure in such cleavages is controversial(7-10). Here we report that 10-13-nucleotide oligomers lacking any stem-loop but containing the RNase E-cleaved sequence of RNA I11-13, the antisense repressor of replication of ColE1-type plasmids, are cut at the same phosphodiester bond as, and 20 times more efficiently than, RNA I. These findings indicate that, contrary to previous proposals(8,9), stem-loops do not serve as entry sites for RNase E, but instead limit cleavage at potentially susceptible sites. Cleavage was reduced further by mutations in a non-adjacent stem-loop, suggesting that distant conformational changes can also affect enzyme access. Modulation of RNase E cleavages by stem-loop regions and to a lesser extent by higher-order structure may explain why this enzyme, which does not have stringent sequence specificity(6,12,13), cleaves complex RNAs at a limited number of sites.	ACAD SINICA, INST MOL BIOL, TAIPEI, 94305, TAIWAN; STANFORD UNIV, SCH MED, DEPT GENET, STANFORD, CA USA	Academia Sinica - Taiwan; Stanford University			Lin-Chao, Sue/AAZ-8246-2021; Lin-Chao, Sue/AGI-2030-2022; Kaberdin, Vladimir/C-3870-2017	Lin-Chao, Sue/0000-0002-8415-9304; Lin-Chao, Sue/0000-0002-8415-9304; Kaberdin, Vladimir/0000-0002-7166-5136				APIRION D, 1978, J BIOL CHEM, V253, P1738; APIRION D, 1992, MOL BIOL LIFE SCI AD, V11, P221; BOUVET P, 1992, NATURE, V360, P488, DOI 10.1038/360488a0; CORMACK RS, 1992, J MOL BIOL, V228, P1078, DOI 10.1016/0022-2836(92)90316-C; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EHRETSMANN CP, 1992, GENE DEV, V6, P149, DOI 10.1101/gad.6.1.149; EHRETSMANN CP, 1992, FASEB J, V6, P3186, DOI 10.1096/fasebj.6.13.1397840; GOLDBLUM K, 1981, CELL, V15, P1055; HELMERCITTERICH M, 1988, EMBO J, V7, P557, DOI 10.1002/j.1460-2075.1988.tb02845.x; Higgins CF, 1992, CURR OPIN GENET DEV, V2, P739, DOI 10.1016/S0959-437X(05)80134-0; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; Lin-Chao S, 1992, MOL MICROBIOL, V6, P3385, DOI 10.1111/j.1365-2958.1992.tb02206.x; LINCHAO S, 1994, J BIOL CHEM, V269, P10797; LINCHAO S, 1991, CELL, V65, P1233, DOI 10.1016/0092-8674(91)90018-T; MACKIE GA, 1992, J BIOL CHEM, V267, P1054; MACKIE GA, 1993, J MOL BIOL, V234, P998, DOI 10.1006/jmbi.1993.1654; MCDOWALL KJ, 1994, J BIOL CHEM, V269, P10790; MELEFORS O, 1993, CONTROL MESSENGER RN, P53; MISRA TK, 1978, J BIOL CHEM, V253, P5594; ONO M, 1979, J MOL BIOL, V129, P343, DOI 10.1016/0022-2836(79)90500-X; TAKAHASHI K, 1961, J BIOCHEM-TOKYO, V49, P1; TAMM J, 1983, NUCLEIC ACIDS RES, V11, P6381, DOI 10.1093/nar/11.18.6381; TOMCSANYI T, 1985, J MOL BIOL, V185, P713, DOI 10.1016/0022-2836(85)90056-7; TUCKER WT, 1984, CELL, V38, P191, DOI 10.1016/0092-8674(84)90540-3	24	124	126	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 16	1995	374	6519					287	290		10.1038/374287a0	http://dx.doi.org/10.1038/374287a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM387	7533896				2022-12-24	WOS:A1995QM38700057
J	JONES, EY; HARLOS, K; BOTTOMLEY, MJ; ROBINSON, RC; DRISCOLL, PC; EDWARDS, RM; CLEMENTS, JM; DUDGEON, TJ; STUART, DI				JONES, EY; HARLOS, K; BOTTOMLEY, MJ; ROBINSON, RC; DRISCOLL, PC; EDWARDS, RM; CLEMENTS, JM; DUDGEON, TJ; STUART, DI			CRYSTAL-STRUCTURE OF AN INTEGRIN-BINDING FRAGMENT OF VASCULAR CELL-ADHESION MOLECULE-1 AT 1.8 ANGSTROM RESOLUTION	NATURE			English	Article							IMMUNOGLOBULIN-LIKE DOMAINS; SOLUBLE FORM; HUMAN CD4; PROTEIN; FIBRONECTIN; SITE; KINASE	THE cell-surface glycoprotein vascular cell adhesion molecule-1 (VCAM-1; ref. 1) mediates intercellular adhesion(2) by specific binding to the integrin very-late antigen-4 (VLA-4, alpha(4) beta(1); ref. 3). VCAM-1, with the intercellular adhesion molecules ICAM-1, ICAM-2, ICAM-3 and the mucosal vascular addressin MAd-CAM-1, forms an integrin-binding subgroup of the immunoglobulin superfamily. In addition to their clinical relevance in inflammation, these molecules act as cellular receptors for viral and parasitic agents(2). The predominant form of VCAM-1 in vivo has an amino-terminal extracellular region comprising seven immunoglobulin-like domains. Functional studies(4-7) have identified a conserved integrin-binding motif in domains 1 and 4, variants of which are present in the N-terminal domain of all members of the immunoglobulin superfamily subgroup. We report here the crystal structure of a VLA-4-binding fragment composed of the first two domains of VCAM-1. The integrin-binding motif (Q38IDSPL) is highly exposed and forms the N-terminal region of the loop between beta-strands C and D of domain 1. This motif exhibits a distinctive conformation which we predict will be common to all the integrin-binding IgSF molecules. These, and additional data, map VLA-4 binding to the face of the CFG beta-sheet, the surface previously identified(8) as the site for intercellular adhesive interactions between members of the immunoglobulin superfamily.	UNIV OXFORD, CTR MOLEC SCI, OXFORD OX1 3QU, ENGLAND; UNIV OXFORD, DEPT BIOCHEM, OXFORD OX1 3QU, ENGLAND; BRITISH BIOTECHNOL LTD, OXFORD OX4 5LY, ENGLAND; NEURES LTD, ABINGDON OX14 3YS, OXON, ENGLAND	University of Oxford; University of Oxford	JONES, EY (corresponding author), LAB MOLEC BIOPHYS, S PARKS RD, OXFORD OX1 3QU, ENGLAND.		Jones, Yvonne/N-8111-2019; Driscoll, Paul C/B-8007-2010; Robinson, Robert/G-9702-2011; Jones, Yvonne/J-2293-2016	Jones, Yvonne/0000-0002-3834-1893; Driscoll, Paul C/0000-0002-4124-6950; Robinson, Robert/0000-0001-6367-6903; Jones, Yvonne/0000-0002-3834-1893; Stuart, David/0000-0002-3426-4210				BODIAN DL, 1994, STRUCTURE, V2, P755, DOI 10.1016/S0969-2126(94)00076-X; BOTTOMLEY MJ, 1994, J MOL BIOL, V244, P464, DOI 10.1006/jmbi.1994.1743; CARDARELLI PM, 1994, J BIOL CHEM, V269, P18668; CLEMENTS JM, 1994, J CELL SCI, V107, P2127; DUDGEON TJ, 1994, EUR J BIOCHEM, V226, P517, DOI 10.1111/j.1432-1033.1994.tb20076.x; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; HARPAZ Y, 1994, J MOL BIOL, V238, P528, DOI 10.1006/jmbi.1994.1312; HOLDEN HM, 1992, J MOL BIOL, V227, P840, DOI 10.1016/0022-2836(92)90226-A; HOLNESS CL, IN PRESS J BIOL CHEM; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KOMORIYA A, 1991, J BIOL CHEM, V266, P15075; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; LOGAN D, 1993, NATURE, V362, P566, DOI 10.1038/362566a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OSBORN L, 1994, J CELL BIOL, V124, P601, DOI 10.1083/jcb.124.4.601; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; RENZ ME, 1994, J CELL BIOL, V125, P1395, DOI 10.1083/jcb.125.6.1395; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SAUL FA, 1978, J BIOL CHEM, V253, P585; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; STUART DI, 1979, J MOL BIOL, V134, P109, DOI 10.1016/0022-2836(79)90416-9; VONDERHEIDE RH, 1994, J CELL BIOL, V125, P215, DOI 10.1083/jcb.125.1.215; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0	28	180	184	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 9	1995	373	6514					539	544		10.1038/373539a0	http://dx.doi.org/10.1038/373539a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QF724	7531291				2022-12-24	WOS:A1995QF72400064
J	CLACKSON, T; WELLS, JA				CLACKSON, T; WELLS, JA			A HOT-SPOT OF BINDING-ENERGY IN A HORMONE-RECEPTOR INTERFACE	SCIENCE			English	Article							HUMAN GROWTH-HORMONE; ANTIBODY-ANTIGEN INTERACTIONS; PROTEIN-PROTEIN RECOGNITION; CRYSTAL-STRUCTURE; EXTRACELLULAR DOMAIN; SCANNING MUTAGENESIS; FUNCTIONAL EPITOPE; RATIONAL DESIGN; COMPLEX; RESOLUTION	The x-ray crystal structure of the complex between human growth hormone (hGH) and the extracellular domain of its first bound receptor (hGHbp) shows that about 30 side chains from each protein make contact. Individual replacement of contact residues in the hGHbp with alanine showed that a central hydrophobic region, dominated by two tryptophan residues, accounts for more than three-quarters of the binding free energy. This ''functional epitope'' is surrounded by less important contact residues that are generally hydrophilic and partially hydrated, so that the interface resembles a cross section through a globular protein. The functionally important residues on the hGHbp directly contact those on hGH. Thus, only a small and complementary set of contact residues maintains binding affinity, a property that may be general to protein-protein interfaces.	GENENTECH INC, DEPT PROT ENGN, S SAN FRANCISCO, CA 94080 USA	Roche Holding; Genentech			Wells, Jim A/O-9854-2016					ARGOS P, 1988, PROTEIN ENG, V2, P101, DOI 10.1093/protein/2.2.101; ATWELL S, UNPUB; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BARNARD R, 1984, ENDOCRINOLOGY, V115, P1805, DOI 10.1210/endo-115-5-1805; BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BHAT TN, 1994, P NATL ACAD SCI USA, V91, P1089, DOI 10.1073/pnas.91.3.1089; BUCKLE AM, 1994, BIOCHEMISTRY-US, V33, P8878, DOI 10.1021/bi00196a004; CHOTHIA C, 1975, NATURE, V256, P705, DOI 10.1038/256705a0; CHOTHIA C, 1974, NATURE, V254, P101; CLACKSON T, UNPUB; CUNNINGHAM BC, 1991, P NATL ACAD SCI USA, V88, P3407, DOI 10.1073/pnas.88.8.3407; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DEVOS AM, UNPUB; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FUH G, 1990, J BIOL CHEM, V265, P3111; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; HAWKINS RE, 1993, J MOL BIOL, V234, P958, DOI 10.1006/jmbi.1993.1650; HORTON N, 1992, PROTEIN SCI, V1, P169; JANIN J, 1990, J BIOL CHEM, V265, P16027; JIN L, 1992, J MOL BIOL, V226, P851, DOI 10.1016/0022-2836(92)90636-X; KELLEY RF, 1993, BIOCHEMISTRY-US, V32, P6828, DOI 10.1021/bi00078a005; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LOWMAN HB, 1993, J MOL BIOL, V234, P564, DOI 10.1006/jmbi.1993.1612; NOVOTNY J, 1989, BIOCHEMISTRY-US, V28, P4735, DOI 10.1021/bi00437a034; NUSS JM, 1993, PROTEINS, V15, P121, DOI 10.1002/prot.340150204; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; QUIOCHO FA, 1989, NATURE, V340, P404, DOI 10.1038/340404a0; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; SPENCER SA, 1988, J BIOL CHEM, V263, P7862; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; TULIP WR, 1994, BIOCHEMISTRY-US, V33, P7986, DOI 10.1021/bi00192a002; WELLS JA, 1991, METHOD ENZYMOL, V202, P390; WELLS JA, 1993, RECENT PROG HORM RES, V48, P253; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; WELLS JC, UNPUB; WILSON IA, 1993, CURR OPIN STRUC BIOL, V3, P113, DOI 10.1016/0959-440X(93)90210-C; YOUNG L, 1994, PROTEIN SCI, V3, P717	43	1707	1826	4	205	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 20	1995	267	5196					383	386		10.1126/science.7529940	http://dx.doi.org/10.1126/science.7529940			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QC273	7529940				2022-12-24	WOS:A1995QC27300037
J	BISHOP, DK				BISHOP, DK			RECA HOMOLOGS DMC1 AND RAD51 INTERACT TO FORM MULTIPLE NUCLEAR-COMPLEXES PRIOR TO MEIOTIC CHROMOSOME SYNAPSIS	CELL			English	Article							LYCOPERSICON-ESCULENTUM TOMATO; TWO-DIMENSIONAL SPREADS; DOUBLE-STRAND BREAKS; SYNAPTONEMAL COMPLEX; RECOMBINATION NODULES; SACCHAROMYCES-CEREVISIAE; DROSOPHILA-MELANOGASTER; SORDARIA-MACROSPORA; SOLANACEOUS PLANTS; WILD-TYPE	Dmc1 and Rad51, yeast homologs of the E. coli RecA protein, are shown by immunostaining to localize to as many as 64 sites within spread meiotic nuclei. Genetic requirements for this punctate pattern suggest It represents recombination intermediates. Dmc1 and Rad51 colocalize and are therefore likely to act together during recombination. Despite their similarities, the two proteins have specialized functions: Dmc1 complexes do not form in rad51 mutants, while Rad51 complexes are retained indefinitely in dmc1 mutants. Dmc1 and, by inference, Rad51 form complexes before synapsis as monitored by immunostaining for Zip1 protein. Analysis of zip1 mutants shows that Zip1 promotes dissociation of Dmc1 complexes. Colocalization of Dmc1 and Zip1 raises the possibility that Dmc1 and Rad51 are components of recombination nodules.			BISHOP, DK (corresponding author), UNIV CHICAGO,DEPT RADIAT & CELLULAR ONCOL,CHICAGO,IL 60638, USA.				NIGMS NIH HHS [GM50936, GM44794] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSSEKHRA A, 1992, MOL CELL BIOL, V12, P3224, DOI 10.1128/MCB.12.7.3224; ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; ALBINI SM, 1987, CHROMOSOMA, V95, P324, DOI 10.1007/BF00293179; ALBINI SM, 1984, EXP CELL RES, V155, P588, DOI 10.1016/0014-4827(84)90219-2; BASILE G, 1992, MOL CELL BIOL, V12, P3235, DOI 10.1128/MCB.12.7.3235; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BYERS B, 1975, P NATL ACAD SCI USA, V72, P5056, DOI 10.1073/pnas.72.12.5056; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; CARPENTER ATC, 1979, CHROMOSOMA, V75, P259, DOI 10.1007/BF00293472; CARPENTER ATC, 1979, GENETICS, V92, P511; Carpenter ATC, 1988, GENETIC RECOMBINATIO, P529, DOI [10.1038/ng1287, DOI 10.1038/NG1287]; DRESSER ME, 1988, J CELL BIOL, V106, P567, DOI 10.1083/jcb.106.3.567; ESPOSITO RE, 1981, MOL BIOL YEAST SACCH, P181; FOGEL S, 1983, YEAST GENETICS FUNDA, P65; Harlow E., 1988, ANTIBODIES LAB MANUA, P553; HOLLINGSWORTH NM, 1989, GENETICS, V121, P445; KADYK LC, 1992, GENETICS, V132, P387; KING JS, 1990, GENETICS, V126, P1127; KLAPHOLZ S, 1985, GENETICS, V110, P187; KLEIN F, 1992, J CELL BIOL, V117, P935, DOI 10.1083/jcb.117.5.935; LOVETT ST, 1994, GENE, V142, P103, DOI 10.1016/0378-1119(94)90362-X; MILNE GT, 1993, GENE DEV, V7, P1755, DOI 10.1101/gad.7.9.1755; MOENS PB, 1978, CAN J GENET CYTOL, V20, P567, DOI 10.1139/g78-066; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; PADMORE R, 1991, CELL, V66, P1239, DOI 10.1016/0092-8674(91)90046-2; PRINGLE JR, 1991, METHODS ENZYMOLOGY G, P565; RADDING CM, 1991, J BIOL CHEM, V266, P5355; RASMUSSEN SW, 1978, CARLSBERG RES COMMUN, V43, P275, DOI 10.1007/BF02906106; RESNICK M A, 1987, P157; ROEDER GS, 1990, TRENDS GENET, V6, P385, DOI 10.1016/0168-9525(90)90297-J; ROSSMACDONALD P, 1994, CELL, V79; SCHWACHA A, 1994, CELL, V76, P51, DOI 10.1016/0092-8674(94)90172-4; Sherman F., 1986, METHODS YEAST GENETI; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; STACK S, 1986, CHROMOSOMA, V94, P253, DOI 10.1007/BF00290853; STACK SM, 1986, AM J BOT, V73, P264, DOI 10.2307/2444181; STAHL FW, 1994, GENETICS, V138, P241; STORY RM, 1993, SCIENCE, V259, P1892, DOI 10.1126/science.8456313; STUDIER FW, 1992, METHOD ENZYMOL, V185, P60; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; SYM M, 1993, CELL, V72, P365, DOI 10.1016/0092-8674(93)90114-6; SYM M, 1994, CELL, V79, P283, DOI 10.1016/0092-8674(94)90197-X; VONWETTSTEIN D, 1984, ANNU REV GENET, V18, P331, DOI 10.1146/annurev.ge.18.120184.001555; WU TC, 1994, SCIENCE, V263, P515, DOI 10.1126/science.8290959; ZICKLER D, 1977, CHROMOSOMA, V61, P289, DOI 10.1007/BF00288615; ZICKLER D, 1992, GENETICS, V132, P135	47	395	412	2	21	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 16	1994	79	6					1081	1092		10.1016/0092-8674(94)90038-8	http://dx.doi.org/10.1016/0092-8674(94)90038-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PY086	7528104				2022-12-24	WOS:A1994PY08600017
J	KOBZIK, L; REID, MB; BREDT, DS; STAMLER, JS				KOBZIK, L; REID, MB; BREDT, DS; STAMLER, JS			NITRIC-OXIDE IN SKELETAL-MUSCLE	NATURE			English	Article							REACTIVE OXYGEN; SARCOPLASMIC-RETICULUM; SYNTHASE; LOCALIZATION; SULFHYDRYLS; MECHANISM; OXIDATION; PROTEINS; RELEASE; FORMS	REACTIVE oxygen intermediates modulate skeletal muscle contraction(1,2), but little is known about the role of nitric oxide (NO). Here we show that rat skeletal muscle expresses neuronal-type NO synthase and that activity varies among several respiratory and limb muscles. Immunohistochemistry showed prominent staining of type II (fast) fibre cell membranes with antibodies against neuronal-type NO synthase. NO synthase activity in muscles correlated with type II fibre density. Resting diaphragm muscle produced detectable NOx, but no reactive oxygen intermediates. In contrast, actively contracting muscle generated increased levels of reactive oxygen intermediates. Contractile function was augmented by blockers of NO synthase, extracellular NO chelation, and guanylyl cyclase inhibition; it was depressed by NO donors and by increased levels of cyclic GMP. Force-frequency plots of different muscles showed an inverse correlation between NO synthase activity and force development. Our results support two physiological functions of NO in skeletal muscle. The first is to promote relaxation through the cGMP pathway(3,4). The second is to modulate increases In contraction that are dependent on reactive oxygen intermediates and which are thought to occur through reactions with regulatory thiols on the sarcoplasmic reticulum(5,6).	DUKE UNIV,MED CTR,DEPT MED,DIV PULM,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DIV CARDIOVASC,DURHAM,NC 27710; BRIGHAM & WOMENS HOSP,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115; BAYLOR COLL MED,HOUSTON,TX 77030; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	Duke University; Duke University; Duke University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Baylor College of Medicine; University of California System; University of California San Francisco				Stamler, Jonathan/0000-0002-6866-1572				ABRAMSON JJ, 1989, J BIOENERG BIOMEMBR, V21, P283, DOI 10.1007/BF00812073; ARMSTRONG RB, 1984, AM J ANAT, V171, P259, DOI 10.1002/aja.1001710303; ARNOLD WP, 1977, P NATL ACAD SCI USA, V74, P3203, DOI 10.1073/pnas.74.8.3203; BELL LC, 1991, BIOCHEM J, V273, P423, DOI 10.1042/bj2730423; BIANCHI CP, 1975, CELLULAR PHARM EXCIT, P485; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BYRD SK, 1993, FASEB J, V7, pA526; EHRENBERG A, 1960, ACTA CHEM SCAND, V14, P1684, DOI 10.3891/acta.chem.scand.14-1684; KANNER J, 1992, LIPIDS, V27, P46, DOI 10.1007/BF02537058; KOBZIK L, 1993, AM J RESP CELL MOL, V9, P371, DOI 10.1165/ajrcmb/9.4.371; KUCERA I, 1987, BIOCHIM BIOPHYS ACTA, V894, P120, DOI 10.1016/0005-2728(87)90181-2; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; METZGER JM, 1985, J APPL PHYSIOL, V58, P1085, DOI 10.1152/jappl.1985.58.4.1085; MOHR S, 1994, FEBS LETT, V348, P223, DOI 10.1016/0014-5793(94)00596-6; NAKANE M, 1993, FEBS LETT, V316, P175, DOI 10.1016/0014-5793(93)81210-Q; REID MB, 1993, J APPL PHYSIOL, V75, P1081, DOI 10.1152/jappl.1993.75.3.1081; REID MB, 1992, J APPL PHYSIOL, V73, P1797, DOI 10.1152/jappl.1992.73.5.1797; REID MB, 1992, J APPL PHYSIOL, V73, P1805, DOI 10.1152/jappl.1992.73.5.1805; SCHERER NM, 1986, ARCH BIOCHEM BIOPHYS, V246, P589, DOI 10.1016/0003-9861(86)90314-0; SCHMIDT HHHW, 1993, BIOCHIM BIOPHYS ACTA, V1178, P153, DOI 10.1016/0167-4889(93)90006-B; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STAMLER JS, 1995, CELL, V78, P931; Stull J T, 1980, Adv Cyclic Nucleotide Res, V13, P39; TRIMM JL, 1986, J BIOL CHEM, V261, P6092; WEISHAAR RE, 1986, BIOCHEM PHARMACOL, V35, P787, DOI 10.1016/0006-2952(86)90247-9; WESCOTT SL, 1985, J CYCLIC NUCL PROT, V10, P189; WU M, 1994, AM J PHYSIOL, V268, pH2108	28	837	856	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 8	1994	372	6506					546	548		10.1038/372546a0	http://dx.doi.org/10.1038/372546a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW082	7527495				2022-12-24	WOS:A1994PW08200051
J	ARAKI, E; LIPES, MA; PATTI, ME; BRUNING, JC; HAAG, B; JOHNSON, RS; KAHN, CR				ARAKI, E; LIPES, MA; PATTI, ME; BRUNING, JC; HAAG, B; JOHNSON, RS; KAHN, CR			ALTERNATIVE PATHWAY OF INSULIN SIGNALING IN MICE WITH TARGETED DISRUPTION OF THE IRS-1 GENE	NATURE			English	Article							GROWTH FACTOR-I; STIMULATES TYROSINE PHOSPHORYLATION; RECEPTOR SUBSTRATE-1; PHOSPHATIDYLINOSITOL 3-KINASE; HEMATOPOIETIC-CELLS; SIGNALING PATHWAYS; PROTEIN; MUSCLE; TRANSMISSION; EXPRESSION	THE principal substrate for the insulin and insulin-like growth factor-1 (IGF-1) receptors is the cytoplasmic protein insulin-receptor substrate-1 (IRS-1/pp185)(1-7). After tyrosine phosphorylation at several sites, IRS-1 binds to and activates phosphatidylinositol-3'-OH kinase (PI(3)K)(8-11) and several other proteins containing SH2 (Src-homology 2) domains(12-14). To elucidate the role of IRS-1 in insulin/IGF-1 action, we created IRS-1-deficient mice by targeted gene mutation. These mice had no IRS-1 and shelved no evidence IRS-1 phosphorylation or IRS-1-associated PI(3)K activity. They also had a 50 per cent reduction in intrauterine growth, impaired glucose tolerance, and a decrease in insulin/IGF-1-stimulated glucose uptake in vivo and in vitro. The residual insulin/ IGF-1 action correlated with the appearance of a new tyrosine-phosphorylated protein (IRS-2) which binds to PI(3)K, but is slightly larger than and immunologically distinct from IRS-1. Our results provide evidence for IRS-1-dependent and IRS-1-independent pathways of insulin/IGF-1 signalling and for the existence of an alternative substrate of these receptor kinases.	JOSLIN DIABET CTR,DIV RES,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02215	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School			Kahn, Ronald/AAY-2435-2021; Johnson, Randall/AAM-1189-2021	Kahn, Ronald/0000-0002-7583-9228; Johnson, Randall/0000-0002-4084-6639				ARAKI E, 1993, DIABETES, V42, P1041, DOI 10.2337/diabetes.42.7.1041; ARAKI E, 1994, BBA-MOL CELL RES, V1221, P353, DOI 10.1016/0167-4889(94)90261-5; BEGUINOT F, 1989, ENDOCRINOLOGY, V125, P1599, DOI 10.1210/endo-125-3-1599; CHUANG LM, 1993, MOL CELL BIOL, V13, P6653, DOI 10.1128/MCB.13.11.6653; FOLLI F, 1992, J BIOL CHEM, V267, P22171; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KELLER SR, 1991, J BIOL CHEM, V266, P12817; KOVACINA KS, 1993, BIOCHEM BIOPH RES CO, V192, P1303, DOI 10.1006/bbrc.1993.1558; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LIPES MA, 1993, SCIENCE, V259, P1165, DOI 10.1126/science.8267690; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; MIRALPEIX M, 1992, BIOCHEMISTRY-US, V31, P9031, DOI 10.1021/bi00152a046; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; PAPAIOANNOU V, 1993, GENE TARGETING PRACT; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SAAD MJA, 1992, J CLIN INVEST, V90, P1839, DOI 10.1172/JCI116060; SHEPHERD PR, 1993, J BIOL CHEM, V269, P22232; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1992, J BIOL CHEM, V267, P22662; SUNG CK, 1994, J BIOL CHEM, V269, P12503; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; VANHORN DJ, 1994, J BIOL CHEM, V269, P29; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WATERS SB, 1993, J BIOL CHEM, V268, P22231; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1994, J BIOL CHEM, V269, P1; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4	31	1049	1072	1	45	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 10	1994	372	6502					186	190		10.1038/372186a0	http://dx.doi.org/10.1038/372186a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ688	7526222				2022-12-24	WOS:A1994PQ68800058
J	GRUBB, BR; PICKLES, RJ; YE, H; YANKASKAS, JR; VICK, RN; ENGELHARDT, JF; WILSON, JM; JOHNSON, LG; BOUCHER, RC				GRUBB, BR; PICKLES, RJ; YE, H; YANKASKAS, JR; VICK, RN; ENGELHARDT, JF; WILSON, JM; JOHNSON, LG; BOUCHER, RC			INEFFICIENT GENE-TRANSFER BY ADENOVIRUS VECTOR TO CYSTIC-FIBROSIS AIRWAY EPITHELIA OF MICE AND HUMANS	NATURE			English	Article							ION-TRANSPORT DEFECT; CHLORIDE TRANSPORT; TRANSGENIC MICE; EXPRESSION; THERAPY; INVIVO; MODEL; CFTR	THE success of adenoviral vectors for gene therapy of lung disease in cystic fibrosis (CF) depends on efficient transfer of the complementary DNA encoding the correct version of the cystic fibrosis transmembrane regulator (CFTR) to the affected columnar epithelial cells lining the airways of the lung. Pre-clinical studies in vitro suggest that low doses of adenovirus vectors carrying this CFTR cDNA fan correct defective Cl- transport in cultured human CF airway epithelia(1). Here He use mice carrying the disrupted CF gene(2) to test the efficacy of this transfer system in vivo. We find that even repeated high doses can only partially (50%) correct the CF defect in Cl- transport in vivo and do not correct the Na+ transport defect at all. We investigated this discrepancy between the in vivo and in vitro transfer efficiency using CF mouse and human samples, and found that it reflects a difference in the susceptibility to adenovirus-5 transduction of the epithelial cell types dosed in vivo (columnar) and in vitro (basal-cell-like). These studies indicate that more efficient adenoviral gene-transfer vectors and/or refinement of dosing strategies are needed for therapy of CF lung disease.	UNIV PENN,INST HUMAN GENE THERAPY,PHILADELPHIA,PA 19104	University of Pennsylvania	GRUBB, BR (corresponding author), UNIV N CAROLINA,CTR CF PULM RES & TREATMENT,CHAPEL HILL,NC 27599, USA.		Wilson, James M/F-9220-2011	Wilson, James M/0000-0002-9630-3131; Engelhardt, John/0000-0003-2389-9277	NIDDK NIH HHS [R01 DK047967] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047967] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTON EWFW, 1993, NAT GENET, V5, P135, DOI 10.1038/ng1093-135; BOAT TF, 1974, AM REV RESPIR DIS, V110, P428; BOUCHER RC, 1994, HUM GENE THER, V5, P615, DOI 10.1089/hum.1994.5.5-615; BOUT A, 1994, HUM GENE THER, V5, P3, DOI 10.1089/hum.1994.5.1-3; CLARKE LL, 1992, SCIENCE, V257, P1125, DOI 10.1126/science.257.5073.1125; CUTTING GR, 1992, NAT GENET, V2, P4, DOI 10.1038/ng0992-4; DOMINEY AM, 1993, CELL GROWTH DIFFER, V4, P1071; ENGELHARDT JF, 1992, NAT GENET, V2, P240, DOI 10.1038/ng1192-240; ENGELHARDT JF, 1993, HUM GENE THER, V4, P759, DOI 10.1089/hum.1993.4.6-759; ENGELHARDT JF, 1993, NAT GENET, V4, P27, DOI 10.1038/ng0593-27; GROSS EA, 1982, J ANAT, V135, P83; GRUBB B, 1994, AM J PHYSIOL, V268, pC1478; HARKEMA JR, 1991, LUNG BIOL HLTH DIS, V0055, P00003; HYDE SC, 1993, NATURE, V362, P250, DOI 10.1038/362250a0; JOHNSON LG, 1992, NAT GENET, V2, P21, DOI 10.1038/ng0992-21; KNOWLES M, 1981, NEW ENGL J MED, V305, P1489, DOI 10.1056/NEJM198112173052502; KNOWLES M, 1983, J CLIN INVEST, V71, P1410, DOI 10.1172/JCI110894; KNOWLES MR, 1981, AM REV RESPIR DIS, V124, P484; MASTRANGELI A, 1993, J CLIN INVEST, V91, P225, DOI 10.1172/JCI116175; SHIMIZU T, 1992, AM J RESP CELL MOL, V7, P30, DOI 10.1165/ajrcmb/7.1.30; SIMON RH, 1993, HUM GENE THER, V4, P771, DOI 10.1089/hum.1993.4.6-771; SNOUWAERT JN, 1992, SCIENCE, V257, P1083, DOI 10.1126/science.257.5073.1083; WILSON JM, 1994, HUM GENE THER, V5, P501, DOI 10.1089/hum.1994.5.4-501; YANG YP, 1994, NAT GENET, V7, P362, DOI 10.1038/ng0794-362; YANKASKAS JR, 1985, AM REV RESPIR DIS, V132, P1281; ZABNER J, 1993, CELL, V75, P207, DOI 10.1016/0092-8674(93)80063-K; ZABNER J, 1994, HUM GENE THER, V5, P585, DOI 10.1089/hum.1994.5.5-585; ZABNER J, 1994, NAT GENET, V6, P75, DOI 10.1038/ng0194-75	28	317	331	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 27	1994	371	6500					802	806		10.1038/371802a0	http://dx.doi.org/10.1038/371802a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP018	7523956				2022-12-24	WOS:A1994PP01800061
J	BRAKE, AJ; WAGENBACH, MJ; JULIUS, D				BRAKE, AJ; WAGENBACH, MJ; JULIUS, D			NEW STRUCTURAL MOTIF FOR LIGAND-GATED ION CHANNELS DEFINED BY AN IONOTROPIC ATP RECEPTOR	NATURE			English	Article							PHEOCHROMOCYTOMA CELLS; FUNCTIONAL EXPRESSION; MAMMALIAN NEURONS; POTASSIUM CHANNEL; NERVOUS-SYSTEM; SMOOTH-MUSCLE; PC12 CELLS; CURRENTS; CONDUCTANCE; CALCIUM	THE adenosine-5'-triphosphate (ATP) molecule is an extracellular messenger in neural and non-neural tissues, where it activates several cell-surface-receptor subtypes, including G-protein-coupled receptors and ligand-gated ion channels(1). ATP-gated channels (termed P-2X receptors) have been characterized on smooth muscle cells and autonomic and sensory neurons, where they mediate membrane depolarization and, in some cases, Ca2+ entry(2). P-2X receptors are functionally heterogeneous, but resemble acetylcholine- and serotonin-gated channels with respect to ion selectivity and kinetic parameters of channel gating. We report here that despite such close functional similarities, the deduced sequence of a cloned P-2X receptor predicts an unusual subunit structure resembling voltage-insensitive cation channels. Thus, the P-2X receptor provides a striking example of convergent evolution, whereby proteins have been fashioned with similar functional properties from subunits having very different structural characteristics. There is sequence similarity between the ATP receptor and RP-2, a gene activated in thymocytes undergoing programmed cell. death(3). RP-2 may encode a receptor for ATP or another metabolite released during apoptosis.	UNIV CALIF SAN FRANCISCO,SILVIO CONTE CTR NEUROSCI RES,CELL BIOL PROGRAM & NEUROSCI,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	BRAKE, AJ (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143, USA.							BEAN BP, 1992, TRENDS PHARMACOL SCI, V13, P87, DOI 10.1016/0165-6147(92)90032-2; BENHAM CD, 1987, NATURE, V328, P275, DOI 10.1038/328275a0; BURNSTOCK G, 1990, ANN NY ACAD SCI, V603, P1; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CLOUES R, 1993, PFLUG ARCH EUR J PHY, V424, P152, DOI 10.1007/BF00374606; EDWARDS FA, 1992, NATURE, V359, P144, DOI 10.1038/359144a0; EVANS RJ, 1992, NATURE, V357, P503, DOI 10.1038/357503a0; FIEBER LA, 1991, J PHYSIOL-LONDON, V434, P239, DOI 10.1113/jphysiol.1991.sp018467; FRIEL DD, 1990, PFLUG ARCH EUR J PHY, V415, P651, DOI 10.1007/BF02584001; FRIEL DD, 1988, J PHYSIOL-LONDON, V401, P361, DOI 10.1113/jphysiol.1988.sp017167; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HONG KS, 1994, NATURE, V367, P470, DOI 10.1038/367470a0; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; LI CY, 1993, P NATL ACAD SCI USA, V90, P8264, DOI 10.1073/pnas.90.17.8264; LI M, 1994, CURR BIOL, V4, P110, DOI 10.1016/S0960-9822(94)00026-6; MAJID MA, 1992, BIOCHIM BIOPHYS ACTA, V1136, P283, DOI 10.1016/0167-4889(92)90118-U; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; NAKAZAWA K, 1991, PFLUG ARCH EUR J PHY, V418, P214, DOI 10.1007/BF00370517; NAKAZAWA K, 1993, J GEN PHYSIOL, V101, P377, DOI 10.1085/jgp.101.3.377; NAKAZAWA K, 1990, NEUROSCI LETT, V119, P5, DOI 10.1016/0304-3940(90)90741-Q; NAKAZAWA K, 1990, J PHYSIOL-LONDON, V428, P257, DOI 10.1113/jphysiol.1990.sp018211; OWENS GP, 1991, MOL CELL BIOL, V11, P4177, DOI 10.1128/MCB.11.8.4177; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SILINSKY EM, 1992, BRIT J PHARMACOL, V106, P762, DOI 10.1111/j.1476-5381.1992.tb14408.x; SUZUKI M, 1994, NATURE, V367, P642, DOI 10.1038/367642a0; TECOTT LH, 1993, P NATL ACAD SCI USA, V90, P1430, DOI 10.1073/pnas.90.4.1430; THOMAS SA, 1990, J GEN PHYSIOL, V95, P569, DOI 10.1085/jgp.95.4.569; UNWIN N, 1993, CELL, V72, P31, DOI 10.1016/S0092-8674(05)80026-1	29	842	862	0	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 6	1994	371	6497					519	523		10.1038/371519a0	http://dx.doi.org/10.1038/371519a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK589	7523952				2022-12-24	WOS:A1994PK58900057
J	HUANG, ZH; HUANG, PL; PANAHIAN, N; DALKARA, T; FISHMAN, MC; MOSKOWITZ, MA				HUANG, ZH; HUANG, PL; PANAHIAN, N; DALKARA, T; FISHMAN, MC; MOSKOWITZ, MA			EFFECTS OF CEREBRAL-ISCHEMIA IN MICE DEFICIENT IN NEURONAL NITRIC-OXIDE SYNTHASE	SCIENCE			English	Article							L-ARGININE; GUANYLATE-CYCLASE; ARTERY OCCLUSION; BRAIN; STIMULATION; MECHANISMS	The proposal that nitric oxide (NO) or its reactant products mediate toxicity in brain remains controversial in part because of the use of nonselective agents that block NO formation in neuronal, glial, and vascular compartments. In mutant mice deficient in neuronal NO synthase (NOS) activity, infarct volumes decreased significantly 24 and 72 hours after middle cerebral artery occlusion, and the neurological deficits were less than those in normal mice. This result could not be accounted for by differences in blood flow or vascular anatomy. However, infarct size in the mutant became larger after endothelial NOS inhibition by nitro-L-arginine administration. Hence, neuronal NO production appears to exacerbate acute ischemic injury, whereas vascular NO protects after middle cerebral artery occlusion. The data emphasize the importance of developing selective inhibitors of the neuronal isoform.	MASSACHUSETTS GEN HOSP,STROKE RES LAB,BOSTON,MA 02129; HARVARD UNIV,SCH MED,NEUROSURG SERV,BOSTON,MA 02139; HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02129; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,CARDIOVASC RES CTR,DEPT MED,BOSTON,MA 02129	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital			Moskowitz, Michael A/D-9916-2011	Dalkara, Turgay/0000-0003-3943-7819	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS010828, P50NS010828] Funding Source: NIH RePORTER; NINDS NIH HHS [NS2636, NS10828] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; CHAN PH, 1994, BRAIN PATHOL, V4, P59; CHOI DW, 1993, P NATL ACAD SCI USA, V90, P9741, DOI 10.1073/pnas.90.21.9741; DALKARA T, 1994, AM J PHYSIOL, V267, pH678, DOI 10.1152/ajpheart.1994.267.2.H678; DALKARA T, 1994, BRAIN PATHOL, V4, P49; DALKARA T, UNPUB; DAWSON TM, 1992, ANN NEUROL, V32, P297, DOI 10.1002/ana.410320302; DAWSON VL, 1993, J NEUROSCI, V13, P2651; DINERMAN JL, 1994, P NATL ACAD SCI USA, V91, P4214, DOI 10.1073/pnas.91.10.4214; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; HUANG Z, UNPUB; IADECOLA C, 1994, J CEREBR BLOOD F MET, V14, P175, DOI 10.1038/jcbfm.1994.25; IRIKURA K, 1994, AM J PHYSIOL, V267, pH837, DOI 10.1152/ajpheart.1994.267.2.H837; KADER A, 1993, STROKE, V24, P1709, DOI 10.1161/01.STR.24.11.1709; KATSUKI S, 1977, J CYCLIC NUCL PROT, V3, P23; KNOWLES RG, 1989, P NATL ACAD SCI USA, V86, P5159, DOI 10.1073/pnas.86.13.5159; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MALINSKI T, 1993, J CEREBR BLOOD F MET, V13, P355, DOI 10.1038/jcbfm.1993.48; MONCADA S, 1991, PHARMACOL REV, V43, P109; MORIKAWA E, 1992, AM J PHYSIOL, V263, pH1632, DOI 10.1152/ajpheart.1992.263.5.H1632; MORIKAWA E, 1992, BRIT J PHARMACOL, V107, P905, DOI 10.1111/j.1476-5381.1992.tb13382.x; MORIKAWA E, 1994, STROKE, V25, P429, DOI 10.1161/01.STR.25.2.429; MOSKOWITZ MA, UNPUB; ODELL TJ, 1994, SCIENCE, V265, P542, DOI 10.1126/science.7518615; PANAHIAN N, UNPUB; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; WARD R, 1990, J ANAT, V173, P87; WINK DA, 1993, P NATL ACAD SCI USA, V90, P9813, DOI 10.1073/pnas.90.21.9813; YANG GY, 1994, STROKE, V25, P165, DOI 10.1161/01.STR.25.1.165; YOSHIDA T, 1994, J CEREBR BLOOD F MET, V14, P924, DOI 10.1038/jcbfm.1994.123; ZHANG J, 1992, P NATL ACAD SCI USA, V89, P9382, DOI 10.1073/pnas.89.20.9382	33	1397	1469	1	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 23	1994	265	5180					1883	1885		10.1126/science.7522345	http://dx.doi.org/10.1126/science.7522345			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH258	7522345				2022-12-24	WOS:A1994PH25800038
J	LORSCH, JR; SZOSTAK, JW				LORSCH, JR; SZOSTAK, JW			IN-VITRO EVOLUTION OF NEW RIBOZYMES WITH POLYNUCLEOTIDE KINASE-ACTIVITY	NATURE			English	Article							STRANDED-DNA MOLECULES; INVITRO SELECTION; RNA ENZYME; CLEAVAGE; RECOGNITION; TETRAHYMENA; POLYMERASE; CATALYSIS; SEQUENCE; LIGANDS	We have isolated a large number of polynucleotide kinase ribozymes from a pool of RNA molecules consisting of an ATP-binding domain flanked by regions of random sequence. Different classes of kinases catalyse the transfer of the gamma-thiophosphate of ATP-gamma S to the 5'-hydroxyl or to internal 2'-hydroxyls. An engineered version of one class is able to catalyse the transfer of thiophosphate from ATP-gamma S to the 5'-hydroxyl of an exogenous oligoribonucleotide substrate with multiple turnover, thus acting as a true enzyme.	HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA; HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02115 USA	Harvard University; Harvard University; Harvard Medical School	LORSCH, JR (corresponding author), MASSACHUSETTS GEN HOSP, DEPT MOLEC BIOL, BOSTON, MA 02114 USA.			Lorsch, Jon/0000-0002-4521-4999				BARTEL DP, 1991, CELL, V67, P529, DOI 10.1016/0092-8674(91)90527-6; BARTEL DP, 1993, SCIENCE, V261, P1411, DOI 10.1126/science.7690155; BASS BL, 1984, NATURE, V308, P820, DOI 10.1038/308820a0; BEAUDRY AA, 1992, SCIENCE, V257, P635, DOI 10.1126/science.1496376; BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0; BRESLOW R, 1968, J AM CHEM SOC, V90, P7376, DOI 10.1021/ja01028a054; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; CHOWRIRA BM, 1991, NATURE, V354, P320, DOI 10.1038/354320a0; CONNELL GJ, 1993, BIOCHEMISTRY-US, V32, P5497, DOI 10.1021/bi00072a002; DAHM SC, 1993, BIOCHEMISTRY-US, V32, P13040, DOI 10.1021/bi00211a013; DOMDEY H, 1979, ANAL BIOCHEM, V98, P346, DOI 10.1016/0003-2697(79)90152-0; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; ELLINGTON AD, 1992, NATURE, V355, P850, DOI 10.1038/355850a0; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; FAMULOK M, 1992, J AM CHEM SOC, V114, P3990, DOI 10.1021/ja00036a065; FAMULOK M, 1994, J AM CHEM SOC, V116, P1698, DOI 10.1021/ja00084a010; Fersht A., 1985, ENZYME STRUCTURE MEC; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; GREEN R, 1992, SCIENCE, V258, P1910, DOI 10.1126/science.1470913; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HERSCHLAG D, 1991, BIOCHEMISTRY-US, V30, P4844, DOI 10.1021/bi00234a003; JENISON RD, 1994, SCIENCE, V263, P1425, DOI 10.1126/science.7510417; KONARSKA M, 1981, NATURE, V293, P112, DOI 10.1038/293112a0; LEHMAN N, 1993, NATURE, V361, P182, DOI 10.1038/361182a0; LILLEHAUG JR, 1975, BIOCHEMISTRY-US, V14, P1221, DOI 10.1021/bi00677a020; LORSCH JR, 1994, BIOCHEMISTRY-US, V33, P973, DOI 10.1021/bi00170a016; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; PAN T, 1992, BIOCHEMISTRY-US, V31, P3887, DOI 10.1021/bi00131a001; PERROTTA AT, 1992, BIOCHEMISTRY-US, V31, P16, DOI 10.1021/bi00116a004; PRUDENT JR, 1994, SCIENCE, V264, P1924; PYLE AM, 1994, BIOCHEMISTRY-US, V33, P2716, DOI 10.1021/bi00175a047; RAMIREZ F, 1980, J ORG CHEM, V45, P4748, DOI 10.1021/jo01311a038; Richardson C.C., 1981, ENZYMES A, V14, P299, DOI DOI 10.1016/S1874-6047(08)60342-X; SASSANFAR M, 1993, NATURE, V364, P550, DOI 10.1038/364550a0; TSAI DE, 1992, P NATL ACAD SCI USA, V89, P8864, DOI 10.1073/pnas.89.19.8864; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; WESTAWAY SK, 1993, J BIOL CHEM, V268, P2435; ZAUG AJ, 1986, BIOCHEMISTRY-US, V25, P4478, DOI 10.1021/bi00364a002; ZIMMERMAN SB, 1981, ENZYMES, V14, P315	39	218	243	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 1	1994	371	6492					31	36		10.1038/371031a0	http://dx.doi.org/10.1038/371031a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE381	7521014				2022-12-24	WOS:A1994PE38100041
J	KOZAL, MJ; KROODSMA, K; WINTERS, MA; SHAFER, RW; EFRON, B; KATZENSTEIN, DA; MERIGAN, TC				KOZAL, MJ; KROODSMA, K; WINTERS, MA; SHAFER, RW; EFRON, B; KATZENSTEIN, DA; MERIGAN, TC			DIDANOSINE RESISTANCE IN HIV-INFECTED PATIENTS SWITCHED FROM ZIDOVUDINE TO DIDANOSINE MONOTHERAPY	ANNALS OF INTERNAL MEDICINE			English	Article						HUMAN IMMUNODEFICIENCY VIRUS; DRUG RESISTANCE; ZIDOVUDINE; DIDANOSINE; ANTIGENS, CD4	HUMAN-IMMUNODEFICIENCY-VIRUS; SYNCYTIUM-INDUCING PHENOTYPE; POLYMERASE CHAIN-REACTION; HIGH-LEVEL RESISTANCE; REVERSE-TRANSCRIPTASE; REDUCED SENSITIVITY; TYPE-1; MUTATIONS; AZT; RNA	Objective: To determine the frequency and pattern of development of specific drug resistance mutations for human immunodeficiency virus (HIV) reverse transcriptase in patients switched from zidovudine to didanosine therapy and to examine the relation of the didanosine resistance mutation at codon 74 of the HIV reverse-transcriptase gene to CD4(+) T-cell changes and virus burden. Design: Retrospective analysis of all patients enrolled at Stanford University in protocols where patients were switched from zidovudine to didanosine monotherapy. Setting: A university hospital. Patients: 64 patients infected with HIV who were switched from zidovudine to didanosine monotherapy. Patients had the acquired immunodeficiency syndrome (AIDS), AIDS-related complex, or were asymptomatic (mean [+/-SD] starting CD4(+) T-cell count of 129 +/- 88 cells/mm(3)). Measurements: Serial serum specimens were tested for the didanosine resistance mutation at codon 74 of the HIV reverse-transcriptase gene and for a zidovudine resistance mutation at codon 215 using selective polymerase chain reactions (PCR). Serum HIV RNA levels were determined by quantitative PCR. CD4(+) T-cell counts were determined at serial time points. Results: By 24 weeks of didanosine therapy, the proportion of patients with the didanosine resistance mutation at codon 74 increased from 0% to 56% (36 of 64). In contrast, the proportion of patients with the zidovudine resistance mutation at codon 215 decreased from 84% at the start to 59% after 24 weeks of didanosine therapy (a 25% decrease, 95% lower CI, 15%; P < 0.0001). Patients who developed the codon 74 mutation had a greater decrease in CD4(+) T cells after the development of the mutation than did patients without the mutation (P < 0.001). In addition, after 24 weeks of didanosine, patients who developed the codon 74 mutation had a greater serum HIV RNA burden than patients who remained wild type (did not have the mutation) at codon 74 (225 000 compared with 82 400 HIV RNA copies/mL serum; P = 0.01). Conclusions: Among patients infected with HIV who had advanced disease and were switched from zidovudine to didanosine therapy, more than one half developed the didanosine resistance mutation at codon 74 by 24 weeks of didanosine therapy. Patients who developed the codon 74 mutation had a greater decline in CD4(+) T cells after the development of the mutation and had a greater serum virus burden than did patients without the codon 74 mutation.			KOZAL, MJ (corresponding author), STANFORD UNIV, MED CTR, DIV INFECT DIS, ROOM S-156, STANFORD, CA 94305 USA.		Merigan, Thomas/AGQ-7464-2022	Kozal, Michael/0000-0002-3100-8254; katzenstein, david/0000-0002-8593-4560; , Michael/0000-0002-7719-7396	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027762, U01AI027666] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-27762, AI-27666] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOUCHER CAB, 1992, J INFECT DIS, V165, P105, DOI 10.1093/infdis/165.1.105; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAQUILA RT, 1993, 1ST NAT C HUM RETR R; DAVEY RT, 1993, P NATL ACAD SCI USA, V90, P5608, DOI 10.1073/pnas.90.12.5608; ERON JJ, 1993, ANTIMICROB AGENTS CH, V37, P1480, DOI 10.1128/AAC.37.7.1480; GU ZX, 1992, J VIROL, V66, P7128, DOI 10.1128/JVI.66.12.7128-7135.1992; JAPOUR AJ, 1991, P NATL ACAD SCI USA, V88, P3092, DOI 10.1073/pnas.88.8.3092; KAHN JO, 1992, NEW ENGL J MED, V327, P581, DOI 10.1056/NEJM199208273270901; KAPPES JC, 1992, 8 INT C AIDS AMST; KATZENSTEIN DA, 1994, J INFECT DIS, V169, P416, DOI 10.1093/infdis/169.2.416; KELLAM P, 1992, P NATL ACAD SCI USA, V89, P1934, DOI 10.1073/pnas.89.5.1934; KOOT M, 1993, ANN INTERN MED, V118, P681, DOI 10.7326/0003-4819-118-9-199305010-00004; KOOT M, 1992, AIDS, V6, P49, DOI 10.1097/00002030-199201000-00006; KOZAL MJ, 1993, J INFECT DIS, V167, P526, DOI 10.1093/infdis/167.3.526; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1991, AIDS, V5, P137, DOI 10.1097/00002030-199102000-00002; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; Larder Brendan A., 1993, P527; MAYERS DL, 1993, 1ST NAT C HUM RETR R; MONTANER JSG, 1993, AIDS, V7, P189, DOI 10.1097/00002030-199302000-00006; REICHMAN RC, 1993, ANTIVIR RES, V20, P267, DOI 10.1016/0166-3542(93)90071-P; RICHMAN DD, 1991, J INFECT DIS, V164, P1075, DOI 10.1093/infdis/164.6.1075; RICHMAN DD, 1990, J ACQ IMMUN DEF SYND, V3, P743; RICHMAN DD, 1993, ANTIMICROB AGENTS CH, V37, P1207, DOI 10.1128/AAC.37.6.1207; RICHMAN DD, 1992, 8 INT C AIDS AMST, P3576; SHAFER RW, 1994, J INFECT DIS, V169, P722, DOI 10.1093/infdis/169.4.722; SHIRASAKA T, 1993, P NATL ACAD SCI USA, V90, P562, DOI 10.1073/pnas.90.2.562; STCLAIR MH, 1993, J ACQ IMMUN DEF SYND, V6, P891; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; TERSMETTE M, 1989, LANCET, V1, P983; TISDALE M, 1993, P NATL ACAD SCI USA, V90, P5653, DOI 10.1073/pnas.90.12.5653; TUDORWILLIAMS G, 1992, LANCET, V339, P15, DOI 10.1016/0140-6736(92)90140-X; Winters M A, 1992, PCR Methods Appl, V1, P257; WINTERS MA, 1993, J CLIN MICROBIOL, V31, P2960, DOI 10.1128/JCM.31.11.2960-2966.1993	34	60	61	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1994	121	4					263	268		10.7326/0003-4819-121-4-199408150-00005	http://dx.doi.org/10.7326/0003-4819-121-4-199408150-00005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB102	7518658				2022-12-24	WOS:A1994PB10200005
J	HOFFMAN, DM; OSULLIVAN, AJ; BAXTER, RC; HO, KKY				HOFFMAN, DM; OSULLIVAN, AJ; BAXTER, RC; HO, KKY			DIAGNOSIS OF GROWTH-HORMONE DEFICIENCY IN ADULTS	LANCET			English	Article							BINDING-PROTEIN; SOMATOMEDIN-C; RADIOIMMUNOASSAY; AGE; MEN; GH; SECRETION; PROFILES; PLASMA	There is no consensus as to the most appropriate method of diagnosing growth-hormone (GH) deficiency in adults. We have evaluated the relative diagnostic merits of measuring peak GH response to insulin-induced hypoglycaemia (insulin tolerance test), mean 24 h GH concentration derived from 20 min sampling, serum insulin-like growth factor I (IGF-I) concentrations, and serum IGF binding protein 3 (IGFBP-3) concentrations. These tests were undertaken in 23 patients considered GH deficient from extensive organic pituitary disease, and in 35 sex-matched normal subjects of similar age and body-mass index. Hypopituitary subjects had significantly lower stimulated peak GH, mean 24 h GH, IGF-I, and IGFBP-3 concentrations than normal subjects. The ranges of stimulated peak GH responses were clearly separated between the hypopituitary (<0.2-3.1 ng/mL) and normal (5.3-42.5 ng/mL) groups, but mean 24 h GH, IGF-I, and IGFBP-3 concentrations overlapped. Mean 24 h GH concentrations were below assay sensitivity in 80% of hypopituitary subjects and 16% of normal subjects. 70% and 72%, respectively, of the IGF-I and IGFBP-3 values in hypopituitary subjects were within the range for normal subjects. We conclude that GH deficiency in adults is most reliably identified by stimulatory testing, and that IGF-I and IGFBP-3 are poor diagnostic tests of adult GH deficiency.	ST VINCENTS HOSP,GARVAN INST MED RES,DARLINGHURST,NSW 2010,AUSTRALIA; ROYAL PRINCE ALFRED HOSP,SYDNEY,AUSTRALIA	Garvan Institute of Medical Research; St Vincents Hospital Sydney; University of Sydney			Ho, Ken/AAA-7428-2019; Ho, Ken KY/E-5832-2011; Baxter, Robert C/F-3927-2012	Ho, Ken/0000-0002-2508-9588; Baxter, Robert C/0000-0001-5061-2142				BARKAN AL, 1988, J CLIN ENDOCR METAB, V67, P69, DOI 10.1210/jcem-67-1-69; BAXTER RC, 1982, CLIN CHEM, V28, P488; BAXTER RC, 1993, TRENDS ENDOCRIN MET, V4, P91, DOI 10.1016/1043-2760(93)90085-S; BAXTER RC, 1986, J CLIN INVEST, V78, P1504, DOI 10.1172/JCI112742; BENGTSSON BA, 1993, J CLIN ENDOCR METAB, V76, P309, DOI 10.1210/jc.76.2.309; BLUM WF, 1993, J CLIN ENDOCR METAB, V76, P1610, DOI 10.1210/jc.76.6.1610; BLUM WF, 1990, J CLIN ENDOCR METAB, V70, P1292, DOI 10.1210/jcem-70-5-1292; CUNEO RC, 1991, J APPL PHYSIOL, V70, P695, DOI 10.1152/jappl.1991.70.2.695; GREENWOO.FC, 1966, J CLIN INVEST, V45, P429, DOI 10.1172/JCI105357; HINTZ RL, 1993, GROWTH HORMONE REPLA, P157; HO KKY, IN PRESS CLIN ENDOCR; HO KY, 1989, CLIN ENDOCRINOL, V30, P335, DOI 10.1111/j.1365-2265.1989.tb00431.x; HO KY, 1987, J CLIN ENDOCR METAB, V64, P51, DOI 10.1210/jcem-64-1-51; IRANMANESH A, 1991, J CLIN ENDOCR METAB, V73, P1081, DOI 10.1210/jcem-73-5-1081; JORGENSEN JOL, 1989, LANCET, V1, P1221; LANDON J, 1966, J CLIN INVEST, V45, P437, DOI 10.1172/JCI105358; LAUGHLIN GA, 1993, 75TH P ANN M END SOC; RUDMAN D, 1990, NEW ENGL J MED, V323, P1, DOI 10.1056/NEJM199007053230101; SAINI S, 1991, CLIN ENDOCRINOL, V34, P455, DOI 10.1111/j.1365-2265.1991.tb00325.x; SALOMON F, 1989, NEW ENGL J MED, V321, P1797, DOI 10.1056/NEJM198912283212605; VELDHUIS JD, 1991, J CLIN ENDOCR METAB, V72, P51, DOI 10.1210/jcem-72-1-51; VERMEULEN A, 1987, J CLIN ENDOCR METAB, V64, P884, DOI 10.1210/jcem-64-5-884; ZADIK Z, 1985, J CLIN ENDOCR METAB, V60, P513, DOI 10.1210/jcem-60-3-513	23	418	423	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 30	1994	343	8905					1064	1068		10.1016/S0140-6736(94)90181-3	http://dx.doi.org/10.1016/S0140-6736(94)90181-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NJ694	7512681				2022-12-24	WOS:A1994NJ69400009
J	CLINTON, JJ				CLINTON, JJ			BENIGN PROSTATIC HYPERPLASIA (BPH) - DIAGNOSIS AND TREATMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											CLINTON, JJ (corresponding author), AGCY HLTH CARE POLICY & RES,POB 8547,SILVER SPRING,MD 20907, USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 20	1994	271	15					1151	1151		10.1001/jama.271.15.1151	http://dx.doi.org/10.1001/jama.271.15.1151			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF207	7512166				2022-12-24	WOS:A1994NF20700006
J	UMEMORI, H; SATO, S; YAGI, T; AIZAWA, S; YAMAMOTO, T				UMEMORI, H; SATO, S; YAGI, T; AIZAWA, S; YAMAMOTO, T			INITIAL EVENTS OF MYELINATION INVOLVE FYN TYROSINE KINASE SIGNALING	NATURE			English	Article							CELL ANTIGEN RECEPTOR; SRC PROTEIN; TERMINAL REGION; GLYCOPROTEIN; ASSOCIATION; FAMILY; ADHESION; BRAIN; EXPRESSION; EFFICIENT	MYELIN is the lipoprotein multimembrane that functions as an insulator preventing the flow of ion currents across the axonal membrane and facilitating the conduction of nerve impulses. It is synthesized by oligodendrocytes in the central nervous system at about the time of birth in mammals1. During the initial stages of myelination, several proteins are phosphorylated on tyrosine. Among these proteins, we identified Fyn tyrosine kinase, one of the non-receptor-type tyrosine kinases of the Src family. Here we report that Fyn tyrosine kinase is activated during the initial stages of myelination and that it is associated with the large myelin-associated glycoprotein (MAG), an adhesion molecule that has been implicated in myelinogenesis2. The Fyn-large MAG association requires amino-terminal domains of Fyn that include SH2 and SH3 (Src homology domains 2 and 3). Crosslinking of large MAG with antibody induces a rapid increase in the specific activity of Fyn kinase. These results indicate that Fyn participates in the initial events of myelination as a signalling molecule downstream of large MAG; indeed, we find that fyn-deficient mice exhibit impaired myelination.	UNIV TOKYO,INST MED SCI,DEPT ONCOL,4-6-1 SHIROKANEDAI,MINATO KU,TOKYO 108,JAPAN; NIIGATA UNIV,BRAIN RES INST,DEPT NEUROL,NIIGATA 951,JAPAN; INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOLEC ONCOL LAB,TSUKUBA,IBARAKI 305,JAPAN	University of Tokyo; Niigata University; RIKEN			Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763; Umemori, Hisashi/0000-0001-7198-2062				Cooper J.A, 1990, PEPT PROT PHOSPH, P85; DUNCAN ID, 1990, MYELINATION DYSMYELI; EDWARDS AM, 1988, MOL CELL BIOL, V8, P2655, DOI 10.1128/MCB.8.6.2655; EISEMAN E, 1992, NATURE, V355, P78; FUJITA N, 1989, BIOCHEM BIOPH RES CO, V165, P1162, DOI 10.1016/0006-291X(89)92724-1; FUJITA N, 1990, J NEUROCHEM, V55, P1056, DOI 10.1111/j.1471-4159.1990.tb04596.x; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; JOHNSON PW, 1989, NEURON, V3, P377, DOI 10.1016/0896-6273(89)90262-6; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEMKE G, 1988, NEURON, V1, P535, DOI 10.1016/0896-6273(88)90103-1; NORTON WT, 1973, J NEUROCHEM, V21, P749, DOI 10.1111/j.1471-4159.1973.tb07519.x; OKADA M, 1991, J BIOL CHEM, V266, P24249; PARSONS SJ, 1986, J VIROL, V59, P755, DOI 10.1128/JVI.59.3.755-758.1986; POLTORAK M, 1987, J CELL BIOL, V105, P1893, DOI 10.1083/jcb.105.4.1893; SALZER JL, 1987, J CELL BIOL, V104, P957, DOI 10.1083/jcb.104.4.957; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; STERNBERGER NH, 1979, P NATL ACAD SCI USA, V76, P1510, DOI 10.1073/pnas.76.3.1510; SUDOL M, 1993, NEUROCHEM INT, V22, P369, DOI 10.1016/0197-0186(93)90019-2; SUKEGAWA J, 1990, ONCOGENE, V5, P611; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TANAKA A, 1987, MOL CELL BIOL, V7, P1978, DOI 10.1128/MCB.7.5.1978; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; UMEMORI H, 1992, MOL BRAIN RES, V16, P303, DOI 10.1016/0169-328X(92)90239-8; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; YAGI T, 1993, NATURE, V366, P742, DOI 10.1038/366742a0; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118	30	342	349	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 10	1994	367	6463					572	576		10.1038/367572a0	http://dx.doi.org/10.1038/367572a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MV863	7509042				2022-12-24	WOS:A1994MV86300063
J	RASSOULZADEGAN, M; PAQUISFLUCKLINGER, V; BERTINO, B; SAGE, J; JASIN, M; MIYAGAWA, K; VANHEYNINGEN, V; BESMER, P; CUZIN, F				RASSOULZADEGAN, M; PAQUISFLUCKLINGER, V; BERTINO, B; SAGE, J; JASIN, M; MIYAGAWA, K; VANHEYNINGEN, V; BESMER, P; CUZIN, F			TRANSMEIOTIC DIFFERENTIATION OF MALE GERM-CELLS IN CULTURE	CELL			English	Article							SEMINIFEROUS EPITHELIAL CYCLE; CYTOMETRIC DNA ANALYSIS; TUMOR GENE WT1; SERTOLI-CELL; TRANSGENIC MICE; MESSENGER-RNA; C-KIT; FLOW-CYTOMETRY; EXPRESSION; MOUSE	A cell culture system that supports the differentiation of male germ cells through meiosis is described. It takes advantage of the properties of a cell line, 15P-1, established from testicular cells of transgenic mice that express the large T protein of polyoma virus in the seminiferous epithelium. This line exhibits features characteristic of Sertoli cells, including transcription of the Wilms' tumor (WT1) and Steel genes. Cells of the 15P-1 type support the meiotic and postmeiotic differentiation in cocultures of diploid premeiotic germ cells into haploid spermatids expressing the protamine (Prm-1) gene. When cocultured with P-15-1 cells, testicular cells explanted from immature 9-day-old animals, before the onset of the first meiosis, generated tetrads of haploid cells with the morphology of round spermatids and initiated protamine transcription.	SLOAN KETTERING INST CANC RES, NEW YORK, NY 10021 USA; WESTERN GEN HOSP, MRC, HUMAN GENET UNIT, EDINBURGH EH4 2X4, SCOTLAND	Memorial Sloan Kettering Cancer Center; University of Edinburgh	RASSOULZADEGAN, M (corresponding author), UNIV NICE, INSERM, U273, F-06108 NICE 2, FRANCE.		VAN HEYNINGEN, Veronica/GYE-0531-2022; Rassoulzadegan, Minoo/O-7939-2016; van Heyningen, Veronica/B-8039-2008	van Heyningen, Veronica/0000-0003-0359-0141	Medical Research Council [MC_U127527199] Funding Source: Medline; MRC [MC_U127527199] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BAUER TW, 1990, AM J CLIN PATHOL, V93, P322, DOI 10.1093/ajcp/93.3.322; BRAUN RE, 1989, GENE DEV, V3, P793, DOI 10.1101/gad.3.6.793; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; CASTELLON E, 1989, MOL CELL ENDOCRINOL, V64, P169, DOI 10.1016/0303-7207(89)90143-3; CELI FS, 1993, NUCLEIC ACIDS RES, V21, P1047, DOI 10.1093/nar/21.4.1047; DJAKIEW D, 1988, BIOL REPROD, V39, P1193, DOI 10.1095/biolreprod39.5.1193; ERICKSONLAWRENCE M, 1991, MOL ENDOCRINOL, V5, P1789, DOI 10.1210/mend-5-12-1789; Fritz I. B., 1990, Biology of mammalian germ cell mutagenesis.., P19; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; GOETZ P, 1984, J CELL SCI, V65, P249; HOFMANN MC, 1992, EXP CELL RES, V201, P417, DOI 10.1016/0014-4827(92)90291-F; JASIN M, 1992, P NATL ACAD SCI USA, V89, P10681, DOI 10.1073/pnas.89.22.10681; JEGOU B, 1991, ANN NY ACAD SCI, V637, P340; KLEENE KC, 1985, BIOCHEMISTRY-US, V24, P719, DOI 10.1021/bi00324a027; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LACROIX M, 1981, BIOL REPROD, V25, P143, DOI 10.1095/biolreprod25.1.143; LEMAGUERESSE B, 1988, J ENDOCRINOL, V118, pR13, DOI 10.1677/joe.0.118R013; Leonard Davis G., 1986, BASIC METHODS MOL BI; MANOVA K, 1990, DEVELOPMENT, V110, P1057; MATHER JP, 1980, BIOL REPROD, V23, P243, DOI 10.1095/biolreprod23.1.243; MURTI JR, 1992, MOL CELL BIOL, V12, P2545, DOI 10.1128/MCB.12.6.2545; NISHIKAWA S, 1991, EMBO J, V10, P2111, DOI 10.1002/j.1460-2075.1991.tb07744.x; PAQUISFLUCKLINGER V, 1993, ONCOGENE, V8, P2087; PARVINEN M, 1986, INT REV CYTOL, V104, P115, DOI 10.1016/S0074-7696(08)61925-7; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PESCHON JJ, 1987, P NATL ACAD SCI USA, V84, P5316, DOI 10.1073/pnas.84.15.5316; ROSSI P, 1991, BIOCHEM BIOPH RES CO, V176, P910, DOI 10.1016/S0006-291X(05)80272-4; Russell L. D., 1990, HISTOLOGICAL HISTOPA; RUSSELL LD, 1983, AM J ANAT, V167, P181, DOI 10.1002/aja.1001670204; SHULDINER AR, 1991, P NATL ACAD SCI USA, V88, P7679, DOI 10.1073/pnas.88.17.7679; SKINNER MK, 1985, P NATL ACAD SCI USA, V82, P114, DOI 10.1073/pnas.82.1.114; STALLARD BJ, 1990, MOL ENDOCRINOL, V4, P393, DOI 10.1210/mend-4-3-393; Steinberger A, 1975, Methods Enzymol, V39, P283; TOKUDA N, 1992, J UROLOGY, V147, P278, DOI 10.1016/S0022-5347(17)37213-0; TOPPARI J, 1985, J ANDROL, V6, P325; VINDELOV LL, 1990, CYTOMETRY, V11, P753, DOI 10.1002/cyto.990110702	36	140	145	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 3	1993	75	5					997	1006		10.1016/0092-8674(93)90543-Y	http://dx.doi.org/10.1016/0092-8674(93)90543-Y			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MK966	7504588				2022-12-24	WOS:A1993MK96600019
J	BRUSA, R; ZIMMERMANN, F; KOH, DS; FELDMEYER, D; GASS, P; SEEBURG, PH; SPRENGEL, R				BRUSA, R; ZIMMERMANN, F; KOH, DS; FELDMEYER, D; GASS, P; SEEBURG, PH; SPRENGEL, R			EARLY-ONSET EPILEPSY AND POSTNATAL LETHALITY ASSOCIATED WITH AN EDITING-DEFICIENT GLUR-B ALLELE IN MICE	SCIENCE			English	Article							RECEPTOR CHANNELS; DIFFERENTIAL EXPRESSION; ION FLOW; GENE; SUBUNITS; NEURONS; PERMEABILITY; HIPPOCAMPUS; SWITCH; FAMILY	The arginine residue at position 586 of the GluR-B subunit renders heteromeric alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA)-sensitive glutamate receptor channels impermeable to calcium. The codon for this arginine is introduced at the precursor messenger RNA (pre-mRNA) stage by site-selective adenosine editing of a glutamine codon. Heterozygous mice engineered by gene targeting to harbor an editing-incompetent GluR-B allele synthesized unedited GluR-B subunits and, in principal neurons and interneurons, expressed AMPA receptors with increased calcium permeability. These mice developed seizures and died by 3 weeks of age, showing that GluR-B pre-mRNA editing is essential for brain function.	MAX PLANCK INST MED RES, ZELLPHYSIOL ABT, D-69120 HEIDELBERG, GERMANY; UNIV HEIDELBERG, INST NEUROPATHOL, D-69120 HEIDELBERG, GERMANY	Max Planck Society; Ruprecht Karls University Heidelberg	BRUSA, R (corresponding author), UNIV HEIDELBERG, CTR MOLEC BIOL, MOLEC NEUROENDOCRINOL LAB, NEUENHEIMER FELD 282, D-69120 HEIDELBERG, GERMANY.		Feldmeyer, Dirk/H-5940-2013	Feldmeyer, Dirk/0000-0002-1716-8972				BECK E, 1982, GENE, V19, P327, DOI 10.1016/0378-1119(82)90023-3; BECK KD, 1995, NEURON, V14, P717, DOI 10.1016/0896-6273(95)90216-3; BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; BURNASHEV N, 1995, J PHYSIOL-LONDON, V485, P403, DOI 10.1113/jphysiol.1995.sp020738; DISTREY BD, 1970, HISTOLOGICAL LABORAT; GALLIN WJ, 1995, CURR OPIN NEUROBIOL, V5, P367, DOI 10.1016/0959-4388(95)80050-6; GASS P, 1992, NEUROSCIENCE, V48, P315, DOI 10.1016/0306-4522(92)90493-L; GEIGER JRP, 1995, NEURON, V15, P193, DOI 10.1016/0896-6273(95)90076-4; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; Hauser W, 1990, EPILEPSY FREQUENCY C; HESTRIN S, 1993, NEURON, V11, P1083, DOI 10.1016/0896-6273(93)90221-C; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; ISHII T, 1993, J BIOL CHEM, V268, P2836; JONAS P, 1994, NEURON, V12, P1281, DOI 10.1016/0896-6273(94)90444-8; Jonas Peter, 1994, Current Opinion in Neurobiology, V4, P366, DOI 10.1016/0959-4388(94)90098-1; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KOH DS, 1995, J PHYSIOL-LONDON, V485, P383, DOI 10.1113/jphysiol.1995.sp020737; KOHLER M, 1994, J BIOL CHEM, V269, P17367; LAMBOLEZ B, 1992, NEURON, V9, P247, DOI 10.1016/0896-6273(92)90164-9; LEWIS CA, 1979, J PHYSIOL-LONDON, V286, P417, DOI 10.1113/jphysiol.1979.sp012629; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; MAYER ML, 1987, J PHYSIOL-LONDON, V394, P501, DOI 10.1113/jphysiol.1987.sp016883; MCNAMARA JO, 1994, J NEUROSCI, V14, P3413; MELCHER T, 1995, J BIOL CHEM, V270, P8566, DOI 10.1074/jbc.270.15.8566; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; NADLER JV, 1981, LIFE SCI, V29, P2031; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nakajima S, 1991, Hippocampus, V1, P67, DOI 10.1002/hipo.450010107; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; RUETER SM, 1995, SCIENCE, V267, P1491, DOI 10.1126/science.7878468; SAKIMURA K, 1990, FEBS LETT, V272, P73, DOI 10.1016/0014-5793(90)80452-O; SATHER W, 1992, J PHYSIOL-LONDON, V450, P643, DOI 10.1113/jphysiol.1992.sp019148; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; STERNBERG N, 1986, J MOL BIOL, V187, P197, DOI 10.1016/0022-2836(86)90228-7; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; WATANABE M, 1992, NEUROREPORT, V3, P1138, DOI 10.1097/00001756-199212000-00027; WISDEN W, 1990, NEURON, V4, P603, DOI 10.1016/0896-6273(90)90118-Y; YANG JH, 1995, NATURE, V374, P77, DOI 10.1038/374077a0	44	457	471	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 8	1995	270	5242					1677	1680		10.1126/science.270.5242.1677	http://dx.doi.org/10.1126/science.270.5242.1677			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ293	7502080				2022-12-24	WOS:A1995TJ29300052
J	YIN, H; WANG, MD; SVOBODA, K; LANDICK, R; BLOCK, SM; GELLES, J				YIN, H; WANG, MD; SVOBODA, K; LANDICK, R; BLOCK, SM; GELLES, J			TRANSCRIPTION AGAINST AN APPLIED FORCE	SCIENCE			English	Article							RNA-POLYMERASE; ESCHERICHIA-COLI; SINGLE MOLECULES; DNA; TEMPLATE	The force produced by a single molecule of Escherichia coli RNA polymerase during transcription was measured optically. Polymerase immobilized on a surface was used to transcribe a DNA template attached to a polystyrene bead 0.5 micrometer in diameter. The bead position was measured by interferometry while a force opposing translocation of the polymerase along the DNA was applied with an optical trap. At saturating nucleoside triphosphate concentrations, polymerase molecules stalled reversibly at a mean applied force estimated to be 14 piconewtons. This force is substantially larger than those measured for the cytoskeletal motors kinesin and myosin and exceeds mechanical loads that are estimated to oppose transcriptional elongation in vivo. The data are consistent with efficient conversion of the free energy liberated by RNA synthesis into mechanical work.	BRANDEIS UNIV, DEPT BIOCHEM, BIOPHYS PROGRAM, WALTHAM, MA 02254 USA; BRANDEIS UNIV, CTR COMPLEX SYST, WALTHAM, MA 02254 USA; PRINCETON UNIV, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA; PRINCETON UNIV, PRINCETON MAT INST, PRINCETON, NJ 08544 USA; AT&T BELL LABS, DEPT BIOL COMPUTAT, MURRAY HILL, NJ 07974 USA; UNIV WISCONSIN, DEPT BACTERIOL, MADISON, WI 53706 USA	Brandeis University; Brandeis University; Princeton University; Princeton University; AT&T; Nokia Corporation; Nokia Bell Labs; University of Wisconsin System; University of Wisconsin Madison								BLOCK SM, 1995, TRENDS CELL BIOL, V5, P169, DOI 10.1016/S0962-8924(00)88982-5; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; BUSTAMANTE C, 1994, SCIENCE, V265, P1599, DOI 10.1126/science.8079175; CHAMBERLIN M, 1963, J MOL BIOL, V7, P334, DOI 10.1016/S0022-2836(63)80028-5; Chamberlin M.J., 1994, HARVEY LECT, V88, P1; CHAN CL, 1994, TRANSCRIPTION MECHAN, P297; COOK DN, 1992, P NATL ACAD SCI USA, V89, P10603, DOI 10.1073/pnas.89.22.10603; COOK DN, 1994, NUCL ACIDS MOL BIOL, V8, P133; COOK PR, 1994, BIOESSAYS, V16, P425, DOI 10.1002/bies.950160611; ERIE DA, 1993, SCIENCE, V262, P867, DOI 10.1126/science.8235608; ERIE DA, 1992, ANNU REV BIOPH BIOM, V21, P379, DOI 10.1146/annurev.bb.21.060192.002115; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; FINER JT, 1995, BIOPHYS J, V68, pS291; HUNT AJ, 1994, BIOPHYS J, V67, P766, DOI 10.1016/S0006-3495(94)80537-5; ISHIJIMA A, 1994, BIOCHEM BIOPH RES CO, V199, P1057, DOI 10.1006/bbrc.1994.1336; KABATA H, 1993, SCIENCE, V262, P1561, DOI 10.1126/science.8248804; KRUMMEL B, 1992, J MOL BIOL, V225, P221, DOI 10.1016/0022-2836(92)90917-9; KRUMMEL B, 1992, J MOL BIOL, V225, P239, DOI 10.1016/0022-2836(92)90918-A; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; MIYATA H, 1995, BIOPHYS J, V68, pS286; NUDLER E, 1995, CELL, V81, P351, DOI 10.1016/0092-8674(95)90388-7; NUDLER E, 1994, SCIENCE, V265, P793, DOI 10.1126/science.8047884; SCHAFER DA, 1991, NATURE, V352, P444, DOI 10.1038/352444a0; SMITH SB, 1992, SCIENCE, V258, P1122, DOI 10.1126/science.1439819; SVOBODA K, 1994, ANNU REV BIOPH BIOM, V23, P247, DOI 10.1146/annurev.bb.23.060194.001335; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; WANG DG, 1995, CELL, V81, P341, DOI 10.1016/0092-8674(95)90387-9; WANG JC, 1992, TRANSCRIPTIONAL REGU, P1253; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8; YAGER TD, 1987, ESCHERICHIA COLI SAL, V2, P1241; YIN H, 1994, BIOPHYS J, V67, P2468, DOI 10.1016/S0006-3495(94)80735-0	32	466	491	0	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 8	1995	270	5242					1653	1657		10.1126/science.270.5242.1653	http://dx.doi.org/10.1126/science.270.5242.1653			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ293	7502073				2022-12-24	WOS:A1995TJ29300045
J	KOUNNAS, MZ; MOIR, RD; REBECK, GW; BUSH, AI; ARGRAVES, WS; TANZI, RE; HYMAN, BT; STRICKLAND, DK				KOUNNAS, MZ; MOIR, RD; REBECK, GW; BUSH, AI; ARGRAVES, WS; TANZI, RE; HYMAN, BT; STRICKLAND, DK			LDL RECEPTOR-RELATED PROTEIN, A MULTIFUNCTIONAL APOE RECEPTOR, BINDS SECRETED BETA-AMYLOID PRECURSOR PROTEIN AND MEDIATES ITS DEGRADATION	CELL			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; SPORADIC ALZHEIMERS-DISEASE; ACTIVATOR INHIBITOR TYPE-1; ALPHA-2-MACROGLOBULIN RECEPTOR; APOLIPOPROTEIN-E; PLASMINOGEN-ACTIVATOR; MESSENGER-RNA; NEXIN-II; CELL; PURIFICATION	The secreted form of beta-amyloid precursor protein (APP) containing the Kunitz proteinase inhibitor (KPI) domain, also called protease nexin II, is internalized and degraded by cells. We show that the low density lipoprotein (LDL) receptor-related protein (LRP) is responsible for the endocytosis of secreted APP. APP(S)770 degradation is inhibited by an LRP antagonist called the receptor-associated protein (RAP) and by LRP antibodies and is greatly diminished in fibroblasts genetically deficient in LRP. APP(S)695, which lacks the KPI domain, isa poor LRP ligand, Since LRP also binds apolipoprotein E (apoE)-enriched lipoproteins and inheritance of the epsilon 4 allele of the apoE gene is a risk factor for Alzheimer's disease (AD), these data link in a single metabolic pathway two molecules strongly implicated in the pathophysiology of AD.	AMER RED CROSS,HOLLAND LABS,DEPT BIOCHEM,ROCKVILLE,MD 20855; MASSACHUSETTS GEN HOSP,GENET & AGING LAB,BOSTON,MA 02129; MASSACHUSETTS GEN HOSP,NEUROL SERV,BOSTON,MA 02114	American Red Cross; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital			Rebeck, George William/J-2192-2012; Moir, Robert D./M-7612-2017; Bush, Ashley/Y-2457-2019; Tanzi, Rudolph/AAE-9622-2019; Bush, Ashley I/A-1186-2007	Rebeck, George William/0000-0001-6276-248X; Moir, Robert D./0000-0001-5431-3553; Bush, Ashley/0000-0001-8259-9069; Tanzi, Rudolph/0000-0002-7032-1454; Bush, Ashley I/0000-0001-8259-9069	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045598] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042581] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50787] Funding Source: Medline; NIDDK NIH HHS [DK45598] Funding Source: Medline; NIGMS NIH HHS [GM42581] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE K, 1991, NEUROSCI LETT, V125, P172, DOI 10.1016/0304-3940(91)90020-T; ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BREEN KC, 1991, J NEUROSCI RES, V28, P90, DOI 10.1002/jnr.490280109; BREEN KC, 1992, MOL CHEM NEUROPATHOL, V16, P109, DOI 10.1007/BF03159964; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; BUSH AI, 1993, J BIOL CHEM, V268, P16109; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GODYNA S, 1995, J CELL BIOL, V129, P1403, DOI 10.1083/jcb.129.5.1403; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HERZ J, 1991, J BIOL CHEM, V266, P21232; HYMAN BT, 1995, P NATL ACAD SCI USA, V92, P3586, DOI 10.1073/pnas.92.8.3586; HYMAN BT, 1992, J NEUROPATH EXP NEUR, V51, P76, DOI 10.1097/00005072-199201000-00009; JIN LW, 1994, J NEUROSCI, V14, P5461; JOHNSONWOOD KL, 1994, BIOCHEM BIOPH RES CO, V200, P1685, DOI 10.1006/bbrc.1994.1646; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KNAUER DJ, 1982, P NATL ACAD SCI-BIOL, V79, P2310, DOI 10.1073/pnas.79.7.2310; KNAUER DJ, 1983, J CELL PHYSIOL, V117, P385, DOI 10.1002/jcp.1041170314; KOO EH, 1990, NEURON, V2, P97; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P21862; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P9307, DOI 10.1074/jbc.270.16.9307; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KOUNNAS MZ, 1994, IN VIVO, V8, P342; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 1995, IN PRESS APOLIPOPROT; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MEDH JD, 1995, J BIOL CHEM, V270, P536, DOI 10.1074/jbc.270.2.536; MIKHAILENKO I, 1995, J BIOL CHEM, V270, P9543, DOI 10.1074/jbc.270.16.9543; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; MOESTRUP SK, 1989, J BIOL CHEM, V264, P15574; MOIR RD, 1992, J NEUROCHEM, V59, P1490, DOI 10.1111/j.1471-4159.1992.tb08465.x; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; NYKJAER A, 1994, J BIOL CHEM, V269, P25668; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; POLLER W, 1995, J BIOL CHEM, V270, P2841, DOI 10.1074/jbc.270.6.2841; QUI WQ, 1995, J NEUROSCI, V15, P2157; REBECK GW, 1995, ANN NEUROL, V37, P211, DOI 10.1002/ana.410370212; REBECK GW, 1993, NEURON, V11, P575; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; SAKAI J, 1994, J BIOL CHEM, V269, P2173; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCHMAIER AH, 1993, J CLIN INVEST, V92, P2540, DOI 10.1172/JCI116863; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; STRICKLAND DK, 1995, IN PRESS FASEB J; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; VANNOSTRAND WE, 1987, J BIOL CHEM, V262, P8508; VANNOSTRAND WE, 1990, J BIOL CHEM, V265, P9591; VANNOSTRAND WE, 1989, NATURE, V341, P546; WARSHAWSKY I, 1994, P NATL ACAD SCI USA, V91, P6664, DOI 10.1073/pnas.91.14.6664; WASCO W, 1993, NAT GENET, V5, P95, DOI 10.1038/ng0993-95; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1994, J CELL SCI, V107, P719; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; ZHENG G, 1994, J HISTOCHEM CYTOCHEM, V42, P531, DOI 10.1177/42.4.7510321	76	435	457	0	15	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 28	1995	82	2					331	340		10.1016/0092-8674(95)90320-8	http://dx.doi.org/10.1016/0092-8674(95)90320-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RL760	7543026	Bronze			2022-12-24	WOS:A1995RL76000020
J	MACSWEENEY, EJ; OADES, PJ; BUCHDAHL, R; ROSENTHAL, M; BUSH, A				MACSWEENEY, EJ; OADES, PJ; BUCHDAHL, R; ROSENTHAL, M; BUSH, A			RELATION OF THICKENING OF COLON WALL TO PANCREATIC-ENZYME TREATMENT IN CYSTIC-FIBROSIS	LANCET			English	Article							TRANSIT-TIME; CHILDREN; APPENDICITIS	Fibrotic strictures of the colon in association with colon-wall thickening on abdominal ultrasound have been described in children with cystic fibrosis. We determined the prevalence of colon-wall thickening in 99 children with cystic fibrosis (aged 6 months to 17 years, 45 male) and 38 healthy controls (aged 1 month to 39 years, 21 male). In controls, peristalsis was uniformly rapid and maximum wall thickness of the fully relaxed colon was 0.8 mm (median 0.6 mm). 24% of the patients had a colon-wall thickness of 1.5 mm or more (maximum 3.4 mm); 48% of children on high-strength pancreatin receiving more than 265 units/kg per day of protease had thickening of more than 1.5 mm compared with less than 12% of children on any other dose. Children on high-strength pancreatin were 5.2 (95% CI 1.2-21) times more likely to have colon-wall thickness of 1.5 mm or more than children taking less than 265 units/kg per day of protease in a standard-strength preparation. This risk rose to 10 (2.5-39) times more likely if laxatives were taken with a high-strength preparation. Lipase or amylase intake, age, sex, genotype, and other medical or drug history were not significantly associated with colon-wall thickening. 1 child required a hemicolectomy for bowel obstruction and another developed haemorrhagic colitis. In 17 children, 2 months after stopping high-strength, high protease, preparations and efforts to reduce enzyme intake, colon-wall thickness had regressed from a median 2.0 mm (range 1.0-3.4) to 1.8 mm (0.9-2.7) (p=0.005). The use of high-strength pancreatin preparations in conjunction with a high protease intake probably causes thickening of the wall of the colon.	ROYAL BROMPTON NATL HEART & LUNG HOSP,DEPT PAEDIAT RESP MED,LONDON SW3 6NP,ENGLAND; RIVERSIDE HOSP,DEPT RADIOL,LONDON,ENGLAND	Imperial College London				Oades, Patrick/0000-0001-5265-6923				Atkinson SN., 1991, EUR J CLIN RES, V1, P37; BALI A, 1983, BRIT MED J, V287, P1011, DOI 10.1136/bmj.287.6398.1011; BOWLER IM, 1993, ARCH DIS CHILD, V68, P227, DOI 10.1136/adc.68.2.227; CAMPBELL CA, 1994, LANCET, V343, P109; CRADY SK, 1993, ANN EMERG MED, V22, P1125, DOI 10.1016/S0196-0644(05)80976-X; DALZELL AM, 1990, ARCH DIS CHILD, V65, P585, DOI 10.1136/adc.65.6.585; DALZELL AM, 1990, ARCH DIS CHILD, V65, P540, DOI 10.1136/adc.65.5.540; Feigelson J, 1990, Acta Univ Carol Med (Praha), V36, P144; GROSS K, 1985, J PEDIATR SURG, V20, P431, DOI 10.1016/S0022-3468(85)80235-9; HOLMES M, 1991, ARCH DIS CHILD, V66, P726, DOI 10.1136/adc.66.6.726; INNES JA, 1994, LANCET, V343, P599; KEDAR RP, 1994, CLIN RADIOL, V49, P24, DOI 10.1016/S0009-9260(05)82909-5; KEELING JW, 1992, OXFORD TXB PATHOLOGY, P1192; KNABE N, 1994, LANCET, V343, P1230, DOI 10.1016/S0140-6736(94)92443-0; MAHONY MJ, 1994, LANCET, V343, P600; MILLA CE, 1994, LANCET, V343, P599, DOI 10.1016/S0140-6736(94)91551-2; MORRISON G, 1991, LANCET, V338, P1596, DOI 10.1016/0140-6736(91)92421-W; OADES PJ, 1994, LANCET, V343, P109, DOI 10.1016/S0140-6736(94)90836-2; OKEEFFE FN, 1991, RADIOLOGY, V178, P827, DOI 10.1148/radiology.178.3.1994426; ROBINSON PJ, 1990, ARCH DIS CHILD, V65, P311, DOI 10.1136/adc.65.3.311; SIEGEL MJ, 1991, JAMA-J AM MED ASSOC, V266, P1987, DOI 10.1001/jama.266.14.1987; SIVIT CJ, 1993, AM J ROENTGENOL, V161, P147, DOI 10.2214/ajr.161.1.8517294; SMYTH RL, 1994, LANCET, V343, P85, DOI 10.1016/S0140-6736(94)90817-6; TAYLOR CJ, 1994, LANCET, V343, P110; ZENTLERMUNRO PL, 1987, GUT, V28, P1531, DOI 10.1136/gut.28.11.1531; ZENTLERMUNRO PL, 1984, GUT, V25, P500, DOI 10.1136/gut.25.5.500; 1994, DATA SHEET CONPENDIU, P385	27	62	62	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 25	1995	345	8952					752	756						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN701	7534369				2022-12-24	WOS:A1995QN70100010
J	SANCHEZTAPIAS, JM; RODES, J				SANCHEZTAPIAS, JM; RODES, J			DILEMMAS OF ORGAN-TRANSPLANTATION FROM ANTI-HCV-POSITIVE DONORS	LANCET			English	Editorial Material							HEPATITIS-C VIRUS; RECIPIENTS				SANCHEZTAPIAS, JM (corresponding author), UNIV BARCELONA,HOSP CLIN,LIVER UNIT,BARCELONA,SPAIN.							FARCI P, 1992, SCIENCE, V258, P135, DOI 10.1126/science.1279801; KROES ACM, 1994, J HEPATOL, V21, P1113, DOI 10.1016/S0168-8278(05)80627-0; LIM HL, 1994, GASTROENTEROLOGY, V106, P248, DOI 10.1016/S0016-5085(94)95829-7; MARTELL M, 1992, J VIROL, V66, P3225, DOI 10.1128/JVI.66.5.3225-3229.1992; MILFRED SK, 1994, TRANSPLANTATION, V57, P568; MORALES JM, 1995, KIDNEY INT, V47, P236, DOI 10.1038/ki.1995.29; PEREIRA BJG, 1992, NEW ENGL J MED, V327, P910, DOI 10.1056/NEJM199209243271302; RAMOS EL, 1994, TRANSPLANTATION, V57, P490; ROTH D, 1992, ANN INTERN MED, V117, P470, DOI 10.7326/0003-4819-117-6-470; SIMMONDS P, 1993, J CLIN MICROBIOL, V31, P1493, DOI 10.1128/JCM.31.6.1493-1503.1993; SIMMONDS P, 1994, HEPATOLOGY, V19, P1321, DOI 10.1016/0270-9139(94)90887-7; TESI RJ, 1994, TRANSPLANTATION, V57, P826, DOI 10.1097/00007890-199403270-00010; VINCENTI F, 1993, TRANSPLANTATION, V55, P674; ZUCKER K, 1994, TRANSPLANTATION, V57, P832, DOI 10.1097/00007890-199403270-00011	14	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 25	1995	345	8948					469	470		10.1016/S0140-6736(95)90579-0	http://dx.doi.org/10.1016/S0140-6736(95)90579-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH929	7532253				2022-12-24	WOS:A1995QH92900006
J	KAVANAUGH, WM; WILLIAMS, LT				KAVANAUGH, WM; WILLIAMS, LT			AN ALTERNATIVE TO SH2 DOMAINS FOR BINDING TYROSINE-PHOSPHORYLATED PROTEINS	SCIENCE			English	Article							GROWTH-FACTOR RECEPTORS; SIGNAL TRANSDUCTION; PHOSPHATIDYLINOSITOL-3 KINASE; TRANSFORMING ACTIVITY; POINT MUTATIONS; PHOSPHOTYROSINE; ASSOCIATION; ACTIVATION; SEQUENCE; RESIDUES	Src homology 2 (SH2) domains bind specifically to tyrosine-phosphorylated proteins that participate in signaling by growth factors and oncogenes. A protein domain was identified that bound specifically to the tyrosine-phosphorylated form of its target protein but differs from known SH2 sequences. Phosphotyrosine-binding (PTB) domains were found in two proteins: SHC, a protein implicated in signaling through Ras; and SCK, encoded by a previously uncharacterized gene. The PTB domain of SHC specifically bound to a tyrosine-phosphorylated 145-kilodalton protein. PTB domains are an alternative to SH2 domains for specifically recruiting tyrosine-phosphorylated proteins into signaling complexes and are likely to take part in signaling by many growth factors.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032898, Z01HL002714] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL32898, K11 HL02714] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS MD, 1993, NAT GENET, V4, P256, DOI 10.1038/ng0793-256; BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KATZAV S, 1993, ONCOGENE, V8, P1757; KAVANAUGH WM, 1992, MOL CELL BIOL, V12, P3415, DOI 10.1128/MCB.12.8.3415; KAVANAUGH WM, UNPUB; MARENGERE LEM, 1992, J BIOL CHEM, V267, P22779; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SAXTON TM, 1994, J IMMUNOL, V153, P623; Summers MD, 1987, MANUAL METHODS BACUL; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	22	471	492	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 16	1994	266	5192					1862	1865		10.1126/science.7527937	http://dx.doi.org/10.1126/science.7527937			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX383	7527937				2022-12-24	WOS:A1994PX38300035
J	AIELLO, LP; AVERY, RL; ARRIGG, PG; KEYT, BA; JAMPEL, HD; SHAH, ST; PASQUALE, LR; THIEME, H; IWAMOTO, MA; PARK, JE; NGUYEN, HV; AIELLO, LM; FERRARA, N; KING, GL				AIELLO, LP; AVERY, RL; ARRIGG, PG; KEYT, BA; JAMPEL, HD; SHAH, ST; PASQUALE, LR; THIEME, H; IWAMOTO, MA; PARK, JE; NGUYEN, HV; AIELLO, LM; FERRARA, N; KING, GL			VASCULAR ENDOTHELIAL GROWTH-FACTOR IN OCULAR FLUID OF PATIENTS WITH DIABETIC-RETINOPATHY AND OTHER RETINAL DISORDERS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PIGMENT EPITHELIAL-CELLS; PERMEABILITY FACTOR; ANGIOGENESIS; NEOVASCULARIZATION; SECRETION; INSULIN; INVIVO	Background. Retinal ischemia induces intraocular neovascularization, which often leads to glaucoma, vitreous hemorrhage, and retinal detachment, presumably by stimulating the release of angiogenic molecules. Vascular endothelial growth factor (VEGF) is an endothelial-cell-specific angiogenic factor whose production is increased by hypoxia. Methods. We measured the concentration of VEGF in 210 specimens of ocular fluid obtained from 164 patients undergoing intraocular surgery, using both radioimmunoassays and radioreceptor assays. Vitreous proliferative potential was measured with in vitro assays of the growth of retinal endothelial cells and with VEGF-neutralizing antibody. Results. VEGF was detected in 69 of 136 ocular-fluid samples from patients with diabetic retinopathy, 29 of 38 samples from patients with neovascularization of the iris, and 3 of 4 samples from patients with ischemic occlusion of the central retinal vein, as compared with 2 of 31 samples from patients with no neovascular disorders (P<0.001, P<0.001, and P = 0.006, respectively). The mean (+/-SD) VEGF concentration in 70 samples of ocular fluid from patients with active proliferative diabetic retinopathy (3.6+/-6.3 ng per milliliter) was higher than that in 25 samples from patients with nonproliferative diabetic retinopathy (0.1+/-0.1 ng per milliliter, P = 0.008), 41 samples from patients with quiescent proliferative diabetic retinopathy (0.2+/-0.6 ng per milliliter, P<0.001), or 31 samples from nondiabetic patients (0.1+/-0.2 ng per milliliter, P = 0.003). Concentrations of VEGF in vitreous fluid (8.8+/-9.9 ng per milliliter) were higher than those in aqueous fluid (5.6+/-8.6 ng per milliliter, P = 0.033) in all 10 pairs of samples obtained simultaneously from the same patient; VEGF concentrations in vitreous fluid declined after successful laser photocoagulation. VEGF stimulated the growth of retinal endothelial cells in vitro, as did vitreous fluid containing measurable VEGF. Stimulation was inhibited by VEGF-neutralizing antibodies. Conclusions. Our data suggest that VEGF plays a major part in mediating active intraocular neovascularization in patients with ischemic retinal diseases, such as diabetic retinopathy and retinal-vein occlusion.	JOSLIN DIABET CTR,DIV RES,BOSTON,MA 02215; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT OPHTHALMOL,BOSTON,MA; HARVARD UNIV,SCH MED,BOSTON,MA; UNIV CALIF SANTA BARBARA,NEUROSCI RES INST,SANTA BARBARA,CA 93106; GENENTECH INC,SAN FRANCISCO,CA; JOHNS HOPKINS UNIV HOSP,WILMER OPHTHALMOL INST,DEPT OPHTHALMOL,BALTIMORE,MD	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of California System; University of California Santa Barbara; Roche Holding; Genentech; Johns Hopkins University; Johns Hopkins Medicine	AIELLO, LP (corresponding author), JOSLIN DIABET CTR,BEETHAM EYE INST,DEPT OPHTHALMOL,1 JOSLIN PL,BOSTON,MA 02215, USA.		CLIHON, Residencia Medica/K-4896-2013	CLIHON, Residencia Medica/0000-0001-6734-2513	NEI NIH HHS [EY05110] Funding Source: Medline; NIDCR NIH HHS [DERC36836-08] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ADAMIS AP, 1993, BIOCHEM BIOPH RES CO, V193, P631, DOI 10.1006/bbrc.1993.1671; ADAMIS AP, 1993, INVEST OPHTH VIS SCI, V34, P1440; AIELLO LP, 1994, INVEST OPHTH VIS SCI, V35, P1868; [Anonymous], 1976, AM J OPHTHALMOL, V81, P383; BLANKENSHIP GW, 1991, OPHTHALMOLOGY, V98, P125; BROWN GC, 1988, INT OPHTHALMOL, V11, P239, DOI 10.1007/BF00131023; BROWN GC, 1989, RETINA, V2, P547; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; GLASER BM, 1980, J CELL BIOL, V84, P298, DOI 10.1083/jcb.84.2.298; HANNEKEN A, 1991, ARCH OPHTHALMOL-CHIC, V109, P1005, DOI 10.1001/archopht.1991.01080070117048; HAYREH SS, 1983, OPHTHALMOLOGY, V90, P488; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; JAKEMAN LB, 1992, J CLIN INVEST, V89, P244, DOI 10.1172/JCI115568; Kim KJ, 1992, GROWTH FACTORS, V7, P53, DOI 10.3109/08977199209023937; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KING GL, 1985, J CLIN INVEST, V75, P1028, DOI 10.1172/JCI111764; MALECAZE F, 1993, INVEST OPHTH VIS SCI, V34, P1039; MEYERSCHWICKERATH R, 1993, J CLIN INVEST, V92, P2620, DOI 10.1172/JCI116877; Michaelson I.C., 1948, T OPHTHALMOL SOC, V68, P137; MUTHUKRISHNAN L, 1991, J CELL PHYSIOL, V148, P1, DOI 10.1002/jcp.1041480102; PARK JE, 1994, J BIOL CHEM, V269, P25646; PATZ A, 1980, INVEST OPHTH VIS SCI, V19, P1133; PEPPER MS, 1992, BIOCHEM BIOPH RES CO, V189, P824, DOI 10.1016/0006-291X(92)92277-5; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PLOUET J, 1993, INVEST OPHTH VIS SCI, V34, P900; RAND LI, 1981, AM J MED, V70, P595, DOI 10.1016/0002-9343(81)90581-7; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SENGER DR, 1986, CANCER RES, V46, P5629; SHIMA D, 1993, INVEST OPHTH VIS SCI, V34, P900; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SIVALINGAM A, 1990, ARCH OPHTHALMOL-CHIC, V108, P869, DOI 10.1001/archopht.1990.01070080113046; THIEME H, IN PRESS DIABETES; TISCHER E, 1991, J BIOL CHEM, V266, P11947; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; WHITE P, 1960, DIABETES, V9, P345, DOI 10.2337/diab.9.5.345; 1991, OPHTHALMOLOGY S, V98, P741	38	3000	3215	4	147	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 1	1994	331	22					1480	1487		10.1056/NEJM199412013312203	http://dx.doi.org/10.1056/NEJM199412013312203			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU866	7526212				2022-12-24	WOS:A1994PU86600003
J	MCWHINNEY, IR; BASS, MJ; DONNER, A				MCWHINNEY, IR; BASS, MJ; DONNER, A			EVALUATION OF A PALLIATIVE CARE SERVICE - PROBLEMS AND PITFALLS	BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED TRIAL; CANCER-PATIENTS; HOSPICE; INDEX	Objective-To evaluate a palliative care home support team based on an inpatient unit. Design-Randomised controlled trial with waiting list. Patients in the study group received the service immediately, those in the control group received it after one month. Main comparison point was at one month. Setting-A city of 300 000 people with a publicly funded home care service and about 200 general practitioners, most of whom provide home care. Main outcome measures-Pain and nausea levels were measured at entry to trial and at one month, as were quality of life for patients and care givers' health. Results-Because of early deaths, problems with recruitment, and a low compliance rate for completion of questionnaires, the required sample size was not attained. Conclusion-in designing evaluations of palliative care services, investigators should be prepared to deal with the following issues: attrition due to early death, opposition to randomisation by patients and referral sources, ethical problems raised by randomisation of dying patients, the appropriate timing of comparison points, and difficulties of collecting data from sick or exhausted patients and care givers. Investigators may choose to evaluate a service from various perspectives using different methods: controlled trials, qualitative studies, surveys, and audits. Randomised trials may prove to be impracticable for evaluation of palliative care.			MCWHINNEY, IR (corresponding author), UNIV WESTERN ONTARIO,CTR STUDIES FAMILY MED,THAMES VALLEY FAMILY PRACTICE RES UNIT,LONDON N6A 5C1,ON,CANADA.							ADDINGTONHALL JM, 1992, BRIT MED J, V305, P1317, DOI 10.1136/bmj.305.6865.1317; AIKEN LH, 1986, J CHRON DIS, V39, P1, DOI 10.1016/0021-9681(86)90101-3; BAUM M, 1993, LANCET, V341, P812, DOI 10.1016/0140-6736(93)90573-Y; BLOOM BS, 1980, J AM GERIATR SOC, V28, P451, DOI 10.1111/j.1532-5415.1980.tb01118.x; DUSH DM, 1984, HOSPICE J, V1, P55; EVANS C, 1985, LANCET, V1, P1204; Goldberg DP, 1972, DETECTION PSYCHIAT I; KANE RL, 1984, LANCET, V1, P890; MELZACK R, 1985, CAN MED ASSOC J, V133, P755; Melzack R, 1985, CAN MED ASSOC J, V133, P761; Melzack R., 1983, PAIN MEASUREMENT ASS; MOR V, 1987, HOSPICE CARE SYSTEMS; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; SCHIPPER H, 1984, J CLIN ONCOL, V2, P472, DOI 10.1200/JCO.1984.2.5.472; SILVERMAN WA, 1994, LANCET, V343, P1586, DOI 10.1016/S0140-6736(94)93053-8; ZIMMER JG, 1985, AM J PUBLIC HEALTH, V75, P134, DOI 10.2105/AJPH.75.2.134	16	178	179	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 19	1994	309	6965					1340	1342		10.1136/bmj.309.6965.1340	http://dx.doi.org/10.1136/bmj.309.6965.1340			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT625	7532501	Green Published			2022-12-24	WOS:A1994PT62500025
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FDA PROPOSES TO REQUIRE FINANCIAL DISCLOSURE BY CLINICAL INVESTIGATORS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1994, FED REGISTER, V59, P48708	1	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 19	1994	272	15					1160	1160		10.1001/jama.272.15.1160	http://dx.doi.org/10.1001/jama.272.15.1160			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL212	7523738				2022-12-24	WOS:A1994PL21200009
J	VALEGARD, K; MURRAY, JB; STOCKLEY, PG; STONEHOUSE, NJ; LILJAS, L				VALEGARD, K; MURRAY, JB; STOCKLEY, PG; STONEHOUSE, NJ; LILJAS, L			CRYSTAL-STRUCTURE OF AN BACTERIOPHAGE-RNA COAT PROTEIN-OPERATOR COMPLEX	NATURE			English	Article							TURNIP CRINKLE VIRUS; BINDING SITE; RESOLUTION; SYNTHETASE; OLIGORIBONUCLEOTIDES; RECOGNITION; MECHANISM; MS2	THE RNA bacteriophage MS2 is a convenient model system for the study-of protein-RNA interactions, The MS2 coat protein achieves control of two distinct processes-sequence-specific RNA encapsidation and repression of replicase translation-by binding to an RNA stem-loop structure of 19 nucleotides containing the initiation codon of the replicase gene. The binding of a coat protein diner to this hairpin shuts off synthesis of the viral replicase(1), switching the viral replication cycle to virion assembly rather than continued replication. The operator fragment alone can trigger self-assembly of the phage capsid at low protein concentrations and a complex of about 90 RNA operator fragments per protein capsid has been described(2). We report here the crystal structure at 3.0 Angstrom resolution of a complex between recombinant MS2 capsids and the 19-nucleotide RNA fragment. It is the first example of a structure at this resolution for a sequence-specific protein-RNA complex apart from the transfer RNA synthetase complexes(3-5). The structure shows sequence-specific interactions between conserved residues on the protein and RNA bases essential for binding.	UNIV LEEDS, DEPT GENET, LEEDS LS2 9JT, W YORKSHIRE, ENGLAND	University of Leeds	VALEGARD, K (corresponding author), UPPSALA UNIV, DEPT MOLEC BIOL, BOX 590, S-75124 UPPSALA, SWEDEN.			Stockley, Peter/0000-0002-1360-2751; Stonehouse, Nicola/0000-0003-1146-5519	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABADZAPATERO C, 1980, NATURE, V286, P33, DOI 10.1038/286033a0; BECKETT D, 1988, J MOL BIOL, V204, P939, DOI 10.1016/0022-2836(88)90053-8; BECKETT D, 1988, J MOL BIOL, V204, P927, DOI 10.1016/0022-2836(88)90052-6; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, XPLOR MANUAL; CAVARELLI J, 1993, NATURE, V362, P181, DOI 10.1038/362181a0; GOLMOHAMMADI R, 1993, J MOL BIOL, V234, P620, DOI 10.1006/jmbi.1993.1616; HARRISON SC, 1978, NATURE, V276, P368, DOI 10.1038/276368a0; HOGLE JM, 1986, J MOL BIOL, V191, P625, DOI 10.1016/0022-2836(86)90450-X; HOSUR MV, 1987, PROTEINS, V2, P167, DOI 10.1002/prot.340020302; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1992, CCP4 STUDY WEEKEND 1, P91; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LIDDINGTON RC, 1991, NATURE, V354, P278, DOI 10.1038/354278a0; LIM F, 1994, J BIOL CHEM, V269, P9006; MASTICO RA, 1993, J GEN VIROL, V74, P541, DOI 10.1099/0022-1317-74-4-541; MURRAY JB, 1994, ANAL BIOCHEM, V218, P177, DOI 10.1006/abio.1994.1157; PEABODY DS, 1993, EMBO J, V12, P595, DOI 10.1002/j.1460-2075.1993.tb05691.x; PEABODY DS, 1989, NUCLEIC ACIDS RES, V17, P6017, DOI 10.1093/nar/17.15.6017; ROMANIUK PJ, 1987, BIOCHEMISTRY-US, V26, P1563, DOI 10.1021/bi00380a011; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SORGER PK, 1986, J MOL BIOL, V191, P639, DOI 10.1016/0022-2836(86)90451-1; STOCKLEY PG, 1993, BIOCHEM SOC T, V21, P627, DOI 10.1042/bst0210627; TALBOT SJ, 1990, NUCLEIC ACIDS RES, V18, P3521, DOI 10.1093/nar/18.12.3521; USMAN N, 1987, J AM CHEM SOC, V109, P7845, DOI 10.1021/ja00259a037; VALEGARD K, 1990, NATURE, V345, P36, DOI 10.1038/345036a0; WITHERELL GW, 1991, PROG NUCLEIC ACID RE, V40, P185	28	328	332	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 13	1994	371	6498					623	626		10.1038/371623a0	http://dx.doi.org/10.1038/371623a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PL559	7523953				2022-12-24	WOS:A1994PL55900057
J	MIKI, Y; SWENSEN, J; SHATTUCKEIDENS, D; FUTREAL, PA; HARSHMAN, K; TAVTIGIAN, S; LIU, QY; COCHRAN, C; BENNETT, LM; DING, W; BELL, R; ROSENTHAL, J; HUSSEY, C; TRAN, T; MCCLURE, M; FRYE, C; HATTIER, T; PHELPS, R; HAUGENSTRANO, A; KATCHER, H; YAKUMO, K; GHOLAMI, Z; SHAFFER, D; STONE, S; BAYER, S; WRAY, C; BOGDEN, R; DAYANANTH, P; WARD, J; TONIN, P; NAROD, S; BRISTOW, PK; NORRIS, FH; HELVERING, L; MORRISON, P; ROSTECK, P; LAI, M; BARRETT, JC; LEWIS, C; NEUHAUSEN, S; CANNONALBRIGHT, L; GOLDGAR, D; WISEMAN, R; KAMB, A; SKOLNICK, MH				MIKI, Y; SWENSEN, J; SHATTUCKEIDENS, D; FUTREAL, PA; HARSHMAN, K; TAVTIGIAN, S; LIU, QY; COCHRAN, C; BENNETT, LM; DING, W; BELL, R; ROSENTHAL, J; HUSSEY, C; TRAN, T; MCCLURE, M; FRYE, C; HATTIER, T; PHELPS, R; HAUGENSTRANO, A; KATCHER, H; YAKUMO, K; GHOLAMI, Z; SHAFFER, D; STONE, S; BAYER, S; WRAY, C; BOGDEN, R; DAYANANTH, P; WARD, J; TONIN, P; NAROD, S; BRISTOW, PK; NORRIS, FH; HELVERING, L; MORRISON, P; ROSTECK, P; LAI, M; BARRETT, JC; LEWIS, C; NEUHAUSEN, S; CANNONALBRIGHT, L; GOLDGAR, D; WISEMAN, R; KAMB, A; SKOLNICK, MH			A STRONG CANDIDATE FOR THE BREAST AND OVARIAN-CANCER SUSCEPTIBILITY GENE BRCA1	SCIENCE			English	Article							FAMILIAL BREAST; ZINC FINGER; WILMS-TUMOR; ATAXIA-TELANGIECTASIA; DNA-BINDING; WT1 GENE; CHROMOSOME-17Q21; IDENTIFICATION; MUTATIONS; P53	A strong candidate for the 17q-linked BRCA1 gene, which influences susceptibility to breast and ovarian cancer, has been identified by positional cloning methods. Probable predisposing mutations have been detected in five of eight kindreds presumed to segregate BRCA1 susceptibility alleles. The mutations include an 11-base pair deletion, a 1-base pair insertion, a stop codon, a missense substitution, and an inferred regulatory mutation. The BRCA1 gene is expressed in numerous tissues, including breast and ovary, and encodes a predicted protein of 1863 amino acids. This protein contains a zinc finger domain in its amino-terminal region, but is otherwise unrelated to previously described proteins, identification of BRCA1 should facilitate early diagnosis of breast and ovarian cancer susceptibility in some individuals as well as a better understanding of breast cancer biology.	UNIV UTAH,MED CTR,DEPT MED INFORMAT,SALT LAKE CITY,UT 84132; MYRIAD GENET,SALT LAKE CITY,UT 84108; NIEHS,MOLEC CARCINOGENESIS LAB,RES TRIANGLE PK,NC 27709; UNIV UTAH,MED CTR,DEPT INTERNAL MED,SALT LAKE CITY,UT 84132; MCGILL UNIV,DEPT MED GENET,MONTREAL H3G 1A4,PQ,CANADA; ELI LILLY & CO,LILLY RES LABS,INDIANAPOLIS,IN 46285; UNIV UTAH,MED CTR,DEPT MED INFORMAT,SALT LAKE CITY,UT 84108	Utah System of Higher Education; University of Utah; Myriad Genetics, Inc; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Utah System of Higher Education; University of Utah; McGill University; Eli Lilly; Utah System of Higher Education; University of Utah			Pinheiro, Maísa/E-7424-2012; Lewis, Cathryn/M-8766-2019; Lewis, Cathryn M/A-5225-2010; Narod, Steven A/AAA-6112-2022	Lewis, Cathryn/0000-0002-8249-8476; Lewis, Cathryn M/0000-0002-8249-8476; Miki, Yoshio/0000-0003-0114-392X; albright, lisa/0000-0003-2602-3668	NCI NIH HHS [CA-55914, CA-54936, CA-48711] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R03CA054936, P01CA048711, R01CA055914] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P195; ANDERSON DM, UNPUB; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; BOWCOCK AM, 1993, AM J HUM GENET, V52, P718; CAMPBELL IG, 1994, HUM MOL GENET, V3, P589, DOI 10.1093/hmg/3.4.589; CANNONALBRIGHT LA, 1994, CANCER RES, V54, P2378; CLAUS EB, 1991, AM J HUM GENET, V48, P232; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; EASTON DF, 1993, AM J HUM GENET, V52, P678; FEUNTEUN J, 1993, AM J HUM GENET, V52, P736; FUTREAL PA, 1994, HUM MOL GENET, V3, P1359, DOI 10.1093/hmg/3.8.1359; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GOLDGAR DE, 1994, J NATL CANCER I, V86, P200, DOI 10.1093/jnci/86.3.200; GOLDGAR DE, UNPUB; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KELSELL DP, 1993, HUM MOL GENET, V2, P1823; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LITTLE MH, 1993, HUM MOL GENET, V2, P259, DOI 10.1093/hmg/2.3.259; LITTLE MH, 1992, P NATL ACAD SCI USA, V89, P4791, DOI 10.1073/pnas.89.11.4791; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; LOVETT M, 1991, P NATL ACAD SCI USA, V88, P9628, DOI 10.1073/pnas.88.21.9628; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; METTLIN C, 1990, AM J EPIDEMIOL, V131, P973, DOI 10.1093/oxfordjournals.aje.a115617; NAROD SA, 1991, LANCET, V338, P82; NEUHAUSEN S, IN PRESS CANCER RES; NEUHAUSEN SL, IN PRESS HUM MOL GEN; PATARCA R, 1988, P NATL ACAD SCI USA, V85, P2733, DOI 10.1073/pnas.85.8.2733; Sambrook J., 1989, MOL CLONING LAB MANU; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SIMARD J, 1993, HUM MOL GENET, V2, P1193, DOI 10.1093/hmg/2.8.1193; SMITH HS, 1993, J CELL BIOCH SG, V14, P144; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; SRIVASTAVA S, 1993, CANCER RES, V53, P4452; SU LK, 1993, CANCER RES, V53, P2728; SWIFT M, 1976, CANCER RES, V36, P209; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; THOMAS A, IN PRESS IMA J MATH; WEAVERFELDHAUS J, 1994, P NATL ACAD SCI USA, V91, P7563, DOI 10.1073/pnas.91.16.7563; WESTIN G, 1984, P NATL ACAD SCI-BIOL, V81, P3811, DOI 10.1073/pnas.81.12.3811; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; 1994, CANCER FACTS FIGURES, P13	44	4861	5083	6	432	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 7	1994	266	5182					66	71		10.1126/science.7545954	http://dx.doi.org/10.1126/science.7545954			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK582	7545954				2022-12-24	WOS:A1994PK58200026
J	PRESTON, GM; SMITH, BL; ZEIDEL, ML; MOULDS, JJ; AGRE, P				PRESTON, GM; SMITH, BL; ZEIDEL, ML; MOULDS, JJ; AGRE, P			MUTATIONS IN AQUAPORIN-1 IN PHENOTYPICALLY NORMAL HUMANS WITHOUT FUNCTIONAL CHIP WATER CHANNELS	SCIENCE			English	Article							INTEGRAL MEMBRANE-PROTEIN; XENOPUS OOCYTES; RAT-KIDNEY; LOCALIZATION; EXPRESSION; FAMILY; GENE; ERYTHROCYTES; ORGANIZATION; APPEARANCE	The gene aquaporin-1 encodes channel-forming integral protein (CHIP), a member of a large family of water transporters found throughout nature. Three rare individuals were identified who do not express CHIP-associated Colton blood group antigens and whose red cells exhibit low osmotic water permeabilities. Genomic DNA analyses demonstrated that two individuals were homozygous for different nonsense mutations (exon deletion or frameshift), and the third had a missense mutation encoding a nonfunctioning CHIP molecule. Surprisingly, none of the three suffers any apparent clinical consequence, which raises questions about the physiologicai importance of CHIP and implies that other mechanisms may compensate for its absence.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; UNIV PITTSBURGH,SCH MED,DEPT MED,PITTSBURGH,PA 15213; GAMMA BIOL,HOUSTON,TX 77092	Johns Hopkins University; Johns Hopkins University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NHLBI NIH HHS [HL48268, HL33991] Funding Source: Medline; NIDDK NIH HHS [DK32753] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048268, R01HL033991, R37HL048268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK032753, R01DK032753] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGRE P, 1994, J CLIN INVEST, V94, P1050, DOI 10.1172/JCI117419; AGRE P, 1993, AM J PHYSIOL, V265, pF463; BENNETT V, 1983, METHOD ENZYMOL, V96, P313; BONDY C, 1993, P NATL ACAD SCI USA, V90, P4500, DOI 10.1073/pnas.90.10.4500; BROWN D, 1993, EUR J CELL BIOL, V61, P264; CHRISPEELS MJ, 1994, J CELL BIOCH SA, V18, P80; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; DENKER BM, 1988, J BIOL CHEM, V263, P15634; ENGEL A, 1994, CURR OPIN STRUC BIOL, V4, P545, DOI 10.1016/S0959-440X(94)90217-8; Finkelstein A., 1987, WATER MOVEMENT LIPID; FOLKESSON HG, 1994, P NATL ACAD SCI USA, V91, P4970, DOI 10.1073/pnas.91.11.4970; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; HARRIS HW, 1991, J CLIN INVEST, V88, P1, DOI 10.1172/JCI115263; KNEPPER MA, 1994, P NATL ACAD SCI USA, V91, P6255, DOI 10.1073/pnas.91.14.6255; LACEY PA, 1987, TRANSFUSION, V27, P268, DOI 10.1046/j.1537-2995.1987.27387235637.x; MOON C, 1993, J BIOL CHEM, V268, P15772; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P7275, DOI 10.1073/pnas.90.15.7275; NIELSEN S, 1993, J CELL BIOL, V120, P371, DOI 10.1083/jcb.120.2.371; OPPERMAN CH, 1994, SCIENCE, V263, P221, DOI 10.1126/science.263.5144.221; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1993, J BIOL CHEM, V268, P17; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; RAO Y, 1990, NATURE, V345, P163, DOI 10.1038/345163a0; REIZER J, 1993, CRIT REV BIOCHEM MOL, V28, P235, DOI 10.3109/10409239309086796; ROBERTS SK, IN PRESS P NATL ACAD; SABOLIC I, 1992, AM J PHYSIOL, V263, pC1225, DOI 10.1152/ajpcell.1992.263.6.C1225; SMITH BL, 1993, J CLIN INVEST, V92, P2035, DOI 10.1172/JCI116798; SMITH BL, 1994, J CLIN INVEST, V94, P1043, DOI 10.1172/JCI117418; SMITH BL, 1991, J BIOL CHEM, V266, P6407; VANOS CH, IN PRESS BIOCH BIOPH; VERKMAN AS, 1992, ANNU REV PHYSIOL, V54, P97, DOI 10.1146/annurev.physiol.54.1.97; WALL DA, 1989, J MEMBRANE BIOL, V107, P189, DOI 10.1007/BF01871724; ZAMPIGHI GA, 1989, J CELL BIOL, V108, P2255, DOI 10.1083/jcb.108.6.2255; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002	34	251	257	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 9	1994	265	5178					1585	1587		10.1126/science.7521540	http://dx.doi.org/10.1126/science.7521540			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PF336	7521540				2022-12-24	WOS:A1994PF33600037
J	TAKAHASHI, T; TANAKA, M; BRANNAN, CI; JENKINS, NA; COPELAND, NG; SUDA, T; NAGATA, S				TAKAHASHI, T; TANAKA, M; BRANNAN, CI; JENKINS, NA; COPELAND, NG; SUDA, T; NAGATA, S			GENERALIZED LYMPHOPROLIFERATIVE DISEASE IN MICE, CAUSED BY A POINT MUTATION IN THE FAS LIGAND	CELL			English	Article							TUMOR-NECROSIS-FACTOR; T-CELL RECEPTOR; GENETIC-LINKAGE MAP; SYSTEMIC AUTOIMMUNITY; NEGATIVE SELECTION; CLONAL ELIMINATION; MOUSE GENOME; FACTOR-ALPHA; LPR; ANTIGEN	Mice homozygous for lpr (lymphoproliferation) or gld (generalized lymphoproliferative disease) develop lymphadenopathy and suffer from autoimmune disease. The lpr mice have a mutation in a cell-surface protein, Fas, that mediates apoptosis. Fas ligand (FasL) is a tumor necrosis factor (TNF)-related type II membrane protein and binds to Fas. Here, mouse Fasl gene was isolated and localized to the gld region of mouse chromosome 1. Activated splenocytes from gld mice express Fasl mRNA. However, FasL in gld mice carries a point mutation in the C-terminal region, which is highly conserved among members of the TNF family. The recombinant gld FasL expressed in COS cells could not induce apoptosis in cells expressing Fas. These results indicate that lpr and gld are mutations in Fas and Fasl, respectively, and suggest important roles of the Fas system in development of T cells as well as cytotoxic T lymphocyte-mediated cytotoxicity.	NCI FREDERICK CANC RES & DEV CTR,ADV BIOSCI LABS,BASIC RES PROGRAM,MAMMALIAN GENET LAB,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	TAKAHASHI, T (corresponding author), OSAKA BIOSCI INST,6-2-4 FURUEDAI,SUITA,OSAKA 565,JAPAN.		Nagata, Shigekazu/AAG-3203-2019	Nagata, Shigekazu/0000-0001-9758-8426	OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI M, 1993, P NATL ACAD SCI USA, V90, P1756, DOI 10.1073/pnas.90.5.1756; ALLEN RD, 1990, J EXP MED, V172, P1367, DOI 10.1084/jem.172.5.1367; ANDREWS BS, 1978, J EXP MED, V148, P1198, DOI 10.1084/jem.148.5.1198; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; BROWNING JL, 1993, CELL, V72, P847, DOI 10.1016/0092-8674(93)90574-A; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; DAVIDSON WF, 1985, P NATL ACAD SCI USA, V82, P1219, DOI 10.1073/pnas.82.4.1219; DRAPPA J, 1993, P NATL ACAD SCI USA, V90, P10340, DOI 10.1073/pnas.90.21.10340; ECK MJ, 1989, J BIOL CHEM, V264, P17595; EGERTON M, 1990, P NATL ACAD SCI USA, V87, P2579, DOI 10.1073/pnas.87.7.2579; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; GASE K, 1990, IMMUNOLOGY, V77, P368; GIESE T, 1992, J IMMUNOL, V149, P3097; Green EL, 1981, GENETICS PROBABILITY, P77; HANG LM, 1984, J IMMUNOL, V132, P1809; HERRON LR, 1993, J IMMUNOL, V151, P3450; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; JONES LA, 1990, SCIENCE, V250, P1726, DOI 10.1126/science.2125368; KABELITZ D, 1993, IMMUNOL TODAY, V14, P338, DOI 10.1016/0167-5699(93)90231-9; KAWABE Y, 1991, NATURE, V349, P245, DOI 10.1038/349245a0; KLAS C, 1993, INT IMMUNOL, V5, P625, DOI 10.1093/intimm/5.6.625; KOTZIN BL, 1988, J EXP MED, V168, P2221, DOI 10.1084/jem.168.6.2221; MATSUMOTO K, 1991, J EXP MED, V173, P127, DOI 10.1084/jem.173.1.127; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOUNTZ JD, 1986, J IMMUNOL, V137, P1029; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NAGATA S, 1994, IN PRESS ADV IMMUNOL; NEDWIN GE, 1985, NUCLEIC ACIDS RES, V13, P6361, DOI 10.1093/nar/13.17.6361; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OWENSCHAUB LB, 1992, CELL IMMUNOL, V140, P197, DOI 10.1016/0008-8749(92)90187-T; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; RAMSDELL F, 1990, SCIENCE, V248, P1342, DOI 10.1126/science.1972593; ROSE NR, 1993, IMMUNOL TODAY, V14, P426, DOI 10.1016/0167-5699(93)90244-F; ROTHS JB, 1984, J EXP MED, V159, P1, DOI 10.1084/jem.159.1.1; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; RUSSELL JH, 1993, P NATL ACAD SCI USA, V90, P4409, DOI 10.1073/pnas.90.10.4409; RUSSELL JH, 1991, P NATL ACAD SCI USA, V88, P2151, DOI 10.1073/pnas.88.6.2151; RUSSELL JH, 1993, EUR J IMMUNOL, V23, P2379, DOI 10.1002/eji.1830230951; SCOLLAY RG, 1980, EUR J IMMUNOL, V10, P210, DOI 10.1002/eji.1830100310; SCOTT DE, 1993, J IMMUNOL, V150, P664; SIDMAN CL, 1992, EUR J IMMUNOL, V22, P499, DOI 10.1002/eji.1830220231; SINGH G, 1991, P NATL ACAD SCI USA, V88, P10706, DOI 10.1073/pnas.88.23.10706; SIRACUSA LD, 1991, GENOMICS, V10, P313, DOI 10.1016/0888-7543(91)90314-5; SMITH RA, 1987, J BIOL CHEM, V262, P6951; SOBEL ES, 1991, J EXP MED, V173, P1441, DOI 10.1084/jem.173.6.1441; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; SUDA T, 1994, IN PRESS J EXP MED; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VANEWIJK W, 1991, ANNU REV IMMUNOL, V9, P591, DOI 10.1146/annurev.iy.09.040191.003111; VANOSTADE X, 1991, EMBO J, V10, P827, DOI 10.1002/j.1460-2075.1991.tb08015.x; VIGNAUX F, 1994, IN PRESS EUR J IMMUN; VONBOEHMER H, 1988, ANNU REV IMMUNOL, V6, P309, DOI 10.1146/annurev.iy.06.040188.001521; WATANABE T, 1991, BIOCHEM GENET, V29, P325, DOI 10.1007/BF00554140; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WATSON ML, 1992, MAMM GENOME, V2, P158, DOI 10.1007/BF00302874; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; YAMAGISHI J, 1990, PROTEIN ENG, V3, P713, DOI 10.1093/protein/3.8.713; ZHOU T, 1993, J IMMUNOL, V150, P3651; [No title captured]	63	1445	1497	0	25	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 25	1994	76	6					969	976		10.1016/0092-8674(94)90375-1	http://dx.doi.org/10.1016/0092-8674(94)90375-1			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ND246	7511063				2022-12-24	WOS:A1994ND24600004
J	FOTSIS, T; ZHANG, YM; PEPPER, MS; ADLERCREUTZ, H; MONTESANO, R; NAWROTH, PP; SCHWEIGERER, L				FOTSIS, T; ZHANG, YM; PEPPER, MS; ADLERCREUTZ, H; MONTESANO, R; NAWROTH, PP; SCHWEIGERER, L			THE ENDOGENOUS ESTROGEN METABOLITE 2-METHOXYOESTRADIOL INHIBITS ANGIOGENESIS AND SUPPRESSES TUMOR-GROWTH	NATURE			English	Article							METASTASIS; CELLS	THE formation of new blood vessels (angiogenesis) is critical for the growth of tumours(1-3) and is; a dominant feature in various angiogenic diseases such as diabetic retinopathy, arthritis, haemangiomas and psoriasis(4). Recognition of the potential therapeutic benefits of controlling pathological angiogenesis has led to a search for angiogenesis inhibitors. Here we report that 2-methoxyoestradiol, an endogenous oestrogen metabolite of previously unknown function, is a potent inhibitor of endothelial cell proliferation and migration as well as angiogenesis in vitro. Moreover, when administered orally in mice, it strongly inhibits the neovascularization of solid tumours and suppresses their growth. Unlike the angiostatic steroids of corticoid structure(5), it does not require the co-administration of heparin or sulphated cyclodextrins for activity. Thus, 2-methoxyoestradiol is the first steroid to have high antiangiogenic activity by itself. Our results suggest that this compound may have therapeutic potential in cancer and other angiogenic diseases.	UNIV HEIDELBERG,DEPT MED & PATHOL,D-69120 HEIDELBERG,GERMANY; UNIV GENEVA,MED CTR,INST HISTOL & EMBRYOL,DEPT MORPHOL,CH-1121 GENEVA 4,SWITZERLAND; UNIV HELSINKI,MEILAHTI HOSP,DEPT CLIN CHEM,SF-00290 HELSINKI,FINLAND	Ruprecht Karls University Heidelberg; University of Geneva; University of Helsinki; Helsinki University Central Hospital	FOTSIS, T (corresponding author), UNIV HEIDELBERG,CHILDRENS UNIV HOSP,DEPT ONCOL & HAEMATOL,INF 150,D-69120 HEIDELBERG,GERMANY.		Pepper, Michael S./M-6143-2014	Pepper, Michael S./0000-0001-6406-2380				BLOOD CH, 1990, BIOCHIM BIOPHYS ACTA, V1032, P89, DOI 10.1016/0304-419X(90)90014-R; CRUM R, 1985, SCIENCE, V230, P1375, DOI 10.1126/science.2416056; DAMATO RJ, IN PRESS P NATN ACAD; EZEKOWITZ A, 1991, BRIT J HAEMATOL, V79, P67, DOI 10.1111/j.1365-2141.1991.tb08123.x; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOTSIS T, 1993, P NATL ACAD SCI USA, V90, P2690, DOI 10.1073/pnas.90.7.2690; KLAGSBRUN M, 1990, PEPTIDE GROWTH FACTO, V2, P549; MACLUSKY NJ, 1983, CATECHOL ESTROGENS, P151; MAHADEVAN V, 1991, EUR J CANCER, V27, P679, DOI 10.1016/0277-5379(91)90163-8; MONTESANO R, 1986, P NATL ACAD SCI USA, V83, P7297, DOI 10.1073/pnas.83.19.7297; PEPPER MS, 1992, BIOCHEM BIOPH RES CO, V189, P824, DOI 10.1016/0006-291X(92)92277-5; SCHWEIGERER L, 1992, EUR J CLIN INVEST, V22, P260, DOI 10.1111/j.1365-2362.1992.tb01460.x; SEEGERS JC, 1989, J STEROID BIOCHEM, V32, P797, DOI 10.1016/0022-4731(89)90455-X; TAKAMIYA Y, 1993, J NEUROSURG, V78, P470, DOI 10.3171/jns.1993.78.3.0470; WHITE CW, 1989, NEW ENGL J MED, V320, P1197, DOI 10.1056/NEJM198905043201807	15	660	743	1	37	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 17	1994	368	6468					237	239		10.1038/368237a0	http://dx.doi.org/10.1038/368237a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA870	7511798				2022-12-24	WOS:A1994NA87000053
J	SUKHAREV, SI; BLOUNT, P; MARTINAC, B; BLATTNER, FR; KUNG, C				SUKHAREV, SI; BLOUNT, P; MARTINAC, B; BLATTNER, FR; KUNG, C			A LARGE-CONDUCTANCE MECHANOSENSITIVE CHANNEL IN E. COLI ENCODED BY MSCL ALONE	NATURE			English	Article							ESCHERICHIA-COLI; ION CHANNELS; TRANSPORT; GENE	ALL cellular organisms respond to vibration, touch, gravity or changes in osmolarity, although the molecules on which such mechanosensations depend are unknown. Candidates include certain channels that gate in response to membrane stretch(1,2). Patch-clamp experiments with Escherichia coli envelope have revealed a mechanosensitive channel with very large conductance (MscL) and one with a smaller conductance (MscS)(3-6) which may be important in osmoregulation. Here we have solubilized and fractionated the envelope, reconstituted the MscL activity in vitro, and traced it to a small protein, whose gene, mscL, we then cloned. Insertional disruption of mscL removes the channel activity, whereas reexpression of mscL borne on an expression plasmid restores it. MscL-channel activities were observed in material from a cell-free expression system with mscL as the only template. The mscL nucleotide sequence predicts a unique protein of only 136 amino acids, with a highly hydrophobic core and very different from porins or other known proteins.	UNIV WISCONSIN,MOLEC BIOL LAB,MADISON,WI 53706; UNIV WISCONSIN,DEPT GENET,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison			Martinac, Boris/A-7178-2018	Martinac, Boris/0000-0001-8422-7082; Sukharev, Sergei/0000-0002-4807-9665				BERRIER C, 1992, EUR J BIOCHEM, V206, P559, DOI 10.1111/j.1432-1033.1992.tb16960.x; BLACHLYDYSON E, 1990, SCIENCE, V247, P1233, DOI 10.1126/science.1690454; BRITTEN RJ, 1962, BACTERIOL REV, V26, P292, DOI 10.1128/MMBR.26.3.292-335.1962; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DANIELS DL, 1987, NATURE, V325, P831, DOI 10.1038/325831a0; DELCOUR AH, 1989, BIOPHYS J, V56, P631, DOI 10.1016/S0006-3495(89)82710-9; EPSTEIN W, 1986, FEMS MICROBIOL LETT, V39, P73; HAMANN A, 1987, J BACTERIOL, V169, P3138, DOI 10.1128/jb.169.7.3138-3145.1987; Jackson M.B., 1993, THERMODYNAMICS MEMBR, P327; MARTINAC B, 1990, NATURE, V348, P261, DOI 10.1038/348261a0; MARTINAC B, 1987, P NATL ACAD SCI USA, V84, P2297, DOI 10.1073/pnas.84.8.2297; SACHS F, 1992, SENSORY TRANSDUCTION, P241; SUKHAREV SI, 1993, BIOPHYS J, V65, P177, DOI 10.1016/S0006-3495(93)81044-0	13	568	590	3	60	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 17	1994	368	6468					265	268		10.1038/368265a0	http://dx.doi.org/10.1038/368265a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA870	7511799				2022-12-24	WOS:A1994NA87000062
J	SAKO, D; CHANG, XJ; BARONE, KM; VACHINO, G; WHITE, HM; SHAW, G; VELDMAN, GM; BEAN, KM; AHERN, TJ; FURIE, B; CUMMING, DA; LARSEN, GR				SAKO, D; CHANG, XJ; BARONE, KM; VACHINO, G; WHITE, HM; SHAW, G; VELDMAN, GM; BEAN, KM; AHERN, TJ; FURIE, B; CUMMING, DA; LARSEN, GR			EXPRESSION CLONING OF A FUNCTIONAL GLYCOPROTEIN LIGAND FOR P-SELECTIN	CELL			English	Article							GRANULE MEMBRANE-PROTEIN; PLASMA-MEMBRANE; ADHESION; GMP-140; NEUTROPHILS; PLATELETS; CELLS; CARBOHYDRATE; SEQUENCE; RECEPTOR	The initial adhesive interactions between circulating leukocytes and endothelia are mediated, in part, by P-selectin. We now report the expression cloning of a functional ligand for P-selectin from an HL-60 cDNA library. The predicted amino acid sequence reveals a novel mucin-like transmembrane protein. Significant binding of transfected COS cells to P-selectin requires coexpression of both the protein ligand and a fucosyltransferase. This binding is calcium dependent and can be inhibited by a neutralizing monoclonal antibody to P-selectin. Cotransfected COS cells express the ligand as a homodimer of 220 kd. A soluble ligand construct, when coexpressed with fucosyltransferase in COS cells, also mediates P-selectin binding and is immunocrossreactive with the major HL-60 glycoprotein that specifically binds P-selectin.	TUFTS UNIV NEW ENGLAND MED CTR,CTR HEMOSTASIS & THROMBOSIS RES,DIV HEMATOL & ONCOL,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT MED,BOSTON,MA 02111	Tufts Medical Center; Tufts University	SAKO, D (corresponding author), SMALL MOLEC DRUG DISCOVERY GRP,INST GENET,87 CAMBRIDGE PK DR,CAMBRIDGE,MA 02140, USA.			Vachino, Gloria/0000-0002-9193-9990				ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BERMAN CL, 1986, J CLIN INVEST, V78, P130, DOI 10.1172/JCI112542; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BONTHRON DT, 1986, NATURE, V324, P270, DOI 10.1038/324270a0; BRENAN M, 1984, J IMMUNOL METHODS, V74, P31, DOI 10.1016/0022-1759(84)90364-8; CARLSSON SR, 1986, J BIOL CHEM, V261, P2779; CAWTHON RM, 1990, GENOMICS, V7, P555, DOI 10.1016/0888-7543(90)90199-5; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DORNER AJ, 1990, METHOD ENZYMOL, V185, P577; GROBER JS, 1993, J CLIN INVEST, V91, P2609, DOI 10.1172/JCI116500; HAMBURGER SA, 1990, BLOOD, V75, P550; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; Huttner WB, 1988, MODERN CELL BIOL, V6, P97; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LARSEN E, 1990, CELL, V63, P467, DOI 10.1016/0092-8674(90)90443-I; LARSEN GR, 1992, J BIOL CHEM, V267, P11104; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEVINOVITZ A, 1993, J CELL BIOL, V121, P449, DOI 10.1083/jcb.121.2.449; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; LUTZFREYERMUTH C, 1990, P NATL ACAD SCI USA, V87, P6393, DOI 10.1073/pnas.87.16.6393; MAEMURA K, 1992, J BIOL CHEM, V267, P24379; MOORE KL, 1991, J CELL BIOL, V112, P491, DOI 10.1083/jcb.112.3.491; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MULLIGAN MS, 1992, J CLIN INVEST, V90, P1600, DOI 10.1172/JCI116029; NORGARD KE, 1993, J BIOL CHEM, V268, P12764; PALABRICA T, 1992, NATURE, V359, P848, DOI 10.1038/359848a0; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; Rehemtulla Alnawaz, 1992, Current Opinion in Biotechnology, V3, P560, DOI 10.1016/0958-1669(92)90086-X; Sambrook J., 1989, MOL CLONING LAB MANU; STENBERG PE, 1985, J CELL BIOL, V101, P880, DOI 10.1083/jcb.101.3.880; VARKI A, 1992, Current Opinion in Cell Biology, V4, P257, DOI 10.1016/0955-0674(92)90041-A; WELLER A, 1992, J BIOL CHEM, V267, P15176; WEYRICH AS, 1993, J CLIN INVEST, V91, P2620, DOI 10.1172/JCI116501; [No title captured]	41	659	698	2	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 17	1993	75	6					1179	1186		10.1016/0092-8674(93)90327-M	http://dx.doi.org/10.1016/0092-8674(93)90327-M			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MM893	7505206				2022-12-24	WOS:A1993MM89300016
J	BOCHKAREV, A; BARWELL, JA; PFUETZNER, RA; FUREY, W; EDWARDS, AM; FRAPPIER, L				BOCHKAREV, A; BARWELL, JA; PFUETZNER, RA; FUREY, W; EDWARDS, AM; FRAPPIER, L			CRYSTAL-STRUCTURE OF THE DNA-BINDING DOMAIN OF THE EPSTEIN-BARR-VIRUS ORIGIN-BINDING PROTEIN EBNA1	CELL			English	Article							LATENT REPLICATION ORIGIN; NUCLEAR ANTIGEN EBNA-1; FUNCTIONAL DOMAINS; HUMAN-CELLS; E1 PROTEIN; E2; ACTIVATION; PLASMIDS; COMPLEX; IDENTIFICATION	The crystal structure of the DNA-binding and dimerization domains of the Epstein-Barr virus nuclear antigen 1 (EBNA1), which binds to and activates DNA replication from the latent origin of replication in Epstein-Barr virus, was solved at 2.5 Angstrom resolution. EBNA1 appears to bind DNA via two independent regions termed the core and the flanking DNA-binding domains. The core DNA-binding domain, which comprises both the dimerization domain and a helix predicted to bind the inner portion of the EBNA1 DNA recognition element, was remarkably similar to the structure of the papillomavirus E2 protein, despite a complete lack of sequence conservation. The flanking DNA-binding domain, only a portion of which is contained in the current structure, consists in part of an a helix whose N-terminus contacts the outer regions of the EBNA1 DNA recognition element.	UNIV PITTSBURGH,VET ADM MED CTR,BIOCRYSTALLOG LAB,PITTSBURGH,PA 15240; UNIV PITTSBURGH,DEPT CRYSTALLOG,PITTSBURGH,PA 15240	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	BOCHKAREV, A (corresponding author), MCMASTER UNIV,DEPT PATHOL,INST MOLEC BIOL & BIOTECHNOL,CANC RES GRP,1200 MAIN ST W,HAMILTON,ON L8N 3Z5,CANADA.			Edwards, Aled/0000-0002-4782-6016				ADAMS A, 1987, J VIROL, V61, P1743, DOI 10.1128/JVI.61.5.1743-1746.1987; AMBINDER RF, 1990, J VIROL, V64, P2369, DOI 10.1128/JVI.64.5.2369-2379.1990; AMBINDER RF, 1991, J VIROL, V65, P1466, DOI 10.1128/JVI.65.3.1466-1478.1991; BARWELL JA, 1995, J BIOL CHEM, V270; BONNEANDREA C, 1995, J VIROL, V69, P3201, DOI 10.1128/JVI.69.5.3201-3205.1995; CHEN MR, 1994, VIROLOGY, V205, P486, DOI 10.1006/viro.1994.1669; CHEN MR, 1993, J VIROL, V67, P4875, DOI 10.1128/JVI.67.8.4875-4885.1993; FRAPPIER L, 1991, P NATL ACAD SCI USA, V88, P10875, DOI 10.1073/pnas.88.23.10875; FRAPPIER L, 1992, J VIROL, V66, P1786, DOI 10.1128/JVI.66.3.1786-1790.1992; FRAPPIER L, 1991, J BIOL CHEM, V266, P7819; FRAPPIER L, 1994, J BIOL CHEM, V269, P1057; FRIEDMAN AM, 1995, SCIENCE, V268, P1721, DOI 10.1126/science.7792597; FUREY W, 1982, J APPL CRYSTALLOGR, V15, P160, DOI 10.1107/S0021889882011716; FUREY W, 1995, IN PRESS METH ENZYMO; GIRI I, 1988, EMBO J, V7, P2823, DOI 10.1002/j.1460-2075.1988.tb03138.x; GOLDSMITH K, 1993, J VIROL, V67, P3418, DOI 10.1128/JVI.67.6.3418-3426.1993; HARRISON S, 1994, J VIROL, V68, P1913, DOI 10.1128/JVI.68.3.1913-1925.1994; HEARING J, 1992, J VIROL, V66, P694, DOI 10.1128/JVI.66.2.694-705.1992; HEGDE RS, 1992, NATURE, V359, P505, DOI 10.1038/359505a0; HENDRICKSON WA, 1980, COMPUTING CRYSTALLOG; HSIEH DJ, 1993, EMBO J, V12, P4933, DOI 10.1002/j.1460-2075.1993.tb06187.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLEIN G, 1989, CELL, V58, P5, DOI 10.1016/0092-8674(89)90394-2; KNIGHT JD, 1991, P NATL ACAD SCI USA, V88, P3204, DOI 10.1073/pnas.88.8.3204; KRYSAN PJ, 1989, MOL CELL BIOL, V9, P1026, DOI 10.1128/MCB.9.3.1026; LUPTON S, 1985, MOL CELL BIOL, V5, P2533, DOI 10.1128/MCB.5.10.2533; MILLER G, 1990, VIROLOGY, P1921; MOHR IJ, 1990, SCIENCE, V250, P1694, DOI 10.1126/science.2176744; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; PRAKASH SS, 1992, GENE DEV, V6, P105, DOI 10.1101/gad.6.1.105; RAWLINS DR, 1985, CELL, V42, P859, DOI 10.1016/0092-8674(85)90282-X; REISMAN D, 1986, MOL CELL BIOL, V6, P3838, DOI 10.1128/MCB.6.11.3838; REISMAN D, 1985, MOL CELL BIOL, V5, P1822, DOI 10.1128/MCB.5.8.1822; ROIZMANN B, 1990, VIROLOGY; SEO YS, 1993, P NATL ACAD SCI USA, V90, P2865, DOI 10.1073/pnas.90.7.2865; SEO YS, 1993, P NATL ACAD SCI USA, V90, P702, DOI 10.1073/pnas.90.2.702; STEGER G, 1995, EMBO J, V14, P329, DOI 10.1002/j.1460-2075.1995.tb07007.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SU W, 1991, P NATL ACAD SCI USA, V88, P10870, DOI 10.1073/pnas.88.23.10870; SUGDEN B, 1989, J VIROL, V63, P2644, DOI 10.1128/JVI.63.6.2644-2649.1989; USTAV M, 1991, EMBO J, V10, P4321, DOI 10.1002/j.1460-2075.1991.tb05010.x; USTAV M, 1991, EMBO J, V10, P449, DOI 10.1002/j.1460-2075.1991.tb07967.x; YANG L, 1993, P NATL ACAD SCI USA, V90, P5086, DOI 10.1073/pnas.90.11.5086; YANG L, 1991, NATURE, V353, P628, DOI 10.1038/353628a0; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; YATES JL, 1991, J VIROL, V65, P483, DOI 10.1128/JVI.65.1.483-488.1991	46	128	133	1	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 6	1995	83	1					39	46		10.1016/0092-8674(95)90232-5	http://dx.doi.org/10.1016/0092-8674(95)90232-5			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RY583	7553871	Bronze			2022-12-24	WOS:A1995RY58300008
J	GENTILELLO, LM; DONOVAN, DM; DUNN, CW; RIVARA, FP				GENTILELLO, LM; DONOVAN, DM; DUNN, CW; RIVARA, FP			ALCOHOL INTERVENTIONS IN TRAUMA CENTERS - CURRENT PRACTICE AND FUTURE-DIRECTIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SCREENING-TEST; PROBLEM DRINKING; BLOOD-ALCOHOL; INTOXICATION; QUESTIONNAIRE; ABUSE; CARE; DEPENDENCE; EMERGENCY; MORTALITY	Nearly half of all trauma beds are occupied by patients who were injured while under the influence of alcohol. Alcoholism plays such a significant role in trauma that efforts to reduce injury recurrence are unlikely to be successful if it remains untreated. An injury requiring hospitalization creates a unique opportunity to intervene and to motivate patients to alter their drinking behavior, thereby making trauma centers ideal sites to implement an alcohol screening, intervention, and referral program. However, despite emphasis on injury control and prevention, little has been done to incorporate alcohol intervention programs into care of the injured patient. Effective means of intervention exist that are consistent with the time, financial, and staffing constraints of trauma centers, and they should be implemented.	UNIV WASHINGTON, HARBORVIEW MED CTR, SCH MED, DEPT PSYCHIAT & BEHAV SCI, SEATTLE, WA 98104 USA; UNIV WASHINGTON, HARBORVIEW MED CTR, SCH MED, DEPT PEDIAT, SEATTLE, WA 98104 USA; UNIV WASHINGTON, INST ALCOHOL & DRUG ABUSE, SEATTLE, WA 98195 USA; HARBORVIEW INJURY PREVENT & RES CTR, SEATTLE, WA USA	Harborview Medical Center; University of Washington; University of Washington Seattle; Harborview Medical Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	GENTILELLO, LM (corresponding author), UNIV WASHINGTON, HARBORVIEW MED CTR,SCH MED,DEPT SURG,325 9TH AVE, MAILSTOP ZA-16, SEATTLE, WA 98104 USA.			Donovan, Dennis/0000-0003-2237-4292	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA009045] Funding Source: NIH RePORTER; NIAAA NIH HHS [R01-AAO9045] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Babor T., 1989, ALCOHOL HEALTH RES W, V13, P371; BABOR TF, 1986, BRIT J ADDICT, V81, P23; BABOR TF, 1992, REPORT PHASE 2 RANDO; Babor TF., 1989, ALCOHOL USE DISORDER, V1, P45; BERNADT MW, 1982, LANCET, V1, P325; BIEN TH, 1993, ADDICTION, V88, P315, DOI 10.1111/j.1360-0443.1993.tb00820.x; BLOSE JO, 1991, AM J PUBLIC HEALTH, V81, P1571, DOI 10.2105/AJPH.81.12.1571; Braiker H.B., 1980, COURSE ALCOHOLISM 4; CALES RH, 1984, ANN EMERG MED, V13, P1, DOI 10.1016/S0196-0644(84)80375-3; CHANG G, 1988, JAMA-J AM MED ASSOC, V260, P2533, DOI 10.1001/jama.260.17.2533; CHERPITEL CJ, 1993, ALCOHOL CLIN EXP RES, V17, P762, DOI 10.1111/j.1530-0277.1993.tb00837.x; CHERPITEL CJS, 1989, DRUG ALCOHOL DEPEN, V24, P195; COLQUITT M, 1987, NEW ENGL J MED, V317, P1262, DOI 10.1056/NEJM198711123172005; DAVIDSON R, 1987, BRIT J CLIN PSYCHOL, V26, P243, DOI 10.1111/j.2044-8260.1987.tb01358.x; DAVIDSON R, 1986, BRIT J ADDICT, V81, P217; DiClemente C C, 1990, J Subst Abuse, V2, P217, DOI 10.1016/S0899-3289(05)80057-4; ELVY GA, 1988, BRIT J ADDICT, V83, P83; EVANS L, 1990, ACCIDENT ANAL PREV, V22, P587, DOI 10.1016/0001-4575(90)90030-O; GENTILELLO LM, 1988, AM J SURG, V156, P558, DOI 10.1016/S0002-9610(88)80553-1; GENTILELLO LM, 1993, J TRAUMA, V34, P669, DOI 10.1097/00005373-199305000-00009; GERBERICH SG, 1989, J TRAUMA, V29, P338, DOI 10.1097/00005373-198903000-00010; GOLDBERG HI, 1991, MED CARE, V29, pJS49; GOODMAN RA, 1991, J STUD ALCOHOL, V52, P156, DOI 10.15288/jsa.1991.52.156; HABERMAN PW, 1986, J STUD ALCOHOL, V47, P316, DOI 10.15288/jsa.1986.47.316; HEATHER N, 1989, HDB ALCOHOLISM TREAT, P93; HOLDER H, 1991, J STUD ALCOHOL, V52, P517, DOI 10.15288/jsa.1991.52.517; HOLDER HD, 1992, J STUD ALCOHOL, V53, P293, DOI 10.15288/jsa.1992.53.293; JACOBS LM, 1988, TRAUMA, P15; Jacobson GR, 1989, HDB ALCOHOLISM TREAT, P17; Jones K R, 1979, Med Care, V17, P1; JURKOVICH GJ, 1992, ANN EMERG MED, V21, P704, DOI 10.1016/S0196-0644(05)82783-0; JURKOVICH GJ, 1993, JAMA-J AM MED ASSOC, V270, P51, DOI 10.1001/jama.270.1.51; KITCHENS JM, 1994, JAMA-J AM MED ASSOC, V272, P1782, DOI 10.1001/jama.272.22.1782; KLATSKY AL, 1981, ANN INTERN MED, V95, P139, DOI 10.7326/0003-4819-95-2-139; LOWENSTEIN SR, 1990, J TRAUMA, V30, P1252, DOI 10.1097/00005373-199010000-00010; Marlatt G. A., 1988, ASSESSMENT ADDICTIVE; MAULL KI, 1982, SOUTHERN MED J, V75, P794, DOI 10.1097/00007611-198207000-00005; MAYFIELD D, 1974, AM J PSYCHIAT, V131, P1121; MAYNARD A, 1994, BRIT MED BULL, V50, P221, DOI 10.1093/oxfordjournals.bmb.a072880; MCLELLAN BA, 1990, J TRAUMA, V30, P418, DOI 10.1097/00005373-199030040-00008; Miller W.R., 2013, MOTIVATIONAL INTERVI, V3rd ed.; Miller W. R., 1986, TREATING ADDICTIVE B, P121; Miller WR, 1989, HDB ALCOHOLISM TREAT, P3; MILLER WR, 1989, HDB ALCOHOLISM TREAT, P67; MILLER WR, 1989, HDB ALCOHOLISM TREAT, P261; MORRIS JA, 1990, JAMA-J AM MED ASSOC, V263, P1942, DOI 10.1001/jama.263.14.1942; NILSSEN O, 1991, PREV MED, V20, P518, DOI 10.1016/0091-7435(91)90049-A; NILSSEN O, 1994, J TRAUMA, V36, P784, DOI 10.1097/00005373-199406000-00006; REYNA TM, 1985, ANN SURG, V201, P194; RIVARA FP, 1993, ARCH SURG-CHICAGO, V128, P907; RIVARA FP, 1992, J ADOLESCENT HEALTH, V13, P663, DOI 10.1016/1054-139X(92)90060-O; RIVARA FP, 1981, B AM COLL SURG, V66, P5; Robins L. N., 1989, NIMH DIAGNOSTIC INTE; ROLLNICK S, 1992, BRIT J ADDICT, V87, P743; RUSSELL M, 1994, ALCOHOL CLIN EXP RES, V18, P1156, DOI 10.1111/j.1530-0277.1994.tb00097.x; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; SAXE L, 1983, OTAHCS22 OFF TECHN A; SELZER ML, 1975, J STUD ALCOHOL, V36, P117, DOI 10.15288/jsa.1975.36.117; SELZER ML, 1971, AM J PSYCHIAT, V127, P1653, DOI 10.1176/ajp.127.12.1653; SILVER BA, 1990, PSYCHOSOMATICS, V31, P420, DOI 10.1016/S0033-3182(90)72138-X; SODERSTROM CA, 1994, J TRAUMA, V36, P68, DOI 10.1097/00005373-199401000-00010; SODERSTROM CA, 1987, ARCH SURG-CHICAGO, V122, P1067; SODERSTROM CA, 1992, JAMA-J AM MED ASSOC, V267, P2756, DOI 10.1001/jama.267.20.2756; SWENSON WM, 1975, MAYO CLIN PROC, V50, P204; WALLER JA, 1990, J TRAUMA, V30, P1298; WALLER JA, 1990, J TRAUMA, V30, P1548, DOI 10.1097/00005373-199012000-00020; WEISBESKI D, 1989, J TRAUMA, V29, P940, DOI 10.1097/00005373-198907000-00006; WELTE JW, 1987, DRUG ALCOHOL DEPEN, V19, P313, DOI 10.1016/0376-8716(87)90018-4; WHITFIELD RA, 1985, ACCIDENT ANAL PREV, V17, P367, DOI 10.1016/0001-4575(85)90090-9; WIECZOREK WF, 1990, J CRIM JUST, V18, P217, DOI 10.1016/0047-2352(90)90002-S; WIECZOREK WF, 1990, PROBLEM DRINKER DRIV, P90; Zuska J J, 1983, Bull Am Coll Surg, V68, P22; Zuska J J, 1981, Bull Am Coll Surg, V66, P5; 1985, MMWR-MORBID MORTAL W, V34, P161; 1986, MMWR-MORBID MORTAL W, V35, P703; 1991, SCREENING ALCOHOL OT; 1987, DIAGNOSTIC STATISTIC; 1966, PHS1071A13 PUBL; 1990, BROADENING BASE TREA; 1989, GUIDE CLIN PREVENTIV, P277; 1993, 3RD NEW YORK STAT OF; 1987, SCREENING ALCOHOLISM; 1993, RESOURCES OPTIMAL CA; 1993, 8TH NAT I ALC AB ALC; 1985, MMWR-MORBID MORTAL W, V34, P493; 1991, PUBLIC POLICY STATEM	86	134	136	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 4	1995	274	13					1043	1048		10.1001/jama.274.13.1043	http://dx.doi.org/10.1001/jama.274.13.1043			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RX108	7563455				2022-12-24	WOS:A1995RX10800027
J	MANTYH, PW; DEMASTER, E; MALHOTRA, A; GHILARDI, JR; ROGERS, SD; MANTYH, CR; LIU, HT; BASBAUM, AI; VIGNA, SR; MAGGIO, JE; SIMONE, DA				MANTYH, PW; DEMASTER, E; MALHOTRA, A; GHILARDI, JR; ROGERS, SD; MANTYH, CR; LIU, HT; BASBAUM, AI; VIGNA, SR; MAGGIO, JE; SIMONE, DA			RECEPTOR ENDOCYTOSIS AND DENDRITE RESHAPING IN SPINAL NEURONS AFTER SOMATOSENSORY STIMULATION	SCIENCE			English	Article							PROTEIN-COUPLED RECEPTORS; EXCITATORY AMINO-ACIDS; PRIMARY SENSORY NEURONS; SUBSTANCE-P RECEPTORS; INTRADERMAL INJECTION; GUINEA-PIG; CORD; RAT; CAT; LOCALIZATION	In vivo somatosensory stimuli evoked the release of substance P from primary afferent neurons that terminate in the spinal cord and stimulated endocytosis of substance P receptors in rat spinal cord neurons. The distal dendrites that showed substance P receptor internalization underwent morphological reorganization, changing from a tubular structure to one characterized by swollen varicosities connected by thin segments. This internalization and dendritic structural reorganization provided a specific image of neurons activated by substance P. Thus receptor internalization can drive reversible structural changes in central nervous system neurons in vivo. Both of these processes may be involved in neuronal plasticity.	UNIV MINNESOTA, DEPT PSYCHIAT, MINNEAPOLIS, MN 55455 USA; DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT SURG, DURHAM, NC 27710 USA; UNIV CALIF SAN FRANCISCO, DEPT ANAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, WM KECK FDN CTR INTEGRAT NEUROSCI, SAN FRANCISCO, CA 94143 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA	University of Minnesota System; University of Minnesota Twin Cities; Duke University; Duke University; Duke University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Harvard University; Harvard Medical School	MANTYH, PW (corresponding author), VET ADM MED CTR, MOLEC NEUROBIOL LAB 151, MINNEAPOLIS, MN 55417 USA.		mantyh, christopher/AAJ-9140-2021		NINDS NIH HHS [NS23970, NS21445, NS14627] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS023970, R01NS023970, R01NS014627, P50NS021445, P01NS021445] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BIGOT D, 1990, NEUROSCI LETT, V111, P275, DOI 10.1016/0304-3940(90)90274-D; BIGOT D, 1991, NEUROSCI LETT, V131, P21, DOI 10.1016/0304-3940(91)90328-Q; BIGOT D, 1991, EUR J NEUROSCI, V3, P551, DOI 10.1111/j.1460-9568.1991.tb00842.x; BOEHMER CG, 1989, PEPTIDES, V10, P1179, DOI 10.1016/0196-9781(89)90011-9; BOWDEN JJ, 1994, P NATL ACAD SCI USA, V91, P8964, DOI 10.1073/pnas.91.19.8964; BRELJE TC, 1989, DIABETES, V38, P808, DOI 10.2337/diabetes.38.6.808; BREWER GJ, 1989, NEUROSCI LETT, V99, P268, DOI 10.1016/0304-3940(89)90458-8; BRIMIJOIN S, 1980, BRAIN RES, V191, P443, DOI 10.1016/0006-8993(80)91293-7; CARON MG, 1993, RECENT PROG HORM RES, V48, P277; CASTEL MN, 1992, NEUROSCIENCE, V50, P269, DOI 10.1016/0306-4522(92)90422-X; COLLINS S, 1992, TRENDS BIOCHEM SCI, V17, P37, DOI 10.1016/0968-0004(92)90425-9; DALSGAARD CJ, 1984, NEUROSCI LETT, V51, P139, DOI 10.1016/0304-3940(84)90275-1; DUBNER R, 1991, PAIN RES CLIN MANAGE, V5, P263; DUGGAN AW, 1991, NEUROSCI LETT, V122, P191, DOI 10.1016/0304-3940(91)90855-N; GARLAND AM, 1994, BIOCHEM J, V303, P177, DOI 10.1042/bj3030177; HOKFELT T, 1975, BRAIN RES, V100, P235, DOI 10.1016/0006-8993(75)90481-3; JACK J, 1979, NEUROSCIENCES 4TH ST, P423; KATZ B, 1966, NERVE MUSCLE SYNAPSE, P12; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; LEFKOWITZ RJ, 1993, ADV SEC MESS PHOSPH, V28, P1; LEVINE JD, 1993, J NEUROSCI, V13, P2273, DOI 10.1523/JNEUROSCI.13-06-02273.1993; LIU HT, 1994, P NATL ACAD SCI USA, V91, P1009, DOI 10.1073/pnas.91.3.1009; MANTYH PW, 1995, J NEUROSCI, V15, P152; MANTYH PW, 1984, NATURE, V309, P795, DOI 10.1038/309795a0; MANTYH PW, 1985, BRAIN RES, V332, P315, DOI 10.1016/0006-8993(85)90600-6; MANTYH PW, UNPUB; MITCHISON T, 1988, NEURON, V1, P761, DOI 10.1016/0896-6273(88)90124-9; REUBI JC, 1990, METABOLISM, V39, P78, DOI 10.1016/0026-0495(90)90217-Z; SALTER MW, 1991, NEUROSCIENCE, V43, P601, DOI 10.1016/0306-4522(91)90319-J; SCHAIBLE HG, 1990, BRAIN RES, V529, P214, DOI 10.1016/0006-8993(90)90830-5; SIMONE DA, 1987, BRAIN RES, V418, P201, DOI 10.1016/0006-8993(87)90982-6; SIMONE DA, 1991, J NEUROPHYSIOL, V66, P228, DOI 10.1152/jn.1991.66.1.228; SIMONE DA, 1989, PAIN, V38, P99, DOI 10.1016/0304-3959(89)90079-1; SJODIN L, 1980, ACTA PHYSIOL SCAND, V109, P97, DOI 10.1111/j.1748-1716.1980.tb06570.x; VIGNA SR, 1994, J NEUROSCI, V14, P834; VONZASTROW M, 1993, J BIOL CHEM, V268, P763; WILCOX GL, 1988, ANN NY ACAD SCI, V525, P228, DOI 10.1111/j.1749-6632.1988.tb38608.x; WOOLF CJ, 1983, NATURE, V306, P686, DOI 10.1038/306686a0; YASHPAL K, 1990, BRAIN RES, V506, P259, DOI 10.1016/0006-8993(90)91260-N	39	419	421	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 16	1995	268	5217					1629	1632		10.1126/science.7539937	http://dx.doi.org/10.1126/science.7539937			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD459	7539937				2022-12-24	WOS:A1995RD45900041
J	MACMICKING, JD; NATHAN, C; HOM, G; CHARTRAIN, N; FLETCHER, DS; TRUMBAUER, M; STEVENS, K; XIE, QW; SOKOL, K; HUTCHINSON, N; CHEN, H; MUDGETT, JS				MACMICKING, JD; NATHAN, C; HOM, G; CHARTRAIN, N; FLETCHER, DS; TRUMBAUER, M; STEVENS, K; XIE, QW; SOKOL, K; HUTCHINSON, N; CHEN, H; MUDGETT, JS			ALTERED RESPONSES TO BACTERIAL-INFECTION AND ENDOTOXIC-SHOCK IN MICE LACKING INDUCIBLE NITRIC-OXIDE SYNTHASE	CELL			English	Article							METHYL-L-ARGININE; INTERFERON-GAMMA; SEPTIC SHOCK; MOLECULAR-CLONING; LISTERIA-MONOCYTOGENES; MACROPHAGE ACTIVATION; PASSIVE-IMMUNIZATION; MOUSE MACROPHAGES; CARDIAC MYOCYTES; INHIBITION	Mice deficient in inducible nitric oxide synthase (iNOS) were generated to test the idea that iNOS defends the host against infectious agents and tumor cells at the risk of contributing to tissue damage and shock. iNOS(-/-) mice failed to restrain the replication of Listeria monocytogenes in vivo or lymphoma cells in vitro. Bacterial endotoxic lipopolysaccharide (LPS) caused shock and death in anesthetized wild-type mice, but in iNOS(-/-) mice, the fall in central arterial blood pressure was markedly attenuated and early death averted. However, unanesthetized iNOS(-/-) mice suffered as much LPS-induced liver damage as wild type, and when primed with Propionobacterium acnes and challenged with LPS, they succumbed at the same rate as wild type. Thus, there exist both iNOS-dependent and iNOS-independent routes to LPS-induced hypotension and death.	MERCK & CO INC,MERCK SHARP & DOHME RES LABS,DEPT IMMUNOL,RAHWAY,NJ 07065; MERCK & CO INC,MERCK SHARP & DOHME RES LABS,DEPT INFLAMMAT,RAHWAY,NJ 07065; MERCK & CO INC,MERCK SHARP & DOHME RES LABS,ANIM RESOURCES LAB,RAHWAY,NJ 07065; CORNELL UNIV,LAB ANIM RES CTR,NEW YORK,NY 10021	Merck & Company; Merck & Company; Merck & Company; Cornell University	MACMICKING, JD (corresponding author), CORNELL UNIV,COLL MED,DEPT MED,BEATRICE & SAMUEL A SEAVER LAB,NEW YORK,NY 10021, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051967] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI034543, R01AI034543] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL51967] Funding Source: Medline; NIAID NIH HHS [AI34543] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALLIGAND JL, 1993, J CLIN INVEST, V91, P2314, DOI 10.1172/JCI116461; BECKERMAN KP, 1993, J IMMUNOL, V150, P888; BELENKY SN, 1993, J LEUKOCYTE BIOL, V53, P498, DOI 10.1002/jlb.53.5.498; BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; BLOCK MI, 1993, J EXP MED, V178, P1085, DOI 10.1084/jem.178.3.1085; BONE RC, 1992, CRIT CARE MED, V20, P884, DOI 10.1097/00003246-199206000-00028; BOOCKVAR KS, 1994, INFECT IMMUN, V62, P1089, DOI 10.1128/IAI.62.3.1089-1100.1994; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BURNETT AL, 1992, SCIENCE, V257, P401, DOI 10.1126/science.1378650; CARRERAS MC, 1994, FEBS LETT, V341, P65, DOI 10.1016/0014-5793(94)80241-6; CLANCY RM, 1992, J CLIN INVEST, V90, P1116, DOI 10.1172/JCI115929; COBB JP, 1992, J EXP MED, V176, P1175, DOI 10.1084/jem.176.4.1175; CONLAN JW, 1994, J EXP MED, V179, P259, DOI 10.1084/jem.179.1.259; CREASEY AA, 1993, J CLIN INVEST, V91, P2850, DOI 10.1172/JCI116529; DING AH, 1988, J IMMUNOL, V141, P2407; EVANS TG, 1993, J IMMUNOL, V151, P907; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; FINKEL MS, 1992, SCIENCE, V257, P387, DOI 10.1126/science.1631560; FLETCHER DS, 1995, J INTERF CYTOK RES, V15, P243, DOI 10.1089/jir.1995.15.243; FLORQUIN S, 1994, J EXP MED, V180, P1153, DOI 10.1084/jem.180.3.1153; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GRANGER DL, 1991, J IMMUNOL, V146, P1294; GREGORY SH, 1993, J IMMUNOL, V150, P2901; HARBRECHT BG, 1992, J LEUKOCYTE BIOL, V52, P390, DOI 10.1002/jlb.52.4.390; HARBRECHT BG, 1994, HEPATOLOGY, V20, P1055, DOI 10.1002/hep.1840200439; HIBBS JB, 1987, SCIENCE, V235, P473, DOI 10.1126/science.2432665; HIBBS JB, 1990, NITRIC OXIDE L ARGIN, P189; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; KAMIJO R, 1993, J EXP MED, V178, P1435, DOI 10.1084/jem.178.4.1435; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KARUPIAH G, 1993, SCIENCE, V261, P1445, DOI 10.1126/science.7690156; KILBOURN RG, 1990, BIOCHEM BIOPH RES CO, V172, P1132, DOI 10.1016/0006-291X(90)91565-A; KILBOURN RG, 1990, P NATL ACAD SCI USA, V87, P3629, DOI 10.1073/pnas.87.9.3629; KOHLER J, 1993, J IMMUNOL, V151, P916; LAI CS, 1994, FEBS LETT, V345, P120, DOI 10.1016/0014-5793(94)00422-6; LORENTE JA, 1993, CRIT CARE MED, V21, P1287, DOI 10.1097/00003246-199309000-00010; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MACNAUL KL, 1993, BIOCHEM BIOPH RES CO, V196, P1330, DOI 10.1006/bbrc.1993.2398; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; MINNARD EA, 1994, ARCH SURG-CHICAGO, V129, P142; MOHAUPT MG, 1994, KIDNEY INT, V46, P653, DOI 10.1038/ki.1994.318; MONCADA S, 1991, PHARMACOL REV, V43, P109; MUDGETT JS, 1990, GENOMICS, V8, P623, DOI 10.1016/0888-7543(90)90248-S; MUDGETT JS, 1995, IN PRESS ELECTROPORA; MULLIGAN MS, 1991, P NATL ACAD SCI USA, V88, P6338, DOI 10.1073/pnas.88.14.6338; NATANSON C, 1994, ANN INTERN MED, V120, P771, DOI 10.7326/0003-4819-120-9-199405010-00009; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; NAVA E, 1991, LANCET, V338, P1555, DOI 10.1016/0140-6736(91)92375-C; NISHIDA K, 1992, J CLIN INVEST, V90, P2092, DOI 10.1172/JCI116092; OCHOA JB, 1991, ANN SURG, V214, P621, DOI 10.1097/00000658-199111000-00013; OHISSON K, 1990, NATURE, V348, P550; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008; PASTOR C, 1994, CRIT CARE MED, V22, P465, DOI 10.1097/00003246-199403000-00017; PETROS A, 1991, LANCET, V338, P1557, DOI 10.1016/0140-6736(91)92376-D; PETROS A, 1994, CARDIOVASC RES, V28, P34, DOI 10.1093/cvr/28.1.34; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; RAJFER J, 1992, NEW ENGL J MED, V326, P90, DOI 10.1056/NEJM199201093260203; ROBERTS AB, 1992, MOL ENDOCRINOL, V6, P1921, DOI 10.1210/me.6.11.1921; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; SALVEMINI D, 1990, P NATL ACAD SCI USA, V87, P6077; SCHILLING J, 1993, INTENS CARE MED, V19, P227, DOI 10.1007/BF01694775; SLADEK SM, 1993, AM J OBSTET GYNECOL, V169, P1285, DOI 10.1016/0002-9378(93)90295-T; STEINMAN RM, 1980, J EXP MED, V151, P1248; STUEHR DJ, 1985, P NATL ACAD SCI USA, V82, P7738, DOI 10.1073/pnas.82.22.7738; STUEHR DJ, 1987, J IMMUNOL, V139, P518; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; SZABO C, 1994, P NATL ACAD SCI USA, V91, P12472, DOI 10.1073/pnas.91.26.12472; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; TAYLOR FB, 1987, J CLIN INVEST, V79, P918, DOI 10.1172/JCI112902; TEALE DM, 1992, J ANTIMICROB CHEMOTH, V30, P839, DOI 10.1093/jac/30.6.839; Thiemermann C, 1994, Adv Pharmacol, V28, P45, DOI 10.1016/S1054-3589(08)60493-7; THIEMERMANN C, 1990, EUR J PHARMACOL, V182, P591, DOI 10.1016/0014-2999(90)90062-B; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; XU H, 1994, J EXP MED, V180, P95, DOI 10.1084/jem.180.1.95; YALLAMPALLI C, 1994, AM J OBSTET GYNECOL, V170, P175	81	1260	1306	0	31	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 19	1995	81	4					641	650		10.1016/0092-8674(95)90085-3	http://dx.doi.org/10.1016/0092-8674(95)90085-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QZ710	7538909	hybrid			2022-12-24	WOS:A1995QZ71000021
J	KAGI, D; VIGNAUX, F; LEDERMANN, B; BURKI, K; DEPRAETERE, V; NAGATA, S; HENGARTNER, H; GOLSTEIN, P				KAGI, D; VIGNAUX, F; LEDERMANN, B; BURKI, K; DEPRAETERE, V; NAGATA, S; HENGARTNER, H; GOLSTEIN, P			FAS AND PERFORIN PATHWAYS AS MAJOR MECHANISMS OF T-CELL-MEDIATED CYTOTOXICITY	SCIENCE			English	Article							TUMOR-NECROSIS-FACTOR; MONOCLONAL-ANTIBODY; TARGET-CELLS; MICE; APOPTOSIS; LYSIS; LYMPHOCYTES; LYMPHOMA; ANTIGEN; DEFECTS	Two molecular mechanisms of T cell-mediated cytotoxicity, one perforin-based, the other Fas-based, have been demonstrated. To determine the extent of their contribution to T cell-mediated cytotoxicity, a range of effector cells from normal control or perforin-deficient mice were tested against a panel of target cells with various levels of Fas expression. All cytotoxicity observed was due to either of these mechanisms, and no third mechanism was detected. Thus, the perforin- and Fas-based mechanisms may account for all T cell-mediated cytotoxicity in short-term in vitro assays.	CNRS MARSEILLE LUMINY,INSERM,CTR IMMUNOL,F-13288 MARSEILLE 9,FRANCE; UNIV ZURICH,INST EXPTL IMMUNOL,DEPT PATHOL,CH-8091 ZURICH,SWITZERLAND; SANDOZ PHARMA LTD,PRECLIN RES,CH-4002 BASEL,SWITZERLAND; OSAKA BIOSCI INST,SUITA,OSAKA 565,JAPAN	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; University of Zurich; Novartis; Sandoz			Golstein, Pierre/A-4954-2014; Nagata, Shigekazu/AAG-3203-2019	Golstein, Pierre/0000-0003-1750-3483; Nagata, Shigekazu/0000-0001-9758-8426				BERKE G, 1972, J EXP MED, V135, P1334, DOI 10.1084/jem.135.6.1334; Berke G, 1980, Prog Allergy, V27, P69; BERKE G, 1989, FUNDAMENTAL IMMUNOLO, P735; Cerottini J C, 1974, Adv Immunol, V18, P67, DOI 10.1016/S0065-2776(08)60308-9; CONZELMANN A, 1982, NATURE, V298, P170, DOI 10.1038/298170a0; DOHERTY PC, 1978, J EXP MED, V148, P534, DOI 10.1084/jem.148.2.534; DUKE RC, 1991, APOPTOSIS MOL BASIS, P209; Golstein P, 1977, Contemp Top Immunobiol, V7, P273; GOLSTEIN P, IN PRESS APOPTOSIS I; HENKART PA, 1985, ANNU REV IMMUNOL, V3, P31, DOI 10.1146/annurev.iy.03.040185.000335; Henney C S, 1977, Contemp Top Immunobiol, V7, P245; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; LJUNGGREN HG, 1989, J IMMUNOL, V142, P2911; Martz E, 1977, Contemp Top Immunobiol, V7, P301; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Perlmann P, 1969, Adv Immunol, V11, P117, DOI 10.1016/S0065-2776(08)60479-4; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; PODACK ER, 1985, IMMUNOL TODAY, V6, P21, DOI 10.1016/0167-5699(85)90164-1; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; SHIVER JW, 1992, CELL, V71, P315, DOI 10.1016/0092-8674(92)90359-K; SITKOVSKY MV, 1993, CYTOTOXIC CELLS; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; TSCHOPP J, 1990, ANNU REV IMMUNOL, V8, P279, DOI 10.1146/annurev.immunol.8.1.279; VIGNAUX F, 1994, EUR J IMMUNOL, V24, P923, DOI 10.1002/eji.1830240421; VIGNAUX F, UNPUB; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; YOUNG JDE, 1989, PHYSIOL REV, V69, P250, DOI 10.1152/physrev.1989.69.1.250	31	1436	1478	2	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 22	1994	265	5171					528	530		10.1126/science.7518614	http://dx.doi.org/10.1126/science.7518614			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NY216	7518614				2022-12-24	WOS:A1994NY21600031
J	CONNELL, GJ; YARUS, M				CONNELL, GJ; YARUS, M			RNAS WITH DUAL-SPECIFICITY AND DUAL RNAS WITH SIMILAR SPECIFICITY	SCIENCE			English	Article							RIBOSOMAL-RNA; TETRAHYMENA; POLYMERASE; SUBSTRATE; STABILITY; ACID; DNA	The biological role of RNA is delimited by its possible reactions, which can be explored by selection. A comparison of selected RNAs that bind one ligand with those that bind two related ligands suggests that a single nucleotide substitution can expand binding specificity. An RNA site with dual (joint) specificity has adenine and cytosine bases whose pK(a)'s appear shifted upward, thereby mimicking an efficient general acid-base catalyst. The joint site also contains two conserved, looped arginine-coding triplets implicated in arginine site formation. Two selected joint RNAs are identical in some regions and distinct in others. The distinct regions, like some peptides, seem to function similarly without being similar in primary structure.	UNIV COLORADO, DEPT MOLEC CELLULAR & DEV BIOL, BOULDER, CO 80309 USA	University of Colorado System; University of Colorado Boulder			Yarus, Michael/Q-9813-2019					ALTMAN S, 1986, BIOCHEMISTRY-US, V25, P1205, DOI 10.1021/bi00354a002; BASS BL, 1984, NATURE, V308, P820, DOI 10.1038/308820a0; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CHEONG CJ, 1990, NATURE, V346, P680, DOI 10.1038/346680a0; CONNELL GJ, 1993, BIOCHEMISTRY-US, V32, P5497, DOI 10.1021/bi00072a002; CONNELL GJ, UNPUB; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; HARTLEY BS, 1974, S SOC GEN MICROBIOL, V24, P151; HENDLER S, 1970, BIOCHEMISTRY-US, V9, P4141, DOI 10.1021/bi00823a017; HEUS HA, 1991, SCIENCE, V253, P191, DOI 10.1126/science.1712983; HUNTER WN, 1986, NATURE, V320, P552, DOI 10.1038/320552a0; INOUE T, 1985, P NATL ACAD SCI USA, V82, P648, DOI 10.1073/pnas.82.3.648; KAO TH, 1980, P NATL ACAD SCI-BIOL, V77, P3360, DOI 10.1073/pnas.77.6.3360; LEGAULT P, UNPUB; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MAJERFELD I, 1994, NAT STRUCT BIOL, V1, P287, DOI 10.1038/nsb0594-287; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; PFEUFFER T, 1975, J BIOL CHEM, V250, P867; SASSANFAR M, 1993, NATURE, V364, P550, DOI 10.1038/364550a0; TOPAL MD, 1976, NATURE, V263, P285, DOI 10.1038/263285a0; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; WEINER AM, 1993, CELL, V72, P161, DOI 10.1016/0092-8674(93)90654-9; YARUS M, 1988, SCIENCE, V240, P1751, DOI 10.1126/science.3381099; Yarus M., 1993, RNA WORLD, P205; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	25	104	116	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 20	1994	264	5162					1137	1141		10.1126/science.7513905	http://dx.doi.org/10.1126/science.7513905			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NM146	7513905				2022-12-24	WOS:A1994NM14600030
J	ERNFORS, P; LEE, KF; KUCERA, J; JAENISCH, R				ERNFORS, P; LEE, KF; KUCERA, J; JAENISCH, R			LACK OF NEUROTROPHIN-3 LEADS TO DEFICIENCIES IN THE PERIPHERAL NERVOUS-SYSTEM AND LOSS OF LIMB PROPRIOCEPTIVE AFFERENTS	CELL			English	Article							DORSAL-ROOT GANGLIA; EXPRESSING MESSENGER-RNA; GROWTH-FACTOR FAMILY; SENSORY NEURONS; MOLECULAR-CLONING; BRAIN; RAT; SURVIVAL; BDNF; RECEPTORS	Neurotrophin-3-deficient (NT-3-deficient) mice were generated by gene targeting. Mutant mice displayed severe movement defects of the limbs, and most died shortly after birth. Substantial portions of peripheral sensory and sympathetic neurons were lost while motor neurons were not affected. Significantly, spinal proprioceptive afferents and their peripheral sense organs (muscle spindles and Golgi tendon organs) were completely absent in homozygous mutant mice. This correlated with a loss of parvalbumin and carbonic anhydrase-positive neurons in the dorsal root ganglion. No gross abnormalities were seen in Pacinian corpuscles, cutaneous afferents containing substance P and calcitonin gene-related peptide, and deep nerve fibers in the joint capsule and tendon. Importantly, the number of muscle spindles in heterozygous mutant mice was half of that in control mice, indicating that NT-3 is present at limiting concentrations in the embryo.	MIT,DEPT BIOL,CAMBRIDGE,MA 02142; BOSTON UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02118	Massachusetts Institute of Technology (MIT); Boston University	ERNFORS, P (corresponding author), WHITEHEAD INST BIOMED RES,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.				NATIONAL CANCER INSTITUTE [R35CA044339] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025796] Funding Source: NIH RePORTER; NCI NIH HHS [5-R35-CA44339] Funding Source: Medline; NINDS NIH HHS [5-R01-NS25796] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARENAS E, 1994, NATURE, V367, P368, DOI 10.1038/367368a0; ARUMAE U, 1993, J CELL BIOL, V122, P1053, DOI 10.1083/jcb.122.5.1053; AVILA MA, 1993, DEV BIOL, V159, P266, DOI 10.1006/dbio.1993.1239; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; BARRES BA, 1994, NATURE, V367, P371, DOI 10.1038/367371a0; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BIRREN SJ, 1993, DEVELOPMENT, V119, P597; BUCHMAN VL, 1993, DEVELOPMENT, V118, P989; CARR PA, 1989, BRAIN RES, V497, P163, DOI 10.1016/0006-8993(89)90983-9; CARR PA, 1993, BRAIN RES BULL, V30, P209, DOI 10.1016/0361-9230(93)90246-8; CARR PA, 1989, NEUROSCIENCE, V33, P363, DOI 10.1016/0306-4522(89)90216-9; DAVIES AM, 1986, J NEUROSCI, V6, P1897; DECHANT G, 1993, J NEUROSCI, V13, P2610, DOI 10.1523/JNEUROSCI.13-06-02610.1993; DICICCOBLOOM E, 1993, NEURON, V11, P1101, DOI 10.1016/0896-6273(93)90223-E; ERNFORS P, 1994, NATURE, V368, P147, DOI 10.1038/368147a0; ERNFORS P, 1992, EUR J NEUROSCI, V4, P1140, DOI 10.1111/j.1460-9568.1992.tb00141.x; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; ERNFORS P, 1990, NEURON, V5, P511, DOI 10.1016/0896-6273(90)90090-3; ERNFORS P, 1991, EUR J NEUROSCI, V3, P953, DOI 10.1111/j.1460-9568.1991.tb00031.x; ERNFORS P, 1994, IN PRESS PROG BRAIN; GRIFFIN JW, 1990, ANN NEUROL, V27, P304, DOI 10.1002/ana.410270313; HALLBOOK F, 1991, NEURON, V6, P1; HENDERSON CE, 1993, NATURE, V363, P213; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HORYLEE F, 1993, P NATL ACAD SCI USA, V90, P2613, DOI 10.1073/pnas.90.7.2613; IBANEZ CF, 1993, DEVELOPMENT, V117, P1345; IP NY, 1992, P NATL ACAD SCI USA, V89, P3060, DOI 10.1073/pnas.89.7.3060; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; KAISHO Y, 1990, FEBS LETT, V266, P187, DOI 10.1016/0014-5793(90)81536-W; KALCHEIM C, 1992, P NATL ACAD SCI USA, V89, P1661, DOI 10.1073/pnas.89.5.1661; KOLIATSOS VE, 1993, NEURON, V10, P359, DOI 10.1016/0896-6273(93)90326-M; KRINKE G, 1978, ACTA NEUROPATHOL, V43, P213; KRINKE G, 1980, NEUROTOXICOLOGY, V2, P13; KUCERA J, 1990, DEVELOPMENT, V110, P483; KUCERA J, 1992, ANAT EMBRYOL, V186, P301; LEE KF, 1994, IN PRESS DEVELOPMENT; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LINDSAY RM, 1985, DEV BIOL, V112, P319, DOI 10.1016/0012-1606(85)90402-6; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MAYEUX V, 1991, DEV BRAIN RES, V71, P201; MU XJ, 1993, J NEUROSCI, V13, P4029; PIRVOLA U, 1992, P NATL ACAD SCI USA, V89, P9915, DOI 10.1073/pnas.89.20.9915; Ranson SW, 1931, J COMP NEUROL, V52, P341, DOI 10.1002/cne.900520206; RITTER AM, 1991, NATURE, V350, P500, DOI 10.1038/350500a0; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; RUIT KG, 1992, NEURON, V8, P573, DOI 10.1016/0896-6273(92)90284-K; SCHECTERSON LC, 1992, NEURON, V9, P449, DOI 10.1016/0896-6273(92)90183-E; SCHNELL L, 1994, NATURE, V367, P170, DOI 10.1038/367170a0; SENDTNER M, 1992, NATURE, V360, P757, DOI 10.1038/360757a0; SMITH BE, 1992, NEUROL CLIN, V10, P735, DOI 10.1016/S0733-8619(18)30206-8; STERMAN AB, 1980, ANN NEUROL, V7, P354, DOI 10.1002/ana.410070413; THOENEN H, 1980, PHYSIOL REV, V60, P1284, DOI 10.1152/physrev.1980.60.4.1284; WIESENDANGER M, 1964, ACTA PHYSIOL SCAND, V62, P160, DOI 10.1111/j.1748-1716.1964.tb03964.x; WOOD JN, 1981, BIOSCIENCE REP, V1, P263, DOI 10.1007/BF01114913; ZELENA J, 1957, J EMBRYOL EXP MORPH, V5, P283	59	608	619	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 20	1994	77	4					503	512		10.1016/0092-8674(94)90213-5	http://dx.doi.org/10.1016/0092-8674(94)90213-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NM832	7514502				2022-12-24	WOS:A1994NM83200006
J	NIETO, MA; SARGENT, MG; WILKINSON, DG; COOKE, J				NIETO, MA; SARGENT, MG; WILKINSON, DG; COOKE, J			CONTROL OF CELL BEHAVIOR DURING VERTEBRATE DEVELOPMENT BY SLUG, A ZINC-FINGER GENE	SCIENCE			English	Article							NEURAL CREST; ADHESION; ANTIBODIES; CADHERIN; ENCODES	Slug, a vertebrate gene encoding a zinc finger protein of the Snail family, is expressed in the neural crest and in mesodermal cells emigrating from the primitive streak. Early chick embryos were incubated with antisense oligonucleotides to chick Slug. These oligonucleotides specifically inhibit the normal change in cell behavior that occurs at the two sites in the emerging body plan in which the gene is expressed. This change, which is the transition from epithelial to mesenchymal character, occurs at the formation of mesoderm during gastrulation and on emigration of the neural crest from the neural tube.	NATL INST MED RES,LONDON NW7 1AA,ENGLAND; CSIC,INST CAJAL,E-28002 MADRID,SPAIN	MRC National Institute for Medical Research; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto Cajal (IC)			Nieto, M. Angela/A-6531-2008	Nieto, M. Angela/0000-0002-3538-840X; Wilkinson, David/0000-0001-6757-7080				BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; Bellairs R., 1987, P123; BOULAY JL, 1987, NATURE, V330, P395, DOI 10.1038/330395a0; BRONNERFRASER M, 1992, DEV BIOL, V153, P291, DOI 10.1016/0012-1606(92)90114-V; BURDSAL CA, 1993, DEVELOPMENT, V118, P829; COOKE J, UNPUB; DAMICOMARTEL A, 1983, AM J ANAT, V166, P445, DOI 10.1002/aja.1001660406; DARRIBERE T, 1988, DEV BIOL, V126, P182, DOI 10.1016/0012-1606(88)90252-7; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; LALLIER T, 1993, SCIENCE, V259, P692, DOI 10.1126/science.8430321; Le Douarin N, 1973, Dev Biol, V30, P217, DOI 10.1016/0012-1606(73)90061-4; Le Douarin N.M., 1982, NEURAL CREST; LELIEVRE C, 1975, J EMBRYOL EXP MORPH, V31, P125; NEW DAT, 1955, J EMBRYOL EXP MORPH, V3, P326; NIETO MA, 1992, DEVELOPMENT, V116, P227; SARGENT MG, 1990, DEVELOPMENT, V109, P963; SCHOENWOLF GC, 1990, DEVELOPMENT, V109, P243; SECHRIST J, 1993, DEVELOPMENT, V118, P691; SERBEDZIJA G, 1989, DEVELOPMENT, V106, P806; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TUCKER GC, 1984, CELL DIFFER DEV, V14, P223, DOI 10.1016/0045-6039(84)90049-6; VINCENT M, 1984, DEV BIOL, V103, P468, DOI 10.1016/0012-1606(84)90334-8; WHITELEY M, 1992, MECH DEVELOP, V36, P117, DOI 10.1016/0925-4773(92)90063-P; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361; ZON G, 1991, OLIGONUCLEOTIDES ANA, P87	26	617	631	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 6	1994	264	5160					835	839		10.1126/science.7513443	http://dx.doi.org/10.1126/science.7513443			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NJ949	7513443				2022-12-24	WOS:A1994NJ94900031
J	IWASHIMA, M; IRVING, BA; VANOERS, NSC; CHAN, AC; WEISS, A				IWASHIMA, M; IRVING, BA; VANOERS, NSC; CHAN, AC; WEISS, A			SEQUENTIAL INTERACTIONS OF THE TCR WITH 2 DISTINCT CYTOPLASMIC TYROSINE KINASES	SCIENCE			English	Article							CELL ANTIGEN RECEPTOR; T-CELL; SIGNAL TRANSDUCTION; ZETA-CHAIN; ACTIVATION; CD4; PHOSPHORYLATION; P56LCK; COMPLEX; DOMAIN	The T cell antigen receptor (TCR) initiates signals by interacting with cytoplasmic protein tyrosine kinases (PTKs) through a 17-residue sequence motif [called the antigen recognition activation motif (ARAM)] that is contained in the TCRzeta and CD3 chains. TCR stimulation induces the tyrosine phosphorylation of several cellular substrates, including the ARAMs. Lck kinase activity is required for phosphorylation of two conserved tyrosine residues in an ARAM. This phosphorylation leads to the recruitment of a second cytoplasmic PTK, ZAP-70, through both of the ZAP-70 Src homology 2 domains and its phosphorylation. Thus, TCR signal transduction is initiated by the sequential interaction of two PTKs with TCR ARAMs.	UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020684] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039553] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-20684] Funding Source: Medline; NIGMS NIH HHS [GM39553] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GOLDSMITH MA, 1987, P NATL ACAD SCI USA, V84, P6879, DOI 10.1073/pnas.84.19.6879; HALL CG, 1993, SCIENCE, V261, P915, DOI 10.1126/science.8346442; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; Iwashima M., UNPUB; Iwashima M., 1992, PROG IMMUNOL, V8, P205; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; Ledbetter J A, 1990, Semin Immunol, V2, P99; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; QIAN DP, 1993, J BIOL CHEM, V268, P4488; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAROSI GA, 1992, INT IMMUNOL, V4, P1211, DOI 10.1093/intimm/4.11.1211; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WANGE RL, 1992, J BIOL CHEM, V267, P11685; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1991, ANNU REV GENET, V25, P487, DOI 10.1146/annurev.ge.25.120191.002415; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; XU H, 1993, CELL, V74, P633, DOI 10.1016/0092-8674(93)90511-N	47	668	679	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 25	1994	263	5150					1136	1139		10.1126/science.7509083	http://dx.doi.org/10.1126/science.7509083			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX759	7509083				2022-12-24	WOS:A1994MX75900032
J	JICK, H; JICK, SS; GUREWICH, V; MYERS, MW; VASILAKIS, C				JICK, H; JICK, SS; GUREWICH, V; MYERS, MW; VASILAKIS, C			RISK OF IDIOPATHIC CARDIOVASCULAR DEATH AND NONFATAL VENOUS THROMBOEMBOLISM IN WOMEN USING ORAL-CONTRACEPTIVES WITH DIFFERING PROGESTAGEN COMPONENTS	LANCET			English	Article							VASCULAR-DISEASE	Concern about the risks of cardiovascular illness in women using combined oral contraceptives (OC) containing the progestagens desogestrel and gestodene prompted two studies of data from the UK General Practice Research Database. We compared the risks of certain cardiovascular illnesses in otherwise healthy women exposed to one of three OCs containing <35 mu g oestrogen plus levonorgestrel, desogestrel, or gestodene. In the first study, based on some 470 general practices, there were 15 cases of unexpected idiopathic cardiovascular death among 303 470 women who were current users of one of the study OCs. The estimated incidence rates were 8/184 536 (4.3 per 100 000) woman-years at risk for users of combined OCs containing levonorgestrel, 2/135 567 (1.5 per 100 000) for desogestrel users, and 5/105 201 (4.8 per 100 000) for gestodene users. The relative risk (RR) estimates were 0.4 (95% CI 0.1-2.1) and 1.4 (CI 0.5-4.5) for desogestrel and gestodene, respectively, compared with levonorgestrel. In the second study, derived from some 370 general practices, there were 80 cases of nonfatal venous thromboembolism (VTE) in a cohort of 238 130 otherwise healthy women. The incidence rates of VTE per 100 000 woman-years at risk were 16.1 for levonorgestrel users, 29.3 for desogestrel, and 28.1 for gestodene. The adjusted RR estimates from the cohort analysis were 1.9 (1.1-3.2) and 1.8 (1.0-3.2) for desogestrel and gestodene users, respectively, compared with users of levonorgestrel. In a nested case-control analysis the adjusted matched RR estimates were 2.2 (1.1-4.4) and 2.1 (1.0-4.4) for desogestrel and gestodene users, respectively, compared with users of levonorgestrel. The excess risk for nonfatal VTE associated with the new generation of combined OCs containing low-dose oestrogen and the progestagens desogestrel or gestodene compared with levonorgestrel is estimated to be 16 per 100 000 woman-years.	HARVARD UNIV,DEACONESS HOSP,SCH MED,VASC RES LAB,CAMBRIDGE,MA 02138; HARVARD UNIV,SCH MED,DEPT MED,CAMBRIDGE,MA 02138	Harvard University; Harvard University	JICK, H (corresponding author), BOSTON UNIV,MED CTR,BOSTON COLLABORAT DRUG SURVEILLANCE PROGRAM,11 MUZZEY ST,LEXINGTON,MA 02173, USA.			Jick, Hershel/0000-0003-4270-5992; Jick, Susan/0000-0002-2215-1067				JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; Jick H., 1992, PHARMACOEPIDEM DR S, V1, P347, DOI DOI 10.1002/PDS.2630010607; JICK SS, 1995, BRIT MED J, V310, P215, DOI 10.1136/bmj.310.6974.215; PORTER JB, 1985, OBSTET GYNECOL, V66, P1; PORTER JB, 1982, OBSTET GYNECOL, V59, P299; RODRIGUEZ LAG, 1994, LANCET, V343, P769, DOI 10.1016/S0140-6736(94)91843-0; SPEROFF L, 1993, OBSTET GYNECOL, V81, P1034; Van Staa TP, 1994, PHARMACOEPIDEM DR S, V3, P15, DOI DOI 10.1002/PDS.2630030106; VANDERVANGE N, 1988, CONTEMP OBSTET GYNEC, P317; 1995, LANCET, V346, P1582	10	623	631	0	19	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 16	1995	346	8990					1589	1593		10.1016/S0140-6736(95)91928-7	http://dx.doi.org/10.1016/S0140-6736(95)91928-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK481	7500750	hybrid			2022-12-24	WOS:A1995TK48100009
J	WHITTAKER, M; WILSONKUBALEK, EM; SMITH, JE; FAUST, L; MILLIGAN, RA; SWEENEY, HL				WHITTAKER, M; WILSONKUBALEK, EM; SMITH, JE; FAUST, L; MILLIGAN, RA; SWEENEY, HL			A 35-ANGSTROM MOVEMENT OF SMOOTH-MUSCLE MYOSIN ON ADP RELEASE	NATURE			English	Article							CROSS-BRIDGE KINETICS; ACTOMYOSIN ATPASE; LIGHT CHAIN; CONTRACTION; ACTIN; FIBERS; PHOTOLYSIS; LOCATION; COMPLEX; BINDING	MYOSIN II crossbridges interact with F-actin producing power-strokes of around 100 Angstrom (refs 1, 2), during which the products of ATP hydrolysis are released(3,5). This has been postulated to involve an articulation of the myosin head (S1) on actin, or substantial conformational changes in S1 itself(6-8). Small movements of the regulatory light chain have been detected (see, for example, refs 9, 10), but most data suggest that the bulk of S1 does not move on actin during crossbridge cyclings(8,11). Here we present three-dimensional maps of S1-decorated F-actin in the presence and absence of MgADP. The myosin motor domain is similar in both states but there are major orientational differences in the chain-binding domain, This domain acts as a rigid level arm pivoting about the end of the motor domain and swinging similar to 23 degrees, resulting in a similar to 35-Angstrom step. Small, nucleotide-mediated conformational changes in the motor domain(14-16) may thus be converted by the light-chain domain into large movement steps.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; UNIV PENN, SCH MED, DEPT PHYSIOL, PHILADELPHIA, PA 19104 USA	Scripps Research Institute; University of Pennsylvania			Sweeney, H Lee/F-1862-2010					BRENNER B, 1987, ANNU REV PHYSIOL, V49, P655; DANTZIG JA, 1985, J GEN PHYSIOL, V86, P305, DOI 10.1085/jgp.86.3.305; DANTZIG JA, 1991, J PHYSIOL-LONDON, V432, P639, DOI 10.1113/jphysiol.1991.sp018405; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; FISHER AJ, 1995, BIOPHYS J, V68, pS19; GEEVES MA, 1991, BIOCHEM J, V274, P1; GOLDMAN YE, 1987, ANNU REV PHYSIOL, V49, P637, DOI 10.1146/annurev.ph.49.030187.003225; HAMBLY B, 1992, BIOPHYS J, V63, P1306, DOI 10.1016/S0006-3495(92)81717-4; HELPER DJ, 1988, J BIOL CHEM, V263, P15748; HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY HE, 1985, J MUSCLE RES CELL M, V6, P153, DOI 10.1007/BF00713057; HUXLEY HE, 1969, SCIENCE, V164, P1356, DOI 10.1126/science.164.3886.1356; IRVING M, 1995, NATURE, V375, P688, DOI 10.1038/375688a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MILLIGAN RA, 1987, J CELL BIOL, V105, P29, DOI 10.1083/jcb.105.1.29; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; MILLIGAN RA, IN PRESS P NATN ACAD; NISHIYE E, 1993, J PHYSIOL-LONDON, V460, P247, DOI 10.1113/jphysiol.1993.sp019470; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; RAYMENT I, 1995, P NATL ACAD SCI USA, V92, P3864, DOI 10.1073/pnas.92.9.3864; REEDY MK, 1965, NATURE, V207, P1276, DOI 10.1038/2071276a0; SMITH CA, 1995, BIOCHEMISTRY-US, V34, P8973, DOI 10.1021/bi00028a005; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SWEENEY HL, 1994, J BIOL CHEM, V269, P1603; SWEENEY HL, IN PRESS BIOPHYS J; THOMAS DD, 1987, ANNU REV PHYSIOL, V49, P691, DOI 10.1146/annurev.ph.49.030187.003355; WHITTAKER M, 1995, ULTRAMICROSCOPY, V58, P245, DOI 10.1016/0304-3991(95)00057-8; [No title captured]	32	341	342	0	16	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 14	1995	378	6558					748	751		10.1038/378748a0	http://dx.doi.org/10.1038/378748a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK379	7501026				2022-12-24	WOS:A1995TK37900061
J	FRANCIS, GS				FRANCIS, GS			ROTATING TOURNIQUETS FOR ACUTE CARDIOGENIC PULMONARY-EDEMA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											FRANCIS, GS (corresponding author), UNIV MINNESOTA,MINNEAPOLIS,MN 55455, USA.							INGRAM RH, 1992, HEART DIS TXB CARDIO, P563	1	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 18	1995	274	15					1192	1192		10.1001/jama.274.15.1192	http://dx.doi.org/10.1001/jama.274.15.1192			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ120	7563500				2022-12-24	WOS:A1995RZ12000011
J	HUANG, PL; HUANG, ZH; MASHIMO, H; BLOCH, KD; MOSKOWITZ, MA; BEVAN, JA; FISHMAN, MC				HUANG, PL; HUANG, ZH; MASHIMO, H; BLOCH, KD; MOSKOWITZ, MA; BEVAN, JA; FISHMAN, MC			HYPERTENSION IN MICE LACKING THE GENE FOR ENDOTHELIAL NITRIC-OXIDE SYNTHASE	NATURE			English	Article							NADPH DIAPHORASE; RELAXING FACTOR; BLOOD-PRESSURE; L-ARGININE; INHIBITORS; NEURONS; INVIVO; NERVE	NITRIC oxide (NO), a potent vasodilator produced by endothelial cells, is thought to be the endothelium-dependent relaxing factor (EDRF) which mediates vascular relaxation in response to acetylcholine, bradykinin and substance P in many vascular besds(1-6). NO has been implicated in the regulation of blood pressure and regional blood flow(4-6), and also affects vascular smooth-muscle proliferation and inhibits platelet aggregation and leukocyte adhesion. Abnormalities in endothelial production of NO occur in atherosclerosis, diabetes and hypertension(7). Pharmacological blockade of NO production with arginine analogues such as L-nitroarginine (L-NA) or L-N-arginine methyl ester affects multiple isoforms of nitric oxide synthase (NOS), and so cannot distinguish their physiological roles(8,9). To study the role of endothelial NOS (eNOS) in vascular function, we disrupted the gene encoding eNOS in mice. Endothelium-derived relaxing factor activity, as assayed by acetylcholine-induced relaxation, is absent, and the eNOS mutant mice are hypertensive. Thus eNOS mediates basal vasodilation. Responses to NOS blockade in the mutant mice suggest that non-endothelial isoforms of NOS mag be involved in maintaining blood pressure.	MASSACHUSETTS GEN HOSP,CARDIOVASC RES CTR,MED SERV,BOSTON,MA 02129; HARVARD UNIV,SCH MED,BOSTON,MA 02129; MASSACHUSETTS GEN HOSP,DEPT NEUROL,STROKE RES LAB,BOSTON,MA 02129; UNIV VERMONT,COLL MED,DEPT PHARMACOL,BURLINGTON,VT 05405	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; University of Vermont			Moskowitz, Michael A/D-9916-2011					ANDERSON CR, 1992, NEUROSCI LETT, V139, P280, DOI 10.1016/0304-3940(92)90571-N; AYAJIKI K, 1993, NEUROSCIENCE, V54, P819, DOI 10.1016/0306-4522(93)90251-A; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; DASILVA SV, 1994, HYPERTENSION S1, V23, P60; FORSTERMANN U, 1994, METHOD ENZYMOL, V233, P258; FREY C, 1994, J BIOL CHEM, V269, P26083; GARDINER SM, 1992, EUR J PHARMACOL, V213, P449, DOI 10.1016/0014-2999(92)90636-I; HEVEL JM, 1994, METHOD ENZYMOL, V233, P250; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; IADECOLA C, 1993, BRAIN RES, V603, P173, DOI 10.1016/0006-8993(93)91318-M; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; IRIKURA K, 1995, P NATL ACAD SCI USA, V92, P6823, DOI 10.1073/pnas.92.15.6823; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; MATSUDA T, 1995, CIRC RES, V76, P426, DOI 10.1161/01.RES.76.3.426; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PEART WS, 1983, HYPERTENSION; REES DD, 1989, P NATL ACAD SCI USA, V86, P3375, DOI 10.1073/pnas.86.9.3375; REES DD, 1990, BRIT J PHARMACOL, V101, P746, DOI 10.1111/j.1476-5381.1990.tb14151.x; SAKUMA I, 1992, CIRC RES, V70, P607, DOI 10.1161/01.RES.70.3.607; SCROGIN KE, 1994, HYPERTENSION, V23, P982, DOI 10.1161/01.HYP.23.6.982; SNYDER SH, 1994, NATURE, V372, P504, DOI 10.1038/372504a0; TODA N, 1993, J VASC RES, V30, P61, DOI 10.1159/000158976; TOGASHI H, 1992, J PHARMACOL EXP THER, V262, P343; VINCENT SR, 1992, NEUROSCIENCE, V48, P755; [No title captured]	27	1683	1735	1	69	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 21	1995	377	6546					239	242		10.1038/377239a0	http://dx.doi.org/10.1038/377239a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV872	7545787				2022-12-24	WOS:A1995RV87200042
J	YU, CL; MEYER, DJ; CAMPBELL, GS; LARNER, AC; CARTERSU, C; SCHWARTZ, J; JOVE, R				YU, CL; MEYER, DJ; CAMPBELL, GS; LARNER, AC; CARTERSU, C; SCHWARTZ, J; JOVE, R			ENHANCED DNA-BINDING ACTIVITY OF A STAT3-RELATED PROTEIN IN CELLS TRANSFORMED BY THE SRC ONCOPROTEIN	SCIENCE			English	Article							TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; INTERFERON-GAMMA; GENE; INDUCIBILITY; ACTIVATION; ELEMENT; KINASE; JAK	Cytokines and growth factors induce tyrosine phosphorylation of signal transducers and activators of transcription (STATs) that directly activate gene expression. Cells stably transformed by the Src oncogene tyrosine kinase were examined for STAT protein activation. Assays of electrophoretic mobility, DNA-binding specificity, and antigenicity indicated that Stat3 or a closely related STAT family member was constitutively activated by the Src oncoprotein. Induction of this DNA-binding activity was accompanied by tyrosine phosphorylation of Stat3 and correlated with Src transformation. These findings demonstrate that Src can activate STAT signaling pathways and raise the possibility that Stat3 contributes to oncogenesis by Src.	UNIV MICHIGAN,SCH MED,DEPT MICROBIOL & IMMUNOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,CTR COMPREHENS CANC,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT PHYSIOL,ANN ARBOR,MI 48109; US FDA,CTR BIOL EVALUAT & RES,DIV CYTOKINE BIOL,BETHESDA,MD 20892	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; US Food & Drug Administration (FDA)			Yu, Chao-Lan/D-1834-2011	Yu, Chao-Lan/0000-0002-9381-6011	NCI NIH HHS [CA55652] Funding Source: Medline; NIDDK NIH HHS [DK34171, R01 DK034171] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055652] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034171, R37DK034171] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BHAVSAR D, COMMUNICATION; CAMPBELL GK, UNPUB; CAMPBELL GS, IN PRESS J BIOL CHEM; COCHRAN BH, UNPUB; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LAMB NJC, 1990, CELL, V61, P485, DOI 10.1016/0092-8674(90)90530-R; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; RAZ R, 1994, J BIOL CHEM, V269, P24391; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; YU CH, UNPUB; YU CL, 1993, MOL CELL BIOL, V13, P2011, DOI 10.1128/MCB.13.4.2011; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	29	797	832	0	40	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 7	1995	269	5220					81	83		10.1126/science.7541555	http://dx.doi.org/10.1126/science.7541555			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RG980	7541555				2022-12-24	WOS:A1995RG98000038
J	SHI, YG; BERG, JM				SHI, YG; BERG, JM			SPECIFIC DNA-RNA HYBRID BINDING BY ZINC-FINGER PROTEINS	SCIENCE			English	Article							CRYSTAL-STRUCTURE; 5S RNA; RECOGNITION; RULES	Zinc finger proteins of the Cys(2)His(2) type represent a large class of proteins that have been assumed to function by means of specific interactions with DNA. Experiments motivated by structural characteristics of zinc finger protein-DNA complexes revealed that certain zinc finger proteins bound DNA-RNA hybrids with affinities comparable to or greater than those for DNA duplexes. The interactions between the zinc finger proteins and the DNA-RNA hybrids were dependent on which strand was RNA and were sequence-specific. Thus, interactions with DNA-RNA hybrids should be considered with regard to the biological roles of zinc finger proteins.			SHI, YG (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT BIOPHYS & BIOPHYS CHEM,BALTIMORE,MD 21205, USA.		Berg, Jeremy/GRY-6706-2022	Berg, Jeremy/0000-0002-2444-8139; Shi, Yigong/0000-0003-2030-168X; Berg, Jeremy/0000-0003-3022-0963	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046257] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46257] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDWIN A, 1989, CURRENT PROTOCOLS MO, V2; BERG JM, 1992, P NATL ACAD SCI USA, V89, P11109, DOI 10.1073/pnas.89.23.11109; CLEMENS KR, 1993, SCIENCE, V260, P530, DOI 10.1126/science.8475383; DESJARLAIS JR, 1993, P NATL ACAD SCI USA, V90, P2256, DOI 10.1073/pnas.90.6.2256; EKKER SC, 1991, EMBO J, V10, P1179, DOI 10.1002/j.1460-2075.1991.tb08058.x; FAIRALL L, 1993, NATURE, V366, P483, DOI 10.1038/366483a0; JOHO KE, 1990, CELL, V61, P293, DOI 10.1016/0092-8674(90)90809-S; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; NEKLUDOVA L, 1994, P NATL ACAD SCI USA, V91, P6948, DOI 10.1073/pnas.91.15.6948; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELHAM HRB, 1980, P NATL ACAD SCI-BIOL, V77, P4170, DOI 10.1073/pnas.77.7.4170; RHODES D, 1993, SCI AM, V268, P56, DOI 10.1038/scientificamerican0293-56; SALAZAR M, 1993, BIOCHEMISTRY-US, V32, P4207, DOI 10.1021/bi00067a007; Shi Y. G., UNPUB	15	82	124	3	43	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 14	1995	268	5208					282	284		10.1126/science.7536342	http://dx.doi.org/10.1126/science.7536342			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT185	7536342				2022-12-24	WOS:A1995QT18500036
J	NOBES, CD; HALL, A				NOBES, CD; HALL, A			RHO, RAC, AND CDC42 GTPASES REGULATE THE ASSEMBLY OF MULTIMOLECULAR FOCAL COMPLEXES ASSOCIATED WITH ACTIN STRESS FIBERS, LAMELLIPODIA, AND FILOPODIA	CELL			English	Article							PROTEIN-KINASE-C; GTP-BINDING PROTEIN; GROWTH CONE FILOPODIA; TYROSINE PHOSPHORYLATION; EXTRACELLULAR-MATRIX; ADHESION PLAQUES; ANIMAL-CELLS; LEADING-EDGE; FIBROBLASTS; CONTACTS	Rho and rac, two members of the ras-related superfamily of small GTPases, regulate the polymerization of actin to produce stress fibers and lamellipodia, respectively. We report here that cdc42, another member of the rho family, triggers the formation of a third type of actin-based structure found at the cell periphery, filopodia. In addition to stress fibers, rho controls the assembly of focal adhesion complexes. We now show that rac and cdc42 also stimulate the assembly of multimolecular focal complexes at the plasma membrane. These complexes, which are associated with lamellipodia and filopodia, contain vinculin, paxillin, and focal adhesion kinase, but are distinct from and formed independently of rho-induced focal adhesions. Activation of cdc42 in Swiss 3T3 cells leads to the sequential activation of rac and then rho, suggesting a molecular model for the coordinated control of cell motility by members of the rho family of GTPases.	UNIV LONDON UNIV COLL,DEPT BIOCHEM,LONDON WC1E 6BT,ENGLAND	University of London; University College London	NOBES, CD (corresponding author), CANC RES CAMPAIGN,ONCOGENE & SIGNAL TRANSDUCT GRP,MRC,MOLEC CELL BIOL LAB,LONDON WC1E 6BT,ENGLAND.							ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; ALBRECHTBUEHLER G, 1976, J CELL BIOL, V69, P275, DOI 10.1083/jcb.69.2.275; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BURRIDGE K, 1983, CELL MOTIL CYTOSKEL, V3, P405, DOI 10.1002/cm.970030509; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CAO LG, 1990, J CELL BIOL, V110, P1089, DOI 10.1083/jcb.110.4.1089; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; DEPASQUALE JA, 1991, J CELL BIOL, V113, P1351, DOI 10.1083/jcb.113.6.1351; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; FLANAGAN MD, 1980, J BIOL CHEM, V255, P835; GUMBINER BM, 1993, NEURON, V11, P551, DOI 10.1016/0896-6273(93)90068-3; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HART MJ, 1994, J BIOL CHEM, V269, P62; HEATH JP, 1978, J CELL SCI, V29, P197; IZZARD CS, 1988, CELL MOTIL CYTOSKEL, V10, P137, DOI 10.1002/cm.970100118; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; Lee Juliet, 1993, Trends in Cell Biology, V3, P366, DOI 10.1016/0962-8924(93)90084-E; Machesky Laura M., 1993, Trends in Cell Biology, V3, P381, DOI 10.1016/0962-8924(93)90087-H; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MATSUI Y, 1992, MOL CELL BIOL, V12, P5690, DOI 10.1128/MCB.12.12.5690; NOBES CD, 1995, J CELL SCI, V108, P225; OCONNOR TP, 1993, J CELL BIOL, V123, P935, DOI 10.1083/jcb.123.4.935; OKABE S, 1989, J CELL BIOL, V109, P1581, DOI 10.1083/jcb.109.4.1581; OSTER GF, 1987, J CELL SCI S, V8, P35; PETERSON J, 1994, J CELL BIOL, V127, P1395, DOI 10.1083/jcb.127.5.1395; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RINNERTHALER G, 1988, J CELL BIOL, V106, P747, DOI 10.1083/jcb.106.3.747; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SHANNON M, 1993, NATURE, V365, P661; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; Small JV, 1989, CURR OPIN CELL BIOL, V1, P75, DOI 10.1016/S0955-0674(89)80040-7; SMALL JV, 1995, TRENDS CELL BIOL, V5, P52, DOI 10.1016/S0962-8924(00)88939-4; SMALL JV, 1981, J CELL BIOL, V91, P695, DOI 10.1083/jcb.91.3.695; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; SYMONS MH, 1991, J CELL BIOL, V114, P503, DOI 10.1083/jcb.114.3.503; THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0; Turner CE, 1991, CURR OPIN CELL BIOL, V3, P849, DOI 10.1016/0955-0674(91)90059-8; VINCENT S, 1992, MOL CELL BIOL, V12, P3138, DOI 10.1128/MCB.12.7.3138; VUORI K, 1993, J BIOL CHEM, V268, P21459; WANG YL, 1985, J CELL BIOL, V101, P597, DOI 10.1083/jcb.101.2.597; WOODS A, 1992, J CELL SCI, V101, P277; WU DY, 1993, J CELL BIOL, V123, P653, DOI 10.1083/jcb.123.3.653; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077; ZHENG Y, 1994, J BIOL CHEM, V269, P2369; Zigmond SH, 1989, CURR OPIN CELL BIOL, V1, P80, DOI 10.1016/S0955-0674(89)80041-9	57	3655	3709	9	283	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 7	1995	81	1					53	62		10.1016/0092-8674(95)90370-4	http://dx.doi.org/10.1016/0092-8674(95)90370-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QR970	7536630	Bronze			2022-12-24	WOS:A1995QR97000007
J	BRUNNER, T; MOGIL, RJ; LAFACE, D; YOO, NJ; MAHBOUBI, A; ECHEVERRI, F; MARTIN, SJ; FORCE, WR; LYNCH, DH; WARE, CF; GREEN, DR				BRUNNER, T; MOGIL, RJ; LAFACE, D; YOO, NJ; MAHBOUBI, A; ECHEVERRI, F; MARTIN, SJ; FORCE, WR; LYNCH, DH; WARE, CF; GREEN, DR			CELL-AUTONOMOUS FAS (CD95) FAS-LIGAND INTERACTION MEDIATES ACTIVATION-INDUCED APOPTOSIS IN T-CELL HYBRIDOMAS	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; MONOCLONAL-ANTIBODY; DNA FRAGMENTATION; CYCLOSPORINE-A; CYCLE BLOCK; DEATH; RECEPTOR; REQUIREMENTS; INVOLVEMENT; THYMOCYTES	A NUMBER of murine T-cell hybridomas undergo apoptosis within a few hours of activation by specific antigens, mitogens, antibodies against the T-cell antigen receptor, or a combination of phorbol ester and calcium ionophore(1-3). This phenomenon has been extensively studied as a model for cional deletion in the immune system, in which potentially autoreactive T cells eliminate themselves by apoptosis after activation, either in the thymus(4) or in the periphery(5). Here we show that the Fas/CD95 receptor, which can transduce a potent apoptotic signal when ligated(6,7), is rapidly expressed following activation of T-cell hybridomas, as is its functional, membrane-bound ligands, Interference with the ensuing Fas/Fas-ligand interaction inhibits activation-induced apoptosis, Because T-cell receptor ligation can induce apoptosis in a single T hybridoma cell, we suggest that the Fas/Fas-ligand interaction can induce cell death in a cell-autonomous manner.	UNIV CALIF RIVERSIDE,DIV BIOMED SCI,RIVERSIDE,CA 92521; IMMUNEX RES & DEV CORP,DEPT IMMUNOL,SEATTLE,WA 98101	University of California System; University of California Riverside	BRUNNER, T (corresponding author), LA JOLLA INST ALLERGY & IMMUNOL,DIV CELLULAR IMMUNOL,11149 N TORREY PINES RD,LA JOLLA,CA 92037, USA.		Green, Douglas R/N-8083-2018	Green, Douglas R/0000-0002-7332-1417; Martin, Seamus/0000-0002-8539-3143				ASHWELL JD, 1987, J EXP MED, V165, P173, DOI 10.1084/jem.165.1.173; BISSONNETTE RP, 1994, J EXP MED, V180, P2413, DOI 10.1084/jem.180.6.2413; CROWE PD, 1994, J IMMUNOL METHODS, V168, P79, DOI 10.1016/0022-1759(94)90212-7; FOTEDAR R, MOL CELL BIOL; Green D R, 1992, Semin Immunol, V4, P379; IWATA M, 1991, EUR J IMMUNOL, V21, P643, DOI 10.1002/eji.1830210316; IWATA M, 1991, J IMMUNOL, V149, P3302; KAWABE Y, 1991, NATURE, V349, P245, DOI 10.1038/349245a0; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; MATZINGER P, 1991, J IMMUNOL METHODS, V145, P185, DOI 10.1016/0022-1759(91)90325-A; MCGAHON AJ, IN PRESS CELL DEATH; MERCEP M, 1989, J IMMUNOL, V142, P4085; RAMSDELL F, 1994, EUR J IMMUNOL, V24, P928, DOI 10.1002/eji.1830240422; RAMSDELL F, 1994, INT IMMUNOL, V6, P1545, DOI 10.1093/intimm/6.10.1545; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; RUSSELL JH, 1993, P NATL ACAD SCI USA, V88, P4409; SARIN A, 1993, J EXP MED, V178, P1693, DOI 10.1084/jem.178.5.1693; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SHI YF, 1989, NATURE, V339, P625, DOI 10.1038/339625a0; SHI YF, 1990, J IMMUNOL, V144, P3326; SINGER GG, 1994, IMMUNITY, V1, P365, DOI 10.1016/1074-7613(94)90067-1; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; UCKER DS, 1989, J IMMUNOL, V143, P3461; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; YANG YL, 1993, P NATL ACAD SCI USA, V90, P6170, DOI 10.1073/pnas.90.13.6170; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; ZACHARCHUK CM, 1990, J IMMUNOL, V145, P4037	30	1253	1273	0	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 2	1995	373	6513					441	444		10.1038/373441a0	http://dx.doi.org/10.1038/373441a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE670	7530336				2022-12-24	WOS:A1995QE67000060
J	GROSSHANS, J; BERGMANN, A; HAFFTER, P; NUSSLEINVOLHARD, C				GROSSHANS, J; BERGMANN, A; HAFFTER, P; NUSSLEINVOLHARD, C			ACTIVATION OF THE KINASE PELLE BY TUBE IN THE DORSOVENTRAL SIGNAL-TRANSDUCTION PATHWAY OF DROSOPHILA EMBRYO	NATURE			English	Article							DORSAL-VENTRAL POLARITY; TOLL GENE-PRODUCT; NUCLEAR-LOCALIZATION; PROTO-ONCOGENE; ESTABLISHMENT; PATTERN; CACTUS; MORPHOGEN; GRADIENT; RECEPTOR	THE concentration of Dorsal protein in the nucleus determines cell fate along the dorsoventral axis of the Drosophila embryo(1-13). The dorsal-group genes and the cactus gene are required for production and transmission of a localized signal an the ventral side of the embryo(4,5) which determines the position of the highest nuclear concentration of Dorsal protein(1-3) The ventralizing signal produced in somatic cells(6) is transmitted through the perivitelline space(7) to the integral membrane protein Toll(8). Inside the embryo it leads to dissociation of the cytoplasmic Dorsal-Cactus complex and subsequent nuclear localization of Dorsal protein(9,10). Two components are known to mediate the signal transduction between Toll and Dorsal-Cactus(11,12): Pelle, a serine/threonine protein kinase(13), and Tube, a protein with an unknown biochemical activity(14). Here we construct gain-of-function alleles of pelle and tube and show that pelle functions downstream of tube. In addition, Pelle and Tube interact directly with one another. We propose that Tube is a direct activator of the protein kinase Pelle.			GROSSHANS, J (corresponding author), MAX PLANCK INST ENTWICKLUNGSBIOL,GENET ABT 3,SPEMANNSTR 35,D-72076 TUBINGEN,GERMANY.		Großhans, Jörg/AAE-9387-2020	Großhans, Jörg/0000-0003-1114-9233				ANDERSON KV, 1985, CELL, V42, P791, DOI 10.1016/0092-8674(85)90275-2; ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GAY NJ, 1991, NATURE, V351, P355, DOI 10.1038/351355b0; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HAGENMEIER S, 1992, THESIS U TUBINGEN; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HECHT PM, 1993, GENETICS, V135, P405; ISODA K, 1994, P NATL ACAD SCI USA, V91, P5350, DOI 10.1073/pnas.91.12.5350; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; KLINGLER M, 1988, NATURE, V335, P275, DOI 10.1038/335275a0; LETSOU A, 1991, P NATL ACAD SCI USA, V88, P810, DOI 10.1073/pnas.88.3.810; MARCEY D, 1991, EMBO J, V10, P4259, DOI 10.1002/j.1460-2075.1991.tb05004.x; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; NISHIDA Y, 1988, EMBO J, V7, P775, DOI 10.1002/j.1460-2075.1988.tb02875.x; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; ROTH S, 1991, DEVELOPMENT, V112, P371; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SHELTON CA, 1993, CELL, V72, P515, DOI 10.1016/0092-8674(93)90071-W; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; SPRENGER F, 1992, CELL, V71, P987, DOI 10.1016/0092-8674(92)90394-R; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STEIN D, 1992, CELL, V68, P429, DOI 10.1016/0092-8674(92)90181-B; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WHALEN AM, 1993, J CELL BIOL, V123, P523, DOI 10.1083/jcb.123.3.523; Wieschaus E., 1986, P199	30	107	112	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 8	1994	372	6506					563	566		10.1038/372563a0	http://dx.doi.org/10.1038/372563a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW082	7527496				2022-12-24	WOS:A1994PW08200056
J	COX, AL; SKIPPER, J; CHEN, Y; HENDERSON, RA; DARROW, TL; SHABANOWITZ, J; ENGELHARD, VH; HUNT, DF; SLINGLUFF, CL				COX, AL; SKIPPER, J; CHEN, Y; HENDERSON, RA; DARROW, TL; SHABANOWITZ, J; ENGELHARD, VH; HUNT, DF; SLINGLUFF, CL			IDENTIFICATION OF A PEPTIDE RECOGNIZED BY 5 MELANOMA-SPECIFIC HUMAN CYTOTOXIC T-CELL LINES	SCIENCE			English	Article							TUMOR-INFILTRATING LYMPHOCYTES; AUTOLOGOUS MELANOMA; HLA-A; ANTIGENS; EXPRESSION; RESPONSES; MOLECULE; CLONES; ALLELE; INTERLEUKIN-2	Of several thousand peptides presented by the major histocompatibility molecule HLA-A2.1, at least nine are recognized by melanoma-specific cytotoxic T lymphocytes (CTLs). Tandem mass spectrometry was used to identify and to sequence one of these peptide epitopes. Melanoma-specific CTLs had an exceptionally high affinity for this nine-residue peptide, which reconstituted an epitope for CTL lines from each of five different melanoma patients tested. Recognition by multiple CTL lines suggests that this may be a promising candidate for use in peptide-based melanoma vaccines.	UNIV VIRGINIA,HLTH SCI CTR,DEPT SURG,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,DEPT CHEM,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,BEIRNE CARTER CTR IMMUNOL RES,CHARLOTTESVILLE,VA 22908; DUKE UNIV,DEPT SURG,DURHAM,NC 27710; UNIV VIRGINIA,DEPT PATHOL,CHARLOTTESVILLE,VA 22908	University of Virginia; University of Virginia; University of Virginia; University of Virginia; Duke University; University of Virginia			Hunt, Donald F/I-6936-2012	Hunt, Donald F/0000-0003-2815-6368; Cox, Andrea/0000-0002-9331-2462; Engelhard, Victor/0000-0002-1741-0925	NCI NIH HHS [CA57653] Funding Source: Medline; NIAID NIH HHS [AI33993] Funding Source: Medline; NIGMS NIH HHS [GM37537] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057653, R29CA057653] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI033993, R01AI033993] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037537] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANICHINI A, 1993, J EXP MED, V177, P989, DOI 10.1084/jem.177.4.989; BEDNAREK MA, 1991, J IMMUNOL, V147, P4047; BERTOLETTI A, 1993, J VIROL, V67, P2376, DOI 10.1128/JVI.67.4.2376-2380.1993; BRICHARD V, 1993, J EXP MED, V178, P489, DOI 10.1084/jem.178.2.489; CHEN QY, 1992, INT J CANCER, V51, P218, DOI 10.1002/ijc.2910510209; CHEN Y, IN PRESS J IMMUNOL; COULIE PG, 1992, INT J CANCER, V50, P289, DOI 10.1002/ijc.2910500220; CROWLEY NJ, 1991, J IMMUNOL, V146, P1692; DARROW TL, 1989, J IMMUNOL, V142, P3329; ENGELHARD VH, UNPUB; Everson TC, 1966, SPONTANEOUS REGRESSI; FALK K, 1991, J EXP MED, V174, P425, DOI 10.1084/jem.174.2.425; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; HAYASHI Y, 1992, CANCER IMMUNOL IMMUN, V34, P419, DOI 10.1007/BF01741754; HENDERSON RA, 1993, P NATL ACAD SCI USA, V90, P10275, DOI 10.1073/pnas.90.21.10275; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HERIN M, 1987, INT J CANCER, V39, P390, DOI 10.1002/ijc.2910390320; HOM SS, 1991, J IMMUNOTHER, V10, P153; HUCZKO EL, 1993, J IMMUNOL, V151, P2572; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; IOANNIDES CG, 1991, J IMMUNOL, V146, P1700; IOANNIDES CG, 1993, SCAND J IMMUNOL, V37, P413, DOI 10.1111/j.1365-3083.1993.tb03312.x; KAWAKAMI Y, 1992, J IMMUNOL, V148, P638; KRADIN RL, 1989, LANCET, V1, P577; KWON BS, 1991, P NATL ACAD SCI USA, V88, P9228, DOI 10.1073/pnas.88.20.9228; KWON BS, 1987, MOL BIOL MED, V4, P339; MITCHELL MS, 1993, ANN NY ACAD SCI, V690, P153; MUUL LM, 1987, J IMMUNOL, V138, P989; PEOPLES GE, 1993, SURGERY, V114, P227; ROSENBERG SA, 1988, NEW ENGL J MED, V319, P1676, DOI 10.1056/NEJM198812223192527; RUPPERT J, 1993, CELL, V74, P929, DOI 10.1016/0092-8674(93)90472-3; SALTER RD, 1985, IMMUNOGENETICS, V21, P235, DOI 10.1007/BF00375376; SLINGLUFF CL, 1988, J NATL CANCER I, V80, P1016, DOI 10.1093/jnci/80.13.1016; SLINGLUFF CL, 1993, J IMMUNOL, V150, P2955; SLINGLUFF CL, IN PRESS CANCER RES; STORKUS WJ, 1993, J IMMUNOL, V151, P3719; STOVIN SF, 1986, J IMMUNOL, V137, P3042; TOPALIAN SL, 1992, J IMMUNOTHER, V12, P203, DOI 10.1097/00002371-199210000-00013; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; UDAKA K, 1992, CELL, V69, P989, DOI 10.1016/0092-8674(92)90617-L; UTZ U, 1992, J IMMUNOL, V149, P214; VANBLEEK GM, 1990, NATURE, V348, P213; VOSE BM, 1982, NATURE, V296, P359, DOI 10.1038/296359a0; WOLFEL T, 1993, INT J CANCER, V55, P237, DOI 10.1002/ijc.2910550212; WOLFEL T, IN PRESS EUR J IMMUN; YASUMURA S, 1993, CANCER RES, V53, P1461	46	792	853	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 29	1994	264	5159					716	719		10.1126/science.7513441	http://dx.doi.org/10.1126/science.7513441			4	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH713	7513441				2022-12-24	WOS:A1994NH71300036
J	SAWYERS, CL; MCLAUGHLIN, J; GOGA, A; HAVLIK, M; WITTE, O				SAWYERS, CL; MCLAUGHLIN, J; GOGA, A; HAVLIK, M; WITTE, O			THE NUCLEAR TYROSINE KINASE C-ABL NEGATIVELY REGULATES CELL-GROWTH	CELL			English	Article							PHILADELPHIA-CHROMOSOME; PROTO-ONCOGENE; CANCER-CELLS; GENE-PRODUCT; B-CELL; BCR; TRANSFORMATION; SUPPRESSION; MICE; MUTATIONS	c-Abl is a tyrosine kinase localized primarily in the nucleus. Previous assays for abl function rely on cellular transformation by abl mutants, which are cytoplasmic. Using a conditional overexpression strategy, we have developed a functional assay for c-abl. Overexpression of c-abl inhibits growth by causing cell cycle arrest. Growth suppression requires tyrosine kinase activity, nuclear localization, and an intact SH2 domain. Overexpression of dominant negative c-abl disrupts cell cycle control and enhances transformation by tyrosine kinases, G proteins, and transcription factor oncogenes. These findings suggest that c-abl acts as a negative regulator of cell growth. This growth suppressive activity is functionally similar to that of tumor suppressor genes such as p53 and Rb.	UNIV CALIF LOS ANGELES, DEPT MICROBIOL & MOLEC GENET, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, HOWARD HUGHES MED INST, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles	SAWYERS, CL (corresponding author), UNIV CALIF LOS ANGELES, DEPT MED, DIV HEMATOL ONCOL, LOS ANGELES, CA 90024 USA.		Sawyers, Charles/G-5327-2016					BALKWILL F, 1978, NATURE, V274, P798, DOI 10.1038/274798a0; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BRUNET LJ, 1988, MOL CELL BIOL, V8, P4799, DOI 10.1128/MCB.8.11.4799; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; DIKSTEIN R, 1992, CELL, V69, P751, DOI 10.1016/0092-8674(92)90287-M; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GERTLER FB, 1993, GENE DEV, V7, P441, DOI 10.1101/gad.7.3.441; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; GOGA A, 1993, MOL CELL BIOL, V13, P4967, DOI 10.1128/MCB.13.8.4967; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HENKEMEYER M, 1990, CELL, V63, P949, DOI 10.1016/0092-8674(90)90498-4; HENKEMEYER MJ, 1987, CELL, V51, P821, DOI 10.1016/0092-8674(87)90105-X; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PENDERGAST AM, 1993, MOL CELL BIOL, V13, P1728, DOI 10.1128/MCB.13.3.1728; PHILIPSON L, 1991, J CELL BIOCHEM, V46, P95, DOI 10.1002/jcb.240460202; REITH AD, 1993, ONCOGENE, V8, P45; RENSHAW MW, 1992, EMBO J, V11, P3941, DOI 10.1002/j.1460-2075.1992.tb05488.x; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SAWYERS CL, 1992, CANCER SURV, V15, P37; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SHTLVELMAN E, 1986, CELL, V47, P277; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; YANG Z, 1987, MOL CELL BIOL, V7, P3923, DOI 10.1128/MCB.7.11.3923; YU G, 1989, J BIOL CHEM, V264, P10276; ZIEGLER SF, 1981, CELL, V27, P477, DOI 10.1016/0092-8674(81)90389-5	56	247	255	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 8	1994	77	1					121	131		10.1016/0092-8674(94)90240-2	http://dx.doi.org/10.1016/0092-8674(94)90240-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NF211	7512450				2022-12-24	WOS:A1994NF21100015
J	BRANCH, DW; MITCHELL, MD; MILLER, E; PALINSKI, W; WITZTUM, JL				BRANCH, DW; MITCHELL, MD; MILLER, E; PALINSKI, W; WITZTUM, JL			PREECLAMPSIA AND SERUM ANTIBODIES TO OXIDIZED LOW-DENSITY-LIPOPROTEIN	LANCET			English	Note							PREGNANCY; PREECLAMPSIA	Oxidised low-density lipoprotein (Ox-LDL) has been associated with arterial foam-cell formation, and autoantibodies to Ox-LDL are present in human serum. Lipid peroxidation is enhanced in pre-eclampsia. We assessed whether the titre of IgG autoantibody to an epitope of Ox-LDL, malondialdehyde-conjugated low-density lipoprotein (MDA-LDL), was increased in the sera of pre-eclamptic patients. 16 such patients had significantly higher mean titres of autoantibodies to MDA-LDL than healthy pregnant women (p = 0.028). In a multiple regression model, pre-eclamptic patients still had a significantly higher mean titre (p = 0.048). Enhanced lipid peroxidation may be involved in the foam-cell formation of decidua and in the pathogenesis of pre-eclampsia.	UNIV CALIF SAN DIEGO, DEPT MED, DIV ENDOCRINOL & METAB, SAN DIEGO, CA 92103 USA	University of California System; University of California San Diego	BRANCH, DW (corresponding author), UNIV UTAH, HLTH SCI CTR, DEPT OBSTET & GYNECOL, ROOM 2B200 MED CTR, 50 N MED DR, SALT LAKE CITY, UT 84132 USA.		Palinski, Wulf/AAW-8032-2021; Mitchell, Murray/A-8639-2010	Mitchell, Murray/0000-0002-6167-7176; Palinski, Wulf/0000-0002-5113-0169	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014197] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL14197] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		HUBEL CA, 1989, AM J OBSTET GYNECOL, V161, P1025, DOI 10.1016/0002-9378(89)90778-3; ISHIHARA M, 1978, CLIN CHIM ACTA, V84, P1; MASEKI M, 1981, CLIN CHIM ACTA, V115, P155; POTTER JM, 1979, AM J OBSTET GYNECOL, V133, P165, DOI 10.1016/0002-9378(79)90469-1; SALONEN JT, 1992, LANCET, V339, P883, DOI 10.1016/0140-6736(92)90926-T; SHEPPARD BL, 1981, BRIT J OBSTET GYNAEC, V88, P695, DOI 10.1111/j.1471-0528.1981.tb01268.x; WANG YP, 1991, AM J OBSTET GYNECOL, V165, P1695, DOI 10.1016/0002-9378(91)90017-L; WICKINS D, 1988, ANN CLIN BIOCHEM, V18, P158; WITZTUM JL, 1993, BRIT HEART J, V69, pS12	9	133	136	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 12	1994	343	8898					645	646		10.1016/S0140-6736(94)92639-5	http://dx.doi.org/10.1016/S0140-6736(94)92639-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA093	7509433	Green Submitted			2022-12-24	WOS:A1994NA09300012
J	TSARFATY, I; RONG, S; RESAU, JH; SHEN, RL; DASILVA, PP; VANDEWOUDE, GF				TSARFATY, I; RONG, S; RESAU, JH; SHEN, RL; DASILVA, PP; VANDEWOUDE, GF			THE MET PROTOONCOGENE MESENCHYMAL TO EPITHELIAL-CELL CONVERSION	SCIENCE			English	Article							HEPATOCYTE GROWTH-FACTOR; SCATTER FACTOR; LIVER-REGENERATION; FACTOR HGF; C-MET; PROTOONCOGENE; VIMENTIN; CYTOKERATINS; EXPRESSION; RECEPTOR	Coexpression of the human Met receptor and its ligand, hepatocyte growth factor/scatter factor (HGF/SF), in NIH 3T3 fibroblasts causes the cells to become tumorigenic in nude mice. The resultant tumors display lumen-like morphology, contain carcinoma-like focal areas with intercellular junctions resembling desmosomes, and coexpress epithelial (cytokeratin) and mesenchymal (vimentin) cytoskeletal markers. The tumor cells also display enhanced expression of desmosomal and tight-junction proteins. The apparent mesenchymal to epithelial conversion of the tumor cells mimics the conversion that occurs during embryonic kidney development, suggesting that Met-HGF/SF signaling plays a role in this process as well as in tumors that express both epithelial and mesenchymal markers.	NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,POB B,FREDERICK,MD 21702; NCI,DIV CANC BIOL DIAG & CTR,INTRAMURAL RES PROGRAM,MATH BIOL LAB,MEMBRANE BIOL SECT,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Shen, Rulong/E-4079-2011	Tsarfaty, Ilan/0000-0002-5230-7093	OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BACALLAO R, 1989, AM J PHYSIOL, V257, P913; BHARGAVA M, 1992, CELL GROWTH DIFFER, V3, P11; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CHEJFEC G, 1991, ULTRASTRUCT PATHOL, V15, P131, DOI 10.3109/01913129109016231; CITI S, 1993, J CELL BIOL, V121, P485, DOI 10.1083/jcb.121.3.485; DOMAGALA W, 1990, AM J PATHOL, V137, P1059; EKBLOM P, 1989, FASEB J, V3, P2141, DOI 10.1096/fasebj.3.10.2666230; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GOULD VE, 1990, AM J PATHOL, V137, P1143; GRONE HJ, 1987, AM J PATHOL, V129, P1; GUMBINER BM, 1992, CELL, V69, P385, DOI 10.1016/0092-8674(92)90440-N; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; KINOSHITA T, 1991, BIOCHEM BIOPH RES CO, V177, P330, DOI 10.1016/0006-291X(91)91987-N; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; NAKAMURA T, 1989, SEIKAGAKU, V61, P1243; NALDINI L, 1991, ONCOGENE, V6, P501; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; RONG S, 1993, CANCER RES, V53, P5355; RONG S, 1993, CELL GROWTH DIFFER, V4, P563; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; ROSEN EM, 1991, CELL GROWTH DIFFER, V2, P603; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TROYANOVSKY SM, 1993, CELL, V72, P561, DOI 10.1016/0092-8674(93)90075-2; TSARFATY I, 1992, SCIENCE, V257, P1258, DOI 10.1126/science.1387731; TSARFATY I, UNPUB; WARD JM, 1992, AM J PATHOL, V141, P955	29	198	210	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 7	1994	263	5143					98	101		10.1126/science.7505952	http://dx.doi.org/10.1126/science.7505952			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ301	7505952				2022-12-24	WOS:A1994MQ30100040
J	STOUTHAMER, R; BREEUWER, JAJ; LUCK, RF; WERREN, JH				STOUTHAMER, R; BREEUWER, JAJ; LUCK, RF; WERREN, JH			MOLECULAR-IDENTIFICATION OF MICROORGANISMS ASSOCIATED WITH PARTHENOGENESIS	NATURE			English	Article							TRICHOGRAMMA HYMENOPTERA; DROSOPHILA-SIMULANS; INCOMPATIBILITY; POPULATIONS; MORMONIELLA	CYTOPLASMICALLY inherited microorganisms are widespread in insects and have been implicated as causes of female parthenogenesis (females developing from unfertilized eggs) and cytoplasmic incompatibility1-15. Normal sexual reproduction can be restored by treatment with antibiotics1-4. Sequence analysis of the DNA encoding 16S ribosomal RNA has shown that cytoplasmic incompatibility bacteria from diverse insect taxa are closely related (they share >95% sequence similarity) and belong to the alpha subdivision of Proteobacteria5-7. Here we show that parthenogenesis-associated bacteria from parasitoid Hymenoptera also fall into this bacterial group, having up to 99% sequence similarity to some incompatibility microorganisms. Both incompatibility and parthenogenesis microorganisms alter host chromosome behaviour during early mitotic divisions of the egg13-17. Incompatibility bacteria act by interfering with paternal chromosome incorporation in fertilized eggs, whereas parthenogenesis bacteria prevent segregation of chromosomes in unfertilized eggs. These traits are adaptive for the microorganisms. On the basis of their sequence similarities, we conclude that parthenogenesis bacteria and cytoplasmic incompatibility bacteria form a monophyletic group of microorganisms that 'specialize' in manipulating chromosome behaviour and reproduction of insects.	UNIV CALIF RIVERSIDE,DEPT BIOL,RIVERSIDE,CA 92521; UNIV CALIF RIVERSIDE,DEPT ENTOMOL,RIVERSIDE,CA 92521	University of California System; University of California Riverside; University of California System; University of California Riverside	STOUTHAMER, R (corresponding author), AGR UNIV WAGENINGEN,DEPT ENTOMOL,POB 8031,6700 EH WAGENINGEN,NETHERLANDS.			Werren, John/0000-0001-9353-2070				ANDERSON BE, 1991, J CLIN MICROBIOL, V29, P2838, DOI 10.1128/JCM.29.12.2838-2842.1991; Breeuwer J.A.J., 1992, Insect Molecular Biology, V1, P25, DOI 10.1111/j.1365-2583.1993.tb00074.x; BREEUWER JAJ, 1990, NATURE, V346, P558, DOI 10.1038/346558a0; BROSIUS J, 1978, P NATL ACAD SCI USA, V75, P4801, DOI 10.1073/pnas.75.10.4801; CASPARI E, 1959, EVOLUTION, V13, P568, DOI 10.1111/j.1558-5646.1959.tb03045.x; HOFFMANN AA, 1986, EVOLUTION, V40, P692, DOI 10.1111/j.1558-5646.1986.tb00531.x; JABLONKA E, 1989, J THEOR BIOL, V139, P69, DOI 10.1016/S0022-5193(89)80058-X; JOST E, 1970, ROUX ARCH DEV BIOL, V166, P173, DOI 10.1007/BF00576992; KELLEN WR, 1981, J INVERTEBR PATHOL, V37, P273, DOI 10.1016/0022-2011(81)90087-2; Lane D.J., 1991, 16S 23S RRNA SEQUENC, P115, DOI DOI 10.1007/S00227-012-2133-0; LEGNER EF, 1985, CAN ENTOMOL, V117, P383, DOI 10.4039/Ent117383-3; ONEILL SL, 1992, P NATL ACAD SCI USA, V89, P2699, DOI 10.1073/pnas.89.7.2699; ONEILL SL, 1990, NATURE, V348, P178, DOI 10.1038/348178a0; RICHARDSON PM, 1987, J INVERTEBR PATHOL, V50, P176, DOI 10.1016/0022-2011(87)90080-2; ROUSSET F, 1992, P ROY SOC B-BIOL SCI, V247, P163, DOI 10.1098/rspb.1992.0023; RYAN SL, 1985, J HERED, V76, P21, DOI 10.1093/oxfordjournals.jhered.a110011; RYAN SL, 1968, MOL GEN GENET, V103, P29, DOI 10.1007/BF00271154; STOUTHAMER R, 1990, P NATL ACAD SCI USA, V87, P2424, DOI 10.1073/pnas.87.7.2424; STOUTHAMER R, 1990, ANN ENTOMOL SOC AM, V83, P475, DOI 10.1093/aesa/83.3.475; STOUTHAMER R, IN PRESS J INVERT PA; SWOFFORD DL, 1990, PAUP V30; VANVLIET AHM, 1992, INT J SYST BACTERIOL, V42, P494, DOI 10.1099/00207713-42-3-494; WADE MJ, 1985, SCIENCE, V278, P527; WEISBURG WG, 1991, J BACTERIOL, V173, P697, DOI 10.1128/JB.173.2.697-703.1991; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; YEN JH, 1973, J INVERTEBR PATHOL, V22, P242, DOI 10.1016/0022-2011(73)90141-9; ZCHORIFEIN E, 1992, EXPERIENTIA, V48, P102, DOI 10.1007/BF01923619	27	396	437	1	59	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 7	1993	361	6407					66	68		10.1038/361066a0	http://dx.doi.org/10.1038/361066a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KF718	7538198				2022-12-24	WOS:A1993KF71800049
J	WARD, CL; OMURA, S; KOPITO, RR				WARD, CL; OMURA, S; KOPITO, RR			DEGRADATION OF CFTR BY THE UBIQUITIN-PROTEASOME PATHWAY	CELL			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; SITE-DIRECTED MUTAGENESIS; CYSTIC-FIBROSIS GENE; ENDOPLASMIC-RETICULUM; DELTA-F508; PROTEIN; IDENTIFICATION; TRANSLOCATION; MUTATIONS; CHAIN	Most cases of cystic fibrosis are caused by mutations that interfere with the biosynthetic folding of the cystic fibrosis transmembrane conductance regulator (CFTR), leading to the rapid degradation of CFTR molecules that have not matured beyond the endoplasmic reticulum (ER). The mechanism by which integral membrane proteins including CFTR are recognized and targeted for ER degradation and the proteolytic machinery involved in this process are not well understood. We show here that the degradation of both wild-type and mutant CFTR is inhibited by two potent proteasome inhibitors that induce the accumulation of polyubiquitinated forms of immature CFTR. CFTR degradation was also inhibited by coexpression of a dominant negative ubiquitin mutant and in cells bearing a temperature-sensitive mutation in the ubiquitin-activating enzyme, confirming that ubiquitination is required for rapid CFTR degradation.	KITASATO INST,MINATO KU,TOKYO 108,JAPAN		WARD, CL (corresponding author), STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043994] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43994] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; Fra A, 1993, Subcell Biochem, V21, P143; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KULKA RG, 1988, J BIOL CHEM, V162, P15726; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LEE BS, 1991, J BIOL CHEM, V266, P11448; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; MARSHALL J, 1994, J BIOL CHEM, V269, P2978; Olson TS, 1989, CURR OPIN CELL BIOL, V1, P1194, DOI 10.1016/S0955-0674(89)80071-7; OMURA S, 1991, J ANTIBIOT, V44, P117, DOI 10.7164/antibiotics.44.117; PIND S, 1994, J BIOL CHEM, V269, P12784; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SHIN J, 1993, SCIENCE, V259, P1901, DOI 10.1126/science.8456316; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; TSUI LC, 1992, TRENDS GENET, V8, P392, DOI 10.1016/0168-9525(92)90301-J; WARD CL, 1994, J BIOL CHEM, V269, P25710; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; YANG YP, 1993, P NATL ACAD SCI USA, V90, P9480, DOI 10.1073/pnas.90.20.9480	31	1101	1130	1	90	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 6	1995	83	1					121	127		10.1016/0092-8674(95)90240-6	http://dx.doi.org/10.1016/0092-8674(95)90240-6			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RY583	7553863	Bronze			2022-12-24	WOS:A1995RY58300016
J	WU, H; LIU, X; JAENISCH, R; LODISH, HF				WU, H; LIU, X; JAENISCH, R; LODISH, HF			GENERATION OF COMMITTED ERYTHROID BFU-E AND CFU-E PROGENITORS DOES NOT REQUIRE ERYTHROPOIETIN OR THE ERYTHROPOIETIN RECEPTOR	CELL			English	Article							COLONY-FORMING CELLS; HEMATOPOIETIC PROGENITORS; INSITU HYBRIDIZATION; GENE; EXPRESSION; MICE; CLONING; PURIFICATION; LOCALIZATION; MATURATION	Erythropoietin (EPO) is the principal growth factor regulating the production of circulating erythrocytes. We introduced null mutations into both Epo and the EPO receptor (EpoR) gene. Both heterozygotes appeared normal. Homozygous animals exhibited reduced primitive erythropoiesis and died around embryonic day 13, owing to failure of definitive fetal liver erythropoiesis. Both types of mutations exhibited identical phenotypes, indicating that EPO and the EPOR are crucial for definitive erythropoiesis in vivo and that no other ligands or receptors can replace them. Committed erythroid BFU-E and CFU-E progenitors were present in both homozygous fetal livers. Thus, neither EPO nor the EPOR is required for erythroid lineage commitment or for the proliferation and differentiation of BFU-E to CFU-E progenitors. EPO and the EPOR are crucial in vivo for the proliferation and survival of CFU-E progenitors and their irreversible terminal differentiation.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)	WU, H (corresponding author), WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.				NATIONAL CANCER INSTITUTE [R35CA044339] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL032262, P01HL041484] Funding Source: NIH RePORTER; NCI NIH HHS [R35-CA44339] Funding Source: Medline; NHLBI NIH HHS [HL32262, P01-HL-41484] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANAGNOSTOU A, 1994, P NATL ACAD SCI USA, V91, P3974, DOI 10.1073/pnas.91.9.3974; COLE RJ, 1966, J EMBRYOL EXP MORPH, V15, P245; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DESSYPRIS EN, 1988, BLOOD, V72, P2060; DRANOFF G, 1994, SCIENCE, V264, P713, DOI 10.1126/science.8171324; EMERSON SG, 1985, J CLIN INVEST, V76, P1286, DOI 10.1172/JCI112087; GREGORY CJ, 1978, BLOOD, V51, P527; GREGORY CJ, 1977, BLOOD, V49, P855; HARA H, 1977, EXP HEMATOL, V5, P141; KOURY MJ, 1988, J CELL PHYSIOL, V137, P65, DOI 10.1002/jcp.1041370108; KOURY MJ, 1988, J CLIN INVEST, V82, P154, DOI 10.1172/JCI113564; KOURY ST, 1988, BLOOD, V71, P524; KOURY ST, 1991, BLOOD, V77, P2497; KRANTZ SB, 1991, BLOOD, V77, P419; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MCDONALD JD, 1986, MOL CELL BIOL, V6, P842, DOI 10.1128/MCB.6.3.842; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MOORE MAS, 1970, BRIT J HAEMATOL, V18, P279, DOI 10.1111/j.1365-2141.1970.tb01443.x; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; PESCHLE C, 1979, EXP HEMATOL, V7, P87; PHARR PN, 1993, P NATL ACAD SCI USA, V90, P938, DOI 10.1073/pnas.90.3.938; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; SAWADA K, 1988, J CELL PHYSIOL, V137, P337, DOI 10.1002/jcp.1041370218; SAWADA K, 1990, J CELL PHYSIOL, V142, P219, DOI 10.1002/jcp.1041420202; SHOEMAKER CB, 1986, MOL CELL BIOL, V6, P849, DOI 10.1128/MCB.6.3.849; Tavassoli M, 1983, BONE MARROW STRUCTUR; WU H, 1994, P NATL ACAD SCI USA, V91, P2819, DOI 10.1073/pnas.91.7.2819; WU H, 1995, NATURE, V377, P242, DOI 10.1038/377242a0; YOUSSOUFIAN H, 1993, BLOOD, V81, P2223; ZANJANI ED, 1993, PATHOBIOLOGY, V61, P211, DOI 10.1159/000163796	31	807	843	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 6	1995	83	1					59	67		10.1016/0092-8674(95)90234-1	http://dx.doi.org/10.1016/0092-8674(95)90234-1			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RY583	7553874	Bronze			2022-12-24	WOS:A1995RY58300010
J	DOHERTY, PC				DOHERTY, PC			THE KEYS TO CELL-MEDIATED-IMMUNITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TOXIC LYMPHOCYTES-T; BIOLOGICAL ROLE; NUCLEOPROTEIN; ANTIGENS				DOHERTY, PC (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT IMMUNOL, 332 N LAUDERDALE ST, MEMPHIS, TN 38105 USA.		Doherty, Peter Charles/C-4185-2013	Doherty, Peter Charles/0000-0002-5028-3489				AMOS DB, 1972, FED PROC, V31, P1087; Benacerraf B, 1975, Adv Cancer Res, V21, P121, DOI 10.1016/S0065-230X(08)60972-0; BLANDEN RV, 1974, TRANSPLANT REV, V19, P56; DOHERTY PC, 1975, LANCET, V1, P1406, DOI 10.1016/S0140-6736(75)92610-0; DOHERTY PC, 1974, TRANSPLANT REV-DENMA, V19, P89; DOHERTY PC, 1977, P NATL ACAD SCI USA, V74, P1209, DOI 10.1073/pnas.74.3.1209; McDevitt H O, 1969, Adv Immunol, V11, P31, DOI 10.1016/S0065-2776(08)60477-0; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; YEWDELL JW, 1985, P NATL ACAD SCI USA, V82, P1785, DOI 10.1073/pnas.82.6.1785; ZINKERNA.RM, 1974, NATURE, V251, P547, DOI 10.1038/251547a0; Zinkernagel R M, 1979, Adv Immunol, V27, P51, DOI 10.1016/S0065-2776(08)60262-X; ZINKERNAGEL RM, 1995, JAMA-J AM MED ASSOC, V274, P1069, DOI 10.1001/jama.274.13.1069	12	7	7	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 4	1995	274	13					1067	1068		10.1001/jama.274.13.1067	http://dx.doi.org/10.1001/jama.274.13.1067			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX108	7563461				2022-12-24	WOS:A1995RX10800033
J	WYSS, DF; CHOI, JS; LI, J; KNOPPERS, MH; WILLIS, KJ; ARULANANDAM, ARN; SMOLYAR, A; REINHERZ, EL; WAGNER, G				WYSS, DF; CHOI, JS; LI, J; KNOPPERS, MH; WILLIS, KJ; ARULANANDAM, ARN; SMOLYAR, A; REINHERZ, EL; WAGNER, G			CONFORMATION AND FUNCTION OF THE N-LINKED GLYCAN IN THE ADHESION DOMAIN OF HUMAN CD2	SCIENCE			English	Article							CELL-SURFACE LIGAND; LYMPHOCYTE-T; ALTERNATIVE PATHWAY; COUPLING-CONSTANTS; MAGNETIC-RESONANCE; BINDING-SITE; PROTEIN; ACTIVATION; RESOLUTION; GLYCOSYLATION	The adhesion domain of human CD2 bears a single N-linked carbohydrate. The solution structure of a fragment of CD2 containing the covalently bound high-mannose N-glycan [-(N-acetylglucosamine)(2)-(mannose)5-8] was solved by nuclear magnetic resonance. The stem and two of three branches of the carbohydrate structure are well defined and the mobility of proximal glycan residues is restricted. Mutagenesis of all residues in the vicinity of the glycan suggests that the glycan is not a component of the CD2-CD58 interface; rather, the carbohydrate stabilizes the protein fold by counterbalancing an unfavorable clustering of five positive charges centered about lysine-61 of CD2.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; PROCEPT INC,CAMBRIDGE,MA 02139; DANA FARBER CANC INST,IMMUNOBIOL LAB,BOSTON,MA; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School								ARCHER SJ, 1991, J MAGN RESON, V95, P636, DOI 10.1016/0022-2364(91)90182-S; ARULANANDAM ARN, 1993, P NATL ACAD SCI USA, V90, P11613, DOI 10.1073/pnas.90.24.11613; ARULANANDAM ARN, 1994, J EXP MED, V180, P1861, DOI 10.1084/jem.180.5.1861; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; BODE W, 1989, BIOCHEMISTRY-US, V28, P1952; BODIAN DL, 1994, STRUCTURE, V2, P755, DOI 10.1016/S0969-2126(94)00076-X; CLORE G M, 1991, Journal of Biomolecular NMR, V1, P13, DOI 10.1007/BF01874566; DAVIS SJ, 1995, J BIOL CHEM, V270, P369, DOI 10.1074/jbc.270.1.369; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DRISCOLL PC, 1991, NATURE, V353, P762, DOI 10.1038/353762a0; DWEK RA, COMMUNICATION; FREYMANN D, 1990, J MOL BIOL, V216, P141, DOI 10.1016/S0022-2836(05)80066-X; GARRETT DS, 1994, J MAGN RESON SER B, V104, P99, DOI 10.1006/jmrb.1994.1061; GOLLOB JA, IN PRESS J EXP MED; Hahn W. C., 1993, LYMPHOCYTE ADHESION, P105; HAVEL TF, 1991, PROG BIOPHYS MOL BIO, V56, P43, DOI 10.1016/0079-6107(91)90007-F; HUNIG T, 1987, NATURE, V326, P298, DOI 10.1038/326298a0; JOAO HC, 1992, FEBS LETT, V307, P343, DOI 10.1016/0014-5793(92)80709-P; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; KATO K, 1992, J EXP MED, V176, P1241, DOI 10.1084/jem.176.5.1241; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANDAU NR, 1992, J VIROL, V66, P5110, DOI 10.1128/JVI.66.8.5110-5113.1992; LUBAS WA, 1988, J BIOL CHEM, V263, P3990; MADSEN JC, 1993, J BIOMOL NMR, V3, P239; MEUER SC, 1984, CELL, V36, P897, DOI 10.1016/0092-8674(84)90039-4; MOINGEON P, 1989, IMMUNOL REV, V111, P111, DOI 10.1111/j.1600-065X.1989.tb00544.x; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; QIN LH, 1994, J EXP MED, V179, P341, DOI 10.1084/jem.179.1.341; RECNY MA, 1990, J BIOL CHEM, V265, P8542; RECNY MA, 1992, J BIOL CHEM, V267, P22428; SELVARAJ P, 1987, NATURE, V326, P400, DOI 10.1038/326400a0; SHAANAN B, 1991, SCIENCE, V254, P862, DOI 10.1126/science.1948067; SHAW S, 1986, NATURE, V323, P262, DOI 10.1038/323262a0; SILICIANO RF, 1985, NATURE, V317, P428, DOI 10.1038/317428a0; SOMOZA C, 1993, J EXP MED, V178, P549, DOI 10.1084/jem.178.2.549; TAVERNOR AS, 1994, EUR J BIOCHEM, V219, P969, DOI 10.1111/j.1432-1033.1994.tb18579.x; VANDENEIJNDEN DH, 1986, CARBOHYD RES, V151, P329, DOI 10.1016/S0008-6215(00)90352-5; VANDERMERWE PA, 1993, EUR J IMMUNOL, V23, P1373, DOI 10.1002/eji.1830230628; VANDERMERWE PA, 1995, CURR BIOL, V5, P74; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; WITHKA JM, 1993, STRUCTURE, V1, P69, DOI 10.1016/0969-2126(93)90009-6; WONG YW, 1990, J EXP MED, V171, P2115, DOI 10.1084/jem.171.6.2115; WOOTEN EW, 1990, EUR BIOPHYS J, V18, P139, DOI 10.1007/BF02427373; WYSS DF, 1995, BIOCHEMISTRY-US, V34, P1622, DOI 10.1021/bi00005a019; WYSS DF, 1993, BIOCHEMISTRY-US, V32, P10995, DOI 10.1021/bi00092a008; WYSS DF, UNPUB; YANG SY, 1986, J IMMUNOL, V137, P1097	50	301	312	1	18	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 1	1995	269	5228					1273	1278		10.1126/science.7544493	http://dx.doi.org/10.1126/science.7544493			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR842	7544493				2022-12-24	WOS:A1995RR84200037
J	MACDONALD, SM; RAFNAR, T; LANGDON, J; LICHTENSTEIN, LM				MACDONALD, SM; RAFNAR, T; LANGDON, J; LICHTENSTEIN, LM			MOLECULAR-IDENTIFICATION OF AN IGE-DEPENDENT HISTAMINE-RELEASING FACTOR	SCIENCE			English	Article							HUMAN BASOPHILS; TRANSLATIONAL CONTROL; ACTIVATING FACTOR; RESPONSES; CHALLENGE; SEQUENCE; AIRWAYS; TUMOR; RNA	An immunoglobulin E (IgE)-dependent histamine-releasing factor (HRF) produced by lymphocytes of atopic children and present in biological fluids of allergic patients has been identified and purified. Amino-terminal sequencing revealed extensive homology to a mouse protein, p21, and its human homolog, p23. Both recombinant proteins caused histamine release from the human basophils of a subpopulation of donors, and this release was dependent on IgE. Polyclonal antibodies recognized and removed the biological activity of recombinant and native HRF. HRF identifies a heterogeneity of IgE and is believed to play a prominent role in chronic allergic disease processes.			MACDONALD, SM (corresponding author), JOHNS HOPKINS UNIV,JOHNS HOPKINS ASTHMA & ALLERGY CTR,SCH MED,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21224, USA.				NIAID NIH HHS [AI 32651, AI 07290] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI032651, R01AI032651] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALAM R, 1992, J CLIN INVEST, V89, P723, DOI 10.1172/JCI115648; AXEN R, 1967, NATURE, V214, P1302, DOI 10.1038/2141302a0; BOHM H, 1989, BIOCHEM INT, V19, P277; BOHM H, 1991, BIOMED BIOCHIM ACTA, V12, P1193; CHITPATIMA ST, 1988, NUCLEIC ACIDS RES, V16, P2350, DOI 10.1093/nar/16.5.2350; DAHLNDEN CA, 1994, J EXP MED, V179, P751; HOGQUIST KA, 1991, P NATL ACAD SCI USA, V88, P8485, DOI 10.1073/pnas.88.19.8485; ILIOPOULOS O, 1987, J ALLERGY CLIN IMMUN, V79, P253; KOSHINO T, 1993, CLIN EXP ALLERGY, V23, P919, DOI 10.1111/j.1365-2222.1993.tb00276.x; KUNA P, 1992, J EXP MED, V175, P489, DOI 10.1084/jem.175.2.489; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY DA, 1966, J IMMUNOL, V97, P203; LIU MC, 1991, AM REV RESPIR DIS, V144, P51, DOI 10.1164/ajrccm/144.1.51; MACDONALD SM, 1989, J IMMUNOL, V142, P3527; MACDONALD SM, 1987, J IMMUNOL, V139, P506; MACDONALD SM, 1993, ALLERGY PRINCIPLES P, P1; MARCH SC, 1974, ANAL BIOCHEM, V60, P149, DOI 10.1016/0003-2697(74)90139-0; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; PRUZANSKY JJ, 1983, J IMMUNOL, V131, P1949; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; SAMPSON HA, 1989, NEW ENGL J MED, V321, P228, DOI 10.1056/NEJM198907273210405; SIRAGANIAN RP, 1975, J IMMUNOL METHODS, V7, P283, DOI 10.1016/0022-1759(75)90025-3; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; THUESON DO, 1979, J IMMUNOL, V123, P633; WARNER JA, 1986, J IMMUNOL, V136, P2583; ZHANG K, 1992, J EXP MED, V176, P233, DOI 10.1084/jem.176.1.233	27	299	324	0	13	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 4	1995	269	5224					688	690		10.1126/science.7542803	http://dx.doi.org/10.1126/science.7542803			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RM702	7542803				2022-12-24	WOS:A1995RM70200033
J	GUNDERSON, KL; KOPITO, RR				GUNDERSON, KL; KOPITO, RR			CONFORMATIONAL STATES OF CFTR ASSOCIATED WITH CHANNEL GATING - THE ROLE OF ATP BINDING AND HYDROLYSIS	CELL			English	Article							SITE-DIRECTED MUTAGENESIS; CYSTIC-FIBROSIS; NUCLEOTIDE-BINDING; ESCHERICHIA-COLI; MULTIDRUG RESISTANCE; CHLORIDE CHANNEL; TRIPHOSPHATE CONFORMATION; CRYSTAL-STRUCTURE; TRANSPORT; PROTEINS	CFTR is a member of the traffic ATPase superfamily and a C1(-) ion channel that appears to require ATP hydrolysis for gating. Analysis of single CFTR C1(-) channels reconstituted into planar lipid bilayers revealed the presence of two open conductance states that are connected to each other and to the closed state by an asymmetric cycle of gating events. We show here that the transition between the two open conductance states is directly coupled to ATP hydrolysis by one of the consensus nucleotide-binding folds, designated NBF2. Moreover, the transition between the closed state and one of the open states is linked to the binding of ATP. This analysis permits real-time visualization of conformational changes associated with a single cycle of ATP hydrolysis by a single protein molecule and suggests a model describing a role for ATP in CFTR gating.	STANFORD UNIV,BIOPHYS PROGRAM,STANFORD,CA 94305	Stanford University	GUNDERSON, KL (corresponding author), STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305, USA.				NIDDK NIH HHS [DK43994] Funding Source: Medline; NIGMS NIH HHS [GM08294] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043994] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMES GF, 1992, FASEB J, V6, P2660, DOI 10.1096/fasebj.6.9.1377140; AMES GF, 1992, ADV ENZYMOL RAMB, V65, P1; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BAUKROWITZ T, 1994, NEURON, V12, P473, DOI 10.1016/0896-6273(94)90206-2; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BELL CL, 1993, AM J PHYSIOL, V264, pC925, DOI 10.1152/ajpcell.1993.264.4.C925; CARSON MR, 1993, AM J PHYSIOL, V265, pL27, DOI 10.1152/ajplung.1993.265.1.L27; CARSON MR, 1995, J BIOL CHEM, V270, P1711, DOI 10.1074/jbc.270.4.1711; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P149, DOI 10.1016/0005-2736(92)90078-Z; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; GADSBY DC, 1994, TRENDS BIOCHEM SCI, V19, P513, DOI 10.1016/0968-0004(94)90141-4; GUNDERSON KL, 1994, J BIOL CHEM, V269, P19349; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P752; HIGGINS CF, 1990, RES MICROBIOL, V141, P353, DOI 10.1016/0923-2508(90)90011-E; HSIEH S, 1992, NUCLEIC ACIDS RES, V20, P5647, DOI 10.1093/nar/20.21.5647; HWANG TC, 1994, P NATL ACAD SCI USA, V91, P4698, DOI 10.1073/pnas.91.11.4698; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JOHN J, 1993, J BIOL CHEM, V268, P923; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; KNOWLES JR, 1980, ANNU REV BIOCHEM, V49, P877, DOI 10.1146/annurev.bi.49.070180.004305; KUCHLER K, 1992, ENDOCR REV, V13, P499, DOI 10.1210/er.13.3.499; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PANAGIOTIDIS CH, 1993, J BIOL CHEM, V268, P23685; QUINTON PM, 1992, NATURE, V360, P79, DOI 10.1038/360079a0; REDDY M, 1994, PEDIATR PULM S, V10, P183; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RICHARD EA, 1990, SCIENCE, V247, P1208, DOI 10.1126/science.2156338; RICHARME G, 1992, BIOCHIM BIOPHYS ACTA, V1104, P201, DOI 10.1016/0005-2736(92)90151-B; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; RUETZ S, 1993, J CELL BIOL, V121, P37, DOI 10.1083/jcb.121.1.37; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHNEIDER E, 1994, J BIOL CHEM, V269, P20456; SHYAMALA V, 1991, J BIOL CHEM, V266, P18714; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; TSAI MD, 1991, BIOCHEMISTRY-US, V30, P6806, DOI 10.1021/bi00242a002; URBATSCH IL, 1994, BIOCHEMISTRY-US, V33, P7069, DOI 10.1021/bi00189a008; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WARD CL, 1994, J BIOL CHEM, V269, P26710	47	184	187	0	7	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 28	1995	82	2					231	239		10.1016/0092-8674(95)90310-0	http://dx.doi.org/10.1016/0092-8674(95)90310-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RL760	7543023	Bronze			2022-12-24	WOS:A1995RL76000010
J	LIN, HH; GROSSCHEDL, R				LIN, HH; GROSSCHEDL, R			FAILURE OF B-CELL DIFFERENTIATION IN MISE LACKING THE TRANSCRIPTION FACTOR EBF	NATURE			English	Article							GENE-TRANSCRIPTION; IMMUNOGLOBULIN HEAVY; ANTIGEN RECEPTOR; BONE-MARROW; EXPRESSION; LINEAGE; REARRANGEMENT; MB-1; REGULATOR; CLONING	EARLY B-cell factor (EBF) is a cell type-specific transcription factor that is expressed at all antigen-independent stages of B-lymphocyte differentiation and participates in the regulation of the mb-1 gene(1-4). Here we show, by targeted gene disruption in mice, that EBF is necessary for the generation of immunoglobulin-expressing B cells. EBF-deficient mice lack B cells that have rearranged their immunoglobulin D and J(H) gene segments, but contain B220(+)CD43(+) progenitor cells that express germline mu and IL-7 receptor transcripts. Various non-lymphoid tissues that express EBF are apparently normal in homozygous mutant mice, including olfactory neurons in which EBF was identified as Olf-1 (refs 5, 6). Together, these data suggest that EBF plays a specific and important role in the transcriptional control of B-cell differentiation at a stage before Ig (immunoglobulin) gene rearrangement but after commitment of cells to the B-lymphoid lineage.			LIN, HH (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143, USA.							BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; CAMPBELL KS, 1990, EMBO J, V9, P441, DOI 10.1002/j.1460-2075.1990.tb08129.x; EHLICH A, 1993, CELL, V72, P695, DOI 10.1016/0092-8674(93)90398-A; FELDHAUS AL, 1992, MOL CELL BIOL, V12, P1126, DOI 10.1128/MCB.12.3.1126; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; HAGMAN J, 1991, EMBO J, V10, P3409, DOI 10.1002/j.1460-2075.1991.tb04905.x; HAGMAN J, 1993, GENE DEV, V7, P760, DOI 10.1101/gad.7.5.760; HAGMAN J, 1995, EMBO J, V14, P2907, DOI 10.1002/j.1460-2075.1995.tb07290.x; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HOMBACH J, 1990, NATURE, V343, P760, DOI 10.1038/343760a0; HUNT CR, 1986, P NATL ACAD SCI USA, V83, P3786, DOI 10.1073/pnas.83.11.3786; KANTOR AB, 1993, ANNU REV IMMUNOL, V11, P501, DOI 10.1146/annurev.immunol.11.1.501; KUDRYCKI K, 1993, MOL CELL BIOL, V13, P3002, DOI 10.1128/MCB.13.5.3002; LI YS, 1993, J EXP MED, V178, P951, DOI 10.1084/jem.178.3.951; MILATOVICH A, 1994, MAMM GENOME, V5, P211, DOI 10.1007/BF00360547; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V255, P855; ROLINK A, 1993, CURR OPIN IMMUNOL, V5, P207, DOI 10.1016/0952-7915(93)90006-E; SAKAGUCHI N, 1988, EMBO J, V7, P3457, DOI 10.1002/j.1460-2075.1988.tb03220.x; SCHLISSEL M, 1991, GENE DEV, V5, P1367, DOI 10.1101/gad.5.8.1367; SCHLISSEL MS, 1989, CELL, V58, P1001, DOI 10.1016/0092-8674(89)90951-3; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; TRAVIS A, 1993, MOL CELL BIOL, V13, P3392, DOI 10.1128/MCB.13.6.3392; URBANEK P, 1994, CELL, V7, P901; VENKITARAMAN AR, 1991, NATURE, V352, P777, DOI 10.1038/352777a0; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0; YOUNG F, 1994, GENE DEV, V8, P1043, DOI 10.1101/gad.8.9.1043; ZHANG Y, 1994, CELL, V79, P875	30	517	527	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 20	1995	376	6537					263	267		10.1038/376263a0	http://dx.doi.org/10.1038/376263a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RK331	7542362				2022-12-24	WOS:A1995RK33100049
J	SIELING, PA; CHATTERJEE, D; PORCELLI, SA; PRIGOZY, TI; MAZZACCARO, RJ; SORIANO, T; BLOOM, BR; BRENNER, MB; KRONENBERG, M; BRENNAN, PJ; MODLIN, RL				SIELING, PA; CHATTERJEE, D; PORCELLI, SA; PRIGOZY, TI; MAZZACCARO, RJ; SORIANO, T; BLOOM, BR; BRENNER, MB; KRONENBERG, M; BRENNAN, PJ; MODLIN, RL			CD1-RESTRICTED T-CELL RECOGNITION OF MICROBIAL LIPOGLYCAN ANTIGENS	SCIENCE			English	Article							MYCOBACTERIUM-TUBERCULOSIS; LIPOARABINOMANNAN; GLYCOPEPTIDES; LYMPHOCYTES; CD1B	It has long been the paradigm that T cells recognize peptide antigens presented by major histocompatibility complex (MHC) molecules. However, nonpeptide antigens can be presented to T cells by human CD1b molecules, which are not encoded by the MHC. A major class of microbial antigens associated with pathogenicity are lipoglycans. It is shown here that human CD1b presents the defined mycobacterial lipoglycan lipoarabinomannan (LAM) to alpha beta T cell receptor-bearing lymphocytes. Presentation of these lipoglycan antigens required internalization and endosomal acidification. The T cell recognition required mannosides with alpha(1-->2) linkages and a phosphatidylinositol unit. T cells activated by LAM produced interferon gamma and were cytolytic. Thus, an important class of microbial molecules, the lipoglycans, is a part of the universe of foreign antigens recognized by human T cells.	UNIV CALIF LOS ANGELES,SCH MED,DIV DERMATOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,DEPT MICROBIOL & IMMUNOL,LOS ANGELES,CA 90095; COLORADO STATE UNIV,DEPT MICROBIOL,FT COLLINS,CO 80523; BRIGHAM & WOMENS HOSP,DEPT RHEUMATOL & IMMUNOL,BOSTON,MA 02115; UNIV CALIF LOS ANGELES,SCH MED,INST MOLEC BIOL,LOS ANGELES,CA 90095; YESHIVA UNIV ALBERT EINSTEIN COLL MED,HOWARD HUGHES MED INST,BRONX,NY 10461	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Colorado State University; Harvard University; Brigham & Women's Hospital; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine			Modlin, Robert L/M-7941-2014	Modlin, Robert L/0000-0003-4720-031X	NIAID NIH HHS [AI 18357, AI 28973, AI 07118] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018357, R22AI018357, R01AI028973, R37AI018357, R37AI028973] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0; BRODSKY FM, 1982, J IMMUNOL, V128, P129; CALABI F, 1991, TISSUE ANTIGENS, V37, P1, DOI 10.1111/j.1399-0039.1991.tb01836.x; CALABI F, 1986, NATURE, V323, P540, DOI 10.1038/323540a0; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6234; CHATTERJEE D, 1993, GLYCOBIOLOGY, V3, P497, DOI 10.1093/glycob/3.5.497; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6228; Chatterjee D., UNPUB; DELASALLE H, 1994, SCIENCE, V265, P237, DOI 10.1126/science.7517574; FAVALORO EJ, 1986, DIS MARKERS, V4, P261; HARDING CV, 1993, J IMMUNOL, V151, P2419; HAURUM JS, 1994, J EXP MED, V180, P739, DOI 10.1084/jem.180.2.739; HUNTER SW, 1982, J BIOL CHEM, V257, P5072; HUNTER SW, 1990, J BIOL CHEM, V265, P14065; HUNTER SW, 1990, J BIOL CHEM, V265, P9272; ISHIOKA GY, 1992, J IMMUNOL, V148, P2446; KHOO KH, 1995, GLYCOBIOLOGY, V5, P117, DOI 10.1093/glycob/5.1.117; MARTIN LH, 1987, P NATL ACAD SCI USA, V84, P9189, DOI 10.1073/pnas.84.24.9189; MICHAELSSON E, 1994, J EXP MED, V180, P745, DOI 10.1084/jem.180.2.745; PORCELI S, UNPUB; PORCELLI S, 1991, IMMUNOL REV, V120, P137, DOI 10.1111/j.1600-065X.1991.tb00591.x; PORCELLI S, 1992, NATURE, V360, P593, DOI 10.1038/360593a0; REINHERZ EL, 1980, P NATL ACAD SCI-BIOL, V77, P1588, DOI 10.1073/pnas.77.3.1588; SHIUE L, 1988, J EXP MED, V168, P1993, DOI 10.1084/jem.168.6.1993; SIELING PA, UNPUB; WOO J, 1995, EUR J BIOCHEM, V207, P383; XU SM, 1994, J IMMUNOL, V153, P2568	27	673	684	0	9	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 14	1995	269	5221					227	230		10.1126/science.7542404	http://dx.doi.org/10.1126/science.7542404			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RJ029	7542404				2022-12-24	WOS:A1995RJ02900041
J	TRAVERS, K; MBOUP, S; MARLINK, R; GUEYENDIAYE, A; SIBY, T; THIOR, I; TRAORE, I; DIENGSARR, A; SANKALE, JL; MULLINS, C; NDOYE, I; HSIEH, CC; ESSEX, M; KANKI, P				TRAVERS, K; MBOUP, S; MARLINK, R; GUEYENDIAYE, A; SIBY, T; THIOR, I; TRAORE, I; DIENGSARR, A; SANKALE, JL; MULLINS, C; NDOYE, I; HSIEH, CC; ESSEX, M; KANKI, P			NATURAL PROTECTION AGAINST HIV-1 INFECTION PROVIDED BY HIV-2	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CD8+ T-CELLS; WEST-AFRICA; NEUTRALIZING ANTIBODIES; VERTICAL TRANSMISSION; CROSS-NEUTRALIZATION; HIV-2-INFECTED CELLS; TYPE-2 HIV-2; IVORY-COAST; AIDS	Significant differences have been observed in the rates of transmission and disease development in human immunodeficiency virus (HIV) types 1 and 2. Because many HIV-2-infected people remain asymptomatic for prolonged periods, the hypothesis that HIV-2 might protect against subsequent infection by HIV-1 was considered. During a 9-year period in Dakar, Senegal, the seroincidence of both HIV types was measured in a cohort of commercial sex workers. Despite a higher incidence of other sexually transmitted diseases (STDs), HIV-2-infected women had a lower incidence of HIV-1 than did HIV-seronegative women, with a relative risk of 0.32 (P = 0.008). An understanding of the cross-protective mechanisms involved may be directly relevant to HIV-1 vaccine development.	HARVARD UNIV, SCH PUBL HLTH, DEPT CANC BIOL, BOSTON, MA 02115 USA; UNIV CHEIKH ANTA DIOP, VIROL & BACTERIOL LAB, DAKAR, SENEGAL; INST SOCIAL HYG, DAKAR, SENEGAL; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; University Cheikh Anta Diop Dakar; Harvard University; Harvard T.H. Chan School of Public Health				Travers, Karin/0000-0002-9097-1710	NATIONAL CANCER INSTITUTE [R35CA039805] Funding Source: NIH RePORTER; NCI NIH HHS [CA 39805] Funding Source: Medline; PHS HHS [P01 A1 30795] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDREASSON PA, 1993, AIDS, V7, P989, DOI 10.1097/00002030-199307000-00013; Arya Suresh K., 1994, AIDS Research and Human Retroviruses, V10, pS158; BARIN F, 1985, LANCET, V2, P1387; BJORLING E, 1993, VIROLOGY, V193, P528, DOI 10.1006/viro.1993.1160; BOTTIGER B, 1990, J VIROL, V64, P3492; BOTTIGER B, 1989, AIDS RES HUM RETROV, V5, P525, DOI 10.1089/aid.1989.5.525; Breslow NE, 1987, STATISTICAL METHODS, P1; CLAVEL F, 1987, NEW ENGL J MED, V316, P1180, DOI 10.1056/NEJM198705073161903; DECOCK KM, 1989, AIDS, V3, pS89, DOI 10.1097/00002030-198901001-00013; DECOCK KM, 1989, LANCET, V2, P408; DENIS F, 1987, LANCET, V1, P408; DONNELLY C, 1993, B MATH BIOL, V55, P731, DOI 10.1007/BF02460671; EVANS LA, 1988, LANCET, V2, P1389; GRANKVIST O, 1990, AIDS, V5, P286; GUEYENDIAYE A, 1993, AIDS, V7, P481; HART AR, 1990, VIROLOGY, V177, P1, DOI 10.1016/0042-6822(90)90454-Y; HORSBURGH CR, 1988, TRANSFUSION, V28, P92; KANKI P, 1992, AM J EPIDEMIOL, V136, P895, DOI 10.1093/aje/136.7.895; KANKI PJ, 1990, ADV AP BIOT, V7, P255; KANKI PJ, 1987, SCIENCE, V236, P827, DOI 10.1126/science.3033826; KANKI PJ, 1994, LANCET, V343, P943, DOI 10.1016/S0140-6736(94)90065-5; Kanki PJ, 1994, AIDS S1, V8, pS85; KANNAGI M, 1990, J VIROL, V64, P3399, DOI 10.1128/JVI.64.7.3399-3406.1990; LAGA M, 1993, AIDS, V7, P95, DOI 10.1097/00002030-199301000-00015; LEGUERN M, 1992, P NATL ACAD SCI USA, V89, P363, DOI 10.1073/pnas.89.1.363; MARLINK R, 1994, SCIENCE, V265, P1587, DOI 10.1126/science.7915856; MARLINK RG, 1988, AIDS RES HUM RETROV, V4, P137, DOI 10.1089/aid.1988.4.137; NIXON DF, 1990, AIDS, V4, P841, DOI 10.1097/00002030-199009000-00002; NORLEY SG, 1990, J IMMUNOL, V145, P1700; PFUTZNER A, 1992, J ACQ IMMUN DEF SYND, V5, P972; POULSEN AG, 1992, J ACQ IMMUN DEF SYND, V5, P25; RAYFIELD M, 1988, J INFECT DIS, V158, P1170, DOI 10.1093/infdis/158.6.1170; ROBERTGUROFF M, 1992, J VIROL, V66, P3602, DOI 10.1128/JVI.66.6.3602-3608.1992; ROMIEU I, 1990, J ACQ IMMUN DEF SYND, V3, P220; SIMMOND P, 1992, J VIROL, V64, P864; SMALLMANRAYNOR M, 1991, INT J EPIDEMIOL, V20, P480, DOI 10.1093/ije/20.2.480; TRAVERS K, UNPUB; VONDALNOK GK, 1993, ARCH VIROL, V131, P419, DOI 10.1007/BF01378642; VONGEGERFELT A, 1993, AIDS RES HUM RETROV, V9, P883, DOI 10.1089/aid.1993.9.883; WALKER CM, 1991, CELL IMMUNOL, V137, P420, DOI 10.1016/0008-8749(91)90090-X; WEIR SS, 1994, AIDS, V8, P1605, DOI 10.1097/00002030-199411000-00013	41	176	180	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 16	1995	268	5217					1612	1615		10.1126/science.7539936	http://dx.doi.org/10.1126/science.7539936			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD459	7539936				2022-12-24	WOS:A1995RD45900036
J	KAVANAUGH, WM; TURCK, CW; WILLIAMS, LT				KAVANAUGH, WM; TURCK, CW; WILLIAMS, LT			PTB DOMAIN BINDING TO SIGNALING PROTEINS THROUGH A SEQUENCE MOTIF CONTAINING PHOSPHOTYROSINE	SCIENCE			English	Article							SRC SH2 DOMAIN; RECEPTOR; KINASE; AUTOPHOSPHORYLATION; IDENTIFICATION; SITES	Src homology 2 (SH2) domains mediate assembly of signaling complexes by binding specifically to tyrosine-phosphorylated proteins. A phosphotyrosine binding (PTB) domain has been identified which also binds specifically to tyrosine-phosphorylated targets, but is structurally different from SH2 domains, Expression cloning was used to identify targets of PTB domains. PTB domains bound to phosphotyrosine within a sequence motif, asparagine-X(1)-X(2)-phosphotyrosine (where X represents any amino acid), that is found in many signaling proteins and is not recognized by SH2 domains. Mutational studies indicated that high affinity binding of PTB domains may require a specific conformation of the motif.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco					NHLBI NIH HHS [R01 HL 32898, K11 HL02714] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032898] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; HAZAN R, 1990, CELL GROWTH DIFFER, V1, P3; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KAVANAUGH WM, UNPUB; KORNBLUTH S, 1990, J VIROL, V64, P1584, DOI 10.1128/JVI.64.4.1584-1589.1990; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OKABAYASHI Y, 1994, J BIOL CHEM, V269, P18674; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; Sambrook J., 1989, MOL CLONING LAB MANU; SEGATTO O, 1990, New Biologist, V2, P187; SEGATTO O, 1993, ONCOGENE, V8, P2105; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Summers MD, 1987, MANUAL METHODS BACUL; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	25	223	229	0	5	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 26	1995	268	5214					1177	1179		10.1126/science.7539155	http://dx.doi.org/10.1126/science.7539155			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA604	7539155				2022-12-24	WOS:A1995RA60400037
J	ARPIN, C; DECHANET, J; VANKOOTEN, C; MERVILLE, P; GROUARD, G; BRIERE, F; BANCHEREAU, J; LIU, YJ				ARPIN, C; DECHANET, J; VANKOOTEN, C; MERVILLE, P; GROUARD, G; BRIERE, F; BANCHEREAU, J; LIU, YJ			GENERATION OF MEMORY B-CELLS AND PLASMA-CELLS IN-VITRO	SCIENCE			English	Article							GERMINAL-CENTERS; IMMUNE-RESPONSE; ANTIGEN; CD40; LYMPHOCYTES; EXPRESSION; IGM	After germinal center B cells undergo somatic mutation and antigen selection, they become either memory B cells or plasma cells, but the signal requirements that control entry into either pathway have been unclear. When purified human germinal center cells were cultured with interleukin-2, interleukin-10, and cells expressing CD40 ligand, cells with characteristics of memory B cells were generated. Removal of CD40 ligand from the system resulted in terminal differentiation of germinal center B cells into cells with the characteristics of plasma cells. These results indicate that CD40 ligand directs the differentiation of germinal center B cells toward memory B cells rather than toward plasma cells.	SCHERING PLOUGH CORP,IMMUNOL RES LAB,F-69571 DARDILLY,FRANCE	Merck & Company; Schering Plough Corporation			Arpin, Christophe/M-3862-2014; van Kooten, Cees/E-5694-2018	Arpin, Christophe/0000-0003-0915-5554; van Kooten, Cees/0000-0002-6257-0899				ANDERSSON J, 1994, IMMUNOLOGY, V83, P16; BANCHEREAU J, 1991, NATURE, V353, P678, DOI 10.1038/353678a0; BEREK C, 1991, CELL, V67, P1121, DOI 10.1016/0092-8674(91)90289-B; BUTCH AW, 1993, J IMMUNOL, V150, P39; CASAMAJORPALLEJ.M, IN PRESS J EXP MED; CLARK EA, 1994, NATURE, V367, P425, DOI 10.1038/367425a0; COLCO RF, 1983, J IMMUNOL, V131, P2254; FLUCKIGER AC, 1993, J EXP MED, V178, P1473, DOI 10.1084/jem.178.5.1473; FOY TM, 1994, J EXP MED, V180, P157, DOI 10.1084/jem.180.1.157; GRAY D, 1994, J EXP MED, V180, P141, DOI 10.1084/jem.180.1.141; HARADA H, 1993, BLOOD, V81, P2658; HOLDER MJ, 1993, INT IMMUNOL, V5, P1059, DOI 10.1093/intimm/5.9.1059; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; JACOB J, 1992, J EXP MED, V176, P679, DOI 10.1084/jem.176.3.679; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; KLAUS GGB, 1980, IMMUNOL REV, V53, P3, DOI 10.1111/j.1600-065X.1980.tb01038.x; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; KOSCO MH, 1989, IMMUNOLOGY, V68, P312; KUPPERS R, 1993, EMBO J, V12, P4955, DOI 10.1002/j.1460-2075.1993.tb06189.x; LEDERMAN S, 1992, J IMMUNOL, V149, P3817; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; LIU YJ, 1991, EUR J IMMUNOL, V21, P2951, DOI 10.1002/eji.1830211209; LIU YJ, 1992, IMMUNOL TODAY, V13, P17, DOI 10.1016/0167-5699(92)90199-H; LIU YJ, IN PRESS IMMUNITY; LIU YJ, IN PRESS HDB EXPT IM, V2; MACHEYZERWILLIA.MG, 1993, J EXP MED, V178, P295; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; PASCUAL V, 1994, J EXP MED, V180, P329, DOI 10.1084/jem.180.1.329; ROLINK A, 1991, EMBO J, V10, P327, DOI 10.1002/j.1460-2075.1991.tb07953.x; STROBER S, 1976, J IMMUNOL, V117, P1288; THORBECKE GJ, 1994, FASEB J, V8, P832, DOI 10.1096/fasebj.8.11.8070632; VANKOOTEN C, 1994, EUR J IMMUNOL, V24, P787, DOI 10.1002/eji.1830240402; VANKOOTEN C, UNPUB; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6	34	489	496	0	22	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 5	1995	268	5211					720	722		10.1126/science.7537388	http://dx.doi.org/10.1126/science.7537388			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW603	7537388				2022-12-24	WOS:A1995QW60300049
J	ALON, R; HAMMER, DA; SPRINGER, TA				ALON, R; HAMMER, DA; SPRINGER, TA			LIFETIME OF THE P-SELECTIN-CARBOHYDRATE BOND AND ITS RESPONSE TO TENSILE FORCE IN HYDRODYNAMIC FLOW	NATURE			English	Article							NEUTROPHIL ADHESION; GLYCOPROTEIN LIGAND; MYELOID CELLS; SHEAR-FLOW; BINDING; IDENTIFICATION; RECOGNITION; DETACHMENT; VENULES	SELECTINS tether to the blood vessel wall leukocytes that are flowing in the bloodstream and support subsequent labile rolling interactions as the leukocytes are subjected to hydrodynamic drag forces(1,2). To support this rolling, selectins have been proposed to have rapid bond association and dissociation rate constants, and special mechanical properties linking tensile forces and bond dissociation(3-6). We have visualized transient tethering and release of neutrophils in hydrodynamic flow on lipid bilayers containing densities of P-selectin below those required to support rolling. We report here that transient tethers had first-order kinetics and other characteristics suggesting a unimolecular interaction between P-selectin and its glycoprotein ligand (PSGL-1). The unstressed dissociation constant (off rate) was 1s(-1) Hydrodynamic shear stresses of up to 1.1 dyn cm(-2), corresponding to a force on the bond of up to 110 pN, increased the off rate only modestly, to 3.5 s(-1). The data was adequately matched by a proposed equation(7) relating off rate to the exponential of tensile force on the bond and the bond interaction distance, and gave a bond interaction distance of 0.5 Angstrom. This distance is compatible with hydrogen and metal coordination bonds between P-selectin and PSGL-1. Fast on and off rates, together with the high tensile strength of the selectin bond, appear necessary to support rolling at physiological shear stresses.	HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; CORNELL UNIV,SCH CHEM ENGN,ITHACA,NY 14853	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; Cornell University								BELL GI, 1984, BIOPHYS J, V45, P1051, DOI 10.1016/S0006-3495(84)84252-6; BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575; CHAN PY, 1991, J CELL BIOL, V115, P245, DOI 10.1083/jcb.115.1.245; DEMBO M, 1988, PROC R SOC SER B-BIO, V234, P55, DOI 10.1098/rspb.1988.0038; DOWDY S, 1985, STATISTICS RES; ERBE DV, 1992, J CELL BIOL, V119, P215, DOI 10.1083/jcb.119.1.215; ERICKSON HP, 1994, P NATL ACAD SCI USA, V91, P10114, DOI 10.1073/pnas.91.21.10114; EVANS E, 1991, BIOPHYS J, V59, P838, DOI 10.1016/S0006-3495(91)82296-2; Fersht A., 1985, ENZYME STRUCTURE MEC; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; GOLDMAN AJ, 1967, CHEM ENG SCI, V22, P653, DOI 10.1016/0009-2509(67)80048-4; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; HAMMER DA, 1992, BIOPHYS J, V63, P35, DOI 10.1016/S0006-3495(92)81577-1; JANIN J, 1990, J BIOL CHEM, V265, P16027; KANSAS GS, 1993, J EXP MED, V177, P833, DOI 10.1084/jem.177.3.833; KAPLANSKI G, 1993, BIOPHYS J, V64, P1922, DOI 10.1016/S0006-3495(93)81563-7; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LAWRENCE MB, 1994, IMMUNITY, V1, P137, DOI 10.1016/1074-7613(94)90107-4; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; MASON DW, 1986, HDB EXPT IMMUNOLOG 1, V4; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MOORE KL, 1994, J BIOL CHEM, V289, P23318; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PRESS WH, 1986, NUMERICAL RECIPES AR; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STEININGER CN, 1992, BIOCHEM BIOPH RES CO, V188, P760, DOI 10.1016/0006-291X(92)91121-6; TEMPELMAN LA, 1994, BIOPHYS J, V66, P1231, DOI 10.1016/S0006-3495(94)80907-5; TOZEREN A, 1992, BIOPHYS J, V63, P700, DOI 10.1016/S0006-3495(92)81660-0; USHIYAMA S, 1993, J BIOL CHEM, V268, P15229	30	577	592	2	49	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 6	1995	374	6522					539	542		10.1038/374539a0	http://dx.doi.org/10.1038/374539a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR069	7535385				2022-12-24	WOS:A1995QR06900051
J	LOVEDAY, C; KAYE, S; TENANTFLOWERS, M; SEMPLE, M; AYLIFFE, U; WELLER, IVD; TEDDER, RS				LOVEDAY, C; KAYE, S; TENANTFLOWERS, M; SEMPLE, M; AYLIFFE, U; WELLER, IVD; TEDDER, RS			HIV-1 RNA SERUM-LOAD AND RESISTANT VIRAL GENOTYPES DURING EARLY ZIDOVUDINE THERAPY	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PLACEBO-CONTROLLED TRIAL; HIGH-LEVEL RESISTANCE; AIDS-RELATED COMPLEX; REVERSE-TRANSCRIPTASE; PLASMA VIREMIA; DOUBLE-BLIND; TYPE-1; AZT; 3'-AZIDO-3'-DEOXYTHYMIDINE	The response of HIV-1 to initial zidovudine (ZDV) treatment was assessed in 11 patients with severe HIV disease. We quantified serum HIV-1 concentrations and mutations associated with ZDV resistance by culture-independent methods. There was a prompt fall in serum HIV-1 RNA within 1-2 days of treatment with maximum suppression by seven days, which was paralleled by changes in serum p24 antigen (p24 Ag). Serum RNA started to return to pretreatment levels within weeks. The HIV reverse transcriptase (RT) gene in most patients developed mutations associated with drug resistance within months and as early as 25 days on therapy in one patient. The codon changes were not sufficient to explain the early return of serum HIV-1 RNA levels and their patterns continued to evolve after patients stopped taking ZDV. The significance of these findings is discussed in relation to the limited long-term efficacy of ZDV. The dynamic time course of viral load and RT responses to ZDV is of particular importance in short-term interventions such as pregnancy.	UCL, SCH MED, ACAD DEPT GENITOURINARY MED, LONDON, ENGLAND; UCL HOSP, LONDON, ENGLAND; CAMDEN & ISLIMGTON COMMUNITY HLTH SERV TRUSTS, LONDON, ENGLAND	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; University College London	LOVEDAY, C (corresponding author), UCL, SCH MED, DIV VIROL, LONDON, ENGLAND.		Semple, Malcolm Gracie/A-8790-2008	Semple, Malcolm Gracie/0000-0001-9700-0418; Tedder, Richard/0000-0002-9672-5721	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BOUCHER CAB, 1992, J INFECT DIS, V165, P105, DOI 10.1093/infdis/165.1.105; BOUCHER CAB, THESIS U AMSTERDAM, P105; BUKRINSKY M, 1993, J VIROL, V67, P6863, DOI 10.1128/JVI.67.11.6863-6865.1993; COLLIER AC, 1990, NEW ENGL J MED, V323, P1015, DOI 10.1056/NEJM199010113231502; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; COOPER DA, 1994, AIDS S4, V3; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; KAYE S, 1992, J MED VIROL, V37, P241, DOI 10.1002/jmv.1890370402; KELLAM P, 1992, P NATL ACAD SCI USA, V89, P1934, DOI 10.1073/pnas.89.5.1934; KOZEL MJ, 1993, J INFECT DIS, V167, P526; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; LARDER BA, 1994, AIDS S4, V8; LOVEDAY C, 1993, J VIROL METHODS, V41, P181, DOI 10.1016/0166-0934(93)90125-B; LOVEDAY C, 1994, 3RD INT WORKSH HIV D; LOVEDAY C, 1995, 1994 ANN SCI M ASS C; MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096; RICHMAN DD, 1990, REV INFECT DIS S5, V12, P507; SAAG M, 1991, J INFECT DIS, V165, P72; SCHUUMAN R, 1994, 3RD INT WORKSH HIV D; SELIGMANN M, 1994, LANCET, V343, P871; SEMPLE MG, 1993, J VIROL METHODS, V41, P167, DOI 10.1016/0166-0934(93)90124-A; STEVENSON M, 1990, J VIROL, V64, P2421, DOI 10.1128/JVI.64.5.2421-2425.1990; YARCHOAN R, 1986, LANCET, V1, P575; YARCHOAN R, 1987, NEW ENGL J MED, V316, P557, DOI 10.1056/NEJM198702263160925; ZHANG LQ, 1991, AIDS, V5, P675, DOI 10.1097/00002030-199106000-00006; 1994, LANCET, V344, P207; 1987, MMWR-MORBID M     S1, V36, P1	32	95	95	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 1	1995	345	8953					820	824		10.1016/S0140-6736(95)92963-0	http://dx.doi.org/10.1016/S0140-6736(95)92963-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QQ195	7534858				2022-12-24	WOS:A1995QQ19500008
J	GANN, PH; HENNEKENS, CH; STAMPFER, MJ				GANN, PH; HENNEKENS, CH; STAMPFER, MJ			A PROSPECTIVE EVALUATION OF PLASMA PROSTATE-SPECIFIC ANTIGEN FOR DETECTION OF PROSTATIC-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIGITAL RECTAL EXAMINATION; RADICAL PROSTATECTOMY; SCREENING-TEST; DIAGNOSIS; SERUM; ULTRASONOGRAPHY; ADENOCARCINOMA; DISEASE; TRENDS; MEN	Objective.-To evaluate the validity of prostate-specific antigen (PSA) in identifying men who subsequently were or were not clinically diagnosed with prostate cancer, assess optimal test cutoff, measure lead time, and estimate relative risks (RRs) associated with discrete PSA levels. Design.-Nested case-control study of men providing plasma samples before a 10-year follow-up. Setting.-The Physicians' Health Study, an ongoing randomized trial that enrolled 22071 men aged 40 to 84 years in 1982. Participants.-A total of 366 men (cases) diagnosed with prostate cancer and 1098 men (three controls per case), matched by age, randomly selected from all cohort members at risk at the time of case diagnosis. Main Outcome Measures.-Sensitivity and specificity for each year of followup and for aggressive and nonaggressive cancers separately. Results.-At a cutoff of 4.0 ng/mL, sensitivity for the entire 10-year follow-up was 46% for total cases. Sensitivities for detection of total, aggressive, and nonaggressive cancers occurring in the first 4 years were 73%, 87%, and 53%. Overall, specificity was 91% and changed little by year of follow-up. Optimal validity was achieved at a cutoff of 3.3 ng/mL, Estimated mean lead time for all cancers was 5.5 years. Only 40% of cancers detected more than 5 years from baseline were nonaggressive. Compared with men with PSA levels less than 1.0 ng/mL, those with PSA levels between 2.0 and 3.0 ng/mL had an RR of 5.5 (95% confidence interval, 3.7 to 9.2). Conclusions.-A single PSA measurement had a relatively high sensitivity and specificity for detection of prostate cancers that arose within 4 years. prostate-specific antigen values less than the usual cutoff were associated with substantial increases in risk compared with the lowest levels. Final evaluation of PSA screening must also consider cost and the ability of current treatments to improve the prognosis of screen-detected cases.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,CHANNING LAB,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV PREVENT MED,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT AMBULATORY CARE & PREVENT,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health					NCI NIH HHS [CA-34944] Funding Source: Medline; NHLBI NIH HHS [HL-34595, HL-26490] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034595] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1989, NEW ENGL J MED, V321, P129; BABAIAN RJ, 1992, CANCER, V69, P1195; CARTER HB, 1992, JAMA-J AM MED ASSOC, V267, P2215, DOI 10.1001/jama.267.16.2215; CATALONA WJ, 1987, ARCH INTERN MED, V147, P361, DOI 10.1001/archinte.147.2.361; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; COONER WH, 1990, J UROLOGY, V143, P1146, DOI 10.1016/S0022-5347(17)40211-4; EPSTEIN JI, 1994, JAMA-J AM MED ASSOC, V271, P368, DOI 10.1001/jama.271.5.368; GORMLEY GJ, 1992, NEW ENGL J MED, V327, P1185, DOI 10.1056/NEJM199210223271701; GRAVES HCB, 1990, J UROLOGY, V144, P1516, DOI 10.1016/S0022-5347(17)39789-6; HELZLSOUER KJ, 1992, CANCER EPIDEM BIOMAR, V1, P537; HOLUND B, 1980, SCAND J UROL NEPHROL, V14, P29, DOI 10.3109/00365598009181186; HORTIN GL, 1988, J UROLOGY, V139, P762, DOI 10.1016/S0022-5347(17)42627-9; LABRIE F, 1992, J UROLOGY, V147, P846, DOI 10.1016/S0022-5347(17)37402-5; LIEDTKE RJ, 1984, CLIN CHEM, V30, P649; LUYAO GL, 1993, JAMA-J AM MED ASSOC, V269, P2633, DOI 10.1001/jama.269.20.2633; LUYAO GL, 1994, LANCET, V343, P251, DOI 10.1016/S0140-6736(94)91109-6; METTLIN C, 1993, CA-CANCER J CLIN, V43, P42, DOI 10.3322/canjclin.43.1.42; METTLIN C, 1993, CA-CANCER J CLIN, V43, P83, DOI 10.3322/canjclin.43.2.83; MORRISON AS, 1992, SCREENING CHRONIC DI; MURPHY GP, 1994, CA-CANCER J CLIN, V44, P91, DOI 10.3322/canjclin.44.2.91; RUCKLE HC, 1994, MAYO CLIN PROC, V69, P59, DOI 10.1016/S0025-6196(12)61614-0; STAMEY TA, 1987, NEW ENGL J MED, V317, P909, DOI 10.1056/NEJM198710083171501; STAMEY TA, 1989, J UROLOGY, V141, P1076, DOI 10.1016/S0022-5347(17)41175-X; WALSH PC, 1992, J UROLOGY, V147, P853, DOI 10.1016/S0022-5347(17)37404-9; WALTER SD, 1983, AM J EPIDEMIOL, V118, P865, DOI 10.1093/oxfordjournals.aje.a113705; 1992, AM UROLOGICAL ASS EX; 1976, CAN MED ASSOC J, V114, P1003	28	571	592	0	26	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 25	1995	273	4					289	294		10.1001/jama.273.4.289	http://dx.doi.org/10.1001/jama.273.4.289			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC057	7529341				2022-12-24	WOS:A1995QC05700026
J	NANGAKU, M; SATOYOSHITAKE, R; OKADA, Y; NODA, Y; TAKEMURA, R; YAMAZAKI, H; HIROKAWA, N				NANGAKU, M; SATOYOSHITAKE, R; OKADA, Y; NODA, Y; TAKEMURA, R; YAMAZAKI, H; HIROKAWA, N			KIF1B, A NOVEL MICROTUBULE PLUS END-DIRECTED MONOMERIC MOTOR PROTEIN FOR TRANSPORT OF MITOCHONDRIA	CELL			English	Article							KINESIN HEAVY-CHAIN; FAST AXONAL-TRANSPORT; BOVINE BRAIN KINESIN; SQUID GIANT-AXON; MEMBRANOUS ORGANELLES; MITOTIC SPINDLE; DROSOPHILA KINESIN; SYNAPTIC VESICLES; NERVOUS-SYSTEM; C-ELEGANS	To further elucidate the mechanism of organelle transport, we cloned a navel member of the mouse kinesin superfamily, KIF1B. This N-terminal-type motor protein is expressed ubiquitously in various kinds of tissues. In situ hybridization revealed that KIF1B is expressed abundantly in differentiated nerve cells. Interestingly, KIF1B works as a monomer, having a microtubule plus end-directed motility, Our rotary shadowing electron microscopy revealed mostly single globular structures. Immunocytochemically, KIF1B was colocalized with mitochondria in vivo. Furthermore, a subcellular fractionation study showed that KIF1B was concentrated in the mitochondrial fraction, and purified KIF1B could transport mitochondria along microtubules in vitro. These data strongly suggested that KIF1B works as a monomeric motor for anterograde transport of mitochondria.	OKINAKA MEM INST MED RES, TOKYO 105, JAPAN		NANGAKU, M (corresponding author), UNIV TOKYO, SCH MED, DEPT ANAT & CELL BIOL, TOKYO 113, JAPAN.		Okada, Yasushi/N-5067-2015	Okada, Yasushi/0000-0003-2601-3689				AIZAWA H, 1992, J CELL BIOL, V119, P1287, DOI 10.1083/jcb.119.5.1287; ALLEN RD, 1985, J CELL BIOL, V100, P1736, DOI 10.1083/jcb.100.5.1736; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; BLOOM G S, 1992, Current Opinion in Cell Biology, V4, P66, DOI 10.1016/0955-0674(92)90060-P; BLOOM GS, 1988, BIOCHEMISTRY-US, V27, P3409, DOI 10.1021/bi00409a043; BRADY ST, 1982, SCIENCE, V218, P1129, DOI 10.1126/science.6183745; BRADY ST, 1991, NEURON, V7, P521, DOI 10.1016/0896-6273(91)90365-7; BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; CHANDRA R, 1993, J BIOL CHEM, V268, P9005; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; DECUEVAS M, 1992, J CELL BIOL, V116, P957, DOI 10.1083/jcb.116.4.957; ENDOW SA, 1991, TRENDS BIOCHEM SCI, V16, P221, DOI 10.1016/0968-0004(91)90089-E; FORMAN DS, 1987, BRAIN RES, V412, P96, DOI 10.1016/0006-8993(87)91443-0; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GHO M, 1992, SCIENCE, V258, P313, DOI 10.1126/science.1384131; Goldstein L S, 1991, Trends Cell Biol, V1, P93, DOI 10.1016/0962-8924(91)90036-9; GRAFSTEIN B, 1980, PHYSIOL REV, V60, P1167, DOI 10.1152/physrev.1980.60.4.1167; HACKNEY DD, 1991, BIOCHEM BIOPH RES CO, V174, P810, DOI 10.1016/0006-291X(91)91490-4; HALL DH, 1991, CELL, V65, P837, DOI 10.1016/0092-8674(91)90391-B; HEGGENESS MH, 1978, P NATL ACAD SCI USA, V75, P3863, DOI 10.1073/pnas.75.8.3863; HENSON JH, 1992, J CELL SCI, V103, P309; HIROKAWA N, 1991, J CELL BIOL, V114, P295, DOI 10.1083/jcb.114.2.295; HIROKAWA N, 1986, CELL MOTIL CYTOSKEL, V6, P458, DOI 10.1002/cm.970060504; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; HIROKAWA N, 1988, J CELL BIOL, V107, P1449, DOI 10.1083/jcb.107.4.1449; HIROKAWA N, 1982, J CELL BIOL, V94, P129, DOI 10.1083/jcb.94.1.129; HIROKAWA N, 1986, J CELL BIOL, V103, P33, DOI 10.1083/jcb.103.1.33; HIROKAWA N, 1991, NEURONAL CYTOSKELETO, P5; Hirokawa Nobutaka, 1993, Current Opinion in Neurobiology, V3, P724, DOI 10.1016/0959-4388(93)90144-N; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HOYT MA, 1992, J CELL BIOL, V118, P109, DOI 10.1083/jcb.118.1.109; HUANG TG, 1994, J BIOL CHEM, V269, P16493; JOHNSON LV, 1981, J CELL BIOL, V88, P526, DOI 10.1083/jcb.88.3.526; KONDO S, 1994, J CELL BIOL, V125, P1095, DOI 10.1083/jcb.125.5.1095; LASEK RJ, 1984, J CELL BIOL, V99, pS212, DOI 10.1083/jcb.99.1.212s; LEOPOLD PL, 1992, CELL MOTIL CYTOSKEL, V23, P19, DOI 10.1002/cm.970230104; LORENZ T, 1978, P NATL ACAD SCI USA, V75, P505, DOI 10.1073/pnas.75.1.505; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MARTZ D, 1984, CELL MOTIL CYTOSKEL, V4, P89, DOI 10.1002/cm.970040203; MILLER RH, 1985, J CELL BIOL, V101, P2181, DOI 10.1083/jcb.101.6.2181; OREILLY DR, 1992, BACULOVIRUS EXPRESSI; OTSUKA AJ, 1991, NEURON, V6, P113, DOI 10.1016/0896-6273(91)90126-K; PARTLOW LM, 1972, J GEN PHYSIOL, V60, P388, DOI 10.1085/jgp.60.4.388; ROMBERG L, 1993, NATURE, V361, P168, DOI 10.1038/361168a0; ROOF DM, 1992, J CELL BIOL, V118, P95, DOI 10.1083/jcb.118.1.95; Sambrook J., 1989, MOL CLONING LAB MANU; SATOYOSHITAKE R, 1992, J BIOL CHEM, V267, P23930; SAXTON WM, 1991, CELL, V64, P1093, DOI 10.1016/0092-8674(91)90264-Y; SAXTON WM, 1988, P NATL ACAD SCI USA, V85, P1109, DOI 10.1073/pnas.85.4.1109; SCHNAPP BJ, 1992, J CELL BIOL, V119, P389, DOI 10.1083/jcb.119.2.389; SCHNAPP BJ, 1990, P NATL ACAD SCI USA, V87, P10053, DOI 10.1073/pnas.87.24.10053; Scholey J. M., 1993, MOTILITY ASSAYS MOTO; SCHOLEY JM, 1985, NATURE, V318, P483, DOI 10.1038/318483a0; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; SEKINE Y, 1994, J CELL BIOL, V127, P187, DOI 10.1083/jcb.127.1.187; STAHL WL, 1963, J CELL BIOL, V19, P293, DOI 10.1083/jcb.19.2.293; TAKEMURA R, 1991, NEUROSCIENCE, V44, P393, DOI 10.1016/0306-4522(91)90064-U; TERASAKI M, 1989, METHOD CELL BIOL, V29, P125; TYLER JM, 1980, J ULTRA MOL STRUCT R, V71, P95, DOI 10.1016/S0022-5320(80)90098-2; UEDA T, 1979, J CELL BIOL, V83, P308, DOI 10.1083/jcb.83.2.308; Vale R D, 1990, Adv Biophys, V26, P97, DOI 10.1016/0065-227X(90)90009-I; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALE RD, 1985, CELL, V40, P559, DOI 10.1016/0092-8674(85)90204-1; VALE RD, 1989, CELL, V59, P915, DOI 10.1016/0092-8674(89)90614-4; VANBLERKOM J, 1991, P NATL ACAD SCI USA, V88, P5031, DOI 10.1073/pnas.88.11.5031; WALKER RA, 1993, ANNU REV BIOCHEM, V62, P429; WHITAKER JE, 1991, BIOCHEM BIOPH RES CO, V175, P387, DOI 10.1016/0006-291X(91)91576-X; WITMAN GB, 1986, METHOD ENZYMOL, V134, P280; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332; Zamyatnin A A, 1972, Prog Biophys Mol Biol, V24, P107, DOI 10.1016/0079-6107(72)90005-3; ZHANG P, 1990, CELL, V62, P1053, DOI 10.1016/0092-8674(90)90383-P	72	475	489	0	26	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 30	1994	79	7					1209	1220		10.1016/0092-8674(94)90012-4	http://dx.doi.org/10.1016/0092-8674(94)90012-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PZ860	7528108				2022-12-24	WOS:A1994PZ86000012
J	PADGETT, RA; PODAR, M; BOULANGER, SC; PERLMAN, PS				PADGETT, RA; PODAR, M; BOULANGER, SC; PERLMAN, PS			THE STEREOCHEMICAL COURSE OF GROUP-II INTRON SELF-SPLICING	SCIENCE			English	Article							TETRAHYMENA RIBOZYME; RNA-POLYMERASE; PHOSPHOROTHIOATE; STEP; SPLICEOSOME; MECHANISM; CLEAVAGE; PRODUCTS; DNA	The stereochemical specificities and reaction courses for both self-splicing steps of a group II intron have been determined by phosphorothioate substitution at the 5' and 3' splice site phosphodiester bonds. Both steps of the splicing reaction proceeded with a phosphorothioate in the Sp configuration but were blocked by the Rp diastereomer. Both steps also proceeded with inversion of stereochemical configuration around phosphorus, consistent with a concerted transesterification reaction. These results are identical to those found for nuclear precursor mRNA (pre-mRNA) splicing and provide support for the hypothesis that group II introns and nuclear pre-mRNA introns share a common evolutionary history.			PADGETT, RA (corresponding author), UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.		Podar, Mircea/B-7299-2012	Podar, Mircea/0000-0003-2776-0205	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031480, R01GM045371] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31480, GM45371] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURGERS PMJ, 1978, P NATL ACAD SCI USA, V75, P4798, DOI 10.1073/pnas.75.10.4798; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; GISH G, 1988, SCIENCE, V240, P1520, DOI 10.1126/science.2453926; GRIFFITHS AD, 1987, NUCLEIC ACIDS RES, V15, P4145, DOI 10.1093/nar/15.10.4145; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; JACQUIER A, 1990, TRENDS BIOCHEM SCI, V15, P351, DOI 10.1016/0968-0004(90)90075-M; JARRELL KA, 1988, J BIOL CHEM, V263, P3432; MASCHHOFF KL, 1993, NUCLEIC ACIDS RES, V21, P5456, DOI 10.1093/nar/21.23.5456; MCSWIGGEN JA, 1989, SCIENCE, V244, P679, DOI 10.1126/science.2470150; MOORE MJ, 1993, NATURE, V365, P364, DOI 10.1038/365364a0; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; NELSON PS, 1984, J ORG CHEM, V49, P2314, DOI 10.1021/jo00187a003; PERLMAN PS, 1990, INTERVENING SEQUENCE, P112; PODAR M, UNPUB; POTTER BVL, 1983, BIOCHEMISTRY-US, V22, P1369, DOI 10.1021/bi00275a008; RAJAGOPAL J, 1989, SCIENCE, V244, P692, DOI 10.1126/science.2470151; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; SLIM G, 1991, NUCLEIC ACIDS RES, V19, P1183, DOI 10.1093/nar/19.6.1183; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; SUH E, 1992, NUCLEIC ACIDS RES, V20, P6303, DOI 10.1093/nar/20.23.6303; WEINER AM, 1993, CELL, V72, P161, DOI 10.1016/0092-8674(93)90654-9; YARUS M, 1993, FASEB J, V7, P31, DOI 10.1096/fasebj.7.1.8422972	23	93	97	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 9	1994	266	5191					1685	1688		10.1126/science.7527587	http://dx.doi.org/10.1126/science.7527587			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW308	7527587				2022-12-24	WOS:A1994PW30800034
J	GRAFF, JM; THIES, RS; SONG, JJ; CELESTE, AJ; MELTON, DA				GRAFF, JM; THIES, RS; SONG, JJ; CELESTE, AJ; MELTON, DA			STUDIES WITH A XENOPUS BMP RECEPTOR SUGGEST THAT VENTRAL MESODERM-INDUCING SIGNALS OVERRIDE DORSAL SIGNALS IN-VIVO	CELL			English	Article							SERINE THREONINE KINASE; BONE MORPHOGENETIC PROTEIN-4; TRANSFORMING GROWTH-FACTOR; EARLY AMPHIBIAN EMBRYOS; DAUER LARVA DEVELOPMENT; TGF-BETA; ACTIVIN RECEPTOR; INOSITOL PHOSPHATES; EXPRESSION CLONING; MESSENGER-RNAS	We report the isolation of a Xenopus BMP receptor that is expressed maternally in the appropriate location to play a role in mesoderm induction. This receptor binds both BMP-2 and BMP-4 with high affinity. A truncated form of this BMP receptor specifically blocks BMP-4 signaling. Expression of this truncated BMP receptor during embryogenesis converts ventral mesoderm to dorsal mesoderm. Contrary to the popularly held view that ventral is the ground state for all mesoderm, our results suggest that formation of ventral mesoderm requires an active signal and that, in the absence of this ventral signal, dorsal mesoderm is formed.	GENET INST INC,CAMBRIDGE,MA 02140		GRAFF, JM (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138, USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647				ALTABA AR, 1989, NATURE, V341, P33; ALTABA ARI, 1991, DEV GROWTH DIFFER, V33, P651; ALTABA ARI, 1992, DEVELOPMENT, V115, P67; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BANVILLE D, 1985, NUCLEIC ACIDS RES, V13, P5407, DOI 10.1093/nar/13.15.5407; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1989, CELL, V59, P411, DOI 10.1016/0092-8674(89)90026-3; BUSA WB, 1989, DEV BIOL, V132, P315, DOI 10.1016/0012-1606(89)90228-5; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CHRISTIAN JL, 1991, DEVELOPMENT, V111, P1045; DALE L, 1993, EMBO J, V12, P4471, DOI 10.1002/j.1460-2075.1993.tb06136.x; DALE L, 1985, J EMBRYOL EXP MORPH, V89, P289; DALE L, 1987, DEVELOPMENT, V100, P279; DALE L, 1992, DEVELOPMENT, V115, P573; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; FROLIK CA, 1984, J BIOL CHEM, V259, P995; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; HELNKOFF S, 1987, METHOD ENZYMOL, V154, P156; HEMMATIBRIVANLOU A, 1992, DEV DYNAM, V194, P1, DOI 10.1002/aja.1001940102; HEMMATIBRIVANLOU A, 1990, DEVELOPMENT, V110, P325; HEMMATIBRIVANLOU A, 1994, CELL, V77, P273, DOI 10.1016/0092-8674(94)90319-0; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; JONES CM, 1992, DEVELOPMENT, V115, P639; KAO KR, 1986, NATURE, V322, P371, DOI 10.1038/322371a0; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KIMELMAN D, 1992, DEVELOPMENT, V116, P1; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KLEIN PS, 1994, ENDOCR REV, V15, P326, DOI 10.1210/er.15.3.326; KOSTER M, 1991, MECH DEVELOP, V33, P191, DOI 10.1016/0925-4773(91)90027-4; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MASLANSKI JA, 1992, SCIENCE, V256, P243, DOI 10.1126/science.1314424; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MOHUN TJ, 1984, NATURE, V311, P716, DOI 10.1038/311716a0; NIEUWKOOP P D, 1969, Wilhelm Roux' Archiv fuer Entwicklungsmechanik der Organismen, V162, P341, DOI 10.1007/BF00578701; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; NISHIMATSU S, 1992, BIOCHEM BIOPH RES CO, V186, P1487, DOI 10.1016/S0006-291X(05)81574-8; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHARF SR, 1983, DEV BIOL, V99, P75, DOI 10.1016/0012-1606(83)90255-5; SIVE HL, 1993, GENE DEV, V7, P1, DOI 10.1101/gad.7.1.1; SLACK JMW, 1992, DEVELOPMENT, V114, P285; SLACK JMW, 1994, CURR BIOL, V4, P116, DOI 10.1016/S0960-9822(94)00027-8; SMITH JC, 1987, DEVELOPMENT, V99, P3; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH JC, 1989, DEVELOPMENT, V105, P665; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; TENDIJKE P, 1993, ONCOGENE, V8, P2879; THIES RS, 1992, ENDOCRINOLOGY, V130, P1319; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; VONDASSOW G, 1993, GENE DEV, V7, P355, DOI 10.1101/gad.7.3.355; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; WILSON P, 1991, DEVELOPMENT, V112, P289; WILSON P, 1994, IN PRESS CURR BIOL; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241	66	436	445	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 7	1994	79	1					169	179		10.1016/0092-8674(94)90409-X	http://dx.doi.org/10.1016/0092-8674(94)90409-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PK585	7522972				2022-12-24	WOS:A1994PK58500017
J	ARAFAH, BM				ARAFAH, BM			DECREASED LEVOTHYROXINE REQUIREMENT IN WOMEN WITH HYPOTHYROIDISM DURING ANDROGEN THERAPY FOR BREAST-CANCER	ANNALS OF INTERNAL MEDICINE			English	Article						BREAST NEOPLASMS; HYPOTHYROIDISM; LEVOTHYROXINE; ANDROGENS; FLUOHOMESTERONE	THYROXINE-BINDING GLOBULIN; NORMAL MEN; ESTROGEN	Objective: To determine the effects of androgen administration on measures of thyroid function and thyroid hormone replacement doses in women with breast cancer. Design: Consecutive patients with metastatic, hormone-dependent breast cancer who were eligible for androgen treatment. Interventions: Androgen therapy (fluoxymesterone, 10 mg orally twice daily) was continued for as long as it was effective in controlling tumor growth. Patients: 7 patients with no known thyroid disease and 4 others receiving long-term treatment for hypothyroidism. Measurements: Serum levels of total and free thyroxine (T-4), thyroid-stimulating hormone (TSH), and T-4-binding globulin were determined before and every 4 weeks after androgen therapy was initiated. Results: Within 4 weeks of androgen administration to the seven patients without thyroid disease, serum levels of total T-4 and T-4-binding globulin decreased (P < 0.001), whereas the calculated free thyroxine index and measured free hormone levels remained unchanged. Six to 12 weeks after androgen therapy was discontinued, all seven patients remained clinically euthyroid, and serum levels returned to baseline values. In contrast, clinical hyperthyroidism developed shortly after androgen was administered to four patients who received long-term thyroid hormone replacement therapy. Within 4 weeks of treatment, the serum free T-4 level increased in each of the four patients, whereas the TSH level decreased. Thyroid hormone doses had to be reduced by 25% to 50% to maintain euthyroidism. Conclusions: The study documents the reversible effects of androgens on thyroid hormone levels and indicates the need to reduce thyroid replacement doses in women during androgen therapy. Monitoring thyroid hormone levels in patients receiving replacement therapy and perhaps in those with autonomous thyroid function is necessary after androgen therapy.			ARAFAH, BM (corresponding author), UNIV CLEVELAND HOSP, DIV CLIN & MOLEC ENDOCRINOL, 11100 EUCLID AVE, ROOM 3128 LAKESIDE, CLEVELAND, OH 44106 USA.							AIN KB, 1987, J CLIN ENDOCR METAB, V65, P689, DOI 10.1210/jcem-65-4-689; BRAVERMA.LE, 1968, J CLIN ENDOCR METAB, V28, P831, DOI 10.1210/jcem-28-6-831; BRAVERMAN LE, 1967, J CLIN ENDOCR METAB, V27, P389, DOI 10.1210/jcem-27-3-389; CAMPBELL MJ, 1989, BRIT MED J, P71; FEDERMAN DD, 1958, J CLIN INVEST, V37, P1024, DOI 10.1172/JCI103683; FELDMAN EB, 1960, J CLIN ENDOCR METAB, V20, P842, DOI 10.1210/jcem-20-6-842; KIRSCHNE.MA, 1972, ACTA ENDOCRINOL-COP, V70, P342, DOI 10.1530/acta.0.0700342; MANDEL SJ, 1990, NEW ENGL J MED, V323, P91, DOI 10.1056/NEJM199007123230204; MANDEL SJ, 1993, ANN INTERN MED, V119, P492, DOI 10.7326/0003-4819-119-6-199309150-00009; MANNI A, 1981, CANCER, V48, P2507, DOI 10.1002/1097-0142(19811201)48:11<2507::AID-CNCR2820481127>3.0.CO;2-E; MORLEY JE, 1981, J CLIN ENDOCR METAB, V52, P173, DOI 10.1210/jcem-52-2-173; REFETOFF S, 1976, J CLIN INVEST, V57, P485, DOI 10.1172/JCI108301; Robbins J, 1978, Recent Prog Horm Res, V34, P477; TORMEY DC, 1983, ANN INTERN MED, V98, P139, DOI 10.7326/0003-4819-98-2-139; UTIGER RD, 1990, NEW ENGL J MED, V323, P126; WILSON JD, 1988, ENDOCR REV, V9, P181, DOI 10.1210/edrv-9-2-181	16	33	34	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1994	121	4					247	251		10.7326/0003-4819-121-4-199408150-00002	http://dx.doi.org/10.7326/0003-4819-121-4-199408150-00002			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB102	7518657				2022-12-24	WOS:A1994PB10200002
J	MAYOR, S; ROTHBERG, KG; MAXFIELD, FR				MAYOR, S; ROTHBERG, KG; MAXFIELD, FR			SEQUESTRATION OF GPI-ANCHORED PROTEINS IN CAVEOLAE TRIGGERED BY CROSS-LINKING	SCIENCE			English	Article							FOLATE-BINDING-PROTEIN; GLYCOSYL-PHOSPHATIDYLINOSITOL; CELL-SURFACE; MEMBRANE-PROTEINS; MOLECULES; 5'-NUCLEOTIDASE; RECEPTOR	Glycosyl-phosphatidylinositol (GPI)-anchored proteins have been reported to reside in clusters collected over small membrane invaginations called caveolae. The detection of different GPI-anchored proteins with fluorescently labeled monoclonal antibodies showed that these proteins are not constitutively concentrated in caveolae; they enter these structures independently after cross-linking with polyclonal secondary antibodies. Analysis of the cell surface distribution of the GPI-anchored folate receptor by electron microscopy confirms these observations. Thus, multimerization of GPI-anchored proteins regulates their sequestration in caveolae, but in the absence of agents that promote clustering they are diffusely distributed over the plasma membrane.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032; UNIV TEXAS,SW MED CTR,DEPT CELL BIOL & NEUROSCI,DALLAS,TX 75235	Columbia University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Maxfield, Fred/A-1718-2011; Maxfield, Fred/M-6747-2019; Eckhardt, Erik/G-1567-2010	Maxfield, Fred/0000-0003-4396-8866; 	NIDDK NIH HHS [DK27083] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027083, R37DK027083] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; Anderson Richard G., 1993, Trends in Cell Biology, V3, P69, DOI 10.1016/0962-8924(93)90065-9; BRETSCHER MS, 1980, P NATL ACAD SCI-BIOL, V77, P4156, DOI 10.1073/pnas.77.7.4156; BROWN D, 1993, CURR OPIN IMMUNOL, V5, P349, DOI 10.1016/0952-7915(93)90052-T; CONEY LR, 1991, CANCER RES, V51, P6125; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DAVITZ MA, 1986, J EXP MED, V163, P1150, DOI 10.1084/jem.163.5.1150; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; FERGUSON MAJ, 1994, PARASITOL TODAY, V10, P48, DOI 10.1016/0169-4758(94)90392-1; FIELD MC, 1992, LIPID MODIFICATION P, P83; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; FUJIMOTO T, 1993, J CELL BIOL, V120, P1147, DOI 10.1083/jcb.120.5.1147; GRIFFITHS G, 1989, J CELL BIOL, V109, P2703, DOI 10.1083/jcb.109.6.2703; HUANG AJ, 1993, J CELL BIOL, V120, P1371, DOI 10.1083/jcb.120.6.1371; KELLER GA, 1992, EMBO J, V11, P863, DOI 10.1002/j.1460-2075.1992.tb05124.x; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; LACEY SW, 1989, J CLIN INVEST, V84, P715, DOI 10.1172/JCI114220; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; ROBINSON PJ, 1991, IMMUNOL TODAY, V12, P35, DOI 10.1016/0167-5699(91)90110-F; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; ROTHBERG KG, 1990, J CELL BIOL, V110, P627; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Van Deurs Bo, 1993, Trends in Cell Biology, V3, P249; VANDENBOSCH RA, 1988, EMBO J, V7, P3345, DOI 10.1002/j.1460-2075.1988.tb03206.x; WIDNELL CC, 1982, CELL, V28, P61, DOI 10.1016/0092-8674(82)90375-0; XU XX, 1991, J BIOL CHEM, V266, P17040; YING YS, 1992, COLD SPRING HARB SYM, V57, P593, DOI 10.1101/SQB.1992.057.01.065	33	449	454	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 24	1994	264	5167					1948	1951		10.1126/science.7516582	http://dx.doi.org/10.1126/science.7516582			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT847	7516582				2022-12-24	WOS:A1994NT84700050
J	WANG, YT; SALTER, MW				WANG, YT; SALTER, MW			REGULATION OF NMDA RECEPTORS BY TYROSINE KINASES AND PHOSPHATASES	NATURE			English	Article							LONG-TERM POTENTIATION; EXCITATORY AMINO-ACIDS; PHOSPHORYLATION; ACTIVATION; INHIBITOR; NEURONS; CELLS	PROTEIN-TYROSINE kinases (PTKs) and protein-tyrosine phosphatases (PTPs) are key enzymes in signal-transduction pathways for a wide range of cellular processes(1,2). PTKs and PTPs are highly expressed in the central nervous system(3), which is consistent with the importance of tyrosine phosphorylation in neuronal function(4-6). Protein phosphorylation is known to be involved in the regulation of neurotransmitter receptors(7,8), but the effects of tyrosine phosphorylation on neurotransmitter receptor function in the central nervous system are unknown. Here we present evidence that in mammalian central neurons tyrosine phosphorylation regulates the function of the NMDA (N-methyl-D-aspartate) receptor, a subtype of excitatory amino-acid receptor(9,10). NMDA-receptor-mediated whole-cell currents and intracellular Ca2+ responses are depressed by inhibition of PTKs. Conversely, NMDA currents are potentiated by intracellular application of the well characterized PTK pp60(c-src). NMDA currents are also potentiated by intracellular administration of an inhibitor of PTPs. Protein-tyrosine phosphorylation is a new mechanism for regulating NMDA receptors and may be important in neuronal development, plasticity and toxicity.	HOSP SICK CHILDREN,DIV NEUROSCI,TORONTO M5G 1X8,ON,CANADA; UNIV TORONTO,DEPT PHYSIOL,TORONTO M5S 1A8,ON,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto			Wang, Yu Tian/J-8255-2015; Wang, Yu Tian/A-4729-2008					AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; BRICKELL P M, 1992, Critical Reviews in Oncogenesis, V3, P401; CATARSI S, 1993, NATURE, V363, P353, DOI 10.1038/363353a0; CHIBA T, 1993, NATURE, V362, P646, DOI 10.1038/362646a0; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GASIC GP, 1992, ANNU REV PHYSIOL, V54, P507, DOI 10.1146/annurev.physiol.54.1.507; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MAYER ML, 1984, J PHYSIOL-LONDON, V354, P29, DOI 10.1113/jphysiol.1984.sp015360; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; ONODA T, 1989, J NAT PROD, V52, P1252, DOI 10.1021/np50066a009; PAN MG, 1992, SCIENCE, V256, P1215, DOI 10.1126/science.256.5060.1215; RAYMOND LA, 1993, TRENDS NEUROSCI, V16, P147, DOI 10.1016/0166-2236(93)90123-4; SALTER MW, 1994, J NEUROSCI, V14, P1563, DOI 10.1523/JNEUROSCI.14-03-01563.1994; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; WAGER KR, 1991, CURR OPIN NEUROBIOL, V1, P65; WALAAS SI, 1991, PHARMACOL REV, V43, P299; WANG LY, 1991, SCIENCE, V253, P1132, DOI 10.1126/science.1653455; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577	24	624	648	2	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 19	1994	369	6477					233	235		10.1038/369233a0	http://dx.doi.org/10.1038/369233a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NM067	7514272				2022-12-24	WOS:A1994NM06700056
J	CARPOUSIS, AJ; VANHOUWE, G; EHRETSMANN, C; KRISCH, HM				CARPOUSIS, AJ; VANHOUWE, G; EHRETSMANN, C; KRISCH, HM			COPURIFICATION OF ESCHERICHIA-COLI RNASE-E AND PNPASE - EVIDENCE FOR A SPECIFIC ASSOCIATION BETWEEN 2 ENZYMES IMPORTANT IN RNA PROCESSING AND DEGRADATION	CELL			English	Article							BACTERIOPHAGE-T4 MESSENGER-RNA; SODIUM DODECYL-SULFATE; ESCHERICHIA-COLI; POLYNUCLEOTIDE PHOSPHORYLASE; NUCLEOTIDE-SEQUENCE; RIBONUCLEASE-E; RIBOSOMAL-RNA; AMS GENE; PROTEIN; DECAY	Ribonuclease E (RNAase E) was isolated in a complex that also contained polynucleotide phosphorylase (PNPase). Besides copurification, evidence for an association of these enzymes comes from sedimentation and immunoprecipitation experiments. Highly purified RNAase E correctly processed E. coli 5S ribosomal RNA, bacteriophage T4 gene 32 mRNA and E. coli ompA mRNA at sites known to depend on the rne gene for cleavage in vivo. The difference between previous smaller estimates of the size of RNAase E and that reported here apparently is due to the sensitivity of the enzyme to proteolysis during purification. The discovery of a specific association between RNAase E and PNPase raises the intriguing possibility that these enzymes act cooperatively in the processing and degradation of RNA.	CNRS,MICROBIOL & GENET MOLEC LAB,F-31062 TOULOUSE,FRANCE	Centre National de la Recherche Scientifique (CNRS)	CARPOUSIS, AJ (corresponding author), UNIV GENEVA,DEPT MOLEC BIOL,CH-1211 GENEVA 4,SWITZERLAND.		Carpousis, Agamemnon/S-2098-2019	Carpousis, Agamemnon/0000-0002-1774-2102				AMANN E, 1985, GENE, V40, P183, DOI 10.1016/0378-1119(85)90041-1; BABITZKE P, 1991, P NATL ACAD SCI USA, V88, P1, DOI 10.1073/pnas.88.1.1; CARPOUSIS AJ, 1989, MOL GEN GENET, V219, P39, DOI 10.1007/BF00261155; CASAREGOLA S, 1992, J MOL BIOL, V228, P30, DOI 10.1016/0022-2836(92)90489-7; CHAUHAN AK, 1991, NUCLEIC ACIDS RES, V19, P125, DOI 10.1093/nar/19.1.125; CLAVERIEMARTIN F, 1991, J BIOL CHEM, V266, P2843; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CORMACK RS, 1992, J MOL BIOL, V228, P1078, DOI 10.1016/0022-2836(92)90316-C; DEUTSCHER MP, 1991, P NATL ACAD SCI USA, V88, P3277, DOI 10.1073/pnas.88.8.3277; DONOVAN WP, 1986, P NATL ACAD SCI USA, V83, P120, DOI 10.1073/pnas.83.1.120; EHRETSMANN CP, 1992, GENE DEV, V6, P149, DOI 10.1101/gad.6.1.149; EHRETSMANN CP, 1992, FASEB J, V6, P3186, DOI 10.1096/fasebj.6.13.1397840; FREUDL R, 1985, EMBO J, V4, P3593, DOI 10.1002/j.1460-2075.1985.tb04122.x; GEORGELLIS D, 1992, J BACTERIOL, V174, P5382, DOI 10.1128/JB.174.16.5382-5390.1992; GHORA BK, 1978, CELL, V15, P1055, DOI 10.1016/0092-8674(78)90289-1; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; LOAYZA D, 1991, MOL MICROBIOL, V5, P715, DOI 10.1111/j.1365-2958.1991.tb00742.x; LUNDBERG U, 1990, EMBO J, V9, P2731, DOI 10.1002/j.1460-2075.1990.tb07460.x; MCLAREN RS, 1991, J MOL BIOL, V221, P81, DOI 10.1016/0022-2836(91)80206-A; MELEFORS O, 1991, MOL MICROBIOL, V5, P857, DOI 10.1111/j.1365-2958.1991.tb00759.x; MICZAK A, 1991, MOL MICROBIOL, V5, P1801, DOI 10.1111/j.1365-2958.1991.tb01929.x; MISRA TK, 1979, J BIOL CHEM, V254, P1154; MISRA TK, 1980, J BACTERIOL, V142, P359, DOI 10.1128/JB.142.1.359-361.1980; MUDD EA, 1990, GENE DEV, V4, P873, DOI 10.1101/gad.4.5.873; MUDD EA, 1990, MOL MICROBIOL, V4, P2127, DOI 10.1111/j.1365-2958.1990.tb00574.x; MUDD EA, 1993, MOL MICROBIOL, V9, P557, DOI 10.1111/j.1365-2958.1993.tb01716.x; ONO M, 1979, J MOL BIOL, V129, P343, DOI 10.1016/0022-2836(79)90500-X; PEDERSEN C, 1992, MOL MICROBIOL, V6, P277; PORTIER C, 1975, EUR J BIOCHEM, V55, P573, DOI 10.1111/j.1432-1033.1975.tb02194.x; REGNIER P, 1987, J BIOL CHEM, V262, P63; ROY MK, 1983, EUR J BIOCHEM, V131, P119, DOI 10.1111/j.1432-1033.1983.tb07238.x; SOHLBERG B, 1993, P NATL ACAD SCI USA, V90, P277, DOI 10.1073/pnas.90.1.277	32	381	382	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 11	1994	76	5					889	900		10.1016/0092-8674(94)90363-8	http://dx.doi.org/10.1016/0092-8674(94)90363-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NA890	7510217				2022-12-24	WOS:A1994NA89000014
J	KOKUBO, T; GONG, DW; WOOTTON, JC; HORIKOSHI, M; ROEDER, RG; NAKATANI, Y				KOKUBO, T; GONG, DW; WOOTTON, JC; HORIKOSHI, M; ROEDER, RG; NAKATANI, Y			MOLECULAR-CLONING OF DROSOPHILA TFIID SUBUNITS	NATURE			English	Article							MAJOR LATE PROMOTER; RNA POLYMERASE-II; TATA BOX-BINDING; TRANSCRIPTION FACTOR; PREINITIATION COMPLEX; PROTEIN; NUCLEOSOME; COACTIVATORS; INITIATION	TRANSCRIPTION initiation factor TFIID is a multisubunit complex containing a TATA-box-binding factor (TFIIDtau/TBP) and associated polypeptide factors (TAFs) with sizes ranging from M(r) approximately 20,000 to >200,000 (refs 1-7). As a result of direct promoter interactions8,9, TFIID nucleates the assembly of RNA polymerase II and other initiation factors into a functional preinitiation complex10. Although the native TFIID complex mediates both basal and activator-dependent transcription in reconstituted systems, TBP itself is competent for only basal transcription. Thus, TAFs are essential cofactors for regulated transcription. The complementary DNAs encoding the p230 (M(r) 230,000), p110 and p85 subunits of TFIID have recently been cloned11-18. Here we report the molecular cloning and characterization of the p62, p42, p28 and p22 subunits. These participate in a network of heterogeneous protein-protein interactions within TFIID. Sequence similarities between p62/p42 and the histones H4/H3, respectively, suggest that these subunits have a functional relationship with chromatin.	NICHHD,BETHESDA,MD 20892; NINCDS,BETHESDA,MD 20892; NATL CTR BIOTECHNOL INFORMAT,BETHESDA,MD 20892; ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,NEW YORK,NY 10021; UNIV TOKYO,INST MOLEC & CELLULAR BIOSCI,BUNKYO KU,TOKYO 113,JAPAN	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Rockefeller University; University of Tokyo								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; DYNLACHT BD, 1993, NATURE, V363, P176, DOI 10.1038/363176a0; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GASH A, 1990, NATURE, V346, P390; HAYES JJ, 1991, P NATL ACAD SCI USA, V88, P6829, DOI 10.1073/pnas.88.15.6829; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; KOKUBO T, 1993, GENE DEV, V7, P1033, DOI 10.1101/gad.7.6.1033; KOKUBO T, 1993, J BIOL CHEM, V268, P17554; KOKUBO T, 1993, P NATL ACAD SCI USA, V90, P5896, DOI 10.1073/pnas.90.13.5896; KOKUBO T, 1993, MOL CELL BIOL, V13, P7859, DOI 10.1128/MCB.13.12.7859; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NAKATANI Y, 1990, NATURE, V348, P86, DOI 10.1038/348086a0; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; STRUHL K, 1986, MOL CELL BIOL, V6, P3847, DOI 10.1128/MCB.6.11.3847; TABASSUM R, 1992, J BACTERIOL, V174, P7890, DOI 10.1128/JB.174.24.7890-7895.1992; TAKADA R, 1992, P NATL ACAD SCI USA, V89, P11809, DOI 10.1073/pnas.89.24.11809; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; Wolffe Alan P., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P167; WOOTTON JC, 1993, COMPUT CHEM, V17, P149, DOI 10.1016/0097-8485(93)85006-X; WORKMAN JL, 1988, CELL, V55, P211, DOI 10.1016/0092-8674(88)90044-X; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	30	105	109	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 3	1994	367	6462					484	487		10.1038/367484a0	http://dx.doi.org/10.1038/367484a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU679	7545910				2022-12-24	WOS:A1994MU67900061
J	EPSTEIN, JI; WALSH, PC; CARMICHAEL, M; BRENDLER, CB				EPSTEIN, JI; WALSH, PC; CARMICHAEL, M; BRENDLER, CB			PATHOLOGICAL AND CLINICAL FINDINGS TO PREDICT TUMOR EXTENT OF NONPALPABLE (STAGE-T1C) PROSTATE-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIGITAL RECTAL EXAMINATION; TRANSRECTAL ULTRASOUND; ANTIGEN; ADENOCARCINOMA; VOLUME; DIFFERENTIATION; PROGNOSIS; DISEASE	Objectives.-We examined preoperative clinical and pathologic parameters in men with clinical stage T1c disease who underwent radical prostatectomy and correlated these findings with the pathologic extent of disease in the surgical specimen in an attempt to identify a subset of patients with potentially biologically insignificant tumor who might be followed up without immediate treatment. Design and Patients.-A case series of 157 consecutive men who underwent radical prostatectomy for clinical stage T1c disease compared with 64 similarly treated clinical stage T1a cancers (incidental minimal cancers found on transurethral resection of prostate) and 439 clinical stage T2 (palpable) cancers. Main Outcome Measures.-Pathologic stage, grade, and margins; tumor volume; and tumor location. Results.-Sixteen percent of tumors were insignificant (<0.2 cm3 and confined to the prostate, with a Gleason score <7); 10% were minimal (0.2 to 0.5 cm3 and confined to the prostate, with a Gleason score <7); 37% were moderate (>0.5 cm3 or capsular penetration, with a Gleason score <7); and 37% were advanced (capsular penetration, with a Gleason score greater-than-or-equal-to 7 or positive margins, seminal vesicles, or lymph nodes). These findings are intermediate between those found in clinical stage T1a and stage T2 disease. The following parameters were not predictive of tumor extent: age, reason for evaluation, method of detection, and transrectal ultrasound. The best model predicting insignificant tumor was prostate-specific antigen (PSA) density less than 0.1 ng/mL per gram and no adverse pathologic findings on needle biopsy, or PSA density of 0.1 to 0.15 ng/mL per gram, with a low- to intermediate-grade cancer smaller than 3 mm found in only one needle biopsy core specimen. The positive predictive value of the model was 95%, with a negative predictive value of 66%. We accurately predicted 73% of cases with insignificant tumor. Conclusions.-Eighty-four percent of nonpalpable prostate cancers diagnosed by screening techniques are significant tumors and warrant definitive therapy. However, 16% are insignificant. Serum PSA level, PSA density, and needle biopsy pathologic findings are accurate predictors of tumor extent. lt may be reasonable to follow up some patients whose tumors are most likely insignificant with serial PSA measurements and repeated biopsies.	JOHNS HOPKINS UNIV HOSP,JAMES BUCHANAN BRADY UROL INST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT UROL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University								BASTACKY SS, 1991, J UROLOGY, V145, P1003, DOI 10.1016/S0022-5347(17)38513-0; BENSON MC, 1992, J UROLOGY, V147, P815, DOI 10.1016/S0022-5347(17)37393-7; BENSON MC, 1992, J UROLOGY, V147, P817, DOI 10.1016/S0022-5347(17)37394-9; CARTER HB, 1992, JAMA-J AM MED ASSOC, V267, P2215, DOI 10.1001/jama.267.16.2215; CARTER HB, 1989, J UROLOGY, V142, P1008, DOI 10.1016/S0022-5347(17)38971-1; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; COONER WH, 1990, J UROLOGY, V143, P1146, DOI 10.1016/S0022-5347(17)40211-4; EPSTEIN JI, 1993, CANCER-AM CANCER SOC, V71, P3582, DOI 10.1002/1097-0142(19930601)71:11<3582::AID-CNCR2820711120>3.0.CO;2-Y; EPSTEIN JI, 1986, J UROLOGY, V136, P837, DOI 10.1016/S0022-5347(17)45097-X; EPSTEIN JI, 1993, J UROLOGY, V149, P1478, DOI 10.1016/S0022-5347(17)36421-2; EPSTEIN JI, 1993, J UROLOGY, V150, P135, DOI 10.1016/S0022-5347(17)35415-0; GLEASON DF, 1974, J UROLOGY, V111, P58, DOI 10.1016/S0022-5347(17)59889-4; LABRIE F, 1992, J UROLOGY, V147, P846, DOI 10.1016/S0022-5347(17)37402-5; LARSEN MP, 1991, J UROLOGY, V146, P1059, DOI 10.1016/S0022-5347(17)38000-X; MCNEAL JE, 1990, CANCER, V66, P1225, DOI 10.1002/1097-0142(19900915)66:6<1225::AID-CNCR2820660624>3.0.CO;2-X; OESTERLING JE, 1991, J UROLOGY, V145, P907, DOI 10.1016/S0022-5347(17)38491-4; PALKEN M, 1991, J UROLOGY, V145, P86, DOI 10.1016/S0022-5347(17)38254-X; PARTIN AW, 1989, J UROLOGY, V141, P341, DOI 10.1016/S0022-5347(17)40761-0; PARTIN AW, 1990, J UROLOGY, V143, P747, DOI 10.1016/S0022-5347(17)40079-6; Stamey TA, 1992, CAMPBELLS UROLOGY, P1200; STORMONT TJ, 1993, UROLOGY, V41, P3, DOI 10.1016/0090-4295(93)90233-Z; TERRIS MK, 1992, J UROLOGY, V148, P829, DOI 10.1016/S0022-5347(17)36735-6; WHITMORE WF, 1990, UROL CLIN N AM, V17, P689	23	1461	1495	0	30	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	1994	271	5					368	374		10.1001/jama.271.5.368	http://dx.doi.org/10.1001/jama.271.5.368			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR983	7506797				2022-12-24	WOS:A1994MR98300032
J	Murakami, S; Mizobuchi, M; Nakashiro, Y; Doi, T; Hato, N; Yanagihara, N				Murakami, S; Mizobuchi, M; Nakashiro, Y; Doi, T; Hato, N; Yanagihara, N			Bell palsy and herpes simplex virus: Identification of viral DNA in endoneurial fluid and muscle	ANNALS OF INTERNAL MEDICINE			English	Note							POLYMERASE CHAIN-REACTION; VARICELLA-ZOSTER VIRUS; CEREBROSPINAL-FLUID; NERVOUS-SYSTEM; GENE	Objective: To determine whether herpes simplex virus type 1 (HSV-1) causes Bell palsy. Design: Prospective study. Setting: University inpatient service. Patients: 14 patients with Bell palsy, 9 patients with the Ramsay-Hunt syndrome, and 12 other controls. Measurements: Viral genomes of HSV-1, varicella-zoster virus, and Epstein-Barr virus were analyzed in clinical samples of facial nerve endoneurial fluid and posterior auricular muscle using polymerase chain reaction (PCR) followed by hybridization with Southern blot analysis. Results: Herpes simplex virus type 1 genomes were detected in 11 of 14 patients (79%) with Bell palsy but not in patients with the Ramsay-Hunt syndrome or in other controls. The nucleotide sequences of the PCR fragments were identical to those of the HSV-1 genome. Conclusions: Herpes simplex virus type 1 is the major etiologic agent in Bell palsy.	EHIME UNIV, SCH MED, DEPT NEUROPSYCHIAT, SHIGENOBU, EHIME 79102, JAPAN	Ehime University	Murakami, S (corresponding author), EHIME UNIV, SCH MED, DEPT OTOLARYNGOL, SHIGENOBU, EHIME 79102, JAPAN.							ABRAMSKY O, 1975, J NEUROL SCI, V26, P13, DOI 10.1016/0022-510X(75)90109-4; ADOUR KK, 1975, JAMA-J AM MED ASSOC, V233, P527, DOI 10.1001/jama.233.6.527; Aitken RS, 1933, LANCET, V1, P19; AURELIUS E, 1991, LANCET, V337, P189, DOI 10.1016/0140-6736(91)92155-U; BURGESS RC, 1994, ANN OTO RHINOL LARYN, V103, P775, DOI 10.1177/000348949410301006; CARTON CA, 1953, J NEUROSURG, V10, P463, DOI 10.3171/jns.1953.10.5.0463; CINQUE P, 1993, LANCET, V342, P398, DOI 10.1016/0140-6736(93)92814-A; DEVRIESE PP, 1974, ACTA OTO-LARYNGOL, V77, P108, DOI 10.3109/00016487409124605; DOWBENKO DJ, 1984, J VIROL, V52, P154, DOI 10.1128/JVI.52.1.154-163.1984; FURUTA Y, 1992, J INFECT DIS, V166, P1157, DOI 10.1093/infdis/166.5.1157; GILDEN DH, 1992, J INFECT DIS, V166, pS30, DOI 10.1093/infdis/166.Supplement_1.S30; HADAR T, 1983, J MED VIROL, V12, P237, DOI 10.1002/jmv.1890120403; LISTON SL, 1989, LARYNGOSCOPE, V99, P23; MCCORMICK DP, 1972, LANCET, V1, P937; MIZOBUCHI M, 1991, MOL ENDOCRINOL, V5, P476, DOI 10.1210/mend-5-4-476; PALVA T, 1978, ACTA OTO-LARYNGOL, V86, P269, DOI 10.3109/00016487809124746; SARTORETTISCHEFER S, 1994, AM J NEURORADIOL, V15, P479; SPRUANCE SL, 1994, ANN INTERN MED, V120, P1045, DOI 10.7326/0003-4819-120-12-199406150-00013; TAKASU T, 1992, ACTA OTO-LARYNGOL, V112, P1004, DOI 10.3109/00016489209137502; TOWNSEND JJ, 1986, J NEUROPATH EXP NEUR, V45, P419, DOI 10.1097/00005072-198607000-00004	20	456	474	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	1				27	30		10.7326/0003-4819-124-1_Part_1-199601010-00005	http://dx.doi.org/10.7326/0003-4819-124-1_Part_1-199601010-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL943	7503474				2022-12-24	WOS:A1996TL94300005
J	RICE, WG; SUPKO, JG; MALSPEIS, L; BUCKHEIT, RW; CLANTON, D; BU, M; GRAHAM, L; SCHAEFFER, CA; TURPIN, JA; DOMAGALA, J; GOGLIOTTI, R; BADER, JP; HALLIDAY, SM; COREN, L; SOWDER, RC; ARTHUR, LO; HENDERSON, LE				RICE, WG; SUPKO, JG; MALSPEIS, L; BUCKHEIT, RW; CLANTON, D; BU, M; GRAHAM, L; SCHAEFFER, CA; TURPIN, JA; DOMAGALA, J; GOGLIOTTI, R; BADER, JP; HALLIDAY, SM; COREN, L; SOWDER, RC; ARTHUR, LO; HENDERSON, LE			INHIBITORS OF HIV NUCLEOCAPSID PROTEIN ZINC FINGERS AS CANDIDATES FOR THE TREATMENT OF AIDS	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; REVERSE-TRANSCRIPTASE; TYPE-1; RETROVIRUSES; INFECTIVITY; SEQUENCES; CLONE; RNA	Strategies for the treatment of human immunodeficiency virus-type 1 (HIV-1) infection must contend with the obstacle of drug resistance. HIV-1 nucleocapsid protein zinc fingers are prime antiviral targets because they are mutationally into lerant and are required both for acute infection and virion assembly. Nontoxic disulfide-substituted benzamides were identified that attack the zinc fingers, inactivate cell-free virions, inhibit acute and chronic infections, and exhibit broad antiretroviral activity. The compounds were highly synergistic with other antiviral agents, and resistant mutants have not been detected. Zinc finger-reactive compounds may offer an anti-HIV strategy that restricts drug-resistance development.	NCI,DIV CANC TREATMENT,PHARMACEUT CHEM LAB,DEV THERAPEUT PROGRAM,FREDERICK,MD 21701; SO RES INST FREDERICK RES CTR,VIROL RES GRP,FREDERICK,MD 21701; NCI,FREDERICK CANC RES & DEV CTR,PRI DYNCORP,ANTI AIDS VIRUS DRUG SCREENING LAB,FREDERICK,MD 21702; WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES DIV,DEPT CHEM,ANN ARBOR,MI 48105; NCI,DIV CANC TREATMENT,DEV THERAPEUT PROGRAM,ANTIVIRAL EVALUAT BRANCH,BETHESDA,MD 20892; NCI,FREDERICK CANC RES & DEV CTR,PRI DYNCORP,AIDS VACCINE PROGRAM,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Pfizer; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	RICE, WG (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,PRI DYNCORP,ANTIVIRAL DRUG MECHANISMS LAB,FREDERICK,MD 21702, USA.							ALDOVINI A, 1990, J VIROL, V64, P1920, DOI 10.1128/JVI.64.5.1920-1926.1990; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BESS JW, 1992, J VIROL, V66, P840, DOI 10.1128/JVI.66.2.840-847.1992; BUCKHEIT RW, 1995, ANTIVIR RES, V26, P117, DOI 10.1016/0166-3542(94)00069-K; BUCKHEIT RW, 1994, ANTIVIR RES, V25, P43, DOI 10.1016/0166-3542(94)90092-2; BUCKHEIT RW, 1993, ANTIVIR RES, V21, P247, DOI 10.1016/0166-3542(93)90031-D; CHANCE MR, 1992, P NATL ACAD SCI USA, V89, P10124; CLOUSE KA, 1989, J IMMUNOL, V142, P431; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; CUSHMAN M, 1994, J MED CHEM, V37, P3040, DOI 10.1021/jm00045a008; FOLKS TM, 1988, J IMMUNOL, V140, P1117; GIBALDI M, 1982, PHARMACOKINETICS, P410; GORELICK RJ, 1993, J VIROL, V67, P4027, DOI 10.1128/JVI.67.7.4027-4036.1993; GORELICK RJ, 1990, J VIROL, V64, P3207, DOI 10.1128/JVI.64.7.3207-3211.1990; HART GJ, 1992, ANTIMICROB AGENTS CH, V36, P1688, DOI 10.1128/AAC.36.8.1688; HENDERSON LE, 1992, J VIROL, V66, P1856, DOI 10.1128/JVI.66.4.1856-1865.1992; KAGEYAMA S, 1994, ANTIMICROB AGENTS CH, V38, P1107, DOI 10.1128/AAC.38.5.1107; Mellors J. W., 1995, International Antiviral News, V3, P8; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P13817, DOI 10.1021/bi00250a036; PRICHARD MN, 1990, ANTIVIR RES, V14, P181, DOI 10.1016/0166-3542(90)90001-N; Rice W. G., 1995, International Antiviral News, V3, P87; RICE WG, 1993, P NATL ACAD SCI USA, V90, P9721, DOI 10.1073/pnas.90.20.9721; RICE WG, 1993, NATURE, V361, P473, DOI 10.1038/361473a0; RICE WG, 1995, ANTIVIR RES, V26, pA235; RICE WG, UNPUB; South T L, 1990, Adv Inorg Biochem, V8, P199; SOUTH TL, 1990, BIOCHEM PHARMACOL, V40, P123, DOI 10.1016/0006-2952(90)90187-P; STAAL FTJ, 1993, AIDS RES HUM RETROV, V9, P4299; SUMMERS MF, 1992, PROTEIN SCI, V1, P563, DOI 10.1002/pro.5560010502; WEISLOW OS, 1989, JNCI-J NATL CANCER I, V81, P577, DOI 10.1093/jnci/81.8.577	30	234	280	0	13	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 17	1995	270	5239					1194	1197		10.1126/science.270.5239.1194	http://dx.doi.org/10.1126/science.270.5239.1194			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE905	7502043				2022-12-24	WOS:A1995TE90500055
J	MINKOFF, H; WILLOUGHBY, A				MINKOFF, H; WILLOUGHBY, A			PEDIATRIC HIV DISEASE, ZIDOVUDINE IN PREGNANCY, AND UNBLINDING HEELSTICK SURVEYS - REFRAMING THE DEBATE ON PRENATAL HIV TESTING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; INFECTION; WOMEN; POPULATION		NICHHD,CTR RES MOTHERS & CHILDREN,PEDIAT ADOLESCENT & MATERNAL AIDS BRANCH,ROCKVILLE,MD	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	MINKOFF, H (corresponding author), SUNY HLTH SCI CTR,DEPT OBSTET & GYNECOL,450 CLARKSON AVE,BOX 24,BROOKLYN,NY 11203, USA.							BAYER R, 1991, NEW ENGL J MED, V324, P1500, DOI 10.1056/NEJM199105233242111; BAYER R, 1995, WASHINGTON POST 0526, pA27; BAYER R, 1994, NEW ENGL J MED, V318, P1223; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; COTTON P, 1994, JAMA-J AM MED ASSOC, V271, P807, DOI 10.1001/jama.271.11.807; KRASINSKI K, 1988, NEW ENGL J MED, V318, P185; LANDESMAN S, 1987, JAMA-J AM MED ASSOC, V258, P2701, DOI 10.1001/jama.258.19.2701; LINDSAY MK, 1989, OBSTET GYNECOL, V74, P289; MINKOFF HL, 1988, NEW ENGL J MED, V319, P1018; SPERLING RS, 1992, NEW ENGL J MED, V326, P857, DOI 10.1056/NEJM199203263261303; WHEAT ME, 1993, AM J PREV MED, V9, P307, DOI 10.1016/S0749-3797(18)30707-4; 1994, MMWR-MORBID MORTAL W, V43, P1; 1994, NATIONAL HIV SEROSUR, P3; 1992, HUMAN IMMUNODEFICIEN, V162, P1	14	32	32	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 11	1995	274	14					1165	1168		10.1001/jama.274.14.1165	http://dx.doi.org/10.1001/jama.274.14.1165			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY056	7563489				2022-12-24	WOS:A1995RY05600033
J	SUTO, R; SRIVASTAVA, PK				SUTO, R; SRIVASTAVA, PK			A MECHANISM FOR THE SPECIFIC IMMUNOGENICITY OF HEAT-SHOCK PROTEIN-CHAPERONED PEPTIDES	SCIENCE			English	Article							ANTIGEN; CELLS; CANCER	Endogenously synthesized antigenic determinants are generally presented on major histocompatibility complex (MHC) class I molecules, whereas exogenous determinants are presented by MHC class II molecules. Here, it is shown that exogenous antigens chaperoned by a heat shock protein can be channeled into the endogenous pathway, presented by MHC class I molecules, and recognized by CD8(+) T lymphocytes. This pathway is functional only in a subset of macrophages among the cell types tested. These observations provide a basis for the tumor-specific and virus-specific immunogenicity of cognate heat shock protein preparations and offer a mechanism for the classical phenomenon of cross-priming.	FORDHAM UNIV, DEPT BIOL SCI, BRONX, NY 10458 USA	Fordham University					NCI NIH HHS [CA44786] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA044786, R01CA044786] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; BLACHERE NE, 1993, J IMMUNOTHER, V14, P352, DOI 10.1097/00002371-199311000-00016; GOODING LR, 1980, J IMMUNOL, V124, P1258; KOVACSOVICSBANKOWSKI M, 1995, SCIENCE, V267, P243, DOI 10.1126/science.7809629; Li Z.B., UNPUB; LI ZH, 1993, EMBO J, V12, P3143, DOI 10.1002/j.1460-2075.1993.tb05983.x; PALLADINO MA, 1987, CANCER RES, V47, P5074; PUDDINGTON L, 1986, J VIROL, V60, P708, DOI 10.1128/JVI.60.2.708-717.1986; ROCK KL, 1993, J IMMUNOL, V150, P438; SCHIRMBECK R, 1994, EUR J IMMUNOL, V24, P1088, DOI 10.1002/eji.1830240512; SCHIRMBECK R, 1995, EUR J IMMUNOL, V25, P1063, DOI 10.1002/eji.1830250431; SRIVASTAVA PK, 1984, INT J CANCER, V33, P417, DOI 10.1002/ijc.2910330321; SRIVASTAVA PK, 1991, CURR TOP MICROBIOL, V167, P109; SRIVASTAVA PK, 1994, IMMUNOGENETICS, V39, P93; SRIVASTAVA PK, UNPUB; SUTO RK, UNPUB; UDONO H, 1994, P NATL ACAD SCI USA, V91, P3077, DOI 10.1073/pnas.91.8.3077; UDONO H, 1994, J IMMUNOL, V152, P5398; UDONO H, 1993, J EXP MED, V178, P1391, DOI 10.1084/jem.178.4.1391; UDONO H, UNPUB	20	711	826	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 15	1995	269	5230					1585	1588		10.1126/science.7545313	http://dx.doi.org/10.1126/science.7545313			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RU813	7545313				2022-12-24	WOS:A1995RU81300045
J	LANNG, S; HANSEN, A; THORSTEINSSON, B; NERUP, J; KOCH, C				LANNG, S; HANSEN, A; THORSTEINSSON, B; NERUP, J; KOCH, C			GLUCOSE-TOLERANCE IN PATIENTS WITH CYSTIC-FIBROSIS - 5-YEAR PROSPECTIVE-STUDY	BRITISH MEDICAL JOURNAL			English	Article							DIABETES-MELLITUS; GLYCOSYLATED HEMOGLOBIN; DELTA-F508 MUTATION; PANCREATIC FUNCTION; ENDOCRINE; EXOCRINE; INTOLERANCE; ADOLESCENTS	Objectives-To study prevalence and incidence of diabetes mellitus in patients with cystic fibrosis. Design-Five year prospective study with annual oral glucose tolerance tests. Setting-CF Center Copenhagen, Denmark. Subjects-191 patients with cystic fibrosis aged above 2 years. Main outcome measures-Glucose tolerance, plasma glucose concentrations after fasting and after glucose loading, and haemoglobin A(1c) levels. Results-Prevalence of diabetes increased from 11% (n=21) to 24% (n=46) during study, with annual age dependent incidence of 4-9%. Diabetes was diagnosed at median age of 21 (range 3-40). At diagnosis of diabetes, symptoms of hyperglycaemia were present in 33% of patients, fasting hyperglycaemia (greater than or equal to 7.8 mmol/l was seen in 16%, and increased haemoglobin A(1c) levels (>6.4%) were seen in 16%. Impaired glucose tolerance implied higher risk for development of diabetes than normal glucose tolerance (odds ratio 5.6). In 58% of cases with impaired glucose tolerance, however, glucose tolerance was normal at next annual test. Normal glucose tolerance was found in only 37% of patients at all five tests. Within this group of patients, median plasma glucose concentrations after fasting and after glucose loading and haemoglobin A(1c) levels increased by 6-8% during study. Conclusions-Prevalence and incidence of diabetes in cystic fibrosis patients was high and increased with age. Since hyperglycaemic symptoms, fasting hyperglycaemia, and increased levels of glycated haemoglobin did not reliably identify diabetes mellitus, we recommend annual oral glucose tolerance tests in all cystic fibrosis patients aged over 10 years.	HILLEROD HOSP,DEPT MED F,HILLEROD,DENMARK; STENO DIABET CTR,GENTOFTE,DENMARK	University of Copenhagen; Steno Diabetes Center	LANNG, S (corresponding author), RIGSHOSP,CF CTR COPENHAGEN,DEPT PAEDIAT,DK-2100 COPENHAGEN,DENMARK.							ABDULKARIM FW, 1986, ARCH PATHOL LAB MED, V110, P602; ARRIGO T, 1993, ACTA PAEDIATR, V82, P249, DOI 10.1111/j.1651-2227.1993.tb12653.x; ARTAL R, 1984, AM J OBSTET GYNECOL, V148, P412, DOI 10.1016/0002-9378(84)90717-8; BANAUCH D, 1975, Z KLIN CHEM KLIN BIO, V13, P101; BANK S, 1975, AM J GASTROENTEROL, V64, P13; BISTRITZER T, 1983, ISRAEL J MED SCI, V19, P600; ELBORN JS, 1991, THORAX, V46, P881, DOI 10.1136/thx.46.12.881; FINKELSTEIN SM, 1988, J PEDIATR-US, V112, P373, DOI 10.1016/S0022-3476(88)80315-9; FITZSIMMONS SC, 1993, J PEDIATR-US, V122, P1, DOI 10.1016/S0022-3476(05)83478-X; GEFFNER ME, 1984, PEDIATR RES, V18, P1107, DOI 10.1203/00006450-198411000-00011; GIBSON LE, 1959, PEDIATRICS, V23, P545; HANDWERG.S, 1969, NEW ENGL J MED, V281, P451, DOI 10.1056/NEJM196908282810901; HOIBY N, 1977, ACTA PATHOLOGIC S262, V85, P3; IANNUCCI A, 1984, HUM PATHOL, V15, P278, DOI 10.1016/S0046-8177(84)80191-4; LAMERS CBHW, 1990, PANCREAS, V5, P65; LANNG S, 1994, ACTA PAEDIATR, V83, P72, DOI 10.1111/j.1651-2227.1994.tb12956.x; LANNG S, 1991, CLIN GENET, V40, P345; LANNG S, 1992, EUR J PEDIATR, V151, P684, DOI 10.1007/BF01957574; LANNG S, 1991, ARCH DIS CHILD, V66, P612, DOI 10.1136/adc.66.5.612; LANNG S, 1994, ACTA PAEDIATR, V83, P849, DOI 10.1111/j.1651-2227.1994.tb13156.x; LANNG S, 1993, ACTA ENDOCRINOL-COP, V128, P207, DOI 10.1530/acta.0.1280207; LANNG S, 1993, ACTA PAEDIATR, V82, P150, DOI 10.1111/j.1651-2227.1993.tb12628.x; LITTLE RR, 1994, DIABETOLOGIA, V37, P252, DOI 10.1007/BF00398051; MORAN A, 1991, J PEDIATR-US, V118, P715, DOI 10.1016/S0022-3476(05)80032-0; NIELSEN O H, 1981, Ugeskrift for Laeger, V143, P2302; NIR M, IN PRESS THORAX; POLGAR G, 1971, PULMONARY FUNCTION T, P88; REISMAN J, 1990, PEDIATRICS, V150, P374; ROBERT JJ, 1992, ARCH FR PEDIATR, V49, P17; RODMAN HM, 1986, MEDICINE, V65, P389, DOI 10.1097/00005792-198611000-00004; SCHWARTZ M, 1990, HUM GENET, V85, P427, DOI 10.1007/BF02428297; SOIJIMA K, 1986, PEDIATR PATHOL, V6, P25; STUTCHFIELD PR, 1987, ARCH DIS CHILD, V62, P805, DOI 10.1136/adc.62.8.805; SVENDSEN PA, 1982, DIABETOLOGIA, V23, P403; TREZISE AEO, 1991, NATURE, V353, P434, DOI 10.1038/353434a0; World Health Organization, 1985, DIAB MELL REP WHO ST, V727; WULFF HR, 1988, MEDSTAT VERSION 2; YUDKIN JS, 1990, BRIT MED J, V301, P397, DOI 10.1136/bmj.301.6749.397	38	175	175	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 9	1995	311	7006					655	659		10.1136/bmj.311.7006.655	http://dx.doi.org/10.1136/bmj.311.7006.655			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU753	7549632	Green Published			2022-12-24	WOS:A1995RU75300016
J	GREGORIO, CC; WEBER, A; BONDAD, M; PENNISE, CR; FOWLER, VM				GREGORIO, CC; WEBER, A; BONDAD, M; PENNISE, CR; FOWLER, VM			REQUIREMENT OF POINTED-END CAPPING BY TROPOMODULIN TO MAINTAIN ACTIN FILAMENT LENGTH IN EMBRYONIC CHICK CARDIAC MYOCYTES	NATURE			English	Article							TROPOMYOSIN-BINDING; MECHANISMS; PROTEIN; MUSCLE; CELLS	CONTROL of actin filament length and dynamics is important for cell motility and architecture and is regulated in part by capping proteins that block elongation and depolymerization at both the fast-growing (barbed) and slow-growing (pointed) ends(1-4). Tropomodulin is a capping protein for the pointed end of the actin filament(5,6); it is associated with the free, pointed ends of the thin filaments in striated muscle, where it is thought to bind to both tropomyosin and actin(7,8). In embryonic chick cardiac myocytes, tropomodulin assembles after the thin, as well as the thick, filaments have become organized into periodic I and A bands(8), suggesting that tropomodulin might be involved in maintaining actin filament length. Here we show that microinjection of an antibody that inhibits tropomodulin's pointed-end-capping activity in vitro results in a marked elongation of actin filaments from their pointed ends and a >80% reduction in the percentage of beating cells. This demonstrates that pointed-end capping by tropomodulin is required to maintain actin filament length in vivo and that this is essential for contractile function in embryonic chick cardiac myocytes.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; UNIV PENN, DEPT BIOCHEM & BIOPHYS, PHILADELPHIA, PA 19104 USA	Scripps Research Institute; University of Pennsylvania								BABCOCK GG, 1994, J BIOL CHEM, V269, P27510; Carlier Marie-France, 1994, Seminars in Cell Biology, V5, P183, DOI 10.1006/scel.1994.1023; COLUCCIO LM, 1994, J CELL BIOL, V127, P1497, DOI 10.1083/jcb.127.6.1497; Ebashi S, 1968, Prog Biophys Mol Biol, V18, P123, DOI 10.1016/0079-6107(68)90023-0; FOWLER VM, 1993, J CELL BIOL, V120, P411, DOI 10.1083/jcb.120.2.411; FOWLER VM, 1990, J CELL BIOL, V111, P471, DOI 10.1083/jcb.111.2.471; GREGORIO CC, 1995, J CELL BIOL, V129, P683, DOI 10.1083/jcb.129.3.683; ITO M, 1995, DEV BIOL, V167, P317, DOI 10.1006/dbio.1995.1026; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; SHUBEITA HE, 1992, CIRCULATION, V85, P2236, DOI 10.1161/01.CIR.85.6.2236; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; SUNG KLP, 1994, MOL BIOL CELL, V5, pA54; SUNG LA, 1992, J BIOL CHEM, V267, P2616; SUSSMAN MA, 1994, CIRC RES, V75, P221, DOI 10.1161/01.RES.75.2.221; SUSSMAN MA, 1994, DEV BRAIN RES, V80, P45, DOI 10.1016/0165-3806(94)90088-4; URSITTI JA, 1994, J CELL SCI, V107, P1633; WEBER A, 1994, J CELL BIOL, V127, P1627, DOI 10.1083/jcb.127.6.1627; WEBER A, 1973, PHYSIOL REV, V53, P612, DOI 10.1152/physrev.1973.53.3.612; Weeds A, 1993, CURR OPIN CELL BIOL, V5, P63, DOI 10.1016/S0955-0674(05)80009-2; WEGNER A, 1979, J MOL BIOL, V131, P839, DOI 10.1016/0022-2836(79)90204-3; WOO MK, 1994, J CELL SCI, V107, P1359	21	146	148	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 7	1995	377	6544					83	86		10.1038/377083a0	http://dx.doi.org/10.1038/377083a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RT725	7544875				2022-12-24	WOS:A1995RT72500062
J	SRETAVAN, DW; PURE, E; SIEGEL, MW; REICHARDT, LF				SRETAVAN, DW; PURE, E; SIEGEL, MW; REICHARDT, LF			DISRUPTION OF RETINAL AXON INGROWTH BY ABLATION OF EMBRYONIC MOUSE OPTIC CHIASM NEURONS	SCIENCE			English	Article							SUBPLATE NEURONS; CONNECTIONS; OUTGROWTH; CELLS	Mouse retinal ganglion cell axons growing from the eye encounter embryonic neurons at the future site of the optic chiasm. After in vivo ablation of these chiasm neurons with a monoclonal antibody and complement, retinal axons did not cross the midline and stalled at approximately the entry site into the chiasm region. Thus, in the mouse, the presence of early-generated neurons that reside at the site of the future chiasm is required for formation of the optic chiasm by retinal ganglion cell axons.	WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104; GENENTECH INC,DEPT METAB & PHARMACOKINET,S SAN FRANCISCO,CA 94080; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,NEUROSCI PROGRAM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	The Wistar Institute; Roche Holding; Genentech; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	SRETAVAN, DW (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT OPHTHALMOL K107,NEUROSCI PROGRAM,10 KIRKHAM ST,SAN FRANCISCO,CA 94143, USA.				NATIONAL EYE INSTITUTE [R01EY010688] Funding Source: NIH RePORTER; NEI NIH HHS [EY10688] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; COLELLO RJ, 1990, DEVELOPMENT, V108, P515; DRAZBA J, 1990, DEV BIOL, V138, P82, DOI 10.1016/0012-1606(90)90178-L; EASTER SS, 1993, J NEUROSCI, V13, P285; GHOSH A, 1990, NATURE, V347, P179, DOI 10.1038/347179a0; GHOSH A, 1993, DEVELOPMENT, V117, P1031; GODEMENT P, 1990, NEURON, V5, P173, DOI 10.1016/0896-6273(90)90307-2; HENRY C, 1980, SELECTED METHODS CEL, P211; KLOSE M, 1989, SCIENCE, V245, P982, DOI 10.1126/science.2772651; LEMMON V, 1989, NEURON, V2, P1597, DOI 10.1016/0896-6273(89)90048-2; SCHLAGGAR BL, 1991, SCIENCE, V252, P1556, DOI 10.1126/science.2047863; SRETAVAN DW, 1994, NEURON, V12, P957, DOI 10.1016/0896-6273(94)90307-7; SRETAVAN DW, 1990, J NEUROSCI, V10, P1995; SRETAVAN DW, 1993, NEURON, V10, P761, DOI 10.1016/0896-6273(93)90176-R; SRETAVAN DW, UNPUB; STRITTMATTER SM, 1995, CELL, V80, P445, DOI 10.1016/0092-8674(95)90495-6; VANVACTOR D, 1993, CELL, V73, P1137, DOI 10.1016/0092-8674(93)90643-5; WILLIAMS RW, 1994, NATURE, V367, P637, DOI 10.1038/367637a0; WISENMANN A, 1993, DEVELOPMENT, V117, P725	19	70	70	0	2	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 7	1995	269	5220					98	101		10.1126/science.7541558	http://dx.doi.org/10.1126/science.7541558			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RG980	7541558				2022-12-24	WOS:A1995RG98000044
J	ROTH, S; NEUMANSILBERBERG, FS; BARCELO, G; SCHUPBACH, T				ROTH, S; NEUMANSILBERBERG, FS; BARCELO, G; SCHUPBACH, T			CORNICHON AND THE EGF RECEPTOR SIGNALING PROCESS ARE NECESSARY FOR BOTH ANTERIOR-POSTERIOR AND DORSAL-VENTRAL PATTERN-FORMATION IN DROSOPHILA	CELL			English	Article							FAINT-LITTLE-BALL; DORSOVENTRAL PATTERN; BICOID RNA; FEMALE GERMLINE; TGF-ALPHA; OOGENESIS; GENE; LOCALIZATION; MELANOGASTER; HOMOLOG	In Drosophila, the dorsal-ventral polarity of the egg chamber depends on the localization of the oocyte nucleus and the gurken RNA to the dorsal-anterior corner of the oocyte. Gurken protein presumably acts as a ligand for the Drosophila EGF receptor (torpedo/DER) expressed in the somatic follicle cells surrounding the oocyte. cornichon is a gene required in the germline for dorsal-ventral signaling, cornichon, gurken, and torpedo also function in an earlier signaling event that establishes posterior follicle cell fates and specifies the anterior-posterior polarity of the egg chamber. Mutations in all three genes prevent the formation of a correctly polarized microtubule cytoskeleton required for proper localization of the anterior and posterior determinants bicoid and oskar and for the asymmetric positioning of the oocyte nucleus.			ROTH, S (corresponding author), MAX PLANCK INST ENTWICKLUNGSBIOL,SPEMANNSTR 35-LL,D-72076 TUBINGEN,GERMANY.		Roth, Siegfried/E-8241-2010	Roth, Siegfried/0000-0001-5772-3558	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040558] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40558] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALPHEY L, 1992, CELL, V69, P977, DOI 10.1016/0092-8674(92)90616-K; ASHBURNER M, 1990, GENETICS, V126, P679; ASHBURNER M, 1989, DROSOPHILA LABORATOR; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; BROWER DL, 1981, J EMBRYOL EXP MORPH, V63, P233; CAROLL SB, 1985, CELL, V43, P47; CHOU TB, 1992, GENETICS, V131, P643; CHOU TB, 1993, DEVELOPMENT, V119, P1359; CLARK I, 1994, CURR BIOL, V4, P289, DOI 10.1016/S0960-9822(00)00068-3; CLIFFORD R, 1992, DEVELOPMENT, V115, P853; CLIFFORD RJ, 1989, GENETICS, V123, P771; DAWSON IA, 1995, J CELL BIOL, V129, P725, DOI 10.1083/jcb.129.3.725; ENDOW SA, 1994, EMBO J, V13, P2708, DOI 10.1002/j.1460-2075.1994.tb06561.x; EPHRUSSI A, 1991, CELL, V66, P23; ESHEL D, 1993, P NATL ACAD SCI USA, V90, P11172, DOI 10.1073/pnas.90.23.11172; FRASCH M, 1987, EMBO J, V6, P749, DOI 10.1002/j.1460-2075.1987.tb04817.x; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; GONZALEZREYES A, 1994, SCIENCE, V266, P639, DOI 10.1126/science.7939717; GROSSNIKLAUS U, 1989, DEVELOPMENT, V107, P189; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; KOCH EA, 1983, CELL TISSUE RES, V228, P21; KYTE J, 1982, J MOL BIOL, V157, P133; LANE ME, 1994, GENE DEV, V8, P2986, DOI 10.1101/gad.8.24.2986; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; Lehmann Ruth, 1995, Seminars in Developmental Biology, V6, P25, DOI 10.1016/S1044-5781(06)80082-4; LI YY, 1993, P NATL ACAD SCI USA, V90, P10096, DOI 10.1073/pnas.90.21.10096; Maniatis T, 1989, DECONTAMINATION DILU; MONTELL DJ, 1992, CELL, V71, P51, DOI 10.1016/0092-8674(92)90265-E; MORISATO D, 1994, CELL, V76, P677, DOI 10.1016/0092-8674(94)90507-X; MULLINS MC, 1989, GENE DEV, V3, P729, DOI 10.1101/gad.3.5.729; NEUMANSILBERBER.FS, 1993, CELL, V75, P165; POKRYWKA NJ, 1991, DEVELOPMENT, V113, P55; PRICE JV, 1989, CELL, V56, P1085, DOI 10.1016/0092-8674(89)90641-7; ROBERTSON HM, 1988, GENETICS, V118, P461; ROTH S, 1994, DEVELOPMENT, V120, P2245; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUOHOLA H, 1991, CELL, V66, P433, DOI 10.1016/0092-8674(81)90008-8; RUOHOLABAKER H, 1994, TRENDS GENET, V10, P89, DOI 10.1016/0168-9525(94)90231-3; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; SCHUPACH T, 1991, CELL-CELL INTERACTIONS IN EARLY DEVELOPMENT, P163; SCHUPBACH T, 1987, CELL, V49, P699, DOI 10.1016/0092-8674(87)90546-0; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; Spradling Allan C., 1993, P1; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THEURKAUF WE, 1993, DEVELOPMENT, V118, P1169, DOI 10.1016/0168-9525(93)90134-4; THEURKAUF WE, 1992, DEVELOPMENT, V115, P923; Thummel CS, 1992, DROS INF SERV, V71, P150; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Wieschaus E., 1986, P199	52	417	426	0	4	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 16	1995	81	6					967	978		10.1016/0092-8674(95)90016-0	http://dx.doi.org/10.1016/0092-8674(95)90016-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RD768	7540118	Bronze			2022-12-24	WOS:A1995RD76800017
J	DHEIN, J; WALCZAK, H; BAUMLER, C; DEBATIN, KM; KRAMMER, PH				DHEIN, J; WALCZAK, H; BAUMLER, C; DEBATIN, KM; KRAMMER, PH			AUTOCRINE T-CELL SUICIDE MEDIATED BY APO-1/(FAS/CD95)	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; MONOCLONAL-ANTIBODY; SURFACE ANTIGEN; MOLECULAR-CLONING; FAS ANTIGEN; APOPTOSIS; RECEPTOR; INDUCTION; MEMBER; MICE	THE APO-1/(Fas/CD95) cell surface receptor is a member of the nerve growth factor (NGF)/tumour necrosis factor (TNF) receptor superfamily and mediates apoptosis(1-4). Peripheral activated T cells (ATC) from lymphoproliferation (lpr/lpr) mutant mice that express a reduced number of APO-1 receptors have a defect in T-cell receptor (TCR)-induced apoptosis(5,6). This suggests that TCR-induced apoptosis involves APO-1. We tested this hypothesis in various human T cells: (1) malignant Jurkat cells, (2) an alloreactive T-cell clone (S13), and (3) peripheral ATC. TCR triggering through immobilized anti-CD3 antibodies or Staphylococcus enterotoxin B (SEB) superantigen induced expression of the APO-1 ligand and apoptosis in these cells. Anti-CD3-induced apoptosis of Jurkat cells was demonstrated even in single-cell cultures. In all cases apoptosis was substantially inhibited by blocking anti-APO-1 antibody fragments and soluble APO-I receptor decoys. The APO-1 ligand was found in the supernatant of activated Jurkat cells as a soluble cytokine. We propose that TCR-induced apoptosis in ATC can occur through an APO-1 ligand-mediated autocrine suicide. These results provide a mechanism for suppression of the immune response and for peripheral tolerance by T-cell deletion.	GERMAN CANC RES CTR,TUMORIMMUNOL PROGRAM,D-69120 HEIDELBERG,GERMANY; UNIV HEIDELBERG,CHILDRENS HOSP,D-69120 HEIDELBERG,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg			Walczak, Henning/AAV-2214-2020; Debatin, Klaus-Michael/J-9704-2014	Walczak, Henning/0000-0002-6312-4591; Debatin, Klaus-Michael/0000-0002-8397-1886; Dhein, Jens/0000-0002-7200-2967				DEBATIN KM, 1994, EUR J IMMUNOL, V24, P753, DOI 10.1002/eji.1830240339; DHEIN J, 1992, J IMMUNOL, V149, P3166; GILLETTEFERGUSO.I, 1994, EUR J IMMUNOL, V24, P1181; Haight F. A., 1967, HDB POISSON DISTRIBU; HANABUCHI S, 1994, P NATL ACAD SCI USA, V91, P4930, DOI 10.1073/pnas.91.11.4930; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JU ST, 1994, P NATL ACAD SCI USA, V91, P4185, DOI 10.1073/pnas.91.10.4185; KABELITZ D, 1989, J EXP MED, V170, P559, DOI 10.1084/jem.170.2.559; KLAS C, 1993, INT IMMUNOL, V5, P625, DOI 10.1093/intimm/5.6.625; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; LYNCH DH, 1994, IMMUNITY, V1, P131, DOI 10.1016/1074-7613(94)90106-6; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OEHM A, 1992, J BIOL CHEM, V267, P10709; PEPPEL K, 1991, J EXP MED, V174, P1483, DOI 10.1084/jem.174.6.1483; RAMSDELL F, 1994, EUR J IMMUNOL, V24, P928, DOI 10.1002/eji.1830240422; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; RUSSELL JH, 1993, P NATL ACAD SCI USA, V90, P4409, DOI 10.1073/pnas.90.10.4409; RUSSELL JH, 1993, EUR J IMMUNOL, V23, P2379, DOI 10.1002/eji.1830230951; STALDER T, 1994, J IMMUNOL, V152, P1127; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VIGNAUX F, 1994, EUR J IMMUNOL, V24, P923, DOI 10.1002/eji.1830240421; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	25	1570	1611	0	31	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 2	1995	373	6513					438	441		10.1038/373438a0	http://dx.doi.org/10.1038/373438a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE670	7530335				2022-12-24	WOS:A1995QE67000059
J	PREDKI, PF; NAYAK, LM; GOTTLIEB, MBC; REGAN, L				PREDKI, PF; NAYAK, LM; GOTTLIEB, MBC; REGAN, L			DISSECTING RNA-PROTEIN INTERACTIONS - RNA-RNA RECOGNITION BY ROP	CELL			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; COLE1 PLASMID REPLICATION; CRYSTAL-STRUCTURE; PRIMER TRANSCRIPT; STEM-LOOPS; BINDING; SYNTHETASE; RESOLUTION; DNA; IDENTIFICATION	The ColE1 plasmid of E. coli encodes a small RNA-binding protein, Rop, which is involved in the regulation of plasmid copy number, Rop, a 4-helix bundle protein, facilitates sense-antisense RNA pairing by binding to the transiently formed hairpin pairs of RNA I and the complementary RNA II. We have identified the residues of Rop that are involved in RNA recognition. The residues form a narrow stripe down one face of the bundle and are symmetrically arranged, with recognition centered about two phenylalanine residues. Our results suggest that these phenylalanine residues interact with the loop region of the hairpin pair, with additional interactions between eight polar residues and the phosphate backbone. By modifying the identity of residue 14, we have created a variant of Rop that displays altered RNA binding specificity. The results of our studies allow us to present a detailed picture of RNA-protein recognition in a novel model system.	YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06511	Yale University					NIGMS NIH HHS [GM49146, GM45340] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049146, R29GM049146] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHLEY CT, 1993, SCIENCE, V262, P563, DOI 10.1126/science.7692601; BANNER DW, 1987, J MOL BIOL, V196, P657, DOI 10.1016/0022-2836(87)90039-8; BHAT TN, 1982, J MOL BIOL, V158, P699, DOI 10.1016/0022-2836(82)90255-8; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; BRICK P, 1988, J MOL BIOL, V208, P83; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CASTAGNOLI L, 1989, EMBO J, V8, P621, DOI 10.1002/j.1460-2075.1989.tb03417.x; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; EBERLE W, 1991, Journal of Biomolecular NMR, V1, P71, DOI 10.1007/BF01874570; EBERLE W, 1990, BIOCHEMISTRY-US, V29, P7402, DOI 10.1021/bi00484a007; EGUCHI Y, 1991, J MOL BIOL, V220, P831, DOI 10.1016/0022-2836(91)90356-B; EGUCHI Y, 1990, CELL, V60, P199, DOI 10.1016/0092-8674(90)90736-X; FOLKERS PJM, 1991, EUR J BIOCHEM, V200, P139, DOI 10.1111/j.1432-1033.1991.tb21060.x; HEAPHY S, 1991, P NATL ACAD SCI USA, V88, P7366, DOI 10.1073/pnas.88.16.7366; ITOH T, 1980, P NATL ACAD SCI-BIOL, V77, P2450, DOI 10.1073/pnas.77.5.2450; JESSEN TH, 1991, EMBO J, V10, P3447, DOI 10.1002/j.1460-2075.1991.tb04909.x; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; LYU PC, 1990, SCIENCE, V260, P669; MERRILL BM, 1988, J BIOL CHEM, V263, P3307; MUNSON M, 1994, GENE, V144, P59, DOI 10.1016/0378-1119(94)90203-8; MUNSON M, 1994, IN PRESS PROT SCI; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; NICHOLLS A, 1991, PROTEIN-STRUCT FUNCT, V11, P282; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; POLISKY B, 1988, CELL, V55, P929, DOI 10.1016/0092-8674(88)90235-8; PRIGODICH RV, 1986, BIOCHEMISTRY-US, V25, P3666, DOI 10.1021/bi00360a029; RAUMANN BE, 1994, NATURE, V367, P754, DOI 10.1038/367754a0; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; RUTENBER E, 1993, PROT STRUCT FUNCT GE, V10, P240; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; SMITH CK, 1994, IN PRESS TECH PROT C; STEIF C, 1993, BIOCHEMISTRY-US, V32, P3867, DOI 10.1021/bi00066a005; TOMIZAWA J, 1984, CELL, V38, P861, DOI 10.1016/0092-8674(84)90281-2; TOMIZAWA J, 1984, CELL, V38, P871, DOI 10.1016/0092-8674(84)90282-4; TOMIZAWA J, 1981, CELL, V31, P575; ZELWER C, 1982, J MOL BIOL, V155, P63, DOI 10.1016/0022-2836(82)90492-2	45	90	91	0	5	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 13	1995	80	1					41	50		10.1016/0092-8674(95)90449-2	http://dx.doi.org/10.1016/0092-8674(95)90449-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QB910	7529141	hybrid			2022-12-24	WOS:A1995QB91000008
J	RESSLER, KJ; SULLIVAN, SL; BUCK, LB				RESSLER, KJ; SULLIVAN, SL; BUCK, LB			INFORMATION CODING IN THE OLFACTORY SYSTEM - EVIDENCE FOR A STEREOTYPED AND HIGHLY ORGANIZED EPITOPE MAP IN THE OLFACTORY-BULB	CELL			English	Article							ODORANT RECEPTOR EXPRESSION; FUNCTIONAL-ORGANIZATION; 2-DEOXYGLUCOSE METHOD; EPITHELIUM; NEURONS; RAT; PROJECTIONS; NERVES; CELLS; GENE	In the mammalian olfactory system, information from similar to 1000 different odorant receptor types is organized in the nose into four spatial zones. Each zone is a mosaic of randomly distributed neurons expressing different receptor types. in these studies, we have obtained evidence that information highly distributed in the nose is transformed in the olfactory bulb of the brain into a highly organized spatial map. We find that specific odorant receptor gene probes hybridize in situ to small, and distinct, subsets of olfactory bulb glomeruli. The spatial and numerical characteristics of the patterns of hybridization that we observe with different receptor probes indicate that, in the olfactory bulb, olfactory information undergoes a remarkable organization into a fine, and perhaps stereotyped, spatial map. In our view, this map is in essence an epitope map, whose similar to 1000 distinct components are used in a multitude of different combinations to discriminate a vast array of different odors.			RESSLER, KJ (corresponding author), HARVARD UNIV, SCH MED, DEPT NEUROBIOL, BOSTON, MA 02115 USA.		Ressler, Kerry J/N-8741-2018	Ressler, Kerry J/0000-0002-5158-1103	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [F32DC000188, R01DC001662] Funding Source: NIH RePORTER; NIDCD NIH HHS [1-RO1-DC01662-01, 5-F32-DC00188-01] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ADRIAN ED, 1950, BRIT MED BULL, V6, P330, DOI 10.1093/oxfordjournals.bmb.a073625; ALLISON AC, 1949, BRAIN, V72, P186, DOI 10.1093/brain/72.2.186; [Anonymous], [No title captured]; ASTIC L, 1983, DEV BRAIN RES, V10, P257, DOI 10.1016/0165-3806(83)90142-6; BRUNJES PC, 1994, BRAIN RES REV, V19, P146; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Buck LB, 1992, CURR OPIN GENET DEV, V2, P467, DOI 10.1016/S0959-437X(05)80159-5; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; CLARK WL, 1957, PROC R SOC SER B-BIO, V146, P299, DOI 10.1098/rspb.1957.0013; COOPERSMITH R, 1986, DEV BRAIN RES, V27, P191, DOI 10.1016/0165-3806(86)90245-2; COSTANZO RM, 1978, BRAIN RES, V139, P327, DOI 10.1016/0006-8993(78)90932-0; DANCIGER E, 1989, P NATL ACAD SCI USA, V86, P8565, DOI 10.1073/pnas.86.21.8565; DAVIS L, 1992, J NEUROSCI, V12, P4867; FIRESTEIN S, 1993, CIBA F SYMP, V179, P115; Gall JG, 1971, METHOD ENZYMOL, V21, P470; GIOIO AE, 1994, J NEUROCHEM, V63, P13; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GRAZIADEI PPC, 1986, NEUROSCIENCE, V19, P1025, DOI 10.1016/0306-4522(86)90119-3; GREER CA, 1981, BRAIN RES, V217, P279, DOI 10.1016/0006-8993(81)90004-4; GUTHRIE KM, 1993, P NATL ACAD SCI USA, V90, P3329, DOI 10.1073/pnas.90.8.3329; IMAMURA K, 1992, J NEUROPHYSIOL, V68, P1986, DOI 10.1152/jn.1992.68.6.1986; JOURDAN F, 1980, BRAIN RES, V188, P139, DOI 10.1016/0006-8993(80)90563-6; Kauer J.S., 1987, P205; KAUER JS, 1993, MICROSC RES TECHNIQ, V24, P157, DOI 10.1002/jemt.1070240207; KLEIMAN R, 1994, J NEUROSCI, V14, P1130, DOI 10.1523/JNEUROSCI.14-03-01130.1994; LANCET D, 1993, CURR BIOL, V3, P668, DOI 10.1016/0960-9822(93)90064-U; LAND LJ, 1973, BRAIN RES, V63, P153, DOI 10.1016/0006-8993(73)90084-X; LAW MI, 1981, J NEUROSCI, V1, P741, DOI 10.1523/JNEUROSCI.01-07-00741.1981; LEVAY S, 1980, J COMP NEUROL, V191, P1, DOI 10.1002/cne.901910102; LEVY NS, 1991, J STEROID BIOCHEM, V39, P633, DOI 10.1016/0960-0760(91)90262-4; MACKAYSIM A, 1991, EUR J NEUROSCI, V3, P209, DOI 10.1111/j.1460-9568.1991.tb00081.x; MONTIGRAZIADEI GA, 1980, NEUROSCIENCE, V5, P1239; MORI K, 1992, J NEUROPHYSIOL, V67, P786, DOI 10.1152/jn.1992.67.3.786; MORI K, 1994, SEMIN CELL BIOL, V13, P771; NEF P, 1992, P NATL ACAD SCI USA, V89, P8948, DOI 10.1073/pnas.89.19.8948; NGAI J, 1993, CELL, V72, P667, DOI 10.1016/0092-8674(93)90396-8; ONODA N, 1992, NEUROSCI LETT, V137, P157, DOI 10.1016/0304-3940(92)90393-L; PINCHING AJ, 1971, J CELL SCI, V8, P253; PINCHING AJ, 1974, BRAIN RES, V82, P195, DOI 10.1016/0006-8993(74)90598-8; POMEROY SL, 1990, J NEUROSCI, V10, P1952; Reed Randall R., 1994, Seminars in Cell Biology, V5, P33, DOI 10.1006/scel.1994.1005; Ressler Kerry J., 1994, Current Opinion in Neurobiology, V4, P588, DOI 10.1016/0959-4388(94)90061-2; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; ROYET JP, 1988, J COMP NEUROL, V270, P559, DOI 10.1002/cne.902700409; SALLAZ M, 1993, NEUROREPORT, V4, P55, DOI 10.1097/00001756-199301000-00014; SASSOON DA, 1988, DEVELOPMENT, V104, P155; SAUCIER D, 1986, BRAIN RES BULL, V16, P455, DOI 10.1016/0361-9230(86)90173-5; SCHOENFELD TA, 1994, BRAIN RES BULL, V34, P183, DOI 10.1016/0361-9230(94)90059-0; SCHWARTING GA, 1991, BRAIN RES, V547, P239, DOI 10.1016/0006-8993(91)90967-Z; SCHWOB JE, 1986, J NEUROSCI, V6, P3393; SCOTT JW, 1993, MICROSC RES TECHNIQ, V24, P142, DOI 10.1002/jemt.1070240206; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; Shepherd G. M., 1988, NEUROBIOLOGY; Shepherd G. M., 1990, SYNAPTIC ORG BRAIN, P133; SHEPHERD GM, 1994, NEURON, V13, P771, DOI 10.1016/0896-6273(94)90245-3; SICARD G, 1984, BRAIN RES, V292, P283, DOI 10.1016/0006-8993(84)90764-9; SKUTELLA T, 1994, MOL BRAIN RES, V23, P179, DOI 10.1016/0169-328X(94)90224-0; STEWARD O, 1992, TRENDS NEUROSCI, V15, P180, DOI 10.1016/0166-2236(92)90170-D; STEWART WB, 1979, J COMP NEUROL, V185, P715, DOI 10.1002/cne.901850407; STEWART WB, 1987, BRAIN RES, V411, P248, DOI 10.1016/0006-8993(87)91076-6; STONE DM, 1991, J COMP NEUROL, V311, P223, DOI 10.1002/cne.903110205; STROTMANN J, 1994, CELL TISSUE RES, V278, P11, DOI 10.1007/s004410050189; STROTMANN J, 1992, NEUROREPORT, V3, P1053, DOI 10.1097/00001756-199212000-00005; UDIN SB, 1988, ANNU REV NEUROSCI, V11, P289, DOI 10.1146/annurev.ne.11.030188.001445; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; WALTER J, 1987, DEVELOPMENT, V101, P685	66	924	940	1	59	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 30	1994	79	7					1245	1255		10.1016/0092-8674(94)90015-9	http://dx.doi.org/10.1016/0092-8674(94)90015-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PZ860	7528109				2022-12-24	WOS:A1994PZ86000015
J	BLUMBERGS, PC; SCOTT, G; MANAVIS, J; WAINWRIGHT, H; SIMPSON, DA; MCLEAN, AJ				BLUMBERGS, PC; SCOTT, G; MANAVIS, J; WAINWRIGHT, H; SIMPSON, DA; MCLEAN, AJ			STAINING OF AMYLOID PRECURSOR PROTEIN TO STUDY AXONAL DAMAGE IN MILD HEAD-INJURY	LANCET			English	Note							DEGENERATION	The most common definition of cerebral concussion is that of a transient loss of neurological function without macroscopic or microscopic abnormality in the brain. However, some patients have persistent symptoms and subtle neuropsychological deficits, particularly affecting memory. We have studied five patients aged 59-89 years who sustained mild concussive head injury and died of other causes (2-99 days post-injury). Immunostaining with an antibody to amyloid precursor protein, a marker oi fast axonal transport, showed multifocal axonal injury in all five. All had axonal damage in the fornices, which are important in memory function.	UNIV ADELAIDE,NHMRC RD ACCID RES UNIT,ADELAIDE,SA,AUSTRALIA	University of Adelaide	BLUMBERGS, PC (corresponding author), INST MED & VET SCI,NEUROPATHOL LAB,POB 14,ADELAIDE,SA 5001,AUSTRALIA.							Amaral D. G., 1987, HDB PHYSL NERVOUS SY, P211; GALE SD, 1993, BRAIN RES BULL, V32, P345, DOI 10.1016/0361-9230(93)90198-K; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GRONWALL D, 1974, LANCET, V2, P605; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; RYAN GA, 1994, J TRAUMA, V36, P469	10	360	368	0	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 15	1994	344	8929					1055	1056		10.1016/S0140-6736(94)91712-4	http://dx.doi.org/10.1016/S0140-6736(94)91712-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL852	7523810				2022-12-24	WOS:A1994PL85200012
J	SABATINI, DM; ERDJUMENTBROMAGE, H; LUI, M; TEMPST, P; SNYDER, SH				SABATINI, DM; ERDJUMENTBROMAGE, H; LUI, M; TEMPST, P; SNYDER, SH			RAFT1 - A MAMMALIAN PROTEIN THAT BINDS TO FKBP12 IN A RAPAMYCIN-DEPENDENT FASHION AND IS HOMOLOGOUS TO YEAST TORS	CELL			English	Article							PEPTIDYL-PROLYL ISOMERASE; CALCIUM-RELEASE CHANNEL; CYCLOSPORINE-A; SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL KINASE; SACCHAROMYCES-CEREVISIAE; IMMUNOSUPPRESSANT FK506; FK-506-BINDING PROTEIN; MOLECULAR-CLONING; SEQUENCE-ANALYSIS	The immunosuppressants rapamycin and FK506 bind to the same intracellular protein, the immunophilin FKBP12. The FKBP12-FK506 complex interacts with and inhibits the Ca2+-activated protein phosphatase calcineurin. The target of the FKBP12-rapamycin complex has not yet been identified. We report that a protein complex containing 245 kDa and 35 kDa components, designated rapamycin and FKBP12 targets 1 and 2 (RAFT1 and RAFT2), interacts with FKBP12 in a rapamycin-dependent manner. Sequences (330 amino acids total) of tryptic peptides derived from the 245 kDa RAFT1 reveal striking homologies to the yeast TOR gene products, which were originally identified by mutations that confer rapamycin resistance in yeast. A RAFT1 cDNA was obtained and found to encode a 289 kDa protein (2549 amino acids) that is 43% and 39% identical to TOR2 and TOR1, respectively. We propose that RAFT1 is the direct target of FKBP12-rapamycin and a mammalian homolog of the TOR proteins.	MEM SLOAN KETTERING CANC CTR, PROGRAM MOLEC BIOL, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center	SABATINI, DM (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROSCI, BALTIMORE, MD 21205 USA.			Erdjument-Bromage, Hediye/0000-0003-0224-3594; /0000-0002-1446-7256	NIDA NIH HHS [DA-00074, DA-00266] Funding Source: Medline; NIGMS NIH HHS [GM-07309] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA000266] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ALBERS MW, 1993, J BIOL CHEM, V268, P22825; ALTIN JG, 1991, J BIOL CHEM, V266, P5401; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BALLA T, 1994, MOL BIOL CELL, V5, P17, DOI 10.1091/mbc.5.1.17; BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BLANAR MA, 1992, NATURE, V256, P1014; BOREL JF, 1986, PROG ALLERGY, V38, P9; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; DUMONT FJ, 1990, J IMMUNOL, V144, P251; ELICONE C, 1994, IN PRESS J CHROMATOG, V676; ERDJUMENTBROMAG.H, 1993, TECHNIQUES PROTEIN C, V4, P419; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FRUMAN DA, 1994, FASEB J, V8, P391, DOI 10.1096/fasebj.8.6.7513288; GEROMANOS S, 1994, TECHNIQUES PROTEIN C, V5, P143; GOULD SJ, 1989, P NATL ACAD SCI USA, V86, P1934, DOI 10.1073/pnas.86.6.1934; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HEITMAN J, 1991, P NATL ACAD SCI USA, V88, P1948, DOI 10.1073/pnas.88.5.1948; HEITMAN J, 1992, NEW BIOL, V4, P448; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; JAYARAMAN T, 1993, J BIOL CHEM, V268, P25385; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; JIN YJ, 1992, J BIOL CHEM, V267, P10942; KINO T, 1987, J ANTIBIOT, V40, P1249, DOI 10.7164/antibiotics.40.1249; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRONKE M, 1984, P NATL ACAD SCI-BIOL, V81, P5214, DOI 10.1073/pnas.81.16.5214; KUNZ J, 1993, TRENDS BIOCHEM SCI, V18, P334, DOI 10.1016/0968-0004(93)90069-Y; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1993, TRENDS PHARMACOL SCI, V14, P182, DOI 10.1016/0165-6147(93)90206-Y; MARTEL RR, 1977, CAN J PHYSIOL PHARM, V55, P48, DOI 10.1139/y77-007; McCombie W R, 1992, DNA Seq, V2, P289, DOI 10.3109/10425179209030961; MORICE WG, 1993, J BIOL CHEM, V268, P22737; Sambrook J., 1989, MOL CLONING LAB MANU; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674a0; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; STEINER JP, 1992, NATURE, V358, P584, DOI 10.1038/358584a0; TEMPST P, 1989, ANAL BIOCHEM, V183, P290, DOI 10.1016/0003-2697(89)90482-X; TEMPST P, 1990, ELECTROPHORESIS, V11, P537, DOI 10.1002/elps.1150110704; TIMERMAN AP, 1993, J BIOL CHEM, V268, P22992; TROPSCHUG M, 1989, NATURE, V342, P953, DOI 10.1038/342953a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0	54	1183	1250	3	54	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 15	1994	78	1					35	43		10.1016/0092-8674(94)90570-3	http://dx.doi.org/10.1016/0092-8674(94)90570-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NX328	7518356				2022-12-24	WOS:A1994NX32800006
J	DELASALLE, H; HANAU, D; FRICKER, D; URLACHER, A; KELLY, A; SALAMERO, J; POWIS, SH; DONATO, L; BAUSINGER, H; LAFORET, M; JERAS, M; SPEHNER, D; BIEBER, T; FALKENRODT, A; CAZENAVE, JP; TROWSDALE, J; TONGIO, MM				DELASALLE, H; HANAU, D; FRICKER, D; URLACHER, A; KELLY, A; SALAMERO, J; POWIS, SH; DONATO, L; BAUSINGER, H; LAFORET, M; JERAS, M; SPEHNER, D; BIEBER, T; FALKENRODT, A; CAZENAVE, JP; TROWSDALE, J; TONGIO, MM			HOMOZYGOUS HUMAN TAP PEPTIDE TRANSPORTER MUTATION IN HLA CLASS-I DEFICIENCY	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; PRIMERS PCR-SSP; T-CELLS; COMBINED IMMUNODEFICIENCY; DEFECTIVE EXPRESSION; ANTIGEN PRESENTATION; BARE LYMPHOCYTE; SURFACE; REGION; MICE	Human lymphocyte antigen (HLA) class I proteins of the major histocompatibility complex are largely dependent for expression on small peptides supplied to them by transporter associated with antigen processing (TAP) protein. An inherited human deficiency in the TAP transporter was identified in two siblings suffering from recurrent respiratory bacterial infections. The expression on the cell surface of class I proteins was very low, whereas that of CD1a was normal, and the cytotoxicity of natural killer cells was affected. In addition, CD8(+) alpha beta T cells were present in low but significant numbers and were cytotoxic in the most severely affected sibling, who also showed an increase in CD4(+)CD8(+) T cells and gamma delta T cells.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND; INST CURIE,INSERM,U255,F-75231 PARIS,FRANCE; UNIV STRASBOURG,HOP HAUTEPIERRE,SERV PEDIAT,F-67098 STRASBOURG,FRANCE; UNIV STRASBOURG 1,INSERM,U74,F-67085 STRASBOURG,FRANCE; UNIV STRASBOURG 1,SYNTHELABO,FAC MED,COMMUN LAB,F-67085 STRASBOURG,FRANCE; CTR REG TRANSFUS SANGUINE,HEMATOL NORMALE & PATHOL LAB,F-67085 STRASBOURG,FRANCE; CTR REG TRANSFUS SANGUINE,INSERM,U311,F-67085 STRASBOURG,FRANCE	Cancer Research UK; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Sanofi-Aventis; Sanofi France; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	DELASALLE, H (corresponding author), CTR REG TRANSFUS SANGUINE,HISTOCOMPATIBIL LAB,F-67085 STRASBOURG,FRANCE.		Cazenave, Jean-Pierre/AAE-2935-2019; De La Salle, Henri/H-9353-2016	De La Salle, Henri/0000-0001-5136-0776; salamero, jean/0000-0002-2610-5826				APASOV S, 1993, P NATL ACAD SCI USA, V90, P2837, DOI 10.1073/pnas.90.7.2837; BAHRAM S, 1991, P NATL ACAD SCI USA, V88, P10094, DOI 10.1073/pnas.88.22.10094; BECK S, 1992, J MOL BIOL, V228, P433, DOI 10.1016/0022-2836(92)90832-5; BERGER AE, 1982, HYBRIDOMA, V1, P87, DOI 10.1089/hyb.1.1982.1.87; BIEBER T, 1989, J INVEST DERMATOL, V93, P215, DOI 10.1111/1523-1747.ep12277574; BIRON CA, 1989, NEW ENGL J MED, V320, P1731, DOI 10.1056/NEJM198906293202605; BIRON CA, 1988, NAT IMMUN CELL GROW, V7, P47; BROWNING MJ, 1993, P NATL ACAD SCI USA, V90, P2842, DOI 10.1073/pnas.90.7.2842; DELASALLE H, UNPUB; DIBRINO M, 1993, P NATL ACAD SCI USA, V90, P1508, DOI 10.1073/pnas.90.4.1508; DOHERTY PC, 1993, CURR OPIN IMMUNOL, V5, P479, DOI 10.1016/0952-7915(93)90026-O; FURUKAWA S, 1992, BLOOD, V80, P3253; GLAS R, 1994, J EXP MED, V179, P661, DOI 10.1084/jem.179.2.661; GLYNNE R, 1993, EUR J IMMUNOL, V23, P860, DOI 10.1002/eji.1830230414; GROH V, 1989, J EXP MED, V169, P1277, DOI 10.1084/jem.169.4.1277; HAMMOND SA, 1993, NATURE, V364, P158, DOI 10.1038/364158a0; HANNET I, 1992, IMMUNOL TODAY, V13, P215, DOI 10.1016/0167-5699(92)90157-3; HEEMELS MT, 1993, CURR BIOL, V3, P380, DOI 10.1016/0960-9822(93)90208-6; KELLY A, 1991, NATURE, V353, P667, DOI 10.1038/353667a0; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; Kimura A., 1991, HLA 1991 P 11 INT HI, VVolume 1, P397; LAMOUSESMITH E, 1993, J IMMUNOL, V151, P6283; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MAEDA H, 1985, IMMUNOGENETICS, V21, P549, DOI 10.1007/BF00395879; MARCADET A, 1985, NEW ENGL J MED, V312, P1287, DOI 10.1056/NEJM198505163122004; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; MURPHY GF, 1983, BRIT J DERMATOL, V108, P423, DOI 10.1111/j.1365-2133.1983.tb04594.x; NEEFJES JJ, 1986, HUM IMMUNOL, V16, P169, DOI 10.1016/0198-8859(86)90046-7; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; OLERUP O, 1993, TISSUE ANTIGENS, V41, P119, DOI 10.1111/j.1399-0039.1993.tb01991.x; OTTEN GR, 1992, J IMMUNOL, V148, P3723; PAYNE R, 1983, HUM IMMUNOL, V6, P219, DOI 10.1016/0198-8859(83)90095-2; PFEIFER JD, 1993, NATURE, V361, P359, DOI 10.1038/361359a0; PORCELLI S, 1992, NATURE, V360, P593, DOI 10.1038/360593a0; POWIS SH, 1992, P NATL ACAD SCI USA, V89, P1463, DOI 10.1073/pnas.89.4.1463; RAULET DH, 1994, ADV IMMUNOL, V55, P381; RITTIG MG, 1994, INT ARCH ALLERGY IMM, V103, P4, DOI 10.1159/000236598; ROCK KL, 1991, P NATL ACAD SCI USA, V88, P4200, DOI 10.1073/pnas.88.10.4200; SALA P, 1993, BLOOD, V82, P1546; SCHUURMAN RKB, 1979, CLIN IMMUNOL IMMUNOP, V14, P418, DOI 10.1016/0090-1229(79)90094-1; SEAMAN WE, 1981, J CLIN INVEST, V67, P1324, DOI 10.1172/JCI110161; SHEPHERD JC, 1993, CELL, V74, P577, DOI 10.1016/0092-8674(93)80058-M; SUGIYAMA Y, 1986, CHEST, V89, P398, DOI 10.1378/chest.89.3.398; Sugiyama Y, 1989, Nihon Kyobu Shikkan Gakkai Zasshi, V27, P980; TERASAKI PI, 1964, NATURE, V204, P998, DOI 10.1038/204998b0; TIERCY JM, 1991, TRANSPLANTATION, V51, P1110, DOI 10.1097/00007890-199105000-00034; TONGIO MM, UNPUB; TOURAINE JL, 1978, J PEDIATR-US, V93, P47, DOI 10.1016/S0022-3476(78)80598-8; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; VANKAER L, 1992, CELL, V71, P1205, DOI 10.1016/S0092-8674(05)80068-6; VARDAL F, 1986, TISSUE ANTIGENS, V28, P301; ZETTERQUIST H, 1992, HUM IMMUNOL, V34, P64, DOI 10.1016/0198-8859(92)90086-3; ZIJILSTA M, 1992, J EXP MED, V175, P885; 1980, TISSUE ANTIGENS, V16, P335	54	252	255	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 8	1994	265	5169					237	241		10.1126/science.7517574	http://dx.doi.org/10.1126/science.7517574			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV957	7517574				2022-12-24	WOS:A1994NV95700038
J	PATTISON, J; NELSON, PJ; HUIE, P; VONLEUTTICHAU, I; FARSHID, G; SIBLEY, RK; KRENSKY, AM				PATTISON, J; NELSON, PJ; HUIE, P; VONLEUTTICHAU, I; FARSHID, G; SIBLEY, RK; KRENSKY, AM			RANTES CHEMOKINE EXPRESSION IN CELL-MEDIATED TRANSPLANT REJECTION OF THE KIDNEY	LANCET			English	Note							MONOCLONAL-ANTIBODIES; FAMILY	RANTES (regulated upon activation, normal T cell expressed and secreted) is a chemotactic cytokine (a chemokine) for memory T lymphocytes, monocytes, and eosinophils. RANTES expression was studied in renal allograft biopsy specimens. Although RANTES was not expressed in samples,taken one hour after transplantation, or in native renal biopsy specimens from patients with cyclosporin nephrotoxicity, it was expressed during cell-mediated transplant rejection. RANTES mRNA was detected in infiltrating mononuclear cells and renal tubular epithelium, and RANTES protein was localised to mononuclear cells, tubular epithelium, and vascular endothelium. This suggests RANTES has a role in allograft rejection.	STANFORD UNIV,MED CTR,DEPT PATHOL,STANFORD,CA 94305	Stanford University	PATTISON, J (corresponding author), STANFORD UNIV,MED CTR,DEPT PEDIAT,STANFORD,CA 94305, USA.		Krensky, Alan/F-7956-2011					BISHOP GA, 1986, KIDNEY INT, V29, P708, DOI 10.1038/ki.1986.56; CHLEQDESCHAMPS CM, 1993, BLOOD, V81, P293; HEEGER P, 1992, KIDNEY INT, V41, P220, DOI 10.1038/ki.1992.31; MCCAUGHAN GW, 1990, HEPATOLOGY, V12, P1305, DOI 10.1002/hep.1840120610; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; RATHANASWAMI P, 1993, J BIOL CHEM, V268, P5834; ROT A, 1993, EUR J IMMUNOL, V23, P303, DOI 10.1002/eji.1830230150; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHALL TJ, 1988, J IMMUNOL, V141, P1018; TAUB DD, 1993, SCIENCE, V260, P355, DOI 10.1126/science.7682337	10	255	267	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 22	1994	343	8891					209	211		10.1016/S0140-6736(94)90992-X	http://dx.doi.org/10.1016/S0140-6736(94)90992-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT332	7507196				2022-12-24	WOS:A1994MT33200011
J	RENAUD, JP; ROCHEL, N; RUFF, M; VIVAT, V; CHAMBON, P; GRONEMEYER, H; MORAS, D				RENAUD, JP; ROCHEL, N; RUFF, M; VIVAT, V; CHAMBON, P; GRONEMEYER, H; MORAS, D			CRYSTAL-STRUCTURE OF THE RAR-GAMMA LIGAND-BINDING DOMAIN BOUND TO ALL-TRANS-RETINOIC ACID	NATURE			English	Article							NUCLEAR RECEPTOR; IDENTIFICATION; ACTIVATION; DNA	The 2.0-Angstrom crystal structure of the ligand-binding domain (LED) of the human retinoic acid receptor (RAR)-gamma bound to all-trans retinoic acid reveals the ligand-binding interactions and suggests an electrostatic guidance mechanism. The overall fold is similar to that of the human RXR-alpha apo-LBD, except for the carboxy-terminal part which folds back towards the LED core, contributing to the hydrophobic ligand pocket and 'sealing' its entry site. We propose a 'mouse trap' mechanism whereby a ligand-induced conformational transition repositions the amphipathic alpha-helix of the AF-2 activating domain and forms a transcriptionally active receptor.	UNIV STRASBOURG 1,COLL FRANCE,CNRS,INSERM,INST GENET & BIOL MOLEC & CELLULAIRE,F-67404 ILLKIRCH GRAFFENS,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Gronemeyer, Hinrich/G-6240-2011; Gronemeyer, Hinrich/AAH-5575-2019; Gronemeyer, Hinrich/H-7002-2016; Renaud, Jean-Paul/AAM-4879-2020; Rochel, Natacha/A-5718-2016; ruff, marc/J-3011-2013	Gronemeyer, Hinrich/0000-0001-9454-2449; Gronemeyer, Hinrich/0000-0001-9454-2449; Gronemeyer, Hinrich/0000-0001-9454-2449; Renaud, Jean-Paul/0000-0001-9180-5426; Rochel, Natacha/0000-0002-3573-5889; ruff, marc/0000-0001-5451-6377				ALLENBY G, 1994, J BIOL CHEM, V269, P16689; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BAUR EV, IN PRESS EMBO J; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, X PLOR VERSION 3 1; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GRONEMEYER H, 1995, NATURE, V375, P190, DOI 10.1038/375190a0; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOSEPH D, 1990, SCIENCE, V249, P1425, DOI 10.1126/science.2402636; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KLEYWEGT GJ, 1994, STRUCTURE, V2, P1241, DOI 10.1016/S0969-2126(94)00125-1; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LEID M, 1994, J BIOL CHEM, V269, P14175; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LENG XH, 1995, MOL CELL BIOL, V15, P255, DOI 10.1128/MCB.15.1.255; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NEWCOMER ME, 1993, STRUCTURE, V1, P7, DOI 10.1016/0969-2126(93)90004-Z; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OSTROWSKI J, 1995, P NATL ACAD SCI USA, V92, P1812, DOI 10.1073/pnas.92.6.1812; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; TAIRIS N, 1994, J BIOL CHEM, V269, P19516; TATE BF, 1995, J BIOL CHEM, V270, P20258, DOI 10.1074/jbc.270.35.20258; WURTZ JM, IN PRESS NATURE STRU; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P	49	987	1003	4	44	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 14	1995	378	6558					681	689		10.1038/378681a0	http://dx.doi.org/10.1038/378681a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK379	7501014				2022-12-24	WOS:A1995TK37900042
J	MEISTER, M; LAGNADO, L; BAYLOR, DA				MEISTER, M; LAGNADO, L; BAYLOR, DA			CONCERTED SIGNALING BY RETINAL GANGLION-CELLS	SCIENCE			English	Article							ROD OUTER SEGMENTS; TIGER SALAMANDER; X-CELL; Y-CELL; GOLDFISH; NEURONS; NOISE; INPUTS	To analyze the rules that govern communication between eye and brain, visual responses were recorded from an intact salamander retina. Parallel observation of many retinal ganglion cells with a microelectrode array showed that nearby neurons often fired synchronously, with spike delays of less than 10 milliseconds. The frequency of such synchronous spikes exceeded the correlation expected from a shared visual stimulus up to 20-fold. Synchronous firing persisted under a variety of visual stimuli and accounted for the majority of action potentials recorded. Analysis of receptive fields showed that concerted spikes encoded information not carried by individual cells; they may represent symbols in a multineuronal code for vision.	STANFORD UNIV,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305	Stanford University	MEISTER, M (corresponding author), HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,16 DIVIN AVE,CAMBRIDGE,MA 02138, USA.			Meister, Markus/0000-0003-2136-6506	NATIONAL EYE INSTITUTE [R01EY010020, R01EY001543, R37EY001543] Funding Source: NIH RePORTER; NEI NIH HHS [EY01543, EY05750, EY10020] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AHO AC, 1988, NATURE, V334, P348, DOI 10.1038/334348a0; ARNETT D, 1981, J PHYSIOL-LONDON, V317, P29, DOI 10.1113/jphysiol.1981.sp013812; ARNETT DW, 1978, EXP BRAIN RES, V32, P49; Aticky JJ, 2011, NETWORK-COMP NEURAL, V22, P4, DOI [10.1088/0954-898X/3/2/009, 10.3109/0954898X.2011.638888]; Barlow H B, 1971, Vision Res, VSuppl 3, P87; Barlow HB, 1961, SENS COMMUN, P217, DOI DOI 10.7551/MITPRESS/9780262518420.003.0013; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P589; BAYLOR DA, 1980, J PHYSIOL-LONDON, V309, P591, DOI 10.1113/jphysiol.1980.sp013529; BUCHSBAUM G, 1983, PROC R SOC SER B-BIO, V220, P89, DOI 10.1098/rspb.1983.0090; FIELD DJ, 1987, J OPT SOC AM A, V4, P2379, DOI 10.1364/JOSAA.4.002379; GHOSE GM, 1994, J NEUROPHYSIOL, V71, P330, DOI 10.1152/jn.1994.71.1.330; GINSBURG KS, 1984, J PHYSIOL-LONDON, V351, P433, DOI 10.1113/jphysiol.1984.sp015254; GLICKMAN RD, 1982, BRAIN RES, V234, P81, DOI 10.1016/0006-8993(82)90474-7; GUILOFF GD, 1992, VISION RES, V32, P2023, DOI 10.1016/0042-6989(92)90063-O; JOHNSEN JA, 1983, J PHYSIOL-LONDON, V345, P439, DOI 10.1113/jphysiol.1983.sp014987; MAPLE BR, 1994, VISION RES, V34, P2357, DOI 10.1016/0042-6989(94)90281-X; MASLAND RH, 1984, PROC R SOC SER B-BIO, V223, P121, DOI 10.1098/rspb.1984.0086; MASTRONARDE DN, 1983, J NEUROPHYSIOL, V49, P303, DOI 10.1152/jn.1983.49.2.303; MASTRONARDE DN, 1983, J NEUROPHYSIOL, V49, P325, DOI 10.1152/jn.1983.49.2.325; MASTRONARDE DN, 1983, J NEUROPHYSIOL, V49, P350, DOI 10.1152/jn.1983.49.2.350; MEISTER M, 1994, J NEUROSCI METH, V51, P95, DOI 10.1016/0165-0270(94)90030-2; MEISTER M, IN PRESS P NATL ACAD; MILLAR T, 1985, NEUROSCI LETT, V61, P311, DOI 10.1016/0304-3940(85)90482-3; MOORE GP, 1970, BIOPHYS J, V10, P876, DOI 10.1016/S0006-3495(70)86341-X; SAKAI HM, 1990, J NEUROPHYSIOL, V63, P105, DOI 10.1152/jn.1990.63.1.105; SCHNITZER MJ, UNPUB; VANEY DI, 1994, PROG RETIN EYE RES, V13, P301, DOI 10.1016/1350-9462(94)90014-0; WERBLIN F, 1988, VISUAL NEUROSCI, V1, P317, DOI 10.1017/S0952523800001978; WUNK DF, 1979, J GEN PHYSIOL, V73, P265, DOI 10.1085/jgp.73.3.265	29	286	292	1	15	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 17	1995	270	5239					1207	1210		10.1126/science.270.5239.1207	http://dx.doi.org/10.1126/science.270.5239.1207			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE905	7502047				2022-12-24	WOS:A1995TE90500059
J	FENG, GP; DEAK, P; CHOPRA, M; HALL, LM				FENG, GP; DEAK, P; CHOPRA, M; HALL, LM			CLONING AND FUNCTIONAL-ANALYSIS OF TIPE, A NOVEL MEMBRANE-PROTEIN THAT ENHANCES DROSOPHILA PARA SODIUM-CHANNEL FUNCTION	CELL			English	Article							TEMPERATURE-SENSITIVE MUTATIONS; CYCLOPHILIN HOMOLOG NINAA; CIS-TRANS ISOMERASE; A-BINDING-PROTEIN; RAT-BRAIN; RETINOTECTAL PROJECTION; SEQUENCE-ANALYSIS; NERVE-CONDUCTION; SKELETAL-MUSCLE; GENE	Voltage-dependent sodium channels are involved in the initiation and propagation of action potentials in many excitable cells. Here we report that tipE, a gene defined by a temperature-sensitive paralytic mutation in Drosophila, encodes a novel integral membrane protein that dramatically stimulates functional expression in Xenopus oocytes of the Drosophila sodium channel a subunit encoded by the paralytic (para) locus. Using a heat shock promoter to control tipE(+) gene expression in transgenic flies, we demonstrate that tipE(+) gene expression is required during pupal development to rescue adult paralysis. In addition, we demonstrate a role for the tipE gene product in adults.	SUNY BUFFALO,DEPT BIOCHEM PHARMACOL,BUFFALO,NY 14260	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo			Deák, Péter/M-5674-2018; Deak, Peter/F-7751-2012; Feng, Guoping/Y-2827-2019	Deak, Peter/0000-0002-8849-0352	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016204] Funding Source: NIH RePORTER; NINDS NIH HHS [NS16204] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ashburner M., 1978, GENETICS BIOL DROS A, P1; AURON PE, 1987, BIOTECHNIQUES, V5, P672; BEZANILLA F, 1977, J GEN PHYSIOL, V70, P549, DOI 10.1085/jgp.70.5.549; BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; BROADIE K, 1993, NEURON, V11, P607, DOI 10.1016/0896-6273(93)90073-Z; BURG MG, 1993, J NEUROBIOL, V24, P803, DOI 10.1002/neu.480240608; CATTERALL WA, 1992, PHYSIOL REV, V72, pS15, DOI 10.1152/physrev.1992.72.suppl_4.S15; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FAWCETT JW, 1985, TRENDS NEUROSCI, V8, P201, DOI 10.1016/0166-2236(85)90079-7; FENG GP, 1995, GENETICS, V139, P1679; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GANETZKY B, 1986, J NEUROGENET, V3, P19, DOI 10.3109/01677068609106892; GAUTRON S, 1992, P NATL ACAD SCI USA, V89, P7272, DOI 10.1073/pnas.89.15.7272; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; Hille B., 1992, IONIC CHANNELS EXCIT; HODGES D, 1994, ADV GENET, V31, P207, DOI 10.1016/S0065-2660(08)60399-5; HONG CS, 1994, J NEUROSCI, V14, P5160; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; ISOM LL, 1994, NEURON, V12, P1183, DOI 10.1016/0896-6273(94)90436-7; ITOH N, 1985, DROS INF SERVICE, V61, P89; JACKSON FR, 1985, J NEUROSCI, V5, P1144; JACKSON FR, 1986, J NEUROGENET, V3, P1, DOI 10.3109/01677068609106891; JACKSON FR, 1984, NATURE, V308, P189, DOI 10.1038/308189a0; KALLEN RG, 1990, NEURON, V4, P233, DOI 10.1016/0896-6273(90)90098-Z; KAYANO T, 1988, FEBS LETT, V228, P187, DOI 10.1016/0014-5793(88)80614-8; KERNAN MJ, 1991, CELL, V66, P949, DOI 10.1016/0092-8674(91)90440-A; KOBAYASHI T, 1990, DEV BRAIN RES, V57, P29, DOI 10.1016/0165-3806(90)90181-W; KRAFTE DS, 1988, J NEUROSCI, V8, P2859; KULKARNI SJ, 1982, GENET RES, V40, P191, DOI 10.1017/S0016672300019054; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOUGHNEY K, 1989, CELL, V58, P1143, DOI 10.1016/0092-8674(89)90512-6; MEYER RL, 1982, SCIENCE, V218, P589, DOI 10.1126/science.7123262; MEYER RL, 1983, DEV BRAIN RES, V6, P293, DOI 10.1016/0165-3806(83)90068-8; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; ODOWD DK, 1988, J NEUROSCI, V8, P3633; ODOWD DK, 1989, NEURON, V2, P1301, DOI 10.1016/0896-6273(89)90068-8; ROGART RB, 1989, P NATL ACAD SCI USA, V86, P8170, DOI 10.1073/pnas.86.20.8170; Sambrook J., 1989, MOL CLONING LAB MANU; SCHMIDT J, 1985, P NATL ACAD SCI USA, V82, P4847, DOI 10.1073/pnas.82.14.4847; SCHMIDT JT, 1983, BRAIN RES, V269, P29, DOI 10.1016/0006-8993(83)90959-9; SCHMIDT JW, 1986, CELL, V46, P437, DOI 10.1016/0092-8674(86)90664-1; SCHNEUWLY S, 1989, P NATL ACAD SCI USA, V86, P5390, DOI 10.1073/pnas.86.14.5390; SCHREIBMAYER W, 1994, PFLUG ARCH EUR J PHY, V426, P453, DOI 10.1007/BF00388310; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; SUZUKI DT, 1970, SCIENCE, V170, P695, DOI 10.1126/science.170.3959.695; SUZUKI DT, 1971, P NATL ACAD SCI USA, V68, P890, DOI 10.1073/pnas.68.5.890; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Thummel CS, 1992, DROS INF SERV, V71, P150; TRIMMER JS, 1989, NEURON, V3, P33, DOI 10.1016/0896-6273(89)90113-X; TRUMAN JW, 1993, DEV DROSOPHILA MELAN, V2, P1245; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; WOLLNER DA, 1987, J BIOL CHEM, V262, P14709; Wu C F, 1992, Ion Channels, V3, P261; WU CF, 1978, P NATL ACAD SCI USA, V75, P4047, DOI 10.1073/pnas.75.8.4047; YOST CS, 1983, CELL, V34, P759; ZHENG W, 1995, J NEUROSCI, V15, P1132	65	180	190	3	17	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 22	1995	82	6					1001	1011		10.1016/0092-8674(95)90279-1	http://dx.doi.org/10.1016/0092-8674(95)90279-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RW693	7553842	Bronze			2022-12-24	WOS:A1995RW69300016
J	FLEISCHMANN, RD; ADAMS, MD; WHITE, O; CLAYTON, RA; KIRKNESS, EF; KERLAVAGE, AR; BULT, CJ; TOMB, JF; DOUGHERTY, BA; MERRICK, JM; MCKENNEY, K; SUTTON, G; FITZHUGH, W; FIELDS, C; GOCAYNE, JD; SCOTT, J; SHIRLEY, R; LIU, LI; GLODEK, A; KELLEY, JM; WEIDMAN, JF; PHILLIPS, CA; SPRIGGS, T; HEDBLOM, E; COTTON, MD; UTTERBACK, TR; HANNA, MC; NGUYEN, DT; SAUDEK, DM; BRANDON, RC; FINE, LD; FRITCHMAN, JL; FUHRMANN, JL; GEOGHAGEN, NSM; GNEHM, CL; MCDONALD, LA; SMALL, KV; FRASER, CM; SMITH, HO; VENTER, JC				FLEISCHMANN, RD; ADAMS, MD; WHITE, O; CLAYTON, RA; KIRKNESS, EF; KERLAVAGE, AR; BULT, CJ; TOMB, JF; DOUGHERTY, BA; MERRICK, JM; MCKENNEY, K; SUTTON, G; FITZHUGH, W; FIELDS, C; GOCAYNE, JD; SCOTT, J; SHIRLEY, R; LIU, LI; GLODEK, A; KELLEY, JM; WEIDMAN, JF; PHILLIPS, CA; SPRIGGS, T; HEDBLOM, E; COTTON, MD; UTTERBACK, TR; HANNA, MC; NGUYEN, DT; SAUDEK, DM; BRANDON, RC; FINE, LD; FRITCHMAN, JL; FUHRMANN, JL; GEOGHAGEN, NSM; GNEHM, CL; MCDONALD, LA; SMALL, KV; FRASER, CM; SMITH, HO; VENTER, JC			WHOLE-GENOME RANDOM SEQUENCING AND ASSEMBLY OF HAEMOPHILUS-INFLUENZAE RD	SCIENCE			English	Article							ESCHERICHIA-COLI GENOME; HEMOPHILUS TRANSFORMATION; DNA-SEQUENCE; GENE; PROTEIN; ORGANIZATION; PROJECT; RECOGNITION; COMPETENCE; COMPUTER	An approach for genome analysis based on sequencing and assembly of unselected pieces of DNA from the whole chromosome has been applied to obtain the complete nucleotide sequence (1,830,137 base pairs) of the genome from the bacterium Haemophilus influenzae Rd. This approach eliminates the need for initial mapping efforts and is therefore applicable to the vast array of microbial species for which genome maps are unavailable. The H. influenzae Rd genome sequence (Genome Sequence DataBase accession number L42023) represents the only complete genome sequence from a free-living organism.	INST GENOM RES, GAITHERSBURG, MD 20878 USA; JOHNS HOPKINS UNIV, SCH MED, BALTIMORE, MD 21205 USA; SUNY BUFFALO, DEPT MICROBIOL, BUFFALO, NY 14214 USA; NIST, GAITHERSBURG, MD 20878 USA	J. Craig Venter Institute; Johns Hopkins University; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; National Institute of Standards & Technology (NIST) - USA			Puigbò, Pere/A-2214-2008	Fraser, Claire/0000-0003-1462-2428; Fields, Chris/0000-0002-4812-0744; Kerlavage, Anthony/0000-0002-3954-9653				Adams M. D., 1994, AUTOMATED DNA SEQUEN; ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ADAMS MD, 1994, NATURE, V368, P474, DOI 10.1038/368474a0; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ADAMS MD, IN PRESS NATURE; ALBRIGHT LM, 1989, ANNU REV GENET, V23, P311, DOI 10.1146/annurev.ge.23.120189.001523; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bankier A T, 1991, DNA Seq, V2, P1, DOI 10.3109/10425179109008433; BAROUKI R, 1985, J BACTERIOL, V163, P629, DOI 10.1128/JB.163.2.629-634.1985; BODMER WF, 1994, REV INVEST CLIN S, P3; BORODOVSKY M, 1993, COMPUT CHEM, V17, P123, DOI 10.1016/0097-8485(93)85004-V; BRUTLAG DL, 1993, COMPUT CHEM, V17, P203, DOI 10.1016/0097-8485(93)85011-Z; BURLAND V, 1993, GENOMICS, V16, P551, DOI 10.1006/geno.1993.1230; CHANDLER MS, 1992, P NATL ACAD SCI USA, V89, P1626, DOI 10.1073/pnas.89.5.1626; CLAVERIE JM, 1993, J MOL BIOL, V234, P1140, DOI 10.1006/jmbi.1993.1666; DANNER DB, 1980, GENE, V11, P311, DOI 10.1016/0378-1119(80)90071-2; DANNER DB, 1982, P NATL ACAD SCI-BIOL, V79, P2393, DOI 10.1073/pnas.79.7.2393; DOROCICZ IR, 1993, J BACTERIOL, V175, P7142, DOI 10.1128/JB.175.22.7142-7149.1993; DOUGHERTY B, UNPUB; GLASER P, 1993, MOL MICROBIOL, V10, P371, DOI 10.1111/j.1365-2958.1993.tb01963.x; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; GREENER A, 1990, STRATEGIES MOL BIOL, V3, P5; HARTL DL, 1993, GENOME RES MOL MED V, P115; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; HONG GF, 1982, J MOL BIOL, V162, P72; JOHNSTON M, 1994, SCIENCE, V265, P2077, DOI 10.1126/science.8091229; KAHN ME, 1984, J MEMBRANE BIOL, V138, P155; KERLAVAGE A, 1993, 26TH P HAW INT C SYS, P585; KERLAVAGE AR, IN PRESS IEEE COMPUT; KIRKNESS EF, 1991, GENOMICS, V10, P985, DOI 10.1016/0888-7543(91)90189-L; KLEIN RD, 1979, J GEN MICROBIOL, V113, P409, DOI 10.1099/00221287-113-2-409; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANDER E S, 1988, Genomics, V2, P231; LEE JJ, 1989, J BACTERIOL, V171, P3016, DOI 10.1128/jb.171.6.3016-3024.1989; LEVY J, 1994, YEAST, V10, P1689, DOI 10.1002/yea.320101304; LEWIN B, 1994, GENES, V5, pCH18; LEWIN B, 1994, GENES, V5, pCH19; MASSUNG RF, 1993, NATURE, V366, P748, DOI 10.1038/366748a0; ODA K, 1992, J MOL BIOL, V223, P1, DOI 10.1016/0022-2836(92)90708-R; OHYAMA K, 1986, NATURE, V322, P572, DOI 10.1038/322572a0; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; REDFIELD RJ, 1991, J BACTERIOL, V173, P5612, DOI 10.1128/jb.173.18.5612-5618.1991; RILEY M, 1993, MICROBIOL REV, V57, P862, DOI 10.1128/MMBR.57.4.862-952.1993; SANGER F, 1977, NATURE, V265, P687, DOI 10.1038/265687a0; SMITH HO, 1995, SCIENCE, V269, P538, DOI 10.1126/science.7542802; SOFIA HJ, 1994, NUCLEIC ACIDS RES, V22, P2576, DOI 10.1093/nar/22.13.2576; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; TOMB JF, 1991, GENE, V104, P1, DOI 10.1016/0378-1119(91)90457-M; TOMB JF, 1992, P NATL ACAD SCI USA, V89, P10252, DOI 10.1073/pnas.89.21.10252; TTOMB JF, UNPUB; UTTERBACK TR, UNPUB; VANHAM SM, 1994, MOL MICROBIOL, V13, P673; WATERMAN MS, 1988, METHOD ENZYMOL, V164, P765; WEISER JN, 1989, CELL, V59, P657, DOI 10.1016/0092-8674(89)90011-1; WILCOX KW, 1975, J BACTERIOL, V122, P443, DOI 10.1128/JB.122.2.443-453.1975; YURA T, 1992, NUCLEIC ACIDS RES, V20, P3305, DOI 10.1093/nar/20.13.3305	57	4337	6350	4	351	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 28	1995	269	5223					496	512		10.1126/science.7542800	http://dx.doi.org/10.1126/science.7542800			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL495	7542800				2022-12-24	WOS:A1995RL49500017
J	ROSENBLOOM, AJ; PINSKY, MR; BRYANT, JL; SHIN, A; TRAN, T; WHITESIDE, T				ROSENBLOOM, AJ; PINSKY, MR; BRYANT, JL; SHIN, A; TRAN, T; WHITESIDE, T			LEUKOCYTE ACTIVATION IN THE PERIPHERAL-BLOOD OF PATIENTS WITH CIRRHOSIS OF THE LIVER AND SIRS - CORRELATION WITH SERUM INTERLEUKIN-6 LEVELS AND ORGAN DYSFUNCTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NECROSIS-FACTOR-ALPHA; SEPTIC SHOCK; UP-REGULATION; TRANSENDOTHELIAL MIGRATION; COMPLEMENT RECEPTOR-1; HYDROGEN-PEROXIDE; FLOW-CYTOMETRY; SEVERE SEPSIS; CD11B CD18; HLA-DR	Objective.-Leukocyte adhesion plays an important role in inflammation. Adhesion molecules such as CD11b on polymorphonuclear neutrophil leukocytes (PMNs) up-regulate in response to tumor necrosis factor-alpha, interleukin-8 (IL-8), and other mediators that are involved in systemic inflammatory response syndrome (SIRS). This study examined the behavior of CD11b and other membrane molecules in SIRS in relation to serum cytokines and the severity of illness. Design.-Survey study. Setting.-Liver transplantation intensive care unit at a tertiary care center. Patients.-A consecutive sample of 22 patients admitted to the liver transplantation intensive care unit for complications related to cirrhosis of the liver in the absence of other disease. Sixteen of the patients developed SIRS and multiple organ dysfunction syndrome with suspected bacterial infections. Seven control subjects were also studied. Main Outcome Measures.-Modified Goris organ failure score and Acute Physiology and Chronic Health Evaluation II score. Results.-Mean serum IL-6 levels, but not IL-1 beta or tumor necrosis factor-alpha levels, correlated with organ failure (r=0.79, P<.001). Leukocyte cell-surface markers fluctuated from day to day. The mean of several values was more stable. Mean CD11b and CD35 on PMNs correlated with serum IL-6 level (r=0.75, P<.001,and r=0.77, P<.005, respectively). Up-regulation of both CD11b and CD35 display on PMNs correlated with organ failure (r=0.74, P<.001, and r=0.71, P<.01, respectively). Polymorphonuclear neutrophil leukocyte L-selectin, CD31, and CD16 were simultaneously decreased, consistent with PMN activation. Monocytes appeared to be activated, but the pattern of surface molecule display was different. Conclusions.-In human SIRS, the circulating monocyte and PMN pools undergo alterations suggestive of leukocyte activation, including up-regulation of PMN CD11b in correlation with the serum IL-6 level and severity of organ dysfunction.	UNIV PITTSBURGH,SCH MED,DEPT PATHOL,PITTSBURGH,PA; UNIV PITTSBURGH,SCH MED,DEPT OTOLARYNGOL,PITTSBURGH,PA; UNIV PITTSBURGH,INST CANC,PITTSBURGH,PA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	ROSENBLOOM, AJ (corresponding author), UNIV PITTSBURGH,MED CTR,DEPT ANESTHESIOL,DIV CRIT CARE MED,200 LOTHROP ST,PITTSBURGH,PA 15213, USA.							ALBERS I, 1989, SCAND J GASTROENTERO, V24, P269, DOI 10.3109/00365528909093045; BERG O, 1989, ACTA OTO-LARYNGOL, V107, P130, DOI 10.3109/00016488909127489; BRIGHAM KL, 1991, KLIN WOCHENSCHR, V69, P1004, DOI 10.1007/BF01645147; BURCH RM, 1993, J IMMUNOL, V150, P3397; BYL B, 1993, GASTROENTEROLOGY, V104, P1492, DOI 10.1016/0016-5085(93)90361-F; CALANDRA T, 1991, AM J MED, V91, P23, DOI 10.1016/0002-9343(91)90069-A; CHULUYAN HE, 1993, J CLIN INVEST, V92, P2768, DOI 10.1172/JCI116895; CREASEY AA, 1991, CIRC SHOCK, V33, P84; CROCKARD AD, 1992, CLIN IMMUNOL IMMUNOP, V65, P135, DOI 10.1016/0090-1229(92)90216-B; DAMAS P, 1992, ANN SURG, V215, P356, DOI 10.1097/00000658-199204000-00009; DETMERS PA, 1990, J EXP MED, V171, P1155, DOI 10.1084/jem.171.4.1155; DIAMOND MS, 1993, J CELL BIOL, V120, P545, DOI 10.1083/jcb.120.2.545; DIXON WJ, 1983, INTRO STATISTICAL AN, P562; DOFFERHOFF ASM, 1992, CRIT CARE MED, V20, P185, DOI 10.1097/00003246-199202000-00007; ELSNER J, 1992, EUR J HAEMATOL, V48, P10; FABIAN TC, 1994, ANN SURG, V220, P552, DOI 10.1097/00000658-199410000-00013; GLANTZ SA, 1992, PRIMER BIOSTATISTICS, P320; GORIS RJA, 1985, ARCH SURG-CHICAGO, V120, P1109; HAMBLIN A, 1992, J IMMUNOL METHODS, V146, P219, DOI 10.1016/0022-1759(92)90231-H; HED J, 1988, SCAND J IMMUNOL, V28, P339, DOI 10.1111/j.1365-3083.1988.tb01458.x; HUGHES BJ, 1992, J CLIN INVEST, V90, P1687, DOI 10.1172/JCI116041; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KUO CH, 1991, LIVER, V11, P334; LIMB GA, 1992, IMMUNOLOGY, V77, P88; LIMB GA, 1991, IMMUNOLOGY, V74, P696; LIN RY, 1993, CHEST, V104, P847, DOI 10.1378/chest.104.3.847; MAURER D, 1991, ANN HEMATOL, V62, P135, DOI 10.1007/BF01702927; MCCARTHY D, 1992, ANN RHEUM DIS, V51, P307, DOI 10.1136/ard.51.3.307; MEERSCHAERT J, 1994, J IMMUNOL, V152, P1915; MOREAU R, 1992, CRIT CARE MED, V20, P746, DOI 10.1097/00003246-199206000-00008; MUNOZ C, 1991, EUR J IMMUNOL, V21, P2177, DOI 10.1002/eji.1830210928; NATHAN CF, 1987, J CLIN INVEST, V80, P1550, DOI 10.1172/JCI113241; Noreen E. W., 1989, COMPUTER INTENSIVE M; OVERTON WR, 1988, CYTOMETRY, V9, P619, DOI 10.1002/cyto.990090617; OVERTON WR, 1989, CYTOMETRY, V10, P492; PINSKY MR, 1993, CHEST, V103, P565, DOI 10.1378/chest.103.2.565; SCHLEIFFENBAUM B, 1990, J CLIN INVEST, V86, P184, DOI 10.1172/JCI114683; SHAPPELL SB, 1990, J IMMUNOL, V144, P2702; SMITH CW, 1988, J CLIN INVEST, V82, P1746, DOI 10.1172/JCI113788; SPERTINI O, 1992, J IMMUNOL METHODS, V156, P115, DOI 10.1016/0022-1759(92)90017-N; STEPHENS KE, 1988, AM REV RESPIR DIS, V138, P1300, DOI 10.1164/ajrccm/138.5.1300; STOCKINGER H, 1990, J IMMUNOL, V145, P3889; TAKAHASHI M, 1994, ATHEROSCLEROSIS, V108, P73, DOI 10.1016/0021-9150(94)90038-8; TILG H, 1993, HEPATOLOGY, V18, P1132; VANDEVENTER SJH, 1990, BLOOD, V76, P2520; VANZEE KJ, 1992, P NATL ACAD SCI USA, V89, P4845, DOI 10.1073/pnas.89.11.4845; WAKEFIELD CH, 1993, ARCH SURG-CHICAGO, V128, P390; WALSH CJ, 1991, SURGERY, V110, P205; WITTHAUT R, 1994, J LEUKOCYTE BIOL, V55, P105, DOI 10.1002/jlb.55.1.105; ZENTELLA A, 1991, PROG CLIN BIOL RES, V367, P9	50	143	151	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 5	1995	274	1					58	65		10.1001/jama.274.1.58	http://dx.doi.org/10.1001/jama.274.1.58			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG233	7540697				2022-12-24	WOS:A1995RG23300031
J	OKADA, Y; YAMAZAKI, H; SEKINEAIZAWA, Y; HIROKAWA, N				OKADA, Y; YAMAZAKI, H; SEKINEAIZAWA, Y; HIROKAWA, N			THE NEURON-SPECIFIC KINESIN SUPERFAMILY PROTEIN KIF1A IS A UNIQUE MONOMERIC MOTOR FOR ANTEROGRADE AXONAL-TRANSPORT OF SYNAPTIC VESICLE PRECURSORS	CELL			English	Article							HEAVY-CHAIN; MONOCLONAL-ANTIBODY; MEMBRANOUS ORGANELLES; SECRETORY VESICLES; C-ELEGANS; IDENTIFICATION; SYNAPTOPHYSIN; MICROTUBULES; DOMAINS; GLYCOPROTEIN	Axonal transport has been intensively examined as a good model for studying the mechanism of organelle transport in cells, but it is still unclear how different types of membrane organelles are transported through the nerve axon. To elucidate the function of this mechanism, we have cloned KIF1A, a novel neuron-specific kinesin superfamily motor that was discovered to be a monomeric, globular molecule and that had the fastest reported anterograde motor activity (1.2 mu m/s). To identify its cargo, membranous organelles were isolated from the axon. KIF1A was associated with organelles that contained synaptic vesicle proteins such as synaptotagmin, synaptophysin, and Rab3A. However, this organelle did not contain SV2, another synaptic vesicle protein, nor did it contain presynaptic membrane proteins, such as syntaxin 1A or SNAP-25, or other known anterograde motor proteins, such as kinesin and KIF3. Thus, we suggest that the membrane proteins are sorted into different classes of transport organelles in the cell body and are transported by their specific motor proteins through the axon.	UNIV TOKYO, FAC MED, DEPT ANAT & CELL BIOL, TOKYO 113, JAPAN	University of Tokyo			Okada, Yasushi/N-5067-2015	Okada, Yasushi/0000-0003-2601-3689				AIZAWA H, 1992, J CELL BIOL, V119, P1287, DOI 10.1083/jcb.119.5.1287; BARNSTABLE CJ, 1985, DEV BRAIN RES, V20, P286, DOI 10.1016/0165-3806(85)90116-6; Bauerfeind R, 1993, CURR OPIN CELL BIOL, V5, P628, DOI 10.1016/0955-0674(93)90132-A; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BERLINER E, 1994, J BIOL CHEM, V269, P8610; BRADY ST, 1990, P NATL ACAD SCI USA, V87, P1061, DOI 10.1073/pnas.87.3.1061; BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; BUCKLEY K, 1985, J CELL BIOL, V100, P1284, DOI 10.1083/jcb.100.4.1284; CHANDRA R, 1993, J BIOL CHEM, V268, P9005; DAVIES AH, 1993, BIO-TECHNOL, V11, P933, DOI 10.1038/nbt0893-933; DECUEVAS M, 1992, J CELL BIOL, V116, P957, DOI 10.1083/jcb.116.4.957; ENDOW SA, 1991, TRENDS BIOCHEM SCI, V16, P221, DOI 10.1016/0968-0004(91)90089-E; GHO M, 1992, SCIENCE, V258, P313, DOI 10.1126/science.1384131; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; GOLDSTEIN LSB, 1993, ANNU REV GENET, V27, P319; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HALL DH, 1991, CELL, V65, P837, DOI 10.1016/0092-8674(91)90391-B; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HIROKAWA N, 1991, J CELL BIOL, V114, P295, DOI 10.1083/jcb.114.2.295; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; HIROKAWA N, 1982, J CELL BIOL, V94, P129, DOI 10.1083/jcb.94.1.129; HIROKAWA N, 1993, NEUROSCI RES, V18, P1, DOI 10.1016/0168-0102(93)90099-C; Hirokawa Nobutaka, 1993, Current Opinion in Neurobiology, V3, P724, DOI 10.1016/0959-4388(93)90144-N; HOLLENBECK PJ, 1989, J CELL BIOL, V108, P2335, DOI 10.1083/jcb.108.6.2335; HOYT MA, 1993, GENETICS, V135, P35; HOYT MA, 1994, CURR OPIN CELL BIOL, V6, P63, DOI 10.1016/0955-0674(94)90117-1; HUANG TG, 1994, J BIOL CHEM, V269, P16502; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; KONDO S, 1994, J CELL BIOL, V125, P1095, DOI 10.1083/jcb.125.5.1095; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MALIK F, 1994, P NATL ACAD SCI USA, V91, P4584, DOI 10.1073/pnas.91.10.4584; MATTEOLI M, 1992, J CELL BIOL, V117, P849, DOI 10.1083/jcb.117.4.849; MIZOGUCHI A, 1989, BIOCHEM BIOPH RES CO, V162, P1438, DOI 10.1016/0006-291X(89)90835-8; MUNDIGL O, 1993, J CELL BIOL, V122, P1207, DOI 10.1083/jcb.122.6.1207; NANGAKU M, 1994, CELL, V79, P1209, DOI 10.1016/0092-8674(94)90012-4; NICLAS J, 1994, NEURON, V12, P1059, DOI 10.1016/0896-6273(94)90314-X; NODA Y, 1995, J CELL BIOL, V129, P157, DOI 10.1083/jcb.129.1.157; OBATA K, 1986, BRAIN RES, V375, P37, DOI 10.1016/0006-8993(86)90956-X; OKADA Y, 1995, J NEUROSCI, V15, P3053; OTSUKA AJ, 1991, NEURON, V6, P113, DOI 10.1016/0896-6273(91)90126-K; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PATEL N, 1993, P NATL ACAD SCI USA, V90, P9181, DOI 10.1073/pnas.90.19.9181; PESAVENTO PA, 1994, J CELL BIOL, V127, P1041, DOI 10.1083/jcb.127.4.1041; PFISTER KK, 1989, J CELL BIOL, V108, P1453, DOI 10.1083/jcb.108.4.1453; REGNIERVIGOUROUX A, 1991, EMBO J, V10, P3589, DOI 10.1002/j.1460-2075.1991.tb04925.x; SATO YR, 1992, J BIOL CHEM, V267, P23930; SCHMIDLE T, 1991, BIOCHIM BIOPHYS ACTA, V1060, P251, DOI 10.1016/S0005-2728(05)80314-7; SEKINE Y, 1994, J CELL BIOL, V127, P187, DOI 10.1083/jcb.127.1.187; SMITH RS, 1980, J NEUROCYTOL, V9, P39, DOI 10.1007/BF01205226; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALE RD, 1985, CELL, V43, P623, DOI 10.1016/0092-8674(85)90234-X; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9; WYATT PJ, 1993, ANAL CHIM ACTA, V272, P1, DOI 10.1016/0003-2670(93)80373-S; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2	58	482	492	3	26	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 2	1995	81	5					769	780		10.1016/0092-8674(95)90538-3	http://dx.doi.org/10.1016/0092-8674(95)90538-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RB961	7539720	Bronze			2022-12-24	WOS:A1995RB96100015
J	RIEUXLAUCAT, F; LEDEIST, F; HIVROZ, C; ROBERTS, IAG; DEBATIN, KM; FISCHER, A; DEVILLARTAY, JP				RIEUXLAUCAT, F; LEDEIST, F; HIVROZ, C; ROBERTS, IAG; DEBATIN, KM; FISCHER, A; DEVILLARTAY, JP			MUTATIONS IN FAS ASSOCIATED WITH HUMAN LYMPHOPROLIFERATIVE SYNDROME AND AUTOIMMUNITY	SCIENCE			English	Article							PROGRAMMED CELL-DEATH; SURFACE ANTIGEN; APOPTOSIS; MICE; LPR	Fas (also known as Apo1 and CD95) is a cell surface receptor involved in apoptotic cell death. Fas expression and function were analyzed in three children (including two siblings) with a lymphoproliferative syndrome, two of whom also had autoimmune disorders. A targe deletion in the gene encoding Fas and no detectable cell surface expression characterized the most affected patient. Clinical manifestations in the two related patients were less severe: Fas-mediated apoptosis was impaired and a deletion within the intracytoplasmic domain was detected. These findings illustrate the crucial regulatory role of Fas and may provide a molecular basis for some autoimmune diseases in humans.	HOP NECKER ENFANTS MALAD,INSERM,U429,F-75743 PARIS 15,FRANCE; HAMMERSMITH HOSP,DEPT HAEMATOL,LONDON W12 0NN,ENGLAND; UNIV HEIDELBERG,CHILDRENS HOSP,HAEMATOL SECT,D-69120 HEIDELBERG,GERMANY	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Imperial College London; Ruprecht Karls University Heidelberg			Hivroz, Claire/H-2711-2014; Rieux-Laucat, Frédéric/A-7916-2017; de Villartay, jean pierre/H-9353-2017; Debatin, Klaus-Michael/J-9704-2014	Hivroz, Claire/0000-0002-6794-2890; Rieux-Laucat, Frédéric/0000-0001-7858-7866; de Villartay, jean pierre/0000-0001-5987-0463; Debatin, Klaus-Michael/0000-0002-8397-1886				COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; DEBATIN KM, 1994, EUR J IMMUNOL, V24, P753, DOI 10.1002/eji.1830240339; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HERON LR, 1993, J IMMUNOL, V151, P3450; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KLAS C, 1993, INT IMMUNOL, V5, P625, DOI 10.1093/intimm/5.6.625; KRAMMER P H, 1992, Current Biology, V2, P383, DOI 10.1016/0960-9822(92)90084-N; KWITEKBLACK AE, 1993, NAT GENET, V5, P392, DOI 10.1038/ng1293-392; LANDOLFI MMT, 1993, J IMMUNOL, V151, P1086; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OEHM A, 1992, J BIOL CHEM, V267, P10709; RIEUXLAUCAT F, 1993, EUR J IMMUNOL, V23, P928, DOI 10.1002/eji.1830230425; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0	17	1113	1145	0	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 2	1995	268	5215					1347	1349		10.1126/science.7539157	http://dx.doi.org/10.1126/science.7539157			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB198	7539157				2022-12-24	WOS:A1995RB19800038
J	SHIEKHATTAR, R; MERMELSTEIN, F; FISHER, RP; DRAPKIN, R; DYNLACHT, B; WESSLING, HC; MORGAN, DO; REINBERG, D				SHIEKHATTAR, R; MERMELSTEIN, F; FISHER, RP; DRAPKIN, R; DYNLACHT, B; WESSLING, HC; MORGAN, DO; REINBERG, D			CDK-ACTIVATING KINASE COMPLEX IS A COMPONENT OF HUMAN TRANSCRIPTION FACTOR TFIIH	NATURE			English	Article							RNA POLYMERASE-II; CARBOXYL-TERMINAL-DOMAIN; INITIATION	TRANSCRIPTION factor IIH (TFIIH) contains a kinase capable of phosphorylating the carboxy-terminal domain (CTD) of the largest subunit of RNA polymerase II (RNAPII)1-3. Here we report the identification of the Cdk-activating kinase (Cak) complex (Cdk7 and cyclin H) as a component of TFIIH after extensive purification of TFIIH by chromatography. We find that affinity-purified antibodies directed against cyclin H inhibit TFIIH-dependent transcription and that both cyclin H and Cdk7 antibodies inhibit phosphorylation of the CTD of the largest subunit of the RNAPII in the preinitiation complex. Cak is present in at least two distinct complexes, TFIIH and a smaller complex that is unable to phosphorylate RNAPII in the preinitiation complex. Both Cak complexes, as well as recombinant Cak, phosphorylate a CTD peptide. Finally, TFIIH was shown to phosphorylate both Cdc2 and Cdk2, suggesting that there could be a link between transcription and the cell cycle machinery.	UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT BIOCHEM, HOWARD HUGHES MED INST, PISCATAWAY, NJ 08854 USA; UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; MASSACHUSETTS GEN HOSP, CTR CANC, MOLEC ONCOL LAB, BOSTON, MA 02129 USA	Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of California System; University of California San Francisco; Harvard University; Massachusetts General Hospital			Drapkin, Ronny/E-9944-2016	Drapkin, Ronny/0000-0002-6912-6977; Morgan, David/0000-0001-8753-4416; Reinberg, Danny/0000-0003-4288-2016				CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CISEK LJ, 1991, METHOD ENZYMOL, V200, P301; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; FLORES O, 1992, J BIOL CHEM, V267, P2786; HARLOW E, 1988, ANTIBODIES LABORATOR; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; VANVUUREN AJ, 1994, EMBO J, V13, P1645, DOI 10.1002/j.1460-2075.1994.tb06428.x; WANG ZG, 1994, NATURE, V368, P74, DOI 10.1038/368074a0; ZAWEL L, 1993, COLD SPRING HARB SYM, V58, P187, DOI 10.1101/SQB.1993.058.01.023	17	364	385	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 16	1995	374	6519					283	287		10.1038/374283a0	http://dx.doi.org/10.1038/374283a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM387	7533895				2022-12-24	WOS:A1995QM38700056
J	FENG, SB; CHEN, JK; YU, HT; SIMON, JA; SCHREIBER, SL				FENG, SB; CHEN, JK; YU, HT; SIMON, JA; SCHREIBER, SL			2 BINDING ORIENTATIONS FOR PEPTIDES TO THE SRC SH3 DOMAIN - DEVELOPMENT OF A GENERAL-MODEL FOR SH3-LIGAND INTERACTIONS	SCIENCE			English	Article							MULTIPLE QUANTUM COHERENCE; NMR-SPECTROSCOPY; C-SRC; PROTEIN; IDENTIFICATION; MAGNETIZATION; DELETIONS; RECEPTOR; SPECTRA; SITE	Solution structures of two Src homology 3 (SH3) domain-ligand complexes have been determined by nuclear magnetic resonance. Each complex consists of the SH3 domain and a nine-residue proline-rich peptide selected from a large library of ligands prepared by combinatorial synthesis. The bound ligands adopt a left-handed polyproline type II (PPII) helix, although the amino to carboxyl directionalities of their helices are opposite. The peptide orientation is determined by a salt bridge formed by the terminal arginine residues of the ligands and the conserved aspartate-99 of the SH3 domain. Residues at positions 3, 4, 6, and 7 of both peptides also intercalate into the ligand-binding site; however, the respective proline and nonproline residues show exchanged binding positions in the two complexes. These structural results led to a model for the interactions of SH3 domains with proline-rich peptides that can be used to predict critical residues in complexes of unknown structure. The model was used to identify correctly both the binding orientation and the contact and noncontact residues of a peptide derived from the nucleotide exchange factor Sos in association with the amino-terminal SH3 domain of the adaptor protein Grb2.	HARVARD UNIV, HOWARD HUGHES MED INST, DEPT CHEM, CAMBRIDGE, MA 02138 USA	Harvard University; Howard Hughes Medical Institute			Chen, James/G-9972-2011	Chen, James/0000-0002-9220-8436; Yu, Hongtao/0000-0002-8861-049X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044993] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44993] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADZHUBEI AA, 1993, J MOL BIOL, V229, P472, DOI 10.1006/jmbi.1993.1047; BARFOD ET, 1993, J BIOL CHEM, V268, P26059; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; BAX A, 1983, J AM CHEM SOC, V105, P7188, DOI 10.1021/ja00362a038; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1988, X PLOR MANUAL; BRUNGER T, 1992, X PLOR MANUAL V 3 1; CHEN JK, 1994, BIOORG MED CHEM LETT, V4, P1755, DOI 10.1016/S0960-894X(00)80375-3; CHEN JK, 1993, J AM CHEM SOC, V115, P12591, DOI 10.1021/ja00079a051; CHENG GH, 1994, P NATL ACAD SCI USA, V91, P8152, DOI 10.1073/pnas.91.17.8152; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; FINAN P, 1994, J BIOL CHEM, V269, P13752; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; IKURA M, 1992, J AM CHEM SOC, V114, P2433, DOI 10.1021/ja00033a019; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KAY LE, 1990, J MAGN RESON, V86, P110, DOI 10.1016/0022-2364(90)90215-U; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LIM WA, 1994, NAT STRUCT BIOL, V1, P221, DOI 10.1038/nsb0494-221; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; MACURA S, 1981, J MAGN RESON, V43, P259, DOI 10.1016/0022-2364(81)90037-8; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MICHNICK SW, 1991, SCIENCE, V252, P836, DOI 10.1126/science.1709301; MULLER N, 1986, J AM CHEM SOC, V108, P6482, DOI 10.1021/ja00281a006; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; NEMETH SP, 1989, MOL CELL BIOL, V9, P1109, DOI 10.1128/MCB.9.3.1109; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PATERSON Y, 1990, SCIENCE, V249, P755, DOI 10.1126/science.1697101; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; Potts W M, 1988, Oncogene Res, V3, P343; REIF K, 1994, J BIOL CHEM, V269, P14081; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SUDOL M, 1994, ONCOGENE, V9, P2145; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; VIGUERA AR, 1994, BIOCHEMISTRY-US, V33, P2142, DOI 10.1021/bi00174a022; WENG ZG, 1993, J BIOL CHEM, V268, P14956; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZUIDERWEG ERP, 1989, BIOCHEMISTRY-US, V28, P2387, DOI 10.1021/bi00432a008	51	753	776	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 18	1994	266	5188					1241	1247		10.1126/science.7526465	http://dx.doi.org/10.1126/science.7526465			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT132	7526465				2022-12-24	WOS:A1994PT13200054
J	DANSKA, JS; PFLUMIO, F; WILLIAMS, CJ; HUNER, O; DICK, JE; GUIDOS, CJ				DANSKA, JS; PFLUMIO, F; WILLIAMS, CJ; HUNER, O; DICK, JE; GUIDOS, CJ			RESCUE OF T-CELL-SPECIFIC V(D)J RECOMBINATION IN SCID MICE BY DNA-DAMAGING AGENTS	SCIENCE			English	Article							ANTIGEN RECEPTOR GENES; STRAND BREAK REPAIR; PRE-B CELLS; COMBINED IMMUNODEFICIENCY MICE; COMBINED IMMUNE-DEFICIENCY; LIGHT CHAIN GENES; BETA-CHAIN; THYMOCYTE DEVELOPMENT; JUNCTIONAL SEQUENCES; MOUSE THYMOCYTES	Assembly of antigen receptor V (variable), D (diversity), and J (joining) gene segments requires lymphocyte-specific genes and ubiquitous DNA repair activities. Severe combined immunodeficient (SCID) mice are defective in general double-strand (ds) DNA break repair and V(D)J coding joint formation, resulting in arrested lymphocyte development. A single treatment of newborn SCID mice with DNA-damaging agents restored functional, diverse, T cell receptor beta chain coding joints, as well as development and expansion oi thymocytes expressing both CD4 and CD8 coreceptors, but did not promote B cell development. Thymic lymphoma developed in all mice treated with DNA-damaging agents, suggesting an Interrelation between V(D)J recombination, dsDNA break repair, and lymphomagenesis.	HOSP SICK CHILDREN, RES INST, DIV IMMUNOL & CANC, TORONTO M5G 1X8, ON, CANADA; UNIV TORONTO, DEPT IMMUNOL, TORONTO, ON, CANADA; HOSP SICK CHILDREN, RES INST, DEPT GENET, TORONTO M5G 1X8, ON, CANADA; UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO, ON, CANADA; UNIV TORONTO, DEPT IMMUNOL, TORONTO, ON, CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto	DANSKA, JS (corresponding author), HOSP SICK CHILDREN, RES INST, DIV SURG RES, TORONTO M5G 1X8, ON, CANADA.		Pflumio, Francoise/E-2074-2017	Pflumio, Francoise/0000-0001-8995-596X; Dick, John/0000-0002-9527-8317				BARRY TS, 1991, J EXP MED, V173, P167, DOI 10.1084/jem.173.1.167; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BLACKWELL TK, 1989, EMBO J, V8, P735, DOI 10.1002/j.1460-2075.1989.tb03433.x; Chabner B., 1990, CANC CHEMOTHERAPY PR, P341; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; DANSKA JS, 1990, J EXP MED, V172, P27, DOI 10.1084/jem.172.1.27; DANSKA JS, UNPUB; DISNEY JE, 1992, CYTOGENET CELL GENET, V59, P39, DOI 10.1159/000133196; EHLICH A, 1993, CELL, V72, P695, DOI 10.1016/0092-8674(93)90398-A; FERRIER P, 1990, J EXP MED, V171, P1909, DOI 10.1084/jem.171.6.1909; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; GILFILLAN S, 1993, SCIENCE, V261, P1175, DOI 10.1126/science.8356452; GROETTRUP M, 1993, CELL, V75, P283, DOI 10.1016/0092-8674(93)80070-U; GUIDOS CJ, 1990, J EXP MED, V172, P835, DOI 10.1084/jem.172.3.835; GUIDOS CJ, 1989, P NATL ACAD SCI USA, V86, P7542, DOI 10.1073/pnas.86.19.7542; HABU S, 1987, EUR J IMMUNOL, V17, P1467, DOI 10.1002/eji.1830171013; HARDY RR, 1989, CURR TOP MICROBIOL, V152, P19; HARRINGTON J, 1992, MOL CELL BIOL, V12, P4758, DOI 10.1128/MCB.12.10.4758; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; HENDRICKSON EA, 1990, MOL CELL BIOL, V10, P5397, DOI 10.1128/MCB.10.10.5397; KAPLAN HS, 1952, J NATL CANCER I, V13, P185; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KIENKER LJ, 1991, J EXP MED, V174, P769, DOI 10.1084/jem.174.4.769; KISHI H, 1991, EMBO J, V10, P93, DOI 10.1002/j.1460-2075.1991.tb07924.x; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; KOMORI T, 1993, SCIENCE, V261, P1171, DOI 10.1126/science.8356451; KOTLOFF DB, 1993, INT IMMUNOL, V5, P383, DOI 10.1093/intimm/5.4.383; KOTLOFF DB, 1993, J EXP MED, V178, P1981, DOI 10.1084/jem.178.6.1981; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAFAILLE JJ, 1989, CELL, V59, P859, DOI 10.1016/0092-8674(89)90609-0; LEVELT CN, 1993, J EXP MED, V178, P1867, DOI 10.1084/jem.178.6.1867; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; LIEBERMAN M, 1992, J EXP MED, V176, P399, DOI 10.1084/jem.176.2.399; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LYNCH F, 1993, INT IMMUNOL, V5, P991, DOI 10.1093/intimm/5.8.991; MACDONALD HR, 1988, EUR J IMMUNOL, V18, P519, DOI 10.1002/eji.1830180405; MALLICK CA, 1993, CELL, V73, P513, DOI 10.1016/0092-8674(93)90138-G; MALYNN BA, 1988, CELL, V54, P453, DOI 10.1016/0092-8674(88)90066-9; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MURPHY WJ, 1994, J IMMUNOL, V153, P1004; NIKOLICZUGIC J, 1988, P NATL ACAD SCI USA, V85, P8633, DOI 10.1073/pnas.85.22.8633; PEARSE M, 1989, P NATL ACAD SCI USA, V86, P1614, DOI 10.1073/pnas.86.5.1614; PENNYCOOK JL, 1993, J EXP MED, V178, P1007, DOI 10.1084/jem.178.3.1007; PERGOLA F, 1993, MOL CELL BIOL, V13, P3464, DOI 10.1128/MCB.13.6.3464; PETRINI JHJ, 1990, P NATL ACAD SCI USA, V87, P3450, DOI 10.1073/pnas.87.9.3450; PFLUMIO F, 1993, INT IMMUNOL, V5, P1509, DOI 10.1093/intimm/5.12.1509; PFLUMIO F, UNPUB; PHILPOTT KL, 1992, SCIENCE, V256, P1448, DOI 10.1126/science.1604321; RAULET DH, 1985, NATURE, V314, P101, DOI 10.1038/314101a0; ROEHM N, 1984, CELL, V38, P577, DOI 10.1016/0092-8674(84)90512-9; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; SCHATZ DG, 1992, ANNU REV IMMUNOL, V10, P359, DOI 10.1146/annurev.iy.10.040192.002043; SCHULER W, 1991, EUR J IMMUNOL, V21, P589, DOI 10.1002/eji.1830210309; SCHULER W, 1988, EMBO J, V7, P2019, DOI 10.1002/j.1460-2075.1988.tb03041.x; SCHULER W, 1986, CELL, V46, P963, DOI 10.1016/0092-8674(86)90695-1; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SHORES EW, 1993, J IMMUNOL, V150, P1263; SHORES EW, 1990, EUR J IMMUNOL, V20, P69, DOI 10.1002/eji.1830200111; SNODGRASS HR, 1985, NATURE, V313, P592, DOI 10.1038/313592a0; STRASSER A, 1994, NATURE, V368, P457, DOI 10.1038/368457a0; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; WILSON RK, 1988, IMMUNOL REV, V101, P149, DOI 10.1111/j.1600-065X.1988.tb00736.x; [No title captured]	68	114	114	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 21	1994	266	5184					450	455		10.1126/science.7524150	http://dx.doi.org/10.1126/science.7524150			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN272	7524150				2022-12-24	WOS:A1994PN27200039
J	NIGHTINGALE, SL				NIGHTINGALE, SL			REPORTS OF SKIN INJURIES FOLLOWING HIGH X-RAY DOSE INTERVENTIONAL PROCEDURES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1994, JAMA-J AM MED ASSOC, V5, P71	1	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 19	1994	272	15					1160	1160		10.1001/jama.272.15.1160	http://dx.doi.org/10.1001/jama.272.15.1160			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL212	7523738				2022-12-24	WOS:A1994PL21200007
J	ROOT, MJ; MACKINNON, R				ROOT, MJ; MACKINNON, R			2 IDENTICAL NONINTERACTING SITES IN AN ION-CHANNEL REVEALED BY PROTON-TRANSFER	SCIENCE			English	Article							INDUCED CURRENT FLUCTUATIONS; OLFACTORY RECEPTOR NEURONS; NUCLEOTIDE-GATED CHANNEL; CALCIUM CHANNELS; CRYSTAL-STRUCTURE; ACTIVATED CHANNEL; DIVALENT-CATIONS; 2.0-A RESOLUTION; K+ CHANNELS; PERMEATION	The functional consequences of single proton transfers occurring in the pore of a cyclic nucleotide-gated channel were observed with patch recording techniques. These results led to three conclusions about the chemical nature of ion binding sites in the conduction pathway: The channel contains two identical titratable sites, even though there are more than two (probably four) identical subunits; the sites are formed by glutamate residues that have a pK(a) (where K-a is the acid constant) of 7.6; and protonation of one site does not perturb the pK(a) of the other. These properties point to an unusual arrangement of carboxyl side-chain residues in the pore of a cation channel.	HARVARD UNIV, SCH MED, BIOPHYS PROGRAM, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	ROOT, MJ (corresponding author), HARVARD UNIV, SCH MED, DEPT NEUROBIOL, BOSTON, MA 02115 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047400, R01GM083113] Funding Source: NIH RePORTER; NIGMS NIH HHS [5 T32 GM083113, GM47400] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMSTRONG CM, 1991, ANN NY ACAD SCI, V635, P18, DOI 10.1111/j.1749-6632.1991.tb36477.x; Bell R.P., 1973, PROTON CHEM; Caldin E. F., 1975, PROTON TRANSFER REAC; Caspar D L, 1990, Adv Biophys, V26, P157, DOI 10.1016/0065-227X(90)90011-H; CHEN TY, 1994, NATURE, V368, P545, DOI 10.1038/368545a0; COLAMARTINO G, 1991, J PHYSIOL-LONDON, V440, P189, DOI 10.1113/jphysiol.1991.sp018703; COLLYER CA, 1990, J MOL BIOL, V211, P617, DOI 10.1016/0022-2836(90)90269-R; EISMANN E, 1994, P NATL ACAD SCI USA, V91, P1109, DOI 10.1073/pnas.91.3.1109; Fersht A., 1985, ENZYME STRUCTURE MEC; GOULDING EH, 1992, NEURON, V8, P45, DOI 10.1016/0896-6273(92)90107-O; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; Jencks W. P., 1987, CATALYSIS CHEM ENZYM; KAUPP UB, 1992, ANNU REV PHYSIOL, V54, P153; KIM MS, 1993, FEBS LETT, V318, P145, DOI 10.1016/0014-5793(93)80009-J; KOHLER HH, 1979, J THEOR BIOL, V79, P381, DOI 10.1016/0022-5193(79)90354-0; KRAMER RH, 1992, NEURON, V9, P897, DOI 10.1016/0896-6273(92)90242-6; MACKINNON R, 1988, NEURON, V1, P997, DOI 10.1016/0896-6273(88)90156-0; MANGANI S, 1992, J MOL BIOL, V223, P573, DOI 10.1016/0022-2836(92)90671-6; MIKALA G, 1993, FEBS LETT, V335, P265, DOI 10.1016/0014-5793(93)80743-E; PENTZ L, 1967, J AM CHEM SOC, V89, P6931, DOI 10.1021/ja01002a022; PIETROBON D, 1989, J GEN PHYSIOL, V94, P1, DOI 10.1085/jgp.94.1.1; PRODHOM B, 1989, J GEN PHYSIOL, V94, P23, DOI 10.1085/jgp.94.1.23; ROOT MJ, 1993, NEURON, V11, P459, DOI 10.1016/0896-6273(93)90150-P; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWYER L, 1982, NATURE, V295, P79, DOI 10.1038/295079a0; SCHUMAKER MF, 1990, BIOPHYS J, V58, P975, DOI 10.1016/S0006-3495(90)82442-5; SIELECKI AR, 1979, J MOL BIOL, V134, P781, DOI 10.1016/0022-2836(79)90486-8; TSIEN RW, 1987, ANNU REV BIOPHYS BIO, V16, P265; TYERMAN SD, 1992, BIOPHYS J, V61, P736, DOI 10.1016/S0006-3495(92)81878-7; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0; YAU KW, 1989, ANNU REV NEUROSCI, V12, P289, DOI 10.1146/annurev.ne.12.030189.001445; ZUFALL F, 1993, J NEUROPHYSIOL, V69, P1758, DOI 10.1152/jn.1993.69.5.1758	33	139	143	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 23	1994	265	5180					1852	1856		10.1126/science.7522344	http://dx.doi.org/10.1126/science.7522344			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH258	7522344				2022-12-24	WOS:A1994PH25800029
J	SHARKEY, J; BUTCHER, SP				SHARKEY, J; BUTCHER, SP			IMMUNOPHILINS MEDIATE THE NEUROPROTECTIVE EFFECTS OF FK506 IN FOCAL CEREBRAL-ISCHEMIA	NATURE			English	Article							CALCINEURIN PHOSPHATASE-ACTIVITY; CYCLOSPORINE-A; NITRIC-OXIDE; IMMUNOSUPPRESSANT FK506; GLUTAMATE NEUROTOXICITY; LYMPHOCYTES-T; BRAIN; COMPLEXES; ISCHEMIA; RAPAMYCIN	THE immunosuppressive action of the drug FK506 involves inhibition of calcineurin in T-lymphocytes by a complex of FK506 and an FK506 binding protein, FKBP 12(1,2), a member of the immunophilin protein family(3,4). The functional role of brain immunophilins is, however, unclear(5,6). We show here that FK506 is a powerful neuroprotective agent in an in vivo model of focal cerebral ischaemia when administered up to 60 min post-occlusion. The minimum effective neuroprotective dose is comparable with the immunosuppressant dose in humans(7), suggesting. that FK506 may have clinical potential for the treatment of stroke. Although the related immunosuppressants rapamycin and cyclosporin failed to reduce brain damage, the finding that rapamycin pretreatment blocked the effect of FK506 confirms a role for immunophilins in the neuroprotective mechanism.			SHARKEY, J (corresponding author), UNIV EDINBURGH,FUJISAWA INST NEUROSCI,DEPT PHARMACOL,EDINBURGH EH8 9JZ,MIDLOTHIAN,SCOTLAND.			Sharkey, John/0000-0001-8288-1857				ARMSTRONG DL, 1989, TRENDS NEUROSCI, V12, P117, DOI 10.1016/0166-2236(89)90168-9; ASAMI M, 1993, BIOCHEM BIOPH RES CO, V192, P1388, DOI 10.1006/bbrc.1993.1570; BEGLEY DJ, 1990, J NEUROCHEM, V55, P1222, DOI 10.1111/j.1471-4159.1990.tb03128.x; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; CHOI DW, 1992, SCIENCE, V258, P241, DOI 10.1126/science.1357748; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; FUNG J, 1991, TRANSPLANT P, V23, P2977; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; KUNO T, 1992, J NEUROCHEM, V58, P1643, DOI 10.1111/j.1471-4159.1992.tb10036.x; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1993, TRENDS PHARMACOL SCI, V14, P182, DOI 10.1016/0165-6147(93)90206-Y; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; MAKAI H, 1993, J BIOCH, V113, P292; NAGASAWA H, 1989, STROKE, V20, P150; NISHINAKA Y, 1993, J CARDIOVASC PHARM, V21, P448, DOI 10.1097/00005344-199303000-00015; PARK CK, 1989, ANN NEUROL, V20, P150; SCHNEIBER SL, 1991, SCIENCE, V251, P283; SHARKEY J, 1993, J CEREBR BLOOD F MET, V13, P865, DOI 10.1038/jcbfm.1993.108; SHARKEY J, IN PRESS J AUTONOM T; SHIGA Y, 1992, BRAIN RES, V595, P145, DOI 10.1016/0006-8993(92)91465-Q; SLEKULERKA JJ, 1989, NATURE, V341, P755; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; STEINER JP, 1992, NATURE, V358, P584, DOI 10.1038/358584a0	29	436	469	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 22	1994	371	6495					336	339		10.1038/371336a0	http://dx.doi.org/10.1038/371336a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH254	7522303				2022-12-24	WOS:A1994PH25400053
J	HUISMAN, GW; KOLTER, R				HUISMAN, GW; KOLTER, R			SENSING STARVATION - A HOMOSERINE LACTONE-DEPENDENT SIGNALING PATHWAY IN ESCHERICHIA-COLI	SCIENCE			English	Article							CELL-DIVISION GENES; STREPTOMYCES-AMBOFACIENS; SIGMA-FACTOR; STRUCTURAL IDENTIFICATION; LUMINESCENCE SYSTEM; MANDELATE RACEMASE; ERWINIA-CAROTOVORA; CARBON-STARVATION; KATF; AUTOINDUCER	When nutrients become limiting, many bacteria differentiate and become resistant to environmental stresses. For Escherichia coli, this process is mediated by the sigma(s) subunit of RNA polymerase. Expression of sigma(s) was induced by homoserine lactone, a metabolite synthesized from intermediates in threonine biosynthesis. Homoserine lactone-dependent synthesis of oS was prevented by overexpression of a newly identified protein, RspA. The function of homoserine lactone derivatives in many cell density-dependent phenomena and the similarity of RspA to a Streptomyces ambofaciens protein suggest that synthesis of homoserine lactone may be a general signal of starvation.	HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School				Huisman, Gjalt/0000-0003-1955-1120				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARONSON BD, 1989, J BIOL CHEM, V264, P5226; BERG CM, 1992, GENE, V113, P9, DOI 10.1016/0378-1119(92)90664-B; BOHANNON DE, 1991, J BACTERIOL, V173, P4482, DOI 10.1128/JB.173.14.4482-4492.1991; CAO JG, 1989, J BIOL CHEM, V264, P21670; CASHEL M, 1987, ESCHERICHIA COLI SAL, V2, pCH87; DUNLAP PV, 1992, J BACTERIOL, V174, P2440, DOI 10.1128/jb.174.8.2440-2448.1992; EBERHARD A, 1981, BIOCHEMISTRY-US, V20, P2444, DOI 10.1021/bi00512a013; EBERHARD A, 1991, ARCH MICROBIOL, V155, P294, DOI 10.1007/BF00252215; FUQUA WC, 1994, J BACTERIOL, V176, P269, DOI 10.1128/JB.176.2.269-275.1994; GALINIER A, 1991, GENE, V97, P149, DOI 10.1016/0378-1119(91)90024-6; GENTRY DR, 1993, J BACTERIOL, V175, P7982, DOI 10.1128/JB.175.24.7982-7989.1993; HENGGEARONIS R, 1993, CELL, V72, P165, DOI 10.1016/0092-8674(93)90655-A; HOFFMAN M, 1991, SCIENCE, V251, P31, DOI 10.1126/science.1986411; HUISMAN G, 1994, REGULATION OF BACTERIAL DIFFERENTIATION, P21; JAKUBOWSKI H, 1992, MICROBIOL REV, V56, P412, DOI 10.1128/MMBR.56.3.412-429.1992; JONES S, 1993, EMBO J, V12, P2477, DOI 10.1002/j.1460-2075.1993.tb05902.x; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KUO AA, UNPUB; LEBLOND P, 1989, J BACTERIOL, V171, P419, DOI 10.1128/jb.171.1.419-423.1989; LOEWEN PC, 1993, J BACTERIOL, V175, P2150, DOI 10.1128/JB.175.7.2150-2153.1993; MATIN A, 1991, MOL MICROBIOL, V5, P3, DOI 10.1111/j.1365-2958.1991.tb01819.x; MCCANN MP, 1993, J BACTERIOL, V175, P2143, DOI 10.1128/JB.175.7.2143-2149.1993; MEIGHEN EA, 1991, MICROBIOL REV, V55, P123, DOI 10.1128/MMBR.55.1.123-142.1991; MRACHKO G, UNPUB; MULVEY MR, 1989, NUCLEIC ACIDS RES, V17, P9979, DOI 10.1093/nar/17.23.9979; NEIDHART DJ, 1991, BIOCHEMISTRY-US, V30, P9264, DOI 10.1021/bi00102a019; NEIDHART DJ, 1990, NATURE, V347, P692, DOI 10.1038/347692a0; NGUYEN LH, 1993, BIOCHEMISTRY-US, V32, P11112, DOI 10.1021/bi00092a021; PEARSON JP, 1994, P NATL ACAD SCI USA, V91, P197, DOI 10.1073/pnas.91.1.197; PIPER KR, 1993, NATURE, V362, P448, DOI 10.1038/362448a0; PIRHONEN M, 1993, EMBO J, V12, P2467, DOI 10.1002/j.1460-2075.1993.tb05901.x; PSSADOR L, 1993, SCIENCE, V260, P1127; ROBINSON AC, 1984, J BACTERIOL, V160, P546, DOI 10.1128/JB.160.2.546-555.1984; RON EZ, 1975, J BACTERIOL, V124, P243, DOI 10.1128/JB.124.1.243-246.1975; SCHELLHORN HE, 1992, J BACTERIOL, V174, P4769, DOI 10.1128/JB.174.14.4769-4776.1992; SCHNEIDER D, 1993, J GEN MICROBIOL, V139, P2559, DOI 10.1099/00221287-139-11-2559; SIEGELE DA, 1992, J BACTERIOL, V174, P345, DOI 10.1128/jb.174.2.345-348.1992; SIMONET JM, 1992, GENE, V115, P49, DOI 10.1016/0378-1119(92)90539-2; SUN HW, 1992, J MOL EVOL, V34, P522, DOI 10.1007/BF00160465; TANAKA K, 1993, P NATL ACAD SCI USA, V90, P3511, DOI 10.1073/pnas.90.8.3511; WANG XD, 1991, EMBO J, V10, P3363, DOI 10.1002/j.1460-2075.1991.tb04900.x; WYMAN A, 1975, J BIOL CHEM, V250, P3904; ZAMBRANO MM, 1993, SCIENCE, V259, P1757, DOI 10.1126/science.7681219; ZHANG LH, 1993, NATURE, V362, P446, DOI 10.1038/362446a0	45	184	197	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 22	1994	265	5171					537	539		10.1126/science.7545940	http://dx.doi.org/10.1126/science.7545940			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NY216	7545940				2022-12-24	WOS:A1994NY21600035
J	BOLOTINA, VM; NAJIBI, S; PALACINO, JJ; PAGANO, PJ; COHEN, RA				BOLOTINA, VM; NAJIBI, S; PALACINO, JJ; PAGANO, PJ; COHEN, RA			NITRIC-OXIDE DIRECTLY ACTIVATES CALCIUM-DEPENDENT POTASSIUM CHANNELS IN VASCULAR SMOOTH-MUSCLE	NATURE			English	Article							K+ CHANNELS; SKELETAL-MUSCLE; RELAXING FACTOR; ENDOTHELIUM; CELLS; RELAXATION; TONE	NITRIC oxide is the major endothelium-derived relaxing factor (EDRF)(1-3), and it is thought to relax smooth muscle cells by stimulation of guanylate cyclase, accumulation of its product cyclic GMP, and cGMP-dependent modification of several intracellular processes(4-5), including activation of potassium channels through cGMP-dependent protein kinase(6,7). Here we present evidence that both exogenous nitric oxide and native EDRF can directly activate single Ca2+-dependent K+ channels (K-Ca(+)) in cell-free membrane patches without requiring cGMP. Under conditions when guanylate cyclase was inhibited by methylene blue, considerable relaxation of rabbit aorta to nitric oxide persisted which was blocked by charybdotoxin, a specific inhibitor of K-Ca(+) channels. These studies demonstrate a novel direct action of nitric oxide on K-Ca(+) channels.			BOLOTINA, VM (corresponding author), BOSTON UNIV,MED CTR,ROBERT DAWSON EVANS DEPT CLIN RES,VASC BIOL UNIT,BOSTON,MA 02118, USA.		Pagano, Patrick/GYO-2619-2022	/0000-0002-1070-6408; Bolotina, Victoria/0000-0001-5862-181X				BARRETT JN, 1982, J PHYSIOL-LONDON, V331, P211, DOI 10.1113/jphysiol.1982.sp014370; BENHAM CD, 1986, J PHYSIOL-LONDON, V371, P45, DOI 10.1113/jphysiol.1986.sp015961; BOLOTINA V, 1989, PFLUG ARCH EUR J PHY, V415, P262, DOI 10.1007/BF00370875; BRAYDEN JE, 1992, SCIENCE, V256, P532, DOI 10.1126/science.1373909; COWAN CL, 1993, J PHARMACOL EXP THER, V266, P1482; GRIFFITH TM, 1984, NATURE, V308, P645, DOI 10.1038/308645a0; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; KNOWLES RG, 1992, TRENDS BIOCHEM SCI, V17, P399, DOI 10.1016/0968-0004(92)90008-W; KRIPPEITDREWS P, 1992, J CARDIOVASC PHARM, V20, pS72, DOI 10.1097/00005344-199204002-00022; LEI SZ, 1992, NEURON, V8, P1087, DOI 10.1016/0896-6273(92)90130-6; LINCOLN TM, 1991, BLOOD VESSELS, V28, P129; LINCOLN TM, 1993, FASEB J, V7, P328, DOI 10.1096/fasebj.7.2.7680013; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MALINSKI T, 1993, BIOCHEM BIOPH RES CO, V193, P1076, DOI 10.1006/bbrc.1993.1735; MILLER C, 1985, NATURE, V313, P316, DOI 10.1038/313316a0; MONCADA S, 1988, BIOCHEM PHARMACOL, V37, P2495, DOI 10.1016/0006-2952(88)90236-5; NAJIBI S, 1994, AM J PHYSL, V266; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; ROBERTSON BE, 1993, AM J PHYSIOL, V265, pC299; SINGER JJ, 1987, PFLUG ARCH EUR J PHY, V408, P98, DOI 10.1007/BF00581337; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; TAHA Z, 1992, BIOCHEM BIOPH RES CO, V188, P734, DOI 10.1016/0006-291X(92)91117-9; TANIGUCHI J, 1993, PFLUG ARCH EUR J PHY, V423, P167, DOI 10.1007/BF00374390; TARE M, 1990, NATURE, V346, P69, DOI 10.1038/346069a0; TORO L, 1991, J BIOENERG BIOMEMBR, V23, P561, DOI 10.1007/BF00785811; WHITE RE, 1993, NATURE, V361, P263, DOI 10.1038/361263a0; WOLIN MS, 1990, J PHARMACOL EXP THER, V254, P872	28	1445	1481	1	42	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 28	1994	368	6474					850	853		10.1038/368850a0	http://dx.doi.org/10.1038/368850a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH717	7512692				2022-12-24	WOS:A1994NH71700070
J	SAITOH, Y; LAEMMLI, UK				SAITOH, Y; LAEMMLI, UK			METAPHASE CHROMOSOME STRUCTURE - BANDS ARISE FROM A DIFFERENTIAL FOLDING PATH OF THE HIGHLY AT-RICH SCAFFOLD	CELL			English	Article							DNA TOPOISOMERASE-II; INDIAN MUNTJAC; MITOTIC CHROMOSOMES; ATTACHMENT SITES; HISTONE H-1; REGIONS; CONDENSATION; PROTEINS; BINDING; ORDER	Using the highly AT-specific fluorchrome daunomycin, a longitudinal optical signal called AT queue, thought to arise from a line-up of the highly AT-rich scaffold-associated regions (SARs) by the scaffolding, was identified in native chromosomes. Fluorescence banding is proposed to result from a differential folding path of the AT queue during its progression from telomere to telomere. The AT queue is tightly coiled or folded in a Q band, the resulting transverse striations across the chromatid, which also represent Giemsa subbands, generating a bright AT-rich signal over the Q region. The R bands, in contrast, contain a more central (unfolded) AT queue, yielding an AT-dull signal over the R regions. The AT queue is identified by immunofluorescence against topoisomerase II (topo II) and HMG-I/Y as the scaffold of native chromosomes; the fluorescence signal from both proteins is akin to a detailed Q-type banding pattern. Native chromosomes appear assembled according to the loop-scaffold model.	UNIV GENEVA,DEPT MOLEC BIOL,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva	SAITOH, Y (corresponding author), UNIV GENEVA,DEPT BIOCHEM,30 QUAI ERNEST ANSRMET,CH-1211 GENEVA 4,SWITZERLAND.			Galora De Mora, Raul Pavlov/0000-0001-8342-9782				ADACHI Y, 1989, EMBO J, V8, P3997, DOI 10.1002/j.1460-2075.1989.tb08582.x; ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; BERNARDI G, 1988, J MOL EVOL, V28, P7, DOI 10.1007/BF02143493; BODE J, 1992, SCIENCE, V255, P195, DOI 10.1126/science.1553545; COMINGS DE, 1971, EXP CELL RES, V67, P441, DOI 10.1016/0014-4827(71)90430-7; COMINGS DE, 1976, CHROMOSOMA, V56, P199, DOI 10.1007/BF00293185; COMINGS DE, 1978, ANNU REV GENET, V12, P25, DOI 10.1146/annurev.ge.12.120178.000325; CRAIG JM, 1993, BIOESSAYS, V15, P349, DOI 10.1002/bies.950150510; DELATOUR EB, 1988, CELL, V55, P937, DOI 10.1016/0092-8674(88)90239-5; DISNEY JE, 1989, J CELL BIOL, V109, P1975, DOI 10.1083/jcb.109.5.1975; EARNSHAW WC, 1985, J CELL BIOL, V100, P1716, DOI 10.1083/jcb.100.5.1716; EARNSHAW WC, 1983, J CELL BIOL, V96, P84, DOI 10.1083/jcb.96.1.84; ERICSSON C, 1990, CELL, V60, P73, DOI 10.1016/0092-8674(90)90717-S; GARRARD WT, 1990, NUCL ACIDS MOL BIOL, P163; GASSER SM, 1987, TRENDS GENET, V3, P16, DOI 10.1016/0168-9525(87)90156-9; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HOLMQUIST G, 1982, CELL, V31, P121, DOI 10.1016/0092-8674(82)90411-1; HOLMQUIST GP, 1992, AM J HUM GENET, V51, P17; HOMBERGER HP, 1989, CHROMOSOMA, V98, P99, DOI 10.1007/BF00291044; IZAURRALDE E, 1989, J MOL BIOL, V210, P573, DOI 10.1016/0022-2836(89)90133-2; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; JOHNSTON FP, 1978, CHROMOSOMA, V68, P115, DOI 10.1007/BF00287144; KAS E, 1989, J MOL BIOL, V210, P587, DOI 10.1016/0022-2836(89)90134-4; KAS E, 1993, EMBO J, V12, P115, DOI 10.1002/j.1460-2075.1993.tb05637.x; KEREM BS, 1984, CELL, V38, P493, DOI 10.1016/0092-8674(84)90504-X; KORENBERG JR, 1978, P NATL ACAD SCI USA, V75, P3382, DOI 10.1073/pnas.75.7.3382; LAEMMLI UK, 1977, COLD SPRING HARB SYM, V42, P351; Laemmli UK, 1992, CURR OPIN GENET DEV, V2, P275, DOI 10.1016/S0959-437X(05)80285-0; LEWIS CD, 1982, CELL, V29, P171, DOI 10.1016/0092-8674(82)90101-5; MARSDEN MPF, 1979, CELL, V17, P849, DOI 10.1016/0092-8674(79)90325-8; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; MULLER W, 1975, EUR J BIOCHEM, V54, P385, DOI 10.1111/j.1432-1033.1975.tb04149.x; PARDUE ML, 1975, J CELL BIOL, V64, P251, DOI 10.1083/jcb.64.1.251; PAULSON JR, 1977, CELL, V12, P817, DOI 10.1016/0092-8674(77)90280-X; RATTNER JB, 1985, CELL, V42, P291, DOI 10.1016/S0092-8674(85)80124-0; REEVES R, 1990, J BIOL CHEM, V265, P8573; REEVES R, 1992, Current Opinion in Cell Biology, V4, P413, DOI 10.1016/0955-0674(92)90006-X; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; ROTH MB, 1987, J CELL BIOL, V105, P1047, DOI 10.1083/jcb.105.3.1047; SAITOH Y, 1984, IN PRESS COLD SPRING, V85; Sambrook J., 1989, MOL CLONING LAB MANU; SCHWEIZER D, 1981, HUM GENET, V57, P1; SCHWEIZER D, 1976, CHROMOSOMA, V58, P307, DOI 10.1007/BF00292840; SEN P, 1985, CYTOGENET CELL GENET, V39, P145, DOI 10.1159/000132124; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; SPERRY AO, 1989, P NATL ACAD SCI USA, V86, P5497, DOI 10.1073/pnas.86.14.5497; Sumner A. T, 1990, CHROMOSOME BANDING; UEMURA T, 1984, EMBO J, V3, P1737, DOI 10.1002/j.1460-2075.1984.tb02040.x; ZHAO K, 1993, EMBO J, V12, P3237, DOI 10.1002/j.1460-2075.1993.tb05993.x	50	323	344	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 25	1994	76	4					609	622		10.1016/0092-8674(94)90502-9	http://dx.doi.org/10.1016/0092-8674(94)90502-9			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MZ285	7510215				2022-12-24	WOS:A1994MZ28500005
J	GRAVES, BJ; CROWTHER, RL; CHANDRAN, C; RUMBERGER, JM; LI, S; HUANG, KS; PRESKY, DH; FAMILLETTI, PC; WOLITZKY, BA; BURNS, DK				GRAVES, BJ; CROWTHER, RL; CHANDRAN, C; RUMBERGER, JM; LI, S; HUANG, KS; PRESKY, DH; FAMILLETTI, PC; WOLITZKY, BA; BURNS, DK			INSIGHT INTO E-SELECTIN LIGAND INTERACTION FROM THE CRYSTAL-STRUCTURE AND MUTAGENESIS OF THE LEC EGF DOMAINS	NATURE			English	Article							LEUKOCYTE-ADHESION MOLECULE-1; GROWTH FACTOR-ALPHA; MANNOSE-BINDING PROTEIN; NODE HOMING RECEPTOR; CARBOHYDRATE-RECOGNITION; EVOLUTIONARY CONSERVATION; FUNCTIONAL INTERACTIONS; NMR-SPECTROSCOPY; CELL-ADHESION; P-SELECTIN	The three-dimensional structure of the ligand-binding region of human E-selectin has been determined at 2.0 angstrom resolution. The structure reveals limited contact between the two domains and a coordination of Ca2+ not predicted from other C-type lectins. Structure/function analysis indicates a defined region and specific amino-acid side chains that may be involved in ligand binding. These features of the E-selectin/ligand interaction have important implications for understanding the recruitment of leukocytes to sites of inflammation.			GRAVES, BJ (corresponding author), HOFFMANN LA ROCHE INC,ROCHE RES CTR,NUTLEY,NJ 07110, USA.							BARON M, 1992, PROTEIN SCI, V1, P81; BECKERANDRE M, 1992, EUR J BIOCHEM, V206, P401, DOI 10.1111/j.1432-1033.1992.tb16940.x; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.iy.11.040193.004003; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BEZOUSKA K, 1991, J BIOL CHEM, V266, P11604; BOWEN BR, 1990, J CELL BIOL, V110, P147, DOI 10.1083/jcb.110.1.147; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; BVALL GE, 1992, J AM CHEM SOC, V114, P5449; DEFREES SA, 1993, J AM CHEM SOC, V115, P7549, DOI 10.1021/ja00069a083; ERBE DV, 1992, J CELL BIOL, V119, P215, DOI 10.1083/jcb.119.1.215; ERBE DV, 1993, J CELL BIOL, V120, P1227, DOI 10.1083/jcb.120.5.1227; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; HARVEY TS, 1991, EUR J BIOCHEM, V198, P555, DOI 10.1111/j.1432-1033.1991.tb16050.x; HESSION C, 1990, P NATL ACAD SCI USA, V87, P1673, DOI 10.1073/pnas.87.5.1673; HOLLENBAUGH D, 1993, BIOCHEMISTRY-US, V32, P2960, DOI 10.1021/bi00063a006; HOMMEL U, 1992, J MOL BIOL, V227, P271, DOI 10.1016/0022-2836(92)90697-I; HUNTER CA, 1991, J MOL BIOL, V218, P837, DOI 10.1016/0022-2836(91)90271-7; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KLINE TP, 1990, BIOCHEMISTRY-US, V29, P7805, DOI 10.1021/bi00486a005; KOHDA D, 1989, BIOCHEMISTRY-US, V28, P953, DOI 10.1021/bi00429a005; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LARIGAN JD, 1992, DNA CELL BIOL, V11, P149, DOI 10.1089/dna.1992.11.149; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LEVINOVITZ A, 1993, J CELL BIOL, V121, P449, DOI 10.1083/jcb.121.2.449; LI SH, IN PRESS J BIOL CHEM; LIN YC, 1992, J AM CHEM SOC, V114, P5452, DOI 10.1021/ja00039a082; MILLER KE, 1992, BIOCHEMISTRY-US, V31, P6703, DOI 10.1021/bi00144a009; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MONTELIONE GT, 1992, BIOCHEMISTRY-US, V31, P236, DOI 10.1021/bi00116a033; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; NORGARD KE, 1993, J BIOL CHEM, V268, P12764; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; PIGOTT R, 1991, J IMMUNOL, V147, P130; QUESENBERRY MS, 1992, J BIOL CHEM, V267, P10831; SCALLON BJ, 1992, BIO-TECHNOL, V10, P550, DOI 10.1038/nbt0592-550; SELANDERSUNNERHAGEN M, 1992, J BIOL CHEM, V267, P19642; SIEGELMAN MH, 1989, P NATL ACAD SCI USA, V86, P5562, DOI 10.1073/pnas.86.14.5562; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; STRUBEL NA, 1993, BIOCHEM BIOPH RES CO, V192, P338, DOI 10.1006/bbrc.1993.1420; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; WELLER A, 1992, J BIOL CHEM, V267, P15176; WORMALD MR, 1991, BIOCHEM BIOPH RES CO, V180, P1214, DOI 10.1016/S0006-291X(05)81325-7; 1992, SYBYL MOL MODELING S	52	403	418	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 10	1994	367	6463					532	538		10.1038/367532a0	http://dx.doi.org/10.1038/367532a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MV863	7509040				2022-12-24	WOS:A1994MV86300050
J	JACOBS, RE; FRASER, SE				JACOBS, RE; FRASER, SE			MAGNETIC-RESONANCE MICROSCOPY OF EMBRYONIC-CELL LINEAGES AND MOVEMENTS	SCIENCE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; XENOPUS-LAEVIS; NMR MICROSCOPY; INTRACELLULAR INJECTION; MOUSE EMBRYOS; FATE MAP; RESOLUTION; RETINA; RETROVIRUS; BLASTOMERE	Key events in vertebrate embryogenesis are difficult to observe in many species. High-resolution magnetic resonance imaging was used to follow cell movements and lineages in developing frog embryos. A single cell was injected at the 16-cell stage with a contrast agent, based on the gadolinium chelate gadolinium-diethylenetriamine pentaacetic acid-dextran. The labeled progeny cells could be followed uniquely in three-dimensional magnetic resonance images, acquired from the embryo over several days. The results show that external ectodermal and internal mesodermal tissues extend at different rates during amphibian gastrulation and neurulation.			JACOBS, RE (corresponding author), CALTECH,BECKMAN INST 13974,DIV BIOL,PASADENA,CA 91125, USA.		Fraser, Scott/Y-3406-2019	Fraser, Scott/0000-0002-5377-0223	NICHD NIH HHS [HD 25390] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025390] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AGUAYO JB, 1986, NATURE, V322, P190, DOI 10.1038/322190a0; AHN CB, 1989, MED PHYS, V16, P22, DOI 10.1118/1.596393; AKERS RM, 1986, SCIENCE, V231, P613, DOI 10.1126/science.3945801; BALAKIER H, 1982, DEV BIOL, V90, P352, DOI 10.1016/0012-1606(82)90384-0; BEHLING RW, 1989, NATURE, V341, P321, DOI 10.1038/341321a0; BRONNERFRASER M, 1988, NATURE, V335, P161, DOI 10.1038/335161a0; CALLAGHAN PT, 1988, J MAGN RESON, V78, P1, DOI 10.1016/0022-2364(88)90151-5; CALLAGHAN PT, 1991, PRINCIPLES NUCLEAR M; CAMERON RA, 1987, GENE DEV, V1, P75, DOI 10.1101/gad.1.1.75; CHO ZH, 1988, MED PHYS, V15, P815, DOI 10.1118/1.596287; CONNER WE, 1988, EXPERIENTIA, V44, P11, DOI 10.1007/BF01960223; DALE L, 1987, DEVELOPMENT, V99, P527; EAGLESON GW, 1990, J NEUROBIOL, V21, P427, DOI 10.1002/neu.480210305; ECCLES CD, 1986, J MAGN RESON, V68, P393, DOI 10.1016/0022-2364(86)90261-1; EFFMANN EL, 1988, TERATOLOGY, V38, P59, DOI 10.1002/tera.1420380109; GIBBY WA, 1989, INVEST RADIOL, V24, P302, DOI 10.1097/00004424-198904000-00009; GIMLICH RL, 1985, DEV BIOL, V109, P509, DOI 10.1016/0012-1606(85)90476-2; GLOVER P, 1989, 8TH ANN M SOC MAGN R, P285; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; HEDGECOCK EM, 1985, TRENDS NEUROSCI, V8, P288, DOI 10.1016/0166-2236(85)90104-3; HOLT CE, 1988, NEURON, V1, P15, DOI 10.1016/0896-6273(88)90205-X; JACKSON GE, 1990, MAGNET RESON MED, V16, P57, DOI 10.1002/mrm.1910160107; JACOBS RR, COMMUNICATION; JENNER CF, 1988, NATURE, V336, P399, DOI 10.1038/336399a0; JOHNSON GA, 1986, J MAGN RESON, V68, P129, DOI 10.1016/0022-2364(86)90322-7; KELLER R, 1991, GASTRULATION MOVEMEN; KELLER RE, 1985, NEW SERIES, V31; KIMBLE J, 1979, DEV BIOL, V70, P396, DOI 10.1016/0012-1606(79)90035-6; KIMMEL CB, 1986, SCIENCE, V231, P365, DOI 10.1126/science.231.4736.365; KUHN W, 1990, ANGEW CHEM INT EDIT, V29, P1, DOI 10.1002/anie.199000013; LAUFFER RB, 1987, CHEM REV, V87, P901, DOI 10.1021/cr00081a003; LEE DH, 1991, J CAN ASSOC RADIOL, V42, P6; MAKI JH, 1988, J MAGN RESON, V80, P482, DOI 10.1016/0022-2364(88)90243-0; Mansfield P., 1982, NMR IMAGING BIOMEDIC; Mathews WW., 1986, ATLAS DESCRIPTIVE EM; MOODY SA, 1987, DEV BIOL, V119, P560, DOI 10.1016/0012-1606(87)90059-5; MOONEN CTW, 1990, SCIENCE, V250, P53, DOI 10.1126/science.2218514; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SLACK JMW, 1992, DEVELOPMENT, V114, P285; STEHLING MK, 1991, SCIENCE, V254, P43, DOI 10.1126/science.1925560; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; WANG SC, 1990, RADIOLOGY, V175, P483, DOI 10.1148/radiology.175.2.1691513; WEISBLAT DA, 1980, SCIENCE, V209, P1538, DOI 10.1126/science.6159680; WEISBLAT DA, 1978, SCIENCE, V202, P1295, DOI 10.1126/science.725606; WETTS R, 1988, SCIENCE, V239, P1142, DOI 10.1126/science.2449732; WETTS R, 1989, DEVELOPMENT, V105, P9; WILSON PA, 1989, DEVELOPMENT, V105, P155; ZHOU X, 1989, 8TH ANN M SOC MAGN R, P286; [No title captured]	52	144	158	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 4	1994	263	5147					681	684		10.1126/science.7508143	http://dx.doi.org/10.1126/science.7508143			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU964	7508143				2022-12-24	WOS:A1994MU96400049
J	LINGUEGLIA, E; CHAMPIGNY, G; LAZDUNSKI, M; BARBRY, P				LINGUEGLIA, E; CHAMPIGNY, G; LAZDUNSKI, M; BARBRY, P			CLONING OF THE AMILORIDE-SENSITIVE FMRFAMIDE PEPTIDE-GATED SODIUM-CHANNEL	NATURE			English	Article							CAENORHABDITIS-ELEGANS; RECEPTOR; BRAIN; NEURODEGENERATION; EXPRESSION	THE peptide Phe-Met-Arg-Phe-NH2 (FMRFamide) and structurally related peptides are present both in invertebrate and vertebrate nervous systems(1,2). Although they constitute a major class of invertebrate peptide neurotransmitters(3), the molecular structure of their receptors has not yet been identified, In neurons of the snail Helix aspersa(4), as well as in Aplysia bursting(5) and motor(6) neurons, FMRFamide induces a fast excitatory depolarizing response due to direct activation of an amiloride-sensitive Na+ channel(4). We have now isolated a complementary DNA from Helix nervous tissue; when expressed in Xenopus oocytes, it encodes an FMRF-amide-activated Na+ channel (FaNaCh) that can be blocked by amiloride. The corresponding protein shares a very low sequence identity with the previously cloned epithelial Na+ channel subunits(7-12) and Caenorhabditis elegans degenerins(13-15), but it displays the same overall structural organization. To our knowledge, this is the first characterization of a peptide-gated ionotropic receptor.	CNRS,INST PHARMACOL MOLEC & CELLULAIRE,F-06560 VALBONNE,FRANCE	Centre National de la Recherche Scientifique (CNRS)			LINGUEGLIA, Eric/F-5509-2013; Barbry, Pascal/O-5021-2016	LINGUEGLIA, Eric/0000-0003-3902-3405; Barbry, Pascal/0000-0001-9632-6483				BELKIN KJ, 1993, J NEUROSCI, V13, P5139, DOI 10.1523/JNEUROSCI.13-12-05139.1993; BETZ H, 1990, NEURON, V5, P383, DOI 10.1016/0896-6273(90)90077-S; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CHALFIE M, 1990, NATURE, V345, P410, DOI 10.1038/345410a0; COTTRELL GA, 1993, COMP MOL NEUROBIOL, V63, P279; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; GALZI JL, 1992, NATURE, V359, P500, DOI 10.1038/359500a0; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; GARCIAANOVEROS J, 1995, CURR BIOL, V5, P441, DOI 10.1016/S0960-9822(95)00085-6; GARTY H, 1994, FASEB J, V8, P523; GREEN KA, 1994, PFLUG ARCH EUR J PHY, V428, P232, DOI 10.1007/BF00724502; GREENBERG MJ, 1992, PROG BRAIN RES, V92, P25, DOI 10.1016/S0079-6123(08)61162-0; HONG KS, 1994, NATURE, V367, P470, DOI 10.1038/367470a0; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; LI XJ, 1994, P NATL ACAD SCI USA, V91, P1814, DOI 10.1073/pnas.91.5.1814; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; LINGUEGLIA E, 1994, J BIOL CHEM, V269, P13736; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; PALMER LG, 1992, ANNU REV PHYSIOL, V54, P51, DOI 10.1146/annurev.ph.54.030192.000411; PRICE DA, 1977, SCIENCE, V197, P670, DOI 10.1126/science.877582; RAFFA RB, 1988, PEPTIDES, V9, P915, DOI 10.1016/0196-9781(88)90141-6; RENARD S, 1994, J BIOL CHEM, V269, P12981; RUBEN P, 1986, J NEUROSCI, V6, P252; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; VOILLEY N, 1995, GENOMICS, V28, P560, DOI 10.1006/geno.1995.1188; VOILLEY N, 1994, P NATL ACAD SCI USA, V91, P247, DOI 10.1073/pnas.91.1.247; WALDMANN R, 1995, J BIOL CHEM, V270, P11735, DOI 10.1074/jbc.270.20.11735; YANG HYT, 1985, P NATL ACAD SCI USA, V82, P7757, DOI 10.1073/pnas.82.22.7757	30	338	344	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 14	1995	378	6558					730	733		10.1038/378730a0	http://dx.doi.org/10.1038/378730a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK379	7501021				2022-12-24	WOS:A1995TK37900056
J	HERMAN, MA; VASSILIEVA, LL; HORVITZ, HR; SHAW, JE; HERMAN, RK				HERMAN, MA; VASSILIEVA, LL; HORVITZ, HR; SHAW, JE; HERMAN, RK			THE C-ELEGANS GENE LIN-44, WHICH CONTROLS THE POLARITY OF CERTAIN ASYMMETRIC CELL DIVISIONS, ENCODES A WNT PROTEIN AND ACTS CELL NONAUTONOMOUSLY	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; DROSOPHILA HOMOLOG; EXPRESSION; WINGLESS; YEAST; REGION; PLAKOGLOBIN; SEQUENCES; VECTORS; LINEAGE	Mutations in the C. elegans gene lin-44 lead to reversals in the polarity of certain asymmetric cell divisions. We have discovered that lin-44 is a member of the Wnt family of genes, which encode secretory glycoproteins implicated in intercellular signaling. Both in situ hybridization experiments using lin-44 transcripts and experiments using reporter constructs designed to mimic patterns of lin-44 expression indicate that lin-44 is expressed in hypodermal cells at the tip of the tail and posterior to the cells with polarities affected by lin-44 mutations. Our mosaic analysis indicates that lin-44 acts cell nonautonomously. We propose that LIN-44 protein is secreted by tail hypodermal cells and affects the polarity of asymmetric cell divisions that occur more anteriorly in the tail.	MIT,HOWARD HUGHES MED INST,DEPT BIOL,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	HERMAN, MA (corresponding author), UNIV MINNESOTA,DEPT GENET & CELL BIOL,ST PAUL,MN 55108, USA.			Herman, Michael/0000-0001-6796-1568	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024943, R01GM022387] Funding Source: NIH RePORTER; NICHD NIH HHS [HD22163] Funding Source: Medline; NIGMS NIH HHS [GM24943, GM22387] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER PN, 1992, BIOESSAYS, V14, P735, DOI 10.1002/bies.950141103; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHISHOLM AD, 1989, GENE DEV, V3, P1413, DOI 10.1101/gad.3.9.1413; COULSON A, 1991, BIOESSAYS, V13, P413, DOI 10.1002/bies.950130809; DEVENISH RJ, 1982, GENE, V18, P277, DOI 10.1016/0378-1119(82)90166-4; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HERMAN MA, 1994, DEVELOPMENT, V120, P1035; HERMAN RK, 1989, J NEUROGENET, V5, P1, DOI 10.3109/01677068909167261; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; HOWELL AM, 1990, GENETICS, V126, P583; Kaiser K, 1985, DNA CLONING PRACTICA, P1; KAMB A, 1989, P NATL ACAD SCI USA, V86, P4372, DOI 10.1073/pnas.86.12.4372; KENYON C, 1986, CELL, V46, P477, DOI 10.1016/0092-8674(86)90668-9; KLINGENSMITH J, 1994, DEV BIOL, V166, P396, DOI 10.1006/dbio.1994.1325; KLINGENSMITH J, 1994, GENE DEV, V8, P118, DOI 10.1101/gad.8.1.118; KRASNOW RE, 1994, DEVELOPMENT, V120, P1883; LACKNER MR, 1994, GENE DEV, V8, P160, DOI 10.1101/gad.8.2.160; MA H, 1987, GENE, V58, P201, DOI 10.1016/0378-1119(87)90376-3; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MELLO CC, 1995, IN PRESS METH CELL B; MILLER LM, 1993, GENE DEV, V7, P933, DOI 10.1101/gad.7.6.933; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PODBILEWICZ B, 1994, DEV BIOL, V161, P408, DOI 10.1006/dbio.1994.1041; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; RUSSELL J, 1992, DEVELOPMENT, V115, P475; SAMBROOK J, 1989, MO LCLONING LABORATO; SCHWARTZ DC, 1984, CELL, V37, P67, DOI 10.1016/0092-8674(84)90301-5; SEYDOUX G, 1995, IN PRES METH CELL BI; SHACKLEFORD GM, 1993, ONCOGENE, V8, P1857; SIDOW A, 1992, P NATL ACAD SCI USA, V89, P5098, DOI 10.1073/pnas.89.11.5098; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; SIEGFRIED E, 1994, BIOESSAYS, V16, P395, DOI 10.1002/bies.950160607; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; Sulston J, 1988, NEMATODE CAENORHABDI, P587; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; THEISEN H, 1994, DEVELOPMENT, V120, P347; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VINCENT JP, 1994, CELL, V77, P9909; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WATERSTON RH, 1981, GENETICS, V97, P307; WYMAN AR, 1987, METHOD ENZYMOL, V152, P173	48	166	173	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 6	1995	83	1					101	110		10.1016/0092-8674(95)90238-4	http://dx.doi.org/10.1016/0092-8674(95)90238-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RY583	7553861	Bronze			2022-12-24	WOS:A1995RY58300014
J	ANDERSSON, N; DASOUSA, CP; PAREDES, S				ANDERSSON, N; DASOUSA, CP; PAREDES, S			SOCIAL COST OF LAND MINES IN 4 COUNTRIES - AFGHANISTAN, BOSNIA, CAMBODIA, AND MOZAMBIQUE	BRITISH MEDICAL JOURNAL			English	Article							COMMUNITY	Objectives-To document the effects of land mines on the health and social conditions of communities in four affected countries. Design-A cross design of cluster survey and rapid appraisal methods including a household questionnaire and qualitative data from key informants, institutional reviews, and focus groups of survivors of landmines from the same communities. Setting-206 communities, 37 in Afghanistan, 66 in Bosnia, 38 in Cambodia, and 65 in Mozambique. Subjects-174 489 people living in 32 904 households in the selected communities. Main outcome measures-Effects of land mines on food security, residence, livestock, and land use; risk factors: extent of individual land mine injuries; physical, psychological, social, and economic costs of injuries during medical care and rehabilitation. Results-Between 25% and 87% of households had daily activities affected by land mines. Based on expected production without the mines, agricultural production could increase by 88-200% in different regions of Afghanistan, 11% in Bosnia, 135% in Cambodia, and 3.6% in Mozambique. A total of 54 554 animals was lost because of land mines, with a minimum cash value of $6.5m, or nearly $200 per household. Overall, 6% of households (1964) reported a land mine victim; a third of victims died in the blast. One in 10 of the victims was a child. The most frequent activities associated with land mine incidents were agricultural or pastoral, except in Bosnia where more than half resulted from military activities, usually during patrols. Incidences have more than doubled between 1980-3 and 1990-3, excluding the incidents in Bosnia. Some 22% of victims (455/2100) were from households reporting attempts to remove land mines; in these households there was a greatly increased risk of injury (odds ratio 4.2 and risk difference 19% across the four countries). Lethality of the mines varied; in Bosnia each blast killed an average of 0.54 people and injured 1.4, whereas in Mozambique each blast killed 1.45 people and wounded 1.27. Households with a land mine victim were 40% more likely to experience difficulty in providing food for the family. Family relationships were affected for around one in every four victims and relationships with colleagues in 40%. Conclusions-Land mines seriously undermine the economy and food security in affected countries; they kill and maim civilians at an increasing rate. The expense of medical care and rehabilitation add economic disability to the physical burden. Awareness of land mines can be targeted at high risk attitudes, such as those associated with tampering with mines.			ANDERSSON, N (corresponding author), CIETINT,847A 2ND AVE,SUITE 387,NEW YORK,NY 10017, USA.							Andersson N., 1989, Health Policy and Planning, V4, P197, DOI 10.1093/heapol/4.3.197; ANDERSSON N, 1992, HEALTH POLICY PLANN, V7, P352, DOI 10.1093/heapol/7.4.352; COUPLAND RM, 1991, BMJ-BRIT MED J, V303, P1509, DOI 10.1136/bmj.303.6816.1509; Coupland Robin M., 1994, MED GLOBAL SURVIVAL, V1, P18; Kakar F, 1995, DIRECT INDIRECT CONS; LEDOGAR RJ, 1993, THIRD WORLD PLAN REV, V15, P263; MANTEL N, 1959, J NATL CANCER I, V22, P719; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; MIETTINEN OS, 1974, AM J EPIDEMIOL, V100, P515; RUIJTER JM, 1991, CONVERGENCE, V34, P3; ZELEN M, 1971, BIOMETRIKA, V58, P129, DOI 10.1093/biomet/58.1.129; 1994, UN A49357 REP; 1993, HIDDEN KILLERS GLOBA; 1994, MAY C DOC CERT CONV; 1993, UNICEF MINE AWARENES; 1994, PROGRAMME TECHNICAL; 1994, INT REV RED CROSS; 1993, LANDMINES DEADLY LEG	19	106	108	0	33	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 16	1995	311	7007					718	721		10.1136/bmj.311.7007.718	http://dx.doi.org/10.1136/bmj.311.7007.718			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RV874	7549685	Green Published			2022-12-24	WOS:A1995RV87400019
J	CROVELLO, CS; FURIE, BC; FURIE, B				CROVELLO, CS; FURIE, BC; FURIE, B			HISTIDINE PHOSPHORYLATION OF P-SELECTIN UPON STIMULATION OF HUMAN PLATELETS - A NOVEL PATHWAY FOR ACTIVATION-DEPENDENT SIGNAL-TRANSDUCTION	CELL			English	Article							GRANULE MEMBRANE-PROTEIN; LABILE HISTONE PHOSPHATES; PHYSARUM-POLYCEPHALUM; DEHYDROGENASE KINASE; SEQUENCE SIMILARITY; MOLECULAR-CLONING; NUCLEAR PROTEINS; PLASMA-MEMBRANE; RAT-LIVER; ADHESION	Transient phosphorylation of histidine characterizes the two-component systems in prokaryotes that control important physiological functions, but analogous events have not been implicated in signal transduction in mammalian cells. To explore histidine phosphorylation during activation of human cells, stimulated platelets were analyzed for the formation of protein phosphohistidine in a model system employing P-selectin. P-selectin, a leukocyte adhesion molecule, undergoes rapid phosphorylation and selective dephosphorylation of tyrosine, serine, and threonine. We now establish that phosphorylation following platelet activation with thrombin or collagen generates phosphohistidine at histidines on the cytoplasmic tail of P-selectin. With thrombin stimulation, the kinetics of phosphohistidine appearance and disappearance on P-selectin are very rapid. Platelets exhibit a novel ligand-induced signaling pathway to generate phosphohistidine. These results provide direct biochemical evidence for the induction of rapid and reversible histidine phosphorylation in mammalian cells upon cell activation and represent a novel paradigm for mammalian cell signaling.	TUFTS UNIV, SCH MED, DEPT MED, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, DEPT BIOCHEM, BOSTON, MA 02111 USA	Tufts University; Tufts University	CROVELLO, CS (corresponding author), TUFTS UNIV, NEW ENGLAND MED CTR, SCH MED, CTR HEMOSTASIS & THROMBOSIS RES, DIV HEMATOL ONCOL, BOSTON, MA 02111 USA.				NHLBI NIH HHS [HL51926] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051926] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERMAN CL, 1986, J CLIN INVEST, V78, P130, DOI 10.1172/JCI112542; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; CELI A, 1994, P NATL ACAD SCI USA, V91, P8767, DOI 10.1073/pnas.91.19.8767; CHEN CC, 1977, BIOCHEMISTRY-US, V16, P4852, DOI 10.1021/bi00641a016; CHEN CC, 1974, BIOCHEMISTRY-US, V13, P3785, DOI 10.1021/bi00715a026; CHONG BH, 1994, BLOOD, V83, P1535; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; COUGHLIN SR, 1994, P NATL ACAD SCI USA, V91, P9200, DOI 10.1073/pnas.91.20.9200; CROVELLO CS, 1993, J BIOL CHEM, V268, P14590; FUJIMOTO T, 1993, BLOOD, V82, P1758; FUJIMOTO T, 1993, J BIOL CHEM, V268, P11394; FUJITAKI JM, 1981, BIOCHEMISTRY-US, V20, P3658, DOI 10.1021/bi00515a055; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; HESS JF, 1988, NATURE, V336, P139, DOI 10.1038/336139a0; HSULIN SC, 1984, J BIOL CHEM, V259, P9121; HUANG JM, 1991, J BIOL CHEM, V266, P9023; HUEBNER VD, 1985, J BIOL CHEM, V260, P6106; HUNG DT, 1992, J BIOL CHEM, V267, P20831; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KIM YH, 1993, J BIOL CHEM, V268, P18513; KUNICKI TJ, 1988, J BIOL CHEM, V263, P4516; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MAYADAS TN, 1993, CELL, V74, P541, DOI 10.1016/0092-8674(93)80055-J; MOORE KL, 1994, J BIOL CHEM, V269, P23318; MOTOJIMA K, 1993, FEBS LETT, V319, P75, DOI 10.1016/0014-5793(93)80040-2; MOTOJIMA K, 1994, J BIOL CHEM, V269, P9030; OHMORI H, 1993, J BIOL CHEM, V268, P7625; PESIS KH, 1988, FEBS LETT, V239, P151, DOI 10.1016/0014-5793(88)80563-5; POPOV KM, 1992, J BIOL CHEM, V267, P13127; POPOV KM, 1993, J BIOL CHEM, V268, P26602; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SHATTIL SJ, 1993, THROMB HAEMOSTASIS, V70, P224; Sheridan R. C., 2007, INORG SYN, P23; SMITH DL, 1974, BIOCHEMISTRY-US, V13, P3780, DOI 10.1021/bi00715a025; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; STENBERG PE, 1985, J CELL BIOL, V101, P880, DOI 10.1083/jcb.101.3.880; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; SWANSON RV, 1994, TRENDS BIOCHEM SCI, V19, P485, DOI 10.1016/0968-0004(94)90135-X; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WALINDER O, 1969, J BIOL CHEM, V244, P1065; WALINDER O, 1968, J BIOL CHEM, V243, P3947; WATSON SP, 1985, BIOCHEM J, V226, P831, DOI 10.1042/bj2260831; WEI YF, 1993, METHOD ENZYMOL, V200, P388; WETTENHALL REH, 1991, METHOD ENZYMOL, V201, P186; WIELAND T, 1993, J BIOL CHEM, V268, P18111; WONG C, 1993, BIOCHEM J, V296, P293, DOI 10.1042/bj2960293; ZETTERQVIST O, 1967, BIOCHIM BIOPHYS ACTA, V136, P279, DOI 10.1016/0304-4165(67)90073-6; ZHANG J, 1993, J BIOL CHEM, V268, P22251	53	88	90	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 28	1995	82	2					279	286		10.1016/0092-8674(95)90315-1	http://dx.doi.org/10.1016/0092-8674(95)90315-1			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RL760	7543025	Bronze			2022-12-24	WOS:A1995RL76000015
J	SATO, T; IRIE, S; KITADA, S; REED, JC				SATO, T; IRIE, S; KITADA, S; REED, JC			FAP-1 - A PROTEIN-TYROSINE-PHOSPHATASE THAT ASSOCIATES WITH FAS	SCIENCE			English	Article							TUMOR-NECROSIS-FACTOR; MONOCLONAL-ANTIBODY; APOPTOSIS; ANTIGEN; EXPRESSION; INTERACTS; BCL-2; CELLS	Fas is a cell surface receptor that controls a poorly understood signal transduction pathway that leads to cell death by means of apoptosis. A protein tyrosine phosphatase, FAP-1, capable of interacting with the cytosolic domain of Fas, was identified. The carboxyl terminal 15 amino acids of Fas are necessary and sufficient for interaction with FAP-1. FAP-1 expression is highest in tissues and cell lines that are relatively resistant to Fas-mediated cytotoxicity. Gene transfer-mediated elevations in FAP-1 partially abolished Fas-induced apoptosis in a T cell line. These findings are consistent with an inhibitory effect of FAP-1 on Fas signal transduction.	LA JOLLA CANC RES FDN,ONCOGENE & TUMOR SUPPRESSOR GENE PROGRAM,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute								ALDERSON MR, 1993, J EXP MED, V178, P2231, DOI 10.1084/jem.178.6.2231; CHENG JH, 1994, SCIENCE, V263, P1759, DOI 10.1126/science.7510905; EISCHEN CM, 1994, J IMMUNOL, V153, P1947; GORCZYCA W, 1993, CANCER RES, V53, P1945; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1993, J IMMUNOL, V151, P621; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KLAS C, 1993, INT IMMUNOL, V5, P625, DOI 10.1093/intimm/5.6.625; LYNCH DH, 1994, IMMUNITY, V1, P131, DOI 10.1016/1074-7613(94)90106-6; MAEKAWA K, 1994, FEBS LETT, V337, P200, DOI 10.1016/0014-5793(94)80273-4; MAPARA MY, 1993, EUR J IMMUNOL, V23, P702, DOI 10.1002/eji.1830230320; MOLLER NPH, 1994, P NATL ACAD SCI USA, V91, P7477, DOI 10.1073/pnas.91.16.7477; OWENSCHAUB LB, 1994, CANCER RES, V54, P1580; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SATO TJ, UNPUB; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TAKAHASHI S, 1993, EUR J IMMUNOL, V23, P1935, DOI 10.1002/eji.1830230831; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	25	684	724	0	9	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 21	1995	268	5209					411	415		10.1126/science.7536343	http://dx.doi.org/10.1126/science.7536343			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU572	7536343				2022-12-24	WOS:A1995QU57200038
J	JOHNSON, TL; CHAMBERLIN, MJ				JOHNSON, TL; CHAMBERLIN, MJ			COMPLEXES OF YEAST RNA-POLYMERASE-II AND RNA ARE SUBSTRATES FAR TFIIS-INDUCED RNA CLEAVAGE	CELL			English	Article							TRANSCRIPTION ELONGATION-FACTOR; RHO-INDEPENDENT TERMINATORS; ESCHERICHIA-COLI; INFLUENZA-VIRUS; FACTOR-SII; INVITRO; ENZYME; DNA	In the absence of DNA, purified yeast RNA polymerase II can bind RNA to form a binary complex. RNA in such RNA-RNA polymerase complexes undergoes reactions previously thought to be unique to nascent RNA in ternary complexes with DNA, including TFIIS-dependent cleavage and elongation by 3'-terminal addition of NMP from NTP. Both of these reactions are inhibited by alpha-amanitin. Hence, by several criteria the RNA in binary complexes is bound to the polymerase in a manner quite similar to that in ternary complexes in which the catalytic site for nucleotide addition is positioned at or near the 3'-OH terminus of the RNA. These findings are consistent with a model for the RNA polymerase ternary complete in which the RNA is bound at the 3' terminus through two protein-binding sites located up to 10 nt apart.			JOHNSON, TL (corresponding author), UNIV CALIF BERKELEY,DIV BIOCHEM & MOLEC BIOL,BERKELEY,CA 94720, USA.				NIGMS NIH HHS [GM34963] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMANN CR, 1994, P NATL ACAD SCI USA, V91, P3784, DOI 10.1073/pnas.91.9.3784; ARNDT KM, 1988, J MOL BIOL, V202, P271, DOI 10.1016/0022-2836(88)90457-3; BORUKHOV S, 1992, P NATL ACAD SCI USA, V89, P8899, DOI 10.1073/pnas.89.19.8899; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; BREMER H, 1966, J MOL BIOL, V16, P94, DOI 10.1016/S0022-2836(66)80265-6; BUSBY S, 1981, EUR J BIOCHEM, V118, P443, DOI 10.1111/j.1432-1033.1981.tb05540.x; CHAMBERLIN M, 1994, IN PRESS HARVEY LECT; CHAN CL, 1994, TRANSCRIPTION MECHAN, P297; CHRISTIE KR, 1994, J BIOL CHEM, V269, P936; FOX CF, 1965, J BIOL CHEM, V240, P2101; GONZALEZ N, 1977, ARCH BIOCHEM BIOPHYS, V182, P404, DOI 10.1016/0003-9861(77)90521-5; GU WG, 1993, J BIOL CHEM, V268, P25604; HONDA A, 1988, J BIOCHEM-TOKYO, V104, P1021, DOI 10.1093/oxfordjournals.jbchem.a122569; ISHIHAMA A, 1986, J BIOL CHEM, V261, P417; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; IZBAN MG, 1993, J BIOL CHEM, V268, P12864; KANE CM, 1993, TRANSCRIPTION MECH R, P279; KASSAVETIS GA, 1993, SCIENCE, V259, P944, DOI 10.1126/science.7679800; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KRAKOW JS, 1970, COLD SPRING HARB SYM, V35, P73, DOI 10.1101/SQB.1970.035.01.013; KURMMEL B, 1992, J MOL BIOL, V225, P221; LIU B, 1993, NATURE, V366, P33, DOI 10.1038/366033a0; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; PLOTCH SJ, 1981, CELL, V23, P847, DOI 10.1016/0092-8674(81)90449-9; REINES D, 1992, J BIOL CHEM, V267, P15516; REINES D, 1989, J BIOL CHEM, V264, P10799; REINES D, 1993, P NATL ACAD SCI USA, V90, P1917, DOI 10.1073/pnas.90.5.1917; REYNOLDS R, 1992, J MOL BIOL, V224, P31, DOI 10.1016/0022-2836(92)90574-4; RICE GA, 1993, NUCLEIC ACIDS RES, V21, P113, DOI 10.1093/nar/21.1.113; ROSENBERG M, 1976, P NATL ACAD SCI USA, V73, P717, DOI 10.1073/pnas.73.3.717; SPENCER CA, 1990, ONCOGENE, V5, P777; STEVENS A, 1969, J BIOL CHEM, V244, P425; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843; WEISSMAN.C, 1967, P NATL ACAD SCI USA, V57, P1870, DOI 10.1073/pnas.57.6.1870; WEIST DK, 1992, J BIOL CHEM, V267, P7733; YAGER TD, 1991, BIOCHEMISTRY-US, V30, P1097, DOI 10.1021/bi00218a032; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241	40	68	69	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 22	1994	77	2					217	224		10.1016/0092-8674(94)90314-X	http://dx.doi.org/10.1016/0092-8674(94)90314-X			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NH634	7513257				2022-12-24	WOS:A1994NH63400007
J	CRITCHFIELD, JM; RACKE, MK; ZUNIGAPFLUCKER, JC; CANNELLA, B; RAINE, CS; GOVERMAN, J; LENARDO, MJ				CRITCHFIELD, JM; RACKE, MK; ZUNIGAPFLUCKER, JC; CANNELLA, B; RAINE, CS; GOVERMAN, J; LENARDO, MJ			T-CELL DELETION IN HIGH ANTIGEN DOSE THERAPY OF AUTOIMMUNE ENCEPHALOMYELITIS	SCIENCE			English	Article							EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MYELIN BASIC-PROTEIN; LYMPHOCYTES-T; CLONAL ANERGY; INVITRO; INTERLEUKIN-2; TOLERANCE; SUPPRESSION; ACTIVATION; RECEPTOR	Encounters with antigen can stimulate T cells to become activated and proliferate, become nonresponsive to antigen, or to die. T cell death was shown to be a physiological response to interleukin-2-stimulated cell cycling and T cell receptor reengagement at high antigen doses. This feedback regulatory mechanism attenuates the immune response by deleting a portion of newly dividing, antigen-reactive T cells. This mechanism deleted autoreactive T cells and abrogated the clinical and pathological signs of autoimmune encephalomyelitis in mice after repetitive administration of myelin basic protein.	NIAID,IMMUNOL LAB,BETHESDA,MD 20892; NINCDS,NEUROIMMUNOL BRANCH,BETHESDA,MD 20892; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT PATHOL,DIV NEUROPATHOL,BRONX,NY 10461; UNIV WASHINGTON,SCH MED,DEPT MOLEC BIOTECHNOL,SEATTLE,WA 98195	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Yeshiva University; Albert Einstein College of Medicine; University of Washington; University of Washington Seattle			Zuniga-Pflucker, Juan C/H-1295-2012	Zuniga-Pflucker, Juan Carlos/0000-0003-2538-3178; Goverman, Joan/0000-0002-7361-9424				ALVORD EC, 1965, ANN NY ACAD SCI, V122, P333; BELL RB, 1993, J IMMUNOL, V150, P4085; BEVERLY B, 1992, INT IMMUNOL, V4, P661, DOI 10.1093/intimm/4.6.661; BOEHME SA, 1993, LEUKEMIA, V7, P545; BOEHME SA, 1903, EUR J IMMUNOL, V23, P152; BYERS VS, 1967, J EXP MED, V125, P307; CEREDIG R, 1986, EUR J IMMUNOL, V16, P30, DOI 10.1002/eji.1830160107; CLAYTON JP, 1989, J EXP MED, V169, P1681, DOI 10.1084/jem.169.5.1681; Cohen I R, 1993, Int Rev Immunol, V9, P243, DOI 10.3109/08830189309051209; COTRAN RS, 1988, J IMMUNOL, V140, P1883; CRITCHFIELD JM, UNPUB; EINSTEIN ER, 1968, IMMUNOCHEMISTRY, V5, P567, DOI 10.1016/0019-2791(68)90092-X; FELTON LD, 1949, J IMMUNOL, V61, P107; GAUR A, 1992, SCIENCE, V258, P1491, DOI 10.1126/science.1279812; GOVERMAN J, 1993, CELL, V72, P551, DOI 10.1016/0092-8674(93)90074-Z; HECHT TT, 1983, J IMMUNOL, V131, P1049; JONES LA, 1990, SCIENCE, V250, P1726, DOI 10.1126/science.2125368; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KANG SM, 1992, SCIENCE, V257, P1134, DOI 10.1126/science.257.5073.1134; KAUFMAN DL, 1993, NATURE, V366, P69, DOI 10.1038/366069a0; KAWABE Y, 1991, NATURE, V349, P245, DOI 10.1038/349245a0; KYBURZ D, IN PRESS EUR J IMMUN; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; LEVINE S, 1968, SCIENCE, V161, P1155, DOI 10.1126/science.161.3846.1155; LIDER O, 1989, J IMMUNOL, V142, P748; LIU Y, 1990, Journal of Experimental Medicine, V172, P1735, DOI 10.1084/jem.172.6.1735; LUPIN C, 1988, J EXP MED, V167, P752; MACDONALD HR, 1974, J EXP MED, V140, P718, DOI 10.1084/jem.140.3.718; MALEK TR, 1984, J IMMUNOL, V133, P1976; MATIS LA, 1983, P NATL ACAD SCI-BIOL, V80, P6019, DOI 10.1073/pnas.80.19.6019; Miller S D, 1992, Int Rev Immunol, V9, P203, DOI 10.3109/08830189209061791; MITCHISON NA, 1964, PROC R SOC SER B-BIO, V161, P275, DOI 10.1098/rspb.1964.0093; MOSKOPHIDIS D, 1993, NATURE, V362, P758, DOI 10.1038/362758a0; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MULE JJ, 1990, BIOL THERAPY CANCER, P142; OHARA J, 1985, NATURE, V315, P333, DOI 10.1038/315333a0; OTTEN G, 1986, EUR J IMMUNOL, V16, P217, DOI 10.1002/eji.1830160302; PETTINELLI CB, 1981, J IMMUNOL, V127, P1420; RACKE MK, 1991, J IMMUNOL, V146, P3012; RADVANYI LG, 1993, J IMMUNOL, V150, P5704; RAINE CS, 1978, SCIENCE, V201, P445, DOI 10.1126/science.78524; RAZVI ES, 1993, J VIROL, V67, P5754, DOI 10.1128/JVI.67.10.5754-5765.1993; ROCHA B, 1991, SCIENCE, V251, P1255; RUSSELL JH, 1991, P NATL ACAD SCI USA, V88, P2151, DOI 10.1073/pnas.88.6.2151; RUSSELL JH, 1993, EUR J IMMUNOL, V23, P2379, DOI 10.1002/eji.1830230951; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SERCARZ E., 1959, NATURE, V184, P1080, DOI 10.1038/1841080a0; SU MWC, 1993, J IMMUNOL, V151, P658; SU XM, 1991, J NEUROIMMUNOL, V34, P181; SUZUKI G, 1988, J IMMUNOL, V140, P1359; TALMAGE DW, 1956, J INFECT DIS, V98, P293, DOI 10.1093/infdis/98.3.293; UCKER DS, 1992, J IMMUNOL, V149, P1583; URBAN JL, 1988, CELL, V54, P577, DOI 10.1016/0092-8674(88)90079-7; VONBOEHMER H, 1993, NATURE, V362, P696, DOI 10.1038/362696a0; WALDEN PR, 1990, P NATL ACAD SCI USA, V87, P9015, DOI 10.1073/pnas.87.22.9015; WANG R, 1993, J IMMUNOL, V150, P3832; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; WESSELBORG O, 1993, J IMMUNOL, V150, P4338; WHITACRE CC, 1991, J IMMUNOL, V147, P2155; WRAITH DC, 1989, CELL, V59, P247, DOI 10.1016/0092-8674(89)90287-0; ZAMVIL SS, 1990, ANNU REV IMMUNOL, V8, P579, DOI 10.1146/annurev.iy.08.040190.003051	62	495	512	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 25	1994	263	5150					1139	1143		10.1126/science.7509084	http://dx.doi.org/10.1126/science.7509084			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX759	7509084				2022-12-24	WOS:A1994MX75900033
J	LAPIDOT, T; SIRARD, C; VORMOOR, J; MURDOCH, B; HOANG, T; CACERESCORTES, J; MINDEN, M; PATERSON, B; CALIGIURI, MA; DICK, JE				LAPIDOT, T; SIRARD, C; VORMOOR, J; MURDOCH, B; HOANG, T; CACERESCORTES, J; MINDEN, M; PATERSON, B; CALIGIURI, MA; DICK, JE			A CELL INITIATING HUMAN ACUTE MYELOID-LEUKEMIA AFTER TRANSPLANTATION INTO SCID MICE	NATURE			English	Article							IMMUNE-DEFICIENT MICE; BONE-MARROW; PROGENITOR CELLS; LEUKEMIA; HEMATOPOIESIS; DIFFERENTIATION; CULTURE; GROWTH; MOUSE	MOST human acute myeloid leukaemia (AML) cells have limited proliferative capacity, suggesting that the leukaemic clone may be maintained. by a rare population of stem cells(1-5). This putative leukaemic stem cell has not been characterized because the available in vitro assays can only detect progenitors with limited proliferative and replating potential(4-7). We have now identified an AML-initiating cell by transplantation into severe combined immune-deficient (SCID) mice. These cells homed to the bone marrow and proliferated extensively in response to in vivo cytokine treatment, resulting in a pattern of dissemination and leukaemic cell morphology similar to that seen in the original patients. Limiting dilution analysis showed that the frequency of these leukaemia-initiating cells in the peripheral blood of AML patients was one engraftment unit in 250,000 cells. We fractionated AML cells on the basis of cell-surface-marker expression and found that the leukaemia-initiating cells that could engraft SCID mice to produce large numbers of colony-forming progenitors were CD34(+) CD38(-); however, the CD34(+) CD38(+) and CD34(-) fractions contained no cells with these properties. This in vivo model replicates many aspects of human AML and defines a new leukaemia-initiating cell which is less mature than colony-forming cells.	UNIV TORONTO, HOSP SICK CHILDREN, RES INST, DEPT GENET, TORONTO M5G 1X8, ON, CANADA; UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO M5G 1X8, ON, CANADA; CLIN RES INST MONTREAL, MONTREAL H2W 1R7, PQ, CANADA; PRINCESS MARGARET HOSP, DEPT MED, TORONTO M4X 1K9, ON, CANADA; PRINCESS MARGARET HOSP, DEPT ONCOL PATHOL, TORONTO M4X 1K9, ON, CANADA; ROSWELL PK CANC INST, DEPT MED, BUFFALO, NY 14263 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Roswell Park Cancer Institute			Lapidot, Tsvee/A-1812-2010; Vormoor, Josef/GPS-7248-2022	Vormoor, Josef/0000-0002-1825-1890; Dick, John/0000-0002-9527-8317				BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BRADY G, 1990, Methods in Molecular and Cellular Biology, V2, P17; CESANO A, 1992, ONCOGENE, V7, P827; CIVIN CI, 1984, J IMMUNOL, V133, P157; COULOMBEL L, 1985, J CLIN INVEST, V75, P961, DOI 10.1172/JCI111797; DELORD C, 1991, EXP HEMATOL, V19, P991; DICK JE, 1991, IMMUNOL REV, V124, P25, DOI 10.1111/j.1600-065X.1991.tb00614.x; FEARON ER, 1986, NEW ENGL J MED, V315, P15, DOI 10.1056/NEJM198607033150103; GRIER HE, 1993, HEMATOLOGY INFANCY C, P1288; GRIFFIN JD, 1986, BLOOD, V68, P1185; KAMELREID S, 1991, BLOOD, V78, P2973; KAMELREID S, 1988, SCIENCE, V242, P1706, DOI 10.1126/science.2904703; KAMELREID S, 1989, SCIENCE, V246, P1597, DOI 10.1126/science.2595371; KEINANEN M, 1988, NEW ENGL J MED, V318, P1153, DOI 10.1056/NEJM198805053181803; LAPIDOT T, 1992, SCIENCE, V255, P1137, DOI 10.1126/science.1372131; LOWENBERG B, 1993, BLOOD, V81, P281; MCCULLOCH EA, 1982, J CELL PHYSIOL, P103; PORTER EH, 1963, BRIT J CANCER, V17, P583, DOI 10.1038/bjc.1963.78; SAWYERS CL, 1992, BLOOD, V79, P2089, DOI 10.1182/blood.V79.8.2089.bloodjournal7982089; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHIRO R, 1990, BLUT, V61, P267, DOI 10.1007/BF01732875; TERSTAPPEN LWMM, 1991, BLOOD, V77, P1218; TERSTAPPEN LWMM, 1992, LEUKEMIA, V6, P993; WAYE JS, 1986, MOL CELL BIOL, V6, P3156, DOI 10.1128/MCB.6.9.3156	24	3377	3661	13	239	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 17	1994	367	6464					645	648		10.1038/367645a0	http://dx.doi.org/10.1038/367645a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MW688	7509044				2022-12-24	WOS:A1994MW68800054
J	SHUAL, K; ZIEMIECKI, A; WILKS, AF; HARPUR, AG; SADOWSKI, HB; GILMAN, MZ; DARNELL, JE				SHUAL, K; ZIEMIECKI, A; WILKS, AF; HARPUR, AG; SADOWSKI, HB; GILMAN, MZ; DARNELL, JE			POLYPEPTIDE SIGNALING TO THE NUCLEUS THROUGH TYROSINE PHOSPHORYLATION OF JAK AND STAT PROTEINS	NATURE			English	Article								BINDING of interferons IFN-alpha and IFN-gamma to their cell surface receptors promptly induces tyrosine phosphorylation of latent cytoplasmic transcriptional activators1-4 (or Stat proteins, for signal transducers and activators of transcription). Interferon-alpha activates both Stat91 (M(r) 91,000; ref. 1) and Stat113 (M(r) 113,000; ref. 2) whereas IFN-gamma activates only Stat91 (refs 3, 4). The activated proteins then move into the nucleus and directly activate genes induced by IFN-alpha and IFN-gamma. Somatic cell genetics experiments have demonstrated a requirement for tyrosine kinase-2 (Tyk2) in the IFN-alpha response pathway5 and for Jak2 (ref. 6), a kinase with similar sequence7, in the IFN-gamma response pathway. Here we investigate the tyrosine phosphorylation events on Stat and Jak proteins after treatment of cells with IFNs alpha and gamma and with epidermal growth factor (EGF). Stat91 is phosphorylated on Tyr 701 after cells are treated with IFN-alpha and EGF, as it was after treatment with IFN-gamma (ref. 8). We find that Jak1 also becomes phosphorylated on tyrosine after cells are treated with these same three ligands, although each ligand is shown to activate at least one other different kinase. Jak1 may therefore be the enzyme that phosphorylates Tyr 701 in Stat91.	UNIV BERN, INST CLIN & EXPTL CANC RES, CH-3004 BERN, SWITZERLAND; ROYAL MELBOURNE HOSP, LUDWIG INST CANC RES, PARKVILLE, VIC 3050, AUSTRALIA; COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA	University of Bern; Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Cold Spring Harbor Laboratory	SHUAL, K (corresponding author), ROCKEFELLER UNIV, MOLEC CELL BIOL LAB, 1230 YORK AVE, NEW YORK, NY 10021 USA.		Wilks, Andrew F/R-5542-2019	Wilks, Andrew F/0000-0002-8554-2399				ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; HOWARD OMZ, 1992, ONCOGENE, V7, P895; KANNO Y, 1993, MOL CELL BIOL, V13, P3951, DOI 10.1128/MCB.13.7.3951; KAWASAKI E, 1990, PRC PROTOCOLS GUIDE, P119; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; SADOWSKI HB, 1993, Z NATURE, V372, P79; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WATING D, 1993, NATURE, V366, P166; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	28	451	461	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 9	1993	366	6455					580	583		10.1038/366580a0	http://dx.doi.org/10.1038/366580a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML218	7504784				2022-12-24	WOS:A1993ML21800074
J	HOCKENBERY, DM; OLTVAI, ZN; YIN, XM; MILLIMAN, CL; KORSMEYER, SJ				HOCKENBERY, DM; OLTVAI, ZN; YIN, XM; MILLIMAN, CL; KORSMEYER, SJ			BCL-2 FUNCTIONS IN AN ANTIOXIDANT PATHWAY TO PREVENT APOPTOSIS	CELL			English	Article							PROGRAMMED CELL-DEATH; MOUSE EPIDERMAL-CELLS; OXIDATIVE STRESS; CAENORHABDITIS-ELEGANS; SUPEROXIDE-DISMUTASE; LIPID-PEROXIDATION; MEMBRANE PROTEIN; OXIDANT STRESS; PARINARIC ACID; CIS-FOS	Bcl-2 inhibits most types of apoptotic cell death, implying a common mechanism of lethality. Bcl-2 is localized to intracellular sites of oxygen free radical generation including mitochondria, endoplasmic reticula, and nuclear membranes. Antioxidants that scavenge peroxides, N-acetylcysteine and glutathione peroxidase, countered apoptotic death, while manganese superoxide dismutase did not. Bcl-2 protected cells from H2O2- and menadione-induced oxidative deaths. Bcl-2 did not prevent the cyanide-resistant oxidative burst generated by menadione. Two model systems of apoptosis showed no increment in cyanide-resistant respiration, and generation of endogenous peroxides continued at an inherent rate that was unaltered by Bcl-2. Following an apoptotic signal, cells sustained progressive lipid peroxidation. Overexpression of Bcl-2 functioned suppress lipid peroxidation completely. We propose a model in which Bcl-2 regulates an antioxidant pathway at sites of free radical generation.	WASHINGTON UNIV, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA; FRED HUTCHINSON CANC RES CTR, DIV CLIN RES, SEATTLE, WA 98104 USA	Washington University (WUSTL); Washington University (WUSTL); Fred Hutchinson Cancer Center	HOCKENBERY, DM (corresponding author), WASHINGTON UNIV, SCH MED, HOWARD HUGHES MED INST, ST LOUIS, MO 63110 USA.				PHS HHS [49712-05] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ABRAMS JM, 1993, DEVELOPMENT, V117, P29; AMSTAD P, 1991, BIOCHEMISTRY-US, V30, P9305, DOI 10.1021/bi00102a024; APPLEGATE LA, 1991, CANCER RES, V51, P974; BASS DA, 1983, J IMMUNOL, V130, P1910; BLOK J, 1986, MECHANISMS DNA DAMAG, P75; BOISSY RE, 1989, CYTOMETRY, V10, P779, DOI 10.1002/cyto.990100616; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; CATHCART R, 1983, ANAL BIOCHEM, V134, P111, DOI 10.1016/0003-2697(83)90270-1; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CRAWFORD D, 1988, ONCOGENE, V3, P27; CROSS AR, 1991, BIOCHIM BIOPHYS ACTA, V1057, P281, DOI 10.1016/S0005-2728(05)80140-9; DEWEY DL, 1960, NATURE, V186, P780, DOI 10.1038/186780a0; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ERNSTER L, 1986, CHEM SCRIPTA, V26, P525; Flohe L., 1982, FREE RADICAL BIO MED, V5, P223; FORMAN HJ, 1982, FREE RADICAL BIO MED, V5, P65; Gutteridge J M, 1986, Free Radic Res Commun, V1, P173, DOI 10.3109/10715768609083149; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HALLIWELL B, 1986, ARCH BIOCHEM BIOPHYS, V246, P501, DOI 10.1016/0003-9861(86)90305-X; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HARLOW E, 1988, ANTIBODIES LABORATOR; HEDLEY D, 1992, CYTOMETRY, V13, P686, DOI 10.1002/cyto.990130704; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HIROSE K, 1993, FASEB J, V7, P361, DOI 10.1096/fasebj.7.2.8440412; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KORSMEYER SJ, 1992, BLOOD, V80, P879; KUYPERS FA, 1987, BIOCHIM BIOPHYS ACTA, V921, P266, DOI 10.1016/0005-2760(87)90027-0; LEBRUN DP, 1993, AM J PATHOL, V142, P743; MCCONKEY DJ, 1988, TOXICOL LETT, V42, P123, DOI 10.1016/0378-4274(88)90069-0; MCCONKEY DJ, 1989, FASEB J, V3, P1843, DOI 10.1096/fasebj.3.7.2497041; MCCORD JM, 1978, FEBS LETT, V86, P139, DOI 10.1016/0014-5793(78)80116-1; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MIYASHITA T, 1993, BLOOD, V81, P151; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; NGUYEN M, 1993, IN PRESS J BIOL CHEM; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OBERLEY LW, 1985, HDB METHODS OXYGEN R, P219; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; POGNONEC P, 1992, J BIOL CHEM, V267, P24563; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SHIBANUMA M, 1988, ONCOGENE, V3, P17; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; THOR H, 1982, J BIOL CHEM, V257, P2419; TSUJIMOTO Y, 1989, ONCOGENE, V4, P1331; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; UCKUN FM, 1992, P NATL ACAD SCI USA, V89, P9005, DOI 10.1073/pnas.89.19.9005; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; WALTON MI, 1993, CANCER RES, V53, P1853; WEISIGER RA, 1973, J BIOL CHEM, V248, P4793; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; ZACHARCHUK CM, 1990, J IMMUNOL, V145, P4037; ZEHAVA CL, 1990, J BIOL CHEM, V265, P4929; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533	67	3305	3471	6	218	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 22	1993	75	2					241	251		10.1016/0092-8674(93)80066-N	http://dx.doi.org/10.1016/0092-8674(93)80066-N			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MD885	7503812				2022-12-24	WOS:A1993MD88500006
J	PERILLO, NL; PACE, KE; SEILHAMER, JJ; BAUM, LG				PERILLO, NL; PACE, KE; SEILHAMER, JJ; BAUM, LG			APOPTOSIS OF T-CELLS MEDIATED BY GALECTIN-1	NATURE			English	Article							GALACTOSIDE-BINDING-PROTEIN; DEATH; ADHESION; IDENTIFICATION; GLYCOSYLATION; BIOSYNTHESIS; GALAPTIN; CD45	GALECTIN-1, a member of the family of beta-galactoside binding proteins(1), has growth regulatory and immunomodulatory activities(2-4). We report here that galectin-1, expressed by stromal cells in human thymus and lymph nodes(5,6), is present at sites of cell death by apoptosis during normal T-cell development and maturation, Galectin-1 induced apoptosis of activated human T cells and human T leukaemia cell lines. Resting T cells also bound galectin-1, but did not undergo apoptosis. Human endothelial cells that expressed galectin-1 induced apoptosis of bound T cells. Galectin-1-induced apoptosis required expression of CD45, and was decreased when N-glycan elongation was blocked by treatment of the cells by swainsonine(7), whereas inhibition of O-glycan elongation(8) potentiated the apoptotic effect of galectin-1. Induction of apoptosis by an endogenous mammalian lectin represents a new mechanism for regulating the immune response.	UNIV CALIF LOS ANGELES, DEPT PATHOL & LAB MED, LOS ANGELES, CA 90095 USA; INCYTE PHARMACEUT INC, PALO ALTO, CA 94304 USA	University of California System; University of California Los Angeles; Incyte								ALLEN HJ, 1990, J CELL BIOCHEM, V43, P43, DOI 10.1002/jcb.240430105; BARONDES SH, 1994, CELL, V76, P597, DOI 10.1016/0092-8674(94)90498-7; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; BAUM LG, 1995, GLYCOCONJUGATE J, V12, P63, DOI 10.1007/BF00731870; BAUM LG, 1995, J EXP MED, V181, P877, DOI 10.1084/jem.181.3.877; BEZOUSKA K, 1994, NATURE, V372, P150, DOI 10.1038/372150a0; BOURNE Y, 1994, NAT STRUCT BIOL, V1, P863, DOI 10.1038/nsb1294-863; CHO MJ, 1995, J BIOL CHEM, V270, P5207, DOI 10.1074/jbc.270.10.5207; Colin Hughes R., 1992, CURR OPIN STRUC BIOL, V2, P687, DOI 10.1016/0959-440X(92)90202-I; COOPER DNW, 1991, J CELL BIOL, V115, P1437, DOI 10.1083/jcb.115.5.1437; DUVALL E, 1986, IMMUNOL TODAY, V7, P115, DOI 10.1016/0167-5699(86)90152-0; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOLDSTONE SD, 1991, BIOCHEM BIOPH RES CO, V178, P746, DOI 10.1016/0006-291X(91)90171-3; HARRISON FL, 1980, FEBS LETT, V122, P157, DOI 10.1016/0014-5793(80)80428-5; HIRABAYASHI J, 1993, GLYCOBIOLOGY, V3, P297, DOI 10.1093/glycob/3.4.297; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KUAN SF, 1989, J BIOL CHEM, V264, P19271; LEE RT, 1990, J BIOL CHEM, V265, P7864; LEVI G, 1983, EUR J IMMUNOL, V13, P500, DOI 10.1002/eji.1830130613; LIAO DI, 1994, P NATL ACAD SCI USA, V91, P1428, DOI 10.1073/pnas.91.4.1428; OFFNER H, 1990, J NEUROIMMUNOL, V28, P177, DOI 10.1016/0165-5728(90)90032-I; ONG CJ, 1994, J IMMUNOL, V152, P3793; PULIDO R, 1990, EUR J IMMUNOL, V20, P2667, DOI 10.1002/eji.1830201221; QUN Z, 1993, ARCH BIOCHEM BIOPHYS, V300, P6, DOI 10.1006/abbi.1993.1002; SU X, 1995, IMMUNITY, V2, P353, DOI 10.1016/1074-7613(95)90143-4; TELFORD WG, 1992, CYTOMETRY, V13, P137, DOI 10.1002/cyto.990130205; TRAUTH BC, 1994, SCIENCE, V245, P150; WELLS V, 1991, CELL, V64, P91, DOI 10.1016/0092-8674(91)90211-G; WESSELBORG S, 1993, J IMMUNOL, V150, P4338	30	904	932	2	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 14	1995	378	6558					736	739		10.1038/378736a0	http://dx.doi.org/10.1038/378736a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK379	7501023				2022-12-24	WOS:A1995TK37900058
J	BROWN, SS; EISENBERG, L				BROWN, SS; EISENBERG, L			UNINTENDED PREGNANCY AND THE WELL-BEING OF CHILDREN AND FAMILIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									HARVARD UNIV,SCH MED,BOSTON,MA	Harvard University; Harvard Medical School	BROWN, SS (corresponding author), NATL ACAD SCI,INST MED,WASHINGTON,DC 20418, USA.								0	12	12	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 1	1995	274	17					1332	1332		10.1001/jama.274.17.1332	http://dx.doi.org/10.1001/jama.274.17.1332			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB278	7563544				2022-12-24	WOS:A1995TB27800003
J	HAIRE, WD; RUBY, EI; GORDON, BG; PATIL, KD; STEPHENS, LC; KOTULAK, GD; REED, EC; VOSE, JM; BIERMAN, PJ; KESSINGER, A; ARMITAGE, JO				HAIRE, WD; RUBY, EI; GORDON, BG; PATIL, KD; STEPHENS, LC; KOTULAK, GD; REED, EC; VOSE, JM; BIERMAN, PJ; KESSINGER, A; ARMITAGE, JO			MULTIPLE ORGAN DYSFUNCTION SYNDROME IN BONE-MARROW TRANSPLANTATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DISSEMINATED INTRAVASCULAR COAGULATION; RESPIRATORY-DISTRESS SYNDROME; TUMOR-NECROSIS-FACTOR; HEPATIC VENOOCCLUSIVE DISEASE; ESCHERICHIA-COLI INFUSION; VENO-OCCLUSIVE DISEASE; PROTEIN-C DEFICIENCY; ANTITHROMBIN-III; SEPTIC SHOCK; MULTIORGAN FAILURE	Objective.-To define the frequency and outcome of organ dysfunction in bone marrow transplantation (BMT) and to determine if patients with organ dysfunction have lower levels of protein C (PC) and/or antithrombin III (ATIII) than those without organ dysfunction. Design.-Inception cohort of patients undergoing BMT, followed for 28 days, until hospital dismissal, or until death. Setting.-Bone marrow transplant department of a university hospital. Patients.-A total of 199 consecutive patients admitted for BMT. Interventions.-Standard supportive care was given to all patients. Main Outcome Measures.-Definitions of organ dysfunction were arrived at prior to beginning the study. They include pulmonary, central nervous system (CNS), hepatic, and renal dysfunction. Protein C and ATIII levels were measured prior to beginning the preparative regimen and weekly thereafter. Results.-Single organ dysfunction, manifesting as pulmonary, CNS, or hepatic dysfunction, occurred in 33 (48.5%) of the 199 patients and was a strong predictor of multiple organ dysfunction syndrome (MODS) and death, Death occurred in 14 (7.0%) of the patients. Cause of death was precisely identified in only four patients. Low levels of either PC or ATIII were associated with death and pulmonary, CNS, and hepatic dysfunction, Multivariate analysis showed ATIII and PC levels were associated with single organ dysfunction independent of the type of transplant, the type of preparative regimen, and the presence of bacteremia. Conclusions.-Single organ dysfunction during BRAT is a marker for a systemic abnormality that has a high likelihood of progressing to MODS, similar to that seen in other critically ill patient populations. MODS is the leading cause of death in series of BMT patients. Low levels of ATIII and PC are markers of and may be involved in the pathogenesis of MODS in BMT.	UNIV NEBRASKA,MED CTR,DEPT PEDIAT,OMAHA,NE 68182; UNIV NEBRASKA,MED CTR,DEPT PREVENT & SOCIAL MED,OMAHA,NE 68182	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	HAIRE, WD (corresponding author), UNIV NEBRASKA,MED CTR,DEPT INTERNAL MED,OMAHA,NE 68198, USA.							AMBRUS JL, 1990, J MED, V21, P67; ARMITAGE JO, 1991, AM J MED, V91, P605, DOI 10.1016/0002-9343(91)90213-H; AYASH LJ, 1990, J CLIN ONCOL, V8, P1699, DOI 10.1200/JCO.1990.8.10.1699; BAGGE L, 1989, SCAND J CLIN LAB INV, V49, P63, DOI 10.3109/00365518909089079; BARTON R, 1989, CHEST, V96, P1153, DOI 10.1378/chest.96.5.1153; BEAL AL, 1994, JAMA-J AM MED ASSOC, V271, P226, DOI 10.1001/jama.271.3.226; BERNAUER W, 1991, ANN INTERN MED, V115, P925, DOI 10.7326/0003-4819-115-12-925; BONE RC, 1991, ANN INTERN MED, V115, P457, DOI 10.7326/0003-4819-115-6-457; BONE RC, 1992, CHEST, V101, P320, DOI 10.1378/chest.101.2.320; BONE RC, 1992, ARCH INTERN MED, V152, P1381, DOI 10.1001/archinte.152.7.1381; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; BONE RC, 1992, CHEST, V101, P594, DOI 10.1378/chest.101.3.594; BRANDTZAEG P, 1989, THROMB RES, V55, P459, DOI 10.1016/0049-3848(89)90054-6; CARRERAS E, 1993, ANN HEMATOL, V66, P77, DOI 10.1007/BF01695888; CARVALHO AC, 1988, J LAB CLIN MED, V112, P270; CASEY LC, 1993, ANN INTERN MED, V119, P771, DOI 10.7326/0003-4819-119-8-199310150-00001; CLARK JG, 1993, AM REV RESPIR DIS, V147, P1601, DOI 10.1164/ajrccm/147.6_Pt_1.1601; DICKNEITE G, 1993, THROMB HAEMOSTASIS, V69, P98; EMERSON TE, 1987, CIRC SHOCK, V21, P1; ESMON CT, 1991, THROMB HAEMOSTASIS, V66, P160; FAIONI EM, 1993, BLOOD, V81, P3458; FAIST FN, 1983, J TRAUMA, V9, P775; FOURRIER F, 1992, CHEST, V101, P816, DOI 10.1378/chest.101.3.816; FOURRIER F, 1990, INTENS CARE MED, V16, P121, DOI 10.1007/BF01699858; FOURRIER F, 1993, CHEST, V104, P882, DOI 10.1378/chest.104.3.882; FUGGER R, 1993, EUR J SURG, V159, P525; GORDON B, 1991, BONE MARROW TRANSPL, V8, P497; GORDON BG, 1993, BONE MARROW TRANSPL, V11, P61; GORIS RJA, 1985, ARCH SURG-CHICAGO, V120, P1109; HARPER PL, 1990, BONE MARROW TRANSPL, V5, P39; HENAO FJ, 1991, J TRAUMA, V31, P74, DOI 10.1097/00005373-199101000-00014; HESSELVIK JF, 1991, THROMB HAEMOSTASIS, V65, P126; HESSELVIK JF, 1989, CRIT CARE MED, V17, P724, DOI 10.1097/00003246-198908000-00002; HOLLER E, 1990, BLOOD, V75, P1011; KAUFMAN PA, 1990, CANCER, V66, P515, DOI 10.1002/1097-0142(19900801)66:3<515::AID-CNCR2820660319>3.0.CO;2-7; KESSINGER A, 1989, BLOOD, V74, P1260; KNAUS WA, 1985, ANN SURG, V202, P685, DOI 10.1097/00000658-198512000-00004; LAMMLE B, 1984, AM J CLIN PATHOL, V823, P396; LAURELL CB, 1966, ANAL BIOCHEM, V15, P45, DOI 10.1016/0003-2697(66)90246-6; LORENTE JA, 1993, CHEST, V103, P1536, DOI 10.1378/chest.103.5.1536; MARSHALL WG, 1983, J TRAUMA, V23, P102, DOI 10.1097/00005373-198302000-00005; MARTINOLI JL, 1986, THROMB RES, V43, P253, DOI 10.1016/0049-3848(86)90145-3; MCDONALD GB, 1993, ANN INTERN MED, V118, P255, DOI 10.7326/0003-4819-118-4-199302150-00003; MCDONALD GB, 1984, HEPATOLOGY, V4, P116, DOI 10.1002/hep.1840040121; MILLER RS, 1994, J TRAUMA, V37, P442, DOI 10.1097/00005373-199409000-00019; MODIG J, 1983, ACTA ANAESTH SCAND, V27, P369, DOI 10.1111/j.1399-6576.1983.tb01970.x; NEDORN E, 1991, KLIN WOCHENSCHR, V69, P817, DOI 10.1007/BF01744277; PRELLWITZ W, 1982, CLIN CHEM, V28, P2249; REDENS TB, 1988, CIRC SHOCK, V26, P15; SCHIPPER HG, 1981, THROMB RES, V21, P73, DOI 10.1016/0049-3848(84)90034-3; SHETH SB, 1991, AM J HEMATOL, V36, P14, DOI 10.1002/ajh.2830360104; STRIETER RM, 1993, CRIT CARE MED, V21, pS447, DOI 10.1097/00003246-199310001-00006; TAYLOR FB, 1987, J CLIN INVEST, V79, P918, DOI 10.1172/JCI112902; TAYLOR FB, 1991, BLOOD, V78, P364; TAYLOR FB, 1988, CIRC SHOCK, V26, P227; TRACEY KJ, 1993, CRIT CARE MED, V21, pS415; WINGARD JR, 1989, BONE MARROW TRANSPL, V4, P685	57	59	63	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 25	1995	274	16					1289	1295		10.1001/jama.274.16.1289	http://dx.doi.org/10.1001/jama.274.16.1289			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA104	7563534				2022-12-24	WOS:A1995TA10400024
J	EARLY, A; ABE, T; WILLIAMS, J				EARLY, A; ABE, T; WILLIAMS, J			EVIDENCE FOR POSITIONAL DIFFERENTIATION OF PRESTALK CELLS AND FOR A MORPHOGENETIC GRADIENT IN DICTYOSTELIUM	CELL			English	Article							ANTERIOR-LIKE CELLS; GENE-EXPRESSION; CYCLE PHASE; STALK-CELL; PATTERN-FORMATION; PRESPORE PATTERN; DISCOIDEUM; SLUG; CAMP; DIF	We present evidence that Dictyostelium slug tip cells, the pstA cells, may arise by positional differentiation, but at a site remote from that which they will eventually occupy. When first detectable, the pstA cells form a peripheral ring surrounding the other prestalk cell subtype, the pstO cells, but subsequently move above the pstO cells to form the tip. Because pstA cell differentiation requires a 10-fold higher concentration of differention-inducing factor, the stalk cell inducer, the initial patterning seems likely to reflect the existence of a morphogenetic gradient. The subsequent redistribution of the two cell types is explicable by their different rates of chemotaxis to cyclic AMP, These results help reconcile the two apparently opposing views of pattern formation in Dictyostelium, that there is positional differentiation and that pattern formation occurs by cell sorting.	UNIV LONDON UNIV COLL,DEPT BIOL,LONDON WC1E 6BT,ENGLAND	University of London; University College London	EARLY, A (corresponding author), UNIV LONDON UNIV COLL,MRC,MOLEC CELL BIOL LAB,TORRINGTON PL,LONDON WC1E 6BT,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABE T, 1994, CELL, V77, P687, DOI 10.1016/0092-8674(94)90053-1; ARAKI T, 1994, DEV BIOL, V162, P221, DOI 10.1006/dbio.1994.1080; BROOKMAN JJ, 1982, DEV BIOL, V91, P191, DOI 10.1016/0012-1606(82)90022-7; BROOKMAN JJ, 1987, DEVELOPMENT, V100, P119; BUHL B, 1993, DEV BIOL, V156, P481, DOI 10.1006/dbio.1993.1094; CECCARELLI A, 1991, CELL, V65, P983, DOI 10.1016/0092-8674(91)90550-I; DATTA S, 1986, MOL CELL BIOL, V6, P811, DOI 10.1128/MCB.6.3.811; DETTERBECK S, 1994, DEVELOPMENT, V120, P2847; DEVINE KM, 1985, DEV BIOL, V107, P364, DOI 10.1016/0012-1606(85)90318-5; DINGERMANN T, 1989, GENE, V85, P353, DOI 10.1016/0378-1119(89)90428-9; DURSTON AJ, 1976, NATURE, V263, P126, DOI 10.1038/263126a0; EARLY AE, 1987, GENE, V59, P99, DOI 10.1016/0378-1119(87)90270-8; EARLY AE, 1993, DEVELOPMENT, V118, P353; EARLY AE, 1989, NUCLEIC ACIDS RES, V17, P6473; ESCH RK, 1991, GENE DEV, V5, P9, DOI 10.1101/gad.5.1.9; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GOMER RH, 1987, SCIENCE, V237, P758, DOI 10.1126/science.3039657; GROSS JD, 1994, MICROBIOL REV, V58, P330, DOI 10.1128/MMBR.58.3.330-351.1994; HOWARD PK, 1992, CELL, V71, P637, DOI 10.1016/0092-8674(92)90597-6; INSALL R, 1992, EMBO J, V11, P2849, DOI 10.1002/j.1460-2075.1992.tb05352.x; JERMYN KA, 1991, DEVELOPMENT, V111, P779; JERMYN KA, 1989, NATURE, V340, P144, DOI 10.1038/340144a0; JERMYN KA, 1987, DEVELOPMENT, V100, P745; KAY RR, 1983, NATURE, V303, P242, DOI 10.1038/303242a0; KAY RR, 1993, P NATL ACAD SCI USA, V90, P487, DOI 10.1073/pnas.90.2.487; KOPACHIK W, 1983, CELL, V33, P397, DOI 10.1016/0092-8674(83)90421-X; KOPACHIK WJ, 1985, DIFFERENTIATION, V28, P209, DOI 10.1111/j.1432-0436.1985.tb00827.x; MAEDA Y, 1989, DIFFERENTIATION, V41, P169, DOI 10.1111/j.1432-0436.1989.tb00744.x; MAEDA Y, 1993, DEV GROWTH DIFFER, V35, P609; MATSUKUMA S, 1979, J EMBRYOL EXP MORPH, V50, P243; MCDONALD SA, 1986, DEV BIOL, V117, P546, DOI 10.1016/0012-1606(86)90322-2; MCDONALD SA, 1984, J CELL SCI, V66, P195; MCROBBIE SJ, 1988, DEVELOPMENT, V104, P275; MEE JD, 1986, BIOCHEM CELL BIOL, V64, P722, DOI 10.1139/o86-099; MEINHARDT H, 1983, DIFFERENTIATION, V24, P191, DOI 10.1111/j.1432-0436.1983.tb01319.x; MORRIS HR, 1987, NATURE, V328, P811, DOI 10.1038/328811a0; MORRISON A, 1992, EXP CELL RES, V199, P383, DOI 10.1016/0014-4827(92)90449-I; NAYLER O, 1992, EUR J BIOCHEM, V208, P531, DOI 10.1111/j.1432-1033.1992.tb17217.x; OHMORI T, 1987, CELL DIFFER DEV, V22, P11, DOI 10.1016/0045-6039(87)90409-X; PEARS CJ, 1988, NUCLEIC ACIDS RES, V16, P8467, DOI 10.1093/nar/16.17.8467; RAPER KENNETH B., 1940, JOUR ELISHA MITCHELL SCI SOC, V56, P241; RUBIN J, 1975, J EMBRYOL EXP MORPH, V33, P227; SCHAAP P, 1986, DIFFERENTIATION, V33, P1, DOI 10.1111/j.1432-0436.1986.tb00404.x; SIEGERT F, 1992, P NATL ACAD SCI USA, V89, P6433, DOI 10.1073/pnas.89.14.6433; STERNFELD J, 1981, DIFFERENTIATION, V20, P10, DOI 10.1111/j.1432-0436.1981.tb01150.x; STERNFELD J, 1982, DEV BIOL, V93, P111, DOI 10.1016/0012-1606(82)90244-5; TAKEUCHI I, 1991, CELL-CELL INTERACTIONS IN EARLY DEVELOPMENT, P249; TAKEUCHI I, 1978, BOT MAG TOKYO, V1, P47; TOWN CD, 1976, NATURE, V262, P717, DOI 10.1038/262717a0; TRAYNOR D, 1992, P NATL ACAD SCI USA, V89, P8303, DOI 10.1073/pnas.89.17.8303; WANG M, 1985, DIFFERENTIATION, V30, P7, DOI 10.1111/j.1432-0436.1985.tb00506.x; WANG M, 1988, DEV BIOL, V125, P410, DOI 10.1016/0012-1606(88)90221-7; WATTS DJ, 1970, BIOCHEM J, V119, P171, DOI 10.1042/bj1190171; WEEKS G, 1991, BIOCHEM CELL BIOL, V69, P608, DOI 10.1139/o91-090; WEIJER CJ, 1984, J CELL SCI, V70, P133; WILLIAMS JG, 1989, CELL, V59, P1157, DOI 10.1016/0092-8674(89)90771-X; WILLIAMS JG, 1987, CELL, V49, P185, DOI 10.1016/0092-8674(87)90559-9; WOLPERT L, 1971, CURR TOP DEV BIOL, V6, P183; ZIMMERMAN W, 1993, DEV BIOL, V160, P178, DOI 10.1006/dbio.1993.1296	59	123	124	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 6	1995	83	1					91	99		10.1016/0092-8674(95)90237-6	http://dx.doi.org/10.1016/0092-8674(95)90237-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RY583	7553878	Bronze			2022-12-24	WOS:A1995RY58300013
J	HALL, CL; YANG, BH; YANG, XW; ZHANG, SW; TURLEY, M; SAMUEL, S; LANGE, LA; WANG, C; CURPEN, GD; SAVANI, RC; GREENBERG, AH; TURLEY, EA				HALL, CL; YANG, BH; YANG, XW; ZHANG, SW; TURLEY, M; SAMUEL, S; LANGE, LA; WANG, C; CURPEN, GD; SAVANI, RC; GREENBERG, AH; TURLEY, EA			OVEREXPRESSION OF THE HYALURONAN RECEPTOR RHAMM IS TRANSFORMING AND IS ALSO REQUIRED FOR H-RAS TRANSFORMATION	CELL			English	Article							CELL-MATRIX INTERACTIONS; DOMINANT NEGATIVE MUTATION; EXTRACELLULAR-MATRIX; FOCAL ADHESIONS; SIGNAL TRANSDUCTION; TISSUE INHIBITOR; BINDING PROTEINS; CARCINOMA-CELLS; GENE-EXPRESSION; GROWTH	Overexpression of the RHAMM gene by transfection into fibroblasts is transforming and causes spontaneous metastases in the lung. H-ras-transformed fibrosarcomas transfected with a dominant suppressor mutant of RHAMM exhibit a so-called revertant phenotype end are completely nontumorigenic and nonmetastatic. Conversely, fibroblasts stably expressing low levels of RHAMM as a result of antisense transfection are resistant to res transformation. Collectively, these results indicate that RHAMM acts downstream of res. The loss of functional RHAMM ablates signaling within focal adhesions, in particular changes in focal adhesion kinase phosphorylation, and as a result these focal adhesions are unable to turn over in response to hyaluronan. These results provide evidence of the oncogenic potential of a novel extracellular matrix receptor and establish a functional link between transformation by ras and signaling within focal adhesions that are required for transformation by this oncogene.	UNIV MANITOBA, DEPT PEDIAT, WINNIPEG, MB R3E 0V9, CANADA	University of Manitoba	HALL, CL (corresponding author), UNIV MANITOBA, MANITOBA INST CELL BIOL, WINNIPEG, MB R3E 0V9, CANADA.		Rashmin C. Savani, MBChB/AAG-2041-2021	Rashmin C. Savani, MBChB/0000-0002-9533-5422				ALEXANDER CM, 1992, J CELL BIOL, V118, P727, DOI 10.1083/jcb.118.3.727; BARTOLAZZI A, 1994, J EXP MED, V180, P53, DOI 10.1084/jem.180.1.53; BEHREND EI, 1994, CANCER RES, V54, P832; BORSI L, 1992, INT J CANCER, V52, P688, DOI 10.1002/ijc.2910520504; BRAND T, 1993, J BIOL CHEM, V268, P11500; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CASTLE VP, 1993, J BIOL CHEM, V268, P2899; CHONG ASF, 1992, CELL IMMUNOL, V144, P69, DOI 10.1016/0008-8749(92)90226-F; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; EGAN SE, 1987, SCIENCE, V238, P202, DOI 10.1126/science.3659911; ENTWISTLE J, 1995, IN PRESS GENE; EVANS SC, 1993, J CELL BIOL, V120, P1045, DOI 10.1083/jcb.120.4.1045; FERNANDEZ JLR, 1993, J CELL BIOL, V122, P1285, DOI 10.1083/jcb.122.6.1285; FRASER R, 1993, FASEB J, V6, P2397; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; Gunthert U, 1993, Curr Top Microbiol Immunol, V184, P47; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HALL CL, 1994, J CELL BIOL, V126, P575, DOI 10.1083/jcb.126.2.575; HARDWICK C, 1992, J CELL BIOL, V117, P1343, DOI 10.1083/jcb.117.6.1343; HIRO D, 1986, BIOCHEM BIOPH RES CO, V140, P715, DOI 10.1016/0006-291X(86)90790-4; HOARE K, 1993, CONNECT TISSUE RES, V30, P117, DOI 10.3109/03008209309041327; HOWLETT AR, 1993, EPITHELIAL CELL BIOL, V2, P79; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Jones Peter Lloyd, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P137; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KARIKO K, 1993, CANCER RES, V53, P3109; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KHOKHA R, 1992, J NATL CANCER I, V84, P1017, DOI 10.1093/jnci/84.13.1017; KLEWES L, 1993, BIOCHEM J, V290, P791, DOI 10.1042/bj2900791; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; LIEBL EC, 1992, ONCOGENE, V7, P2417; LIN CQ, 1993, FASEB J, V7, P737, DOI 10.1096/fasebj.7.9.8330681; LO SH, 1994, CANCER METAST REV, V13, P9, DOI 10.1007/BF00690415; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; MURPHYULLRICH JE, 1989, J CELL BIOL, V109, P1309, DOI 10.1083/jcb.109.3.1309; MURPHYULLRICH JE, 1991, J CELL BIOL, V115, P1127, DOI 10.1083/jcb.115.4.1127; NOBLE PW, 1993, J CLIN INVEST, V91, P2368, DOI 10.1172/JCI116469; QIAN F, 1994, CELL, V77, P335, DOI 10.1016/0092-8674(94)90149-X; RATNER S, 1992, INVAS METAST, V12, P82; RUOSLAHTI E, 1994, KIDNEY INT, V45, pS17; SAARIALHOKERE UK, 1993, J CLIN INVEST, V92, P2858, DOI 10.1172/JCI116906; SAMUEL SK, 1993, J CELL BIOL, V123, P749, DOI 10.1083/jcb.123.3.749; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHWARTZ MA, 1993, CANCER RES, V53, P1503; SHAPIRO SD, 1993, BIOCHEMISTRY-US, V32, P4286, DOI 10.1021/bi00067a018; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; SY MS, 1991, J EXP MED, V174, P859, DOI 10.1084/jem.174.4.859; TURLEY E, 1987, JNCI-J NATL CANCER I, V78, P787; TURLEY EA, 1991, J CELL BIOL, V112, P1041, DOI 10.1083/jcb.112.5.1041; TURLEY EA, 1985, CANCER RES, V45, P5098; TURLEY EA, 1992, CANCER METAST REV, V11, P21, DOI 10.1007/BF00047600; VARNER JA, 1992, MOL BIOL CELL, V3, pA232; WEHRLEHALLER B, 1993, J CELL SCI, V106, P597; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WOODS A, 1988, COLLAGEN REL RES, V8, P155; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P	62	251	267	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 14	1995	82	1					19	28		10.1016/0092-8674(95)90048-9	http://dx.doi.org/10.1016/0092-8674(95)90048-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RK424	7541721	Bronze			2022-12-24	WOS:A1995RK42400005
J	BOUDREAU, N; SYMPSON, CJ; WERB, Z; BISSELL, MJ				BOUDREAU, N; SYMPSON, CJ; WERB, Z; BISSELL, MJ			SUPPRESSION OF ICE AND APOPTOSIS IN MAMMARY EPITHELIAL-CELLS BY EXTRACELLULAR-MATRIX	SCIENCE			English	Article							DEATH GENE CED-3; INVOLUTION; ENZYME; DIFFERENTIATION; GLYCOPROTEINS; PROTEINASES; COLLAGENASE; INHIBITION; SECRETION; ENCODES	Apoptosis (programmed cell death) plays a major role in development and tissue regeneration. Basement membrane extracellular matrix (ECM), but not fibronectin or collagen, was shown to suppress apoptosis of mammary epithelial cells in tissue culture and in vivo. Apoptosis was induced by antibodies to beta(1) integrins or by overexpression of stromelysin-1, which degrades ECM. Expression of interleukin-1 beta converting enzyme (ICE) correlated with the loss of ECM, and inhibitors of ICE activity prevented apoptosis. These results suggest that ECM regulates apoptosis in mammary epithelial cells through an integrin-dependent negative regulation of ICE expression.	UNIV CALIF SAN FRANCISCO,RADIOBIOL & ENVIRONM HLTH LAB,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	BOUDREAU, N (corresponding author), UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,DIV LIFE SCI,1 CYCLOTRON RD,BLDG 83,BERKELEY,CA 94720, USA.				NATIONAL CANCER INSTITUTE [R01CA057621] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007106] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA057621, R01 CA057621-07, CA 57621] Funding Source: Medline; NIEHS NIH HHS [ES 07106, T32 ES007106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BOUDREAU N, UNPUB; DAMSKY CH, 1982, J CELL BIOCHEM, V18, P1, DOI 10.1002/jcb.1982.240180102; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GROBELNY D, 1992, BIOCHEMISTRY-US, V31, P7152, DOI 10.1021/bi00146a017; HENTGARTNER MO, 1994, CELL, V76, P665; KLEINMAN H, 1986, BIOCHEMISTRY-US, V26, P312; KORSMEYER SJ, 1992, CANCER SURV, V5, P105; KRAMER RH, 1985, J CELL PHYSIOL, V123, P1, DOI 10.1002/jcp.1041230102; LI LM, 1987, P NATL ACAD SCI USA, V84, P136; LIN CQ, 1993, FASEB J, V7, P737, DOI 10.1096/fasebj.7.9.8330681; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; PARRY G, 1987, J CELL BIOL, V105, P2043, DOI 10.1083/jcb.105.5.2043; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; REICHMANN E, 1989, J CELL BIOL, V108, P1127, DOI 10.1083/jcb.108.3.1127; SANCHEZLOPEZ R, 1988, J BIOL CHEM, V263, P11892; SCHMIDHAUSER C, 1990, P NATL ACAD SCI USA, V87, P9118, DOI 10.1073/pnas.87.23.9118; STRANGE R, 1992, DEVELOPMENT, V115, P49; SYMPSON CJ, 1994, J CELL BIOL, V125, P681, DOI 10.1083/jcb.125.3.681; TALHOUK RS, 1991, DEVELOPMENT, V112, P439; TALHOUK RS, 1992, J CELL BIOL, V118, P1271, DOI 10.1083/jcb.118.5.1271; TAUB M, 1990, P NATL ACAD SCI USA, V87, P4002, DOI 10.1073/pnas.87.10.4002; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WALKER NI, 1989, AM J ANAT, V185, P19, DOI 10.1002/aja.1001850104; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	27	1095	1133	0	30	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 10	1995	267	5199					891	893		10.1126/science.7531366	http://dx.doi.org/10.1126/science.7531366			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG207	7531366	Green Submitted, Green Accepted			2022-12-24	WOS:A1995QG20700060
J	TSUCHIDA, T; ENSINI, M; MORTON, SB; BALDASSARE, M; EDLUND, T; JESSELL, TM; PFAFF, SL				TSUCHIDA, T; ENSINI, M; MORTON, SB; BALDASSARE, M; EDLUND, T; JESSELL, TM; PFAFF, SL			TOPOGRAPHIC ORGANIZATION OF EMBRYONIC MOTOR-NEURONS DEFINED BY EXPRESSION OF LIM HOMEOBOX GENES	CELL			English	Article							MOTONEURON PROJECTION PATTERNS; DIFFERENT SEGMENTAL LEVELS; CHICK HIND LIMB; PATHWAY SELECTION; NEURITE OUTGROWTH; PROTEIN ISL-1; SPINAL-CORD; LUMBOSACRAL LEVEL; PROXIMAL TISSUES; NERVOUS-SYSTEM	Motor neurons located at different positions in the embryonic spinal cord innervate distinct targets in the periphery, establishing a topographic neural map. The topographic organization of motor projections depends on the generation of subclasses of motor neurons that select specific paths to their targets. We have cloned a family of LIM homeobox genes in chick and show here that the combinatorial expression of four of these genes, Islet-1, Islet-2, Lim-1, and Lim-3, defines subclasses of motor neurons that segregate into columns in the spinal cord and select distinct axonal pathways. These genes are expressed prior to the formation of distinct motor axon pathways and before motor columns appear. Our results suggest that LIM homeobox genes contribute to the generation of motor neuron diversity and may confer subclasses of motor neurons with the ability to select specific axon pathways, thereby initiating the topographic organization of motor projections.	COLUMBIA UNIV,CTR NEUROBIOL & BEHAV,HOWARD HUGHES MED INST,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032; UMEA UNIV,DEPT MICROBIOL,S-90187 UMEA,SWEDEN	Columbia University; Howard Hughes Medical Institute; Umea University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007367] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033245] Funding Source: NIH RePORTER; NIGMS NIH HHS [5T32GMO7367] Funding Source: Medline; NINDS NIH HHS [NS33245] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARNES D, 1994, DEV BIOL, V161, P168; BOURGOUIN C, 1992, NEURON, V9, P549, DOI 10.1016/0896-6273(92)90192-G; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; DUBEY PN, 1968, J ANAT, V102, P407; EISEN JS, 1994, ANNU REV NEUROSCI, V17, P1; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; FERGUSON BA, 1983, J NEUROSCI, V3, P1760; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; FUJII T, 1994, DEV DYNAM, V199, P73, DOI 10.1002/aja.1001990108; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; GRAHAM A, 1991, DEVELOPMENT, V112, P255; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; GUTMAN CR, 1993, BRAIN RES, V609, P129, DOI 10.1016/0006-8993(93)90865-K; HAMBURGER V, 1948, J COMP NEUROL, V88, P221, DOI 10.1002/cne.900880204; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HOLLYDAY M, 1977, BRAIN RES, V132, P197, DOI 10.1016/0006-8993(77)90416-4; HOLLYDAY M, 1980, J COMP NEUROL, V194, P143, DOI 10.1002/cne.901940108; HOLLYDAY M, 1990, J COMP NEUROL, V302, P575, DOI 10.1002/cne.903020313; Huber JF, 1936, J COMP NEUROL, V65, P43, DOI 10.1002/cne.900650109; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; HUNT RK, 1990, BRAIN CIRCUITS FUNCT, P19; INOUE A, 1994, DEV DYNAM, V199, P1, DOI 10.1002/aja.1001990102; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KORZH V, 1993, DEVELOPMENT, V118, P417; LANCEJONES C, 1981, PROC R SOC SER B-BIO, V214, P19, DOI 10.1098/rspb.1981.0080; LANCEJONES C, 1980, J PHYSIOL-LONDON, V302, P559; LANCEJONES C, 1981, PROC R SOC SER B-BIO, V214, P1, DOI 10.1098/rspb.1981.0079; LANCEJONES C, 1980, J PHYSIOL-LONDON, V302, P581; LANCEJONES C, 1991, DEV BIOL, V143, P93, DOI 10.1016/0012-1606(91)90057-A; LANDMESSER L, 1978, J PHYSIOL-LONDON, V284, P371, DOI 10.1113/jphysiol.1978.sp012545; LANDMESSER L, 1978, J PHYSIOL-LONDON, V284, P391, DOI 10.1113/jphysiol.1978.sp012546; LANDMESSER LT, 1992, NERVE GROWTH CONE, P373; LANGMAN J, 1970, J COMP NEUROL, V138, P419, DOI 10.1002/cne.901380403; LASKOWSKI MB, 1987, J NEUROSCI, V7, P252; LEVIMONTALCINI R, 1950, J MORPHOL, V86, P253, DOI 10.1002/jmor.1050860203; LI H, 1994, EMBO J, V13, P2876, DOI 10.1002/j.1460-2075.1994.tb06582.x; LICHTMAN JW, 1980, J PHYSIOL-LONDON, V298, P285, DOI 10.1113/jphysiol.1980.sp013081; PHELAN KA, 1990, J NEUROSCI, V10, P2699; PRASAD A, 1991, J COMP NEUROL, V307, P237, DOI 10.1002/cne.903070207; PUELLES L, 1993, TRENDS NEUROSCI, V16, P472, DOI 10.1016/0166-2236(93)90080-6; Sanes J R, 1993, Curr Opin Neurobiol, V3, P67, DOI 10.1016/0959-4388(93)90037-Y; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; STRAZNICKY C, 1983, ANAT EMBRYOL, V166, P209, DOI 10.1007/BF00305083; SULLIVAN G. E., 1962, AUSTRALIAN JOUR ZOOL, V10, P458, DOI 10.1071/ZO9620458; TAIRA M, 1993, DEV BIOL, V159, P245, DOI 10.1006/dbio.1993.1237; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; THOR S, 1991, NEURON, V7, P881, DOI 10.1016/0896-6273(91)90334-V; TOSNEY KW, 1987, DEV BIOL, V122, P540, DOI 10.1016/0012-1606(87)90318-6; TOSNEY KW, 1985, DEV BIOL, V109, P193, DOI 10.1016/0012-1606(85)90360-4; TOSNEY KW, 1985, J NEUROSCI, V5, P2336; TOSNEY KW, 1988, DEV BIOL, V127, P266, DOI 10.1016/0012-1606(88)90314-4; TOSNEY KW, 1984, J NEUROSCI, V4, P2518; TOSNEY KW, 1991, BIOESSAYS, V13, P17; UDIN SB, 1988, ANNU REV NEUROSCI, V11, P289, DOI 10.1146/annurev.ne.11.030188.001445; Wachtler F., 1992, SEMIN DEV BIOL, V3, P217; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WHITELAW V, 1983, J NEUROSCI, V3, P1226; WHITELAW V, 1983, J NEUROSCI, V3, P1199; WIGSTON DJ, 1985, J NEUROSCI, V5, P1208; WIGSTON DJ, 1982, NATURE, V299, P464, DOI 10.1038/299464a0; XU Y, 1993, P NATL ACAD SCI USA, V90, P227, DOI 10.1073/pnas.90.1.227; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O; YIP JW, 1990, J NEUROSCI, V10, P2476	65	859	868	0	17	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 16	1994	79	6					957	970		10.1016/0092-8674(94)90027-2	http://dx.doi.org/10.1016/0092-8674(94)90027-2			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PY086	7528105				2022-12-24	WOS:A1994PY08600006
J	JACKSON, D; VOLPERT, OV; BOUCK, N; LINZER, DIH				JACKSON, D; VOLPERT, OV; BOUCK, N; LINZER, DIH			STIMULATION AND INHIBITION OF ANGIOGENESIS BY PLACENTAL PROLIFERIN AND PROLIFERIN-RELATED PROTEIN	SCIENCE			English	Article							MOUSE PLACENTA; MESSENGER-RNA; GIANT-CELLS; PROLACTIN; FAMILY; EXPRESSION; GENE; DIFFERENTIATION; MEMBER; SITE	In many mammalian species, the placenta is the site of synthesis of proteins in the prolactin and growth hormone family. Analysis of two such proteins, proliferin (PLF) and proliferin-related protein (PRP), revealed that they are potent regulators of angiogenesis; PLF stimulated and PRP inhibited endothelial cell migration in cell culture and neovascularization in vivo. The mouse placenta secretes an angiogenic activity during the middle of pregnancy that corresponds primarily to PLF, but later in gestation releases a factor that inhibits angiogenesis, which was identified as PRP. Incubation of placental tissue with PLF led to the specific binding of this hormone to capillary endothelial cells. Thus PLF and PRP may regulate the initiation and then the cessation of placental neovascularization.	NORTHWESTERN UNIV, DEPT BIOCHEM MOLEC BIOL & CELL BIOL, EVANSTON, IL 60208 USA; NORTHWESTERN UNIV, SCH MED, DEPT MICROBIOL IMMUNOL, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, SCH MED, RH LURIE CANC CTR, CHICAGO, IL 60611 USA	Northwestern University; Northwestern University; Northwestern University; Robert H. Lurie Comprehensive Cancer Center				Volpert, Olga/0000-0003-1381-5543	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024518, R01HD029962] Funding Source: NIH RePORTER; NCI NIH HHS [CA52750] Funding Source: Medline; NICHD NIH HHS [HD24518, HD29962] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		CARNEY EW, 1993, MOL REPROD DEV, V34, P357, DOI 10.1002/mrd.1080340403; CLAPP C, 1992, ENDOCRINOLOGY, V130, P1380, DOI 10.1210/en.130.3.1380; COFFIN JD, 1991, DEV BIOL, V148, P51, DOI 10.1016/0012-1606(91)90316-U; COLOSI P, 1988, MOL ENDOCRINOL, V2, P579, DOI 10.1210/mend-2-6-579; HORSEMAN N, COMMUNICATION; JACKSON DJC, UNPUB; LEE SJ, 1988, ENDOCRINOLOGY, V122, P1761, DOI 10.1210/endo-122-5-1761; LEE SJ, 1988, J BIOL CHEM, V263, P3521; LINZER DIH, 1985, EMBO J, V4, P1419, DOI 10.1002/j.1460-2075.1985.tb03796.x; LINZER DIH, 1985, P NATL ACAD SCI USA, V82, P4356, DOI 10.1073/pnas.82.13.4356; LINZER DIH, 1984, P NATL ACAD SCI-BIOL, V81, P4255, DOI 10.1073/pnas.81.14.4255; LINZER DIH, 1983, P NATL ACAD SCI-BIOL, V80, P4271, DOI 10.1073/pnas.80.14.4271; LOPEZ MF, 1993, ENDOCR J, V1, P513; MORDACQ JC, 1989, GENE DEV, V3, P760, DOI 10.1101/gad.3.6.760; MUSCAT GEO, 1991, MOL ENDOCRINOL, V5, P802, DOI 10.1210/mend-5-6-802; NILSENHAMILTON M, 1980, CELL, V20, P19, DOI 10.1016/0092-8674(80)90230-5; POLVERINI PJ, 1991, METHOD ENZYMOL, V198, P440; RAMSEY EM, 1982, PLACENTA; RASTINEJAD F, 1989, CELL, V56, P345, DOI 10.1016/0092-8674(89)90238-9; SOARES MJ, 1991, ENDOCR REV, V12, P402, DOI 10.1210/edrv-12-4-402; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; WILDER EL, 1989, MOL CELL BIOL, V9, P430, DOI 10.1128/MCB.9.2.430	22	194	200	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 2	1994	266	5190					1581	1584		10.1126/science.7527157	http://dx.doi.org/10.1126/science.7527157			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV015	7527157				2022-12-24	WOS:A1994PV01500050
J	VALERA, S; HUSSY, N; EVANS, RJ; ADAMI, N; NORTH, RA; SURPRENANT, A; BUELL, G				VALERA, S; HUSSY, N; EVANS, RJ; ADAMI, N; NORTH, RA; SURPRENANT, A; BUELL, G			NEW CLASS OF LIGAND-GATED ION-CHANNEL DEFINED BY P-2X RECEPTOR FOR EXTRACELLULAR ATP	NATURE			English	Article							PROGRAMMED CELL-DEATH; FUNCTIONAL EXPRESSION; POTASSIUM CHANNEL; TRANSMISSION	EXTRACELLULAR ATP exerts its effects through P-2 purinoceptors(1): these are ligand-gated ion channels (P-2X)(2,3) or G-protein-coupled receptors (P-2Y, P-2U)(4). ATP at P-2X receptors mediates synaptic transmission between neurons(5-7) and from neurons to smooth muscle(1), being responsible, for example, for sympathetic vasoconstriction in small arteries and arterioles(8,9) We have now cloned a complementary DNA encoding the P-2X receptor from rat vas deferens and expressed it in Xenopus oocytes and mammalian cells. ATP activates a cation-selective ion channel with relatively high calcium permeability. Structural predictions suggest that the protein (399 amino acids long) is mostly extracellular and contains only two transmembrane domains plus a pore-forming motif which resembles that of potassium channels. The P-2X receptor thus defines a new family of ligand-gated ion channels.			VALERA, S (corresponding author), GLAXO INST MOLEC BIOL SA,14 CHEMIN AUIX,PLAN OUATES,CH-1228 GENEVA,SWITZERLAND.		North, Richard/GQA-6156-2022					ABBRACHIO MP, IN PRESS PHARM THERA; ADAMS DJ, 1980, J GEN PHYSIOL, V75, P493, DOI 10.1085/jgp.75.5.493; ASHFORD MLJ, 1994, NATURE, V370, P456, DOI 10.1038/370456a0; BARNARD EA, 1994, TRENDS PHARMACOL SCI, V15, P67, DOI 10.1016/0165-6147(94)90280-1; BARNARD EA, 1992, TRENDS BIOCHEM SCI, V17, P368, DOI 10.1016/0968-0004(92)90002-Q; Bean B P, 1990, Ion Channels, V2, P169; BEAN BP, 1992, TRENDS PHARMACOL SCI, V13, P87, DOI 10.1016/0165-6147(92)90032-2; BENHAM CD, 1987, NATURE, V328, P275, DOI 10.1038/328275a0; BO XN, 1992, J BIOL CHEM, V267, P17581; BURNSTOCK G, 1988, TRENDS PHARMACOL SCI, V9, P116, DOI 10.1016/0165-6147(88)90185-X; BURNSTOCK G, 1990, ANN NY ACAD SCI, V603, P1; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CHALFIE M, 1993, NATURE, V361, P504, DOI 10.1038/361504a0; DURELL SR, 1992, BIOPHYS J, V62, P238, DOI 10.1016/S0006-3495(92)81809-X; EDWARDS FA, 1992, NATURE, V359, P144, DOI 10.1038/359144a0; EVANS RJ, 1992, BRIT J PHARMACOL, V106, P242, DOI 10.1111/j.1476-5381.1992.tb14323.x; EVANS RJ, 1992, NATURE, V357, P503, DOI 10.1038/357503a0; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; NORTH RA, IN PRESS HDB RECEPTO, V2; OWENS GP, 1991, MOL CELL BIOL, V11, P4177, DOI 10.1128/MCB.11.8.4177; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SILINSKY EM, 1992, BRIT J PHARMACOL, V106, P762, DOI 10.1111/j.1476-5381.1992.tb14408.x; SPRANZI E, 1993, BLOOD, V82, P1578; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; ZHENG LM, 1991, J CELL BIOL, V112, P279, DOI 10.1083/jcb.112.2.279; ZIGANSHIN AU, 1994, BRIT J PHARMACOL, V111, P923, DOI 10.1111/j.1476-5381.1994.tb14827.x; ZOETEWEIJ JP, 1992, BIOCHEM J, V288, P207, DOI 10.1042/bj2880207	30	886	908	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 6	1994	371	6497					516	519		10.1038/371516a0	http://dx.doi.org/10.1038/371516a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK589	7523951				2022-12-24	WOS:A1994PK58900056
J	MACPHERSON, AJS; BJARNASON, I				MACPHERSON, AJS; BJARNASON, I			COLONOCYTES IN BARRETTS METAPLASIA	LANCET			English	Editorial Material							ULCERATIVE-COLITIS				MACPHERSON, AJS (corresponding author), UNIV LONDON KINGS COLL,SCH MED,DEPT MED,LONDON,ENGLAND.							DAS KM, 1990, GASTROENTEROLOGY, V98, P464, DOI 10.1016/0016-5085(90)90839-S; DAS KM, 1994, ANN INTERN MED, V120, P753, DOI 10.7326/0003-4819-120-9-199405010-00006; DAS KM, 1993, J IMMUNOL, V150, P2487; HALSTENSEN TS, 1993, GUT, V34, P650, DOI 10.1136/gut.34.5.650; PAULL A, 1976, NEW ENGL J MED, V295, P476, DOI 10.1056/NEJM197608262950904	5	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 1	1994	344	8927					903	904		10.1016/S0140-6736(94)92264-0	http://dx.doi.org/10.1016/S0140-6736(94)92264-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ287	7523804				2022-12-24	WOS:A1994PJ28700005
J	KIRBY, RS				KIRBY, RS			ARE THE DAYS OF TRANSURETHRAL RESECTION OF PROSTATE FOR BENIGN PROSTATIC HYPERPLASIA NUMBERED - UROLOGISTS MUST GRASP THE FUTURE .3.	BRITISH MEDICAL JOURNAL			English	Article							OBSTRUCTION; FINASTERIDE				KIRBY, RS (corresponding author), ST BARTHOLOMEWS HOSP,LONDON EC1,ENGLAND.							GORMLEY GJ, 1992, NEW ENGL J MED, V327, P1185, DOI 10.1056/NEJM199210223271701; KIRBY RS, 1987, BRIT J UROL, V60, P136, DOI 10.1111/j.1464-410X.1987.tb04950.x; KIRBY RS, 1993, EUR UROL, V24, P20; LEPOR H, 1992, J UROLOGY, V148, P1467, DOI 10.1016/S0022-5347(17)36941-0; LEPOR H, 1991, Journal of Urology, V145, p362A; NEAL DE, 1989, BRIT MED J, V299, P762, DOI 10.1136/bmj.299.6702.762; Ng J., 1993, Journal of Urology, V149, p449A; NORRIS JP, 1993, J UROLOGY, V150, P1612, DOI 10.1016/S0022-5347(17)35857-3; OGDEN CW, 1993, LANCET, V341, P14, DOI 10.1016/0140-6736(93)92482-9; WENNBERG JE, 1987, JAMA-J AM MED ASSOC, V257, P933, DOI 10.1001/jama.257.7.933	10	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 17	1994	309	6956					716	717		10.1136/bmj.309.6956.716	http://dx.doi.org/10.1136/bmj.309.6956.716			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH407	7524872	Green Published			2022-12-24	WOS:A1994PH40700022
J	KRAHN, MD; MAHONEY, JE; ECKMAN, MH; TRACHTENBERG, J; PAUKER, SG; DETSKY, AS				KRAHN, MD; MAHONEY, JE; ECKMAN, MH; TRACHTENBERG, J; PAUKER, SG; DETSKY, AS			SCREENING FOR PROSTATE-CANCER - A DECISION-ANALYTIC VIEW	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RADICAL RETROPUBIC PROSTATECTOMY; TERM FOLLOW-UP; STAGE-A ADENOCARCINOMA; DEFINITIVE RADIOTHERAPY; PELVIC LYMPHADENECTOMY; EXPECTANT MANAGEMENT; DETECTION-PROJECT; NATURAL COURSE; CARCINOMA; COMPLICATIONS	Objective.-To determine the clinical and economic effects of screening for prostate cancer with prostate-specific antigen (PSA), transrectal ultrasound (TRUS), and digital rectal examination (DRE). Design.-Decision analytic cost-utility analysis comparing four screening strategies with a strategy of not screening. We assumed that the cancer detection rate and stage distribution were predicted by each combination of tests and that localized cancer was treated with radical prostatectomy. For each strategy, we calculated life expectancy, quality-adjusted life expectancy (QALE), and cost-utility ratios for unselected and high-prevalence populations. Data.-Probabilities and rates for clinical events were gathered from published data. We assessed utilities by the time-trade-off method using urologists, radiation oncologists, and internists as subjects. The Clinical Cost Manager at the New England Medical Center provided cost data. Results.-ln unselected men between the ages of 50 and 70 years, screening with PSA or TRUS prolonged unadjusted life expectancy but diminished QALE. Screening with DRE alone yielded no reduction in mortality at any age. All programs increased costs. Results were sensitive only to assumptions about the efficacy of treatment. In high-prevalence populations, screening produced a similar pattern: gains in unadjusted life expectancy, losses in QALE, and increased costs. Conclusions.-Our analysis does not support using PSA, TRUS, or DRE to screen asymptomatic men for prostatic cancer. Screening may result in poorer health outcomes and will increase costs dramatically. Assessment of comorbidity, risk attitude, and valuation of sexual function may identify individuals who will benefit from screening, but selecting high-prevalence populations will not improve the benefit of screening.	UNIV TORONTO, DEPT MED, TORONTO, ON, CANADA; UNIV TORONTO, DEPT CLIN BIOCHEM, TORONTO, ON, CANADA; UNIV TORONTO, DEPT HLTH ADM, TORONTO M5S 1A1, ON, CANADA; UNIV TORONTO, DEPT UROL, TORONTO, ON, CANADA; TORONTO HOSP, CTR PROSTATE, TORONTO M5T 2S8, ON, CANADA; WELLESLEY COLL HOSP, TORONTO M4Y 1J3, ON, CANADA; TUFTS UNIV NEW ENGLAND MED CTR, DEPT MED, DIV CLIN DECIS MAKING, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, BOSTON, MA 02111 USA	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; Tufts Medical Center; Tufts University	KRAHN, MD (corresponding author), TORONTO HOSP, CLIN EPIDEMIOL UNIT, EN G-248, 200 ELIZABETH ST, TORONTO M5G 2C4, ON, CANADA.			Krahn, Murray/0000-0001-5836-397X				ADOLFSSON J, 1991, J UROLOGY, V146, P96, DOI 10.1016/S0022-5347(17)37722-4; ADOLFSSON J, 1990, BRIT J UROL, V65, P611, DOI 10.1111/j.1464-410X.1990.tb14829.x; BABAIAN RJ, 1992, CANCER, V69, P1195; BAGSHAW MA, 1990, UROL CLIN N AM, V17, P787; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BLACK WC, 1993, NEW ENGL J MED, V328, P1237, DOI 10.1056/NEJM199304293281706; BLUTE ML, 1989, J UROLOGY, V142, P1262, DOI 10.1016/S0022-5347(17)39051-1; BLUTE ML, 1986, J UROLOGY, V136, P840, DOI 10.1016/S0022-5347(17)45098-1; BORING CC, 1992, CA-CANCER J CLIN, V42, P19, DOI 10.3322/canjclin.42.1.19; BOWERSOX J, 1992, J NATL CANCER I, V84, P1857, DOI 10.1093/jnci/84.24.1857; Burks D A, 1992, Henry Ford Hosp Med J, V40, P89; BYAR DP, 1981, UROLOGY, V17, P7; CANTRELL BB, 1981, J UROLOGY, V125, P516, DOI 10.1016/S0022-5347(17)55092-2; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; CATALONA WJ, 1993, JAMA-J AM MED ASSOC, V270, P948, DOI 10.1001/jama.270.8.948; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; COWEN ME, 1994, J CLIN EPIDEMIOL, V47, P3, DOI 10.1016/0895-4356(94)90029-9; DAVIES AH, 1990, EUR UROL, V18, P117; DAYAL HH, 1982, J CHRON DIS, V35, P553, DOI 10.1016/0021-9681(82)90074-1; DETSKY AS, 1990, ANN INTERN MED, V113, P147, DOI 10.7326/0003-4819-113-2-147; DORR VJ, 1993, ARCH INTERN MED, V153, P2529, DOI 10.1001/archinte.153.22.2529; EDDY DM, 1983, CANCER, V51, P2440, DOI 10.1002/1097-0142(19830615)51:12+<2440::AID-CNCR2820511309>3.0.CO;2-M; EPSTEIN JI, 1986, J UROLOGY, V136, P837, DOI 10.1016/S0022-5347(17)45097-X; FINCHAM SM, 1990, PROSTATE, V17, P189, DOI 10.1002/pros.2990170303; FLEMING C, 1993, JAMA-J AM MED ASSOC, V269, P2650, DOI 10.1001/jama.269.20.2650; FORMAN JD, 1986, INT J RADIAT ONCOL, V12, P185, DOI 10.1016/0360-3016(86)90092-1; FOWLER FJ, 1993, UROLOGY, V42, P622, DOI 10.1016/0090-4295(93)90524-E; FOWLER JE, 1985, UROLOGY, V24, P243; GIBBONS R P, 1988, NCI (National Cancer Institute) Monographs, P123; GIBBONS RP, 1984, J UROLOGY, V131, P73, DOI 10.1016/S0022-5347(17)50210-4; GIBBONS RP, 1989, J UROLOGY, V141, P564, DOI 10.1016/S0022-5347(17)40895-0; GONZALEZ EF, 1992, 14TH ANN M SOC MED D; GREEN CJ, 1993, PROSTATE SPECIFIC AN; HANKS GE, 1991, ACTA ONCOL, V30, P231, DOI 10.3109/02841869109092359; IGEL TC, 1987, J UROLOGY, V137, P1189, DOI 10.1016/S0022-5347(17)44445-4; Jewett H J, 1975, Urol Clin North Am, V2, P105; JOHANSSON JE, 1992, JAMA-J AM MED ASSOC, V267, P2191, DOI 10.1001/jama.267.16.2191; KINSEY AC, 1948, SEXUAL BEHAV HUMAN M, P218; KRAHN M, 1993, MED CARE, V31, P403, DOI 10.1097/00005650-199305000-00003; KRAMER BS, 1993, ANN INTERN MED, V119, P914, DOI 10.7326/0003-4819-119-9-199311010-00009; LABRIE F, 1993, CLIN INVEST MED, V16, P425; LABRIE F, 1992, J UROLOGY, V147, P846, DOI 10.1016/S0022-5347(17)37402-5; LANGE PH, 1987, J UROLOGY, V138, P348, DOI 10.1016/S0022-5347(17)43143-0; LAUPACIS A, 1993, CAN MED ASSOC J, V148, P927; LAWRENCE RS, 1992, SCREENING PROSTATE C, P1; LEANDRI P, 1992, J UROLOGY, V147, P883, DOI 10.1016/S0022-5347(17)37412-8; LEPOR H, 1989, J UROLOGY, V141, P82, DOI 10.1016/S0022-5347(17)40596-9; LEPOR H, 1988, NATL CANCER I MONOGR, V7, P117; LOWE BA, 1988, J UROLOGY, V140, P1345, DOI 10.1016/S0022-5347(17)42040-4; LUYAO GL, 1993, JAMA-J AM MED ASSOC, V269, P2633, DOI 10.1001/jama.269.20.2633; MEBANE C, 1990, J NATL MED ASSOC, V82, P782; METTLIN C, 1991, CANCER, V67, P2949, DOI 10.1002/1097-0142(19910615)67:12<2949::AID-CNCR2820671202>3.0.CO;2-X; MIDDLETON AW, 1987, J UROLOGY, V138, P1185, DOI 10.1016/S0022-5347(17)43544-0; MIDDLETON RG, 1990, UROL CLIN N AM, V17, P779; MIDDLETON RG, 1986, J UROLOGY, V136, P422, DOI 10.1016/S0022-5347(17)44890-7; MILLER AB, 1989, WORLD J SURG, V13, P79, DOI 10.1007/BF01671158; MORTON RA, 1991, J UROLOGY, V145, P1197, DOI 10.1016/S0022-5347(17)38574-9; NEWLING D, 1992, PROSTATE S4, V19, P139; OPTENBERG SA, 1990, UROL CLIN N AM, V17, P719; PATTERSON DE, 1984, UROLOGY, V23, P243, DOI 10.1016/S0090-4295(84)90038-4; PAULSON DF, 1990, J UROLOGY, V144, P1180, DOI 10.1016/S0022-5347(17)39686-6; PILEPICH M V, 1988, NCI (National Cancer Institute) Monographs, P61; PILEPICH MV, 1981, INT J RADIAT ONCOL, V7, P1341, DOI 10.1016/0360-3016(81)90029-8; RITCHIE AWS, 1989, BRIT J UROL, V64, P511, DOI 10.1111/j.1464-410X.1989.tb05289.x; ROOS LL, 1990, JAMA-J AM MED ASSOC, V263, P2453, DOI 10.1001/jama.263.18.2453; ROOS NP, 1987, J UROLOGY, V137, P1184, DOI 10.1016/S0022-5347(17)44442-9; SCHELLHAMMER PF, 1990, UROL CLIN N AM, V17, P835; SCHUMAN LM, 1980, PREV MED, V9, P630, DOI 10.1016/0091-7435(80)90035-3; SINGER PA, 1991, J CLIN ONCOL, V9, P328, DOI 10.1200/JCO.1991.9.2.328; SPITZ MR, 1991, J UROLOGY, V146, P1305, DOI 10.1016/S0022-5347(17)38074-6; STEINBERG GD, 1990, PROSTATE, V17, P337, DOI 10.1002/pros.2990170409; STEINECK G, 1991, SCAND J UROL NEPHROL, P121; STEINER MS, 1991, J UROLOGY, V145, P512, DOI 10.1016/S0022-5347(17)38382-9; WALSH PC, 1992, J UROLOGY, V147, P853, DOI 10.1016/S0022-5347(17)37404-9; WALSH PC, 1987, CANCER, V60, P526, DOI 10.1002/1097-0142(19870801)60:3+<526::AID-CNCR2820601515>3.0.CO;2-9; WALSH PC, 1982, J UROLOGY, V128, P492, DOI 10.1016/S0022-5347(17)53012-8; Weinstein MC, 1980, CLIN DECISION ANAL; WENNBERG JE, 1987, JAMA-J AM MED ASSOC, V257, P933, DOI 10.1001/jama.257.7.933; WHITMORE WF, 1991, CANCER, V67, P1091, DOI 10.1002/1097-0142(19910215)67:4<1091::AID-CNCR2820670437>3.0.CO;2-J; ZHANG G, 1991, J UROLOGY, V146, P99, DOI 10.1016/S0022-5347(17)37723-6; ZINCKE H, 1991, J UROLOGY, V146, P1053, DOI 10.1016/S0022-5347(17)37999-5; 1989, GUIDE CLIN PREVENTIV, P63; 1991, CAN MED ASSOC J, V145, P413	83	321	323	0	20	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 14	1994	272	10					773	780		10.1001/jama.272.10.773	http://dx.doi.org/10.1001/jama.272.10.773			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF188	7521400				2022-12-24	WOS:A1994PF18800025
J	BROWN, SC; THOMSON, SA; VEAL, JM; DAVIS, DG				BROWN, SC; THOMSON, SA; VEAL, JM; DAVIS, DG			NMR SOLUTION STRUCTURE OF A PEPTIDE NUCLEIC-ACID COMPLEXED WITH RNA	SCIENCE			English	Article							DNA; PNA; SPECTROSCOPY; INHIBITION; ANTISENSE; PROTEINS; OLIGONUCLEOTIDES; MACROMOLECULES; POLYAMIDE; EFFICIENT	Peptide nucleic acids (PNA) incorporating nucleic acid bases into an achiral polyamide backbone bind to DNA in a sequence-dependent manner. The structure of a PNA-ribonucleic acid (RNA) complex was determined with nuclear magnetic resonance methods. A hexameric PNA formed a 1:1 complex with a complementary RNA that is an antiparallel, right-handed double helix with Watson-Crick base pairing similar to the ''A'' form structure of RNA duplexes. The achiral PNA backbone assumed a distinct conformation upon binding that differed from previously proposed models and provides a basis for further structure-based design of antisense agents.			BROWN, SC (corresponding author), GLAXO INC,RES INST,RES TRIANGLE PK,NC 27709, USA.							ALMARSSON O, 1993, P NATL ACAD SCI USA, V90, P7518, DOI 10.1073/pnas.90.16.7518; ALMARSSON O, 1993, P NATL ACAD SCI USA, V90, P9542, DOI 10.1073/pnas.90.20.9542; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1983, J MAGN RESON, V55, P81; BAX A, 1989, METHOD ENZYMOL, V176, P164; Brunger A.T., 1992, X PLOR VERSION 3 1 M; BUCHARDT O, 1993, TRENDS BIOTECHNOL, V11, P384, DOI 10.1016/0167-7799(93)90097-S; CHANDRASEKARAN R, 1989, LANDOLTBORNSTEIN NUC, V7, P55; COHEN JS, 1989, OLIGODEOXYNUCLEOTIDE; EGHOLM M, 1993, NATURE, V365, P566, DOI 10.1038/365566a0; EGHOLM M, 1992, J AM CHEM SOC, V114, P1895, DOI 10.1021/ja00031a062; EGHOLM M, 1992, J AM CHEM SOC, V114, P114; FEHRENTZ JA, 1983, SYNTHESIS-STUTTGART, P676; HANVEY JC, 1992, SCIENCE, V258, P1481, DOI 10.1126/science.1279811; JONES AS, 1973, TETRAHEDRON, V29, P2293, DOI 10.1016/S0040-4020(01)93352-6; KELLOGG GW, 1992, J MAGN RESON, V98, P176, DOI 10.1016/0022-2364(92)90122-N; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; MILLIGAN JF, 1993, J MED CHEM, V36, P1923, DOI 10.1021/jm00066a001; NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210; NIELSEN PE, 1993, NUCLEIC ACIDS RES, V21, P197, DOI 10.1093/nar/21.2.197; OTTING G, 1986, J MAGN RESON, V70, P500, DOI 10.1016/0022-2364(86)90144-7; PEFFER NJ, 1993, P NATL ACAD SCI USA, V90, P10648, DOI 10.1073/pnas.90.22.10648; PINES O, 1986, TRENDS GENET, P284; SKLENAR V, 1987, J MAGN RESON, V75, P352, DOI 10.1016/0022-2364(87)90041-2; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; STEPHENSON ML, 1978, P NATL ACAD SCI USA, V75, P285, DOI 10.1073/pnas.75.1.285; Thomson S., UNPUB; UHLMANN E, 1990, CHEM REV, V90, P544; VARANI G, 1991, Q REV BIOPHYS, V24, P479, DOI 10.1017/S0033583500003875; WAGNER G, 1983, BIOCHEM BIOPH RES CO, V113, P854, DOI 10.1016/0006-291X(83)91077-X; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; Wuthrich K., 1986, NMR PROTEINS NUCL AC; ZAMECNIK PC, 1978, P NATL ACAD SCI USA, V75, P280, DOI 10.1073/pnas.75.1.280; ZYDOWSKY TM, 1988, J ORG CHEM, V53, P5607, DOI 10.1021/jo00259a003	34	215	232	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 5	1994	265	5173					777	780		10.1126/science.7519361	http://dx.doi.org/10.1126/science.7519361			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA372	7519361				2022-12-24	WOS:A1994PA37200032
J	DISANTO, JP; MARKIEWICZ, S; GAUCHAT, JF; BONNEFOY, JY; FISCHER, A; DESAINTBASILE, G				DISANTO, JP; MARKIEWICZ, S; GAUCHAT, JF; BONNEFOY, JY; FISCHER, A; DESAINTBASILE, G			PRENATAL-DIAGNOSIS OF X-LINKED HYPER-IGM SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							HUMAN T-CELLS; HYPERIMMUNOGLOBULINEMIA-M; CLOSE LINKAGE; LIGAND; CD40; IMMUNODEFICIENCY; ACTIVATION; RECEPTOR; LOCUS; FORM		GLAXO INST MOLEC BIOL,GENEVA,SWITZERLAND	GlaxoSmithKline	DISANTO, JP (corresponding author), HOP NECKER ENFANTS MALAD,INSERM,U132,149 RUE SEVRES,F-75743 PARIS 15,FRANCE.		Di Santo, James P/M-4298-2014; de Saint Basile, Genevieve/G-9731-2017	Di Santo, James P/0000-0002-7146-1862; de Saint Basile, Genevieve/0000-0002-1913-5269				ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; DESAINTBASILE G, 1987, P NATL ACAD SCI USA, V84, P7576; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; GAUCHAT JF, 1993, FEBS LETT, V315, P259, DOI 10.1016/0014-5793(93)81175-Y; GRAF D, 1992, EUR J IMMUNOL, V22, P3191, DOI 10.1002/eji.1830221226; HENDRIKS RW, 1990, EUR J IMMUNOL, V20, P2603, DOI 10.1002/eji.1830201212; HOLLENBAUGH D, 1992, EMBO J, V11, P4313, DOI 10.1002/j.1460-2075.1992.tb05530.x; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; LANE P, 1992, EUR J IMMUNOL, V22, P2573, DOI 10.1002/eji.1830221016; MENSINK EJBM, 1987, HUM GENET, V76, P96; NOELLE RJ, 1992, IMMUNOL TODAY, V13, P431, DOI 10.1016/0167-5699(92)90068-I; NOTARANGELO L D, 1992, Immunodeficiency Reviews, V3, P101; PADAYACHEE M, 1992, GENOMICS, V14, P551, DOI 10.1016/S0888-7543(05)80270-8; PEAKMAN DC, 1977, J MED GENET, V14, P37, DOI 10.1136/jmg.14.1.37; ROSEN FS, 1961, PEDIATRICS, V28, P182; WEBER JL, 1989, AM J HUM GENET, V44, P388; 1992, IMMUNODEFIC REV, V3, P195	19	38	39	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 7	1994	330	14					969	973		10.1056/NEJM199404073301404	http://dx.doi.org/10.1056/NEJM199404073301404			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND793	7510042				2022-12-24	WOS:A1994ND79300004
J	CHENG, JH; ZHOU, T; LIU, CD; SHAPIRO, JP; BRAUER, MJ; KIEFER, MC; BARR, PJ; MOUNTZ, JD				CHENG, JH; ZHOU, T; LIU, CD; SHAPIRO, JP; BRAUER, MJ; KIEFER, MC; BARR, PJ; MOUNTZ, JD			PROTECTION FROM FAS-MEDIATED APOPTOSIS BY A SOLUBLE FORM OF THE FAS MOLECULE	SCIENCE			English	Article							TUMOR-NECROSIS-FACTOR; CELL-SURFACE ANTIGEN; RECEPTOR SUPERFAMILY; DNA FRAGMENTATION; CLONING; EXPRESSION; DEATH; CDNA; MICE	Fas is an apoptosis-signaling receptor molecule on the surface of a number of cell types. Molecular cloning and nucleotide sequence analysis revealed a human Fas messenger RNA variant capable of encoding a soluble Fas molecule lacking the transmembrane domain because of the deletion of an exon encoding this region. The expression of soluble Fas was confirmed by flow cytometry and immunocytochemical analysis. Supernatants from cells transfected with the variant messenger RNA blocked apoptosis induced by the antibody to Fas. Levels of soluble Fas were elevated in patients with systemic lupus erythematosus, and mice injected with soluble Fas displayed autoimmune features.	UNIV ALABAMA,BIRMINGHAM,AL 35294; VET ADM MED CTR,BIRMINGHAM,AL 35294; LXR BIOTECHNOL INC,RICHMOND,CA 94804	University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI023694] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR003555, P60AR020614] Funding Source: NIH RePORTER; NIAID NIH HHS [P50 AI23694] Funding Source: Medline; NIAMS NIH HHS [P60 AR20614, P01 AR03555] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADACHI M, 1993, P NATL ACAD SCI USA, V90, P1756, DOI 10.1073/pnas.90.5.1756; FERNANDEZBOTRAN R, 1991, FASEB J, V5, P2567, DOI 10.1096/fasebj.5.11.1868981; FRIZZERA G, 1989, LEUKEMIA, V3, P1; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; GOODWIN RG, 1993, CELL, V73, P447, DOI 10.1016/0092-8674(93)90133-B; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JOSIMOVICALASEV.O, 1988, EUR J IMMUNOL, V18, P855; KLINMAN DM, 1986, J EXP MED, V163, P1292, DOI 10.1084/jem.163.5.1292; KROWKA J, UNPUB; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; OEHM A, 1992, J BIOL CHEM, V267, P10709; OHSAKA A, 1992, J CANCER, V69, P1259; OWENSCHAUB LB, 1992, CELL IMMUNOL, V140, P197, DOI 10.1016/0008-8749(92)90187-T; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; TAKASHI S, 1993, CELL, V75, P1169; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1277; WALLACE DJ, 1992, NEW ENGL J MED, V327, P1029; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WATSON ML, 1992, J EXP MED, V176, P1645, DOI 10.1084/jem.176.6.1645; WU JG, 1993, J EXP MED, V178, P461, DOI 10.1084/jem.178.2.461	23	1064	1172	1	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 25	1994	263	5154					1759	1762		10.1126/science.7510905	http://dx.doi.org/10.1126/science.7510905			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NC040	7510905				2022-12-24	WOS:A1994NC04000035
J	BERG, EL; MCEVOY, LM; BERLIN, C; BARGATZE, RF; BUTCHER, EC				BERG, EL; MCEVOY, LM; BERLIN, C; BARGATZE, RF; BUTCHER, EC			L-SELECTIN-MEDIATED LYMPHOCYTE ROLLING ON MADCAM-1	NATURE			English	Article							ENDOTHELIAL CELL RECOGNITION; NODE HOMING RECEPTOR; VASCULAR ADDRESSIN; LIGAND; MOLECULE; IDENTIFICATION; MIGRATION; ADHESION; VENULES; SPECIFICITY	THE L-selectin, a cell surface C-type lectin, directs lymphocyte traffic to lymph nodes1, and contributes to lymphocyte homing to Peyer's patches2,3 and to leukocyte interactions with inflamed venules4,5. Here we report that the mucosal vascular addressin MAdCAM-1, a mucosal endothelial adhesion molecule with immunoglobulin- and mucin-like domains6, is a facultative ligand for L-selectin. MAdCAM-1 isolated from mesenteric lymph nodes, but not from cultured endothelioma cells, bears N-glycanase-resistant sialic acid-containing carbohydrate which supports adhesion of L-selectin-transfected lymphoid cells under shear. Interacting lymphoid cells display a 'rolling' behaviour similar to the selectin-dependent rolling of neutrophils observed in inflamed venules. MAdCAM-1 is also a ligand for the lymphocyte integrin homing receptor for Peyer's patches, alpha4beta7 (ref. 7), and may be uniquely adapted to support both selectin-mediated lymphocyte rolling and integrin-mediated adhesion and arrest in vivo.	STANFORD UNIV,DEPT PATHOL,IMMUNOL & VASC BIOL LAB,STANFORD,CA 94305; VET ADM MED CTR,FOOTHILL RES CTR,CTR MOLEC BIOL & MED,PALO ALTO,CA 94304	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Berg, Ellen/D-9076-2014; Berg, Ellen/T-8827-2019	Berg, Ellen/0000-0001-5149-6665; 				BARGATZE RF, 1990, J CELL BIOCHEM, V42, P219, DOI 10.1002/jcb.240420405; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; BERG E L, 1991, P111; BERG EL, 1992, BIOCHEM BIOPH RES CO, V184, P1048, DOI 10.1016/0006-291X(92)90697-J; BERG EL, 1991, J CELL BIOL, V114, P343, DOI 10.1083/jcb.114.2.343; BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; BJERKNES M, 1986, SCIENCE, V231, P402, DOI 10.1126/science.3941903; BRISKIN MJ, 1993, NATURE, V363, P461, DOI 10.1038/363461a0; BRUSTEIN M, 1992, J EXP MED, V176, P1415, DOI 10.1084/jem.176.5.1415; BUTCHER EC, 1980, EUR J IMMUNOL, V10, P556, DOI 10.1002/eji.1830100713; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; HAMANN A, 1991, EUR J IMMUNOL, V21, P2925, DOI 10.1002/eji.1830211205; HOLTZMANN B, 1989, CELL, V56, P37; IMAI Y, 1991, J CELL BIOL, V113, P1213, DOI 10.1083/jcb.113.5.1213; ISSEKUTZ TB, 1991, J IMMUNOL, V147, P4178; KISHIMOTO TK, 1990, P NATL ACAD SCI USA, V87, P2244, DOI 10.1073/pnas.87.6.2244; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEWINSOHN DM, 1987, J IMMUNOL, V138, P4313; NAKACHE M, 1988, NATURE, V304, P32; PERRY MA, 1991, J CLIN INVEST, V87, P1798, DOI 10.1172/JCI115200; PICKER LJ, 1989, J CELL BIOL, V109, P927, DOI 10.1083/jcb.109.2.927; SHIMIZU Y, 1992, IMMUNOL TODAY, V13, P106, DOI 10.1016/0167-5699(92)90151-V; SIMMONS DL, 1992, J IMMUNOL, V148, P267; STREETER PR, 1988, J CELL BIOL, V107, P1853, DOI 10.1083/jcb.107.5.1853; STREETER PR, 1988, NATURE, V331, P41, DOI 10.1038/331041a0; UMEMOTO J, 1977, J BIOL CHEM, V252, P8609; VONANDRIAN UH, 1992, AM J PHYSIOL, V263, pH1034, DOI 10.1152/ajpheart.1992.263.4.H1034; WATSON SR, 1990, J CELL BIOL, V110, P2221, DOI 10.1083/jcb.110.6.2221	30	487	502	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 16	1993	366	6456					695	698		10.1038/366695a0	http://dx.doi.org/10.1038/366695a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM265	7505053				2022-12-24	WOS:A1993MM26500072
J	LAUNER, LJ; MASAKI, K; PETROVITCH, H; FOLEY, D; HAVLIK, RJ				LAUNER, LJ; MASAKI, K; PETROVITCH, H; FOLEY, D; HAVLIK, RJ			THE ASSOCIATION BETWEEN MIDLIFE BLOOD-PRESSURE LEVELS AND LATE-LIFE COGNITIVE FUNCTION - THE HONOLULU-ASIA AGING STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; WHITE MATTER LESIONS; MINI-MENTAL STATE; JAPANESE MEN; HYPERTENSION; STROKE; HAWAII; CALIFORNIA; MORTALITY; DEMENTIA	Objective.-To assess the long-term relationship of midlife blood pressure levels to late-life cognitive function. Design.-The 4678 surviving cohort members of the prospective Honolulu Heart Program (baseline, 1965-1968) were examined a fourth time in 1991 through 1993 and given a cognitive test. Participants.-The subjects were 3735 Japanese-American men living in Hawaii in the community or in institutions, with an average age of 78 years at the fourth examination. Main Outcome Measures.-Cognitive function, measured by the 100-point Cognitive Abilities Screening Instrument (CASI), was categorized into good (reference: a CASI score of 92 to 100), intermediate (<92 to 82), and poor (<82). Midlife systolic blood pressure (SEP) and diastolic blood pressure (DBP) values were measured in 1965, 1968, and 1971. A respondent was classified into the following categories if two of three measurements fell into the following groups: for SEP, <110, 110 to 139, 140 to 159, and greater than or equal to 160 mm Hg; and for DBP, <80, 80 to 89, 90 to 94, and greater than or equal to 95 mm Hg. Results.-When we controlled for age and education, the risk for intermediate and poor cognitive function increased progressively with increasing level of midlife SEP category (P for trend <.03 and <.001, respectively). for every 10-mm Hg increase in SEP there was an increase in risk for intermediate cognitive function of 7% (95% confidence interval [C], 3% to 11%) and for poor cognitive function of 9% (95% CI, 3% to 16%). Adjustment for prevalent stroke, coronary heart disease, and subclinical atherosclerosis reduced the strength of the relationship between midlife SEP and poor cognitive function to 5% (95% CI, 0% to 12%). The level of cognitive function was not associated with midlife DBP. Conclusions.-Midlife SEP is a significant predictor of reduced cognitive function in later life. Early control of SEP levels may reduce the risk for cognitive impairment in old age.	ERASMUS UNIV ROTTERDAM,SCH MED,DEPT EPIDEMIOL & BIOSTAT,BILTHOVEN,NETHERLANDS; UNIV HAWAII,DEPT MED,HONOLULU,HI; KUAKINI MED CTR,HONOLULU,HI 96817; NIA,EPIDEMIOL DEMOG & BIOMETRY PROGRAM,BETHESDA,MD 20892	Erasmus University Rotterdam; University of Hawaii System; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	LAUNER, LJ (corresponding author), NATL INST PUBL HLTH & ENVIRONM PROTECT,POB 1,3720 BA BILTHOVEN,NETHERLANDS.				NATIONAL INSTITUTE ON AGING [N01AG042149] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HR-02901] Funding Source: Medline; NIA NIH HHS [N01-AG-4-2149] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		APPLEGATE WB, 1989, ANN INTERN MED, V110, P901, DOI 10.7326/0003-4819-110-11-901; BOTS ML, 1993, LANCET, V341, P1232, DOI 10.1016/0140-6736(93)91144-B; BOTS ML, 1991, EPIDEMIOL REV, V13, P294, DOI 10.1093/oxfordjournals.epirev.a036073; BRETELER MMB, 1994, STROKE, V25, P1109, DOI 10.1161/01.STR.25.6.1109; COLSHER PL, 1991, EPIDEMIOL REV, V13, P1; ELIAS MF, 1993, AM J EPIDEMIOL, V138, P353, DOI 10.1093/oxfordjournals.aje.a116868; ELIAS MF, 1989, J GERONTOL, V44, pP25, DOI 10.1093/geronj/44.1.P25; ERKINJUNTTI T, 1993, CEREBROVASC DIS, V3, P3, DOI 10.1159/000108661; FARACI FM, 1990, CIRC RES, V66, P8, DOI 10.1161/01.RES.66.1.8; FARMER ME, 1987, AM J EPIDEMIOL, V126, P1103, DOI 10.1093/oxfordjournals.aje.a114749; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FUMTA A, 1991, STROKE, V22, P442; GRAVES AB, 1993, ALZHEIMERS DIS ADV C, P113; Hasegawa K, 1983, AGING 80S, P207; HAVLIK RJ, 1992, NESTLE NUTR WORKSHOP, P7; KANNEL WB, 1985, HDB BIOL AGING, P859; KANNEL WB, 1976, STROKE, V4, P327; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MILLER VT, 1983, ARCH NEUROL-CHICAGO, V40, P129, DOI 10.1001/archneur.1983.04050030023002; NAG S, 1984, ACTA NEUROPATHOL, V62, P178, DOI 10.1007/BF00691850; REED D, 1994, STROKE, V25, P60, DOI 10.1161/01.STR.25.1.60; SALERNO JA, 1992, HYPERTENSION, V20, P340, DOI 10.1161/01.HYP.20.3.340; SANDS LP, 1992, J GERONTOL, V47, pP81, DOI 10.1093/geronj/47.2.P81; SCHERR PA, 1991, AM J EPIDEMIOL, V134, P1303, DOI 10.1093/oxfordjournals.aje.a116033; SIU AL, 1991, ANN INTERN MED, V115, P122, DOI 10.7326/0003-4819-115-2-122; STAMLER J, 1987, NEW PERSPECTIVES CAR, P13; STARR JM, 1993, J AM GERIATR SOC, V41, P753, DOI 10.1111/j.1532-5415.1993.tb07466.x; SYME SL, 1975, AM J EPIDEMIOL, V102, P477, DOI 10.1093/oxfordjournals.aje.a112185; TATAMICHI TK, 1994, J NEUROL NEUROSUR PS, V57, P202; Teng E L, 1994, Int Psychogeriatr, V6, P45, DOI 10.1017/S1041610294001602; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; VANSWIETEN JC, 1991, ANN NEUROL, V30, P825, DOI 10.1002/ana.410300612; VOGT MT, 1992, J CLIN EPIDEMIOL, V45, P529, DOI 10.1016/0895-4356(92)90102-S; WALLACE RB, 1985, J CHRON DIS, V38, P475, DOI 10.1016/0021-9681(85)90031-1; WHITE LR, 1992, CURR SCI INDIA, V63, P456; WILKIE F, 1971, SCIENCE, V172, P959, DOI 10.1126/science.172.3986.959; WILKIE F L, 1976, Experimental Aging Research, V2, P3; WINKELSTEIN W, 1975, AM J EPIDEMIOL, V102, P502, DOI 10.1093/oxfordjournals.aje.a112188; WITTEMAN JCM, 1994, LANCET, V343, P504, DOI 10.1016/S0140-6736(94)91459-1; WORTH RM, 1975, AM J EPIDEMIOL, V102, P481, DOI 10.1093/oxfordjournals.aje.a112186; YANO K, 1983, J CHRON DIS, V36, P569, DOI 10.1016/0021-9681(83)90145-5; 1987, DIAGNOSTIC STATISTIC; 1993, SAS STAT USERS GUIDE	43	699	728	1	38	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 20	1995	274	23					1846	1851		10.1001/jama.274.23.1846	http://dx.doi.org/10.1001/jama.274.23.1846			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TK147	7500533				2022-12-24	WOS:A1995TK14700025
J	STUDITSKY, VM; CLARK, DJ; FELSENFELD, G				STUDITSKY, VM; CLARK, DJ; FELSENFELD, G			OVERCOMING A NUCLEOSOMAL BARRIER TO TRANSCRIPTION	CELL			English	Article							RNA-POLYMERASE-II; ELONGATION COMPLEXES; HISTONE ACETYLATION; CHROMATIN STRUCTURE; BACTERIOPHAGE-T7; INITIATION; INVITRO; DNA; INHIBIT; GENES	We have studied the kinetics of transcription through a nucleosome core. RNA polymerase transcribes the first similar to 25 bp of nucleosomal DNA rapidly, but then hits a barrier and continues slowly to the nucleosomal dyad region. Here, the barrier disappears and the transcript is completed at a rapid rate, as if on free DNA, indicating that histone octamer transfer is completed as polymerase reaches the dyad, If DNA behind the polymerase is removed during transcription, the barrier does not appear until the polymerase has penetrated up to 15 bp farther into the nucleosome. On a longer template, the barrier is almost eliminated. We have shown previously that the octamer is transferred around the transcribing polymerase via an intermediate containing an intranucleosomal DNA loop, Our results exclude the possibility that polymerase has difficulty breaking histone-DNA contacts and suggest instead that polymerase pauses because it has difficulty transcribing DNA in the loop.	NIDDKD,MOLEC BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Studitsky, Vasily/A-9382-2014					ARENTS G, 1993, P NATL ACAD SCI USA, V90, P10489, DOI 10.1073/pnas.90.22.10489; AXELROD VD, 1985, BIOCHEMISTRY-US, V24, P5716, DOI 10.1021/bi00342a005; BJORKROTH B, 1988, CHROMOSOMA, V96, P333, DOI 10.1007/BF00330699; CAVALLI G, 1993, EMBO J, V12, P4603, DOI 10.1002/j.1460-2075.1993.tb06149.x; CLARK DJ, 1992, CELL, V71, P11, DOI 10.1016/0092-8674(92)90262-B; CSORDAS A, 1990, BIOCHEM J, V265, P23, DOI 10.1042/bj2650023; DARST SA, 1991, CELL, V66, P121, DOI 10.1016/0092-8674(91)90144-N; DEBERNARDIN W, 1986, J MOL BIOL, V191, P469, DOI 10.1016/0022-2836(86)90142-7; DING HF, 1994, SCIENCE, V265, P796, DOI 10.1126/science.8047885; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; JORGENSEN ED, 1991, J BIOL CHEM, V266, P645; KAMAKAKA RT, 1990, EMBO J, V9, P3997, DOI 10.1002/j.1460-2075.1990.tb07621.x; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KNEZETIC JA, 1988, MOL CELL BIOL, V8, P3114, DOI 10.1128/MCB.8.8.3114; KORNBERG RD, 1991, CELL, V67, P833, DOI 10.1016/0092-8674(91)90354-2; KORNBERG RD, 1992, ANNU REV CELL BIOL, V8, P563, DOI 10.1146/annurev.cellbio.8.1.563; LEVIN JR, 1987, J MOL BIOL, V196, P61, DOI 10.1016/0022-2836(87)90511-0; LEWIN B, 1994, CELL, V79, P397, DOI 10.1016/0092-8674(94)90249-6; LINN SC, 1991, MOL CELL BIOL, V11, P1508, DOI 10.1128/MCB.11.3.1508; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; LORCH Y, 1988, CELL, V55, P203; LOSA R, 1987, CELL, V50, P801, DOI 10.1016/0092-8674(87)90338-2; MATSUZAKI H, 1994, J MOL BIOL, V235, P1173, DOI 10.1006/jmbi.1994.1072; MCKNIGHT SL, 1979, CELL, V7, P551; MORSE RH, 1989, EMBO J, V8, P2343, DOI 10.1002/j.1460-2075.1989.tb08362.x; MORSE RH, 1992, TRENDS BIOCHEM SCI, V17, P23, DOI 10.1016/0968-0004(92)90422-6; ODONOHUE MF, 1994, NUCLEIC ACIDS RES, V22, P937, DOI 10.1093/nar/22.6.937; ONEILL TE, 1992, J MOL BIOL, V223, P67, DOI 10.1016/0022-2836(92)90716-W; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; POSTNIKOV YV, 1991, NUCLEIC ACIDS RES, V19, P717, DOI 10.1093/nar/19.4.717; REES WA, 1993, SCIENCE, V260, P1646, DOI 10.1126/science.8503010; RICHMOND TJ, 1993, COLD SPRING HARB SYM, V58, P265, DOI 10.1101/SQB.1993.058.01.031; SASTRY SS, 1991, J MOL BIOL, V221, P1091, DOI 10.1016/0022-2836(91)90921-R; SCHULTZ P, 1993, EMBO J, V12, P2601, DOI 10.1002/j.1460-2075.1993.tb05920.x; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; STUDITSKY VM, 1994, CELL, V76, P371, DOI 10.1016/0092-8674(94)90343-3; TRAVERS AA, 1994, BIOESSAYS, V16, P657, DOI 10.1002/bies.950160911; TURNER BM, 1991, J CELL SCI, V99, P13; VANHOLDE KE, 1992, J BIOL CHEM, V267, P2837; WASYLYK B, 1979, EUR J BIOCHEM, V98, P317, DOI 10.1111/j.1432-1033.1979.tb13191.x; WILLIAMSON P, 1978, BIOCHEMISTRY-US, V26, P5695; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2	43	128	133	0	6	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 6	1995	83	1					19	27		10.1016/0092-8674(95)90230-9	http://dx.doi.org/10.1016/0092-8674(95)90230-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RY583	7553869	Bronze			2022-12-24	WOS:A1995RY58300006
J	UNANUE, ER				UNANUE, ER			THE CONCEPT OF ANTIGEN-PROCESSING AND PRESENTATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							T-CELL; LYMPHOCYTES-T; IDENTIFICATION; MACROPHAGES; LYSOZYME; PEPTIDES; BINDING		WASHINGTON UNIV,SCH MED,CTR IMMUNOL,ST LOUIS,MO 63110	Washington University (WUSTL)	UNANUE, ER (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PATHOL,660 S EUCLID ST,CAMPUS BOX 8118,ST LOUIS,MO 63110, USA.							ALLEN PM, 1984, P NATL ACAD SCI-BIOL, V81, P2489, DOI 10.1073/pnas.81.8.2489; ALLEN PM, 1987, NATURE, V327, P713, DOI 10.1038/327713a0; BABBITT BP, 1986, P NATL ACAD SCI USA, V83, P4509, DOI 10.1073/pnas.83.12.4509; BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BENACERRAF B, 1967, COLD SPRING HARB SYM, V32, P569, DOI 10.1101/SQB.1967.032.01.069; BUUS S, 1991, SCIENCE, V235, P1353; CALDERON J, 1975, NATURE, V253, P359, DOI 10.1038/253359a0; KATZ DH, 1973, J EXP MED, V137, P1405, DOI 10.1084/jem.137.6.1405; LORENZ RG, 1988, P NATL ACAD SCI USA, V85, P5220, DOI 10.1073/pnas.85.14.5220; MCDEVITT HO, 1969, SCIENCE, V163, P1207, DOI 10.1126/science.163.3872.1207; NELSON CA, 1992, P NATL ACAD SCI USA, V89, P7380, DOI 10.1073/pnas.89.16.7380; ROSENTHA.AS, 1973, J EXP MED, V138, P1194, DOI 10.1084/jem.138.5.1194; Schwartz R., 1984, FUNDAMENTAL IMMUNOLO, P379; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; UNANUE ER, 1968, IMMUNOLOGY, V15, P287; UNANUE ER, 1981, ADV IMMUNOL, V31, P1, DOI 10.1016/S0065-2776(08)60919-0; ZIEGLER K, 1981, J IMMUNOL, V127, P1869; ZIEGLER K, 1982, P NATL ACAD SCI USA, V78, P175; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0	19	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 4	1995	274	13					1071	1073		10.1001/jama.274.13.1071	http://dx.doi.org/10.1001/jama.274.13.1071			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX108	7563463				2022-12-24	WOS:A1995RX10800035
J	CUI, KH; HAAN, EA; WANG, LJ; MATTHEWS, CD				CUI, KH; HAAN, EA; WANG, LJ; MATTHEWS, CD			OPTIMAL POLYMERASE CHAIN-REACTION AMPLIFICATION FOR PREIMPLANTATION DIAGNOSIS IN CYSTIC-FIBROSIS (DELTA-F508)	BRITISH MEDICAL JOURNAL			English	Article							PRENATAL SEX DETERMINATION; GENETIC DIAGNOSIS; DNA AMPLIFICATION; EMBRYO BIOPSY; SINGLE CELLS; IDENTIFICATION; PRECONCEPTION; RELIABILITY; CHROMOSOME; MUTATIONS	Objective-To evaluate direct polymerase chain reaction amplification of mutation on single embryo cells for the routine preimplantation diagnosis of cystic fibrosis. Design-Direct polymerase chain reaction amplification of mutation was performed to identify the cystic fibrosis Delta F508 mutation in human blood DNA, single lymphocytes, embryos, and embryo cells obtained by biopsy. Preimplantation diagnosis was performed for a couple who were heterozygous carriers of the Delta F508 mutation. Setting-Laboratory for preimplantation diagnosis in a reproductive medicine unit. Main outcome measure-Correct diagnosis of homozygous normal, heterozygous, and homozygous abnormal DNA of the cystic fibrosis Delta F508 mutation. Results-45 blood samples (18 homozygous normal, 17 heterozygous, and 10 homozygous abnormal) and 204 single lymphocytes from known sources showed 100% amplification and were diagnosed correctly. 17 human embryos and 52 normal nucleated embryo cells obtained by single cell embryo biopsy also showed 100% amplification. After a miscarriage of the initial pregnancy (diagnosed at preimplantation to be homozygous normal) in the heterozygous carrier couple, fetal tissue was confirmed to be homozygous normal. Conclusion-Direct polymerase chain reaction amplification of mutation is a simple, fast, reliable test for the common cystic fibrosis mutation (Delta F508) in blood DNA and single cells and should be applicable to routine programmes of general screening, maternal blood examination, and preimplantation diagnosis.	WOMENS & CHILDRENS HOSP,DEPT MED GENET,ADELAIDE,SA 5006,AUSTRALIA	Womens & Childrens Hospital Australia	CUI, KH (corresponding author), UNIV ADELAIDE,QUEEN ELIZABETH HOSP,DEPT OBSTET & GYNAECOL,ADELAIDE,SA 5011,AUSTRALIA.							Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; CIU KH, 1994, LANCET, V343, P79; COUTELLE C, 1989, BRIT MED J, V299, P22, DOI 10.1136/bmj.299.6690.22; CUI KH, 1993, HUM REPROD, V8, P621, DOI 10.1093/oxfordjournals.humrep.a138107; CUI KH, 1993, THSIS U ADELAIDE, P1; CUI KJH, 1994, 13TH P ANN SCI M FER; GRIFO JA, 1992, JAMA-J AM MED ASSOC, V268, P727, DOI 10.1001/jama.268.6.727; HANDYSIDE AH, 1989, LANCET, V1, P347; HANDYSIDE AH, 1990, NATURE, V344, P768, DOI 10.1038/344768a0; HANDYSIDE AH, 1992, NEW ENGL J MED, V327, P905, DOI 10.1056/NEJM199209243271301; HARRIS A, 1992, BRIT MED BULL, V48, P738, DOI 10.1093/oxfordjournals.bmb.a072575; JARMULOWICZ M, 1989, LANCET, V1, P547; Kawasaki E. S., 1990, PCR PROTOCOLS GUIDE, P146; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; LESKO J, 1991, AM J HUM GENET, V49, P223; LO YMD, 1989, LANCET, V2, P1363; MEYERS RM, 1985, SCIENCE, V230, P1242; MYERS RM, 1985, NATURE, V313, P495, DOI 10.1038/313495a0; NAKAGOME Y, 1990, LANCET, V335, P291, DOI 10.1016/0140-6736(90)90109-I; PICKERING SJ, 1992, HUM REPROD, V7, P630, DOI 10.1093/oxfordjournals.humrep.a137710; ROMMENS J, 1990, AM J HUM GENET, V46, P395; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SHENK TE, 1975, P NATL ACAD SCI USA, V72, P989, DOI 10.1073/pnas.72.3.989; SIMPSON JL, 1992, NEW ENGL J MED, V327, P951, DOI 10.1056/NEJM199209243271309; STROM CM, 1991, J IN VITRO FERTIL EM, V8, P225, DOI 10.1007/BF01130810; STROM CM, 1990, LANCET, V336, P306, DOI 10.1016/0140-6736(90)91835-X; STROM CM, 1991, PREIMPLANTATION GENETICS, P131; TROUNSON AL, 1992, HUM REPROD, V7, P583; VERLINSKY Y, 1992, PRENATAL DIAG, V12, P103, DOI 10.1002/pd.1970120205; WINSTON RML, 1991, HUM REPROD, V6, P281	30	10	14	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 26	1995	311	7004					536	540		10.1136/bmj.311.7004.536	http://dx.doi.org/10.1136/bmj.311.7004.536			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RR737	7545043	Green Published			2022-12-24	WOS:A1995RR73700017
J	WEI, XQ; CHARLES, IG; SMITH, A; URE, J; FENG, CJ; HUANG, FP; XU, DM; MULLER, W; MONCADA, S; LIEW, FY				WEI, XQ; CHARLES, IG; SMITH, A; URE, J; FENG, CJ; HUANG, FP; XU, DM; MULLER, W; MONCADA, S; LIEW, FY			ALTERED IMMUNE-RESPONSES IN MICE LACKING INDUCIBLE NITRIC-OXIDE SYNTHASE	NATURE			English	Article							L-ARGININE; INFECTION; CYTOKINE	NITRIC oxide (NO) is important in many biological functions(1-5). It is generated from L-arginine by the enzyme NO synthase (NOS), The cytokine-inducible NOS (iNOS) is activated by several immunological stimuli, leading to the production of large quantities of NO which can be cytotoxic(6). To define the biological role of iNOS further, we generated iNOS mutant mice. These are viable, fertile and without evident histopathological abnormalities, However, in contrast to wild-type and heterozygous mice, which are highly resistant to the protozoa parasite Leishmania major infection, mutant mice are uniformly susceptible, The infected mutant mice developed a significantly stronger Th1 type of immune response than the wild-type or heterozygous mice, The mutant mice showed reduced nonspecific inflammatory response to carrageenin, and were resistant to lipopolysaccharide-induced mortality.	UNIV GLASGOW, DEPT IMMUNOL, GLASGOW G11 6NT, LANARK, SCOTLAND; WELLCOME RES LABS, BECKENHAM BR3 3BS, KENT, ENGLAND; UNIV EDINBURGH, CTR GENOME RES, GENE TARGETING LAB, EDINBURGH EH9 3JQ, MIDLOTHIAN, SCOTLAND; UNIV COLOGNE, INST GENET, D-50931 COLOGNE, GERMANY	University of Glasgow; GlaxoSmithKline; Wellcome Research Laboratories; University of Edinburgh; University of Cologne			Xu, Damo/A-8212-2011; Muller, Werner/B-9044-2008	Muller, Werner/0000-0002-1297-9725; Smith, Austin/0000-0002-3029-4682	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; DEMARIA R, 1994, J EXP MED, V180, P1999, DOI 10.1084/jem.180.5.1999; EFRON DT, 1991, SURGERY, V110, P327; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GREEN SJ, 1993, CURR OPIN INFECT DIS, V6, P384; HIBBS JB, 1990, INT CONGR SER, V897, P189; JAMES SL, 1990, PARASITOL TODAY, V6, P303, DOI 10.1016/0169-4758(90)90261-2; JENKINS DC, IN PRESS P NATN ACAD; LIEW FY, 1991, IMMUNOL TODAY, pA17; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; MORRALAYI MD, 1994, INT IMMUN, V6, P931; NATHAN C, 1994, J BIOL CHEM, V269, P13725; PETROS A, 1991, LANCET, V338, P1557, DOI 10.1016/0140-6736(91)92376-D; TAYLORROBINSON AW, 1993, SCIENCE, V260, P1931, DOI 10.1126/science.8100366; TAYLORROBINSON AW, 1994, EUR J IMMUNOL, V24, P980, DOI 10.1002/eji.1830240430; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D; VOULDOUKIS I, IN PRESS P NATN ACAD; WEINER CP, 1994, P NATL ACAD SCI USA, V91, P5212, DOI 10.1073/pnas.91.11.5212; XU D, 1995, IMMUNOLOGY, V85, P1	21	1096	1136	3	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 1	1995	375	6530					408	411		10.1038/375408a0	http://dx.doi.org/10.1038/375408a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB101	7539113				2022-12-24	WOS:A1995RB10100054
J	ROSENBERG, WMC; PRINCE, C; KAKLAMANIS, L; FOX, SB; JACKSON, DG; SIMMONS, DL; CHAPMAN, RW; TROWELL, JM; JEWELL, DP; BELL, JI				ROSENBERG, WMC; PRINCE, C; KAKLAMANIS, L; FOX, SB; JACKSON, DG; SIMMONS, DL; CHAPMAN, RW; TROWELL, JM; JEWELL, DP; BELL, JI			INCREASED EXPRESSION OF CD44V6 AND CD44V3 IN ULCERATIVE-COLITIS BUT NOT COLONIC CROHNS-DISEASE	LANCET			English	Article							LYMPHOCYTE; FAMILY	Immune mechanisms, possibly involving cell-surface molecules such as CD44, have been invoked to explain the pathogenesis of inflammatory bowel disease. We used monoclonal antibodies against epitopes encoded within the variable region of CD44 to investigate CD44 isoform expression in colon, small intestine, and liver in patients with various intestinal disorders and in controls. Biopsy samples from patients with ulcerative colitis showed significantly increased epithelial expression of CD44 isoforms containing the v6 and v3 epitopes, detected with antibodies 2F10 and 3G5, respectively. CD44v6 was detected on colonic crypt epithelial cells in 23 of 25 ulcerative colitis samples compared with 3 of 18 colonic Crohn's disease samples (p=3.0x10(-6); odds ratio 57.5 [95% CI 6.83-702]) and 3 of 52 controls (22 normal colon, 10 infective colitis, 2 radiation colitis, and 18 colonic Crohn's disease; p<1x10(-8); odds ratio 199 [25.5-2294]). No significant expression of CD44v6, CD44v3, or CD44v8/9 was found in samples of normal proximal colon from 4 patients with distal ulcerative colitis, whereas samples from the affected area showed staining for CD44v6 and CD44v3. No expression of CD44 variants was found in 15 samples of normal small intestine, 11 small-bowel pouchitis, 8 coeliac disease, 3 small-bowel Crohn's disease, 6 normal liver, 6 primary biliary cirrhosis, or 9 primary sclerosing cholangitis. The high intensity of CD44v6 and v3 epitope expression on crypt epithelial cells in ulcerative colitis suggests that CD44 isoforms may have an important role in ulcerative colitis. Their detection could have diagnostic potential in differentiating ulcerative colitis from other forms of colonic inflammation including Crohn's disease.	JOHN RADCLIFFE HOSP,GASTROENTEROL UNIT,OXFORD OX3 9DU,ENGLAND; JOHN RADCLIFFE HOSP,DEPT CELLULAR SCI,OXFORD OX3 9DU,ENGLAND; JOHN RADCLIFFE HOSP,INST MOLEC MED,IMPERIAL CANC RES FUND,OXFORD OX3 9DU,ENGLAND	University of Oxford; University of Oxford; University of Oxford	ROSENBERG, WMC (corresponding author), JOHN RADCLIFFE HOSP,NUFFIELD DEPT CLIN MED,OXFORD OX3 9DU,ENGLAND.		Rosenberg, William/ABA-1071-2021; Fox, Stephen/G-9719-2016	Rosenberg, William/0000-0002-2732-2304; Fox, Stephen/0000-0002-7648-8896; , david/0000-0002-4133-9364				BENNETT KL, 1995, J CELL BIOL, V128, P687, DOI 10.1083/jcb.128.4.687; BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; FOX SB, 1994, CANCER RES, V54, P4539; GUNTHERT U, 1991, CELL, V65; HAYNES BF, 1989, IMMUNOL TODAY, V10, P423, DOI 10.1016/0167-5699(89)90040-6; HEIDER KH, 1992, J CELL BIOL, V120, P623; HODGSON HJF, 1983, INFLAMM BOWEL DIS, P86; JACKSON DG, 1995, J CELL BIOL, V128, P673, DOI 10.1083/jcb.128.4.673; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; MACKAY CR, 1994, J CELL BIOL, V124, P71, DOI 10.1083/jcb.124.1.71; PARKER CM, 1992, P NATL ACAD SCI USA, V89, P1924, DOI 10.1073/pnas.89.5.1924; PODOLSKY DK, 1993, J CLIN INVEST, V92, P372, DOI 10.1172/JCI116575; SATSANGI J, 1994, EUR J GASTROEN HEPAT, V6, P413; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; STREETER PR, 1988, NATURE, V331, P41, DOI 10.1038/331041a0; SY MS, 1991, J EXP MED, V174, P859, DOI 10.1084/jem.174.4.859; WAKEFIELD AJ, 1989, LANCET, V2, P1057	19	76	79	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 13	1995	345	8959					1205	1209		10.1016/S0140-6736(95)91991-0	http://dx.doi.org/10.1016/S0140-6736(95)91991-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX861	7537840				2022-12-24	WOS:A1995QX86100009
J	WOHRL, BM; GEORGIADIS, MM; TELESNITSKY, A; HENDRICKSON, WA; LEGRICE, SFJ				WOHRL, BM; GEORGIADIS, MM; TELESNITSKY, A; HENDRICKSON, WA; LEGRICE, SFJ			FOOTPRINT ANALYSIS OF REPLICATING MURINE LEUKEMIA-VIRUS REVERSE-TRANSCRIPTASE	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; AIDS	Replication complexes that contained either murine leukemia virus reverse transcriptase (MLV RT) or a variant reverse transcriptase without a ribonuclease (RNase) H domain (Delta RH MLV RT) were visualized by enzymatic footprinting. Wild-type MLV RT protected template nucleotides +6 to -27, and primer nucleotides -1 to -26 of primers that had first been extended by one or four nucleotides. Although it catalyzed DNA synthesis, Delta RH MLV RT stably bound template-primer only under conditions of reduced ionic strength and protected the duplex portion only as far as position -15. Despite altered hydrolysis profiles, both enzymes covered primarily the template-primer duplex, contradicting recent predictions based on the structure of rat DNA polymerase beta.	CASE WESTERN RESERVE UNIV, SCH MED, DIV INFECT DIS, CLEVELAND, OH 44106 USA; RUTGERS STATE UNIV, DEPT CHEM, PISCATAWAY, NJ 08855 USA; RUTGERS STATE UNIV, WAKSMAN INST, PISCATAWAY, NJ 08855 USA; UNIV MICHIGAN, SCH MED, DEPT MICROBIOL & IMMUNOL, ANN ARBOR, MI 48109 USA; COLUMBIA UNIV, HOWARD HUGHES MED INST, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10032 USA	Case Western Reserve University; Rutgers State University New Brunswick; Rutgers State University New Brunswick; University of Michigan System; University of Michigan; Columbia University; Howard Hughes Medical Institute					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031147] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046623] Funding Source: NIH RePORTER; NCI NIH HHS [CA09021] Funding Source: Medline; NIAID NIH HHS [AI 31147] Funding Source: Medline; NIGMS NIH HHS [GM 46623] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOYER PL, 1994, P NATL ACAD SCI USA, V91, P4882, DOI 10.1073/pnas.91.11.4882; GEORGIADIS M, UNPUB; GUYADER M, 1987, NATURE, V326, P662, DOI 10.1038/326662a0; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; METZGER W, 1993, P NATL ACAD SCI USA, V90, P5909, DOI 10.1073/pnas.90.13.5909; MURPHEYCORB M, 1986, NATURE, V321, P435, DOI 10.1038/321435a0; NAKAMURA H, 1991, NUCLEIC ACIDS RES, V19, P1817, DOI 10.1093/nar/19.8.1817; Nanni Raymond G., 1993, Perspectives in Drug Discovery and Design, V1, P129, DOI 10.1007/BF02171659; OLMSTED RA, 1989, P NATL ACAD SCI USA, V86, P2448, DOI 10.1073/pnas.86.7.2448; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; RAUSCH JS, UNPUB; SAWAYA MR, 1994, SCIENCE, V264, P1930, DOI 10.1126/science.7516581; SKALKA AM, 1993, REVERSE TRANSCRIPTAS, P193; STEPHENS RM, 1986, SCIENCE, V231, P589, DOI 10.1126/science.3003905; TELESNITSKY A, 1993, P NATL ACAD SCI USA, V90, P1276, DOI 10.1073/pnas.90.4.1276; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; WOHRL BM, 1994, J BIOL CHEM, V269, P8541; WOHRL BM, UNPUB	19	49	50	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 6	1995	267	5194					96	99		10.1126/science.7528942	http://dx.doi.org/10.1126/science.7528942			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA235	7528942				2022-12-24	WOS:A1995QA23500038
J	MANNICK, JB; ASANO, K; IZUMI, K; KIEFF, E; STAMLER, JS				MANNICK, JB; ASANO, K; IZUMI, K; KIEFF, E; STAMLER, JS			NITRIC-OXIDE PRODUCED BY HUMAN B-LYMPHOCYTES INHIBITS APOPTOSIS AND EPSTEIN-BARR-VIRUS REACTIVATION	CELL			English	Article							DNA-BINDING ACTIVITY; L-ARGININE; KAPPA-B; TYROSINE PHOSPHORYLATION; BURKITT-LYMPHOMA; ANTIMICROBIAL ACTIVITY; TRANSCRIPTION FACTOR; PHENYLARSINE OXIDE; NITROGEN-OXIDES; S-NITROSYLATION	Nitric oxide (NO) produced by murine macrophages is important in murine resistance to ectromelia virus, herpes simplex virus, and vaccinia virus infection. In contrast, NO production by human mononuclear cells has been difficult to demonstrate, and a role for NO in human responses to infection is uncertain. We report constitutive, low level, macrophage-type NO synthase (iNOS) expression in Epstein-Barr virus (EBV)-transformed human B lymphocytes and Burkitt's lymphoma cell lines. Immune NOS activity is involved in maintaining EBV latency through down-regulation of the expression of the immediate-early EBV transactivator Zta. NO also inhibits apoptosis in B lymphocyte cell lines. The effects of NO are largely independent of cGMP and influential on signaling pathways regulated by (sulfhydryl) redox status. These results suggest that NO plays a physiological role in human a cell biology by inhibiting programmed cell death and maintaining viral latency.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV RESP,BOSTON,MA 02115; DUKE UNIV,MED CTR,DEPT MED,DIV RESP,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DIV CARDIOVASC MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710	Harvard University; Brigham & Women's Hospital; Duke University; Duke University; Duke University	MANNICK, JB (corresponding author), HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115, USA.			Stamler, Jonathan/0000-0002-6866-1572	NHLBI NIH HHS [HL52529, HL02582] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002582, R01HL052529] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ALBINA JE, 1991, J SURG RES, V50, P403, DOI 10.1016/0022-4804(91)90210-D; ALFIERI C, 1991, VIROLOGY, V181, P595, DOI 10.1016/0042-6822(91)90893-G; ASANO K, 1994, P NATL ACAD SCI USA, V91, P10089, DOI 10.1073/pnas.91.21.10089; BANNISTER AJ, 1991, ONCOGENE, V6, P1243; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BOLOTINA VM, 1994, NATURE, V368, P850, DOI 10.1038/368850a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALENDER A, 1987, P NATL ACAD SCI USA, V84, P8060, DOI 10.1073/pnas.84.22.8060; CAMERON ML, 1990, AM REV RESPIR DIS, V142, P1313, DOI 10.1164/ajrccm/142.6_Pt_1.1313; CHEVALLIERGRECO A, 1986, EMBO J, V5, P3243, DOI 10.1002/j.1460-2075.1986.tb04635.x; CRAPO JD, 1994, J CLIN INVEST, V93, P2304, DOI 10.1172/JCI117233; CROEN KD, 1993, J CLIN INVEST, V91, P2446, DOI 10.1172/JCI116479; DAIBATA M, 1990, J IMMUNOL, V144, P4788; DENIS M, 1991, J LEUKOCYTE BIOL, V49, P380, DOI 10.1002/jlb.49.4.380; DUNCAN DD, 1989, TOXICOL APPL PHARM, V100, P485, DOI 10.1016/0041-008X(89)90296-2; FARRELL PJ, 1989, EMBO J, V8, P127, DOI 10.1002/j.1460-2075.1989.tb03356.x; FLEMINGTON E, 1990, J VIROL, V64, P1227, DOI 10.1128/JVI.64.3.1227-1232.1990; FREED BM, 1991, TOXICOL APPL PHARM, V107, P173, DOI 10.1016/0041-008X(91)90341-B; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GITSCJ DE, 1994, MOL CELL BIOL, V14, P1939; GOPALAKRISHNA R, 1993, J BIOL CHEM, V268, P27180; GRANGER DL, 1991, RES IMMUNOL, V142, P570, DOI 10.1016/0923-2494(91)90104-Q; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; GROSS SS, 1990, BIOCHEM BIOPH RES CO, V170, P96, DOI 10.1016/0006-291X(90)91245-N; GROSS SS, 1992, J BIOL CHEM, V267, P25722; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HENLE W, 1968, J VIROL, V2, P182, DOI 10.1128/JVI.2.3.182-191.1968; HESTON L, 1982, NATURE, V295, P160, DOI 10.1038/295160a0; HIBBS JB, 1987, SCIENCE, V235, P473, DOI 10.1126/science.2432665; HIBBS JB, 1991, RES IMMUNOL, V142, P565, DOI 10.1016/0923-2494(91)90103-P; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOFFMAN RA, 1990, J IMMUNOL, V145, P2220; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KANNER J, 1992, LIPIDS, V27, P46, DOI 10.1007/BF02537058; KANNER SB, 1992, P NATL ACAD SCI USA, V89, P300, DOI 10.1073/pnas.89.1.300; KARUPIAH G, 1993, SCIENCE, V261, P1445, DOI 10.1126/science.7690156; KIRK SJ, 1990, BIOCHEM BIOPH RES CO, V173, P660, DOI 10.1016/S0006-291X(05)80086-5; KISHISHITA M, 1984, VIROLOGY, V133, P363, DOI 10.1016/0042-6822(84)90402-1; KOBZIK L, 1993, AM J RESP CELL MOL, V9, P371, DOI 10.1165/ajrcmb/9.4.371; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; LANCASTER JR, 1990, P NATL ACAD SCI USA, V87, P1223, DOI 10.1073/pnas.87.3.1223; LANDER HM, 1993, J IMMUNOL, V151, P7182; LANDER HM, 1993, J IMMUNOL, V150, P1509; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; LORSBACH RB, 1993, J BIOL CHEM, V268, P908; MANNICK JB, 1991, J VIROL, V65, P6826, DOI 10.1128/JVI.65.12.6826-6837.1991; MENEZES J, 1975, BIOMEDICINE, V22, P276; MOHR S, 1994, FEBS LETT, V348, P223, DOI 10.1016/0014-5793(94)00596-6; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; RABSON M, 1982, J VIROL, V44, P834, DOI 10.1128/JVI.44.3.834-844.1982; RADI R, 1991, J BIOL CHEM, V266, P4244; ROONEY C, 1988, P NATL ACAD SCI USA, V85, P9801, DOI 10.1073/pnas.85.24.9801; ROZSNYAY Z, 1993, IMMUNOL LETT, V37, P197, DOI 10.1016/0165-2478(93)90031-V; SANDSTROM PA, 1994, J LEUKOCYTE BIOL, V55, P221, DOI 10.1002/jlb.55.2.221; SARIH M, 1993, BIOCHEM BIOPH RES CO, V191, P503, DOI 10.1006/bbrc.1993.1246; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Schreck R, 1991, Trends Cell Biol, V1, P39, DOI 10.1016/0962-8924(91)90072-H; SMITH CA, 1989, NATURE, V337, P161; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; STAMLER JS, 1994, IN PRESS CURR TOPICS; TAKADA K, 1986, J VIROL, V57, P1016, DOI 10.1128/JVI.57.3.1016-1022.1986; TAKADA K, 1984, INT J CANCER, V33, P27, DOI 10.1002/ijc.2910330106; TAYLORROBINSON AW, 1994, EUR J IMMUNOL, V24, P980, DOI 10.1002/eji.1830240430; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; VEDIA LM, 1992, J BIOL CHEM, V267, P24929; YOUNG LS, 1991, J VIROL, V65, P2868, DOI 10.1128/JVI.65.6.2868-2874.1991; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500	78	457	472	2	21	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 30	1994	79	7					1137	1146		10.1016/0092-8674(94)90005-1	http://dx.doi.org/10.1016/0092-8674(94)90005-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PZ860	7528106				2022-12-24	WOS:A1994PZ86000005
J	VUORI, K; RUOSLAHTI, E				VUORI, K; RUOSLAHTI, E			ASSOCIATION OF INSULIN-RECEPTOR SUBSTRATE-1 WITH INTEGRINS	SCIENCE			English	Article							EPIDERMAL GROWTH-FACTOR; CARCINOMA-CELLS; ADHESION RECEPTORS; VITRONECTIN; TYROSINE	Insulin stimulation was found to promote association of the alpha(v) beta(3) integrin (a vitronectin receptor) with insulin receptor substrate-1 (IRS-1), an intracellular protein that mediates insulin signaling by binding other signaling molecules, including growth factor receptor-bound protein 2 (Grb2) and phosphatidylinositol-3' kinase. Insulin-treated cells expressing the alpha(v) beta(3) integrin showed 2.5 times more DNA synthesis when plated on vitronectin than on other substrates, whereas cells expressing another vitronectin receptor, alpha(v) beta(5), did not show this difference. The association between integrin and IRS-1 may be a mechanism for the synergistic action of growth factor and extracellular matrix receptors.	LA JOLLA CANC RES FDN, CANC RES CTR, LA JOLLA, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute					NATIONAL CANCER INSTITUTE [R35CA042507, P30CA030199, P01CA028896] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42507, CA 30199, CA 28896] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTFELD NS, 1993, J BIOL CHEM, V268, P17270; BOCKUS BJ, 1984, EXP CELL RES, V153, P186, DOI 10.1016/0014-4827(84)90460-9; CHERESH DA, 1989, CELL, V57, P59, DOI 10.1016/0092-8674(89)90172-4; DEJANA E, 1988, J CELL BIOL, V107, P1215, DOI 10.1083/jcb.107.3.1215; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KADOWAKI T, 1986, J BIOL CHEM, V261, P6141; Keller Susanne R., 1994, Trends in Cell Biology, V4, P115, DOI 10.1016/0962-8924(94)90065-5; LEAVESLEY DI, 1992, J CELL BIOL, V117, P1101, DOI 10.1083/jcb.117.5.1101; LILIEN LE, 1990, J CELL BIOL, V111, P635; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; PYTELA R, 1987, METHOD ENZYMOL, V144, P475; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; Schaller Michael D., 1993, Trends in Cell Biology, V3, P258, DOI 10.1016/0962-8924(93)90053-4; SCHLESSINGER J, 1981, EXP CELL RES, V134, P273, DOI 10.1016/0014-4827(81)90426-2; SCHUBERT D, 1991, J CELL BIOL, V114, P841, DOI 10.1083/jcb.114.4.841; STOKER M, 1968, INT J CANCER, V3, P683, DOI 10.1002/ijc.2910030517; STRACKE ML, 1988, BIOCHEM BIOPH RES CO, V153, P1076, DOI 10.1016/S0006-291X(88)81338-X; VUORI K, UNPUB; WAYNER EA, 1991, J CELL BIOL, V113, P919, DOI 10.1083/jcb.113.4.919; WHITE MF, 1994, J BIOL CHEM, V269, P1	26	344	348	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 2	1994	266	5190					1576	1578		10.1126/science.7527156	http://dx.doi.org/10.1126/science.7527156			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV015	7527156				2022-12-24	WOS:A1994PV01500048
J	PALLER, AS; SYDER, AJ; CHAN, YM; HUTTON, E; TADINI, G; FUCHS, E; YU, QC				PALLER, AS; SYDER, AJ; CHAN, YM; HUTTON, E; TADINI, G; FUCHS, E; YU, QC			GENETIC AND CLINICAL MOSAICISM IN A TYPE OF EPIDERMAL NEVUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EPIDERMOLYSIS-BULLOSA SIMPLEX; KERATIN EXPRESSION; POINT MUTATIONS; ALPHA-SUBUNIT; HYPERKERATOSIS; SKIN; MICE; DIFFERENTIATION; ABNORMALITIES; ERYTHRODERMA	Background. Many skin disorders are characterized by a mosaic pattern, often with alternating stripes of affected and unaffected skin that follow the lines of Blaschko. These nonrandom patterns may be caused by a postzygotic mutation during embryogenesis. We studied the genetic basis of one such disorder, epidermal nevus of the epidermolytic hyperkeratotic type. Epidermolytic hyperkeratosis is an autosomal dominant blistering skin disease arising from mutations in the genes for keratin (K) 1 and 10. The offspring of patients with epidermal nevi may have generalized epidermolytic hyperkeratosis. Methods. We studied the K1 and K10 genes in blood and in the keratinocytes and fibroblasts of lesional and nonlesional skin from three patients with epidermal nevi and four of their offspring with epidermolytic hyperkeratosis. Results. In the patients with epidermal nevi, point mutations in 50 percent of the K10 alleles of epidermal cells were found in keratinocytes from lesional skin; no mutations were detected in normal skin. This mutation was-absent or underrepresented in blood and skin fibroblasts. In the offspring with epidermolytic hyperkeratosis, the same mutations as those in the parents were found in 50 percent of the K10 alleles from all cell types examined. Conclusions. Epidermal nevus of the epidermolytic hyperkeratotic type is a mosaic genetic disorder of suprabasal keratin. The correlation of mutations in the K10 gene with lesional skin and the correlation of the normal gene with normal skin provide evidence that genetic mosaicism can cause clinical mosaicism.	NORTHWESTERN UNIV, SCH MED, DEPT PEDIAT, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, SCH MED, DEPT DERMATOL, CHICAGO, IL 60611 USA; UNIV CHICAGO, HOWARD HUGHES MED INST, DEPT MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA; UNIV MILAN, DEPT DERMATOL, MILAN, ITALY	Northwestern University; Northwestern University; Howard Hughes Medical Institute; University of Chicago; University of Milan			Fuchs, Elaine/G-1565-2016	Paller, Amy/0000-0001-6187-6549	NIAMS NIH HHS [AR01811, R01-AR27883] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR027883, K08AR001811] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALBERS K, 1989, J CELL BIOL, V108, P1477, DOI 10.1083/jcb.108.4.1477; ANTONLAMPRECHT I, 1983, J INVEST DERMATOL, V81, pS149, DOI 10.1111/1523-1747.ep12540961; BARKER LP, 1953, AMA ARCH DERM SYPH, V67, P443, DOI 10.1001/archderm.1953.01540050007002; BLASCHKO A, 1901, VERHANDLUNGEN DTSCH; BONAFE JL, 1987, ANN DERMATOL VENER, V114, P916; BONIFAS JM, 1991, SCIENCE, V254, P1202, DOI 10.1126/science.1720261; CHENG J, 1992, CELL, V70, P811, DOI 10.1016/0092-8674(92)90314-3; CHIPEV CC, 1994, AM J HUM GENET, V54, P179; CHIPEV CC, 1992, CELL, V70, P821, DOI 10.1016/0092-8674(92)90315-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COMPTON JG, 1992, NAT GENET, V1, P301, DOI 10.1038/ng0792-301; COULOMBE PA, 1990, J CELL BIOL, V111, P3049, DOI 10.1083/jcb.111.6.3049; COULOMBE PA, 1991, CELL, V66, P1301, DOI 10.1016/0092-8674(91)90051-Y; FUCHS E, 1994, J CELL BIOL, V125, P511, DOI 10.1083/jcb.125.3.511; FUCHS E, 1992, CELL, V69, P899, DOI 10.1016/0092-8674(92)90607-E; FUCHS E, 1992, P NATL ACAD SCI USA, V89, P6906, DOI 10.1073/pnas.89.15.6906; HAPPLE R, 1990, HAUTARZT, V41, P117; HAPPLE R, 1993, ARCH DERMATOL, V129, P1460, DOI 10.1001/archderm.129.11.1460; HAPPLE R, 1985, HUM GENET, V70, P200; LANE EB, 1992, NATURE, V356, P244, DOI 10.1038/356244a0; LETAI A, 1993, P NATL ACAD SCI USA, V90, P3197, DOI 10.1073/pnas.90.8.3197; LORETTE G, 1984, ANN DERMATOL VENER, V111, P858; MALCHOFF CD, 1994, J CLIN ENDOCR METAB, V78, P803, DOI 10.1210/jc.78.3.803; MCLEAN WHI, 1994, J INVEST DERMATOL, V102, P24, DOI 10.1111/1523-1747.ep12371726; NAZZARO V, 1990, BRIT J DERMATOL, V122, P417, DOI 10.1111/j.1365-2133.1990.tb08292.x; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; RIEGER E, 1994, BRIT J DERMATOL, V130, P215, DOI 10.1111/j.1365-2133.1994.tb02903.x; ROTHNAGEL JA, 1993, HUM MOL GENET, V2, P2147, DOI 10.1093/hmg/2.12.2147; ROTHNAGEL JA, 1992, SCIENCE, V257, P1128, DOI 10.1126/science.257.5073.1128; ROTHNAGEL JA, 1994, J INVEST DERMATOL, V102, P13, DOI 10.1111/1523-1747.ep12371723; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWINDINGER WF, 1992, P NATL ACAD SCI USA, V89, P5152, DOI 10.1073/pnas.89.11.5152; STOLER A, 1988, J CELL BIOL, V107, P427, DOI 10.1083/jcb.107.2.427; SYDER AJ, 1994, J CLIN INVEST, V93, P1533, DOI 10.1172/JCI117132; VASSAR R, 1991, CELL, V64, P365, DOI 10.1016/0092-8674(91)90645-F; WEINSTEIN LS, 1990, P NATL ACAD SCI USA, V87, P8287, DOI 10.1073/pnas.87.21.8287; YANG JM, 1994, J INVEST DERMATOL, V102, P17, DOI 10.1111/1523-1747.ep12371725; [No title captured]	38	208	213	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 24	1994	331	21					1408	1415		10.1056/NEJM199411243312103	http://dx.doi.org/10.1056/NEJM199411243312103			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU533	7526210	Bronze			2022-12-24	WOS:A1994PU53300003
J	SHORES, EW; HUANG, K; TRAN, T; LEE, E; GRINBERG, A; LOVE, PE				SHORES, EW; HUANG, K; TRAN, T; LEE, E; GRINBERG, A; LOVE, PE			ROLE OF TCR ZETA-CHAIN IN T-CELL DEVELOPMENT AND SELECTION	SCIENCE			English	Article							ANTIGEN RECEPTOR; TRANSGENIC MICE; ACTIVATION; EXPRESSION; COMPLEX; THYMOCYTES; LACKING; DOMAIN; RAG-1; TAIL	Signals mediated by the T cell receptor (TCR) are required for thymocyte maturation and selection. To examine the role of TCR zeta chain signals in development, TCR expression was restored in zeta-deficient mice with transgenic zeta chains that partially or completely lacked sequences required for signal transduction. The zeta chain played a role in thymic development by promoting TCR surface expression, but zeta-mediated signals were not essential because TCRs that contained signaling-deficient zeta chains promoted T cell maturation and transduced signals associated with thymic selection.	NICHHD, MAMMALIAN GENES & DEV LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	SHORES, EW (corresponding author), US FDA, CTR BIOL, DIV HEMATOL PROD, BETHESDA, MD 20892 USA.							BORGULYA P, 1992, CELL, V69, P529, DOI 10.1016/0092-8674(92)90453-J; BRANDLE D, 1994, EUR J IMMUNOL, V24, P145, DOI 10.1002/eji.1830240122; BRANDLE D, 1992, P NATL ACAD SCI USA, V89, P9529, DOI 10.1073/pnas.89.20.9529; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; EXLEY M, 1994, J BIOL CHEM, V269, P15140; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207; FRANK SJ, 1990, SCIENCE, V249, P174, DOI 10.1126/science.2371564; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LIU CP, 1993, EMBO J, V12, P4863, DOI 10.1002/j.1460-2075.1993.tb06176.x; LOVE PE, 1994, J EXP MED, V179, P1485, DOI 10.1084/jem.179.5.1485; LOVE PE, 1993, SCIENCE, V261, P918, DOI 10.1126/science.7688481; MALISSEN M, 1993, EMBO J, V12, P4347, DOI 10.1002/j.1460-2075.1993.tb06119.x; NAKAYAMA T, 1989, NATURE, V341, P651, DOI 10.1038/341651a0; OHNO H, 1993, EMBO J, V12, P4357, DOI 10.1002/j.1460-2075.1993.tb06120.x; ORLOFF DG, 1990, NATURE, V347, P189, DOI 10.1038/347189a0; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SHORES EW, UNPUB; SWAT W, 1993, EUR J IMMUNOL, V23, P739, DOI 10.1002/eji.1830230326; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; TESTI R, 1989, J IMMUNOL, V143, P1123; THOMPSON JA, 1987, BIOCHEMISTRY-US, V26, P743, DOI 10.1021/bi00377a014; TURKA LA, 1991, SCIENCE, V253, P778, DOI 10.1126/science.1831564; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4	33	129	130	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 11	1994	266	5187					1047	1050		10.1126/science.7526464	http://dx.doi.org/10.1126/science.7526464			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7526464				2022-12-24	WOS:A1994PQ92400046
J	CHENG, HJ; FLANAGAN, JG				CHENG, HJ; FLANAGAN, JG			IDENTIFICATION AND CLONING OF ELF-1, A DEVELOPMENTALLY EXPRESSED LIGAND FOR THE MEK4 AND SEK RECEPTOR TYROSINE KINASES	CELL			English	Article							GROWTH-FACTOR; KIT LIGAND; W-LOCUS; PROTO-ONCOGENE; SI-LOCUS; MOUSE; ENCODES; GENE; TRANSMEMBRANE; MUTANT	Mek4 and Sek are tyrosine kinases with expression patterns in the mouse embryo that suggest important functions in early development. However, like all Eph family kinases, both were identified as orphan receptors without known ligands. We show that Mek4 and Sek soluble receptor-alkaline phosphatase fusion proteins can be used in a procedure termed RAP in situ to identify regions of ligand expression in the mouse embryo. Based on this spatial information, a cDNA expression library was prepared, and was screened with the fusion proteins to identify Eph ligand family-1 (ELF-1). In cell lines and embryos, ELF-1 is membrane bound by a phosphatidylinositol tail, a feature that may account for unique biological functions. Its sequence is homologous with B61, a ligand for the Eck kinase, defining a family of related ligands. The expression domains of ELF-1, Mek4 and Sek indicate potential roles in embryonic patterning.			CHENG, HJ (corresponding author), HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115, USA.		Cheng, Hwai-Jong/AAY-5067-2021; Flanagan, John/AAM-2995-2020	Cheng, Hwai-Jong/0000-0003-0647-0567; 	NICHD NIH HHS [HD29417] Funding Source: Medline; NIDDK NIH HHS [DK45580] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029417, R37HD029417] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045580] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ANDRES AC, 1994, ONCOGENE, V9, P1461; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BECKER N, 1994, MECH DEVELOP, V47, P3, DOI 10.1016/0925-4773(94)90091-4; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BRANNAN CI, 1991, P NATL ACAD SCI USA, V88, P4671, DOI 10.1073/pnas.88.11.4671; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GILARDIHEBENSTREIT P, 1992, ONCOGENE, V7, P2499; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; JESSELL TM, 1992, CELL, V68, P257, DOI 10.1016/0092-8674(92)90469-S; KRUMLAUF R, 1993, TRENDS GENET, V9, P106, DOI 10.1016/0168-9525(93)90203-T; LYMAN SD, 1993, CELL, V75, P1157, DOI 10.1016/0092-8674(93)90325-K; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; NIETO MA, 1992, DEVELOPMENT, V116, P1137; RUIZ JC, 1994, MECH DEVELOP, V46, P87; SAJJADI FG, 1991, NEW BIOL, V3, P769; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHILO BZ, 1992, FASEB J, V6, P2915, DOI 10.1096/fasebj.6.11.1322852; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; TUZI NL, 1994, BRIT J CANCER, V69, P417, DOI 10.1038/bjc.1994.77; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; XU QL, 1994, DEVELOPMENT, V120, P287; ZHOU R, 1994, J NEUROSCI RES, V37, P129, DOI 10.1002/jnr.490370117; ZIPURSKY SL, 1992, COLD SPRING HARB SYM, V57, P381, DOI 10.1101/SQB.1992.057.01.043; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	38	254	278	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 7	1994	79	1					157	168		10.1016/0092-8674(94)90408-1	http://dx.doi.org/10.1016/0092-8674(94)90408-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PK585	7522971				2022-12-24	WOS:A1994PK58500016
J	WILLBOLD, D; ROSINARBESFELD, R; STICHT, H; FRANK, R; ROSCH, P				WILLBOLD, D; ROSINARBESFELD, R; STICHT, H; FRANK, R; ROSCH, P			STRUCTURE OF THE EQUINE INFECTIOUS-ANEMIA VIRUS TAT PROTEIN	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TRANSACTIVATION RESPONSE RNA; HIV-1 TAT; CIRCULAR-DICHROISM; LENTIVIRUS TAT; SEQUENCE; PEPTIDES; BINDING; REGION; RECOGNITION	Trans-activator (Tat) proteins regulate the transcription of lentiviral DNA in the host cell genome. These RNA binding proteins participate in the life cycle of all known lentiviruses, such as the human immunodeficiency viruses (HIV) or the equine infectious anemia virus (EIAV). The consensus RNA binding motifs [the trans-activation responsive element (TAR)] of HIV-1 as well as EIAV Tat proteins are well characterized. The structure of the 75-amino acid EIAV Tat protein in solution was determined by two- and three-dimensional nuclear magnetic resonance methods and molecular dynamics calculations. The protein structure exhibits a well-defined hydrophobic core of 15 amino acids that serves as a scaffold for two flexible domains corresponding to the NH2- and COOH-terminal regions. The core region is a strictly conserved sequence region among the known Tat proteins. The structural data can be used to explain several of the observed features of Tat proteins.	UNIV BAYREUTH,LEHRSTUHL BIOPOLYMERE,D-95440 BAYREUTH,GERMANY; UNIV BAYREUTH,BAYREUTHER INST MAKROMOLEK FORSCH,D-95440 BAYREUTH,GERMANY; TEL AVIV UNIV,SACKLER FAC MED,DEPT HUMAN MICROBIOL,IL-69978 TEL AVIV,ISRAEL; ZENTRUM MOLEK BIOL HEIDELBERG,D-69120 HEIDELBERG,GERMANY	University of Bayreuth; University of Bayreuth; Tel Aviv University; Sackler Faculty of Medicine; Ruprecht Karls University Heidelberg			Willbold, Dieter/A-6280-2013; Rösch, Paul/I-5445-2014	Willbold, Dieter/0000-0002-0065-7366; Rösch, Paul/0000-0003-3330-2446; Sticht, Heinrich/0000-0001-5644-045X				BRUNGER AT, 1993, X PLOR 3 1; CALNAN BJ, 1991, GENE DEV, V5, P201, DOI 10.1101/gad.5.2.201; CARROLL R, 1991, J VIROL, V65, P3460, DOI 10.1128/JVI.65.7.3460-3467.1991; CARROLL R, 1992, J VIROL, V66, P2000, DOI 10.1128/JVI.66.4.2000-2007.1992; CHURCHER MJ, 1993, J MOL BIOL, V230, P90, DOI 10.1006/jmbi.1993.1128; CORDINGLEY MG, 1990, P NATL ACAD SCI USA, V87, P8985, DOI 10.1073/pnas.87.22.8985; DERSE D, 1991, J VIROL, V65, P7012, DOI 10.1128/JVI.65.12.7012-7015.1991; DERSE D, 1992, VIROLOGY, V194, P530; DORN P, 1990, J VIROL, V64, P1616, DOI 10.1128/JVI.64.4.1616-1624.1990; GAIT MJ, 1993, TRENDS BIOCHEM SCI, V18, P255, DOI 10.1016/0968-0004(93)90176-N; HERRMANN F, UNPUB; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HOFFMAN DW, 1993, BIOCHEMISTRY-US, V32, P1096, DOI 10.1021/bi00055a015; KASHANSHI F, 1993, NATURE, V267, P295; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; LORET EP, 1991, BIOCHEMISTRY-US, V30, P6013, DOI 10.1021/bi00238a027; LORET EP, 1992, P NATL ACAD SCI USA, V89, P9734, DOI 10.1073/pnas.89.20.9734; NOIMAN S, 1991, VIROLOGY, V184, P521, DOI 10.1016/0042-6822(91)90422-8; PATAK D, 1992, CURR OPIN STRUCT BIO, V2, P115; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; RAINER L, 1985, NATURE, V313, P277; RICE AP, 1990, J VIROL, V64, P6018, DOI 10.1128/JVI.64.12.6018-6026.1990; SLICE LW, 1992, BIOCHEMISTRY-US, V31, P12062, DOI 10.1021/bi00163a014; SPIRE B, 1989, GENE, V81, P275, DOI 10.1016/0378-1119(89)90188-1; STICHT H, 1993, EUR J BIOCHEM, V218, P973, DOI 10.1111/j.1432-1033.1993.tb18455.x; WEEKS KM, 1991, CELL, V66, P577, DOI 10.1016/0092-8674(81)90020-9; WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002; WILLBOLD D, 1993, BIOCHEMISTRY-US, V32, P8439, DOI 10.1021/bi00084a008; Wuthrich K., 1986, NMR PROTEINS NUCL AC	29	44	45	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 10	1994	264	5165					1584	1587		10.1126/science.7515512	http://dx.doi.org/10.1126/science.7515512			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NQ285	7515512				2022-12-24	WOS:A1994NQ28500034
J	LIEBERMAN, DN; MODY, I				LIEBERMAN, DN; MODY, I			REGULATION OF NMDA CHANNEL FUNCTION BY ENDOGENOUS CA2+-DEPENDENT PHOSPHATASE	NATURE			English	Article							D-ASPARTATE RECEPTORS; OKADAIC ACID; PROTEIN PHOSPHATASE; CENTRAL NEURONS; RAT-BRAIN; CALCINEURIN; ACTIVATION; GLUTAMATE; DEPHOSPHORYLATION; HIPPOCAMPUS	PROTEIN kinases modulate the activity of several ligand-gated ion channels(1), including the NMDA (N-methyl-D-aspartate)(2) subtype of glutamate receptor. Although phosphorylation and dephosphorylation of glutamate receptors may participate in several lasting physiological and pathological alterations of neuronal excitability(3-7), the physiological control of this cycle for NMDA channels has not yet been established. Using cell-attached recordings in acutely dissociated adult rat dentate gyrus granule cells, we now demonstrate that inhibitors of an endogenous serine/threonine phosphatase prolong the duration of single NMDA channel openings, bursts, clusters and superclusters. Okadaic acid, a non-selective phosphatase inhibitor, prolongs channel openings only at a concentration that inhibits the Ca2+/calmodulin-dependent phosphatase 2B (calcineurin)(8), and is ineffective when Ca2+ entry through NMDA channels is prevented. Furthermore, FK506, an inhibitor of calcineurin(9,10), mimics the effects of okadaic acid. Thus in adult neurons, calcineurin, activated by calcium entry through native NMDA channels, shortens the duration of channel openings. Simulated synaptic currents(11) were enhanced after phosphatase inhibition, which is consistent with the importance of phosphorylation of the NMDA-receptor complex in the short- and longterm control of neuronal excitability.	UNIV TEXAS,SW MED CTR,DEPT ANESTESIOL & PAIN MANAGEMENT,DALLAS,TX 75235; STANFORD UNIV,SCH MED,GRAD PROGRAM NEUROSCI,STANFORD,CA 94305	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Stanford University								ABDULGHANI M, 1991, P NATL ACAD SCI USA, V88, P1803, DOI 10.1073/pnas.88.5.1803; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CREPEL V, 1993, J NEUROPHYSIOL, V69, P1774, DOI 10.1152/jn.1993.69.5.1774; EDMONDS B, 1992, P ROY SOC B-BIOL SCI, V250, P279, DOI 10.1098/rspb.1992.0160; FIGUROV A, 1993, EUR J NEUROSCI, V5, P1035, DOI 10.1111/j.1460-9568.1993.tb00956.x; GIBB AJ, 1992, J PHYSIOL-LONDON, V456, P143, DOI 10.1113/jphysiol.1992.sp019331; GOTO S, 1985, J NEUROCHEM, V45, P276, DOI 10.1111/j.1471-4159.1985.tb05504.x; HALPAIN S, 1990, NEURON, V5, P237, DOI 10.1016/0896-6273(90)90161-8; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; KOHR G, 1993, J NEUROSCI, V13, P3612; LEGENDRE P, 1993, J NEUROSCI, V13, P674; LESTER RAJ, 1992, J NEUROSCI, V12, P635; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MACDONALD JF, 1989, J PHYSIOL-LONDON, V414, P17, DOI 10.1113/jphysiol.1989.sp017674; MAYER ML, 1987, J PHYSIOL-LONDON, V394, P501, DOI 10.1113/jphysiol.1987.sp016883; MORIOKA M, 1992, J NEUROCHEM, V58, P1798, DOI 10.1111/j.1471-4159.1992.tb10056.x; MULKEY RM, 1993, SCIENCE, V261, P1051, DOI 10.1126/science.8394601; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; POLLI JW, 1991, DEV BRAIN RES, V63, P105, DOI 10.1016/0165-3806(91)90071-P; RAYMOND LA, 1993, TRENDS NEUROSCI, V16, P147, DOI 10.1016/0166-2236(93)90123-4; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y; SAH P, 1989, SCIENCE, V246, P815, DOI 10.1126/science.2573153; SCHNEGGENBURGER R, 1993, NEURON, V11, P133, DOI 10.1016/0896-6273(93)90277-X; STEINER JP, 1992, NATURE, V358, P584, DOI 10.1038/358584a0; TINGLEY WG, 1993, NATURE, V364, P70, DOI 10.1038/364070a0; WATANABE M, 1992, NEUROREPORT, V3, P1138, DOI 10.1097/00001756-199212000-00027	30	425	435	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 19	1994	369	6477					235	239		10.1038/369235a0	http://dx.doi.org/10.1038/369235a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NM067	7514273				2022-12-24	WOS:A1994NM06700057
J	FUMAGALLI, S; TOTTY, NF; HSUAN, JJ; COURTNEIDGE, SA				FUMAGALLI, S; TOTTY, NF; HSUAN, JJ; COURTNEIDGE, SA			A TARGET FOR SRC IN MITOSIS	NATURE			English	Article							TYROSINE KINASES; GROWTH-FACTOR; SIGNAL TRANSDUCTION; C-SRC; PROTEIN; PHOSPHORYLATION; ACTIVATION; GAP; IDENTIFICATION; ASSOCIATION	THE activity of the c-Src protein is increased during cell-cycle stage G1 in fibroblasts stimulated with certain growth factors(1-4), and at the G2/M transition(5), but little is known about Src substrates in these circumstances. In contrast, cells transformed with activated Src contain many tyrosine-phosphorylated proteins. We compared the phosphotyrosine content of growing and mitotically arrested Src-transformed cells. We report here that although phosphorylation of most proteins was unchanged during mitosis, phosphorylation of one of about 68K was greatly enhanced. The p68. was physically associated with activated c-Src, and it bound to the SH3 domain of c-Src in vitro. Tyrosine-phosphorylated p68 was also present in mitotic extracts of normal cells, suggesting that its phosphorylation was not just a consequence of transformation; Purification and microsequencing of p68 showed that it was related to the previously described GAP-associated protein p62 (ref. 6).	EUROPEAN MOLEC BIOL LAB,D-69012 HEIDELBERG,GERMANY; LUDWIG INST CANC RES,MIDDLESEX BRANCH,LONDON W1P 8BT,ENGLAND	European Molecular Biology Laboratory (EMBL); Ludwig Institute for Cancer Research			FUMAGALLI, Stefano/C-2914-2019; Hsuan, Justin/C-8825-2009	Hsuan, Justin/0000-0001-6083-7564; Fumagalli, Stefano/0000-0001-5832-8680				BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; REYNOLDS AB, 1992, ONCOGENE, V7, P2439; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; TOTTY NF, 1992, PROTEIN SCI, V1, P1215, DOI 10.1002/pro.5560010914; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113	24	336	347	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 28	1994	368	6474					871	874		10.1038/368871a0	http://dx.doi.org/10.1038/368871a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH717	7512695				2022-12-24	WOS:A1994NH71700076
J	HADDOW, JE; PALOMAKI, GE; KNIGHT, GJ; CUNNINGHAM, GC; LUSTIG, LS; BOYD, PA				HADDOW, JE; PALOMAKI, GE; KNIGHT, GJ; CUNNINGHAM, GC; LUSTIG, LS; BOYD, PA			REDUCING THE NEED FOR AMNIOCENTESIS IN WOMEN 35 YEARS OF AGE OR OLDER WITH SERUM MARKERS FOR SCREENING	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MATERNAL SERUM; ALPHA-FETOPROTEIN; DOWNS-SYNDROME; UNCONJUGATED ESTRIOL; CHORIONIC-GONADOTROPIN; ABNORMALITIES; PREGNANCIES; DIAGNOSIS; WEIGHT; TRIAL	Background. As maternal age advances, the risk of fetal Down's syndrome increases. Pregnant women 35 years of age or older are routinely offered amniocentesis because of this risk. Recently, maternal serum markers have been reported to be useful in screening for Down's syndrome, primarily in younger women. We therefore investigated whether offering amniocentesis only to selected women 35 years of age or older who were identified by screening measurements in serum might prove a useful alternative to the current practice. Methods. We studied 5385 women with singleton pregnancies who were 35 years of age or older and were undergoing routine amniocentesis. Along with information about the pregnancy, we obtained a serum sample for measurement of alpha-fetoprotein, unconjugated estriol, and human chorionic gonadotropin. Individual estimates of the risk of Down's syndrome in the fetus were calculated for each pregnancy before the karyotype was known. Results. If amniocentesis had been reserved for the women calculated to have a risk greater than 1 in 200 of having a fetus with Down's syndrome, 48 of the 54 cases of Down's syndrome (89 percent) would have been identified; 25 percent of the unaffected pregnancies would also have been identified as being at high risk for Down's syndrome (false positives). Seven of 15 fetuses (47 percent) with other trisomies, 11 of 25 (44 percent) with sex aneuploidy, and 1 of 9 (11 percent) with miscellaneous chromosomal abnormalities would also have been detected. In practice, such screening would have made 75 percent of the amniocenteses unnecessary, along with a proportion of the amniocentesis-associated fetal losses. If the cutoff for the risk of Down's syndrome were set higher than 1 in 200, both the rate of detection and the false positive rate would be lower. Conversely, these rates would be higher if the cutoff were set lower. Conclusions. Prenatal screening of serum to generate individual estimates of the risk of Down's syndrome in the fetus can provide a basis for decision making in the cases of women 35 years of age or older, as it does in younger pregnant women, and is an alternative to current testing practices.	CALIF PUBL HLTH FDN,BERKELEY,CA; CALIF DEPT HLTH SERV,GENET DIS BRANCH,BERKELEY,CA 94704	California Department of Health Care Services	HADDOW, JE (corresponding author), FDN BLOOD RES,SCARBOROUGH,ME 04074, USA.				PHS HHS [MCJ-237014-02-2] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BOGART MH, 1987, PRENATAL DIAG, V7, P623, DOI 10.1002/pd.1970070904; CANICK JA, 1988, BRIT J OBSTET GYNAEC, V95, P330, DOI 10.1111/j.1471-0528.1988.tb06601.x; CANICK JA, 1990, J CLIN IMMUNOASSAY, V13, P30; CHENG EY, 1993, OBSTET GYNECOL, V81, P72; CRANDALL BF, 1983, CLIN CHEM, V29, P531; CUCKLE HS, 1984, LANCET, V1, P926; DIMAIO MS, 1987, NEW ENGL J MED, V317, P342, DOI 10.1056/NEJM198708063170603; GREENE MF, 1988, LANCET, V2, P345; HADDOW JE, 1992, NEW ENGL J MED, V327, P588, DOI 10.1056/NEJM199208273270902; HOLMESSIEDLE M, 1987, PRENAT DIAGN, V77, P239; HOOK EB, 1983, JAMA-J AM MED ASSOC, V249, P2034, DOI 10.1001/jama.249.15.2034; HOOK EB, 1981, TRISOMY, V21, P3; KNIGHT GJ, 1987, METHODS CLIN CHEM, P459; MERKATZ IR, 1984, AM J OBSTET GYNECOL, V148, P886, DOI 10.1016/0002-9378(84)90530-1; PALOMAKI GE, 1992, PRENATAL DIAG, V12, P925, DOI 10.1002/pd.1970121112; PALOMAKI GE, 1990, AM J HUM GENET, V47, pA282; PHILLIPS OP, 1992, OBSTET GYNECOL, V80, P353; ROBINSON A, 1989, AM J MED GENET, V34, P552, DOI 10.1002/ajmg.1320340420; ROBINSON A, 1992, GENETIC DISORDERS FE, P211; TABOR A, 1986, LANCET, V1, P1287; WALD NJ, 1988, BRIT MED J, V297, P1029; WALD NJ, 1992, BRIT J OBSTET GYNAEC, V99, P144, DOI 10.1111/j.1471-0528.1992.tb14474.x; WALD NJ, 1988, BRIT MED J, V297, P883, DOI 10.1136/bmj.297.6653.883; WALD NJ, 1992, BMJ-BRIT MED J, V305, P391, DOI 10.1136/bmj.305.6850.391; WALD NJ, 1993, PRENATAL DIAG, V13, P1149, DOI 10.1002/pd.1970131211; WARBURTON D, 1991, AM J HUM GENET, V49, P995; 1989, AM J OBSTET GYNECOL, V160, P575; 1976, JAMA-J AM MED ASSOC, V236, P1471; 1990, DHHS PHS901100 PUBL, P89	29	155	159	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 21	1994	330	16					1114	1118		10.1056/NEJM199404213301603	http://dx.doi.org/10.1056/NEJM199404213301603			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF699	7510852				2022-12-24	WOS:A1994NF69900003
J	BODMER, H; VIVILLE, S; BENOIST, C; MATHIS, D				BODMER, H; VIVILLE, S; BENOIST, C; MATHIS, D			DIVERSITY OF ENDOGENOUS EPITOPES BOUND TO MHC CLASS-II MOLECULES LIMITED BY INVARIANT CHAIN	SCIENCE			English	Article							MYELIN BASIC-PROTEIN; T-CELL DETERMINANTS; HLA-DR MOLECULES; ANTIGEN PRESENTATION; PEPTIDE BINDING; SURFACE EXPRESSION; INFLUENZA-VIRUS; COMPLEX; PH; DISTINCT	The invariant chain (li) binds nascent major histocompatibility complex (MHC) class II molecules, blocking peptide binding until the complex dissociates in the endosomes. This may serve to differentiate the MHC class I and II antigen presentation pathways and enable class II molecules to efficiently bind peptides in the endosomes. This hypothesis was addressed by probing spleen cells from a combination of knock-out and transgenic mice with a large panel of T cell hybridomas. The li molecule blocked the presentation of a range of endogenously synthesized epitopes, but some epitopes actually required li. Thus, the influence of li on presentation does not follow simple rules. In addition, mice expressing li were not tolerant to epitopes unmasked in its absence, a finding with possible implications for autoimmunity.	INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES,F-67000 STRASBOURG,FRANCE; INST CHIM BIOL,INSERM,UNITE BIOL MOLEC 184,F-67000 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg				Viville, Stephane/0000-0002-5088-3003				BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BIKOFF EK, 1993, J EXP MED, V177, P1699, DOI 10.1084/jem.177.6.1699; BIKOFF EK, 1992, J IMMUNOL, V149, P1; BODMER H, UNPUB; BRODSKY FM, 1991, ANNU REV IMMUNOL, V9, P707; BROOKS A, 1991, P NATL ACAD SCI USA, V88, P3290, DOI 10.1073/pnas.88.8.3290; BROOKS AG, 1993, J IMMUNOL, V150, P3690; CALINLAURENS V, 1992, INT IMMUNOL, V4, P1113, DOI 10.1093/intimm/4.10.1113; CRESSWELL P, 1992, CURR OPIN IMMUNOL, V4, P87, DOI 10.1016/0952-7915(92)90131-W; EISENLOHR LC, 1989, J EXP MED, V169, P921, DOI 10.1084/jem.169.3.921; HARDING CV, 1991, P NATL ACAD SCI USA, V88, P2740, DOI 10.1073/pnas.88.7.2740; HUMBERT M, 1993, EUR J IMMUNOL, V23, P3167, DOI 10.1002/eji.1830231219; JENSEN PE, 1991, J EXP MED, V174, P1111, DOI 10.1084/jem.174.5.1111; KONO DH, 1988, J EXP MED, V168, P213, DOI 10.1084/jem.168.1.213; KOUSKOFF V, IN PRESS METHODS IMM; LAMB CA, 1991, P NATL ACAD SCI USA, V88, P5998, DOI 10.1073/pnas.88.14.5998; LEHMANN PV, 1993, IMMUNOL TODAY, V14, P203, DOI 10.1016/0167-5699(93)90163-F; LOSS GE, 1993, J EXP MED, V178, P73, DOI 10.1084/jem.178.1.73; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MALNATI MS, 1992, NATURE, V357, P702, DOI 10.1038/357702a0; MOMBURG F, 1988, CLIN EXP IMMUNOL, V72, P367; MOMBURG F, 1986, J IMMUNOL, V136, P940; MOORE MJ, 1993, CELL BIOCH C S, V17, P70; MORENO J, 1991, J IMMUNOL, V147, P3306; MOURITSEN S, 1992, J IMMUNOL, V148, P1438; MURPHY DB, 1992, J IMMUNOL, V148, P3483; NEEFJES JJ, 1992, EMBO J, V11, P411, DOI 10.1002/j.1460-2075.1992.tb05069.x; NUCHTERN JG, 1990, NATURE, V343, P74, DOI 10.1038/343074a0; PURE E, 1990, J EXP MED, V172, P1459, DOI 10.1084/jem.172.5.1459; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; ROCHE PA, 1991, P NATL ACAD SCI USA, V88, P3150, DOI 10.1073/pnas.88.8.3150; ROCHE PA, 1992, EMBO J, V11, P2841, DOI 10.1002/j.1460-2075.1992.tb05351.x; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SAKAI K, 1988, P NATL ACAD SCI USA, V85, P8608, DOI 10.1073/pnas.85.22.8608; SETTE A, 1992, J IMMUNOL, V148, P844; TAKAHASHI N, 1985, CELL, V42, P139, DOI 10.1016/S0092-8674(85)80109-4; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; VIDAL K, 1993, J IMMUNOL, V151, P4642; VIDARD L, 1992, J IMMUNOL, V149, P498; VIVILLE S, 1993, CELL, V72, P635, DOI 10.1016/0092-8674(93)90081-Z; YAO XR, 1988, LEUKEMIA RES, V12, P787, DOI 10.1016/0145-2126(88)90030-6	41	112	112	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 4	1994	263	5151					1284	1286		10.1126/science.7510069	http://dx.doi.org/10.1126/science.7510069			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MY570	7510069				2022-12-24	WOS:A1994MY57000038
J	HAMID, Q; SPRINGALL, DR; RIVEROSMORENO, V; CHANEZ, P; HOWARTH, P; REDINGTON, A; BOUSQUET, J; GODARD, P; HOLGATE, S; POLAK, JM				HAMID, Q; SPRINGALL, DR; RIVEROSMORENO, V; CHANEZ, P; HOWARTH, P; REDINGTON, A; BOUSQUET, J; GODARD, P; HOLGATE, S; POLAK, JM			INDUCTION OF NITRIC-OXIDE SYNTHASE IN ASTHMA	LANCET			English	Article							NECROSIS-FACTOR-ALPHA; MAST-CELLS; BRONCHIAL HYPERRESPONSIVENESS; PULMONARY VASODILATOR; GUINEA-PIGS; L-ARGININE; EXPRESSION; MACROPHAGES; EOSINOPHILS; EPITHELIUM	Nitric oxide (NO) is a mediator of vasodilatation and bronchodilatation synthesised from L-arginine by the enzyme NO synthase, which is either constitutive or induced by lipopolysaccharides and/or cytokines. The presence and function of NO synthase in normal or diseased lung is not yet clear. Asthma is characterised by bronchial hyperresponsiveness, epithelial damage, inflammation, and increased cytokine production. To investigate the presence of NO synthase in asthma, we immunostained bronchial biopsies from non-steroid-treated people with asthma and non-asthmatic controls with specific polyvalent antisera to purified inducible NO synthase and to a selected peptide sequence of the same enzyme. Immunoreactivity was seen in the epithelium and some inflammatory cells in 22 of 23 biopsies from people with asthma, but in only 2 of 20 controls. To assess the relation of cytokines to NO synthase induction, bronchial epithelial cells in culture were stimulated with tumour necrosis factor (TNFalpha). Inducible enzyme immunoreactivity was found only in the treated cells. The existence of inducible NO synthase in human lungs suggests that increased production of NO, probably induced by cytokines, may be relevant to the pathology of asthma.	ROYAL POSTGRAD MED SCH,DEPT HISTOCHEM,DU CANE RD,LONDON W12 0NN,ENGLAND; WELLCOME RES LABS,BECKENHAM BR3 3BS,KENT,ENGLAND; NATL HEART & LUNG INST,LONDON,ENGLAND; HOP ARNAUD VILLENEUVE,SERV MALAD RESP,F-34059 MONTPELLIER,FRANCE; SOUTHAMPTON GEN HOSP,DEPT MED,IMMUNOPHARMACOL GRP,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND	Imperial College London; GlaxoSmithKline; Wellcome Research Laboratories; Imperial College London; Universite de Montpellier; CHU de Montpellier; University of Southampton				Howarth, Peter/0000-0003-0619-7927; chanez, pascal/0000-0003-4059-0917				BELVISI MG, 1992, EUR J PHARMACOL, V210, P221, DOI 10.1016/0014-2999(92)90676-U; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; CRAWLEY DE, 1992, J APPL PHYSIOL, V72, P1425, DOI 10.1152/jappl.1992.72.4.1425; CROMWELL O, 1992, IMMUNOLOGY, V77, P330; CURRAN RD, 1989, J EXP MED, V170, P1769, DOI 10.1084/jem.170.5.1769; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P863, DOI 10.1164/ajrccm/142.4.863; DUPUY PM, 1992, J CLIN INVEST, V90, P421, DOI 10.1172/JCI115877; FORSTERMANN U, 1991, BIOCHEM PHARMACOL, V42, P1849, DOI 10.1016/0006-2952(91)90581-O; FROSTELL C, 1991, CIRCULATION, V83, P2038, DOI 10.1161/01.CIR.83.6.2038; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GUSTAFSSON LE, 1991, BIOCHEM BIOPH RES CO, V181, P852, DOI 10.1016/0006-291X(91)91268-H; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; KIPS JC, 1992, AM REV RESPIR DIS, V145, P332, DOI 10.1164/ajrccm/145.2_Pt_1.332; KNOWLES RG, 1990, BIOCHEM BIOPH RES CO, V172, P1042, DOI 10.1016/0006-291X(90)91551-3; LUNDGREN R, 1988, EUR RESPIR J, V1, P883; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MASON DY, 1985, TECH IMMUNOCYTOCHEM, V3, P25; MONCADA S, 1991, PHARMACOL REV, V43, P109; MONTEFORT S, 1992, CLIN EXP ALLERGY, V22, P511, DOI 10.1111/j.1365-2222.1992.tb00159.x; MULLIGAN MS, 1991, P NATL ACAD SCI USA, V88, P6338, DOI 10.1073/pnas.88.14.6338; OGUCHI S, 1992, FEBS LETT, V308, P22, DOI 10.1016/0014-5793(92)81041-J; PEPKEZABA J, 1991, LANCET, V338, P1173, DOI 10.1016/0140-6736(91)92033-X; RIVEROSMORENO V, 1993, IN PRESS EUR J BIOCH; ROCHE WR, 1989, LANCET, V1, P520; SPRINGALL DR, 1991, LANCET, V337, P697, DOI 10.1016/0140-6736(91)90279-X; SPRINGALL DR, 1992, HISTOCHEMISTRY, V98, P259, DOI 10.1007/BF00271040; STUEHR DJ, 1989, J EXP MED, V169, P1011, DOI 10.1084/jem.169.3.1011; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; WALSH LJ, 1991, P NATL ACAD SCI USA, V88, P4220, DOI 10.1073/pnas.88.10.4220; YING S, 1991, Clinical and Experimental Allergy, V21, P745, DOI 10.1111/j.1365-2222.1991.tb03205.x	31	719	740	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 18	1993	342	8886-7					1510	1513		10.1016/S0140-6736(05)80083-2	http://dx.doi.org/10.1016/S0140-6736(05)80083-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM402	7504773				2022-12-24	WOS:A1993MM40200010
J	ARIDOR, M; RAJMILEVICH, G; BEAVEN, MA; SAGIEISENBERG, R				ARIDOR, M; RAJMILEVICH, G; BEAVEN, MA; SAGIEISENBERG, R			ACTIVATION OF EXOCYTOSIS BY THE HETEROTRIMERIC-G PROTEIN-G(I3)	SCIENCE			English	Article							RAT MAST-CELLS; GTP-BINDING PROTEINS; SYNTHETIC PEPTIDES; ALPHA-SUBUNIT; SUBSTANCE-P; MASTOPARAN; IDENTIFICATION; NUCLEOTIDE; SECRETION; MEMBRANES	Secretagogues of rat peritoneal mast cells, such as mastoparan and compound 48/80, induce mast cell exocytosis by activating directly the guanosine triphosphate-binding proteins that are required for exocytosis. The introduction of a synthetic peptide that corresponds to the carboxyl-terminal end sequence of Galpha(i3) into the cells specifically blocked this secretion. Similar results were obtained when antibodies to this peptide were introduced. The Galpha(i3) was located in both the Golgi and the plasma membrane, but only the latter source of Galpha(i3) appeared to be essential for secretion. These results indicate that Galpha(i3) functions to control regulated exocytosis in mast cells.	NHLBI,CHEM PHARMACOL LAB,BLDG 10,ROOM 8H108,BETHESDA,MD 20892; WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Weizmann Institute of Science								ARIDOR M, 1990, J CELL BIOL, V111, P2885, DOI 10.1083/jcb.111.6.2885; ARIDOR M, 1990, J CELL BIOL, V111, P909, DOI 10.1083/jcb.111.3.909; ARIDOR M, UNPUB; BARSAGI D, 1988, ONCOGENE, V3, P463; BUEB JL, 1990, MOL PHARMACOL, V38, P816; CERIONE RA, 1988, J BIOL CHEM, V262, P14683; COCKCROFT S, 1979, NATURE, V279, P541, DOI 10.1038/279541a0; COCKCROFT S, 1987, J CELL BIOL, V105, P2745, DOI 10.1083/jcb.105.6.2745; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; FERNANDEZ JM, 1984, NATURE, V312, P453, DOI 10.1038/312453a0; GIERSCHIK P, 1989, J BIOL CHEM, V264, P21470; GOMPERTS BD, 1990, ANNU REV PHYSIOL, V52, P591; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; HOWELL TW, 1987, J CELL BIOL, V105, P191, DOI 10.1083/jcb.105.1.191; KAHN RA, 1991, J BIOL CHEM, V266, P15595; LILLIE THW, 1992, BIOCHEM J, V288, P181, DOI 10.1042/bj2880181; MOUSLI M, 1990, FEBS LETT, V259, P260, DOI 10.1016/0014-5793(90)80023-C; MOUSLI M, 1990, IMMUNOL LETT, V25, P355, DOI 10.1016/0165-2478(90)90207-7; OBERHAUSER AF, 1992, NATURE, V360, P270, DOI 10.1038/360270a0; ORTNER MJ, 1981, BIOCHEM PHARMACOL, V30, P283, DOI 10.1016/0006-2952(81)90055-1; PALM D, 1990, FEBS LETT, V261, P294, DOI 10.1016/0014-5793(90)80575-4; PLUTNER H, 1990, EMBO J, V9, P2375, DOI 10.1002/j.1460-2075.1990.tb07412.x; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; STOW JL, 1991, J CELL BIOL, V114, P113; TRAUB LM, 1991, J BIOL CHEM, V266, P24642	27	230	236	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 3	1993	262	5139					1569	1572		10.1126/science.7504324	http://dx.doi.org/10.1126/science.7504324			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MK329	7504324				2022-12-24	WOS:A1993MK32900040
J	Zignego, AL; Ferri, C; Giannini, C; Monti, M; LaCivita, L; Careccia, G; Longombardo, G; Lombardini, F; Bombardieri, S; Gentilini, P				Zignego, AL; Ferri, C; Giannini, C; Monti, M; LaCivita, L; Careccia, G; Longombardo, G; Lombardini, F; Bombardieri, S; Gentilini, P			Hepatitis C virus genotype analysis in patients with type II mixed cryoglobulinemia	ANNALS OF INTERNAL MEDICINE			English	Note							POLYMERASE CHAIN-REACTION; INTERFERON-ALPHA; LIVER-DISEASE; ANTIBODIES; INFECTION; CELLS	Objective: To investigate the possible role of HCV variants in the pathogenesis of mixed cryoglobulinemia. Setting: Medical service (rheumatology and hepatology units) of urban, university-affiliate teaching hospitals. Design: Analysis of vira I genotypes in a cohort of patients with hepatitis C virus (HCV) infection and mixed cryoglobulinemia. Patients: 90 unselected HCV-positive (anti-HCV antibody-positive and HCV RNA-positive) patients consecutively recruited at routine ambulatory visits: 29 with and 61 without (control group) mixed cryoglobulinemia. Measurements: Clinical and histologic data; HCV RNA detection in serum and peripheral blood mononuclear cells by polymerase chain reaction (PCR); HCV genotype determination by two methods based on genotype specific primer PCR and genotype-specific probe hybridization, respectively. Results: Persistent aminotransferase increases were found in 55% of patients with mixed cryoglobulinemia. Peripheral blood mononuclear cells were infected in 80% of cases. In serum samples, HCV genotype 2a/III was detected with a higher prevalence in patients with mixed cryoglobulinemia than in controls (41% compared with 15%). The overall prevalence of genotype 2a/III in mixed cryoglobulinemia increased to 52% when findings in peripheral blood mononuclear cells were also considered. Among patients with mixed cryoglobulinemia, this genotype was more frequent in those without clinical and biochemical signs of liver disease (85%) or with serum autoantibodies (75%). Conclusions: Mixed cryoglobulinemia may be related, at least in part, to the HCV genotype infecting the host.	IST PATOL MED 1, PISA, ITALY		Zignego, AL (corresponding author), UNIV FLORENCE, IST MED INTERNA, V MORGAGNI 85, I-50134 FLORENCE, ITALY.		Zignego, Anna Linda/AAL-8205-2021					BUNN CC, 1982, J CLIN LAB IMMUNOL, V8, P13; FERRI C, 1994, J INTERN MED, V236, P31, DOI 10.1111/j.1365-2796.1994.tb01116.x; FERRI C, 1994, EUR J CLIN INVEST, V24, P781, DOI 10.1111/j.1365-2362.1994.tb01077.x; FERRI C, 1993, BLOOD, V82, P3701; FERRI C, 1993, BLOOD, V81, P1132; FERRI C, 1991, ARTHRITIS RHEUM, V34, P1606; GIANNINI C, 1995, J HEPATOL, V23, P246, DOI 10.1016/S0168-8278(95)80002-6; GOREVIC PD, 1991, SEMIN HEMATOL, V28, P79; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; LENZI M, 1991, LANCET, V338, P277, DOI 10.1016/0140-6736(91)90418-O; MANNS MP, 1989, J CLIN INVEST, V83, P1066, DOI 10.1172/JCI113949; MICHITAKA K, 1994, GASTROENTEROLOGY, V106, P1603, DOI 10.1016/0016-5085(94)90417-0; OKAMOTO H, 1992, J GEN VIROL, V73, P673, DOI 10.1099/0022-1317-73-3-673; PASCUAL M, 1990, J INFECT DIS, V162, P569, DOI 10.1093/infdis/162.2.569; POZZATO G, 1991, LANCET, V338, P509, DOI 10.1016/0140-6736(91)90578-D; TAKADA N, 1992, J HEPATOL, V14, P35, DOI 10.1016/0168-8278(92)90128-C; YOSHIOKA K, 1992, HEPATOLOGY, V16, P293, DOI 10.1002/hep.1840160203; ZIGNEGO AL, 1992, J HEPATOL, V15, P382, DOI 10.1016/0168-8278(92)90073-X; ZIGNEGO AL, 1995, J MED VIROL, V47, P58, DOI 10.1002/jmv.1890470112; ZIGNEGO AL, 1994, HEPATOLOGY, V19, P577, DOI 10.1002/hep.1840190306	20	166	170	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	1				31	34		10.7326/0003-4819-124-1_Part_1-199601010-00006	http://dx.doi.org/10.7326/0003-4819-124-1_Part_1-199601010-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL943	7503475				2022-12-24	WOS:A1996TL94300006
J	CARRERA, MRA; ASHLEY, JA; PARSONS, LH; WIRSCHING, P; KOOB, GF; JANDA, KD				CARRERA, MRA; ASHLEY, JA; PARSONS, LH; WIRSCHING, P; KOOB, GF; JANDA, KD			SUPPRESSION OF PSYCHOACTIVE EFFECTS OF COCAINE BY ACTIVE IMMUNIZATION	NATURE			English	Article							AMPHETAMINE; APOMORPHINE; METABOLISM; SEROTONIN; MORPHINE; NEURONS; HUMANS; MICE; RATS	COCAINE is a powerfully addictive substance and new strategies are needed to treat its abuse. Generating an active immunization(1,2) to cocaine offers a means of blocking the actions of the drug by preventing it from entering the central nervous system, and should have fewer side effects than treatments based on manipulation of central neurotransmitter function. The design and preparation of a cocaine immunogen requires special regard for the stability of cocaine both free and as a haptenic determinant. Immunochemistry and a well defined behavioural model were brought together to address the problem of inactivation of the psychostimulant actions of cocaine. We report here that active immunization with a new, stable cocaine conjugate suppressed locomotor activity and stereotyped behaviour in rats induced by cocaine but not by amphetamine, Moreover, following acute injection of cocaine, levels of cocaine in the striatum and cerebellum of the immunized animals were lower than those of control animals, These results suggest that immunopharmacotherapy may be a promising means by which to explore new treatments for cocaine abuse.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CHEM, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute								BAGASRA O, 1992, IMMUNOPHARMACOLOGY, V23, P173, DOI 10.1016/0162-3109(92)90023-6; BENUCK M, 1987, J PHARMACOL EXP THER, V243, P144; BERKOWITZ B, 1972, SCIENCE, V178, P1290, DOI 10.1126/science.178.4067.1290; CUNNINGHAM KA, 1990, NEUROPSYCHOPHARMACOL, V3, P41; EISEN HN, 1964, METHOD MED RES, P106; FISCHMAN MW, 1983, PHARMACOL BIOCHEM BE, V18, P123, DOI 10.1016/0091-3057(83)90261-7; FRAY PJ, 1980, PSYCHOPHARMACOLOGY, V69, P253, DOI 10.1007/BF00433091; GALLACHER G, 1994, IMMUNOPHARMACOLOGY, V27, P79, DOI 10.1016/0162-3109(94)90009-4; GARRETT ER, 1983, J PHARM SCI, V72, P258, DOI 10.1002/jps.2600720314; GOLD LH, 1988, PHARMACOL BIOCHEM BE, V29, P645, DOI 10.1016/0091-3057(88)90034-2; HILL JH, 1973, CLIN EXP IMMUNOL, V15, P213; JAVAID JI, 1978, SCIENCE, V202, P227, DOI 10.1126/science.694530; KELLY PH, 1975, BRAIN RES, V94, P507, DOI 10.1016/0006-8993(75)90233-4; KELLY PH, 1976, EUR J PHARMACOL, V40, P45, DOI 10.1016/0014-2999(76)90352-6; KULLBACK S, 1968, INFORMATION THEORY S; LANDRY DW, 1993, SCIENCE, V259, P1899, DOI 10.1126/science.8456315; LYON M, 1975, CURRENT DEV PSYCHOPH, V2, P89; MATSUBARA K, 1984, FORENSIC SCI INT, V26, P169, DOI 10.1016/0379-0738(84)90215-9; MINDEN P, 1967, HDB EXPT IMMUNOLOGY, P463; MISRA AL, 1976, RES COMMUN CHEM PATH, V13, P579; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; ROBBINS TW, 1977, HDB PSYCHOPHARMACOLO, V7, P37; SPECTOR S, 1973, PHARMACOL REV, V25, P281; Steward M.W., 1983, ANTIBODY AFFINITY TH; STEWART DJ, 1979, CLIN PHARMACOL THER, V25, P464; Taussig M J, 1973, Curr Top Microbiol Immunol, V60, P125	26	170	180	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 14	1995	378	6558					727	730		10.1038/378727a0	http://dx.doi.org/10.1038/378727a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK379	7501020				2022-12-24	WOS:A1995TK37900055
J	LI, M; SENDTNER, M; SMITH, A				LI, M; SENDTNER, M; SMITH, A			ESSENTIAL FUNCTION OF LIF RECEPTOR IN MOTOR-NEURONS	NATURE			English	Article							LEUKEMIA-INHIBITORY FACTOR; IL-6 SIGNAL TRANSDUCER; EMBRYONIC MOTONEURONS; CNTF RECEPTOR; ONCOSTATIN-M; STEM-CELLS; SURVIVAL; RAT; DEGENERATION; EXPRESSION	DEVELOPMENT and maintenance of the mammalian nervous system is dependent upon neurotrophic cytokines. One class of neurotrophic factor acts through receptor complexes involving the low-affinity leukaemia inhibitory factor receptor subunit (LIF-R)(1-3). Members of this family of cytokines, such as ciliary neurotrophic factor (CNTF) and leukaemia inhibitory factor (LIF), have profound effects on the survival and maintenance of motor neurons(4-10). Recently it was reported that mice lacking LIF-R die shortly after birth(11) unlike mice lacking CNTF or LIF which are viable. Here we describe histopathological analyses of lifr mutants that reveal a loss >35% of facial motor neurons, 40% of spinal motor neurons and 50% of neurons in the nucleus ambiguus. These findings point to the existence of a ligand for LIF-R that is required for the normal development of motor neurons in both brainstem nuclei and spinal cord.	UNIV EDINBURGH,CTR GENOME RES,EDINBURGH EH9 3JQ,MIDLOTHIAN,SCOTLAND; UNIV WURZBURG,DEPT NEUROL,CLIN RES UNIT NEUROREGENERAT,D-97080 WURZBURG,GERMANY	University of Edinburgh; University of Wurzburg			Sendtner, Michael/J-1542-2012; Sendtner, Michael/M-8137-2014; Li, Meng/I-6941-2013	Sendtner, Michael/0000-0002-4737-2974; Sendtner, Michael/0000-0002-4737-2974; Smith, Austin/0000-0002-3029-4682				ARAKAWA Y, 1990, J NEUROSCI, V10, P3507; BEDDINGTON RSP, 1989, DEVELOPMENT, V106, P37; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; ELLENBERGER HH, 1990, J COMP NEUROL, V294, P202, DOI 10.1002/cne.902940205; ESCARY JL, 1993, NATURE, V363, P361, DOI 10.1038/363361a0; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; HUGHES RA, 1993, J NEUROSCI RES, V36, P663, DOI 10.1002/jnr.490360607; IP NY, 1993, NEURON, V10, P89, DOI 10.1016/0896-6273(93)90245-M; MARTINOU JC, 1992, NEURON, V8, P737, DOI 10.1016/0896-6273(92)90094-T; MASU Y, 1993, NATURE, V365, P27, DOI 10.1038/365027a0; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; MOUNTFORD PS, 1995, TRENDS GENET, V11, P179, DOI 10.1016/S0168-9525(00)89040-X; PATON JFR, 1994, PFLUG ARCH EUR J PHY, V428, P250, DOI 10.1007/BF00724504; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; RICHARDS LJ, 1992, J NEUROSCI RES, V33, P476, DOI 10.1002/jnr.490330314; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; SKARNES WC, 1992, GENE DEV, V6, P903, DOI 10.1101/gad.6.6.903; Smith AG., 1991, J TISSUE CULT METHOD, V13, P89, DOI [10.1007/bf01666137, DOI 10.1007/BF01666137, 10.1007/BF01666137]; SMITH JC, 1990, J NEUROPHYSIOL, V64, P1149, DOI 10.1152/jn.1990.64.4.1149; STAHL N, 1994, J NEUROBIOL, V25, P1454, DOI 10.1002/neu.480251111; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; WARE CB, 1995, DEVELOPMENT, V121, P1283; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO; ZURN AD, 1994, DEV BIOL, V163, P309, DOI 10.1006/dbio.1994.1150	26	263	268	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 14	1995	378	6558					724	727		10.1038/378724a0	http://dx.doi.org/10.1038/378724a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK379	7501019	Green Submitted			2022-12-24	WOS:A1995TK37900054
J	STROMINGER, JL; WILEY, DC				STROMINGER, JL; WILEY, DC			THE CLASS-I AND CLASS-II PROTEINS OF THE HUMAN MAJOR HISTOCOMPATIBILITY COMPLEX	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MOLECULES; ANTIGEN; PEPTIDE; HLA-A2		DANA FARBER CANC INST,DIV TUMOR VIROL,BOSTON,MA 02115; CHILDRENS HOSP,HOWARD HUGHES MED INST,DEPT MED,MOLEC MED LAB,BOSTON,MA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute	STROMINGER, JL (corresponding author), HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138, USA.							BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P513; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; KAUFMAN JF, 1984, CELL, V36, P1, DOI 10.1016/0092-8674(84)90068-0; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; MADDEN DR, 1992, CURR OPIN STRUC BIOL, V2, P300; PLOEGH HL, 1981, CELL, V24, P287, DOI 10.1016/0092-8674(81)90318-4; SILVER ML, 1992, NATURE, V360, P367, DOI 10.1038/360367a0; STERN LJ, 1994, STRUCTURE, V2, P245, DOI 10.1016/S0969-2126(00)00026-5; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; Urban R G, 1993, Chem Immunol, V57, P197; WUCHERPFENNIG KW, 1995, J EXP MED, V181, P1597, DOI 10.1084/jem.181.5.1597; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8; WUCHERPFENNIG KW, IN PRESS P NATL ACAD	16	9	10	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 4	1995	274	13					1074	1076		10.1001/jama.274.13.1074	http://dx.doi.org/10.1001/jama.274.13.1074			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX108	7563464				2022-12-24	WOS:A1995RX10800036
J	AITTOMAKI, K; LUCENA, JLD; PAKARINEN, P; SISTONEN, P; TAPANAINEN, J; GROMOLL, J; KASKIKARI, R; SANKILA, EM; LEHVASLAIHO, H; ENGEL, AR; NIESCHLAG, E; HUHTANIEMI, I; DELACHAPELLE, A				AITTOMAKI, K; LUCENA, JLD; PAKARINEN, P; SISTONEN, P; TAPANAINEN, J; GROMOLL, J; KASKIKARI, R; SANKILA, EM; LEHVASLAIHO, H; ENGEL, AR; NIESCHLAG, E; HUHTANIEMI, I; DELACHAPELLE, A			MUTATION IN THE FOLLICLE-STIMULATING-HORMONE RECEPTOR GENE CAUSES HEREDITARY HYPERGONADOTROPIC OVARIAN FAILURE	CELL			English	Article							LUTEINIZING-HORMONE; MOLECULAR-CLONING; GONADOTROPIN-DEFICIENCY; CHORIONIC-GONADOTROPIN; FUNCTIONAL EXPRESSION; PRECOCIOUS PUBERTY; CYCLIC-AMP; CDNA; RAT; LOCALIZATION	Hypergonadotropic ovarian dysgenesis (ODG) with normal karyotype is a heterogeneous condition that in some cases displays Mendelian recessive inheritance, By systematically searching for linkage in multiplex affected families, we mapped a locus for ODG to chromosome 2p, As the previously cloned follicle-stimulating hormone receptor (FSHR) gene had been assigned to 2p, we searched it for mutations, A C566T transition in exon 7 of FSHR predicting an Ala to Val substitution at residue 189 in the extracellular ligand-binding domain segregated perfectly with the disease phenotype. Expression of the gene in transfected cells demonstrated a dramatic reduction of binding capacity and signal transduction, but apparently normal ligand-binding affinity of the mutated receptor. We conclude that the mutation causes ODG in these families.	UNIV TURKU,DEPT PHYSIOL,SF-20520 TURKU,FINLAND; FINNISH RED CROSS & BLOOD TRANSFUS SERV,SF-00310 HELSINKI,FINLAND; UNIV OULU,CENT HOSP,DEPT OBSTET & GYNECOL,SF-90220 OULU,FINLAND; UNIV MUNSTER,INST REPROD MED,D-48149 MUNSTER,GERMANY; UNIV MALAGA,FAC MED,DEPT BIOCHEM & MOLEC BIOL,E-29080 MALAGA,SPAIN; UNIV HELSINKI,CENT HOSP,DEPT CLIN GENET,SF-00290 HELSINKI,FINLAND; UNIV HELSINKI,CENT HOSP,DEPT OBSTET & GYNECOL,SF-00290 HELSINKI,FINLAND	University of Turku; University of Oulu; University of Munster; Universidad de Malaga; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital	AITTOMAKI, K (corresponding author), UNIV HELSINKI,DEPT MED GENET,HAARTMANINKATU 3,SF-00290 HELSINKI,FINLAND.		Gromoll, Joerg/AAB-2146-2019	Gromoll, Joerg/0000-0002-7788-8138; REYES ENGEL, ARMANDO/0000-0002-7294-8103				AIMAN J, 1985, OBSTET GYNECOL, V66, P9; AITTOMAKI K, 1994, AM J HUM GENET, V54, P844; BROOKER G, 1979, ADV CYCLIC NUCLEOTID, P1; CATT K, 1976, METHODS RECEPTOR RES, P175; CHELLY J, 1989, P NATL ACAD SCI USA, V86, P2617, DOI 10.1073/pnas.86.8.2617; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COUZINET B, 1988, J CLIN ENDOCR METAB, V66, P552, DOI 10.1210/jcem-66-3-552; DAVIS D, 1995, MOL ENDOCRINOL, V9, P169; DELACHAPELLE A, 1993, J MED GENET, V30, P857, DOI 10.1136/jmg.30.10.857; DUPREZ L, 1994, NAT GENET, V7, P396, DOI 10.1038/ng0794-396; GRANAT M, 1983, FERTIL STERIL, V40, P215; GROMOLL J, 1994, J MOL ENDOCRINOL, V12, P265, DOI 10.1677/jme.0.0120265; GROMOLL J, 1993, BIOCHEM BIOPH RES CO, V196, P1066, DOI 10.1006/bbrc.1993.2359; GROMOLL J, 1992, BIOCHEM BIOPH RES CO, V188, P1077, DOI 10.1016/0006-291X(92)91341-M; GUDERMANN T, 1994, ENDOCRINOLOGY, V135, P2204, DOI 10.1210/en.135.5.2204; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HALPIN DMG, 1986, J REPROD FERTIL, V78, P119, DOI 10.1530/jrf.0.0780119; HARPER JF, 1975, J CYCLIC NUCL PROT, V1, P207; HECKERT LL, 1992, MOL ENDOCRINOL, V6, P70, DOI 10.1210/me.6.1.70; HEMMINKI A, 1994, NAT GENET, V8, P405, DOI 10.1038/ng1294-405; JIA XC, 1991, MOL ENDOCRINOL, V5, P759, DOI 10.1210/mend-5-6-759; JONES GS, 1969, AM J OBSTET GYNECOL, V104, P597, DOI 10.1016/S0002-9378(16)34255-7; KARONEN SL, 1975, ANAL BIOCHEM, V67, P1, DOI 10.1016/0003-2697(75)90266-3; KELTON CA, 1992, MOL CELL ENDOCRINOL, V89, P141, DOI 10.1016/0303-7207(92)90220-Z; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KREMER H, 1995, NAT GENET, V9, P160, DOI 10.1038/ng0295-160; KREMER H, 1993, HUM MOL GENET, V2, P1779, DOI 10.1093/hmg/2.11.1779; LAPOLT PS, 1992, ENDOCRINOLOGY, V130, P1289, DOI 10.1210/en.130.3.1289; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LEACH FS, 1994, HUM MOL GENET, V3, P2082; LERMAN LS, 1987, METHOD ENZYMOL, V155, P482; MATSUMOTO AM, 1989, TESTIS, P181; MATTHEWS CH, 1993, NAT GENET, V5, P83, DOI 10.1038/ng0993-83; MAXSON WS, 1983, SEMIN REPROD ENDOCR, V1, P147, DOI 10.1055/s-2007-1022585; MINEGISH T, 1990, BIOCHEM BIOPH RES CO, V172, P1049, DOI 10.1016/0006-291X(90)91552-4; MINEGISH T, 1991, BIOCHEM BIOPH RES CO, V175, P1125, DOI 10.1016/0006-291X(91)91682-3; Myers R. M., 1988, Genome analysis: a practical approach., P95; NAGAYAMA Y, 1989, BIOCHEM BIOPH RES CO, V165, P1184, DOI 10.1016/0006-291X(89)92727-7; NEVANLINNA HR, 1972, HEREDITAS-GENETISK A, V71, P195; Norio R., 1981, BIOCULTURAL ASPECTS, P359; PESCHON JJ, 1992, MOL ENDOCRINOL, V6, P1403, DOI 10.1210/me.6.9.1403; RANNIKKO AS, 1995, MOL CELL ENDOCRINOL, V107, P196; REBAR RW, 1990, FERTIL STERIL, V53, P804; REINDOLLAR RH, 1984, J REPROD MED, V29, P391; RICHARDS JS, 1995, ENDOCR REV, V15, P725; ROUSSEAUMERCK MF, 1990, CYTOGENET CELL GENET, V54, P77, DOI 10.1159/000132962; ROUSSEAUMERCK MF, 1993, GENOMICS, V15, P222, DOI 10.1006/geno.1993.1041; Sambrook J., 1989, MOL CLONING LAB MANU; SANKILA EM, 1995, HUM MOL GENET, V4, P93, DOI 10.1093/hmg/4.1.93; SARKAR G, 1989, SCIENCE, V244, P331, DOI 10.1126/science.2565599; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; SIMPSON J L, 1971, Birth Defects Original Article Series, V7, P215; SIMPSON JL, 1979, GENETIC MECHANISMS S, P365; SMITH A, 1979, FERTIL STERIL, V32, P528; SOKKA T, 1990, J ENDOCRINOL, V127, P297, DOI 10.1677/joe.0.1270297; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; TILLY JL, 1992, ENDOCRINOLOGY, V130, P1296, DOI 10.1210/en.130.3.1296; VANCAMPENHOUT J, 1972, OBSTET GYNECOL, V40, P6; WAHLSTROM T, 1983, J CLIN ENDOCR METAB, V57, P825, DOI 10.1210/jcem-57-4-825; WEINBAUER GF, 1993, MOL BIOL MALE REPROD, P99; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; YANO K, 1995, J CLIN ENDOCR METAB, V80, P1162, DOI 10.1210/jc.80.4.1162; YARNEY TA, 1993, MOL CELL ENDOCRINOL, V93, P219, DOI 10.1016/0303-7207(93)90127-6; ZIRKIN BR, 1994, J ANDROL, V15, P273	64	686	717	0	24	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 22	1995	82	6					959	968		10.1016/0092-8674(95)90275-9	http://dx.doi.org/10.1016/0092-8674(95)90275-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RW693	7553856	Bronze			2022-12-24	WOS:A1995RW69300012
J	HISLOP, LJ; WYATT, JP; MCNAUGHTON, GW; IRELAND, AJ; RAINER, TH; OLVERMAN, G; LAUGHTON, LM				HISLOP, LJ; WYATT, JP; MCNAUGHTON, GW; IRELAND, AJ; RAINER, TH; OLVERMAN, G; LAUGHTON, LM			URBAN HYPOTHERMIA IN THE WEST OF SCOTLAND	BMJ-BRITISH MEDICAL JOURNAL			English	Article									ROYAL ALEXANDRA HOSP, DEPT ACCID & EMERGENCY MED, PAISLEY PA2 9PL, RENFREW, SCOTLAND; ROYAL INFIRM, DEPT ACCID & EMERGENCY MED, EDINBURGH EH3 9YW, MIDLOTHIAN, SCOTLAND; WESTERN INFIRM, DEPT ACCID & EMERGENCY MED, GLASGOW G11 6NT, LANARK, SCOTLAND; GLASGOW ROYAL INFIRM, DEPT ACCID & EMERGENCY MED, GLASGOW G4 0SF, LANARK, SCOTLAND; MONKLANDS DIST GEN HOSP, DEPT ACCID & EMERGENCY MED, AIRDRIE, LANARK ML6 0JS, SCOTLAND; VICTORIA INFIRM, DEPT ACCID & EMERGENCY MED, GLASGOW G42 9TY, LANARK, SCOTLAND; SO GEN HOSP, DEPT ACCID & EMERGENCY MED, GLASGOW G51 4TF, LANARK, SCOTLAND	Royal Infirmary of Edinburgh; University of Glasgow; University of Glasgow			Rainer, Timothy/I-2591-2013	Rainer, Timothy/0000-0003-3355-3237				[Anonymous], 1985, LANCET, V2, P987; OTTY CJ, 1987, BRIT MED J, V295, P419, DOI 10.1136/bmj.295.6595.419; WATT GCM, 1994, BRIT MED J, V309, P1030, DOI 10.1136/bmj.309.6961.1030; WILMSHURST P, 1994, BMJ-BRIT MED J, V309, P1029, DOI 10.1136/bmj.309.6961.1029; 1991, POP CENS	5	31	31	3	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 16	1995	311	7007					725	725		10.1136/bmj.311.7007.725	http://dx.doi.org/10.1136/bmj.311.7007.725			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RV874	7549687	Green Published			2022-12-24	WOS:A1995RV87400021
J	HUBER, R; BURGGRAF, S; MAYER, T; BARNS, SM; ROSSNAGEL, P; STETTER, KO				HUBER, R; BURGGRAF, S; MAYER, T; BARNS, SM; ROSSNAGEL, P; STETTER, KO			ISOLATION OF A HYPERTHERMOPHILIC ARCHAEUM PREDICTED BY IN-SITU RNA ANALYSIS	NATURE			English	Article							SINGLE CELLS; BACTERIA; ARCHAEBACTERIA; MANIPULATION; ORGANISMS; PROBES	A variety of hyperthermophilic bacteria and archaea(1) have been isolated from high-temperature environments by plating and serial dilutions(2). However, these techniques allow only the small percentage of organisms able to form colonies, or those that are predominant within environmental samples, to be obtained in pure culture, Recently, in situ 16S ribosomal RNA analyses of samples from the Obsidian hot pool at Yellowstone National Park, Wyoming, revealed a variety of archaeal sequences, which,were all different from those of previously isolated species(3,4). This suggests substantial diversity of archaea with so far unknown morphological, physiological and biochemical features, which may play an important part within high-temperature ecosystems, Here we describe a procedure to obtain pure cultures of unknown organisms harbouring specific 16S rRNA sequences identified previously within the environment, It combines visual recognition of single cells by phylogenetic staining(5-9) and cloning by 'optical tweezers'(10,11). Our result validates polymerase chain reaction data on the existence of large archaeal communities.	UNIV REGENSBURG,ARCHAEENZENTRUM,D-93053 REGENSBURG,GERMANY; INDIANA UNIV,DEPT BIOL,BLOOMINGTON,IN 47405; INDIANA UNIV,INST MOLEC & CELLULAR BIOL,BLOOMINGTON,IN 47405	University of Regensburg; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington	HUBER, R (corresponding author), UNIV REGENSBURG,LEHRSTUHL MIKROBIOL,UNIV STR 31,D-93053 REGENSBURG,GERMANY.			Burggraf, Siegfried/0000-0002-2116-0156				AMANN RI, 1990, J BACTERIOL, V172, P762, DOI 10.1128/jb.172.2.762-770.1990; ASHKIN A, 1987, SCIENCE, V235, P1517, DOI 10.1126/science.3547653; ASHKIN A, 1987, NATURE, V330, P769, DOI 10.1038/330769a0; BALCH WE, 1979, MICROBIOL REV, V43, P260, DOI 10.1128/MMBR.43.2.260-296.1979; BARNS SM, 1994, 94 GEN M AM SOC MICR, P253; BARNS SM, 1994, P NATL ACAD SCI USA, V9, P1609; BIOCHL E, 1995, WLD J MICRBIOL BIOTE, V11, P9; BROSIUS J, 1978, P NATL ACAD SCI USA, V75, P4801, DOI 10.1073/pnas.75.10.4801; BURGGRAF S, 1994, APPL ENVIRON MICROB, V60, P3112, DOI 10.1128/AEM.60.9.3112-3119.1994; BURGGRAF S, 1994, APPL ENV MICORBIOL, V330, P3112; DELONG EF, 1989, SCIENCE, V243, P1360, DOI 10.1126/science.2466341; HUBER R, 1989, NATURE, V342, P833, DOI 10.1038/342833a0; HUBER R, 1992, PROKARYOTES, P677; KANE MD, 1993, APPL ENVIRON MICROB, V59, P682, DOI 10.1128/AEM.59.3.682-686.1993; Stahl D.A., 1991, SEQUENCING HYBRIDIZA, P205; STETTER KO, 1982, NATURE, V300, P258, DOI 10.1038/300258a0; STETTER KO, 1981, ZBL BAKT MIK HYG I C, V2, P166, DOI 10.1016/S0721-9571(81)80038-5; STETTER KO, 1987, SCIENCE, V236, P822, DOI 10.1126/science.236.4803.822; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576	19	151	162	0	22	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 6	1995	376	6535					57	58		10.1038/376057a0	http://dx.doi.org/10.1038/376057a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RH111	7541115				2022-12-24	WOS:A1995RH11100060
J	ROITBERG, A; GERBER, RB; ELBER, R; RATNER, MA				ROITBERG, A; GERBER, RB; ELBER, R; RATNER, MA			ANHARMONIC WAVE-FUNCTIONS OF PROTEINS - QUANTUM SELF-CONSISTENT-FIELD CALCULATIONS OF BPTI	SCIENCE			English	Article							PANCREATIC TRYPSIN-INHIBITOR; NEUTRON-SCATTERING ANALYSIS; VIBRATIONAL-STATES; NORMAL-MODES; DYNAMICS; MYOGLOBIN; LYSOZYME; ENERGY	The harmonic approximation for the potential energy of proteins is known to be inadequate for the calculation of many protein properties. To study the effect of anharmonic terms on protein vibrations, the anharmonic wave functions for the ground state and low-lying excited states of the bovine pancreatic trypsin inhibitor (BPTI) were calculated. The results suggest that anharmonic treatments are essential for protein vibrational spectroscopy. The calculation uses the Vibrational self-consistent field approximation, which includes anharmonicity and interaction among modes in a mean-field sense. Properties obtained include the quantum coordinate fluctuations, zero-point energies, and the vibrational absorption spectrum.	NORTHWESTERN UNIV, DEPT CHEM, EVANSTON, IL 60208 USA; HEBREW UNIV JERUSALEM, DEPT PHYS CHEM, IL-91904 JERUSALEM, ISRAEL; HEBREW UNIV JERUSALEM, FRITZ HABER INST, IL-91904 JERUSALEM, ISRAEL; UNIV ILLINOIS, DEPT CHEM, CHICAGO, IL 60680 USA	Northwestern University; Hebrew University of Jerusalem; Hebrew University of Jerusalem; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital			Roitberg, Adrian E/A-2378-2009					AUSTIN RH, 1975, BIOCHEMISTRY-US, V14, P5355, DOI 10.1021/bi00695a021; BOWMAN JM, 1978, J CHEM PHYS, V68, P608, DOI 10.1063/1.435782; BROOKS B, 1983, P NATL ACAD SCI-BIOL, V80, P6571, DOI 10.1073/pnas.80.21.6571; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUCCOLERI RE, 1986, BIOPOLYMERS, V25, P1767, DOI 10.1002/bip.360250916; CUSACK S, 1988, J MOL BIOL, V202, P903, DOI 10.1016/0022-2836(88)90566-9; DEISENHOFER J, 1975, ACTA CRYSTALLOGR B, V31, P238, DOI 10.1107/S0567740875002415; ELBER R, 1987, SCIENCE, V235, P318, DOI 10.1126/science.3798113; ELBER R, IN PRESS COMPUT PHYS; GERBER RB, 1988, ADV CHEM PHYS, V70, P97, DOI 10.1002/9780470141199.ch4; GO N, 1983, P NATL ACAD SCI-BIOL, V80, P3696, DOI 10.1073/pnas.80.12.3696; HORN TR, 1989, J CHEM PHYS, V91, P1813, DOI 10.1063/1.457086; JORGENSEN WL, 1988, J AM CHEM SOC, V110, P1657, DOI 10.1021/ja00214a001; LAANE J, 1994, ANNU REV PHYS CHEM, V45, P179; LEVITT M, 1985, J MOL BIOL, V181, P423, DOI 10.1016/0022-2836(85)90230-X; LEVY RM, 1984, J PHYS CHEM-US, V88, P4233, DOI 10.1021/j150663a009; NESBITT DJ, 1994, ANNU REV PHYS CHEM, V45, P367; NISHIKAWA T, 1987, PROTEINS, V2, P308, DOI 10.1002/prot.340020407; QIAN WL, 1994, BIOPOLYMERS, V34, P1377, DOI 10.1002/bip.360341009; RATNER MA, 1986, J PHYS CHEM-US, V90, P20, DOI 10.1021/j100273a008; ROMANOWSKI H, 1985, J CHEM PHYS, V82, P4155, DOI 10.1063/1.448858; SMITH J, 1990, J CHEM PHYS, V93, P2974, DOI 10.1063/1.458885; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051	23	116	119	0	17	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 2	1995	268	5215					1319	1322		10.1126/science.7539156	http://dx.doi.org/10.1126/science.7539156			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB198	7539156				2022-12-24	WOS:A1995RB19800029
J	WANG, DG; MEIER, TI; CHAN, CL; FENG, GH; LEE, DN; LANDICK, R				WANG, DG; MEIER, TI; CHAN, CL; FENG, GH; LEE, DN; LANDICK, R			DISCONTINUOUS MOVEMENTS OF DNA AND RNA IN RNA-POLYMERASE ACCOMPANY FORMATION OF A PAUSED TRANSCRIPTION COMPLEX	CELL			English	Article							ESCHERICHIA-COLI RNA; STRUCTURAL-ANALYSIS; TERNARY COMPLEXES; TERMINATION; BACTERIOPHAGE-T7; DISSECTION; SEQUENCES; CLEAVAGE; PROTEINS; INVITRO	A central enigma of transcriptional regulation is how the normally efficient transcription elongation complex stops at pause and termination signals. One possibility, raised by the discovery that RNA polymerase sometimes contracts its DNA footprint, is that discontinuous movements contribute to recognizing these signals. We report that E. coli RNA polymerase responds to sequences immediately downstream and upstream from the his leader pause site by changing neither its downstream DNA contact nor its upstream RNA contact for 8 bp preceding the pause. This compressed complex isomerizes to a paused conformation by an similar to 10 bp jump of its downstream DNA contact and simultaneous extrusion of an RNA hairpin that stabilizes the paused conformation. We suggest pausing and termination could be alternative outcomes of a similar isomerization that depend on the strength of contacts to 3'-proximal RNA remaining after the jump.	WASHINGTON UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,ST LOUIS,MO 63130	Washington University (WUSTL)	WANG, DG (corresponding author), WASHINGTON UNIV,DEPT BIOL,CAMPUS BOX 1137,ST LOUIS,MO 63130, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038660, R01GM038660, R37GM038660] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-38660] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], [No title captured]; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; CHAMBERLIN M, 1983, METHOD ENZYMOL, V101, P540; Chamberlin M.J., 1994, HARVEY LECT, V88, P1; CHAN CL, 1989, J BIOL CHEM, V264, P20796; CHAN CL, 1993, J MOL BIOL, V233, P25, DOI 10.1006/jmbi.1993.1482; CHAN CL, 1994, TRANSCRIPTION MECHAN, P297; DAS A, 1993, ANNU REV BIOCHEM, V62, P893; FENG GH, 1994, J BIOL CHEM, V269, P22282; HAGER DA, 1990, BIOCHEMISTRY-US, V29, P7890, DOI 10.1021/bi00486a016; Kane C. M., 1994, TRANSCRIPTION MECH R, P279; KASHLEV M, 1993, GENE, V130, P9, DOI 10.1016/0378-1119(93)90340-9; KRUMMEL B, 1992, J MOL BIOL, V225, P221, DOI 10.1016/0022-2836(92)90917-9; KRUMMEL B, 1992, J MOL BIOL, V225, P239, DOI 10.1016/0022-2836(92)90918-A; LANDICK R, 1987, J MOL BIOL, V196, P363, DOI 10.1016/0022-2836(87)90697-8; LANDICK R, 1987, ESCHERICHIA COLI SAL, P1276; LEE DN, 1990, J BIOL CHEM, V265, P15145; LEE DN, 1994, J BIOL CHEM, V269, P22295; LEE DN, 1992, J MOL BIOL, V228, P759, DOI 10.1016/0022-2836(92)90862-E; LEVIN JR, 1987, J MOL BIOL, V196, P61, DOI 10.1016/0022-2836(87)90511-0; LOWMAN HB, 1986, J BIOL CHEM, V261, P5396; LUI B, 1994, P NATL ACAD SCI USA, V91, P10660; MASON SW, 1992, J BIOL CHEM, V267, P19418; Maxam A M, 1980, Methods Enzymol, V65, P499; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; NUDLER E, 1994, SCIENCE, V265, P793, DOI 10.1126/science.8047884; REYNOLDS R, 1992, J MOL BIOL, V224, P53, DOI 10.1016/0022-2836(92)90575-5; RICHARDSON JP, 1993, CRIT REV BIOCHEM MOL, V28, P1, DOI 10.3109/10409239309082571; RING BZ, 1994, CELL, V78, P317, DOI 10.1016/0092-8674(94)90300-X; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; TELESNITSKY A, 1989, BIOCHEMISTRY-US, V28, P5210, DOI 10.1021/bi00438a044; VOGEL U, 1994, J BACTERIOL, V176, P2807, DOI 10.1128/JB.176.10.2807-2813.1994; WEILBAECHER R, 1994, GENE DEV, V8, P2913, DOI 10.1101/gad.8.23.2913; WILSON K, 1995, J MOL BIOL, V244, P36; WRIGHT S, 1993, MOL BIOL CELL, V4, P661, DOI 10.1091/mbc.4.7.661; YANG XJ, 1989, P NATL ACAD SCI USA, V86, P5301, DOI 10.1073/pnas.86.14.5301; ZAYCHIKOV E, 1995, P NATL ACAD SCI USA, V92, P1739, DOI 10.1073/pnas.92.5.1739	37	123	127	0	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 5	1995	81	3					341	350		10.1016/0092-8674(95)90387-9	http://dx.doi.org/10.1016/0092-8674(95)90387-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QW894	7537637	Bronze			2022-12-24	WOS:A1995QW89400006
J	SPACH, DH; KANTER, AS; DOUGHERTY, MJ; LARSON, AM; COYLE, MB; BRENNER, DJ; SWAMINATHAN, B; MATAR, GM; WELCH, DF; ROOT, RK; STAMM, WE				SPACH, DH; KANTER, AS; DOUGHERTY, MJ; LARSON, AM; COYLE, MB; BRENNER, DJ; SWAMINATHAN, B; MATAR, GM; WELCH, DF; ROOT, RK; STAMM, WE			BARTONELLA (ROCHALIMAEA) QUINTANA BACTEREMIA IN INNER-CITY PATIENTS WITH CHRONIC-ALCOHOLISM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CAT-SCRATCH DISEASE; HENSELAE SP-NOV; BACILLARY ANGIOMATOSIS; PELIOSIS HEPATIS; FEVER; AGENT	Background. Bartonella (Rochalimaea) quintana is a fastidious gram-negative bacterium known to cause trench fever, cutaneous bacillary angiomatosis, and endocarditis. Between January and June 1993 in Seattle, we isolated B. quintana from 34 blood cultures obtained from 10 patients not known to be infected with the human immunodeficiency virus (HIV). Methods. After identifying the isolates as B. quintana by direct immunofluorescence and DNA-hybridization studies, we determined strain hybridization with studies of restriction-fragment-length polymorphisms (RFLPs) of the intergenic spacer (noncoding) region of ribosomal DNA amplified by the polymerase chain reaction (PCR). To characterize the epidemiologic and clinical features of bartonella infections in these patients, we performed a retrospective case-control study using as controls 20 patients from whom blood was obtained for culture at approximately the same time as from the index patients. Results. B. quintana isolates from the 10 patients were indistinguishable by PCR-RFLP typing. All 10 patients had chronic alcoholism, and 8 were homeless (P=0.001 for both comparisons with controls). The six patients who underwent HIV testing were seronegative. At the time of their initial presentation, seven patients had temperatures of at least 38.5 degrees C. Six patients had three or more blood cultures that were positive for B. quintana, and in four of these patients B. quintana was isolated from blood cultures obtained 10 or more days apart. Subacute endocarditis developed in two patients and required surgical removal of the infected aortic valve in one of them. Nine patients recovered; one died of sepsis from Streptococcus pneumoniae infection. Conclusions. B. quintana is a cause of fever, bacteremia, and endocarditis in HIV-seronegative, homeless, inner-city patients with chronic alcoholism.	HARBORVIEW MED CTR,DIV INFECT DIS,SEATTLE,WA; HARBORVIEW MED CTR,DEPT MED,SEATTLE,WA; HARBORVIEW MED CTR,DEPT LAB MED,SEATTLE,WA; UNIV WASHINGTON,MED CTR,DEPT MED,SEATTLE,WA 98195; NATL CTR INFECTIOUS DIS,DIV BACTERIAL & MYCOT DIS,EMERGING BACTERIAL & MYCOT DIS BRANCH,ATLANTA,GA; NATL CTR INFECTIOUS DIS,DIV BACTERIAL & MYCOT DIS,FOODBORNE & DIARRHEAL DIS BRANCH,ATLANTA,GA; UNIV OKLAHOMA,HLTH SCI CTR,DEPT PEDIAT,OKLAHOMA CITY,OK 73190; UNIV OKLAHOMA,HLTH SCI CTR,CLIN MICROBIOL LABS,OKLAHOMA CITY,OK 73190	Harborview Medical Center; Harborview Medical Center; Harborview Medical Center; University of Washington; University of Washington Seattle; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center				Kanter, Andrew/0000-0002-4019-7894				BRENNER DJ, 1993, INT J SYST BACTERIOL, V43, P777, DOI 10.1099/00207713-43-4-777; BRENNER DJ, 1982, J CLIN MICROBIOL, V15, P1133, DOI 10.1128/JCM.15.6.1133-1140.1982; DOLAN MJ, 1993, ANN INTERN MED, V118, P331, DOI 10.7326/0003-4819-118-5-199303010-00002; HADFIELD TL, 1993, HUM PATHOL, V24, P1140, DOI 10.1016/0046-8177(93)90196-N; KOEHLER JE, 1993, CLIN INFECT DIS, V17, P612, DOI 10.1093/clinids/17.4.612; KOEHLER JE, 1994, JAMA-J AM MED ASSOC, V271, P531, DOI 10.1001/jama.271.7.531; KOEHLER JE, 1992, NEW ENGL J MED, V327, P1625, DOI 10.1056/NEJM199212033272303; LARSON AM, 1994, J CLIN MICROBIOL, V32, P1492, DOI 10.1128/JCM.32.6.1492-1496.1994; LUCEY D, 1992, CLIN INFECT DIS, V14, P683, DOI 10.1093/clinids/14.3.683; MATAR GM, 1993, J CLIN MICROBIOL, V31, P1730, DOI 10.1128/JCM.31.7.1730-1734.1993; MAURIN M, 1994, J CLIN MICROBIOL, V32, P1166, DOI 10.1128/JCM.32.5.1166-1171.1994; MYERS WF, 1984, ANTIMICROB AGENTS CH, V25, P690, DOI 10.1128/AAC.25.6.690; PERKOCHA LA, 1990, NEW ENGL J MED, V323, P1581, DOI 10.1056/NEJM199012063232302; RAOULT D, 1994, LANCET, V343, P977, DOI 10.1016/S0140-6736(94)90102-3; REGNERY RL, 1992, J CLIN MICROBIOL, V30, P265, DOI 10.1128/JCM.30.2.265-274.1992; RELMAN DA, 1991, NEW ENGL J MED, V324, P1514; RELMAN DA, 1990, NEW ENGL J MED, V323, P1573, DOI 10.1056/NEJM199012063232301; SCHWARTZMAN WA, 1992, CLIN INFECT DIS, V15, P893, DOI 10.1093/clind/15.6.893; SLATER LN, 1990, NEW ENGL J MED, V323, P1587, DOI 10.1056/NEJM199012063232303; SLATER LN, 1992, ARCH INTERN MED, V152, P602, DOI 10.1001/archinte.152.3.602; SLATER LN, 1992, J CLIN MICROBIOL, V30, P1722, DOI 10.1128/JCM.30.7.1722-1727.1992; SLATER LN, 1995, PRINCIPLES PRACTICE, P1741; SPACH DH, 1993, J CLIN MICROBIOL, V31, P692, DOI 10.1128/JCM.31.3.692-694.1993; SPACH DH, IN PRESS CLIN INFECT; TAPPERO JW, 1993, ANN INTERN MED, V118, P363, DOI 10.7326/0003-4819-118-5-199303010-00007; VINSON JW, 1969, AM J TROP MED HYG, V18, P713, DOI 10.4269/ajtmh.1969.18.713; WELCH DF, 1992, J CLIN MICROBIOL, V30, P275, DOI 10.1128/JCM.30.2.275-280.1992; ZANGWILL KM, 1993, NEW ENGL J MED, V329, P8, DOI 10.1056/NEJM199307013290102	28	196	204	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 16	1995	332	7					424	428		10.1056/NEJM199502163320703	http://dx.doi.org/10.1056/NEJM199502163320703			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF770	7529895				2022-12-24	WOS:A1995QF77000003
J	BJORO, K; FROLAND, SS; YUN, ZB; SAMDAL, HH; HAALAND, T				BJORO, K; FROLAND, SS; YUN, ZB; SAMDAL, HH; HAALAND, T			HEPATITIS-C INFECTION IN PATIENTS WITH PRIMARY HYPOGAMMAGLOBULINEMIA AFTER TREATMENT WITH CONTAMINATED IMMUNE GLOBULIN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NON-B-HEPATITIS; NON-A-HEPATITIS; INTRAVENOUS GAMMA-GLOBULIN; ALPHA-INTERFERON THERAPY; VIRUS HCV RNA; BLOOD-DONORS; IMMUNOGLOBULIN; SERUM; DEFICIENCY; GENOTYPES	Background. In Scandinavia many patients with primary hypogammaglobulinemia contracted non-A, non-B hepatitis after intravenous treatment with an immune globulin product that was later found to contain a non-A, non-B hepatitis virus. Methods. We studied the prevalence and clinical course of hepatitis C virus (HCV) infection in a group of 55 Norwegian patients with primary hypogammaglobulinemia and investigated its association with the use of contaminated immune globulin. We used the polymerase chain reaction to detect HCV RNA and performed HCV genotyping. We also analyzed the responses to treatment with interferon. Results. Of 20 patients who received the contaminated immune globulin, 17 were seropositive for HCV RNA, In addition, 1 of 35 patients not exposed to the contaminated immune globulin was HCV RNA-positive. HCV genotype V was found in all 12 patients for whom genotyping was performed, but 8 patients also had genotype II or III, or both. All HCV RNA-positive patients had abnormal results on biochemical liver tests. All liver-biopsy specimens (from 15 patients) were abnormal, with portal inflammation, bile-duct damage, and focal necrosis. In six patients there was cirrhosis. Two patients died of liver failure. In 4 of the 10 patients treated with interferon there were complete, though transient, biochemical responses, but the follow-up biopsy specimens showed evidence of histologic progression. The poorest responses to interferon were among the patients with multiple HCV genotypes. All but one patient remained positive for HCV RNA. Conclusions. In patients with primary hypogammaglobulinemia there was a high rate of HCV infection after treatment with contaminated immune globulin. In these immunocompromised patients HCV infection has a severe and rapidly progressive course, and responses to interferon are poor.	NATL HOSP NORWAY, DEPT MED A, HEPATOL & GASTROENTEROL SECT, N-0027 OSLO, NORWAY; NATL HOSP NORWAY, DEPT PATHOL, N-0027 OSLO, NORWAY; NATL INST PUBL HLTH, DEPT VIROL, OSLO, NORWAY; KAROLINSKA INST, HUDDINGE HOSP, INST CLIN VIROL, S-10401 STOCKHOLM, SWEDEN	University of Oslo; National Hospital Norway; University of Oslo; National Hospital Norway; Karolinska Institutet	BJORO, K (corresponding author), NATL HOSP NORWAY, DEPT MED A, CLIN IMMUNOL & INFECT DIS SECT, N-0027 OSLO, NORWAY.							ALTER HJ, 1992, VIRAL HEPATITIS LIVE, P396; AUKRUST P, 1992, CLIN EXP IMMUNOL, V89, P211; BJORKANDER J, 1988, AM J MED, V84, P107, DOI 10.1016/0002-9343(88)90016-2; CHEMELLO L, 1994, NEW ENGL J MED, V330, P143, DOI 10.1056/NEJM199401133300215; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUNNINGHAMRUNDLES C, 1989, J CLIN IMMUNOL, V9, P22, DOI 10.1007/BF00917124; DUSHEIKO G, 1994, HEPATOLOGY, V19, P13, DOI 10.1016/0270-9139(94)90046-9; FORBES A, 1993, GUT, V34, P116, DOI 10.1136/gut.34.1.116; GARSON JA, 1991, LANCET, V338, P1466, DOI 10.1016/0140-6736(91)92775-W; GEROLAMI V, 1993, J INFECT DIS, V168, P1328, DOI 10.1093/infdis/168.5.1328; HAGIWARA H, 1992, HEPATOLOGY, V15, P37, DOI 10.1002/hep.1840150108; IWARSON S, 1987, SERODIAGN IMMUNOTHER, V1, P261; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; LANE RS, 1983, LANCET, V2, P974; LEVER AML, 1984, LANCET, V2, P1062; NORDOY I, 1994, SCAND J GASTROENTERO, V29, P77, DOI 10.3109/00365529409090441; OKAMOTO H, 1993, J GEN VIROL, V74, P2385, DOI 10.1099/0022-1317-74-11-2385; REINHERZ EL, 1979, NEW ENGL J MED, V301, P1018, DOI 10.1056/NEJM197911083011902; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; SHINDO M, 1991, ANN INTERN MED, V115, P700, DOI 10.7326/0003-4819-115-9-700; SIMMONDS P, 1993, J GEN VIROL, V74, P2391, DOI 10.1099/0022-1317-74-11-2391; SKAUG K, 1993, VOX SANG, V64, P215, DOI 10.1111/j.1423-0410.1993.tb03058.x; SPICKETT GP, 1991, LANCET, V337, P281, DOI 10.1016/0140-6736(91)90882-P; THOMSON BJ, 1987, LANCET, V1, P539; TINE F, 1991, J HEPATOL, V13, P192, DOI 10.1016/0168-8278(91)90814-R; WEBSTER ADB, 1988, IMMUNOL INVEST, V17, P93, DOI 10.3109/08820138809055722; WEBSTER ADB, 1986, LANCET, V1, P322; WEILAND O, 1986, LANCET, V1, P976; WILLIAMS PE, 1989, VOX SANG, V57, P15, DOI 10.1111/j.1423-0410.1989.tb04977.x; YEI S, 1992, TRANSFUSION, V32, P824, DOI 10.1046/j.1537-2995.1992.32993110753.x; YUN ZB, 1993, J MED VIROL, V39, P57, DOI 10.1002/jmv.1890390111; 1989, IMMUNODEFIC REV, V1, P173	32	336	340	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 15	1994	331	24					1607	1611		10.1056/NEJM199412153312402	http://dx.doi.org/10.1056/NEJM199412153312402			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW446	7526215				2022-12-24	WOS:A1994PW44600002
J	MUTIMER, DJ; HARRISON, RF; ODONNELL, KB; SHAW, J; MARTIN, BAB; ATRAH, H; ALA, FA; SKIDMORE, S; HUBSCHER, SG; NEUBERGER, JM; ELIAS, E				MUTIMER, DJ; HARRISON, RF; ODONNELL, KB; SHAW, J; MARTIN, BAB; ATRAH, H; ALA, FA; SKIDMORE, S; HUBSCHER, SG; NEUBERGER, JM; ELIAS, E			HEPATITIS-C IN ASYMPTOMATIC BRITISH BLOOD-DONORS WITH INDETERMINATE SEROPOSITIVITY	BRITISH MEDICAL JOURNAL			English	Article							VIRUS		UNIV BIRMINGHAM,DEPT PATHOL,BIRMINGHAM,ENGLAND; UNIV BIRMINGHAM,DEPT INFECT,BIRMINGHAM,ENGLAND; W MIDLANDS REG HLTH AUTHOR,BLOOD TRANSFUS SERV,BIRMINGHAM,W MIDLANDS,ENGLAND; REG VIROL LABS,E BIRMINGHAM,ENGLAND	University of Birmingham; University of Birmingham	MUTIMER, DJ (corresponding author), QUEEN ELIZABETH HOSP,LIVER UNIT,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND.		Neuberger, James/ABG-3010-2020					CHEMELLO L, 1993, HEPATOLOGY, V17, P179, DOI 10.1002/hep.1840170203; FOLLETT EAC, 1992, LANCET, V339, P928, DOI 10.1016/0140-6736(92)90964-5; IRVING WL, 1994, BRIT MED J, V308, P695, DOI 10.1136/bmj.308.6930.695; SCHEUER PJ, 1992, HEPATOLOGY, V15, P567, DOI 10.1002/hep.1840150402; SERFATY L, 1993, HEPATOLOGY, V17, P183, DOI 10.1002/hep.1840170204	5	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 1	1994	309	6958					847	848		10.1136/bmj.309.6958.847	http://dx.doi.org/10.1136/bmj.309.6958.847			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK501	7524875	Green Published			2022-12-24	WOS:A1994PK50100023
J	BENSIMON, A; SIMON, A; CHIFFAUDEL, A; CROQUETTE, V; HESLOT, F; BENSIMON, D				BENSIMON, A; SIMON, A; CHIFFAUDEL, A; CROQUETTE, V; HESLOT, F; BENSIMON, D			ALIGNMENT AND SENSITIVE DETECTION OF DNA BY A MOVING INTERFACE	SCIENCE			English	Article							NUCLEIC-ACIDS; GEL-ELECTROPHORESIS; MAGNETIC BEADS; MOLECULES; HYBRIDIZATION; MICROSCOPY; ASSEMBLIES	In a process called ''molecular combing,'' DNA molecules attached at one end to a solid surface were extended and aligned by a receding air-water interface and left to dry on the surface. Molecular combing was observed to extend the length of the bacteriophage lambda DNA molecule to 21.5 +/- 0.5 micrometers (unextended length, 16.2 micrometers). With the combing process, it was possible to (i) extend a chromosomal Escherichia coli DNA fragment (10(6) base pairs) and (ii) detect a minute quantity of DNA (10(3) molecules). These results open the way for a faster physical mapping of the genome and for the detection of small quantities of target DNA from a population of molecules.	ECOLE NORMALE SUPER,PHYS STAT LAB,F-75005 PARIS,FRANCE; ECOLE NORMALE SUPER,PHYS MAT CONDENSEE LAB,F-75005 PARIS,FRANCE	UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	BENSIMON, A (corresponding author), INST PASTEUR,F-75015 PARIS,FRANCE.		heslot, françois/AAF-9406-2021; Bensimon, David/E-7768-2015	Bensimon, David/0000-0003-1971-9907; Croquette, Vincent/0000-0003-1400-0039				BENSIMON D, UNPUB; BRZOSKA JB, 1992, NATURE, V360, P719, DOI 10.1038/360719a0; BUSTAMANTE C, 1993, CURR OPIN STRUC BIOL, V3, P363, DOI 10.1016/S0959-440X(05)80107-1; CHU S, 1991, SCIENCE, V253, P861, DOI 10.1126/science.253.5022.861; DICKERSON RE, 1983, COLD SPRING HARB SYM, V47, P13; GUESDON JL, 1992, J IMMUNOL METHODS, V150, P33, DOI 10.1016/0022-1759(92)90063-Y; HOUSEAL TW, 1989, BIOPHYS J, V56, P507, DOI 10.1016/S0006-3495(89)82697-9; INNIS MA, 1990, PCR PROTOCOLS; ISRAELACHVILI JN, 1985, INTERMOLECULAR SURFA, P24; KABATA H, 1993, SCIENCE, V262, P1561, DOI 10.1126/science.8248804; LABROUSSE H, 1982, J IMMUNOL METHODS, V48, P133, DOI 10.1016/0022-1759(82)90188-0; LANGDALE JA, 1985, GENE, V36, P201, DOI 10.1016/0378-1119(85)90175-1; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; LUND V, 1988, NUCLEIC ACIDS RES, V16, P10861, DOI 10.1093/nar/16.22.10861; NETZER L, 1983, J AM CHEM SOC, V105, P674, DOI 10.1021/ja00341a087; PARRA I, 1993, NAT GENET, V5, P17, DOI 10.1038/ng0993-17; PERKINS TT, 1994, SCIENCE, V264, P819, DOI 10.1126/science.8171335; PERKINS TT, 1994, SCIENCE, V264, P822, DOI 10.1126/science.8171336; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SCHWARTZ DC, 1993, SCIENCE, V262, P110, DOI 10.1126/science.8211116; SCHWARTZ DC, 1989, NATURE, V338, P520, DOI 10.1038/338520a0; SMITH SB, 1992, SCIENCE, V258, P1122, DOI 10.1126/science.1439819; SMITH SB, 1989, SCIENCE, V243, P203, DOI 10.1126/science.2911733; VOLKMUTH WD, 1992, NATURE, V358, P600, DOI 10.1038/358600a0; Yanagida M, 1983, Cold Spring Harb Symp Quant Biol, V47 Pt 1, P177; YANAGIDA M, 1986, APPLICATIONS FLUORES, P321; ZIMMERMANN RM, 1994, NUCLEIC ACIDS RES, V22, P492, DOI 10.1093/nar/22.3.492	27	691	767	3	134	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 30	1994	265	5181					2096	2098		10.1126/science.7522347	http://dx.doi.org/10.1126/science.7522347			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PJ912	7522347				2022-12-24	WOS:A1994PJ91200031
J	MARENGERE, LEM; ZHOU, SY; GISH, GD; SCHALLER, MD; PARSONS, JT; STERN, MJ; CANTLEY, LC; PAWSON, T				MARENGERE, LEM; ZHOU, SY; GISH, GD; SCHALLER, MD; PARSONS, JT; STERN, MJ; CANTLEY, LC; PAWSON, T			SH2 DOMAIN SPECIFICITY AND ACTIVITY MODIFIED BY A SINGLE RESIDUE	NATURE			English	Article							TYROSINE-PHOSPHORYLATED PEPTIDES; AFFINITY PHOSPHOTYROSYL PEPTIDE; GROWTH-FACTOR RECEPTORS; SIGNALING GENE SEM-5; TRANSFORMING PROTEIN; SRC; BINDING; GRB2; TRANSDUCTION; RECOGNITION	MANY intracellular targets of protein-tyrosine kinases possess Src homology 2 (SH2) domains that directly recognize phosphotyrosine-containing sites on autophosphorylated growth factor receptors and cytoplasmic proteins, and thereby mediate the activation of biochemical signalling pathways(1-7) SH2 domains possess relatively well conserved residues that form the phosphotyrosine-binding pocket(8-11), and more variable residues that are implicated in determining binding specificity by recognition of the three amino acids carboxy-terminal to phosphotyrosine (the +1 to +3 positions)(5,7,12,13). One such residue, occupying the EF1 position of the +3-binding pocket, is a Thr in the SH2 domain of the Src tyrosine kinase(12), but is predicted to be a Trp in the SH2 domain of the Sem-5/drk/Grb2 adaptor protein(5). Here eve report that changing this residue in the Src SH2 domain from Thr to Trp switches its selectivity to resemble that of the Sem-5-/drk/Grb2 SH2 domain. Furthermore, this mutant Src SH2 domain effectively substitutes for the SH2 domain of the Sem-5 protein in activation of the Ras pathway in vivo. These results identify a residue that can modify SH2 selectivity, and indicate that the biological activity of an SH2 domain correlates with its binding specificity.	UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO M5S 1A8, ON, CANADA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, DEPT MED, BOSTON, MA 02115 USA; UNIV VIRGINIA, DEPT MICROBIOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, CTR CANC, CHARLOTTESVILLE, VA 22908 USA; YALE UNIV, BOYER CTR MOLEC MED, NEW HAVEN, CT 06536 USA	University of Toronto; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; University of Virginia; University of Virginia; Yale University	MARENGERE, LEM (corresponding author), MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, 600 UNIV AVE, TORONTO M5G 1X5, ON, CANADA.		Pawson, Tony J/E-4578-2013; Cantley, Lewis C/D-1800-2014; Gish, Gerald D/C-7228-2017	Cantley, Lewis C/0000-0002-1298-7653; 				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COBB BS, 1984, MOL CELL BIOL, V14, P1147; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARENGERE LEM, 1992, J BIOL CHEM, V267, P22779; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PAWSON T, 1993, J CURR BIOL, V4, P434; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PUIL L, 1994, EMBO J, V764, P773; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STERN MJ, 1993, MOL BIOL CELL, V4, P1175, DOI 10.1091/mbc.4.11.1175; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	31	172	182	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 9	1994	369	6480					502	505		10.1038/369502a0	http://dx.doi.org/10.1038/369502a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NQ286	7515480	Green Submitted			2022-12-24	WOS:A1994NQ28600062
J	KUPFER, A; AESCHLIMANN, C; WERMUTH, B; CERNY, T				KUPFER, A; AESCHLIMANN, C; WERMUTH, B; CERNY, T			PROPHYLAXIS AND REVERSAL OF IFOSFAMIDE ENCEPHALOPATHY WITH METHYLENE-BLUE	LANCET			English	Note								The antineoplastic ifosfamide produces dose-dependent signs of neurotoxicity. After ifosfamide overdose in a patient, we found excessive urinary excretion of glutaric acid and sarcosine, which is compatible with glutaric aciduria type II, a defect in mitochondrial fatty acid oxidation that results from defective electron transfer to flavoproteins. We therefore used the electron-accepting drug methylene-blue as an antidote for ifosfamide encephalopathy. In one patient, ifosfamide neurotoxicity was rapidly reversed by methylene-blue 50 mg intravenously. In another patient with previous episodes of ifosfamide encephalopathy, methylene-blue was administered orally prophylactically. No symptoms of neurotoxicity were noted.	UNIV BERN,INSELSPITAL,DEPT CLIN CHEM,BERN,SWITZERLAND; UNIV HOSP BERNE,DEPT MED ONCOL,BERN,SWITZERLAND	University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern	KUPFER, A (corresponding author), UNIV BERN,DEPT CLIN PHARMACOL,MURTENSTR 35,CH-3010 BERN,SWITZERLAND.							BHAT HK, 1991, TOXICOL LETT, V59, P203, DOI 10.1016/0378-4274(91)90073-F; CERNY T, 1992, ANN ONCOL, V3, P679, DOI 10.1093/oxfordjournals.annonc.a058317; GOODMAN SI, 1989, METABOLIC BASIS INHE, V1, P915; HARPEY JP, 1986, LANCET, V1, P391; KUPFER A, 1990, LANCET, V335, P1461, DOI 10.1016/0140-6736(90)91487-U; KUPFER A, 1990, N-S ARCH PHARMACOL S, V342, pR20; PETERS RA, 1952, PROC R SOC SER B-BIO, V139, P143, DOI 10.1098/rspb.1952.0001; SOOD C, 1993, BIOCHEM PHARMACOL, V46, P1621, DOI 10.1016/0006-2952(93)90332-Q; WOLFF SN, 1990, SEMIN ONCOL, V17, P2	9	138	138	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 26	1994	343	8900					763	764		10.1016/S0140-6736(94)91839-2	http://dx.doi.org/10.1016/S0140-6736(94)91839-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC351	7510815				2022-12-24	WOS:A1994NC35100011
J	HUANG, PL; DAWSON, TM; BREDT, DS; SNYDER, SH; FISHMAN, MC				HUANG, PL; DAWSON, TM; BREDT, DS; SNYDER, SH; FISHMAN, MC			TARGETED DISRUPTION OF THE NEURONAL NITRIC-OXIDE SYNTHASE GENE	CELL			English	Article							LONG-TERM POTENTIATION; HYPERTROPHIC PYLORIC-STENOSIS; RAT ANOCOCCYGEUS MUSCLE; MONOMETHYL-L-ARGININE; NADPH-DIAPHORASE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; HUNTINGTONS-DISEASE; ADP-RIBOSYLATION; STRIATAL NEURONS; PENILE ERECTION	By homologous recombination, we have generated mice that lack the neuronal nitric oxide synthase (NOS) gene. Neuronal NOS expression and NADPH-diaphorase (NDP) staining are absent in the mutant mice. Very low level residual catalytic activity suggests that other enzymes in the brain may generate nitric oxide. The neurons normally expressing NOS appear intact, and the mutant NOS mice are viable, fertile, and without evident histopathological abnormalities in the central nervous system. The most evident effect of disrupting the neuronal NOS gene is the development of grossly enlarged stomachs, with hypertrophy of the pyloric sphincter and the circular muscle layer. This phenotype resembles the human disorder infantile pyloric stenosis, in which gastric outlet obstruction is associated with the lack of NDP neurons in the pylorus.	JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROSCI, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PHARMACOL & MOLEC SCI, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PSYCHIAT & BEHAV SCI, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROL, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	HUANG, PL (corresponding author), MASSACHUSETTS GEN HOSP, CARDIOVASC RES CTR, BOSTON, MA 02129 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002792] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH018501, R37MH018501] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001578] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-02792-02] Funding Source: Medline; NIMH NIH HHS [MH-18501] Funding Source: Medline; NINDS NIH HHS [CIDA NS-01578] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BEAL MF, 1986, NATURE, V321, P168, DOI 10.1038/321168a0; BOECKXSTAENS GE, 1991, BRIT J PHARMACOL, V102, P434, DOI 10.1111/j.1476-5381.1991.tb12191.x; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1991, NEURON, V7, P615, DOI 10.1016/0896-6273(91)90374-9; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BRESLOW MJ, 1987, AM J PHYSIOL, V252, pH521, DOI 10.1152/ajpheart.1987.252.3.H521; BRESLOW MJ, 1992, EUR J PHARMACOL, V87, P682; BULT H, 1990, NATURE, V345, P3469; BURNETT AL, 1992, SCIENCE, V257, P401, DOI 10.1126/science.1378650; DAWSON TM, 1992, ANN NEUROL, V32, P297, DOI 10.1002/ana.410320302; DAWSON TM, 1991, P NATL ACAD SCI USA, V88, P7797, DOI 10.1073/pnas.88.17.7797; DAWSON VL, 1993, J NEUROSCI, V13, P2651; DESAI KM, 1991, NATURE, V351, P477, DOI 10.1038/351477a0; DICKIE BGM, 1992, NEUROSCI LETT, V138, P145, DOI 10.1016/0304-3940(92)90492-P; DIMMELER S, 1992, J BIOL CHEM, V267, P16771; EDELMAN GM, 1992, P NATL ACAD SCI USA, V89, P11651, DOI 10.1073/pnas.89.24.11651; FARACI FM, 1992, PHARMACOL THERAPEUT, V56, P1, DOI 10.1016/0163-7258(92)90035-X; FERRANTE RJ, 1985, SCIENCE, V230, P561, DOI 10.1126/science.2931802; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; GALLY JA, 1990, P NATL ACAD SCI USA, V87, P3547, DOI 10.1073/pnas.87.9.3547; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GHOSH A, 1992, SCIENCE, V255, P1441, DOI 10.1126/science.1542795; GIBSON A, 1990, BRIT J PHARMACOL, V99, P602, DOI 10.1111/j.1476-5381.1990.tb12976.x; GILLESPIE JS, 1989, BRIT J PHARMACOL, V98, P1080, DOI 10.1111/j.1476-5381.1989.tb12650.x; HALEY JE, 1992, NEURON, V8, P211, DOI 10.1016/0896-6273(92)90288-O; HANBAUER I, 1992, NEUROREPORT, V3, P409, DOI 10.1097/00001756-199205000-00008; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HIRSCH DP, 1993, IN PRESS CURR BIOL; HOPE BT, 1991, P NATL ACAD SCI USA, V88, P2811, DOI 10.1073/pnas.88.7.2811; IADECOLA C, 1993, TRENDS NEUROSCI, V16, P206, DOI 10.1016/0166-2236(93)90156-G; IGNARRO LJ, 1989, FASEB J, V3, P31, DOI 10.1096/fasebj.3.1.2642868; KOH JY, 1986, SCIENCE, V234, P73, DOI 10.1126/science.2875522; KOTS AY, 1992, FEBS LETT, V300, P9, DOI 10.1016/0014-5793(92)80153-8; LE E, 1992, CELL, V69, P915; LI CG, 1990, EUR J PHARMACOL, V191, P303; LONART G, 1992, EUR J PHARMACOL, V220, P271, DOI 10.1016/0014-2999(92)90759-W; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MARLETTA MA, 1989, TRENDS BIOCHEM SCI, V14, P88; MCDONALD LJ, 1993, P NATL ACAD SCI USA, V90, P6238, DOI 10.1073/pnas.90.13.6238; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NOZAKI K, 1993, J CEREBR BLOOD F MET, V13, P70, DOI 10.1038/jcbfm.1993.9; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; POLAK JM, 1981, LANCET, V2, P217; PRADO R, 1992, STROKE, V23, P1118, DOI 10.1161/01.STR.23.8.1118; RAJFER J, 1992, NEW ENGL J MED, V326, P90, DOI 10.1056/NEJM199201093260203; RAMAGOPAL MV, 1989, EUR J PHARMACOL, V174, P297, DOI 10.1016/0014-2999(89)90325-7; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SHIBUKI K, 1991, NATURE, V349, P326, DOI 10.1038/349326a0; SNYDER SH, 1992, SCIENCE, V257, P494, DOI 10.1126/science.1353273; SPICER RD, 1982, BRIT J SURG, V69, P128, DOI 10.1002/bjs.1800690304; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STEVENS CF, 1993, NATURE, V364, P147, DOI 10.1038/364147a0; THOMAS E, 1961, HISTOCHEMISTRY, V2, P266, DOI 10.1007/BF00736504; THOMAS E., 1964, ACTA NEUROPATHOL, V3, P238; TODA N, 1990, BIOCHEM BIOPH RES CO, V170, P308, DOI 10.1016/0006-291X(90)91275-W; TOTTRUP A, 1991, AM J PHYSIOL, V260, pG385, DOI 10.1152/ajpgi.1991.260.3.G385; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; UEMURA Y, 1990, ANN NEUROL, V27, P620, DOI 10.1002/ana.410270606; VANDERWINDEN JM, 1992, NEW ENGL J MED, V327, P511, DOI 10.1056/NEJM199208203270802; VINCENT SR, 1983, J COMP NEUROL, V217, P252, DOI 10.1002/cne.902170303; WHITTLE BJR, 1992, ANN NY ACAD SCI, V664, P126, DOI 10.1111/j.1749-6632.1992.tb39755.x; WILCOX CS, 1992, P NATL ACAD SCI USA, V89, P11993, DOI 10.1073/pnas.89.24.11993; WILLIS EA, 1983, LIFE SCI, V33, P383, DOI 10.1016/S0024-3205(83)80013-7; ZHANG J, 1992, P NATL ACAD SCI USA, V89, P9382, DOI 10.1073/pnas.89.20.9382; ZHU XZ, 1992, J NEUROCHEM, V59, P932, DOI 10.1111/j.1471-4159.1992.tb08332.x; ZHUO M, 1993, SCIENCE, V260, P1946, DOI 10.1126/science.8100368	71	1133	1155	1	14	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	DEC 31	1993	75	7					1273	1286		10.1016/0092-8674(93)90615-W	http://dx.doi.org/10.1016/0092-8674(93)90615-W			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MP869	7505721				2022-12-24	WOS:A1993MP86900007
J	DOLE, VP				DOLE, VP			ON FEDERAL-REGULATION OF METHADONE TREATMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MAINTENANCE				DOLE, VP (corresponding author), ROCKEFELLER UNIV,1230 YORK AVE,NEW YORK,NY 10021, USA.							[Anonymous], 1995, FEDERAL REGULATION M; COOPER JR, 1995, JAMA-J AM MED ASSOC, V273, P1619, DOI 10.1001/jama.273.20.1619; DOLE VP, 1982, NEW ENGL J MED, V306, P169, DOI 10.1056/NEJM198201213060310; DOLE VP, 1992, JAMA-J AM MED ASSOC, V267, P2234, DOI 10.1001/jama.267.16.2234	4	9	9	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 25	1995	274	16					1307	1307						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA104	7563538				2022-12-24	WOS:A1995TA10400028
J	OSSIPOW, V; TASSAN, JP; NIGG, EA; SCHIBLER, U				OSSIPOW, V; TASSAN, JP; NIGG, EA; SCHIBLER, U			A MAMMALIAN RNA-POLYMERASE-II HOLOENZYME CONTAINING ALL COMPONENTS REQUIRED FOR PROMOTER-SPECIFIC TRANSCRIPTION INITIATION	CELL			English	Article							TATA-BINDING PROTEIN; ALBUMIN GENE; BASAL TRANSCRIPTION; CATALYTIC SUBUNIT; ACTIVATION DOMAIN; PHOSPHORYLATION; EXPRESSION; KINASE; P40(MO15); P34(CDC2)	The protein kinase MO15/CDK7 has recently been shown to be associated with the general transcription factor TFIIH and to be capable of phosphorylating the RNA polymerase II carboxy-terminal domain. Here, we show that a monoclonal MO15/CDK7 antibody coimmunoprecipitates, from a rat liver nuclear extract, all components of the RNA polymerase II transcription apparatus required for initiation at the albumin and adenovirus major late promoters. The immunoprecipitate includes RNA polymerase II, TFIID, TFIIB, TFIIH, TFIIF, and TFIIE, but is devoid of transcriptional activator proteins, such as HNF1, HNF4, and C/EBP alpha. The finding of an autonomously initiating RNA polymerase II holoenzyme in mammalian cells suggests conceptual similarities between transcription initiation in prokaryotes and eukaryotes.	INST SUISSE RECH EXPTL CANC,CH-1066 EPALINGES,SWITZERLAND		OSSIPOW, V (corresponding author), UNIV GENEVA,DEPT BIOL MOLEC SCI 2,CH-1211 GENEVA 4,SWITZERLAND.			nigg, erich/0000-0003-4835-5719				BUSBY S, 1994, CELL, V79, P743, DOI 10.1016/0092-8674(94)90063-9; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CHIANG SY, 1994, BIOCHEMISTRY-US, V33, P7033, DOI 10.1021/bi00189a003; CORDEN JL, 1993, CURR OPIN GENET DEV, V3, P213, DOI 10.1016/0959-437X(93)90025-K; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; DAHMUS ME, 1994, PROG NUCLEIC ACID RE, V48, P143, DOI 10.1016/S0079-6603(08)60855-7; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DRAPKIN R, 1994, TRENDS BIOCHEM SCI, V19, P504, DOI 10.1016/0968-0004(94)90139-2; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EICK D, 1994, TRENDS GENET, V10, P292, DOI 10.1016/0168-9525(90)90013-V; EMILI A, 1995, CURR OPIN GENET DEV, V5, P204, DOI 10.1016/0959-437X(95)80009-3; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISCHER L, 1992, SCIENCE, V257, P1392, DOI 10.1126/science.1529339; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GERBER HP, 1995, NATURE, V374, P660, DOI 10.1038/374660a0; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HEARD JM, 1987, MOL CELL BIOL, V7, P2425, DOI 10.1128/MCB.7.7.2425; KIM TK, 1994, P NATL ACAD SCI USA, V91, P4170, DOI 10.1073/pnas.91.10.4170; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KNAUS R, 1990, NUCLEIC ACIDS MOL BI, V4, P110; KOKUBO T, 1994, NATURE, V367, P484, DOI 10.1038/367484a0; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1989, GENE DEV, V2, P786; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; LICHTSTEINER S, 1989, CELL, V57, P1179, DOI 10.1016/0092-8674(89)90055-X; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MALDONADO E, 1995, CURR OPIN CELL BIOL, V7, P352, DOI 10.1016/0955-0674(95)80090-5; MCCLURE WR, 1980, P NATL ACAD SCI-BIOL, V77, P5634, DOI 10.1073/pnas.77.10.5634; MENENDEZ M, 1987, EMBO J, V6, P4227, DOI 10.1002/j.1460-2075.1987.tb02771.x; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PETERSON SR, 1992, GENE DEV, V6, P426, DOI 10.1101/gad.6.3.426; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; ROBERTS SGE, 1994, NATURE, V371, P717, DOI 10.1038/371717a0; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; TIAN JM, 1991, GENE DEV, V5, P2225, DOI 10.1101/gad.5.12a.2225; TRUANT R, 1993, J BIOL CHEM, V268, P2284; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; WUARIN J, 1994, MOL CELL BIOL, V14, P7219, DOI 10.1128/MCB.14.11.7219; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.bi.60.070191.003353; ZHU KY, 1994, BIOTECHNIQUES, V18, P222	61	181	182	0	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 6	1995	83	1					137	146		10.1016/0092-8674(95)90242-2	http://dx.doi.org/10.1016/0092-8674(95)90242-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RY583	7553866	Bronze			2022-12-24	WOS:A1995RY58300018
J	TELLING, GC; SCOTT, M; MASTRIANNI, J; GABIZON, R; TORCHIA, M; COHEN, FE; DEARMOND, SJ; PRUSINER, SB				TELLING, GC; SCOTT, M; MASTRIANNI, J; GABIZON, R; TORCHIA, M; COHEN, FE; DEARMOND, SJ; PRUSINER, SB			PRION PROPAGATION IN MICE EXPRESSING HUMAN AND CHIMERIC PRP TRANSGENES IMPLICATES THE INTERACTION OF CELLULAR PRP WITH ANOTHER PROTEIN	CELL			English	Article							CREUTZFELDT-JAKOB DISEASE; GERSTMANN-STRAUSSLER SYNDROME; CULTURED-CELLS; MISSENSE VARIANT; SCRAPIE ISOFORM; REPLICATION; CONVERSION; FORM	Transgenic (Tg) mice expressing human (Hu) and chimeric prion protein (PrP) genes were inoculated with brain extracts from humans with inherited or sporadic prion disease to investigate the mechanism by which PrPC is transformed into PrPSc. Although Tg(HuPrP) mice expressed high levels of HUPrPC, they were resistant to human prions, They became susceptible to human prions upon ablation of the mouse (Mo) PrP gene. In contrast, mice expressing low levels of the chimeric transgene were susceptible to human prions and registered only a modest decrease in incubation times upon MoPrP gene disruption. These and other findings argue that a species-specific macromolecule, provisionally designated protein X, participates in prion formation. While the results demonstrate that PrPSc binds to PrPC in a region delimited by codons 96 to 167, they also suggest that PrPC binds protein X through residues near the C-terminus. Protein X might function as a molecular chaperone in the formation of PrPSc.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MOLEC & CELLULAR PHARMACOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PATHOL, SAN FRANCISCO, CA 94143 USA; HADASSAH UNIV HOSP, DEPT NEUROL, IL-91120 JERUSALEM, ISRAEL	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Hebrew University of Jerusalem	TELLING, GC (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT NEUROL, SAN FRANCISCO, CA 94143 USA.		Telling, Glenn C/G-1217-2019	Telling, Glenn C/0000-0002-6294-1805				BESSEN RA, 1995, NATURE, V375, P698, DOI 10.1038/375698a0; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; BROWN P, 1994, ANN NEUROL, V35, P513, DOI 10.1002/ana.410350504; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; CARLSON GA, 1994, P NATL ACAD SCI USA, V91, P5690, DOI 10.1073/pnas.91.12.5690; CARLSON GA, 1986, CLIN RES, V34, pA675; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CHANDLER RL, 1961, LANCET, V1, P1378; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; COHEN FE, 1994, SCIENCE, V264, P530, DOI 10.1126/science.7909169; GABIZON R, 1993, AM J HUM GENET, V53, P828; GAJDUSEK DC, 1966, NATURE, V209, P794, DOI 10.1038/209794a0; GAJDUSEK DC, 1993, BRIT MED BULL, V49, P913, DOI 10.1093/oxfordjournals.bmb.a072653; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; HECKER R, 1992, GENE DEV, V6, P1213, DOI 10.1101/gad.6.7.1213; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; HSIAO KK, 1994, P NATL ACAD SCI USA, V91, P9126, DOI 10.1073/pnas.91.19.9126; HSIAO KK, 1990, SCIENCE, V250, P1587, DOI 10.1126/science.1980379; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KITAMOTO T, 1991, NEUROLOGY, V41, P306, DOI 10.1212/WNL.41.2_Part_1.306; KOCISKO DA, 1995, P NATL ACAD SCI USA, V92, P3923, DOI 10.1073/pnas.92.9.3923; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; KURSCHNER C, 1995, MOL BRAIN RES, V30, P165, DOI 10.1016/0169-328X(95)00013-I; Liautard J P, 1993, Arch Virol Suppl, V7, P227; MANUELIDIS EE, 1978, P NATL ACAD SCI USA, V75, P3432, DOI 10.1073/pnas.75.7.3432; MCKINLEY MP, 1991, J VIROL, V65, P1340, DOI 10.1128/JVI.65.3.1340-1351.1991; MURAMOTO T, 1992, AM J PATHOL, V140, P1411; NGUYEN J, 1995, BIOCHEMISTRY-US, V34, P4186, DOI 10.1021/bi00013a006; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Pattison I. H., 1965, NINDB MONOGRAPH, V2, P249; PETERSEN RB, 1995, NEUROLOGY, V45, P1062, DOI 10.1212/WNL.45.6.1062; PRUSINER S B, 1987, P83; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P10608, DOI 10.1073/pnas.90.22.10608; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; RAEBER AJ, 1992, J VIROL, V66, P6155, DOI 10.1128/JVI.66.10.6155-6163.1992; ROGERS M, 1993, P NATL ACAD SCI USA, V90, P3182, DOI 10.1073/pnas.90.8.3182; SCOTT M, 1993, CELL, V73, P979, DOI 10.1016/0092-8674(93)90275-U; SCOTT M, 1989, CELL, V59, P847, DOI 10.1016/0092-8674(89)90608-9; SCOTT MR, 1992, PROTEIN SCI, V1, P986, DOI 10.1002/pro.5560010804; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; TAGLIAVINI F, 1994, CELL, V79, P695, DOI 10.1016/0092-8674(94)90554-1; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; TATEISHI J, 1995, BRAIN PATHOL, V5, P53, DOI 10.1111/j.1750-3639.1995.tb00577.x; TATEISHI J, 1983, PROG NEUROPATH, V5, P195; TATEISHI J, 1993, BRIT MED BULL, V49, P971, DOI 10.1093/oxfordjournals.bmb.a072656; TATZELT J, 1995, P NATL ACAD SCI USA, V92, P2944, DOI 10.1073/pnas.92.7.2944; TELLING GC, 1994, P NATL ACAD SCI USA, V91, P9936, DOI 10.1073/pnas.91.21.9936; WELLS GAH, 1995, BRAIN PATHOL, V5, P91, DOI 10.1111/j.1750-3639.1995.tb00580.x; WESTAWAY D, 1987, CELL, V51, P651, DOI 10.1016/0092-8674(87)90134-6; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; ZHANG H, 1995, J MOL BIOL, V250, P514, DOI 10.1006/jmbi.1995.0395	56	727	763	1	28	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 6	1995	83	1					79	90		10.1016/0092-8674(95)90236-8	http://dx.doi.org/10.1016/0092-8674(95)90236-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RY583	7553876	Bronze			2022-12-24	WOS:A1995RY58300012
J	PEUNOVA, N; ENIKOLOPOV, G				PEUNOVA, N; ENIKOLOPOV, G			NITRIC-OXIDE TRIGGERS A SWITCH TO GROWTH ARREST DURING DIFFERENTIATION OF NEURONAL CELLS	NATURE			English	Article							CENTRAL-NERVOUS-SYSTEM; SMOOTH-MUSCLE CELLS; RIBONUCLEOTIDE REDUCTASE; NADPH DIAPHORASE; SYNTHASE; PROLIFERATION; CLONING; MACROPHAGES; HEPATOCYTES; GENE	ARREST Of cell division is a prerequisite for cells to enter a program of terminal differentiation. Mitogenesis and cytostasis of neuronal cell precursors can be induced by the same or by different growth or trophic factors(1-9). Response of PC12 cells to nerve growth factor (NGF) involves a proliferative phase that is followed by growth arrest and differentiation. Here we present evidence that the cytostatic effect of NGF is mediated by nitric oxide (NO), a second messenger molecule with both para- and autocrine properties ties that can diffuse freely and act within a restricted volume(10-14). We show that NGF induces different forms of nitric oxide synthase (NOS) in neuronal cells, that nitric oxide (NO) acts as a cytostatic agent in these cells, that inhibition of NOS leads to reversal of NGF-induced cytostasis and thereby prevents full differentiation, and that capacity of a mutant cell line to differentiate can be rescued by exogenous NO, We suggest that induction of NOS is an important step in the commitment of neuronal precursors and that NOS serves as a growth arrest gene, initiating the switch to cytostasis during differentiation.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory			Enikolopov, Grigori/P-5731-2019; Enikolopov, Grigori N/B-7771-2009	Enikolopov, Grigori/0000-0001-8178-8917; Enikolopov, Grigori N/0000-0001-8178-8917				ANDERSON DJA, 1993, REV NEUROSCI, V16, P129; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BUCHKOVICH KJ, 1994, MOL BIOL CELL, V5, P1225, DOI 10.1091/mbc.5.11.1225; BURSTEIN DE, 1982, DEV BIOL, V94, P477, DOI 10.1016/0012-1606(82)90364-5; DAWSON TM, 1991, P NATL ACAD SCI USA, V88, P7797, DOI 10.1073/pnas.88.17.7797; DRAGO J, 1991, P NATL ACAD SCI USA, V88, P2199, DOI 10.1073/pnas.88.6.2199; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HIRSCH DB, 1993, CURR BIOL, V3, P749, DOI 10.1016/0960-9822(93)90022-G; HOGAN M, 1992, J CLIN INVEST, V90, P1110, DOI 10.1172/JCI115928; HOPE BT, 1991, P NATL ACAD SCI USA, V88, P2811, DOI 10.1073/pnas.88.7.2811; Jacobson M., 1991, DEV NEUROBIOLOGY; KWON NS, 1991, J EXP MED, V174, P761, DOI 10.1084/jem.174.4.761; LEPOIVRE M, 1991, BIOCHEM BIOPH RES CO, V179, P442, DOI 10.1016/0006-291X(91)91390-X; LILIEN LE, 1985, NATURE, V317, P632; MCKAY R, 1990, COLD SH Q B, V55, P291; MCKAY RDG, 1989, CELL, V58, P815, DOI 10.1016/0092-8674(89)90934-3; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NUNOKAWA Y, 1993, BIOCHEM BIOPH RES CO, V191, P89, DOI 10.1006/bbrc.1993.1188; PEUNOVA N, 1993, NATURE, V364, P450, DOI 10.1038/364450a0; RUDKIN BB, 1989, EMBO J, V8, P3319, DOI 10.1002/j.1460-2075.1989.tb08493.x; WOOD ER, 1993, BIOCHEM BIOPH RES CO, V191, P767, DOI 10.1006/bbrc.1993.1283; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	28	455	469	1	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 4	1995	375	6526					68	73		10.1038/375068a0	http://dx.doi.org/10.1038/375068a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW604	7536899				2022-12-24	WOS:A1995QW60400057
J	BEEKMAN, EM; PORCELLI, SA; MORITA, CT; BEHAR, SM; FURLONG, ST; BRENNER, MB				BEEKMAN, EM; PORCELLI, SA; MORITA, CT; BEHAR, SM; FURLONG, ST; BRENNER, MB			RECOGNITION OF A LIPID ANTIGEN BY CD1-RESTRICTED ALPHA-BETA(+) T-CELLS	NATURE			English	Article							LYMPHOCYTES-T; CORD FACTOR; PEPTIDES; BIOLOGY; GENES	MAJOR histocompatibility complex (MHC) class I and class II molecules bind immunogenic peptides and present them to lymphocytes bearing the alpha beta T-cell antigen receptor (TCR)(1-4). An analogous antigen-presenting function also has been proposed for the non-MHC-encoded CDI molecules: a family of non-polymorphic, beta(2)-microglobulin-associated glycoproteins(5-8) expressed on most professional antigen-presenting cells(9-11). In support of this hypothesis, CD1 molecules are recognized by selected CD4(-)CD8(-)alpha beta or gamma delta TCR(+) T-cell clones(12-14), and we have recently shown that CD1 molecules restrict the recognition of foreign microbial antigens by alpha beta TCR(+) T cells(10). But the substantial structural divergence of CD1 from MHC class I and class II molecules(7), raises the possibility that the antigens presented by the CD1 system may differ fundamentally from those presented by MHC-encoded molecules. Here we report that a purified CD1b-restricted antigen of Mycobacterium tuberculosis presented to alpha beta TCR(+) T cells is mycolic acid, a family of alpha-branched, beta-hydroxy, long-chain fatty acids found in mycobacteria(15-16). This example of non-protein microbial antigen recognition suggests that alpha beta TCR(+) T cells recognize a broader range of antigens than previously appreciated and that at least one member of the CD1 family has evolved the ability to present lipid antigens.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	BEEKMAN, EM (corresponding author), BRIGHAM & WOMENS HOSP, DEPT RHEUMATOL & IMMUNOL, LYMPHOCYTE BIOL SECT, BOSTON, MA 02115 USA.		Morita, Craig T/C-1365-2011	Morita, Craig T/0000-0001-8496-8294; Behar, Samuel/0000-0002-3374-6699				BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BALK SP, 1989, P NATL ACAD SCI USA, V86, P252, DOI 10.1073/pnas.86.1.252; BALK SP, 1991, SCIENCE, V253, P1411, DOI 10.1126/science.1716785; BEKIERKUNST A, 1971, SCIENCE, V174, P1240, DOI 10.1126/science.174.4015.1240; BOUMSELL L, 1989, LEUCOCYTE TYPING, V4, P251; BUUS S, 1986, CELL, V47, P1071, DOI 10.1016/0092-8674(86)90822-6; CALABI F, 1989, EUR J IMMUNOL, V19, P285, DOI 10.1002/eji.1830190211; CALABI F, 1986, NATURE, V323, P540, DOI 10.1038/323540a0; CHRISTIE WW, 1982, LIPID ANAL, P117; CONSTANT P, 1994, SCIENCE, V264, P267, DOI 10.1126/science.8146660; FAURE F, 1990, EUR J IMMUNOL, V20, P703, DOI 10.1002/eji.1830200336; FLING SP, 1994, NATURE, V368, P554, DOI 10.1038/368554a0; FLOYD MM, 1992, J CLIN MICROBIOL, V30, P1327, DOI 10.1128/JCM.30.5.1327-1330.1992; FOLCH J, 1957, J BIOL CHEM, V226, P497; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.iy.11.040193.002155; Goren M. B., 1979, TUBERCULOSIS, P63; LECHEVALIER MP, 1977, CRC CR REV MICROBIOL, V5, P109, DOI 10.3109/10408417709102311; MCNEIL M, 1991, J BIOL CHEM, V266, P13217; Minnikin D. E., 1980, MICROBIOLOGICAL CLAS, P189; MINNIKIN DE, 1982, BIOL MYCOBACTERIA, V1, P95; MORITA CT, 1991, EUR J IMMUNOL, V21, P2999, DOI 10.1002/eji.1830211215; MORRIS P, 1994, NATURE, V368, P551, DOI 10.1038/368551a0; PARANT M, 1978, INFECT IMMUN, V20, P12, DOI 10.1128/IAI.20.1.12-19.1978; PORCELLI S, 1991, IMMUNOL REV, V120, P137, DOI 10.1111/j.1600-065X.1991.tb00591.x; PORCELLI S, 1989, NATURE, V341, P447, DOI 10.1038/341447a0; PORCELLI S, 1992, NATURE, V360, P593, DOI 10.1038/360593a0; RONCAROLO MG, 1988, J EXP MED, V168, P2139, DOI 10.1084/jem.168.6.2139; TANAKA Y, 1994, P NATL ACAD SCI USA, V91, P8175, DOI 10.1073/pnas.91.17.8175; TERHORST C, 1981, CELL, V23, P771, DOI 10.1016/0092-8674(81)90441-4; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0	30	868	889	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 15	1994	372	6507					691	694		10.1038/372691a0	http://dx.doi.org/10.1038/372691a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX307	7527500				2022-12-24	WOS:A1994PX30700090
J	ZHOU, L; DEY, CR; WERT, SE; DUVALL, MD; FRIZZELL, RA; WHITSETT, JA				ZHOU, L; DEY, CR; WERT, SE; DUVALL, MD; FRIZZELL, RA; WHITSETT, JA			CORRECTION OF LETHAL INTESTINAL DEFECT IN A MOUSE MODEL OF CYSTIC-FIBROSIS BY HUMAN CFTR	SCIENCE			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; TRANSGENIC MICE; EXPRESSION; CRYPT; CELLS	Cystic fibrosis (CF) is caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR). A potential animal model of CF, the CFTR(-/-) mouse, has had limited utility because most mice die from intestinal obstruction during the first month of life. Human CFTR (hCFTR) was expressed in CFTR(-/-) mice under the control of the rat intestinal fatty acid-binding protein gene promoter. The mice survived and showed functional correction of ileal goblet cell and crypt cell hyperplasia and cyclic adenosine monophosphate-stimulated chloride secretion. These results support the concept that transfer of the hCFTR gene may be a useful strategy for correcting physiologic defects in patients with CF.	CHILDRENS HOSP,MED CTR,DIV PULM BIOL,CINCINNATI,OH 45229; UNIV ALABAMA,DEPT PHYSIOL & BIOPHYS,BIRMINGHAM,AL 35294	Cincinnati Children's Hospital Medical Center; University of Alabama System; University of Alabama Birmingham					NHLBI NIH HHS [HL51832, HL49004] Funding Source: Medline; NIDDK NIH HHS [DK38518] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049004, P01HL051832] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038518] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; CLARKE LL, 1992, SCIENCE, V257, P1125, DOI 10.1126/science.257.5073.1125; COHN SM, 1992, J CELL BIOL, V119, P27, DOI 10.1083/jcb.119.1.27; SIEMER C, 1993, PFLUG ARCH EUR J PHY, V424, P321, DOI 10.1007/BF00384359; SNOUWAERT JN, 1992, SCIENCE, V257, P1083, DOI 10.1126/science.257.5073.1083; STRONG TV, 1994, J CLIN INVEST, V93, P347, DOI 10.1172/JCI116966; TREZISE AEO, 1991, NATURE, V353, P434, DOI 10.1038/353434a0; WELSH MJ, 1982, SCIENCE, V218, P1219, DOI 10.1126/science.6293054; WHITSETT JA, 1992, NAT GENET, V2, P13, DOI 10.1038/ng0992-13	9	204	212	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 9	1994	266	5191					1705	1708		10.1126/science.7527588	http://dx.doi.org/10.1126/science.7527588			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW308	7527588				2022-12-24	WOS:A1994PW30800040
J	HIGHSMITH, WE; BURCH, LH; ZHOU, ZQ; OLSEN, JC; BOAT, TE; SPOCK, A; GORVOY, JD; QUITTELL, L; FRIEDMAN, KJ; SILVERMAN, LM; BOUCHER, RC; KNOWLES, MR				HIGHSMITH, WE; BURCH, LH; ZHOU, ZQ; OLSEN, JC; BOAT, TE; SPOCK, A; GORVOY, JD; QUITTELL, L; FRIEDMAN, KJ; SILVERMAN, LM; BOUCHER, RC; KNOWLES, MR			A NOVEL MUTATION IN THE CYSTIC-FIBROSIS GENE IN PATIENTS WITH PULMONARY-DISEASE BUT NORMAL SWEAT CHLORIDE CONCENTRATIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONDUCTANCE REGULATOR GENE; POLYMERASE CHAIN-REACTION; ION PERMEABILITY; SUBJECTS INVIVO; MESSENGER-RNA; CFTR; GLANDS; ACTIN; DNA	Background. Many patients with chronic pulmonary disease similar to that seen in cystic fibrosis have normal (or nondiagnostic) sweat chloride values. It has been difficult to make the diagnosis of cystic fibrosis in these patients because no associated mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene has been identified. Methods. We evaluated 23 patients with pulmonary disease characteristic of cystic fibrosis but with sweat chloride concentrations in the normal range. Mutations in the CFTR gene were sought by direct sequencing of polymerase chain reaction-amplified nasal epithelial messenger RNA and by testing the functioning of affected epithelium. Results. A cytidine phosphate guanosine dinucleotide C-to-T point mutation in intron 19 of the CFTR gene, termed 3849+10 kb C to TI was identified in 13 patients from eight unrelated families. This mutation was found in patients from three different ethnic groups with three different extended haplotypes. The mutation leads to the creation of a partially active splice site in intron 19 and to the insertion into most CFTR transcripts of a new 84-base-pair ''exon,'' containing an in-frame stop codon, between exons 19 and 20. Normally spliced transcripts were also detected at a level approximately 8 percent of that found in normal subjects. This mutation is associated with abnormal nasal epithelial and sweat acinar epithelial function. Conclusions. We have identified a point mutation in intron 19 of CFTR and abnormal epithelial function in patients who have cystic fibrosis-like lung disease but normal sweat chloride values. The identification of this mutation indicates that this syndrome is a form of cystic fibrosis. Screening for the mutation should prove diagnostically useful in this population of patients.	UNIV N CAROLINA, DEPT MED, DIV PULM DIS, CHAPEL HILL, NC 27599 USA; APPL TECHNOL GENET CORP, MALVERN, PA USA; UNIV N CAROLINA, DIV MOLEC PATHOL, CHAPEL HILL, NC USA; CHILDRENS HOSP, MED CTR, CINCINNATI, OH USA; DUKE UNIV, DEPT PEDIAT, DURHAM, NC 27706 USA; LONG ISL JEWISH MED CTR, SCHNEIDER CHILDRENS HOSP, NEW HYDE PK, NY 11042 USA; COLUMBIA PRESBYTERIAN MED CTR, DIV PEDIAT PULM, NEW YORK, NY USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Cincinnati Children's Hospital Medical Center; Duke University; Northwell Health; North Shore University Hospital; Steven & Alexandra Cohen Children's Medical Center of New York; Columbia University; NewYork-Presbyterian Hospital			Highsmith, William E/B-6175-2008		NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000046] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034322] Funding Source: NIH RePORTER; NCRR NIH HHS [RR000046] Funding Source: Medline; NHLBI NIH HHS [HL34322] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABELIOVICH D, 1992, AM J HUM GENET, V51, P951; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; AUGARTEN A, 1993, LANCET, V342, P25, DOI 10.1016/0140-6736(93)91885-P; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BEAUDET AL, 1988, NEW ENGL J MED, V318, P50; BIJMAN J, 1984, AM J PHYSIOL, V247, pC3, DOI 10.1152/ajpcell.1984.247.1.C3; Boat T.J., 1989, METABOLIC BASIS INHE, P2649; CHENG TC, 1984, P NATL ACAD SCI-BIOL, V81, P2821, DOI 10.1073/pnas.81.9.2821; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHU CS, 1992, J CLIN INVEST, V90, P785, DOI 10.1172/JCI115952; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; COOPER DN, 1990, HUM GENET, V85, P55; DAVIS PB, 1983, AM REV RESPIR DIS, V128, P34, DOI 10.1164/arrd.1983.128.1.34; DAVIS PB, 1980, AM J MED, V69, P643, DOI 10.1016/0002-9343(80)90482-9; DORK T, 1992, HUM GENET, V88, P417, DOI 10.1007/BF00215676; ERBA HP, 1986, NUCLEIC ACIDS RES, V14, P5275, DOI 10.1093/nar/14.13.5275; FRIEDMAN KJ, 1991, CLIN CHEM, V37, P753; GIBSON LE, 1959, PEDIATRICS, V23, P545; GILBERT F, 1992, PEDIATR PULM S, V14, P240; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; KAZAZIAN HH, 1994, HUM MUTAT, V4, P167; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KEREM E, 1990, NEW ENGL J MED, V323, P1517, DOI 10.1056/NEJM199011293232203; KNOWLES M, 1983, CLIN RES, V31, pA858; KNOWLES M, 1981, NEW ENGL J MED, V305, P1489, DOI 10.1056/NEJM198112173052502; KNOWLES M, 1983, J CLIN INVEST, V71, P1410, DOI 10.1172/JCI110894; KNOWLES MR, 1981, AM REV RESPIR DIS, V124, P484; QUINTON PM, 1983, NEW ENGL J MED, V308, P1185, DOI 10.1056/NEJM198305193082002; RIORDAN JR, 1989, SCIENCE, V245, P1437; SATO K, 1984, J CLIN INVEST, V73, P1763, DOI 10.1172/JCI111385; SATO K, 1988, J LAB CLIN MED, V111, P511; SHWACHMAN H, 1972, BIRTH DEFECTS ORGINA, P102; STERN RC, 1978, JAMA-J AM MED ASSOC, V239, P2676, DOI 10.1001/jama.239.25.2676; STRONG TV, 1991, NEW ENGL J MED, V325, P1630, DOI 10.1056/NEJM199112053252307; TRAPNELL BC, 1991, P NATL ACAD SCI USA, V88, P6565, DOI 10.1073/pnas.88.15.6565; WEATHERALL DJ, 1989, METABOLIC BASIS INHE, V2, P2281	38	344	351	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 13	1994	331	15					974	980		10.1056/NEJM199410133311503	http://dx.doi.org/10.1056/NEJM199410133311503			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK504	7521937	Green Submitted			2022-12-24	WOS:A1994PK50400003
J	BISHOP, MC				BISHOP, MC			ALTERNATIVES ARE STILL UNPROVED	BRITISH MEDICAL JOURNAL			English	Article							BENIGN PROSTATIC HYPERTROPHY; PROSTATECTOMY; RESECTION				BISHOP, MC (corresponding author), CITY HOSP,NOTTINGHAM NG5 1PB,ENGLAND.							ABRAMS PH, 1979, J UROLOGY, V121, P640, DOI 10.1016/S0022-5347(17)56918-9; BALL AJ, 1981, BRIT J UROL, V53, P613, DOI 10.1111/j.1464-410X.1981.tb03273.x; BDESHA AS, 1993, BRIT MED J, V306, P1293, DOI 10.1136/bmj.306.6888.1293; DOLL HA, 1993, BRIT J UROL, V72, P322, DOI 10.1111/j.1464-410X.1993.tb00727.x; EVANS JWH, 1992, BMJ-BRIT MED J, V304, P666, DOI 10.1136/bmj.304.6828.666; MEBUST WK, 1989, J UROLOGY, V141, P243, DOI 10.1016/S0022-5347(17)40731-2; NEAL DE, 1990, BRIT J UROL, V66, P449, DOI 10.1111/j.1464-410X.1990.tb14986.x; ROOS NP, 1989, NEW ENGL J MED, V320, P1120, DOI 10.1056/NEJM198904273201705	8	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 17	1994	309	6956					717	718		10.1136/bmj.309.6956.717	http://dx.doi.org/10.1136/bmj.309.6956.717			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH407	7524873	Green Published			2022-12-24	WOS:A1994PH40700023
J	CHEN, YH; KUCHROO, VK; INOBE, J; HAFLER, DA; WEINER, HL				CHEN, YH; KUCHROO, VK; INOBE, J; HAFLER, DA; WEINER, HL			REGULATORY T-CELL CLONES INDUCED BY ORAL TOLERANCE - SUPPRESSION OF AUTOIMMUNE ENCEPHALOMYELITIS	SCIENCE			English	Article							MYELIN BASIC-PROTEIN; GROWTH-FACTOR-BETA; DRIVEN BYSTANDER SUPPRESSION; IMMUNE-RESPONSES; TRANSGENIC MICE; EFFECTOR-CELLS; IGA PRODUCTION; LYMPHOCYTES; TOLERIZATION; ANTIGENS	Experimental autoimmune encephalomyelitis (EAE) is a cell-mediated autoimmune disease that serves as an animal model for multiple sclerosis. Oral administration of myelin basic protein (MBP) suppresses EAE by inducing peripheral tolerance. T cell clones were isolated from the mesenteric lymph nodes of SJL mice that had been orally tolerized to MBP. These clones were CD4(+) and were structurally identical to T helper cell type 1 (T(H)1) encephalitogenic CD4(+) clones in T cell receptor usage, major histocompatibility complex restriction, and epitope recognition. However, they produced transforming growth factor-beta with various amounts of interleukin-4 and interleukin-10 and suppressed EAE induced with either MBP or proteolipid protein. Thus, mucosally derived T(H)2-like clones induced by oral antigen can actively regulate immune responses in vivo and may represent a different subset of T cells.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,CTR NEUROL DIS,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School			Chen, Youhai/AAJ-4031-2021		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030843, R29NS030843, R01NS029352, R37NS030843] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR/A143220] Funding Source: Medline; NINDS NIH HHS [NS29352, NS30843] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALSABBAGH A, IN PRESS EUR J IMMUN; CHASE MW, 1946, P SOC EXP BIOL MED, V61, P257; Chen Y, UNPUB; CHEN YH, 1994, J IMMUNOL, V152, P3; CHIN YH, 1992, J IMMUNOL, V148, P1106; COFFMAN RL, 1989, J EXP MED, V170, P1039, DOI 10.1084/jem.170.3.1039; FRIEDMAN R, 1994, P NATL ACAD SCI USA, V91, P6688; GERMAIN RN, 1981, SCAND J IMMUNOL, V13, P1, DOI 10.1111/j.1365-3083.1981.tb00104.x; GERSHON RK, 1970, IMMUNOLOGY, V18, P723; GOVERMAN J, 1993, CELL, V72, P551, DOI 10.1016/0092-8674(93)90074-Z; GREGERSON DS, 1993, J IMMUNOL, V151, P5751; JENKINS MK, 1990, J IMMUNOL, V144, P16; KARPUS WJ, 1992, EUR J IMMUNOL, V22, P1757, DOI 10.1002/eji.1830220714; KARPUS WJ, 1991, J IMMUNOL, V146, P1163; KENNEDY MK, 1992, J IMMUNOL, V149, P2496; KHOURY SJ, 1992, J EXP MED, V176, P1355, DOI 10.1084/jem.176.5.1355; KIM PH, 1990, J IMMUNOL, V144, P3411; LIDER O, 1989, J IMMUNOL, V142, P748; LIDER O, 1988, SCIENCE, V239, P181, DOI 10.1126/science.2447648; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MILLER A, 1991, J EXP MED, V174, P791, DOI 10.1084/jem.174.4.791; MILLER A, 1992, P NATL ACAD SCI USA, V89, P421, DOI 10.1073/pnas.89.1.421; MILLER A, 1993, J IMMUNOL, V151, P7307; MOWAT AM, 1987, IMMUNOL TODAY, V8, P93, DOI 10.1016/0167-5699(87)90853-X; Nossal G J, 1987, Int Rev Immunol, V2, P321, DOI 10.3109/08830188709044760; PRABHUDAS M, UNPUB; ROCHA B, 1991, SCIENCE, V251, P1225, DOI 10.1126/science.1900951; SALGAME P, 1991, P NATL ACAD SCI USA, V88, P2598, DOI 10.1073/pnas.88.6.2598; SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SUN D, 1988, NATURE, V332, P843, DOI 10.1038/332843a0; TRENTHAM DE, 1993, SCIENCE, V261, P1727, DOI 10.1126/science.8378772; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WEINER HL, 1993, SCIENCE, V259, P1321, DOI 10.1126/science.7680493; WEINER HL, 1994, ANNU REV IMMUNOL, V12, P809, DOI 10.1146/annurev.immunol.12.1.809; Wells HG, 1911, J INFECT DIS, V9, P147, DOI 10.1093/infdis/9.2.147; WHITACRE CC, 1991, J IMMUNOL, V147, P2155; WUCHERPFENNIG KW, 1994, J IMMUNOL, V152, P5581; YAMAMURA M, 1991, SCIENCE, V254, P5029	39	1643	1721	1	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 26	1994	265	5176					1237	1240		10.1126/science.7520605	http://dx.doi.org/10.1126/science.7520605			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PD422	7520605				2022-12-24	WOS:A1994PD42200039
J	HOU, S; HYLAND, L; RYAN, KW; PORTNER, A; DOHERTY, PC				HOU, S; HYLAND, L; RYAN, KW; PORTNER, A; DOHERTY, PC			VIRUS-SPECIFIC CD8+ T-CELL MEMORY DETERMINED BY CLONAL BURST SIZE	NATURE			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; SENDAI VIRUS; INVIVO; MICE; EXPRESSION; INFLUENZA; INFECTION; IMMUNITY; ANTIGEN; BETA	Although some viruses, particularly the herpes viruses, may never be eliminated from the body(1), others like influenza A, regularly reinfect humans and boost waning crossreactive CD8(+) T-cell immunity(2). Prolonged T-cell memory is found for viruses that are unlikely to be re-encountered and which do not persist in the host genome(3-5), indicating that CD8(+) T-cell memory might be independent dent of continued (or sporadic) antigenic exposure. A feature of virus-specific CD8(+) T-cell memory is that antigen-specific cytotoxic T-lymphocyte precursors (CTLp) are greatly increased and remain high throughout life. The idea that persistence of the inducing antigen is essential is based on experiments in which adoptively transferred CD8(+) memory T cells could not be detected for more than a few weeks in naive recipient mice without secondary challenge(6,7). Here we show that restimulation of such chimaeric mice with an inducing Sendai virus antigen increases the clonal burst size more than 7-fold within 8 days, making memory CTLp easier to detect in the longer term. We find that Sendai-virus-specific CTLp are maintained for >250 days in irradiated uninfected recipients, including reconstituted beta(2)-microglobulin(-/-) mice. To determine whether a source of viral peptide can persist after primary infection, we gave Sendai-virus-specific Thy1.1(+) memory spleen cells to naive mice that had been minimally depleted of Thy1.2(+) T cells, or to comparable recipients that had recovered from infection with Sendai virus or influenza virus. Although antibody against Sendai virus was never found in the naive recipients, Sendai-virus-specific CD8(+) memory T cells were maintained equally well in each case for >100 days after cell transfer. We find so evidence for persisting depots of viral protein that might feed into the endogenous processing pathway and maintain virus-specific CD8(+) T-cell memory.	ST JUDE CHILDRENS RES HOSP, DEPT VIROL & IMMUNOL, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT MOLEC BIOL, MEMPHIS, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital			Doherty, Peter Charles/C-4185-2013	Doherty, Peter Charles/0000-0002-5028-3489				BEVERLEY PCL, 1990, IMMUNOL TODAY, V11, P203, DOI 10.1016/0167-5699(90)90083-L; BURTON GF, 1993, J IMMUNOL, V150, P31; CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P3403, DOI 10.1128/MCB.5.12.3403; DEMKOWICZ WE, 1993, J VIROL, V67, P1538, DOI 10.1128/JVI.67.3.1538-1544.1993; DOHERTY PC, 1981, IMMUNOL REV, V58, P37, DOI 10.1111/j.1600-065X.1981.tb00349.x; DOHERTY PC, 1992, ANNU REV IMMUNOL, V10, P123; DOHERTY PC, 1988, CLIN IMMUNOL IMMUNOP, V47, P19, DOI 10.1016/0090-1229(88)90141-9; DOHERTY PC, 1989, IMMUNOLOGY, V66, P631; DOHERTY PC, 1994, STRATEGIES VACCINE D, P51; FINK PJ, 1988, ANNU REV IMMUNOL, V6, P115; FRASER JD, 1987, IMMUNOGENETICS, V26, P31, DOI 10.1007/BF00345451; GRAY D, 1991, J EXP MED, V174, P969, DOI 10.1084/jem.174.5.969; GRAY D, 1993, ANNU REV IMMUNOL, V11, P49, DOI 10.1146/annurev.immunol.11.1.49; HOU S, 1992, J IMMUNOL, V149, P1319; HOU S, 1993, J IMMUNOL, V150, P5494; KAST WM, 1991, P NATL ACAD SCI USA, V88, P2283, DOI 10.1073/pnas.88.6.2283; KING CC, 1990, J VIROL, V64, P5611, DOI 10.1128/JVI.64.11.5611-5616.1990; LAU LL, 1994, NATURE, V369, P648, DOI 10.1038/369648a0; MACKAY CR, 1993, ADV IMMUNOL, V53, P217, DOI 10.1016/S0065-2776(08)60501-5; MCMICHAEL AJ, 1983, LANCET, V2, P762; Moss D J, 1992, Semin Immunol, V4, P97; MULLBACHER A, 1994, J EXP MED, V179, P317, DOI 10.1084/jem.179.1.317; OEHEN S, 1992, J EXP MED, V176, P1273, DOI 10.1084/jem.176.5.1273; ROCHA B, 1989, EUR J IMMUNOL, V19, P905, DOI 10.1002/eji.1830190518; SEDGWICK JD, 1986, J IMMUNOL METHODS, V87, P37, DOI 10.1016/0022-1759(86)90341-8; SMITH GL, 1987, VIROLOGY, V160, P336, DOI 10.1016/0042-6822(87)90004-3; SPRENT J, 1993, CURR OPIN IMMUNOL, V5, P433, DOI 10.1016/0952-7915(93)90065-Z; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	28	465	475	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 23	1994	369	6482					652	654		10.1038/369652a0	http://dx.doi.org/10.1038/369652a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT459	7516039				2022-12-24	WOS:A1994NT45900056
J	NELSON, BH; LORD, JD; GREENBERG, PD				NELSON, BH; LORD, JD; GREENBERG, PD			CYTOPLASMIC DOMAINS OF THE INTERLEUKIN-2 RECEPTOR BETA-CHAIN AND GAMMA-CHAIN MEDIATE THE SIGNAL FOR T-CELL PROLIFERATION	NATURE			English	Article							IL-2 RECEPTOR; TYROSINE KINASE; FUNCTIONAL COMPONENT; GM-CSF; TRANSDUCTION; ACTIVATION; BINDING; PHOSPHORYLATION; INVOLVEMENT; EXPRESSION	The interleukin-2 (IL-2R) consists of three distinct chains (alpha, beta, gamma) which bind IL-2 and generate a proliferative signal in T cells(1). To define the mechanism of receptor activation, chimaeric receptors were constructed from the intracellular region of either IL-2R beta or IL-2R gamma and the extracellular region of c-kit, a receptor tyrosine kinase that homodimerizes on binding stem cell factor (SCF)(2). We report here that binding of SCF to the beta-chain chimaera induced proliferation of the pro-B-cell line BA/F3, but not T cells. But in T cells expressing both the beta- and gamma-chain chimaeras, SCF induced proliferation and tyrosine phosphorylation characteristic of the native IL-2R signal. Chimaeric IL-2 receptor beta and gamma chains constructed with the heterodimeric extracellular regions of the granulocyte-macrophage colony stimulating factor receptor (GM-CSFR) also provided the IL-2R signal. Thus, heterodimerization of the cytoplasmic domains of n-2R beta and -gamma appears necessary and sufficient for signalling in T cells.	UNIV WASHINGTON,DEPT IMMUNOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	NELSON, BH (corresponding author), FRED HUTCHINSON CANC RES CTR,1124 COLUMBIA ST M758,SEATTLE,WA 98104, USA.		Nelson, Brad H/K-2622-2014	Nelson, Brad/0000-0002-4445-5539				ARIMA N, 1992, J EXP MED, V176, P1265, DOI 10.1084/jem.176.5.1265; ASAO H, 1990, J EXP MED, V171, P637, DOI 10.1084/jem.171.3.637; ASAO H, 1993, P NATL ACAD SCI USA, V90, P4127, DOI 10.1073/pnas.90.9.4127; BECKMANN MP, 1990, J IMMUNOL, V144, P4212; BICHTHUY LT, 1987, J IMMUNOL, V139, P1550; CHIBA T, 1993, NATURE, V362, P646, DOI 10.1038/362646a0; DANDREA A, 1989, CELL, V58, P1023, DOI 10.1016/0092-8674(89)90499-6; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; LEV S, 1992, J BIOL CHEM, V267, P15970; LINNEKIN D, 1992, J BIOL CHEM, V267, P23993; MOREAU JL, 1987, EUR J IMMUNOL, V17, P929, DOI 10.1002/eji.1830170706; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SHANAFELT AB, 1991, EMBO J, V10, P4105, DOI 10.1002/j.1460-2075.1991.tb04987.x; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; SMITH KA, 1985, P NATL ACAD SCI USA, V82, P864, DOI 10.1073/pnas.82.3.864; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; SUGAMURA K, 1990, LYMPHOKINE RES, V9, P539; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WALDMANN TA, 1991, J BIOL CHEM, V266, P2681; ZIEGLER SF, 1991, NEW BIOL, V3, P1242	30	294	310	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 26	1994	369	6478					333	336		10.1038/369333a0	http://dx.doi.org/10.1038/369333a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NN109	7514277				2022-12-24	WOS:A1994NN10900054
J	ECK, MJ; ATWELL, SK; SHOELSON, SE; HARRISON, SC				ECK, MJ; ATWELL, SK; SHOELSON, SE; HARRISON, SC			STRUCTURE OF THE REGULATORY DOMAINS OF THE SRC-FAMILY TYROSINE KINASE LCK	NATURE			English	Article							PROTEIN STRUCTURES; CRYSTAL-STRUCTURE; SH3 DOMAIN; IDENTIFICATION; P60C-SRC; BINDING	THE kinase p56(lck) (Lck) is a T-lymphocyte-specific member of the Src family of non-receptor tyrosine kinases(1). Members of the Src family each contain unique amino-terminal regions, followed by Src-homology domains SH3 and SH2, and a tyrosine kinase domain. SH3 and SH2 domains mediate critical protein interactions in many signal-transducing pathways(2). They are small, independently folded modules of about 60 and 100 residues, respectively, and they are often but not always found together in the same molecule. Like all nine Src-family kinases (reviewed in ref. 3), Lck is regulated by phosphorylation of a tyrosine in the short C-terminal tail of its catalytic domain(4). There is evidence that binding of the phosphorylated tail to the SH2 domain inhibits catalytic activity of the kinase domain(5,6) and that the SH3 and SH2 domains may act together to effect this regulation(7). Here we report the crystal structures for a fragment of Lck bearing its SH3 and SH2 domains, alone and in complex with a phosphotyrosyl peptide containing the sequence of the Lck C-terminal regulatory tail. The latter complex represents the regulatory apparatus of Lck. The SH3-SH2 fragment forms similar dimers in both crystals, and the tail peptide binds at the intermolecular SH3/SH2 contact. The two structures show how an SH3 domain might recognize a specific target and suggest how dimerization could play a role in regulating Src-family kinases.	CHILDRENS HOSP MED CTR, MOLEC MED LAB, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOLEC GENET, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,JOSLIN DIABET CTR, DIV RES, BOSTON, MA 02115 USA; HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University	ECK, MJ (corresponding author), CHILDRENS HOSP MED CTR, HOWARD HUGHES MED INST, 300 LONGWOOD AVE, BOSTON, MA 02115 USA.							ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; BOOKER GW, 1993, CELL, V73, P813, DOI 10.1016/0092-8674(93)90259-S; Brunger AT, 1992, X PLOR VERSION 3 0 S; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; GRANDORI C, 1988, J CELL BIOL, V107, P2125, DOI 10.1083/jcb.107.6.2125; JANIN J, 1990, J BIOL CHEM, V265, P16027; JONES TA, 1989, CRYSTALLOGRAPHIC COM; JONES TA, 1992, MOL REPLACEMENT, P91; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; NAVAZA J, 1992, AMORE NEW PACKAGE MO; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PICCIONE E, 1993, BIOCHEMISTRY-US, V32, P3197, DOI 10.1021/bi00064a001; Potts W M, 1988, Oncogene Res, V3, P343; PRASAD KVS, 1993, MOL CELL BIOL, V13, P7708, DOI 10.1128/MCB.13.12.7708; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	30	263	268	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 21	1994	368	6473					764	769		10.1038/368764a0	http://dx.doi.org/10.1038/368764a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG553	7512222				2022-12-24	WOS:A1994NG55300065
J	AMIN, J; WEISS, DS				AMIN, J; WEISS, DS			GABA(A) RECEPTOR NEEDS 2 HOMOLOGOUS DOMAINS OF THE BETA-SUBUNIT FOR ACTIVATION BY GABA BUT NOT BY PENTOBARBITAL	NATURE			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; GLYCINE RECEPTOR; ALPHA-SUBUNIT; BINDING-SITE; ION CHANNELS; AMINO-ACIDS; A RECEPTORS; AGONIST; RAT; NEURONS	THE predominant inhibitory neurotrasmitter of the brain, GABA (gamma-antinobutyric acid), activates chloride-selective ion pores integral to the receptor complex. Subunits comprising the presumed hetero-pentameric GABA channel have been cloned1-4, but little information is available on the domains important for activation. Rat wild-type or mutated alpha1-, beta2- and gamma2-subunits (designated alpha, beta and gamma) were coexpressed in Xenopus oocytes and examined electrophysiologically. We report here the identification of two separate and homologous domains of the beta-subunit, each of which contributes a tyrosine and threonine essential for activation by GABA. Conservative substitution of each of these four amino acids dramatically decreased GABA channel sensitivity to activation by GABA and the GABA agonist muscimol. These substitutions, however, did not impair activation by the barbiturate pentobarbital, indicating these two different classes of agonists activate GABA channels through distinct mechanisms. We also present evidence suggesting that the two identified domains of the beta-subunit contribute a major component of the GABA receptor.	UNIV S FLORIDA,COLL MED,DEPT PHYSIOL & BIOPHYS,12901 BRUCE B DOWNS BLVD,TAMPA,FL 33612; UNIV S FLORIDA,COLL MED,INST BIOMOLEC SCI,TAMPA,FL 33612	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida			Amin, Jahanshah/I-7174-2012					BARKER JL, 1978, J PHYSIOL-LONDON, V280, P355, DOI 10.1113/jphysiol.1978.sp012388; BrõndÚn CI., 1991, INTRO PROTEIN STRUCT; CASALOTTI SO, 1986, J BIOL CHEM, V261, P5013; COLQUHOUN D, 1988, J PHYSIOL-LONDON, V395, P131, DOI 10.1113/jphysiol.1988.sp016912; COLQUHOUN D, 1981, PROC R SOC SER B-BIO, V211, P205, DOI 10.1098/rspb.1981.0003; COLQUHOUN D, 1986, ION CHANNELS NEURAL; CRAWFORD JL, 1973, P NATL ACAD SCI USA, V70, P538, DOI 10.1073/pnas.70.2.538; DELCASTILLO J, 1957, PROC R SOC SER B-BIO, V146, P369; DENG L, 1986, BIOCHEM BIOPH RES CO, V138, P1308, DOI 10.1016/S0006-291X(86)80425-9; DENNIS M, 1988, BIOCHEMISTRY-US, V27, P2346, DOI 10.1021/bi00407a016; FRIEDA S, 1990, P R SOC B, V241, P207; GALZI JL, 1991, FEBS LETT, V294, P198, DOI 10.1016/0014-5793(91)80668-S; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; KHRESTCHATISKY M, 1989, NEURON, V3, P745, DOI 10.1016/0896-6273(89)90243-2; LEVITAN ES, 1988, NEURON, V1, P773, DOI 10.1016/0896-6273(88)90125-0; LOLAIT SJ, 1989, FEBS LETT, V246, P145, DOI 10.1016/0014-5793(89)80271-6; NEWLAND CF, 1991, J PHYSIOL-LONDON, V432, P203, DOI 10.1113/jphysiol.1991.sp018382; NICOLL RA, 1980, BRAIN RES, V191, P225, DOI 10.1016/0006-8993(80)90325-X; NICOLL RA, 1975, NATURE, V258, P625, DOI 10.1038/258625a0; OLEARY ME, 1992, J BIOL CHEM, V267, P8360; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; SAIKI RK, 1988, SCIENCE, V239, P481; Sakmann B, 1983, J Neural Transm Suppl, V18, P83; SCHMIEDEN V, 1992, EMBO J, V11, P2025, DOI 10.1002/j.1460-2075.1992.tb05259.x; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SCHULZ DW, 1981, BRAIN RES, V209, P177, DOI 10.1016/0006-8993(81)91179-3; SHIVERS BD, 1989, NEURON, V3, P327, DOI 10.1016/0896-6273(89)90257-2; SIGEL E, 1992, EMBO J, V11, P2017, DOI 10.1002/j.1460-2075.1992.tb05258.x; SIGEL E, 1990, NEURON, V5, P703, DOI 10.1016/0896-6273(90)90224-4; TOMASELLI GF, 1991, BIOPHYS J, V60, P721, DOI 10.1016/S0006-3495(91)82102-6; TWYMAN RE, 1990, J PHYSIOL-LONDON, V423, P193, DOI 10.1113/jphysiol.1990.sp018018; VANDENBERG RJ, 1992, NEURON, V9, P491, DOI 10.1016/0896-6273(92)90186-H; VERDOORN TA, 1990, NEURON, V4, P919, DOI 10.1016/0896-6273(90)90145-6; WEISS DS, 1989, J NEUROSCI, V9, P1314	34	384	386	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 9	1993	366	6455					565	569		10.1038/366565a0	http://dx.doi.org/10.1038/366565a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML218	7504783				2022-12-24	WOS:A1993ML21800070
J	BUNDENS, WP; BERGAN, JJ; HALASZ, NA; MURRAY, J; DREHOBL, M				BUNDENS, WP; BERGAN, JJ; HALASZ, NA; MURRAY, J; DREHOBL, M			THE SUPERFICIAL FEMORAL VEIN - A POTENTIALLY LETHAL MISNOMER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							THROMBOSIS; ULTRASOUND; DIAGNOSIS	Objective.-To assess the potential for error in interpretation of venous duplex reports that use the term ''superficial femoral vein.'' Design.-Three surveys conducted by mail. Setting-Three multispecialty medical groups, anatomy departments of all US medical schools, and vascular laboratories. Participants.-A total of 46 family practitioners and general internists, 95 chairpersons of departments of anatomy, and 85 laboratory directors. Main Outcome Measures.-Proposed treatment of a patient with leg pain and an acute thrombosis of the superficial femoral vein; what nomenclature(s) for the deep thigh veins is (are) felt to be correct, what are acceptable alternatives, what is taught to students and which is preferred; and what terminology is being used in lower limb venous duplex reports. Results.-Only 24% (11/46) of the respondents would have administered anticoagulants to the patient as described. Only 3% (3/95) of anatomists felt the term ''superficial femoral vein'' was correct, 22% (21/95) felt it was an acceptable alternative (though only 9% [9/95] taught it to medical students), and only 7% (7/95) of anatomists felt the term was preferred for everyday use, The term ''superficial femoral vein'' is used by 93% (79/85) of vascular laboratories in lower limb venous duplex reports. Conclusion.-Although the overwhelming majority of vascular laboratories use the term ''superficial femoral vein'' in venous duplex reports, the use of this term is potentially hazardous to patients. Most primary care physicians have not been taught and are not aware that the superficial femoral vein is a deep vein and that acute thrombosis of this vessel is potentially life threatening.	USN,MED CTR,SAN DIEGO,CA 92152; USN,CTR HLTH CARE,SAN DIEGO,CA 92152	United States Department of Defense; United States Navy; United States Department of Defense; United States Navy	BUNDENS, WP (corresponding author), UNIV CALIF SAN DIEGO,DEPT SURG,9500 GILMAN DR,0643,ROOM 147,LA JOLLA,CA 92093, USA.							BILLINGS JS, 1890, NATIONAL MED DICT, V1, P507; DOUGHERTY J, 1940, SURG GYNECOL OBSTET, V71, P697; ELIAS A, 1987, INT ANGIOL, V6, P175; Homans J, 1941, NEW ENGL J MED, V224, P179, DOI 10.1056/NEJM194101302240501; Homans J, 1934, N ENGL J MED, V211, P993; HOMANS J, 1937, AM J SURG, V38, P316; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; MARKEL A, 1992, ARCH SURG-CHICAGO, V127, P305; Markel A, 1991, J VASC MED BIOL, V3, P432; RABINOV K, 1972, ARCH SURG-CHICAGO, V104, P133; RUBIN BG, 1994, J VASC SURG, V20, P698, DOI 10.1016/S0741-5214(94)70156-3; STRANDNESS DE, 1993, VASCULAR DIAGNOSIS, P772; WHITE RH, 1989, ANN INTERN MED, V111, P297, DOI 10.7326/0003-4819-111-4-297; 1989, NOMINA ANATOMICA, pA65	14	37	38	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 25	1995	274	16					1296	1298						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA104	7563535				2022-12-24	WOS:A1995TA10400025
J	MARSHALL, BJ				MARSHALL, BJ			HELICOBACTER-PYLORI - THE ETIOLOGIC AGENT FOR PEPTIC-ULCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CAMPYLOBACTER-PYLORI; GASTRITIS; ERADICATION; BISMUTH; TRIAL		UNIV VIRGINIA,HLTH SCI CTR,DEPT MED,CHARLOTTESVILLE,VA	University of Virginia				Marshall, Barry/0000-0003-4853-5015				CULLEN DJE, 1993, GUT, V34, P1681, DOI 10.1136/gut.34.12.1681; GRAHAM DY, 1991, ANN INTERN MED, V115, P266, DOI 10.7326/0003-4819-115-4-266; MARSHALL BJ, 1987, AM J GASTROENTEROL, V82, P200; MARSHALL BJ, 1988, J NUCL MED, V29, P11; MARSHALL BJ, 1994, AM J GASTROENTEROL, V89, pS116; MARSHALL BJ, 1987, DIGESTION, V37, P16, DOI 10.1159/000199555; MARSHALL BJ, 1988, LANCET, V2, P1437; MARSHALL BJ, 1984, LANCET, V1, P1311; MARSHALL BJ, 1985, MED J AUSTRALIA, V142, P436, DOI 10.5694/j.1326-5377.1985.tb113443.x; MARSHALL BJ, 1986, J INFECT DIS, V52, P650; MARSHALL BJ, 1985, CAMPYLOBACTER, V3, P188; MARSHALL BJ, 1985, MED J AUSTRALIA, V149, P439; The EUROGAST Study Group, 1993, GUT, V34, P1672; WARREN JR, 1983, LANCET, V1, P273; WOTHERSPOON AC, 1993, LANCET, V342, P575, DOI 10.1016/0140-6736(93)91409-F; 1994, JAMA-J AM MED ASSOC, V272, P65	16	136	139	2	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 4	1995	274	13					1064	1066		10.1001/jama.274.13.1064	http://dx.doi.org/10.1001/jama.274.13.1064			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX108	7563460				2022-12-24	WOS:A1995RX10800032
J	HOSOYA, T; TAKIZAWA, K; NITTA, K; HOTTA, Y				HOSOYA, T; TAKIZAWA, K; NITTA, K; HOTTA, Y			GLIAL-CELLS MISSING - A BINARY SWITCH BETWEEN NEURONAL AND GLIAL DETERMINATION IN DROSOPHILA	CELL			English	Article							PERIPHERAL NERVOUS-SYSTEM; GROWTH CONES; GENE ENCODES; NEUROGENESIS; MELANOGASTER; EXPRESSION; PROTEINS; SEQUENCE; CNS; CONSENSUS	In the Drosophila CNS, both neurons and glia are derived from neuroblasts. We have identified a gene, glial cells missing (gcm), that encodes a novel nuclear protein expressed transiently in early glial cells. Its mutation causes presumptive glial cells to differentiate into neurons, whereas its ectopic expression forces virtually all CNS cells to become glial cells. Thus, gem functions as a binary switch that turns on glial fate while inhibiting default neuronal fate of the neuroblasts and their progeny. Similar results are also obtained in the PNS. Analyses of the mutant revealed that ''pioneer neurons'' can find correct pathways without glial cells and that neurons and glia have a common molecular basis for individual identity.	UNIV TOKYO,GRAD SCH SCI,DEPT PHYS,TOKYO 113,JAPAN	University of Tokyo			Hosoya, Toshihiko/Q-2514-2018	Hosoya, Toshihiko/0000-0001-8559-8344				BASTIANI MJ, 1986, J NEUROSCI, V6, P3542; BELLEN HJ, 1992, GENE DEV, V6, P2125, DOI 10.1101/gad.6.11.2125; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BODMER R, 1989, NEURON, V3, P21, DOI 10.1016/0896-6273(89)90112-8; BRAND AH, 1993, DEVELOPMENT, V118, P401; BUCHANAN RL, 1993, NEURON, V10, P839, DOI 10.1016/0896-6273(93)90200-B; CAMPBELL G, 1994, DEVELOPMENT, V120, P2957; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CHIBA A, 1995, NATURE, V374, P166, DOI 10.1038/374166a0; CONDRON BG, 1994, NEURON, V13, P541, DOI 10.1016/0896-6273(94)90024-8; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DOE CQ, 1991, CELL, V65, P451, DOI 10.1016/0092-8674(91)90463-9; DOE CQ, 1988, SCIENCE, V239, P170, DOI 10.1126/science.2892267; FINKELSTEIN R, 1990, GENE DEV, V4, P1516, DOI 10.1101/gad.4.9.1516; GIANGRANDE A, 1994, DEVELOPMENT, V120, P523; GIANGRANDE A, 1993, DEVELOPMENT, V117, P895; Goodman C. S., 1993, DEV DROSOPHILA MELAN, VII, P1131; HALTER DA, 1995, DEVELOPMENT, V121, P317; ITO K, 1995, ROUX ARCH DEV BIOL, V204, P284, DOI 10.1007/BF02179499; JACOBS JR, 1989, NEURON, V2, P1625; JACOBS JR, 1989, J NEUROSCI, V9, P2402; JACOBS JR, 1993, J NEUROBIOL, V24, P611, DOI 10.1002/neu.480240507; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; JONES BW, 1995, CELL, V82, P1013, DOI 10.1016/0092-8674(95)90280-5; KANIA A, 1995, GENETICS, V139, P1663; KLAES A, 1994, CELL, V78, P149, DOI 10.1016/0092-8674(94)90581-9; KLAMBT C, 1991, CELL, V64, P801, DOI 10.1016/0092-8674(91)90509-W; KLAMBT C, 1991, GLIA, V4, P205, DOI 10.1002/glia.440040212; KLAMBT C, 1993, DEVELOPMENT, V117, P163; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MASAI I, 1993, P NATL ACAD SCI USA, V90, P11157, DOI 10.1073/pnas.90.23.11157; MLODZIK M, 1990, GENE DEV, V4, P1848, DOI 10.1101/gad.4.11.1848; MLODZIK M, 1992, METHODS NEUROSCIENCE, V9, P397; NOSE A, 1994, NEURON, V13, P525, DOI 10.1016/0896-6273(94)90023-X; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROBINOW S, 1988, DEV BIOL, V126, P294, DOI 10.1016/0012-1606(88)90139-X; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SALZBERG A, 1994, NEURON, V13, P269, DOI 10.1016/0896-6273(94)90346-8; Sambrook J., 1989, MOL CLONING LAB MANU; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; UDOLPH G, 1993, DEVELOPMENT, V118, P765; Waddington C. H, 1940, ORG AND GENES; WINBERG ML, 1992, DEVELOPMENT, V115, P903; XIONG WC, 1994, GENE DEV, V8, P981, DOI 10.1101/gad.8.8.981	48	360	366	0	6	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 22	1995	82	6					1025	1036		10.1016/0092-8674(95)90281-3	http://dx.doi.org/10.1016/0092-8674(95)90281-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RW693	7553844	Bronze			2022-12-24	WOS:A1995RW69300018
J	THRASHER, AJ; CASIMIR, CM; KINNON, C; MORGAN, G; SEGAL, AW; LEVINSKY, RJ				THRASHER, AJ; CASIMIR, CM; KINNON, C; MORGAN, G; SEGAL, AW; LEVINSKY, RJ			GENE-TRANSFER TO PRIMARY CHRONIC GRANULOMATOUS-DISEASE MONOCYTES	LANCET			English	Note								For somatic gene therapy to become a realistic therapeutic strategy for chronic granulomatous disease (CGD),we have to be able to assign the molecular lesion to a specific component of the NADPH oxidase and to confirm that transfer of a functional copy of the corresponding defective gene will result in correction of the cellular defect. We used an adenovirus Vector expressing p47phox to transduce monocytes from patients with CGD. We showed by nitroblue-tetrazolium staining that NADPH-oxidase activity was restored to these cells. This technique offers a rapid means for molecular diagnosis. in the short term, this approach may have therapeutic potential.	UCL, SCH MED, LONDON W1N 8AA, ENGLAND	University of London; University College London; UCL Medical School	THRASHER, AJ (corresponding author), INST CHILD HLTH, MOLEC IMMUNOL UNIT, 30 GUILFORD ST, LONDON WC1N 1EH, ENGLAND.		Kinnon, Christine/A-1585-2010	Segal, Anthony/0000-0001-7602-9043	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BUESCHER ES, 1982, NEW ENGL J MED, V307, P800, DOI 10.1056/NEJM198209233071306; CASIMIR C, 1992, EUR J CLIN INVEST, V22, P403, DOI 10.1111/j.1365-2362.1992.tb01481.x; LEI F, 1994, BLOOD, V84, P53; OCHS HD, 1973, J PEDIATR-US, V83, P77, DOI 10.1016/S0022-3476(73)80316-6; PORTER CD, 1993, BLOOD, V82, P2196; THRASHER A, 1992, BLOOD, V80, P1125; THRASHER AJ, 1994, BBA-MOL BASIS DIS, V1227, P1, DOI 10.1016/0925-4439(94)90100-7	7	15	16	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 8	1995	346	8967					92	93		10.1016/S0140-6736(95)92116-8	http://dx.doi.org/10.1016/S0140-6736(95)92116-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH220	7541496				2022-12-24	WOS:A1995RH22000014
J	LOS, M; VANDECRAEN, M; PENNING, LC; SCHENK, H; WESTENDORP, M; BAEUERLE, PA; DROGE, W; KRAMMER, PH; FIERS, W; SCHULZEOSTHOFF, K				LOS, M; VANDECRAEN, M; PENNING, LC; SCHENK, H; WESTENDORP, M; BAEUERLE, PA; DROGE, W; KRAMMER, PH; FIERS, W; SCHULZEOSTHOFF, K			REQUIREMENT OF AN ICE/CED-3 PROTEASE FOR FAS/APO-1-MEDIATED APOPTOSIS	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; CELL-SURFACE ANTIGEN; INTERLEUKIN-1-BETA CONVERTING ENZYME; DEATH GENE CED-3; MOLECULAR-CLONING; MONOCLONAL-ANTIBODY; VIRUS ENCODES; FAS; INDUCTION; RECEPTOR	THE Fas/APO-1 receptor is one of the major regulators of apoptosis(1-7). We report here that Fas/APO-1-mediated apoptosis requires the activation of a new class of cysteine proteases, including interleukin-1 beta-converting enzyme (ICE)(8-10) which are homologous to the product of the Caenorhabditis elegans cell-death gene ced-3 (refs 11, 12). Triggering of Fas/APO-1 rapidly stimulated the proteolytic activity of ICE. Overexpression of ICE, achieved by electroporation and microinjection, strongly potentiated Fas/APO-1-mediated cell death. In addition, inhibition of ICE activity by protease inhibitors, as well as by transient expression of the pox virus-derived serpin inhibitor CrmA or an antisense ICE construct, substantially suppressed Fas/APO-1-triggered cell death. We conclude that activation of ICE or an ICE-related protease is a critical event in Fas/APO-1-mediated cell death.	GERMAN CANC RES CTR,DIV IMMUNOCHEM,W-6900 HEIDELBERG,GERMANY; GERMAN CANC RES CTR,IMMUNOGENET TUMOIMMUNOL PROGRAM,W-6900 HEIDELBERG,GERMANY; UNIV FREIBURG,INST BIOCHEM,D-79104 FREIBURG,GERMANY; STATE UNIV GHENT,MOLEC BIOL LAB,B-9000 GHENT,BELGIUM	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); University of Freiburg; Ghent University			Łos, Marek J/C-4038-2013; Schulze-Osthoff, Klaus/N-9025-2013; Penning, Louis/AAC-7524-2019	Schulze-Osthoff, Klaus/0000-0003-1443-2720; Los, Marek/0000-0001-9518-1411				CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; FERNANDESALNEMR.T, 1994, J BIOL CHEM, V269, P30761; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; HARDIN JA, 1992, J IMMUNOL METHODS, V154, P99, DOI 10.1016/0022-1759(92)90217-H; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; KRAMMER PH, 1994, CURR OPIN IMMUNOL, V6, P279, DOI 10.1016/0952-7915(94)90102-3; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; NETT MA, 1992, J IMMUNOL, V149, P3254; NIWA H, 1994, GENE, V108, P193; OEHM A, 1992, J BIOL CHEM, V267, P10709; PENNINGTON MW, 1994, PEPTIDE RES, V7, P72; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Schulze-Osthoff Klaus, 1994, Trends in Cell Biology, V4, P421, DOI 10.1016/0962-8924(94)90102-3; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; SCHULZEOSTHOFF K, 1994, J CELL BIOL, V127, P15, DOI 10.1083/jcb.127.1.15; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SMITH GL, 1989, J GEN VIROL, V70, P2333, DOI 10.1099/0022-1317-70-9-2333; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	26	654	677	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 4	1995	375	6526					81	83		10.1038/375081a0	http://dx.doi.org/10.1038/375081a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW604	7536901	Green Submitted			2022-12-24	WOS:A1995QW60400060
J	AVIEZER, D; HECHT, D; SAFRAN, M; EISINGER, M; DAVID, G; YAYON, A				AVIEZER, D; HECHT, D; SAFRAN, M; EISINGER, M; DAVID, G; YAYON, A			PERLECAN, BASAL LAMINA PROTEOGLYCAN, PROMOTES BASIC FIBROBLAST GROWTH FACTOR-RECEPTOR BINDING, MITOGENESIS, AND ANGIOGENESIS	CELL			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; NEURAL-TUBE DEFECTS; BASEMENT-MEMBRANE; MOUSE EMBRYOS; CELL-SURFACE; SEQUENCE; EXPRESSION; REQUIREMENT; PROTEIN; REGION	A survey of defined species of cell surface and extracellular matrix heparan sulfate proteoglycans (HSPG) was performed in a search for cellular proteoglycans that can promote bFGF receptor binding and biological activity. Of the various affinity-purified HSPGs tested, perlecan, the large basement membrane HSPG, is found to induce high affinity binding of bFGF both to cells deficient in HS and to soluble FGF receptors. Heparin-dependent mitogenic activity of bFGF is strongly augmented by perlecan. Monoclonal antibodies to perlecan extract the receptor binding promoting activity from active HSPG preparations. In a rabbit ear model for in vivo angiogenesis, perlecan is a potent inducer of bFGF-mediated neovascularization. These results identify perlecan as a major candidate for a bFGF low affinity, accessory receptor and an angiogenic modulator.	WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL; AMER CYANAMID CO,DEPT CELL BIOL,DIV MED RES,PEARL RIVER,NY 10965; CATHOLIC UNIV LEUVEN,CTR HUMAN GENET,B-3000 LOUVAIN,BELGIUM	Weizmann Institute of Science; KU Leuven								AVIEZER D, 1994, J BIOL CHEM, V269, P114; BERNARD O, 1991, P NATL ACAD SCI USA, V88, P7625, DOI 10.1073/pnas.88.17.7625; CARSON DD, 1993, DEV BIOL, V155, P97, DOI 10.1006/dbio.1993.1010; COPP AJ, 1988, DEVELOPMENT, V104, P285; COPP AJ, 1988, DEV BIOL, V130, P583, DOI 10.1016/0012-1606(88)90353-3; DAVID G, 1992, J CELL BIOL, V119, P961, DOI 10.1083/jcb.119.4.961; EDELMAN ER, 1991, BIOMATERIALS, V12, P619, DOI 10.1016/0142-9612(91)90107-L; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1988, AM J PATHOL, V130, P393; FRANSSON LA, 1981, J BIOL CHEM, V256, P3039; GALLAGHER JT, 1992, INT J BIOCHEM, V24, P553, DOI 10.1016/0020-711X(92)90326-V; GUELSTEIN VI, 1993, INT J CANCER, V53, P267; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; Howden G F, 1980, Int Endod J, V13, P3, DOI 10.1111/j.1365-2591.1980.tb00832.x; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MALI M, 1993, J BIOL CHEM, V268, P24215; MANSUKHANI A, 1992, P NATL ACAD SCI USA, V89, P3305, DOI 10.1073/pnas.89.8.3305; MERTENS G, 1992, J BIOL CHEM, V267, P20435; NADER HB, 1987, P NATL ACAD SCI USA, V84, P3566; NEUMANN PE, 1994, NAT GENET, V6, P357, DOI 10.1038/ng0494-357; NOONAN DM, 1991, J BIOL CHEM, V266, P22939; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RESCAN PY, 1993, AM J PATHOL, V142, P199; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; WALKER A, 1994, J BIOL CHEM, V269, P931; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	39	473	486	0	20	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 16	1994	79	6					1005	1013		10.1016/0092-8674(94)90031-0	http://dx.doi.org/10.1016/0092-8674(94)90031-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PY086	7528102				2022-12-24	WOS:A1994PY08600010
J	HOLTON, JB; LEONARD, JV				HOLTON, JB; LEONARD, JV			CLOUDS STILL GATHERING OVER GALACTOSEMIA	LANCET			English	Editorial Material							URIDINE-DIPHOSPHATE GALACTOSE; DEFICIENCY		INST CHILD HLTH,LONDON CTR PAEDIAT ENDOCRINOL & METAB,METAB UNIT,LONDON,ENGLAND	University of London; University College London	HOLTON, JB (corresponding author), UNIV BRISTOL,DEPT CHILD HLTH,BRISTOL BS8 1TH,AVON,ENGLAND.							ALLEN JT, 1980, LANCET, V1, P603; BAKKER HD, 1993, INT PEDIATR, V8, P135; Elsas LJ, 1993, INT PEDIATR, V8, P101; HOLTON JB, 1993, J PEDIATR-US, V123, P1009, DOI 10.1016/S0022-3476(05)80404-4; HOLTON JB, 1994, 32ND ANN S SOC STUD; JACOBS C, 1988, PRENAT DIAGN, V8, P641; KAUFMAN FR, 1994, J PEDIATR-US, V125, P225, DOI 10.1016/S0022-3476(94)70197-0; KEEVILL NJ, 1994, J INHERIT METAB DIS, V17, P23, DOI 10.1007/BF00735392; MATTISON DR, 1993, GALACTOSEMIA NEW FRO, P109; NG WG, 1989, J INHERIT METAB DIS, V12, P257, DOI 10.1007/BF01799215; ORNSTEIN KS, 1992, PEDIATR RES, V31, P508, DOI 10.1203/00006450-199205000-00020; SCHWEITZER S, 1993, EUR J PEDIATR, V152, P36, DOI 10.1007/BF02072514; Segal S, 1989, METABOLIC BASIS INHE, P453; SEGAL S, 1993, INT PEDIATR, V8, P125; Waggoner D. D., 1993, INT PEDIAT, V8, P97; WAGGONER DD, 1990, J INHERIT METAB DIS, V13, P802, DOI 10.1007/BF01800204; 1984, LANCET, V2, P1379	17	17	17	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 5	1994	344	8932					1242	1243		10.1016/S0140-6736(94)90745-5	http://dx.doi.org/10.1016/S0140-6736(94)90745-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP701	7526095				2022-12-24	WOS:A1994PP70100003
J	TAKESHIMA, H; IINO, M; TAKEKURA, H; NISHI, M; KUNO, J; MINOWA, O; TAKANO, H; NODA, T				TAKESHIMA, H; IINO, M; TAKEKURA, H; NISHI, M; KUNO, J; MINOWA, O; TAKANO, H; NODA, T			EXCITATION-CONTRACTION UNCOUPLING AND MUSCULAR DEGENERATION IN MICE LACKING FUNCTIONAL SKELETAL-MUSCLE RYANODINE-RECEPTOR GENE	NATURE			English	Article							CALCIUM RELEASE CHANNEL; SARCOPLASMIC-RETICULUM; CA-2+ RELEASE; MOLECULAR-CLONING; TARGETED MUTATION; MYOGENIN GENE; DNA; CDNA; INACTIVATION; EXPRESSION	CONTRACTION of skeletal muscle is triggered by the release of Ca2+ from the sarcoplasmic reticulum (SR) after depolarization of transverse tubules(1,2). The ryanodine receptor exists as a 'foot' protein in the junctional gap between the sarcoplasmic reticulum and the transverse tubule in skeletal muscle, and is proposed to function as a calcium-release channel during excitation-contraction (E-C) coupling(3-6). Previous complementary DNA-cloning studies have defined three distinct subtypes of the ryanodine receptor in mammalian tissues, namely skeletal muscle, cardiac and brain types(7-12). We report here mice with a targeted mutation in the skeletal muscle ryanodine receptor gene. Mice homozygous for the mutation die perinatally with gross abnormalities of the skeletal muscle. The contractile response to electrical stimulation under physiological conditions is totally abolished in the mutant muscle, although ryanodine receptors other than the skeletal-muscle type seem to exist because the response to caffeine is retained. Our results show that the skeletal muscle ryanodine receptor is essential for both muscular maturation and E-C coupling, and also imply that the function of the skeletal muscle ryanodine receptor during E-C coupling cannot be substituted by other subtypes of the receptor.	INT INST ADV STUDIES,KYOTO 604,JAPAN; UNIV TOKYO,FAC MED,DEPT PHARMACOL,BUNKYO KU,TOKYO 113,JAPAN; NATL INST FITNESS & SPORTS,DEPT PHYSIOL,KANOYA,KAGOSHIMA 89123,JAPAN; JAPANESE FDN CANC RES,INST CANC,DEPT CELL BIOL,TOSHIMA KU,TOKYO 170,JAPAN	University of Tokyo; National Institute Fitness & Sports Kanoya; Japanese Foundation for Cancer Research			Tuluc, Petronel/C-2527-2011; Minowa, Osamu/AAM-1238-2020; Noda, Tetsuo/B-1667-2016	Takeshima, Hiroshi/0000-0003-4525-3725				BEAM KG, 1986, NATURE, V320, P168, DOI 10.1038/320168a0; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; CHAUDHARI N, 1992, J BIOL CHEM, V267, P25636; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; GLIANNINI G, 1992, SCIENCE, V257, P91; GLUECKSOHNWAELS.S, 1963, SCIENCE, V142, P1269, DOI 10.1126/science.142.3597.1269; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; KLAUS MM, 1983, DEV BIOL, V99, P152, DOI 10.1016/0012-1606(83)90262-2; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MANSOUR AP, 1990, CELL, V62, P1073; MARTONOSI AN, 1984, PHYSIOL REV, V64, P1240, DOI 10.1152/physrev.1984.64.4.1240; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; NUMA S, 1990, COLD SPRING HARB SYM, V40, P1; OTSU K, 1990, J BIOL CHEM, V265, P13472; PAI AC, 1965, DEV BIOL, V11, P82, DOI 10.1016/0012-1606(65)90038-2; PAI AC, 1965, DEV BIOL, V11, P93, DOI 10.1016/0012-1606(65)90039-4; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAITO A, 1986, J CELL BIOL, V103, P741; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUTHERN EM, 1979, METHOD ENZYMOL, V88, P152; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TAKESHIMA H, 1993, FEBS LETT, V322, P105, DOI 10.1016/0014-5793(93)81547-D; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	34	329	337	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 16	1994	369	6481					556	559		10.1038/369556a0	http://dx.doi.org/10.1038/369556a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NR294	7515481				2022-12-24	WOS:A1994NR29400048
J	JAGOX, A; CARR, DB; PAYNE, R				JAGOX, A; CARR, DB; PAYNE, R			NEW CLINICAL-PRACTICE GUIDELINES FOR THE MANAGEMENT OF PAIN IN PATIENTS WITH CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									MASSACHUSETTS GEN HOSP,CTR PAIN,DEPT ANESTHESIA,BOSTON,MA 02114; JOHNS HOPKINS UNIV,SCH NURSING,BALTIMORE,MD 21205; MD ANDERSON CANC CTR,HOUSTON,TX 77030	Harvard University; Massachusetts General Hospital; Johns Hopkins University; University of Texas System; UTMD Anderson Cancer Center								ARCANGELI G, 1989, RADIOTHER ONCOL, V14, P95, DOI 10.1016/0167-8140(89)90053-4; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; FERRANTE FM, 1990, PATIENT CONTROLLED A; Field MJ, 1990, CLIN PRACTICE GUIDEL; FOLEY KM, 1985, NEW ENGL J MED, V313, P84, DOI 10.1056/NEJM198507113130205; GALER BS, 1992, PAIN, V49, P87, DOI 10.1016/0304-3959(92)90192-E; GROSSMAN SA, 1991, J PAIN SYMPTOM MANAG, V6, P53, DOI 10.1016/0885-3924(91)90518-9; Jacox A, 1994, CLIN PRACTICE GUIDEL; JACOX AK, 1994, AHCPR940594 AG HLTH; JACOX AK, 1994, AHCPR940593 PUBL; JACOX AK, 1994, AHCPR940596 AG HLTH; JACOX AK, 1994, AHCPR940595 AG HLTH; KAIKO RF, 1983, ANN NEUROL, V13, P180, DOI 10.1002/ana.410130213; PATT RB, 1993, CANCER PAIN; VONROENN JH, 1993, ANN INTERN MED, V119, P121, DOI 10.7326/0003-4819-119-2-199307150-00005; 1986, CANCER PAIN RELIEF; 1994, CANCER FACTS FIGURES, P2	17	207	214	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 3	1994	330	9					651	655		10.1056/NEJM199403033300926	http://dx.doi.org/10.1056/NEJM199403033300926			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY573	7508094	Bronze			2022-12-24	WOS:A1994MY57300037
J	GUSTAFSONBROWN, C; SAVIDGE, B; YANOFSKY, MF				GUSTAFSONBROWN, C; SAVIDGE, B; YANOFSKY, MF			REGULATION OF THE ARABIDOPSIS FLORAL HOMEOTIC GENE APETALA1	CELL			English	Article							FLOWER DEVELOPMENT; INFLORESCENCE DEVELOPMENT; TRANSCRIPTION FACTOR; DNA-BINDING; MADS-BOX; LEAFY; INTERACTS; DEFICIENS; THALIANA	The Arabidopsis floral homeotic gene APETALA1 (AP1) encodes a putative transcription factor that acts locally to specify the identity of the floral meristem and to determine sepal and petal development. RNA tissue in situ hybridization studies show that AP1 RNA accumulates uniformly throughout young floral primordia, but is absent from the inflorescence meristem. Later in development, AP1 RNA is excluded from cells that will give rise to the two inner whorls of organs. Here we show that AP1 expression is under the control of two negative regulators: the meristem identity gene TERMINAL FLOWER represses AP1 RNA accumulation in the inflorescence meristem, and the organ identity gene AGAMOUS prevents AP1 RNA accumulation in the two inner whorls of wild-type flowers. These and other data presented here lead to a revised model for the regulatory interactions among the genes specifying floral organ identity in Arabidopsis.	UNIV CALIF SAN DIEGO,CTR MOLEC GENET,LA JOLLA,CA 92093	University of California System; University of California San Diego	GUSTAFSONBROWN, C (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093, USA.				NIGMS NIH HHS [GMO7313] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALVAREZ J, 1992, PLANT J, V2, P103, DOI 10.1111/j.1365-313X.1992.00103.x; BOWMAN JL, 1991, DEVELOPMENT, V112, P1; BOWMAN JL, 1992, DEVELOPMENT, V114, P599; BOWMAN JL, 1993, DEVELOPMENT, V119, P721; BOWMAN JL, 1989, PLANT CELL, V1, P37, DOI 10.1105/tpc.1.1.37; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; HAYES TE, 1988, GENE DEV, V2, P1713, DOI 10.1101/gad.2.12b.1713; HUALA E, 1992, PLANT CELL, V4, P901, DOI 10.1105/tpc.4.8.901; IRISH VF, 1990, PLANT CELL, V2, P741, DOI 10.1105/tpc.2.8.741; JACK T, 1992, CELL, V68, P683, DOI 10.1016/0092-8674(92)90144-2; MA H, 1991, GENE DEV, V5, P484, DOI 10.1101/gad.5.3.484; MANDEL MA, 1992, NATURE, V360, P273, DOI 10.1038/360273a0; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; SCHULTZ EA, 1991, PLANT CELL, V3, P771, DOI 10.1105/tpc.3.8.771; SCHWARZSOMMER Z, 1992, EMBO J, V11, P251, DOI 10.1002/j.1460-2075.1992.tb05048.x; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; SHANNON S, 1991, PLANT CELL, V3, P877, DOI 10.1105/tpc.3.9.877; SHANNON S, 1993, PLANT CELL, V5, P639, DOI 10.1105/tpc.5.6.639; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; TROBNER W, 1992, EMBO J, V11, P4693, DOI 10.1002/j.1460-2075.1992.tb05574.x; WEIGEL D, 1993, SCIENCE, V261, P1723, DOI 10.1126/science.261.5129.1723; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0	24	320	344	1	48	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 14	1994	76	1					131	143		10.1016/0092-8674(94)90178-3	http://dx.doi.org/10.1016/0092-8674(94)90178-3			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MR495	7506995				2022-12-24	WOS:A1994MR49500012
J	RASTINEJAD, F; CONBOY, MJ; RANDO, TA; BLAU, HM				RASTINEJAD, F; CONBOY, MJ; RANDO, TA; BLAU, HM			TUMOR SUPPRESSION BY RNA FROM THE 3' UNTRANSLATED REGION OF ALPHA-TROPOMYOSIN	CELL			English	Article							TRANSFORMED-CELLS; MOLECULAR-CLONING; EPITHELIAL-CELLS; GENE-EXPRESSION; PROTEIN-KINASE; GROWTH-FACTOR; CANCER-CELLS; BHK CELLS; RETINOBLASTOMA; ONCOGENE	NMU2, a nondifferentiating mutant myogenic cell line, gives rise to rhabdomyosarcomas in mice. We show that constitutive expression of RNA from 0.2 kb of the alpha-tropomyosin (Tm) 3' untranslated region (UTR), but not control 3'UTRs, suppresses anchorage-independent growth and tumor formation by NMU2 cells. When beta-galactosidase (beta-gal)-labeled cells were implanted into muscles of adult mouse hindlimbs, Tm 3'UTR expression suppressed the proliferation, invasion, and destruction of muscle tissues characteristic of NMU2. In the rare tumors that developed from Tm 3'UTR transfectants, RNA expression was extinguished. These results suggest that suppression of tumorigenicity is dependent on the continued expression of Tm transcripts lacking a coding region. We conclude that untranslated RNAs can function as regulators (riboregulators) that suppress tumor formation.			RASTINEJAD, F (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT MOLEC PHARMACOL,STANFORD,CA 94305, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020203] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014588] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 20203, HD 07249-11] Funding Source: Medline; NIGMS NIH HHS [GM 14588] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; BOUCK N, 1982, MOL CELL BIOL, V2, P97, DOI 10.1128/MCB.2.2.97; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHAN D, 1989, P NATL ACAD SCI USA, V86, P2747, DOI 10.1073/pnas.86.8.2747; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHO M, 1993, J CELL BIOL, V121, P795, DOI 10.1083/jcb.121.4.795; COOPER HL, 1985, MOL CELL BIOL, V5, P972, DOI 10.1128/MCB.5.5.972; COOPER HL, 1987, CANCER RES, V47, P4493; EIDEN MV, 1991, MOL CELL BIOL, V11, P5321, DOI 10.1128/MCB.11.10.5321; ENZINGER FM, 1988, SOFT TISSUE TUMORS, P448; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; FERNANDEZ JLR, 1993, J CELL BIOL, V122, P1285, DOI 10.1083/jcb.122.6.1285; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOINTOURA BMA, 1992, MOL CELL BIOL, V12, P5145; FUKUI T, 1982, J BIOCHEM-TOKYO, V91, P331, DOI 10.1093/oxfordjournals.jbchem.a133692; GABBIANI G, 1976, AM J PATHOL, V83, P457; GERWIN BI, 1992, P NATL ACAD SCI USA, V89, P2759, DOI 10.1073/pnas.89.7.2759; GLUCK U, 1993, P NATL ACAD SCI USA, V90, P383, DOI 10.1073/pnas.90.2.383; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GRAHAM F, 1973, VIROLOGY, V52, P452; HARRIS H, 1985, J CELL SCI, V79, P83; HARRIS H, 1969, NATURE, V223, P363, DOI 10.1038/223363a0; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HITI AL, 1989, MOL CELL BIOL, V9, P4722, DOI 10.1128/MCB.9.11.4722; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUGHES SM, 1992, CELL, V68, P659, DOI 10.1016/0092-8674(92)90142-Y; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; LEAVITT J, 1982, CELL, V28, P259, DOI 10.1016/0092-8674(82)90344-0; LEAVITT J, 1985, NATURE, V316, P840, DOI 10.1038/316840a0; LEESMILLER JP, 1991, BIOESSAYS, V13, P429, DOI 10.1002/bies.950130902; LIN JJC, 1985, J CELL BIOL, V100, P692, DOI 10.1083/jcb.100.3.692; LIU DG, 1992, SCI CHINA SER B, V35, P822; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; MARTINZANCA D, 1986, COLD SPRING HARB SYM, V51, P983, DOI 10.1101/SQB.1986.051.01.112; MATSUMURA F, 1983, J BIOL CHEM, V258, P3954; MECHLER BM, 1985, EMBO J, V4, P1551, DOI 10.1002/j.1460-2075.1985.tb03816.x; Mintz B, 1981, Adv Cancer Res, V34, P211, DOI 10.1016/S0065-230X(08)60243-2; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NIGRO JM, 1992, MOL CELL BIOL, V12, P1357, DOI 10.1128/MCB.12.3.1357; OSKAM R, 1988, P NATL ACAD SCI USA, V85, P2964, DOI 10.1073/pnas.85.9.2964; PETERSON CA, 1990, CELL, V62, P493, DOI 10.1016/0092-8674(90)90014-6; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; RASTINEJAD F, 1993, CELL, V72, P903, DOI 10.1016/0092-8674(93)90579-F; RASTINEJAD F, 1989, CELL, V56, P345, DOI 10.1016/0092-8674(89)90238-9; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; SACHS L, 1981, BLOOD CELLS, V7, P31; Sachs L, 1984, Symp Fundam Cancer Res, V37, P341; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SHIMOYAMA Y, 1992, CANCER RES, V52, P5770; VANDERIJN M, 1993, IN PRESS APPL IMMUNO; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; ZAJCHOWSKI DA, 1990, P NATL ACAD SCI USA, V87, P2314, DOI 10.1073/pnas.87.6.2314; ZELENETZ AD, 1993, GENE CHROMOSOME CANC, V6, P140, DOI 10.1002/gcc.2870060303	61	200	203	1	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 17	1993	75	6					1107	1117		10.1016/0092-8674(93)90320-P	http://dx.doi.org/10.1016/0092-8674(93)90320-P			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MM893	7505203				2022-12-24	WOS:A1993MM89300009
J	LIEM, KF; TREMML, G; ROELINK, H; JESSELL, TM				LIEM, KF; TREMML, G; ROELINK, H; JESSELL, TM			DORSAL DIFFERENTIATION OF NEURAL PLATE CELLS INDUCED BY BMP-MEDIATED SIGNALS FROM EPIDERMAL ECTODERM	CELL			English	Article							FLOOR PLATE; SPINAL-CORD; HOMEOBOX GENE; CREST CELLS; LIMB BUDS; NOTOCHORD; PATTERN; EXPRESSION; INDUCTION; TUBE	The cellular interactions that control the differentiation of dorsal cell types from neural progenitors have been examined in neural plate explants. Certain genes that are expressed in the dorsal neural tube are initially expressed uniformly within the neural plate and appear to achieve their dorsal restriction through a Sonic hedgehog (SHH)-mediated repressive signal from the notochord. The acquisition of definitive dorsal cell fates, however, requires a contact-dependent signal from the epidermal ectoderm, BMP4 and BMP7 are expressed in the epidermal ectoderm, and both proteins mimic its inductive activity, BMP4 and a related gene, DSL1, are subsequently expressed by cells in the dorsal neural tube. The differentiation of dorsal cell types, therefore, appears to be initiated at the neural plate stage and to involve the opponent activities of a BMP-mediated dorsalizing signal from the epidermal ectoderm and a SHH-mediated ventralizing signal from the notochord.			LIEM, KF (corresponding author), COLUMBIA UNIV,CTR NEUROBIOL & BEHAV,DEPT BIOCHEM & MOLEC BIOPHYS,HOWARD HUGHES MED INST,NEW YORK,NY 10032, USA.			Roelink, Henk/0000-0002-5260-3634	NIGMS NIH HHS [5-T32-GM07367] Funding Source: Medline; NIMH NIH HHS [IP50 MH5000733-2] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007367] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARTINGER KB, 1992, DEVELOPMENT, V116, P877; BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; BRANDSABERI B, 1993, ANAT EMBRYOL, V188, P239; DICKINSON ME, 1995, DEVELOPMENT, V121, P2099; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; ERICSON J, 1995, CELL, V81, P747, DOI 10.1016/0092-8674(95)90536-7; FAINSOD A, 1994, EMBO J, V13, P5015, DOI 10.1002/j.1460-2075.1994.tb06830.x; FAN CM, 1994, CELL, V79, P1175, DOI 10.1016/0092-8674(94)90009-4; FAN CM, 1995, CELL, V81, P457, DOI 10.1016/0092-8674(95)90398-4; FRANCIS PH, 1994, DEVELOPMENT, V120, P209; GOULDING MD, 1993, DEVELOPMENT, V117, P1001; GRAHAM A, 1994, NATURE, V372, P684, DOI 10.1038/372684a0; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HOUSTON B, 1994, J MOL ENDOCRINOL, V13, P289, DOI 10.1677/jme.0.0130289; JOHNSON RL, 1995, CELL, V81, P313, DOI 10.1016/0092-8674(95)90381-X; JOHNSON RL, 1994, CELL, V79, P1165, DOI 10.1016/0092-8674(94)90008-6; JONES CM, 1991, DEVELOPMENT, V111, P531; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LU S, 1992, P NATL ACAD SCI USA, V89, P8053, DOI 10.1073/pnas.89.17.8053; LYONS KM, 1995, MECH DEVELOP, V50, P71, DOI 10.1016/0925-4773(94)00326-I; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; MARTINSGREEN M, 1988, DEVELOPMENT, V103, P607; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MAYOR R, 1995, DEVELOPMENT, V121, P767; MOURY JD, 1990, DEV BIOL, V141, P243, DOI 10.1016/0012-1606(90)90380-2; MOURY JD, 1989, DEV BIOL, V133, P44, DOI 10.1016/0012-1606(89)90295-9; NAKAGAWA S, 1995, DEVELOPMENT, V121, P1321; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; PLACZEK M, 1993, DEVELOPMENT, V117, P205; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; POURQUIE O, 1993, P NATL ACAD SCI USA, V90, P5242, DOI 10.1073/pnas.90.11.5242; RANGINI Z, 1991, MECH DEVELOP, V35, P13, DOI 10.1016/0925-4773(91)90037-7; ROBERT B, 1991, GENE DEV, V5, P2363, DOI 10.1101/gad.5.12b.2363; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; SATOKATA I, 1994, NAT GENET, V6, P348, DOI 10.1038/ng0494-348; SCHERSON T, 1993, DEVELOPMENT, V118, P1049; SELLECK MAJ, 1995, DEVELOPMENT, V121, P525; SMITH JC, 1994, CELL, V76, P193, DOI 10.1016/0092-8674(94)90325-5; STUART ET, 1994, ANNU REV GENET, V28, P219, DOI 10.1146/annurev.ge.28.120194.001251; TAKADA S, 1994, GENE DEV, V8, P174, DOI 10.1101/gad.8.2.174; TAKAHASHI Y, 1992, P NATL ACAD SCI USA, V89, P10237, DOI 10.1073/pnas.89.21.10237; TANABE Y, 1995, CURR BIOL, V5, P651, DOI 10.1016/S0960-9822(95)00130-8; TRUEB B, 1988, NUCLEIC ACIDS RES, V16, P4723, DOI 10.1093/nar/16.10.4723; TUCKER GC, 1984, CELL DIFFER DEV, V14, P223, DOI 10.1016/0045-6039(84)90049-6; VAINIO S, 1993, CELL, V75, P45, DOI 10.1016/S0092-8674(05)80083-2; VANSTRAATEN HWM, 1991, ANAT EMBRYOL, V184, P55; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O; YOKOUCHI Y, 1991, DEVELOPMENT, V113, P431; ZIMMERMAN K, 1993, DEVELOPMENT, V119, P221	53	879	901	2	36	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 22	1995	82	6					969	979		10.1016/0092-8674(95)90276-7	http://dx.doi.org/10.1016/0092-8674(95)90276-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RW693	7553857	hybrid			2022-12-24	WOS:A1995RW69300013
J	SCOTT, DM; EHRMANN, IE; ELLIS, PS; BISHOP, CE; AGULNIK, AI; SIMPSON, E; MITCHELL, MJ				SCOTT, DM; EHRMANN, IE; ELLIS, PS; BISHOP, CE; AGULNIK, AI; SIMPSON, E; MITCHELL, MJ			IDENTIFICATION OF A MOUSE MALE-SPECIFIC TRANSPLANTATION ANTIGEN, H-Y	NATURE			English	Article							UBIQUITIN-ACTIVATING ENZYME-E1; T-CELLS; GENE; EXPRESSION; CHROMOSOME; RESPONSES; LOCATION; EPITOPES; PEPTIDE; MICE	THE male-specific transplantation antigen, H-Y, causes rejection of male tissue grafts by genotypically identical female mice(1) and contributes to the rejection of human leukocyte antigen-matched male organ grafts by human females(2). Although first recognized 40 years ago(1), the identity of H-Y has remained elusive. T cells detect several distinct H-Y epitopes(3-5), and these are probably peptides, derived from intracellular proteins, that are presented at the cell surface with major histocompatibility complex (MHC) molecules(6). In the mouse, the gene(s) controlling H-Y expression (Hya) are located on the short arm of the Y chromosome(7,8) between the zinc-finger genes Zfy-1 and Zfy-2 (ref. 9). We have recently identified Smcy, a ubiquitously expressed gene, in this region(10) and its X-chromosome homologue, Smcx(11). Here we report that Smcy encodes an H-YKk epitope that is defined by the octamer peptide TENSGKDI: no similar peptide is found in Smcx. These findings provide a genetic basis for the antigenic difference between males and females that contributes towards a tissue transplant rejection response.	INSERM, U406, F-13005 MARSEILLE, FRANCE; BAYLOR COLL MED, DEPT OBSTET & GYNAECOL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT HUMAN & MOLEC GENET, HOUSTON, TX 77030 USA; UNIV TENNESSEE, DEPT OBSTET & GYNAECOL, MEMPHIS, TN 38105 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Baylor College of Medicine; Baylor College of Medicine; University of Tennessee System; University of Tennessee Health Science Center	SCOTT, DM (corresponding author), HAMMERSMITH HOSP, ROYAL POSTGRAD MED SCH, MRC, CTR CLIN SCI, DU CANE RD, LONDON W12 0NN, ENGLAND.		Agoulnik, Alexander/AAK-3213-2020; Mitchell, Michael/I-3987-2016	Agoulnik, Alexander/0000-0001-6587-6845; Mitchell, Michael/0000-0003-2052-7347; Simpson, Elizabeth/0000-0002-2118-3139				AGULNIK AI, 1994, HUM MOL GENET, V3, P873, DOI 10.1093/hmg/3.6.873; AGULNIK AI, 1994, HUM MOL GENET, V3, P879, DOI 10.1093/hmg/3.6.879; BURGOYNE PS, 1986, NATURE, V320, P170, DOI 10.1038/320170a0; CHOMEZ P, 1992, IMMUNOGENETICS, V35, P241, DOI 10.1007/BF00166829; EICHWALD EJ, 1955, TRANSPLAN B, V2, P121; FATTAEY AR, 1993, ONCOGENE, V8, P3149; GAVIN MA, 1994, EUR J IMMUNOL, V24, P2124, DOI 10.1002/eji.1830240929; GORDON RD, 1975, J EXP MED, V142, P1108, DOI 10.1084/jem.142.5.1108; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; KAY GF, 1991, NATURE, V354, P486, DOI 10.1038/354486a0; KING TR, 1994, GENOMICS, V24, P159, DOI 10.1006/geno.1994.1593; LURQUIN C, 1989, CELL, V58, P293, DOI 10.1016/0092-8674(89)90844-1; MCLAREN A, 1988, P NATL ACAD SCI USA, V85, P6442, DOI 10.1073/pnas.85.17.6442; MITCHELL MJ, 1991, NATURE, V354, P483, DOI 10.1038/354483a0; PFEFFER PF, 1982, TRANSPLANTATION, V33, P52, DOI 10.1097/00007890-198201000-00011; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; ROBERTS C, 1988, P NATL ACAD SCI USA, V85, P6446, DOI 10.1073/pnas.85.17.6446; ROOPENIAN DC, 1992, IMMUNOL TODAY, V13, P7, DOI 10.1016/0167-5699(92)90197-F; ROOPENIAN DC, 1989, IMMUNOGENETICS, V30, P335, DOI 10.1007/BF02425273; ROTZSCHKE O, 1990, SCIENCE, V249, P283, DOI 10.1126/science.1695760; SCOTT D, 1991, IMMUNOGENETICS, V33, P54, DOI 10.1007/BF00211696; SCOTT DM, 1992, IMMUNOGENETICS, V36, P86, DOI 10.1007/BF00215284; SIBILLE C, 1990, J EXP MED, V172, P35, DOI 10.1084/jem.172.1.35; SIMPSON E, 1982, IMMUNOL TODAY, V3, P97, DOI 10.1016/S0167-5699(82)80025-X; SIMPSON E, 1989, K IMMUNOLOGY S, V2, P42; SIMPSON EM, 1991, GENOMICS, V11, P601, DOI 10.1016/0888-7543(91)90067-O; TOMONARI K, 1983, J IMMUNOL, V131, P1641; WU JS, 1994, HUM MOL GENET, V3, P153, DOI 10.1093/hmg/3.1.153	28	171	178	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 24	1995	376	6542					695	698		10.1038/376695a0	http://dx.doi.org/10.1038/376695a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RQ672	7544442				2022-12-24	WOS:A1995RQ67200062
J	KOOYMAN, DL; BYRNE, GW; MCCLELLAN, S; NIELSEN, D; TONE, M; WALDMANN, H; COFFMAN, TM; MCCURRY, KR; PLATT, JL; LOGAN, JS				KOOYMAN, DL; BYRNE, GW; MCCLELLAN, S; NIELSEN, D; TONE, M; WALDMANN, H; COFFMAN, TM; MCCURRY, KR; PLATT, JL; LOGAN, JS			IN-VIVO TRANSFER OF GPI-LINKED COMPLEMENT RESTRICTION FACTORS FROM ERYTHROCYTES TO THE ENDOTHELIUM	SCIENCE			English	Article							DECAY-ACCELERATING FACTOR; VARIANT SURFACE GLYCOPROTEIN; RAPID LATERAL DIFFUSION; TRANSGENIC MICE; MEMBRANE-PROTEIN; HUMAN-HEMOGLOBIN; LYMPHOID-CELLS; GLOBIN GENE; HIGH-LEVEL; EXPRESSION	Many proteins are associated with the outer layer of the cell membrane through a posttranslationally added glycosyl phosphatidylinositol (GPI) anchor. The functional significance of this type of protein linkage is unclear, although it results in increased lateral mobility, sorting to the apical surface of the cell, reinsertion into cell membranes, and possibly cell signaling. Here evidence is presented that GPI-linked proteins can undergo intermembrane transfer in vivo. GPI-linked proteins expressed on the surface of transgenic mouse red blood cells were transferred in a functional form to endothelial cells in vivo. This feature of GPI linkage may be potentially useful for the delivery of therapeutic proteins to vascular endothelium.	UNIV OXFORD,SIR WILLIAM DUNN SCH PATHOL,OXFORD OX1 3RE,ENGLAND; DUKE UNIV,MED CTR,DURHAM,NC 27705; DUKE UNIV,MED CTR,DEPT SURG,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PEDIAT,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT IMMUNOL,DURHAM,NC 27710	University of Oxford; Duke University; Duke University; Duke University; Duke University	KOOYMAN, DL (corresponding author), NEXTRAN,303B COLL RD E,PRINCETON,NJ 08540, USA.		waldmann, herman/W-8051-2019	Waldmann, Herman/0000-0001-7519-6720; Platt, Jeffrey/0000-0002-4915-0419	NHLBI NIH HHS [HL 52297, HL 46810, HL 50985] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL050985, R01HL052297, R37HL052297, R01HL046810] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEHRINGER RR, 1989, SCIENCE, V245, P971, DOI 10.1126/science.2772649; BULOW R, 1988, BIOCHEMISTRY-US, V27, P2384; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DALMASSO AP, 1991, TRANSPLANTATION, V52, P530, DOI 10.1097/00007890-199109000-00029; DAVIES A, 1989, J EXP MED, V170, P637, DOI 10.1084/jem.170.3.637; FALK RJ, 1983, J CLIN INVEST, V72, P560, DOI 10.1172/JCI111004; GREAVES DR, 1990, NATURE, V343, P183, DOI 10.1038/343183a0; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HANSCOMBE O, 1989, GENE DEV, V3, P1572, DOI 10.1101/gad.3.10.1572; Hogan B., 1986, MANIPULATING MOUSE E; HUANG JH, 1994, IMMUNITY, V1, P607, DOI 10.1016/1074-7613(94)90050-7; ISHIHARA A, 1987, P NATL ACAD SCI USA, V84, P1290, DOI 10.1073/pnas.84.5.1290; KINOSHITA T, 1991, IMMUNOL TODAY, V12, P291, DOI 10.1016/0167-5699(91)90001-A; LEONG LYW, 1992, EUR J IMMUNOL, V22, P2825, DOI 10.1002/eji.1830221111; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LISANTI MP, 1990, J MEMBRANE BIOL, V117, P1, DOI 10.1007/BF01871561; MEDOF ME, 1984, J EXP MED, V160, P1558, DOI 10.1084/jem.160.5.1558; MERI S, 1990, IMMUNOLOGY, V71, P1; NICHOLSONWELLER A, 1982, J IMMUNOL, V129, P184; PEARCE EJ, 1990, J IMMUNOL, V144, P2751; PLATT JL, 1983, J EXP MED, V158, P1227, DOI 10.1084/jem.158.4.1227; RIFKIN MR, 1990, P NATL ACAD SCI USA, V87, P801, DOI 10.1073/pnas.87.2.801; ROLLINS SA, 1990, J IMMUNOL, V144, P3478; SUGITA Y, 1988, J BIOCHEM-TOKYO, V104, P633, DOI 10.1093/oxfordjournals.jbchem.a122524; TOWNES TM, 1985, EMBO J, V4, P1715, DOI 10.1002/j.1460-2075.1985.tb03841.x; VAKEVA A, 1994, IMMUNOLOGY, V82, P28; WAGNER RC, 1975, MICROVASC RES, V10, P286, DOI 10.1016/0026-2862(75)90033-3; ZHANG F, 1992, P NATL ACAD SCI USA, V89, P5231, DOI 10.1073/pnas.89.12.5231	28	221	228	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 7	1995	269	5220					89	92		10.1126/science.7541557	http://dx.doi.org/10.1126/science.7541557			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RG980	7541557				2022-12-24	WOS:A1995RG98000041
J	SCHWIEBERT, EM; EGAN, ME; HWANG, TH; FULMER, SB; ALLEN, SS; CUTTING, GR; GUGGINO, WB				SCHWIEBERT, EM; EGAN, ME; HWANG, TH; FULMER, SB; ALLEN, SS; CUTTING, GR; GUGGINO, WB			CFTR REGULATES OUTWARDLY RECTIFYING CHLORIDE CHANNELS THROUGH AN AUTOCRINE MECHANISM INVOLVING ATP	CELL			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; ION-TRANSPORT DEFECT; CYSTIC-FIBROSIS GENE; EPITHELIAL-CELLS; CL CHANNELS; EXTRACELLULAR ATP; PROTEIN-KINASE; ACTIVATION; IDENTIFICATION; EXPRESSION	The cystic fibrosis transmembrane conductance regulator (CFTR) functions to regulate both Cl- and Na+ conductive pathways; however, the cellular mechanisms whereby CFTR acts as a conductance regulator are unknown. CFTR and outwardly rectifying Cl- channels (ORCCs) are distinct channels but are linked functionally via an unknown regulatory mechanism. We present results from whole-cell and single-channel patch-clamp recordings, short-circuit current recordings, and [gamma-P-32]ATP release assays of normal, CF, and wild-type or mutant CFTR-transfected CF airway cultured epithelial cells wherein CFTR regulates ORCCs by triggering the transport of the potent agonist, ATP, out of the cell. Once released, ATP stimulates ORCCs through a P-2U purinergic receptor-dependent signaling mechanism. Our results suggest that CFTR functions to regulate other Cl- secretory pathways in addition to itself conducting Cl-.	JOHNS HOPKINS UNIV, SCH MED, DEPT PEDIAT, BALTIMORE, MD 21205 USA; JOHNS HOPKINS MED INST, CTR MED GENET, DEPT PEDIAT, BALTIMORE, MD 21287 USA; YALE UNIV, SCH MED, DEPT PEDIAT, NEW HAVEN, CT 06520 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Yale University	SCHWIEBERT, EM (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT PHYSIOL, BALTIMORE, MD 21205 USA.							ALTON EWFW, 1993, NAT GENET, V5, P135, DOI 10.1038/ng1093-135; AMBUDKAR SV, 1984, J BIOL CHEM, V259, P2576; BARNARD EA, 1994, TRENDS PHARMACOL SCI, V15, P67, DOI 10.1016/0165-6147(94)90280-1; CHINET TC, 1994, AM J PHYSIOL, V266, pC1061, DOI 10.1152/ajpcell.1994.266.4.C1061; CHU CS, 1991, EMBO J, V10, P1355, DOI 10.1002/j.1460-2075.1991.tb07655.x; CLARKE LL, 1992, AM J PHYSIOL, V263, pC348, DOI 10.1152/ajpcell.1992.263.2.C348; CLIFF WH, 1992, AM J PHYSIOL, V262, pC1154, DOI 10.1152/ajpcell.1992.262.5.C1154; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; FLOTTE TR, 1993, J BIOL CHEM, V268, P3781; FULMER SB, 1995, IN PRESS P NATL ACAD, V92; GABRIEL SE, 1993, NATURE, V363, P263, DOI 10.1038/363263a0; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; GRUBB BR, 1994, AM J PHYSIOL, V266, pC1478, DOI 10.1152/ajpcell.1994.266.5.C1478; GRUENERT DC, 1988, P NATL ACAD SCI USA, V85, P5951, DOI 10.1073/pnas.85.16.5951; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; HYDE SC, 1993, NATURE, V362, P250, DOI 10.1038/362250a0; JOHNSON LJ, 1995, IN PRESS J CLIN INVE; KNOWLES MR, 1991, NEW ENGL J MED, V325, P533, DOI 10.1056/NEJM199108223250802; KUNZELMANN K, 1993, AM J RESP CELL MOL, V8, P522, DOI 10.1165/ajrcmb/8.5.522; LUSTIG KD, 1993, P NATL ACAD SCI USA, V90, P5113, DOI 10.1073/pnas.90.11.5113; PARR CE, 1994, P NATL ACAD SCI USA, V91, P3275, DOI 10.1073/pnas.91.8.3275; QUINTON PM, 1992, NATURE, V360, P79, DOI 10.1038/360079a0; QUINTON PM, 1983, NATURE, V301, P421, DOI 10.1038/301421a0; REISIN IL, 1994, J BIOL CHEM, V269, P20584; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SCHWIEBERT EM, 1992, P NATL ACAD SCI USA, V89, P10623, DOI 10.1073/pnas.89.22.10623; SCHWIEBERT EM, 1994, AM J PHYSIOL, V267, pC272, DOI 10.1152/ajpcell.1994.267.1.C272; SCHWIEBERT EM, 1994, AM J PHYSIOL, V266, pC1464, DOI 10.1152/ajpcell.1994.266.5.C1464; SHEPPARD DN, 1993, ANN NY ACAD SCI, V707, P275, DOI 10.1111/j.1749-6632.1993.tb38058.x; SINGH AK, 1993, BIOPHYS J, V64, pA17; STUTTS MJ, 1994, AM J PHYSIOL-CELL PH, V267, pC1442, DOI 10.1152/ajpcell.1994.267.5.C1442; WELSH MJ, 1986, CLIN CHEST MED, V7, P273; WORRELL RT, 1989, AM J PHYSIOL, V256, pC1111, DOI 10.1152/ajpcell.1989.256.6.C1111; ZEITLIN PL, 1991, AM J RESP CELL MOL, V4, P313, DOI 10.1165/ajrcmb/4.4.313	36	584	587	1	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 30	1995	81	7					1063	1073		10.1016/S0092-8674(05)80011-X	http://dx.doi.org/10.1016/S0092-8674(05)80011-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RG910	7541313	Bronze			2022-12-24	WOS:A1995RG91000011
J	MUKHOPADHYAY, D; TSIOKAS, L; ZHOU, XM; FOSTER, D; BRUGGE, JS; SUKHATME, VP				MUKHOPADHYAY, D; TSIOKAS, L; ZHOU, XM; FOSTER, D; BRUGGE, JS; SUKHATME, VP			HYPOXIC INDUCTION OF HUMAN VASCULAR ENDOTHELIAL GROWTH-FACTOR EXPRESSION THROUGH C-SRC ACTIVATION	NATURE			English	Article							PROTEIN-TYROSINE KINASE; OVEREXPRESSED PP60C-SRC; CELL-TRANSFORMATION; ANGIOGENESIS; GENE; PHOSPHORYLATION; FAMILY	ANGIOGENESIS the formation of new microvasculature by capillary sprouting, is crucial for tumour development(1). Hypoxic regions of solid tumours produce the powerful and directly acting angiogenic protein VEGF/VPF (vascular endothelial growth factor/vascular permeability factor)(2-6). We now investigate the signal transduction pathway involved in hypoxic induction of VEGF expression. Hypoxia is known to induce a tyrosine kinase cascade that results in the activation of nitrogen-fixation genes in Rhizobium meliloti(7), and activation of tyrosine kinases is critical in signalling triggered by growth factors and ultraviolet light. We show here that genistein, an inhibitor of protein tyrosine kinases blocks VEGF induction. Hypoxia increases the kinase activity of pp60(c-src) and its phosphorylation on tyrosine 416 but does not activate Fyn or Yes. Expression of either a dominant-negative mutant form of c-Src or of Raf-1 markedly reduces VEGF induction. VEGF induction by hypoxia in c-src(-) cells is impaired, although there is a compensatory activation of Fyn. Our results provide an insight into hypoxia-triggered intracellular signalling, define VEGF as a new downstream target for c-Src, and suggest a role for c-Src in promoting angiogenesis.	BETH ISRAEL HOSP, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02215 USA; ARIAD PHARMACEUT INC, CAMBRIDGE, MA 02139 USA; CUNY HUNTER COLL, NEW YORK, NY 10018 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Takeda Pharmaceutical Company Ltd; Takeda Oncology; City University of New York (CUNY) System; Hunter College (CUNY)			Sukhatme, Vikas/W-2776-2019	Tsiokas, Leonidas/0000-0002-3659-1813				AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BREIER G, 1992, DEVELOPMENT, V114, P521; BREWER CB, 1994, METHOD CELL BIOL, V43, P233; CHENG HC, 1992, J BIOL CHEM, V267, P9248; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; FOLKMAN J, 1975, ANN INTERN MED, V82, P96, DOI 10.7326/0003-4819-82-1-96; GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOONG AC, 1994, CANCER RES, V54, P5273; KOUREMBANAS S, 1991, J CLIN INVEST, V88, P1054, DOI 10.1172/JCI115367; KOUREMBANAS S, 1990, J CLIN INVEST, V86, P670, DOI 10.1172/JCI114759; LABOW MA, 1990, MOL CELL BIOL, V10, P3343, DOI 10.1128/MCB.10.7.3343; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; THOMAS JE, 1993, ONCOGENE, V8, P2521; THOMAS JE, 1991, SCIENCE, V254, P568, DOI 10.1126/science.1719633; UCKUN FM, 1995, SCIENCE, V267, P886, DOI 10.1126/science.7531365; WEBSTER KA, 1993, J BIOL CHEM, V268, P16852	28	540	558	0	10	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 15	1995	375	6532					577	581		10.1038/375577a0	http://dx.doi.org/10.1038/375577a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD287	7540725				2022-12-24	WOS:A1995RD28700048
J	COLLARD, JF; COTE, F; JULIEN, JP				COLLARD, JF; COTE, F; JULIEN, JP			DEFECTIVE AXONAL-TRANSPORT IN A TRANSGENIC MOUSE MODEL OF AMYOTROPHIC-LATERAL-SCLEROSIS	NATURE			English	Article							DISEASE	AMYOTROPHIC lateral sclerosis (ALS) is a degenerative disease of motor neurons, characterized by depositions of neurofilaments in the perikarya and proximal axons. The pathogenesis of ALS remains poorly understood, but two lines of evidence suggest that neurofilament accumulation may play a causal role. First, transgenic mice that overexpress neurofilament proteins show motor neuron degeneration(1-3) and, second, variant alleles of the neurofilament heavy-subunit gene (NF-H) have been found in some human ALS patients(4). To investigate hom disorganized neurofilaments might cause neurodegeneration, we examined axonal transport of newly synthesized proteins in mice that overexpress the human NF-H gene(1). We observed dramatic defects of axonal transport, not only of neurofilament proteins but also of other proteins, including tubulin and actin. Ultrastructural analysis revealed a paucity of cytoskeletal elements, smooth endoplasmic reticulum and especially mitochondria in the degenerating axons, We therefore propose that the neurofilament accumulations observed in these mice cause axonal degeneration by impeding the transport of components required for axonal maintenance, and that a similar mechanism may account for the pathogenesis of ALS in human patients.	MCGILL UNIV,MONTREAL GEN HOSP,RES INST,CTR RES NEUROSCI,MONTREAL,PQ H3G 1A4,CANADA	McGill University								Chou SM., 1992, HDB AMYOTROPHIC LATE, P133; COTE F, 1993, CELL, V73, P35, DOI 10.1016/0092-8674(93)90158-M; DELISLE M, J NEUROL SCI, V63, P241; FIGLEWICZ DA, 1994, HUM MOL GENET, V3, P1751; GRIFFIN JW, 1978, SCIENCE, V202, P633, DOI 10.1126/science.81524; GRIFFIN JW, 1988, ANN NEUROL, V23, P3, DOI 10.1002/ana.410230103; GUMEY ME, 1994, SCIENCE, V264, P1772; HIRANO A, 1984, J NEUROPATH EXP NEUR, V43, P461, DOI 10.1097/00005072-198409000-00001; HOFFMAN PN, 1975, J CELL BIOL, V66, P315; LEE MK, 1994, NEURON, V13, P975, DOI 10.1016/0896-6273(94)90263-1; MCQUARRIE IG, 1989, NEUROBIOL AGING, V10, P359, DOI 10.1016/0197-4580(89)90049-3; Nixon RA, 1991, NEURONAL CYTOSKELETO, P283; OBLINGER MM, 1987, J NEUROSCI, V7, P453; XU ZS, 1993, CELL, V73, P23, DOI 10.1016/0092-8674(93)90157-L	14	395	405	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 4	1995	375	6526					61	64		10.1038/375061a0	http://dx.doi.org/10.1038/375061a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW604	7536898				2022-12-24	WOS:A1995QW60400055
J	AIDOO, M; LALVANI, A; ALLSOPP, CEM; PLEBANSKI, M; MEISNER, SJ; KRAUSA, P; BROWNING, M; MORRISJONES, S; GOTCH, F; FIDOCK, DA; TAKIGUCHI, M; ROBSON, KJH; GREENWOOD, BM; DRUILHE, P; WHITTLE, HC; HILL, AVS				AIDOO, M; LALVANI, A; ALLSOPP, CEM; PLEBANSKI, M; MEISNER, SJ; KRAUSA, P; BROWNING, M; MORRISJONES, S; GOTCH, F; FIDOCK, DA; TAKIGUCHI, M; ROBSON, KJH; GREENWOOD, BM; DRUILHE, P; WHITTLE, HC; HILL, AVS			IDENTIFICATION OF CONSERVED ANTIGENIC COMPONENTS FOR A CYTOTOXIC T-LYMPHOCYTE-INDUCING VACCINE AGAINST MALARIA	LANCET			English	Article							FALCIPARUM CIRCUMSPOROZOITE PROTEIN; PARASITE PLASMODIUM-FALCIPARUM; CELL RESPONSE; SPOROZOITES; SURFACE; PROTECTION; EXPRESSION; SEQUENCE; PEPTIDES; THROMBOSPONDIN	Several cellular and humoral mechanisms probably play a role in natural immunity to Plasmodium falciparum malaria, but the development of an effective vaccine has been impeded by uncertainty as to which antigens are targeted by protective immune responses. Experimental models of malaria have shown that cytotoxic T lymphocytes (CTL) which kill parasite-infected hepatocytes can provide complete protective immunity against certain species of Plasmodium in mice, and studies in The Gambia have provided indirect evidence that CTL play a protective role against P falciparum in humans. By using an HLA-based approach, termed reverse immunogenetics, we have previously identified peptide epitopes for CTL in liver-stage antigen-1 and the circumsporozoite protein of P falciparum, We have extended this work to identify CTL epitopes for HLA class I antigens that are found in most individuals from Caucasian and African populations. Most of these epitopes are in conserved regions of P falciparum. CTL peptide epitopes were found in a further two antigens, thrombospondin-related anonymous protein and sporozoite threonine and asparagine rich protein, indicating that a subunit vaccine designed to induce a protective CTL response may need to include parts of several parasite antigens. However, CTL levels in both children with malaria and in semi-immune adults from an endemic area were low suggesting that boosting these low levels by immunisation might provide substantial or even complete protection against infection and disease.	UNIV OXFORD, JOHN RADCLIFFE HOSP, INST MOLEC MED, OXFORD OX3 9DU, ENGLAND; MRC LABS, Fajara, SENEGAL; INST PASTEUR, PARIS, FRANCE; UNIV TOKYO, INST MED SCI, MINATO KU, TOKYO 108, JAPAN	University of Oxford; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Tokyo			HILL, Adrian V>S>/C-1306-2008; Plebanski, Magdalena/AAU-3144-2021; Takiguchi, Masafumi/E-7468-2013	Lalvani, Ajit/0000-0002-2396-246X; , Magdalena/0000-0001-6889-3667; Fidock, David/0000-0001-6753-8938	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLSOPP CEM, 1992, AM J HUM GENET, V50, P411; ANDO K, 1994, J IMMUNOL, V153, P482; BOURGAULT I, 1994, J IMMUNOL, V152, P2530; BROWN F, 1994, DEV BIOL STAND BASEL, V82, P1; BROWNING MJ, 1993, P NATL ACAD SCI USA, V90, P2842, DOI 10.1073/pnas.90.7.2842; BROWNING MJ, 1995, TISSUE ANTIGENS, V45, P177, DOI 10.1111/j.1399-0039.1995.tb02437.x; COWAN G, 1992, LANCET, V339, P1412, DOI 10.1016/0140-6736(92)91229-2; COX WI, 1993, VIROLOGY, V195, P845, DOI 10.1006/viro.1993.1442; DAME JB, 1984, SCIENCE, V225, P593, DOI 10.1126/science.6204383; DOOLAN DL, 1993, INT IMMUNOL, V5, P37, DOI 10.1093/intimm/5.1.37; DOOLAN DL, 1992, INFECT IMMUN, V60, P675, DOI 10.1128/IAI.60.2.675-682.1992; DOOLAN DL, 1991, INT IMMUNOL, V3, P511, DOI 10.1093/intimm/3.6.511; ELVIN J, 1991, EUR J IMMUNOL, V21, P2025, DOI 10.1002/eji.1830210909; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FIDOCK DA, 1994, MOL BIOCHEM PARASIT, V64, P219, DOI 10.1016/0166-6851(94)00012-3; FIDOCK DA, 1994, J IMMUNOL, V153, P190; FIDOCK DA, 1994, MOL BIOCHEM PARASIT, V67, P255, DOI 10.1016/0166-6851(94)00138-3; GOOD MF, 1988, IMMUNOL TODAY, V9, P351, DOI 10.1016/0167-5699(88)91336-9; GOOD MF, 1988, ANNU REV IMMUNOL, V6, P663, DOI 10.1146/annurev.iy.06.040188.003311; HILL AVS, 1994, PHILOS T R SOC B, V346, P379, DOI 10.1098/rstb.1994.0155; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; HUCZKO EL, 1993, J IMMUNOL, V151, P2572; KHUSMITH S, 1994, INFECT IMMUN, V62, P2979, DOI 10.1128/IAI.62.7.2979-2983.1994; LALVANI A, 1994, RES IMMUNOL, V145, P461, DOI 10.1016/S0923-2494(94)80177-0; LAYTON GT, 1993, J IMMUNOL, V151, P1097; Marsh K., 1986, Clinics in Tropical Medicine and Communicable Diseases, V1, P91; MCADAM S, IN PRESS J IMMUNOL; MOELANS IIMD, 1991, MOL BIOCHEM PARASIT, V45, P193, DOI 10.1016/0166-6851(91)90086-L; MURRAY RJ, 1992, J EXP MED, V176, P157, DOI 10.1084/jem.176.1.157; NUSSENZWEIG RS, 1969, NATURE, V222, P488, DOI 10.1038/222488a0; PAMER EG, 1991, NATURE, V353, P852, DOI 10.1038/353852a0; ROBSON KJH, 1990, P ROY SOC B-BIOL SCI, V242, P205, DOI 10.1098/rspb.1990.0126; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; RODRIGUES M, 1992, J EXP MED, V175, P895, DOI 10.1084/jem.175.4.895; ROGERS WO, 1992, P NATL ACAD SCI USA, V89, P9176, DOI 10.1073/pnas.89.19.9176; ROMERO P, 1989, NATURE, V341, P323, DOI 10.1038/341323a0; ROSENBERG R, 1990, T ROY SOC TROP MED H, V84, P209, DOI 10.1016/0035-9203(90)90258-G; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; SCHOFIELD L, 1987, NATURE, V330, P664, DOI 10.1038/330664a0; SEDEGAH M, 1992, J IMMUNOL, V149, P966; SUTTON J, 1993, EUR J IMMUNOL, V23, P447, DOI 10.1002/eji.1830230222; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; WEISS WR, 1988, P NATL ACAD SCI USA, V85, P573, DOI 10.1073/pnas.85.2.573; YASUTOMI Y, 1993, J IMMUNOL, V150, P3101; ZHU JD, 1991, MOL BIOCHEM PARASIT, V48, P223, DOI 10.1016/0166-6851(91)90117-O	46	134	140	1	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 22	1995	345	8956					1003	1007		10.1016/S0140-6736(95)90754-8	http://dx.doi.org/10.1016/S0140-6736(95)90754-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QU573	7536870				2022-12-24	WOS:A1995QU57300006
J	JENISON, RD; GILL, SC; PARDI, A; POLISKY, B				JENISON, RD; GILL, SC; PARDI, A; POLISKY, B			HIGH-RESOLUTION MOLECULAR DISCRIMINATION BY RNA	SCIENCE			English	Article							STRANDED-DNA MOLECULES; THEOPHYLLINE; SELECTION; INVITRO; RECOGNITION; IMMUNOASSAY; POLYMERASE; LIGANDS; BIND	Species of RNA that bind with high affinity and specificity to the bronchodilator theophylline were identified by selection from an oligonucleotide library. One RNA molecule binds to theophylline with a dissociation constant K-d of 0.1 mu M. This binding affinity is 10,000-fold greater than the RNA molecule's affinity for caffeine, which differs from theophylline only by a methyl group at nitrogen atom N-7. Analysis by nuclear magnetic resonance indicates that this RNA molecule undergoes a significant change in its conformation or dynamics upon theophylline binding. Binding studies of compounds chemically related to theophylline have revealed structural features required for the observed binding specificity. These results demonstrate the ability of RNA molecules to exhibit an extremely high degree of ligand recognition and discrimination.	NEXAGEN INC,BOULDER,CO 80301; UNIV COLORADO,DEPT CHEM & BIOCHEM,BOULDER,CO 80309	University of Colorado System; University of Colorado Boulder					NCRR NIH HHS [RR03283] Funding Source: Medline; NIAID NIH HHS [AI01051, AI33098] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033098] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANTONI G, 1983, ANAL BIOCHEM, V129, P60, DOI 10.1016/0003-2697(83)90052-0; BARTEL DP, 1991, CELL, V67, P529, DOI 10.1016/0092-8674(91)90527-6; BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0; BROUSSARD LA, 1981, CLIN CHEM, V27, P1931; CONNELL GJ, 1993, BIOCHEMISTRY-US, V32, P5497, DOI 10.1021/bi00072a002; ELLINGTON AD, 1992, NATURE, V355, P850, DOI 10.1038/355850a0; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; FAMULOK M, 1992, J AM CHEM SOC, V114, P3990, DOI 10.1021/ja00036a065; GILL SC, 1991, J MOL BIOL, V220, P307, DOI 10.1016/0022-2836(91)90015-X; HENDELES L, 1983, PHARMACOTHERAPY, V3, P2; JELLINEK D, 1993, P NATL ACAD SCI USA, V90, P11227, DOI 10.1073/pnas.90.23.11227; JOLLEY ME, 1981, CLIN CHEM, V27, P1575; PLATEAU P, 1982, J AM CHEM SOC, V104, P731; PONCELET SM, 1990, J IMMUNOASSAY, V11, P77, DOI 10.1080/01971529008053259; REINECKE T, 1986, ANN EMERG MED, V15, P147, DOI 10.1016/S0196-0644(86)80009-9; SASSANFAR M, 1993, NATURE, V364, P550, DOI 10.1038/364550a0; SCHNEIDER D, 1992, J MOL BIOL, V228, P862, DOI 10.1016/0022-2836(92)90870-P; SKIENAR V, 1990, NATURE, V345, P836; TUERK C, 1992, P NATL ACAD SCI USA, V89, P6988, DOI 10.1073/pnas.89.15.6988; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; TUERK C, IN PRESS GENE; VANDEVEN FJM, 1988, EUR J BIOCHEM, V178, P1; VARANI G, 1991, Q REV BIOPHYS, V24, P479, DOI 10.1017/S0033583500003875	23	859	932	7	208	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 11	1994	263	5152					1425	1429		10.1126/science.7510417	http://dx.doi.org/10.1126/science.7510417			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MZ927	7510417				2022-12-24	WOS:A1994MZ92700028
J	WOODHOUSE, PR; KHAW, KT; PLUMMER, M; FOLEY, A; MEADE, TW				WOODHOUSE, PR; KHAW, KT; PLUMMER, M; FOLEY, A; MEADE, TW			SEASONAL-VARIATIONS OF PLASMA-FIBRINOGEN AND FACTOR-VII ACTIVITY IN THE ELDERLY - WINTER INFECTIONS AND DEATH FROM CARDIOVASCULAR-DISEASE	LANCET			English	Article							ISCHEMIC HEART-DISEASE; RISK-FACTORS; MYOCARDIAL-INFARCTION; HEMOSTATIC VARIABLES; HYPERLIPEMIA	There are approximately 20 000 excess deaths from cardiovascular disease each winter in England and Wales, The reasons for the excess have not been fully elucidated. For one year, we studied 96 men and women aged 65-74 living in their own homes in order to examine seasonal variation in plasma fibrinogen and factor VII clotting activity (fVIIc), and to investigate relationships with infection and other cardiovascular-disease risk factors. Both fibrinogen and FVIIc plasma values were greater in winter with estimated winter-summer differences (confidence intervals) of 0.13 (0.05-0.20) g/L for fibrinogen and 4.2 (1.2-7.1)% of standard for FVIIc. These differences could account for 15% and 9% increases in ischaemic heart disease risk in winter respectively. After adjustment for confounding by season, fibrinogen was strongly related to neutrophil count (p<0.0001), C-reactive protein (p<0.0001), alpha 1-antichymotrypsin (p<0.0001), and self-reported cough (p<0.0001) and coryza (p=0.0004), but not to ambient temperature. Therefore, we suggest that seasonal variation in fibrinogen might be induced by winter respiratory infections via activation of the acute phase response. Seasonal variations in the cardiovascular risk factors fibrinogen and FVIIc provide further possible explanations for the marked seasonal variation in death from ischaemic heart disease and stroke in the elderly.	UNIV CAMBRIDGE, CLIN GERONTOL UNIT, CAMBRIDGE, CAMBS, ENGLAND; INST PUBL HLTH, MRC, BIOSTAT UNIT, CAMBRIDGE, CAMBS, ENGLAND; WOLFSON INST PREVENT MED, MRC, EPIDEMIOL & MED CARE UNIT, LONDON, ENGLAND	University of Cambridge; MRC Biostatistics Unit; University of Cambridge; University of London; Queen Mary University London				Plummer, Martyn/0000-0001-5130-6497				AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; BAINTON D, 1978, INT J EPIDEMIOL, V7, P231, DOI 10.1093/ije/7.3.231; BRENNAN PJ, 1982, BMJ-BRIT MED J, V285, P919, DOI 10.1136/bmj.285.6346.919; CHOOI CC, 1989, THROMB RES, V53, P493, DOI 10.1016/0049-3848(89)90204-1; CLAUSS A., 1957, ACTA HAEMATOL, V17, P237; COOK NS, 1990, TRENDS PHARMACOL SCI, V11, P444, DOI 10.1016/0165-6147(90)90125-R; Curwen M., 1991, HLTH TRENDS, V22, P169; DURRINGTON PN, 1990, SCAND J CLIN LAB INV, V50, P86, DOI 10.3109/00365519009091092; ELKELES RS, 1980, BRIT MED J, V281, P973, DOI 10.1136/bmj.281.6246.973; FOLSOM AR, 1991, ATHEROSCLEROSIS, V91, P191, DOI 10.1016/0021-9150(91)90167-2; GORDON DJ, 1988, J CLIN EPIDEMIOL, V41, P679, DOI 10.1016/0895-4356(88)90120-5; ISO H, 1989, AM J EPIDEMIOL, V130, P925, DOI 10.1093/oxfordjournals.aje.a115425; KANNEL WB, 1992, JAMA-J AM MED ASSOC, V267, P1253, DOI 10.1001/jama.267.9.1253; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; MARCKMANN P, 1990, ATHEROSCLEROSIS, V80, P227, DOI 10.1016/0021-9150(90)90030-M; MEADE TW, 1987, LANCET, V2, P986; MEADE TW, 1979, BMJ-BRIT MED J, V1, P153, DOI 10.1136/bmj.1.6157.153; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MILLER GJ, 1991, LANCET, V338, P1079, DOI 10.1016/0140-6736(91)91936-O; MILLER GJ, 1985, BRIT J HAEMATOL, V59, P249, DOI 10.1111/j.1365-2141.1985.tb02991.x; NASKI MC, 1991, J BIOL CHEM, V266, P13003; PRICE CP, 1987, J IMMUNOL METHODS, V99, P205, DOI 10.1016/0022-1759(87)90129-3; QIZILBASH N, 1991, BRIT MED J, V303, P605, DOI 10.1136/bmj.303.6803.605; RAO CR, 1973, LINEAR STATISTICAL I, P418; SPODICK DH, 1984, AM J CARDIOL, V53, P481, DOI 10.1016/0002-9149(84)90016-X; STOUT RW, 1991, LANCET, V338, P9, DOI 10.1016/0140-6736(91)90004-9; SYRJANEN J, 1988, BRIT MED J, V296, P1156, DOI 10.1136/bmj.296.6630.1156; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; WOODHOUSE PR, 1993, J HYPERTENS, V11, P1267; WOODHOUSE PR, 1993, AGE AGEING, V22, P273, DOI 10.1093/ageing/22.4.273; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	31	463	479	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 19	1994	343	8895					435	439		10.1016/S0140-6736(94)92689-1	http://dx.doi.org/10.1016/S0140-6736(94)92689-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW690	7508540				2022-12-24	WOS:A1994MW69000007
J	Genc, M; Mardh, PA				Genc, M; Mardh, PA			A cost-effectiveness analysis of screening and treatment for Chlamydia trachomatis infection in asymptomatic women	ANNALS OF INTERNAL MEDICINE			English	Article							PELVIC INFLAMMATORY DISEASE; ECONOMIC-EVALUATION; DECISION-ANALYSIS; ADOLESCENT MALES; SPECIMENS; ASSAY; RISK	Objective: To assess the cost-effectiveness of identifying and treating asymptomatic female carriers of Chlamydia trachomatis. Design: Cost-effectiveness analysis based on previously reported cohort analytic studies and average salaries and costs of medical care in Sweden. Setting: Women attending youth, family planning, and gynecology clinics. Participants: 1000 women and their male sex partners. Intervention: Screening with tissue cell culture, confirmed enzyme immunoassay, and DNA amplification as says based on either polymerase chain reaction or ligase chain reaction was compared with no screening (no treatment and no tracing of sexual contacts). The effect of antibiotic regimens on the outcome of the screening strategies was also evaluated. Results: When the prevalence of chlamydial infection exceeded 6%, screening of women with DNA amplification assay and treatment of positive patients with a single oral dose of azithromycin given under supervision in the clinic was the most cost-effective intervention strategy. At greater prevalences, screening with enzyme immunoassay also generated savings and improved the cure rates compared with no screening, but such screening was less cost-effective than screening with a DNA amplification assay. Compared with no intervention, tissue cell culture is cost-effective only when the prevalence of infection is greater than 14%. Compared with the azithromycin regimen, the standard 7-day, twice-daily doxycycline regimen resulted in significantly lower cure rates because of patients' poor compliance with this regimen. Conclusion: For asymptomatic female carriers of C. trachomatis, screening with a DNA amplification assay combined with the single-dose azithromycin treatment of positive patients is the most cost-effective strategy when the prevalence is 6%. When the prevalence is lower than 6%, the decision to choose a competing strategy depends on the physician's view of the value of preventing an illness caused by untreated chlamydial infection.			Genc, M (corresponding author), UPPSALA UNIV, CTR STD RES, INST CLIN BACTERIOL, BOX 552, S-75122 UPPSALA, SWEDEN.							BASS CA, 1993, J CLIN MICROBIOL, V31, P2648, DOI 10.1128/JCM.31.10.2648-2653.1993; CHERNESKY M, 1994, CHLAMYDIAL INFECTION, P333; ESTANY A, 1989, SEX TRANSM DIS, V16, P21, DOI 10.1097/00007435-198901000-00005; GENC M, 1993, JAMA-J AM MED ASSOC, V270, P2057, DOI 10.1001/jama.270.17.2057; GENC M, 1994, JAMA-J AM MED ASSOC, V271, P1741, DOI 10.1001/jama.1994.03510460033017; GENC M, 1991, CHLAMYDIAL INFECTION, P112; HADDIX A, 1994, CHLAMYDIAL INFECTION, P55; HELLBERG D, 1995, GENITOURIN MED, V71, P88; HILLIS SD, 1993, AM J OBSTET GYNECOL, V168, P1503, DOI 10.1016/S0002-9378(11)90790-X; HOOK EW, 1994, JAMA-J AM MED ASSOC, V272, P867, DOI 10.1001/jama.272.11.867; KATZ BP, 1988, SEX TRANSM DIS, V15, P11, DOI 10.1097/00007435-198801000-00003; LANGILLE DB, 1992, CAN J PUBLIC HEALTH, V83, P358; LEE HH, 1995, LANCET, V345, P213, DOI 10.1016/S0140-6736(95)90221-X; MAHONY JB, 1992, MOL CELL PROBE, V6, P381, DOI 10.1016/0890-8508(92)90031-R; MARTIN DH, 1992, NEW ENGL J MED, V327, P921, DOI 10.1056/NEJM199209243271304; MONCADA J, 1990, J CLIN MICROBIOL, V28, P1770, DOI 10.1128/JCM.28.8.1770-1773.1990; NETTLEMAN MD, 1988, JAMA-J AM MED ASSOC, V260, P207, DOI 10.1001/jama.260.2.207; PHILLIPS RS, 1987, ANN INTERN MED, V107, P188, DOI 10.7326/0003-4819-107-2-188; PIOT P, 1994, CHLAMYDIAL INFECTION, P7; QUINN TC, 1994, CHLAMYDIAL INFECTION, P21; RAMSTEDT K, 1991, SEX TRANSM DIS, V18, P205, DOI 10.1097/00007435-199110000-00002; RAMSTEDT K, 1991, INT J STD AIDS, V2, P428, DOI 10.1177/095646249100200607; RANDOLPH AG, 1990, AM J PUBLIC HEALTH, V80, P545, DOI 10.2105/AJPH.80.5.545; SCHACHTER J, 1994, J CLIN MICROBIOL, V32, P2540, DOI 10.1128/JCM.32.10.2540-2543.1994; TRACHTENBERG AI, 1988, OBSTET GYNECOL, V71, P101; WASHINGTON AE, 1987, JAMA-J AM MED ASSOC, V257, P2056, DOI 10.1001/jama.257.15.2056; WESTROM L, 1993, GENITOURIN MED, V69, P9; Whatley J D, 1991, Int J STD AIDS, V2, P248	28	113	113	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	1				1	7		10.7326/0003-4819-124-1_Part_1-199601010-00001	http://dx.doi.org/10.7326/0003-4819-124-1_Part_1-199601010-00001			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL943	7503471				2022-12-24	WOS:A1996TL94300001
J	BONDY, S				BONDY, S			ALCOHOL AVAILABILITY AND ALCOHOLISM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							CONSUMPTION; STRIKE				BONDY, S (corresponding author), ADDICT RES FDN,TORONTO,ON M5S 2S1,CANADA.		Bondy, Susan J/C-6737-2014	Bondy, Susan J/0000-0002-6516-4159				BASS K, DEV LOCAL CONTROL AL; BLOSE JO, 1987, J STUD ALCOHOL, V48, P52, DOI 10.15288/jsa.1987.48.52; Bruun K., 1975, ALCOHOL CONTROL POLI; EDWARDS G, 1994, ALCOHOL POLICY PUBLI, pCH6; GODFREY C, 1988, APPL ECON, V20, P1541, DOI 10.1080/00036848800000085; GRUENEWALD PJ, 1993, ALCOHOL CLIN EXP RES, V17, P38, DOI 10.1111/j.1530-0277.1993.tb00723.x; GRUENEWALD PJ, 1993, NIAAA RES MONOGRAPH, V25, P59; HOLDER HD, 1987, CONTROL ISSUES ALCOH; HORVERAK O, 1983, BRIT J ADDICT, V78, P51; Lenke L., 1990, ALCOHOL CRIMINAL VIO; LESTER D, 1988, SOC PSYCH PSYCH EPID, V23, P202, DOI 10.1007/BF01794789; MAKELA K, 1980, J DRUG ISSUES, V10, P131; Mosher J. F., 1994, CONFRONTING SACRAMEN; MOSKOWITZ JM, 1989, J STUD ALCOHOL, V30, P54; OSTERBERG E, 1991, NATURAL EXPT DECREAS; OSTERBERG E, 1993, ALCOHOL HEALTH RES W, V17, P205; ROOM R, 1984, ANNU REV PUBL HEALTH, V5, P293, DOI 10.1146/annurev.pu.05.050184.001453; RUSH BR, 1986, J STUD ALCOHOL, V47, P1; SCHECHTER EJ, 1986, CONT DRUG PROBL, V15, P587; SCRIBNER RA, 1994, J STUD ALCOHOL, V55, P447, DOI 10.15288/jsa.1994.55.447; SKOG OJ, 1980, J DRUG ISSUES, V10, P71, DOI 10.1177/002204268001000105; SONENSHEIM RJ, 1993, BATTLE LIQUOR STORES; WATTS RK, 1983, ALCOHOL CLIN EXP RES, V7, P47, DOI 10.1111/j.1530-0277.1983.tb05410.x; WILKINSON JT, 1987, SOUTHERN ECON J, V54, P322, DOI 10.2307/1059317	24	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 20	1995	274	23					1832	1832		10.1001/jama.274.23.1832	http://dx.doi.org/10.1001/jama.274.23.1832			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TK147	7500522				2022-12-24	WOS:A1995TK14700008
J	LEEUW, T; FOURESTLIEUVIN, A; WU, CL; CHENEVERT, J; CLARK, K; WHITEWAY, M; THOMAS, DY; LEBERER, E				LEEUW, T; FOURESTLIEUVIN, A; WU, CL; CHENEVERT, J; CLARK, K; WHITEWAY, M; THOMAS, DY; LEBERER, E			PHEROMONE RESPONSE IN YEAST - ASSOCIATION OF BEM1P WITH PROTEINS OF THE MAP KINASE CASCADE AND ACTIN	SCIENCE			English	Article							BUD SITE SELECTION; SACCHAROMYCES-CEREVISIAE; CELLULAR MORPHOGENESIS; GENE BEM1; GROWTH; POLARITY; DICTYOSTELIUM; POLARIZATION; INTERACTS; IDENTIFY	Haploid cells of the yeast Saccharomyces cerevisiae respond to mating pheromones with polarized growth toward the mating partner. This morphological response requires the function of the cell polarity establishment protein Bem1p. Immunochemical and two-hybrid protein interaction assays revealed that Bem1p interacts with two components of the pheromone-responsive mitogen-activated protein (MAP) kinase cascade, Ste20p and Ste5p, as well as with actin. Mutants of Bem1p that are associated with defective pheromone-induced polarized morphogenesis interacted with Ste5p and actin but not with Ste20p. Thus, the association of Bem1p with Ste20p and Ste5p may contribute to the conveyance of spatial information that regulates polarized rearrangement of the actin cytoskeleton during yeast mating.	NATL RES COUNCIL CANADA,BIOTECHNOL RES INST,EUKARYOT GENET GRP,MONTREAL,PQ H4P 2R2,CANADA; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	National Research Council Canada; University of California System; University of California San Francisco			Fourest-Lieuvin, Anne/AGA-6504-2022; Thomas, David/M-7661-2017	Fourest-Lieuvin, Anne/0000-0003-1325-6788; Thomas, David/0000-0002-8854-762X				ABEIJON C, 1989, P NATL ACAD SCI USA, V86, P6935, DOI 10.1073/pnas.86.18.6935; ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; BENDER A, 1991, MOL CELL BIOL, V11, P1295, DOI 10.1128/MCB.11.3.1295; BOWMAN BJ, 1979, J BIOL CHEM, V254, P2928; BRAY D, 1988, ANNU REV CELL BIOL, V4, P43, DOI 10.1146/annurev.cb.04.110188.000355; CHANT J, 1991, CELL, V65, P1213, DOI 10.1016/0092-8674(91)90016-R; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; CHENEVERT J, 1994, MOL BIOL CELL, V5, P1169, DOI 10.1091/mbc.5.11.1169; CHENEVERT J, 1992, NATURE, V356, P77, DOI 10.1038/356077a0; CHENEVERT J, 1994, GENETICS, V136, P1287; CHENEVERT J, UNPUB; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHOI KY, 1994, CELL, V78, P499; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cb.04.110188.003245; DOWNEY GP, 1994, CURR OPIN IMMUNOL, V6, P113, DOI 10.1016/0952-7915(94)90042-6; FIELD C, 1980, J CELL BIOL, V86, P123, DOI 10.1083/jcb.86.1.123; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GERISCH G, 1987, ANNU REV BIOCHEM, V56, P853, DOI 10.1146/annurev.bi.56.070187.004225; HARLOW E, 1988, ANTIBODIES LABORATOR; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBERER E, 1993, MOL GEN GENET, V241, P241, DOI 10.1007/BF00284675; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LEBERER E, UNPUB; LEEUW T, UNPUB; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PARLATI F, 1995, J BIOL CHEM, V270, P244, DOI 10.1074/jbc.270.1.244; PETERSON J, 1994, J CELL BIOL, V127, P1395, DOI 10.1083/jcb.127.5.1395; PRINTEN JA, 1994, GENETICS, V138, P609; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; REID BJ, 1977, J CELL BIOL, V75, P355, DOI 10.1083/jcb.75.2.355; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; Rose MD., 1990, METHODS YEAST GENETI; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGALL JE, 1993, P NATL ACAD SCI USA, V90, P8332, DOI 10.1073/pnas.90.18.8332; SIMON MN, 1995, NATURE, V376, P702, DOI 10.1038/376702a0; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; SLOAT BF, 1978, SCIENCE, V200, P1171, DOI 10.1126/science.349694; SLOAT BF, 1981, J CELL BIOL, V89, P395, DOI 10.1083/jcb.89.3.395; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WHITEWAY MS, 1995, SCIENCE, V269, P1572, DOI 10.1126/science.7667635; WU CL, 1995, J BIOL CHEM, V270, P15984, DOI 10.1074/jbc.270.27.15984; ZIMAN M, 1993, MOL BIOL CELL, V4, P1307, DOI 10.1091/mbc.4.12.1307	52	178	178	0	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 17	1995	270	5239					1210	1213		10.1126/science.270.5239.1210	http://dx.doi.org/10.1126/science.270.5239.1210			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE905	7502048				2022-12-24	WOS:A1995TE90500060
J	KILGORE, PE; HOLMAN, RC; CLARKE, MJ; GLASS, RI				KILGORE, PE; HOLMAN, RC; CLARKE, MJ; GLASS, RI			TRENDS OF DIARRHEAL DISEASE - ASSOCIATED MORTALITY IN US CHILDREN, 1968 THROUGH 1991	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; DEATHS; CARE; INTERVENTIONS; ROTAVIRUS; THERAPY; MEASLES; MEXICO	Objectives.-To describe temporal patterns in mortality related to diarrheal disease in US children and to assess progress toward its prevention and control. Design.-Retrospective analyses of death certificate data on diarrhea of all causes compiled by the National Center for Health Statistics, Centers for Disease Control and Prevention, Atlanta, Ga. Patients.-Children aged 1 month through 4 years who died with diarrhea. Setting.-United States, 1968 through 1991. Results.-A total of 14 137 deaths associated with diarrhea among children were reported in the United States between 1968 and 1991. Of these, 78% occurred in infants (ie, aged 1 to 11 months); the median age at the time of death has declined from 5 to 1.5 months. Diarrheal disease mortality dropped by approximately 75% during the first 18 years of the study, but no decline has occurred since 1985. Infant mortality due to diarrhea (per 100 000 live births) averaged 12.8 and was found to be high for blacks (33.1) and for residents of the southern United States (18.5). The infant mortality due to diarrhea from 1986 through 1991 is 5.9. Peaks in winter deaths previously associated with rotavirus were prominent in the early years among infants aged 4 through 11 months. Such peaks have virtually disappeared since 1985. Diarrhea was the principal cause of death, as the leading associated diagnoses (electrolyte disorders [30%], cardiac arrest [16%], shock [8%], and nausea/vomiting [4%]) were commonly recognized complications of diarrhea. Since 1979, prematurity has emerged as a common associated diagnosis. Conclusions.-Diarrheal deaths nationwide have declined 75% from 1968 to 1985 but stabilized since then at about 300 deaths per year. Because many of these deaths may still be preventable by early rehydration, future prevention efforts should be directed at educating health care providers about the continuing problem and recognition of the high-risk infant and at teaching mothers of such infants to begin rehydration early and to seek medical attention when their infant develops diarrhea.	CTR DIS CONTROL & PREVENT,DIV VIRAL & RICKETTSIAL DIS,EPIDEM INTELLIGENCE SERV,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA	KILGORE, PE (corresponding author), CTR DIS CONTROL & PREVENT,DIV VIRAL & RICKETTSIAL DIS,VIRAL GASTROENTERITIS SECT,MAILSTOP G-04,ATLANTA,GA 30333, USA.		Kilgore, Paul E/L-1462-2013; Kilgore, Paul/AAD-2869-2019	Kilgore, Paul E/0000-0003-3214-4482; Kilgore, Paul/0000-0003-3214-4482				AVERY ME, 1990, NEW ENGL J MED, V323, P891, DOI 10.1056/NEJM199009273231307; BERN C, 1993, J PEDIATR-US, V122, P920, DOI 10.1016/S0022-3476(09)90020-8; BERN C, 1992, B WORLD HEALTH ORGAN, V70, P705; CHAMBLEE RF, 1986, VITAL HLTH STAT 1, V20; CHURCH DL, 1995, 95TH GEN M AM SOC MI; Duggan C, 1992, MMWR Recomm Rep, V41, P1; FEACHEM RG, 1983, B WORLD HEALTH ORGAN, V61, P641; GANGAROSA RE, 1992, AM J EPIDEMIOL, V135, P281, DOI 10.1093/oxfordjournals.aje.a116282; GARTHRIGHT WE, 1988, PUBLIC HEALTH REP, V103, P107; GLASS RI, 1991, J PEDIATR, V118, P527; HEMMING VG, 1976, NEW ENGL J MED, V294, P1310, DOI 10.1056/NEJM197606102942403; HO MS, 1988, JAMA-J AM MED ASSOC, V260, P3281, DOI 10.1001/jama.260.22.3281; HOLMAN RC, 1989, AM J PUBLIC HEALTH, V79, P987, DOI 10.2105/AJPH.79.8.987; ISRAEL RA, 1986, AM J EPIDEMIOL, V124, P161, DOI 10.1093/oxfordjournals.aje.a114375; KLEIN JD, 1982, REPORT COMMITTEE INF; KLEINBAUM DG, 1988, APPLIED REGRESSION A; KOSTER FT, 1981, B WORLD HEALTH ORGAN, V59, P901; LEBARON CW, 1990, JAMA-J AM MED ASSOC, V264, P983, DOI 10.1001/jama.264.8.983; LEW JF, 1991, JAMA-J AM MED ASSOC, V265, P3280, DOI 10.1001/jama.265.24.3280; MEYERS A, 1991, JAMA-J AM MED ASSOC, V265, P1724, DOI 10.1001/jama.265.13.1724; Millman M., 1993, ACCESS HLTH CARE AM; MURRAY JL, 1988, NEW ENGL J MED, V319, P1385, DOI 10.1056/NEJM198811243192105; SNYDER J, 1988, JAMA-J AM MED ASSOC, V260, P3329; STPETER RF, 1992, JAMA-J AM MED ASSOC, V267, P2760, DOI 10.1001/jama.267.20.2760; VICTORA CG, 1989, AM J EPIDEMIOL, V129, P1032, DOI 10.1093/oxfordjournals.aje.a115207; WOODS PA, 1992, J CLIN MICROBIOL, V30, P781, DOI 10.1128/JCM.30.4.781-785.1992; 1977, MANUAL INT STATISTIC, P1; 1981, PHS911101 US DEP HLT, P91; 1993, 1991 US DEP HLTH HUM; 1993, MULTIPLE CAUSE DEATH; 1975, INT CLASSIFICATION D, P1; 1985, PEDIATRICS, V75, P358	32	108	116	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 11	1995	274	14					1143	1148		10.1001/jama.274.14.1143	http://dx.doi.org/10.1001/jama.274.14.1143			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY056	7563485				2022-12-24	WOS:A1995RY05600029
J	COHEN, G; FORBES, J; GARRAWAY, M				COHEN, G; FORBES, J; GARRAWAY, M			INTERPRETING SELF-REPORTED LIMITING LONG-TERM ILLNESS	BRITISH MEDICAL JOURNAL			English	Article							HEALTH SURVEY QUESTIONNAIRE; SF-36	Objective-To examine the association between self reported limiting long term illness and other dimensions of self reported health. Design-Stratified random sample of general population. Setting-Lothian region, Scotland, in 1993. Subjects-6212 men and women aged 16 and over. Main outcome measures-Limiting long term illness was assessed by the same question as used in the 1991 United Kingdom census. The shea form 36 health survey was used to assess other dimensions of health. Results-Rates of limiting long term illness were much higher than reported in the census. Scores on general and physical health scales had strong associations with limiting long term illness, but after adjustment for these associations psychosocial health measures had Little influence on limiting long term illness. Being at the lower rather than the upper quartile on the physical functioning scale more than doubled the odds of having limiting long term illness. Reported prevalence of many common illnesses was between two and three times higher among those with limiting long term illness. Conclusions-A positive response to the question used by the census to define limiting long term illness was strongly associated with physical limitations on activity and less strongly influenced by scores on scales of mental and social wellbeing. Socioeconomic effects on limiting long term illness seem largely mediated through measures of general health and physical limitations on health.			COHEN, G (corresponding author), UNIV EDINBURGH,SCH MED,DEPT PUBL HLTH SCI,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND.							BRAZIER JE, 1993, BRIT MED J, V305, P160; CHARLTON J, 1994, POPULATION TRENDS, V75, P18; COHEN G, 1994, LOTHIAN HLTH SURVEY; GARRATT AM, 1993, BMJ-BRIT MED J, V306, P1440, DOI 10.1136/bmj.306.6890.1440; JENKINSON C, 1993, BRIT MED J, V306, P1437, DOI 10.1136/bmj.306.6890.1437; JENKINSON CM, 1993, PUBLIC HEALTH, V107, P305, DOI 10.1016/S0033-3506(05)80122-2; KAPLAN GA, 1988, ANN CLIN RES, V20, P131; LYONS RA, 1994, AGE AGEING, V23, P182, DOI 10.1093/ageing/23.3.182; ROSENGREN A, 1993, BRIT MED J, V307, P102; SHELTON TA, 1994, BRIT MED J, V109, P1059; SMITH P, 1994, BRIT MED J, V309, P1050, DOI 10.1136/bmj.309.6961.1050; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; 1993, SAS P243 I TECHN REP; 1994, GENERAL HOUSEHOLD SU, P33	14	89	90	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 16	1995	311	7007					722	724		10.1136/bmj.311.7007.722	http://dx.doi.org/10.1136/bmj.311.7007.722			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RV874	7549686	Green Published			2022-12-24	WOS:A1995RV87400020
J	RAVINA, JH; HERBRETEAU, D; CIRARUVIGNERON, N; BOURET, JM; HOUDART, E; AYMARD, A; MERLAND, JJ				RAVINA, JH; HERBRETEAU, D; CIRARUVIGNERON, N; BOURET, JM; HOUDART, E; AYMARD, A; MERLAND, JJ			ARTERIAL EMBOLIZATION TO TREAT UTERINE MYOMATA	LANCET			English	Note								Haemorrhage, probably related to hypervascularisation, is the commonest complication of uterine myomata and is difficult to treat. 16 patients, aged 34-48 years, with symptomatic uterine myomata, for which a major surgical procedure was planned after failure of medical treatment, were treated by selective free-flow arterial embolisation of the myomata with Ivalon particles. With a mean follow-up of 20 months (range 11-48) in the responders, symptoms resolved in 11 patients; menstrual cycles returned to normal in ten of these. Three patients had partial improvement. Two failures required surgery. In 14 cases embolisation caused pelvic pain, which required analgesia in all.	UNIV PARIS 07,HOP LARIBOISIERE,RADIOL INTERVENT SERV,F-75475 PARIS 10,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite	RAVINA, JH (corresponding author), UNIV PARIS 07,HOP LARIBOISIERE,SERV GYNECOL OBSTET,F-75475 PARIS 10,FRANCE.							COHEN J, 1993, 3RD INT S GNRH AN CA, P25; FARRER-BROWN G, 1970, Journal of Obstetrics and Gynaecology of the British Commonwealth, V77, P967; HERBRETEAU D, 1993, ACTUALITE REANIMATIO, P17; RAVINA JH, 1994, PRESSE MED, V23, P1540; Sampson JA, 1912, SURG GYNECOL OBSTET, V14, P215	5	719	873	1	20	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 9	1995	346	8976					671	672		10.1016/S0140-6736(95)92282-2	http://dx.doi.org/10.1016/S0140-6736(95)92282-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU048	7544859				2022-12-24	WOS:A1995RU04800011
J	MEISEL, H; REIP, A; FALTUS, B; LU, MJ; PORST, H; WIESE, M; ROGGENDORF, M; KRUGER, DH				MEISEL, H; REIP, A; FALTUS, B; LU, MJ; PORST, H; WIESE, M; ROGGENDORF, M; KRUGER, DH			TRANSMISSION OF HEPATITIS-C VIRUS TO CHILDREN AND HUSBANDS BY WOMEN INFECTED WITH CONTAMINATED ANTI-D IMMUNOGLOBULIN	LANCET			English	Note								In 1978-79 a single-source outbreak of hepatitis C occurred in 2533 women who had received contaminated anti-D immunoglobulin. Children husbands of 74 women with self-limited, and of 86 women with chronic, hepatitis C were followed up for over 10-15 years. In 3 of 231 investigated children (1.3%) serological evidence for HCV infection was found. However, none of the children developed an apparent or chronic hepatitis. Serum samples oi the 94 husbands investigated showed no HCV antibodies or HCV RNA. We consider the risk of intrauterine or perinatal transmission of HCV, as welt as that of transmission through close family contacts, to be low. No evidence was found for sexual transmission from women to. men.	ST GEORGE HOSP, MED CLIN 2, LEIPZIG, GERMANY; CITY HOSP, MED CLIN 3, DRESDEN, GERMANY; UNIV ESSEN GESAMTHSCH, SCH MED, INST VIROL, ESSEN, GERMANY	Technische Universitat Dresden; Municipal Hospital Dresden; University of Duisburg Essen	MEISEL, H (corresponding author), HUMBOLDT UNIV BERLIN, CHARITE MED SCH, INST MED VIROL, D-10098 BERLIN, GERMANY.		Lu, Mengji/ABF-9410-2020					ALTER MJ, 1993, INFECT AGENT DIS, V2, P155; BRESTERS D, 1993, LANCET, V342, P210, DOI 10.1016/0140-6736(93)92300-I; DITTMANN S, 1991, J HEPATOL, V13, P323, DOI 10.1016/0168-8278(91)90076-N; GARSON JA, 1990, LANCET, V336, P878, DOI 10.1016/0140-6736(90)92384-T; KOFF RS, 1992, ANN INTERN MED, V117, P967, DOI 10.7326/0003-4819-117-11-967; NI YH, 1994, J HEPATOL, V20, P641, DOI 10.1016/S0168-8278(05)80353-8; OHTO H, 1994, NEW ENGL J MED, V330, P744, DOI 10.1056/NEJM199403173301103; POWER JP, 1994, LANCET, V344, P1166, DOI 10.1016/S0140-6736(94)90679-3; Roggendorf M, 1993, Arch Virol Suppl, V7, P27; TANZI E, 1993, ARCH VIROL, P229	10	121	122	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 13	1995	345	8959					1209	1211		10.1016/S0140-6736(95)91992-9	http://dx.doi.org/10.1016/S0140-6736(95)91992-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX861	7537841				2022-12-24	WOS:A1995QX86100010
J	BENDELAC, A; LANTZ, O; QUIMBY, ME; YEWDELL, JW; BENNINK, JR; BRUTKIEWICZ, RR				BENDELAC, A; LANTZ, O; QUIMBY, ME; YEWDELL, JW; BENNINK, JR; BRUTKIEWICZ, RR			CD1 RECOGNITION BY MOUSE NK1(+) T-LYMPHOCYTES	SCIENCE			English	Article							ALPHA-BETA+ THYMOCYTES; LYMPHOKINE SECRETION; ANTIGEN; EXPRESSION; CELLS; THYMUS; CD4+; EPITHELIUM; SELECTION; MOLECULES	Rare major histocompatibility complex (MHC) class I-like CD1-specific T cells have been isolated from human blood, but it has not been determined whether these clones are part of a defined subset of CD1-specific T cells selected during T cell development, or whether their recognition of CD1 is a fortuitous cross-reaction. In mice, an entire subset of alpha beta thymocytes with a unique phenotype was found to be CD1-specific. This particular subset, and its human counterpart, provide evidence that CD1 has a general role in selecting and interacting with specialized alpha beta T cells.	NIAID,CELLULAR & MOLEC IMMUNOL LAB,BETHESDA,MD 20892; PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544; NIAID,VIRAL DIS LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Princeton University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	BENDELAC, A (corresponding author), PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544, USA.		Lantz, Olivier J/J-4960-2012; yewdell, jyewdell@nih.gov jonathan/A-1702-2012	Lantz, Olivier J/0000-0003-3161-7719; Brutkiewicz, Randy/0000-0002-7396-480X				AHOUSE JJ, 1993, J IMMUNOL, V151, P6076; ARASE H, 1994, J EXP MED, V180, P423, DOI 10.1084/jem.180.2.423; ARASE H, 1992, P NATL ACAD SCI USA, V89, P6506, DOI 10.1073/pnas.89.14.6506; ARASE H, 1993, EUR J IMMUNOL, V23, P307, DOI 10.1002/eji.1830230151; BALK SP, 1991, J IMMUNOL, V146, P768; BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0; BENDELAC A, 1991, NATURE, V353, P68, DOI 10.1038/353068a0; BENDELAC A, 1992, J EXP MED, V175, P731, DOI 10.1084/jem.175.3.731; BENDELAC A, 1994, SCIENCE, V263, P1774, DOI 10.1126/science.7907820; Bendelac A, 1992, Semin Immunol, V4, P187; BENDELAC A, UNPUB; BIX M, 1993, J EXP MED, V178, P901, DOI 10.1084/jem.178.3.901; BLEICHER PA, 1990, SCIENCE, V250, P679, DOI 10.1126/science.1700477; Blumberg R S, 1994, Int Rev Immunol, V11, P15, DOI 10.3109/08830189409061714; BRADBURY A, 1988, EMBO J, V7, P3081, DOI 10.1002/j.1460-2075.1988.tb03173.x; CALABI F, 1989, EUR J IMMUNOL, V19, P285, DOI 10.1002/eji.1830190211; CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P3403, DOI 10.1128/MCB.5.12.3403; COLES MC, 1994, J EXP MED, V180, P395, DOI 10.1084/jem.180.1.395; COOK RG, 1983, J EXP MED, V158, P1012, DOI 10.1084/jem.158.3.1012; DELLABONA P, 1994, J EXP MED, V180, P1171, DOI 10.1084/jem.180.3.1171; DELLABONA P, 1993, J EXP MED, V177, P1763, DOI 10.1084/jem.177.6.1763; HAYAKAWA K, 1992, J EXP MED, V176, P269, DOI 10.1084/jem.176.1.269; HERSHBERG R, 1990, P NATL ACAD SCI USA, V87, P9527; KOYASU S, 1994, J EXP MED, V179, P1957, DOI 10.1084/jem.179.6.1957; KOYASU S, 1992, J EXP MED, V175, P203, DOI 10.1084/jem.175.1.203; LANTZ O, 1994, J EXP MED, V180, P1097, DOI 10.1084/jem.180.3.1097; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; LEVITSKY HI, 1991, J IMMUNOL, V146, P1113; MARRACK P, 1989, NATURE, V338, P503, DOI 10.1038/338503a0; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.immunol.12.1.991; MATZINGER P, UNPUB; OHTEKI T, 1994, J EXP MED, V180, P699, DOI 10.1084/jem.180.2.699; PANJA A, 1993, J EXP MED, V178, P1115, DOI 10.1084/jem.178.3.1115; PORCELLI S, 1993, J EXP MED, V178, P1, DOI 10.1084/jem.178.1.1; PORCELLI S, 1989, NATURE, V341, P447, DOI 10.1038/341447a0; PORCELLI S, 1992, NATURE, V360, P593, DOI 10.1038/360593a0; QUILL H, 1987, J IMMUNOL, V138, P3704; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; SYKES M, 1990, J IMMUNOL, V145, P3209; TAKAHAMA Y, 1991, J IMMUNOL, V146, P1134; TAKAHAMA Y, 1992, J IMMUNOL, V147, P2883; YOSHIMOTO T, 1994, J EXP MED, V179, P1285, DOI 10.1084/jem.179.4.1285	42	805	828	0	10	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 12	1995	268	5212					863	865		10.1126/science.7538697	http://dx.doi.org/10.1126/science.7538697			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX850	7538697				2022-12-24	WOS:A1995QX85000035
J	XU, FF; COHEN, SN				XU, FF; COHEN, SN			RNA DEGRADATION IN ESCHERICHIA-COLI REGULATED BY 3' ADENYLATION AND 5' PHOSPHORYLATIAN	NATURE			English	Article							ANTISENSE RNAI; COPY NUMBER; GENE; STABILITY; PLASMIDS; PCNB; REPLICATION; TRANSCRIPT; EXPRESSION; INVIVO	ALTHOUGH polyadenylation has commonly been regarded as a special feature of eukaryotic messenger RNA(1,2), there are many reports of polyA tails on bacterial RNA (for example, refs 3-8). In Escherichia coli, adenylation mediated by the pcnB gene greatly accelerates decay of RNA I-8, an antisense repressor of replication of ColE1 type plasmids that resembles highly structured transfer RNA but shows the rapid turnover characteristic: of mRNA, Here we report that both 3' adenylation and 5' phosphorylation affect the rate of digestion of RNA I by the 3' exonuclease, polynucleotide phosphorylase(9); conversely, mutation of the polynucleotide phosphorylase-encoding pnp gene affects ribonuclease acting at the 5' end. Together these findings indicate that enzymes attacking RNA I at its separate termini can interact functionally, Additionally, our discovery that adenylation-mediated degradation by polynucleotide phosphorylase imparts an mRNA-like half-life to RNA I suggests a possible mechanism to account for the rapid decay of mRNA(10) in E. coli.	STANFORD UNIV,SCH MED,DEPT GENET,STANFORD,CA 94305	Stanford University								Baker EJ, 1993, CONTROL MESSENGER RN, P367; BELASCO JG, 1985, CELL, V40, P171, DOI 10.1016/0092-8674(85)90320-4; BELTCHEV B, 1971, EUR J BIOCHEM, V19, P194, DOI 10.1111/j.1432-1033.1971.tb01304.x; BROWN JW, 1985, J BACTERIOL, V162, P909, DOI 10.1128/JB.162.3.909-917.1985; CAO GJ, 1992, P NATL ACAD SCI USA, V89, P10380, DOI 10.1073/pnas.89.21.10380; CAO GJ, 1992, P NATL ACAD SCI USA, V89, P7546, DOI 10.1073/pnas.89.16.7546; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; GOPALAKRISHNA Y, 1981, BIOCHEM BIOPH RES CO, V103, P454, DOI 10.1016/0006-291X(81)90474-5; HAJNSDORF E, IN PRESS P NATN ACAD; HE L, 1993, MOL MICROBIOL, V9, P1131, DOI 10.1111/j.1365-2958.1993.tb01243.x; HELMERCITTERICH M, 1988, EMBO J, V7, P557, DOI 10.1002/j.1460-2075.1988.tb02845.x; KELLY KO, 1992, J BIOL CHEM, V267, P16015; KING TC, 1987, CELLULAR MOL BIOL, P703; KLUG G, 1987, EMBO J, V6, P3515, DOI 10.1002/j.1460-2075.1987.tb02677.x; LINCHAO S, 1994, J BIOL CHEM, V269, P10797; LINCHAO S, 1991, CELL, V65, P1233, DOI 10.1016/0092-8674(91)90018-T; LITTAUER UZ, 1982, ENZYMES, P518; LOPILATO J, 1986, MOL GEN GENET, V205, P285, DOI 10.1007/BF00430440; MCLAREN RS, 1991, J MOL BIOL, V221, P81, DOI 10.1016/0022-2836(91)80206-A; NAKAZATO H, 1975, NATURE, V256, P144, DOI 10.1038/256144a0; NEWBURY SF, 1987, CELL, V51, P1131, DOI 10.1016/0092-8674(87)90599-X; OHARA EB, 1995, P NATL ACAD SCI USA, V92, P1807, DOI 10.1073/pnas.92.6.1807; SACHS A, 1993, J BIOL CHEM, V268, P22955; SHEN V, 1982, ENZYMES, P518; SIPPEL AE, 1973, EUR J BIOCHEM, V37, P31, DOI 10.1111/j.1432-1033.1973.tb02953.x; THANG MN, 1971, EUR J BIOCHEM, V19, P184, DOI 10.1111/j.1432-1033.1971.tb01303.x; TOMCSANYI T, 1985, J MOL BIOL, V185, P713, DOI 10.1016/0022-2836(85)90056-7; XU FF, 1993, P NATL ACAD SCI USA, V90, P6756, DOI 10.1073/pnas.90.14.6756; YU PL, 1982, FEMS MICROBIOL LETT, V14, P233	29	177	179	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 9	1995	374	6518					180	183		10.1038/374180a0	http://dx.doi.org/10.1038/374180a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL397	7533264				2022-12-24	WOS:A1995QL39700064
J	ZANETTI, AR; TANZI, E; PACCAGNINI, S; PRINCIPI, N; PIZZOCOLO, G; CACCAMO, ML; DAMICO, E; CAMBIE, G; VECCHI, L; BRESCIANI, S; MARIN, MG; PADULA, D; RODELLA, A; BULGARELLI, I; CHIODO, F; MAGLIANO, E; MIOTTO, G; MUGGIASCA, ML; PILLOTON, E; POZZOLI, R; PREGLIASCO, F; ROMANO, L; STRINGHI, C; DAGOSTINO, F; PAOLILLO, F; ZAPPAROLI, B				ZANETTI, AR; TANZI, E; PACCAGNINI, S; PRINCIPI, N; PIZZOCOLO, G; CACCAMO, ML; DAMICO, E; CAMBIE, G; VECCHI, L; BRESCIANI, S; MARIN, MG; PADULA, D; RODELLA, A; BULGARELLI, I; CHIODO, F; MAGLIANO, E; MIOTTO, G; MUGGIASCA, ML; PILLOTON, E; POZZOLI, R; PREGLIASCO, F; ROMANO, L; STRINGHI, C; DAGOSTINO, F; PAOLILLO, F; ZAPPAROLI, B			MOTHER-TO-INFANT TRANSMISSION OF HEPATITIS-C VIRUS	LANCET			English	Note							VERTICAL TRANSMISSION	To assess the risk of mother-to-infant transmission of hepatitis C virus (HCV), we followed up 116 babies of anti-HCV positive mothers, of whom 22 were coinfected with HIV and 94 had HCV alone. None of the babies whose mothers had HCV alone required HCV, while 8 babies (36%; p<0.001) of mothers co-infected with HIV acquired HCV (5 babies) or HCV and HIV (3). There was no association between any specific maternal HCV genotype and enhanced risk of neonatal infection. HCV-RNA levels were significantly higher (p<0.05) in mothers with HIV coinfection than in those with HCV alone. These data indicate that maternal HIV status correlates with enhanced level of viraemia which favours neonatal infection.	UNIV MILAN,DEPT PAEDIAT 4,I-20133 MILAN,ITALY; UNIV BRESCIA,SCH MED,INST CHEM,BRESCIA,ITALY; UNIV MILAN,HOSP L MANGIAGALLI,DEPT OBSTET & GYNAECOL,MILAN,ITALY; HOSP NIGUARDA CA GRANDA,DEPT PAEDIAT,MILAN,ITALY; HOSP MAGGIORE,CTR BLOOD TRANSFUS,LODI,ITALY; HOSP S GERARDO,CLIN PATHOL LAB,MONZA,ITALY	University of Milan; University of Brescia; University of Milan	ZANETTI, AR (corresponding author), UNIV MILAN,INST VIROL,VIA C PASCAL 38,I-20133 MILAN,ITALY.		Pregliasco, Fabrizio Ernesto/D-1642-2012; pregliasco, fabrizio/AAD-7499-2022	Pregliasco, Fabrizio Ernesto/0000-0002-3919-0679; 				KUROKI T, 1991, J INFECT DIS, V164, P427, DOI 10.1093/infdis/164.2.427; LAM JPH, 1993, J INFECT DIS, V167, P572, DOI 10.1093/infdis/167.3.572; OHTO H, 1994, NEW ENGL J MED, V330, P744, DOI 10.1056/NEJM199403173301103; PUOTI M, 1992, HEPATOLOGY, V4, P877; REINUS JF, 1992, ANN INTERN MED, V117, P881, DOI 10.7326/0003-4819-117-11-881; ROMANO L, 1994, INFECTION, V22, P350, DOI 10.1007/BF01715545; THALER MM, 1991, LANCET, V338, P17, DOI 10.1016/0140-6736(91)90006-B; WEINTRUB PS, 1991, J PEDIATR-US, V119, P869, DOI 10.1016/S0022-3476(05)83035-5; Wejstal R, 1992, ANN INTERN MED, V117, P887, DOI 10.7326/0003-4819-117-11-887; 1992, MMWR-MORBID MORTAL W, V41, P1	10	315	323	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 4	1995	345	8945					289	291		10.1016/S0140-6736(95)90277-5	http://dx.doi.org/10.1016/S0140-6736(95)90277-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QE731	7530793				2022-12-24	WOS:A1995QE73100011
J	JU, ST; PANKA, DJ; CUI, HL; ETTINGER, R; ELKHATIB, M; SHERR, DH; STANGER, BZ; MARSHAKROTHSTEIN, A				JU, ST; PANKA, DJ; CUI, HL; ETTINGER, R; ELKHATIB, M; SHERR, DH; STANGER, BZ; MARSHAKROTHSTEIN, A			FAS(CD95) FASL INTERACTIONS REQUIRED FOR PROGRAMMED CELL-DEATH AFTER T-CELL ACTIVATION	NATURE			English	Article							THYMOCYTE DEVELOPMENT; CYCLOSPORINE-A; HYBRIDOMAS; EXPRESSION; MICE; ANTIGEN; LYMPHOCYTE; PATHWAYS; SUICIDE; LPR	RECEPTOR crosslinking of T-cell hybridomas induces cell activation followed by apoptosis(1-6). This activation-induced cell death requires de novo synthesis of RNA and proteins(1-3), but the actual gene products that provide the death signal have not been identified(4-6). We show here that receptor crosslinking induces Fas ligand and upregulates Fas, and that the ensuing engagement of Fas by Fas ligand activates the cell-death programme. Cell death, but not activation, can be selectively prevented by a soluble Fas-immunoglobulin fusion protein. Thus, Fas and Fas ligand are the death-gene products, and their interaction accounts for the molecular mechanism of activation-induced T-cell death.	BOSTON UNIV,SCH MED,DEPT PATHOL & LAB MED,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT MICROBIOL,BOSTON,MA 02118; BOSTON UNIV,SCH MED,SCH PUBL HLTH,BOSTON,MA 02118; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115	Boston University; Boston University; Boston University; Harvard University; Harvard Medical School	JU, ST (corresponding author), BOSTON UNIV,SCH MED,CTR ARTHRITIS,80 E CONCORD ST,BOSTON,MA 02118, USA.			Sherr, David/0000-0003-3353-0553				ASHWELL JD, 1987, J EXP MED, V165, P173, DOI 10.1084/jem.165.1.173; BRINER TJ, 1989, THESIS MIT; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; GAO EK, 1988, NATURE, V336, P176, DOI 10.1038/336176a0; JENKINS MK, 1988, SCIENCE, V241, P1655, DOI 10.1126/science.3262237; JU ST, 1990, J IMMUNOL, V144, P23; JU ST, 1994, P NATL ACAD SCI USA, V91, P4185, DOI 10.1073/pnas.91.10.4185; JU ST, 1988, CELL IMMUNOL, V117, P399, DOI 10.1016/0008-8749(88)90129-3; KOZIN RL, 1988, J EXP MED, V168, P2221; LEO O, 1986, J IMMUNOL, V137, P3874; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; MOHLER KM, 1993, J IMMUNOL, V151, P1548; RUSSELL JH, 1993, P NATL ACAD SCI USA, V90, P4409, DOI 10.1073/pnas.90.10.4409; RUSSELL JH, 1993, EUR J IMMUNOL, V23, P2379, DOI 10.1002/eji.1830230951; SABATH DE, 1990, GENE, V91, P185, DOI 10.1016/0378-1119(90)90087-8; SARIN A, 1994, J IMMUNOL, V153, P862; SHEN MM, 1992, P NATL ACAD SCI USA, V89, P8240, DOI 10.1073/pnas.89.17.8240; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SHI YF, 1989, NATURE, V339, P625, DOI 10.1038/339625a0; SIDMAN CL, 1992, EUR J IMMUNOL, V22, P499, DOI 10.1002/eji.1830220231; SINGER PA, 1989, J EXP MED, V170, P1869, DOI 10.1084/jem.170.6.1869; STALDER T, 1994, J IMMUNOL, V152, P1127; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; UCKER DS, 1989, J IMMUNOL, V143, P3461; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; YANG YL, 1993, P NATL ACAD SCI USA, V90, P6170, DOI 10.1073/pnas.90.13.6170; ZACHARCHUK CM, 1990, J IMMUNOL, V145, P4037; ZETTLMEISSL G, 1990, DNA CELL BIOL, V9, P347, DOI 10.1089/dna.1990.9.347; ZHOU T, 1991, J IMMUNOL, V147, P466	30	1424	1485	2	31	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 2	1995	373	6513					444	448		10.1038/373444a0	http://dx.doi.org/10.1038/373444a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE670	7530337				2022-12-24	WOS:A1995QE67000061
J	HUIZINGA, JD; THUNEBERG, L; KLUPPEL, M; MALYSZ, J; MIKKELSEN, HB; BERNSTEIN, A				HUIZINGA, JD; THUNEBERG, L; KLUPPEL, M; MALYSZ, J; MIKKELSEN, HB; BERNSTEIN, A			W/KIT GENE REQUIRED FOR INTERSTITIAL-CELLS OF CAJAL AND FOR INTESTINAL PACEMAKER ACTIVITY	NATURE			English	Article							C-KIT; CANINE COLON; W-LOCUS; PROTO-ONCOGENE; PROTOONCOGENE; EXPRESSION; MUSCLE	THE pacemaker activity in the mammalian gut is responsible for generating anally propagating phasic contractions, The cellular basis for this intrinsic activity is unknown. The smooth muscle cells of the external muscle layers and the innervated cellular network of interstitial cells of Cajal, which is closely associated with the external muscle layers of the mammalian gut, have both been proposed to stimulate pacemaker activity(1-5). The interstitial cells of Cajal were identified in the last century but their developmental origin and function have remained unclear. Here we show that the interstitial cells of Cajal express the Kit receptor tyrosine kinase. Furthermore, mice with mutations in the dominant white spotting (W) locus, which have cellular defects in haematopoiesis, melanogenesis and gametogenesis(6) as a result of mutations in the Kit gene(7,8) also lack the network of intestitial cells of Cajal associated with Auerbach's nerve plexus and intestinal pacemaker activity.	UNIV COPENHAGEN,DEPT ANAT,COPENHAGEN,DENMARK; MT SINAI HOSP,SAMUEL LUNENFELD RES INST,TORONTO,ON M5G 1X5,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO,ON,CANADA	University of Copenhagen; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	HUIZINGA, JD (corresponding author), MCMASTER UNIV,DEPT BIOMED SCI,INTESTINAL DIS RES UNIT,1200 MAIN ST W,HAMILTON,ON L8N 3Z5,CANADA.							BOLOGNIA JL, 1988, J AM ACAD DERMATOL, V19, P217, DOI 10.1016/S0190-9622(88)70168-1; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; DURDLE NG, 1983, GASTROENTEROLOGY, V84, P375; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; FLEISCHMAN RA, 1991, P NATL ACAD SCI USA, V88, P10885, DOI 10.1073/pnas.88.23.10885; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GIEBEL LB, 1991, P NATL ACAD SCI USA, V88, P8696, DOI 10.1073/pnas.88.19.8696; HUIZINGA JD, 1991, J PHYSIOL-LONDON, V442, P15, DOI 10.1113/jphysiol.1991.sp018779; LIU LWC, 1993, J PHYSIOL-LONDON, V470, P445, DOI 10.1113/jphysiol.1993.sp019868; LIU LWC, 1994, AM J PHYSIOL, V266, pG485, DOI 10.1152/ajpgi.1994.266.3.G485; MAEDA H, 1992, DEVELOPMENT, V116, P369; MIKKELSEN HB, 1993, CELL TISSUE RES, V274, P249, DOI 10.1007/BF00318744; MIKKELSEN HB, 1988, ANAT EMBRYOL, V17, P191; MOTRO B, 1991, DEVELOPMENT, V113, P1207; ORRURTREGER A, 1990, DEVELOPMENT, V109, P911; REITH AD, 1991, GENOME ANAL, V3, P105; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; THUNEBERG L, 1982, ADV ANAT EMBRYOL CEL, V71, P1; THUNEBERG L, 1992, GASTROENTEROLOGY, V103, P1388, DOI 10.1016/0016-5085(92)91601-Y; THUNEBERG L, 1989, HDB PHYSL GASTROINTE, P349	21	1132	1176	0	30	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 26	1995	373	6512					347	349						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD404	7530333				2022-12-24	WOS:A1995QD40400061
J	BROOKS, PC; MONTGOMERY, AMP; ROSENFELD, M; REISFELD, RA; HU, TH; KLIER, G; CHERESH, DA				BROOKS, PC; MONTGOMERY, AMP; ROSENFELD, M; REISFELD, RA; HU, TH; KLIER, G; CHERESH, DA			INTEGRIN ALPHA(V)BETA(3) ANTAGONISTS PROMOTE TUMOR-REGRESSION BY INDUCING APOPTOSIS OF ANGIOGENIC BLOOD-VESSELS	CELL			English	Article							EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; VONWILLEBRAND-FACTOR; VITRONECTIN; ADHESION; EXPRESSION; FIBRINOGEN; CARCINOMA; ATTACHMENT; MIGRATION	A single intravascular injection of a cyclic peptide or monoclonal antibody antagonist of integrin alpha(v) beta(3) disrupts ongoing angiogenesis on the chick chorioallantoic membrane (CAM). This leads to the rapid regression of histologically distinct human tumors transplanted onto the CAM. Induction of angiogenesis by a tumor or cytokine promotes vascular cell entry into the cell cycle and expression of integrin alpha(v) beta(3). After angiogenesis is initiated, antagonists of this integrin induce apoptosis of the proliferative angiogenic vascular cells, leaving preexisting quiescent blood vessels unaffected. We demonstrate therefore that ligation of integrin alpha(v) beta(3) is required for the survival and maturation of newly forming blood vessels, an event essential for the proliferation of tumors.	SCRIPPS RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, DEPT VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute	BROOKS, PC (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA.				NCI NIH HHS [CA45726, CA50286] Funding Source: Medline; NIAID NIH HHS [T32 AI 072 44-11] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA050286, R01CA045726, R01CA050286] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007244] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUMAILLEY M, 1991, FEBS LETT, V291, P50, DOI 10.1016/0014-5793(91)81101-D; BASSON CT, 1992, J CELL PHYSIOL, V153, P118, DOI 10.1002/jcp.1041530116; BIANCHINE PJ, 1992, J IMMUNOL, V149, P3665; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BLOOD CH, 1990, BIOCHIM BIOPHYS ACTA, V1032, P89, DOI 10.1016/0304-419X(90)90014-R; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; CHERESH DA, 1991, CANCER METAST REV, V10, P3, DOI 10.1007/BF00046839; CHERESH DA, 1989, CELL, V58, P945, DOI 10.1016/0092-8674(89)90946-X; CHERESH DA, 1989, CELL, V57, P59, DOI 10.1016/0092-8674(89)90172-4; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DAMORE PA, 1987, ANNU REV PHYSIOL, V49, P453; DEFILIPPI P, 1994, CELL ADHES COMMUN, V2, P75, DOI 10.3109/15419069409014203; ENENSTEIN J, 1992, EXP CELL RES, V203, P499, DOI 10.1016/0014-4827(92)90028-7; ENENSTEIN J, 1994, J INVEST DERMATOL, V103, P381, DOI 10.1111/1523-1747.ep12395390; FELDINGHABERMANN B, 1992, J CLIN INVEST, V89, P2018, DOI 10.1172/JCI115811; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Folkman J, 1992, Semin Cancer Biol, V3, P65; FOTSIS T, 1994, NATURE, V368, P237, DOI 10.1038/368237a0; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GLADSON CL, 1991, J CLIN INVEST, V88, P1924, DOI 10.1172/JCI115516; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0; INGBER D, 1991, J CELL BIOCHEM, V47, P236, DOI 10.1002/jcb.240470309; INGBER DE, 1989, J CELL BIOL, V109, P317, DOI 10.1083/jcb.109.1.317; INGBER DE, 1986, ENDOCRINOLOGY, V119, P1768, DOI 10.1210/endo-119-4-1768; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KOYAMA N, 1994, J CELL PHYSIOL, V158, P1, DOI 10.1002/jcp.1041580102; LEAVESLEY DI, 1992, J CELL BIOL, V117, P1101, DOI 10.1083/jcb.117.5.1101; LEAVESLEY DI, 1993, J CELL BIOL, V121, P163, DOI 10.1083/jcb.121.1.163; LIN CQ, 1993, FASEB J, V7, P737, DOI 10.1096/fasebj.7.9.8330681; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MIGNATTI P, 1991, J CELL BIOCHEM, V47, P201, DOI 10.1002/jcb.240470303; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; PAKU S, 1991, LAB INVEST, V65, P334; PFAFF M, 1994, J BIOL CHEM, V269, P20233; ROMER LH, 1994, MOL BIOL CELL, V5, P349, DOI 10.1091/mbc.5.3.349; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SCHWARTZ MA, 1993, CANCER RES, V53, P1503; TAKESHITA S, 1994, J CLIN INVEST, V93, P662, DOI 10.1172/JCI117018; TELFORD WG, 1992, CYTOMETRY, V13, P137, DOI 10.1002/cyto.990130205; WAYNER EA, 1991, J CELL BIOL, V113, P919, DOI 10.1083/jcb.113.4.919; WEIDNER N, 1992, JNCI-J NATL CANCER I, V84, P1875, DOI 10.1093/jnci/84.24.1875; WEIDNER N, 1993, AM J PATHOL, V143, P401; WEINSTATSASLOW D, 1994, FASEB J, V8, P401, DOI 10.1096/fasebj.8.6.7513289	48	2050	2230	2	95	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 30	1994	79	7					1157	1164		10.1016/0092-8674(94)90007-8	http://dx.doi.org/10.1016/0092-8674(94)90007-8			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PZ860	7528107				2022-12-24	WOS:A1994PZ86000007
J	STENMAN, UH; HAKAMA, M; KNEKT, P; AROMAA, A; TEPPO, L; LEINONEN, J				STENMAN, UH; HAKAMA, M; KNEKT, P; AROMAA, A; TEPPO, L; LEINONEN, J			SERUM CONCENTRATIONS OF PROSTATE-SPECIFIC ANTIGEN AND ITS COMPLEX WITH ALPHA(1)-ANTICHYMOTRYPSIN BEFORE DIAGNOSIS OF PROSTATE-CANCER	LANCET			English	Article							SCREENING-TEST; ALPHA-1-ANTICHYMOTRYPSIN; ASSAY; MEN	Prostate cancer can be detected at an early, potentially curable stage by screening based on digital rectal examination and serum prostate specific antigen (PSA). The value of screening appears doubtful, based on high 10-year survival rates in selected cases of early prostate cancer, but this follow-up time may be insufficient. By linking the information on 21172 men who took part in a screening examination in Finland, 1968-73, with data from the Finnish Cancer Registry, 44 cases of prostate cancer diagnosed up to 1980 were identified. Serum samples from cancer cases and from 74 controls matched for age and time of sampling were assayed for PSA and its complex with alpha(1)-antichymotrypsin (PSA-ACT). With a cut-off for PSA of 2.5 mu g/L giving 92% specificity, 95% of the cancers developing within the first 5 years, and 52% developing in 6-10 years tested positive. As a potential screening test with a 5-year interval for men under 65, the sensitivity would be 92% and specificity 97%. The ratio of PSA-ACT to total PSA was lower in controls than in patients wih cancer. Using this ratio, we could eliminate half of the false-positive results in the range 2.5-25 mu g/L without loss of sensitivity. Cancer was typically diagnosed 5-10 years after PSA exceeded 2.5 mu g/L, and the median survival after diagnosis was 3.6 years. 10-year survivat after drawing the sample was 71% in cancer cases with a PSA concentration less than 4 mu g/L and 48% in those with higher concentrations. The corresponding figures at 15 years were 53% and 27%, and at 20 years 43% and 18%, respectively. These results suggest it is advisable to confine screening for prostate cancer to men with a life expectancy of clearly more than 10 years-ie, younger men, who have the greatest chance to benefit from early detection.	UNIV TAMPERE,DEPT PUBL HLTH,TAMPERE,FINLAND; SOCIAL INSURANCE INST,RES & DEV UNIT,HELSINKI,FINLAND; FINNISH CANC REGISTRY,HELSINKI,FINLAND	Tampere University; Finnish Cancer Registry	STENMAN, UH (corresponding author), HELSINKI UNIV HOSP,DEPT CLIN CHEM,HAARTMANINKATU 2,SF-00290 HELSINKI,FINLAND.							ADAMI HO, 1994, LANCET, V343, P958, DOI 10.1016/S0140-6736(94)90071-X; AUS G, 1994, J UROLOGY, V151, P278; BABAIAN RJ, 1990, J CLIN LAB ANAL, V4, P135, DOI 10.1002/jcla.1860040212; BRAWER MK, 1992, J UROLOGY, V147, P841, DOI 10.1016/S0022-5347(17)37401-3; CARTER HB, 1992, CANCER RES, V52, P3323; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; CHADWICK DJ, 1991, LANCET, V338, P613; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; CHRISTENSSON A, 1993, J UROLOGY, V150, P100, DOI 10.1016/S0022-5347(17)35408-3; COLBERG JW, 1993, J UROLOGY, V149, P507, DOI 10.1016/S0022-5347(17)36130-X; FELDMANN U, 1981, J CLIN CHEM CLIN BIO, V19, P121; FRANKS LM, 1954, J PATHOL BACTERIOL, V68, P603, DOI 10.1002/path.1700680233; KABALIN JN, 1989, J UROLOGY, V141, P1091, DOI 10.1016/S0022-5347(17)41178-5; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; Knekt P, 1988, PUBLICATIONS SOCIAL, V83, P1; LABRIE F, 1993, CLIN INVEST MED, V16, P425; LABRIE F, 1992, J UROLOGY, V147, P846, DOI 10.1016/S0022-5347(17)37402-5; LEINONEN J, 1993, CLIN CHEM, V39, P2098; LILJA H, 1991, CLIN CHEM, V37, P1618; METTLIN C, 1993, CANCER, V72, P1050, DOI 10.1002/1097-0142(19930801)72:3+<1050::AID-CNCR2820721318>3.0.CO;2-J; METTLIN C, 1993, CANCER, V72, P1701, DOI 10.1002/1097-0142(19930901)72:5<1701::AID-CNCR2820720534>3.0.CO;2-E; MILLER AB, 1991, CANCER SCREENING, P289; OESTERLING JE, 1993, JAMA-J AM MED ASSOC, V269, P57; PARTIN AW, 1993, UROL CLIN N AM, V20, P713; SCHMID HP, 1993, EUR UROL, V2, P60; SCHRODER FH, 1993, BRIT MED J, V306, P407, DOI 10.1136/bmj.306.6875.407; STAMEY TA, 1987, NEW ENGL J MED, V317, P909, DOI 10.1056/NEJM198710083171501; STENMAN UH, 1991, CANCER RES, V51, P222; STENMAN UH, 1990, J NUCL MED ALLIED S3, V34, P249; TEPPO L, 1994, ACTA ONCOL, V33, P365, DOI 10.3109/02841869409098430; ZWEIG MH, 1993, CLIN CHEM, V39, P561	31	218	222	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 10	1994	344	8937					1594	1598		10.1016/S0140-6736(94)90405-7	http://dx.doi.org/10.1016/S0140-6736(94)90405-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW051	7527116				2022-12-24	WOS:A1994PW05100008
J	BURTON, JL				BURTON, JL			KERATIN GENES AND EPIDERMOLYTIC HYPERKERATOSIS	LANCET			English	Editorial Material							ICHTHYOSIS BULLOSA; SIEMENS; DIFFERENTIATION				BURTON, JL (corresponding author), BRISTOL ROYAL INFIRM & GEN HOSP,DEPT DERMATOL,BRISTOL,AVON,ENGLAND.							CHENG J, 1992, CELL, V70, P811, DOI 10.1016/0092-8674(92)90314-3; COLLIN C, 1992, EXP CELL RES, V202, P132, DOI 10.1016/0014-4827(92)90412-2; KREMER H, 1994, J INVEST DERMATOL, V103, P286, DOI 10.1111/1523-1747.ep12394414; LANE EB, 1994, CURR OPIN GENET DEV, V4, P412, DOI 10.1016/0959-437X(94)90030-2; LEIGH IM, 1993, ARCH DERMATOL, V129, P1571, DOI 10.1001/archderm.129.12.1571; MCLEAN WHI, 1994, J INVEST DERMATOL, V103, P277, DOI 10.1111/1523-1747.ep12394307; MURDOCH ME, 1990, CLIN EXP DERMATOL, V15, P53, DOI 10.1111/j.1365-2230.1990.tb02021.x; REIS A, 1994, NAT GENET, V6, P174, DOI 10.1038/ng0294-174; ROTHNAGEL JA, 1994, NAT GENET, V7, P485, DOI 10.1038/ng0894-485; STEIJLEN PM, 1990, ARCH DERMATOL RES, V282, P1, DOI 10.1007/BF00505636; STEIJLEN PM, 1994, J INVEST DERMATOL, V103, P282, DOI 10.1111/1523-1747.ep12394335; TRAUPE H, 1986, J AM ACAD DERMATOL, V14, P1000, DOI 10.1016/S0190-9622(86)70123-0; VAKILZADEH F, 1991, BRIT J DERMATOL, V124, P191, DOI 10.1111/j.1365-2133.1991.tb00432.x; 1993, LANCET, V339, P29	14	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 22	1994	344	8930					1103	1104		10.1016/S0140-6736(94)90626-2	http://dx.doi.org/10.1016/S0140-6736(94)90626-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN066	7523811				2022-12-24	WOS:A1994PN06600005
J	KLOC, M; ETKIN, LD				KLOC, M; ETKIN, LD			DELOCALIZATION OF VG1 MESSENGER-RNA FROM THE VEGETAL CORTEX IN XENOPUS-OOCYTES AFTER DESTRUCTION OF XLSIRT RNA	SCIENCE			English	Article							MATERNAL MESSENGER-RNA; CELL-FORMATION; LAEVIS; ABLATION; PROTEIN; EMBRYOS; NANOS; XLGV7; OSKAR; EGGS	The Xlsirts are a family of transcribed repeat sequence genes that do not code for protein. Xlsirt RNAs become localized to the vegetal cortex of Xenopus oocytes early in oogenesis, before the localization of the messenger RNA Vg1, which encodes a transforming growth factor-beta-like molecule involved in mesoderm formation, and coincident with the localization of Xcat2 transcripts, which encode a nanos-like molecule. Destruction of the localized Xlsirts by injection of antisense oligodeoxynucleotides into stage 4 oocytes resulted in the release of Vg1 transcripts but not Xcat2 transcripts from the vegetal cortex. Xlsirt RNAs, which may be a structural component of the vegetal cortex, are a crucial part of a genetic pathway necessary for the proper localization of Vg1 that leads to subsequent normal pattern formation.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT MOLEC GENET, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center			Kloc, Malgorzata/AAF-6982-2020					DING D, 1993, BIOESSAYS, V15, P651, DOI 10.1002/bies.950151004; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; King Jr Martin Luther, COMMUNICATION; KLOC M, 1989, DEVELOPMENT, V107, P899; KLOC M, 1993, SCIENCE, V262, P1712, DOI 10.1126/science.7505061; KLOC M, UNPUB; MILLER M, 1989, GENE DEV, V3, P572, DOI 10.1101/gad.3.4.572; MORGAN R, 1993, NUCLEIC ACIDS RES, V21, P4615, DOI 10.1093/nar/21.19.4615; MOSQUERA L, 1993, DEVELOPMENT, V117, P377; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; SMITH JL, 1992, CELL, V70, P849, DOI 10.1016/0092-8674(92)90318-7; SMITH RC, 1990, DEVELOPMENT, V110, P769; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; YISRAELI JK, 1990, DEVELOPMENT, V108, P289	17	128	131	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 19	1994	265	5175					1101	1103		10.1126/science.7520603	http://dx.doi.org/10.1126/science.7520603			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC539	7520603				2022-12-24	WOS:A1994PC53900039
J	OPAL, SM; PALARDY, JE; MARRA, MN; FISHER, CJ; MCKELLIGON, BM; SCOTT, RW				OPAL, SM; PALARDY, JE; MARRA, MN; FISHER, CJ; MCKELLIGON, BM; SCOTT, RW			RELATIVE CONCENTRATIONS OF ENDOTOXIN-BINDING PROTEINS IN BODY-FLUIDS DURING INFECTION	LANCET			English	Article							PERMEABILITY-INCREASING PROTEIN; GRAM-NEGATIVE BACTERIA; LIPOPOLYSACCHARIDE; SEPSIS; DISEASE; MECHANISMS; LPS	Endotoxin initiates the systemic inflammatory response, haemodynamic changes, and multi-organ failure that may occur as a consequence of systemic gram-negative bacterial infection. The serum protein lipopolysaccharide-binding protein (LBP) binds to the lipid A component of bacterial endotoxin and facilitates its delivery to the CD14 antigen on the macrophage, where proinflammatory cytokines are released and a cascade of host mediators is initiated. The neutrophil granular protein bactericidal/permeability-increasing protein (BPI) competes with LBP for endotoxin binding and functions as a molecular antagonist of LBP-endotoxin interactions. We have measured concentrations of both proteins in body fluids from 49 consecutive patients. In 16 of 17 samples of fluid from closed-space infections, BPI was present in greater concentration than LBP (median BPI/LBP ratio 7.6 [95% CI 2.32-22.1]), The ratio of BPI and LBP was not significantly different from 1.0 in abdominal fluid from 10 patients with peritonitis (ratio 0.235 [0.18-0.47]), whereas the BPI/LBP ratio was low in 22 non-infected body fluids (0.01 [0.001-0.04]) and concentrations of both proteins approached those in normal human plasma. BPI concentrations were directly correlated with the quantity of neutrophils within clinical samples (r(s) = 0.81, p < 0.0001). Thus, within abscess cavities BPI is available in sufficient quantities for effective competition with LBP for endotoxin. BPI may attenuate the local inflammatory response and the systemic toxicity of endotoxin release during gram-negative infections.	BROWN UNIV,SCH MED,PAWTUCKET,RI; INCYTE PHARMACEUT,PALO ALTO,CA; CLEVELAND CLIN FDN,CLEVELAND,OH	Brown University; Incyte; Cleveland Clinic Foundation	OPAL, SM (corresponding author), MEM HOSP RHODE ISL,DIV INFECT DIS,111 BREWSTER ST,PAWTUCKET,RI 02860, USA.							BONE RC, 1991, ANN INTERN MED, V115, P457, DOI 10.7326/0003-4819-115-6-457; BRANDTZAEG P, 1989, J INFECT DIS, V159, P195, DOI 10.1093/infdis/159.2.195; CASEY LC, 1993, ANN INTERN MED, V119, P771, DOI 10.7326/0003-4819-119-8-199310150-00001; CROSS AS, 1993, J INFECT DIS, V167, P112, DOI 10.1093/infdis/167.1.112; FISHER CJ, 1994, CRIT CARE MED, V22, P553, DOI 10.1097/00003246-199404000-00008; GAZZANOSANTORO H, 1994, INFECT IMMUN, V62, P1185, DOI 10.1128/IAI.62.4.1185-1191.1994; GRAY PW, 1989, J BIOL CHEM, V264, P9595; HEUMANN D, 1993, J INFECT DIS, V167, P1351, DOI 10.1093/infdis/167.6.1351; HOESS A, 1993, EMBO J, V12, P3351, DOI 10.1002/j.1460-2075.1993.tb06008.x; MARRA MN, 1992, J IMMUNOL, V148, P532; MARRA MN, 1990, J IMMUNOL, V144, P622; MORRISON DC, 1987, ANNU REV MED, V38, P417, DOI 10.1146/annurev.me.38.020187.002221; OPAL SM, 1991, CLIN RES, V30, pA451; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008; RIVEAU GR, 1987, J CLIN MICROBIOL, V25, P889, DOI 10.1128/JCM.25.5.889-892.1987; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; TOBIAS PS, 1988, J BIOL CHEM, V263, P13479; WEISS J, 1980, J CLIN INVEST, V65, P619, DOI 10.1172/JCI109707; WEISS J, 1992, J CLIN INVEST, V90, P1122, DOI 10.1172/JCI115930; WEISS J, 1978, J BIOL CHEM, V253, P2664; WILDE CG, IN PRESS J BIOL CHEM; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	22	77	78	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 13	1994	344	8920					429	431		10.1016/S0140-6736(94)91767-1	http://dx.doi.org/10.1016/S0140-6736(94)91767-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB761	7520106				2022-12-24	WOS:A1994PB76100007
J	WANG, TW; DONAHOE, PK; ZERVOS, AS				WANG, TW; DONAHOE, PK; ZERVOS, AS			SPECIFIC INTERACTION OF TYPE-I RECEPTORS OF THE TGF-BETA FAMILY WITH THE IMMUNOPHILIN FKBP-12	SCIENCE			English	Article							TRANSMEMBRANE SERINE KINASE; GROWTH-FACTOR-BETA; PROTEIN-KINASE; THREONINE KINASE; ACTIVIN; COMPLEX; EXPRESSION; CLONING	Transforming growth factor-beta (TGF-beta) family members bind to receptors that consist of heteromeric serine-threonine kinase subunits (type I and type II). In a yeast genetic screen, the immunophilin FKBP-12, a target of the macrolides FK506 and rapamycin, interacted with the type I receptor for TGF-beta and with other type I receptors. Deletion, point mutation, and co-immunoprecipitation studies further demonstrated the specificity of the interaction. Excess FK506 competed with type I receptors for binding to FKBP-12, which suggests that these receptors share or overlap the macrolide binding site on FKBP-12, and therefore they may represent its natural ligand. The specific interaction between the type I receptors and FKBP-12 suggests that FKBP-12 may play a role in type I receptor-mediated signaling.	MASSACHUSETTS GEN HOSP,CUTANEOUS BIOL RES CTR,BOSTON,MA 02129; MASSACHUSETTS GEN HOSP,CUTANEOUS BIOL RES CTR,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,PEDIAT SURG RES LAB,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD028138] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA017393] Funding Source: NIH RePORTER; NCI NIH HHS [CA17393] Funding Source: Medline; NICHD NIH HHS [NICHD P-30 HD28138, NICHD P-32 HD07396] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRAZEN P, 1993, CELL, V75, P681; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HE WW, 1993, DEV DYNAM, V196, P133, DOI 10.1002/aja.1001960207; Lin Herbert Y., 1993, Trends in Cell Biology, V3, P14, DOI 10.1016/0962-8924(93)90195-7; LIN HY, 1992, CELL, V68, P1; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MATSUZAKI K, 1993, J BIOL CHEM, V268, P12719; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TSUCHIDA K, 1993, P NATL ACAD SCI USA, V90, P11242, DOI 10.1073/pnas.90.23.11242; VANDUYNE GD, 1991, J AM CHEM SOC, V113, P7433, DOI 10.1021/ja00019a057; WANG TW, UNPUB; WITTENBERG C, 1988, CELL, V54, P1061, DOI 10.1016/0092-8674(88)90121-3; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; YAMAZAKI Y, 1993, DNA SEQUENCE, V3, P297; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	21	308	336	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 29	1994	265	5172					674	676		10.1126/science.7518616	http://dx.doi.org/10.1126/science.7518616			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ538	7518616				2022-12-24	WOS:A1994NZ53800037
J	ZUCKERMAN, J; CLEWLEY, G; GRIFFITHS, P; COCKCROFT, A				ZUCKERMAN, J; CLEWLEY, G; GRIFFITHS, P; COCKCROFT, A			PREVALENCE OF HEPATITIS-C ANTIBODIES IN CLINICAL HEALTH-CARE WORKERS	LANCET			English	Article							VIRUS-INFECTION; NEEDLESTICK INJURY; HCV; BLOOD; RISK	Health-care workers are known to be at risk from occupational transmission of blood-borne viruses, including hepatitis C. There may be serious implications following infection with hepatitis C including possible transmission to patients. We determined the prevalence of hepatitis C virus (HCV) antibodies among health-care workers at risk of occupational contact with blood and body fluids and among source patients in reported blood-exposure incidents. Anonymised stored blood samples from health-care workers immunised against hepatitis B virus since 1991 (n=1053) and blood samples from source patients in needlestick injuries (retrospective and prospective) since 1989 (n=373) were analysed. 3 (0.28%) of the serum samples from health-care workers were found to be anti-HCV-positive. 17 (8.5%) of 200 source patients tested retrospectively between January 1989 and January 1992, and 24 (13.9%) of 173 source patients tested prospectively between January 1992 and June 1993 were anti-HCV-positive. During the second period, 15 (10.6%) of 142 source patients tested for human immunodeficiency virus (HIV) were positive and 7 (3.8%) of 184 source patients tested for hepatitis B surface antigen were positive. 6 of 24 (25%) HCV-infected patients were diagnosed only after the incident; for hepatitis B, 2 (33%) of patients were diagnosed after the incident, and for HIV all patients were previously diagnosed. The seroprevalence of HCV among these health-care workers is no higher than that reported in blood donors. This suggests that there has not been significant occupational transmission of HCV to these health-care workers despite the high prevalence of HCV (often covert) among source patients in reported blood exposure in the same hospital.	ROYAL FREE NHS TRUST,OCCUPAT HLTH UNIT,LONDON,ENGLAND; ROYAL FREE NHS TRUST,DEPT VIROL,DIV COMMUNICABLE DIS,LONDON,ENGLAND; ROYAL FREE HOSP,SCH MED,LONDON,ENGLAND	University of London; University College London; University of London; University College London; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School								CARIANI E, 1991, LANCET, V337, P850, DOI 10.1016/0140-6736(91)92555-G; COCKCROFT A, 1990, BRIT J IND MED, V47, P199; DUSHEIKO GM, 1990, LANCET, V336, P503, DOI 10.1016/0140-6736(90)92049-N; GARSON JA, 1991, LANCET, V335, P1419; HERBERT AM, 1992, LANCET, V339, P304; JOCHEN ABB, 1992, LANCET, V339, P304, DOI 10.1016/0140-6736(92)91373-G; KIYOSAWA K, 1991, ANN INTERN MED, V115, P367, DOI 10.7326/0003-4819-115-5-367; KLEIN RS, 1991, LANCET, V338, P1539, DOI 10.1016/0140-6736(91)92369-D; MACLENNAN S, 1992, LANCET, V339, P131, DOI 10.1016/0140-6736(92)91048-D; MITSUI T, 1992, HEPATOLOGY, V16, P1109, DOI 10.1016/0270-9139(92)90001-P; OAKLEY K, 1992, BRIT MED J, V304, P949, DOI 10.1136/bmj.304.6832.949; RYAN KE, 1994, BRIT MED J, V308, P696, DOI 10.1136/bmj.308.6930.696; SCHLIPKOTER U, 1990, SCAND J INFECT DIS, V22, P757, DOI 10.3109/00365549009027136; SEEFF LB, 1991, ANN INTERN MED, V115, P411, DOI 10.7326/0003-4819-115-5-411_1; VAGLIA A, 1990, LANCET, V336, P1315, DOI 10.1016/0140-6736(90)92997-V; WEST DJ, 1984, AM J MED SCI, V287, P26, DOI 10.1097/00000441-198403000-00006; 1988, MMWR-MORBID MORTAL W, V37, P377; 1993, COMMUNICAB DIS REP, V3, pR135	18	100	102	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 25	1994	343	8913					1618	1620		10.1016/S0140-6736(94)93064-3	http://dx.doi.org/10.1016/S0140-6736(94)93064-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU354	7516460				2022-12-24	WOS:A1994NU35400017
J	MULKEY, RM; ENDO, S; SHENOLIKAR, S; MALENKA, RC				MULKEY, RM; ENDO, S; SHENOLIKAR, S; MALENKA, RC			INVOLVEMENT OF A CALCINEURIN/INHIBITOR-1 PHOSPHATASE CASCADE IN HIPPOCAMPAL LONG-TERM DEPRESSION	NATURE			English	Article							PROTEIN PHOSPHATASES; AREA CA1; PHOSPHORYLATION; IDENTIFICATION; MEMORY	LONG-TERM potentiation (LTP) is a synaptic mechanism thought to be involved in learning and memory(1). Long-term depression (LTD), an activity-dependent decrease in synaptic efficacy, may be an equally important mechanism which permits neural networks to store information more effectively(2,3). One form of LTD that has been observed in the hippocampus(4) requires activation of postsynaptic NMDA (N-methyl-D-aspartate) receptors(4,5), a change in postsynaptic calcium concentration(5), and activation of postsynaptic serine/threonine protein phosphatase 1 (PP1) or 2A (PP2A)(6). The mechanism by which PP1 or PP2A is regulated by synaptic activity is unclear because these protein phosphatases are not directly influenced by calcium concentration. LTD induction may require activation of a more complex protein phosphatase cascade consisting of the Ca2+/calmodulin-dependent protein phosphatase, calcineurin, its phosphoprotein substrate, inhibitor-1, and PP1(7,8). We tested this hypothesis using calcineurin inhibitors as well as different forms of inhibitor-1 loaded into postsynaptic cells. Our results suggest a signalling pathway in which calcineurin dephosphorylates and inactivates inhibitor-1. This in turn increases PP1 activity and contributes to the generation of LTD.	UNIV CALIF SAN FRANCISCO, DEPT PSYCHIAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; DUKE UNIV, MED CTR, DEPT PHARMACOL, DURHAM, NC 27710 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Duke University								BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; COHEN P, 1988, PROC R SOC SER B-BIO, V234, P115, DOI 10.1098/rspb.1988.0040; Cohen P, 1988, CALMODULIN; DOSEMECI A, 1993, J NEUROCHEM, V61, P550; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; GRATECOS D, 1974, BIOCHEM BIOPH RES CO, V58, P960, DOI 10.1016/S0006-291X(74)80237-8; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; KUNZ J, 1993, TRENDS BIOCHEM SCI, V18, P334, DOI 10.1016/0968-0004(93)90069-Y; LISMAN J, 1989, P NATL ACAD SCI USA, V86, P9574, DOI 10.1073/pnas.86.23.9574; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; MULKEY RM, 1993, SCIENCE, V261, P1051, DOI 10.1126/science.8394601; SEJNOWSKI TJ, 1977, J MATH BIOL, V4, P303, DOI 10.1007/BF00275079; SHENOLIKAR S, 1984, METHOD ENZYMOL, V107, P102; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SHIELDS SM, 1985, J NEUROSCI, V5, P3414; Stemmer P, 1991, Curr Opin Neurobiol, V1, P53, DOI 10.1016/0959-4388(91)90010-5; Willshaw D, 1990, NEURAL COMPUT, V2, P85, DOI 10.1162/neco.1990.2.1.85	17	874	897	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 9	1994	369	6480					486	488		10.1038/369486a0	http://dx.doi.org/10.1038/369486a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NQ286	7515479				2022-12-24	WOS:A1994NQ28600057
J	BOWCOCK, AM; RUIZLINARES, A; TOMFOHRDE, J; MINCH, E; KIDD, JR; CAVALLISFORZA, LL				BOWCOCK, AM; RUIZLINARES, A; TOMFOHRDE, J; MINCH, E; KIDD, JR; CAVALLISFORZA, LL			HIGH-RESOLUTION OF HUMAN EVOLUTIONARY TREES WITH POLYMORPHIC MICROSATELLITES	NATURE			English	Article							MITOCHONDRIAL-DNA; POPULATIONS; PERSISTENCE; LOCI	GENETIC variation at hypervariable loci is being used extensively for linkage analysis1 and individual identification2, and may be useful for inter-population studies2-5. Here we show that polymorphic microsatellites (primarily CA repeats) allow trees of human individuals to be constructed that reflect their geographic origin with remarkable accuracy. This is achieved by the analysis of a large number of loci for each individual, in spite of the small variations in allele frequencies existing between populations6,7. Reliable evolutionary relationships could also be established in comparisons among human populations but not among great ape species, probably because of constraints on allele length variation. Among human populations, diversity of microsatellites is highest in Africa, which is in contrast to other nuclear markers and supports the hypothesis of an African origin for humans.	STANFORD UNIV, DEPT GENET, STANFORD, CA 94305 USA; YALE UNIV, SCH MED, DEPT GENET, NEW HAVEN, CT 06510 USA	Stanford University; Yale University	BOWCOCK, AM (corresponding author), UNIV TEXAS, SW MED CTR, DEPT PEDIAT, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA.		Klein, Richard G/B-5910-2009; Ruiz-Linares, Andres/AAR-1104-2021	Ruiz-Linares, Andres/0000-0001-8372-1011; Bowcock, Anne/0000-0001-8691-9090				BARBUJANI G, 1990, P NATL ACAD SCI USA, V87, P1816, DOI 10.1073/pnas.87.5.1816; BOWCOCK A, 1993, GENOMICS, V15, P376, DOI 10.1006/geno.1993.1071; Bowcock A M, 1991, Gene Geogr, V5, P151; BOWCOCK AM, 1991, P NATL ACAD SCI USA, V88, P839, DOI 10.1073/pnas.88.3.839; CANN RL, 1987, NATURE, V325, P31, DOI 10.1038/325031a0; CAVALLISFORZA LL, 1993, SCIENCE, V259, P639, DOI 10.1126/science.8430313; CAVALLISFORZA LL, 1988, P NATL ACAD SCI USA, V85, P6002, DOI 10.1073/pnas.85.16.6002; CAVALLISFORZA LL, 1967, EVOLUTION, V21, P550, DOI 10.1111/j.1558-5646.1967.tb03411.x; CAVALLISFORZA LL, IN PRESS HIST GEOGRA; CHAKRABORTY R, 1992, AM J HUM BIOL, V4, P387, DOI 10.1002/ajhb.1310040315; EDWARDS A, 1992, GENOMICS, V12, P241, DOI 10.1016/0888-7543(92)90371-X; Felsenstein J., 1993, PHYLIP PHYLOGENY INF; GILBERT DA, 1990, NATURE, V344, P764, DOI 10.1038/344764a0; HORAI S, 1993, MOL BIOL EVOL, V10, P23; Lewontin RC, 1972, EVOLUTIONARY BIOL, V6, P381, DOI [10.1007/978-1-4684-9063-3_14, DOI 10.1007/978-1-4684-9063-3_14]; MITTON JB, 1977, AM NAT, V111, P203, DOI 10.1086/283155; NEI M, 1993, MOL BIOL EVOL, V10, P927; NEI M, 1972, SCIENCE, V177, P434, DOI 10.1126/science.177.4047.434; Pena Sergio D. J., 1993, DNA FINGERPRINTING S; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SMOUSE PE, 1982, AM NAT, V119, P445, DOI 10.1086/283925; TACHIDA H, 1992, GENETICS, V131, P471; TEMPLETON AR, 1993, AM ANTHROPOL, V95, P51, DOI 10.1525/aa.1993.95.1.02a00030; VIGILANT L, 1991, SCIENCE, V253, P1503, DOI 10.1126/science.1840702; WALSH JB, 1987, GENETICS, V115, P553; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; ZEI G, 1993, ANN HUM GENET, V57, P123, DOI 10.1111/j.1469-1809.1993.tb00894.x; [No title captured]	28	1506	1559	2	119	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 31	1994	368	6470					455	457		10.1038/368455a0	http://dx.doi.org/10.1038/368455a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ND120	7510853				2022-12-24	WOS:A1994ND12000063
J	SHIOZAKI, K; RUSSELL, P				SHIOZAKI, K; RUSSELL, P			CELL-CYCLE CONTROL LINKED TO EXTRACELLULAR ENVIRONMENT BY MAP KINASE PATHWAY IN FISSION YEAST	NATURE			English	Article							SCHIZOSACCHAROMYCES-POMBE; TYROSINE PHOSPHORYLATION; PROTEIN PHOSPHATASE; MITOSIS	IN fission yeast the onset of mitosis is brought about by Cdc2/Cdc13 kinase, which is inhibited by the Wee1/Mik1 tyrosine kinases and activated by Cdc25 tyrosine phosphatase(1). This control network integrates many signals, including those that monitor DNA replication, DNA damage and cell size, We report here that a fission yeast MAP kinase pathway links the cell-cycle G(2)/M control with changes in the extracellular environment that affect cell physiology. Fission yeast spc1(-) mutants have a G(2) delay that is greatly exacerbated by growth in high osmolarity media and nutrient limitation. A lethal interaction of spc1 and cdc25 mutations shows that Spc1 promotes the onset of mitosis, Spc1 is a MAP kinase homologue that is activated by Wis1 kinase in response to osmotic stress and nutrient limitation, Spc1 is inactivated by Pyp1, a phosphatase previously identified as a mitotic inhibitor(2,3). Pyp1 dephosphorylates only tyrosine-173 of Spc1, unlike the dual-specificity phosphatases that have been shown to regulate other MAP kinases(4).	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute			Shiozaki, Kazuhiro/K-3440-2019	Shiozaki, Kazuhiro/0000-0002-0395-5457				ALESSI DR, 1993, ONCOGENE, V8, P2015; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DOI K, 1994, EMBO J, V13, P61, DOI 10.1002/j.1460-2075.1994.tb06235.x; Dunphy William G., 1994, Trends in Cell Biology, V4, P202; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; GOMEZ N, 1990, FEBS LETT, V271, P119, DOI 10.1016/0014-5793(90)80386-W; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HANNIG G, 1994, P NATL ACAD SCI USA, V91, P10084, DOI 10.1073/pnas.91.21.10084; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MILLAR JBA, 1992, EMBO J, V11, P4943, DOI 10.1002/j.1460-2075.1992.tb05601.x; MILLAR JBA, 1995, GENE DEV, V9, P2117, DOI 10.1101/gad.9.17.2117; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OTTILIE S, 1992, MOL CELL BIOL, V12, P5571, DOI 10.1128/MCB.12.12.5571; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SHIOZAKI K, 1995, EMBO J, V14, P492, DOI 10.1002/j.1460-2075.1995.tb07025.x; SHIOZAKI K, 1994, MOL CELL BIOL, V14, P3742, DOI 10.1128/MCB.14.6.3742; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; WARBRICK E, 1991, EMBO J, V10, P4291, DOI 10.1002/j.1460-2075.1991.tb05007.x; WU L, 1993, NATURE, V363, P738, DOI 10.1038/363738a0; ZHENG CF, 1993, J BIOL CHEM, V268, P16116	29	392	398	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 14	1995	378	6558					739	743		10.1038/378739a0	http://dx.doi.org/10.1038/378739a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK379	7501024				2022-12-24	WOS:A1995TK37900059
J	GOSSEN, M; PAK, DTS; HANSEN, SK; ACHARYA, JK; BOTCHAN, MR				GOSSEN, M; PAK, DTS; HANSEN, SK; ACHARYA, JK; BOTCHAN, MR			A DROSOPHILA HOMOLOG OF THE YEAST ORIGIN RECOGNITION COMPLEX	SCIENCE			English	Article							ELECTRON-MICROSCOPIC ANALYSIS; DNA-REPLICATION; MELANOGASTER; EMBRYOS	Genes from Drosophila melanogaster have been identified that encode proteins homologous to Orc2p and Orc5p of the Saccharomyces cerevisiae origin recognition complex (ORC). The abundance of the Drosophila Orc2p homolog DmORC2 is developmentally regulated and is greatest during the earliest stages of embryogenesis, concomitant with the highest rate of DNA replication. Fractionation of embryo nuclear extracts revealed that DmORC2 is found in a tightly associated complex with five additional polypeptides, much like the yeast ORC. These studies will enable direct testing of the initiator-based model of replication in a metazoan.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV BIOCHEM & MOLEC BIOL,BERKELEY,CA 94720; UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720; UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT NEUROSCI,LA JOLLA,CA 92093	University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego			Gossen, Manfred/K-9602-2013	Gossen, Manfred/0000-0002-1761-4063; Acharya, Jairaj/0000-0001-7366-4228	NATIONAL CANCER INSTITUTE [R01CA030490, R37CA030490] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001896] Funding Source: NIH RePORTER; NCI NIH HHS [CA30490] Funding Source: Medline; NIEHS NIH HHS [ES-01896] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BLUMENTH.AB, 1973, COLD SPRING HARB SYM, V38, P205, DOI 10.1101/SQB.1974.038.01.024; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CHIANG CS, 1993, P NATL ACAD SCI USA, V90, P9105, DOI 10.1073/pnas.90.19.9105; EHRENHOFERMURRA.AE, 1995, SCIENCE, V270, P1671; FOE VE, 1993, DEV DROSOPHILA MELAN, V1, P149; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; HAMLIN JL, 1995, CURR OPIN GENET DEV, V5, P153, DOI 10.1016/0959-437X(95)80002-6; HANAHAN D, 1989, RECOMBINANT DNA METH, P267; HANSEN SB, UNPUB; HARLOW E, 1988, ANTIBODIES; HEBERLEIN U, 1988, NATURE, V331, P410, DOI 10.1038/331410a0; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; KAMAKAKA RT, 1994, MOL CELL BIOL, V14, P5114, DOI 10.1128/MCB.14.8.5114; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P2541, DOI 10.1093/nar/21.11.2541; Kornberg A., 1992, DNA REPLICATION; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MCKNIGHT SL, 1977, CELL, V12, P795, DOI 10.1016/0092-8674(77)90278-1; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; ZAKIAN VA, 1976, J MOL BIOL, V108, P305, DOI 10.1016/S0022-2836(76)80123-4	25	125	131	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 8	1995	270	5242					1674	1677		10.1126/science.270.5242.1674	http://dx.doi.org/10.1126/science.270.5242.1674			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ293	7502079				2022-12-24	WOS:A1995TJ29300051
J	HUMMEL, M; ZIEMANN, K; LAMMERT, H; PILERI, S; SABATTINI, E; STEIN, H				HUMMEL, M; ZIEMANN, K; LAMMERT, H; PILERI, S; SABATTINI, E; STEIN, H			HODGKINS-DISEASE WITH MONOCLONAL AND POLYCLONAL POPULATIONS OF REED-STERNBERG CELLS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RECEPTOR BETA-CHAIN; GENE REARRANGEMENTS; LYMPHOID-TISSUE; BIOPSY MATERIAL; IMMUNOGLOBULIN; EXPRESSION; PHENOTYPE; INFECTION; ANTIGENS; GENOTYPE	Background. There is strong evidence that Reed-Sternberg cells have a lymphoid phenotype, but clonally rearranged genes for B-cell and T-cell antigen receptors have not been demonstrable in tumor tissue from most patients with Hodgkin's disease. To elucidate this issue, we assayed single Reed-Sternberg cells from 12 patients with classic Hodgkin's disease of a B-cell immunophenotype to detect rearranged immunoglobulin variable-region heavy-chain (V-H) genes. Methods. We isolated single Reed-Sternberg cells from frozen sections that had been immunostained for CD30. The rearranged V-H genes of these cells were amplified by the polymerase chain reaction and analyzed by gel electrophoresis and nucleotide sequencing. Results. In all 12 patients, the Reed-Sternberg cells studied contained rearranged V-H genes. Three patterns were observed: in three patients the rearrangements in each patient were identical, in six patients all the rearrangements were unrelated and unique, and in three patients both identical and unrelated rearrangements were detected. Apparently somatic mutations of V-H genes were present in some Reed-Sternberg cells but absent in others. Conclusions. Reed-Sternberg cells with B-cell phenotypes have rearranged V-H genes; therefore, these cells arise from B cells. The pattern of V-H gene mutations suggests that Reed-Sternberg cells can correspond to either immunologically naive or memory B cells. In half our patients the population of Reed-Sternberg cells was polyclonal; in the other half, monoclonal or mixed cell populations were found. Correlation with the clinical stage suggests that polyclonal Hodgkin's disease can present as a widespread lymphoma.	FREE UNIV BERLIN, KLINIKUM BENJAMIN FRANKLIN, INST PATHOL, D-12200 BERLIN, GERMANY; UNIV BOLOGNA, SERV PATHOL ANAT 2, HEMATOPATHOL UNIT, BOLOGNA, ITALY	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Bologna			Pileri, Stefano/AAP-6337-2020; Sabattini, Elena/K-6720-2016	Sabattini, Elena/0000-0002-4136-3591				ANAGNOSTOPOULOS I, 1989, BLOOD, V74, P810; BARRIOS L, 1988, HUM GENET, V78, P320, DOI 10.1007/BF00291727; BEREK C, 1993, IMMUNOL TODAY, V14, P400, DOI 10.1016/0167-5699(93)90143-9; BEREK C, 1993, IMMUNOL TODAY, V14, P479; CIBULL ML, 1989, HISTOPATHOLOGY, V15, P597, DOI 10.1111/j.1365-2559.1989.tb01625.x; COOK GP, 1995, IMMUNOL TODAY, V16, P237, DOI 10.1016/0167-5699(95)80166-9; DALLENBACH FE, 1989, LANCET, V2, P828; DELABIE J, 1994, BLOOD, V84, P3291; DIEHL V, 1989, MED ONCOL TUMOR PHAR, V6, P155; DREXLER HG, 1992, LEUKEMIA LYMPHOMA, V8, P283, DOI 10.3109/10428199209051008; FALINI B, 1987, HISTOPATHOLOGY, V11, P1229, DOI 10.1111/j.1365-2559.1987.tb01869.x; FALK MH, 1987, INT J CANCER, V40, P262, DOI 10.1002/ijc.2910400223; GUPTA RK, 1993, P NATL ACAD SCI USA, V90, P2817, DOI 10.1073/pnas.90.7.2817; HABER MM, 1992, BLOOD, V80, P2851; HALUSKA FG, 1994, BLOOD, V84, P1005, DOI 10.1182/blood.V84.4.1005.bloodjournal8441005; HERBST H, 1989, LEUKEMIA RES, V13, P103, DOI 10.1016/0145-2126(89)90134-3; HESSOL NA, 1992, ANN INTERN MED, V117, P309, DOI 10.7326/0003-4819-117-4-309; HUMMEL M, 1994, BLOOD, V84, P403; HUMMEL M, 1992, BRIT J HAEMATOL, V82, P689, DOI 10.1111/j.1365-2141.1992.tb06945.x; INGHIRAMI G, 1994, P NATL ACAD SCI USA, V91, P9842, DOI 10.1073/pnas.91.21.9842; KADIN ME, 1988, AM J PATHOL, V130, P345; KAPP U, 1993, BLOOD, V82, P1247; KLITZ W, 1994, AM J HUM GENET, V54, P497; KNOWLES DM, 1986, P NATL ACAD SCI USA, V83, P7942, DOI 10.1073/pnas.83.20.7942; KODURU PRK, 1989, CANCER GENET CYTOGEN, V43, P109, DOI 10.1016/0165-4608(89)90134-9; KUPPERS R, 1994, P NATL ACAD SCI USA, V91, P10962, DOI 10.1073/pnas.91.23.10962; KUPPERS R, 1993, EMBO J, V12, P4955, DOI 10.1002/j.1460-2075.1993.tb06189.x; MACK TM, 1995, NEW ENGL J MED, V332, P413, DOI 10.1056/NEJM199502163320701; MARKS JD, 1991, EUR J IMMUNOL, V21, P985, DOI 10.1002/eji.1830210419; MASIH A, 1991, AM J PATHOL, V139, P37; PASMAN PC, 1994, ANN ONCOL, V5, pS89, DOI 10.1093/annonc/5.suppl_1.S89; RAABTRAUB N, 1986, CELL, V47, P883, DOI 10.1016/0092-8674(86)90803-2; RAMASAMY I, 1992, J CLIN PATHOL, V45, P770, DOI 10.1136/jcp.45.9.770; RAPHAEL MM, 1994, AM J CLIN PATHOL, V101, P773, DOI 10.1093/ajcp/101.6.773; ROTH J, 1994, INT J CANCER, V57, P799, DOI 10.1002/ijc.2910570607; STEIN H, 1982, INT J CANCER, V30, P445, DOI 10.1002/ijc.2910300411; STEIN H, 1985, BLOOD, V66, P848; Stein H, 1983, Hematol Oncol, V1, P21; TAMARU J, 1994, BLOOD, V84, P708; Teale J M, 1992, Int Rev Immunol, V8, P95, DOI 10.3109/08830189209055566; TEERENHOVI L, 1988, CANCER GENET CYTOGEN, V34, P305, DOI 10.1016/0165-4608(88)90277-4; WEISS LM, 1986, HUM PATHOL, V17, P1009, DOI 10.1016/S0046-8177(86)80084-3; WEISS LM, 1987, AM J PATHOL, V129, P86; WOLF J, 1994, ANN ONCOL, V5, pS105, DOI 10.1093/annonc/5.suppl_1.S105	44	179	180	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 5	1995	333	14					901	906		10.1056/NEJM199510053331403	http://dx.doi.org/10.1056/NEJM199510053331403			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX199	7545266				2022-12-24	WOS:A1995RX19900003
J	WU, H; KLINGMULLER, U; BESMER, P; LODISH, HF				WU, H; KLINGMULLER, U; BESMER, P; LODISH, HF			INTERACTION OF THE ERYTHROPOIETIN AND STEM-CELL-FACTOR RECEPTORS	NATURE			English	Article							C-KIT; KINASE; PROTEIN; EXPRESSION; PHOSPHORYLATION	MUTATIONS in the KIT transmembrane protein-tyrosine kinase receptor(1) affect erythropoiesis, resulting in fewer committed late progenitors (colony-forming unit erythroid, CFU-E) in the fetal liver(2). As the survival and proliferation of CFU-Es depend absolutely on erythropoietin (EPO)(3), these results suggest that CFU-Es cannot proliferate or mature further unless both the KIT and EPO receptor(4) signalling pathways are functional. How KIT affects proliferation or differentiation of CFU-Es is not clear. Here we show that the KIT ligand SCF (for stem-cell factor) can replace EPO in supporting the growth and survival of HCD57 cells, an EPO-dependent erythroid-progenitor cell line expressing high levels of KIT5. SCF supports the proliferation of 32D cells(6) that express KIT only if they also express the EPO receptor. In HCD57 cells, SCF rapidly induces tyrosine phosphorylation of the EPO receptor, and KIT physically associates with the extended box 2 region(7) in the cytoplasmic domain of the EPO receptor. Our results indicate that KIT may activate the EPO receptor by tyrosine phosphorylation to induce further proliferation and maturation of CFU-Es.	WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02139; SLOAN KETTERING INST,PROGRAM MOLEC BIOL,NEW YORK,NY 10021	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Memorial Sloan Kettering Cancer Center			Klingmüller, Ursula/G-8477-2013	Klingmüller, Ursula/0000-0001-9845-3099				Besmer P, 1991, CURR OPIN CELL BIOL, V3, P939, DOI 10.1016/0955-0674(91)90111-B; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; GREGORY CJ, 1976, J CELL PHYSIOL, V89, P289, DOI 10.1002/jcp.1040890212; HE TC, 1994, J BIOL CHEM, V269, P18291; HILTON DJ, 1995, P NATL ACAD SCI USA, V92, P190, DOI 10.1073/pnas.92.1.190; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; LETWIN K, 1988, ONCOGENE, V3, P621; LIU L, 1994, J BIOL CHEM, V269, P16774; MAJUMDER S, 1988, MOL CELL BIOL, V8, P4896, DOI 10.1128/MCB.8.11.4896; MIURA Y, 1994, J BIOL CHEM, V269, P29962; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; SAWYER ST, 1993, P NATL ACAD SCI USA, V90, P6849, DOI 10.1073/pnas.90.14.6849; SERVE H, 1995, EMBO J, V14, P473, DOI 10.1002/j.1460-2075.1995.tb07023.x; SPIVAK JL, 1991, BLOOD, V77, P1228; TSUJIMURA T, 1994, BLOOD, V83, P2619; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139; YOSHIMURA A, 1992, MOL CELL BIOL, V12, P706, DOI 10.1128/MCB.12.2.706	21	241	245	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 21	1995	377	6546					242	246		10.1038/377242a0	http://dx.doi.org/10.1038/377242a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RV872	7545788				2022-12-24	WOS:A1995RV87200043
J	BLASCO, MA; FUNK, W; VILLEPONTEAU, B; GREIDER, CW				BLASCO, MA; FUNK, W; VILLEPONTEAU, B; GREIDER, CW			FUNCTIONAL-CHARACTERIZATION AND DEVELOPMENTAL REGULATION OF MOUSE TELOMERASE RNA	SCIENCE			English	Article							IDENTIFICATION; SEQUENCES	Telomerase synthesizes telomeric DNA repeats onto chromosome ends de novo. The mouse telomerase RNA component was cloned and contained only 65 percent sequence identity with the human telomerase RNA. Alteration of the template region in vivo generated altered telomerase products. The shorter template regions of the mouse and other rodent telomerase RNAs could account for the shorter distribution of products (processivity) generated by the mouse enzyme relative to the human telomerase. Amounts of telomerase RNA increased in immortal cells derived from primary mouse fibroblasts. RNA was detected in all newborn mouse tissues tested but was decreased during postnatal development.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724; GERON CORP,MENLO PK,CA 94025	Cold Spring Harbor Laboratory; Geron Corporation			Blasco, Maria A./M-1694-2014	Blasco, Maria A./0000-0002-4211-233X	NATIONAL INSTITUTE ON AGING [R01AG009383, R37AG009383] Funding Source: NIH RePORTER; NIA NIH HHS [AG09383] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		CHADENEAU C, 1995, ONCOGENE, V11, P841; FENG J, UNPUB; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KIPLING D, 1990, NATURE, V347, P400, DOI 10.1038/347400a0; LINGNER J, 1994, GENE DEV, V8, P1984, DOI 10.1101/gad.8.16.1984; MACIEIRACOELHO A, 1988, ANTICANCER RES, V8, P669; MCEACHEM MJ, 1995, NATURE, V346, P403; PROWSE KR, 1993, P NATL ACAD SCI USA, V90, P1493, DOI 10.1073/pnas.90.4.1493; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; SHUMYATSKY G, 1992, NUCLEIC ACIDS RES, V20, P2159, DOI 10.1093/nar/20.suppl.2159; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0	15	336	347	0	15	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 1	1995	269	5228					1267	1270		10.1126/science.7544492	http://dx.doi.org/10.1126/science.7544492			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR842	7544492				2022-12-24	WOS:A1995RR84200035
J	CHANG, HY; TAKEI, K; SYDOR, AM; BORN, T; RUSNAK, F; JAY, DG				CHANG, HY; TAKEI, K; SYDOR, AM; BORN, T; RUSNAK, F; JAY, DG			ASYMMETRIC RETRACTION OF GROWTH CONE FILOPODIA FOLLOWING FOCAL INACTIVATION OF CALCINEURIN	NATURE			English	Article							GRASSHOPPER PIONEER NEURONS; CYCLOSPORINE-A; NERVE GROWTH; LASER INACTIVATION; FASCICLIN-I; INHIBITION; PHOSPHORYLATION; TRANSDUCTION; PHOSPHATASE; COMPLEXES	THE neuronal growth cone is thought to be the site of decision making in nerve growth and guidance(1,2). One likely mechanism of how the growth cone translates various extracellular cues into directed motility involves rises in intracellular calcium, A variety of physiological cues, such as adhesion molecules and neurotransmitters, increases intracellular calcium(1), and artificial manipulations of growth cone calcium levels affect growth cone morphology and neurite outgrowth(3). The molecular events downstream of calcium fluxes are incompletely understood, Here we show that calcineurin, a protein phosphatase enriched in growth cones that is dependent on calcium ions and calmodulin(4), functions in neurite outgrowth and directed filopodial motility in cultured chick dorsal root ganglia neurons. Cyclosporin A and FK506, inhibitors of calcineurin(5), delayed neuritogenesis and inhibited neurite extension, Chromophore-assisted laser inactivation of calcineurin io regions of growth cones causes localized filopodial and lamellipodial retraction and influences the direction of subsequent outgrowth. We suggest that a spatial distribution of calcineurin activity within the growth cone can regulate motility and direct outgrowth.	MAYO CLIN & MAYO FDN,HEMATOL RES SECT,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic	CHANG, HY (corresponding author), HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138, USA.							BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; BRAY D, 1991, CULTURING NERVE CELL, P104; CLARKE MSF, 1992, J CELL SCI, V102, P533; CLIPSTONE NA, 1993, NATURE, V357, P695; DAVENPORT RW, 1993, NATURE, V361, P721, DOI 10.1038/361721a0; DIAMOND P, 1993, NEURON, V11, P409, DOI 10.1016/0896-6273(93)90146-I; FERREIRA A, 1993, MOL BIOL CELL, V4, P1225, DOI 10.1091/mbc.4.12.1225; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; HADDY A, 1992, FEBS LETT, V314, P37, DOI 10.1016/0014-5793(92)81456-V; HENDEY B, 1992, SCIENCE, V258, P296, DOI 10.1126/science.1384129; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; JAY DG, 1990, NATURE, V348, P548, DOI 10.1038/348548a0; KLEE CB, 1983, METHOD ENZYMOL, V102, P227; LETOURNEAU PC, 1989, DEVELOPMENT, V105, P505; LIAO JC, 1994, P NATL ACAD SCI USA, V91, P2659, DOI 10.1073/pnas.91.7.2659; LINDEN KG, 1992, BIOPHYS J, V61, P956, DOI 10.1016/S0006-3495(92)81902-1; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; LIU JP, 1994, SCIENCE, V265, P970, DOI 10.1126/science.8052858; MITCHISON T, 1988, NEURON, V1, P761, DOI 10.1016/0896-6273(88)90124-9; REHDER V, 1992, J NEUROSCI, V12, P3175, DOI 10.1523/JNEUROSCI.12-08-03175.1992; Sambrook J., 1989, MOL CLONING LAB MANU; SCHMUCKER D, 1994, P NATL ACAD SCI USA, V91, P2664, DOI 10.1073/pnas.91.7.2664; SELDEN SC, 1983, J BIOL CHEM, V258, P7064; SNYDER SH, 1995, NAT MED, V1, P32, DOI 10.1038/nm0195-32; STEINER JP, 1992, NATURE, V358, P584, DOI 10.1038/358584a0; STRITTMATTER SM, 1991, BIOESSAYS, V13, P127, DOI 10.1002/bies.950130306; SYDOR AM, 1994, ABS SOC NEUR, V20, P1474; VANHOOFF COM, 1988, J NEUROSCI, V8, P1789; ZHENG JQ, 1994, NATURE, V368, P140, DOI 10.1038/368140a0	30	143	144	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 24	1995	376	6542					686	690		10.1038/376686a0	http://dx.doi.org/10.1038/376686a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RQ672	7544441				2022-12-24	WOS:A1995RQ67200060
J	STUTTS, MJ; CANESSA, CM; OLSEN, JC; HAMRICK, M; COHN, JA; ROSSIER, BC; BOUCHER, RC				STUTTS, MJ; CANESSA, CM; OLSEN, JC; HAMRICK, M; COHN, JA; ROSSIER, BC; BOUCHER, RC			CFTR AS A CAMP-DEPENDENT REGULATOR OF SODIUM-CHANNELS	SCIENCE			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; HUMAN NASAL EPITHELIUM; FIBROSIS; TRANSPORT; MEMBRANE; CELLS; PROTEIN	Cystic fibrosis transmembrane regulator (CFTR), the gene product that is mutated in cystic fibrosis (CF) patients, has a well-recognized function as a cyclic adenosine 3',5'-monophosphate (cAMP)-regulated chloride channel, but this property does not account for the abnormally high basal rate and cAMP sensitivity of sodium ion absorption in CF airway epithelia. Expression of complementary DNAs for rat epithelial Na+ channel (rENaC) alone in Madin Darby canine kidney (MDCK) epithelial cells generated large amiloride-sensitive sodium currents that were stimulated by cAMP, whereas coexpression of human CFTR with rENaC generated smaller basal sodium currents that were inhibited by cAMP. Parallel studies that measured regulation of sodium permeability in fibroblasts showed similar results. In CF airway epithelia, the absence of this second function of CFTR as a cAMP-dependent regulator likely accounts for abnormal sodium transport.	UNIV LAUSANNE, INST PHARMACOL & TOXICOL, CH-1005 LAUSANNE, SWITZERLAND; DUKE UNIV, DURHAM, NC 27710 USA; VET ADM MED CTR, DURHAM, NC 27710 USA	University of Lausanne	STUTTS, MJ (corresponding author), UNIV N CAROLINA, CYST FIBROSIS PULM RES & TREATMENT CTR, CHAPEL HILL, NC 27599 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042384, P01HL034322] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 42384, HL 34322] Funding Source: Medline; PHS HHS [CFF R026] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AUSIELLO DA, 1992, J BIOL CHEM, V267, P4759; BOUCHER RC, 1986, J CLIN INVEST, V78, P1245, DOI 10.1172/JCI112708; BOUCHER RC, 1994, AM J RESP CRIT CARE, V150, P271, DOI 10.1164/ajrccm.150.1.8025763; BURCH LH, IN PRESS AM J PHYSL; CANESSA C, UNPUB; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CHAMPIGNY G, 1994, EMBO J, V13, P2177, DOI 10.1002/j.1460-2075.1994.tb06494.x; CHINET TC, 1994, AM J PHYSIOL, V266, pC1061, DOI 10.1152/ajpcell.1994.266.4.C1061; COHN JA, 1991, BIOCHEM BIOPH RES CO, V181, P36, DOI 10.1016/S0006-291X(05)81378-6; COTTON CU, 1987, J CLIN INVEST, V79, P80, DOI 10.1172/JCI112812; GRUBB BR, 1994, AM J PHYSIOL, V266, pC1478, DOI 10.1152/ajpcell.1994.266.5.C1478; GRUBB BR, 1994, NATURE, V371, P802, DOI 10.1038/371802a0; GRUBB BR, 1994, AM J PHYSIOL, V267, pC293, DOI 10.1152/ajpcell.1994.267.1.C293; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HIRT RP, 1992, GENE, V111, P199, DOI 10.1016/0378-1119(92)90687-K; LAFERTE S, 1992, BIOCHEM J, V283, P193, DOI 10.1042/bj2830193; OLSEN JC, 1992, HUM GENE THER, V3, P253, DOI 10.1089/hum.1992.3.3-253; ONEAL W, 1994, PEDIATR PULM S, V10, P194; REISIN IL, 1994, J BIOL CHEM, V269, P20584; RIOS RM, 1992, EMBO J, V11, P1723, DOI 10.1002/j.1460-2075.1992.tb05224.x; SARKADI B, 1992, J BIOL CHEM, V267, P2087; SCHWIEBERT EM, 1994, AM J PHYSIOL, V266, pC1464, DOI 10.1152/ajpcell.1994.266.5.C1464; STUTTS MJ, 1994, J BIOL CHEM, V269, P8667; STUTTS MJ, 1993, J BIOL CHEM, V268, P20653; TALBOT CR, 1995, FASEB J, V9, pA304; USSING HH, 1949, PHYSIOL REV, V29, P127, DOI 10.1152/physrev.1949.29.2.127; WILLUMSEN NJ, 1989, AM J PHYSIOL, V256, pC1033, DOI 10.1152/ajpcell.1989.256.5.C1033; WILLUMSEN NJ, 1991, AM J PHYSIOL, V261, pC319, DOI 10.1152/ajpcell.1991.261.2.C319; WILLUMSEN NJ, 1991, AM J PHYSIOL, V261, pC332, DOI 10.1152/ajpcell.1991.261.2.C332	31	902	921	0	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 11	1995	269	5225					847	850		10.1126/science.7543698	http://dx.doi.org/10.1126/science.7543698			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN650	7543698				2022-12-24	WOS:A1995RN65000047
J	TARAKHOVSKY, A; KANNER, SB; HOMBACH, J; LEDBETTER, JA; MULLER, W; KILLEEN, N; RAJEWSKY, K				TARAKHOVSKY, A; KANNER, SB; HOMBACH, J; LEDBETTER, JA; MULLER, W; KILLEEN, N; RAJEWSKY, K			A ROLE FOR CD5 IN TCR-MEDIATED SIGNAL-TRANSDUCTION AND THYMOCYTE SELECTION	SCIENCE			English	Article							RECEPTOR TRANSGENIC MICE; PROTEIN-TYROSINE KINASES; T-CELL; POSITIVE SELECTION; CD4+8+ THYMOCYTES; ANTIGEN; ACTIVATION; COMPLEX; PHOSPHORYLATION; STIMULATION	CD5 is a transmembrane protein that is expressed on the surface of T cells and a subset of B cells. The absence of CD5 rendered thymocytes hyperresponsive to stimulation through the T cell antigen receptor (TCR) in vitro. Selection of T cells expressing three distinct transgenic TCRs was also abnormal in CD5-deficient mice. These observations indicate that CD5 can influence the fate of developing thymocytes by acting as a negative regulator of TCR-mediated signal transduction.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121; UNIV ZURICH,DEPT PATHOL,INST EXPTL IMMUNOL,CH-8091 ZURICH,SWITZERLAND; UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143	Bristol-Myers Squibb; University of Zurich; University of California System; University of California San Francisco	TARAKHOVSKY, A (corresponding author), UNIV COLOGNE,INST GENET,D-50937 COLOGNE,GERMANY.		Muller, Werner/B-9044-2008	Muller, Werner/0000-0002-1297-9725; Rajewsky, Klaus/0000-0002-6633-6370				ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; BEYERS AD, 1992, P NATL ACAD SCI USA, V89, P2945, DOI 10.1073/pnas.89.7.2945; BORGULYA P, 1992, CELL, V69, P529, DOI 10.1016/0092-8674(92)90453-J; BURGESS KE, 1992, P NATL ACAD SCI USA, V89, P9311, DOI 10.1073/pnas.89.19.9311; CEUPPENS JL, 1986, J IMMUNOL, V137, P1816; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CROMPTON T, 1993, P NATL ACAD SCI USA, V90, P8982, DOI 10.1073/pnas.90.19.8982; DAVIES AA, 1992, P NATL ACAD SCI USA, V89, P6368, DOI 10.1073/pnas.89.14.6368; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; JAMESON SC, 1995, IMMUNITY, V2, P1, DOI 10.1016/1074-7613(95)90074-8; KANNER SB, 1992, J IMMUNOL, V148, P2023; KANNER SB, 1994, P NATL ACAD SCI USA, V91, P10484, DOI 10.1073/pnas.91.22.10484; KANNER SB, 1992, IMMUNOLOGY, V75, P441; KEARSE KP, 1965, J EXP MED, V181, P193; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; LEDBETTER JA, 1985, J IMMUNOL, V135, P2331; MADRENAS J, 1995, SCIENCE, V267, P515, DOI 10.1126/science.7824949; MAMALAKI C, 1992, P NATL ACAD SCI USA, V89, P11342, DOI 10.1073/pnas.89.23.11342; MCATEER MJ, 1988, EUR J IMMUNOL, V18, P1111, DOI 10.1002/eji.1830180721; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; PIRCHER H, 1994, EUR J IMMUNOL, V24, P1982, DOI 10.1002/eji.1830240907; RAAB M, 1994, MOL CELL BIOL, V14, P2862, DOI 10.1128/MCB.14.5.2862; RABINOVITCH PS, 1986, J IMMUNOL, V137, P952; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; SWAT W, 1993, EUR J IMMUNOL, V23, P739, DOI 10.1002/eji.1830230326; SWAT W, 1992, EUR J IMMUNOL, V22, P2367, DOI 10.1002/eji.1830220928; TARAKHOVSKY A, 1994, EUR J IMMUNOL, V24, P1678, DOI 10.1002/eji.1830240733; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; VANOERS NSC, 1994, IMMUNITY, V1, P675, DOI 10.1016/1074-7613(94)90038-8; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1986, P NATL ACAD SCI USA, V83, P6998, DOI 10.1073/pnas.83.18.6998; WEISS A, 1987, ADV IMMUNOL, V41, P1, DOI 10.1016/S0065-2776(08)60029-2; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0	35	362	365	0	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 28	1995	269	5223					535	537		10.1126/science.7542801	http://dx.doi.org/10.1126/science.7542801			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL495	7542801				2022-12-24	WOS:A1995RL49500026
J	GIAID, A; SALEH, D				GIAID, A; SALEH, D			REDUCED EXPRESSION OF ENDOTHELIAL NITRIC-OXIDE SYNTHASE IN THE LUNGS OF PATIENTS WITH PULMONARY-HYPERTENSION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RELAXING FACTOR; RELAXATION; IMPAIRMENT; CLONING; DISEASE	Background. Pulmonary hypertension is characterized by abnormal thickening of the pulmonary arteries and increased pulmonary vascular resistance. Nitric oxide is a potent endothelium-derived vasorelaxant substance and an inhibitor of smooth-muscle-cell growth. Nitric oxide is produced in various cell types by the action of an enzyme, nitric oxide synthase. We compared the expression of endothelial nitric oxide synthase in the lungs of control subjects with that in the lungs of patients with pulmonary hypertension. Methods. We investigated the expression of endothelial nitric oxide synthase by histochemical and immunohistochemical analysis, in situ hybridization, and Northern blot analysis in the lungs of 22 patients with plexogenic pulmonary arteriopathy (arteriopathy of grades 4 through 6), 24 patients with secondary pulmonary hypertension (arteriopathy of grades 1 through 3), and 23 control subjects. Results. In the lungs of the control subjects, nitric oxide synthase was expressed at a high level in the vascular endothelium of all types of vessels and in the pulmonary epithelium. In contrast, little or no expression of the enzyme was found in the vascular endothelium of pulmonary arteries with severe histologic abnormalities (i.e., plexiform lesions) in patients with pulmonary hypertension. The intensity of the enzyme immunoreactivity correlated inversely with the severity of histologic changes. There was an inverse correlation between the arterial expression of the enzyme and total pulmonary resistance in patients with plexogenic pulmonary arteriopathy (r = -0.766, P = 0.004). Conclusions. Pulmonary hypertension is associated with diminished expression of endothelial nitric oxide synthase. It is possible that decreased expression of nitric oxide synthase may contribute to pulmonary vasoconstriction and to the excessive growth of the tunica media observed in this disease.	MCGILL UNIV, MONTREAL, PQ, CANADA	McGill University	GIAID, A (corresponding author), MONTREAL GEN HOSP, DEPT PATHOL, 1650 CEDAR AVE, MONTREAL, PQ H3G 1A4, CANADA.							BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; CHRISTMAN BW, 1992, NEW ENGL J MED, V327, P70, DOI 10.1056/NEJM199207093270202; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DINHXUAN AT, 1993, BRIT J PHARMACOL, V109, P587, DOI 10.1111/j.1476-5381.1993.tb13611.x; DINHXUAN AT, 1991, NEW ENGL J MED, V324, P1539, DOI 10.1056/NEJM199105303242203; FINEMAN JR, 1994, J CLIN INVEST, V93, P2675, DOI 10.1172/JCI117281; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; GIAID A, 1993, NEW ENGL J MED, V328, P1732, DOI 10.1056/NEJM199306173282402; GLANTZ SA, 1987, PRIMER BIOSTATISTICS, P287; GOLDIE RG, 1990, TRENDS PHARMACOL SCI, V11, P67, DOI 10.1016/0165-6147(90)90320-8; GRIFFITH TM, 1988, J AM COLL CARDIOL, V12, P797, DOI 10.1016/0735-1097(88)90324-5; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; HEATH D, 1958, CIRCULATION, V18, P533, DOI 10.1161/01.CIR.18.4.533; HEATH D, 1993, EUR RESPIR REV, V3, P555; HIGENBOTTAM T, 1993, EUR RESPIR J, V6, P1207; HOPE BT, 1991, P NATL ACAD SCI USA, V88, P2811, DOI 10.1073/pnas.88.7.2811; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; IVY DD, 1994, AM J CARDIOL, V74, P414, DOI 10.1016/0002-9149(94)90420-0; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; JANSSENS SP, 1992, J BIOL CHEM, V267, P22964; KOBZIK L, 1993, AM J RESP CELL MOL, V9, P371, DOI 10.1165/ajrcmb/9.4.371; KOUYOUMDJIAN C, 1994, J CLIN INVEST, V94, P578, DOI 10.1172/JCI117372; LAMONTAGNE D, 1992, CIRC RES, V70, P123, DOI 10.1161/01.RES.70.1.123; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MILLER VM, 1992, AM J PHYSIOL, V263, pH103, DOI 10.1152/ajpheart.1992.263.1.H103; MONCADA S, 1978, PHARMACOL REV, V30, P293; MONCADA S, 1991, PHARMACOL REV, V43, P109; NAGASAKA Y, 1984, CIRC RES, V54, P90, DOI 10.1161/01.RES.54.1.90; PEPKEZABA J, 1991, LANCET, V338, P1173, DOI 10.1016/0140-6736(91)92033-X; Reeves JT, 1984, PULMONARY HYPERTENSI, P1; RICH S, 1987, ANN INTERN MED, V107, P216, DOI 10.7326/0003-4819-107-2-216; ROBBINS RA, 1994, BIOCHEM BIOPH RES CO, V198, P835, DOI 10.1006/bbrc.1994.1119; ROSSAINT R, 1993, NEW ENGL J MED, V328, P399, DOI 10.1056/NEJM199302113280605; STUARTSMITH K, 1987, J APPL PHYSIOL, V63, P2510, DOI 10.1152/jappl.1987.63.6.2510; WAGENVOORT CA, 1981, HISTOPATHOLOGY, V5, P595, DOI 10.1111/j.1365-2559.1981.tb01826.x; WOOD P, 1958, BRIT HEART J, V20, P557; ZAPOL WM, 1994, AM J RESP CRIT CARE, V149, P1375, DOI 10.1164/ajrccm.149.5.8173780	38	1010	1062	1	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 27	1995	333	4					214	221		10.1056/NEJM199507273330403	http://dx.doi.org/10.1056/NEJM199507273330403			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK423	7540722				2022-12-24	WOS:A1995RK42300003
J	LAIRD, PW; JACKSONGRUSBY, L; FAZELI, A; DICKINSON, SL; JUNG, WE; LI, E; WEINBERG, RA; JAENISCH, R				LAIRD, PW; JACKSONGRUSBY, L; FAZELI, A; DICKINSON, SL; JUNG, WE; LI, E; WEINBERG, RA; JAENISCH, R			SUPPRESSION OF INTESTINAL NEOPLASIA BY DNA HYPOMETHYLATION	CELL			English	Article							CYTOSINE METHYLTRANSFERASES; 5-METHYLCYTOSINE CONTENT; INDUCED DEAMINATION; RAS ONCOGENES; HUMAN CANCERS; COLON-CANCER; CPG ISLANDS; METHYLATION; MOUSE; GENE	We have used a combination of genetics and pharmacology to assess the effects of reduced DNA methyltransferase activity on Apc(Min)-induced intestinal neoplasia in mice. A reduction in the DNA methyltransferase activity in Min mice due to heterozygosity of the DNA methyltransferase gene, in conjunction with a weekly dose of the DNA methyltransferase inhibitor 5-azadeoxycytidine, reduced the average number of intestinal adenomas from 113 in the control mice to only 2 polyps in the treated heterozygotes. Hence, DNA methyltransferase activity contributes substantially to tumor development in this mouse model of intestinal neoplasia. Our results argue against an oncogenic effect of DNA hypomethylation. Moreover, they are consistent with a role for DNA methyltransferase in the generation of the C to T transitions seen at high frequency in human colorectal tumors.	MIT,DEPT BIOL,CAMBRIDGE,MA 02142; MASSACHUSETTS GEN HOSP E,CARDIOVASC RES CTR,BOSTON,MA 02129	Massachusetts Institute of Technology (MIT)	LAIRD, PW (corresponding author), MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142, USA.		Laird, Peter W/G-8683-2012	Laird, Peter W/0000-0001-9117-3641	NATIONAL CANCER INSTITUTE [R35CA044339, F32CA009097] Funding Source: NIH RePORTER; NCI NIH HHS [R35 CA 44339, F32 CA 09097] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS RLP, 1982, CRC CR REV BIOCH MOL, V13, P349, DOI 10.3109/10409238209108714; ANTEQUERA F, 1993, DNA METHYLATION MOL, P169; BARLOW DP, 1993, SCIENCE, V260, P309, DOI 10.1126/science.8469984; BAYLIN SB, 1991, CANCER CELL-MON REV, V3, P383; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BOYNTON RF, 1992, P NATL ACAD SCI USA, V89, P3385, DOI 10.1073/pnas.89.8.3385; BREWSTER SF, 1994, J UROLOGY, V151, P1073, DOI 10.1016/S0022-5347(17)35186-8; BROWN TC, 1989, MUTAT RES, V227, P233, DOI 10.1016/0165-7992(89)90102-4; CHAPMAN V, 1984, NATURE, V307, P284, DOI 10.1038/307284a0; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; EHRLICH M, 1986, BIOSCIENCE REP, V6, P387, DOI 10.1007/BF01116426; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; FEINBERG AP, 1983, BIOCHEM BIOPH RES CO, V111, P47, DOI 10.1016/S0006-291X(83)80115-6; FEINBERG AP, 1988, CANCER RES, V48, P1159; FREDERICO LA, 1990, BIOCHEMISTRY-US, V29, P2532, DOI 10.1021/bi00462a015; GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P6883, DOI 10.1093/nar/11.19.6883; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GIOVANNUCCI E, 1993, J NATL CANCER I, V85, P875, DOI 10.1093/jnci/85.11.875; GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GREGER V, 1989, HUM GENET, V83, P155, DOI 10.1007/BF00286709; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HANADA M, 1993, BLOOD, V82, P1820; Ichii Shigetoshi, 1992, Human Molecular Genetics, V1, P387, DOI 10.1093/hmg/1.6.387; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; ISSA JPJ, 1993, J NATL CANCER I, V85, P1235, DOI 10.1093/jnci/85.15.1235; Jones P A, 1990, Adv Cancer Res, V54, P1, DOI 10.1016/S0065-230X(08)60806-4; JONES PA, 1992, BIOESSAYS, V14, P33, DOI 10.1002/bies.950140107; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; KASS SU, 1993, MOL CELL BIOL, V13, P7372, DOI 10.1128/MCB.13.12.7372; KAUTIAINEN TL, 1986, J BIOL CHEM, V261, P1594; KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1; KUMAR S, 1994, NUCLEIC ACIDS RES, V22, P1, DOI 10.1093/nar/22.1.1; LAIRD PW, 1994, HUM MOL GENET, V3, P1487, DOI 10.1093/hmg/3.suppl_1.1487; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LAUSTER R, 1989, J MOL BIOL, V206, P305, DOI 10.1016/0022-2836(89)90480-4; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; Leonhardt H., 1993, DNA methylation: molecular biology and biological significance., P109; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; LUONGO C, 1993, GENOMICS, V15, P3, DOI 10.1006/geno.1993.1002; LUONGO C, 1994, CANCER RES, V54, P5947; MIKOL YB, 1983, CARCINOGENESIS, V4, P1619, DOI 10.1093/carcin/4.12.1619; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; MONK M, 1990, DEVELOPMENT S, P66; MOSER AR, 1992, J CELL BIOL, V116, P1517, DOI 10.1083/jcb.116.6.1517; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; NAKAMURA Y, 1993, ADV CANCER RES, V62, P65, DOI 10.1016/S0065-230X(08)60315-2; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2421, DOI 10.1093/nar/17.7.2421; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; RAO PM, 1989, CARCINOGENESIS, V10, P933, DOI 10.1093/carcin/10.5.933; SANTI DV, 1984, P NATL ACAD SCI-BIOL, V81, P6993, DOI 10.1073/pnas.81.22.6993; SANTI DV, 1983, CELL, V33, P9, DOI 10.1016/0092-8674(83)90327-6; Scrable H J, 1990, Adv Cancer Res, V54, P25, DOI 10.1016/S0065-230X(08)60807-6; SELIG S, 1988, EMBO J, V7, P419, DOI 10.1002/j.1460-2075.1988.tb02829.x; SHEN JC, 1994, NUCLEIC ACIDS RES, V22, P972, DOI 10.1093/nar/22.6.972; SHEN JC, 1992, CELL, V71, P1073, DOI 10.1016/S0092-8674(05)80057-1; SHENOY S, 1987, J MOL BIOL, V197, P617, DOI 10.1016/0022-2836(87)90468-2; SHIVAPURKAR N, 1986, J NATL CANCER I, V77, P213; SILVERMAN AL, 1989, CANCER RES, V49, P3468; Singer-Sam J., 1993, DNA methylation: molecular biology and biological significance., P358; SPRUCK CH, 1993, DNA METHYLATION MOL, P487; SU LK, 1992, SCIENCE, V256, P1114, DOI 10.1126/science.256.5060.1114-c; TAMURA G, 1994, CANCER RES, V54, P1149; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; VORCE RL, 1991, J TOXICOL ENV HEALTH, V34, P367, DOI 10.1080/15287399109531574; WANG RYH, 1982, BIOCHIM BIOPHYS ACTA, V697, P371, DOI 10.1016/0167-4781(82)90101-4; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; Yeivin A, 1993, EXS, V64, P523	74	636	653	0	20	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 21	1995	81	2					197	205		10.1016/0092-8674(95)90329-1	http://dx.doi.org/10.1016/0092-8674(95)90329-1			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QV410	7537636	Bronze			2022-12-24	WOS:A1995QV41000008
J	CHENG, Y; DAHLBERG, JE; LUND, E				CHENG, Y; DAHLBERG, JE; LUND, E			DIVERSE EFFECTS OF THE GUANINE-NUCLEOTIDE EXCHANGE FACTOR RCC1 ON RNA TRANSPORT	SCIENCE			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEINS; VESICULAR STOMATITIS-VIRUS; CHROMOSOME CONDENSATION; MESSENGER-RNA; BINDING PROTEIN; PORE COMPLEX; CELL-CYCLE; DNA; REGULATOR; MUTANT	Transport of RNAs within nuclei and through nuclear pore complexes (NPCs) are essential, but poorly understood, steps in gene expression. In experiments with mammalian cells, RCC1, the abundant nuclear guanine nucleotide exchange factor for the guanosine triphosphatase Ran/TC4, was shown to be required for nucleocytoplasmic transport of precursors of spliceosomal small nuclear RNAs (snRNAs), intranuclear transport of U3 snRNA, and processing of ribosomal RNAs, but not for export of transfer RNAs. It is proposed that guanosine triphosphate (GTP)-bound Ran/TC4 associates with ribonucleoprotein particles (RNPs) during intranuclear movement, and that GTP hydrolysis promotes deposition of RNPs at targeted sites such as NPCs or nucleoli.	UNIV WISCONSIN, DEPT BIOMOLEC CHEM, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison					NIGMS NIH HHS [GM 30220] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030220, R01GM030220] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBI M, 1990, MOL GEN GENET, V224, P72, DOI 10.1007/BF00259453; BELHUMEUR P, 1993, MOL CELL BIOL, V13, P2152, DOI 10.1128/MCB.13.4.2152; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; BREWER G, 1990, METHOD ENZYMOL, V181, P202; BRINGMANN P, 1983, EMBO J, V2, P1129, DOI 10.1002/j.1460-2075.1983.tb01557.x; Cheng Y., UNPUB; CLARK MW, 1987, J CELL BIOL, V105, P1515, DOI 10.1083/jcb.105.4.1515; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; CRONE DE, 1989, J VIROL, V63, P4172, DOI 10.1128/JVI.63.10.4172-4180.1989; DASSO M, 1993, TRENDS BIOCHEM SCI, V18, P96, DOI 10.1016/0968-0004(93)90161-F; DEVEGVAR HEN, 1990, MOL CELL BIOL, V10, P3365, DOI 10.1128/MCB.10.7.3365; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; DWORETZKY SI, 1988, J CELL BIOL, V106, P575, DOI 10.1083/jcb.106.3.575; ELLIOTT DJ, 1994, CURR OPIN GENET DEV, V4, P305, DOI 10.1016/S0959-437X(05)80058-9; FILIPOWICZ W, 1993, MOL BIOL REP, V18, P149, DOI 10.1007/BF00986770; FORBES DJ, 1992, ANNU REV CELL BIOL, V8, P495, DOI 10.1146/annurev.cb.08.110192.002431; FORRESTER W, 1992, GENE DEV, V6, P1914, DOI 10.1101/gad.6.10.1914; FOURNIER MJ, 1993, TRENDS BIOCHEM SCI, V18, P131, DOI 10.1016/0968-0004(93)90020-N; FRESCO LD, 1987, MOL CELL BIOL, V7, P1148, DOI 10.1128/MCB.7.3.1148; GURNEY T, 1980, J CELL BIOL, V87, P398, DOI 10.1083/jcb.87.2.398; HUANG SD, COMMUNICATION; Izaurralde E, 1992, Semin Cell Biol, V3, P279, DOI 10.1016/1043-4682(92)90029-U; KADOWAKI T, 1993, EMBO J, V12, P2929, DOI 10.1002/j.1460-2075.1993.tb05955.x; KLEINSCHMIDT AM, 1987, MOL CELL BIOL, V7, P3131, DOI 10.1128/MCB.7.9.3131; LERNER EA, 1981, P NATL ACAD SCI-BIOL, V78, P2737, DOI 10.1073/pnas.78.5.2737; Maquat LE, 1991, CURR OPIN CELL BIOL, V3, P1004, DOI 10.1016/0955-0674(91)90121-E; MATTAJ IW, 1988, STRUCTURE FUNCTION M, P100; MEHLIN H, 1992, CELL, V69, P605, DOI 10.1016/0092-8674(92)90224-Z; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MOORE MS, 1994, TRENDS BIOCHEM SCI, V19, P211, DOI 10.1016/0968-0004(94)90024-8; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MUNNS TW, 1982, BIOCHEMISTRY-US, V21, P2922, DOI 10.1021/bi00541a018; NISHIMOTO T, 1978, CELL, V15, P475, DOI 10.1016/0092-8674(78)90017-X; NISHITANI H, 1991, EMBO J, V10, P1555, DOI 10.1002/j.1460-2075.1991.tb07675.x; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; PANTE N, 1993, J CELL BIOL, V122, P977, DOI 10.1083/jcb.122.5.977; PATTON JR, 1987, MOL CELL BIOL, V7, P4030, DOI 10.1128/MCB.7.11.4030; Reddy R., 1988, STRUCTURE FUNCTION M, P1, DOI 10.1007/978-3-642-73020-7_1; REIMER G, 1987, ARTHRITIS RHEUM, V30, P793, DOI 10.1002/art.1780300709; ROSBASH M, 1993, CELL, V75, P399, DOI 10.1016/0092-8674(93)90373-X; ROSS J, 1976, J MOL BIOL, V106, P403, DOI 10.1016/0022-2836(76)90093-0; SCHLENSTEDT G, 1995, P NATL ACAD SCI USA, V92, P225, DOI 10.1073/pnas.92.1.225; TARTAKOFF A, COMMUNICATION; TERNS MP, 1994, SCIENCE, V264, P959, DOI 10.1126/science.8178154; ZACHAR Z, 1993, J CELL BIOL, V121, P729, DOI 10.1083/jcb.121.4.729; ZIEVE GW, 1990, CRIT REV BIOCHEM MOL, V25, P1, DOI 10.3109/10409239009090604; ZIEVE GW, 1987, J CELL PHYSIOL, V131, P247, DOI 10.1002/jcp.1041310215	48	113	114	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 24	1995	267	5205					1807	1810		10.1126/science.7534442	http://dx.doi.org/10.1126/science.7534442			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN702	7534442				2022-12-24	WOS:A1995QN70200035
J	WEI, XP; GHOSH, SK; TAYLOR, ME; JOHNSON, VA; EMINI, EA; DEUTSCH, P; LIFSON, JD; BONHOEFFER, S; NOWAK, MA; HAHN, BH; SAAG, MS; SHAW, GM				WEI, XP; GHOSH, SK; TAYLOR, ME; JOHNSON, VA; EMINI, EA; DEUTSCH, P; LIFSON, JD; BONHOEFFER, S; NOWAK, MA; HAHN, BH; SAAG, MS; SHAW, GM			VIRAL DYNAMICS IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION	NATURE			English	Article							PRIMARY HIV-1 INFECTION; POLYMERASE CHAIN-REACTION; REVERSE-TRANSCRIPTASE; MESSENGER-RNA; PLASMA; VIREMIA; DISEASE; DNA; INDIVIDUALS; RESISTANT	The dynamics of HIV-1 replication in vivo are largely unknown yet they are critical to our understanding of disease pathogenesis. Experimental drugs that are potent inhibitors of viral replication can be used to show that the composite lifespan of plasma virus and virus-producing cells is remarkably short (half-life similar to 2 days). Almost complete replacement of wild-type virus in plasma by drug-resistant variants occurs after fourteen days, indicating that HIV-1 viraemia is sustained primarily by a dynamic process involving continuous rounds of de novo virus infection and replication and rapid cell turnover.	UNIV ALABAMA,DIV HEMATOL ONCOL,BIRMINGHAM,AL 35294; UNIV ALABAMA,DIV INFECT DIS,BIRMINGHAM,AL 35294; MERCK SHARP & DOHME LTD,RES LABS,DEPT ANTIVIRAL RES,W POINT,PA 19486; MERCK SHARP & DOHME LTD,RES LABS,DEPT CLIN PHARMACOL,W POINT,PA 19486; GENELABS TECHNOL INC,DIV HIV & EXPLORATORY RES,REDWOOD CITY,CA 94063; UNIV OXFORD,DEPT ZOOL,OXFORD OX1 3PS,ENGLAND	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Merck & Company; Merck & Company; University of Oxford			Nowak, Martin A/A-6977-2008; Yang, Chen/G-1379-2010; Bonhoeffer, Sebastian/A-2735-2008	Bonhoeffer, Sebastian/0000-0001-8052-3925; Ghosh, Sajal/0000-0002-1187-6994; Hahn, Beatrice/0000-0002-9400-9887	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AOKISEI S, 1992, AIDS RES HUM RETROV, V8, P1263, DOI 10.1089/aid.1992.8.1263; BAGNARELLI P, 1994, J VIROL, V68, P2495, DOI 10.1128/JVI.68.4.2495-2502.1994; BAGNARELLI P, 1992, J VIROL, V66, P7328, DOI 10.1128/JVI.66.12.7328-7335.1992; BALZARINI J, 1994, P NATL ACAD SCI USA, V91, P6599, DOI 10.1073/pnas.91.14.6599; CAO Y, IN PRESS AIDS RES HU; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; COFFIN JM, 1992, CURR TOP MICROBIOL, V176, P143; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; GRAZIOSI C, 1993, P NATL ACAD SCI USA, V90, P6405, DOI 10.1073/pnas.90.14.6405; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; JAPOUR AJ, 1993, ANTIMICROB AGENTS CH, V37, P1095, DOI 10.1128/AAC.37.5.1095; KEMPF D, IN PRESS P NATN ACAD; LARDER BA, 1993, NATURE, V365, P671, DOI 10.1038/365671a0; MCLEAN AR, 1992, AIDS, V6, P71, DOI 10.1097/00002030-199201000-00009; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; MEYERHANS A, 1989, CELL, V58, P901, DOI 10.1016/0092-8674(89)90942-2; MICHAEL NL, 1992, J VIROL, V66, P310, DOI 10.1128/JVI.66.1.310-316.1992; MICHIE CA, 1992, NATURE, V360, P264, DOI 10.1038/360264a0; MULDER J, 1994, J CLIN MICROBIOL, V32, P292, DOI 10.1128/JCM.32.2.292-300.1994; MYEERS GK, 1993, HUMAN RETROVIRUSES A; NOWAK MA, 1991, SCIENCE, V254, P963, DOI 10.1126/science.1683006; PANTALEO G, 1991, P NATL ACAD SCI USA, V88, P9838, DOI 10.1073/pnas.88.21.9838; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PATTERSON BK, 1993, SCIENCE, V260, P976, DOI 10.1126/science.8493534; PIATAK M, 1993, LANCET, V341, P1099, DOI 10.1016/0140-6736(93)92463-4; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; PRASAD VR, 1989, J BIOL CHEM, V284, P16689; RICHMAN D, 1991, P NATL ACAD SCI USA, V88, P11241, DOI 10.1073/pnas.88.24.11241; RICHMAN DD, 1994, J VIROL, V68, P1660, DOI 10.1128/JVI.68.3.1660-1666.1994; SAAG MS, 1991, J INFECT DIS, V164, P72, DOI 10.1093/infdis/164.1.72; SAAG MS, 1993, NEW ENGL J MED, V329, P1065, DOI 10.1056/NEJM199310073291502; SAKSELA K, 1994, P NATL ACAD SCI USA, V91, P1104, DOI 10.1073/pnas.91.3.1104; SCHNITTMAN SM, 1991, AIDS RES HUM RETROV, V7, P361, DOI 10.1089/aid.1991.7.361; SHAW GM, 1984, SCIENCE, V226, P1165, DOI 10.1126/science.6095449; SIMMONDS P, 1991, J VIROL, V65, P6266, DOI 10.1128/JVI.65.11.6266-6276.1991; SMITH MS, 1993, J INFECT DIS, V167, P445, DOI 10.1093/infdis/167.2.445; SPRENT J, 1994, SCIENCE, V265, P1395, DOI 10.1126/science.8073282; VACCA JP, 1994, P NATL ACAD SCI USA, V91, P4096, DOI 10.1073/pnas.91.9.4096; WAINHOBSON S, 1993, CURR OPIN GENET DEV, V3, P878, DOI 10.1016/0959-437X(93)90008-D; WINTERS MA, 1993, J CLIN MICROBIOL, V31, P2960, DOI 10.1128/JCM.31.11.2960-2966.1993; ZHANG YM, 1994, J VIROL, V68, P425, DOI 10.1128/JVI.68.1.425-432.1994	44	2879	2947	4	210	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 12	1995	373	6510					117	122		10.1038/373117a0	http://dx.doi.org/10.1038/373117a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB063	7529365				2022-12-24	WOS:A1995QB06300048
J	GILLESPIE, DH; CUDDY, KK; KOLBE, T; MARKS, DI				GILLESPIE, DH; CUDDY, KK; KOLBE, T; MARKS, DI			DISSOLVE AND CAPTURE - A STRATEGY FOR ANALYZING MESSENGER-RNA IN BLOOD	NATURE			English	Article							THIOCYANATE; DNA		RNA LAB INC,EAGLE,PA 19480		GILLESPIE, DH (corresponding author), HAHNEMANN UNIV,DEPT NEOPLAST DIS,ROAD & VINE,PHILADELPHIA,PA 19102, USA.							CASEY J, 1977, NUCLEIC ACIDS RES, V4, P1539, DOI 10.1093/nar/4.5.1539; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUDDY K, 1993, NUCLEIC ACIDS RES, V21, P2281, DOI 10.1093/nar/21.9.2281; CUDDY KK, 1993, IN PRESS NOV EDGW RE; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING; THOMPSON J, 1987, ANAL BIOCHEM, V163, P281, DOI 10.1016/0003-2697(87)90225-9; THOMPSON JD, 1992, BLOOD, V79, P1629; VOGELSTEIN B, 1977, BIOCHEM BIOPH RES CO, V75, P1127, DOI 10.1016/0006-291X(77)91500-5	9	9	9	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 27	1994	367	6461					390	391		10.1038/367390a0	http://dx.doi.org/10.1038/367390a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT540	7509457				2022-12-24	WOS:A1994MT54000075
J	Gardner, P; Eickhoff, T; Poland, GA; Gross, P; Griffin, M; LaForce, M; Schaffner, W; Strikas, R				Gardner, P; Eickhoff, T; Poland, GA; Gross, P; Griffin, M; LaForce, M; Schaffner, W; Strikas, R			Adult immunizations	ANNALS OF INTERNAL MEDICINE			English	Article							ATTENUATED VARICELLA VACCINE; HEPATITIS-A VACCINE; HEALTHY-CHILDREN; UNITED-STATES; SALMONELLA-TYPHI; ZOSTER VIRUS; SUSCEPTIBILITY; INFECTIONS; SEROSURVEY; RECRUITS	New vaccines have been licensed for hepatitis A, varicella, and typhoid. This paper reviews these Vaccines and their recommended uses in adults. Special attention is given to a new national policy establishing age 50 years as a time for review of preventive health measures with emphasis on evaluating risk factors that indicate a need for pneumococcal vaccine and the initiation of annual influenza immunization.	UNIV COLORADO, HLTH SCI CTR, DIV INFECT DIS, DENVER, CO 80262 USA; MAYO CLIN & MAYO FDN, MAYO VACCINE RES GRP, DEPT MED & CLIN PHARMACOL, ROCHESTER, MN 55905 USA; HACKENSACK MED CTR, DEPT INTERNAL MED, HACKENSACK, NJ 07601 USA; VANDERBILT UNIV, SCH MED, DEPT MED, NASHVILLE, TN 37232 USA; UNIV ROCHESTER, GENESSEE HOSP, SCH MED & DENT, ROCHESTER, NY 14607 USA; VANDERBILT UNIV, SCH MED, DEPT PREVENT MED, DIV INFECT DIS, NASHVILLE, TN 37232 USA; CTR DIS CONTROL & PREVENT, NATL IMMUNIZATION PROGRAM, ATLANTA, GA 30333 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Mayo Clinic; Hackensack University Medical Center; Vanderbilt University; University of Rochester; Vanderbilt University; Centers for Disease Control & Prevention - USA	Gardner, P (corresponding author), SUNY STONY BROOK, HLTH SCI CTR, SCH MED, STONY BROOK, NY 11794 USA.							ACHARYA IL, 1987, NEW ENGL J MED, V317, P1101, DOI 10.1056/NEJM198710293171801; AKRIVIADIS EA, 1989, ANN INTERN MED, V110, P838, DOI 10.7326/0003-4819-110-10-838; ALTER SJ, 1986, INFECT CONT HOSP EP, V7, P448, DOI 10.1017/S0195941700064936; Centers for Disease Control and Prevention (CDC), 1994, MMWR Morb Mortal Wkly Rep, V43, P1; FEDSON DS, 1994, JAMA-J AM MED ASSOC, V272, P1133, DOI 10.1001/jama.272.14.1133; Gershon A A, 1994, Clin Diagn Virol, V2, P271, DOI 10.1016/0928-0197(94)90051-5; GERSHON AA, 1988, J INFECT DIS, V158, P132, DOI 10.1093/infdis/158.1.132; GERSHON AA, 1989, NEW ENGL J MED, V320, P892, DOI 10.1056/NEJM198904063201403; GREEN MS, 1993, J INFECT DIS, V168, P740, DOI 10.1093/infdis/168.3.740; GROSS PA, 1995, ANN INTERN MED, V123, P518, DOI 10.7326/0003-4819-123-7-199510010-00008; HARRIS RE, 1965, OBSTET GYNECOL, V25, P734; HOPESIMPSON RE, 1965, P ROY SOC MED, V58, P9, DOI 10.1177/003591576505800106; INNIS BL, 1994, JAMA-J AM MED ASSOC, V271, P1328, DOI 10.1001/jama.271.17.1328; JILIG W, 1994, VACCINES, P583; KANE MA, 1992, VACCINE, V10, pS93, DOI 10.1016/0264-410X(92)90555-X; KELLEY PW, 1991, JAMA-J AM MED ASSOC, V266, P2724, DOI 10.1001/jama.266.19.2724; KLUGMAN KP, 1987, LANCET, V2, P1165; KUTER BJ, 1991, VACCINE, V9, P643, DOI 10.1016/0264-410X(91)90189-D; LEMON SM, 1994, INFECT AGENT DIS, V3, P38; MCMAHON BJ, 1994, 34TH INT C ANT AG CH, pH11; MORENS DM, 1980, ANN INTERN MED, V93, P414, DOI 10.7326/0003-4819-93-3-414; NICHOL KL, 1995, NEW ENGL J MED, V333, P889, DOI 10.1056/NEJM199510053331401; NICHOL KL, 1994, NEW ENGL J MED, V331, P778, DOI 10.1056/NEJM199409223311206; RYAN CA, 1989, REV INFECT DIS, V11, P1; SHAPIRO CN, 1992, VACCINE, V10, pS59, DOI 10.1016/0264-410X(92)90545-U; STRUEWING JP, 1993, AM J PUBLIC HEALTH, V83, P1717, DOI 10.2105/AJPH.83.12.1717; TSOLIA M, 1990, J PEDIATR-US, V116, P184, DOI 10.1016/S0022-3476(05)82872-0; USA Adult Vaccine Preventable Disease Br., 1995, Morbidity and Mortality Weekly Report, V44, P506; WAGNER G, 1993, VACCINE, V11, P1027, DOI 10.1016/0264-410X(93)90128-K; WEIBEL RE, 1984, NEW ENGL J MED, V310, P1409, DOI 10.1056/NEJM198405313102201; WERZBERGER A, 1992, NEW ENGL J MED, V327, P453, DOI 10.1056/NEJM199208133270702; WHITE CJ, 1991, PEDIATRICS, V87, P604; 1995, MMWR-MORBID MORTAL W, V44, P561; 1994, GUIDE ADULT IMMUNIZA	34	46	46	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	1				35	40		10.7326/0003-4819-124-1_Part_1-199601010-00007	http://dx.doi.org/10.7326/0003-4819-124-1_Part_1-199601010-00007			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL943	7503476				2022-12-24	WOS:A1996TL94300007
J	ACHARYA, U; JACOBS, R; PETERS, JM; WATSON, N; FARQUHAR, MG; MALHOTRA, V				ACHARYA, U; JACOBS, R; PETERS, JM; WATSON, N; FARQUHAR, MG; MALHOTRA, V			THE FORMATION OF GOLGI STACKS FROM VESICULATED GOLGI MEMBRANES REQUIRES 2 DISTINCT FUSION EVENTS	CELL			English	Article							GTP-BINDING PROTEINS; VESICLE FUSION; STOMATITIS-VIRUS; TRANSPORT; PURIFICATION; ENDOCYTOSIS; INVITRO; FAMILY; YEAST; NSF	We have reconstituted the fusion and assembly of vesiculated Golgi membranes (VGMs) into functionally active stacks of cisternae. A kinetic analysis of this assembly process revealed that highly dispersed VGMs of 60-90 nm diameter first fuse to form larger vesicles of 200-300 nm diameter that are clustered together. These vesicles then fuse to form tubular elements and short cisternae, which finally assemble into stacks of cisternae. We now provide evidence that the sequential stack formation from VGMs reflects two distinct fusion processes: the first event is N-ethylmaleimide (NEM)-sensitive factor (NSF) dependent, and the second fusion event requires an NSF-like NEM-sensitive ATPase called p97. Interestingly, while the earliest steps in stack formation share some similarities with events catalyzing fusion of transport vesicles to its target membrane, neither GTP IS nor Rab-GDI, inhibitors of vesicular protein traffic, inhibit stack formation.	UNIV CALIF SAN DIEGO,DIV CELLULAR & MOLEC MED,LA JOLLA,CA 92093; SALK INST BIOL STUDIES,MOLEC & NEUROBIOL LABS,LA JOLLA,CA 92093; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	University of California System; University of California San Diego; Salk Institute; Harvard University; Harvard Medical School	ACHARYA, U (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093, USA.		Malhotra, Vivek/O-9811-2014	Malhotra, Vivek/0000-0001-6198-7943	NCI NIH HHS [CA58689] Funding Source: Medline; NIGMS NIH HHS [GM46224] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA058689] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACHARYA U, 1995, J CELL BIOL, V129, P577, DOI 10.1083/jcb.129.3.577; BALCH WE, 1986, J BIOL CHEM, V261, P4681; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BOMAN AL, 1992, J CELL BIOL, V116, P281, DOI 10.1083/jcb.116.2.281; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; DIRACSVEJSTRUP AB, 1994, J BIOL CHEM, V269, P15427; ELAZAR Z, 1994, J BIOL CHEM, V269, P794; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; HEYMAN JA, 1994, J CELL BIOL, V127, P1259, DOI 10.1083/jcb.127.5.1259; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAFAY F, 1974, J VIROL, V14, P1220, DOI 10.1128/JVI.14.5.1220-1228.1974; LATTERICH M, 1994, CELL, V78, P87, DOI 10.1016/0092-8674(94)90575-4; LATTERICH M, 1995, CELL, V82, P885, DOI 10.1016/0092-8674(95)90268-6; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MAYORGA LS, 1989, SCIENCE, V244, P1475, DOI 10.1126/science.2499930; NEWPORT J, 1992, J CELL BIOL, V116, P295, DOI 10.1083/jcb.116.2.295; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; PETER F, 1994, J CELL BIOL, V126, P1393, DOI 10.1083/jcb.126.6.1393; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; RABOUILLE C, 1995, J CELL BIOL, V129, P605, DOI 10.1083/jcb.129.3.605; RODRIGUEZ L, 1994, MOL BIOL CELL, V5, P773, DOI 10.1091/mbc.5.7.773; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SPONG AP, 1993, J CELL BIOL, V123, P535, DOI 10.1083/jcb.123.3.535; TAKIZAWA PA, 1993, CELL, V73, P1079, DOI 10.1016/0092-8674(93)90638-7; VEIT B, 1993, J CELL BIOL, V122, P1197, DOI 10.1083/jcb.122.6.1197; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39	31	178	179	0	5	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 22	1995	82	6					895	904		10.1016/0092-8674(95)90269-4	http://dx.doi.org/10.1016/0092-8674(95)90269-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RW693	7553850	Bronze			2022-12-24	WOS:A1995RW69300006
J	GOGA, A; MCLAUGHLIN, J; AFAR, DEH; SAFFRAN, DC; WITTE, ON				GOGA, A; MCLAUGHLIN, J; AFAR, DEH; SAFFRAN, DC; WITTE, ON			ALTERNATIVE SIGNALS TO RAS FOR HEMATOPOIETIC TRANSFORMATION BY THE BCR-ABL ONCOGENE	CELL			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE-ACTIVITY; PHILADELPHIA-CHROMOSOME; BONE-MARROW; SH2 DOMAIN; CELL LINE; C-ABL; PROTEIN; MICE; BCR/ABL	Biological function of the BCR-ABL oncogene is dependent on its activated tyrosine kinase. Mutations that Inactivate the SRC homology 2 (SH2) domain, the GRB2-binding site in BCR, or the major autophosphorylation site of the kinase domain selectively disrupt downstream signaling but not tyrosine kinase activity. Despite a loss of fibroblast transformation activity, all three mutants retain the ability to render hematopoietic cell lines growth factor independent and transform primary bone marrow cells in vitro. In vivo tests of malignant potential reveal a most critical role for signals dependent on the BCR-ABL SH2 domain. The efficiency of both fibroblast and hematopoietic transformation by BCR-ABL is strongly affected by increased dosage of the SHC adapter protein, which can connect tyrosine kinase signals to RAS. The BCR-ABL oncogene activates multiple alternative pathways to RAS for hematopoietic transformation.	UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, HOWARD HUGHES MED INST, LOS ANGELES, CA 90095 USA	University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles	GOGA, A (corresponding author), UNIV CALIF LOS ANGELES, DEPT MICROBIOL & MOLEC GENET, LOS ANGELES, CA 90095 USA.				NATIONAL CANCER INSTITUTE [R35CA053867] Funding Source: NIH RePORTER; NCI NIH HHS [CA-53867] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; AFAR DEH, 1995, IN PRESS P NATL ACAD; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DICK JE, 1991, IMMUNOL REV, V124, P25, DOI 10.1111/j.1600-065X.1991.tb00614.x; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; GISHIZKY ML, 1993, P NATL ACAD SCI USA, V90, P3755, DOI 10.1073/pnas.90.8.3755; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; JANSSEN JWG, 1987, P NATL ACAD SCI USA, V84, P9228, DOI 10.1073/pnas.84.24.9228; KELLIHER M, 1991, MOL CELL BIOL, V11, P4710, DOI 10.1128/MCB.11.9.4710; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MANDANAS RA, 1993, BLOOD, V82, P1838; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MCLAUGHLIN J, 1989, MOL CELL BIOL, V9, P1866, DOI 10.1128/MCB.9.5.1866; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NICHOLS GL, 1994, BLOOD, V84, P2912; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; PAWSON T, 1994, ADV CANCER RES, V64, P87, DOI 10.1016/S0065-230X(08)60835-0; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PENDERGAST AM, 1993, MOL CELL BIOL, V13, P1728, DOI 10.1128/MCB.13.3.1728; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; RENNICK D, 1987, BLOOD, V69, P682; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; SALCINI AE, 1994, ONCOGENE, V9, P2827; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; SAWYERS CL, 1994, CELL, V77, P171, DOI 10.1016/0092-8674(94)90307-7; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TENHOEVE J, 1994, BLOOD, V84, P1731; WHITLOCK CA, 1982, P NATL ACAD SCI-BIOL, V79, P3608, DOI 10.1073/pnas.79.11.3608; WHITLOCK CA, 1981, J VIROL, V40, P577, DOI 10.1128/JVI.40.2.577-584.1981; YOUNG JC, 1991, MOL CELL BIOL, V11, P854, DOI 10.1128/MCB.11.2.854	45	248	251	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 22	1995	82	6					981	988		10.1016/0092-8674(95)90277-5	http://dx.doi.org/10.1016/0092-8674(95)90277-5			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RW693	7553858	Bronze			2022-12-24	WOS:A1995RW69300014
J	SLATER, S; WOLD, S; LU, M; BOYE, E; SKARSTAD, K; KLECKNER, N				SLATER, S; WOLD, S; LU, M; BOYE, E; SKARSTAD, K; KLECKNER, N			ESCHERICHIA-COLI SEQA PROTEIN BINDS ORIC IN 2 DIFFERENT METHYL-MODULATED REACTIONS APPROPRIATE TO ITS ROLES IN DNA-REPLICATION INITIATION AND ORIGIN SEQUESTRATION	CELL			English	Article							ESCHERICHIA-COLI; CHROMOSOME-REPLICATION; FIS PROTEIN; MEMBRANE; PREVENTS; DOMAINS; HYBRID; SITES; IHF; HU	The seqA gene negatively modulates replication initiation at the E. coli origin, oriC. seqA is also essential for sequestration, which acts at oriC and the dnaA promoter to ensure that replication initiation occurs exactly once per chromosome per cell cycle. Initiation is promoted by full methylation of GATC sites clustered in oriC; sequestration is specific to the hemimethylated forms generated by replication, SeqA protein purification and DNA binding are described. SeqA interacts with fully methylated oriC strongly and specifically, This reaction requires multiple molecules of SeqA and determinants throughout oriC, including segments involved in open complex formation. SeqA interacts more strongly with hemimethylated DNA; in this case, oriC and non-oriC sequences are bound similarly. Also, binding of hemimethylated oriC by membrane fractions is due to SeqA. Direct interaction of SeqA protein with the replication origin is likely to be involved in both replication initiation and sequestration.	INST CANC RES,DEPT BIOPHYS,N-0310 MONTEBELLO,NORWAY		SLATER, S (corresponding author), HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025326] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM25326] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bachmann B.J., 1987, ESCHERICHIA COLI SAL, P1190; BAKER TA, 1902, ANNU REV GENET, V26, P447; BONNEFOY E, 1992, EMBO J, V11, P4489, DOI 10.1002/j.1460-2075.1992.tb05550.x; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; BRENDLER T, 1995, IN PRESS EMBO J; CAMPBELL JL, 1990, CELL, V62, P967, DOI 10.1016/0092-8674(90)90271-F; CHAKRABORTI A, 1992, J BACTERIOL, V174, P7202, DOI 10.1128/jb.174.22.7202-7206.1992; FILUTOWICZ M, 1990, New Biologist, V2, P818; FILUTOWICZ M, 1992, J BACTERIOL, V174, P398, DOI 10.1128/jb.174.2.398-407.1992; GILLE H, 1991, NUCLEIC ACIDS RES, V19, P4167, DOI 10.1093/nar/19.15.4167; GILLE H, 1991, EMBO J, V10, P1579, DOI 10.1002/j.1460-2075.1991.tb07678.x; HANSEN FG, 1991, RES MICROBIOL, V142, P161, DOI 10.1016/0923-2508(91)90025-6; HERRICK J, 1994, EMBO J, V13, P4695, DOI 10.1002/j.1460-2075.1994.tb06793.x; HORIUCHI K, 1972, P NATL ACAD SCI USA, V69, P3220, DOI 10.1073/pnas.69.11.3220; HWANG DS, 1992, J BIOL CHEM, V267, P23083; ISHIDATE K, 1986, J BIOL CHEM, V261, P428; KOPPES L, 1986, CELL, V44, P117, DOI 10.1016/0092-8674(86)90490-3; KUSANO T, 1984, J BACTERIOL, V158, P313, DOI 10.1128/JB.158.1.313-316.1984; LANDOULSI A, 1990, CELL, V63, P1053, DOI 10.1016/0092-8674(90)90508-C; LOBNEROLESEN A, 1994, EMBO J, V13, P1856; LU M, 1994, CELL, V77, P413, DOI 10.1016/0092-8674(94)90156-2; MESSER W, 1985, EMBO J, V4, P1327, DOI 10.1002/j.1460-2075.1985.tb03780.x; MESSER W, 1995, IN PRESS ESCHERICHIA; OGDEN GB, 1988, CELL, V54, P127, DOI 10.1016/0092-8674(88)90186-9; POLACZEK P, 1990, New Biologist, V2, P265; RUSSELL DW, 1987, CELL, V50, P1071, DOI 10.1016/0092-8674(87)90173-5; Sambrook J., 1989, MOL CLONING LAB MANU; SKARSTAD K, 1986, EMBO J, V5, P1711, DOI 10.1002/j.1460-2075.1986.tb04415.x; SKARSTAD K, 1994, BBA-GENE STRUCT EXPR, V1217, P111, DOI 10.1016/0167-4781(94)90025-6; SKARSTAD K, 1990, EMBO J, V9, P2341, DOI 10.1002/j.1460-2075.1990.tb07406.x; SMITH DW, 1985, EMBO J, V4, P1319, DOI 10.1002/j.1460-2075.1985.tb03779.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THEISEN PW, 1993, MOL MICROBIOL, V10, P575, DOI 10.1111/j.1365-2958.1993.tb00929.x; VONFREIESLEBEN U, 1994, MOL MICROBIOL, V14, P763; YUNG BYM, 1989, J BIOL CHEM, V264, P6146	35	238	241	0	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 22	1995	82	6					927	936		10.1016/0092-8674(95)90272-4	http://dx.doi.org/10.1016/0092-8674(95)90272-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RW693	7553853	Bronze			2022-12-24	WOS:A1995RW69300009
J	PATEL, P; MENDALL, MA; CARRINGTON, D; STRACHAN, DP; LEATHAM, E; MOLINEAUX, N; LEVY, J; BLAKESTON, C; SEYMOUR, CA; CAMM, AJ; NORTHFIELD, TC				PATEL, P; MENDALL, MA; CARRINGTON, D; STRACHAN, DP; LEATHAM, E; MOLINEAUX, N; LEVY, J; BLAKESTON, C; SEYMOUR, CA; CAMM, AJ; NORTHFIELD, TC			ASSOCIATION OF HELICOBACTER-PYLORI AND CHLAMYDIA-PNEUMONIAE INFECTIONS WITH CORONARY HEART-DISEASE AND CARDIOVASCULAR RISK-FACTORS	BRITISH MEDICAL JOURNAL			English	Article							ACUTE MYOCARDIAL-INFARCTION; CELL COUNT; FIBRINOGEN; PLAQUES; HEALTH; LIFE	Objective-To investigate the relation between seropositivity to chronic infections with Helicobacter pylori and Chlamydia pneumoniae and both coronary heart disease and cardiovascular risk factors. Design-Cross sectional study of a population based random sample of men. Coronary heart disease was assessed by electrocardiography, Rose angina questionnaire, and a history of myocardial infarction; serum antibody levels to H pylori and C pneumoniae were measured, risk factor levels determined, and a questionnaire administered. Setting-General practices in Merton, Sutton, and Wandsworth, south London. Subjects-388 white south London men aged 50-69. Main outcome measures-Evidence of coronary risk factors and infection with H pylori or C pneumoniae. Results-47 men (12.1%) had electrocardiographic evidence of ischaemia or infarction. 36 (76.6%) and 18 (38.3%) were seropositive for H pylori and C pneumoniae, respectively, compared with 155 (45.5%) and 62 (18.2%) men with normal electrocardiograms. Odds ratios for abnormal electrocardiograms were 3.82 (95% confidence interval 1.60 to 9.10) and 3.06 (1.33 to 7.01) in men seropositive for H pylori and C pneumoniae, respectively, after adjustment for a range of socioeconomic indicators and risk factors for coronary heart disease. Cardiovascular risk factors that were independently associated with seropositivity to H pylori included fibrinogen concentration and total leucocyte count. Seropositivity to C pneumoniae was independently associated with raised fibrinogen and malondialdehyde concentrations. Conclusions-Both H pylori and C pneumoniae infections are associated with coronary heart disease. These relations are not explained by a wide range of confounding factors. Possible mechanisms include an increase in risk factor levels due to a low grade chronic inflammatory response.	UNIV LONDON ST GEORGES HOSP,SCH MED,DIV BIOCHEM MED,LONDON SW17 0RE,ENGLAND	St Georges University London								BAKER RJ, 1978, GLIM SYSTEM; CLAUSS A., 1957, ACTA HAEMATOL, V17, P237; CRABTREE JE, 1991, GUT, V32, P1473, DOI 10.1136/gut.32.12.1473; DAROUGAR S, 1983, BRIT MED BULL, V39, P117, DOI 10.1093/oxfordjournals.bmb.a071801; ELFORD J, 1991, INT J EPIDEMIOL, V20, P833, DOI 10.1093/ije/20.4.833; GLYNN JR, 1994, LANCET, V344, P146, DOI 10.1016/S0140-6736(94)92754-5; HENDRIKS T, 1988, CLIN CHIM ACTA, V174, P263, DOI 10.1016/0009-8981(88)90052-6; KUO CC, 1993, J INFECT DIS, V167, P841, DOI 10.1093/infdis/167.4.841; KWEIDER M, 1993, SCOT MED J, V38, P73, DOI 10.1177/003693309303800304; LEE AJ, 1990, J CLIN EPIDEMIOL, V43, P913, DOI 10.1016/0895-4356(90)90075-Z; LINDBERG G, 1991, BRIT MED J, V302, P143, DOI 10.1136/bmj.302.6769.143; MATTILA KJ, 1989, BRIT MED J, V298, P779, DOI 10.1136/bmj.298.6676.779; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MENDALL MA, 1994, BRIT HEART J, V71, P437; MENDALL MA, 1992, LANCET, V339, P896, DOI 10.1016/0140-6736(92)90931-R; MENDALL MA, 1995, J INFECTION, V30, P121, DOI 10.1016/S0163-4453(95)80006-9; MENDALL MA, 1992, EUR J GASTROEN HEPAT, V4, P713; MORRISSEY JH, 1993, BLOOD, V81, P734; PATEL P, 1994, LANCET, V343, P1634, DOI 10.1016/S0140-6736(94)93084-8; PUOLAKKAINEN M, 1993, J CLIN MICROBIOL, V31, P2212, DOI 10.1128/JCM.31.8.2212-2214.1993; ROSE GA, 1962, B WORLD HEALTH ORGAN, V27, P645; ROSE GA, 1982, WHO MONOGR SER, V56, P123; SAIKKU P, 1992, ANN INTERN MED, V116, P273, DOI 10.7326/0003-4819-116-4-273; SAIKKU P, 1988, LANCET, V2, P983, DOI 10.1016/S0140-6736(88)90741-6; SHAPER AG, 1984, BRIT HEART J, V51, P595, DOI 10.1136/hrt.51.6.595; THOM DH, 1992, JAMA-J AM MED ASSOC, V268, P68, DOI 10.1001/jama.268.1.68; TIPPING PG, 1989, ATHEROSCLEROSIS, V79, P237, DOI 10.1016/0021-9150(89)90129-9; WANG SP, 1994, J INFECT DIS, V130, P388; WILLIAMS D, 1989, INFECT IMMUN, V58, P1351; XU QB, 1993, LANCET, V341, P255, DOI 10.1016/0140-6736(93)92613-X; YARNELL JWG, 1991, CIRCULATION, V83, P836, DOI 10.1161/01.CIR.83.3.836; 1985, SAS USERS GUIDE STAT	32	514	530	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 16	1995	311	7007					711	714		10.1136/bmj.311.7007.711	http://dx.doi.org/10.1136/bmj.311.7007.711			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RV874	7549683	Green Published			2022-12-24	WOS:A1995RV87400017
J	FENG, JL; FUNK, WD; WANG, SS; WEINRICH, SL; AVILION, AA; CHIU, CP; ADAMS, RR; CHANG, E; ALLSOPP, RC; YU, JH; LE, SY; WEST, MD; HARLEY, CB; ANDREWS, WH; GREIDER, CW; VILLEPONTEAU, B				FENG, JL; FUNK, WD; WANG, SS; WEINRICH, SL; AVILION, AA; CHIU, CP; ADAMS, RR; CHANG, E; ALLSOPP, RC; YU, JH; LE, SY; WEST, MD; HARLEY, CB; ANDREWS, WH; GREIDER, CW; VILLEPONTEAU, B			THE RNA COMPONENT OF HUMAN TELOMERASE	SCIENCE			English	Article							U3 SNRNA GENES; HUMAN FIBROBLASTS; TETRAHYMENA; REPEATS; DNA; SENESCENCE; REDUCTION; CELLS	Eukaryotic chromosomes are capped with repetitive telomere sequences that protect the ends from damage and rearrangements. Telomere repeats are synthesized by telomerase, a ribonucleic acid (RNA)-protein complex. Here, the cloning of the RNA component of human telomerase, termed hTR, is described. The template region of hTR encompasses 11 nucleotides (5'-CUAACCCUAAC) complementary to the human telomere sequence (TTAGGG)(n). Germline tissues and tumor cell lines expressed more hTR than normal somatic cells and tissues, which have no detectable telomerase activity. Human cell lines that expressed hTR mutated in the template region generated the predicted mutant telomerase activity. HeLa cells transfected with an antisense hTR lost telomeric DNA and began to die after 23 to 26 doublings. Thus, human telomerase is a critical enzyme for the long-term proliferation of immortal tumor cells.	GERON CORP,MENLO PK,CA 94025; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Geron Corporation; Cold Spring Harbor Laboratory				West, Michael/0000-0002-4842-5468	NATIONAL INSTITUTE ON AGING [R01AG009383, R37AG009383] Funding Source: NIH RePORTER; NIA NIH HHS [AG09383] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADAMSON DJA, 1992, CANCER GENET CYTOGEN, V61, P204, DOI 10.1016/0165-4608(92)90088-P; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; AUTEXIER C, 1994, GENE DEV, V8, P563, DOI 10.1101/gad.8.5.563; AVILION AA, 1992, DEV GENET, V13, P80, DOI 10.1002/dvg.1020130113; AVILION AA, 1995, THESIS STATE U NEW Y; BLASCO MA, 1995, SCIENCE, V269, P1267, DOI 10.1126/science.7544492; BROCCOLI D, IN PRESS P NATL ACAD; CHADENEAU C, 1995, ONCOGENE, V11, P841; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; FENG J, UNPUB; FUNK W, UNPUB; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Hernandez N, 1992, TRANSCRIPTIONAL REGU, P281; HIYAMA E, 1995, NAT MED, V1, P249, DOI 10.1038/nm0395-249; HOLZMANN K, 1993, GENE CHROMOSOME CANC, V6, P178, DOI 10.1002/gcc.2870060308; IRVING J, 1992, EXP CELL RES, V202, P161, DOI 10.1016/0014-4827(92)90415-5; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KISS T, 1991, CELL, V65, P517, DOI 10.1016/0092-8674(91)90469-F; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; LIN JH, 1994, GENE, V147, P287, DOI 10.1016/0378-1119(94)90083-3; LINDSEY J, 1991, MUTAT RES, V256, P45, DOI 10.1016/0921-8734(91)90032-7; LINGNER J, 1994, GENE DEV, V8, P1984, DOI 10.1101/gad.8.16.1984; MARSHALLSAY C, 1992, PLANT MOL BIOL, V19, P973, DOI 10.1007/BF00040529; McClintock B, 1939, P NATL ACAD SCI USA, V25, P405, DOI 10.1073/pnas.25.8.405; MCEACHERN MJ, IN PRESS NATURE; MILLER RA, 1991, CANCER, V68, P2496, DOI 10.1002/1097-0142(19911201)68:11+<2496::AID-CNCR2820681503>3.0.CO;2-B; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Muller H.J., 1938, COLLECTING NET, V13, P181; NILSSON P, 1994, ONCOGENE, V9, P3043; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; PEREZ HD, 1994, J BIOL CHEM, V269, P22485; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARTZ HS, 1993, CANCER GENET CYTOGEN, V71, P132, DOI 10.1016/0165-4608(93)90018-H; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; SMITH JK, 1992, AM J OBSTET GYNECOL, V167, P1883, DOI 10.1016/0002-9378(92)91791-8; VAZIRI H, 1994, P NATL ACAD SCI USA, V91, P9857, DOI 10.1073/pnas.91.21.9857; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; YU GL, 1991, CELL, V67, P823, DOI 10.1016/0092-8674(91)90077-C; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0	49	1995	2253	4	170	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 1	1995	269	5228					1236	1241		10.1126/science.7544491	http://dx.doi.org/10.1126/science.7544491			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR842	7544491				2022-12-24	WOS:A1995RR84200024
J	DALE, DC				DALE, DC			WHERE NOW FOR COLONY-STIMULATING FACTORS	LANCET			English	Editorial Material							GRANULOCYTE; NEUTROPENIA				DALE, DC (corresponding author), UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195, USA.							BENSINGER WI, 1993, BLOOD, V81, P1883, DOI 10.1182/blood.V81.7.1883.1883; BIESMA DH, 1994, LANCET, V344, P367, DOI 10.1016/S0140-6736(94)91401-X; DALE DC, 1993, BLOOD, V81, P2496; DALE DC, 1995, STEM CELLS, V13, P94, DOI 10.1002/stem.5530130201; Demirer T, 1995, Curr Opin Hematol, V2, P219; ESCHBACH JW, 1994, KIDNEY INT, V45, pS70; Jones E A, 1993, JAMA, V270, P1132, DOI 10.1001/jama.270.9.1132; Kaushansky K, 1995, Curr Opin Hematol, V2, P172; KUHNS DB, 1995, J INFECT DIS, V171, P145, DOI 10.1093/infdis/171.1.145; NELSON S, 1994, CLIN INFECT DIS, V18, pS197, DOI 10.1093/clinids/18.Supplement_2.S197; STEWARD WP, 1993, LANCET, V342, P153, DOI 10.1016/0140-6736(93)91350-U; TO LB, 1994, BLOOD, V84, P2930; WELTE K, 1990, BLOOD, V75, P1056	13	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 15	1995	346	8968					135	136		10.1016/S0140-6736(95)91206-1	http://dx.doi.org/10.1016/S0140-6736(95)91206-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ031	7541497				2022-12-24	WOS:A1995RJ03100006
J	FUNG, DC; BERG, HC				FUNG, DC; BERG, HC			POWERING THE FLAGELLAR MOTOR OF ESCHERICHIA-COLI WITH AN EXTERNAL VOLTAGE-SOURCE	NATURE			English	Article							BACTERIAL FLAGELLA; OPTICAL TWEEZERS; ROTATION; TORQUE; FORCE; STREPTOCOCCUS; LIGHT	ROTARY motors of bacterial flagella are driven by ions that move across the cytoplasmic membrane down an electrochemical gradient(1-4). For Escherichia coli, the ions are protons, and the maximum work per unit charge that they can do is the protonmotive force. To test whether motor efficiency is limited by proton leakage or mechanical nonlinearities, we measured torque as a function of protonmotive force. Filamentous cells were drawn into micropipettes and energized with an external voltage source. Torque was proportional to protonmotive force up to -150 mV, twice the span accessible by earlier techniques(5-9). This is consistent with a mechanism in which a fixed number of protons, working at unit efficiency, carry the motor through each revolution. We also found that individual torque-generating elements inactivate at low potentials or potentials of reverse sign. When normal potentials are restored, they reactivate sequentially.	UNIV HARTFORD, DEPT MOLEC & CELLULAR BIOL, CAMBRIDGE 02138, ENGLAND									ARMITAGE JP, 1985, BIOCHIM BIOPHYS ACTA, V806, P42, DOI 10.1016/0005-2728(85)90080-5; BERG HC, 1993, BIOPHYS J, V65, P2201, DOI 10.1016/S0006-3495(93)81278-5; BERG HC, 1982, SYM SOC EXP BIOL, P1; BERG HC, 1990, BIOPHYS J, V58, P919, DOI 10.1016/S0006-3495(90)82436-X; Blair D F, 1990, Semin Cell Biol, V1, P75; BLAIR DF, 1988, SCIENCE, V242, P1678, DOI 10.1126/science.2849208; BLOCK SM, 1984, NATURE, V309, P470, DOI 10.1038/309470a0; BLOCK SM, 1991, CYTOMETRY, V12, P492, DOI 10.1002/cyto.990120605; BLOCK SM, 1989, NATURE, V338, P514, DOI 10.1038/338514a0; Brown KT, 1986, ADV MICROPIPETTE TEC; CONLEY MP, 1984, J BACTERIOL, V158, P832, DOI 10.1128/JB.158.3.832-843.1984; FUNG DCY, 1994, THESIS HARVARD U CAM; ISHIHARA A, 1983, J BACTERIOL, V155, P228, DOI 10.1128/JB.155.1.228-237.1983; JONES CJ, 1991, ADV MICROB PHYSIOL, V32, P109, DOI 10.1016/S0065-2911(08)60007-7; KAMIIKE N, 1991, BIOPHYS J, V60, P1350, DOI 10.1016/S0006-3495(91)82172-5; KASHKET ER, 1985, ANNU REV MICROBIOL, V39, P219, DOI 10.1146/annurev.mi.39.100185.001251; KATSU T, 1986, BIOCHIM BIOPHYS ACTA, V860, P608, DOI 10.1016/0005-2736(86)90560-2; KHAN S, 1983, CELL, V32, P913, DOI 10.1016/0092-8674(83)90076-4; KHAN S, 1985, J MOL BIOL, V184, P645, DOI 10.1016/0022-2836(85)90310-9; KHAN S, 1990, BIOPHYS J, V57, P779, DOI 10.1016/S0006-3495(90)82598-4; MACNAB RM, 1992, ANNU REV GENET, V26, P131, DOI 10.1146/annurev.ge.26.120192.001023; MANSON MD, 1980, J MOL BIOL, V138, P541, DOI 10.1016/S0022-2836(80)80017-9; MEISTER M, 1987, CELL, V49, P643, DOI 10.1016/0092-8674(87)90540-X; MEISTER M, 1987, BIOPHYS J, V52, P413, DOI 10.1016/S0006-3495(87)83230-7; MEISTER M, 1987, THESIS CALTECH PASAD; OVCHINNIKOV YA, 1982, PROTEINS, V5, P307; RAVID S, 1984, J BACTERIOL, V158, P222, DOI 10.1128/JB.158.1.222-230.1984; SCHUSTER SC, 1994, ANNU REV BIOPH BIOM, V23, P509, DOI 10.1146/annurev.bb.23.060194.002453	28	83	83	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 29	1995	375	6534					809	812		10.1038/375809a0	http://dx.doi.org/10.1038/375809a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RF989	7541114				2022-12-24	WOS:A1995RF98900084
J	ORNITZ, DM; HERR, AB; NILSSON, M; WESTMAN, J; SVAHN, CM; WAKSMAN, G				ORNITZ, DM; HERR, AB; NILSSON, M; WESTMAN, J; SVAHN, CM; WAKSMAN, G			FGF BINDING AND FGF RECEPTOR ACTIVATION BY SYNTHETIC HEPARAN-DERIVED DISACCHARIDES AND TRISACCHARIDES	SCIENCE			English	Article							FIBROBLAST GROWTH-FACTOR; 3-DIMENSIONAL STRUCTURE; SULFATE; REFINEMENT; DOMAINS; CELLS	Fibroblast growth factors (FGFs) require a polysaccharide cofactor, heparin or heparan sulfate (HS), for receptor binding and activation. To probe the molecular mechanism by which heparin or HS (heparin/HS) activates FGF, small nonsulfated oligosaccharides found within heparin/HS were assayed for activity, These synthetic and isomerically pure compounds can activate the FGF signaling pathway. The crystal structures of complexes between FGF and these heparin/HS oligosaccharides reveal several binding sites on FGF and constrain possible mechanisms by which heparin/HS can activate the FGF receptor. These studies establish a framework for the molecular design of compounds capable of modulating FGF activity.	WASHINGTON UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOPHYS, ST LOUIS, MO 63110 USA; PHARMACIA AB, DEPT ORGAN CHEM, S-11287 STOCKHOLM, SWEDEN	Washington University (WUSTL); Pfizer; Pharmacia Corporation	ORNITZ, DM (corresponding author), WASHINGTON UNIV, SCH MED, DEPT MOLEC BIOL & PHARMACOL, ST LOUIS, MO 63110 USA.		Herr, Andrew/R-3049-2019	Herr, Andrew/0000-0002-3598-3399; Ornitz, David/0000-0003-1592-7629	NATIONAL CANCER INSTITUTE [R01CA060673] Funding Source: NIH RePORTER; NCI NIH HHS [CA60673] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVIEZER D, 1994, J BIOL CHEM, V269, P114; BAIRD A, 1988, P NATL ACAD SCI USA, V85, P2324, DOI 10.1073/pnas.85.7.2324; BAKER EN, 1984, PROG BIOPHYS MOL BIO, V44, P97, DOI 10.1016/0079-6107(84)90007-5; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1992, X PLOR MANUAL VERSIO; BURRUS LW, 1989, J BIOL CHEM, V264, P18647; CASU B, 1989, ANN NY ACAD SCI, V556, P1; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; ERIKSSON AE, 1991, P NATL ACAD SCI USA, V88, P3441, DOI 10.1073/pnas.88.8.3441; FOLKMAN J, 1991, ANN SURG, V214, P414, DOI 10.1097/00000658-199110000-00006; GLABE CG, 1983, ANAL BIOCHEM, V130, P287, DOI 10.1016/0003-2697(83)90590-0; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; HEATH WF, 1991, BIOCHEMISTRY-US, V30, P5608, DOI 10.1021/bi00236a039; ISHIHARA M, 1993, J BIOL CHEM, V268, P4675; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MACH H, 1993, BIOCHEMISTRY-US, V32, P5480, DOI 10.1021/bi00071a026; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; MCPHERSON A, 1990, EUR J BIOCHEM, V189, P1, DOI 10.1111/j.1432-1033.1990.tb15454.x; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROSSMANN MG, 1972, INT SCI REV SERIES, V13; Roussel A, 1991, SILICON GRAPHICS GEO, P86; SVAHN C, UNPUB; WEIS WI, 1990, J MOL BIOL, V212, P737, DOI 10.1016/0022-2836(90)90234-D; WESTMAN J, 1995, J CARBOHYD CHEM, V14, P95, DOI 10.1080/07328309508006439; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZHANG JD, 1991, P NATL ACAD SCI USA, V88, P3446, DOI 10.1073/pnas.88.8.3446; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556; ZHU XT, 1993, STRUCTURE, V1, P27, DOI 10.1016/0969-2126(93)90006-3	37	269	288	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 21	1995	268	5209					432	436		10.1126/science.7536345	http://dx.doi.org/10.1126/science.7536345			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU572	7536345				2022-12-24	WOS:A1995QU57200045
J	FIELDS, BA; GOLDBAUM, FA; YSERN, X; POLJAK, RJ; MARIUZZA, RA				FIELDS, BA; GOLDBAUM, FA; YSERN, X; POLJAK, RJ; MARIUZZA, RA			MOLECULAR-BASIS OF ANTIGEN MIMICRY BY AN ANTI-IDIOTOPE	NATURE			English	Article							3-DIMENSIONAL STRUCTURE; IDIOTYPIC ANTIBODIES; COMPLEX; LYSOZYME; D1.3	IDIOTOPES are antigenic determinants, unique to an antibody or group of antibodies, defined by the reaction of anti-idiotopic antibodies with the antibodies bearing the idiotopes. The ensemble of idiotopes of an antibody constitutes its idiotype. Idiotypes are useful as markers to follow specific antibodies and clones of cells in immune responses and the inheritance of immunoglobulin genes. As external antigens and anti-idiotypic antibodies can competitively bind the combining site of specific antibodies, some antiidiotypic antibodies may resemble the external antigen, thus mimicking its structure. It has been proposed(1-5) that an anti-idiotypic antibody, anti-anti-X, may resemble the external antigen X and thus carry its 'internal image', but this idea is not unequivocally supported by the three-dimensional structures of anti-idiotopic antibodies(6-9), either because the structures of the external antigen(8) or of the anti-idiotopic antibody(7) were unknown, or because the anti-idiotopic antibodies showed no resemblance to the external antigens(6,9) (reviewed in ref. 10). Functional mimicry of ligands of biological receptors by anti-idiotypic antibodies has been described in several systems (reviewed in ref. 11). But how closely can antibodies mimic antigens at the molecular level? Here we present the crystal structure of an idiotope-anti-idiotope complex between the Fv fragments of the anti-lysozyme antibody D1.3 and the anti-D1.3 antibody E5.2. D1.3 contacts the antigen, lysozyme and the anti-idiotopic E5.2 through essentially the same combining-site residues, In addition, E5.2 interacts with D1.3, making contacts similar to those between lysozyme and D1.3. Thus, the anti-idiotopic antibody E5.2 mimics lysozyme in its binding interactions with D1.3. Validating these observations, E5.2, used as an immunogen, induces an anti-lysozyme response.	US FDA,CTR DRUG EVALUAT & RES,ROCKVILLE,MD 20857	US Food & Drug Administration (FDA)	FIELDS, BA (corresponding author), UNIV MARYLAND,CTR ADV RES BIOTECHNOL,INST BIOTECHNOL,9600 GUDELSKY DR,ROCKVILLE,MD 20850, USA.			Goldbaum, Fernando/0000-0001-6235-3002; Fields, Barry/0000-0003-0628-1328				AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; BAN N, 1994, P NATL ACAD SCI USA, V91, P1604, DOI 10.1073/pnas.91.5.1604; BENTLEY GA, 1990, NATURE, V348, P254, DOI 10.1038/348254a0; BHAT TN, 1994, P NATL ACAD SCI USA, V91, P1089, DOI 10.1073/pnas.91.3.1089; BOULOT G, 1987, J MOL BIOL, V194, P577, DOI 10.1016/0022-2836(87)90685-1; BOULOT G, 1990, J MOL BIOL, V213, P617, DOI 10.1016/S0022-2836(05)80248-7; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; EVANS SV, 1994, J MOL BIOL, V241, P691, DOI 10.1006/jmbi.1994.1544; GARCIA KC, 1992, SCIENCE, V257, P502, DOI 10.1126/science.1636085; GAULTON GN, 1986, ANNU REV IMMUNOL, V4, P253, DOI 10.1146/annurev.iy.04.040186.001345; GOLDBAUM FA, 1994, J MOL BIOL, V241, P739, DOI 10.1006/jmbi.1994.1549; HARPER M, 1987, MOL IMMUNOL, V2, P97; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; KABAT EA, 1991, NIH913242 US DEP HLT; LEU JG, 1994, P NATL ACAD SCI USA, V91, P10690, DOI 10.1073/pnas.91.22.10690; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NISONOFF A, 1981, CLIN IMMUNOL IMMUNOP, V21, P397, DOI 10.1016/0090-1229(81)90228-2; POLJAK RJ, 1994, P NATL ACAD SCI USA, V91, P1599, DOI 10.1073/pnas.91.5.1599; ROITT IM, 1981, LANCET, V1, P1041; SACKS DL, 1983, SPRINGER SEMIN IMMUN, V6, P79, DOI 10.1007/BF01857368; Tello Diana, 1994, Journal of Molecular Recognition, V7, P57, DOI 10.1002/jmr.300070108	21	152	160	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 20	1995	374	6524					739	742		10.1038/374739a0	http://dx.doi.org/10.1038/374739a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU304	7536303				2022-12-24	WOS:A1995QU30400055
J	JERMANN, TM; OPITZ, JG; STACKHOUSE, J; BENNER, SA				JERMANN, TM; OPITZ, JG; STACKHOUSE, J; BENNER, SA			RECONSTRUCTING THE EVOLUTIONARY HISTORY OF THE ARTIODACTYL RIBONUCLEASE SUPERFAMILY	NATURE			English	Article							AMINO-ACID-SEQUENCE; PANCREATIC RIBONUCLEASE; ESCHERICHIA-COLI; LYSOZYMES; PROTEIN; TUMOR	THE sequences of proteins from ancient organisms can be reconstructed from the sequences of their descendants by a procedure that assumes that the descendant proteins arose from the extinct ancestor by the smallest number of independent evolutionary events ('parsimony')(1,2). Tbe reconstructed sequences can then be prepared in the laboratory and studied(3,4). Thirteen ancient ribonucleases (RNases) have been reconstructed as intermediates in the evolution of the RNase protein family in artiodactyls (the mammal order that includes pig, camel, deer, sheep and ox)(5). The properties of the reconstructed proteins suggest that parsimony yields plausible ancient sequences. Going back in time, a significant change in behaviour, namely a fivefold increase in catalytic activity against double-stranded RNA, appears in the RNase reconstructed for the founding ancestor of the artiodactyl lineage, which lived about 40 million years ago(6). This corresponds to the period when ruminant digestion arose in the artiodactyls, suggests that contemporary artiodactyl digestive RNases arose from a non-digestive ancestor, and illustrates how evolutionary reconstructions can help in tbe understanding of physiological function within a protein family(7-9).			JERMANN, TM (corresponding author), ETH ZURICH,DEPT CHEM,CH-8092 ZURICH,SWITZERLAND.							ADEY NB, 1994, P NATL ACAD SCI USA, V91, P1569, DOI 10.1073/pnas.91.4.1569; ARDELT W, 1991, J BIOL CHEM, V266, P245; BARNARD EA, 1969, NATURE, V221, P340, DOI 10.1038/221340a0; BELNTEMA JJ, 1986, MOL BIOL EVOL, V3, P262; Blackburn P, 1982, ENZYMES, VXV, P317; BREUKELMAN HJ, 1993, J MOL EVOL, V37, P29; Carroll RL, 1988, VERTEBRATE PALEONTOL; CIGLIC M, 1994, THESIS ETH ZURICH; FITCH WM, 1971, SYST ZOOL, V20, P406, DOI 10.2307/2412116; GRAUR D, 1993, FEBS LETT, V325, P152, DOI 10.1016/0014-5793(93)81432-Y; HILLIS DM, 1994, SCIENCE, V264, P671, DOI 10.1126/science.8171318; Ipata P L., 1968, FEBS Lett, V1, P29, DOI 10.1016/0014-5793(68)80010-9; JOLLES J, 1989, J MOL EVOL, V28, P528, DOI 10.1007/BF02602933; LANG K, 1986, EUR J BIOCHEM, V159, P275, DOI 10.1111/j.1432-1033.1986.tb09864.x; LIBONATI M, 1969, EUR J BIOCHEM, V8, P81, DOI 10.1111/j.1432-1033.1969.tb00498.x; MALCOLM BA, 1990, NATURE, V345, P86, DOI 10.1038/345086a0; MATOUSEK J, 1973, EXPERIENTIA, V29, P858, DOI 10.1007/BF01946329; MCGEEHAN GM, 1989, FEBS LETT, V247, P55, DOI 10.1016/0014-5793(89)81239-6; NAMBIAR KP, 1984, SCIENCE, V223, P1299, DOI 10.1126/science.6322300; NAMBIAR KP, 1987, EUR J BIOCHEM, V163, P67, DOI 10.1111/j.1432-1033.1987.tb10737.x; OKABE Y, 1991, J BIOCHEM-TOKYO, V109, P786, DOI 10.1093/oxfordjournals.jbchem.a123457; PAULING I, 1963, ACTA CHEM SCAND S1, V17, pS9; ROSE KD, 1982, SCIENCE, V216, P621, DOI 10.1126/science.216.4546.621; SORRENTINO S, 1980, BIOCHIM BIOPHYS ACTA, V609, P40, DOI 10.1016/0005-2787(80)90199-9; SOUCEK J, 1986, NAT IMMUN CELL GROW, V5, P250; STACKHOUSE J, 1990, FEBS LETT, V262, P104, DOI 10.1016/0014-5793(90)80164-E; Stevens C.E., 1988, COMP PHYSL VERTEBRAT; STRYDOM DJ, 1985, BIOCHEMISTRY-US, V24, P5486, DOI 10.1021/bi00341a031; TRAUTWEIN K, 1991, SITE-DIRECTED MUTAGENESIS AND PROTEIN ENGINEERING, P53; WATANABE H, 1988, J BIOCHEM-TOKYO, V104, P939, DOI 10.1093/oxfordjournals.jbchem.a122587	30	184	190	0	21	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 2	1995	374	6517					57	59		10.1038/374057a0	http://dx.doi.org/10.1038/374057a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK079	7532788				2022-12-24	WOS:A1995QK07900050
J	SLATIN, SL; QIU, XQ; JAKES, KS; FINKELSTEIN, A				SLATIN, SL; QIU, XQ; JAKES, KS; FINKELSTEIN, A			IDENTIFICATION OF A TRANSLOCATED PROTEIN SEGMENT IN A VOLTAGE-DEPENDENT CHANNEL	NATURE			English	Article							COLICIN-E1 ION CHANNEL; PLANAR LIPID BILAYERS; HELICAL HAIRPIN; MEMBRANE; TOPOGRAPHY	VOLTAGE-GATED channels undergo a conformational change in response to changes in transmembrane voltage. Here we use site-directed biotinylation to create conformation-sensitive sites on colicin Ia, a bacteriocidal protein that forms a voltage-sensitive membrane channel, which can be monitored by electrophysiological methods(1,2). We investigated a model of gating developed for the partly homologous colicin E1 that is based on the insertion of regions of the protein into the membrane in response to cis-positive voltages(3-6). Site-directed cysteine mutagenesis, followed by chemical modification, was used to attach a biotin molecule covalently to a series of unique sites on colicin Ia. The modified protein was incorporated into planar lipid membranes, where the introduced biotin moiety served as a site to bind the water-soluble protein streptavidin, added to one side of the membrane or the other. Our results show that colicin gating is associated with the translocation across the membrane of a segment of the protein of at least 31 amino acids.			SLATIN, SL (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT PHYSIOL & BIOPHYS,BRONX,NY 10461, USA.							ABRAMS CK, 1991, J GEN PHYSIOL, V98, P77, DOI 10.1085/jgp.98.1.77; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; CRAMER WA, 1990, MOL MICROBIOL, V4, P519, DOI 10.1111/j.1365-2958.1990.tb00619.x; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; DUCHE D, 1994, J BIOL CHEM, V269, P6332; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; GREEN NM, 1971, BIOCHEM J, V125, P781, DOI 10.1042/bj1250781; LAKEY JH, 1993, J MOL BIOL, V230, P1055, DOI 10.1006/jmbi.1993.1218; MANKOVICH JA, 1986, J BACTERIOL, V168, P228, DOI 10.1128/jb.168.1.228-236.1986; MERRILL AR, 1990, BIOCHEMISTRY-US, V29, P8529, DOI 10.1021/bi00489a004; PALMER LR, 1994, J BIOL CHEM, V269, P4187; PARKER MW, 1989, NATURE, V337, P93, DOI 10.1038/337093a0; PATTUS F, 1990, EXPERIENTIA, V46, P180; QIU XQ, 1994, J BIOL CHEM, V269, P7483; SHIN YK, 1993, SCIENCE, V259, P960, DOI 10.1126/science.8382373; SLATIN SL, 1986, J MEMBRANE BIOL, V92, P247, DOI 10.1007/BF01869393; SLATIN SL, 1988, INT J BIOCHEM, V20, P737, DOI 10.1016/0020-711X(88)90058-4; SONG HY, 1991, J BACTERIOL, V173, P2927, DOI 10.1128/JB.173.9.2927-2934.1991; ZHANG YL, 1992, PROTEIN SCI, V1, P1666, DOI 10.1002/pro.5560011215	19	153	157	1	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 8	1994	371	6493					158	161		10.1038/371158a0	http://dx.doi.org/10.1038/371158a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PF191	7521016				2022-12-24	WOS:A1994PF19100064
J	WANG, H; LAMBOWITZ, AM				WANG, H; LAMBOWITZ, AM			THE MAURICEVILLE PLASMID REVERSE-TRANSCRIPTASE CAN INITIATE CDNA SYNTHESIS DE-NOVO AND MAY BE RELATED TO REVERSE-TRANSCRIPTASE AND DNA-POLYMERASE PROGENITOR	CELL			English	Article							RNA-LIKE STRUCTURES; MITOCHONDRIAL PLASMIDS; VIRUS RNA; 3' END; NEUROSPORA; ORIGIN; REPLICATION; EVOLUTION; SEQUENCE; ELEMENTS	We show that the reverse transcriptase (RT) encoded by the Mauriceville mitochondrial plasmid of Neurospora closely resembles viral RNA-dependent RNA polymerases in initiating cDNA synthesis opposite the penultimate C residue of a 3' tRNA-like structure and has the unprecedented ability for a DNA polymerase to initiate DNA synthesis at a specific site in a natural template without a primer. The Mauriceville plasmid enzyme can also use DNA or RNA primers in a manner suggesting how a primitive RT could have evolved from an RNA-dependent RNA polymerase into retroviral and other types of RTs. The characteristics of the Mauriceville plasmid RT suggest that it may be related to the progenitor of present-day RTs and DNA polymerases.	OHIO STATE UNIV,DEPT BIOCHEM,COLUMBUS,OH 43210; OHIO STATE UNIV,DEPT MED BIOCHEM,COLUMBUS,OH 43210; OHIO STATE UNIV,CTR BIOTECHNOL,COLUMBUS,OH 43210	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	WANG, H (corresponding author), OHIO STATE UNIV,DEPT MOLEC GENET,COLUMBUS,OH 43210, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037949] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37949] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKINS RA, 1988, J MOL BIOL, V204, P1, DOI 10.1016/0022-2836(88)90594-3; AKINS RA, 1989, MOL CELL BIOL, V9, P678, DOI 10.1128/MCB.9.2.678; AKINS RA, 1986, CELL, V47, P505, DOI 10.1016/0092-8674(86)90615-X; BARAT C, 1989, EMBO J, V8, P3279, DOI 10.1002/j.1460-2075.1989.tb08488.x; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BLUMENTHAL T, 1979, ANNU REV BIOCHEM, V48, P525, DOI 10.1146/annurev.bi.48.070179.002521; BRUCE AG, 1978, NUCLEIC ACIDS RES, V5, P3665, DOI 10.1093/nar/5.10.3665; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; COLLINS RA, 1981, CELL, V24, P443, DOI 10.1016/0092-8674(81)90335-4; DARNELL JE, 1986, P NATL ACAD SCI USA, V83, P1271, DOI 10.1073/pnas.83.5.1271; Davis R.H., 1970, 789 METHODS ENZYMOLO, VVolume 17, P79, DOI DOI 10.1016/0076-6879(71)17168-6; Deininger PL, 1989, MOBILE DNA, P619; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; Eickbush Thomas H., 1994, P121; FERAT JL, 1993, NATURE, V364, P358, DOI 10.1038/364358a0; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; GROSSHANS CA, 1991, NUCLEIC ACIDS RES, V19, P3875, DOI 10.1093/nar/19.14.3875; INOUYE M, 1991, ANNU REV MICROBIOL, V45, P163; KENNELL JC, 1993, CELL, V73, P133, DOI 10.1016/0092-8674(93)90166-N; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; Kornberg A., 1992, DNA REPLICATION; KUIPER MTR, 1988, CELL, V55, P693, DOI 10.1016/0092-8674(88)90228-0; KUIPER MTR, 1990, J BIOL CHEM, V265, P6936; Lambowitz A M, 1979, Methods Enzymol, V59, P421; LAMBOWITZ AM, 1993, ANNU REV BIOCHEM, V62, P587, DOI 10.1146/annurev.bi.62.070193.003103; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; MAIZELS N, 1993, IN PRESS RNA WORLD; MANS RMW, 1991, EUR J BIOCHEM, V201, P303, DOI 10.1111/j.1432-1033.1991.tb16288.x; MILLER WA, 1986, J MOL BIOL, V187, P537, DOI 10.1016/0022-2836(86)90332-3; NARGANG FE, 1984, CELL, V38, P441, DOI 10.1016/0092-8674(84)90499-9; PANET A, 1975, P NATL ACAD SCI USA, V72, P2535, DOI 10.1073/pnas.72.7.2535; RAO ALN, 1989, P NATL ACAD SCI USA, V86, P5335, DOI 10.1073/pnas.86.14.5335; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVILLE BJ, 1990, CELL, V61, P685, DOI 10.1016/0092-8674(90)90480-3; TEMIN HM, 1989, NATURE, V339, P254, DOI 10.1038/339254a0; TEMIN HM, 1980, CELL, V21, P599, DOI 10.1016/0092-8674(80)90420-1; TEMIN HM, 1970, PERSPECT BIOL MED, V14, P11; TESSIER DC, 1986, ANAL BIOCHEM, V158, P171, DOI 10.1016/0003-2697(86)90606-8; VARMUS H, 1989, MOBILE DNA, P53; WANG GH, 1992, CELL, V71, P663, DOI 10.1016/0092-8674(92)90599-8; WANG H, 1992, MOL CELL BIOL, V12, P5131, DOI 10.1128/MCB.12.11.5131; WANG H, 1993, J BIOL CHEM, V268, P18951; WEINER AM, 1987, P NATL ACAD SCI USA, V84, P7383, DOI 10.1073/pnas.84.21.7383; WINTERSBERGER U, 1987, TRENDS GENET, V3, P198, DOI 10.1016/0168-9525(87)90233-2; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x	45	82	84	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 17	1993	75	6					1071	1081		10.1016/0092-8674(93)90317-J	http://dx.doi.org/10.1016/0092-8674(93)90317-J			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MM893	7505202				2022-12-24	WOS:A1993MM89300006
J	KRISHNAN, SC; SHIVKUMAR, K; GARAN, H; RUSKIN, JN				KRISHNAN, SC; SHIVKUMAR, K; GARAN, H; RUSKIN, JN			INCREASED VULNERABILITY OF THE SUBENDOCARDIUM TO ISCHEMIC-INJURY - AN ELECTROPHYSIOLOGICAL EXPLANATION	LANCET			English	Note							MYOCARDIAL BLOOD-FLOW; CORONARY-ARTERY OCCLUSION; ISCHEMIC CELL-DEATH; INFARCT SIZE; VENTRICULAR WALL; COLLATERAL FLOW; DOG HEART; EPICARDIUM; PRESSURE; TENSION		HENRY FORD HOSP,DETROIT,MI 48202	Henry Ford Health System; Henry Ford Hospital	KRISHNAN, SC (corresponding author), MASSACHUSETTS GEN HOSP,DEPT MED,CARDIAC UNIT,BOSTON,MA 02114, USA.		Shivkumar, Kalyanam/AAI-1085-2019	Shivkumar, Kalyanam/0000-0002-4121-1766				ALLEN DG, 1989, J PHYSIOL-LONDON, V410, P297, DOI 10.1113/jphysiol.1989.sp017534; ANTZELEVITCH C, 1991, CIRC RES, V69, P1427, DOI 10.1161/01.RES.69.6.1427; AUCHAMPACH JA, 1991, J PHARMACOL EXP THER, V259, P961; CAMICI P, 1984, BASIC RES CARDIOL, V79, P454, DOI 10.1007/BF01908146; DIDIEGO JM, 1993, CIRCULATION, V88, P1177, DOI 10.1161/01.CIR.88.3.1177; DOWNAR E, 1977, CIRCULATION, V56, P217, DOI 10.1161/01.CIR.56.2.217; ENG C, 1987, J AM COLL CARDIOL, V9, P374, DOI 10.1016/S0735-1097(87)80391-1; FUKUNAMI M, 1987, Canadian Journal of Cardiology, V3, P94; GAMBLE WJ, 1974, CIRC RES, V34, P672, DOI 10.1161/01.RES.34.5.672; GETTES LS, 1992, HEART CARDIOVASCULAR, P2021; GOLDNER MG, 1971, J AMER MED ASSOC, V218, P1400, DOI 10.1001/jama.218.9.1400; GRIGGS DM, 1972, AM J PHYSIOL, V222, P705; HOMANS DC, 1988, CIRCULATION, V78, P1267, DOI 10.1161/01.CIR.78.5.1267; HORN H, 1950, AM HEART J, V40, P63, DOI 10.1016/0002-8703(50)90150-5; KIMURA S, 1986, CIRCULATION, V74, P401, DOI 10.1161/01.CIR.74.2.401; KIRK ES, 1964, AM J PHYSIOL, V207, P361, DOI 10.1152/ajplegacy.1964.207.2.361; KLEBER AG, 1984, J MOL CELL CARDIOL, V16, P389, DOI 10.1016/S0022-2828(84)80610-0; KRISHNAN SC, 1991, CIRC RES, V69, P277, DOI 10.1161/01.RES.69.2.277; Krishnan Subramaniam, 1993, Journal of the American College of Cardiology, V21, p220A; LANGER GA, 1987, WESTERN J MED, V146, P713; LEE JT, 1981, CIRCULATION, V64, P526, DOI 10.1161/01.CIR.64.3.526; LOWE JE, 1983, CIRCULATION, V68, P190, DOI 10.1161/01.CIR.68.1.190; MARQUIS RM, 1955, BRIT HEART J, V17, P373; MASTER AM, 1950, CIRCULATION, V1, P1302, DOI 10.1161/01.CIR.1.6.1302; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; OPIE LH, 1993, CARDIOVASC DRUG THER, V7, P507, DOI 10.1007/BF00877615; PATH G, 1990, CIRC RES, V67, P660, DOI 10.1161/01.RES.67.3.660; REIMER KA, 1977, CIRCULATION, V56, P786, DOI 10.1161/01.CIR.56.5.786; RIVAS F, 1976, CIRC RES, V38, P439, DOI 10.1161/01.RES.38.5.439; RUBIO R, 1975, PROG CARDIOVASC DIS, V18, P105, DOI 10.1016/0033-0620(75)90001-8; RUFFY R, 1979, CIRC RES, V45, P764, DOI 10.1161/01.RES.45.6.764; SABBAH HN, 1982, AM J PHYSIOL, V242, pH240, DOI 10.1152/ajpheart.1982.242.2.H240; SEDEK G, 1986, BASIC RES CARDIOL, V81, P219; STEIN PD, 1980, AM J PHYSIOL, V238, pH625, DOI 10.1152/ajpheart.1980.238.5.H625; WEINTRAUB WS, 1981, CIRC RES, V48, P430, DOI 10.1161/01.RES.48.3.430; WEISS HR, 1978, CIRC RES, V42, P394, DOI 10.1161/01.RES.42.3.394; WETTWER E, 1994, CIRC RES, V75, P473, DOI 10.1161/01.RES.75.3.473; WHITE FC, 1981, BASIC RES CARDIOL, V76, P189, DOI 10.1007/BF01907957	38	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 16	1995	346	8990					1612	1614		10.1016/S0140-6736(95)91936-8	http://dx.doi.org/10.1016/S0140-6736(95)91936-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK481	7500758	Bronze			2022-12-24	WOS:A1995TK48100017
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PROPOSED RULE RESTRICTING SALE OF TOBACCO PRODUCTS TO CHILDREN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1995, FED REG         0811, V60, P41313	1	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 11	1995	274	14					1109	1109						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY056	7563473				2022-12-24	WOS:A1995RY05600007
J	BARUCH, DI; PASLOSKE, BL; SINGH, HB; BI, XH; MA, XC; FELDMAN, M; TARASCHI, TF; HOWARD, RJ				BARUCH, DI; PASLOSKE, BL; SINGH, HB; BI, XH; MA, XC; FELDMAN, M; TARASCHI, TF; HOWARD, RJ			CLONING THE PLASMODIUM-FALCIPARUM GENE ENCODING PFEMP1, A MALARIAL VARIANT ANTIGEN AND ADHERENCE RECEPTOR ON THE SURFACE OF PARASITIZED HUMAN ERYTHROCYTES	CELL			English	Article							PLASMODIUM-FALCIPARUM; INFECTED ERYTHROCYTES; MEMBRANE; EXPRESSION; PROTEINS; CELLS; CD36; SEQUESTRATION; ASSOCIATION; PHENOTYPES	Plasmodium falciparum-infected human erythrocytes evade host immunity by expression of a cell-surface variant antigen and receptors for adherence to endothelial cells. These properties have been ascribed to P. falciparum erythrocyte membrane protein 1 (PfEMP1), an antigenically diverse malarial protein of 200-350 kDa on the surface of parasitized erythrocytes (PEs). We describe the cloning of two related PfEMP1 genes from the Malayan Camp (MC) parasite strain. Antibodies generated against recombinant protein fragments of the genes were specific for MC strain PfEMP1 protein. These antibodies reacted only with the surface of MC strain PEs and blocked adherence of these cells to CD36 but without effect on adherence to thrombospondin. Multiple forms of the PfEMP1 gene are apparent in MC parasites. The molecular basis for antigenic variation in malaria and adherence of infected erythrocytes to host cells can now be pursued.	AFFYMAX RES INST, SANTA CLARA, CA 95051 USA; JEFFERSON MED COLL, DEPT PATHOL ANAT & CELL BIOL, PHILADELPHIA, PA 19107 USA	Jefferson University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027247, R22AI027247] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 27247] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGUIAR JC, 1992, AM J TROP MED HYG, V47, P621; ALEY SB, 1984, J EXP MED, V160, P1585, DOI 10.1084/jem.160.5.1585; [Anonymous], REFORMA MED; BARNWELL JW, 1983, INFECT IMMUN, V40, P985, DOI 10.1128/IAI.40.3.985-994.1983; BIGGS BA, 1992, J IMMUNOL, V149, P2047; BRANNAN LR, 1994, P ROY SOC B-BIOL SCI, V256, P71, DOI 10.1098/rspb.1994.0051; BROWN KN, 1965, NATURE, V208, P1286, DOI 10.1038/2081286a0; CHITNIS CE, 1994, J EXP MED, V180, P497, DOI 10.1084/jem.180.2.497; ELLIOTT JF, 1990, P NATL ACAD SCI USA, V87, P6363, DOI 10.1073/pnas.87.16.6363; GIBBONS IR, 1991, P NATL ACAD SCI USA, V88, P8563, DOI 10.1073/pnas.88.19.8563; GILKS CF, 1990, PARASITE IMMUNOL, V12, P45, DOI 10.1111/j.1365-3024.1990.tb00935.x; GORMLEY JA, 1992, J CELL BIOL, V119, P1481, DOI 10.1083/jcb.119.6.1481; HANDUNNETTI SM, 1992, AM J TROP MED HYG, V46, P371, DOI 10.4269/ajtmh.1992.46.371; HANDUNNETTI SM, 1987, J EXP MED, V165, P1269, DOI 10.1084/jem.165.5.1269; HASLER T, 1993, AM J TROP MED HYG, V48, P332, DOI 10.4269/ajtmh.1993.48.332; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOMMEL M, 1983, J EXP MED, V157, P1137, DOI 10.1084/jem.157.4.1137; HOWARD RJ, 1989, BLOOD, V74, P2603; HOWARD RJ, 1988, MOL BIOCHEM PARASIT, V27, P207, DOI 10.1016/0166-6851(88)90040-0; Kuhn K, 1994, Trends Cell Biol, V4, P256, DOI 10.1016/0962-8924(94)90124-4; KUTNER S, 1985, J CELL PHYSIOL, V125, P521, DOI 10.1002/jcp.1041250323; LEECH JH, 1984, J CELL BIOL, V98, P1256, DOI 10.1083/jcb.98.4.1256; LEECH JH, 1984, J EXP MED, V159, P1567, DOI 10.1084/jem.159.6.1567; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; MARSH K, 1986, SCIENCE, V231, P150, DOI 10.1126/science.2417315; MENDIS KN, 1988, AM J TROP MED HYG, V38, P42, DOI 10.4269/ajtmh.1988.38.42; MILLER LH, 1969, AM J TROP MED HYG, V18, P860, DOI 10.4269/ajtmh.1969.18.860; MILLER LH, 1994, SCIENCE, V264, P1878, DOI 10.1126/science.8009217; NAKAMURA KI, 1992, J HISTOCHEM CYTOCHEM, V40, P1419, DOI 10.1177/40.9.1380530; OCKENHOUSE CF, 1991, J INFECT DIS, V164, P163, DOI 10.1093/infdis/164.1.163; PASLOSKE BL, 1993, MOL BIOCHEM PARASIT, V59, P59, DOI 10.1016/0166-6851(93)90007-K; PASLOSKE BL, 1994, ANNU REV MED, V45, P283; PATNAIK JK, 1994, AM J TROP MED HYG, V51, P642, DOI 10.4269/ajtmh.1994.51.642; ROBERTS DJ, 1992, NATURE, V357, P689, DOI 10.1038/357689a0; SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X; SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1; UDEINYA IJ, 1981, SCIENCE, V213, P555, DOI 10.1126/science.7017935; VANSCHRAVENDIJK MR, 1993, AM J TROP MED HYG, V49, P552, DOI 10.4269/ajtmh.1993.49.552; VANSCHRAVENDIJK MR, 1991, BLOOD, V78, P226	39	843	853	0	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 14	1995	82	1					77	87		10.1016/0092-8674(95)90054-3	http://dx.doi.org/10.1016/0092-8674(95)90054-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RK424	7541722	Bronze			2022-12-24	WOS:A1995RK42400011
J	JIA, ZC; BARFORD, D; FLINT, AJ; TONKS, NK				JIA, ZC; BARFORD, D; FLINT, AJ; TONKS, NK			STRUCTURAL BASIS FOR PHOSPHOTYROSINE PEPTIDE RECOGNITION BY PROTEIN-TYROSINE-PHOSPHATASE 1B	SCIENCE			English	Article							HUMAN-PLACENTA; MAP KINASE; SPECIFICITY; PHOSPHORYLATION; PURIFICATION; DOMAIN; LAR	The crystal structures of a cysteine-215 --> serine mutant of protein tyrosine phosphatase 1B complexed with high-affinity peptide substrates corresponding to an autophosphorylation site of the epidermal growth factor receptor were determined. Peptide binding to the protein phosphatase was accompanied by a conformational change of a surface loop that created a phosphotyrosine recognition pocket and induced a catalytically competent form of the enzyme. The phosphotyrosine side chain is buried within the protein and anchors the peptide substrate to its binding site. Hydrogen bonds between peptide main-chain atoms and the protein contribute to binding affinity, and specific interactions of acidic residues of the peptide with basic residues on the surface of the enzyme confer sequence specificity.	UNIV OXFORD, MOLEC BIOPHYS LAB, OXFORD OX1 3QU, ENGLAND; COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA	University of Oxford; Cold Spring Harbor Laboratory					NATIONAL CANCER INSTITUTE [R37CA053840, R01CA053840] Funding Source: NIH RePORTER; NCI NIH HHS [CA53840] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Wellcome Trust(Wellcome TrustEuropean Commission)		ALESSI DR, 1993, ONCOGENE, V8, P2015; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BARFORD D, 1994, J MOL BIOL, V239, P726, DOI 10.1006/jmbi.1994.1409; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BRUNGER AT, 1993, XPLOR; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHO HJ, 1993, PROTEIN SCI, V2, P977, DOI 10.1002/pro.5560020611; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FLINT AJ, 1993, EMBO J, V12, P1937, DOI 10.1002/j.1460-2075.1993.tb05843.x; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HIPPEN KL, 1993, BIOCHEMISTRY-US, V32, P12405, DOI 10.1021/bi00097a019; JIA ZF, UNPUB; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; LOGAN TM, 1994, BIOCHEMISTRY-US, V33, P11087, DOI 10.1021/bi00203a005; Madhusudan Elzbieta A. Trafny, 1994, Protein Science, V3, P176; MILLAR JBA, 1992, CELL, V68, P407, DOI 10.1016/0092-8674(92)90177-E; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PALLEN CJ, 1991, BIOCHEM J, V276, P315, DOI 10.1042/bj2760315; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PINNA LA, 1994, BBA-MOL CELL RES, V1222, P415, DOI 10.1016/0167-4889(94)90050-7; POT DA, 1992, J AM CHEM SOC, V114, P7296; RUZZENE M, 1993, EUR J BIOCHEM, V211, P289, DOI 10.1111/j.1432-1033.1993.tb19897.x; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; SU XD, 1994, NATURE, V370, P575, DOI 10.1038/370575a0; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TADDEI N, 1994, FEBS LETT, V350, P328, DOI 10.1016/0014-5793(94)00805-1; Tonks N K, 1993, Semin Cell Biol, V4, P373, DOI 10.1006/scel.1993.1044; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; ZHANG M, 1994, BIOCHEMISTRY-US, V33, P11097, DOI 10.1021/bi00203a006; ZHANG ZT, 1994, J BIOL CHEM, V269, P25947; ZHANG ZY, 1993, P NATL ACAD SCI USA, V90, P4446, DOI 10.1073/pnas.90.10.4446; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P2285, DOI 10.1021/bi00174a040; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624; [No title captured]	47	532	545	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 23	1995	268	5218					1754	1758		10.1126/science.7540771	http://dx.doi.org/10.1126/science.7540771			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RE668	7540771				2022-12-24	WOS:A1995RE66800043
J	AULD, VJ; FETTER, RD; BROADIE, K; GOODMAN, CS				AULD, VJ; FETTER, RD; BROADIE, K; GOODMAN, CS			GLIOTACTIN, A NOVEL TRANSMEMBRANE PROTEIN ON PERIPHERAL GLIA, IS REQUIRED TO FORM THE BLOOD-NERVE BARRIER IN DROSOPHILA	CELL			English	Article							CELL-ADHESION; MOLECULAR-GENETICS; SERINE ESTERASES; RUTHENIUM RED; MELANOGASTER; GLYCOPROTEIN; EXPRESSION; MUSCLES; CLONING; AXON	Peripheral glia help ensure that motor and sensory axons are bathed in the appropriate ionic and biochemical environment. In Drosophila, peripheral glia help shield these axons against the high K+ concentration of the hemolymph, which would largely abolish their excitability. Here, we describe the molecular genetic analysis of gliotactin, a novel transmembrane protein that is transiently expressed on peripheral glia and that is required for the formation of the peripheral blood-nerve barrier, In gliotactin mutant embryos, the peripheral glia develop normally in many respects, except that ultrastructurally and physiologically they do not form a complete blood-nerve barrier. As a result, peripheral motor axons are exposed to the high K+ hemolymph, action potentials fail to propagate, and the embryos are nearly paralyzed.	UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, DEPT MOLEC & CELL BIOL, DIV NEUROBIOL, BERKELEY, CA 94720 USA; UNIV CAMBRIDGE, DEPT ZOOL, CAMBRIDGE CB2 3EJ, ENGLAND	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of Cambridge				Auld, Vanessa/0000-0003-3976-9186	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ASHBURNER M, 1989, DROSOPHILA LABORATOR; ATWOOD HL, 1993, J NEUROBIOL, V24, P1008, DOI 10.1002/neu.480240803; BARTHALAY Y, 1990, EMBO J, V9, P3603, DOI 10.1002/j.1460-2075.1990.tb07571.x; BATE M, 1990, DEVELOPMENT, V110, P791; BROADIE KS, 1993, J NEUROSCI, V13, P144; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; CAMPBELL G, 1994, DEVELOPMENT, V120, P2957; Doyle JP, 1993, CURR OPIN CELL BIOL, V5, P779, DOI 10.1016/0955-0674(93)90025-L; FUJITA SC, 1982, P NATL ACAD SCI-BIOL, V79, P7929, DOI 10.1073/pnas.79.24.7929; GRENNINGLOH G, 1990, COLD SH Q B, V55, P327; GROSSMAN Y, 1979, J PHYSIOL-LONDON, V295, P307, DOI 10.1113/jphysiol.1979.sp012970; HALL LMC, 1986, EMBO J, V5, P2949, DOI 10.1002/j.1460-2075.1986.tb04591.x; HORTSCH M, 1990, DEVELOPMENT, V110, P1327; HULTMARK D, 1986, CELL, V44, P429, DOI 10.1016/0092-8674(86)90464-2; KLAMBT C, 1991, CELL, V64, P801, DOI 10.1016/0092-8674(91)90509-W; KLAMBT C, 1991, GLIA, V4, P205, DOI 10.1002/glia.440040212; KOCSIS JD, 1983, J PHYSIOL-LONDON, V334, P225, DOI 10.1113/jphysiol.1983.sp014491; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; KOPCZYNSKI CC, 1992, J CELL BIOL, V119, P503, DOI 10.1083/jcb.119.3.503; LANE NJ, 1975, J CELL SCI, V18, P179; LEMKE G, 1993, GLIA, V7, P263, DOI 10.1002/glia.440070402; LONG RM, 1991, LIFE SCI, V48, P43; LUFT JH, 1971, ANAT RECORD, V171, P369, DOI 10.1002/ar.1091710303; LUFT JH, 1971, ANAT REC, V171, P347, DOI 10.1002/ar.1091710302; MACPHEEQUIGLEY K, 1985, J BIOL CHEM, V260, P2185; Maniatis T., 1982, MOL CLONING; Manning Gerards, 1993, P609; MESSING A, 1992, NEURON, V8, P507, DOI 10.1016/0896-6273(92)90279-M; NOSE A, 1992, CELL, V70, P553, DOI 10.1016/0092-8674(92)90426-D; OLSON PF, 1990, EMBO J, V9, P1219, DOI 10.1002/j.1460-2075.1990.tb08229.x; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; ROBERTSON HM, 1988, GENETICS, V118, P461; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sato T, 1968, J Electron Microsc (Tokyo), V17, P158; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SOREQ H, 1990, P NATL ACAD SCI USA, V87, P9688, DOI 10.1073/pnas.87.24.9688; TEPASS U, 1993, DEV BIOL, V159, P311, DOI 10.1006/dbio.1993.1243; Treherne J.E., 1972, Advances Insect Physiol, V9, P257, DOI 10.1016/S0065-2806(08)60278-7; ZINN K, 1988, CELL, V53, P577, DOI 10.1016/0092-8674(88)90574-0	39	223	228	0	1	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 2	1995	81	5					757	767		10.1016/0092-8674(95)90537-5	http://dx.doi.org/10.1016/0092-8674(95)90537-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RB961	7539719	Bronze			2022-12-24	WOS:A1995RB96100014
J	COGHLAN, VM; PERRINO, BA; HOWARD, M; LANGEBERG, LK; HICKS, JB; GALLATIN, WM; SCOTT, JD				COGHLAN, VM; PERRINO, BA; HOWARD, M; LANGEBERG, LK; HICKS, JB; GALLATIN, WM; SCOTT, JD			ASSOCIATION OF PROTEIN-KINASE-A AND PROTEIN-PHOSPHATASE-2B WITH A COMMON ANCHORING PROTEIN	SCIENCE			English	Article							HIGH-AFFINITY BINDING; REGULATORY SUBUNIT RII; IMMUNOCYTOCHEMICAL LOCALIZATION; POSTSYNAPTIC DENSITIES; CATALYTIC SUBUNIT; CALCINEURIN-A; RAT-BRAIN; II-BETA; CALMODULIN; PHOSPHORYLATION	Specificity of protein kinases and phosphatases may be achieved through compartmentalization with preferred substrates. In neurons, adenosine 3',5'-monophosphate (cAMP)-dependent protein kinase (PKA) is localized at postsynaptic densities by association of its regulatory subunit with an A kinase anchor protein, AKAP79. Interaction cloning experiments demonstrated that AKAP79 also binds protein phosphatase 2B, or calcineurin (CaN). A ternary complex of PKA, AKAP, and CaN was isolated from bovine brain, and colocalization of the kinase and the phosphatase was established in neurites of cultured hippocampal neurons. The putative CaN-binding domain of AKAP79 is similar to that of the immunophilin FKBP-12, and AKAP79 inhibited CaN phosphatase activity. These results suggest that both PKA and CaN are targeted to subcellular sites by association with a common anchor protein and thereby regulate the phosphorylation state of key neuronal substrates.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201; ICOS CORP,BOTHELL,WA 98021	Oregon Health & Science University; Icos Corporation					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009059] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048231, R37GM048231] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK09059] Funding Source: Medline; NIGMS NIH HHS [GM48231] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALDAPE RA, 1992, J BIOL CHEM, V267, P16029; BRAUTIGAN DL, 1994, RECENT PROG HORM RES, V49, P197; BREGMAN DB, 1991, J BIOL CHEM, V266, P7207; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; CARR DW, 1992, J BIOL CHEM, V267, P16816; CARR DW, 1992, J BIOL CHEM, V267, P13376; CARR DW, 1991, J BIOL CHEM, V266, P14188; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; COGHLAN VM, 1993, MOL CELL BIOCHEM, V128, P309, DOI 10.1007/BF01076780; COGHLAN VM, 1994, J BIOL CHEM, V269, P7658; COGHLAN VM, THESIS; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; GRAB DJ, 1979, J BIOL CHEM, V254, P8690; HARLOW E, 1988, ANTIBODIES LABORATOR, P421; HATHAWAY DR, 1981, J BIOL CHEM, V256, P8183; HEMMINGS HC, 1989, FASEB J, V3, P1583, DOI 10.1096/fasebj.3.5.2493406; HIRSCH AH, 1992, J BIOL CHEM, V267, P2131; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; KOFRON JL, 1991, BIOCHEMISTRY-US, V30, P6127, DOI 10.1021/bi00239a007; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; KUNO T, 1989, BIOCHEM BIOPH RES CO, V165, P1352, DOI 10.1016/0006-291X(89)92752-6; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LOHMANN SM, 1984, P NATL ACAD SCI-BIOL, V81, P6723, DOI 10.1073/pnas.81.21.6723; LUDVIG N, 1990, BRAIN RES, V520, P90, DOI 10.1016/0006-8993(90)91694-C; PERRINO BA, 1992, J BIOL CHEM, V267, P15965; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; SCOTT JD, 1985, P NATL ACAD SCI USA, V82, P4379, DOI 10.1073/pnas.82.13.4379; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; Stemmer P, 1991, Curr Opin Neurobiol, V1, P53, DOI 10.1016/0959-4388(91)90010-5; WOOD JG, 1980, J CELL BIOL, V84, P66, DOI 10.1083/jcb.84.1.66	32	498	516	2	12	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 6	1995	267	5194					108	111		10.1126/science.7528941	http://dx.doi.org/10.1126/science.7528941			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA235	7528941				2022-12-24	WOS:A1995QA23500041
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PSA TEST IS APPROVED FOR USE IN CONJUNCTION WITH DIGITAL RECTAL EXAMINATION AS AID IN PROSTATE-CANCER DETECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 19	1994	272	15					1160	1160		10.1001/jama.272.15.1160	http://dx.doi.org/10.1001/jama.272.15.1160			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL212	7523738				2022-12-24	WOS:A1994PL21200008
J	NILSSON, M; MALMGREN, H; SAMIOTAKI, M; KWIATKOWSKI, M; CHOWDHARY, BP; LANDEGREN, U				NILSSON, M; MALMGREN, H; SAMIOTAKI, M; KWIATKOWSKI, M; CHOWDHARY, BP; LANDEGREN, U			PADLOCK PROBES - CIRCULARIZING OLIGONUCLEOTIDES FOR LOCALIZED DNA DETECTION	SCIENCE			English	Article							ALPHA-SATELLITE DNA; LIGASE; HYBRIDIZATION; GENE	Nucleotide sequence information derived from DNA segments of the human and other genomes is accumulating rapidly. However, it frequently proves difficult to use such short DNA segments to identify clones in genomic libraries or fragments in blots of the whole genome or for in situ analysis of chromosomes. Oligonucleotide probes, consisting of two target-complementary segments, connected by a linker sequence, were designed. Upon recognition of the specific nucleic acid molecule the ends of the probes were joined through the action of a ligase, creating circular DNA molecules catenated to the target sequence. These probes thus provide highly specific detection with minimal background.	BIOMED CTR,DEPT MED GENET,BEIJER LAB,S-75123 UPPSALA,SWEDEN; SWEDISH UNIV AGR SCI,DEPT ANIM BREEDING & GENET,S-75007 UPPSALA,SWEDEN	Swedish University of Agricultural Sciences			Landegren, Ulf D/A-8197-2019; Samiotaki, Martina/B-3851-2018	Samiotaki, Martina/0000-0001-9952-0636; Nilsson, Mats/0000-0001-9985-0387				ALVES AM, 1988, NUCLEIC ACIDS RES, V16, P8723, DOI 10.1093/nar/16.17.8723; BALDINI A, 1990, AM J HUM GENET, V46, P784; BARANY F, 1991, P NATL ACAD SCI USA, V88, P189, DOI 10.1073/pnas.88.1.189; DOLINNAYA NG, 1993, NUCLEIC ACIDS RES, V21, P5403, DOI 10.1093/nar/21.23.5403; Higgins N P, 1979, Methods Enzymol, V68, P50; JASCHKE A, 1993, TETRAHEDRON LETT, V34, P301, DOI 10.1016/S0040-4039(00)60572-5; LANDEGREN U, 1988, SCIENCE, V241, P1077, DOI 10.1126/science.3413476; Maniatis T., 1982, MOL CLONING; MATERA AG, 1992, HUM MOL GENET, V1, P535, DOI 10.1093/hmg/1.7.535; Nilsson M., UNPUB; PINKEL D, 1988, P NATL ACAD SCI USA, V85, P9138, DOI 10.1073/pnas.85.23.9138; PRAKASH G, 1992, J AM CHEM SOC, V114, P3523, DOI 10.1021/ja00035a056; RIORDAN JR, 1989, SCIENCE, V245, P1066; SUND C, 1988, NUCLEOS NUCLEOT, V7, P655, DOI 10.1080/07328318808056303; WILLARD HF, 1987, TRENDS GENET, V3, P192, DOI 10.1016/0168-9525(87)90232-0; WU DY, 1989, GENE, V76, P245, DOI 10.1016/0378-1119(89)90165-0	16	548	712	10	130	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 30	1994	265	5181					2085	2088		10.1126/science.7522346	http://dx.doi.org/10.1126/science.7522346			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PJ912	7522346				2022-12-24	WOS:A1994PJ91200027
J	PRUKSAKORN, S; CURRIE, B; BRANDT, E; MARTIN, D; GALBRAITH, A; PHORNPHUTKUL, C; HUNSAKUNACHAI, S; MANMONTRI, A; GOOD, MF				PRUKSAKORN, S; CURRIE, B; BRANDT, E; MARTIN, D; GALBRAITH, A; PHORNPHUTKUL, C; HUNSAKUNACHAI, S; MANMONTRI, A; GOOD, MF			TOWARDS A VACCINE FOR RHEUMATIC-FEVER - IDENTIFICATION OF A CONSERVED TARGET EPITOPE ON M-PROTEIN OF GROUP-A STREPTOCOCCI	LANCET			English	Article							GROUP-A STREPTOCOCCI; NUCLEOTIDE-SEQUENCE; PROTECTIVE IMMUNOGENICITY; MUCOSAL COLONIZATION; SYNTHETIC PEPTIDE; HEART-DISEASE; TYPE-5; IMMUNIZATION; SPECIFICITY; FRAGMENT	Rheumatic fever and rheumatic heart disease remain very common in developing countries, and a vaccine to protect against these disorders would have a great impact on public health. A vaccine must target the M protein of group A streptococci (Streptococcus pyogenes), but until lately immunity was thought to be strain-specific and dependent on antibodies to the variable serotype-specific regions of the protein. Experiments in animals have suggested the conserved region of the M protein as a possible alternative target for protective antibodies. We constructed a 20-aminoacid peptide (peptide 145) within the conserved region of the carboxyl terminus of the protein. In mice the peptide induced serum antibodies that could opsonise reference type 5 streptococci. By enzyme-linked immunosorbent assay, positive responses to peptide 145 were obtained with serum from 77 (90%) of 86 Aboriginal subjects and 135 (81%) of 167 Thai subjects living in areas with high exposure to streptococci. Only 10 (14%) of 71 Caucasian subjects with low exposure to streptococci showed positive responses. There was no difference in the proportion positive between subjects with rheumatic heart disease and control groups (other or no heart disease). Antibodies to peptide 145 were able to opsonise isolates of streptococci from Aboriginal and Thai subjects with acute rheumatic fever as well as reference strains. This highly conserved part of the M protein may be a suitable target for vaccines to prevent steptococcal infections and their sequelae.	QUEENSLAND INST MED RES,MOLEC IMMUNOL LAB,BRISBANE,QLD 4029,AUSTRALIA; MENZIES SCH HLTH RES,CASUARINA,NT,AUSTRALIA; INST ENVIRONM SCI & RES LTD,WELLINGTON,NEW ZEALAND; PRINCE CHARLES HOSP,BRISBANE,QLD 4032,AUSTRALIA; CHIANG MAI UNIV,DEPT PEDIAT,CHIANG MAI 50000,THAILAND; CHIANG MAI UNIV,DEPT MED,CHIANG MAI 50000,THAILAND	QIMR Berghofer Medical Research Institute; Charles Darwin University; Menzies School of Health Research; Institute of Environmental Science & Research (ESR) - New Zealand; Prince Charles Hospital; Chiang Mai University; Chiang Mai University								BEACHEY EH, 1984, P NATL ACAD SCI-BIOL, V81, P2203, DOI 10.1073/pnas.81.7.2203; BEACHEY EH, 1981, NATURE, V292, P457, DOI 10.1038/292457a0; BEACHEY EH, 1986, J IMMUNOL, V136, P2287; BEACHEY EH, 1987, J EXP MED, V166, P647, DOI 10.1084/jem.166.3.647; BEACHEY EH, 1973, INFECT IMMUN, V8, P19, DOI 10.1128/IAI.8.1.19-24.1973; BEACHEY EH, 1988, VACCINE, V6, P192, DOI 10.1016/S0264-410X(88)80027-6; BEACHEY EH, 1979, J EXP MED, V150, P862, DOI 10.1084/jem.150.4.862; BESSEN D, 1990, J IMMUNOL, V145, P1251; BESSEN D, 1988, INFECT IMMUN, V56, P2666, DOI 10.1128/IAI.56.10.2666-2672.1988; BRENNAN RE, 1990, MED J AUSTRALIA, V153, P335, DOI 10.5694/j.1326-5377.1990.tb136942.x; COLIGAN JE, 1992, CURRENT PROTOCOLS IM, V2; CURRIE B, 1993, MED J AUSTRALIA, V153, P609; DALE JB, 1986, J EXP MED, V163, P1191, DOI 10.1084/jem.163.5.1191; DALE JB, 1983, J EXP MED, V158, P1727, DOI 10.1084/jem.158.5.1727; Devanesen D, 1986, HLTH INDICATORS NO T; HOLLINGSHEAD SK, 1986, J BIOL CHEM, V261, P1677; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; JOSE DG, 1969, AUST PAEDIATR J, V5, P209; LANCEFIELD RC, 1957, J EXP MED, V106, P525, DOI 10.1084/jem.106.4.525; MACDONALD KT, 1989, MED J AUSTRALIA, V150, P503, DOI 10.5694/j.1326-5377.1989.tb136596.x; MARTIN DR, 1983, NEW ZEAL MED J, V96, P298; MILLER L, 1988, J BIOL CHEM, V263, P5668; MOUW AR, 1988, J BACTERIOL, V170, P676, DOI 10.1128/jb.170.2.676-684.1988; PHORNPHUTKUL C, 1981, CHIANG MAI MED B, V23, P275; PRUKSAKORN S, 1992, J IMMUNOL, V149, P2729; PRUKSAKORN S, 1990, CHIANG MAI MED B, V29, P15; RELF WA, 1992, J CLIN MICROBIOL, V30, P3190, DOI 10.1128/JCM.30.12.3190-3194.1992; ROBINSON JH, 1992, IMMUNOL TODAY, V13, P362, DOI 10.1016/0167-5699(92)90173-5; Shulman ST, 1984, CIRCULATION, V69, p203A; VEASY LG, 1987, NEW ENGL J MED, V316, P421, DOI 10.1056/NEJM198702193160801; 1992, B WORLD HEALTH ORGAN, V70, P213	31	72	79	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 3	1994	344	8923					639	642		10.1016/S0140-6736(94)92083-4	http://dx.doi.org/10.1016/S0140-6736(94)92083-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE386	7520963				2022-12-24	WOS:A1994PE38600008
J	DONNELLY, SC; HASLETT, C; DRANSFIELD, I; ROBERTSON, CE; CARTER, DC; ROSS, JA; GRANT, IS; TEDDER, TF				DONNELLY, SC; HASLETT, C; DRANSFIELD, I; ROBERTSON, CE; CARTER, DC; ROSS, JA; GRANT, IS; TEDDER, TF			ROLE OF SELECTINS IN DEVELOPMENT OF ADULT-RESPIRATORY-DISTRESS-SYNDROME	LANCET			English	Article							LEUKOCYTE ADHESION MOLECULE-1; ENDOTHELIAL-CELLS; LUNG INJURY; SUPERNATANTS; NEUTROPHILS; RISK	The acute lung injury of adult respiratory distress syndrome (ARDS) is characterised by inflammatory cell accumulation and activation in the lung. Selectins are a family of adhesion molecules implicated in leucocyte-endothelial adhesion, whose receptors can exist in a cleaved, soluble form. We investigated whether circulating soluble selectin adhesion molecules, obtained from ARDS at-risk patients, were associated with subsequent ARDS development. 82 patients, at risk of ARDS, were enrolled from three well-defined groups (multiple trauma, pancreatitis, perforated bowel). Plasma samples were obtained on hospital presentation and soluble L, E, and P, selectins were quantified with a sandwich enzyme-linked immunosorbent assay (ELISA). 14 patients subsequently developed ARDS. Initial plasma soluble L-selectin (sL-selectin) levels were significantly lower in patients who progressed to ARDS compared to those who did not (p = 0.0001; 95% Cl for mean in ARDS patients as percent of that in non-ARDS patients, 27-61%). Moreover concentrations were lower than in 62 normal volunteers (range 0.37-6.55, median 1.83 mu g/mL, n = 62), suggesting that a selective reduction of sL-selectin correlates with susceptibility. In addition, a significant correlation was found between low values of sL-selectin and indices of subsequent lung injury including requirement for ventilation (p = 0.0001) and degree of respiratory failure (p = 0.0001). A significant correlation was also found between low values of sL-selectin and patient mortality(p = 0.002). These results elucidate the inflammatory cell endothelial interactions in the early stages of ARDS and may be of prognostic value.	UNIV EDINBURGH,RAYNE LAB,RESP MED UNIT,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND; ROYAL INFIRM,DEPT ACCID & EMERGENCY,EDINBURGH,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,ROYAL INFIRM,DEPT SURG,EDINBURGH,MIDLOTHIAN,SCOTLAND; WESTERN GEN HOSP,INTENS THERAPY UNIT,EDINBURGH,MIDLOTHIAN,SCOTLAND; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR IMMUNOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	University of Edinburgh; Royal Infirmary of Edinburgh; Royal Infirmary of Edinburgh; University of Edinburgh; University of Edinburgh; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School				Donnelly, Seamas/0000-0001-7145-1843; Dransfield, Ian/0000-0001-5848-7059	NATIONAL CANCER INSTITUTE [R55CA054464, R01CA054464] Funding Source: NIH RePORTER; NCI NIH HHS [CA54464] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CHRISTNER P, 1985, AM REV RESPIR DIS, V131, P690; DONNELLY SC, 1993, LANCET, V341, P643, DOI 10.1016/0140-6736(93)90416-E; DONNELLY SC, 1992, EUR RESPIR J, V5; ETZIONI A, 1992, NEW ENGL J MED, V327, P1789, DOI 10.1056/NEJM199212173272505; FOWLER AA, 1983, ANN INTERN MED, V98, P593, DOI 10.7326/0003-4819-98-5-593; GORIS RJA, 1985, ARCH SURG-CHICAGO, V120, P1109; GRIFFIN JD, 1990, J IMMUNOL, V145, P576; KATAYAMA M, 1992, J IMMUNOL METHODS, V153, P41, DOI 10.1016/0022-1759(92)90303-B; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; MACNAUGHTON PD, 1992, LANCET, V339, P469, DOI 10.1016/0140-6736(92)91068-J; MCEVER R, 1989, J CLIN INVEST, V112, P491; MILLER EJ, 1992, AM REV RESPIR DIS, V146, P427, DOI 10.1164/ajrccm/146.2.427; MULLIGAN MS, 1993, NATURE, V364, P149, DOI 10.1038/364149a0; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; NEWMAN W, 1993, J IMMUNOL, V150, P644; OSBORNE DH, 1981, BRIT J SURG, V68, P758, DOI 10.1002/bjs.1800681103; PARSONS PE, 1985, AM REV RESPIR DIS, V132, P490; PARSONS PE, 1989, AM REV RESPIR DIS, V140, P294, DOI 10.1164/ajrccm/140.2.294; PIGOTT R, 1992, BIOCHEM BIOPH RES CO, V187, P584, DOI 10.1016/0006-291X(92)91234-H; REPINE JE, 1992, LANCET, V339, P466, DOI 10.1016/0140-6736(92)91067-I; RINALDO JE, 1982, NEW ENGL J MED, V306, P900, DOI 10.1056/NEJM198204153061504; ROCKER GM, 1989, LANCET, V1, P120; SCHLEIFFENBAUM B, 1992, J CELL BIOL, V119, P229, DOI 10.1083/jcb.119.1.229; SPERTINI O, 1991, J IMMUNOL, V147, P2565; SPERTINI O, 1992, J IMMUNOL METHODS, V156, P115, DOI 10.1016/0022-1759(92)90017-N; WEILAND JE, 1986, AM REV RESPIR DIS, V133, P218	29	216	221	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 23	1994	344	8917					215	219		10.1016/S0140-6736(94)92995-5	http://dx.doi.org/10.1016/S0140-6736(94)92995-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY060	7518025				2022-12-24	WOS:A1994NY06000007
J	ODELL, TJ; HUANG, PL; DAWSON, TM; DINERMAN, JL; SNYDER, SH; KANDEL, ER; FISHMAN, MC				ODELL, TJ; HUANG, PL; DAWSON, TM; DINERMAN, JL; SNYDER, SH; KANDEL, ER; FISHMAN, MC			ENDOTHELIAL NOS AND THE BLOCKADE OF LTP BY NOS INHIBITORS IN MICE LACKING NEURONAL NOS	SCIENCE			English	Article							LONG-TERM POTENTIATION; NITRIC-OXIDE SYNTHASE; PLATELET-ACTIVATING-FACTOR; HIPPOCAMPAL SLICES; INTERCELLULAR MESSENGER; RAT HIPPOCAMPUS; CARBON-MONOXIDE; ENHANCEMENT; STIMULATION; RELEASE	Long-term potentiation (LTP) is a persistent increase in synaptic strength implicated in certain forms of learning and memory. In the CA1 region of the hippocampus, LTP is thought to involve the release of one or more retrograde messengers from the postsynaptic cell that act on the presynaptic terminal to enhance transmitter release. One candidate retrograde messenger is the membrane-permeant gas nitric oxide (NO), which in the brain is released after activation of the neuronal-specific NO synthase isoform (nNOS). To assess the importance of NO in hippocampal synaptic plasticity, LTP was examined in mice where the gene encoding nNOS was disrupted by gene targeting. In nNOS(-) mice, LTP induced by weak intensity tetanic stimulation was normal except for a slight reduction in comparison to that in wild-type mice and was blocked by NOS inhibitors, just as it was in wild-type mice. Immunocytochemical studies indicate that in the nNOS(-) mice as in wild-type mice, the endothelial form of NOS (eNOS) is expressed in CA1 neurons. These findings suggest that eNOS, rather than nNOS, generates NO within the postsynaptic cell during LTP.	COLUMBIA UNIV,COLL PHYS & SURG,HOWARD HUGHES MED INST,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032; MASSACHUSETTS GEN HOSP E,CARDIOVASC RES CTR,BOSTON,MA 02129; HARVARD UNIV,SCH MED,BOSTON,MA 02129; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV CARDIOL,BALTIMORE,MD 21205	Columbia University; Howard Hughes Medical Institute; Columbia University; Harvard University; Harvard Medical School; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University					NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH045923, R37MH045923] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA000266] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-00074, DA-00266] Funding Source: Medline; NIMH NIH HHS [MH-45923] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARAI A, 1992, EUR J NEUROSCI, V4, P411, DOI 10.1111/j.1460-9568.1992.tb00890.x; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; BON C, 1992, EUR J NEUROSCI, V4, P420, DOI 10.1111/j.1460-9568.1992.tb00891.x; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; BREDT DS, 1991, NEURON, V7, P615, DOI 10.1016/0896-6273(91)90374-9; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; CHETKOVICH DM, 1993, NEUROREPORT, V4, P919, DOI 10.1097/00001756-199307000-00020; CLARK GD, 1992, NEURON, V9, P1211, DOI 10.1016/0896-6273(92)90078-R; DINERMAN JL, 1994, P NATL ACAD SCI USA, V91, P4214, DOI 10.1073/pnas.91.10.4214; EAST SJ, 1991, NEUROSCI LETT, V123, P17, DOI 10.1016/0304-3940(91)90147-L; FURTINE ES, 1993, BIOCHEMISTRY-US, V32, P8512; GALLY JA, 1990, P NATL ACAD SCI USA, V87, P3547, DOI 10.1073/pnas.87.9.3547; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; GRIBKOFF VK, 1992, J NEUROPHYSIOL, V68, P639, DOI 10.1152/jn.1992.68.2.639; HALEY JE, 1992, NEURON, V8, P211, DOI 10.1016/0896-6273(92)90288-O; HALEY JE, 1993, NEUROSCI LETT, V160, P85, DOI 10.1016/0304-3940(93)90919-C; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; IZUMI Y, 1992, SCIENCE, V257, P1273, DOI 10.1126/science.1519065; KATO K, 1994, NATURE, V367, P175, DOI 10.1038/367175a0; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; KULLMANN DM, 1992, NATURE, V357, P240, DOI 10.1038/357240a0; LARKMAN A, 1992, NATURE, V360, P70, DOI 10.1038/360070a0; LARSON J, 1986, BRAIN RES, V368, P347, DOI 10.1016/0006-8993(86)90579-2; LUMRAGAN JT, 1993, NEUROSCIENCE, V57, P973, DOI 10.1016/0306-4522(93)90042-E; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; MUSLEH WY, 1993, SYNAPSE, V13, P370, DOI 10.1002/syn.890130409; NATHAN C, 1992, FASEB J, V3, P31; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; SCHMIDT HH, 1992, J HISTOCHEM CYTOCHEM, V90, P1439; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SCHUMAN EM, 1994, SCIENCE, V263, P532, DOI 10.1126/science.8290963; Schweizer F. E., 1993, Society for Neuroscience Abstracts, V19, P241; SHUMAN EM, 1993, SEMIN NEUROSCI, V5, P207; STEVENS CF, 1993, NATURE, V364, P147, DOI 10.1038/364147a0; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; WIERASZKO A, 1993, NEURON, V10, P553, DOI 10.1016/0896-6273(93)90342-O; WILLIAMS JH, 1993, SEMIN NEUROSCI, V5, P149, DOI 10.1016/S1044-5765(05)80048-X; WILLIAMS JH, 1993, NEURON, V11, P877, DOI 10.1016/0896-6273(93)90117-A; ZHUO M, 1993, SCIENCE, V260, P1946, DOI 10.1126/science.8100368	45	374	382	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 22	1994	265	5171					542	546		10.1126/science.7518615	http://dx.doi.org/10.1126/science.7518615			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NY216	7518615				2022-12-24	WOS:A1994NY21600037
J	LI, CM; TROPAK, MB; GERLAI, R; CLAPOFF, S; ABRAMOWNEWERLY, W; TRAPP, B; PETERSON, A; RODER, J				LI, CM; TROPAK, MB; GERLAI, R; CLAPOFF, S; ABRAMOWNEWERLY, W; TRAPP, B; PETERSON, A; RODER, J			MYELINATION IN THE ABSENCE OF MYELIN-ASSOCIATED GLYCOPROTEIN	NATURE			English	Article							CELL-ADHESION MOLECULES; EMBRYONIC STEM-CELLS; SCHWANN-CELLS; PERIAXONAL SPACE; MICE; GENE; MAG; L1	THE hypothesis that myelin-associated glycoprotein (MAG) initiates myelin formation is based in part on observations that MAG has an adhesive role in interactions between oligodendrocytes and neurons(1). Furthermore, the over- or underexpression of MAG in transfected Schwann cells in vitro leads to accelerated myelination(2) or hypomyelination(3), respectively. Here we test this idea by creating a null mutation in the mag locus and deriving mice that are totally deficient in MAG expression at the RNA and protein level. In adult mutant animals the degree of myelination and its compaction are normal, whereas the organization of the periaxonal region is partially impaired. Mutant animals show a subtle intention tremor. Our findings do not support the widely held view that MAG is critical for myelin formation but rather indicate that MAG is necessary for maintenance of the cytoplasmic collar and periaxonal space of myelinated fibres.	UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO M5G 1X5, ON, CANADA; CLEVELAND CLIN FDN, DEPT NEUROSCI, CLEVELAND, OH 44195 USA; MCGILL UNIV, ROYAL VICTORIA HOSP, MONTREAL H3A 1A1, PQ, CANADA	University of Toronto; Cleveland Clinic Foundation; McGill University; Royal Victoria Hospital	LI, CM (corresponding author), MT SINAI HOSP, SAMUEL LUNENFELD RES INST, 600 UNIV AVE, TORONTO M5G 1X5, ON, CANADA.		Roder, John/G-6468-2013					ARQUINT M, 1987, P NATL ACAD SCI USA, V84, P600, DOI 10.1073/pnas.84.2.600; CAPECCHI MR, 1994, SCI AM, V270, P52, DOI 10.1038/scientificamerican0394-52; DULAC C, 1992, NEURON, V8, P323, DOI 10.1016/0896-6273(92)90298-R; EDWARDS AM, 1988, MOL CELL BIOL, V8, P2655, DOI 10.1128/MCB.8.6.2655; GERLAI R, 1993, BEHAV BRAIN RES, V55, P51, DOI 10.1016/0166-4328(93)90006-C; HIRANO A, 1983, PROG NEUROPATH, V5, P99; HUNTINGFORD F, 1984, STUDY ANIMAL BEHAVIO; JOHNSON PW, 1989, NEURON, V3, P377, DOI 10.1016/0896-6273(89)90262-6; Kirschner D., 1984, MYELIN, P51; LAI C, 1987, P NATL ACAD SCI USA, V84, P4337, DOI 10.1073/pnas.84.12.4337; MARTINI R, 1986, J CELL BIOL, V103, P2439, DOI 10.1083/jcb.103.6.2439; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; OWENS GC, 1991, NEURON, V7, P565, DOI 10.1016/0896-6273(91)90369-B; OWENS GC, 1990, J CELL BIOL, V111, P1171, DOI 10.1083/jcb.111.3.1171; POLTORAK M, 1987, J CELL BIOL, V105, P1893, DOI 10.1083/jcb.105.4.1893; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; SALZER JL, 1987, J CELL BIOL, V104, P957, DOI 10.1083/jcb.104.4.957; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STERNBERGER NH, 1979, P NATL ACAD SCI USA, V76, P1510, DOI 10.1073/pnas.76.3.1510; TRAPP BD, 1982, J CELL BIOL, V92, P877, DOI 10.1083/jcb.92.3.877; TRAPP BD, 1984, J CELL BIOL, V98, P1272, DOI 10.1083/jcb.98.4.1272; TRAPP BD, 1984, J CELL BIOL, V99, P594, DOI 10.1083/jcb.99.2.594; TROPAK MB, 1988, MOL BRAIN RES, V4, P143, DOI 10.1016/0169-328X(88)90006-X; UMERMORI H, 1994, NATURE, V367, P572; VANDEURSEN J, 1992, NUCLEIC ACIDS RES, V20, P3815, DOI 10.1093/nar/20.15.3815; WOOD PM, 1990, J NEUROSCI, V10, P3635; WOOD SA, 1993, NATURE, V365, P87, DOI 10.1038/365025a0	27	308	310	0	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 30	1994	369	6483					747	750		10.1038/369747a0	http://dx.doi.org/10.1038/369747a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NU581	7516497				2022-12-24	WOS:A1994NU58100061
J	BONNI, A; FRANK, DA; SCHINDLER, C; GREENBERG, ME				BONNI, A; FRANK, DA; SCHINDLER, C; GREENBERG, ME			CHARACTERIZATION OF A PATHWAY FOR CILIARY NEUROTROPHIC FACTOR SIGNALING TO THE NUCLEUS	SCIENCE			English	Article							LEUKEMIA INHIBITORY FACTOR; PROTEIN-TYROSINE KINASES; C-FOS PROMOTER; TRANSCRIPTION FACTOR; CYTOPLASMIC ACTIVATION; BINDING PROTEIN; FACTOR PREVENTS; FACTOR RECEPTOR; MOTOR NEURONS; IFN-GAMMA	Components of a signaling pathway that couples the ciliary neurotrophic factor (CNTF) receptor to induction of transcription were identified. CNTF stimulated the tyrosine phosphorylation of p91, a protein implicated in interferon signaling pathways, and of two proteins that are distinct but related to p91. Tyrosine-phosphorylated p91 translocated to the nucleus, where p91 and p91-related proteins bound to a DNA sequence found in promoters of genes responsive to CNTF. This DNA sequence, when inserted upstream of a reporter gene, conferred a transcriptional response to CNTF. A pathway that transduces interferon signals may therefore have a more general function in the propagation of responses to certain neurotrophic factors.	HARVARD UNIV, SCH MED, PROGRAM NEUROSCI, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOLEC GENET, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA; COLUMBIA UNIV, DEPT MED, NEW YORK, NY 10032 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Columbia University					NCI NIH HHS [R01 CA43855] Funding Source: Medline; NHLBI NIH HHS [HL21006-17] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043855] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL021006] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BONNI A, UNPUB; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; Davis S, 1993, CURR OPIN CELL BIOL, V5, P281, DOI 10.1016/0955-0674(93)90117-9; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; GEARING DP, 1992, NEW BIOL, V4, P61; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; HARPUR AG, 1992, ONCOGENE, V7, P1347; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; Ip Nancy Y., 1992, Progress in Growth Factor Research, V4, P139, DOI 10.1016/0955-2235(92)90028-G; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; LARNER AC, 1993, IN PRESS SCIENCE, V261, P1730; LEVY D, 1990, New Biologist, V2, P923; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; LOUIS JC, 1993, SCIENCE, V259, P689, DOI 10.1126/science.8430320; MASIAKOWSKI P, 1991, J NEUROCHEM, V57, P1003, DOI 10.1111/j.1471-4159.1991.tb08250.x; MASU Y, 1993, NATURE, V365, P27, DOI 10.1038/365027a0; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; Patterson P H, 1992, Curr Opin Neurobiol, V2, P94, DOI 10.1016/0959-4388(92)90169-L; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; PINE R, IN PRESS TRENDS BIOC; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SENDTNER M, 1992, NATURE, V358, P502, DOI 10.1038/358502a0; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SQUINTO SP, 1990, NEURON, V5, P757, DOI 10.1016/0896-6273(90)90334-C; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; STAHL N, IN PRESS SCIENCE; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	57	179	182	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 3	1993	262	5139					1575	1579		10.1126/science.7504325	http://dx.doi.org/10.1126/science.7504325			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MK329	7504325				2022-12-24	WOS:A1993MK32900042
J	KOEKEMOER, AM; HENKEL, C; GREENHILL, LJ; DEY, A; VANBREUGEL, W; ANTONUCCI, R; CODELLA, C				KOEKEMOER, AM; HENKEL, C; GREENHILL, LJ; DEY, A; VANBREUGEL, W; ANTONUCCI, R; CODELLA, C			A WATER-VAPOR GIGA-MASER IN THE ACTIVE GALAXY TXFS2226-184	NATURE			English	Article							STAR-FORMING REGIONS; GALACTIC NUCLEI; H2O MASERS; EMISSION; NGC-3079	ACTIVE galactic nuclei are thought to be powered by gas falling into a massive black hole; the different types of active galaxy mag arise because we view them through a thick torus of molecular gas at varying angles of inclination(1). One way to determine whether the black hole is surrounded by a torus, which would obscure the accretion disk around the black hole along certain lines of sight, is to search for water masers, as these exist only in regions with plentiful molecular gas. Since the first detection(2) of an extragalactic water maser in 1979, they have come to be associated primarily with active galaxies, and have even been used to probe the mass of the central engine(3). Here we report the detection of a water giga-maser in the radio galaxy TXFS2226-184. The strength of the emission supports a recently proposed theory of maser pumping(4) that allows for even more powerful masers, which might be detectable at cosmological distances. Water masers may accordingly provide a may to determine distances to galaxies outside the usual distance ladder, providing an independent calibration of the Hubble constant(3,5).	MAX PLANCK INST RADIOASTRON,D-53121 BONN,GERMANY; HARVARD SMITHSONIAN CTR ASTROPHYS,CAMBRIDGE,MA 02138; UNIV CALIF BERKELEY,DEPT ASTRON,BERKELEY,CA 94720; LAWRENCE LIVERMORE NATL LAB,LIVERMORE,CA 94550; UNIV CALIF SANTA BARBARA,DEPT PHYS,SANTA BARBARA,CA 93106	Max Planck Society; Harvard University; Smithsonian Astrophysical Observatory; Smithsonian Institution; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System; University of California Santa Barbara	KOEKEMOER, AM (corresponding author), MT STROMLO & SIDING SPRING OBSERV,WESTON,ACT 2611,AUSTRALIA.		Koekemoer, Anton M./F-8400-2014; Codella, Claudio/AAB-2539-2021	Koekemoer, Anton M./0000-0002-6610-2048; Codella, Claudio/0000-0003-1514-3074				ANTONUCCI RRJ, 1985, ASTROPHYS J, V297, P621, DOI 10.1086/163559; BAARS JWM, 1977, ASTRON ASTROPHYS, V61, P99; BARTHEL PD, 1989, ASTROPHYS J, V336, P606, DOI 10.1086/167038; BICAY MD, 1990, ASTROPHYS J, V362, P59, DOI 10.1086/169243; BRAATZ JA, 1994, ASTROPHYS J, V437, pL99, DOI 10.1086/187692; BRAATZ JA, 1995, P OXF TOR WORKSH, P77; BURDYUZHA VV, 1990, ASTRON ASTROPHYS, V234, P40; CLAUSSEN MJ, 1984, NATURE, V310, P298, DOI 10.1038/310298a0; CLAUSSEN MJ, 1986, ASTROPHYS J, V308, P592, DOI 10.1086/164529; DOSSANTOS PM, 1979, NATURE, V278, P34, DOI 10.1038/278034a0; ELITZUR M, 1992, ASTROPHYS J, V394, P221, DOI 10.1086/171574; ELITZUR M, 1989, ASTROPHYS J, V346, P983, DOI 10.1086/168080; FALCKE H, 1995, ASTRON ASTROPHYS, V298, P395; GREENHILL LJ, 1995, ASTROPHYS J, V440, P619, DOI 10.1086/175301; GREENHILL LJ, 1993, ASTROPHYS J, V406, P482, DOI 10.1086/172460; GREENHILL LJ, 1990, ASTROPHYS J, V364, P513, DOI 10.1086/169433; GREENHILL LJ, IN PRESS ASTR ASTROP; HASCHICK AD, 1985, NATURE, V314, P144, DOI 10.1038/314144a0; HASCHICK AD, 1994, ASTROPHYS J, V437, pL35, DOI 10.1086/187676; HASCHICK AD, 1990, ASTROPHYS J, V356, P149, DOI 10.1086/168825; Heckman T. M., 1980, Astronomy & Astrophysics Supplement Series, V40, P295; HENKEL C, 1990, ASTRON ASTROPHYS, V229, P431; HENKEL C, 1984, ASTRON ASTROPHYS, V141, pL1; HO PTP, 1987, ASTROPHYS J, V320, P663, DOI 10.1086/165583; MAOZ E, 1995, ASTROPHYS J, V447, pL91, DOI 10.1086/175250; MIYOSHI M, 1995, NATURE, V373, P127, DOI 10.1038/373127a0; NEUFELD DA, 1994, ASTROPHYS J, V436, pL127, DOI 10.1086/187649; NEUFELD DA, 1995, ASTROPHYS J, V447, pL17, DOI 10.1086/309553; OTT M, 1994, ASTRON ASTROPHYS, V284, P331; PADOVANI P, 1991, ASTROPHYS J, V368, P373, DOI 10.1086/169701; SHLOSMAN I, 1990, NATURE, V345, P679, DOI 10.1038/345679a0	31	44	46	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 14	1995	378	6558					697	699		10.1038/378697a0	http://dx.doi.org/10.1038/378697a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK379	7501016				2022-12-24	WOS:A1995TK37900044
J	SCHIAVO, G; GMACHL, MJS; STENBECK, G; SOLLNER, TH; ROTHMAN, JE				SCHIAVO, G; GMACHL, MJS; STENBECK, G; SOLLNER, TH; ROTHMAN, JE			A POSSIBLE DOCKING AND FUSION PARTICLE FOR SYNAPTIC TRANSMISSION	NATURE			English	Article							SECRETION; PROTEINS; FAMILY; STEPS	SEVERAL proteins have been implicated in the rapid (millisecond) calcium-controlled release of transmitters at nerve endings(1,2), including soluble N-ethylmaleimide-sensitive fusion protein (NSF3-5) and soluble NSF attachment protein (alpha-SNAP(3,6)), the synaptic SNAP receptor (SNARE)(3,7) and the calcium-binding protein synaptotagmin(2), which may function as a calcium sensor in exocytosis(8). A second SNAP isoform (beta-SNAP), which is 83% identical to alpha-SNAP, is highly expressed in brain(9), but its role is still unclear. Here we show that these proteins assemble cooperatively to form a docking and fusion complex. beta-SNAP (but not alpha-SNAP) binds synaptotagmin and recruits NSF, indicating that the complex may link the process of membrane fusion to calcium entry by attaching a specialized fusion protein (beta-SNAP) to a calcium sensor (synaptotagmin). Polyphosphoinositols that block transmitter release, inositol 1,3,4,5-tetrakisphosphate (InsP(4)), inositol 1,3,4,5,6-pentakisphosphate (InsP(5)) and inositol 1,2,3,4,5,6-hexakisphosphate (InsP(6)), also block the assembly of the particle by preventing beta-SNAP from binding to synaptotagmin.			SCHIAVO, G (corresponding author), MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,1275 YORK AVE,NEW YORK,NY 10021, USA.			Schiavo, Giampietro/0000-0002-4319-8745				BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BITTNER MA, 1992, J BIOL CHEM, V267, P16219; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; BROADIE K, 1995, NEURON, V15, P663, DOI 10.1016/0896-6273(95)90154-X; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DEBELLO WM, 1995, NATURE, V373, P626, DOI 10.1038/373626a0; DIANTONIO A, 1994, NEURON, V12, P909, DOI 10.1016/0896-6273(94)90342-5; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; HONG RM, 1994, FEBS LETT, V350, P253, DOI 10.1016/0014-5793(94)00778-0; HUNT JM, 1994, NEURON, V12, P1269, DOI 10.1016/0896-6273(94)90443-X; LLINAS R, 1994, P NATL ACAD SCI USA, V91, P12990, DOI 10.1073/pnas.91.26.12990; PALLANCK L, 1995, NATURE, V376, P25, DOI 10.1038/376025a0; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHELLER RH, 1993, NEURON, V14, P893; SCHIAVO G, 1994, MOL MICROBIOL, V13, P1; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SUTTON RB, 1994, CELL, V80, P929; THOMAS P, 1993, NEURON, V11, P93, DOI 10.1016/0896-6273(93)90274-U; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0	26	161	163	1	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 14	1995	378	6558					733	736		10.1038/378733a0	http://dx.doi.org/10.1038/378733a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK379	7501022				2022-12-24	WOS:A1995TK37900057
J	MARGOLIS, HS; COLEMAN, PJ; BROWN, RE; MAST, EE; SHEINGOLD, SH; AREVALO, JA				MARGOLIS, HS; COLEMAN, PJ; BROWN, RE; MAST, EE; SHEINGOLD, SH; AREVALO, JA			PREVENTION OF HEPATITIS-B VIRUS TRANSMISSION BY IMMUNIZATION - AN ECONOMIC-ANALYSIS OF CURRENT RECOMMENDATIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COST-EFFECTIVENESS ANALYSIS; UNITED-STATES; CARRIER STATE; FOLLOW-UP; HEPATOCELLULAR-CARCINOMA; VACCINATION STRATEGIES; IMMUNE GLOBULIN; NATURAL-HISTORY; LIVER-DISEASE; DOUBLE-BLIND	Objective.-To evaluate the outcome of immunization strategies to prevent hepatitis B virus (HBV) transmission. Design and Setting.-A decision model was used to determine the incremental effects of the following hepatitis B immunization strategies in a birth cohort receiving immunization services in the public sector: (1) prevention of perinatal HBV infection, (2) routine infant vaccination, or (3) routine adolescent vaccination. Main Outcome Measures.-Over the lifetime of the cohort, the reduction in infections and medical and work-loss costs of HBV-related liver disease were determined for each strategy and compared with the outcome without immunization. Results.-Prevention of perinatal infection and routine infant vaccination would lower the 4.8% lifetime risk of HBV infection by at least 68%, compared with a 45% reduction for adolescent vaccination. From a societal perspective, each strategy was found to be cost saving, but was not cost saving with respect to direct medical costs. The estimated cost per year of life saved was $164 to prevent perinatal HBV infection, $1522 for infant vaccination, and $3730 for adolescent vaccination. Conclusions.-Routine vaccination of infants in successive birth cohorts to prevent HBV transmission is cost-effective over a wide range of assumptions. While economically less attractive than infant vaccination, adolescent vaccination could serve to protect those children who were not vaccinated as infants.	BATTELLE HUMAN AFFAIRS RES CTR,WASHINGTON,DC; US HLTH CARE FINANCING ADM,BUR POLICY DEV,OFF TECHNOL & SPECIAL ANAL,WASHINGTON,DC; PLANNED PARENTHOOD SACRAMENTO VALLEY,SACRAMENTO,CA		MARGOLIS, HS (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV VIRAL & RICKETTSIAL DIS,HEPATITIS BRANCH A-33,ATLANTA,GA 30333, USA.		Ibrahim, Essam Hassan/G-1960-2018	Ibrahim, Essam Hassan/0000-0003-0130-2257				ALTER MJ, 1990, JAMA-J AM MED ASSOC, V263, P1218, DOI 10.1001/jama.263.9.1218; ANDRE FE, 1994, J MED VIROL, V44, P144, DOI 10.1002/jmv.1890440206; AREVALO JA, 1988, JAMA-J AM MED ASSOC, V259, P365, DOI 10.1001/jama.259.3.365; BEASLEY RP, 1983, HEPATOLOGY, V3, P135; BEASLEY RP, 1983, LANCET, V2, P1099; BEASLEY RP, 1983, J INFECT DIS, V147, P185, DOI 10.1093/infdis/147.2.185; BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J; BEASLEY RP, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P532; BLOOM BS, 1993, ANN INTERN MED, V118, P298, DOI 10.7326/0003-4819-118-4-199302150-00009; BRUCE BR, 1990, STANDARDS SOCIOECONO; BUYLE MH, 1983, NEW ENGL J MED, V308, P1330; CHEN DS, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P716; CHOTARD J, 1992, J INFECT DIS, V166, P764, DOI 10.1093/infdis/166.4.764; COCHI SL, 1985, JAMA-J AM MED ASSOC, V253, P521, DOI 10.1001/jama.253.4.521; DEJONGH FE, 1992, GASTROENTEROLOGY, V103, P1630, DOI 10.1016/0016-5085(92)91188-A; FATTOVICH G, 1991, GUT, V32, P294, DOI 10.1136/gut.32.3.294; FRANKS AL, 1989, NEW ENGL J MED, V321, P1301, DOI 10.1056/NEJM198911093211905; GANIATS TG, 1993, J FAM PRACTICE, V36, P147; GOH KT, 1992, B WORLD HEALTH ORGAN, V70, P233; GREENBERG DP, 1992, 32ND INT C ANT AG CH; HADLER SC, 1986, NEW ENGL J MED, V215, P209; HADLER SC, 1992, CURRENT CLIN TOPICS, P282; HEYWARD WL, 1985, AM J EPIDEMIOL, V121, P914, DOI 10.1093/oxfordjournals.aje.a114061; HOOFNAGLE JH, 1987, HEPATOLOGY, V7, P758, DOI 10.1002/hep.1840070424; HORNEY JT, 1977, GASTROENTEROLOGY, V73, P639; HSIEH CC, 1992, AM J EPIDEMIOL, V136, P1115, DOI 10.1093/oxfordjournals.aje.a116577; HURIE MB, 1992, PEDIATRICS, V89, P269; JONAS MM, 1987, ANN INTERN MED, V107, P335, DOI 10.7326/0003-4819-107-2-335; KARVOUNTZIS GG, 1974, GASTROENTEROLOGY, V67, P870; KRAHN M, 1993, MED DECIS MAKING, V13, P4, DOI 10.1177/0272989X9301300103; LASHNER BA, 1988, AM J MED, V85, P609; LIAW YF, 1988, HEPATOLOGY, V8, P493, DOI 10.1002/hep.1840080310; LO KJ, 1982, J INFECT DIS, V146, P205, DOI 10.1093/infdis/146.2.205; MAHONEY FJ, 1993, J INFECT DIS, V167, P203, DOI 10.1093/infdis/167.1.203; MARGOLIS HS, 1991, SEMIN LIVER DIS, V11, P84, DOI 10.1055/s-2008-1040427; MARGOLIS HS, 1993, J INFECT DIS, V168, P9, DOI 10.1093/infdis/168.1.9; MARGOLIS HS, 1990, VACCINE, V8, pS81, DOI 10.1016/0264-410X(90)90224-A; MARGOLIS HS, 1993, PEDIATR INFECT DIS J, V12, P542; MARION SA, 1994, AM J EPIDEMIOL, V140, P734, DOI 10.1093/oxfordjournals.aje.a117321; MAST EE, 1990, JAMA-J AM MED ASSOC, V264, P2529, DOI 10.1001/jama.264.19.2529; MCMAHON BJ, 1985, J INFECT DIS, V151, P599, DOI 10.1093/infdis/151.4.599; MCMAHON BJ, 1987, LANCET, V2, P1134; MCMAHON BJ, 1990, ARCH INTERN MED, V150, P1051, DOI 10.1001/archinte.150.5.1051; MCQUILLAN GM, 1989, AM J MED S3A, V87, P5; MULLEY AG, 1982, NEW ENGL J MED, V307, P644, DOI 10.1056/NEJM198209093071103; SCHARTZ G, 1990, PROGR HEPATITIS B IM, P533; SINGH S, 1989, PRENATAL CARE US STA; SISK JE, 1986, ANN INTERN MED, V104, P79, DOI 10.7326/0003-4819-104-1-79; STEVENS CE, 1992, PEDIATRICS, V90, P170; STEVENS CE, 1995, UNPUB INFANTS HIGH R; STRATTON KR, 1994, ADVERSE EVENTS ASS C, P211; TONG MJ, 1984, J PEDIATR-US, V105, P945, DOI 10.1016/S0022-3476(84)80084-0; TORRANCE GW, 1984, CLIN PERINATOL, V11, P267, DOI 10.1016/S0095-5108(18)30920-5; VIOLA LA, 1981, LANCET, V2, P1156; WAINWRIGHT RB, 1989, JAMA-J AM MED ASSOC, V261, P2362, DOI 10.1001/jama.261.16.2362; WEINSTEIN MC, 1985, ANNU REV PUBL HEALTH, V6, P41; Weinstein MC, 1980, CLIN DECISION ANAL; WEISSBERG JI, 1984, ANN INTERN MED, V101, P613, DOI 10.7326/0003-4819-101-5-613; WEST DJ, 1992, PEDIATR INFECT DIS J, V11, P866, DOI 10.1097/00006454-199210000-00012; XU ZY, 1985, PEDIATRICS, V76, P713; 1992, PEDIATRICS, V89, P795; 1991, FED REGISTER, V56, P64004; 1994, MMWR-MORBID MORTAL W, V43, P605; 1991, EMPLOY EARN, P37; 1990, 52 CTR DIS CONTR HEP; [No title captured]; 1991, JAMA-J AM MED ASSOC, V266, P1547; 1994, MMWR-MORBID MORTAL W, V43, P317; 1988, MMWR-MORBID MORTAL W, V37, P341; 1994, MMWR-MORBID MORTAL W, V43, P311; 1991, MMWR-MORBID MORTAL W, V40, P1; 1991, MMWR-MORBID MORTAL W, V40, P700	72	232	239	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 18	1995	274	15					1201	1208		10.1001/jama.274.15.1201	http://dx.doi.org/10.1001/jama.274.15.1201			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ120	7563509				2022-12-24	WOS:A1995RZ12000028
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PHARMACEUTICAL PROMOTION HEARINGS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1995, FED REG         0814, V60, P41891; 1995, FED REG         0816, V60, P42581	2	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 11	1995	274	14					1109	1109						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY056	7563473				2022-12-24	WOS:A1995RY05600006
J	WARNER, JO				WARNER, JO			REVIEW OF PRESCRIBED TREATMENT FOR CHILDREN WITH ASTHMA IN 1990	BRITISH MEDICAL JOURNAL			English	Article							BECLOMETHASONE DIPROPIONATE; CHILDHOOD	Objective-To review treatment prescribed to asthmatic children in Great Britain during the 12 months after publication of the first guidelines and to assess effectiveness of prophylactic treatment. Design-Review of prescribing information from January 1990 to June 1991 in a representative sample of general practices in Great Britain with a Compufile/AAH Meditel computer. Subjects-17 846 children with asthma aged 4-17 years. Main outcome measures-Numbers of children prescribed different asthma treatments; estimated use of inhaled beta agonists in those receiving prophylactic treatment. Results-From January to December 1990, 9362 (52.5%) children were prescribed preventive treatments. 16211 (90.8%) children were prescribed bronchodilators of some kind. 3055 (17.1%) were prescribed sodium cromoglycate, and the proportion decreased significantly during the study (from 19.5% (95% confidence interval 18.6% to 20.4%) to 17.2% (16.4% to 18.1%), P<0.001, in children aged 4-11 years and from 14.9% (14.0% to 15.9%) to 11.3% (10.4% to 12.2%), P<0.001, in those aged 12-17 during January-July 1991). 6952 (39.0%) were prescribed inhaled steroids, and the proportion increased during the study (from 35.1% (34.0% to 36.2%) to 44.1% (43.0% to 45.2%), P<0.001, in children aged 4-11 years and hem 38.7% (37.40% to 40.0%) to 44.1% (42.7% to 45.5%), P<0.001, in those aged 12-17 during January-July 1991). Only 1358 of the 9362 children (14.5%) received sufficient repeat prescriptions to suggest that they might be taking the prophylactic treatment regularly. Among these children short acting inhaled beta agonists were being used on average four to eight times a day. Conclusions-These results are useful baseline data for audit of the impact of published clinical guidelines, particularly in terms of reducing the need for short acting inhaled beta agonists with prophylactic treatment.			WARNER, JO (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,DEPT CHILD HLTH,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND.		Warner, John/AAF-9587-2020					ANDERSON HR, 1994, BRIT MED J, V308, P1600, DOI 10.1136/bmj.308.6944.1600; ANDERSON SD, 1976, AM REV RESPIR DIS, V114, P493; BEARDON PHG, 1993, BRIT MED J, V307, P846, DOI 10.1136/bmj.307.6908.846; British Thoracic Society (BTS), 1993, THORAX, V48, pS1; CHAPMAN KR, 1994, LANCET, V343, P1379, DOI 10.1016/S0140-6736(94)92520-8; GODFREY S, 1978, J ALLERGY CLIN IMMUN, V62, P335, DOI 10.1016/0091-6749(78)90133-1; HILL RA, 1989, ARCH DIS CHILD, V64, P246, DOI 10.1136/adc.64.2.246; JONES K, 1989, PRACTITIONER, V233, P265; KAARGAREN RJ, 1994, RESP MED, V88, P883; KAARSGAREN RJ, 1994, RESP MED, V88, P383, DOI 10.1016/0954-6111(94)90045-0; LAW CM, 1986, LANCET, V1, P942; REISER J, 1985, LANCET, V1, P206; ROBERTSON CF, 1993, AM REV RESPIR DIS, V147, pA372; SPEIGHT ANP, 1983, BRIT MED J, V286, P1253, DOI 10.1136/bmj.286.6373.1253; WARNER JO, 1989, RESP MED, V83, P33, DOI 10.1016/S0954-6111(89)80248-3; WARNER JO, 1989, ARCH DIS CHILD, V64, P1065, DOI 10.1136/adc.64.7.1065; WARNER JO, 1994, EUR RESPIR REV, V4, P21; 1993, SCOTTISH HLTH STATIS; 1992, ARCH DIS CHILD, V67, P240; 1992, CLIN EXP ALLERGY S1, V22, P1; 1993, HLTH PERSONAL SOCIAL; 1994, HLTH PERSONAL SOCIAL, V20	22	71	74	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 9	1995	311	7006					663	666		10.1136/bmj.311.7006.663	http://dx.doi.org/10.1136/bmj.311.7006.663			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU753	7549637	Green Published			2022-12-24	WOS:A1995RU75300021
J	SMITH, HO; TOMB, JF; DOUGHERTY, BA; FLEISCHMANN, RD; VENTER, JC				SMITH, HO; TOMB, JF; DOUGHERTY, BA; FLEISCHMANN, RD; VENTER, JC			FREQUENCY AND DISTRIBUTION OF DNA UPTAKE SIGNAL SEQUENCES IN THE HAEMOPHILUS-INFLUENZAE RD GENOME	SCIENCE			English	Article							HEMOPHILUS TRANSFORMATION; RECOGNITION SITES; SPECIFICITY	The naturally transformable, Gram-negative bacterium Haemophilus influenzae Rd preferentially takes up DNA of its own species by recognizing a 9-base pair sequence, 5'-AAGTGCGGT, carried in multiple copies in its chromosome. With the availability of the complete genome sequence, 1465 copies of the 9-base pair uptake site have been identified. Alignment of these sites unexpectedly reveals an extended consensus region of 29 base pairs containing the core 9-base pair region and two downstream 6- base pair A/T-rich regions, each spaced about one helix turn apart. Seventeen percent of the sites are in inverted repeat pairs, many of which are located downstream to gene termini and are capable of forming stem-loop structures in messenger RNA that might function as signals for transcription termination.	INST GENOM RES,GAITHERSBURG,MD 20878	J. Craig Venter Institute	SMITH, HO (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205, USA.							BURLAND V, 1993, GENOMICS, V16, P551, DOI 10.1006/geno.1993.1230; DANNER DB, 1980, GENE, V11, P311, DOI 10.1016/0378-1119(80)90071-2; DANNER DB, 1982, P NATL ACAD SCI-BIOL, V79, P2393, DOI 10.1073/pnas.79.7.2393; FITZMAURICE WP, 1984, GENE, V31, P187, DOI 10.1016/0378-1119(84)90209-9; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRIEDMAN EA, 1972, J BIOL CHEM, V247, P2846; GOODGAL SH, 1990, J BACTERIOL, V172, P5924, DOI 10.1128/jb.172.10.5924-5928.1990; GOODMAN SD, 1988, P NATL ACAD SCI USA, V85, P6982, DOI 10.1073/pnas.85.18.6982; HIGGINS CF, 1988, GENE, V72, P3, DOI 10.1016/0378-1119(88)90122-9; KAHN ME, 1984, J MEMBRANE BIOL, V81, P89, DOI 10.1007/BF01868974; KAUC L, 1990, GENE, V95, P149, DOI 10.1016/0378-1119(90)90427-S; REDFIELD RJ, 1991, NATURE, V352, P25, DOI 10.1038/352025b0; SCOCCA JJ, 1974, J BACTERIOL, V118, P369, DOI 10.1128/JB.118.2.369-373.1974; SISCO KL, 1979, P NATL ACAD SCI USA, V76, P972, DOI 10.1073/pnas.76.2.972; SMITH GR, 1994, EXPERIENTIA, V50, P234, DOI 10.1007/BF01924006; TOMB JF, 1991, GENE, V104, P1, DOI 10.1016/0378-1119(91)90457-M; WILCOX KW, 1976, J BIOL CHEM, V251, P6127	17	167	174	0	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 28	1995	269	5223					538	540		10.1126/science.7542802	http://dx.doi.org/10.1126/science.7542802			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RL495	7542802				2022-12-24	WOS:A1995RL49500027
J	FRENCH, RR; HAMBLIN, TJ; BELL, AJ; TUTT, AL; GLENNIE, MJ				FRENCH, RR; HAMBLIN, TJ; BELL, AJ; TUTT, AL; GLENNIE, MJ			TREATMENT OF B-CELL LYMPHOMAS WITH COMBINATION OF BISPECIFIC ANTIBODIES AND SAPORIN	LANCET			English	Note							IMMUNOTOXIN	We report the use of a bispecific F(ab')(2) antibody to target the ribosome-inactivating protein saporin to the surface antigen CD22 in the treatment of low-grade, end-stage, B-cell lymphoma. Four patients were treated. Toxic effects were minimal (grade I), with mild fever, weakness, and myalgia for 1-2 days after treatment. One patient showed an antibody response to mouse Fab' and saporin. All patients showed rapid and beneficial responses to treatment with improvements in most disease sites and in peripheral blood cytopenia. The responses were short-lived (less than 28 days) but further study of this targeting system is warranted.	ROYAL BOURNEMOUTH HOSP,DEPT HAEMATOL,BOURNEMOUTH BH7 7DW,DORSET,ENGLAND; SOUTHAMPTON GEN HOSP,TENOVUS RES LAB,SOUTHAMPTON,HANTS,ENGLAND; POOLE GEN HOSP,POOLE,DORSET,ENGLAND	University of Southampton; Poole Hospital								AMLOT PL, 1993, BLOOD, V82, P2624; BONARDI MA, 1993, CANCER RES, V53, P3015; FALINI B, 1992, LANCET, V339, P1195, DOI 10.1016/0140-6736(92)91135-U; FRENCH RR, 1991, CANCER RES, V51, P2353; GLENNIE MJ, 1993, TUMOUR IMMUNOBIOLOGY, P225; GROSSBARD ML, 1991, BLOOD, V78, P174; STANSFELD AG, 1988, LANCET, V1, P292; VITETTA ES, 1993, IMMUNOL TODAY, V14, P252, DOI 10.1016/0167-5699(93)90041-I; 1979, WHO OFFSET PUBLICATI, V48	9	37	38	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 22	1995	346	8969					223	224		10.1016/S0140-6736(95)91271-1	http://dx.doi.org/10.1016/S0140-6736(95)91271-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK419	7542357				2022-12-24	WOS:A1995RK41900013
J	MCHEYZERWILLIAMS, MG; DAVIS, MM				MCHEYZERWILLIAMS, MG; DAVIS, MM			ANTIGEN-SPECIFIC DEVELOPMENT OF PRIMARY AND MEMORY T-CELLS IN-VIVO	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; POLYMERASE CHAIN-REACTION; PRIMARY IMMUNE-RESPONSE; B-CELLS; FINE SPECIFICITY; CELLULAR BASIS; CYTOCHROME-C; RECEPTOR; RECOGNITION; INVIVO	The expansion and contraction of specific helper T cells in the draining lymph nodes of normal mice after injection with antigen was followed. T cell receptors from purified primary and memory responder cells had highly restricted junctional regions, indicating antigen-driven selection. Selection for homogeneity in the length of the third complementarity-determining region (CDR3) occurs before selection for some of the characteristic amino acids, indicating the importance of this parameter in T cell receptor recognition. Ultimately, particular T cell receptor sequences come to predominate in the secondary response and others disappear, showing the selective presentation or expansion of specific T cell clones.	STANFORD UNIV, MED CTR, SCH MED, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA	Howard Hughes Medical Institute; Stanford University	MCHEYZERWILLIAMS, MG (corresponding author), STANFORD UNIV, MED CTR, SCH MED, DEPT MICROBIOL & IMMUNOL, STANFORD, CA 94305 USA.			Davis, Mark/0000-0001-6868-657X				Ahmed R, 1992, Semin Immunol, V4, P105; BARTH RK, 1985, NATURE, V316, P517, DOI 10.1038/316517a0; BEVERLEY PCL, 1990, CURR TOP MICROBIOL, V159, P111; BRADLEY LM, 1993, J IMMUNOL, V150, P3119; BRADLEY LM, 1991, J EXP MED, V174, P547, DOI 10.1084/jem.174.3.547; BUDD RC, 1987, J IMMUNOL, V138, P3120; Burnet F., 1959, CLONAL SELECTION THE, DOI DOI 10.5962/BHL.TITLE.8281; CELADA F, 1971, PROG ALLERGY, V15, P223; CEROTTINI JC, 1989, ANNU REV IMMUNOL, V7, P77, DOI 10.1146/annurev.iy.07.040189.000453; CHANG HL, 1989, J IMMUNOL, V143, P315; CHIEN YH, 1984, NATURE, V309, P322, DOI 10.1038/309322a0; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; COCHET M, 1992, EUR J IMMUNOL, V22, P2639, DOI 10.1002/eji.1830221025; CORRADIN G, 1979, J EXP MED, V149, P436, DOI 10.1084/jem.149.2.436; DONG RP, 1992, TISSUE ANTIGENS, V39, P106, DOI 10.1111/j.1399-0039.1992.tb01918.x; FINK PJ, 1986, NATURE, V321, P219, DOI 10.1038/321219a0; FORD JE, 1994, EUR J IMMUNOL, V24, P1816, DOI 10.1002/eji.1830240814; FORD JE, 1994, GENE, V142, P279, DOI 10.1016/0378-1119(94)90275-5; FULLER KA, 1993, J IMMUNOL, V151, P4505; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; HAYAKAWA K, 1987, P NATL ACAD SCI USA, V84, P1379, DOI 10.1073/pnas.84.5.1379; HEDRICK SM, 1982, CELL, V30, P141, DOI 10.1016/0092-8674(82)90020-4; HEDRICK SM, 1988, SCIENCE, V239, P1541, DOI 10.1126/science.2832942; HOU S, 1993, J IMMUNOL, V150, P5494; HOU S, 1992, NATURE, V369, P651; HSIEH CL, 1991, MOL CELL BIOL, V11, P3972, DOI 10.1128/MCB.11.8.3972; JACOB J, 1991, J EXP MED, V173, P1165, DOI 10.1084/jem.173.5.1165; JAMESON SC, 1991, J IMMUNOL, V147, P3185; JORGENSEN JL, 1992, ANNU REV IMMUNOL, V10, P835, DOI 10.1146/annurev.iy.10.040192.004155; JORGENSEN JL, 1992, NATURE, V355, P224, DOI 10.1038/355224a0; KAWABE Y, 1991, NATURE, V349, P245, DOI 10.1038/349245a0; KEARNEY ER, 1994, IMMUNITY, V1, P327, DOI 10.1016/1074-7613(94)90084-1; KELSO A, 1991, IMMUNOL REV, V123, P85, DOI 10.1111/j.1600-065X.1991.tb00607.x; KOOP BF, 1994, GENOMICS, V19, P478, DOI 10.1006/geno.1994.1097; KRONENBERG M, 1986, ANNU REV IMMUNOL, V4, P529, DOI 10.1146/annurev.iy.04.040186.002525; LAU LL, 1994, NATURE, V369, P648, DOI 10.1038/369648a0; MACDONALD HR, 1993, J EXP MED, V177, P1487, DOI 10.1084/jem.177.5.1487; MACKAY CR, 1993, ADV IMMUNOL, V53, P217, DOI 10.1016/S0065-2776(08)60501-5; MACLENNAN ICM, 1986, IMMUNOL REV, V91, P61, DOI 10.1111/j.1600-065X.1986.tb01484.x; MATSUI K, 1991, SCIENCE, V254, P1788, DOI 10.1126/science.1763329; MCHEYZERWILLIAMS MG, 1991, NATURE, V350, P502, DOI 10.1038/350502a0; MCHEYZERWILLIAMS MG, 1993, J EXP MED, V178, P295, DOI 10.1084/jem.178.1.295; MOSKOPHIDIS D, 1993, NATURE, V362, P758, DOI 10.1038/362758a0; OEHEN S, 1992, J EXP MED, V176, P1273, DOI 10.1084/jem.176.5.1273; PADLAN EA, 1977, Q REV BIOPHYS, V10, P35, DOI 10.1017/S0033583500000135; PANTALEO G, 1994, NATURE, V370, P463, DOI 10.1038/370463a0; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; REAY PA, UNPUB; REINER SL, 1993, SCIENCE, V259, P1457, DOI 10.1126/science.8451641; ROCK EP, 1994, J EXP MED, V179, P323, DOI 10.1084/jem.179.1.323; SCHWARTZ RH, 1985, ANNU REV IMMUNOL, V3, P237, DOI 10.1146/annurev.iy.03.040185.001321; SPRENT J, 1994, CELL, V76, P315, DOI 10.1016/0092-8674(94)90338-7; SPRENT J, 1976, CELL IMMUNOL, V21, P278, DOI 10.1016/0008-8749(76)90057-5; STRENT J, 1994, SCIENCE, V265, P1395; Swain S L, 1992, Semin Immunol, V4, P59; SWAIN SL, 1991, IMMUNOL REV, V123, P115, DOI 10.1111/j.1600-065X.1991.tb00608.x; SYKULEV Y, 1994, IMMUNITY, V1, P15, DOI 10.1016/1074-7613(94)90005-1; TOUGH DF, 1994, J EXP MED, V179, P1127, DOI 10.1084/jem.179.4.1127; VITETTA ES, 1991, ANNU REV IMMUNOL, V9, P193, DOI 10.1146/annurev.iy.09.040191.001205; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; WEBER S, 1992, NATURE, V356, P793, DOI 10.1038/356793a0; WURZBURG U, 1973, EUR J IMMUNOL, V3, P762, DOI 10.1002/eji.1830031205; ZHENG B, 1994, NATURE, V372, P556, DOI 10.1038/372556a0; ZINKERNAGEL RM, 1993, IMMUNOL REV, V133, P199, DOI 10.1111/j.1600-065X.1993.tb01517.x	64	389	396	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 7	1995	268	5207					106	111		10.1126/science.7535476	http://dx.doi.org/10.1126/science.7535476			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR454	7535476				2022-12-24	WOS:A1995QR45400037
J	SAITOU, M; SUGAI, S; TANAKA, T; SHIMOUCHI, K; FUCHS, E; NARUMIYA, S; KAKIZUKA, A				SAITOU, M; SUGAI, S; TANAKA, T; SHIMOUCHI, K; FUCHS, E; NARUMIYA, S; KAKIZUKA, A			INHIBITION OF SKIN DEVELOPMENT BY TARGETED EXPRESSION OF A DOMINANT-NEGATIVE RETINOLE ACID RECEPTOR	NATURE			English	Article							KERATIN EXPRESSION; EPIDERMAL DIFFERENTIATION; TERMINAL DIFFERENTIATION; TRANSGENIC MICE; GENE; MOUSE; ALPHA; TRANSCRIPTION; TISSUE	ALTHOUGH pharmacological doses of retinoic acid (RA) have a wide variety of actions in vivo(1), experimental difficulties have prevented a definitive assignment of its physiological functions, We recently made a dominant-negative retinoic acid receptor (RAR) by a single amino-acid substitution(2) which creates a dominant-negative thyroid hormone receptor(3). The mutated RAR efficiently inhibited the endogenous activities of RARs (alpha, beta, gamma)(2). Thus, targeted expression of the mutated receptor should reveal RA functions during organogenesis by blocking RA signalling in the tissues concerned. To address this possibility, we expressed the dominant-negative RAR in the epidermis, a potential target organ of RA(4). We report here that the resultant transgenic mice exhibited dramatic suppression of epidermal maturation, demonstrating the requirement of RA in normal skin development.	KYOTO UNIV,FAC MED,DEPT PHARMACOL,KYOTO 60601,JAPAN; KYOTO UNIV,FAC MED,DEPT DERMATOL,KYOTO 60601,JAPAN; ONO PHARMACEUT,FUKUI INST SAFETY RES,FUKUI 913,JAPAN; UNIV CHICAGO,HOWARD HUGHES MED INST,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637	Kyoto University; Kyoto University; Ono Pharmaceutical Co Ltd; Howard Hughes Medical Institute; University of Chicago			Fuchs, Elaine/G-1565-2016					Armstrong Robert B., 1994, P545; BYRNE C, 1994, DEVELOPMENT, V120, P2369; DALE BA, 1985, J CELL BIOL, V101, P1257, DOI 10.1083/jcb.101.4.1257; DAVIDSON P, 1952, J ANAT, V86, P342; FUCHS E, 1980, CELL, V19, P1033, DOI 10.1016/0092-8674(80)90094-X; FUCHS E, 1981, CELL, V25, P617, DOI 10.1016/0092-8674(81)90169-0; GORDON JW, 1993, GUIDE TECHNIQUES MOU, P174; Gruneberg H, 1943, J HERED, V34, P89, DOI 10.1093/oxfordjournals.jhered.a105255; HANSON J, 1947, J ANAT, V81, P174; HARDISON RC, 1979, CELL, V18, P1285, DOI 10.1016/0092-8674(79)90239-3; IVANYI D, 1989, J PATHOL, V159, P7, DOI 10.1002/path.1711590105; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KAKIZUKA A, 1992, GENE DEV, V6, P578, DOI 10.1101/gad.6.4.578; KOPAN R, 1989, J CELL BIOL, V109, P295, DOI 10.1083/jcb.109.1.295; LI E, 1993, P NATL ACAD SCI USA, V90, P1590, DOI 10.1073/pnas.90.4.1590; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; LUFKIN T, 1993, P NATL ACAD SCI USA, V90, P7225, DOI 10.1073/pnas.90.15.7225; OHKUBO H, 1990, P NATL ACAD SCI USA, V87, P5153, DOI 10.1073/pnas.87.13.5153; PARRILLA R, 1991, J CLIN INVEST, V88, P2123, DOI 10.1172/JCI115542; Peck Gary L., 1994, P631; SAITOU M, 1994, J BIOL CHEM, V269, P19101; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; STEINERT PM, 1975, BIOCHEM J, V149, P39, DOI 10.1042/bj1490039; STOLER A, 1989, J INVEST DERMATOL, V93, P728, DOI 10.1111/1523-1747.ep12284397; STOLER A, 1988, J CELL BIOL, V107, P427, DOI 10.1083/jcb.107.2.427; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VASSAR R, 1989, P NATL ACAD SCI USA, V86, P1563, DOI 10.1073/pnas.86.5.1563; WEISS RA, 1984, J CELL BIOL, V98, P1397, DOI 10.1083/jcb.98.4.1397; Wolbach SB, 1925, J EXP MED, V42, P753, DOI 10.1084/jem.42.6.753	29	158	160	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 9	1995	374	6518					159	162		10.1038/374159a0	http://dx.doi.org/10.1038/374159a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL397	7533262				2022-12-24	WOS:A1995QL39700058
J	STEEGMAIER, M; LEVINOVITZ, A; ISENMANN, S; BORGES, E; LENTER, M; KOCHER, HP; KLEUSER, B; VESTWEBER, D				STEEGMAIER, M; LEVINOVITZ, A; ISENMANN, S; BORGES, E; LENTER, M; KOCHER, HP; KLEUSER, B; VESTWEBER, D			THE E-SELECTIN-LIGAND ESL-1 IS A VARIANT OF A RECEPTOR FOR FIBROBLAST GROWTH-FACTOR	NATURE			English	Article							LEUKOCYTE ADHESION MOLECULE-1; P-SELECTIN; GLYCOPROTEIN LIGAND; EXPRESSION; CELLS; ANTIGEN; IDENTIFICATION; SPECIFICITIES; DISTINCT; SURFACE	E-SELECTIN is an inducible cell-adhesion molecule on endothelial cells, which mediates the binding of neutrophils and functions as a Ca2+-dependent lectin(1-3). We have recently identified a 150K glycoprotein as the major ligand for E-selectin on myeloid cells, using a recombinant antibody-like form of mouse E-selectin as an affinity probe(4,5). Here we report the isolation of a mouse complementary DNA for this E-selectin ligand (ESL-1). The predicted amino-acid sequence of ESL-1 is 94% identical (over 1,078 amino acids) to the recently identified chicken cysteine-rich fibroblast growth-factor receptor(6), except for a unique 70-amino-acid amino-terminal domain of mature ESL-1. Fucosylation of ESL-1 is imperative for affinity isolation with E-selectin-IgG. A fucosylated, recombinant antibody-like form of ESL-1, but not for L-selectin, supports adhesion of E-selectin-transfected Chinese hamster ovary cells. Antibodies against ESL-1 block the binding of mouse myeloid cells to E-selectin. ESL-1, with a structure essentially identical to that of a receptor, thus functions as a cell adhesion ligand of E-selectin.	MAX PLANCK INST IMMUNBIOL,HANS SPEMANN LAB,D-79108 FREIBURG,GERMANY; SANDOZ PHARMA LTD,CH-4002 BASEL,SWITZERLAND	Max Planck Society; Novartis; Sandoz			Isenmann, Stefan/AAJ-3788-2020					BERG EL, 1991, J EXP MED, V174, P1461, DOI 10.1084/jem.174.6.1461; BOSSE R, 1994, EUR J IMMUNOL, V24, P3019, DOI 10.1002/eji.1830241215; BURRUS LW, 1992, MOL CELL BIOL, V12, P5600, DOI 10.1128/MCB.12.12.5600; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; HAHNE M, 1993, J CELL BIOL, V121, P655, DOI 10.1083/jcb.121.3.655; KISHIMOTO TK, 1991, BLOOD, V78, P805; KOTOVUORI P, 1993, GLYCOBIOLOGY, V3, P131, DOI 10.1093/glycob/3.2.131; KUIJPERS TW, 1992, J CELL BIOL, V118, P457, DOI 10.1083/jcb.118.2.457; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LARSEN GR, 1992, J BIOL CHEM, V267, P11104; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LENTER M, 1994, J CELL BIOL, V125, P471, DOI 10.1083/jcb.125.2.471; LEVINOVITZ A, 1993, J CELL BIOL, V121, P449, DOI 10.1083/jcb.121.2.449; LO SK, 1991, J EXP MED, V173, P1493, DOI 10.1084/jem.173.6.1493; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SAWADA R, 1993, J BIOL CHEM, V268, P12675; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; VESTWEBER D, 1994, RES IMMUNOL, V144, P704; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WELLER A, 1992, J BIOL CHEM, V267, P15176; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WILLIAMS RL, 1988, CELL, V52, P121	24	322	328	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 16	1995	373	6515					615	620		10.1038/373615a0	http://dx.doi.org/10.1038/373615a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG997	7531823				2022-12-24	WOS:A1995QG99700055
J	SPIVAKKROIZMAN, T; LEMMON, MA; DIKIC, I; LADBURY, JE; PINCHASI, D; HUANG, J; JAYE, M; CRUMLEY, G; SCHLESSINGER, J; LAX, I				SPIVAKKROIZMAN, T; LEMMON, MA; DIKIC, I; LADBURY, JE; PINCHASI, D; HUANG, J; JAYE, M; CRUMLEY, G; SCHLESSINGER, J; LAX, I			HEPARIN-INDUCED OLIGOMERIZATION OF FGF MOLECULES IS RESPONSIBLE FOR FGF RECEPTOR DIMERIZATION, ACTIVATION, AND CELL-PROLIFERATION	CELL			English	Article							FIBROBLAST GROWTH-FACTOR; LIGAND-BINDING DOMAIN; EXTRACELLULAR DOMAIN; EGF RECEPTOR; HORMONE RECEPTOR; MAMMALIAN-CELLS; AFFINITY; TRANSFORMATION; ECTODOMAIN; CLONING	Heparin is required for fibroblast growth factor (FGF) stimulation of biological responses. Using isothermal titration calorimetry, we show that acidic FGF (aFGF) forms a 1:1 complex with the soluble extracellular domain of FGF receptor (FGFR). Heparin exerts its effect by binding to many molecules of aFGF. The resulting aFGF-heparin complex can bind to several receptor molecules, leading to FGFR dimerization. In two cell lines lacking endogenous heparan sulfate, exogenous heparin is required for FGFR dimerization, tyrosine kinase activation, c-fos mRNA transcription, and cell proliferation. Moreover, a synthetic heparin analog that binds monovalently to aFGF blocks FGFR dimerization, activation, and signaling via FGFR. We propose that heparin causes oligomerization of aFGF such that its binding to FGFR results in dimerization and activation. This represents a novel mechanism for transmembrane signaling and may account for the action of many heparin-bound growth factors.	NYU, MED CTR, DEPT PHARMACOL, NEW YORK, NY 10016 USA; RHONE POULENC RORER, CENT RES, COLLEGEVILLE, PA 19426 USA	New York University			Dikic, Ivan/O-4650-2015	Dikic, Ivan/0000-0001-8156-9511; Ladbury, John/0000-0002-6328-7200; Lemmon, Mark/0000-0002-3379-5319	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM004725] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM04725] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BIEMANN HP, 1994, BIOCHEMISTRY-US, V33, P629, DOI 10.1021/bi00169a002; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DEMEYTS P, 1994, DIABETOLOGIA, V37, pS135, DOI 10.1007/BF00400837; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; GREENFIELD C, 1989, EMBO J, V8, P4115, DOI 10.1002/j.1460-2075.1989.tb08596.x; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; HURWITZ DR, 1991, J BIOL CHEM, V266, P22035; JAYE M, 1987, J BIOL CHEM, V262, P16612; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; LAX I, 1991, J BIOL CHEM, V266, P13828; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LEV S, 1992, J BIOL CHEM, V267, P10866; MACH H, 1993, BIOCHEMISTRY-US, V32, P5480, DOI 10.1021/bi00071a026; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; SCHAEFER EM, 1992, J BIOL CHEM, V267, P23393; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; WAGNER JA, 1991, CURR TOP MICROBIOL, V165, P95; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; YEH JI, 1993, J BIOL CHEM, V268, P9787; ZHOU M, 1993, BIOCHEMISTRY-US, V32, P8193, DOI 10.1021/bi00083a020; ZHU XT, 1993, STRUCTURE, V1, P27, DOI 10.1016/0969-2126(93)90006-3	39	589	597	1	37	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 16	1994	79	6					1015	1024		10.1016/0092-8674(94)90032-9	http://dx.doi.org/10.1016/0092-8674(94)90032-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PY086	7528103				2022-12-24	WOS:A1994PY08600011
J	GAVIS, ER; LEHMANN, R				GAVIS, ER; LEHMANN, R			TRANSLATIONAL REGULATION OF NANOS BY RNA LOCALIZATION	NATURE			English	Article							SEGMENTATION GENE HUNCHBACK; POSTERIOR DETERMINANT NANOS; POLE CELL-FORMATION; DROSOPHILA-MELANOGASTER; MATERNAL GENE; EMBRYONIC POLARITY; ANTERIOR PATTERN; GERM PLASM; OSKAR; PROTEIN	LOCALIZATION of the maternally synthesized nanos (nos) RNA to the posterior pole of the Drosophila embryo provides the source for a posterior-to-anterior gradient of Nos protein(1,2). Correct spatial regulation of nos activity is essential for normal pattern formation. High local concentrations of Nos protein in the posterior of the embryo are necessary to inhibit translation of the transcription factor Hunchback in this region(3,4), ana thus permit expression of genes required for abdomen formation (see ref. 5 for review). By contrast, misexpression of Nos protein at the anterior of the embryo prevents translation of the anterior morphogen Bicoid, suppressing head and thorax development(1,6-9). Posterior localization of nos RNA is mediated by sequences within the nos 3' untranslated region (3'UTR)(1) and requires the function of eight genes of the 'posterior group'(2,6). Although the unlocalized nos RNA is stable in embryos from females mutant for any of the posterior group genes, these embryos appear to lack nos activity because they develop the abdominal defects characteristic of embryos produced by nos mutant females(2,6,10-14). We report here that unlocalized nos RNA is translationally repressed. Translational repression is mediated by the nos 3'UTR and can be alleviated either by replacement of the 3'UTR with heterologous 3'UTR sequences or by posterior localization. Thus, RNA localization provides a novel mechanism for translational regulation.	MIT, DEPT BIOL, CAMBRIDGE, MA 02142 USA	Massachusetts Institute of Technology (MIT)	GAVIS, ER (corresponding author), MIT, WHITEHEAD INST BIOMED RES, HOWARD HUGHES MED INST, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.			Gavis, Elizabeth/0000-0003-0251-0760; Lehmann, Ruth/0000-0002-8454-5651				BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BOSWELL RE, 1985, CELL, V43, P97, DOI 10.1016/0092-8674(85)90015-7; BOSWELL RE, 1991, DEVELOPMENT, V113, P373; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; Ephrussi B, 1936, AM NAT, V70, P218, DOI 10.1086/280658; Evans T.C., 1992, Seminars in Developmental Biology, V3, P381; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; GAVIS ER, 1992, CELL, V71, P301, DOI 10.1016/0092-8674(92)90358-J; GAVIS ER, 1991, DEVELOPMENT, V112, P1077; GAVIS ER, IN PRESS ADV DEV BIO, V3; HULSKAMP M, 1991, BIOESSAYS, V13, P261, DOI 10.1002/bies.950130602; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; LEHMANN R, 1991, DEVELOPMENT, V112, P679; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; MOHLER J, 1986, GENETICS, V112, P808; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; SCHUEPBACH T, 1986, Wilhelm Roux's Archives of Developmental Biology, V195, P302; SMITH JL, 1992, CELL, V70, P849, DOI 10.1016/0092-8674(92)90318-7; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; Standart Nancy, 1992, Seminars in Developmental Biology, V3, P367; SUTER B, 1989, GENE DEV, V3, P1957, DOI 10.1101/gad.3.12a.1957; TAUTZ D, 1988, NATURE, V332, P281, DOI 10.1038/332281a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THEURKAUF WE, 1986, P NATL ACAD SCI USA, V83, P8477, DOI 10.1073/pnas.83.22.8477; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WANG C, 1994, DEV DYNAM, V199, P103, DOI 10.1002/aja.1001990204; WHARTON RP, 1989, CELL, V59, P881, DOI 10.1016/0092-8674(89)90611-9; WILHELM JE, 1993, J CELL BIOL, V123, P269, DOI 10.1083/jcb.123.2.269	30	243	247	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 26	1994	369	6478					315	318		10.1038/369315a0	http://dx.doi.org/10.1038/369315a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NN109	7514276				2022-12-24	WOS:A1994NN10900048
J	NEFF, JM; ANDERSON, G				NEFF, JM; ANDERSON, G			CARING FOR THE UNINSURED AND UNDERINSURED - PROTECTING CHILDREN WITH CHRONIC ILLNESS IN A COMPETITIVE MARKETPLACE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CAPITATION RATES	Health care for children with chronic illnesses is significantly more expensive than for the average child. Children with chronic illnesses are especially vulnerable in a competitive health care environment because of the higher ongoing cost associated with treating their illnesses and the inherent pressures to reduce services to manage within the capitated rate. To minimize the adverse impact a competitive market could have on these children, a ''carve-out'' for specific medical conditions is discussed. A capitation pricing system that reflects their higher costs is proposed, as well as a delivery system that is focused on their needs.	UNIV WASHINGTON,DEPT PEDIAT,SEATTLE,WA 98195; JOHNS HOPKINS MED INST,CTR HOSP FINANCE MANAGEMENT,BALTIMORE,MD 21205	University of Washington; University of Washington Seattle; Johns Hopkins University; Johns Hopkins Medicine	NEFF, JM (corresponding author), CHILDRENS HOSP & MED CTR,4800 SAND POINT WAY NE,POB 5371,SEATTLE,WA 98105, USA.							ACKERLOFF GA, 1970, Q J ECON, V84, P489; ANDERSON GF, 1990, INQUIRY-J HEALTH CAR, V27, P225; ARROW KJ, 1963, AM ECON REV, V53, P941; Ash A, 1989, Health Care Financ Rev, V10, P17; ATKINSON MA, 1994, NEW ENGL J MED, V331, P1428; BEHRMAN RE, 1992, NELSON TXB PAEDIAT, P1; BOYLE CA, 1994, PEDIATRICS, V93, P399; CONE TE, 1979, HIST AM PEDIATRICS, P159; ELSAS LJ, 1991, RUDOLPHS PEDIATRICS, P281; ELWOOD JM, 1992, EPIDEMIOLOGY CONTROL, P110; EPSTEIN A, 1995, NEW ENGL J MED, V333, P57, DOI 10.1056/NEJM199507063330114; Epstein A M, 1988, Health Care Financ Rev, V10, P51; FITZSIMMONS SC, 1993, J PEDIATR-US, V122, P1, DOI 10.1016/S0022-3476(05)83478-X; FOX HB, 1993, AM J DIS CHILD, V147, P546, DOI 10.1001/archpedi.1993.02160290052025; GILLUM RF, 1994, AM HEART J, V127, P919, DOI 10.1016/0002-8703(94)90562-2; Hahn J A, 1993, Paediatr Perinat Epidemiol, V7, P450, DOI 10.1111/j.1365-3016.1993.tb00426.x; HOWARD WT, 1924, PUBLIC HLTH ADM NATU; HOYER LW, 1994, NEW ENGL J MED, V330, P38, DOI 10.1056/NEJM199401063300108; HUGHES DC, 1995, PEDIATRICS, V95, P591; IANNACCONE ST, 1992, PEDIATR CLIN N AM, V39, P879; MCCLURE W, 1984, INQUIRY-J HEALTH CAR, V21, P205; NEWACHECK PW, 1994, J PEDIATR-US, V124, P40, DOI 10.1016/S0022-3476(94)70252-7; NEWACHECK PW, 1992, AM J PUBLIC HEALTH, V82, P364, DOI 10.2105/AJPH.82.3.364; Newhouse J P, 1989, Health Care Financ Rev, V10, P41; ROSS JA, 1994, EPIDEMIOL REV, V16, P243, DOI 10.1093/oxfordjournals.epirev.a036153; RUDOLPH AM, 1991, RUDOLPHS PEDIATRICS, P1; SAMANEK M, 1992, PEDIATR CARDIOL, V13, P152; Starfield B, 1985, EFFECTIVENESS MED CA; THOMAS JW, 1986, MED CARE, V24, P259, DOI 10.1097/00005650-198603000-00008; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WEINER JP, 1991, MED CARE, V29, P452, DOI 10.1097/00005650-199105000-00006; 1992, CTR FUTURE CHILDREN, P102; 1987, NATIONAL MED EXPENDI, P37; 1994, ANN REPORT C 1994; 1992, VITAL HLTH STAT 10, V189; 1994, WASHINGTON HLTH SERV; 1995, MMWR-MORBID MORTAL W, V43, P952	37	88	88	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 20	1995	274	23					1866	1869		10.1001/jama.274.23.1866	http://dx.doi.org/10.1001/jama.274.23.1866			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TK147	7500537				2022-12-24	WOS:A1995TK14700029
J	GAVIN, KA; HIDAKA, M; STILLMAN, B				GAVIN, KA; HIDAKA, M; STILLMAN, B			CONSERVED INITIATOR PROTEINS IN EUKARYOTES	SCIENCE			English	Article							ORIGIN RECOGNITION COMPLEX; DNA-REPLICATION; SACCHAROMYCES-CEREVISIAE; YEAST; GENES; START; EGGS	The origin recognition complex (ORC), a multisubunit protein identified in Saccharomyces cerevisiae, binds to chromosomal replicators and is required for the initiation of cellular DNA replication. complementary DNAs (cDNAs) encoding proteins related to the two largest subunits of ORC were cloned from various eukaryotes. The cDNAs encoding proteins related to S. cerevisiae Orc1p were cloned from the budding yeast Kluyveromyces lactis, the fission yeast Schizosaccharomyces pombe, and human cells. These proteins show similarity to regulators of the S and M phases of the cell cycle. Genetic analysis of orc1(+) from S. pombe reveals that it is essential for cell viability. The cDNAs encoding proteins related to S. cerevisiae Orc2p were cloned from Arabidopsis thaliana, Caenorhabditis elegans, and human cells. The human ORC-related proteins interact in vivo to form a complex. These studies suggest that ORC subunits are conserved and that the role of ORC is a general feature of eukaryotic DNA replication.	COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA; SUNY STONY BROOK, GENET PROGRAM, STONY BROOK, NY 11794 USA	Cold Spring Harbor Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook				Stillman, Bruce/0000-0002-9453-4091	NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER; NCI NIH HHS [CA13106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Baker T, 1991, DNA REPLICATION, V2; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1995, CELL, V83, P563, DOI 10.1016/0092-8674(95)90096-9; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BLOW JJ, 1990, J CELL SCI, V95, P383; BUENO A, 1992, EMBO J, V11, P2167, DOI 10.1002/j.1460-2075.1992.tb05276.x; CALIGIURI M, 1993, CELL, V72, P607, DOI 10.1016/0092-8674(93)90079-6; Campbell JL, 1991, MOL CELLULAR BIOL YE, P41; DEPAMPHILIS ML, 1993, J BIOL CHEM, V268, P1; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; EHRENHOFERMURRAY AE, 1995, SCIENCE, V270, P1671, DOI 10.1126/science.270.5242.1671; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; GAVIN KA, UNPUB; GOSSEN M, 1995, SCIENCE, V270, P1674, DOI 10.1126/science.270.5242.1674; HAMLIN JL, 1995, CURR OPIN GENET DEV, V5, P153, DOI 10.1016/0959-437X(95)80002-6; HARLAND RM, 1980, CELL, V21, P761, DOI 10.1016/0092-8674(80)90439-0; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P2541, DOI 10.1093/nar/21.11.2541; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MECHALI M, 1984, CELL, V38, P55, DOI 10.1016/0092-8674(84)90526-9; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; MIZUKAMI T, 1993, CELL, V73, P121, DOI 10.1016/0092-8674(93)90165-M; MORENO S, 1991, METHOD ENZYMOL, V194, P795; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; RAO H, 1994, MOL CELL BIOL, V14, P7643, DOI 10.1128/MCB.14.11.7643; RAO H, 1995, P NATL ACAD SCI USA, V92, P2224, DOI 10.1073/pnas.92.6.2224; ROWLEY A, 1994, BBA-GENE STRUCT EXPR, V1217, P239, DOI 10.1016/0167-4781(94)90283-6; ROWLEY A, 1995, EMBO J, V14, P2631, DOI 10.1002/j.1460-2075.1995.tb07261.x; SHORE D, 1984, EMBO J, V3, P2817, DOI 10.1002/j.1460-2075.1984.tb02214.x; SKOWRONSKI J, 1988, MOL CELL BIOL, V8, P1385, DOI 10.1128/MCB.8.4.1385; STARK MJR, 1989, YEAST, V5, P35, DOI 10.1002/yea.320050106; THEIS JF, 1994, MOL CELL BIOL, V14, P7652, DOI 10.1128/MCB.14.11.7652; WALKER SS, 1991, NUCLEIC ACIDS RES, V19, P6255, DOI 10.1093/nar/19.22.6255; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; WILSON AC, 1995, GENE DEV, V9, P2445, DOI 10.1101/gad.9.20.2445	43	205	216	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 8	1995	270	5242					1667	1671		10.1126/science.270.5242.1667	http://dx.doi.org/10.1126/science.270.5242.1667			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ293	7502077				2022-12-24	WOS:A1995TJ29300049
J	RUBIO, F; GASSMANN, W; SCHROEDER, JI				RUBIO, F; GASSMANN, W; SCHROEDER, JI			SODIUM-DRIVEN POTASSIUM UPTAKE BY THE PLANT POTASSIUM TRANSPORTER HKT1 AND MUTATIONS CONFERRING SALT TOLERANCE	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; CULTIVARS; MECHANISM; PROTEIN; MUTANT; YEAST	Sodium (Na+) at high millimolar concentrations in soils is toxic to most higher plants and severely reduces agricultural production worldwide. However, the molecular mechanisms for plant Na+ uptake remain unknown. Here, the wheat root high-affinity potassium (K+) uptake transporter HKT1 was shown to function as a high-affinity K+-Na+ cotransporter. High-affinity K+ uptake was activated by micromolar Na+ concentrations; moreover, high-affinity Na+ uptake was activated by K+ (half-activation constant, 2.8 mu M K+). However, at physiologically detrimental concentrations of Na+, K+ accumulation mediated by HKT1 was blocked and low-affinity Na+ uptake occurred (Michaelis constant, similar to 16 mM Na+), which correlated to Na+ toxicity in plants. Point mutations in the sixth putative transmembrane domain of HKT1 that increase Na+ tolerance were isolated with the use of yeast as a screening system. Na+ uptake and Na+ inhibition of K+ accumulation indicate a possible role for HKT1 in physiological Na+ toxicity in plants.					Rubio, Francisco/K-2854-2014; Rubio, Francisco/ABF-8662-2020	Rubio, Francisco/0000-0001-7640-9548; Rubio, Francisco/0000-0001-7640-9548; Schroeder, Julian/0000-0002-3283-5972; Gassmann, Walter/0000-0002-7527-0385				ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; BARKLA BJ, 1991, P NATL ACAD SCI USA, V88, P11177, DOI 10.1073/pnas.88.24.11177; BORSTPAUWELS GWFH, 1981, BIOCHIM BIOPHYS ACTA, V650, P88, DOI 10.1016/0304-4157(81)90002-2; FAN TWM, 1989, P NATL ACAD SCI USA, V86, P9856, DOI 10.1073/pnas.86.24.9856; FLOWERS TJ, 1983, ENCY PLANT PHYSL B, V15, P651; GASSMANN W, UNPUB; GAXIOLA R, 1992, EMBO J, V11, P3157, DOI 10.1002/j.1460-2075.1992.tb05392.x; GREENWAY H, 1980, ANNU REV PLANT PHYS, V31, P149, DOI 10.1146/annurev.pp.31.060180.001053; LEYH TS, 1993, CRIT REV BIOCHEM MOL, V28, P515, DOI 10.3109/10409239309085137; MAATHUIS FJM, 1994, P NATL ACAD SCI USA, V91, P9272, DOI 10.1073/pnas.91.20.9272; MURGUIA JR, 1995, SCIENCE, V267, P232; RAINS DW, 1967, PLANT PHYSIOL, V42, P314, DOI 10.1104/pp.42.3.314; RAINS DW, 1965, SCIENCE, V148, P1611, DOI 10.1126/science.148.3677.1611; RAMOS J, 1985, ARCH MICROBIOL, V143, P88, DOI 10.1007/BF00414774; RAMOS J, 1986, EUR J BIOCHEM, V154, P307, DOI 10.1111/j.1432-1033.1986.tb09398.x; RODRIGUEZNAVARR.A, 1984, J BACTERIOL, V159, P940; RUBIO F, UNPUB; SCHACHTMAN DP, 1994, NATURE, V370, P655, DOI 10.1038/370655a0; SCHROEDER JI, 1994, ANNU REV BIOPH BIOM, V23, P441, DOI 10.1146/annurev.bb.23.060194.002301; SCHUBERT S, 1990, PLANT SOIL, V123, P205, DOI 10.1007/BF00011269; SERRANO R, 1985, PLASMA MEMBRANE ATPA; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; SMITH FA, 1989, J MEMBRANE BIOL, V108, P125, DOI 10.1007/BF01871024; SUSSMAN MR, 1994, ANNU REV PLANT PHYS, V45, P211, DOI 10.1146/annurev.pp.45.060194.001235; TARCZYNSKI MC, 1993, SCIENCE, V259, P508, DOI 10.1126/science.259.5094.508; WALKER NA, 1991, PLANTA, V185, P443, DOI 10.1007/BF00201070	26	476	536	6	84	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 8	1995	270	5242					1660	1663		10.1126/science.270.5242.1660	http://dx.doi.org/10.1126/science.270.5242.1660			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ293	7502075				2022-12-24	WOS:A1995TJ29300047
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PATIENT EDUCATION-PROGRAM PROPOSED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1995, FED REG         0823, V60, P44182	1	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 11	1995	274	14					1109	1109						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY056	7563473				2022-12-24	WOS:A1995RY05600009
J	MORROW, DM; MORROW, M; TAGLE, DA; SHILOH, Y; COLLINS, FS; HIETER, P				MORROW, DM; MORROW, M; TAGLE, DA; SHILOH, Y; COLLINS, FS; HIETER, P			TEL1, AN SACCHAROMYCES-CEREVISIAE HOMOLOG OF THE HUMAN GENE MUTATED IN ATAXIA-TELANGIECTASIA, IS FUNCTIONALLY RELATED TO THE YEAST CHECKPOINT GENE MEC1	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; PHOSPHATIDYLINOSITOL 3-KINASE; RADIATION SENSITIVITY; PROTEIN; CELLS; CANCER; DNA; RAPAMYCIN; VPS34; IDENTIFICATION	Patients with the genetic disorder ataxia telangiectasia (AT) have mutations in the AT mutated (ATM) gene, which is homologous to TEL1 and the checkpoint gene MEC1. A tel1 deletion mutant, unlike a mec1 deletion, is viable and does not exhibit increased sensitivity to DNA-damaging agents. However, increased dosage of TEL1 rescues sensitivity of a mec1 mutant, mec1-1, to DNA-damaging agents and rescues viability of a mec1 disruption. mec1-1 tel1 Delta 1 double mutants are synergistically sensitive to DNA-damaging agents, including radiomimetic drugs. These data indicate that TEL1 and MEC1 are functionally related and that functions of the ATM gene are apparently divided between at least two S. cerevisiae homologs.	NIH,NATL CTR HUMAN GENOME RES,GENE TRANSFER LAB,BETHESDA,MD 20892; TEL AVIV UNIV,SACKLER SCH MED,DEPT HUMAN GENET,IL-69978 TEL AVIV,ISRAEL	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Tel Aviv University; Sackler Faculty of Medicine	MORROW, DM (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205, USA.				NATIONAL CANCER INSTITUTE [P01CA016519] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031763] Funding Source: NIH RePORTER; NCI NIH HHS [CA16519] Funding Source: Medline; NIGMS NIH HHS [GM162283] Funding Source: Medline; NINDS NIH HHS [NS31763] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BOEKE JD, 1984, MOL GEN GENET, V197, P3445; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; FELDMANN H, 1994, EMBO J, V13, P5795, DOI 10.1002/j.1460-2075.1994.tb06923.x; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FRIEDBERG EC, 1995, DNA REPAIR; FRY MJ, 1994, BBA-MOL BASIS DIS, V1226, P237, DOI 10.1016/0925-4439(94)90036-1; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KATO R, 1994, NUCLEIC ACIDS RES, V22, P3104, DOI 10.1093/nar/22.15.3104; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEHMANN AR, 1979, NUCLEIC ACIDS RES, V6, P1953, DOI 10.1093/nar/6.5.1953; LUSTIG AJ, 1986, P NATL ACAD SCI USA, V83, P1398, DOI 10.1073/pnas.83.5.1398; MCKINNON PJ, 1987, HUM GENET, V75, P197, DOI 10.1007/BF00281059; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; MORRELL D, 1986, J NATL CANCER I, V77, P89; MURNANE JP, 1994, EMBO J, V13, P4953, DOI 10.1002/j.1460-2075.1994.tb06822.x; PAINTER RB, 1982, MECHANISMS CHEM CARC; PAINTER RB, 1985, ATAXIA TELANGIECTASI; PANDITA TK, 1995, IN PRESS CYTOGENET C; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; REENAN RAG, 1992, GENETICS, V132, P963; Rose MD., 1990, METHODS YEAST GENETI; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SEATON BL, 1992, GENE, V119, P83, DOI 10.1016/0378-1119(92)90069-2; SHANI N, 1995, P NATL ACAD SCI USA, V92, P6012, DOI 10.1073/pnas.92.13.6012; SHILOH Y, 1983, CARCINOGENESIS, V4, P1317, DOI 10.1093/carcin/4.10.1317; SHILOH Y, 1995, EUR J HUM GENET, V3, P116; SIKORSKI RS, 1989, GENETICS, V122, P19; SWIFT M, 1986, AM J HUM GENET, V39, P573; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TAYLOR AMR, 1983, CANCER RES, V43, P2700; TAYLOR AMR, 1979, CANCER RES, V39, P1046; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652	48	336	343	0	5	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 8	1995	82	5					831	840		10.1016/0092-8674(95)90480-8	http://dx.doi.org/10.1016/0092-8674(95)90480-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RU755	7545545	hybrid			2022-12-24	WOS:A1995RU75500018
J	GRIFFITH, JP; KIM, JL; KIM, EE; SINTCHAK, MD; THOMSON, JA; FITZGIBBON, MJ; FLEMING, MA; CARON, PR; HSIAO, K; NAVIA, MA				GRIFFITH, JP; KIM, JL; KIM, EE; SINTCHAK, MD; THOMSON, JA; FITZGIBBON, MJ; FLEMING, MA; CARON, PR; HSIAO, K; NAVIA, MA			X-RAY STRUCTURE OF CALCINEURIN INHIBITED BY THE IMMUNOPHILIN IMMUNOSUPPRESSANT FKBP12-FK506 COMPLEX	CELL			English	Article							LYMPHOCYTE-T ACTIVATION; CYCLOSPORINE-A; BINDING-PROTEIN; SACCHAROMYCES-CEREVISIAE; 3-DIMENSIONAL STRUCTURE; FK-506-BINDING PROTEIN; CATALYTIC SUBUNIT; ATOMIC-STRUCTURE; CELL ACTIVATION; PEPTIDE COMPLEX	The X-ray structure of the ternary complex of a calcineurin A fragment, calcineurin B, FKBP12, and the immunosuppressant drug FK506 (also known as tacrolimus) has been determined at 2.5 Angstrom resolution, providing a description of how FK506 functions at the atomic level. In the structure, the FKBP12-FK506 binary complex does not contact the phosphatase active site on calcineurin A that is more than 10 Angstrom removed. Instead, FKBP12-FK506 is so positioned that it can inhibit the dephosphorylation of its macromolecular substrates by physically hindering their approach to the active site. The ternary complex described here represents the three-dimensional structure of a Ser/Thr protein phosphatase and provides a structural basis for understanding calcineurin inhibition by FKBP12-FK506.			GRIFFITH, JP (corresponding author), VERTEX PHARMACEUT INC,40 ALLSTON ST,CAMBRIDGE,MA 02139, USA.							ALDAPE RA, 1992, J BIOL CHEM, V267, P16029; AMES JB, 1995, J BIOL CHEM, V270, P4526, DOI 10.1074/jbc.270.9.4526; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BECKER JW, 1993, J BIOL CHEM, V268, P11335; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BOREL JF, 1989, PHARMACOL REV, V41, P259; BOREL JF, 1976, AGENTS ACTIONS, V6, P468, DOI 10.1007/BF01973261; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1993, X PLOR SYSTEM XRAY C; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1989, J BIOL CHEM, V264, P21435; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; Di Padova F. E., 1994, Perspectives in Drug Discovery and Design, V2, P49; DONELLADEANA A, 1994, EUR J BIOCHEM, V219, P109, DOI 10.1111/j.1432-1033.1994.tb19920.x; DUMONT FJ, 1992, J EXP MED, V176, P751, DOI 10.1084/jem.176.3.751; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; FUTER O, 1995, J BIOL CHEM, V270, P18935, DOI 10.1074/jbc.270.32.18935; GORDON JI, 1991, J BIOL CHEM, V266, P8647; Goulet Mark T., 1994, Perspectives in Drug Discovery and Design, V2, P145, DOI 10.1007/BF02171741; GUERINI D, 1989, P NATL ACAD SCI USA, V86, P9183, DOI 10.1073/pnas.86.23.9183; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; HEITMAN J, 1991, P NATL ACAD SCI USA, V88, P1948, DOI 10.1073/pnas.88.5.1948; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; ITO A, 1989, BIOCHEM BIOPH RES CO, V163, P1492, DOI 10.1016/0006-291X(89)91148-0; ITOH S, 1995, IN PRESS BIOORG MED, V5; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; KAKALIS LT, 1995, FEBS LETT, V362, P55, DOI 10.1016/0014-5793(95)00207-P; KINCAID RL, 1990, J BIOL CHEM, V265, P11312; KINCAID RL, 1988, P NATL ACAD SCI USA, V85, P8983, DOI 10.1073/pnas.85.23.8983; KING MM, 1984, J BIOL CHEM, V259, P8847; KINO T, 1987, J ANTIBIOT, V40, P1249, DOI 10.7164/antibiotics.40.1249; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; KOLTIN Y, 1991, MOL CELL BIOL, V11, P1718, DOI 10.1128/MCB.11.3.1718; KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MARTIN BL, 1994, BBA-PROTEIN STRUCT M, V1206, P136, DOI 10.1016/0167-4838(94)90082-5; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MILAN D, 1994, CELL, V79, P437, DOI 10.1016/0092-8674(94)90253-4; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; MUELLER EG, 1993, J AM CHEM SOC, V115, P2974, DOI 10.1021/ja00060a055; NARGANG CE, 1994, DNA SEQUENCE, V4, P313, DOI 10.3109/10425179409020857; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; OEFNER C, 1986, J MOL BIOL, V192, P605, DOI 10.1016/0022-2836(86)90280-9; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; PERRINO BA, 1995, J BIOL CHEM, V270, P340, DOI 10.1074/jbc.270.1.340; REED RJ, 1986, ACTA CRYSTALLOGR A, V42, P140; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; SHARMA RK, 1986, J BIOL CHEM, V261, P1322; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; SIKKINK R, 1995, BIOCHEMISTRY-US, V34, P8348, DOI 10.1021/bi00026a016; STRATER N, 1995, SCIENCE, V268, P1489, DOI 10.1126/science.7770774; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; TOCCI MJ, 1989, J IMMUNOL, V143, P718; VANDUYNE GD, 1991, J AM CHEM SOC, V113, P7433, DOI 10.1021/ja00019a057; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; VEZINA C, 1975, J ANTIBIOT, V28, P721, DOI 10.7164/antibiotics.28.721; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WILSON KP, 1995, ACTA CRYSTALLOGR D, V51, P511, DOI 10.1107/S0907444994014514; YANG D, 1993, J AM CHEM SOC, V115, P819, DOI 10.1021/ja00055a081; YONEMOTO W, 1993, J BIOL CHEM, V268, P2348; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158; ZHUO SQ, 1994, J BIOL CHEM, V269, P26234	75	752	786	5	25	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 11	1995	82	3					507	522		10.1016/0092-8674(95)90439-5	http://dx.doi.org/10.1016/0092-8674(95)90439-5			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RP242	7543369	Bronze			2022-12-24	WOS:A1995RP24200020
J	TYCKO, R; BARRETT, SE; DABBAGH, G; PFEIFFER, LN; WEST, KW				TYCKO, R; BARRETT, SE; DABBAGH, G; PFEIFFER, LN; WEST, KW			ELECTRONIC STATES IN GALLIUM-ARSENIDE QUANTUM-WELLS PROBED BY OPTICALLY PUMPED NMR	SCIENCE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; SPIN-LATTICE RELAXATION; FIELD DEPENDENCE; GAS; DIFFUSION; ENERGIES	An optical pumping technique was used to enhance and localize nuclear magnetic resonance (NMR) signals from an n-doped GaAs/Al0.1Ga0.9As multiple quantum well structure, permitting direct radio-frequency measurements of gallium-71 NMR spectra and nuclear spin-lattice relaxation rates (1/T-1) as functions of temperature (1.6 K < T < 4.2 K) and the Landau level filling factor (0.66 < nu < 1.76). The measurements reveal effects of electron-electron interactions on the energy levels and spin states of the two-dimensional electron system confined in the GaAs wells. Minima in 1/T-1 at nu approximate to 1 and nu approximate to 2/3 indicate energy gaps for electronic excitations in both integer and fractional quantum Hall states. Rapid, temperature-independent relaxation at intermediate v values indicates a manifold of low-lying electronic states with mixed spin polarizations.	AT&T BELL LABS,MURRAY HILL,NJ 07974	AT&T; Nokia Corporation; Nokia Bell Labs			Barrett, Sean E/F-1274-2015	Barrett, Sean E/0000-0002-0498-2027				ANTONIOU D, 1991, PHYS REV B, V43, P11686, DOI 10.1103/PhysRevB.43.11686; BARRETT SE, 1994, PHYS REV LETT, V72, P1368, DOI 10.1103/PhysRevLett.72.1368; BARRETT SE, IN PRESS PHYS REV LE; BERG A, 1990, PHYS REV LETT, V64, P2563, DOI 10.1103/PhysRevLett.64.2563; BOEBINGER GS, 1985, PHYS REV LETT, V55, P1606, DOI 10.1103/PhysRevLett.55.1606; BURATTO SK, 1992, J VAC SCI TECHNOL B, V10, P1740, DOI 10.1116/1.586233; BURATTO SK, 1991, PHYS REV B, V44, P9035, DOI 10.1103/PhysRevB.44.9035; DEVREESE JT, 1987, PHYSICS 2 DIMENSIONA; EISENSTEIN JP, 1990, SCIENCE, V248, P1510, DOI 10.1126/science.248.4962.1510; EISENSTEIN JP, 1994, SCIENCE, V266, P1199; FERTIG HA, 1994, PHYS REV B, V50, P11018, DOI 10.1103/PhysRevB.50.11018; FLINN GP, 1990, SEMICOND SCI TECH, V5, P533, DOI 10.1088/0268-1242/5/6/012; FURNEAUX JE, 1989, PHYS REV LETT, V63, P1098, DOI 10.1103/PhysRevLett.63.1098; IORDANSKII SV, 1991, PHYS REV B, V44, P6554, DOI 10.1103/PhysRevB.44.6554; KALEVICH VK, 1990, JETP LETT+, V52, P349; KIM JH, 1994, PHYS REV B, V49, P16777, DOI 10.1103/PhysRevB.49.16777; KRAPF M, 1991, SOLID STATE COMMUN, V78, P459, DOI 10.1016/0038-1098(91)90704-Y; LAMPEL G, 1968, PHYS REV LETT, V20, P491, DOI 10.1103/PhysRevLett.20.491; MARTINDALE JA, 1992, PHYS REV LETT, V68, P702, DOI 10.1103/PhysRevLett.68.702; OVCHINNIKOV YN, 1994, JETP LETT+, V59, P569; PAGET D, 1977, PHYS REV B, V15, P5780, DOI 10.1103/PhysRevB.15.5780; RICHARDSON SL, 1986, PHYS REV B, V33, P1177, DOI 10.1103/PhysRevB.33.1177; SONDHI SL, 1993, PHYS REV B, V47, P16419, DOI 10.1103/PhysRevB.47.16419; SUTER D, 1985, PHYS REV B, V32, P5608, DOI 10.1103/PhysRevB.32.5608; TYCKO R, 1991, SCIENCE, V253, P884, DOI 10.1126/science.253.5022.884; TYCKO R, 1992, ISRAEL J CHEM, V32, P179; TYCKO R, 1993, J PHYS CHEM SOLIDS, V54, P1713, DOI 10.1016/0022-3697(93)90286-Z; WALSTEDT RE, 1990, SCIENCE, V248, P1082, DOI 10.1126/science.248.4959.1082; WEISBUCH C, 1991, QUANTUM SEMICONDUCTO, P123; Winter J., 1971, MAGNETIC RESONANCE M	30	246	247	1	32	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 9	1995	268	5216					1460	1463		10.1126/science.7539550	http://dx.doi.org/10.1126/science.7539550			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC190	7539550				2022-12-24	WOS:A1995RC19000029
J	BERLIN, C; BARGATZE, RF; CAMPBELL, JJ; VONANDRIAN, UH; SZABO, MC; HASSLEN, SR; NELSON, RD; BERG, EL; ERLANDSEN, SL; BUTCHER, EC				BERLIN, C; BARGATZE, RF; CAMPBELL, JJ; VONANDRIAN, UH; SZABO, MC; HASSLEN, SR; NELSON, RD; BERG, EL; ERLANDSEN, SL; BUTCHER, EC			ALPHA-4 INTEGRINS MEDIATE LYMPHOCYTE ATTACHMENT AND ROLLING UNDER PHYSIOLOGICAL FLOW	CELL			English	Article							HIGH ENDOTHELIAL VENULES; VASCULAR ADDRESSIN; SELECTIN; ADHESION; MADCAM-1; LECAM-1; SPECIFICITY; LEUKOCYTES; MECHANISMS; EXPRESSION	Of the several families of adhesion receptors involved in leukocyte-endoethelial cell interactions, only the selectins have been shown to initiate leukocyte interaction under physiologic shear; indeed, beta 2 (CD18) integrins responsible for neutrophil arrest are unable to engage without prior selectin-mediated rolling. In contrast, alpha 4 (CD49d) integrins are shown here to initiate lymphocyte contact (''tethering'') In vitro under shear and in the absence of a selectin contribution. The alpha 4 integrin ligands MAdCAM-1 and VCAM-1 support loose reversible interactions including rolling, as well as rapid sticking and arrest that is favored following integrin activation. Moreover, alpha 4 beta 7 mediates L-selectin (CD62L)-independent attachment of blood-borne lymphocytes to lamina propria venules in situ. Scanning electron microscopy of alpha 4 beta 7(hi) lymphoid cells reveals that, like L-selectin, alpha 4 beta 7 is highly concentrated on microvillous sites of initial cellular contact, whereas the beta 2 integrin LFA-1 is excluded from villi. Thus, alpha 4 but not beta 2 integrins can initiate leukocyte adhesion under flow, a capacity that may be in part a function of topographic presentation on microvilli.	VET AFFAIRS MED CTR,CTR MOLEC BIOL & MED,FOOTHILL RES CTR,PALO ALTO,CA 94304; MONTANA STATE UNIV,VET MOLEC BIOL LAB,BOZEMAN,MT 59717; UNIV MINNESOTA,DEPT LAB MED & PATHOL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,DEPT DERMATOL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,DEPT CELL BIOL & NEUROANAT,MINNEAPOLIS,MN 55455; CTR BLOOD RES,BOSTON,MA 02115; PROT DESIGN LABS,MT VIEW,CA 94043	US Department of Veterans Affairs; Veterans Health Administration (VHA); Montana State University System; Montana State University Bozeman; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM)	BERLIN, C (corresponding author), STANFORD UNIV,DEPT PATHOL,IMMUNOL & VASC BIOL LAB,STANFORD,CA 94305, USA.		Berg, Ellen/T-8827-2019; Berg, Ellen/D-9076-2014; von Andrian, Ulrich H/A-5775-2008	Berg, Ellen/0000-0001-5149-6665; 	NIAID NIH HHS [AI19957, AI37832] Funding Source: Medline; NIGMS NIH HHS [GM37734] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037832, R01AI019957] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM037734, R01GM037734] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABASSI O, 1993, BLOOD CELLS, V19, P245; ALON R, 1995, IN PRESS J CELL BIOL; ANDREW DP, 1994, J IMMUNOL, V153, P3847; ATHERTON A, 1972, J PHYSIOL-LONDON, V222, P447, DOI 10.1113/jphysiol.1972.sp009808; BARGATZE RF, 1993, J EXP MED, V178, P367, DOI 10.1084/jem.178.1.367; BERG EL, 1991, J CELL BIOL, V114, P343, DOI 10.1083/jcb.114.2.343; BERG EL, 1993, NATURE, V366, P695, DOI 10.1038/366695a0; BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; BRISKIN MJ, 1993, NATURE, V363, P461, DOI 10.1038/363461a0; BUTCHER EC, 1980, EUR J IMMUNOL, V10, P556, DOI 10.1002/eji.1830100713; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; DUNON D, 1993, BLOOD, V81, P1; ERLANDSEN SL, 1993, J HISTOCHEM CYTOCHEM, V41, P327, DOI 10.1177/41.3.7679125; ERLE DJ, 1994, J IMMUNOL, V153, P517; HAMANN A, 1994, J IMMUNOL, V52, P3282; HU MCT, 1992, P NATL ACAD SCI USA, V89, P8254, DOI 10.1073/pnas.89.17.8254; JONES DA, 1995, IN PRESS J CLIN INVE; JUTILA MA, 1989, CELL IMMUNOL, V132, P201; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; MACKAY CR, 1993, CURR OPIN IMMUNOL, V5, P423, DOI 10.1016/0952-7915(93)90063-X; NAKACHE M, 1988, NATURE, V304, P32; PERRY MA, 1991, J CLIN INVEST, V87, P1798, DOI 10.1172/JCI115200; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; PICKER LJ, 1992, ANNU REV IMMUNOL, V10, P561, DOI 10.1146/annurev.immunol.10.1.561; POSTIGO AA, 1993, RES IMMUNOL, V144, P723, DOI 10.1016/S0923-2494(93)80057-6; SCHWEIGHOFFER T, 1993, J IMMUNOL, V151, P717; SHIMIZU Y, 1992, IMMUNOL TODAY, V13, P106, DOI 10.1016/0167-5699(92)90151-V; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; SRIRAMARAO P, 1994, J IMMUNOL, V153, P4238; STREETER PR, 1988, J CELL BIOL, V107, P1853, DOI 10.1083/jcb.107.5.1853; STREETER PR, 1988, NATURE, V331, P41, DOI 10.1038/331041a0; VANEWIJK WV, 1980, DIBA F S, V71, P21; VONANDRIAN UH, 1992, AM J PHYSIOL, V263, pH1034, DOI 10.1152/ajpheart.1992.263.4.H1034; VONANDRIAN UH, 1993, AGENT ACTION SUPPL, V41, P153; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; WOLBER F, 1993, FASEB J, V7, P3704	38	868	890	0	22	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 10	1995	80	3					413	422		10.1016/0092-8674(95)90491-3	http://dx.doi.org/10.1016/0092-8674(95)90491-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QG470	7532110	Bronze			2022-12-24	WOS:A1995QG47000007
J	UCKUN, FM; EVANS, WE; FORSYTH, CJ; WADDICK, KG; AHLGREN, LT; CHELSTROM, LM; BURKHARDT, A; BOLEN, J; MYERS, DE				UCKUN, FM; EVANS, WE; FORSYTH, CJ; WADDICK, KG; AHLGREN, LT; CHELSTROM, LM; BURKHARDT, A; BOLEN, J; MYERS, DE			BIOTHERAPY OF B-CELL PRECURSOR LEUKEMIA BY TARGETING GENISTEIN TO CD19-ASSOCIATED TYROSINE KINASES	SCIENCE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; POKEWEED ANTIVIRAL PROTEIN; SEVERE COMBINED IMMUNODEFICIENCY; DISCRETE DEVELOPMENTAL STAGES; EXPRESS FUNCTIONAL RECEPTORS; BONE-MARROW TRANSPLANTATION; SIGNAL-TRANSDUCTION COMPLEX; LYMPHOCYTES-B; GROWTH-FACTOR; PROGENITOR CELLS	B-cell precursor (BCP) leukemia is the most common form of childhood cancer and the second most common form of acute leukemia in adults. Human BCP leukemia was treated in a severe combined immunodeficient mouse model by targeting of the tyrosine kinase inhibitor Genistein (Gen) to the B cell-specific receptor CD19 with the monoclonal antibody B43. The B43-Gen immunoconjugate bound with high affinity to BCP leukemia cells, selectively inhibited CD19-associated tyrosine kinases, and triggered rapid apoptotic cell death. At less than one-tenth the maximum tolerated dose more than 99.999 percent of human BCP leukemia cells were killed, which led to 100 percent long-term event-free survival from an otherwise invariably fatal leukemia. The B43-Gen immunoconjugate might be useful in eliminating leukemia cells in patients who have failed conventional therapy.	UNIV MINNESOTA, DEPT PEDIAT, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, DEPT PHARMACOL, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, CHILDRENS CANC GRP, CENTRALIZED IMMUNOCONJUGATE REFERENCE LAB, MINNEAPOLIS, MN 55455 USA; ST JUDE CHILDRENS RES HOSP, DEPT PHARMACEUT, MEMPHIS, TN 38101 USA; UNIV MINNESOTA, DEPT CHEM, MINNEAPOLIS, MN 55455 USA; BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT MOLEC BIOL, SIGNAL TRANSDUCT LAB, PRINCETON, NJ 08543 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; St Jude Children's Research Hospital; University of Minnesota System; University of Minnesota Twin Cities; Bristol-Myers Squibb	UCKUN, FM (corresponding author), UNIV MINNESOTA, DEPT THERAPEUT RADIOL RADIAT ONCOL, BIOTHERAPY PROGRAM, MINNEAPOLIS, MN 55455 USA.		Evans, William E./C-2069-2012	Evans, William E./0000-0002-9333-5322; Uckun, Fatih M./0000-0001-9334-183X	NCI NIH HHS [CA-42111, CA-51425, CA-42633] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA042111, R01CA042111, R01CA042633, R01CA051425] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLERCREUTZ H, 1991, AM J CLIN NUTR, V54, P1093, DOI 10.1093/ajcn/54.6.1093; ADLERCREUTZ H, 1991, CLIN CHIM ACTA, V199, P263, DOI 10.1016/0009-8981(91)90120-2; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BARRY MA, 1990, BIOCHEM PHARMACOL, V40, P2353, DOI 10.1016/0006-2952(90)90733-2; BOLEN JB, 1991, ADV CANCER RES, V57, P103; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BRADBURY LE, 1993, J IMMUNOL, V151, P2915; BURKE TR, 1993, J MED CHEM, V36, P425, DOI 10.1021/jm00056a001; CALLARD RE, 1992, J IMMUNOL, V148, P2983; CARTER RH, 1992, SCIENCE, V256, P105, DOI 10.1126/science.1373518; CHALUPNY NJ, 1993, EMBO J, V12, P2691, DOI 10.1002/j.1460-2075.1993.tb05930.x; COHEN DI, 1992, SCIENCE, V256, P542, DOI 10.1126/science.1570514; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; Cope FO., 1991, APOPTOSIS MOL BASIS, P47; CUSHMAN M, 1991, J MED CHEM, V34, P798, DOI 10.1021/jm00106a047; CUSHMAN M, 1994, J MED CHEM, V37, P3353, DOI 10.1021/jm00046a020; DARGENIO DZ, 1979, COMPUT PROG BIOMED, V9, P115, DOI 10.1016/0010-468X(79)90025-4; DICKSON RB, 1983, BIOCHEMISTRY-US, V22, P5667, DOI 10.1021/bi00293a033; EVANS CA, 1993, CANCER RES, V53, P1735; GERLOWSKI LE, 1983, J PHARM SCI, V72, P1103, DOI 10.1002/jps.2600721003; GREAVES M, 1993, BLOOD, V82, P1043; GREAVES MF, 1986, SCIENCE, V234, P697, DOI 10.1126/science.3535067; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Jin J., UNPUB; KAUFMANN SH, 1989, CANCER RES, V49, P5870; LEDBETTER JA, 1988, P NATL ACAD SCI USA, V85, P1897, DOI 10.1073/pnas.85.6.1897; MANSKE J, 1986, THESIS U MINNESOTA; MATSUMOTO AK, 1991, J EXP MED, V173, P55, DOI 10.1084/jem.173.1.55; MYERS DE, UNPUB KINASE RENATUR; MYERS DE, 1987, BLOOD, V70, P1020; NADLER LM, 1983, J IMMUNOL, V131, P244; OTANI H, 1993, J BIOL CHEM, V268, P22733; PASTAN I, 1986, CELL, V47, P641, DOI 10.1016/0092-8674(86)90506-4; PETTERSSON H, 1984, J ASSOC OFF ANA CHEM, V67, P503; REAMAN G, IN PRESS LEUKEMIA LY; RENNER C, 1994, SCIENCE, V264, P833, DOI 10.1126/science.8171337; RIVERA GK, 1993, NEW ENGL J MED, V329, P1289, DOI 10.1056/NEJM199310283291801; SCHEUERMANN RH, 1994, P NATL ACAD SCI USA, V91, P4048, DOI 10.1073/pnas.91.9.4048; SCHIEVEN GL, 1993, BLOOD, V82, P1212, DOI 10.1182/blood.V82.4.1212.bloodjournal8241212; STAMENKOVIC I, 1988, J EXP MED, V168, P1205, DOI 10.1084/jem.168.3.1205; TEDDER TF, 1989, J IMMUNOL, V143, P712; TRAIL PA, 1993, SCIENCE, V261, P212, DOI 10.1126/science.8327892; TREVILLYAN JM, 1990, J IMMUNOL, V145, P3223; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; UCKUN FM, 1991, P NATL ACAD SCI USA, V88, P3589, DOI 10.1073/pnas.88.9.3589; UCKUN FM, 1992, P NATL ACAD SCI USA, V89, P9005, DOI 10.1073/pnas.89.19.9005; UCKUN FM, 1992, BLOOD, V79, P3369; UCKUN FM, 1993, BRIT J HAEMATOL, V85, P435; UCKUN FM, 1985, J IMMUNOL, V134, P3504; UCKUN FM, 1992, BLOOD, V79, P2201; UCKUN FM, 1992, BLOOD, V79, P3116; UCKUN FM, 1993, BLOOD, V81, P1323; UCKUN FM, 1993, NEW ENGL J MED, V329, P1296, DOI 10.1056/NEJM199310283291802; UCKUN FM, 1989, BLOOD, V73, P533; UCKUN FM, 1988, P NATL ACAD SCI USA, V85, P8603, DOI 10.1073/pnas.85.22.8603; UCKUN FM, 1989, BLOOD, V74, P761; UCKUN FM, 1991, J BIOL CHEM, V266, P17478; UCKUN FM, 1986, J EXP MED, V163, P347, DOI 10.1084/jem.163.2.347; UCKUN FM, 1990, BLOOD, V76, P1908; UCKUN FM, 1988, BLOOD, V71, P13; UCKUN FM, 1993, J BIOL CHEM, V268, P21172; UCKUN FM, 1993, P NATL ACAD SCI USA, V90, P252, DOI 10.1073/pnas.90.1.252; UCKUN FM, UNPUB; VITETTA ES, 1987, SCIENCE, V238, P1098, DOI 10.1126/science.3317828	64	256	284	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 10	1995	267	5199					886	891		10.1126/science.7531365	http://dx.doi.org/10.1126/science.7531365			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG207	7531365				2022-12-24	WOS:A1995QG20700059
J	ILLANGASEKARE, M; SANCHEZ, G; NICKLES, T; YARUS, M				ILLANGASEKARE, M; SANCHEZ, G; NICKLES, T; YARUS, M			AMINOACYL-RNA SYNTHESIS CATALYZED BY AN RNA	SCIENCE			English	Article							NUCLEOTIDES; TETRAHYMENA; POLYMERASE; BINDING	An RNA has been selected that rapidly aminoacylates its 2'(3') terminus when provided with phenylalanyl-adenosine monophosphate. That is, the RNA accelerates the same aminoacyl group transfer catalyzed by protein aminoacyl-transfer RNA synthetases. The best characterized RNA reaction requires both Mg2+ and Ca2+. These results confirm a necessary prediction of the RNA world hypothesis and represent efficient RNA reaction (greater than or equal to 10(5) times accelerated) at a carbonyl carbon, exemplifying a little explored type of RNA catalysis.			ILLANGASEKARE, M (corresponding author), UNIV COLORADO, DEPT MOLEC CELLULAR & DEV BIOL, BOULDER, CO 80309 USA.		Yarus, Michael/Q-9813-2019		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030881, R01GM048080, R37GM030881] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30881, GM48080] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASS BL, 1984, NATURE, V308, P820, DOI 10.1038/308820a0; BELRHALI H, 1994, SCIENCE, V263, P1432, DOI 10.1126/science.8128224; BERG P, 1958, J BIOL CHEM, V233, P608; BROWN EA, 1980, ACTA CRYSTALLOGR B, V36, P2597, DOI 10.1107/S0567740880009508; CAVARELLI J, 1994, EMBO J, V13, P327, DOI 10.1002/j.1460-2075.1994.tb06265.x; CONNELL GJ, 1993, BIOCHEMISTRY-US, V32, P5497, DOI 10.1021/bi00072a002; CONNELL GJ, 1994, SCIENCE, V264, P1137, DOI 10.1126/science.7513905; FERSHT AR, 1987, BIOCHEMISTRY-US, V26, P8031, DOI 10.1021/bi00399a001; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; GILLAM I, 1968, BIOCHEMISTRY-US, V7, P3459, DOI 10.1021/bi00850a022; GOTTIKH BP, 1970, TETRAHEDRON, V26, P4419, DOI 10.1016/S0040-4020(01)93090-X; JAEGER JA, 1990, METHOD ENZYMOL, V183, P281; MAJERFELD I, 1994, NAT STRUCT BIOL, V1, P287, DOI 10.1038/nsb0594-287; MCLAUGHLIN CS, 1965, BIOCHEMISTRY-US, V4, P1442, DOI 10.1021/bi00883a032; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; PICCIRILLI JA, 1992, SCIENCE, V256, P1420, DOI 10.1126/science.1604316; SASSANFAR M, 1993, NATURE, V364, P550, DOI 10.1038/364550a0; SCHOFIEL.P, 1968, BIOCHIM BIOPHYS ACTA, V155, P410, DOI 10.1016/0005-2787(68)90185-8; STEINSCHNEIDER A, 1966, BIOCHEMISTRY-US, V5, P2729, DOI 10.1021/bi00872a033; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; WEBER AL, 1975, J MOL EVOL, V6, P309, DOI 10.1007/BF01794637; WELCH M, 1995, BIOCHEMISTRY-US, V34, P385, DOI 10.1021/bi00002a001; WICKRAMASINGHE NSMD, 1991, BIOCHEMISTRY-US, V30, P2768, DOI 10.1021/bi00225a005; WOLFENDEN R, 1964, BIOCHEMISTRY-US, V3, P329, DOI 10.1021/bi00891a006; YARUS M, 1993, FASEB J, V7, P31, DOI 10.1096/fasebj.7.1.8422972; YARUS M, 1988, SCIENCE, V240, P1751, DOI 10.1126/science.3381099; Yarus M., 1993, RNA WORLD, P205	28	269	286	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 3	1995	267	5198					643	647		10.1126/science.7530860	http://dx.doi.org/10.1126/science.7530860			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE733	7530860				2022-12-24	WOS:A1995QE73300028
J	BLECHMAN, JM; LEV, S; BARG, J; EISENSTEIN, M; VAKS, B; VOGEL, Z; GIVOL, D; YARDEN, Y				BLECHMAN, JM; LEV, S; BARG, J; EISENSTEIN, M; VAKS, B; VOGEL, Z; GIVOL, D; YARDEN, Y			THE 4TH IMMUNOGLOBULIN DOMAIN OF THE STEM-CELL FACTOR-RECEPTOR COUPLES LIGAND-BINDING TO SIGNAL-TRANSDUCTION	CELL			English	Article							GROWTH-FACTOR RECEPTORS; ACTIN REORGANIZATION; INDUCED DIMERIZATION; CRYSTAL-STRUCTURE; KIT RECEPTOR; ACTIVATION; PROTEIN; KINASE; SITE; HETERODIMERIZATION	Receptor dimerization is ubiquitous to the action of all receptor tyrosine kinases, and in the case of dimeric ligands, such as the stem cell factor (SCF), it was attributed to ligand bivalency. However, by using a dimerization-inhibitory monoclonal antibody to the SCF receptor, we confined a putative dimerization site to the nonstandard fourth immunoglobulin-like domain of the receptor. Deletion of this domain not only abolished ligand-induced dimerization and completely inhibited signal transduction, but also provided insights into the mechanism of the coupling of ligand binding to dimer formation. These results identify an intrinsic receptor dimerization site and suggest that similar sites may exist in other receptors.	WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT NEUROBIOL,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT BIOL STRUCT,IL-76100 REHOVOT,ISRAEL; TEL AVIV UNIV,EDITH WOLFSON MED CTR,SCH MED,CARDIOVASC & HYPERTENS RES LAB,IL-58100 HOLON,ISRAEL; BIOMAKOR,IL-76326 REHOVOT,ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science; Weizmann Institute of Science; Tel Aviv University			YARDEN, YOSEF/K-1467-2012; Lev, Sima/AAP-7880-2020	Lev, Sima/0000-0002-2108-3330				AMSTERCHODER O, 1992, SCIENCE, V257, P1395, DOI 10.1126/science.1382312; BENLEVY R, 1992, J BIOL CHEM, V265, P17304; BERKERS JAM, 1991, J BIOL CHEM, V266, P922; Besmer P, 1991, CURR OPIN CELL BIOL, V3, P939, DOI 10.1016/0955-0674(91)90111-B; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; BLECHMAN JM, 1993, J BIOL CHEM, V268, P4399; BLUMEJENSEN P, 1991, EMBO J, V10, P4121, DOI 10.1002/j.1460-2075.1991.tb04989.x; BRADY RL, 1993, SCIENCE, V260, P979, DOI 10.1126/science.8493535; CARLBERG K, 1994, MOL BIOL CELL, V5, P81, DOI 10.1091/mbc.5.1.81; COCHET C, 1988, J BIOL CHEM, V263, P3290; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V420, P2361; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; HAMMACHER A, 1989, EMBO J, V8, P2489, DOI 10.1002/j.1460-2075.1989.tb08385.x; HERREN B, 1993, J BIOL CHEM, V268, P15088; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KRAUTWALD S, 1993, BIOCHEM BIOPH RES CO, V192, P720, DOI 10.1006/bbrc.1993.1474; LEV S, 1993, MOL CELL BIOL, V13, P2224, DOI 10.1128/MCB.13.4.2224; LEV S, 1992, J BIOL CHEM, V267, P15970; LEV S, 1992, P NATL ACAD SCI USA, V89, P678, DOI 10.1073/pnas.89.2.678; LEV S, 1992, J BIOL CHEM, V267, P10866; LEVITT M, 1983, J MOL BIOL, V168, P595, DOI 10.1016/S0022-2836(83)80304-0; LI W, 1991, EMBO J, V10, P277, DOI 10.1002/j.1460-2075.1991.tb07948.x; MACCUMBER MW, 1990, P NATL ACAD SCI USA, V87, P2359, DOI 10.1073/pnas.87.6.2359; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; RAMACHANDRAN GN, 1968, ADV PROTEIN CHEM, V28, P283; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035	35	131	146	0	0	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 13	1995	80	1					103	113		10.1016/0092-8674(95)90455-7	http://dx.doi.org/10.1016/0092-8674(95)90455-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QB910	7529140	Bronze			2022-12-24	WOS:A1995QB91000014
J	BERARDI, AC; WANG, AL; LEVINE, JD; LOPEZ, P; SCADDEN, DT				BERARDI, AC; WANG, AL; LEVINE, JD; LOPEZ, P; SCADDEN, DT			FUNCTIONAL ISOLATION AND CHARACTERIZATION OF HUMAN HEMATOPOIETIC STEM-CELLS	SCIENCE			English	Article							ERYTHROPOIETIN RECEPTOR GENE; IL-6 SIGNAL TRANSDUCER; COLONY-FORMING CELLS; MURINE BONE-MARROW; LONG-TERM CULTURE; PROGENITOR CELLS; LIMITING-DILUTION; C-KIT; MONOCLONAL-ANTIBODY; SOYBEAN AGGLUTININ	Hematopoietic cells differentiate in steps marked by the acquisition or loss of specific phenotypic characteristics. Human bone marrow cells that were responsive to the early-acting cytokines Kit ligand and interleukin-3 were forced to a metabolic death. The subfraction remaining represented 1 in 10(5) bone marrow mononuclear cells, was determined to be quiescent by cell cycle analysis, and had a stem cell immunophenotype, The cells were highly enriched for long-term culture-initiating cells, were capable of secondary colony formation, and produced both myeloid and lymphoid progeny. Thus, this technically simple strategy led to the efficient purification of cells with characteristics of hematopoietic stem cells.	HARVARD UNIV, DEACONESS HOSP, SCH MED, DIV HEMATOL ONCOL, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, CELL SORTING FACIL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School			Berardi, Anna Concetta/M-6769-2019; Cosset, François-Loïc/M-5862-2019; Lopez, Peter/AAP-7234-2020	Berardi, Anna Concetta/0000-0002-5078-6158; Cosset, François-Loïc/0000-0001-8842-3726; Lopez, Peter/0000-0002-8587-7148	NHLBI NIH HHS [R01-HL44851] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044851] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRADY G, 1990, Methods in Molecular and Cellular Biology, V2, P17; BRANDT J, 1992, BLOOD, V79, P634; BRIDDELL RA, 1992, BLOOD, V79, P3159; CHIBA S, 1990, CELL REGUL, V1, P327, DOI 10.1091/mbc.1.4.327; CIVIN CI, 1984, J IMMUNOL, V133, P157; CIVIN CI, 1987, EXP HEMATOL, V15, P10; COULOMBEL L, 1983, BLOOD, V62, P291; CRAIG W, 1993, J EXP MED, V177, P1331, DOI 10.1084/jem.177.5.1331; DEXTER TM, 1977, J CELL PHYSIOL, V91, P335, DOI 10.1002/jcp.1040910303; EBELL W, 1985, BLOOD, V65, P1105; ESCARY JL, 1993, NATURE, V363, P361, DOI 10.1038/363361a0; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GORDON MY, 1985, LEUKEMIA RES, V9, P1017, DOI 10.1016/0145-2126(85)90072-4; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HUANG S, 1994, BLOOD, V83, P1515, DOI 10.1182/blood.V83.6.1515.bloodjournal8361515; INABA M, 1990, JPN J CANCER RES, V81, P1039, DOI 10.1111/j.1349-7006.1990.tb03343.x; KATAYAMA N, 1993, BLOOD, V81, P610; KRIEGLER AB, 1994, EXP HEMATOL, V22, P432; LEMIEUX ME, 1993, BLOOD, V82, pA13; LERNER C, 1990, EXP HEMATOL, V18, P114; MCNIECE IK, 1990, INT J CELL CLONING, V8, P146, DOI 10.1002/stem.5530080302; MUENCH MO, 1992, EXP HEMATOL, V20, P339; NAKAGUA Y, 1994, D26616 GENB ACC; OGATA H, 1992, BLOOD, V80, P91; PLOEMACHER RE, 1988, EXP HEMATOL, V16, P903; PLOEMACHER RE, 1989, BLOOD, V74, P2755; Pollack A, 1990, Methods Cell Biol, V33, P19; PORTER EH, 1963, BRIT J CANCER, V17, P583, DOI 10.1038/bjc.1963.78; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; REISNER Y, 1982, BLOOD, V59, P360; SATO N, 1993, BLOOD, V82, P3600; SIMS JE, 1989, P NATL ACAD SCI USA, V86, P8946, DOI 10.1073/pnas.86.22.8946; SISTONEN P, 1993, HUM GENET, V92, P299, DOI 10.1007/BF00244476; SKODA RC, 1993, EMBO J, V12, P2645, DOI 10.1002/j.1460-2075.1993.tb05925.x; SMITH C, 1991, BLOOD, V77, P2122; SPANGRUDE GJ, 1990, P NATL ACAD SCI USA, V87, P7433, DOI 10.1073/pnas.87.19.7433; SROUR EF, 1993, BLOOD, V82, P3333; STEWART FM, 1993, BLOOD, V81, P2283; SUTHERLAND HJ, 1990, P NATL ACAD SCI USA, V87, P3584, DOI 10.1073/pnas.87.9.3584; SUTHERLAND HJ, 1993, BLOOD, V81, P1465; TAKIMOTO CH, 1993, J BIOL CHEM, V268, P21438; TASWELL C, 1981, J IMMUNOL, V126, P1614; TERSTAPPEN LWMM, 1991, BLOOD, V77, P1218; TESTA U, 1993, BLOOD, V81, P1442; TRUMPER LH, 1993, BLOOD, V81, P3097; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; WHITLOCK CA, 1982, P NATL ACAD SCI-BIOL, V79, P3608, DOI 10.1073/pnas.79.11.3608; WHITLOCK CA, 1984, J IMMUNOL METHODS, V67, P353, DOI 10.1016/0022-1759(84)90475-7; WICKREMA A, 1992, BLOOD, V80, P1940, DOI 10.1182/blood.V80.8.1940.1940; WOLF NS, 1993, EXP HEMATOL, V21, P614; YAMAGUCHI Y, 1993, EXP HEMATOL, V21, P1233; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YOUSSOUFIAN H, 1993, BLOOD, V81, P2223; ZIPORI D, 1988, BLOOD, V71, P586	55	358	385	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 6	1995	267	5194					104	108		10.1126/science.7528940	http://dx.doi.org/10.1126/science.7528940			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA235	7528940				2022-12-24	WOS:A1995QA23500040
J	OREILLY, MS; HOLMGREN, L; SHING, Y; CHEN, C; ROSENTHAL, RA; MOSES, M; LANE, WS; CAO, YH; SAGE, EH; FOLKMAN, J				OREILLY, MS; HOLMGREN, L; SHING, Y; CHEN, C; ROSENTHAL, RA; MOSES, M; LANE, WS; CAO, YH; SAGE, EH; FOLKMAN, J			ANGIOSTATIN - A NOVEL ANGIOGENESIS INHIBITOR THAT MEDIATES THE SUPPRESSION OF METASTASES BY A LEWIS LUNG-CARCINOMA	CELL			English	Article							PRIMARY TUMOR REMOVAL; CONCOMITANT IMMUNITY; ENDOTHELIAL-CELLS; RESIDUAL TUMOR; GROWTH-FACTOR; PLASMINOGEN; RESISTANCE; BINDING; CANCER; MICE	The phenomenon of inhibition of tumor growth by tumor mass has been repeatedly studied, but without elucidation of a satisfactory mechanism. In our animal model, a primary tumor inhibits its remote metastases. After tumor removal, metastases neovascularize and grow. When the primary tumor is present, metastatic growth is suppressed by a circulating angiogenesis inhibitor. Serum and urine from tumor-bearing mice, but not from controls, specifically inhibit endothelial cell proliferation. The activity copurifies with a 38 kDa plasminogen fragment that we have sequenced and named angiostatin. A corresponding fragment of human plasminogen has similar activity. Systemic administration of angiostatin, but not intact plasminogen, potently blocks neovascularization and growth of metastases. We here show that the inhibition of metastases by a primary mouse tumor is mediated, at least in part, by angiostatin.	HARVARD UNIV,SCH MED,DEPT BIOL CELULAR,BOSTON,MA 02115; HARVARD UNIV,HARVARD MICROCHEM FACIL,CAMBRIDGE,MA 02138; UNIV WASHINGTON,DEPT BIOL STRUCT,SEATTLE,WA 98195	Harvard University; Harvard Medical School; Harvard University; University of Washington; University of Washington Seattle	OREILLY, MS (corresponding author), CHILDRENS HOSP,DEPT SURG,300 LONGWOOD AVE,BOSTON,MA 02115, USA.				NCI NIH HHS [P01-CA45548] Funding Source: Medline; NHLBI NIH HHS [HL40711] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA045548] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040711] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Apolant, 1905, BERL KLIN WSCHR, V42, P871; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; Bashford EF, 1907, P R SOC LOND B-CONTA, V79, P164, DOI 10.1098/rspb.1907.0014; BICHEL P, 1971, EUR J CANCER, V7, P349, DOI 10.1016/0014-2964(71)90079-X; BOK RA, 1985, BIOCHEMISTRY-US, V24, P3279, DOI 10.1021/bi00334a031; BONFIL RD, 1988, INT J CANCER, V41, P415, DOI 10.1002/ijc.2910410317; BRUNSCHW.A, 1965, ANN SURG, V162, P416, DOI 10.1097/00000658-196509000-00011; BURSCH W, 1990, CARCINOGENESIS, V11, P847, DOI 10.1093/carcin/11.5.847; CASTLE V, 1991, J CLIN INVEST, V87, P1883, DOI 10.1172/JCI115212; CLAPP C, 1993, ENDOCRINOLOGY, V133, P1292, DOI 10.1210/en.133.3.1292; CLARK WH, 1989, JNCI-J NATL CANCER I, V81, P1893, DOI 10.1093/jnci/81.24.1893; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; DEWYS WD, 1972, CANCER RES, V32, P374; ELLEMAN CJ, 1977, J NATL CANCER I, V59, P925, DOI 10.1093/jnci/59.3.925; FIDLER IJ, 1991, BRIT MED BULL, V47, P157, DOI 10.1093/oxfordjournals.bmb.a072453; FISHER B, 1989, CANCER RES, V49, P1996; FISHER B, 1983, CANCER RES, V43, P1488; FOLKMAN J, 1979, P NATL ACAD SCI USA, V76, P5217, DOI 10.1073/pnas.76.10.5217; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FOLKMAN J, 1994, J CLIN ONCOL, V12, P441, DOI 10.1200/JCO.1994.12.3.441; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GERSHON RK, 1967, NATURE, V213, P674, DOI 10.1038/213674a0; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GORELIK E, 1978, INT J CANCER, V21, P617, DOI 10.1002/ijc.2910210512; GORELIK E, 1981, INT J CANCER, V27, P847, DOI 10.1002/ijc.2910270618; GORELIK E, 1983, CANCER RES, V43, P138; GORELIK E, 1983, ADV CANCER RES, V39, P71, DOI 10.1016/S0065-230X(08)61033-7; GORELLK E, 1980, J NATL CANCER I, V65, P1257; GREENE HSN, 1960, CANCER RES, V20, P1094; GUNDUZ N, 1979, CANCER RES, V39, P3861; HIMMELE JC, 1986, J CANCER RES CLIN, V111, P160, DOI 10.1007/BF00400757; HOMANDBERG GA, 1985, AM J PATHOL, V120, P327; HORI A, 1991, CANCER RES, V51, P6180; HOWARD JM, 1963, SURG GYNECOL OBSTET, V117, P567; ICHINOSE A, 1992, BIOCHEMISTRY-US, V31, P3113, DOI 10.1021/bi00127a011; INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0; IRUELAARISPE ML, 1991, P NATL ACAD SCI USA, V88, P5026, DOI 10.1073/pnas.88.11.5026; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KOIKE A, 1963, CANCER, V16, P1065, DOI 10.1002/1097-0142(196308)16:8<1065::AID-CNCR2820160814>3.0.CO;2-O; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LANGE PH, 1980, CANCER-AM CANCER SOC, V45, P1498, DOI 10.1002/1097-0142(19800315)45:6<1498::AID-CNCR2820450633>3.0.CO;2-7; LAUSCH RN, 1969, INT J CANCER, V4, P226, DOI 10.1002/ijc.2910040213; LERCH PG, 1980, EUR J BIOCHEM, V107, P7, DOI 10.1111/j.1432-1033.1980.tb04617.x; MACHOVICH R, 1989, BIOCHEMISTRY-US, V28, P4517, DOI 10.1021/bi00436a059; Machovich R, 1990, Blood Coagul Fibrinolysis, V1, P273, DOI 10.1097/00001721-199008000-00004; Marie P., 1910, B ASS FR ETUD CANC, V3, P19; MILAS L, 1974, CANCER RES, V34, P61; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MOHR U, 1968, NATURE, V220, P138, DOI 10.1038/220138a0; MUTHUKKARUPPAN V, 1979, SCIENCE, V28, P1416; NAKAJIMA K, 1993, J NEUROCHEM, V61, P2155, DOI 10.1111/j.1471-4159.1993.tb07454.x; NGUYEN M, 1994, MICROVASC RES, V47, P31, DOI 10.1006/mvre.1994.1003; NICKOLOFF BJ, 1994, AM J PATHOL, V144, P820; O'Reilly Michael, 1993, Surgical Forum, V44, P474; OBESO J, 1990, LAB INVEST, V63, P259; PONTING CP, 1992, BLOOD COAGUL FIBRIN, V3, P605, DOI 10.1097/00001721-199210000-00012; PREHN RT, 1993, CANCER RES, V53, P3266; PREHN RT, 1991, CANCER RES, V51, P2; RASTINEJAD F, 1989, CELL, V56, P345, DOI 10.1016/0092-8674(89)90238-9; ROTHBARTH K, 1977, EUR J CANCER, V13, P1195, DOI 10.1016/0014-2964(77)90021-4; ROUNDS DE, 1970, CANCER RES, V30, P2847; RUGGIERO RA, 1985, BRIT J CANCER, V51, P37, DOI 10.1038/bjc.1985.6; RUGGIERO RA, 1990, CANCER RES, V50, P7159; SCHATTEN WE, 1958, CANCER, V11, P455, DOI 10.1002/1097-0142(195805/06)11:3<455::AID-CNCR2820110303>3.0.CO;2-3; SIMPSONHERREN L, 1976, CANCER TREAT REP, V60, P1749; SOTTRUPJENSEN L, 1978, PROGR CHEM FIBRINOLY, P191; SOUTHAM CM, 1961, CANCER, V14, P971, DOI 10.1002/1097-0142(196109/10)14:5<971::AID-CNCR2820140510>3.0.CO;2-O; SUGARBAKER EV, 1977, PROGR CANC RES THERA, P227; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; Tyzzer EE, 1913, J MED RES, V28, P309; WARREN BA, 1977, PROGR CANC RES THERA, P185; WEISSBACH L, 1992, BIOCHEM BIOPH RES CO, V186, P1108, DOI 10.1016/0006-291X(92)90861-E; WOODRUFF M, 1990, CELLULAR VARIATION A; WOODRUFF M, 1980, INTERACTIONS CANCER; WYLLIE AH, 1993, BRIT J CANCER, V67, P205, DOI 10.1038/bjc.1993.40; YUHAS JM, 1974, CANCER RES, V34, P2005; [No title captured]	77	2837	3232	3	144	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 21	1994	79	2					315	328		10.1016/0092-8674(94)90200-3	http://dx.doi.org/10.1016/0092-8674(94)90200-3			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PN630	7525077				2022-12-24	WOS:A1994PN63000015
J	DUCLOSVALLEE, JC; JOHANET, C; TRINCHET, JC; DENY, P; LAURENT, MF; DURON, F; VALENSI, P; WEIL, B; HOMBERG, JC; PATERON, D; BEAUGRAND, M				DUCLOSVALLEE, JC; JOHANET, C; TRINCHET, JC; DENY, P; LAURENT, MF; DURON, F; VALENSI, P; WEIL, B; HOMBERG, JC; PATERON, D; BEAUGRAND, M			HIGH PREVALENCE OF SERUM ANTIBODIES TO HEPATITIS-C VIRUS IN PATIENTS WITH HASHIMOTOS-THYROIDITIS	BRITISH MEDICAL JOURNAL			English	Article							DISEASE		HOP JEAN VERDIER,SERV HEPATOGASTROENTEROL,F-93140 BONDY,FRANCE; HOP ST ANTOINE,IMMUNOL LAB,F-75012 PARIS,FRANCE; HOP AVICENNE,SERV MICROBIOL,F-93000 BOBIGNY,FRANCE; HOP LA PITIE SALPETRIERE,NUCL MED SERV,F-75013 PARIS,FRANCE; HOP ST ANTOINE,SERV ENDOCRINOL,F-75012 PARIS,FRANCE; HOP JEAN VERDIER,SERV ENDOCRINOL,F-93140 BONDY,FRANCE; HOP COCHIN,CLIN IMMUNOL LAB,F-75014 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Jean-Verdier - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Jean-Verdier - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite			Deny, Paul/C-6099-2011					ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; CIAMPOLILLO A, 1989, LANCET, V1, P1096; ESTEBAN JI, 1992, PROGR LIVER DISEASE, P219; HADDAD J, 1992, LANCET, V339, P321, DOI 10.1016/0140-6736(92)91645-O; MANNS MP, 1993, PROGRESS IN HEPATOLOGY 93, P79	5	30	31	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 1	1994	309	6958					846	847		10.1136/bmj.309.6958.846	http://dx.doi.org/10.1136/bmj.309.6958.846			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK501	7524874	Green Published			2022-12-24	WOS:A1994PK50100022
J	BILGRAMI, S; GREENBERG, BR				BILGRAMI, S; GREENBERG, BR			WHY SO MANY OPERATIONS FOR LOCALIZED PROSTATE-CANCER	LANCET			English	Editorial Material									VET AFFAIRS MED CTR,NEWINGTON,CT	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System	BILGRAMI, S (corresponding author), UNIV CONNECTICUT,CTR HLTH,DIV HEMATOL ONCOL,FARMINGTON,CT, USA.							ADOLFSSON J, 1993, CANCER-AM CANCER SOC, V72, P310, DOI 10.1002/1097-0142(19930715)72:2<310::AID-CNCR2820720203>3.0.CO;2-T; BADALAMENT RA, 1991, DISEASE A MONTH, V37, P203; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; JOHANSSON JE, 1992, JAMA-J AM MED ASSOC, V267, P2191, DOI 10.1001/jama.267.16.2191; LUYAO GL, 1993, JAMA-J AM MED ASSOC, V269, P2633, DOI 10.1001/jama.269.20.2633; LUYAO GL, 1994, LANCET, V343, P251, DOI 10.1016/S0140-6736(94)91109-6; METTLIN C, 1994, UROLOGY, V43, P488, DOI 10.1016/0090-4295(94)90236-4; MOORE MJ, 1988, J CLIN ONCOL, V6, P1736, DOI 10.1200/JCO.1988.6.11.1736; PEZZINO G, 1994, J NATL CANCER I, V86, P1083, DOI 10.1093/jnci/86.14.1083	9	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 10	1994	344	8924					700	701		10.1016/S0140-6736(94)92202-0	http://dx.doi.org/10.1016/S0140-6736(94)92202-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF187	7521501				2022-12-24	WOS:A1994PF18700004
J	DAMERON, KM; VOLPERT, OV; TAINSKY, MA; BOUCK, N				DAMERON, KM; VOLPERT, OV; TAINSKY, MA; BOUCK, N			CONTROL OF ANGIOGENESIS IN FIBROBLASTS BY P53 REGULATION OF THROMBOSPONDIN-1	SCIENCE			English	Article							TUMOR-SUPPRESSOR GENES; CANCER SYNDROME; WILD-TYPE; EXPRESSION; INHIBITOR; MUTANT; TRANSFORMATION; PROTEIN; FAMILY; CYCLE	As normal cells progress toward malignancy, they must switch to an angiogenic phenotype to attract the nourishing vasculature that they depend on for their growth. In cultured fibroblasts from Li-Fraumeni patients, this switch was found to coincide with loss of the wild-type allele of the p53 tumor suppressor gene and to be the result of reduced expression of thrombospondin-1 (TSP-1), a potent inhibitor of angiogenesis. Transfection assays revealed that p53 can stimulate the endogenous TSP-1 gene and positively regulate TSP-1 promoter sequences. These data indicate that, in fibroblasts, wild-type p53 inhibits angiogenesis through regulation of TSP-1 synthesis.	NORTHWESTERN UNIV, SCH MED, DEPT MICROBIOL IMMUNOL, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, SCH MED, RH LURIE CANC CTR, CHICAGO, IL 60611 USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT TUMOR BIOL, HOUSTON, TX 77030 USA	Northwestern University; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; University of Texas System; UTMD Anderson Cancer Center				Volpert, Olga/0000-0003-1381-5543; Tainsky, Michael/0000-0002-0261-831X	NCI NIH HHS [P01 CA34936, CA52750, CA64239] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA034936, R01CA064239] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASCH AS, 1989, PROG HEMOST THROMB, V9, P157; BICKNELL R, 1991, EUR J CANCER, V27, P781, DOI 10.1016/0277-5379(91)90189-K; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BISCHOFF FZ, 1991, ONCOGENE, V6, P183; BLOOD CH, 1990, BIOCHIM BIOPHYS ACTA, V1032, P89, DOI 10.1016/0304-419X(90)90014-R; BORNSTEIN P, 1990, J BIOL CHEM, V265, P16691; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; BOUCK N, 1990, CANCER CELL-MON REV, V2, P179; DAMERON KM, IN PRESS COLD SPRING; DAMERON KM, UNPUB; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DONOVIEL DB, 1988, J BIOL CHEM, V263, P18590; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Folkman J, 1992, Semin Cancer Biol, V3, P65; FOLKMAN J, 1992, PRINCESS TAKAMATSU S, V22, P339; Frazier WA, 1991, CURR OPIN CELL BIOL, V3, P792, DOI 10.1016/0955-0674(91)90052-Z; GANNON JV, 1991, NATURE, V349, P802; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; HARVEY M, 1993, ONCOGENE, V8, P2457; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LABELL TL, 1992, GENOMICS, V12, P421, DOI 10.1016/0888-7543(92)90430-Z; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; PIETENPOL JA, 1993, NATURE, V365, P17, DOI 10.1038/365017a0; POLVERINI PJ, 1991, METHOD ENZYMOL, V198, P440; RASTINEJAD F, 1989, CELL, V56, P345, DOI 10.1016/0092-8674(89)90238-9; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; TAINSKY MA, UNPUB; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VIRBASIUS JV, 1991, MOL CELL BIOL, V11, P5631, DOI 10.1128/MCB.11.11.5631; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	34	1259	1314	1	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 9	1994	265	5178					1582	1584		10.1126/science.7521539	http://dx.doi.org/10.1126/science.7521539			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PF336	7521539				2022-12-24	WOS:A1994PF33600036
J	SHEPPARD, DN; OSTEDGAARD, LS; RICH, DP; WELSH, MJ				SHEPPARD, DN; OSTEDGAARD, LS; RICH, DP; WELSH, MJ			THE AMINO-TERMINAL PORTION OF CFTR FORMS A REGULATED CL- CHANNEL	CELL			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CYSTIC-FIBROSIS GENE; NUCLEOTIDE-BINDING; CHLORIDE CHANNEL; ESCHERICHIA-COLI; R-DOMAIN; ATP; TRANSPORT; IDENTIFICATION; EXPRESSION	The cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channel consists of two motifs (each containing a membrane-spanning domain [MSD] and a nucleotide-binding domain [NBD]) linked by an R domain. We tested the hypothesis that one MSD-NBD motif could form a Cl- channel. The amino-terminal portion of CFTR (D836X, which contains MSD1, NBD1, and the R domain) formed Cl- channels with conductive properties identical to those of CFTR. However, channel regulation differed. Although phosphorylation increased activity, channels opened without phosphorylation. MgATP stimulated D836X more potently than CFTR and may interact at more than one site. These data and migration of D836X on sucrose density gradients suggest that D836X may function as a multimer. Thus, the amino-terminal portion of CFTR contains all of the structures required to build a regulated Cl- channel.	UNIV IOWA,COLL MED,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	University of Iowa; University of Iowa	SHEPPARD, DN (corresponding author), UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,IOWA CITY,IA 52242, USA.		Sheppard, David N/AAV-4187-2021	Sheppard, David N/0000-0001-5533-9130; Ostedgaard, Lynda/0000-0001-7717-3442; Welsh, Michael/0000-0002-1646-6206				AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; CHANG XB, 1993, J BIOL CHEM, V268, P11304; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FELMLEE T, 1985, J BACTERIOL, V163, P94, DOI 10.1128/JB.163.1.94-105.1985; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAMOSH A, 1991, J CLIN INVEST, V88, P1880, DOI 10.1172/JCI115510; HARTMAN J, 1992, J BIOL CHEM, V267, P6455; Hille B., 1992, IONIC CHANNELS EXCIT; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KAMIJO K, 1990, J BIOL CHEM, V265, P4534; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MARSHALL J, 1994, IN PRESS J BIOL CHEM; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1993, J BIOL CHEM, V268, P20259; RIORDAN JR, 1989, SCIENCE, V245, P1066; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; SHEPPARD DN, 1993, NATURE, V362, P160, DOI 10.1038/362160a0; SMIT LS, 1993, P NATL ACAD SCI USA, V90, P9963, DOI 10.1073/pnas.90.21.9963; TABCHARANI JA, 1993, NATURE, V366, P79, DOI 10.1038/366079a0; THOMAS PJ, 1991, SCIENCE, V251, P555, DOI 10.1126/science.1703660; TRAVIS SM, 1993, J BIOL CHEM, V268, P15336; VIDAUD M, 1990, HUM GENET, V85, P446, DOI 10.1007/BF02428305; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WELSH MJ, 1992, NEURON, V8, P821, DOI 10.1016/0896-6273(92)90196-K; WHITE MB, 1991, GENOMICS, V11, P778, DOI 10.1016/0888-7543(91)90092-S; 1993, NEW ENGL J MED, V329, P1308	32	103	105	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 25	1994	76	6					1091	1098		10.1016/0092-8674(94)90385-9	http://dx.doi.org/10.1016/0092-8674(94)90385-9			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ND246	7511062				2022-12-24	WOS:A1994ND24600014
J	LEE, HS; HUANG, SS; KAO, TH				LEE, HS; HUANG, SS; KAO, TH			S-PROTEINS CONTROL REJECTION OF INCOMPATIBLE POLLEN IN PETUNIA-INFLATA	NATURE			English	Article							SELF-INCOMPATIBILITY; NICOTIANA-ALATA; RIBONUCLEASE-ACTIVITY; ALLELES; EXPRESSION; HYBRIDA	FLOWERING plants have evolved various stratagems to prevent inbreeding and promote outcrosses1. One such mechanism, gametophytic self-incompatibility, provides a genetic barrier to self-fertilization, and in the simplest cases is controlled by the highly polymorphic S locus2. Growth of a pollen tube in the style is arrested when the S allele carried by the pollen matches one of the two S alleles carried by the pistil. Putative S allele proteins of the pistil have been identified in several solanaceous species based on their co-segregation with S alleles3-12, and they have been shown to be ribonucleases13-15. So far. there has been only correlative or indirect evidence for the claim that these S allele-associated proteins (S proteins) are involved in recognition and rejection of self pollen16,17. Here we show that inhibition of synthesis of S3 and S2 proteins in Petunia inflata plants of S2S3 genotype by the antisense S3 gene resulted in failure of the transgenic plants to reject S3 and S2 pollen. We further show that expression of the transgene encoding S3 protein in P. inflata plants of S1S2 genotype confers on the transgenic plants the ability to reject S3 pollen. The self-incompatibility behaviour of the pollen was not affected by the transgene in either set of experiments. Taken together, these findings provide direct in vivo evidence that S proteins control the self-incompatibility behaviour of the pistil.	PENN STATE UNIV,DEPT BIOCHEM & MOLEC BIOL,UNIV PK,PA 16802; PENN STATE UNIV,CTR GENE REGULAT,UNIV PK,PA 16802	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University								AI YJ, 1991, MOL GEN GENET, V230, P353, DOI 10.1007/BF00280291; AI YJ, 1990, SEX PLANT REPROD, V3, P130, DOI 10.1007/BF00198857; ANDERSON MA, 1986, NATURE, V321, P38, DOI 10.1038/321038a0; BREDEMEIJER GMM, 1981, THEOR APPL GENET, V59, P185, DOI 10.1007/BF00264974; BROOTHAERTS W, 1991, SEX PLANT REPROD, V4, P258, DOI 10.1007/BF00200545; BROOTHAERTS WJ, 1989, PLANT MOL BIOL, V14, P93; CLARK KR, 1990, PLANT CELL, V2, P815, DOI 10.1105/tpc.2.8.815; COLEMAN CE, 1992, PLANT MOL BIOL, V18, P725, DOI 10.1007/BF00020014; De Nettancourt D., 1977, MONOGRAPHS THEORETIC, P28; FRANKEL R, 1977, MONOGRAPHS THEORETIC, P5; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; IOERGER TR, 1991, SEX PLANT REPROD, V4, P81; KAMBOJ RK, 1986, THEOR APPL GENET, V71, P815, DOI 10.1007/BF00276423; KHEYRPOUR A, 1990, SEX PLANT REPROD, V3, P88, DOI 10.1007/BF00198851; KIRCH HH, 1989, THEOR APPL GENET, V78, P581, DOI 10.1007/BF00290845; LEE HS, 1992, PLANT MOL BIOL, V20, P1131, DOI 10.1007/BF00028899; LEWIS D, 1949, HEREDITY, V3, P339, DOI 10.1038/hdy.1949.25; LINSMAIER EM, 1965, PHYSIOL PLANTARUM, V18, P100, DOI 10.1111/j.1399-3054.1965.tb06874.x; MAU SL, 1986, PLANTA, V169, P184, DOI 10.1007/BF00392312; MCCLURE BA, 1989, NATURE, V342, P955, DOI 10.1038/342955a0; OELLER PW, 1991, SCIENCE, V254, P437, DOI 10.1126/science.1925603; SIMS TL, 1993, CRIT REV PLANT SCI, V12, P129, DOI 10.1080/07352689309382359; SINGH A, 1991, PLANT PHYSIOL, V96, P61, DOI 10.1104/pp.96.1.61; SINGH A, 1992, SEXUAL REPRODUCTION, P449; XU B, 1990, SEX PLANT REPROD, V3, P54, DOI 10.1007/BF00189952	25	333	375	2	47	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 10	1994	367	6463					560	563		10.1038/367560a0	http://dx.doi.org/10.1038/367560a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MV863	7509041				2022-12-24	WOS:A1994MV86300059
J	PARKER, MW; BUCKLEY, JT; POSTMA, JPM; TUCKER, AD; LEONARD, K; PATTUS, F; TSERNOGLOU, D				PARKER, MW; BUCKLEY, JT; POSTMA, JPM; TUCKER, AD; LEONARD, K; PATTUS, F; TSERNOGLOU, D			STRUCTURE OF THE AEROMONAS TOXIN PROAEROLYSIN IN ITS WATER-SOLUBLE AND MEMBRANE-CHANNEL STATES	NATURE			English	Article							SITE-DIRECTED MUTAGENESIS; HOLE-FORMING TOXIN; AEROLYSIN; HYDROPHILA; OLIGOMERIZATION; HISTIDINES; MONOMER; VIRUS	AEROLYSIN is chiefly responsible for the pathogenicity of Aeromonas hydrophila, a bacterium associated with diarrhoeal diseases and deep wound infections1. Like many other microbial toxins, the protein changes in a multistep process from a completely water-soluble form to produce a transmembrane channel that destroys sensitive cells by breaking their permeability barriers2. Here we describe the structure of proaerolysin determined by X-ray crystallography at 2.8 angstrom resolution. The protoxin (M(r) 52,000) adopts a novel protein fold. Images of an aerolysin oligomer derived from electron microscopy have assisted in constructing a model of the membrane channel and have led to the proposal of a scheme to account for insertion of the protein into lipid bilayers to form ion channels.	UNIV VICTORIA,DEPT BIOCHEM & MOLEC BIOL,VICTORIA V8W 2Y2,BC,CANADA; EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY	University of Victoria; European Molecular Biology Laboratory (EMBL)	PARKER, MW (corresponding author), ST VINCENTS INST MED RES,41 VICTORIA PARADE,FITZROY,VIC 3065,AUSTRALIA.		Parker, Michael W/F-9069-2013	Parker, Michael W/0000-0002-3101-1138	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALTWEGG M, 1989, CRC CR REV MICROBIOL, V16, P253, DOI 10.3109/10408418909105478; ARGOS P, 1988, PROTEIN ENG, V2, P101, DOI 10.1093/protein/2.2.101; ARNOLD E, 1990, J MOL BIOL, V211, P763, DOI 10.1016/0022-2836(90)90076-X; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BHAKDI S, 1987, REV PHYSL BIOCH PHAR, V107, P148; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; GARLAND WJ, 1988, INFECT IMMUN, V56, P1249, DOI 10.1128/IAI.56.5.1249-1253.1988; GREEN MJ, 1990, BIOCHEMISTRY-US, V29, P2177, DOI 10.1021/bi00460a031; HENDRICKSON WA, 1980, COMPUTING CRYSTALLOG; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; PARKER MW, 1990, TRENDS BIOCHEM SCI, V15, P126, DOI 10.1016/0968-0004(90)90205-P; TUCKER AD, 1990, J MOL BIOL, V212, P561, DOI 10.1016/0022-2836(90)90222-8; VANDERGOOT FG, 1992, BIOCHEMISTRY-US, V31, P8566, DOI 10.1021/bi00151a026; VANDERGOOT FG, 1993, J BIOL CHEM, V268, P18272; VANDERGOOT FG, 1993, BIOCHEMISTRY-US, V32, P2636, DOI 10.1021/bi00061a023; VANGUNSTEREN WF, 1988, PROTEIN ENG, V2, P5, DOI 10.1093/protein/2.1.5; VELLIEUX FMD, 1993, P NATL ACAD SCI USA, V90, P2355, DOI 10.1073/pnas.90.6.2355; WEISS MS, 1991, SCIENCE, V254, P1627, DOI 10.1126/science.1721242; WICKNER W, 1989, TRENDS BIOCHEM SCI, V14, P280, DOI 10.1016/0968-0004(89)90064-9; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.biochem.56.1.365; WILMSEN HU, 1990, J MEMBRANE BIOL, V115, P71, DOI 10.1007/BF01869107; WILMSEN HU, 1992, EMBO J, V11, P2457, DOI 10.1002/j.1460-2075.1992.tb05310.x; WILMSEN HU, 1991, MOL MICROBIOL, V5, P2745, DOI 10.1111/j.1365-2958.1991.tb01983.x; 1979, CCP4 DAR LAB	27	367	376	2	57	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 20	1994	367	6460					292	295		10.1038/367292a0	http://dx.doi.org/10.1038/367292a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MR494	7510043				2022-12-24	WOS:A1994MR49400062
J	KLOC, M; SPOHR, G; ETKIN, LD				KLOC, M; SPOHR, G; ETKIN, LD			TRANSLOCATION OF REPETITIVE RNA SEQUENCES WITH THE GERM PLASM IN XENOPUS-OOCYTES	SCIENCE			English	Article							MATERNAL MESSENGER-RNA; DROSOPHILA EMBRYOS; ANIMAL DEVELOPMENT; CELL-FORMATION; XIST GENE; LOCALIZATION; LAEVIS; PATTERN; PRODUCT; NUCLEUS	Xlsirts are a family of interspersed repeat RNAs from Xenopus laevis that contain from 3 to 13 repeat units (each 79 to 81 nucleotides long) flanked by unique sequences. They are homologous to the mammalian Xist gene that is involved in X chromosome inactivation. Xlsirt RNA appears first in the mitochondrial cloud (Balbiani body) in stage 2 oocytes and is then translocated as island-like structures to the vegetal cortex at early stage 3 coincident with the localization of the germ plasm. Exogenous Xlsirt RNA injected into oocytes translocates to the location of the endogenous RNA at that particular stage. The Xlsirt RNA repeat sequences are required for translocation and can cause the translocation of heterologous unique RNAs to the vegetal cortex.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT MOLEC GENET, 1515 HOLCOMBE BLVD, HOUSTON, TX 77030 USA; UNIV GENEVA, DEPT CELL BIOL, CH-1211 GENEVA 4, SWITZERLAND	University of Texas System; UTMD Anderson Cancer Center; University of Geneva			Kloc, Malgorzata/AAF-6982-2020					BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; ELLINGERZIEGELBAUER H, 1991, GENE DEV, V5, P94, DOI 10.1101/gad.5.1.94; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; GERHART J, 1989, DEVELOPMENT S; GURDON JB, 1992, CELL, V68, P185, DOI 10.1016/0092-8674(92)90465-O; HEASMAN J, 1984, DEV BIOL, V105, P458, DOI 10.1016/0012-1606(84)90303-8; JAMRICH M, 1983, P NATL ACAD SCI-BIOL, V80, P3364, DOI 10.1073/pnas.80.11.3364; KLOC M, UNPUB; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; MACDONALD PM, 1990, DEVELOPMENT, V110, P161; MACDONALD PM, 1988, NATURE, V336, P595, DOI 10.1038/336595a0; MAHOWALD AP, 1992, SCIENCE, V255, P1216, DOI 10.1126/science.1372132; MELTON DA, 1987, NATURE, V328, P80, DOI 10.1038/328080a0; MELTON DA, 1991, SCIENCE, V252, P234, DOI 10.1126/science.1672778; MILLER M, 1989, GENE DEV, V3, P572, DOI 10.1101/gad.3.4.572; MOSQUERA L, 1993, DEVELOPMENT, V117, P377; MOWRY KL, 1992, SCIENCE, V255, P991, DOI 10.1126/science.1546297; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; REITH W, 1982, EMBRYONIC DEV A, P139; SMITH JL, 1992, CELL, V70, P849, DOI 10.1016/0092-8674(92)90318-7; SMITH LD, 1975, MATERNAL EFFECTS DEV, P167; SPOHR G, 1983, MOL BIOL REP, V9, P33, DOI 10.1007/BF00777471; SPOHR G, 1981, J MOL BIOL, V151, P573, DOI 10.1016/0022-2836(81)90424-1; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; WYLIE CC, 1985, J EMBRYOL EXP MORPH, V89, P1	26	127	127	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 10	1993	262	5140					1712	1714		10.1126/science.7505061	http://dx.doi.org/10.1126/science.7505061			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML220	7505061				2022-12-24	WOS:A1993ML22000035
